gene_name	omim_inheritance	omim_phenotype
1-8D		
1-8U		{influenza, severe, susceptibility to}, 614680 (3)
1-Cys		
10-fTHF		
101F6		
103AS		
10C		
11B6	XLR,XL	bartter syndrome, type 5, antenatal, transient, 300971 (3),
12-HETER		
123F2		
12CC4	AD	intellectual developmental disorder with language impairment with or without autistic features, 613670 (3),
12R-LOX	AR	ichthyosis, congenital, 2, 242100 (3),
12S-LOX		
13CDNA73		
14-3-3		
14-3-3-zeta		
14-3-3GAMMA	AD	developmental and epileptic encephalopathy 56, 617665 (3),
14-3-3Î³	AD	developmental and epileptic encephalopathy 56, 617665 (3),
14.1	AR	agammaglobulinemia 2, 613500 (3),
14q(0)		
14q(I-1)		
14q(II-1)		
15-LOX-1		
15-LOX-2		
15.212		
15.5K		
156DAG	AR	muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 9, 616538 (3), ; muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 9, 613818 (3),
15E1.2	AR	combined oxidative phosphorylation deficiency 42, 618839 (3),
16.3A5	AR	hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy, 612300 (3),
16A	XLR,XL	immunodeficiency 47, 300972 (3),
16E1BP	AR	oocyte/zygote/embryo maturation arrest 9, 619011 (3), ; mosaic variegated aneuploidy syndrome 3, 617598 (3),
17-BETA-HSD11		
17-BETA-HSDXI		
1700010H15RiK	AR	ciliary dyskinesia, primary, 16, 614017 (3),
170A	AR	trichohepatoenteric syndrome 2, 614602 (3),
17b-HSD10	XLD,XL	hsd10 mitochondrial disease, 300438 (3),
182-FIP		
183ActI		
18A2		
19A		
1A1-3B		
1A6/DRIM		
1C7		{malaria, mild, susceptibility to}, 609148 (3)
1D	AR	?megacystis-microcolon-intestinal hypoperistalsis syndrome 3, 619362 (3),
1R20		
2-19		
2-21		
2-COP		
2-HPCL		
2'-PDE		
209L8		
20D7-FC4		
21-GARP		
225		
2310005P21Rik		
2310047H23Rik	AR	meckel syndrome 14, 619879 (3),
239AB		
239FB		
24p3		
2610509L04Rik		
26RFa		
2700066J21Rik		
2A9		
2B28		
2B4		{rheumatoid arthritis, susceptibility to}, 180300 (3)
2C18		
2C4D		
2E4	AR	intellectual developmental disorder, 41, 615637 (3),
2F1		
2H9		
2HOR0202		
2OST		
2P1	AR	mitochondrial complex i deficiency, nuclear type 18, 618240 (3),
2PP2A	AD	intellectual developmental disorder, 58, 618106 (3),
3-10C		
3-alpha-HSD	AR	{46xy sex reversal 8, modifier of}, 614279 (3),
3-OST-5		
3-PAP		
3'aHIF-1A		
3'HEXO		
30K		
30ST3A1		
30ST3B1		
3635		
37LRP	AD	asplenia, isolated congenital, 271400 (3),
384D8-2		
39K2		
3alpha-HSD		
3D3		
3G2		
3H11Ag	AR	leber congenital amaurosis 10, 611755 (3); joubert syndrome 5, 610188 (3), ; senior-loken syndrome 6, 610189 (3), ; ?bardet-biedl syndrome 14, 615991 (3), ; meckel syndrome 4, 611134 (3),
3M3	AR	3-m syndrome 3, 614205 (3),
3OST1		
3OST2		
3OST3A1		
3OST3B1		
3OST4		
3PAP		
3pK	AD	?macular dystrophy, patterned, 3, 617111 (3),
3PK	AD	?macular dystrophy, patterned, 3, 617111 (3),
4-1BB	AR	immunodeficiency 109 with lymphoproliferation, 620282 (3),
4-1BB-L		
4-1BBL		
4-HPPD	AD,AR	hawkinsinuria, 140350 (3), ; tyrosinemia, type iii, 276710 (3),
4-HPPD-L	AR	neurodevelopmental disorder with progressive spasticity and brain white matter abnormalities, 619026 (3), ; spastic paraplegia 83, 619027 (3),
4.1-G		
4.1B		
4.1G		
4.1N	AD	?intellectual developmental disorder, 11, 614257 (3),
4.1R	AR,AD	elliptocytosis-1, 611804 (3),
42A		
42C		
47.11		
4832404P21Rik		
4833431A01Rik	AD	dystonia 6, torsion, 602629 (3),
4E-BP1		
4E-BP3		
4E-T		
4EHP		
4F2		
4F2HC		
4F5		
4F5REL		
4HPPD	AD,AR	hawkinsinuria, 140350 (3), ; tyrosinemia, type iii, 276710 (3),
4P11		
4T2HC		
5-HT(2B)		
5-HT1A	AD	periodic fever, menstrual cycle dependent, 614674 (3),
5-HT1B		
5-HT1D		
5-HT1DB		
5-HT1E		
5-HT1F		
5-HT2A	MF,AD	{alcohol dependence, susceptibility to}, 103780 (3), ; {anorexia nervosa, susceptibility to}, 606788 (3); {major depressive disorder, response to citalopram therapy in}, 608516 (3); {seasonal affective disorder, susceptibility to}, 608516 (3); {obsessive-compulsive disorder, susceptibility to}, 164230 (3), ; {schizophrenia, susceptibility to}, 181500 (3),
5-HT2B		
5-HT2C		
5-HT3A		
5-HT3B		
5-HT3R		
5-HT4		
5-HT5A		
5-HT6		
5-HT6R		
5-HT7		
5-HTT	AD	{obsessive-compulsive disorder}, 164230 (3), ; {anxiety-related personality traits}, 607834 (3)
5-LOX	AD	{atherosclerosis, susceptibility to} (3); {asthma, diminished response to antileukotriene treatment in}, 600807 (3),
5-Opase	AR,AD	5-oxoprolinase deficiency, 260005 (3),
5'aHIF-1A		
52		
53BP1		
53BP2		
54TM		
59-DAP		
59K		
5HTR2C		
5MP1		
5MP2		
5PTASE		
5T4		
5T4-AG		
6-16		
6.3		
6.8PL		
60B8AG		
64kD	AR	?megacystis-microcolon-intestinal hypoperistalsis syndrome 3, 619362 (3),
6A3-5	AD	coffin-siris syndrome 1, 135900 (3),
6C6-Ag	XLR,XL	deafness, dystonia, and cerebral hypomyelination, 300475 (3),
6Ckine		
6PGL		
7-60		
71-7A	XLR,XL,XLD	simpson-golabi-behmel syndrome, type 2, 300209 (3), ; ?retinitis pigmentosa 23, 300424 (3), ; orofaciodigital syndrome i, 311200 (3), ; joubert syndrome 10, 300804 (3),
721P		
753P9	XLR,XL	immunodeficiency 102, 301082 (3),
76P	AR	microcephaly and chorioretinopathy, 3, 616335 (3),
7A5		
7B2		
7B4		
7h3		
7L1a		
7L30.1		
7L30.2		
7SK		
7SL		
7SL1c		
80K-L		
82-FIP		
87U6	AD	auriculocondylar syndrome 1, 602483 (3),
8B	AR,AD	arthrogryposis multiplex congenita 3, myogenic type, 618484 (3), ; emery-dreifuss muscular dystrophy 4, 612998 (3), ; spinocerebellar ataxia, 8, 610743 (3),
8D6	AR	methylmalonic aciduria, transient, due to transcobalamin receptor defect, 613646 (3),
8D6A	AR	methylmalonic aciduria, transient, due to transcobalamin receptor defect, 613646 (3),
8HS20		
9-27		
90K		
9630046K23Rik	AD,AR	dowling-degos disease 4, 615696 (3), ; muscular dystrophy, limb-girdle, 21, 617232 (3),
9F	XL,XLR	intellectual developmental disorder, syndromic, armfield type, 300261 (3),
9G8		
A-152E5.1		
A-923A4.1		
A-C1		
A-FABP		
A-LAP		
A-myb		
A-SCID	AR	severe combined immunodeficiency, athabascan type, 602450 (3), ; omenn syndrome, 603554 (3),
a1	AR,AD	neurodevelopmental disorder with epilepsy and brain atrophy, 619971 (3), ; developmental and epileptic encephalopathy 104, 619970 (3),
A1	AR	cerebellar ataxia, neuropathy, and vestibular areflexia syndrome, 614575 (3),
A1-5		
A12.2		
A121		
A14GALT		[blood group, p1pk system, p(2) phenotype], 111400 (3); nor polyagglutination syndrome, 111400 (3); [blood group, p1pk system, p phenotype], 111400 (3)
A15	XL,XLR	intellectual developmental disorder, 58, 300210 (3),
A170	AR,AD	neurodegeneration with ataxia, dystonia, and gaze palsy, childhood-onset, 617145 (3), ; frontotemporal dementia and/or amyotrophic lateral sclerosis 3, 616437 (3), ; myopathy, distal, with rimmed vacuoles, 617158 (3), ; paget disease of bone 3, 167250 (3),
A1A	AR	hemorrhagic diathesis due to antithrombin pittsburgh, 613490 (3), ; emphysema due to aat deficiency, 613490 (3), ; emphysema-cirrhosis, due to aat deficiency, 613490 (3),
A1AG1		
A1AT	AR	hemorrhagic diathesis due to antithrombin pittsburgh, 613490 (3), ; emphysema due to aat deficiency, 613490 (3), ; emphysema-cirrhosis, due to aat deficiency, 613490 (3),
A1B		
A1BG		
A1CF		
A1S9T	XL,XLR	spinal muscular atrophy, 2, infantile, 301830 (3), ; vexas syndrome, somatic, 301054 (3)
A1U		
a2	AR	wrinkly skin syndrome, 278250 (3), ; cutis laxa, type iia, 219200 (3),
A2	AR,AR	muscular dystrophy, limb-girdle, 3, 608099 (3), |retinal dystrophy with macular staphyloma, 617547 (3), ; spondylometaphyseal dysplasia, axial, 602271 (3),
A20	AD	autoinflammatory syndrome, familial, behcet-like 1, 616744 (3),
A211C6.1		
A214N16.3		
A26A1		
A26B1		
A26B3		
A26C1		
A26C1A		
A26C2		
A26C3		
A28-RGS14		
A2AP	AR	alpha-2-plasmin inhibitor deficiency, 262850 (3),
A2BP1		
A2D		
A2HS	AR	?alopecia-intellectual disability syndrome 1, 203650 (3),
A2LD1		
A2lp		
A2M		
A2ML1	AD	{otitis media, susceptibility to}, 166760 (3),
A2MR	AR	?keratosis pilaris atrophicans, 604093 (3),
A2MRAP	AR	myopia 23, 615431 (3),
a2V	AR	wrinkly skin syndrome, 278250 (3), ; cutis laxa, type iia, 219200 (3),
a3	AR	osteopetrosis, 1, 259700 (3),
A33		
A34.5		
A3a	AR	muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 9, 616538 (3), ; muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 9, 613818 (3),
A3AR		
A3b	AR	muscular dystrophy, limb-girdle, 4, 604286 (3),
A3GALNT		[blood group, abo system], 616093 (3)
A3GALT1		[blood group, abo system], 616093 (3)
A3GALT2		
A3GALT2P		
a4	AR	distal renal tubular acidosis 3, with or without sensorineural hearing loss, 602722 (3),
A4	AR	muscular dystrophy, limb-girdle, 5, 253700 (3),
A4-LSB		
A43		
A4GALT		[blood group, p1pk system, p(2) phenotype], 111400 (3); nor polyagglutination syndrome, 111400 (3); [blood group, p1pk system, p phenotype], 111400 (3)
A4GNT		
A6		
A6r		
A6RP		
A8-51		
AA	AD	sveinsson chorioretinal atrophy, 108985 (3),
AAA1		
AAAS	AR	achalasia-addisonianism-alacrimia syndrome, 231550 (3),
AAAT		
AAC-11		
AAC1	AR,AD	mitochondrial dna depletion syndrome 12b (cardiomyopathic type) ar, 615418 (3), ; progressive external ophthalmoplegia with mitochondrial dna deletions, 2, 609283 (3), ; mitochondrial dna depletion syndrome 12a (cardiomyopathic type) ad, 617184 (3),
AAC11		
AAC2	AR	[acetylation, slow], 243400 (3),
AACS		
AACT		alpha-1-antichymotrypsin deficiency (3); cerebrovascular disease, occlusive (3)
AADAC		
AADACL1		
AADAT		
AADC	AR	aromatic l-amino acid decarboxylase deficiency, 608643 (3),
AAF132	AR	cerebroretinal microangiopathy with calcifications and cysts, 612199 (3),
AAG3		
AAGAB	AD	keratoderma, palmoplantar, punctate type ia, 148600 (3),
AAIR8193		
AAK1		
AAKG	AD	glycogen storage disease of heart, lethal congenital, 261740 (3), ; wolff-parkinson-white syndrome, 194200 (3), ; cardiomyopathy, hypertrophic 6, 600858 (3),
AAKG2	AD	glycogen storage disease of heart, lethal congenital, 261740 (3), ; wolff-parkinson-white syndrome, 194200 (3), ; cardiomyopathy, hypertrophic 6, 600858 (3),
AAMP		
AANAT		
AAP	AR	alpha-2-plasmin inhibitor deficiency, 262850 (3),
AAP1		
AAR2		
AARS	AR,AD	developmental and epileptic encephalopathy 29, 616339 (3), ; charcot-marie-tooth disease, axonal, type 2n, 613287 (3), ; ?leukoencephalopathy, hereditary diffuse, with spheroids 2, 619661 (3), ; trichothiodystrophy 8, nonphotosensitive, 619691 (3),
AARS1	AR,AD	developmental and epileptic encephalopathy 29, 616339 (3), ; charcot-marie-tooth disease, axonal, type 2n, 613287 (3), ; ?leukoencephalopathy, hereditary diffuse, with spheroids 2, 619661 (3), ; trichothiodystrophy 8, nonphotosensitive, 619691 (3),
AARS2	AR	leukoencephalopathy, progressive, with ovarian failure, 615889 (3), ; combined oxidative phosphorylation deficiency 8, 614096 (3),
AARSD1		
AARSL	AR	leukoencephalopathy, progressive, with ovarian failure, 615889 (3), ; combined oxidative phosphorylation deficiency 8, 614096 (3),
AASD-PPT		
AASDH		
AASDHPPT		
AASS	AR	hyperlysinemia, 238700 (3),
AAT	AR	hemorrhagic diathesis due to antithrombin pittsburgh, 613490 (3), ; emphysema due to aat deficiency, 613490 (3), ; emphysema-cirrhosis, due to aat deficiency, 613490 (3),
AAT-1	AR	spermatogenic failure 51, 619177 (3),
AAT1	AR	spermatogenic failure 51, 619177 (3),
AAT1alpha	AR	spermatogenic failure 51, 619177 (3),
AATF		
AATK		
AATYK		
AATYK1		
AATYK2		
AAVR		
AAVS1		
AB-DIP	AD	ververi-brady syndrome, 617982 (3),
AB073614	AR	cerebellar ataxia, 604290 (3), ; [hypoceruloplasminemia, hereditary], 604290 (3), ; hemosiderosis, systemic, due to aceruloplasminemia, 604290 (3),
ABAD	XLD,XL	hsd10 mitochondrial disease, 300438 (3),
ABAT	AR	gaba-transaminase deficiency, 613163 (3),
ABBA	AD	intellectual developmental disorder with ocular anomalies and distinctive facial features, 620086 (3),
ABBA-1	AD	intellectual developmental disorder with ocular anomalies and distinctive facial features, 620086 (3),
ABBP1		
ABC-C	AR	surfactant metabolism dysfunction, pulmonary, 3, 610921 (3),
ABC1	AR,AD	tangier disease, 205400 (3), ; hdl deficiency, familial, 1, 604091 (3),
ABC16	AR	cholestasis, benign recurrent intrahepatic, 2, 605479 (3), ; cholestasis, progressive familial intrahepatic 2, 601847 (3),
ABC2	AR	intellectual developmental disorder with poor growth and with or without seizures or ataxia, 618808 (3),
ABC20		{inflammatory bowel disease 13}, 612244 (3); {colchicine resistance}, 120080 (3)
ABC28		
ABC3	AR	surfactant metabolism dysfunction, pulmonary, 3, 610921 (3),
ABC35	AR,AD	cystic fibrosis, 219700 (3), ; sweat chloride elevation without cf (3); congenital bilateral absence of vas deferens, 277180 (3), ; {pancreatitis, hereditary}, 167800 (3), ; {bronchiectasis with or without elevated sweat chloride 1, modifier of}, 211400 (3), ; {hypertrypsinemia, neonatal} (3)
ABC36	AR,AD	diabetes mellitus, permanent neonatal 3, with or without neurologic features, 618857 (3), ; diabetes mellitus, transient neonatal 2, 610374 (3); diabetes mellitus, noninsulin-dependent, 125853 (3), ; hypoglycemia of infancy, leucine-sensitive, 240800 (3), ; hyperinsulinemic hypoglycemia, familial, 1, 256450 (3),
ABC50		
ABC7	XLR,XL	anemia, sideroblastic, with ataxia, 301310 (3),
ABC8		
ABCA1	AR,AD	tangier disease, 205400 (3), ; hdl deficiency, familial, 1, 604091 (3),
ABCA10		
ABCA12	AR	ichthyosis, congenital, 4b (harlequin), 242500 (3), ; ichthyosis, congenital, 4a, 601277 (3),
ABCA13		
ABCA2	AR	intellectual developmental disorder with poor growth and with or without seizures or ataxia, 618808 (3),
ABCA3	AR	surfactant metabolism dysfunction, pulmonary, 3, 610921 (3),
ABCA4	AR,AD	retinal dystrophy, early-onset severe, 248200 (3), ; retinitis pigmentosa 19, 601718 (3), ; {macular degeneration, age-related, 2}, 153800 (3), ; cone-rod dystrophy 3, 604116 (3), ; fundus flavimaculatus, 248200 (3), ; stargardt disease 1, 248200 (3),
ABCA5	AR	?hypertrichosis, congenital generalized, with gingival hyperplasia, 135400 (3),
ABCA6		
ABCA7	AD	{alzheimer disease 9, susceptibility to}, 608907 (3),
ABCA8		
ABCA9		
ABCB1		{inflammatory bowel disease 13}, 612244 (3); {colchicine resistance}, 120080 (3)
ABCB10		
ABCB11	AR	cholestasis, benign recurrent intrahepatic, 2, 605479 (3), ; cholestasis, progressive familial intrahepatic 2, 601847 (3),
ABCB2	AR	bare lymphocyte syndrome, type i, 604571 (3),
ABCB3	AR	bare lymphocyte syndrome, type i, due to tap2 deficiency, 604571 (3),
ABCB4	AR,AD	gallbladder disease 1, 600803 (3), ; cholestasis, intrahepatic, of pregnancy, 3, 614972 (3), ; cholestasis, progressive familial intrahepatic 3, 602347 (3),
ABCB5		
ABCB5alpha		
ABCB5beta		
ABCB6	AD	microphthalmia, isolated, with coloboma 7, 614497 (3), ; dyschromatosis universalis hereditaria 3, 615402 (3), ; [blood group, langereis system], 111600 (3); pseudohyperkalemia, familial, 2, due to red cell leak, 609153 (3),
ABCB7	XLR,XL	anemia, sideroblastic, with ataxia, 301310 (3),
ABCB8		
ABCB9		
ABCC1	AD	?deafness, 77, 618915 (3),
ABCC10		
ABCC11	AD	[axillary odor, variation in], 117800 (3), ; [earwax, wet/dry], 117800 (3), ; [colostrum secretion, variation in], 117800 (3),
ABCC12		
ABCC13		
ABCC13P		
ABCC2	AR	dubin-johnson syndrome, 237500 (3),
ABCC3		
ABCC4		
ABCC5		
ABCC6	AR,AD	pseudoxanthoma elasticum, 264800 (3), ; arterial calcification, generalized, of infancy, 2, 614473 (3), ; pseudoxanthoma elasticum, forme fruste, 177850 (3),
ABCC7	AR,AD	cystic fibrosis, 219700 (3), ; sweat chloride elevation without cf (3); congenital bilateral absence of vas deferens, 277180 (3), ; {pancreatitis, hereditary}, 167800 (3), ; {bronchiectasis with or without elevated sweat chloride 1, modifier of}, 211400 (3), ; {hypertrypsinemia, neonatal} (3)
ABCC8	AR,AD	diabetes mellitus, permanent neonatal 3, with or without neurologic features, 618857 (3), ; diabetes mellitus, transient neonatal 2, 610374 (3); diabetes mellitus, noninsulin-dependent, 125853 (3), ; hypoglycemia of infancy, leucine-sensitive, 240800 (3), ; hyperinsulinemic hypoglycemia, familial, 1, 256450 (3),
ABCC9	AD,AR	cardiomyopathy, dilated, 1o, 608569 (3), ; hypertrichotic osteochondrodysplasia (cantu syndrome), 239850 (3), ; ?atrial fibrillation, familial, 12, 614050 (3), ; intellectual disability and myopathy syndrome, 619719 (3),
ABCD-1		
ABCD-2		
ABCD-3		
ABCD1	XLR,XL	adrenoleukodystrophy, 300100 (3), ; adrenomyeloneuropathy, adult, 300100 (3),
ABCD2		
ABCD3	AR	?bile acid synthesis defect, congenital, 5, 616278 (3),
ABCD4	AR	methylmalonic aciduria and homocystinuria, cblj type, 614857 (3),
ABCE1		
ABCF1		
ABCF2		
ABCF3		
ABCG1		
ABCG2	AD	[junior blood group system], 614490 (3); [uric acid concentration, serum, qtl1], 138900 (3), ?
ABCG4		
ABCG5	AR	sitosterolemia 2, 618666 (3),
ABCG8	AR	sitosterolemia 1, 210250 (3), ; {gallbladder disease 4}, 611465 (3)
ABCP	AD	[junior blood group system], 614490 (3); [uric acid concentration, serum, qtl1], 138900 (3), ?
ABCR	AR,AD	retinal dystrophy, early-onset severe, 248200 (3), ; retinitis pigmentosa 19, 601718 (3), ; {macular degeneration, age-related, 2}, 153800 (3), ; cone-rod dystrophy 3, 604116 (3), ; fundus flavimaculatus, 248200 (3), ; stargardt disease 1, 248200 (3),
ABCX	AD	{alzheimer disease 9, susceptibility to}, 608907 (3),
ABDH19		
ABF-1		
ABH		
ABH2		
ABHD1		
ABHD10		
ABHD11-AS1		
ABHD12	AR	polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract, 612674 (3),
ABHD12A	AR	polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract, 612674 (3),
ABHD14A		
ABHD15		
ABHD16A	AR	spastic paraplegia 86, 619735 (3),
ABHD16B		
ABHD17A		
ABHD17B		
ABHD17C		
ABHD2		
ABHD20	AR,AD	{hypercholesterolemia, familial, due to ldlr defect, modifier of}, 143890 (3),
ABHD21	AR	mast syndrome, 248900 (3),
ABHD3		
ABHD4		
ABHD5	AR	chanarin-dorfman syndrome, 275630 (3),
ABHD6		
ABHD7		
ABHD9		
ABI-1		
ABI-2		
ABI1		
ABI2		
ABI2B		
ABI3		
ABI3BP		
ABIN-1		
ABIN-2		
ABIN-3		
ABITRAM		
ABL	AR,AD	abetalipoproteinemia, 200100 (3), |leukemia, philadelphia chromosome-positive, resistant to imatinib, 608232 (3), somatic mutation; congenital heart defects and skeletal malformations syndrome, 617602 (3),
ABL1	AD	leukemia, philadelphia chromosome-positive, resistant to imatinib, 608232 (3), somatic mutation; congenital heart defects and skeletal malformations syndrome, 617602 (3),
ABL2		
AblBP3		
abLIM		
ABLIM		
ABLIM1		
ABLIM2		
ABLIM3		
ABLL		
ABO		[blood group, abo system], 616093 (3)
ABP		
ABP-278	AD,AR	larsen syndrome, 150250 (3), ; atelosteogenesis, type i, 108720 (3), ; atelosteogenesis, type iii, 108721 (3), ; spondylocarpotarsal synostosis syndrome, 272460 (3), ; boomerang dysplasia, 112310 (3),
ABP-280	AD,XLD,XLR,XL	cardiomyopathy, familial hypertrophic, 26, 617047 (3), ; cardiomyopathy, familial restrictive 5, 617047 (3), ; myopathy, distal, 4, 614065 (3), ; myopathy, myofibrillar, 5, 609524 (3), |otopalatodigital syndrome, type ii, 304120 (3), ; intestinal pseudoobstruction, neuronal, 300048 (3), ; cardiac valvular dysplasia, 314400 (3), ; ?fg syndrome 2, 300321 (3), ; melnick-needles syndrome, 309350 (3), ; terminal osseous dysplasia, 300244 (3), ; congenital short bowel syndrome, 300048 (3), ; otopalatodigital syndrome, type i, 311300 (3), ; heterotopia, periventricular, 1, 300049 (3), ; frontometaphyseal dysplasia 1, 305620 (3),
ABP1		
ABP125	AR	?halperin-birk syndrome, 618651 (3),
ABP130	AR	?halperin-birk syndrome, 618651 (3),
ABP620	AD	lissencephaly 9 with complex brainstem malformation, 618325 (3),
ABPL	AD	cardiomyopathy, familial hypertrophic, 26, 617047 (3), ; cardiomyopathy, familial restrictive 5, 617047 (3), ; myopathy, distal, 4, 614065 (3), ; myopathy, myofibrillar, 5, 609524 (3),
ABR		
ABRA		
ABRA1		
ABRAXAS		
ABRAXAS1		
ABRAXAS2		
ABRO1		
ABS	AD	{myeloproliferative/lymphoproliferative neoplasms, familial (multiple types), susceptibility to}, 616871 (3),
ABT1		
ABTB1		
AC	AR	spinal muscular atrophy with progressive myoclonic epilepsy, 159950 (3), ; farber lipogranulomatosis, 228000 (3),
AC004542.C22.1	AD	charcot-marie-tooth disease, axonal, type 2z, 616688 (3), ; developmental delay, impaired growth, dysmorphic facies, and axonal neuropathy, 619090 (3),
AC004997.C22.2		
AC008560.1		
AC023283.3		
AC1	AR	?deafness, 44, 610154 (3),
AC133	AD,AR	macular dystrophy, retinal, 2, 608051 (3), ; retinitis pigmentosa 41, 612095 (3), ; stargardt disease 4, 603786 (3), ; cone-rod dystrophy 12, 612657 (3),
AC19	AR,AD	treacher collins syndrome 2, 613717 (3),
AC2		
AC3	AR	{obesity, susceptibility to, bmiq19}, 617885 (3),
AC3-33		
AC4		
AC40	AR	leukodystrophy, hypomyelinating, 11, 616494 (3), ; treacher collins syndrome 3, 248390 (3),
Ac45	XLR,XL	immunodeficiency 47, 300972 (3),
AC5	AD,AR	dyskinesia with orofacial involvement, 606703 (3), ; neurodevelopmental disorder with hyperkinetic movements and dyskinesia, 619651 (3), ; dyskinesia with orofacial involvement, 619647 (3),
AC6	AR	lethal congenital contracture syndrome 8, 616287 (3),
AC7		
AC8		
AC9		
ACA3-2		
ACA31	AD	{encephalopathy, acute, infection-induced (herpes-specific), susceptibility to, 10}, 619396 (3),
ACA34		
ACA45		
ACA5c		
ACAA1		
ACAA2		
ACAC	AR	acetyl-coa carboxylase deficiency, 613933 (1),
Acac1	AR	acetyl-coa carboxylase deficiency, 613933 (1),
ACACA	AR	acetyl-coa carboxylase deficiency, 613933 (1),
ACACalpha	AR	acetyl-coa carboxylase deficiency, 613933 (1),
ACACB		
ACACbeta		
ACAD1	AR	acyl-coa dehydrogenase, medium chain, deficiency of, 201450 (3),
ACAD10		
ACAD11		
ACAD2	AR	isovaleric acidemia, 243500 (3),
ACAD3	AR	acyl-coa dehydrogenase, short-chain, deficiency of, 201470 (3),
ACAD4		
ACAD5	AR	glutaricaciduria, type i, 231670 (3),
ACAD6	AR	vlcad deficiency, 201475 (3),
ACAD7	AR	2-methylbutyrylglycinuria, 610006 (3),
ACAD8	AR	isobutyryl-coa dehydrogenase deficiency, 611283 (3),
ACAD9	AR	mitochondrial complex i deficiency, nuclear type 20, 611126 (3),
ACADL		
ACADM	AR	acyl-coa dehydrogenase, medium chain, deficiency of, 201450 (3),
ACADS	AR	acyl-coa dehydrogenase, short-chain, deficiency of, 201470 (3),
ACADSB	AR	2-methylbutyrylglycinuria, 610006 (3),
ACADVL	AR	vlcad deficiency, 201475 (3),
ACAM	AR	congenital short bowel syndrome, 615237 (3),
ACAN	AD,AR	?spondyloepiphyseal dysplasia, kimberley type, 608361 (3), ; short stature and advanced bone age, with or without early-onset osteoarthritis and/or osteochondritis dissecans, 165800 (3), ; spondyloepimetaphyseal dysplasia, aggrecan type, 612813 (3),
ACAP1		
ACAP2		
ACAS2		
ACAS2L		
ACAT	AR	alpha-methylacetoacetic aciduria, 203750 (3),
ACAT1	AR	alpha-methylacetoacetic aciduria, 203750 (3),
ACAT2		?acat2 deficiency, 614055 (1), isolated cases
ACATE2		
ACATN	AD,AR	spastic paraplegia 42, 612539 (3), ; congenital cataracts, hearing loss, and neurodegeneration, 614482 (3),
ACBD1		
ACBD2		
ACBD3		
ACBD4		
ACBD5	AR	retinal dystrophy with leukodystrophy, 618863 (3),
ACBD6		
ACBP		
ACC	AR	acetyl-coa carboxylase deficiency, 613933 (1),
ACC-1		
ACC-2		
ACC-4		
ACC-5		
ACC-6		
ACC-alpha	AR	acetyl-coa carboxylase deficiency, 613933 (1),
ACC-beta		
ACC1	AR	acetyl-coa carboxylase deficiency, 613933 (1),
ACC2		
ACC4		
ACC5		
ACC6		
ACCA	AR	acetyl-coa carboxylase deficiency, 613933 (1),
ACCalpha	AR	acetyl-coa carboxylase deficiency, 613933 (1),
ACCB		
ACCbeta		
ACCN		
ACCN1		
ACCN2		
ACCN3		
ACCN4		
ACCN5		
ACCPN	AR,AD	agenesis of the corpus callosum with peripheral neuropathy, 218000 (3), ; charcot-marie-tooth disease, axonal, type 2ii, 620068 (3),
ACCS		
ACD	AR,AD	?dyskeratosis congenita, 7, 616553 (3), ; ?dyskeratosis congenita, 6, 616553 (3),
ACDase	AR	spinal muscular atrophy with progressive myoclonic epilepsy, 159950 (3), ; farber lipogranulomatosis, 228000 (3),
ACDC	AD	adiponectin deficiency, 612556 (3),
ACDCR1		
ACDCR2		
ACDP1		
ACDP2	AD,AR	hypomagnesemia 6, renal, 613882 (3), ; hypomagnesemia, seizures, and impaired intellectual development 1, 616418 (3),
ACDP3		
ACDP4	AR	jalili syndrome, 217080 (3),
ACE	AR	{stroke, hemorrhagic}, 614519 (3); renal tubular dysgenesis, 267430 (3), ; {myocardial infarction, susceptibility to} (3); {microvascular complications of diabetes 3}, 612624 (3); [angiotensin i-converting enzyme, benign serum increase] (3); {sars, progression of} (3)
ACE1	AR	{stroke, hemorrhagic}, 614519 (3); renal tubular dysgenesis, 267430 (3), ; {myocardial infarction, susceptibility to} (3); {microvascular complications of diabetes 3}, 612624 (3); [angiotensin i-converting enzyme, benign serum increase] (3); {sars, progression of} (3)
ACE2		
AceCS		
AceCS2L		
ACEH		
ACER1		
ACER2		
ACER3	AR	?leukodystrophy, progressive, early childhood-onset, 617762 (3),
ACF		
ACF1		
ACF64		
ACF65		
ACF7	AD	lissencephaly 9 with complex brainstem malformation, 618325 (3),
ACG		
ACGNAT		
ACH	AD,AR	muenke syndrome, 602849 (3), ; saddan, 616482 (3), ; hypochondroplasia, 146000 (3), ; thanatophoric dysplasia, type ii, 187601 (3), ; nevus, epidermal, somatic, 162900 (3); catshl syndrome, 610474 (3), ; thanatophoric dysplasia, type i, 187600 (3), ; spermatocytic seminoma, somatic, 273300 (3); bladder cancer, somatic, 109800 (3); ladd syndrome 2, 620192 (3), ; achondroplasia, 100800 (3), ; cervical cancer, somatic, 603956 (3); colorectal cancer, somatic, 114500 (3); crouzon syndrome with acanthosis nigricans, 612247 (3),
ACH1		
ACH2		
ACHAP		
ACHE		[blood group, yt system], 112100 (3)
acheron		
ACHM1	AR	achromatopsia 3, 262300 (3),
ACHM2	AR	achromatopsia 2, 216900 (3),
ACHM3	AR	achromatopsia 3, 262300 (3),
ACHM4		achromatopsia 4, 613856 (3)
ACHM5	AR	cone dystrophy 4, 613093 (3),
ACHP	AD,AR	triphalangeal thumb, type i, 174500 (3), ; syndactyly, type iv, 186200 (3), ; laurin-sandrow syndrome, 135750 (3), ; hypoplastic or aplastic tibia with polydactyly, 188740 (3), ; polydactyly, preaxial type ii, 174500 (3), ; acheiropody, 200500 (3), ; triphalangeal thumb-polysyndactyly syndrome, 190605 (3),
ACHRD	AR,AD	?myasthenic syndrome, congenital, 3c, associated with acetylcholine receptor deficiency, 616323 (3), ; multiple pterygium syndrome, lethal type, 253290 (3), ; myasthenic syndrome, congenital, 3b, fast-channel, 616322 (3), ; ?myasthenic syndrome, congenital, 3a, slow-channel, 616321 (3),
ACHRE	AR,AD	myasthenic syndrome, congenital, 4a, slow-channel, 605809 (3), ; myasthenic syndrome, congenital, 4c, associated with acetylcholine receptor deficiency, 608931 (3), ; myasthenic syndrome, congenital, 4b, fast-channel, 616324 (3),
ACHRG	AR	multiple pterygium syndrome, lethal type, 253290 (3), ; escobar syndrome, 265000 (3),
ACID1	AR	basel-vanagait-smirin-yosef syndrome, 616449 (3),
ACIN1		
ACINUS		
ACK		
ACK1		
ACKR1	AR,AD	[blood group, duffy system], 110700 (3), ; [white blood cell count qtl], 611862 (3), ; {malaria, vivax, protection against}, 611162 (3)
ACKR2		
ACKR3	AR	?oculomotor-abducens synkinesis, 619215 (3),
ACKR4		
ACKR5		
ACKR6	AD	cone-rod dystrophy 5, 600977 (3),
ACL		
ACLP	AR	ehlers-danlos syndrome, classic-like, 2, 618000 (3),
ACLS	AD	greig cephalopolysyndactyly syndrome, 175700 (3), ; polydactyly, postaxial, types a1 and b, 174200 (3), ; pallister-hall syndrome, 146510 (3), ; polydactyly, preaxial, type iv, 174700 (3),
ACLY		
ACMSD		
ACN	AD	neurofibromatosis, type 2, 101000 (3), ; meningioma, nf2-related, somatic, 607174 (3); schwannomatosis, somatic, 162091 (3)
ACN9		
ACO		
ACO1		
ACO2	AR,AD	optic atrophy 9, 616289 (3), ; infantile cerebellar-retinal degeneration, 614559 (3),
ACOD1		
ACOD4	AD	?deafness, 79, 619086 (3),
ACONM	AR,AD	optic atrophy 9, 616289 (3), ; infantile cerebellar-retinal degeneration, 614559 (3),
ACOT1		
ACOT11		
ACOT12		
ACOT13		
ACOT2		
ACOT4		
ACOT6		
ACOT7		
ACOT8		
ACOT9		
ACOX1	AD,AR	mitchell syndrome, 618960 (3), ; peroxisomal acyl-coa oxidase deficiency, 264470 (3),
ACOX2	AR	bile acid synthesis defect, congenital, 6, 617308 (3),
ACOX3		
ACP		
ACP-3		
ACP1		
ACP2	AR	?lysosomal acid phosphatase deficiency, 200950 (1),
ACP3		
ACP33	AR	mast syndrome, 248900 (3),
ACP4	AR	amelogenesis imperfecta, type ij, 617297 (3),
ACP5	AR	spondyloenchondrodysplasia with immune dysregulation, 607944 (3),
ACP6		
ACP7		
ACPA		
ACPIN1		
AcPL		
ACPL1		
ACPL2		
ACPP		
ACPS		
ACPT	AR	amelogenesis imperfecta, type ij, 617297 (3),
ACR		?male infertility due to acrosin deficiency, 102480 (2)
ACR1		
ACRBP		
ACRC	XL	spermatogenic failure, 4, 301077 (3),
Acrg		
ACRP		
ACRP30	AD	adiponectin deficiency, 612556 (3),
ACRV1		
ACS		
ACS1		
ACS2	AR	?diarrhea 13, 620357 (3), |myelodysplastic syndrome (3); myelogenous leukemia, acute (3)
ACS3	AD	craniosynostosis 1, 123100 (3), ; robinow-sorauf syndrome, 180750 (3), ; sweeney-cox syndrome, 617746 (3), ; saethre-chotzen syndrome with or without eyelid anomalies, 101400 (3),
ACS4	XL,XLD	intellectual developmental disorder, 63, 300387 (3),
ACS5	AR	?diarrhea 13, 620357 (3),
ACSA		
ACSB		
ACSBG1		
ACSBG2		
ACSF1		
ACSF2		
ACSF3		combined malonic and methylmalonic aciduria, 614265 (3)
ACSF4		
ACSL1		
ACSL3		
ACSL4	XL,XLD	intellectual developmental disorder, 63, 300387 (3),
ACSL5	AR	?diarrhea 13, 620357 (3),
ACSL6		myelodysplastic syndrome (3); myelogenous leukemia, acute (3)
ACSM1		
ACSM2		
ACSM2A		
ACSM2B		
ACSM3		{?hypertension, essential} (1)
ACSM4		
ACSM5		
ACSMW		
ACSS1		
ACSS2		
ACSS3		
ACSVL1		
ACSVL2		
ACSVL3		
ACSVL4	AR	ichthyosis prematurity syndrome, 608649 (3),
ACSVL5		
ACSVL6		
ACT		alpha-1-antichymotrypsin deficiency (3); cerebrovascular disease, occlusive (3)
Act-2		
ACT1	AR	?candidiasis, familial, 8, 615527 (3), ; {psoriasis susceptibility 13}, 614070 (3)
ACT35	AR	?immunodeficiency 16, 615593 (3),
ACTA	AR,AD	congenital myopathy 2b, severe infantile, 620265 (3), ; ?myopathy, scapulohumeroperoneal, 616852 (3), ; congenital myopathy 2c, severe infantile, 620278 (3), ; congenital myopathy 2a, typical, 161800 (3),
ACTA1	AR,AD	congenital myopathy 2b, severe infantile, 620265 (3), ; ?myopathy, scapulohumeroperoneal, 616852 (3), ; congenital myopathy 2c, severe infantile, 620278 (3), ; congenital myopathy 2a, typical, 161800 (3),
ACTA2	AD	multisystemic smooth muscle dysfunction syndrome, 613834 (3), ; aortic aneurysm, familial thoracic 6, 611788 (3), ; moyamoya disease 5, 614042 (3)
ACTA3	AD	megacystis-microcolon-intestinal hypoperistalsis syndrome 5, 619431 (3), ; visceral myopathy 1, 155310 (3),
ACTB	AD	baraitser-winter syndrome 1, 243310 (3), ; ?dystonia, juvenile-onset, 607371 (3),
ACTBL1		
ACTBL2		
ACTBL3		
ACTC	AD	left ventricular noncompaction 4, 613424 (3), ; cardiomyopathy, hypertrophic, 11, 612098 (3), ; atrial septal defect 5, 612794 (3), ; cardiomyopathy, dilated, 1r, 613424 (3),
ACTC1	AD	left ventricular noncompaction 4, 613424 (3), ; cardiomyopathy, hypertrophic, 11, 612098 (3), ; atrial septal defect 5, 612794 (3), ; cardiomyopathy, dilated, 1r, 613424 (3),
ACTDP		
ACTG	AD	deafness, 20/26, 604717 (3), ; baraitser-winter syndrome 2, 614583 (3),
ACTG1	AD	deafness, 20/26, 604717 (3), ; baraitser-winter syndrome 2, 614583 (3),
ACTG2	AD	megacystis-microcolon-intestinal hypoperistalsis syndrome 5, 619431 (3), ; visceral myopathy 1, 155310 (3),
ACTH	AR,MF,AD	{obesity, early-onset, susceptibility to}, 601665 (3), , ; obesity, adrenal insufficiency, and red hair due to pomc deficiency, 609734 (3),
ACTHR	AR	glucocorticoid deficiency, due to acth unresponsiveness, 202200 (3),
activin		
ACTL3	AD	megacystis-microcolon-intestinal hypoperistalsis syndrome 5, 619431 (3), ; visceral myopathy 1, 155310 (3),
Actl6		
ACTL6	AR,AD	developmental and epileptic encephalopathy 76, 618468 (3), ; intellectual developmental disorder with severe speech and ambulation defects, 618470 (3),
ACTL6A		
ACTL6B	AR,AD	developmental and epileptic encephalopathy 76, 618468 (3), ; intellectual developmental disorder with severe speech and ambulation defects, 618470 (3),
ACTL7A		
ACTL7B		
ACTL9	AR	spermatogenic failure 53, 619258 (3),
ACTMAP		
ACTN1	AD	bleeding disorder, platelet-type, 15, 615193 (3),
ACTN2	AD	myopathy, distal, 6, adult onset, 618655 (3), ; cardiomyopathy, hypertrophic, 23, with or without lvnc, 612158 (3), ; congenital myopathy 8, 618654 (3), ; cardiomyopathy, dilated, 1aa, with or without lvnc, 612158 (3),
ACTN3	AR	[sprinting performance], 617749 (3), ; [alpha-actinin-3 deficiency], 617749 (3),
ACTN4	AD	glomerulosclerosis, focal segmental, 1, 603278 (3),
ACTR		
ActR-IIB		heterotaxy, visceral, 4, 613751 (3)
ACTR10		
ACTR11		
ACTR1A		
ACTR1B		
ACTR2		
ACTR3		
ACTR5		
ACTR6		
ACTR8		
ActRIB		pancreatic cancer, somatic, 260350 (3)
ACTRII		
ACTRT1		
ACTRT2		
ACTRT3		
ACTSA	AD	multisystemic smooth muscle dysfunction syndrome, 613834 (3), ; aortic aneurysm, familial thoracic 6, 611788 (3), ; moyamoya disease 5, 614042 (3)
ACTSG	AD	megacystis-microcolon-intestinal hypoperistalsis syndrome 5, 619431 (3), ; visceral myopathy 1, 155310 (3),
ACV	AR,AD	gillespie syndrome, 206700 (3), ; spinocerebellar ataxia 29, congenital nonprogressive, 117360 (3), ; spinocerebellar ataxia 15, 606658 (3),
ACVR1	AD	fibrodysplasia ossificans progressiva, 135100 (3),
ACVR1A	AD	fibrodysplasia ossificans progressiva, 135100 (3),
ACVR1B		pancreatic cancer, somatic, 260350 (3)
ACVR1C		
ACVR2		
ACVR2A		
ACVR2B		heterotaxy, visceral, 4, 613751 (3)
ACVRIP1	AR	nephrotic syndrome, type 15, 617609 (3),
ACVRL1	AD	telangiectasia, hereditary hemorrhagic, type 2, 600376 (3),
ACVRLK1	AD	telangiectasia, hereditary hemorrhagic, type 2, 600376 (3),
ACVRLK2	AD	fibrodysplasia ossificans progressiva, 135100 (3),
ACVRLK3	AD	polyposis syndrome, hereditary mixed, 2, 610069 (3); polyposis, juvenile intestinal, 174900 (3),
ACVRLK4	AD	{multiple self-healing squamous epithelioma, susceptibility to}, 132800 (3), ; loeys-dietz syndrome 1, 609192 (3), |pancreatic cancer, somatic, 260350 (3)
ACVRLK7		
ACY-3		
ACY1	AR	aminoacylase 1 deficiency, 609924 (3),
ACY1L2		
ACY2	AR	canavan disease, 271900 (3),
ACY3		
ACYP1		
ACYP2		
ACZ	AR	?pontocerebellar hypoplasia, type 3, 608027 (3),
AD-003		
AD-004		
AD-005	AD	vissers-bodmer syndrome, 619033 (3), ; holoprosencephaly 12, with or without pancreatic agenesis, 618500 (3),
AD-015		
AD-017		
AD-FSP	AD	spastic paraplegia 3a, 182600 (3), ; neuropathy, hereditary sensory, type id, 613708 (3),
AD023		
AD024		
AD025		
AD026		
AD031		
AD034		
AD035	AR	spastic paraplegia 46, 614409 (3),
AD037		
AD1	AD	cerebral amyloid angiopathy, dutch, italian, iowa, flemish, arctic variants, 605714 (3), ; alzheimer disease 1, familial, 104300 (3),
AD158		
AD2	AD,AR	alzheimer disease 2, 104310 (3), ; sea-blue histiocyte disease, 269600 (3), ; {?alzheimer disease, protection against, due to apoe3-christchurch}, 607822 (3), ; {coronary artery disease, severe, susceptibility to}, 617347 (3); lipoprotein glomerulopathy, 611771 (3); {?macular degeneration, age-related}, 603075 (3), ; hyperlipoproteinemia, type iii, 617347 (3)
AD24		
AD3	AD	pick disease, 172700 (3), ; alzheimer disease, type 3, with spastic paraparesis and apraxia, 607822 (3), ; dementia, frontotemporal, 600274 (3), ; ?acne inversa, familial, 3, 613737 (3), ; cardiomyopathy, dilated, 1u, 613694 (3), ; alzheimer disease, type 3, with spastic paraparesis and unusual plaques, 607822 (3), ; alzheimer disease, type 3, 607822 (3),
AD3L	AD	alzheimer disease-4, 606889 (3), ; cardiomyopathy, dilated, 1v, 613697 (3),
AD4	AD	alzheimer disease-4, 606889 (3), ; cardiomyopathy, dilated, 1v, 613697 (3),
AD4BP	AD	46xx sex reversal 4, 617480 (3), ; premature ovarian failure 7, 612964 (3), ; 46xy sex reversal 3, 612965 (3), ; adrenocortical insufficiency, 612964 (3), ; spermatogenic failure 8, 613957 (3),
ADA	AR	adenosine deaminase deficiency, partial, 102700 (3), somatic mosaicism; severe combined immunodeficiency due to ada deficiency, 102700 (3), somatic mosaicism
ADA1	AR	adenosine deaminase deficiency, partial, 102700 (3), somatic mosaicism; severe combined immunodeficiency due to ada deficiency, 102700 (3), somatic mosaicism
ADA2	AR	sneddon syndrome, 182410 (3), ; vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome, 615688 (3),
ADA2A		
ADA3		
ADAD1		
ADAD2		
ADAL		
ADAM-TS10	AR	weill-marchesani syndrome 1, 277600 (3),
ADAM-TS2	AR	ehlers-danlos syndrome, dermatosparaxis type, 225410 (3),
ADAM-TS6		
ADAM-TS7		
ADAM-TS8		
ADAM10	AD	{alzheimer disease 18, susceptibility to}, 615590 (3); reticulate acropigmentation of kitamura, 615537 (3),
ADAM11		
ADAM12		
ADAM15		
ADAM17	AR	?inflammatory skin and bowel disease, neonatal, 1, 614328 (3),
ADAM18		
ADAM19		
ADAM2		
ADAM20		
ADAM21		
ADAM22	AR	developmental and epileptic encephalopathy 61, 617933 (3),
ADAM23		
ADAM27		
ADAM28		
ADAM29		
ADAM30		
ADAM31		
ADAM32		
ADAM33		
ADAM7		
ADAM8		
ADAM9	AR	cone-rod dystrophy 9, 612775 (3),
ADAMDEC1		
ADAMTS-2		
ADAMTS-3	AR	ehlers-danlos syndrome, dermatosparaxis type, 225410 (3),
ADAMTS-4	AR	hennekam lymphangiectasia-lymphedema syndrome 3, 618154 (3),
ADAMTS1		
ADAMTS10	AR	weill-marchesani syndrome 1, 277600 (3),
ADAMTS11		
ADAMTS12		
ADAMTS13	AR	thrombotic thrombocytopenic purpura, hereditary, 274150 (3),
ADAMTS14		
ADAMTS15		
ADAMTS16		
ADAMTS16s		
ADAMTS17	AR	weill-marchesani 4 syndrome, 613195 (3),
ADAMTS18	AR	microcornea, myopic chorioretinal atrophy, and telecanthus, 615458 (3),
ADAMTS19	AR	cardiac valvular dysplasia 2, 620067 (3),
ADAMTS2	AR	ehlers-danlos syndrome, dermatosparaxis type, 225410 (3),
ADAMTS20		
ADAMTS21	AR	microcornea, myopic chorioretinal atrophy, and telecanthus, 615458 (3),
ADAMTS3	AR	hennekam lymphangiectasia-lymphedema syndrome 3, 618154 (3),
ADAMTS4		
ADAMTS5		
ADAMTS6		
ADAMTS7		
ADAMTS8		
ADAMTS9		
ADAMTSL1		
ADAMTSL2	AR	geleophysic dysplasia 1, 231050 (3),
ADAMTSL3		
ADAMTSL4	AR	ectopia lentis et pupillae, 225200 (3), ; ectopia lentis, isolated, 225100 (3),
ADAMTSL6	AD	aortic aneurysm, familial thoracic 12, 619825 (3),
ADAMTSR1		
ADANE	AD	{encephalopathy, acute, infection-induced, 3, susceptibility to}, 608033 (3),
ADAP	AR	thrombocytopenia 3, 273900 (3),
ADAP-S	AR	rhizomelic chondrodysplasia punctata, type 3, 600121 (3),
ADAP1		
ADAP2		
ADAP6		
ADAR	AD,AR	dyschromatosis symmetrica hereditaria, 127400 (3), ; aicardi-goutieres syndrome 6, 615010 (3),
ADAR1	AD,AR	dyschromatosis symmetrica hereditaria, 127400 (3), ; aicardi-goutieres syndrome 6, 615010 (3),
ADAR2	AR	neurodevelopmental disorder with hypotonia, microcephaly, and seizures, 618862 (3),
ADAR2a	AR	neurodevelopmental disorder with hypotonia, microcephaly, and seizures, 618862 (3),
ADAR2a-L1	AR	neurodevelopmental disorder with hypotonia, microcephaly, and seizures, 618862 (3),
ADAR2a-L2	AR	neurodevelopmental disorder with hypotonia, microcephaly, and seizures, 618862 (3),
ADAR2a-L3	AR	neurodevelopmental disorder with hypotonia, microcephaly, and seizures, 618862 (3),
ADAR2b	AR	neurodevelopmental disorder with hypotonia, microcephaly, and seizures, 618862 (3),
ADAR2c	AR	neurodevelopmental disorder with hypotonia, microcephaly, and seizures, 618862 (3),
ADAR2d	AR	neurodevelopmental disorder with hypotonia, microcephaly, and seizures, 618862 (3),
ADAR2g	AR	neurodevelopmental disorder with hypotonia, microcephaly, and seizures, 618862 (3),
ADAR3		
ADARB1	AR	neurodevelopmental disorder with hypotonia, microcephaly, and seizures, 618862 (3),
ADARB2		
ADAS	AR	rhizomelic chondrodysplasia punctata, type 3, 600121 (3),
ADAT1		
ADAT2		
ADAT3	AR	neurodevelopmental disorder with brain abnormalities, poor growth, and dysmorphic facies, 615286 (3),
ADB2		
ADC		
ADCA	AD	spinocerebellar ataxia 23, 610245 (3),
ADCAD2	AD	{coronary artery disease, 2}, 610947 (3), ; tooth agenesis, selective, 7, 616724 (3),
ADCAII	AD	spinocerebellar ataxia 7, 164500 (3),
ADCK1		
ADCK3	AR	coenzyme q10 deficiency, primary, 4, 612016 (3),
ADCK4	AR	nephrotic syndrome, type 9, 615573 (3),
ADCP2		
ADCR	AD	wilms tumor 2, 194071 (3), somatic mutation, ; beckwith-wiedemann syndrome, 130650 (3), ; silver-russell syndrome 1, 180860 (3),
ADCY1	AR	?deafness, 44, 610154 (3),
ADCY10	AD	{hypercalciuria, absorptive, susceptibility to}, 143870 (3),
ADCY2		
ADCY3	AR	{obesity, susceptibility to, bmiq19}, 617885 (3),
ADCY4		
ADCY5	AD,AR	dyskinesia with orofacial involvement, 606703 (3), ; neurodevelopmental disorder with hyperkinetic movements and dyskinesia, 619651 (3), ; dyskinesia with orofacial involvement, 619647 (3),
ADCY6	AR	lethal congenital contracture syndrome 8, 616287 (3),
ADCY7		
ADCY8		
ADCY9		
ADCYAP1		
ADCYAP1R1		
ADD1	MF	{hypertension, essential, salt-sensitive}, 145500 (3),
ADD2		
ADD3	AR	cerebral palsy, spastic quadriplegic, 3, 617008 (3),
ADDB		
ADDL	AR	cerebral palsy, spastic quadriplegic, 3, 617008 (3),
ADE2H1	AR	?phosphoribosylaminoimidazole carboxylase deficiency, 619859 (3),
ADF		
ADFP		
ADG-90		
ADGB		
ADGF	AR	sneddon syndrome, 182410 (3), ; vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome, 615688 (3),
ADGRA1		
ADGRA2		
ADGRA3		
ADGRB1		
ADGRB2		
ADGRB3		
ADGRC1	AD	lymphatic malformation 9, 619319 (3),
ADGRC2		
ADGRC3		
ADGRD1		
ADGRE1		
ADGRE2	AD	vibratory urticaria, 125630 (3),
ADGRE3		
ADGRE4P		
ADGRE5		
ADGRF1		
ADGRF4		
ADGRG1	AR	polymicrogyria, bilateral frontoparietal, 606854 (3), ; polymicrogyria, bilateral perisylvian, 615752 (3)
ADGRG2	XL	congenital bilateral absence of vas deferens, 300985 (3),
ADGRG3		
ADGRG4		
ADGRG5		
ADGRG6	AR	lethal congenital contracture syndrome 9, 616503 (3),
ADGRG7		
ADGRL1	AD	developmental delay, behavioral abnormalities, and neuropsychiatric disorders, 620065 (3),
ADGRL2		
ADGRL3		
ADGRL4		
ADGRV1	AR,AD	usher syndrome, type 2c, 605472 (3), digenic ; usher syndrome, type 2c, gpr98/pdzd7 digenic, 605472 (3), digenic ; ?febrile seizures, familial, 4, 604352 (3),
ADH	AD	diabetes insipidus, neurohypophyseal, 125700 (3),
ADH-2		
ADH-3		amed syndrome, digenic, 619151 (3), digenic
ADH-4		
ADH-5		
ADH1		
ADH1A		
ADH1B	MF	{aerodigestive tract cancer, squamous cell, alcohol-related, protection against}, 103780 (3), ; {alcohol dependence, protection against}, 103780 (3),
ADH1C	MF,AD	{alcohol dependence, protection against}, 103780 (3), ; {parkinson disease, susceptibility to}, 168600 (3),
ADH2	MF	{aerodigestive tract cancer, squamous cell, alcohol-related, protection against}, 103780 (3), ; {alcohol dependence, protection against}, 103780 (3),
ADH3	MF,AD	{alcohol dependence, protection against}, 103780 (3), ; {parkinson disease, susceptibility to}, 168600 (3),
ADH4		
ADH5		amed syndrome, digenic, 619151 (3), digenic
ADH6		
ADH7		
adhalin	AR	muscular dystrophy, limb-girdle, 3, 608099 (3),
ADHAPS	AR	rhizomelic chondrodysplasia punctata, type 3, 600121 (3),
ADHFE1		
ADHX		amed syndrome, digenic, 619151 (3), digenic
ADI1		
ADIG		
ADIPOLIN		
adiponectin	AD	adiponectin deficiency, 612556 (3),
adiponutrin		
ADIPOQ	AD	adiponectin deficiency, 612556 (3),
ADIPOR1		
ADIPOR2		
ADIR		
ADIR2		
ADISSP		
ADK	AR	hypermethioninemia due to adenosine kinase deficiency, 614300 (3),
ADL	AR	muscular dystrophy, limb-girdle, 3, 608099 (3),
ADM		
ADM2		
ADMCKD	AD	tubulointerstitial kidney disease, 2, 174000 (3),
ADMCKD1	AD	tubulointerstitial kidney disease, 2, 174000 (3),
ADMLX	XLR,XL	hypogonadotropic hypogonadism 1 with or without anosmia (kallmann syndrome 1), 308700 (3),
ADMP		
ADMP-1		
ADMP-2		
ADMR		
ADN	AR	complement factor d deficiency, 613912 (3),
ADNIV	AD	vitreoretinopathy, neovascular inflammatory, 193235 (3),
ADNP	AD	helsmoortel-van der aa syndrome, 615873 (3),
ADNP1	AD	helsmoortel-van der aa syndrome, 615873 (3),
ADNP2		
ADO		
AdoHcyase	AR	hypermethioninemia with deficiency of s-adenosylhomocysteine hydrolase, 613752 (3),
ADOHCYASE3		
adoplin-2		
ADORA1		
ADORA2		
ADORA2A		
ADORA2B		
ADORA3		
ADP		
ADP-GK		
ADPGK		
AdPLA		
ADPN		
ADPRH		
ADPRHL1		
ADPRHL2	AR	neurodegeneration, childhood-onset, stress-induced, with variable ataxia and seizures, 618170 (3),
ADPRS	AR	neurodegeneration, childhood-onset, stress-induced, with variable ataxia and seizures, 618170 (3),
ADPRT		
ADPRT3		
ADPRTL1		
ADPRTL2		
ADPRTL3		
ADPS	AR	rhizomelic chondrodysplasia punctata, type 3, 600121 (3),
ADPSP	AD	spastic paraplegia 4, 182601 (3),
ADR	AR	auditory neuropathy and optic atrophy, 617717 (3),
ADRA1		
ADRA1A		
ADRA1B		
ADRA1C		
ADRA1D		
ADRA1L1		
ADRA1R		
ADRA2		
ADRA2A		
ADRA2B		
ADRA2C		{congestive heart failure and beta-blocker response, modifier of} (3)
ADRA2L1		
ADRA2L2		{congestive heart failure and beta-blocker response, modifier of} (3)
ADRA2R		
ADRA2RL1		
ADRA2RL2		{congestive heart failure and beta-blocker response, modifier of} (3)
ADRAR		
ADRARL1		
ADRARL2		{congestive heart failure and beta-blocker response, modifier of} (3)
ADRB1	AD	[short sleep, familial natural, 2], 618591 (3), ; [resting heart rate], 607276 (3)
ADRB1R	AD	[short sleep, familial natural, 2], 618591 (3), ; [resting heart rate], 607276 (3)
ADRB2		beta-2-adrenoreceptor agonist, reduced response to (3)
ADRB2R		beta-2-adrenoreceptor agonist, reduced response to (3)
ADRB2RL1	AD	periodic fever, menstrual cycle dependent, 614674 (3),
ADRB3	AR,MF,AD	{obesity, susceptibility to}, 601665 (3), ,
ADRBK1		
ADRBK2		
ADRBR		beta-2-adrenoreceptor agonist, reduced response to (3)
ADRBRL1	AD	periodic fever, menstrual cycle dependent, 614674 (3),
adrenoleukodystrophy	XLR,XL	adrenoleukodystrophy, 300100 (3), ; adrenomyeloneuropathy, adult, 300100 (3),
ADRM1		
ADRP		
Adrx		
ADSA	AD,AR	ataxia, sensory, 1, 608984 (3), ; spastic paraplegia 85, 619686 (3),
ADSF	AD	{hypertension, insulin resistance-related, susceptibility to}, 125853 (3), ; {diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3),
ADSL	AR	adenylosuccinase deficiency, 103050 (3),
ADSS		
ADSS1	AR	myopathy, distal, 5, 617030 (3),
ADSS2		
ADSSL1	AR	myopathy, distal, 5, 617030 (3),
ADTAA		
ADTAB		
ADTB1	AR	keratitis-ichthyosis-deafness syndrome, 242150 (3),
ADTB2		
ADTB3A	AR	hermansky-pudlak syndrome 2, 608233 (3),
ADTD	AR	?hermansky-pudlak syndrome 10, 617050 (3),
ADTG	AR,AD	usmani-riazuddin syndrome, 619548 (3); usmani-riazuddin syndrome, 619467 (3),
ADTRP		
ADVIL	AR	nephrotic syndrome, type 21, 618594 (3),
ADX		
ADXR	AR	auditory neuropathy and optic atrophy, 617717 (3),
AE01		
AE1	AD,AR	[blood group, swann], 601550 (3); [blood group, wright], 112050 (3); distal renal tubular acidosis 1, 179800 (3), ; [blood group, waldner], 112010 (3); spherocytosis, type 4, 612653 (3), ; [blood group, froese], 601551 (3); distal renal tubular acidosis 4 with hemolytic anemia, 611590 (3), ; {malaria, resistance to}, 611162 (3); cryohydrocytosis, 185020 (3), ; ovalocytosis, sa type, 166900 (3), ; [blood group, diego], 110500 (3)
AE2	AR	?osteopetrosis, 9, 620366 (3),
AE3	AD	short qt syndrome 7, 620231 (3),
AE4		
AEBP1	AR	ehlers-danlos syndrome, classic-like, 2, 618000 (3),
AEBP2		
AEG-1		
Aeg2		
AEGL1		
AEGP		
AEMK	AD	episodic ataxia/myokymia syndrome, 160120 (3),
AEN		
AEPLC		
AER61	AR	adams-oliver syndrome 4, 615297 (3),
AES		
AEZ	AR	acrodermatitis enteropathica, 201100 (3),
AF		
AF-1	AR	immunodeficiency 28, mycobacteriosis, 614889 (3),
AF-1P		
AF-4		
AF-6		
AF-9		
AF1		
AF10	AD	leukemia, acute myeloid, 601626 (3), somatic mutation,
AF15Q14	AR	microcephaly 4, primary, 604321 (3),
AF17		
AF17q25	AD	amyotrophy, hereditary neuralgic, 162100 (3),
AF1Q		
AF3P21		
AF4		
AF5Q31	AD	chops syndrome, 616368 (3),
AF6		
AF6q21		
AF9		
AF9Q34		
AFAF		
AFAP		
AFAP-110		
AFAP1		
AFAP1-AS		
AFAP1-AS1		
AFAP1AS		
AFAP1L1		
AFAP1L2		
AFAR		
AFAR3		
AFBP		
AFCP		
AFDN		
AFF1		
AFF2	XL,XLR	intellectual developmental disorder, 109, 309548 (3),
AFF3	AD	kinsship syndrome, 619297 (3),
AFF4	AD	chops syndrome, 616368 (3),
AFG1		
AFG1L		
AFG2	AR	neurodevelopmental disorder with hearing loss, seizures, and brain abnormalities, 616577 (3),
AFG2A	AR	neurodevelopmental disorder with hearing loss, seizures, and brain abnormalities, 616577 (3),
AFG2B	AR	deafness, 119, 619615 (3), ; neurodevelopmental disorder with hearing loss and spasticity, 619616 (3),
AFG3		
AFG3L1		
AFG3L1P		
AFG3L2	AR,AD	spastic ataxia 5, 614487 (3), ; optic atrophy 12, 618977 (3), ; spinocerebellar ataxia 28, 610246 (3),
AFGF		
AFM		
AFP	AD,AR	[hereditary persistence of alpha-fetoprotein], 615970 (3), ; alpha-fetoprotein deficiency, 615969 (3),
AFT		
AFTPH		
AFURS1	AR	pulmonary hypertension, primary, 5, 265400 (3),
AFX1		
AG1		
AG2	AR	respiratory infections, recurrent, and failure to thrive with or without diarrhea, 620233 (3),
AG2S	MF,AR	{hypertension, essential}, 145500 (3), ; renal tubular dysgenesis, 267430 (3),
AGA	AR	aspartylglucosaminuria, 208400 (3),
AGAP1		
AGAP2		
AGAP3		
AGAS	AR	n-acetylglutamate synthase deficiency, 237310 (3),
AGAT	AR,AD	cerebral creatine deficiency syndrome 3, 612718 (3), ; fanconi renotubular syndrome 1, 134600 (3),
AGBL1	AD	corneal dystrophy, fuchs endothelial, 8, 615523 (3),
AGBL2		
AGBL3		
AGBL4		
AGBL5	AR	retinitis pigmentosa 75, 617023 (3),
AGC1	AD,AR,AR	?spondyloepiphyseal dysplasia, kimberley type, 608361 (3), ; short stature and advanced bone age, with or without early-onset osteoarthritis and/or osteochondritis dissecans, 165800 (3), ; spondyloepimetaphyseal dysplasia, aggrecan type, 612813 (3), |developmental and epileptic encephalopathy 39, 612949 (3),
AGD1		
AGD2		
AGER		
AGF		
AGFG1		
AGFG2		
AGGF1		
AGGG		
aggrus		
AGIF		
AGK	AR	cataract 38, 614691 (3), ; sengers syndrome, 212350 (3),
AGL	AR	glycogen storage disease iiia, 232400 (3), ; glycogen storage disease iiib, 232400 (3),
AGM1	AR	immunodeficiency 23, 615816 (3),
AGMAT		
AGMO		
AGMX1	XL,XLR	agammaglobulinemia, 1, 300755 (3), ; isolated growth hormone deficiency, type iii, with agammaglobulinemia, 307200 (3),
AGO	AD	developmental delay, hypotonia, and impaired language, 620012 (3),
AGO1	AD	neurodevelopmental disorder with language delay and behavioral abnormalities, with or without seizures, 620292 (3),
AGO2	AD	lessel-kreienkamp syndrome, 619149 (3),
AGO3		
AGO4		
AGO61	AR	muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 8, 614830 (3), ; muscular dystrophy-dystroglycanopathy (limb-girdle) type c, 8, 618135 (3),
AGP	AR	mitochondrial complex v (atp synthase) deficiency, nuclear type 6, 618683 (3),
AGP-B		
AGP-B'		
AGP2		
AGP7		
AGPAT1		
AGPAT10		
AGPAT11		
AGPAT2	AR	lipodystrophy, congenital generalized, type 1, 608594 (3),
AGPAT3		
AGPAT4		
AGPAT5		
AGPAT6		
AGPAT7		
AGPAT8		
AGPAT9		
AGPHD1		
AGPS	AR	rhizomelic chondrodysplasia punctata, type 3, 600121 (3),
AGPT-1	AD	?angioedema, hereditary, 5, 619361 (3),
AGR1		
AGR16	AR	deafness, 68, 610419 (3),
AGR2	AR	respiratory infections, recurrent, and failure to thrive with or without diarrhea, 620233 (3),
AGR3		
AGRIN	AR	myasthenic syndrome, congenital, 8, with pre- and postsynaptic defects, 615120 (3),
AGRINL		
AGRN	AR	myasthenic syndrome, congenital, 8, with pre- and postsynaptic defects, 615120 (3),
AGRNL		
AGRNR	AR	muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 9, 616538 (3), ; muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 9, 613818 (3),
AGRP	AR,MF,AD	{leanness, inherited}, 601665 (3), , ; {obesity, late-onset}, 601665 (3), ,
Agrt	AR,MF,AD	{leanness, inherited}, 601665 (3), , ; {obesity, late-onset}, 601665 (3), ,
AGS	AD	?deafness, congenital heart defects, and posterior embryotoxon, 617992 (3), ; charcot-marie-tooth disease, axonal, type 2hh, 619574 (3), ; alagille syndrome 1, 118450 (3), ; tetralogy of fallot, 187500 (3),
AGS1	AD,AR	vasculopathy, retinal, with cerebral leukoencephalopathy and systemic manifestations, 192315 (3), ; aicardi-goutieres syndrome 1, and , 225750 (3), ; {systemic lupus erythematosus, susceptibility to}, 152700 (3), ; chilblain lupus, 610448 (3),
AGS2	AR	aicardi-goutieres syndrome 2, 610181 (3),
AGS3	AR	aicardi-goutieres syndrome 3, 610329 (3),
AGS4	AR	aicardi-goutieres syndrome 4, 610333 (3),
AGS5	AD,AR	?chilblain lupus 2, 614415 (3), ; aicardi-goutieres syndrome 5, 612952 (3),
AGT	AR,AR,MF	hyperoxaluria, primary, type 1, 259900 (3), |renal tubular dysgenesis, 267430 (3), ; {preeclampsia, susceptibility to} (3); {hypertension, essential, susceptibility to}, 145500 (3),
AGT-1		
AGT1	AR	hyperoxaluria, primary, type 1, 259900 (3),
AGT2	AR	[beta-aminoisobutyric acid, urinary excretion of], 210100 (3),
AGTAVPRL	AD	cinca syndrome, 607115 (3), ; familial cold inflammatory syndrome 1, 120100 (3), ; keratoendothelitis fugax hereditaria, 148200 (3), ; deafness, 34, with or without inflammation, 617772 (3), ; muckle-wells syndrome, 191900 (3),
AGTBP		
AGTIL		[skin/hair/eye pigmentation 9, brown/nonbrown eyes], 611742 (3); [skin/hair/eye pigmentation 9, dark/light hair], 611742 (3)
AGTPBP1	AR	neurodegeneration, childhood-onset, with cerebellar atrophy, 618276 (3),
AGTR1	MF,AR	{hypertension, essential}, 145500 (3), ; renal tubular dysgenesis, 267430 (3),
AGTR1A	MF,AR	{hypertension, essential}, 145500 (3), ; renal tubular dysgenesis, 267430 (3),
AGTR1B	MF,AR	{hypertension, essential}, 145500 (3), ; renal tubular dysgenesis, 267430 (3),
AGTR2		
AGTRAP		
AGTRL1		
AGU2		
AgX		
AGX1		
AGXT	AR	hyperoxaluria, primary, type 1, 259900 (3),
AGXT1	AR	hyperoxaluria, primary, type 1, 259900 (3),
AGXT2	AR	[beta-aminoisobutyric acid, urinary excretion of], 210100 (3),
AGXT2L1		
AGXT2L2	AR	[?phosphohydroxylysinuria], 615011 (3),
AH2		
Aha1		
AHAS		
AHC	XLR,XL	adrenal hypoplasia, congenital, 300200 (3), ; 46xy sex reversal 2, dosage-sensitive, 300018 (3),
AHCH	XLR,XL	adrenal hypoplasia, congenital, 300200 (3), ; 46xy sex reversal 2, dosage-sensitive, 300018 (3),
AHCP		
AHCTF1		
AHCY	AR	hypermethioninemia with deficiency of s-adenosylhomocysteine hydrolase, 613752 (3),
AHCYL1		
AHCYL2		
AHD	AD	?deafness, congenital heart defects, and posterior embryotoxon, 617992 (3), ; charcot-marie-tooth disease, axonal, type 2hh, 619574 (3), ; alagille syndrome 1, 118450 (3), ; tetralogy of fallot, 187500 (3),
AHDC1	AD	xia-gibbs syndrome, 615829 (3),
AHDS	XL	allan-herndon-dudley syndrome, 300523 (3),
AHH		
AHHR		
AHI1	AR	joubert syndrome 3, 608629 (3),
aHIF		
AHNAK		
AHNAK1		
AHNAK2		
AHR	AR	?retinitis pigmentosa 85, 618345 (3),
AHRR		
AHSA1		
AHSG	AR	?alopecia-intellectual disability syndrome 1, 203650 (3),
AHSP		
AI2A4	AR	amelogenesis imperfecta, type iia4, 614832 (3),
AIB1		
AIB3		
AIBC1		
AIBp		
AIBP	AR	encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy, 617186 (3),
AIBP63	AR	hermansky-pudlak syndrome 5, 614074 (3),
AIbZIP		
AICARFT	AR	aica-ribosiduria due to atic deficiency, 608688 (3),
AICDA	AR	immunodeficiency with hyper-igm, type 2, 605258 (3),
AICL		
AID	AR	immunodeficiency with hyper-igm, type 2, 605258 (3),
AIDA		
AIDA-1		
AIDD		
AIE-75	AR	usher syndrome, type 1c, 276904 (3), ; deafness, 18a, 602092 (3),
AIEBP		
AIED	XL,XLR	cone-rod dystrophy, 3, 300476 (3), ; night blindness, congenital stationary (incomplete), 2a, 300071 (3), ; aland island eye disease, 300600 (3),
AIF	XLR,XL	combined oxidative phosphorylation deficiency 6, 300816 (3), ; cowchock syndrome, 310490 (3), ; spondyloepimetaphyseal dysplasia, with hypomyelinating leukodystrophy, 300232 (3), ; deafness, 5, 300614 (3),
AIF-1		
AIF1		
AIFL		
AIFM1	XLR,XL	combined oxidative phosphorylation deficiency 6, 300816 (3), ; cowchock syndrome, 310490 (3), ; spondyloepimetaphyseal dysplasia, with hypomyelinating leukodystrophy, 300232 (3), ; deafness, 5, 300614 (3),
AIFM2		
AIFM3		
AIG-1		
AIG1		
AIG1L		
AIGF	AD	hypogonadotropic hypogonadism 6 with or without anosmia, 612702 (3),
AIGP1		
AIH1	XLD,XL	amelogenesis imperfecta, type 1e, 301200 (3),
AIH2	AR,AD	amelogenesis imperfecta, type ic, 204650 (3), ; amelogenesis imperfecta, type ib, 104500 (3),
AII	AD	cinca syndrome, 607115 (3), ; familial cold inflammatory syndrome 1, 120100 (3), ; keratoendothelitis fugax hereditaria, 148200 (3), ; deafness, 34, with or without inflammation, 617772 (3), ; muckle-wells syndrome, 191900 (3),
AIID	XL,XLR	immunodysregulation, polyendocrinopathy, and enteropathy, 304790 (3),
AIK	AD	{colon cancer, susceptibility to}, 114500 (3), somatic mutation,
Aik2		
AILIM	AR	immunodeficiency, common variable, 1, 607594 (3),
AIM-1	AR	[skin/hair/eye pigmentation 5, dark/light eyes], 227240 (3), ; [skin/hair/eye pigmentation 5, black/nonblack hair], 227240 (3), ; albinism, oculocutaneous, type iv, 606574 (3), ; [skin/hair/eye pigmentation 5, dark/fair skin], 227240 (3),
AIM1		
AIM1L		
AIM2		
AIMP1	AR	leukodystrophy, hypomyelinating, 3, 260600 (3),
AIMP2	AR	leukodystrophy, hypomyelinating, 17, 618006 (3),
AIMP3		
Aiolos	AD	?immunodeficiency 84, 619437 (3),
AIP	AD	pituitary adenoma 1, multiple types, 102200 (3), somatic mutation, ; pituitary adenoma predisposition, 102200 (3), somatic mutation,
AIP-1		
AIP1	AR,AR,AR,AR	?microcephaly 29, primary, 620047 (3), |?spastic paraplegia 61, 615685 (3), |nephrotic syndrome, type 15, 617609 (3), |periodic fever, immunodeficiency, and thrombocytopenia syndrome, 150550 (3),
AIP2		
AIP3		
AIP4	AR	autoimmune disease, multisystem, with facial dysmorphism, 613385 (3),
AIP5		
AIP70		
AIPL1	AR,AD	leber congenital amaurosis 4, 604393 (3), ; retinitis pigmentosa, juvenile, 604393 (3), ; cone-rod dystrophy, 604393 (3),
aiPLA2		
AIR		
AIRAP		
AIRAPL		
AIRC	AR	?phosphoribosylaminoimidazole carboxylase deficiency, 619859 (3),
AIRE	AR,AD	autoimmune polyendocrinopathy syndrome , type i, with or without reversible metaphyseal dysplasia, 240300 (3),
AIRIM		
AIRN		
AIRP		
AIS	XLR,AD,XL	androgen insensitivity, partial, with or without breast cancer, 312300 (3), ; {prostate cancer, susceptibility to}, 176807 (3), somatic mutation, ; androgen insensitivity, 300068 (3), ; spinal and bulbar muscular atrophy of kennedy, 313200 (3), ; hypospadias 1, 300633 (3),
AIT		
AITD3	AR	{autoimmune thyroid disease, susceptibility to, 3}, 608175 (3); thyroid dyshormonogenesis 3, 274700 (3),
AITR		
AITRL		
AJAP1		
AJUBA		
AK	AR	hypermethioninemia due to adenosine kinase deficiency, 614300 (3),
AK001796		
AK023948		
AK1	AR	hemolytic anemia due to adenylate kinase deficiency, 612631 (3),
AK155		
AK2	AR	reticular dysgenesis, 267500 (3),
AK3		
AK3L1		
AK4		
AK5		
AK6		
AK7	AR	?spermatogenic failure 27, 617965 (3),
AK8		
AK9		
AKA		
AKAIN1		
AKAP-Lbc		
AKAP1		
AKAP10		
AKAP100		
AKAP11		
AKAP110	AR	spermatogenic failure 82, 620353 (3),
AKAP12		
AKAP121		
AKAP13		
AKAP14		
AKAP149		
AKAP15		
AKAP17A		
AKAP18		
AKAP220		
AKAP250		
AKAP28		
AKAP3	AR	spermatogenic failure 82, 620353 (3),
AKAP350	AD	?long qt syndrome 11, 611820 (3),
AKAP4		
AKAP450	AD	?long qt syndrome 11, 611820 (3),
AKAP5		
AKAP6		
AKAP7		
AKAP75		
AKAP79		
AKAP8		
AKAP82		
AKAP84		
AKAP8L		
AKAP9	AD	?long qt syndrome 11, 611820 (3),
AKAP95		
AKD1		
AKD2		
aKGR	AD	nephrolithiasis, calcium oxalate, 2, with nephrocalcinosis, 620374 (3),
Aki-1	AR	intellectual developmental disorder, 3, 608443 (3),
AKIP		
AKIP1		
AKIRIN1		
AKIRIN2		
AKL3L1		
AKNA		
AKR1A1		
AKR1B1		
AKR1B10		
AKR1B11		
AKR1B12		
AKR1B15		
AKR1C1		
AKR1C2	AR	46xy sex reversal 8, 614279 (3),
AKR1C3		
AKR1C4	AR	{46xy sex reversal 8, modifier of}, 614279 (3),
AKR1CL2		
AKR1D1	AR	bile acid synthesis defect, congenital, 2, 235555 (3),
AKR1E2		
AKR6A3		
AKR6A5		
AKR6A9		
AKR7A2		
AKR7A3		
AKR7L		
AKRDC1		
AKT		breast cancer, somatic, 114480 (3); cowden syndrome 6, 615109 (3); colorectal cancer, somatic, 114500 (3); proteus syndrome, somatic, 176920 (3); ovarian cancer, somatic, 167000 (3)
AKT1		breast cancer, somatic, 114480 (3); cowden syndrome 6, 615109 (3); colorectal cancer, somatic, 114500 (3); proteus syndrome, somatic, 176920 (3); ovarian cancer, somatic, 167000 (3)
AKT1S1		
AKT2	AD	diabetes mellitus, type ii, 125853 (3), ; hypoinsulinemic hypoglycemia with hemihypertrophy, 240900 (3),
AKT3	AD	megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 2, 615937 (3),
AKTIP		
AKU	AR	alkaptonuria, 203500 (3),
AL132709.8		
AL928768.3		
ALAD	AR	porphyria, acute hepatic, 612740 (3), ; {lead poisoning, susceptibility to}, 612740 (3),
ALADH	AR	porphyria, acute hepatic, 612740 (3), ; {lead poisoning, susceptibility to}, 612740 (3),
AlaRS	AR,AD	developmental and epileptic encephalopathy 29, 616339 (3), ; charcot-marie-tooth disease, axonal, type 2n, 613287 (3), ; ?leukoencephalopathy, hereditary diffuse, with spheroids 2, 619661 (3), ; trichothiodystrophy 8, nonphotosensitive, 619691 (3),
ALAS		
ALAS-E	XLR,XL	anemia, sideroblastic, 1, 300751 (3), ; protoporphyria, erythropoietic, 300752 (3),
ALAS-H		
ALAS1		
ALAS2	XLR,XL	anemia, sideroblastic, 1, 300751 (3), ; protoporphyria, erythropoietic, 300752 (3),
ALAS3		
AlaXp		
ALB	AR,AD	?[dysalbuminemic hypertriiodothyroninemia], 615999 (3), ; analbuminemia, 616000 (3), ; [dysalbuminemic hyperthyroxinemia], 615999 (3),
ALB2		
ALBA		
ALC1	AD	?atrial fibrillation, familial, 18, 617280 (3),
ALCAM		
ALCAT1		
ALD	XLR,XL	adrenoleukodystrophy, 300100 (3), ; adrenomyeloneuropathy, adult, 300100 (3),
ALDH1		
ALDH10	AR	sjogren-larsson syndrome, 270200 (3),
ALDH12		
ALDH16A1		
ALDH18A1	AD,AR	spastic paraplegia 9a, 601162 (3), ; cutis laxa, type iiia, 219150 (3), ; spastic paraplegia 9b, 616586 (3), ; cutis laxa, 3, 616603 (3),
ALDH1A1		
ALDH1A2	AR	diaphragmatic hernia 4, with cardiovascular defects, 620025 (3),
ALDH1A3	AR	microphthalmia, isolated 8, 615113 (3),
ALDH1B1		
ALDH1L1		
ALDH1L2		
ALDH2	AD	{esophageal cancer, alcohol-related, susceptibility to} (3); {sublingual nitroglycerin, susceptibility to poor response to} (3); alcohol sensitivity, acute, 610251 (3), ; {hangover, susceptibility to}, 610251 (3),
ALDH3		
ALDH3A1		
ALDH3A2	AR	sjogren-larsson syndrome, 270200 (3),
ALDH3B1		
ALDH3B2		
ALDH4	AR	hyperprolinemia, type ii, 239510 (3),
ALDH4A1	AR	hyperprolinemia, type ii, 239510 (3),
ALDH5		
ALDH5A1	AR	succinic semialdehyde dehydrogenase deficiency, 271980 (3),
ALDH6	AR	microphthalmia, isolated 8, 615113 (3),
ALDH6A1	AR	methylmalonate semialdehyde dehydrogenase deficiency, 614105 (3),
ALDH7		
ALDH7A1	AR	epilepsy, pyridoxine-dependent, 266100 (3),
ALDH8		
ALDH8A1		
ALDH9		
ALDH9A1		
ALDHPSY	AR	rhizomelic chondrodysplasia punctata, type 3, 600121 (3),
ALDHX		
ALDL1		
ALDOA	AR	glycogen storage disease xii, 611881 (3),
ALDOB	AR	fructose intolerance, hereditary, 229600 (3),
ALDOC		
ALDOS	AR	hypoaldosteronism, congenital, due to cmo i deficiency, 203400 (3), ; aldosterone to renin ratio raised (3); {low renin hypertension, susceptibility to} (3); hypoaldosteronism, congenital, due to cmo ii deficiency, 610600 (3),
ALDP	XLR,XL	adrenoleukodystrophy, 300100 (3), ; adrenomyeloneuropathy, adult, 300100 (3),
ALDR		
ALDR1		
ALDRL6		
ALDRLn		
ALDRP		
ALEX1		
ALEX2		
ALEX3		
ALF		
ALFY	AD	?microcephaly 18, primary, 617520 (3),
ALG-2		
ALG-4		
ALG1	AR	congenital disorder of glycosylation, type ik, 608540 (3),
ALG10		
ALG10A		
ALG10B	AD	{long qt syndrome, acquired, reduced susceptibility to}, 613688 (3),
ALG11	AR	congenital disorder of glycosylation, type ip, 613661 (3),
ALG12	AR	congenital disorder of glycosylation, type ig, 607143 (3),
ALG13	XL	developmental and epileptic encephalopathy 36, 300884 (3),
ALG14	AR	intellectual developmental disorder with epilepsy, behavioral abnormalities, and coarse facies, 619031 (3), ; myopathy, epilepsy, and progressive cerebral atrophy, 619036 (3), ; ?myasthenic syndrome, congenital, 15, without tubular aggregates, 616227 (3),
ALG2	AR	congenital disorder of glycosylation, type ii, 607906 (3), ; myasthenic syndrome, congenital, 14, with tubular aggregates, 616228 (3),
ALG3	AR	congenital disorder of glycosylation, type id, 601110 (3),
ALG5	AD	polycystic kidney disease 7, 620056 (3),
ALG6	AR	congenital disorder of glycosylation, type ic, 603147 (3),
ALG7	AR	myasthenic syndrome, congenital, 13, with tubular aggregates, 614750 (3), ; congenital disorder of glycosylation, type ij, 608093 (3),
ALG8	AR,AD	congenital disorder of glycosylation, type ih, 608104 (3), ; polycystic liver disease 3 with or without kidney cysts, 617874 (3),
ALG9	AR	gillessen-kaesbach-nishimura syndrome, 263210 (3), ; congenital disorder of glycosylation, type il, 608776 (3),
ALGV3072		
ALI1		
ALIEN		
Alix	AR	?microcephaly 29, primary, 620047 (3),
ALK		{neuroblastoma, susceptibility to, 3}, 613014 (3)
ALK-5	AD	{multiple self-healing squamous epithelioma, susceptibility to}, 132800 (3), ; loeys-dietz syndrome 1, 609192 (3),
alk-SMase		
ALK1	AD	{neuroblastoma, susceptibility to, 3}, 613014 (3)|telangiectasia, hereditary hemorrhagic, type 2, 600376 (3),
ALK2	AD	fibrodysplasia ossificans progressiva, 135100 (3),
ALK3	AD	polyposis syndrome, hereditary mixed, 2, 610069 (3); polyposis, juvenile intestinal, 174900 (3),
ALK4		pancreatic cancer, somatic, 260350 (3)
ALK5	AD	{multiple self-healing squamous epithelioma, susceptibility to}, 132800 (3), ; loeys-dietz syndrome 1, 609192 (3),
ALK6	AR,AD	acromesomelic dysplasia 3, 609441 (3), ; brachydactyly, type a2, 112600 (3), ; brachydactyly, type a1, d, 616849 (3),
ALK7		
ALKAL1		
ALKAL2		
alkB		
ALKBH		
ALKBH1		
ALKBH2		
ALKBH3		
ALKBH4		
ALKBH5		
ALKBH6		
ALKBH7		
ALKBH8	AR	intellectual developmental disorder, 71, 618504 (3),
ALKBH9	AR	growth retardation, developmental delay, facial dysmorphism, 612938 (3), ; {obesity, susceptibility to, bmiq14}, 612460 (3),
ALKCDase2		
ALL		leukemia, chronic myeloid, philadelphia chromosome positive, somatic, 608232 (4); leukemia, acute lymphocytic, philadelphia chromosome positive, somatic, 613065 (4)
ALL-1	AD	wiedemann-steiner syndrome, 605130 (3),
ALL1	AD	wiedemann-steiner syndrome, 605130 (3),
ALLP17		
ALMalpha		
ALMS1	AR	alstrom syndrome, 203800 (3),
ALO17	AR,AD	{moyamoya disease 2, susceptibility to}, 607151 (3),
ALOX12		
ALOX12B	AR	ichthyosis, congenital, 2, 242100 (3),
ALOX15		
ALOX15B		
ALOX5	AD	{atherosclerosis, susceptibility to} (3); {asthma, diminished response to antileukotriene treatment in}, 600807 (3),
ALOX5AP	MF	{stroke, susceptibility to}, 601367 (3),
ALOXE3	AR	ichthyosis, congenital, 3, 606545 (3),
ALP		
ALP1		
ALP4	AR	pachygyria, microcephaly, developmental delay, and dysmorphic facies, with or without seizures, 618737 (3),
ALP56		
ALPG		
alpha-1-antitrypsin	AR	hemorrhagic diathesis due to antithrombin pittsburgh, 613490 (3), ; emphysema due to aat deficiency, 613490 (3), ; emphysema-cirrhosis, due to aat deficiency, 613490 (3),
Alpha-2-MRAP	AR	myopia 23, 615431 (3),
ALPHA-2-PI	AR	alpha-2-plasmin inhibitor deficiency, 262850 (3),
alpha-CATU		
Alpha-MPP	AR	spinocerebellar ataxia, 2, 213200 (3),
Alpha-NAC		
ALPHA-PAL		
alpha-PIX		
ALPHA-RLC		
alpha-sAPP	AD	cerebral amyloid angiopathy, dutch, italian, iowa, flemish, arctic variants, 605714 (3), ; alzheimer disease 1, familial, 104300 (3),
alpha1AT	AR	hemorrhagic diathesis due to antithrombin pittsburgh, 613490 (3), ; emphysema due to aat deficiency, 613490 (3), ; emphysema-cirrhosis, due to aat deficiency, 613490 (3),
alpha2AP	AR	alpha-2-plasmin inhibitor deficiency, 262850 (3),
alpha2delta-1	AR	developmental and epileptic encephalopathy 110, 620149 (3),
alpha2delta-2	AR	cerebellar atrophy with seizures and variable developmental delay, 618501 (3),
alpha2delta-3		
alpha2delta-4	AR	retinal cone dystrophy 4, 610478 (3),
alpha4GnT		
alphaGMR		surfactant metabolism dysfunction, pulmonary, 4, 300770 (3)
alphaPIX		
alphaSGT		
ALPI		
ALPK1	AD	rosah syndrome, 614979 (3),
ALPK2		
ALPK3	AR	cardiomyopathy, familial hypertrophic 27, 618052 (3),
ALPL	AR,AD	odontohypophosphatasia, 146300 (3), ; hypophosphatasia, infantile, 241500 (3), ; hypophosphatasia, childhood, 241510 (3), ; hypophosphatasia, adult, 146300 (3),
ALPP		
ALPPL2		
ALR	AD,AR	branchial arch abnormalities, choanal atresia, athelia, hearing loss, and hypothyroidism syndrome, 620186 (3), ; kabuki syndrome 1, 147920 (3), |myopathy, mitochondrial progressive, with congenital cataract and developmental delay, 613076 (3),
ALRH	AD	{asthma, susceptibility to}, 600807 (3), ; {allergic rhinitis, susceptibility to}, 607154 (3)
ALRP		
ALS	AR,AR,AD	acid-labile subunit, deficiency of, 615961 (3), |spastic tetraplegia and axial hypotonia, progressive, 618598 (3), ; amyotrophic lateral sclerosis 1, 105400 (3),
ALS1	AR,AD	spastic tetraplegia and axial hypotonia, progressive, 618598 (3), ; amyotrophic lateral sclerosis 1, 105400 (3),
ALS10	AD	frontotemporal lobar degeneration, tardbp-related, 612069 (3), ; amyotrophic lateral sclerosis 10, with or without ftd, 612069 (3),
ALS11	AR,AD	yunis-varon syndrome, 216340 (3), ; ?polymicrogyria, bilateral temporooccipital, 612691 (3), ; amyotrophic lateral sclerosis 11, 612577 (3), ; charcot-marie-tooth disease, type 4j, 611228 (3),
ALS19	AD	amyotrophic lateral sclerosis 19, 615515 (3),
ALS2	AR	primary lateral sclerosis, juvenile, 606353 (3), ; spastic paralysis, infantile onset ascending, 607225 (3), ; amyotrophic lateral sclerosis 2, juvenile, 205100 (3),
ALS20	AD	?inclusion body myopathy with early-onset paget disease without frontotemporal dementia 3, 615424 (3), ; amyotrophic lateral sclerosis 20, 615426 (3),
ALS2CL		
ALS2CR1		
ALS2CR11	AR	?spermatogenic failure 68, 619805 (3),
ALS2CR12		
ALS2CR16		
ALS2CR17		
ALS2CR18		
ALS2CR19		
ALS2CR2		
ALS2CR3		
ALS2CR4	AR	joubert syndrome 14, 614424 (3),
ALS2CR6	AR	primary lateral sclerosis, juvenile, 606353 (3), ; spastic paralysis, infantile onset ascending, 607225 (3), ; amyotrophic lateral sclerosis 2, juvenile, 205100 (3),
ALS2CR7		
ALS2CR8		
ALS2CR9		
ALS4	AR,AD	spinocerebellar ataxia, with axonal neuropathy 2, 606002 (3), ; amyotrophic lateral sclerosis 4, juvenile, 602433 (3),
ALS5	AR	amyotrophic lateral sclerosis 5, juvenile, 602099 (3), ; charcot-marie-tooth disease, axonal, type 2x, 616668 (3), ; spastic paraplegia 11, 604360 (3),
ALS6	AD	amyotrophic lateral sclerosis 6, with or without frontotemporal dementia, 608030 (3); essential tremor, hereditary, 4, 614782 (3),
ALS8	AD	spinal muscular atrophy, late-onset, finkel type, 182980 (3), ; amyotrophic lateral sclerosis 8, 608627 (3),
ALT		
ALT1		
ALT2	AR	neurodevelopmental disorder with microcephaly and spastic paraplegia, 616281 (3),
ALTE		
AltPrP	AD	spongiform encephalopathy with neuropsychiatric features, 606688 (3), ; gerstmann-straussler disease, 137440 (3), ; huntington disease-like 1, 603218 (3), ; insomnia, fatal familial, 600072 (3), ; {kuru, susceptibility to}, 245300 (3); cerebral amyloid angiopathy, prnp-related, 137440 (3), ; creutzfeldt-jakob disease, 123400 (3),
ALUNC	AR	atrichia with papular lesions, 209500 (3), ; alopecia universalis, 203655 (3),
ALURBP		
ALX		
ALX1	AR	frontonasal dysplasia 3, 613456 (3),
ALX3	AR	frontonasal dysplasia 1, 136760 (3),
ALX4	AD,AR	parietal foramina 2, 609597 (3), ; {craniosynostosis 5, susceptibility to}, 615529 (3), ; frontonasal dysplasia 2, 613451 (3),
ALXR		
ALY		
ALY/REF		
ALYE870	AR	joubert syndrome 20, 614970 (3), ; meckel syndrome 11, 615397 (3),
ALYREF		
AM		
AM-R		
AM2		
AMAC		
AMAC-1		
AMAC1L2		
AMACO		
AMACR	AR	alpha-methylacyl-coa racemase deficiency, 614307 (3), ; bile acid synthesis defect, congenital, 4, 214950 (3),
AMAP-1		
AMB11		{aids, delayed/rapid progression to}, 609423 (3)
AMBN	AR	amelogenesis imperfecta, type if, 616270 (3),
AMBP		
AMBRA1		
AMCase		
AMCD1	AD	arthrogryposis, distal, type 2b4, 108120 (3), ; arthrogryposis, distal, type 1a, 108120 (3), ; congenital myopathy 23, 609285 (3),
AMCD2B	AD,AD	arthrogryposis, distal, type 2b1, 601680 (3), |arthrogryposis, distal, type 2b2, 618435 (3),
AMCF-I		
AMD1		
AMDD		
AMDM	AD,AR	epiphyseal chondrodysplasia, miura type, 615923 (3), ; short stature with nonspecific skeletal abnormalities, 616255 (3), ; acromesomelic dysplasia 1, maroteaux type, 602875 (3),
AMELX	XLD,XL	amelogenesis imperfecta, type 1e, 301200 (3),
AMELY		
AMER1	XLD,XL	osteopathia striata with cranial sclerosis, 300373 (3),
AMER2		
AMF	AR	hemolytic anemia, nonspherocytic, due to glucose phosphate isomerase deficiency, 613470 (3),
AMFR	AR	spastic paraplegia 89, 620379 (3),
AMG	XLD,XL	amelogenesis imperfecta, type 1e, 301200 (3),
AMGL		
AMH	AR	persistent mullerian duct syndrome, type i, 261550 (3),
AMHR2	AR	persistent mullerian duct syndrome, type ii, 261550 (3),
AMICA		
AMICA1		
AMID		
amida		
AMIGO		
AMIGO1		
AMIGO2		
AMIGO3		
amisyn		
AML1	AD	platelet disorder, familial, with associated myeloid malignancy, 601399 (3), ; leukemia, acute myeloid, 601626 (3), somatic mutation,
AML1T1		
AML2		
AML3	AD	metaphyseal dysplasia with maxillary hypoplasia with or without brachydactyly, 156510 (3), ; cleidocranial dysplasia, forme fruste, with brachydactyly, 119600 (3), ; cleidocranial dysplasia, forme fruste, dental anomalies only, 119600 (3), ; cleidocranial dysplasia, 119600 (3),
AMLC	AD	?atrial fibrillation, familial, 18, 617280 (3),
AMLCR1	AD	platelet disorder, familial, with associated myeloid malignancy, 601399 (3), ; leukemia, acute myeloid, 601626 (3), somatic mutation,
AMMECR1	XLR	midface hypoplasia, hearing impairment, elliptocytosis, and nephrocalcinosis, 300990 (3),
AMN	XLR,XL,AR	adrenoleukodystrophy, 300100 (3), ; adrenomyeloneuropathy, adult, 300100 (3), |imerslund-grasbeck syndrome 2, 618882 (3),
amnionless	AR	imerslund-grasbeck syndrome 2, 618882 (3),
AMOG		
AMOT		
AMOTL1		
AMOTL2		
AMP		
AMP18		
AMPD1	AR	myopathy due to myoadenylate deaminase deficiency, 615511 (3),
AMPD2	AR	?spastic paraplegia 63, 615686 (3), ; pontocerebellar hypoplasia, type 9, 615809 (3),
AMPD3	AR	[amp deaminase deficiency, erythrocytic], 612874 (3),
AMPH		
AMPH2	AR	centronuclear myopathy 2, 255200 (3),
amphiglycan		
AMPHL	AR	centronuclear myopathy 2, 255200 (3),
AMPK		
AMPKa1		
AMPKa2		
AMSH	AR	microcephaly-capillary malformation syndrome, 614261 (3),
AMSH-FP		
AMSH-LP		
AMT		glycine encephalopathy 2, 620398 (3)
AMTN	AD	?amelogenesis imperfecta, type iiib, 617607 (3),
AMY		
AMY-1		
AMY1		
AMY1A		
AMY1B		
AMY1C		
AMY2		
AMY2A		
AMY2B		
AMYB		
AMYLIN		
AMZ1		
AMZ2		
AN	AD,AD	auditory neuropathy, 1, 609129 (3), |optic nerve hypoplasia, 165550 (3), ; cataract with late-onset corneal dystrophy, 106210 (3), ; ?coloboma, ocular, 120200 (3), ; ?coloboma of optic nerve, 120430 (3), ; aniridia, 106210 (3), ; anterior segment dysgenesis 5, multiple subtypes, 604229 (3), ; ?morning glory disc anomaly, 120430 (3), ; foveal hypoplasia 1, 136520 (3), ; keratitis, 148190 (3),
AN1	AD	optic nerve hypoplasia, 165550 (3), ; cataract with late-onset corneal dystrophy, 106210 (3), ; ?coloboma, ocular, 120200 (3), ; ?coloboma of optic nerve, 120430 (3), ; aniridia, 106210 (3), ; anterior segment dysgenesis 5, multiple subtypes, 604229 (3), ; ?morning glory disc anomaly, 120430 (3), ; foveal hypoplasia 1, 136520 (3), ; keratitis, 148190 (3),
AN2	AD	optic nerve hypoplasia, 165550 (3), ; cataract with late-onset corneal dystrophy, 106210 (3), ; ?coloboma, ocular, 120200 (3), ; ?coloboma of optic nerve, 120430 (3), ; aniridia, 106210 (3), ; anterior segment dysgenesis 5, multiple subtypes, 604229 (3), ; ?morning glory disc anomaly, 120430 (3), ; foveal hypoplasia 1, 136520 (3), ; keratitis, 148190 (3),
ANA		
ANA/BTG3		
ANAPC1	AR	rothmund-thomson syndrome, type 1, 618625 (3),
ANAPC10		
ANAPC11		
ANAPC12		
ANAPC13		
ANAPC15		
ANAPC16		
ANAPC2		
ANAPC3		
ANAPC4		
ANAPC5		
ANAPC6		
ANAPC7	AR	ferguson-bonni neurodevelopmental syndrome, 619699 (3),
ANAPC8		
ANC-2H01		
ANCCA		
ANCHR	AR	cholestasis, progressive familial intrahepatic, 9, 619849 (3),
ANCO-1	AD	kbg syndrome, 148050 (3),
ANCO-2		
ANCO1	AD	kbg syndrome, 148050 (3),
ANCR	AD	angelman syndrome, 105830 (3),
AND-1		
AND-34		
ANE1	AD	{encephalopathy, acute, infection-induced, 3, susceptibility to}, 608033 (3),
ANF	AR,AD	pituitary hormone deficiency, combined, 5, 182230 (3), ; septooptic dysplasia, 182230 (3), ; growth hormone deficiency with pituitary anomalies, 182230 (3),
ANF270		
ANG		amyotrophic lateral sclerosis 9, 611895 (3)
Ang1	AD	?angioedema, hereditary, 5, 619361 (3),
ANG1		
Ang2	AD	lymphatic malformation 10, 619369 (3),
ANG2	AR	pontocerebellar hypoplasia, type 13, 618606 (3),
ANG3	AR	pontocerebellar hypoplasia, type 13, 618606 (3),
ANGEL1		
ANGEL2		
ANGIE		
ANGIE2		
ANGPT1	AD	?angioedema, hereditary, 5, 619361 (3),
ANGPT2	AD	lymphatic malformation 10, 619369 (3),
ANGPT3		
ANGPT4		
ANGPT5	AR	hypobetalipoproteinemia, familial, 2, 605019 (3),
ANGPTL1		
ANGPTL2		
ANGPTL3	AR	hypobetalipoproteinemia, familial, 2, 605019 (3),
ANGPTL4	AD	plasma triglyceride level qtl, low, 615881 (3),
ANGPTL5		
ANGPTL6		
ANGPTL7		
ANGPTL8		
AngX		
AngY		
ania-6a		
ania-6b		
ANILLIN	AD	focal segmental glomerulosclerosis 8, 616032 (3),
ANK	AD,AR,AD	chondrocalcinosis 2, 118600 (3), ; craniometaphyseal dysplasia, 123000 (3), |spherocytosis, type 1, 182900 (3),
ANK1	AR,AD	spherocytosis, type 1, 182900 (3),
ANK2	AD	long qt syndrome 4, 600919 (3), ; cardiac arrhythmia, ankyrin-b-related, 600919 (3),
ANK3	AR	intellectual developmental disorder, 37, 615493 (3),
ANKAR		
ANKCLP	AD,AR	neutropenia, severe congenital, 9, 619813 (3), ; 3-methylglutaconic aciduria, type viib, 616271 (3), ; 3-methylglutaconic aciduria, type viia, 619835 (3),
ANKDD1B		
ANKFY1		
ANKH	AD	chondrocalcinosis 2, 118600 (3), ; craniometaphyseal dysplasia, 123000 (3),
ANKHD1		
ANKHZN		
ANKIB1		
ANKK1		
ANKK2	AR	chand syndrome, 214350 (3), ; popliteal pterygium syndrome, bartsocas-papas type 1, 263650 (3),
ANKL1		
ANKLE1		
ANKLE2	AR	microcephaly 16, primary, 616681 (3),
ANKRA1	AR	bare lymphocyte syndrome, type ii, complementation group b, 209920 (3),
ANKRA2		
ANKRD1		
ANKRD11	AD	kbg syndrome, 148050 (3),
ANKRD12		
ANKRD13		
ANKRD13A		
ANKRD13B		
ANKRD13C		
ANKRD13C-DT		
ANKRD13D		
ANKRD14	AR	nephronophthisis 16, 615382 (3),
ANKRD15		cerebral palsy, spastic quadriplegic, 2, 612900 (3)
ANKRD16		
ANKRD17	AD	chopra-amiel-gordon syndrome, 619504 (3),
ANKRD18A		
ANKRD18B		
ANKRD2		
ANKRD21		
ANKRD23		
ANKRD24		
ANKRD25	AR	nephrotic syndrome, type 16, 617783 (3), ; palmoplantar keratoderma and woolly hair, 616099 (3),
ANKRD26	AD	thrombocytopenia 2, 188000 (3),
ANKRD27		
ANKRD28		
ANKRD3	AR	chand syndrome, 214350 (3), ; popliteal pterygium syndrome, bartsocas-papas type 1, 263650 (3),
ANKRD30A		
ANKRD30B		
ANKRD31		
ANKRD32		
ANKRD34B		
ANKRD36		
ANKRD37		
ANKRD38		
ANKRD4		
ANKRD41		
ANKRD42		
ANKRD45		
ANKRD47		
ANKRD49		
ANKRD50		
ANKRD53		
ANKRD54		
ANKRD55		
ANKRD59		
ANKRD6		
ANKRD7		
ANKRD9		
ANKS1		
ANKS1A		
ANKS1B		
ANKS2		
ANKS3		
ANKS4A	AR	usher syndrome, type 1g, 606943 (3),
ANKS4B		
ANKS5A		
ANKS5B		
ANKS6	AR	nephronophthisis 16, 615382 (3),
ANKT		
ANKTM1	AD	?episodic pain syndrome, familial, 1, 615040 (3),
ANKZF1		
ANLN	AD	focal segmental glomerulosclerosis 8, 616032 (3),
ANM	AD,AR	nemaline myopathy 5c, 620389 (3), ; nemaline myopathy 5a, severe infantile, 605355 (3), ; nemaline myopathy 5b, childhood-onset, 620386 (3),
ANM1		
ANO1	AR	?intestinal dysmotility syndrome, 620045 (3),
ANO10	AR	spinocerebellar ataxia, 10, 613728 (3),
ANO2		
ANO3	AD	dystonia 24, 615034 (3),
ANO4		
ANO5	AR,AD	muscular dystrophy, limb-girdle, 12, 611307 (3), ; miyoshi muscular dystrophy 3, 613319 (3), ; gnathodiaphyseal dysplasia, 166260 (3),
ANO6	AR	scott syndrome, 262890 (3),
ANO7		
ANO8		
ANO9		
ANOS1	XLR,XL	hypogonadotropic hypogonadism 1 with or without anosmia (kallmann syndrome 1), 308700 (3),
ANOVA	AD	neurodevelopmental disorder with or without autistic features and/or structural brain abnormalities, 618859 (3),
ANP	AR,AD	atrial standstill 2, 615745 (3), ; atrial fibrillation, familial, 6, 612201 (3),
ANP32A		
ANP32B		
ANP32C		
ANP32CP		
ANP32D		
ANP32E		
ANPa		
ANPb	AD,AR	epiphyseal chondrodysplasia, miura type, 615923 (3), ; short stature with nonspecific skeletal abnormalities, 616255 (3), ; acromesomelic dysplasia 1, maroteaux type, 602875 (3),
ANPEP		
ANPRA		
ANPRB	AD,AR	epiphyseal chondrodysplasia, miura type, 615923 (3), ; short stature with nonspecific skeletal abnormalities, 616255 (3), ; acromesomelic dysplasia 1, maroteaux type, 602875 (3),
ANPRC	AR	boudin-mortier syndrome, 619543 (3),
ANRIL		
ANT-1	AD	retinitis pigmentosa 60, 613983 (3),
ANT1	AR,AD	mitochondrial dna depletion syndrome 12b (cardiomyopathic type) ar, 615418 (3), ; progressive external ophthalmoplegia with mitochondrial dna deletions, 2, 609283 (3), ; mitochondrial dna depletion syndrome 12a (cardiomyopathic type) ad, 617184 (3),
ANT2		
ANT2BP		
ANT3		
ANT3Y		
ANT4		
ANTKMT		
ANTXR1	AR,AD	gapo syndrome, 230740 (3), ; {?hemangioma, capillary infantile, susceptibility to}, 602089 (3),
ANTXR2	AR	hyaline fibromatosis syndrome, 228600 (3),
ANUP	AR	meleda disease, 248300 (3),
ANX1		
ANX11	AD	amyotrophic lateral sclerosis 23, 617839 (3), ; inclusion body myopathy and brain white matter abnormalities, 619733 (3),
ANX13		
ANX14		
ANX2		
ANX2L4		
ANX2LG		
ANX3		
ANX31		
ANX4		
ANX5	AD	{pregnancy loss, recurrent, susceptibility to, 3}, 614391 (3),
ANX6		
ANX7		
ANX8		
ANXA1		
ANXA10		
ANXA11	AD	amyotrophic lateral sclerosis 23, 617839 (3), ; inclusion body myopathy and brain white matter abnormalities, 619733 (3),
ANXA13		
ANXA2		
ANXA2R		
ANXA3		
ANXA4		
ANXA5	AD	{pregnancy loss, recurrent, susceptibility to, 3}, 614391 (3),
ANXA6		
ANXA7		
ANXA8		
ANXA9		
AO		
AO7		
AOA	AR	ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia, 208920 (3),
AOA1	AR	ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia, 208920 (3),
AOA2	AR,AD	spinocerebellar ataxia, with axonal neuropathy 2, 606002 (3), ; amyotrophic lateral sclerosis 4, juvenile, 602433 (3),
AOAH		
AOC1		
AOC2		
AOC3		
AOE37-2		
AOEB166		
AOF1		
AOF2	AD	cleft palate, psychomotor retardation, and distinctive facial features, 616728 (3),
AOH1		
AOM	AD	?vitreoretinopathy with phalangeal epiphyseal dysplasia, 619248 (3), ; czech dysplasia, 609162 (3), ; achondrogenesis, type ii or hypochondrogenesis, 200610 (3), ; spondyloperipheral dysplasia, 271700 (3), ; smed strudwick type, 184250 (3), ; ?epiphyseal dysplasia, multiple, with myopia and deafness, 132450 (3), ; sed congenita, 183900 (3), ; kniest dysplasia, 156550 (3), ; stickler syndrome, type i, nonsyndromic ocular, 609508 (3), ; osteoarthritis with mild chondrodysplasia, 604864 (3), ; stickler syndrome, type i, 108300 (3), ; platyspondylic skeletal dysplasia, torrance type, 151210 (3), ; spondyloepiphyseal dysplasia, stanescu type, 616583 (3), ; avascular necrosis of the femoral head, 608805 (3), ; legg-calve-perthes disease, 150600 (3),
AOP-1	AR,AD	spinocerebellar ataxia, 32, 619862 (3), ; corneal dystrophy, punctiform and polychromatic pre-descemet, 619871 (3),
AOP1	AR,AD	spinocerebellar ataxia, 32, 619862 (3), ; corneal dystrophy, punctiform and polychromatic pre-descemet, 619871 (3),
AOP2		
AOPEP	AR	dystonia 31, 619565 (3),
AOS1		
AOX1		
AP-1		
AP-2	AD	branchiooculofacial syndrome, 113620 (3),
AP-2alpha	AD	branchiooculofacial syndrome, 113620 (3),
AP-2beta	AD	patent ductus arteriosus 2, 617035 (3), ; char syndrome, 169100 (3),
AP-2delta		
AP-2epsilon		
AP-2rep		
AP-4		
AP-4-EPSILON	AD,AR	stuttering, familial persistent, 1, 184450 (3), ; spastic paraplegia 51, 613744 (3),
AP-5		
AP-57		
AP-N		
AP-O	AR	dystonia 31, 619565 (3),
AP000439.2		
AP000439.3		
AP000553.C22.4		
AP1-mu2		
AP105A	AR	keratitis-ichthyosis-deafness syndrome, 242150 (3),
AP180		
AP19	AR	mednik syndrome, 609313 (3),
AP1AR		
AP1B1	AR	keratitis-ichthyosis-deafness syndrome, 242150 (3),
AP1G1	AR,AD	usmani-riazuddin syndrome, 619548 (3); usmani-riazuddin syndrome, 619467 (3),
AP1G2		
AP1GBP1		
AP1M1		
AP1M2		
AP1S1	AR	mednik syndrome, 609313 (3),
AP1S2	XLR,XL	pettigrew syndrome, 304340 (3),
AP1S3	AD	{psoriasis 15, pustular, susceptibility to}, 616106 (3),
aP2		
AP2		
AP2-B	AD	patent ductus arteriosus 2, 617035 (3), ; char syndrome, 169100 (3),
AP2-GAMMA		
AP2A1		
AP2A2		
AP2B1		
AP2E		
AP2M1	AD	intellectual developmental disorder 60 with seizures, 618587 (3),
AP2REP		
AP2S1	AD	hypocalciuric hypercalcemia, type iii, 600740 (3),
AP2TF	AD	branchiooculofacial syndrome, 113620 (3),
AP3Aase		
AP3B1	AR	hermansky-pudlak syndrome 2, 608233 (3),
AP3B2	AR	developmental and epileptic encephalopathy 48, 617276 (3),
AP3D1	AR	?hermansky-pudlak syndrome 10, 617050 (3),
AP3M1		
AP3M2		
AP3S1		
AP3S2		
AP4		
AP47		
AP47B	AR	spastic paraplegia 52, 614067 (3),
AP4B1	AR	spastic paraplegia 47, 614066 (3),
AP4E1	AD,AR	stuttering, familial persistent, 1, 184450 (3), ; spastic paraplegia 51, 613744 (3),
AP4M1	AR	spastic paraplegia 50, 612936 (3),
AP4S1	AR	spastic paraplegia 52, 614067 (3),
AP50	AD	intellectual developmental disorder 60 with seizures, 618587 (3),
AP5B1		
AP5M1		
AP5S1		
AP5Z1	AR	spastic paraplegia 48, 613647 (3),
APA-1		
APA1		
APAA		
APACD		
APache		
APAF-1		
APAF-3		
APAF1		
APAH1	AR	intellectual developmental disorder with or without peripheral neuropathy, 619844 (3),
APB		
APBA1		
APBA2		
APBA2BP		
APBA3		
APBB1		
APBB1IP		
APBB2		
APBB3		
APC	AD	colorectal cancer, somatic, 114500 (3); brain tumor-polyposis syndrome 2, 175100 (3), ; desmoid disease, hereditary, 135290 (3), ; adenoma, periampullary, somatic, 175100 (3); hepatoblastoma, somatic, 114550 (3); gastric cancer, somatic, 613659 (3); gastric adenocarcinoma and proximal polyposis of the stomach, 619182 (3), ; gardner syndrome, 175100 (3), ; adenomatous polyposis coli, 175100 (3),
APC1	AD,AR	fontaine progeroid syndrome, 612289 (3), |rothmund-thomson syndrome, type 1, 618625 (3),
APC10		
APC11		
Apc11p		
APC12		
APC13		
APC15		
APC16		
APC2	AR	cortical dysplasia, complex, with other brain malformations 10, 618677 (3), ; intellectual developmental disorder, 74, 617169 (3),
APC3		
APC4		
APC5		
APC6		
APC7	AR	ferguson-bonni neurodevelopmental syndrome, 619699 (3),
APC8		
APCA	AD	spinocerebellar ataxia 6, 183086 (3), ; episodic ataxia, type 2, 108500 (3), ; developmental and epileptic encephalopathy 42, 617106 (3), ; migraine, familial hemiplegic, 1, with progressive cerebellar ataxia, 141500 (3), ; migraine, familial hemiplegic, 1, 141500 (3),
APCDD1	AD	hypotrichosis 1, 605389 (3),
APCL	AR	cortical dysplasia, complex, with other brain malformations 10, 618677 (3), ; intellectual developmental disorder, 74, 617169 (3),
APCS		{?amyloidosis, secondary, susceptibility to} (1)
APE	AR	?peho syndrome-like, 617507 (3),
APE-1		
APE2		
APECED	AR,AD	autoimmune polyendocrinopathy syndrome , type i, with or without reversible metaphyseal dysplasia, 240300 (3),
APEG1	AR	centronuclear myopathy 5, 615959 (3),
APEH		
APELA		
apelin		
APEN		
APEX		
APEX1		
APEX2		
APEXL2		
APG-1		
APG10L		
APG12		
APG12L		
APG16L		{inflammatory bowel disease (crohn disease) 10}, 611081 (3)
APG3L		
APG4-D		
APG4A		
Apg4B		
APG4B		
APG4C		
APG4D		
APG5	AR	?spinocerebellar ataxia, 25, 617584 (3),
APG5L	AR	?spinocerebellar ataxia, 25, 617584 (3),
APG7L	AR	spinocerebellar ataxia, 31, 619422 (3),
APG8L		
APG9L1		
APG9L2		
APH-1A		
APH-1B		
APH1A		
APH1B		
APH2	AD	acne inversa, familial, 1, 142690 (3),
APHC	AR	?leukodystrophy, progressive, early childhood-onset, 617762 (3),
API	AR	alpha-2-plasmin inhibitor deficiency, 262850 (3),
API1		
API2		
API3	XL,XLR	lymphoproliferative syndrome, 2, 300635 (3),
API4		
API5		
API5L1		
API6		
APin		
APIP		
APIP2		
APITD1		
APJ		
APJR		
APK1		
APL1		
APLF		
APLN		
APLNR		
APLP		
APLP1		
APLP2		
apM1	AD	adiponectin deficiency, 612556 (3),
APMAP		
APMCF1		
APNH	AR	lichtenstein-knorr syndrome, 616291 (3),
APO	AR	dystonia 31, 619565 (3),
APO-1	AD	squamous cell carcinoma, burn scar-related, somatic (3); autoimmune lymphoproliferative syndrome, type ia, 601859 (3), ; {autoimmune lymphoproliferative syndrome}, 601859 (3),
Apo-2L		
APO-3		
Apo-C3		apolipoprotein c-iii deficiency, 614028 (3)
Apo-CIII		apolipoprotein c-iii deficiency, 614028 (3)
Apo-D		
Apo-M		
Apo2		
APO3L		
APOA-V	AD	hyperchylomicronemia, late-onset, 144650 (3), ; {hypertriglyceridemia, susceptibility to}, 145750 (3),
APOA1	AR,AD	hypoalphalipoproteinemia, primary, 2, 618463 (3), ; amyloidosis, 3 or more types, 105200 (3), ; hypoalphalipoproteinemia, primary, 2, intermediate, 619836 (3),
APOA1-AS		
APOA1BP	AR	encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy, 617186 (3),
APOA2	AR,AD	apolipoprotein a-ii deficiency (3); {hypercholesterolemia, familial, modifier of}, 143890 (3),
APOA4		
APOA5	AD	hyperchylomicronemia, late-onset, 144650 (3), ; {hypertriglyceridemia, susceptibility to}, 145750 (3),
APOAL		
APOARGC		
APOB	AD,AR	hypercholesterolemia, familial, 2, 144010 (3), ; hypobetalipoproteinemia, 615558 (3),
APOB100R		
APOB48R		
APOBEC-1		
APOBEC1		
APOBEC1CF		
APOBEC1L		
APOBEC2		
APOBEC3A		
APOBEC3B		
APOBEC3C		
APOBEC3D		
APOBEC3DE		
APOBEC3E		
APOBEC3F		
APOBEC3G		
APOBEC3H		
APOBEC4		
APOBR		
ApoC-3		apolipoprotein c-iii deficiency, 614028 (3)
ApoC-III		apolipoprotein c-iii deficiency, 614028 (3)
APOC1		
APOC2	AR	hyperlipoproteinemia, type ib, 207750 (3),
APOC3		apolipoprotein c-iii deficiency, 614028 (3)
APOC4		
APOCIII		apolipoprotein c-iii deficiency, 614028 (3)
APOD		
APOE	AD,AR	alzheimer disease 2, 104310 (3), ; sea-blue histiocyte disease, 269600 (3), ; {?alzheimer disease, protection against, due to apoe3-christchurch}, 607822 (3), ; {coronary artery disease, severe, susceptibility to}, 617347 (3); lipoprotein glomerulopathy, 611771 (3); {?macular degeneration, age-related}, 603075 (3), ; hyperlipoproteinemia, type iii, 617347 (3)
APOER	AR	?keratosis pilaris atrophicans, 604093 (3),
APOER2		{myocardial infarction, susceptibility to}, 608446 (3)
APOF		
APOH		
APOJ		
APOL	AD	{glomerulosclerosis, focal segmental, 4, susceptibility to}, 612551 (3),
APOL-II	AD	{schizophrenia}, 181500 (1),
APOL-VI		
APOL1	AD	{glomerulosclerosis, focal segmental, 4, susceptibility to}, 612551 (3),
APOL2	AD	{schizophrenia}, 181500 (1),
APOL3		
APOL4	AD	{schizophrenia}, 181500 (1),
APOL5		
APOL6		
APOLD1		
APOLIII		
APOLIV	AD	{schizophrenia}, 181500 (1),
APOLLO	AR	dyskeratosis congenita, 8, 620133 (3),
APOLMT	AR,AD	combined oxidative phosphorylation deficiency 55, 619743 (3),
APOLV		
APOLVI		
APOM		
APOO		
APOOL		
APOP-1	AR	mitochondrial complex iv deficiency, nuclear type 17, 619061 (3),
apopain		
APOPT1	AR	mitochondrial complex iv deficiency, nuclear type 17, 619061 (3),
APP	AD	cerebral amyloid angiopathy, dutch, italian, iowa, flemish, arctic variants, 605714 (3), ; alzheimer disease 1, familial, 104300 (3),
APP-1		
APP-BP1	AR	neurodevelopmental disorder with dysmorphic facies and ischiopubic hypoplasia, 620210 (3),
APP3	AR	nephronophthisis-like nephropathy 1, 613159 (3),
APPBP1	AR	neurodevelopmental disorder with dysmorphic facies and ischiopubic hypoplasia, 620210 (3),
APPBP2		
APPD		
APPH		
APPL	AD	{maturity-onset diabetes of the young, type 14}, 616511 (3),
APPL1	AD	{maturity-onset diabetes of the young, type 14}, 616511 (3),
APPL2		
APQ		
APR	AR	?keratosis pilaris atrophicans, 604093 (3),
APR-5		
APR1		
APR3		
APRF	AD	hyper-ige recurrent infection syndrome, 147060 (3), ; autoimmune disease, multisystem, infantile-onset, 1, 615952 (3),
APRG1		
APRIL		
APRIN		
APRO1		
APRO2		
APRO3	AR	oocyte/zygote/embryo maturation arrest 8, 619009 (3),
APRO4		
APRO5		
APRT	AR	adenine phosphoribosyltransferase deficiency, 614723 (3),
APS		
APS1	AR,AD	autoimmune polyendocrinopathy syndrome , type i, with or without reversible metaphyseal dysplasia, 240300 (3),
APT-1		
APT-2		
APT-B7		
APT1	AD	squamous cell carcinoma, burn scar-related, somatic (3); autoimmune lymphoproliferative syndrome, type ia, 601859 (3), ; {autoimmune lymphoproliferative syndrome}, 601859 (3),
APT1LG1	AD	autoimmune lymphoproliferative syndrome, type ib, 601859 (3), ; {lung cancer, susceptibility to}, 211980 (3), somatic mutation,
APT6M8-9	XL,XLR	intellectual developmental disorder, syndromic, hedera type, 300423 (3), ; ?parkinsonism with spasticity, 300911 (3), ; congenital disorder of glycosylation, type iir, 301045 (3),
APTR		
APTX	AR	ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia, 208920 (3),
APX		
APXL		
APXL2		
APXL3		
APY	AD	{atopy, susceptibility to}, 147050 (3),
AQDQ	AR	mitochondrial complex i deficiency, nuclear type 1, 252010 (3),
AQL1		
AQP-4		
AQP0	AD	cataract 15, multiple types, 615274 (3),
AQP1		[aquaporin-1 deficiency], 110450 (3); [blood group, colton], 110450 (3)
AQP10		
AQP11		
AQP12		
AQP12A		
AQP2	AR,AD	diabetes insipidus, nephrogenic, 2, 125800 (3),
AQP2L		
AQP3		[blood group gil], 607457 (3)
AQP4		
AQP5	AD	palmoplantar keratoderma, bothnian type, 600231 (3),
AQP6		
AQP7	AR	[glycerol quantitative trait locus], 614411 (3),
AQP7L	AR	[glycerol quantitative trait locus], 614411 (3),
AQP8		
AQP9	AR	[glycerol quantitative trait locus], 614411 (3),
AQPap	AR	[glycerol quantitative trait locus], 614411 (3),
AQPEP		
AQPX1		
AQR		
AR	XLR,AD,XL	androgen insensitivity, partial, with or without breast cancer, 312300 (3), ; {prostate cancer, susceptibility to}, 176807 (3), somatic mutation, ; androgen insensitivity, 300068 (3), ; spinal and bulbar muscular atrophy of kennedy, 313200 (3), ; hypospadias 1, 300633 (3),
AR-JP	AR	adenocarcinoma of lung, somatic, 211980 (3); parkinson disease, juvenile, type 2, 600116 (3), ; ovarian cancer, somatic, 167000 (3)
AR1	AD	developmental delay with variable intellectual impairment and behavioral abnormalities, 618430 (3),
AR7	AD	hypothyroidism, congenital, nongoitrous, 6, 614450 (3),
ARA	AD,AR,AD	axenfeld-rieger syndrome, type 3, 602482 (3), ; anterior segment dysgenesis 3, multiple subtypes, 601631 (3), |pseudoxanthoma elasticum, 264800 (3), ; arterial calcification, generalized, of infancy, 2, 614473 (3), ; pseudoxanthoma elasticum, forme fruste, 177850 (3),
Ara1		
ARA160		
ARA24		
ARA267	AD	sotos syndrome, 117550 (3),
ARA3	AD	immunodeficiency 70, 618969 (3),
ARA54		
ARA55		
ARA70		
ARA9	AD	pituitary adenoma 1, multiple types, 102200 (3), somatic mutation, ; pituitary adenoma predisposition, 102200 (3), somatic mutation,
ARAF		
ARAF1		
Aralar	AR	developmental and epileptic encephalopathy 39, 612949 (3),
aralar1	AR	developmental and epileptic encephalopathy 39, 612949 (3),
ARALAR2	AR	citrullinemia, type ii, neonatal-onset, 605814 (3), ; citrullinemia, adult-onset type ii, 603471 (3),
ARAP		
ARAP1		
ARAP2		
ARAP3		
ARC	AD	?myoclonus, familial, 1, 614937 (3),
Arc105		
ARC16		
ARC20	AD	developmental delay, language impairment, and ocular abnormalities, 620141 (3),
ARC21		
ARC240	XLR,XL,XLD	lujan-fryns syndrome, 309520 (3), ; ohdo syndrome, 300895 (3), ; hardikar syndrome, 301068 (3), ; opitz-kaveggia syndrome, 305450 (3),
ARC32		
ARC34		
Arc40		
ARC41	AR	immunodeficiency 71 with inflammatory disease and congenital thrombocytopenia, 617718 (3),
ARC92	AR	basel-vanagait-smirin-yosef syndrome, 616449 (3),
ARCA1	AR,AD	arthrogryposis multiplex congenita 3, myogenic type, 618484 (3), ; emery-dreifuss muscular dystrophy 4, 612998 (3), ; spinocerebellar ataxia, 8, 610743 (3),
ARCADLIN		
ARCD1		
ARCH		
ARCN1	AD	short stature-micrognathia syndrome, 617164 (3),
Arcp		
ARD		
ard-1		
ARD1	XL,XLD,XLR	microphthalmia, syndromic 1, 309800 (3), ; ogden syndrome, 300855 (3),
ARD1A	XL,XLD,XLR	microphthalmia, syndromic 1, 309800 (3), ; ogden syndrome, 300855 (3),
ARD1B		
ARD2		
ARDC2		
ARDC4		
ARE1		
AREB6	AD	corneal dystrophy, posterior polymorphous, 3, 609141 (3), ; corneal dystrophy, fuchs endothelial, 6, 613270 (3),
AREBP		
AREC3		
AREG		
AREGB		
AREL1		
ARF	AD	{melanoma and neural system tumor syndrome}, 155755 (3), ; {melanoma, cutaneous malignant, 2}, 155601 (3), ; {melanoma-pancreatic cancer syndrome}, 606719 (3),
ARF-GEP100	AR	intellectual developmental disorder with short stature and behavioral abnormalities, 618687 (3),
ARF1	AD	periventricular nodular heterotopia 8, 618185 (3),
ARF1GAP		
ARF1GEF	AD	charcot-marie-tooth disease, axonal, type 2gg, 606483 (3),
ARF2		
ARF3		
ARF4		
ARF4L		
ARF5		
ARF6		
ARF7		
ARF7EP		
ARFD1		
ARFGAP1		
ARFGAP2		
ARFGAP3		
ARFGEF1	AD	developmental delay, impaired speech, and behavioral abnormalities, with or without seizures, 619964 (3),
ARFGEF2	AR	periventricular heterotopia with microcephaly, 608097 (3),
ARFGEF3		
ARFGEP1	AD	developmental delay, impaired speech, and behavioral abnormalities, with or without seizures, 619964 (3),
ARFIP1		
ARFIP2		
ARFL1		
ARFL2	AD	?microcornea, rod-cone dystrophy, cataract, and posterior staphyloma 1, 619082 (3),
ARFL3	AD,AR	retinitis pigmentosa 83, 618173 (3), ; joubert syndrome 35, 618161 (3),
ARFRP1		
ARG	AD	neurodevelopmental disorder with or without anomalies of the brain, eye, or heart, 616975 (3),
ARG1	AR	argininemia, 207800 (3),
ARG134		
ARG147		
ARG2		
Arg3.1		
ARG99		
ARGA	AR	n-acetylglutamate synthase deficiency, 237310 (3),
ARGBP2		
argBPIA		
ARGEF15		
ARGFX		
ARGLU1		
ARGP1	AR	diarrhea 7, protein-losing enteropathy type, 615863 (3),
ARH	AR	hypercholesterolemia, familial, 4, 603813 (3),
ARH1		
ARH12		ectodermal dysplasia with facial dysmorphism and acral, ocular, and brain anomalies, somatic mosaic, 618727 (3)
ARH2	AR	hypercholesterolemia, familial, 4, 603813 (3),
ARH3	AR	neurodegeneration, childhood-onset, stress-induced, with variable ataxia and seizures, 618170 (3),
ARH6		
ARH9		
ARHA		ectodermal dysplasia with facial dysmorphism and acral, ocular, and brain anomalies, somatic mosaic, 618727 (3)
ARHB		
ARHC		
ARHCL1		
ARHD		
ARHE		
ARHF		
ARHG		
ARHGAP1		
ARHGAP10		
ARHGAP11A		
ARHGAP11B		
ARHGAP12		
ARHGAP13	AD	{thyroid cancer, nonmedullary, 2}, 188470 (3), somatic mutation,
ARHGAP14		
ARHGAP15		
ARHGAP17		
ARHGAP18		
ARHGAP19		
ARHGAP2	AD	duane retraction syndrome 2, 604356 (3),
ARHGAP20		
ARHGAP21		
ARHGAP22		
ARHGAP23		
ARHGAP24		
ARHGAP25		
ARHGAP26		leukemia, juvenile myelomonocytic, somatic, 607785 (3)
ARHGAP27		
ARHGAP28		
ARHGAP29		
ARHGAP3		
ARHGAP30		
ARHGAP31	AD	adams-oliver syndrome 1, 100300 (3),
ARHGAP32		
ARHGAP33		
ARHGAP34		
ARHGAP35		
ARHGAP36		
ARHGAP37		
ARHGAP38		
ARHGAP39		
ARHGAP4		
ARHGAP41	XL,XLR	intellectual developmental disorder, syndromic, billuart type, 300486 (3),
ARHGAP42		
ARHGAP43		
ARHGAP44		
ARHGAP45		
ARHGAP46		
ARHGAP47		
ARHGAP48		
ARHGAP49		
ARHGAP5		
ARHGAP6		
ARHGAP7		colorectal cancer, somatic, 114500 (3)
ARHGAP8		
ARHGAP9		
ARHGDIA	AR	nephrotic syndrome, type 8, 615244 (3),
ARHGDIB		
ARHGDIG		
ARHGEF1	AR	?immunodeficiency 62, 618459 (3),
ARHGEF10	AD	?slowed nerve conduction velocity, ad, 608236 (3),
ARHGEF10L		
ARHGEF11		
ARHGEF12		
ARHGEF13		
ARHGEF14		
ARHGEF15		
ARHGEF16		
ARHGEF17		
ARHGEF18	AR	retinitis pigmentosa 78, 617433 (3),
ARHGEF19		
ARHGEF2	AR	?neurodevelopmental disorder with midbrain and hindbrain malformations, 617523 (3),
ARHGEF21		
ARHGEF22		
ARHGEF23	AD	intellectual developmental disorder, 44, with microcephaly, 617061 (3), ; intellectual developmental disorder, 63, with macrocephaly, 618825 (3),
ARHGEF24		
ARHGEF25		
ARHGEF26		
ARHGEF27		
ARHGEF28		
ARHGEF29		
ARHGEF3		
ARHGEF30	AR	{rhabdomyolysis, susceptibility to, 1}, 620235 (3),
ARHGEF31		
ARHGEF36	AR	cataract 48, 618415 (3),
ARHGEF38		
ARHGEF4		
ARHGEF40		
ARHGEF41		
ARHGEF42	AR	leukodystrophy and acquired microcephaly with or without dystonia, 616763 (3),
ARHGEF43		
ARHGEF44		
ARHGEF45	AR	spinal muscular atrophy, distal, 4, 611067 (3), ; charcot-marie-tooth disease, intermediate c, 615376 (3),
ARHGEF46		
ARHGEF5		
ARHGEF6		
ARHGEF7		
ARHGEF8		
ARHGEF9	XL	developmental and epileptic encephalopathy 8, 300607 (3),
ARHH	AR	{?epidermodysplasia verruciformis, susceptibility to, 4}, 618307 (3),
ARHI		
ARHJ		
ARHN		
ARHQ		
ARHS		
ARHT1		
ARHT2		
ARHU		
ARHV		
ARI		
ARIA		
ARID1A	AD	coffin-siris syndrome 2, 614607 (3),
ARID1B	AD	coffin-siris syndrome 1, 135900 (3),
ARID2	AD	coffin-siris syndrome 6, 617808 (3),
ARID3A		
ARID3B		
ARID4A		
ARID4B		
ARID5A		
ARID5B		
ARIH1		
ARIH2		
ARIP1	AR	nephrotic syndrome, type 15, 617609 (3),
Arip2		
ARIP3		
ARIP4		
ARIX	AR	fibrosis of extraocular muscles, congenital, 2, 602078 (3),
ARK		
ARK1	AD	{colon cancer, susceptibility to}, 114500 (3), somatic mutation,
ARK2		
ARK3	AR	spermatogenic failure 5, 243060 (3),
ARK5		
Arkadia		
ARL-1		
ARL1		
ARL10B		
ARL10C		
ARL11		
ARL13B	AR	joubert syndrome 8, 612291 (3),
ARL14		
ARL14EP		
ARL16		
ARL18		
ARL2	AD	?microcornea, rod-cone dystrophy, cataract, and posterior staphyloma 1, 619082 (3),
ARL2BP	AR	retinitis pigmentosa with or without situs inversus, 615434 (3),
ARL2L1	AR	joubert syndrome 8, 612291 (3),
ARL3	AD,AR	retinitis pigmentosa 83, 618173 (3), ; joubert syndrome 35, 618161 (3),
ARL4		
ARL4A		
ARL4C		
ARL4D		
ARL5		
ARL5A		
ARL5B		
ARL5B-AS1		
ARL6	AR	retinitis pigmentosa 55, 613575 (3), ; {bardet-biedl syndrome 1, modifier of}, 209900 (3), digenic ; bardet-biedl syndrome 3, 600151 (3),
ARL6IP	AR	?spastic paraplegia 61, 615685 (3),
ARL6IP1	AR	?spastic paraplegia 61, 615685 (3),
ARL6IP2		
ARL6IP4		
ARL6IP5		
ARL6IP6		
ARL7		
ARL8		
ARL8A		
ARL8B		
ARL9		
ARLNC1		
ARLTS1		
ARM	AR	joubert syndrome 30, 617622 (3),
ARM1		
ARM2		
armadillo	AD	exudative vitreoretinopathy 7, 617572 (3), ; pilomatricoma, somatic, 132600 (3); colorectal cancer, somatic, 114500 (3); neurodevelopmental disorder with spastic diplegia and visual defects, 615075 (3), ; medulloblastoma, somatic, 155255 (3); ovarian cancer, somatic, 167000 (3); hepatocellular carcinoma, somatic, 114550 (3)
ARMC1		
ARMC10		
ARMC12		
ARMC13		
ARMC2	AR	spermatogenic failure 38, 618433 (3),
ARMC3		
ARMC4	AR	ciliary dyskinesia, primary, 23, 615451 (3),
ARMC5	AD	acth-independent macronodular adrenal hyperplasia 2, 615954 (3), somatic mutation,
ARMC8		
ARMC9	AR	joubert syndrome 30, 617622 (3),
ARMCX1		
ARMCX2		
ARMCX3		
ARMCX4		
ARMCX5		
ARMCX6		
ARMD1	AD	{macular degeneration, age-related, 1}, 603075 (3),
ARMD10		
ARMD2	AR,AD	retinal dystrophy, early-onset severe, 248200 (3), ; retinitis pigmentosa 19, 601718 (3), ; {macular degeneration, age-related, 2}, 153800 (3), ; cone-rod dystrophy 3, 604116 (3), ; fundus flavimaculatus, 248200 (3), ; stargardt disease 1, 248200 (3),
ARMD3	AR,AD	cutis laxa, type ia, 219100 (3), ; charcot-marie-tooth disease, demyelinating, type 1h, 619764 (3), ; macular degeneration, age-related, 3, 608895 (3), ; neuropathy, hereditary, with or without age-related macular degeneration, 608895 (3), ; ?cutis laxa, 2, 614434 (3),
ARMD4	AD,AR	{macular degeneration, age-related, 4}, 610698 (3), ; basal laminar drusen, 126700 (3), ; complement factor h deficiency, 609814 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to, 1}, 235400 (3),
ARMD5	AR,AD	uv-sensitive syndrome 1, 600630 (3), ; cerebrooculofacioskeletal syndrome 1, 214150 (3), ; ?de sanctis-cacchione syndrome, 278800 (3), ; cockayne syndrome, type b, 133540 (3), ; {macular degeneration, age-related, susceptibility to, 5}, 613761 (3); premature ovarian failure 11, 616946 (3), ; {lung cancer, susceptibility to}, 211980 (3), somatic mutation,
ARMD6	AR,AD	retinitis pigmentosa 95, 620102 (3), ; cone-rod dystrophy 11, 610381 (3), ; ?macular degeneration, age-related, 6, 613757 (3)
ARMD7	AR,AD	{macular degeneration, age-related, neovascular type}, 610149 (3); {macular degeneration, age-related, 7}, 610149 (3); carasil syndrome, 600142 (3), ; cerebral arteriopathy, with subcortical infarcts and leukoencephalopathy, type 2, 616779 (3),
ARMD8		{macular degeneration, age-related, 8}, 613778 (3)
ARMD9	AR,AD	c3 deficiency, 613779 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to, 5}, 612925 (3), ; {macular degeneration, age-related, 9}, 611378 (3)
ARMER	AR	?spastic paraplegia 61, 615685 (3),
ARMET		
ARMETL1		
ARMS	AD,AR	spastic paraplegia, intellectual disability, nystagmus, and obesity, 617296 (3), ; ventriculomegaly and arthrogryposis, 619501 (3),
ARMS1	AD,AR	{macular degeneration, age-related, 4}, 610698 (3), ; basal laminar drusen, 126700 (3), ; complement factor h deficiency, 609814 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to, 1}, 235400 (3),
ARMS2		{macular degeneration, age-related, 8}, 613778 (3)
ARMT1		
Armus		
ARNIP		
ARNO		
ARNO3		
ARNT		
ARNT1		
ARNT2	AR	?webb-dattani syndrome, 615926 (3),
ARNTL		
ARNTL1		
ARNTL2		
ARO	AD	aromatase deficiency, 613546 (3); aromatase excess syndrome, 139300 (3),
ARO1	AD	aromatase deficiency, 613546 (3); aromatase excess syndrome, 139300 (3),
aromatase	AD	aromatase deficiency, 613546 (3); aromatase excess syndrome, 139300 (3),
ARP	AD	neurodevelopmental disorder with or without anomalies of the brain, eye, or heart, 616975 (3),
Arp-T1		
Arp-T2		
Arp1		
ARP1	AD,AD	46xx sex reversal 5, 618901 (3), ; congenital heart defects, multiple types, 4, 615779 (3), |ring dermoid of cornea, 180550 (3), ; axenfeld-rieger syndrome, type 1, 180500 (3), ; anterior segment dysgenesis 4, 137600 (3),
Arp10		
ARP10		
Arp11		
Arp1A		
Arp1B		
ARP2	AR	immunodeficiency with hyper-igm, type 2, 605258 (3),
ARP3		
Arp4		
ARP4	AD	plasma triglyceride level qtl, low, 615881 (3),
Arp5		
ARP5		
ARP6		
ARP8		
ARPC1A		
ARPC1B	AR	immunodeficiency 71 with inflammatory disease and congenital thrombocytopenia, 617718 (3),
ARPC2		
ARPC3		
ARPC4	AD	developmental delay, language impairment, and ocular abnormalities, 620141 (3),
ARPC5		
ArPIKfyve	AR	striatonigral degeneration, childhood-onset, 617054 (3),
ARPIN		
ARPKD	AR	polycystic kidney disease 4, with or without hepatic disease, 263200 (3),
ARPM1		
ARPM2		
ARPP		
ARPP-16		
ARPP-19		
ARPP-19e		
ARPP-21		
ARPP16		
ARPP19		
ARPP21		
ARR1		
ARR2		
ARR3	XL	myopia 26, female-limited, 301010 (3),
ARRB1		
ARRB2		
ARRDC1		
ARRDC3		
ARRDC4		
ARRDC6		
ARRESTIN	AR,AD	retinitis pigmentosa 47, 613758 (3), ; retinitis pigmentosa 96, 620228 (3), ; oguchi disease-1, 258100 (3),
ARRS1		
ARRS2		
ARRX	XL	myopia 26, female-limited, 301010 (3),
ARS	AR	meleda disease, 248300 (3),
ARS2		
ARSA	AR	metachromatic leukodystrophy, 250100 (3),
ARSA-I	AR	?cardiomyopathy, dilated, 2h, 620203 (3),
ARSACS	AR	spastic ataxia, charlevoix-saguenay type, 270550 (3),
ArsB	AR	meleda disease, 248300 (3),
ARSB	AR	mucopolysaccharidosis type vi (maroteaux-lamy), 253200 (3),
ARSC	XL,XLR	ichthyosis, 308100 (3),
ARSC1	XL,XLR	ichthyosis, 308100 (3),
ARSC2		
ARSD		
ARSDR1	AR	?retinal dystrophy, juvenile cataracts, and short stature syndrome, 616108 (3),
ARSE	XLR,XL	chondrodysplasia punctata, 302950 (3),
ARSF		
ARSG	AR	usher syndrome, type iv, 618144 (3),
ARSH		
ARSI		
ARSJ		
ARSK	AR	mucopolysaccharidosis, type x, 619698 (3),
ARSL	XLR,XL	chondrodysplasia punctata, 302950 (3),
ART	AR,MF,AD	{leanness, inherited}, 601665 (3), , ; {obesity, late-onset}, 601665 (3), ,
ART-27		
ART-4		
ART1		
ART2		
ART3		
ART4		[blood group, dombrock], 616060 (3)
ART5		
ARTC1		
ARTC3		
ARTC4		[blood group, dombrock], 616060 (3)
ARTC5		
ARTD1		
ARTD10		
ARTD11		
ARTD12		
ARTD13		
ARTD14		
ARTD15		
ARTD17		
ARTD2		
ARTD3		
ARTD4		
ARTD5		
ARTD6		
ARTD7		
ARTD8		
ARTD9		
ARTEMIS	AR	severe combined immunodeficiency, athabascan type, 602450 (3), ; omenn syndrome, 603554 (3),
ARTN		
ARTS		
ARTS-1		
ARV1	AR	developmental and epileptic encephalopathy 38, 617020 (3),
ARVC2	AD	ventricular tachycardia, catecholaminergic polymorphic, 1, 604772 (3), ; ventricular arrhythmias due to cardiac ryanodine receptor calcium release deficiency syndrome, 115000 (3),
ARVCF		
ARVD	AD	arrhythmogenic right ventricular dysplasia 1, 107970 (3), ; loeys-dietz syndrome 5, 615582 (3),
ARVD1	AD	arrhythmogenic right ventricular dysplasia 1, 107970 (3), ; loeys-dietz syndrome 5, 615582 (3),
ARVD2	AD	ventricular tachycardia, catecholaminergic polymorphic, 1, 604772 (3), ; ventricular arrhythmias due to cardiac ryanodine receptor calcium release deficiency syndrome, 115000 (3),
ARVD5	AD	arrhythmogenic right ventricular dysplasia 5, 604400 (3), ; auditory neuropathy, 3, 619832 (3), ; emery-dreifuss muscular dystrophy 7, ad, 614302 (3),
ARVP	AD	diabetes insipidus, neurohypophyseal, 125700 (3),
ARX	XL,XLR	proud syndrome, 300004 (3), ; hydranencephaly with abnormal genitalia, 300215 (3), ; partington syndrome, 309510 (3), ; developmental and epileptic encephalopathy 1, 308350 (3), ; lissencephaly, 2, 300215 (3), ; intellectual developmental disorder, 29, 300419 (3),
AS	MF,AD	{synovitis, chronic, susceptibility to} (3); {abacavir hypersensitivity, susceptibility to} (3); {spondyloarthropathy, susceptibility to, 1}, 106300 (3), ; {stevens-johnson syndrome, susceptibility to}, 608579 (3); {drug-induced liver injury due to flucloxacillin} (3); {toxic epidermal necrolysis, susceptibility to}, 608579 (3)|angelman syndrome, 105830 (3),
AS160		{diabetes mellitus, noninsulin-dependent, 5}, 616087 (3)
AS1DHRS4		
AS250		
AS3		
AS3MT		
ASA	AR	metachromatic leukodystrophy, 250100 (3),
ASAH	AR	spinal muscular atrophy with progressive myoclonic epilepsy, 159950 (3), ; farber lipogranulomatosis, 228000 (3),
ASAH1	AR	spinal muscular atrophy with progressive myoclonic epilepsy, 159950 (3), ; farber lipogranulomatosis, 228000 (3),
ASAH2		
ASAH2B		
ASAH2C		
ASAH2L		
ASAH3		
ASAH3L		
ASAHL		
ASAL	AR	argininosuccinic aciduria, 207900 (3),
ASAM	AR	congenital short bowel syndrome, 615237 (3),
ASAP		
ASAP1		
ASAP2		
ASAP3		
ASAT	XLR,XL	anemia, sideroblastic, with ataxia, 301310 (3),
ASB	XLR,XL,AR	anemia, sideroblastic, 1, 300751 (3), ; protoporphyria, erythropoietic, 300752 (3), |mucopolysaccharidosis type vi (maroteaux-lamy), 253200 (3),
ASB-1		
ASB-2		
ASB-3		
ASB-4		
ASB1		
ASB10	AD	glaucoma 1, open angle, f, 603383 (3),
ASB11		
ASB12		
ASB13		
ASB15		
ASB16		
ASB17		
ASB2		
ASB3		
ASB4		
ASB5		
ASB6		
ASB7		
ASB8		
ASB9		
ASBABP1		
ASBABP2		
ASBT	AR	?bile acid malabsorption, primary, 1, 613291 (3),
ASC		
asc-1		
ASC-1	AR	?muscular dystrophy, congenital, davignon-chauveau type, 617066 (3), ; spinal muscular atrophy with congenital bone fractures 1, 616866 (3),
ASC1p100		
ASC1p200		
ASC1p50	AR	spinal muscular atrophy with congenital bone fractures 2, 616867 (3), ; barrett esophagus/esophageal adenocarcinoma, 614266 (3)
ASC2		
ASCC1	AR	spinal muscular atrophy with congenital bone fractures 2, 616867 (3), ; barrett esophagus/esophageal adenocarcinoma, 614266 (3)
ASCC2		
ASCC3		
ASCC3L1	AD	retinitis pigmentosa 33, 610359 (3),
ASCIZ		
ASCL1		
ASCL2		
ASCL3		
ASCL4		
ASCT-1	AR	spastic tetraplegia, thin corpus callosum, and progressive microcephaly, 616657 (3),
ASCT1	AR	spastic tetraplegia, thin corpus callosum, and progressive microcephaly, 616657 (3),
ASCT2		
ASD		
ASDURF		
ASE-1		
ASE1		
ASEF		
ASEF1		
ASEF2		
ASF		
ASF1A		
ASF1B		
ASFMR1		
ASGR1		
ASGR2		
ASH1	AD	intellectual developmental disorder, 52, 617796 (3),
ASH1L	AD	intellectual developmental disorder, 52, 617796 (3),
ASH1L1	AD	intellectual developmental disorder, 52, 617796 (3),
ASH2		
ASH2L		
ASH2L1		
ASH2L2		
ASHI	AR	mitochondrial complex i deficiency, nuclear type 32, 618252 (3),
ASIC1		
ASIC2		
ASIC2a		
ASIC3		
ASIC4		
ASIC5		
ASIP		[skin/hair/eye pigmentation 9, brown/nonbrown eyes], 611742 (3); [skin/hair/eye pigmentation 9, dark/light hair], 611742 (3)
ASIP2	AR,MF,AD	{leanness, inherited}, 601665 (3), , ; {obesity, late-onset}, 601665 (3), ,
ASK		
ASK1		
ASK2		
ASK3		
ASKL1		
ASL	AR	argininosuccinic aciduria, 207900 (3),
ASLN	XL,XLD	alport syndrome 1, 301050 (3),
ASM	AR	niemann-pick disease, type b, 607616 (3), ; niemann-pick disease, type a, 257200 (3),
ASM1		
ASM3A		
ASMD	AR,AD	cataract 11, multiple types, 610623 (3), ; anterior segment dysgenesis 1, multiple subtypes, 107250 (3), ; cataract 11, syndromic, 610623 (3),
ASML3a		
ASML3B		
ASMT		
ASMTL		
ASMTY		
ASNA1	AR	?cardiomyopathy, dilated, 2h, 620203 (3),
AsnRS	AD,AR	neurodevelopmental disorder with microcephaly, impaired language, epilepsy, and gait abnormalities, 619092 (3), ; neurodevelopmental disorder with microcephaly, impaired language, and gait abnormalities, 619091 (3),
ASNS	AR	asparagine synthetase deficiency, 615574 (3),
ASNSD1		
ASOR		
ASP	AR,AR,AR	?spinocerebellar ataxia, 25, 617584 (3), |[skin/hair/eye pigmentation 9, brown/nonbrown eyes], 611742 (3); [skin/hair/eye pigmentation 9, dark/light hair], 611742 (3)|canavan disease, 271900 (3), |microcephaly 5, primary, 608716 (3),
ASPA	AR	canavan disease, 271900 (3),
ASPEP		
ASPG		
ASPGX1	XL	{autism susceptibility, 1}, 300425 (3),
ASPH	AR	traboulsi syndrome, 601552 (3),
ASPIC1		
ASPL		alveolar soft-part sarcoma, 606243 (3)
ASPM	AR	microcephaly 5, primary, 608716 (3),
ASPN	AD	{lumbar disc degeneration}, 603932 (3); {osteoarthritis susceptibility 3}, 607850 (3),
ASPP1		
ASPP2		
ASPRV1	AD	ichthyosis, lamellar, 146750 (3),
ASPS		alveolar soft-part sarcoma, 606243 (3)
ASPSCR1		alveolar soft-part sarcoma, 606243 (3)
asr1		
Asr2		
ASRG	AR	aspartylglucosaminuria, 208400 (3),
ASRGL1		
Asrij		
ASS	AR	citrullinemia, 215700 (3),
ASS1	AR	citrullinemia, 215700 (3),
AST	AR	aspartate aminotransferase, serum level of, qtl1, 614419 (3)|salla disease, 604369 (3), ; sialic acid storage disorder, infantile, 269920 (3),
AST1		aspartate aminotransferase, serum level of, qtl1, 614419 (3)
Asterix		
ASTL	AR	?oocyte/zygote/embryo maturation arrest 11, 619643 (3),
ASTN		
ASTN1		
ASTN2		
AsTP2		
ASUN		
ASV	AD	?thrombocytopenia 6, 616937 (3), ; colon cancer, advanced, somatic, 114500 (3)
ASXH2	AD	shashi-pena syndrome, 617190 (3),
ASXL1	AD	myelodysplastic syndrome, somatic, 614286 (3); bohring-opitz syndrome, 605039 (3),
ASXL2	AD	shashi-pena syndrome, 617190 (3),
ASXL3	AD	bainbridge-ropers syndrome, 615485 (3),
ASY		
ASYIP		
ASZ1		
AT-1	AD,AR	spastic paraplegia 42, 612539 (3), ; congenital cataracts, hearing loss, and neurodegeneration, 614482 (3),
AT-V1	AR	leukemia, acute lymphoblastic, 613065 (3); aplastic anemia, 609135 (3); nijmegen breakage syndrome, 251260 (3),
AT-V2	AR	leukemia, acute lymphoblastic, 613065 (3); aplastic anemia, 609135 (3); nijmegen breakage syndrome, 251260 (3),
AT1	MF,AR,AD,AR	{hypertension, essential}, 145500 (3), ; renal tubular dysgenesis, 267430 (3), |spastic paraplegia 42, 612539 (3), ; congenital cataracts, hearing loss, and neurodegeneration, 614482 (3),
AT1B	MF,AR	{hypertension, essential}, 145500 (3), ; renal tubular dysgenesis, 267430 (3),
AT2		
AT225		
AT2R1	MF,AR	{hypertension, essential}, 145500 (3), ; renal tubular dysgenesis, 267430 (3),
AT2R1A	MF,AR	{hypertension, essential}, 145500 (3), ; renal tubular dysgenesis, 267430 (3),
AT2R1B	MF,AR	{hypertension, essential}, 145500 (3), ; renal tubular dysgenesis, 267430 (3),
AT3	AR,AD	thrombophilia 7 due to antithrombin iii deficiency, 613118 (3),
AT744.1		
AT744.2		
ATA	AR,AD	lymphoma, b-cell non-hodgkin, somatic (3); ataxia-telangiectasia, 208900 (3), ; {breast cancer, susceptibility to}, 114480 (3), somatic mutation, ; t-cell prolymphocytic leukemia, somatic (3); lymphoma, mantle cell, somatic (3)
ATA1		
ATA2		
ATA3		
ATAC		
ATAC1		
ATAC2		
ATAD1	AR	hyperekplexia 4, 618011 (3),
ATAD2		
ATAD2B		
ATAD3A	AR,AD	harel-yoon syndrome, 617183 (3), ; pontocerebellar hypoplasia, hypotonia, and respiratory insufficiency syndrome, neonatal lethal, 618810 (3),
ATAD3B		
ATAD3C		
ATAD5		
ATAR		
ATase2		
ATAT1		
ATBF1		prostate cancer, somatic, 176807 (3)
ATBP		
ATC	AR,AD	lymphoma, b-cell non-hodgkin, somatic (3); ataxia-telangiectasia, 208900 (3), ; {breast cancer, susceptibility to}, 114480 (3), somatic mutation, ; t-cell prolymphocytic leukemia, somatic (3); lymphoma, mantle cell, somatic (3)
ATC2		preeclampsia/eclampsia 5, 614595 (3)
ATCAY	AR	ataxia, cerebellar, cayman type, 601238 (3),
ATCE1		
ATD	AR,AD	lymphoma, b-cell non-hodgkin, somatic (3); ataxia-telangiectasia, 208900 (3), ; {breast cancer, susceptibility to}, 114480 (3), somatic mutation, ; t-cell prolymphocytic leukemia, somatic (3); lymphoma, mantle cell, somatic (3)
ATDC	AR,AD	lymphoma, b-cell non-hodgkin, somatic (3); ataxia-telangiectasia, 208900 (3), ; {breast cancer, susceptibility to}, 114480 (3), somatic mutation, ; t-cell prolymphocytic leukemia, somatic (3); lymphoma, mantle cell, somatic (3)
ATE1		
ATF1	AD	{hirschsprung disease, susceptibility to, 3}, 613711 (3),
ATF2	AD	{hirschsprung disease, susceptibility to, 3}, 613711 (3),
ATF3		
ATF4		
ATF5		
ATF6	AR	achromatopsia 7, 616517 (3),
ATF6A	AR	achromatopsia 7, 616517 (3),
ATF6B		
ATF7		
ATF7IP		
ATF7IP1		
ATF7IP2		
ATFA		
ATG1		
ATG10		
ATG101		
ATG12		
ATG13		
ATG14		
ATG14L		
ATG16A		{inflammatory bowel disease (crohn disease) 10}, 611081 (3)
ATG16B		
ATG16L		{inflammatory bowel disease (crohn disease) 10}, 611081 (3)
ATG16L1		{inflammatory bowel disease (crohn disease) 10}, 611081 (3)
ATG16L2		
ATG17		breast cancer, somatic, 114480 (3)
ATG18		
ATG18A		
ATG18B	AR	?intellectual developmental disorder with short stature and variable skeletal anomalies, 618453 (3),
ATG1A		
ATG1B		
ATG21	AR	?intellectual developmental disorder with short stature and variable skeletal anomalies, 618453 (3),
ATG24B		
ATG2A		
ATG2B		
ATG3		
ATG4A		
ATG4B		
ATG4C		
ATG4D		
ATG5	AR	?spinocerebellar ataxia, 25, 617584 (3),
ATG6		
ATG7	AR	spinocerebellar ataxia, 31, 619422 (3),
ATG8		
ATG8A		
ATG8B		
ATG8C		
ATG8E		
ATG8F		
ATG8J		
ATG8L		
ATG9A		
ATG9B		
ATGL	AR	neutral lipid storage disease with myopathy, 610717 (3),
ATH-3		
ATHL1		
ATIC	AR	aica-ribosiduria due to atic deficiency, 608688 (3),
ATIII	AR,AD	thrombophilia 7 due to antithrombin iii deficiency, 613118 (3),
ATIP1		
ATIP3		
ATK	XL,XLR	agammaglobulinemia, 1, 300755 (3), ; isolated growth hormone deficiency, type iii, with agammaglobulinemia, 307200 (3),
ATL1	AD	spastic paraplegia 3a, 182600 (3), ; neuropathy, hereditary sensory, type id, 613708 (3),
ATL2		
ATL3	AD	neuropathy, hereditary sensory, type if, 615632 (3),
atlastin2		
ATLD	AR	ataxia-telangiectasia-like disorder 1, 604391 (3),
ATM	AR,AD	lymphoma, b-cell non-hodgkin, somatic (3); ataxia-telangiectasia, 208900 (3), ; {breast cancer, susceptibility to}, 114480 (3), somatic mutation, ; t-cell prolymphocytic leukemia, somatic (3); lymphoma, mantle cell, somatic (3)
Atm1p	XLR,XL	anemia, sideroblastic, with ataxia, 301310 (3),
ATMIN		
ATN1	AD	dentatorubral-pallidoluysian atrophy, 125370 (3), ; congenital hypotonia, epilepsy, developmental delay, and digital anomalies, 618494 (3),
ATN1L	AD	neurodevelopmental disorder with or without anomalies of the brain, eye, or heart, 616975 (3),
ATN2	AD	neurodevelopmental disorder with or without anomalies of the brain, eye, or heart, 616975 (3),
ATOH1	AD	?deafness, 89, 620284 (3),
Atoh2		
Atoh3		
Atoh4		
Atoh5	AR	diarrhea 4, malabsorptive, congenital, 610370 (3),
ATOH7	AR	persistent hyperplastic primary vitreous, 221900 (3),
ATOH8		
ATOSA		
ATOSB		
ATOX1		
ATP-BL		
ATP10A		
ATP10B		
ATP10C		
ATP10D		
ATP11		
ATP11A	AD	?auditory neuropathy, 2, 620384 (3), ; ?leukodystrophy, hypomyelinating, 24, 619851 (3), ; deafness, 84, 619810 (3),
ATP11B		
ATP11C	XL,XLR	?hemolytic anemia, congenital, 301015 (3),
Atp11p		
ATP12	AR	?mitochondrial complex v (atp synthase) deficiency, nuclear type 1, 604273 (3),
ATP12A		
Atp12p	AR	?mitochondrial complex v (atp synthase) deficiency, nuclear type 1, 604273 (3),
ATP13A		
ATP13A1		
ATP13A2	AR	spastic paraplegia 78, 617225 (3), ; kufor-rakeb syndrome, 606693 (3),
ATP13A3	AR	pulmonary hypertension, primary, 5, 265400 (3),
ATP13A4		
ATP13A5		
ATP1A1	AD	hypomagnesemia, seizures, and impaired intellectual development 2, 618314 (3), ; charcot-marie-tooth disease, axonal, type 2dd, 618036 (3),
ATP1A1-AS1		
ATP1A1OS		
ATP1A2	AD,AR	developmental and epileptic encephalopathy 98, 619605 (3), ; fetal akinesia, respiratory insufficiency, microcephaly, polymicrogyria, and dysmorphic facies, 619602 (3), ; alternating hemiplegia of childhood 1, 104290 (3), ; migraine, familial basilar, 602481 (3), ; migraine, familial hemiplegic, 2, 602481 (3),
ATP1A3	AD	alternating hemiplegia of childhood 2, 614820 (3), ; dystonia-12, 128235 (3), ; capos syndrome, 601338 (3), ; developmental and epileptic encephalopathy 99, 619606 (3),
ATP1A4		
ATP1AL1		
ATP1AL2		
ATP1B	MF	[blood pressure regulation qtl], 145500 (2),
ATP1B1	MF	[blood pressure regulation qtl], 145500 (2),
ATP1B2		
ATP1B3		
ATP1B4		
ATP1G1	AD	hypomagnesemia 2, renal, 154020 (3),
ATP23		
ATP2A	AR	brody myopathy, 601003 (3),
ATP2A1	AR	brody myopathy, 601003 (3),
ATP2A2	AD	acrokeratosis verruciformis, 101900 (3), ; darier disease, 124200 (3),
ATP2A3		
ATP2B	AD	acrokeratosis verruciformis, 101900 (3), ; darier disease, 124200 (3),
ATP2B1	AD	intellectual developmental disorder, 66, 619910 (3),
ATP2B2	AD,AR	deafness, 82, 619804 (3), ; {deafness, 12, modifier of}, 601386 (3),
ATP2B3	XL,XLR	?spinocerebellar ataxia, 1, 302500 (3),
ATP2B4		
ATP2C1	AD	hailey-hailey disease, 169600 (3),
ATP2C1A	AD	hailey-hailey disease, 169600 (3),
ATP2C2		
ATP4A		
ATP4B		
ATP5		
ATP5A	AD,AR	mitochondrial complex v (atp synthase) deficiency, nuclear type 4a, 620358 (3), ; ?combined oxidative phosphorylation deficiency 22, 616045 (3), ; ?mitochondrial complex v (atp synthase) deficiency, nuclear type 4b, encephalopathic type, 615228 (3),
ATP5A1	AD,AR	mitochondrial complex v (atp synthase) deficiency, nuclear type 4a, 620358 (3), ; ?combined oxidative phosphorylation deficiency 22, 616045 (3), ; ?mitochondrial complex v (atp synthase) deficiency, nuclear type 4b, encephalopathic type, 615228 (3),
ATP5AL2	AD,AR	mitochondrial complex v (atp synthase) deficiency, nuclear type 4a, 620358 (3), ; ?combined oxidative phosphorylation deficiency 22, 616045 (3), ; ?mitochondrial complex v (atp synthase) deficiency, nuclear type 4b, encephalopathic type, 615228 (3),
ATP5B	AD	?hypermetabolism due to uncoupled mitochondrial oxidative phosphorylation 2, 620085 (3),
ATP5C		
ATP5C1		
ATP5CL1		
ATP5D	AR	mitochondrial complex v (atp synthase) deficiency, 618120 (3),
ATP5E	AR	mitochondrial complex v (atp synthase) deficiency, nuclear type 3, 614053 (3),
ATP5F1		
ATP5F1A	AD,AR	mitochondrial complex v (atp synthase) deficiency, nuclear type 4a, 620358 (3), ; ?combined oxidative phosphorylation deficiency 22, 616045 (3), ; ?mitochondrial complex v (atp synthase) deficiency, nuclear type 4b, encephalopathic type, 615228 (3),
ATP5F1B	AD	?hypermetabolism due to uncoupled mitochondrial oxidative phosphorylation 2, 620085 (3),
ATP5F1C		
ATP5F1D	AR	mitochondrial complex v (atp synthase) deficiency, 618120 (3),
ATP5F1E	AR	mitochondrial complex v (atp synthase) deficiency, nuclear type 3, 614053 (3),
ATP5G		
ATP5G1		
ATP5G2		
ATP5G3	AD	dystonia, early-onset, and/or spastic paraplegia, 619681 (3),
ATP5H		
ATP5I		
ATP5IF1		
ATP5J		
ATP5J2		
ATP5JD		
ATP5JG		
ATP5JL		
ATP5L		
ATP5MC1		
ATP5MC2		
ATP5MC3	AD	dystonia, early-onset, and/or spastic paraplegia, 619681 (3),
ATP5MD	AR	mitochondrial complex v (atp synthase) deficiency, nuclear type 6, 618683 (3),
ATP5ME		
ATP5MF		
ATP5MG		
ATP5MJ		
ATP5MK	AR	mitochondrial complex v (atp synthase) deficiency, nuclear type 6, 618683 (3),
ATP5MPL		
ATP5O	AR	mitochondrial complex v (atp synthase) deficiency, nuclear type 7, 620359 (3),
ATP5PB		
ATP5PD		
ATP5PF		
ATP5PO	AR	mitochondrial complex v (atp synthase) deficiency, nuclear type 7, 620359 (3),
ATP5S		
ATP5SL		
ATP6A		
ATP6A1	AR,AD	cutis laxa, type iid, 617403 (3), ; developmental and epileptic encephalopathy 93, 618012 (3),
ATP6a2	AR	wrinkly skin syndrome, 278250 (3), ; cutis laxa, type iia, 219200 (3),
ATP6AP1	XLR,XL	immunodeficiency 47, 300972 (3),
ATP6AP2	XL,XLR	intellectual developmental disorder, syndromic, hedera type, 300423 (3), ; ?parkinsonism with spasticity, 300911 (3), ; congenital disorder of glycosylation, type iir, 301045 (3),
ATP6B		
ATP6B1	AR	distal renal tubular acidosis 2 with progressive sensorineural hearing loss, 267300 (3),
ATP6B2	AD	zimmermann-laband syndrome 2, 616455 (3), ; deafness, congenital, with onychodystrophy, 124480 (3),
ATP6C		
ATP6C2		
ATP6D		
ATP6D2		
ATP6DV		
ATP6E	AR	cutis laxa, type iic, 617402 (3),
ATP6E1		
ATP6E2	AR	cutis laxa, type iic, 617402 (3),
ATP6EL2		
ATP6F		
ATP6G		
ATP6G1		
ATP6G2		
ATP6G3		
ATP6GL		
ATP6H		
Atp6i	AR	osteopetrosis, 1, 259700 (3),
ATP6IP1	XLR,XL	immunodeficiency 47, 300972 (3),
ATP6IP2	XL,XLR	intellectual developmental disorder, syndromic, hedera type, 300423 (3), ; ?parkinsonism with spasticity, 300911 (3), ; congenital disorder of glycosylation, type iir, 301045 (3),
ATP6J		
ATP6L		
ATP6M		
ATP6M8-9	XL,XLR	intellectual developmental disorder, syndromic, hedera type, 300423 (3), ; ?parkinsonism with spasticity, 300911 (3), ; congenital disorder of glycosylation, type iir, 301045 (3),
ATP6N1	AR,AD	neurodevelopmental disorder with epilepsy and brain atrophy, 619971 (3), ; developmental and epileptic encephalopathy 104, 619970 (3),
ATP6N1A	AR,AD	neurodevelopmental disorder with epilepsy and brain atrophy, 619971 (3), ; developmental and epileptic encephalopathy 104, 619970 (3),
ATP6N1B	AR	distal renal tubular acidosis 3, with or without sensorineural hearing loss, 602722 (3),
ATP6N1C	AR	osteopetrosis, 1, 259700 (3),
ATP6N1D	AR	wrinkly skin syndrome, 278250 (3), ; cutis laxa, type iia, 219200 (3),
ATP6N2	AR	distal renal tubular acidosis 3, with or without sensorineural hearing loss, 602722 (3),
ATP6S1	XLR,XL	immunodeficiency 47, 300972 (3),
ATP6S14		
ATP6V0A1	AR,AD	neurodevelopmental disorder with epilepsy and brain atrophy, 619971 (3), ; developmental and epileptic encephalopathy 104, 619970 (3),
ATP6V0A2	AR	wrinkly skin syndrome, 278250 (3), ; cutis laxa, type iia, 219200 (3),
ATP6V0A3	AR	osteopetrosis, 1, 259700 (3),
ATP6V0A4	AR	distal renal tubular acidosis 3, with or without sensorineural hearing loss, 602722 (3),
ATP6V0B		
ATP6V0C		
ATP6V0D1		
ATP6V0D2		
ATP6V0E		
ATP6V0E1		
ATP6V0E2		
ATP6V0E2L		
ATP6V1A	AR,AD	cutis laxa, type iid, 617403 (3), ; developmental and epileptic encephalopathy 93, 618012 (3),
ATP6V1A1	AR,AD	cutis laxa, type iid, 617403 (3), ; developmental and epileptic encephalopathy 93, 618012 (3),
ATP6V1B1	AR	distal renal tubular acidosis 2 with progressive sensorineural hearing loss, 267300 (3),
ATP6V1B2	AD	zimmermann-laband syndrome 2, 616455 (3), ; deafness, congenital, with onychodystrophy, 124480 (3),
ATP6V1C1		
ATP6V1C2		
ATP6V1D		
ATP6V1E	AR	cutis laxa, type iic, 617402 (3),
ATP6V1E1	AR	cutis laxa, type iic, 617402 (3),
ATP6V1E2		
ATP6V1EL2		
ATP6V1F		
ATP6V1G1		
ATP6V1G2		
ATP6V1G3		
ATP6V1H		
ATP7A	XLR,XL	occipital horn syndrome, 304150 (3), ; spinal muscular atrophy, distal, 3, 300489 (3), ; menkes disease, 309400 (3),
ATP7B	AR	wilson disease, 277900 (3),
ATP8A1		
ATP8A2	AR	?cerebellar ataxia, impaired intellectual development, and dysequilibrium syndrome 4, 615268 (3),
ATP8B1	AR,AD	cholestasis, progressive familial intrahepatic 1, 211600 (3), ; cholestasis, intrahepatic, of pregnancy, 1, 147480 (3), ; cholestasis, benign recurrent intrahepatic, 243300 (3),
ATP8B2		
ATP8B3		
ATP8B4		
ATP9A	AR	neurodevelopmental disorder with poor growth and behavioral abnormalities, 620242 (3),
ATP9B		
ATPAF1		
ATPAF2	AR	?mitochondrial complex v (atp synthase) deficiency, nuclear type 1, 604273 (3),
ATPBD1A		
ATPBD3		
ATPBD4		
ATPCL		
ATPDase	AR	spastic paraplegia 64, 615683 (3),
ATPGD1		
ATPI		
ATPIA		
ATPIB	AR	?cerebellar ataxia, impaired intellectual development, and dysequilibrium syndrome 4, 615268 (3),
ATPIC	AR,AD	cholestasis, progressive familial intrahepatic 1, 211600 (3), ; cholestasis, intrahepatic, of pregnancy, 1, 147480 (3), ; cholestasis, benign recurrent intrahepatic, 243300 (3),
ATPID		
ATPIF		
ATPIF1		
ATPIG	XL,XLR	?hemolytic anemia, congenital, 301015 (3),
ATPIH	AD	?auditory neuropathy, 2, 620384 (3), ; ?leukodystrophy, hypomyelinating, 24, 619851 (3), ; deafness, 84, 619810 (3),
ATPIIA	AR	neurodevelopmental disorder with poor growth and behavioral abnormalities, 620242 (3),
ATPIIB		
ATPIK		
ATPIM		
ATPIP		
ATPIQ	XL,XLR	?hemolytic anemia, congenital, 301015 (3),
ATPIR		
ATPIS	AD	?auditory neuropathy, 2, 620384 (3), ; ?leukodystrophy, hypomyelinating, 24, 619851 (3), ; deafness, 84, 619810 (3),
ATPL		
ATPM	AD,AR	mitochondrial complex v (atp synthase) deficiency, nuclear type 4a, 620358 (3), ; ?combined oxidative phosphorylation deficiency 22, 616045 (3), ; ?mitochondrial complex v (atp synthase) deficiency, nuclear type 4b, encephalopathic type, 615228 (3),
ATPO	AR	mitochondrial complex v (atp synthase) deficiency, nuclear type 7, 620359 (3),
ATPQ		
ATPSB	AD	?hypermetabolism due to uncoupled mitochondrial oxidative phosphorylation 2, 620085 (3),
ATPSCKMT		
ATPSK1		
ATPSK2	AR	brachyolmia 4 with mild epiphyseal and metaphyseal changes, 612847 (3),
ATPVA		
ATPVB		
ATPVC		
ATPVD		
ATPW		
ATQ1	AR	epilepsy, pyridoxine-dependent, 266100 (3),
ATR	AR,AD,AR,AD	gapo syndrome, 230740 (3), ; {?hemangioma, capillary infantile, susceptibility to}, 602089 (3), |seckel syndrome 1, 210600 (3), ; ?cutaneous telangiectasia and cancer syndrome, familial, 614564 (3),
ATR1	MF,AR,AR,AD	{hypertension, essential}, 145500 (3), ; renal tubular dysgenesis, 267430 (3), |cystinuria, 220100 (3),
ATRAID		
ATRAP		
ATRC1		
ATRC2		
ATRC3		
ATRIP		
ATRN		
ATRNL1		
ATROGIN1		
ATRX	XLD,XL,XLR	alpha-thalassemia/mental retardation syndrome, 301040 (3), ; alpha-thalassemia myelodysplasia syndrome, somatic, 300448 (3); intellectual disability-hypotonic facies syndrome, 309580 (3),
ATS	XL,XLD	alport syndrome 1, 301050 (3),
ATSV	AD,AR	nescav syndrome, 614255 (3), ; neuropathy, hereditary sensory, type iic, 614213 (3), ; spastic paraplegia 30, 610357 (3), ; spastic paraplegia 30, 610357 (3),
Attp		
ATV	AR	leukemia, acute lymphoblastic, 613065 (3); aplastic anemia, 609135 (3); nijmegen breakage syndrome, 251260 (3),
Atx		
ATX		
ATX1	AD	spinocerebellar ataxia 1, 164400 (3),
ATX10	AD	spinocerebellar ataxia 10, 603516 (3),
ATX2	AD,MF	{amyotrophic lateral sclerosis, susceptibility to, 13}, 183090 (3), ; spinocerebellar ataxia 2, 183090 (3), ; {parkinson disease, late-onset, susceptibility to}, 168600 (3),
ATX3	AD	machado-joseph disease, 109150 (3),
ATXN1	AD	spinocerebellar ataxia 1, 164400 (3),
ATXN10	AD	spinocerebellar ataxia 10, 603516 (3),
ATXN1L		
ATXN2	AD,MF	{amyotrophic lateral sclerosis, susceptibility to, 13}, 183090 (3), ; spinocerebellar ataxia 2, 183090 (3), ; {parkinson disease, late-onset, susceptibility to}, 168600 (3),
ATXN2L		
ATXN3	AD	machado-joseph disease, 109150 (3),
ATXN3L		
ATXN7	AD	spinocerebellar ataxia 7, 164500 (3),
ATXN7-AS1		
ATXN7L3		
ATXN7L3B		
ATXN8	AD	spinocerebellar ataxia 8, 608768 (3),
ATXN8OS	MF,AD	{parkinson disease, susceptibility to}, 168600 (3), ; spinocerebellar ataxia 8, 608768 (3),
AU	AR	atrichia with papular lesions, 209500 (3), ; alopecia universalis, 203655 (3),
AUF1		
AUGA		
AUGB		
augurin		
AUH	AR	3-methylglutaconic aciduria, type i, 250950 (3),
AUNA1	AD	auditory neuropathy, 1, 609129 (3),
AUNIP		
AUNX1	XLR,XL	combined oxidative phosphorylation deficiency 6, 300816 (3), ; cowchock syndrome, 310490 (3), ; spondyloepimetaphyseal dysplasia, with hypomyelinating leukodystrophy, 300232 (3), ; deafness, 5, 300614 (3),
AUP1		
AurA	AD	{colon cancer, susceptibility to}, 114500 (3), somatic mutation,
AurB		
AurC	AR	spermatogenic failure 5, 243060 (3),
AURKA	AD	{colon cancer, susceptibility to}, 114500 (3), somatic mutation,
AURKAIP1		
AURKB		
AURKC	AR	spermatogenic failure 5, 243060 (3),
AUTL1		
AUTL2		
AUTL3		
AUTL4		
AUTS2	AD	intellectual developmental disorder, 26, 615834 (3),
AUTSX1	XL	{autism susceptibility, 1}, 300425 (3),
AVED	AR	ataxia with isolated vitamin e deficiency, 277460 (3),
AVEN		
AVIL	AR	nephrotic syndrome, type 21, 618594 (3),
AVL9		
AVO3		
AVP	AD,AD	cinca syndrome, 607115 (3), ; familial cold inflammatory syndrome 1, 120100 (3), ; keratoendothelitis fugax hereditaria, 148200 (3), ; deafness, 34, with or without inflammation, 617772 (3), ; muckle-wells syndrome, 191900 (3), |diabetes insipidus, neurohypophyseal, 125700 (3),
AVPI1		
AVPR1		
AVPR1A		
AVPR1B		
AVPR2	XLR,XL	diabetes insipidus, nephrogenic, 1, 304800 (3), ; nephrogenic syndrome of inappropriate antidiuresis, 300539 (3),
AVPR3		
AVSD2	AD	atrioventricular septal defect, partial, with heterotaxy syndrome, 606217 (3), ; {atrioventricular septal defect, susceptibility to, 2}, 606217 (3),
AVT2		
AWAL		
AWAT1		
AWAT2		
AWMS1		
AWMS2	AR	acrodermatitis enteropathica, 201100 (3),
AWP1		
AWS	AD	?deafness, congenital heart defects, and posterior embryotoxon, 617992 (3), ; charcot-marie-tooth disease, axonal, type 2hh, 619574 (3), ; alagille syndrome 1, 118450 (3), ; tetralogy of fallot, 187500 (3),
AWT1	AD	mesothelioma, somatic, 156240 (3); meacham syndrome, 608978 (3), ; frasier syndrome, 136680 (3), somatic mutation, ; nephrotic syndrome, type 4, 256370 (3), ; denys-drash syndrome, 194080 (3), somatic mutation, ; wilms tumor, type 1, 194070 (3), somatic mutation,
AXA1	AR	ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia, 208920 (3),
AXAM2		
AXER		
AXIIR		
AXIN1		hepatocellular carcinoma, somatic, 114550 (3); ?caudal duplication anomaly, 607864 (3)
AXIN2	AD	colorectal cancer, somatic, 114500 (3); oligodontia-colorectal cancer syndrome, 608615 (3),
AXL		
AXLLG		
AXOR12	AR,AD	hypogonadotropic hypogonadism 8 with or without anosmia, 614837 (3), ; ?precocious puberty, central, 1, 176400 (3),
AXOR35		
AXOT		
AXPC1	AR	ataxia, posterior column, with retinitis pigmentosa, 609033 (3),
AXSF		
AXT	AR	?epilepsy, myoclonic, familial adult, 5, 615400 (3),
AXUD1		
AYP1	AR	aicardi-goutieres syndrome 3, 610329 (3),
AYST720		
AYTL1		
AYTL2		
AYTL3		
AZ1		
AZ2		
AZ3B		
AZAMP		
AZFA	YL	spermatogenic failure, 2, 415000 (3),
AZGP1		
AZI		
AZI1		
AZI2		
AZIN1		
AZIN2		
AZU		
AZU-1		
AZU1		
B	AR	osteogenesis imperfecta, type ix, 259440 (3),
B-50		
B-ALPHA-1	AD	lissencephaly 3, 611603 (3),
B-ATF		
B-DIOX-II		
b-ENAP		
B-FABP		
B-ind1		
B-MYB		
b-PROTEIN	AR	[skin/hair/eye pigmentation, variation in, 11 (melanesian blond hair)], 612271 (3); albinism, oculocutaneous, type iii, 203290 (3),
b-R1		
b-TG1		
B'-T		
b(2)gcn		
B0AT1	AR	hartnup disorder, 234500 (3),
B1	AR,AR	?immunodeficiency, common variable, 5, 613495 (3), |bardet-biedl syndrome 9, 615986 (3),
B10		
B12	AR	mitochondrial complex i deficiency, nuclear type 25, 618246 (3),
B120	AD	coffin-siris syndrome 2, 614607 (3),
B13		
B14	AR	mitochondrial complex i deficiency, nuclear type 33, 618253 (3),
B14.5a		
B14.5b	AR	mitochondrial complex i deficiency, nuclear type 36, 619170 (3),
B14.7	AR	mitochondrial complex i deficiency, nuclear type 14, 618236 (3),
B144		
B15		
B16.6	AR	{thyroid carcinoma, hurthle cell}, 607464 (3); ?mitochondrial complex i deficiency, nuclear type 28, 618249 (3),
B166		
B17	AR	microcephaly, short stature, and limb abnormalities, 617604 (3), ; microcephaly-micromelia syndrome, 251230 (3),
B17.2	AR	mitochondrial complex i deficiency, nuclear type 23, 618244 (3),
B17.2L	AR	mitochondrial complex i deficiency, nuclear type 10, 618233 (3),
B18	AR	?mitochondrial complex i deficiency, nuclear type 39, 620135 (3),
B1BKR		
B1F2		
B2-1		
B22	AR	?mitochondrial complex i deficiency, nuclear type 24, 618245 (3),
B23		leukemia, acute myeloid, somatic, 601626 (3)
B27	AR	glucocorticoid deficiency 2, 607398 (3),
B28		
B29	AR	agammaglobulinemia 6, 612692 (3),
B2AR		beta-2-adrenoreceptor agonist, reduced response to (3)
B2G1		
B2M	AD,AR	?amyloidosis, familial visceral, 105200 (3), ; immunodeficiency 43, 241600 (3),
B2MR		
B3-1		
B37	AD	dentatorubral-pallidoluysian atrophy, 125370 (3), ; congenital hypotonia, epilepsy, developmental delay, and digital anomalies, 618494 (3),
B3BP		
B3GALANT1		[blood group, p1pk system, p(k) phenotype], 111400 (3); [blood group, globoside system], 615021 (3)
B3GALNT1		[blood group, p1pk system, p(k) phenotype], 111400 (3); [blood group, globoside system], 615021 (3)
B3GALNT2	AR	muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies, type a, 11, 615181 (3),
B3GalT-V		
B3GALT1		
B3GALT2		
B3GALT3		[blood group, p1pk system, p(k) phenotype], 111400 (3); [blood group, globoside system], 615021 (3)
B3GALT4		
B3GALT5		
B3GALT6	AR	ehlers-danlos syndrome, spondylodysplastic type, 2, 615349 (3), ; spondyloepimetaphyseal dysplasia with joint laxity, type 1, with or without fractures, 271640 (3), ; al-gazali syndrome, 609465 (3),
B3GALT7		
B3GALT9		
B3GALTL	AR	peters-plus syndrome, 261540 (3),
B3GAT1		
B3GAT2		
B3GAT3	AR	multiple joint dislocations, short stature, craniofacial dysmorphism, with or without congenital heart defects, 245600 (3),
B3Glc-T	AR	peters-plus syndrome, 261540 (3),
B3GLCT	AR	peters-plus syndrome, 261540 (3),
B3GN-T1	AR	muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 13, 615287 (3),
B3GN-T2		
B3GN-T3		
B3GN-T4		
B3GN-T5		
B3Gn-T6		
B3GNT-2		
B3GNT-3		
B3GNT1	AR	muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 13, 615287 (3),
B3GNT10		
B3GNT2		
B3GNT3		
B3GNT4		
B3GNT5		
B3GNT6	AR	muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 13, 615287 (3),
B3GNT7		
B3GNT8		
B3GNTL1		
B3GTL	AR	peters-plus syndrome, 261540 (3),
B3T5		
B4-2		
B4GalNac-T3		
B4GALNT1	AR	spastic paraplegia 26, 609195 (3),
B4GALNT2		[blood group, sid system], 615018 (3); sd(a) polyagglutination syndrome, 615018 (3)
B4GALNT3		
B4GALNT4		
B4GALT1	AR	combined low ldl and fibrinogen, 620364 (3), ; congenital disorder of glycosylation, type iid, 607091 (3),
B4GALT2		
B4GALT3		
B4GALT4		
B4GALT5		
B4GALT6		
B4GALT7	AR	ehlers-danlos syndrome, spondylodysplastic type, 1, 130070 (3),
B4GAT1	AR	muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 13, 615287 (3),
B5		
b5+b5R		
B52		
B55		
B55A		
B55alpha		
B55beta	AD	spinocerebellar ataxia 12, 604326 (3),
B55D		
B55delta		
B55gamma		
B56A		
B56alpha		
B56B		
B56beta		
B56D	AD	intellectual developmental disorder, 35, 616355 (3),
B56delta	AD	intellectual developmental disorder, 35, 616355 (3),
B56E		
B56epsilon		
B56G		
B56gamma		
B5R	AR	methemoglobinemia, type i, 250800 (3), ; methemoglobinemia, type ii, 250800 (3),
B61		
B6P	AR	ectodermal dysplasia/skin fragility syndrome, 604536 (3),
B7-1		
B7-2		
B7-DC		
B7-H		
B7-H1		
B7-H2		
B7-H3		
B7-H4		
B7-H5		
B7-H6		
B7-H7		
B7.1		
B7.2		
B7323	AD	hypotrichosis 1, 605389 (3),
B7DC		
B7h		
B7H1		
B7H2		
B7H3		
B7H4		
B7H5		
B7H7		
B7RP-1		
B7RP-2		
B7RP1		
B7S1		
B7x		
B7y		
B8	AR	mitochondrial complex i deficiency, nuclear type 13, 618235 (3),
B9	AR	?meckel syndrome 9, 614209 (3), ; joubert syndrome 27, 617120 (3),
B94		
B99		
B9D1	AR	?meckel syndrome 9, 614209 (3), ; joubert syndrome 27, 617120 (3),
B9D2	AR	?meckel syndrome 10, 614175 (3), ; joubert syndrome 34, 614175 (3),
B9L		
bA100C15.3	AR,AD	ovarian dysgenesis 5, 617690 (3), ; spermatogenic failure 32, 618115 (3),
bA101E13.1		
bA103J18.3		
bA106M7.3		
bA108K14.1		
bA108K14.6	AR	?spermatogenic failure 15, 616950 (3), ; ?premature ovarian failure 12, 616947 (3),
bA108L7.8	AR	deafness, 57, 618003 (3), ; {retinal disease in usher syndrome type iia, modifier of}, 276901 (3), ; usher syndrome, type iic, gpr98/pdzd7 digenic, 605472 (3), digenic
bA113O24.1		
bA119F7.1		
bA11D8.2.1	AD	hypomagnesemia 7, renal, with or without dilated cardiomyopathy, 620152 (3),
bA120J8.2	AR	trichothiodystrophy 3, photosensitive, 616395 (3),
bA121O19.1		
bA122O1.1		
bA127L20.2		
bA129M16.2	AR	intellectual developmental disorder with autism and dysmorphic facies, 620021 (3),
bA12D24.1.1		
bA12D24.1.2		
bA12J10.2		
bA131P10.1	AR	leukodystrophy, hypomyelinating, 14, 617899 (3),
bA136M9.1		
bA140A10.5		
bA142I17.1		
bA145L22	AR,AD	diabetes mellitus, transient neonatal 1, 601410 (3),
bA145L22.2	AR,AD	diabetes mellitus, transient neonatal 1, 601410 (3),
bA149I18.1		
bA157L14.2		
bA159H20.4		
bA160A10.4		
bA160E12.4		
bA163M19.1		
bA165O3.1		
bA166P24.2	AR	retinitis pigmentosa 25, 602772 (3),
bA182N22.6		
bA186O14.2		
bA186O14.3	AR	ichthyosis, congenital, 8, 613943 (3),
bA188C12.1	AD	kleefstra syndrome 1, 610253 (3),
bA196N14.1		
BA2		
bA203I16.5		
bA203J24.5		
bA203J24.7		
bA204B7.2	AR	epilepsy, progressive myoclonic 2b (lafora), 254780 (3),
bA204B7.3		
bA207C16.1	AR	catifa syndrome, 618761 (3),
bA208F1.2		
bA20A20.1		
bA214N16.3		
bA216B9.3	AR	short-rib thoracic dysplasia 11 with or without polydactyly, 615633 (3),
bA216C10.1		
bA216L13.10		
bA216L13.7		
bA216L13.9		
bA218C14.1		
bA219P18.1	AR	osteogenesis imperfecta, type xiv, 615066 (3),
bA225H22.7		
bA22L21.1	AR	mitochondrial complex i deficiency, nuclear type 15, 618237 (3),
bA234K24.2		
bA235O14.1		
bA235O14.2		
bA243J16.5		
bA243J16.6		
bA243O10.1		
bA255A11.3		
bA257K9.4		
bA259P20.2		
bA261N11.2		
bA261N11.3		
bA265G8.2		
bA288G11.4		
bA288G11.5		
bA288G3.1		
bA28H17.2		
bA295P9.4	AR	?corpus callosum, agenesis of, with facial anomalies and cerebellar ataxia, 616819 (3),
bA2K17.3		
BA2R	XL,XLR	intellectual developmental disorder, syndromic 33, 300966 (3), ; dystonia-parkinsonism, 314250 (3),
bA304I5.1		
bA305P22.1		
bA305P22.3		
bA307F22.3	AR	retinitis pigmentosa 25, 602772 (3),
bA307O14.2		
bA311H10.1		
bA314N13.5		
bA317E16.2		
bA317E16.3		
bA325O24.3		
bA325O24.4		
bA33E24.2		
bA340N12.1		
bA345L23.2		
bA346C16.3	AD	developmental and epileptic encephalopathy 87, 618916 (3),
bA346K17.2	AR	neurodevelopmental disorder with brain anomalies, seizures, and scoliosis, 618590 (3),
bA348N5.3	AR	?bardet-biedl syndrome 18, 615995 (3),
bA34D15.5		
bA350J20.1		
bA350J20.7		
bA350O14.10		
bA350O14.9		
bA351K16.2		
bA351K16.3	AR	combined oxidative phosphorylation deficiency 11, 614922 (3),
bA353C18.2		
bA355M14.1	AR	muscular dystrophy, limb-girdle, 26, 618848 (3),
bA356B19.6		
bA360D14.1		
bA360O19.2	AD,AR	[blood group, ii], 110800 (3), ; adult i phenotype without cataract, 110800 (3), ; cataract 13 with adult i phenotype, 116700 (3),
bA364G4.2		
bA36D19.5		
bA370F5.1		
bA371L19.1	AR	?fazio-londe disease, 211500 (3), ; brown-vialetto-van laere syndrome 1, 211530 (3),
bA371L19.3		
bA373N18.1		
bA373N18.2	AD,AR	hydrocephalus, normal pressure, 1, 236690 (3), ; spermatogenic failure 19, 617592 (3),
bA375E1.3		
bA379C10.2		
bA379J5.3		
bA379P1.1		
bA379P1.3		
bA37E23.1		
bA393I2.3	AD	intellectual developmental disorder, 64, 619188 (3),
bA394O2.1		
bA395P17.9		
bA397G5.3		
bA397G5.4		
bA398O19.2		
bA399O19.2		
bA3L8.2		
bA408E5.3		
bA416N4.2	AD	?myasthenic syndrome, congenital, 18, 616330 (3),
bA418P12.1		
bA4204.1		
bA420G6.2		
bA421M1.1	AD,AR	[blood group, ii], 110800 (3), ; adult i phenotype without cataract, 110800 (3), ; cataract 13 with adult i phenotype, 116700 (3),
bA421M1.5		
bA421M1.6		
bA421P11.2	AD	polycystic kidney disease 7, 620056 (3),
bA421P11.3	AR	pontocerebellar hypoplasia, type 1c, 616081 (3),
bA421P11.4		
bA422P15.2		
bA425M17.2		
bA427L11.2		
bA427L11.3		
bA428J1.3		
bA42B19.1		
bA430M15.1	AD,AR	congenital contractures of the limbs and face, hypotonia, and developmental delay, 616266 (3), ; hypotonia, infantile, with psychomotor retardation and characteristic facies 1, 615419 (3),
bA43P8.1		
bA444E17.1	AR	leukoencephalopathy, progressive, with ovarian failure, 615889 (3), ; combined oxidative phosphorylation deficiency 8, 614096 (3),
bA444G7	AD	{colorectal cancer, susceptibility to}, 114500 (3), somatic mutation, ; osteosarcoma, somatic, 259500 (3); {breast cancer, susceptibility to}, 114480 (3), somatic mutation, ; {prostate cancer, familial, susceptibility to}, 176807 (3), somatic mutation, ; li-fraumeni syndrome 2, 609265 (3)
bA446F17.4		
bA449O16.3		
bA451M19.3		
bA457M11.2		
bA457M11.3		
bA459F3.4		
BA46		
bA460E7.2		
bA465L10.1		
bA465L10.2	AR	microcephaly 10, primary, 615095 (3),
bA465L10.6		
bA49A4.1		
bA49G10.5		
bA500C11.2		
bA500G10.4		
bA500G22.3		
bA503C24.7		
bA504H3.3	AD	corneal dystrophy, posterior polymorphous, 1, 122000 (3),
bA504H3.4	AR	mitochondrial dna depletion syndrome 11, 615084 (3),
bA506K6.1	AD	cortical dysplasia, complex, with other brain malformations 7, 610031 (3),
bA514O12.3	AR	leukoencephalopathy, cystic, without megalencephaly, 612951 (3),
bA51G5.2	AD	{?obesity, susceptibility to, bmiq18}, 615457 (3),
bA522I20.2		
bA526K24.1		
bA528A10.3		
bA530N10.1		
bA531F24.1		
bA535K18.1	XL,XLR,XLD	myopathy, with postural muscle atrophy, 300696 (3), ; emery-dreifuss muscular dystrophy 6, 300696 (3), ; ?uruguay faciocardiomusculoskeletal syndrome, 300280 (3), ; scapuloperoneal myopathy, 300695 (3), ; reducing body myopathy, 1b, with late childhood or adult onset, 300718 (3), ; reducing body myopathy, 1a, severe, infantile or early childhood onset, 300717 (3),
bA541I19.1		
bA541N10.2	AR	cerebroretinal microangiopathy with calcifications and cysts 2, 617341 (3),
bA545I5.2		
bA548K23.4		
bA548K23.8		
bA550O8.2		
BA554C12.1		
bA554P13.1	AR	spermatogenic failure 49, 619144 (3),
bA555E18.1		
bA561O23.1		
bA570G20.3		
bA571F15.4		
bA573M23.4		
bA574F11.2		
bA57K17.2	AD	lissencephaly 10, 618873 (3),
bA57L9.1		
bA59I9.3	AR	coenzyme q10 deficiency, primary, 3, 614652 (3),
bA613M10.3		
bA631M21.2	AR,AD	oocyte/zygote/embryo maturation arrest 2, 616780 (3),
bA63L7.3		
bA65N13.1		
bA690P14.1		
bA69L16.7		
bA6B20.2	AR	mitochondrial complex iii deficiency, nuclear type 7, 615824 (3),
bA723P2.3		
bA74E24.1	AR	retinitis pigmentosa 25, 602772 (3),
bA77C3.1		
bA787I22.1	AR	spermatogenic failure 38, 618433 (3),
bA791O21.3		
bA792D24.4	AR	mitochondrial complex v (atp synthase) deficiency, nuclear type 6, 618683 (3),
bA810I22.1	AR	methylmalonic aciduria and homocystinuria, cblf type, 277380 (3),
bA86F4.3		
bA9819.1		
bA98I6.3		
bA98I9.2		
BAALC		
BAAT	AR	bile acid conjugation defect 1, 619232 (3),
BAAT1	AR	neurodevelopmental disorder with cerebellar atrophy and with or without seizures, 618056 (3), ; rigidity and multifocal seizure syndrome, lethal neonatal, 614498 (3),
BABAM1		
BABAM2		
BABL	AD	silver-russell syndrome 5, 618908 (3),
BABP	AR	46xy sex reversal 8, 614279 (3),
BACE		
BACE1		
BACE1-AS		
BACE1-AS1		
BACE1AS		
BACE2		
BACH		
BACH-1		
BACH1	AD	fanconi anemia, complementation group j, 609054 (3); {breast cancer, early-onset, susceptibility to}, 114480 (3), somatic mutation,
BACH2	AD	immunodeficiency 60 and autoimmunity, 618394 (3),
BAD		
BAD-LAMP		
BAF	AR	nestor-guillermo progeria syndrome, 614008 (3),
BAF155	AD	{hydrocephalus, congenital, 5, susceptibility to}, 620241 (3),
BAF170	AD	coffin-siris syndrome 8, 618362 (3),
BAF180		?renal cell carcinoma, clear cell, 144700 (3)
BAF190	AD,AD	coffin-siris syndrome 4, 614609 (3), ; {rhabdoid tumor predisposition syndrome 2}, 613325 (3), |nicolaides-baraitser syndrome, 601358 (3), ; blepharophimosis-impaired intellectual development syndrome, 619293 (3),
BAF200	AD	coffin-siris syndrome 6, 617808 (3),
BAF250	AD	coffin-siris syndrome 2, 614607 (3),
BAF250a	AD	coffin-siris syndrome 2, 614607 (3),
BAF250b	AD	coffin-siris syndrome 1, 135900 (3),
BAF45a		
BAF45b		
BAF45c		
BAF45d	AD	coffin-siris syndrome 7, 618027 (3),
BAF47	AD	rhabdoid tumors, somatic, 609322 (3); {schwannomatosis-1, susceptibility to}, 162091 (3), ; coffin-siris syndrome 3, 614608 (3), ; {rhabdoid tumor predisposition syndrome 1}, 609322 (3),
Baf53a		
BAF53A		
BAF53B	AR,AD	developmental and epileptic encephalopathy 76, 618468 (3), ; intellectual developmental disorder with severe speech and ambulation defects, 618470 (3),
BAF57	AD	{meningioma, familial, susceptibility to}, 607174 (3), ; coffin-siris syndrome 5, 616938 (3),
BAF60A	AD	coffin-siris syndrome 11, 618779 (3),
BAF60B	AR	specific granule deficiency 2, 617475 (3),
BAF60C		
BAFF		
BAFFR	AR	immunodeficiency, common variable, 4, 613494 (3),
BAG1		
BAG2		
BAG3	AD	cardiomyopathy, dilated, 1hh, 613881 (3), ; myopathy, myofibrillar, 6, 612954 (3),
BAG4		
BAG5	AR	cardiomyopathy, dilated, 2f, 619747 (3),
BAG6		
BAGE		
BAGE1		
BAGE2		
BAGE3		
BAH	AR	traboulsi syndrome, 601552 (3),
BAHCC1		
BAHD1		
BAHD2		
BAI1		
BAI2		
BAI3		
BAIAP1		
BAIAP2		
BAIAP2L1		
BAIAP2L2		
BAIAP3		
BAK		
BAK1		
BAL		
BAL1		
BAL2		
BAL3		
BALGR		
BAM	AD	cornelia de lange syndrome 3, 610759 (3),
BAM22	AR	keratitis-ichthyosis-deafness syndrome, 242150 (3),
BAM32		
bamacan	AD	cornelia de lange syndrome 3, 610759 (3),
BAMBI		
BANCR		
BANF	AD	neurofibromatosis, type 2, 101000 (3), ; meningioma, nf2-related, somatic, 607174 (3); schwannomatosis, somatic, 162091 (3)
BANF1	AR	nestor-guillermo progeria syndrome, 614008 (3),
BANK		
BANK1		
BANP		
BAP	AR	marinesco-sjogren syndrome, 248800 (3),
BAP-1	AD	luo-schoch-yamamoto syndrome, 619460 (3),
BAP-135		
BAP1	AD,AD	kury-isidor syndrome, 619762 (3), ; tumor predisposition syndrome 1, 614327 (3), ; {uveal melanoma, susceptibility to, 2}, 606661 (3), |luo-schoch-yamamoto syndrome, 619460 (3),
BAP18		
BAP2		
BAP28		
BAP29		
BAP3		
BAP31	XLR,XL	deafness, dystonia, and cerebral hypomyelination, 300475 (3),
Bap37		
BAPX1	AR	spondylo-megaepiphyseal-metaphyseal dysplasia, 613330 (3),
BAPX2		
BAR		beta-2-adrenoreceptor agonist, reduced response to (3)
BARD1	AD	{breast cancer, susceptibility to}, 114480 (3), somatic mutation,
BARHL1		
BARHL2		
BARK1		
BARK2		
BARMR1	AR	?polydactyly, postaxial, type a9, 618219 (3),
BARR2		
BARS	AD	hypotonia, ataxia, developmental delay, and tooth enamel defect syndrome, 617915 (3),
BART	AR,AR	retinitis pigmentosa with or without situs inversus, 615434 (3), |sensorineural deafness with mild renal dysfunction, 602522 (3), ; bartter syndrome, type 4a, 602522 (3),
BART1	AR	retinitis pigmentosa with or without situs inversus, 615434 (3),
BARX1		
BARX2		
BASE		
BASH	AR	?agammaglobulinemia 4, 613502 (3),
BASP1		
BASS1	AD	zttk syndrome, 617140 (3),
BASS2		
BAT	AR	bile acid conjugation defect 1, 619232 (3),
BAT1	AR,AD	cystinuria, 220100 (3),
BAT1L		
BAT2		
BAT2D1		
BAT2L		
BAT2L1		
BAT2L2		
BAT3		
BAT4		
BAT5	AR	spastic paraplegia 86, 619735 (3),
BAT8		
BATF		
BATF1		
BATF2		
BATF3		
BAX		colorectal cancer, somatic, 114500 (3); t-cell acute lymphoblastic leukemia, somatic, 613065 (3)
BAXI1		
Baz		
BAZ1A		
BAZ1B		
BAZ2A		
BAZ2B		
BAZF		
Bazooka		
BB1	AR	intellectual developmental disorder, 57, 617188 (3),
bB137A17.2		
bB137A17.3		
bB152O15.1	AD	retinitis pigmentosa 60, 613983 (3),
BB1R		
BB2		{malaria, cerebral, susceptibility to}, 611162 (3)
BB2R		
BB3		
bB379O24.1	AR,AD	congenital heart defects, multiple types, 5, 617912 (3),
BB3R		
bB439H18.3		
BBAP		
BBC1	AD	spondyloepimetaphyseal dysplasia, isidor-toutain type, 618728 (3),
BBC2		
BBC3		
BBF2H7		
BBG-TCC		
BBH		
BBIP1	AR	?bardet-biedl syndrome 18, 615995 (3),
BBIP10	AR	?bardet-biedl syndrome 18, 615995 (3),
BBMI		
BBOX		
BBOX1		
BBOX2	XL,XLR	{autism, susceptibility to, 6}, 300872 (3),
BBP		
BBR3		
BBS	AR	retinitis pigmentosa 74, 616562 (3), ; bardet-biedl syndrome 2, 615981 (3),
BBS1	AR	bardet-biedl syndrome 1, 209900 (3), digenic
BBS10	AR	bardet-biedl syndrome 10, 615987 (3),
BBS11	AR	?bardet-biedl syndrome 11, 615988 (3), ; muscular dystrophy, limb-girdle, 8, 254110 (3),
BBS12	AR	bardet-biedl syndrome 12, 615989 (3),
BBS13	AR	bardet-biedl syndrome 13, 615990 (3), ; meckel syndrome 1, 249000 (3), ; joubert syndrome 28, 617121 (3),
BBS14	AR	leber congenital amaurosis 10, 611755 (3); joubert syndrome 5, 610188 (3), ; senior-loken syndrome 6, 610189 (3), ; ?bardet-biedl syndrome 14, 615991 (3), ; meckel syndrome 4, 611134 (3),
BBS15	AR	?bardet-biedl syndrome 15, 615992 (3), ; congenital heart defects, hamartomas of tongue, and polysyndactyly, 217085 (3),
BBS16	AR	senior-loken syndrome 7, 613615 (3), ; bardet-biedl syndrome 16, 615993 (3),
BBS17	AR	bardet-biedl syndrome 17, 615994 (3),
BBS18	AR	?bardet-biedl syndrome 18, 615995 (3),
BBS19	AR	bardet-biedl syndrome 19, 615996 (3),
BBS2	AR	retinitis pigmentosa 74, 616562 (3), ; bardet-biedl syndrome 2, 615981 (3),
BBS20	AR	retinitis pigmentosa 71, 616394 (3), ; bardet-biedl syndrome 20, 619471 (3), ; short-rib thoracic dysplasia 10 with or without polydactyly, 615630 (3),
BBS21	AR	retinitis pigmentosa 64, 614500 (3), ; cone-rod dystrophy 16, 614500 (3), ; bardet-biedl syndrome 21, 617406 (3),
BBS2L1	AR	bardet-biedl syndrome 7, 615984 (3),
BBS3	AR	retinitis pigmentosa 55, 613575 (3), ; {bardet-biedl syndrome 1, modifier of}, 209900 (3), digenic ; bardet-biedl syndrome 3, 600151 (3),
BBS4	AR	bardet-biedl syndrome 4, 615982 (3),
BBS5	AR	bardet-biedl syndrome 5, 615983 (3),
BBS6	AR	mckusick-kaufman syndrome, 236700 (3), ; bardet-biedl syndrome 6, 605231 (3),
BBS7	AR	bardet-biedl syndrome 7, 615984 (3),
BBS8	AR	bardet-biedl syndrome 8, 615985 (3), ; ?retinitis pigmentosa 51, 613464 (3),
BBS9	AR	bardet-biedl syndrome 9, 615986 (3),
BC-2		
BC006151		
BC008134		
BC017397		
BC022889		
BC037316		
BC10		
BC200		
BC200a		
bca	AR	?agammaglobulinemia 4, 613502 (3),
BCA-1		
BCA3		
BCAA		
BCAM	AR,AR	?hypervalinemia or hyperleucine-isoleucinemia, 618850 (3), |[blood group, lutheran system], 111200 (3); [blood group, auberger system], 111200 (3); [blood group, lutheran null], 247420 (3),
BCAN		
BCAP		
BCAP29		
BCAP31	XLR,XL	deafness, dystonia, and cerebral hypomyelination, 300475 (3),
BCAP37		
BCAR1		
BCAR2		
BCAR3		
BCAR4		
BCAS1		
BCAS2		
BCAS3	AR	hengel-maroofian-schols syndrome, 619641 (3),
BCAS4		
BCAS4L		
BCAT1		
BCAT2	AR	?hypervalinemia or hyperleucine-isoleucinemia, 618850 (3),
BCATc		
BCATm	AR	?hypervalinemia or hyperleucine-isoleucinemia, 618850 (3),
BCCIP		
BCCIPalpha		
BCD1		gastric cancer, somatic, 613659 (3); prostate cancer, somatic, 176807 (3)
BCD541	AR,AR	{spinal muscular atrophy, type iii, modifier of}, 253400 (3), |spinal muscular atrophy-2, 253550 (3), ; spinal muscular atrophy-4, 271150 (3), ; spinal muscular atrophy-3, 253400 (3), ; spinal muscular atrophy-1, 253300 (3),
BCDIN3		
BCDIN3D		
BCDO	AD	?hypercarotenemia and vitamin a deficiency, 115300 (3),
BCDO1	AD	?hypercarotenemia and vitamin a deficiency, 115300 (3),
BCDO2		
BCEI		
BCG1	XLR,XL	bartter syndrome, type 5, antenatal, transient, 300971 (3),
BCGF-1		
BCGF1		
BCH	AD	chorea, hereditary benign, 118700 (3), ; {thyroid cancer, nonmedullary, 1}, 188550 (3), ; choreoathetosis, hypothyroidism, and neonatal respiratory distress, 610978 (3),
BCHE	AR	butyrylcholinesterase deficiency, 617936 (3), ; {apnea, postanesthetic, susceptibility to, due to bche deficiency}, 617936 (3),
BCKAD-E2	AR	maple syrup urine disease, type ii, 248600 (3),
BCKDH-E2	AR	maple syrup urine disease, type ii, 248600 (3),
BCKDHA	AR	maple syrup urine disease, type ia, 248600 (3),
BCKDHB	AR	maple syrup urine disease, type ib, 248600 (3),
BCKDK		branched-chain keto acid dehydrogenase kinase deficiency, 614923 (3)
Bcl-2		leukemia/lymphoma, b-cell, 2 (3)
BCL-B		
BCL-G		
BCL-RAMBO		
BCL-W		
Bcl-X		
bcl-xL		
bcl-xS		
BCL1	AD	{von hippel-lindau syndrome, modifier of}, 193300 (3), ; {colorectal cancer, susceptibility to}, 114500 (3), somatic mutation, ; {multiple myeloma, susceptibility to}, 254500 (3), somatic mutation
BCL10	AR	{lymphoma, follicular, somatic}, 605027 (3); ?immunodeficiency 37, 616098 (3), ; {sezary syndrome, somatic} (3); {male germ cell tumor, somatic}, 273300 (3); lymphoma, malt, somatic, 137245 (3); {mesothelioma, somatic}, 156240 (3)
BCL11A	AD	dias-logan syndrome, 617101 (3),
BCL11A-L	AD	dias-logan syndrome, 617101 (3),
BCL11A-S	AD	dias-logan syndrome, 617101 (3),
BCL11A-XL	AD	dias-logan syndrome, 617101 (3),
BCL11B	AD	immunodeficiency 49, severe combined, 617237 (3), ; intellectual developmental disorder with dysmorphic facies, speech delay, and t-cell abnormalities, 618092 (3),
BCL2		leukemia/lymphoma, b-cell, 2 (3)
BCL2A1		
BCL2L		
BCL2L1		
BCL2L10		
BCL2L11		
BCL2L12		
BCL2L13		
BCL2L14		
BCL2L15		
BCL2L2		
BCL2L3		
BCL2L4		colorectal cancer, somatic, 114500 (3); t-cell acute lymphoblastic leukemia, somatic, 613065 (3)
BCL2L5		
BCL2L7		
BCL2L8		
BCL2L9		
BCL3		leukemia/lymphoma, b-cell, 3, 109560 (2)
BCL4		leukemia/lymphoma, b-cell, 3, 109560 (2)
BCL5		
BCL6		
BCL6A		
BCL6B		
BCL7		
BCL7A		
BCL7B		
BCL7C		
BCL8		
BCL8A		
BCL8B	AD	neurodevelopmental disorder with or without early-onset generalized epilepsy, 619157 (3),
BCL9		
Bcl9-2		
BCL9L		
BCLAF1		
BCLAF2		
BCLF-1		
BCLG		
BCLX		
BCM		
BCM1		
bcm910		
BCMA		
BCMO	AD	?hypercarotenemia and vitamin a deficiency, 115300 (3),
BCMO1	AD	?hypercarotenemia and vitamin a deficiency, 115300 (3),
BCMP1		
BCMP101		
BCMP11		
BCMP84		
BCMS		
BCMS1		
BCMSUN		
BCNG-1	AD	developmental and epileptic encephalopathy 24, 615871 (3), ; generalized epilepsy with febrile seizures plus, type 10, 618482 (3),
BCNG-2	AD	febrile seizures, familial, 2, 602477 (3), ; {epilepsy, idiopathic generalized, susceptibility to, 17}, 602477 (3), ; generalized epilepsy with febrile seizures plus, type 11, 602477 (3),
BCNG1	AD	developmental and epileptic encephalopathy 24, 615871 (3), ; generalized epilepsy with febrile seizures plus, type 10, 618482 (3),
BCNG2	AD	febrile seizures, familial, 2, 602477 (3), ; {epilepsy, idiopathic generalized, susceptibility to, 17}, 602477 (3), ; generalized epilepsy with febrile seizures plus, type 11, 602477 (3),
BCNP1		
BCNS	AD	basal cell nevus syndrome 1, 109400 (3), ; basal cell carcinoma, somatic, 605462 (3); holoprosencephaly 7, 610828 (3),
BCNT		
BCO1	AD	?hypercarotenemia and vitamin a deficiency, 115300 (3),
BCO2		
BCO3	AR,AD	retinitis pigmentosa 20, 613794 (3), ; retinitis pigmentosa 87 with choroidal involvement, 618697 (3), ; leber congenital amaurosis 2, 204100 (3),
BCOADC-E2	AR	maple syrup urine disease, type ii, 248600 (3),
BCON3		
BCOR	XLD,XL	microphthalmia, syndromic 2, 300166 (3),
BCORL1	XLR,XL	shukla-vernon syndrome, 301029 (3),
BCOX		
BCOX1		
BCP	AD	colorblindness, tritan, 190900 (3),
BCPM	AD	hailey-hailey disease, 169600 (3),
BCR		leukemia, chronic myeloid, philadelphia chromosome positive, somatic, 608232 (4); leukemia, acute lymphocytic, philadelphia chromosome positive, somatic, 613065 (4)
BCR1		leukemia, chronic myeloid, philadelphia chromosome positive, somatic, 608232 (4); leukemia, acute lymphocytic, philadelphia chromosome positive, somatic, 613065 (4)
BCRG2		
BCRP	AD	[junior blood group system], 614490 (3); [uric acid concentration, serum, qtl1], 138900 (3), ?
BCRP2		
BCS	AR	gracile syndrome, 603358 (3), ; mitochondrial complex iii deficiency, nuclear type 1, 124000 (3), ; bjornstad syndrome, 262000 (3),
BCS1L	AR	gracile syndrome, 603358 (3), ; mitochondrial complex iii deficiency, nuclear type 1, 124000 (3), ; bjornstad syndrome, 262000 (3),
BCSC-1		
BCSG1		
BCT1		
BCT2	AR	?hypervalinemia or hyperleucine-isoleucinemia, 618850 (3),
BCTL1		
BCUR1		
bCX105N19.6		
bCX31G15.2		
BCYRN1		
BD1		
BD73		
BDA1	AR,AD	acrocapitofemoral dysplasia, 607778 (3), ; brachydactyly, type a1, 112500 (3),
BDB	AD,AR	brachydactyly, type b1, 113000 (3), ; robinow syndrome, 268310 (3),
BDB1	AD,AR	brachydactyly, type b1, 113000 (3), ; robinow syndrome, 268310 (3),
BDCA-3	AD	thrombophilia 12 due to thrombomodulin defect, 614486 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to, 6}, 612926 (3),
BDCA2		
BDGI		
BDH		
BDH1		
BDK	AR,AD	[kininogen deficiency], 228960 (3), ; angioedema, hereditary, 6, 619363 (3), ; [high molecular weight kininogen deficiency], 228960 (3),
BDKRB1		
BDKRB2		
BDMR	AD	neurodevelopmental disorder with central hypotonia and dysmorphic facies, 619797 (3),
BDNF		
BDNF-AS		
BDNF-AS1		
BDNFAS		
BDNFOS		
BDP	AR	?maple syrup urine disease, mild variant, 615135 (3),
BDP1	AR	?deafness, 112, 618257 (3),
BDR1		
BE37		
BEAN1	AD	spinocerebellar ataxia 31, 117210 (3),
BEC-1		
BEC1		
BECN1		
BECN1P1		
BECN2		
BEDP		
BEF		
BEGAIN		
BEHAB		
BEK	AD	bent bone dysplasia syndrome, 614592 (3), ; ladd syndrome 1, 149730 (3), ; antley-bixler syndrome without genital anomalies or disordered steroidogenesis, 207410 (3), ; scaphocephaly and axenfeld-rieger anomaly (3); jackson-weiss syndrome, 123150 (3), ; gastric cancer, somatic, 613659 (3); craniofacial-skeletal-dermatologic dysplasia, 101600 (3), ; apert syndrome, 101200 (3), ; pfeiffer syndrome, 101600 (3), ; craniosynostosis, nonspecific (3); ?scaphocephaly, maxillary retrusion, and impaired intellectual development, 609579 (3); beare-stevenson cutis gyrata syndrome, 123790 (3), ; crouzon syndrome, 123500 (3), ; saethre-chotzen syndrome, 101400 (3),
BEM46L2	AR	polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract, 612674 (3),
BEN		
BEND1		
BEND3		
BEND8	AD	neurodevelopmental disorder with epilepsy, cataracts, feeding difficulties, and delayed brain myelination, 617393 (3),
BEND9		
BENE		
BERF-1	AD	global developmental delay, absent or hypoplastic corpus callosum, and dysmorphic facies, 617260 (3),
Berg36		
BERP		
BEST	AD,AR	macular dystrophy, vitelliform, 2, 153700 (3), ; ?microcornea, rod-cone dystrophy, cataract, and posterior staphyloma 2, 193220 (3), ; retinitis pigmentosa-50, 613194 (3); retinitis pigmentosa, concentric, 613194 (3); vitreoretinochoroidopathy, 193220 (3), ; bestrophinopathy, 611809 (3)
BEST1	AD,AR	macular dystrophy, vitelliform, 2, 153700 (3), ; ?microcornea, rod-cone dystrophy, cataract, and posterior staphyloma 2, 193220 (3), ; retinitis pigmentosa-50, 613194 (3); retinitis pigmentosa, concentric, 613194 (3); vitreoretinochoroidopathy, 193220 (3), ; bestrophinopathy, 611809 (3)
BEST2		
BEST3		
BEST4		
bet		
BET1		
BET1L		
BET3		
BET3L		
BET5		
beta-4	AD	fibrosis of extraocular muscles, congenital, 3a, 600638 (3), ; cortical dysplasia, complex, with other brain malformations 1, 614039 (3),
BETA-4	AR	spastic paraplegia 47, 614066 (3),
beta-5	AD	dystonia 4, torsion, 128101 (3), ; leukodystrophy, hypomyelinating, 6, 612438 (3),
beta-catenin	AD	exudative vitreoretinopathy 7, 617572 (3), ; pilomatricoma, somatic, 132600 (3); colorectal cancer, somatic, 114500 (3); neurodevelopmental disorder with spastic diplegia and visual defects, 615075 (3), ; medulloblastoma, somatic, 155255 (3); ovarian cancer, somatic, 167000 (3); hepatocellular carcinoma, somatic, 114550 (3)
beta-globin	AD,AR	methemoglobinemia, beta type, 617971 (3), ; thalassemia-beta, inclusion-body, 603902 (3), ; sickle cell anemia, 603903 (3), ; thalassemia, beta, 613985 (3); delta-beta thalassemia, 141749 (3), ; {malaria, resistance to}, 611162 (3); hereditary persistence of fetal hemoglobin, 141749 (3), ; erythrocytosis, familial, 6, 617980 (3), ; heinz body anemia, 140700 (3),
beta-MPP	AR	multiple mitochondrial dysfunctions syndrome 6, 617954 (3),
BETA-PIX		
Beta-TG		
beta-TrCP1		
beta'-COP	AD,AR	osteoporosis, childhood- or juvenile-onset, with developmental delay, 619884 (3), ; ?microcephaly 19, primary, 617800 (3),
beta1-4GalNAc-T	AR	spastic paraplegia 26, 609195 (3),
beta1i	AR	?proteasome-associated autoinflammatory syndrome 3, digenic, 617591 (3),
Beta2	AD	leber congenital amaurosis with early-onset deafness, 617879 (3),
BETA2	AD	{type 2 diabetes mellitus, susceptibility to}, 125853 (3), ; maturity-onset diabetes of the young 6, 606394 (3)
beta2i	AR	proteasome-associated autoinflammatory syndrome 5, 619175 (3),
Beta3		
beta3Gal-T1		
beta3Gal-T2		
beta3Gal-T3		[blood group, p1pk system, p(k) phenotype], 111400 (3); [blood group, globoside system], 615021 (3)
beta3Gal-T4		
beta3Gal-T5		
beta3GalT6	AR	ehlers-danlos syndrome, spondylodysplastic type, 2, 615349 (3), ; spondyloepimetaphyseal dysplasia with joint laxity, type 1, with or without fractures, 271640 (3), ; al-gazali syndrome, 609465 (3),
beta3Gn-T3		
beta3Gn-T4		
beta3Gn-T5		
beta3Gn-T8		
BETA3GNT		
beta3GnT7		
BETA3GNTI	AR	muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 13, 615287 (3),
Beta4		
beta4Gal-T1	AR	combined low ldl and fibrinogen, 620364 (3), ; congenital disorder of glycosylation, type iid, 607091 (3),
beta4Gal-T2		
beta4Gal-T3		
beta4Gal-T4		
beta4Gal-T7	AR	ehlers-danlos syndrome, spondylodysplastic type, 1, 130070 (3),
beta4GalT-V		
beta4GalT-VI		
beta5i	AR	proteasome-associated autoinflammatory syndrome 1 and digenic forms, 256040 (3),
beta5t		
betaglycan		
betaGMR	AR	surfactant metabolism dysfunction, pulmonary, 5, 614370 (3),
betaprime-COP	AD,AR	osteoporosis, childhood- or juvenile-onset, with developmental delay, 619884 (3), ; ?microcephaly 19, primary, 617800 (3),
betaTrCP		
Bex		
BEX1		
BEX2		
BEX3		
BEX4		
BEX5		
BEXL1		
BEY	AR	[skin/hair/eye pigmentation 1, blue/nonblue eyes], 227220 (3), ; [skin/hair/eye pigmentation 1, blond/brown hair], 227220 (3), ; albinism, brown oculocutaneous, 203200 (3), ; albinism, oculocutaneous, type ii, 203200 (3),
BEY1	AR	[skin/hair/eye pigmentation 1, blue/nonblue eyes], 227220 (3), ; [skin/hair/eye pigmentation 1, blond/brown hair], 227220 (3), ; albinism, brown oculocutaneous, 203200 (3), ; albinism, oculocutaneous, type ii, 203200 (3),
BEY2	AR	[skin/hair/eye pigmentation 1, blue/nonblue eyes], 227220 (3), ; [skin/hair/eye pigmentation 1, blond/brown hair], 227220 (3), ; albinism, brown oculocutaneous, 203200 (3), ; albinism, oculocutaneous, type ii, 203200 (3),
BEYLA		
BF	AR,AD	?complement factor b deficiency, 615561 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to, 4}, 612924 (3), ; {macular degeneration, age-related, 14, reduced risk of}, 615489 (3), digenic
BF1	AD	rett syndrome, congenital variant, 613454 (3),
BFAR		
BFCOL1	AD	global developmental delay, absent or hypoplastic corpus callosum, and dysmorphic facies, 617260 (3),
BFD	AR,AD	?complement factor b deficiency, 615561 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to, 4}, 612924 (3), ; {macular degeneration, age-related, 14, reduced risk of}, 615489 (3), digenic
BFGFR	AD	pfeiffer syndrome, 101600 (3), ; hypogonadotropic hypogonadism 2 with or without anosmia, 147950 (3), ; jackson-weiss syndrome, 123150 (3), ; hartsfield syndrome, 615465 (3), ; trigonocephaly 1, 190440 (3), ; osteoglophonic dysplasia, 166250 (3), ; encephalocraniocutaneous lipomatosis, somatic mosaic, 613001 (3)
BFIT		
BFIT1		
Bfk		
BFL1		
BFLS	XLR,XL	borjeson-forssman-lehmann syndrome, 301900 (3),
BFNC	AD,AD	{nicotine addiction, susceptibility to}, 188890 (3); epilepsy, nocturnal frontal lobe, 1, 600513 (3), |developmental and epileptic encephalopathy 7, 613720 (3), ; seizures, benign neonatal, 1, 121200 (3), ; myokymia, 121200 (3),
BFP		
BFR2		
BFSP1	AR,AD	cataract 33, multiple types, 611391 (3),
BFSP2	AD	cataract 12, multiple types, 611597 (3),
BFT	AD	liebenberg syndrome, 186550 (4), ; clubfoot, congenital, with or without deficiency of long bones and/or mirror-image polydactyly, 119800 (3),
BFZB		
BG		
BG1		
bG174L6.2	AR	camptodactyly-arthropathy-coxa vara-pericarditis syndrome, 208250 (3),
BG37		
BGALT15		
BGCAN		
BGGI		
BGL	AR	immunodeficiency, common variable, 8, with autoimmunity, 614700 (3),
BGL3		
BGLAP		
BGLT3		
BGM		
BGN	XL,XLR	meester-loeys syndrome, 300989 (3), ; spondyloepimetaphyseal dysplasia, 300106 (3),
BGP		
BGP1		
BGR		
BGT-1		
BH		
BH-Pcdh		
BHC110	AD	cleft palate, psychomotor retardation, and distinctive facial features, 616728 (3),
BHC80	AD	intellectual developmental disorder with behavioral abnormalities and craniofacial dysmorphism with or without seizures, 618725 (3),
BHC80L		
BHD	AD	birt-hogg-dube syndrome, 135150 (3), ; colorectal cancer, somatic, 114500 (3); pneumothorax, primary spontaneous, 173600 (3), ; renal carcinoma, chromophobe, somatic, 144700 (3)
BHF-1	AD	{type 2 diabetes mellitus, susceptibility to}, 125853 (3), ; maturity-onset diabetes of the young 6, 606394 (3)
bHLHa1	AD	developmental and epileptic encephalopathy 72, 618374 (3),
bHLHa13	AR	persistent hyperplastic primary vitreous, 221900 (3),
bHLHa14	AD	?deafness, 89, 620284 (3),
BHLHA15		
bHLHa17		leukemia, t-cell acute lymphocytic, somatic, 613065 (3)
bHLHa18		leukemia, t-cell acute lymphoblastoid, 151440 (2)
bHLHa19		leukemia, t-cell acute lymphocytic, somatic, 613065 (3)
bHLHa2		
bHLHa21		
bHLHa22		
bHLHa23		
bHLHa24		
bHLHa26		
bHLHa27		
bHLHa29	AR	pancreatic and cerebellar agenesis, 609069 (3), ; pancreatic agenesis 2, 615935 (3),
bHLHa3	AD	{type 2 diabetes mellitus, susceptibility to}, 125853 (3), ; maturity-onset diabetes of the young 6, 606394 (3)
bHLHa31		
bHLHa34	AR	?hypogonadotropic hypogonadism 27 without anosmia, 619755 (3),
bHLHa35		
bHLHa38	AD	craniosynostosis 1, 123100 (3), ; robinow-sorauf syndrome, 180750 (3), ; sweeney-cox syndrome, 617746 (3), ; saethre-chotzen syndrome with or without eyelid anomalies, 101400 (3),
bHLHa39	AD,AR	ablepharon-macrostomia syndrome, 200110 (3), ; barber-say syndrome, 209885 (3), ; focal facial dermal dysplasia 3, setleis type, 227260 (3),
bHLHa4		
bHLHa40		
bHLHa41		
bHLHa42		
bHLHa44		
bHLHa45		
bHLHa46		
bHLHa48		
bHLHa6		
bHLHa7	AR	diarrhea 4, malabsorptive, congenital, 610370 (3),
bHLHa8		
BHLHA9	AR	?camptosynpolydactyly, complex, 607539 (3), ; syndactyly, mesoaxial synostotic, with phalangeal reduction, 609432 (3),
BHLHB1		
bHLHb11		{hyperlipidemia, familial combined, susceptibility to}, 602491 (3)
bHLHb12		
bHLHb19	AD	pitt-hopkins syndrome, 610954 (3), ; corneal dystrophy, fuchs endothelial, 3, 613267 (3),
BHLHB2		
bHLHb20	AD,AR	craniosynostosis 3, 615314 (3), ; hypogonadotropic hypogonadism 26 with or without anosmia, 619718 (3),
bHLHb21	AR,AD	agammaglobulinemia 8b, 619824 (3), ; agammaglobulinemia 8a, 616941 (3),
bHLHb24		
bHLHb25		
bHLHb26		
bHLHb27		
BHLHB3	AD	[short sleep, familial natural, 1], 612975 (3),
bHLHb31		
bHLHb32		
bHLHb33		
bHLHb37	AR	spondylocostal dysostosis 4, 613686 (3),
bHLHb38		
bHLHb39		
BHLHB4		
bHLHb40		
bHLHb41		
bHLHb42		
bHLHb43		
bHLHb44		
BHLHB5		
BHLHB6		
Bhlhb7		
BHLHB8		
BHLHB9		
bHLHc1	AR	congenital myopathy 17, 618975 (3),
bHLHc11		prostate cancer, somatic, 176807 (3); neurofibrosarcoma, somatic (3)
bHLHc12		
bHLHc13		
bHLHc2	AR	ophthalmoplegia, external, with rib and vertebral anomalies, 618155 (3),
bHLHc3		
bHLHc4		
bHLHc41		
bHLHc5		
bHLHc58		
bHLHc6	AR	spondylocostal dysostosis 2, 608681 (3),
bHLHc8	AD	premature ovarian failure 6, 612310 (3),
bHLHd1	AD	ichthyosis, follicular, with atrichia and photophobia syndrome 2, 619016 (3), ; mucoepithelial dysplasia, hereditary, 158310 (3),
bHLHd13		
bHLHd14		
bHLHd2		
bHLHd3		
bHLHd4	AD	{pheochromocytoma, susceptibility to}, 171300 (3),
bHLHd5	AD	{pheochromocytoma, susceptibility to}, 171300 (3),
bHLHd6	AD	{pheochromocytoma, susceptibility to}, 171300 (3),
bHLHd7	AD	{pheochromocytoma, susceptibility to}, 171300 (3),
bHLHd8	AD	{pheochromocytoma, susceptibility to}, 171300 (3),
bHLHe1	AR	?webb-dattani syndrome, 615926 (3),
bHLHe11		
bHLHe12		
bHLHe14		
bHLHe15		
bHLHe17		
bHLHe19		
bHLHe2		
bHLHe20		
bHLHe21		
BHLHE22		
BHLHE23		
bHLHe32	AD,AR	waardenburg syndrome, type 2a, 193510 (3), ; {melanoma, cutaneous malignant, susceptibility to, 8}, 614456 (3); tietz albinism-deafness syndrome, 103500 (3), ; commad syndrome, 617306 (3),
bHLHe33	XL	intellectual developmental disorder, syndromic, with pigmentary mosaicism and coarse facies, 301066 (3), ; renal cell carcinoma, papillary, 1, 300854 (3)
bHLHe34		
bHLHe35		
bHLHe36		
bHLHe37	AD	feingold syndrome 1, 164280 (3),
bHLHe38		
bHLHe39		burkitt lymphoma, somatic, 113970 (3)
BHLHE40		
BHLHE41	AD	[short sleep, familial natural, 1], 612975 (3),
bHLHe42		
bHLHe5		
bHLHe6		
bHLHe73	AD	erythrocytosis, familial, 4, 611783 (3),
bHLHe74		
bHLHe75		
bHLHe76	AR	?retinitis pigmentosa 85, 618345 (3),
bHLHe77		
bHLHe78		
bHLHe79		
bHLHe8		
bHLHe80	AR,AD	ovarian dysgenesis 5, 617690 (3), ; spermatogenic failure 32, 618115 (3),
bHLHe81		
bHLHe82		
bHLHe9		
BHLHF42	AR	?camptosynpolydactyly, complex, 607539 (3), ; syndactyly, mesoaxial synostotic, with phalangeal reduction, 609432 (3),
BHMT		
BHMT1		
BHMT2		
BHR1	AD	{asthma, susceptibility to}, 600807 (3), ; {allergic rhinitis, susceptibility to}, 607154 (3)
BI-1		
BIA1		
BICC1	AD	{renal dysplasia, cystic, susceptibility to}, 601331 (3),
BICD1		
BICD2	AD	spinal muscular atrophy, lower extremity-pre, 2b, 618291 (3), ; spinal muscular atrophy, lower extremity-pre, 2a, 615290 (3),
BICDL1		
BICDL2		
BICDL3P		
BICDR-1		
BICRA	AD	coffin-siris syndrome 12, 619325 (3),
BICRAL		
BID		
Bif-1		
BIF1	AR	immunodeficiency-centromeric instability-facial anomalies syndrome 2, 614069 (3),
BIG-1		
BIG-2		
BIG1	AD	developmental delay, impaired speech, and behavioral abnormalities, with or without seizures, 619964 (3),
BIG2	AR	periventricular heterotopia with microcephaly, 608097 (3),
BIG3		
BIGH3	AD	corneal dystrophy, avellino type, 607541 (3), ; corneal dystrophy, reis-bucklers type, 608470 (3), ; corneal dystrophy, thiel-behnke type, 602082 (3), ; corneal dystrophy, groenouw type i, 121900 (3), ; corneal dystrophy, epithelial basement membrane, 121820 (3), ; corneal dystrophy, lattice type i, 122200 (3), ; corneal dystrophy, lattice type iiia, 608471 (3),
BigLEN		
BIGM103	AR	congenital disorder of glycosylation, type iin, 616721 (3),
BIgR	AD	charcot-marie-tooth disease, axonal, type 2ff, 619519 (3),
BII	AD	developmental and epileptic encephalopathy 69, 618285 (3),
BIK		
BIKe		
BIM		
BimEL		
BimL		
BIMLEC		
BIMP1	AR	?immunodeficiency 89 and autoimmunity, 619632 (3),
BIMP2	AD	psoriasis 2, 602723 (3), ; pityriasis rubra pilaris, 173200 (3),
BIMP3	AD,AR	b-cell expansion with nfkb and t-cell anergy, 616452 (3), ; immunodeficiency 11b with atopic dermatitis, 617638 (3), ; immunodeficiency 11a, 615206 (3),
BimS		
BIN1	AR	centronuclear myopathy 2, 255200 (3),
BIN2		
BIN3		
BinCARD		
BING1		
BING4		
BIOT2		
BiP		
BIR	AD,AR	diabetes, permanent neonatal 2, with or without neurologic features, 618856 (3), ; {diabetes mellitus, type 2, susceptibility to}, 125853 (3), ; maturity-onset diabetes of the young, type 13, 616329 (3), ; diabetes mellitus, transient neonatal 3, 610582 (3), ; hyperinsulinemic hypoglycemia, familial, 2, 601820 (3),
BIR1	AD	keppen-lubinsky syndrome, 614098 (3),
BIR9	AR	hypokalemic tubulopathy and deafness, 619406 (3),
BIRC1		
BIRC2		
BIRC3		
BIRC4	XL,XLR	lymphoproliferative syndrome, 2, 300635 (3),
BIRC4BP		
BIRC5		
BIRC5-AS1		
BIRC5AS		
BIRC6		
BIRC7		
bis1		
BIT		
BIT1	AR	infantile-onset multisystem neurologic, endocrine, and pancreatic disease, 616263 (3),
BITE		
BIVM		
BJS	AR	gracile syndrome, 603358 (3), ; mitochondrial complex iii deficiency, nuclear type 1, 124000 (3), ; bjornstad syndrome, 262000 (3),
BK	AR,AD	[kininogen deficiency], 228960 (3), ; angioedema, hereditary, 6, 619363 (3), ; [high molecular weight kininogen deficiency], 228960 (3),
BK-2		
BK125H2.1	AR	klippel-feil syndrome 4, with myopathy and facial dysmorphism, 616549 (3),
BK126B4.1		
bK150C2.3		
BK150C2.4.MRNA		
bK150C2.7		
bK223H9		
bK223H9.2		
bK268H5		
bK268H5.C22.1		
bK286B10	AR	heme oxygenase-1 deficiency, 614034 (3), ; {pulmonary disease, chronic obstructive, susceptibility to}, 606963 (3)
bK3184A7.3	AD,AR	dyskeratosis congenita, 4, 615190 (3), ; dyskeratosis congenita, 5, 615190 (3), ; pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 3, 616373 (3),
BK65A6.2		
BK747E2.3		
BKLF		
BKLF3		
BKLHD1		
BKLHD2		
BKLHD4		
BKLHD6		
BKR1		
BKS		
BL11		
BL2		
BL34		
BL44		
BLACAT1		
BLACE		
BLAME		
BLAP18		
BLAP75		
BLAST		
BLAU	AD,MF	blau syndrome, 186580 (3), ; {yao syndrome}, 617321 (3), ; {inflammatory bowel disease 1, crohn disease}, 266600 (3),
BLBP		
BLC		
BLCAP		
BLID		
BLIMP1		
BLK	AD	maturity-onset diabetes of the young, type 11, 613375 (3),
BLM	AR	bloom syndrome, 210900 (3),
BLMH		
BLNC1		
BLNK	AR	?agammaglobulinemia 4, 613502 (3),
BLNK-s	AR	?agammaglobulinemia 4, 613502 (3),
BLOC1S1		
BLOC1S2		
BLOC1S3	AR	hermansky-pudlak syndrome 8, 614077 (3),
BLOC1S4		
BLOC1S5	AR	hermansky-pudlak syndrome 11, 619172 (3),
BLOC1S6	AR	?hermansky-pudlak syndrome 9, 614171 (3),
BLOC1S7		
BLOC1S8	AR	hermansky-pudlak syndrome 7, 614076 (3),
BLOC2S1	AR	hermansky-pudlak syndrome 3, 614072 (3),
BLOC2S2	AR	hermansky-pudlak syndrome 5, 614074 (3),
BLOC2S3	AR	hermansky-pudlak syndrome 6, 614075 (3),
BLOC3S1	AR	hermansky-pudlak syndrome 1, 203300 (3),
BLOC3S2	AR	hermansky-pudlak syndrome 4, 614073 (3),
BLOM4	AR	neurodevelopmental disorder with seizures and brain atrophy, 619072 (3),
BLOM7		
BLOS1		
BLOS2		
BLOS3	AR	hermansky-pudlak syndrome 8, 614077 (3),
blottin		
BLOV1		
BLP1		
BLP2		
BLPI		
BLR1		
BLR1L		
BLR2		
BLS	AR	bare lymphocyte syndrome, type ii, complementation group b, 209920 (3),
BLT2		
BLTP1	AR	alkuraya-kucinskas syndrome, 617822 (3),
BLTP2		
BLTP3A		
BLTP3B		
BLTP4A		
BLTP4B		
BLTP5A	AR	choreoacanthocytosis, 200150 (3),
BLTP5B	AR	cohen syndrome, 216550 (3),
BLTP5C	AR	parkinson disease 23, early onset, 616840 (3),
BLTP5D	AR	spinocerebellar ataxia, 4, 607317 (3),
BLTR		
BLTR2		
BLU	AR	ciliary dyskinesia, primary, 22, 615444 (3),
BLVR	AR,AD	hyperbiliverdinemia, 614156 (3),
BLVRA	AR,AD	hyperbiliverdinemia, 614156 (3),
BLVRB		
BLYS		
BLZF1		
BM-005	AD	myopia 21, 614167 (3),
BM-006	AD	intellectual developmental disorder with behavioral abnormalities and craniofacial dysmorphism with or without seizures, 618725 (3),
BM-009		
BM-010		
BM-011	AR	intellectual developmental disorder, 70, 618402 (3),
BM-016	AD	desanto-shinawi syndrome, 616708 (3),
BM-019	AR	mast syndrome, 248900 (3),
BM-102		
BM-40	AR	osteogenesis imperfecta, type xvii, 616507 (3),
BM022		
BM032	AR	microcephaly 6, primary, 608393 (3), ; ?seckel syndrome 4, 613676 (3),
BM036		
BM037		
BM039		
BM040		
BM042		
BM045		
BM046		
BM28	AD	?deafness, 70, 616968 (3),
BM32A	AR	neurodevelopmental disorder with hypotonia, dysmorphic facies, and skin abnormalities, 620191 (3),
BM600-100kDa	AR	epidermolysis bullosa, junctional 3b, severe, 619786 (3), ; epidermolysis bullosa, junctional 3a, intermediate, 619785 (3),
BM600-125kDa	AR,AD	epidermolysis bullosa, junctional 1b, severe, 226700 (3), ; epidermolysis bullosa, junctional 1a, intermediate, 226650 (3), ; amelogenesis imperfecta, type ia, 104530 (3),
BM600-150kDa	AR	epidermolysis bullosa, junctional 2a, intermediate, 619783 (3), ; epidermolysis bullosa, junctional 2c, laryngoonychocutaneous, 245660 (3), ; epidermolysis bullosa, junctional 2b, severe, 619784 (3),
BM88		
BMAC		
BMAL1		
BMAL2		
BMCC1		
BMCP1		
BMD	XLR,XL,AD,AR	becker muscular dystrophy, 300376 (3), ; cardiomyopathy, dilated, 3b, 302045 (3), ; duchenne muscular dystrophy, 310200 (3), |macular dystrophy, vitelliform, 2, 153700 (3), ; ?microcornea, rod-cone dystrophy, cataract, and posterior staphyloma 2, 193220 (3), ; retinitis pigmentosa-50, 613194 (3); retinitis pigmentosa, concentric, 613194 (3); vitreoretinochoroidopathy, 193220 (3), ; bestrophinopathy, 611809 (3)
BMF		
BMI1		
BMIQ4		{obesity, susceptibility to, bmiq4}, 607447 (3)
BMK1		
BMNCR		
BMND1	AD,AR	osteopetrosis, 1, 607634 (3), ; [bone mineral density variability 1], 601884 (3), ; polycystic liver disease 4 with or without kidney cysts, 617875 (3), ; endosteal hyperostosis, 144750 (3), ; osteoporosis-pseudoglioma syndrome, 259770 (3), ; exudative vitreoretinopathy 4, 601813 (3),
BMP-1	AR	osteogenesis imperfecta, type xiii, 614856 (3),
BMP-11	AD	?vertebral hypersegmentation and orofacial anomalies, 619122 (3),
BMP-3b		
BMP-9	AD	telangiectasia, hereditary hemorrhagic, type 5, 615506 (3),
BMP1	AR	osteogenesis imperfecta, type xiii, 614856 (3),
BMP10		
BMP11	AD	?vertebral hypersegmentation and orofacial anomalies, 619122 (3),
BMP12		
BMP13	AD,AR	microphthalmia with coloboma 6, digenic, 613703 (3), ; microphthalmia, isolated 4, 613094 (3); leber congenital amaurosis 17, 615360 (3), ; multiple synostoses syndrome 4, 617898 (3), ; klippel-feil syndrome 1, 118100 (3),
BMP14	AR,AD	acromesomelic dysplasia 2a, 200700 (3), ; acromesomelic dysplasia 2b, 228900 (3), ; multiple synostoses syndrome 2, 610017 (3), ; symphalangism, proximal, 1b, 615298 (3), ; brachydactyly, type a2, 112600 (3), ; ?acromesomelic dysplasia 2c, hunter-thompson type, 201250 (3), ; brachydactyly, type c, 113100 (3), ; {osteoarthritis-5}, 612400 (3); brachydactyly, type a1, c, 615072 (3),
BMP15	XL	premature ovarian failure 4, 300510 (3), ; ovarian dysgenesis 2, 300510 (3),
BMP2	AD,AR	short stature, facial dysmorphism, and skeletal anomalies with or without cardiac anomalies 1, 617877 (3), ; brachydactyly, type a2, 112600 (3), ; {hfe hemochromatosis, modifier of}, 235200 (3),
BMP2A	AD,AR	short stature, facial dysmorphism, and skeletal anomalies with or without cardiac anomalies 1, 617877 (3), ; brachydactyly, type a2, 112600 (3), ; {hfe hemochromatosis, modifier of}, 235200 (3),
BMP2B	AD	orofacial cleft 11, 600625 (3); microphthalmia, syndromic 6, 607932 (3),
BMP2K		
BMP3		
BMP4	AD	orofacial cleft 11, 600625 (3); microphthalmia, syndromic 6, 607932 (3),
BMP5		
BMP6	AD	{iron overload, susceptibility to}, 620121 (3),
BMP7		
BMP8		
BMP8B		
BMP9	AD	telangiectasia, hereditary hemorrhagic, type 5, 615506 (3),
BMPER	AR	diaphanospondylodysostosis, 608022 (3),
BMPG		
BMPR-II	AD	pulmonary hypertension, familial primary, 1, with or without hht, 178600 (3), ; pulmonary hypertension, primary, fenfluramine or dexfenfluramine-associated, 178600 (3), ; pulmonary venoocclusive disease 1, 265450 (3),
BMPR1A	AD	polyposis syndrome, hereditary mixed, 2, 610069 (3); polyposis, juvenile intestinal, 174900 (3),
BMPR1B	AR,AD	acromesomelic dysplasia 3, 609441 (3), ; brachydactyly, type a2, 112600 (3), ; brachydactyly, type a1, d, 616849 (3),
BMPR2	AD	pulmonary hypertension, familial primary, 1, with or without hht, 178600 (3), ; pulmonary hypertension, primary, fenfluramine or dexfenfluramine-associated, 178600 (3), ; pulmonary venoocclusive disease 1, 265450 (3),
BMPR3	AD	pulmonary hypertension, familial primary, 1, with or without hht, 178600 (3), ; pulmonary hypertension, primary, fenfluramine or dexfenfluramine-associated, 178600 (3), ; pulmonary venoocclusive disease 1, 265450 (3),
BMRP		
bMRP-10		
bMRP-59b		
bMRP36a		
bMRP64		
BMS1	AD	?aplasia cutis congenita, nonsyndromic, 107600 (3),
BMS1L	AD	?aplasia cutis congenita, nonsyndromic, 107600 (3),
BMSC-MCP		
BMSC-UbP		
BMT2		
BMX		
BMYB		
BMZF-1		
BMZF-2		
BMZF-3		
BMZF-4		
BMZF-5		
BN-1		
bn1	AD	?premature ovarian failure 16, 618723 (3),
bn2	AD	lower urinary tract obstruction, congenital, 618612 (3),
BN51T		
BNaC1		
BNaC2		
BNAC4		
BNAS1		
BNAS2		
BNC	AD	?premature ovarian failure 16, 618723 (3),
BNC1	AD	?premature ovarian failure 16, 618723 (3),
BNC2	AD	lower urinary tract obstruction, congenital, 618612 (3),
BND3L	AR	?osteopetrosis, 9, 620366 (3),
BND7		
BNF1		
BNIP-2		
BNIP-H	AR	ataxia, cerebellar, cayman type, 601238 (3),
BNIP-S		
BNIP-Salpha		
BNIP-Sbeta		
BNIP1		
BNIP2		
BNIP3		
BNIP3a		
BNIP3L		
BNIPL		
BNIPl-1		
BNIPL-2		
BNIPXL		
BNLN		
BNPI		
BNSP		
BOAT1		
BOB1		
BOC		
BOCA	AR	osteogenesis imperfecta, type xx, 618644 (3),
BOCT		
BOD		
BOD1		
BOD1L		
BOD1L1		
Bog		
Boi		
BOIT		
BOK		
BOKL		
BOLA1		
BOLA2		
BOLA2A		
BOLA3	AR	multiple mitochondrial dysfunctions syndrome 2 with hyperglycinemia, 614299 (3),
bolekine		
BOLL		
BOM	AD,AR	deafness, 28, 608641 (3), ; ectodermal dysplasia/short stature syndrome, 616029 (3), ; corneal dystrophy, posterior polymorphous, 4, 618031 (3),
BOMB		
BONZO		
Boo		
BOP	AD	colorblindness, tritan, 190900 (3),
BOP1		
BOR	AD	branchiootic syndrome 1, 602588 (3), ; branchiootorenal syndrome 1, with or without cataracts, 113650 (3), ; anterior segment anomalies with or without cataract, 602588 (3), ; ?otofaciocervical syndrome, 166780 (3),
BORA		
BORCS1		
BORCS2		
BORCS3		
BORCS4		
BORCS5		
BORCS6		
BORCS7		
BORCS8		
BORG1		
BORG2		
Borg3		
BORG4		
Borg5		
BORIS		
BORJ	XLR,XL	borjeson-forssman-lehmann syndrome, 301900 (3),
Bos1	AR	epilepsy, progressive myoclonic 6, 614018 (3), ; muscular dystrophy, congenital, with or without seizures, 620166 (3),
botv	AR	immunoskeletal dysplasia with neurodevelopmental abnormalities, 617425 (3),
BOULE		
BOV-1A	AR	thrombocytopenia-absent radius syndrome, 274000 (3),
BOV-1B	AR	thrombocytopenia-absent radius syndrome, 274000 (3),
BOV-1C	AR	thrombocytopenia-absent radius syndrome, 274000 (3),
BOZF1		
BP-4		
BP-53		
BP-8		
BP1	AD	?orofacial cleft 15, 616788 (3),
BP180	AD,AR	epithelial recurrent erosion dystrophy, 122400 (3), ; epidermolysis bullosa, junctional 4, intermediate, 619787 (3),
BP240	AR	neuropathy, hereditary sensory and autonomic, type vi, 614653 (3), ; epidermolysis bullosa simplex 3, localized or generalized intermediate, with bp230 deficiency, 615425 (3),
Bp35	AR	?immunodeficiency, common variable, 5, 613495 (3),
Bp50	AR	immunodeficiency with hyper-igm, type 3, 606843 (3),
BP75		
BPA	AR	neuropathy, hereditary sensory and autonomic, type vi, 614653 (3), ; epidermolysis bullosa simplex 3, localized or generalized intermediate, with bp230 deficiency, 615425 (3),
BPAG1	AR	neuropathy, hereditary sensory and autonomic, type vi, 614653 (3), ; epidermolysis bullosa simplex 3, localized or generalized intermediate, with bp230 deficiency, 615425 (3),
BPAG2	AD,AR	epithelial recurrent erosion dystrophy, 122400 (3), ; epidermolysis bullosa, junctional 4, intermediate, 619787 (3),
bPAK	XL,XLR	intellectual developmental disorder, 30, 300558 (3),
BPEG	AR	centronuclear myopathy 5, 615959 (3),
BPES	AR,AD	blepharophimosis, epicanthus inversus, and ptosis, type 2, 110100 (3), ; blepharophimosis, epicanthus inversus, and ptosis, type 1, 110100 (3), ; premature ovarian failure 3, 608996 (3),
BPES1	AR,AD	blepharophimosis, epicanthus inversus, and ptosis, type 2, 110100 (3), ; blepharophimosis, epicanthus inversus, and ptosis, type 1, 110100 (3), ; premature ovarian failure 3, 608996 (3),
BPES2	AD	craniosynostosis 1, 123100 (3), ; robinow-sorauf syndrome, 180750 (3), ; sweeney-cox syndrome, 617746 (3), ; saethre-chotzen syndrome with or without eyelid anomalies, 101400 (3),
BPES3	AD	craniosynostosis 1, 123100 (3), ; robinow-sorauf syndrome, 180750 (3), ; sweeney-cox syndrome, 617746 (3), ; saethre-chotzen syndrome with or without eyelid anomalies, 101400 (3),
BPESC1		
BPGAP1		
BPGM	AR	erythrocytosis, familial, 8, 222800 (3),
Bph-rp		
BPHL		
BPI		
BPIFA1		
BPIFA4P		
BPIFB2		
BPIFB3		
BPIFB4		
BPIFB6		
BPIFC		
BPIFD1		
BPIFD2		
BPIFE		
BPIFF	AD	[high density lipoprotein cholesterol level qtl 10], 143470 (3), ; hyperalphalipoproteinemia, 143470 (3),
BPIL1		
BPIL2		
BPIL3		
BPLP		
BPNT1		
BPNT2	AR	chondrodysplasia with joint dislocations, gpapp type, 614078 (3),
BPOZ		
BPTF	AD	neurodevelopmental disorder with dysmorphic facies and distal limb anomalies, 617755 (3),
BPTP3	AD	noonan syndrome 1, 163950 (3), ; leopard syndrome 1, 151100 (3), ; metachondromatosis, 156250 (3), ; leukemia, juvenile myelomonocytic, somatic, 607785 (3)
BPX		
BPY1		
BPY1B		
BPY2		
BPY2A		
BPY2IP1		
BR		
Br-cadherin		
BR140	AD	intellectual developmental disorder with dysmorphic facies and ptosis, 617333 (3),
BR22		
bradyb1		
BRAF	AD	melanoma, malignant, somatic, 155600 (3); leopard syndrome 3, 613707 (3), ; cardiofaciocutaneous syndrome, 115150 (3), ; adenocarcinoma of lung, somatic, 211980 (3); noonan syndrome 7, 613706 (3), ; colorectal cancer, somatic, 114500 (3); nonsmall cell lung cancer, somatic, 211980 (3)
BRAF-1	AD	melanoma, malignant, somatic, 155600 (3); leopard syndrome 3, 613707 (3), ; cardiofaciocutaneous syndrome, 115150 (3), ; adenocarcinoma of lung, somatic, 211980 (3); noonan syndrome 7, 613706 (3), ; colorectal cancer, somatic, 114500 (3); nonsmall cell lung cancer, somatic, 211980 (3)
BRAF1	AD	melanoma, malignant, somatic, 155600 (3); leopard syndrome 3, 613707 (3), ; cardiofaciocutaneous syndrome, 115150 (3), ; adenocarcinoma of lung, somatic, 211980 (3); noonan syndrome 7, 613706 (3), ; colorectal cancer, somatic, 114500 (3); nonsmall cell lung cancer, somatic, 211980 (3)
BRAF2		
BRAF25		
BRAF35		
BRAFP1		
BRAFPS2		
BRAG		
BRAG1	XL,XLD	intellectual developmental disorder, 1, 309530 (3),
BRAG2	AR	intellectual developmental disorder with short stature and behavioral abnormalities, 618687 (3),
BRAK		
BRAL1		
BRAL2		
BRAM1	AD	intellectual developmental disorder, 30, 616083 (3),
BRAP		
BRAP-1		
BRAP2		
BRAT1	AR	neurodevelopmental disorder with cerebellar atrophy and with or without seizures, 618056 (3), ; rigidity and multifocal seizure syndrome, lethal neonatal, 614498 (3),
Bravo	AR	neurodevelopmental disorder with neuromuscular and skeletal abnormalities, 619833 (3),
BRCA1	AR,MF,AD	fanconi anemia, complementation group s, 617883 (3), ; {breast-ovarian cancer, familial, 1}, 604370 (3), ; {pancreatic cancer, susceptibility to, 4}, 614320 (3)
BRCA2	AR,AD	fanconi anemia, complementation group d1, 605724 (3), ; {glioblastoma 3}, 613029 (3), ; {medulloblastoma}, 155255 (3), somatic mutation, ; {prostate cancer}, 176807 (3), somatic mutation, ; {breast-ovarian cancer, familial, 2}, 612555 (3), ; {breast cancer, male, susceptibility to}, 114480 (3), somatic mutation, ; {pancreatic cancer 2}, 613347 (3); wilms tumor, 194070 (3), somatic mutation,
BRCAA1		
BRCACOX	AR	bile acid synthesis defect, congenital, 6, 617308 (3),
BRCC1	AR,MF,AD	fanconi anemia, complementation group s, 617883 (3), ; {breast-ovarian cancer, familial, 1}, 604370 (3), ; {pancreatic cancer, susceptibility to, 4}, 614320 (3)
BRCC2	AR,AD	fanconi anemia, complementation group d1, 605724 (3), ; {glioblastoma 3}, 613029 (3), ; {medulloblastoma}, 155255 (3), somatic mutation, ; {prostate cancer}, 176807 (3), somatic mutation, ; {breast-ovarian cancer, familial, 2}, 612555 (3), ; {breast cancer, male, susceptibility to}, 114480 (3), somatic mutation, ; {pancreatic cancer 2}, 613347 (3); wilms tumor, 194070 (3), somatic mutation,
BRCC3		
BRCC36		
BRCC4		
BRCC45		
BRCC5	AD	mirror movements 2, 614508 (3), ; {breast cancer, susceptibility to}, 114480 (3), somatic mutation, ; fanconi anemia, complementation group r, 617244 (3),
BRCOX	AR	bile acid synthesis defect, congenital, 6, 617308 (3),
BRCTD1		
BRCTx		
BRD1		
BRD2		
BRD2-IT1		
BRD3		
BRD4		
BRD6	AR	?spermatogenic failure 21, 617644 (3),
BRD7		
BRD8		
BRD9		
BRDG1		
BRDt	AR	?spermatogenic failure 21, 617644 (3),
BRDT	AR	?spermatogenic failure 21, 617644 (3),
BRE		
BRE1		
BRE1A		
BRE1B		
Bre2		
BREK		
BRESI1		
BRF	AR	cerebellofaciodental syndrome, 616202 (3),
BRF1	AR	cerebellofaciodental syndrome, 616202 (3),
BRF2	AR	oocyte/zygote/embryo maturation arrest 13, 620154 (3),
BRFU		
BRG1	AD	coffin-siris syndrome 4, 614609 (3), ; {rhabdoid tumor predisposition syndrome 2}, 613325 (3),
BRI	AD	?retinal dystrophy with inner retinal dysfunction and ganglion cell abnormalities, 616079 (3), ; dementia, familial british, 176500 (3), ; dementia, familial danish, 117300 (3),
BRI2	AD	?retinal dystrophy with inner retinal dysfunction and ganglion cell abnormalities, 616079 (3), ; dementia, familial british, 176500 (3), ; dementia, familial danish, 117300 (3),
BRI3		
BRI3BP		
BRI3BP-AS1		
BRIC	AR,AD	cholestasis, progressive familial intrahepatic 1, 211600 (3), ; cholestasis, intrahepatic, of pregnancy, 1, 147480 (3), ; cholestasis, benign recurrent intrahepatic, 243300 (3),
BRICD1		
BRICD1B		
BRICD2A		
BRICD2B	AD	?retinal dystrophy with inner retinal dysfunction and ganglion cell abnormalities, 616079 (3), ; dementia, familial british, 176500 (3), ; dementia, familial danish, 117300 (3),
BRICD2C		
BRICD3		
BRICD4		
BRICD6	AD	surfactant metabolism dysfunction, pulmonary, 2, 610913 (3),
BRIGHT		
BRIL	AD	osteogenesis imperfecta, type v, 610967 (3),
BRINP1		
BRINP2		
BRINP3		
BRIP1	AD	fanconi anemia, complementation group j, 609054 (3); {breast cancer, early-onset, susceptibility to}, 114480 (3), somatic mutation,
BRIT1	AR	microcephaly 1, primary, 251200 (3),
BRIX		
BRIX1		
BRK		
BRK-3	AD	pulmonary hypertension, familial primary, 1, with or without hht, 178600 (3), ; pulmonary hypertension, primary, fenfluramine or dexfenfluramine-associated, 178600 (3), ; pulmonary venoocclusive disease 1, 265450 (3),
BRK1		
BRL		
BRLZ		
BRM	AD	nicolaides-baraitser syndrome, 601358 (3), ; blepharophimosis-impaired intellectual development syndrome, 619293 (3),
BRME1		
BRMS1		
BRMS1L		
BRMS2		
Brn-3b		
BRN1	AD	snijders blok-fisher syndrome, 618604 (3),
BRN2		
BRN3A	AD	ataxia, intention tremor, and hypotonia syndrome, childhood-onset, 619352 (3),
BRN3B		
BRN3C	AD	deafness, 15, 602459 (3),
BRN4	XL,XLR	deafness, 2, 304400 (3),
BRN5		
BROMI		
BRP17	AD	paroxysmal nonkinesigenic dyskinesia 1, 118800 (3),
BRP44		
BRP44L	AR	mitochondrial pyruvate carrier deficiency, 614741 (3),
BRPF1	AD	intellectual developmental disorder with dysmorphic facies and ptosis, 617333 (3),
BRPF2		
BRPF3		
BRPK	AR	parkinson disease 6, early onset, 605909 (3),
brPTB		
Brr2	AD	retinitis pigmentosa 33, 610359 (3),
BRRN1	AR	?microcephaly 23, primary, 617985 (3),
BRS1		
BRS2		
BRS3		
BRSK1		
BRSK2		
BRST-2		
Brt		
BRUCE		
BRUNOL1		
BRUNOL2		
BRUNOL3	AD	developmental and epileptic encephalopathy 97, 619561 (3),
BRUNOL4		
BRUNOL5		
BRUNOL6		
BRWD1		
BRWD2	AD,AR,AD	chung-jansen syndrome, 617991 (3), |intellectual developmental disorder, 78, 620237 (3), ; hypogonadotropic hypogonadism 14 with or without anosmia, 614858 (3),
BRWD3	XL,XLR	intellectual developmental disorder, 93, 300659 (3),
BRX		
Brx1	AD	ring dermoid of cornea, 180550 (3), ; axenfeld-rieger syndrome, type 1, 180500 (3), ; anterior segment dysgenesis 4, 137600 (3),
BS	AR	bloom syndrome, 210900 (3),
BS-63		
BS-84		
BS4		
BS69	AD	intellectual developmental disorder, 30, 616083 (3),
BSAC	AR	?immunodeficiency 66, 618847 (3),
BSAP		{leukemia, acute lymphoblastic, susceptibility to, 3}, 615545 (3)
BSC	AR	bartter syndrome, type 1, 601678 (3),
BSC-1	AR	bartter syndrome, type 1, 601678 (3),
BSC-2	AR,AD	kilquist syndrome, 619080 (3), ; delpire-mcneill syndrome, 619083 (3), ; deafness, 78, 619081 (3),
BSC1	AR	bartter syndrome, type 1, 601678 (3),
BSC2	AR,AD	kilquist syndrome, 619080 (3), ; delpire-mcneill syndrome, 619083 (3), ; deafness, 78, 619081 (3),
BSCL	AR	lipodystrophy, congenital generalized, type 1, 608594 (3),
BSCL2	AR,AD	lipodystrophy, congenital generalized, type 2, 269700 (3), ; neuropathy, distal hereditary motor, type vc, 619112 (3), ; silver spastic paraplegia syndrome, 270685 (3), ; encephalopathy, progressive, with or without lipodystrophy, 615924 (3),
BSCv		
BSDC1		
BSEP	AR	cholestasis, benign recurrent intrahepatic, 2, 605479 (3), ; cholestasis, progressive familial intrahepatic 2, 601847 (3),
BSF-3	AR	cold-induced sweating syndrome 2, 610313 (3),
BSF1		
BSF2	AD,AR,MF	{type 2 diabetes mellitus}, 125853 (3), ; {rheumatoid arthritis, systemic juvenile}, 604302 (3); {intracranial hemorrhage in brain cerebrovascular malformations, susceptibility to}, 108010 (3), somatic mutation; {type 1 diabetes mellitus}, 222100 (3), ; {crohn disease-associated growth failure}, 266600 (3), ; {kaposi sarcoma, susceptibility to}, 148000 (3),
BSF3	AR	cold-induced sweating syndrome 2, 610313 (3),
BSG		[blood group, ok], 111380 (3)
BSMAP		
BSN		
BSN1	AD	?premature ovarian failure 16, 618723 (3),
BSN2	AD	lower urinary tract obstruction, congenital, 618612 (3),
BSND	AR	sensorineural deafness with mild renal dysfunction, 602522 (3), ; bartter syndrome, type 4a, 602522 (3),
BSP		
BSP-II		
BSP1		
BSPECV		
BSPH1		
BSPI		
BSPRY		
Bsr		
BSSL	AD	maturity-onset diabetes of the young, type viii, 609812 (3),
Bssp		
BSSP-3	AR	intellectual developmental disorder, 1, 249500 (3),
BSSP-4		
BST-1		
BST-2		
Bst1	AR	neurodevelopmental disorder with dysmorphic features, spasticity, and brain abnormalities, 615802 (3),
BST1		
BST2		
BSX		
BSX1		
BSYN2		
BT		
BT-IgSF		
BT2.1		
BT2.2		
BT2A		
BT2B		
BT2C		
BT2D		
BT3.1		
BTAF1		
BTAK	AD	{colon cancer, susceptibility to}, 114500 (3), somatic mutation,
Btb3		
BTBD1		
BTBD10		
BTBD12	AR	fanconi anemia, complementation group p, 613951 (3),
BTBD13		
BTBD14A		
BTBD14B	AD	neurodevelopmental disorder with epilepsy, cataracts, feeding difficulties, and delayed brain myelination, 617393 (3),
BTBD17B		
BTBD2		
BTBD20		
BTBD21		
BTBD23		
BTBD24		
BTBD25	AD	immunodeficiency 60 and autoimmunity, 618394 (3),
BTBD26		
BTBD27		
BTBD28		
BTBD29	AR,AD	noonan syndrome 2, 605275 (3), ; noonan syndrome 10, 616564 (3), ; {schwannomatosis-2, susceptibility to}, 615670 (3),
BTBD3		
BTBD30	AD	neurodevelopmental disorder with epilepsy, cataracts, feeding difficulties, and delayed brain myelination, 617393 (3),
BTBD31		
BTBD32	AD	nabais sa-de vries syndrome, type 1, 618828 (3), ; nabais sa-de vries syndrome, type 2, 618829 (3),
BTBD34		
BTBD4		
BTBD7		
BTBD8		
BTBD9		
BTC		
BTCL1		
BTD	AR	biotinidase deficiency, 253260 (3),
Btdc		
BTEB1		
BTEB2		
BTEB3		
BTEB4		
BTEB5		
BTF		
BTF1		
BTF2	AR	trichothiodystrophy 2, photosensitive, 616390 (3), ; xeroderma pigmentosum, group b, 610651 (3),
BTF2P44		
BTF3		
BTF3a		
BTF3b		
BTF3L1		
BTF3P11		
BTF4		
BTF5		
BTG1		
BTG2		
BTG3		
BTG4	AR	oocyte/zygote/embryo maturation arrest 8, 619009 (3),
BTHS	XLR,XL	barth syndrome, 302060 (3),
BTK	XL,XLR	agammaglobulinemia, 1, 300755 (3), ; isolated growth hormone deficiency, type iii, with agammaglobulinemia, 307200 (3),
BTKAP1		
BTKI		
BTKL		
BTL	AD	{leukemia, acute myeloid}, 601626 (3), somatic mutation,
BTL-II	AD	{sarcoidosis, susceptibility to, 2}, 612387 (3),
BTLA		
BTLA1		
BTN		
BTN1	AR	ceroid lipofuscinosis, neuronal, 3, 204200 (3),
BTN1A1		
BTN2.1		
BTN2.2		
BTN2.3		
BTN2A1		
BTN2A2		
BTN2A3		
BTN2A3P		
BTN3.1		
BTN3.2		
BTN3.3		
BTN3A1		
BTN3A2		
BTN3A3		
BTN5		[blood group, scianna system], 111750 (3); [blood group, radin], 111620 (3)
BTN6	AD	?narcolepsy 7, 614250 (3),
BTN7	AD	{sarcoidosis, susceptibility to, 2}, 612387 (3),
BTN9.1		
BTN9.2		
BTNL11	AD	?narcolepsy 7, 614250 (3),
BTNL2	AD	{sarcoidosis, susceptibility to, 2}, 612387 (3),
BTNL3		
BTNL8		
BTNLR		
BTR1	AR	corneal endothelial dystrophy, 217700 (3), ; corneal dystrophy, fuchs endothelial, 4, 613268 (3); corneal endothelial dystrophy and perceptive deafness, 217400 (3),
BTRC		
BTRC2	AD	neurodevelopmental, jaw, eye, and digital syndrome, 618914 (3),
bTrCP		
bTrCP1		
BTRCP2	AD	neurodevelopmental, jaw, eye, and digital syndrome, 618914 (3),
BTS	AR	ceroid lipofuscinosis, neuronal, 3, 204200 (3),
BTZ		
BUB1	AR	colorectal cancer with chromosomal instability, somatic, 114500 (3); microcephaly 30, primary, 620183 (3),
Bub1A	AD,AR	colorectal cancer, somatic, 114500 (3); [premature chromatid separation trait], 176430 (3), ; mosaic variegated aneuploidy syndrome 1, 257300 (3),
BUB1A	AR	colorectal cancer with chromosomal instability, somatic, 114500 (3); microcephaly 30, primary, 620183 (3),
BUB1B	AD,AR	colorectal cancer, somatic, 114500 (3); [premature chromatid separation trait], 176430 (3), ; mosaic variegated aneuploidy syndrome 1, 257300 (3),
BUB1L	AR	colorectal cancer with chromosomal instability, somatic, 114500 (3); microcephaly 30, primary, 620183 (3),
BUB3		
BUB3L		
BUBR1	AD,AR	colorectal cancer, somatic, 114500 (3); [premature chromatid separation trait], 176430 (3), ; mosaic variegated aneuploidy syndrome 1, 257300 (3),
BUCS1		
BUD22		
BUD23		
BUD31		
BUD32	AR	galloway-mowat syndrome 4, 617730 (3),
BUG13	AD	vertebral, cardiac, tracheoesophageal, renal, and limb defects, 619227 (3),
BuGZ		
Bun107		
Bun62		
BUP		
BUP1	AR	beta-ureidopropionase deficiency, 613161 (3),
BUSI2		
Buster1		
Buster2		
Buster3		
Buster4		
BV05S1J2.2		
BV8	AD	hypogonadotropic hypogonadism 4 with or without anosmia, 610628 (3),
BVES	AR	muscular dystrophy, limb-girdle, 25, 616812 (3),
BWCR	AD,AD,AD	image syndrome, 614732 (3), ; beckwith-wiedemann syndrome, 130650 (3), |wilms tumor 2, 194071 (3), somatic mutation, ; beckwith-wiedemann syndrome, 130650 (3), ; silver-russell syndrome 1, 180860 (3), |wilms tumor 2, 194071 (3), somatic mutation, ; beckwith-wiedemann syndrome, 130650 (3), ; silver-russell syndrome 1, 180860 (3),
BWD		
BWR1A		breast cancer, somatic, 114480 (3); lung cancer, somatic, 211980 (3); rhabdomyosarcoma, somatic, 268210 (3)
BWR1B		
BWR1C		
BWRT		
BWS	AD,AD,AD	image syndrome, 614732 (3), ; beckwith-wiedemann syndrome, 130650 (3), |wilms tumor 2, 194071 (3), somatic mutation, ; beckwith-wiedemann syndrome, 130650 (3), ; silver-russell syndrome 1, 180860 (3), |wilms tumor 2, 194071 (3), somatic mutation, ; beckwith-wiedemann syndrome, 130650 (3), ; silver-russell syndrome 1, 180860 (3),
BWSCR1A		breast cancer, somatic, 114480 (3); lung cancer, somatic, 211980 (3); rhabdomyosarcoma, somatic, 268210 (3)
BWSCR1B		
Bx42		
BXDC1		
BXDC2		
BXDC3		
BXDC4		
BXLBv68		
BXMAS1		
BXMAS2-10		
BXR		
BY55		
BYE1		
BYSL		
BZAP45		
BZEL		
BZP	AD	corneal dystrophy, posterior polymorphous, 3, 609141 (3), ; corneal dystrophy, fuchs endothelial, 6, 613270 (3),
BZRAP1		
BZRP		
BZRPL1		
BZS	AD	{glioma susceptibility 2}, 613028 (3), ; {meningioma}, 607174 (3), ; cowden syndrome 1, 158350 (3), ; lhermitte-duclos disease, 158350 (3), ; prostate cancer, somatic, 176807 (3); macrocephaly/autism syndrome, 605309 (3),
BZW1		
BZW2		
C-1		
C-193		
C-2k		
c-ABL	AD	leukemia, philadelphia chromosome-positive, resistant to imatinib, 608232 (3), somatic mutation; congenital heart defects and skeletal malformations syndrome, 617602 (3),
C-ANCA		
c-Cbl	AD	noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia, 613563 (3), ; ?juvenile myelomonocytic leukemia, 607785 (3), somatic mutation,
c-COT		lung cancer, somatic, 211980 (3)
c-E10	AR	{lymphoma, follicular, somatic}, 605027 (3); ?immunodeficiency 37, 616098 (3), ; {sezary syndrome, somatic} (3); {male germ cell tumor, somatic}, 273300 (3); lymphoma, malt, somatic, 137245 (3); {mesothelioma, somatic}, 156240 (3)
c-ERB-2	AR	gastric cancer, somatic, 613659 (3); adenocarcinoma of lung, somatic, 211980 (3); ovarian cancer, somatic, 167000 (3); ?visceral neuropathy, familial, 2, 619465 (3), ; glioblastoma, somatic, 137800 (3)
c-ERB2	AR	gastric cancer, somatic, 613659 (3); adenocarcinoma of lung, somatic, 211980 (3); ovarian cancer, somatic, 167000 (3); ?visceral neuropathy, familial, 2, 619465 (3), ; glioblastoma, somatic, 137800 (3)
c-erbA	AD	hypothyroidism, congenital, nongoitrous, 6, 614450 (3),
c-ERBA-1	AD	hypothyroidism, congenital, nongoitrous, 6, 614450 (3),
c-erbA-2	AR,AD	thyroid hormone resistance, 274300 (3), ; thyroid hormone resistance, 188570 (3), ; thyroid hormone resistance, selective pituitary, 145650 (3),
c-erbA-beta	AR,AD	thyroid hormone resistance, 274300 (3), ; thyroid hormone resistance, 188570 (3), ; thyroid hormone resistance, selective pituitary, 145650 (3),
c-Eyk	AR	retinitis pigmentosa 38, 613862 (3),
c-fgr		
c-FLIP		
C-FMS	AR,AD	brain abnormalities, neurodegeneration, and dysosteosclerosis, 618476 (3), ; leukoencephalopathy, diffuse hereditary, with spheroids 1, 221820 (3),
c-fos		
c-IAP1		
c-IAP2		
c-Jun		
C-Kit	AD	gastrointestinal stromal tumor, familial, 606764 (3), isolated cases, ; mastocytosis, cutaneous, 154800 (3), ; piebaldism, 172800 (3), ; germ cell tumors, somatic, 273300 (3); mastocytosis, systemic, somatic, 154800 (3); leukemia, acute myeloid, somatic, 601626 (3)
c-Krox		
c-lbc		
c-MAF	AD	cataract 21, multiple types, 610202 (3), ; ayme-gripp syndrome, 601088 (3),
c-MIR		
c-myb		{t-cell acute lymphoblastic leukemia} (3)
c-Myc		burkitt lymphoma, somatic, 113970 (3)
C-NAP1	AR	cone-rod dystrophy and hearing loss 2, 618358 (3),
C-P4Halpha(I)		
C-P4Halpha(II)	AD	myopia 25, 617238 (3),
C-P4Halpha(III)		
c-Raf	AD	cardiomyopathy, dilated, 1nn, 615916 (3), ; noonan syndrome 5, 611553 (3), ; leopard syndrome 2, 611554 (3)
c-Rel	AR	immunodeficiency 92, 619652 (3),
c-ros-1		
C-SAA		
c-src	AD	?thrombocytopenia 6, 616937 (3), ; colon cancer, advanced, somatic, 114500 (3)
c-yes		
C(27)-3BETA-HSD	AR	bile acid synthesis defect, congenital, 1, 607765 (3),
C/EBP-alpha	AD	leukemia, acute myeloid, somatic, 601626 (3); ?leukemia, acute myeloid, 601626 (3), somatic mutation,
C/EBP-beta		
C/EBP-delta		
C1		
C1-INH	AR,AD	angioedema, hereditary, 1 and 2, 106100 (3), ; complement component 4, partial deficiency of, 120790 (3),
C1-TEN		
C10	AR	temtamy syndrome, 218340 (3),
C10orf10		
C10orf104		
C10orf11	AR	albinism, oculocutaneous, type vii, 615179 (3),
C10orf110		
C10orf112		
C10orf113		
C10orf117		
C10orf118		
C10orf119		
C10orf12		
C10orf123		
C10orf124		
C10orf125		
C10orf132		
C10orf133		
C10orf134		
C10orf138		
C10orf14		
C10orf141		
C10orf2	AR,AD	mitochondrial dna depletion syndrome 7 (hepatocerebral type), 271245 (3), ; progressive external ophthalmoplegia with mitochondrial dna deletions, 3, 609286 (3), ; perrault syndrome 5, 616138 (3),
C10orf22		
C10orf23		
C10orf24	AD	preeclampsia/eclampsia 4, 609404 (3),
C10orf26		
C10orf27		
C10orf3	AR	multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly, 236500 (3),
C10orf32		
C10orf33		
C10orf34		
C10orf36		
C10orf39		
C10orf4	AR	neurodevelopmental disorder with growth retardation, dysmorphic facies, and corpus callosum abnormalities, 620113 (3),
C10orf42		
C10orf46		
C10orf48		
C10orf5		
C10orf54		
C10orf58		
C10orf59		
C10orf6	AR	atelis syndrome 1, 620184 (3),
C10orf60		
C10orf61	AR	joubert syndrome 18, 614815 (3), ; orofaciodigital syndrome iv, 258860 (3),
C10orf63		
C10orf64		
C10orf65	AR	hyperoxaluria, primary, type iii, 613616 (3),
C10orf66		
C10orf68		
C10orf69	AR	spastic paraplegia 62, 615681 (3),
C10orf7		
C10orf70		
C10orf74		
C10orf75		
C10orf78		
C10orf79	AD,AR	hydrocephalus, normal pressure, 1, 236690 (3), ; spermatogenic failure 19, 617592 (3),
C10orf8		
C10orf80	AR	spermatogenic failure 49, 619144 (3),
C10orf83		
C10orf86		
C10orf89		
C10orf9		
C10orf90		
C10orf92		
C10orf93		
C10orf94	AR	?spermatogenic failure 15, 616950 (3), ; ?premature ovarian failure 12, 616947 (3),
C10orf97		
C10orf99		
C10rf4	AD	coffin-siris syndrome 2, 614607 (3),
C11	AR,AR	{46xy sex reversal 8, modifier of}, 614279 (3), |leukodystrophy, hypomyelinating, 21, 619310 (3),
C114		
C11orf10		
C11orf11		
C11orf13		
C11orf14		
C11orf15		
C11orf17		
C11orf19	AD	?aniridia 2, 617141 (3),
C11orf2	AR	pontocerebellar hypoplasia, type 13, 618606 (3),
C11orf20		
C11orf21		
C11orf23		
C11orf24		
C11orf25	AD	dystonia 24, 615034 (3),
C11orf27		
C11orf29		
C11orf3	AR	pontocerebellar hypoplasia, type 13, 618606 (3),
C11orf30		
C11orf31		
C11orf32		
C11orf33		
C11orf34		
C11orf4		
C11orf41		
C11orf43	AD	silver-russell syndrome 3, 616489 (3),
C11orf46		
C11orf47	AR	spermatogenic failure 65, 619712 (3),
C11orf5		
C11orf51		
C11orf54		
C11orf56		
C11orf58		
C11orf59		
C11orf63		
C11orf66		
C11orf69		
C11orf7		
C11orf70	AR	ciliary dyskinesia, primary, 38, 618063 (3),
C11orf73	AR	leukodystrophy, hypomyelinating, 13, 616881 (3),
C11orf74		
C11orf75		
C11orf77		
C11orf79	AD	paragangliomas 2, 601650 (3),
C11orf8		
C11orf80	AR	hydatidiform mole, recurrent, 4, 618432 (3),
C11orf81		
C11orf82		
C11orf83	AR	?mitochondrial complex iii deficiency, nuclear type 9, 616111 (3),
C11orf85		
C11orf9	AD	encephalitis/encephalopathy, mild, with reversible myelin vacuolization, 618113 (3), ; cardiac-urogenital syndrome, 618280 (3),
C11orf92		
C11orf93		
C11orf95		
C128	AR,AD	leukodystrophy, hypomyelinating, 8, with or without oligodontia and/or hypogonadotropic hypogonadism, 614381 (3), ; charcot-marie-tooth disease, demyelinating, type 1i, 619742 (3),
C12orf1		
C12orf10		
C12orf11		
C12orf14		
C12orf2		
C12ORF2		
C12orf22		
C12orf3		
C12orf30		
C12orf31		
C12orf32		
C12orf35		
C12orf38	AR	joubert syndrome 24, 616654 (3), ; ?meckel syndrome 8, 613885 (3),
C12orf39		
C12orf4	AR	intellectual developmental disorder, 66, 618221 (3),
C12orf41		
C12orf44		
C12orf46		
C12orf48		
C12orf5		
C12orf51	AR	neurodevelopmental disorder with seizures, spasticity, and complete or partial agenesis of the corpus callosum, 620250 (3),
C12orf53		
C12orf57	AR	temtamy syndrome, 218340 (3),
C12orf58	AR	bardet-biedl syndrome 10, 615987 (3),
C12orf6		
C12orf62	AR	?mitochondrial complex iv deficiency, nuclear type 10, 619053 (3),
C12orf64	AR	deafness, 84b, 614944 (3),
C12orf65	AR	spastic paraplegia 55, 615035 (3), ; combined oxidative phosphorylation deficiency 7, 613559 (3),
C12orf66		
C12orf72		
C12orf73		
C12orf8		
C13orf1		
C13orf10		
C13orf11		
C13orf12	AD,AR	proteasome-associated autoinflammatory syndrome 2, 618048 (3), ; keratosis linearis with ichthyosis congenita and sclerosing keratoderma, 601952 (3),
C13orf13		
C13orf14		
C13orf15		
C13orf18		
C13orf19		
C13orf2		
C13orf20	AR	leukodystrophy, hypomyelinating, 14, 617899 (3),
C13orf22		
C13orf24	AR	joubert syndrome 33, 617767 (3),
C13orf25		
C13orf3		
C13orf31	AR	juvenile arthritis, 618795 (3),
C13orf32		
C13orf34		
C13orf37		
C13orf39		
C13orf4		
C13orf7		
C13orf8	AD	neurodevelopmental disorder with hypotonia, impaired language, and dysmorphic features, 616579 (3),
C13orf9		
C14orf1		
C14orf10	AD,AR	spermatogenic failure 36, 618420 (3), ; myoectodermal gonadal dysgenesis syndrome, 618419 (3),
C14orf100		
C14orf101	AR	structural heart defects and renal anomalies syndrome, 617478 (3),
C14orf102		
C14orf103		
C14orf104	AR	ciliary dyskinesia, primary, 10, 612518 (3),
C14orf106		
C14orf108		
C14orf109	AR	dysostosis multiplex, ain-naz type, 619345 (3),
C14orf11		
C14orf110		
C14orf112	AR	mitochondrial complex iv deficiency, nuclear type 22, 619355 (3),
C14orf114		
C14orf116		
C14orf120		
C14orf121		
C14orf123		
C14orf124		
C14orf127	AR	mitochondrial complex i deficiency, nuclear type 21, 618242 (3),
C14orf129		
C14orf130	AR	li-campeau syndrome, 619189 (3),
C14orf133	AR	arthrogryposis, renal dysfunction, and cholestasis 2, 613404 (3),
C14orf134		
C14orf137		
C14orf138		
C14orf139		
C14orf141	AR	glaucoma 3, primary congenital, d, 613086 (3); microspherophakia and/or megalocornea, with ectopia lentis and with or without secondary glaucoma, 251750 (3), ; ?weill-marchesani syndrome 3, 614819 (3),
C14orf142	AR	galloway-mowat syndrome 9, 619603 (3),
C14orf146		
C14orf147	AD,AR	spastic paraplegia 90a, 620416 (3); ?spastic paraplegia 90b, 620417 (3)
C14orf149		
C14orf151	AD	glomerulosclerosis, focal segmental, 5, 613237 (3); charcot-marie-tooth disease, intermediate e, 614455 (3),
C14orf153	AR	mitochondrial complex iv deficiency, nuclear type 17, 619061 (3),
C14orf154		
C14orf155		
C14orf156		
C14orf160	AR	l-2-hydroxyglutaric aciduria, 236792 (3),
C14orf161		
C14orf163		
C14orf166		
C14orf167		
C14orf168	AR	ciliary dyskinesia, primary, 16, 614017 (3),
C14orf169		
C14orf170		
C14orf171	AR	spastic paraplegia 87, 619966 (3),
C14orf173	AD	glomerulosclerosis, focal segmental, 5, 613237 (3); charcot-marie-tooth disease, intermediate e, 614455 (3),
C14orf175		
C14orf179	AR	?cranioectodermal dysplasia 3, 614099 (3), ; ?retinitis pigmentosa 81, 617871 (3), ; short-rib thoracic dysplasia 18 with polydactyly, 617866 (3),
C14orf18		
C14orf180		
C14orf2		
C14orf20		
C14orf21		
C14orf24		
C14orf27		
C14orf3		
C14orf31		
C14orf32		
C14orf35		
C14orf39	AR	spermatogenic failure 52, 619202 (3), ; ?premature ovarian failure 18, 619203 (3),
C14orf4	AD	neurodevelopmental disorder with regression, abnormal movements, loss of speech, and seizures, 618088 (3),
C14orf41		
C14orf42		
C14orf47		
C14orf49		
C14orf50		
C14orf51		
C14orf52		
C14orf54		
C14orf58	AR	proliferative vasculopathy and hydranencephaly-hydrocephaly syndrome, 225790 (3),
C14orf60		
C14orf66		
C14orf67		
C14orf68		
C14orf69		
C14orf75	AR	?spermatogenic failure 30, 618110 (3),
C14orf76		
C14orf77		
C14orf78		
C14orf8		
C14orf83		
C14orf87	AR	anemia, sideroblastic, 3, pyridoxine-refractory, 616860 (3), ; spasticity, childhood-onset, with hyperglycinemia, 616859 (3),
C14orf9		
C14orf92		
C14orf94		
C15		
C15orf1		
C15orf12		
C15orf13	AD	left ventricular noncompaction 9, 611878 (3), ; cardiomyopathy, hypertrophic, 3, 115196 (3), ; cardiomyopathy, dilated, 1y, 611878 (3),
C15orf15		
C15orf16		
C15orf18		
C15orf2		
C15orf20		
C15orf21		
C15orf23		?roifman-chitayat syndrome, digenic, 613328 (3), digenic
C15orf25		
C15orf27		
C15orf29		
C15orf3		
C15orf30		
C15orf36		
C15orf38		
C15orf4		
C15orf41	AR	dyserythropoietic anemia, congenital, type ib, 615631 (3),
C15orf42		
C15orf43	AR	?spermatogenic failure 59, 619645 (3),
C15orf48		
C15orf55		
C15orf57	AR	cardiofacioneurodevelopmental syndrome, 619123 (3),
C15orf58		
C15orf59		
C15orf6		
C15orf60	AR	oocyte/zygote/embryo maturation arrest 10, 619176 (3),
C15orf63		
C15orf65		
C160	AR	wiedemann-rautenstrauch syndrome, 264090 (3), ; leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism, 607694 (3),
C16orf12		
C16orf15		
C16orf16		
C16orf17		
C16orf18		
C16orf19		
C16orf2		
C16orf21		
C16orf22		
C16orf23		
C16orf24		
C16orf25	AD	?centronuclear myopathy 4, 614807 (3),
C16orf26	AR	lipase deficiency, combined, 246650 (3),
C16orf27	AR	mucolipidosis iii gamma, 252605 (3),
C16orf28		
C16orf29		
C16orf3		
C16orf30		
C16orf31		
C16orf34		
C16orf35	AD	epilepsy, familial focal, with variable foci 3, 617118 (3),
C16orf36		
C16orf38		
C16orf39		
C16orf4		
C16orf41		
C16orf42		
C16orf47		prostate cancer, somatic, 176807 (3)
C16orf49	AR	coenzyme q10 deficiency, primary, 5, 614654 (3),
C16orf5		
C16orf50		
C16orf53		
C16orf55		
C16orf56	AR	?short stature and microcephaly with genital anomalies, 618702 (3),
C16orf57	AR	poikiloderma with neutropenia, 604173 (3),
C16orf60		
C16orf62	AR	ritscher-schinzel syndrome 3, 619135 (3),
C16orf63		
C16orf68		
C16orf69		
C16orf7		
C16orf73	AR	?spermatogenic failure 22, 617706 (3),
C16orf75		
C16orf77		
C16orf8		
C16orf80		
C16orf84	AR	microcephaly, facial dysmorphism, renal agenesis, and ambiguous genitalia syndrome, 618142 (3),
C16orf92		
C16orf93		
C16orf94		
C17		
C17orf1		
C17orf104		
C17orf105		
C17orf106		
C17orf1A		
C17orf1B		
C17orf26		
C17orf27	AR,AD	{moyamoya disease 2, susceptibility to}, 607151 (3),
C17orf28	AR	developmental and epileptic encephalopathy 105 with hypopituitarism, 619983 (3),
C17orf29		
C17orf31		
C17orf32	AR	congenital disorder of glycosylation, type iip, 616829 (3),
C17orf33		
C17orf35		
C17orf36		
C17orf37		
C17orf38		
C17orf39		
C17orf41		
C17orf42		
C17orf47		
C17orf49		
C17orf53		
C17orf59		
C17orf61		
C17orf62	AR	chronic granulomatous disease 5, 618935 (3),
C17orf68	AR	cerebroretinal microangiopathy with calcifications and cysts, 612199 (3),
C17orf70		
C17orf71	AR	alzahrani-kuwahara syndrome, 619268 (3),
C17orf81		
C17orf83		
C17orf85		
C17orf87		
C17orf89	AR	mitochondrial complex i deficiency, nuclear type 34, 618776 (3),
C17orf92		
C17orf93		
C17orf95	AR	intellectual developmental disorder, 44, 615942 (3),
C17orf96		
C18orf1		
C18orf11		
C18orf19		
C18orf2		
C18orf20		
C18orf24		
C18orf26		
C18orf3		
C18orf30	AD,AR	arthrogryposis, distal, type 5, 108145 (3), ; arthrogryposis, distal, with impaired proprioception and touch, 617146 (3), ; arthrogryposis, distal, type 3, 114300 (3), ; ?marden-walker syndrome, 248700 (3),
C18orf32	AR	?glycosylphosphatidylinositol biosynthesis defect 25, 619985 (3),
C18orf4		
C18orf42		
C18orf43		
C18orf45		
C18orf49		
C18orf5	AD	scalp-ear-nipple syndrome, 181270 (3),
C18orf51		
C18orf53		
C18orf54		
C18orf55		
C18orf58	AD,AR	arthrogryposis, distal, type 5, 108145 (3), ; arthrogryposis, distal, with impaired proprioception and touch, 617146 (3), ; arthrogryposis, distal, type 3, 114300 (3), ; ?marden-walker syndrome, 248700 (3),
C18orf6	AD	deafness, 80, 619274 (3), ; renal hypodysplasia/aplasia 3, 617805 (3),
C18orf8		
C19orf1		
C19orf10		
C19orf12	AR,AD	neurodegeneration with brain iron accumulation 4, 614298 (3), ; ?spastic paraplegia 43, 615043 (3),
C19orf13		
C19orf14	AR	microcephaly 2, primary, with or without cortical malformations, 604317 (3),
C19orf15		
C19orf17		
C19orf2		
C19orf21		
C19orf27		
C19orf28		
C19orf29		
C19orf3	AD	oculopharyngodistal myopathy 2, 618940 (3),
C19orf32	AR	retinitis pigmentosa 77, 617304 (3),
C19orf33		
C19orf35		
C19orf36		
C19orf39		
C19orf4		
C19orf40		
C19orf41		
C19orf46	AR	deafness, 76, 615540 (3),
C19orf48		
C19orf48P		
C19orf49	AR	carpenter syndrome 2, 614976 (3),
C19orf5		
C19orf50		
C19orf51	AR	ciliary dyskinesia, primary, 2, 606763 (3),
C19orf52		
C19orf54		
C19orf56		
C19orf57		
C19orf59		
C19orf6		
C19orf61	AR	heart and brain malformation syndrome, 616920 (3), ; neurodevelopmental disorder with intention tremor, pyramidal signs, dyspraxia, and ocular anomalies, 619995 (3),
C19orf62		
C19orf63	AR	neurodevelopmental disorder with dysmorphic facies and variable seizures, 619264 (3),
C19orf64	AR	deafness, 15, 601869 (3),
C19orf66		
C19orf7		
C19orf70	AR	combined oxidative phosphorylation deficiency 37, 618329 (3),
C19orf72		
C19orf79	AR	mitochondrial complex iv deficiency, nuclear type 12, 619055 (3),
C19orf80		
C19orf9		
C1D		
C1d-87		
C1GALT		
C1GALT1		
C1GALT1C1		tn polyagglutination syndrome, somatic, 300622 (3)
C1GALT2		tn polyagglutination syndrome, somatic, 300622 (3)
C1IN	AR,AD	angioedema, hereditary, 1 and 2, 106100 (3), ; complement component 4, partial deficiency of, 120790 (3),
C1INH	AR,AD	angioedema, hereditary, 1 and 2, 106100 (3), ; complement component 4, partial deficiency of, 120790 (3),
C1NH	AR,AD	angioedema, hereditary, 1 and 2, 106100 (3), ; complement component 4, partial deficiency of, 120790 (3),
C1orf10		
C1orf101		
C1orf102		
C1orf103		?facioscapulohumeral muscular dystrophy 3, digenic, 619477 (3), digenic
C1orf106	AD	{inflammatory bowel disease 29}, 618077 (3),
C1orf107		
C1orf108		
C1orf109		
C1orf11		
C1orf111		
C1orf116		
C1orf118		
C1orf12	AD	erythrocytosis, familial, 3, 609820 (3), ; [hemoglobin, high altitude adaptation], 609070 (3),
C1orf121		
C1orf124	AR	ruijs-aalfs syndrome, 616200 (3),
C1orf127		
C1orf128		
C1orf13		
C1orf135		
C1orf139	AR	zaki syndrome, 619648 (3),
C1orf14		
C1orf142		
C1orf146		
C1orf149		
C1orf15		
C1orf151		
C1orf152		
C1orf155		
C1orf156		
C1orf16		
C1orf160	AR	neurodevelopmental disorder with motor and speech delay and behavioral abnormalities, 619470 (3),
C1orf163	AR	spinocerebellar ataxia, with axonal neuropathy 3, 618387 (3),
C1orf164	AR	leukodystrophy, hypomyelinating, 23, with ataxia, deafness, liver dysfunction, and dilated cardiomyopathy, 619688 (3),
C1orf166		
C1orf168		
C1orf169		
C1orf17		
C1orf170		
C1orf171		
C1orf172	AD	?ectodermal dysplasia 12, hypohidrotic/hair/tooth/nail type, 617337 (3),
C1orf176		
C1orf177		
C1orf178		
C1orf182		
C1orf183		
C1orf186		
C1orf187		
C1orf188		
C1orf19	AR	pontocerebellar hypoplasia, type 2f, 617026 (3),
C1orf190		
C1orf192		
C1orf194		
C1orf196		
C1orf199	AD	developmental and epileptic encephalopathy 54, 617391 (3),
C1orf2		
C1orf201		
C1orf203		
C1orf215		
C1orf218		
C1orf22	AR	congenital disorder of glycosylation, type iiv, 619493 (3),
C1orf222	AR	ciliary dyskinesia, primary, 49, without situs inversus, 620197 (3),
C1orf225		
C1orf24		
C1orf25		
C1orf26		
C1orf27		
C1orf28	AD	hyperparathyroidism, familial primary, 145000 (3), ; parathyroid adenoma with cystic changes, 145001 (3), ; parathyroid carcinoma, 608266 (3); hyperparathyroidism-jaw tumor syndrome, 145001 (3),
C1orf29		
C1orf3		
C1orf30		
C1orf31	AR	mitochondrial complex iv deficiency, nuclear type 13, 616501 (3),
C1orf32		
C1orf34		
C1orf36	AR	leber congenital amaurosis 12, 610612 (3),
C1orf37-DUP		
C1orf38		
C1orf39		
C1orf4	AD	coffin-siris syndrome 2, 614607 (3),
C1orf40		
C1orf42		
C1orf43		
C1orf45		
C1orf48		
C1orf51		
C1orf59		
C1orf6		
C1orf60		
C1orf61		
C1orf63		
C1orf64		
C1orf67		
C1orf69	AR	multiple mitochondrial dysfunctions syndrome 3, 615330 (3), ; ?spastic paraplegia 74, 616451 (3),
C1orf7	AD	cinca syndrome, 607115 (3), ; familial cold inflammatory syndrome 1, 120100 (3), ; keratoendothelitis fugax hereditaria, 148200 (3), ; deafness, 34, with or without inflammation, 617772 (3), ; muckle-wells syndrome, 191900 (3),
C1orf70	AD	spinocerebellar ataxia 21, 607454 (3),
C1orf71		
C1orf73		
C1orf75		
C1orf76		
C1orf77		
C1orf8		
C1orf80		
C1orf82		
C1orf84	AR	developmental and epileptic encephalopathy 18, 615476 (3),
C1orf85		
C1orf86		
C1orf87		
C1orf88		
C1orf9		
C1orf91		
C1orf96		
C1orf97		
C1QA	AR	c1q deficiency 1, 613652 (3),
C1QB		c1q deficiency 2, 620321 (3)
C1QBP	AR	combined oxidative phosphorylation deficiency 33, 617713 (3),
C1QC		c1q deficiency 3, 620322 (3)
C1QDC1		
C1QDC2		
C1QG		c1q deficiency 3, 620322 (3)
C1ql		
C1QL1		
C1QL2		
C1QL3		
C1QL4		
C1qR(P)		
C1QR1		
C1QRF		
C1qRP		
C1QTNF1		
C1QTNF10		
C1QTNF11		
C1QTNF12		
C1QTNF13		
C1QTNF14		
C1QTNF15		
C1QTNF2		
C1QTNF3		
C1QTNF4		
C1QTNF5	AR,AD	microphthalmia, isolated 5, 611040 (3), ; nanophthalmos 2, 609549 (3)|retinal degeneration, late-onset, 605670 (3),
C1QTNF6		
C1QTNF8		
C1QTNF9		
C1QTNF9A		
C1QTNF9B		
C1QTNF9B-AS1		
C1R	AD	ehlers-danlos syndrome, periodontal type, 1, 130080 (3),
C1r-LP		
C1RL		
C1RL1		
C1S	AD	c1s deficiency, 613783 (3); ehlers-danlos syndrome, periodontal type, 2, 617174 (3),
C2	AR	c2 deficiency, 217000 (3), ; {macular degeneration, age-related, 14, reduced risk of}, 615489 (3), digenic
C2-PI3K		
C2/4GnT		
C20orf1		
C20orf10		
C20orf100		
C20orf101		
C20orf102		
C20orf103		
C20orf104		
C20orf108		
C20orf11		
C20orf110		
C20orf112		
C20orf113		
C20orf116	AR	spondyloepimetaphyseal dysplasia, shohat type, 602557 (3),
C20orf117		
C20orf122		
C20orf125		
C20orf126		
C20orf129		
C20orf13	AR	suleiman-el-hattab syndrome, 618950 (3),
C20orf130		
C20orf133		
C20orf135		
C20orf137		
C20orf139		
C20orf14	AD	retinitis pigmentosa 60, 613983 (3),
C20orf140	AR	warburg micro syndrome 4, 615663 (3),
C20orf142	AR	siddiqi syndrome, 618635 (3),
C20orf145		
C20orf147		
C20orf148		
C20orf150		
C20orf153		
C20orf154	AR	?premature ovarian failure 10, 612885 (3),
C20orf155	AR	combined oxidative phosphorylation deficiency 57, 620167 (3),
C20orf156		
C20orf158		
C20orf16		
C20orf161		
C20orf163		
C20orf164		
C20orf165		
C20orf167		
C20orf169		
C20orf17		
C20orf172		
C20orf178	AD	cataract 31, multiple types, 605387 (3),
C20orf18	AR	polyglucosan body myopathy 1 with or without immunodeficiency, 615895 (3),
C20orf180		
C20orf182	AR	anonychia congenita, 206800 (3),
C20orf183		
C20orf184		
C20orf185		
C20orf186		
C20orf188		
C20orf19	AR	retinitis pigmentosa 69, 615780 (3),
C20orf190		
C20orf193		
C20orf194		
C20orf196		
C20orf198		
C20orf2		
C20orf20		
C20orf21		
C20orf22	AR	polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract, 612674 (3),
C20orf23		
C20orf24	AR	?craniofacial dysmorphism, skeletal anomalies, and impaired intellectual development syndrome 2, 616994 (3),
C20orf25		
C20orf26	AR	spermatogenic failure 84, 620409 (3),
C20orf27		
C20orf28		
C20orf29		
C20orf3		
C20orf30		
C20orf31		
C20orf32		
C20orf33	AR	?immunodeficiency 99 with hypogammaglobulinemia and autoimmune cytopenias, 619846 (3),
C20orf34		
C20orf35		
C20orf36		
C20orf37	AR	[inosine triphosphatase deficiency], 613850 (3); developmental and epileptic encephalopathy 35, 616647 (3),
C20orf38		
C20orf39		
C20orf4		
C20orf41	AD,AR	dyskeratosis congenita, 4, 615190 (3), ; dyskeratosis congenita, 5, 615190 (3), ; pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 3, 616373 (3),
C20orf42	AR	kindler syndrome, 173650 (3),
C20orf44		
C20orf47		
C20orf48	AR	harp syndrome, 607236 (3), ; neurodegeneration with brain iron accumulation 1, 234200 (3),
C20orf49		
C20orf5		
C20orf50		
C20orf52		
C20orf54	AR	?fazio-londe disease, 211500 (3), ; brown-vialetto-van laere syndrome 1, 211530 (3),
C20orf55		
C20orf56		
C20orf57		
C20orf58		
C20orf59	AD	porokeratosis 8, disseminated superficial actinic type, 616063 (3),
C20orf6		
C20orf60		
C20orf63		
C20orf64	AR	galloway-mowat syndrome 4, 617730 (3),
C20orf67		
C20orf7	AR	mitochondrial complex i deficiency, nuclear type 16, 618238 (3),
C20orf72	AR	mitochondrial dna depletion syndrome 11, 615084 (3),
C20orf74		
C20orf75		
C20orf77		
C20orf8		
C20orf82		
C20orf85		
C20orf88		
C20orf9	AR	short-rib thoracic dysplasia 16 with or without polydactyly, 617102 (3),
C20orf92		
C20orf94		
C20orf97		
C20orf98		
C20orf99		
C21	AD	intellectual developmental disorder, 41, 616944 (3), ; pierpont syndrome, 602342 (3),
c21-LRP		
C21orf1		
C21orf10		
C21orf101		
C21orf102		
C21orf106		
C21orf107		
C21orf108		
C21orf11		
C21orf112		
C21orf113		
C21orf115		
C21orf124	AR	neuropathy, hereditary motor and sensory, type vic, with optic atrophy, 618511 (3),
C21orf127		
C21orf134		
C21orf2	AR	retinal dystrophy with macular staphyloma, 617547 (3), ; spondylometaphyseal dysplasia, axial, 602271 (3),
C21orf24		
C21orf25		
C21orf258		
C21orf29	AR	tooth agenesis, selective, 10, 620173 (3), ; ?deafness, 98, 614861 (3), ; ectodermal dysplasia 14, hair/tooth type with or without hypohidrosis, 618180 (3),
C21orf3		
C21orf30		
C21orf33		
C21orf34		
C21orf35		
C21orf4		
C21orf43	AR	basal ganglia calcification, idiopathic, 8, 618824 (3),
C21orf45		
C21orf46		
C21orf48	AR	ciliary dyskinesia, primary, 26, 615500 (3),
C21orf5		
C21orf50	AD	zttk syndrome, 617140 (3),
C21orf56		
C21orf57		
C21orf59	AR	ciliary dyskinesia, primary, 26, 615500 (3),
C21orf6		
C21orf60	AR	microcephaly, short stature, and limb abnormalities, 617604 (3), ; microcephaly-micromelia syndrome, 251230 (3),
C21orf61	AR	glucocorticoid deficiency 2, 607398 (3),
C21orf65		
C21orf66		
C21orf68		
C21orf7		
C21orf73		
C21orf76		
C21orf80		
C21orf83		
C21orf92		
C21orf95		
C21orf97	AR	neuropathy, hereditary motor and sensory, type vic, with optic atrophy, 618511 (3),
C21orf98		
C22orf1		
C22orf12		
C22orf13		
C22orf14		
C22orf16	AD	?myopathy, isolated mitochondrial, 616209 (3), ; spinal muscular atrophy, jokela type, 615048 (3), ; frontotemporal dementia and/or amyotrophic lateral sclerosis 2, 615911 (3),
C22orf17		
C22orf18		
C22orf19		
C22orf2		
C22orf20		
C22orf23		
C22orf25	AR	metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration, 616878 (3),
C22orf28		
C22orf32		
C22orf35		{myocardial infarction, susceptibility to}, 608446 (3)
C22orf4		
C22orf41		
C22orf6		
C22orf7		
C22orf9		
C23		
C25		
C2CD1		
C2CD2		
C2CD2L		
C2CD3	AR	orofaciodigital syndrome xiv, 615948 (3),
C2CD4A		
C2CD4B		
C2CD4C		
C2CD5		
C2CD6	AR	?spermatogenic failure 68, 619805 (3),
C2F	AR	bowen-conradi syndrome, 211180 (3),
C2GNT		
C2GnT-M		
C2GnT2		
C2GNT3		
C2H2-150		
C2H2-171	AD	intellectual developmental disorder, 22, 612337 (3),
C2orf1		
C2orf10		
C2orf11		
C2orf12		
C2orf13		
C2orf18		
C2orf2		
C2orf20	AD,AR	nescav syndrome, 614255 (3), ; neuropathy, hereditary sensory, type iic, 614213 (3), ; spastic paraplegia 30, 610357 (3), ; spastic paraplegia 30, 610357 (3),
C2orf21	AR	hypotonia, infantile, with psychomotor retardation and characteristic facies 2, 616801 (3),
C2orf23	AD,AR	?neuronopathy, distal hereditary motor, type vb, 614751 (3), ; spastic paraplegia 31, 610250 (3), ; spinal muscular atrophy, distal, 6, 620011 (3),
C2orf25	AR	methylmalonic aciduria, cbld type, variant 2, 277410 (3), ; methylmalonic aciduria and homocystinuria, cbld type, 277410 (3), ; homocystinuria, cbld type, variant 1, 277410 (3),
C2orf28		
C2orf3		
C2orf30		
C2orf31		
C2orf32		
C2orf33	AR	encephalopathy due to defective mitochondrial and peroxisomal fission 2, 617086 (3),
C2orf34		
C2orf37	AR	woodhouse-sakati syndrome, 241080 (3),
C2orf39	AR	spermatogenic failure 80, 620222 (3), ; ciliary dyskinesia, primary, 21, 615294 (3),
C2orf4		
C2orf40		
C2orf43		
C2orf44		
C2orf47		
C2orf48		
C2orf5		
C2orf51		
C2orf56		
C2orf6		
C2orf60		
C2orf62	AR	?spermatogenic failure 54, 619379 (3),
C2orf64	AR	?mitochondrial complex iv, deficiency, nuclear type 9, 616500 (3),
C2orf65	AR	spermatogenic failure 48, 619108 (3),
C2orf67		
C2orf68		
C2orf69	AR	combined oxidative phosphorylation deficiency 53, 619423 (3),
C2orf7		
C2orf71	AR	retinitis pigmentosa 54, 613428 (3),
C2orf79		
C2orf8		
C2orf80		
C2orf86	AR	?bardet-biedl syndrome 15, 615992 (3), ; congenital heart defects, hamartomas of tongue, and polysyndactyly, 217085 (3),
C2orf88		
C2orf89		
C2orf9		
C2PA		
C2TA	AR,AR	{rheumatoid arthritis, susceptibility to}, 180300 (3); bare lymphocyte syndrome, type ii, complementation group a, 209920 (3), |microcephaly, short stature, and limb abnormalities, 617604 (3), ; microcephaly-micromelia syndrome, 251230 (3),
C3	AR,AD	c3 deficiency, 613779 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to, 5}, 612925 (3), ; {macular degeneration, age-related, 9}, 611378 (3)
C3-C5		
C31		
c316G12.3	AR	mucolipidosis iii gamma, 252605 (3),
C32		
C321D2.4		
C34	AD	?immunodeficiency 101 (varicella zoster virus-specific), 619872 (3),
C35		
C37		
C3a	AR,AD	c3 deficiency, 613779 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to, 5}, 612925 (3), ; {macular degeneration, age-related, 9}, 611378 (3)
C3AR		
C3AR1		
C3b	AR,AD	c3 deficiency, 613779 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to, 5}, 612925 (3), ; {macular degeneration, age-related, 9}, 611378 (3)
C3b-INA	AD,AR	{hemolytic uremic syndrome, atypical, susceptibility to, 3}, 612923 (3), ; {macular degeneration, age-related, 13, susceptibility to}, 615439 (3), ; complement factor i deficiency, 610984 (3),
C3DR	AR	{systemic lupus erythematosus, susceptibility to, 9}, 610927 (3); ?immunodeficiency, common variable, 7, 614699 (3),
C3F		
C3G		
C3IP1		
C3orf1	AR	mitochondrial complex i deficiency, nuclear type 31, 618251 (3),
C3orf10		
C3orf11		
C3orf13		
C3orf15	AR	spermatogenic failure 51, 619177 (3),
C3orf17	AR	anauxetic dysplasia 3, 618853 (3),
C3orf19	AR	hypotonia, infantile, with psychomotor retardation, 616816 (3),
C3orf20		
C3orf21		
C3orf27		
C3orf28		
C3orf29	AD	{centronuclear myopathy, modifier of}, 160150 (3),
C3orf3		
C3orf31		combined oxidative phosphorylation deficiency 56, 620139 (3)
C3orf32		
C3orf33		
C3orf34	AR	morbid obesity and spermatogenic failure, 615703 (3),
C3orf35		
C3orf37		
C3orf39	AR	muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 8, 614830 (3), ; muscular dystrophy-dystroglycanopathy (limb-girdle) type c, 8, 618135 (3),
C3orf4		
C3orf41		
C3orf5	AR	ovarian dysgenesis 7, 618117 (3), ; combined oxidative phosphorylation deficiency 5, 611719 (3),
C3orf52	AR	hypotrichosis 15, 620177 (3),
C3orf57		
C3orf58		
C3orf6	AD	?deafness, 44, 607453 (3),
C3orf60	AR	mitochondrial complex i deficiency, nuclear type 18, 618240 (3),
C3orf63		
C3orf64	AR	adams-oliver syndrome 4, 615297 (3),
C3orf68		
C3orf7		
C3orf75		
C3orf77		
C3orf8		
C3orf9	AD,AR	dowling-degos disease 4, 615696 (3), ; muscular dystrophy, limb-girdle, 21, 617232 (3),
C3PO		
C3Xkine		
C4	AR	[blood group, rodgers], 614374 (3); c4a deficiency, 614380 (3),
C4.4A		
C42		
C48	AR	microcephaly 3, primary, 604804 (3),
C49A		
C4A	AR	[blood group, rodgers], 614374 (3); c4a deficiency, 614380 (3),
C4A2	AR	[blood group, rodgers], 614374 (3); c4a deficiency, 614380 (3),
C4A3	AR	[blood group, rodgers], 614374 (3); c4a deficiency, 614380 (3),
C4A4	AR	[blood group, rodgers], 614374 (3); c4a deficiency, 614380 (3),
C4A6	AR	[blood group, rodgers], 614374 (3); c4a deficiency, 614380 (3),
C4B	AR	[blood group, rodgers], 614374 (3); c4a deficiency, 614380 (3), |c4b deficiency, 614379 (3)
C4B1		c4b deficiency, 614379 (3)
C4B3		c4b deficiency, 614379 (3)
C4BP		
C4BPA		
C4BPB		
C4F		c4b deficiency, 614379 (3)
C4orf1	AR	birk-landau-perez syndrome, 617595 (3),
C4orf13	AR	short stature, amelogenesis imperfecta, and skeletal dysplasia with scoliosis, 618363 (3),
C4orf14		
C4orf15		
C4orf16		
C4orf20	AD,AR	?hip dysplasia, beukes type, 142669 (3), ; spondyloepimetaphyseal dysplasia, di rocco type, 617974 (3), ; developmental and epileptic encephalopathy 106, 620028 (3),
C4orf23		
C4orf24	AR	bardet-biedl syndrome 12, 615989 (3),
C4orf25	AR	fetal akinesia deformation sequence 3, 618389 (3), ; myasthenic syndrome, congenital, 10, 254300 (3),
C4orf26	AR	amelogenesis imperfecta, type iia4, 614832 (3),
C4orf27		
C4orf31	AD	hypogonadotropic hypogonadism 25 with anosmia, 618841 (3),
C4orf35		
C4orf4		
C4orf41	AR	muscular dystrophy, limb-girdle, 18, 615356 (3),
C4orf46		
C4orf48		
C4orf49		
C4orf5	AD	cardiomyopathy, hypertrophic, 16, 613838 (3),
C4orf52		
C4orf54		
C4orf7		
C4orf8		
C4orf9		
C4S	AR	[blood group, rodgers], 614374 (3); c4a deficiency, 614380 (3),
C4S-2		
C4ST	AR	?osteochondrodysplasia, brachydactyly, and overlapping malformed digits, 618167 (3),
C4St-1	AR	?osteochondrodysplasia, brachydactyly, and overlapping malformed digits, 618167 (3),
C4ST1	AR	?osteochondrodysplasia, brachydactyly, and overlapping malformed digits, 618167 (3),
C4ST2		
C4ST3		
C5	AR,AD	c5 deficiency, 609536 (3), ; [eculizumab, poor response to], 615749 (3),
C53		
C5a	AR,AD	c5 deficiency, 609536 (3), ; [eculizumab, poor response to], 615749 (3),
C5A		
C5AR		
C5AR1		
C5AR2		
C5b	AR,AD	c5 deficiency, 609536 (3), ; [eculizumab, poor response to], 615749 (3),
C5L2		
C5orf10		
C5orf11		
C5orf12		
C5orf13		
C5orf14	AR	meckel syndrome 14, 619879 (3),
C5orf16		
C5orf18		
C5orf19	AD,AR	?spastic paraplegia 72, 615625 (3), ; ?spastic paraplegia 72, 615625 (3),
C5orf20		
C5orf23	AR	boudin-mortier syndrome, 619543 (3),
C5orf25		
C5orf30		
C5orf31	AR	mitochondrial complex iii deficiency, nuclear type 8, 615838 (3),
C5orf33	AR	2,4-dienoyl-coa reductase deficiency, 616034 (3),
C5orf36	AR	polydactyly, postaxial, type a10, 618498 (3),
C5orf37		
C5orf38		
C5orf39		
C5orf4		
C5orf41		
C5orf42	AR	orofaciodigital syndrome vi, 277170 (3), ; joubert syndrome 17, 614615 (3),
C5orf45		
C5orf47		
C5orf5		
C5orf51		
C5orf54		
C5orf6		
C5orf62		
C5orf7	AD	diets-jongmans syndrome, 618846 (3),
C5orf8		
C5R1		
C6	AR	c6 deficiency, 612446 (3),
C6.1A		
C6orf1		
C6orf10		
C6orf102		
C6orf103		
C6orf105		
C6orf106		
C6orf107		
C6orf108		
C6orf109		
C6orf11		
C6orf110		
C6orf111		
C6orf114		
C6orf116		
C6orf117	AD	{?obesity, susceptibility to, bmiq18}, 615457 (3),
C6orf12		
C6orf120		
C6orf125	AR	mitochondrial complex iii deficiency, nuclear type 7, 615824 (3),
C6orf13		
C6orf130		
C6orf131	AD	cone-rod dystrophy 14, 602093 (3), ; cone dystrophy-3, 602093 (3),
C6orf133		
C6orf134		
C6orf135		
C6orf138		
C6orf139		
C6orf14		
C6orf140		
C6orf142	AR	myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis, 620138 (3),
C6orf144		
C6orf147		
C6orf148		
C6orf149	AR	?combined oxidative phosphorylation deficiency 19, 615595 (3),
C6orf15		
C6orf150		
C6orf152	AR	leber congenital amaurosis 5, 604537 (3),
C6orf153		
C6orf155		
C6orf156		
C6orf157		
C6orf159	AR	?spondylocostal dysostosis 6, 616566 (3),
C6orf16		
C6orf160		
C6orf166		
C6orf167		
C6orf169		
C6orf17		
C6orf170		
C6orf171		
C6orf172		
C6orf173		
C6orf175	AR	trichothiodystrophy 3, photosensitive, 616395 (3),
C6orf177		
C6orf178	AR	retinitis pigmentosa 25, 602772 (3),
C6orf179	AR	retinitis pigmentosa 25, 602772 (3),
C6orf18		
C6orf180	AR	retinitis pigmentosa 25, 602772 (3),
C6orf187		
C6orf19		
C6orf190		
C6orf192		
C6orf193		
C6orf196		
C6orf197		
C6orf198		
C6orf199		
C6orf2	AR	?candidiasis, familial, 8, 615527 (3), ; {psoriasis susceptibility 13}, 614070 (3)
C6orf20		
C6orf203		
C6orf204	AD	lissencephaly 10, 618873 (3),
C6orf205		
C6orf206	AR	ciliary dyskinesia, primary, 12, 612650 (3),
C6orf207		
C6orf209	AR	methylmalonic aciduria and homocystinuria, cblf type, 277380 (3),
C6orf21		
C6orf210	AR	coenzyme q10 deficiency, primary, 3, 614652 (3),
C6orf211		
C6orf212		
C6orf212L		
C6orf213		
C6orf22		
C6orf221	AR	hydatidiform mole, recurrent, 2, 614293 (3),
C6orf224		
C6orf23		
C6orf24		
C6orf25	AR	?thrombocytopenia, anemia, and myelofibrosis, 617441 (3),
C6orf27		
C6orf28		
C6orf29	AD	?deafness, 72, 617606 (3),
C6orf30		
C6orf31		
C6orf32	AD,AR	deafness, 21, 607017 (3), ; ?deafness, 104, 616515 (3),
C6orf33		
C6orf34		
C6orf37	AR	osteogenesis imperfecta, type xviii, 617952 (3),
C6orf4	AR	?candidiasis, familial, 8, 615527 (3), ; {psoriasis susceptibility 13}, 614070 (3)
C6orf40	AR,AD	diabetes mellitus, transient neonatal 1, 601410 (3),
C6orf48		
C6orf49		
C6orf5	AR	?candidiasis, familial, 8, 615527 (3), ; {psoriasis susceptibility 13}, 614070 (3)
C6orf51		
C6orf53		
C6orf55		
C6orf56		
C6orf57		
C6orf6	AR	?candidiasis, familial, 8, 615527 (3), ; {psoriasis susceptibility 13}, 614070 (3)
C6orf61	AR	ovarian dysgenesis 4, 616185 (3),
C6orf63		
C6orf66	AR	mitochondrial complex i deficiency, nuclear type 15, 618237 (3),
C6orf67		
C6orf68	AD,AR	intellectual developmental disorder, 55, with seizures, 617831 (3), ; ?congenital disorder of glycosylation, type 1aa, 617082 (3),
C6orf69		
C6orf70	AD	?periventricular nodular heterotopia 6, 615544 (3),
C6orf71	AR	thyroid dyshormonogenesis 4, 274800 (3),
C6orf73		
C6orf76		
C6orf79		
C6orf8		
C6orf80		
C6orf81		
C6orf82		
C6orf84		
C6orf85		
C6orf86		
C6orf89		
C6orf9		
C6orf90		
C6orf92		
C6orf93	AR	inflammatory poikiloderma with hair abnormalities and acral keratoses, 620199 (3),
C6orf95		
C6orf96	AR	combined oxidative phosphorylation deficiency 11, 614922 (3),
C6orf98	AR,AD	arthrogryposis multiplex congenita 3, myogenic type, 618484 (3), ; emery-dreifuss muscular dystrophy 4, 612998 (3), ; spinocerebellar ataxia, 8, 610743 (3),
C6ST	AR	spondyloepiphyseal dysplasia with congenital joint dislocations, 143095 (3),
C6ST-2		
C6ST1	AR	spondyloepiphyseal dysplasia with congenital joint dislocations, 143095 (3),
C6ST2		
C7		c7 deficiency, 610102 (3)
C77032		
C7orf1		
C7orf10	AR	glutaric aciduria iii, 231690 (3),
C7orf11	AR	trichothiodystrophy 4, nonphotosensitive, 234050 (3),
C7orf12		
C7orf13		
C7orf14	AR	?nephrotic syndrome, type 13, 616893 (3),
C7orf15		
C7orf16	AR,AD	{hypercholesterolemia, susceptibility to}, 143890 (3),
C7orf17	AD	parkinson disease 22, 616710 (3),
C7orf18		
C7orf19		
C7orf2	AD,AR	triphalangeal thumb, type i, 174500 (3), ; syndactyly, type iv, 186200 (3), ; laurin-sandrow syndrome, 135750 (3), ; hypoplastic or aplastic tibia with polydactyly, 188740 (3), ; polydactyly, preaxial type ii, 174500 (3), ; acheiropody, 200500 (3), ; triphalangeal thumb-polysyndactyly syndrome, 190605 (3),
C7orf20	AR	?congenital disorder of glycosylation, type iiy, 620200 (3),
C7orf21		
C7orf22	AD	cerebral cavernous malformations-2, 603284 (3),
C7orf23		
C7orf24		
C7orf27	AR	neurodevelopmental disorder with cerebellar atrophy and with or without seizures, 618056 (3), ; rigidity and multifocal seizure syndrome, lethal neonatal, 614498 (3),
C7orf29		
C7orf3		
C7orf30		
C7orf31		
C7orf32		
C7orf34		
C7orf43	AR	?microcephaly 25, primary, 618351 (3),
C7orf44		
C7orf47		
C7orf48		
C7orf49		
C7orf5	AR,AD	tumoral calcinosis, familial, normophosphatemic, 610455 (3), ; monosomy 7 myelodysplasia and leukemia syndrome 2, 619041 (3), ; mirage syndrome, 617053 (3),
C7orf51		
C7orf52		
C7orf59		
C7orf6	AD	ataxia-pancytopenia syndrome, 159550 (3), ; monosomy 7 myelodysplasia and leukemia syndrome 1, 252270 (3), ; spinocerebellar ataxia 49, 619806 (3),
C7orf60		
C7orf61		
C7orf63	AR	spermatogenic failure 24, 617959 (3),
C7orf68		
C7orf7		
C7orf70		
C7orf73		
C7orf76		
C7orf8		
C7orf9		
C82		
c86fus	AD	diaphyseal medullary stenosis with malignant fibrous histiocytoma, 112250 (3),
C8A	AR	c8 deficiency, type i, 613790 (3),
C8B	AR	c8 deficiency, type ii, 613789 (3),
C8FW		
C8G		
C8orf1		
C8orf13		
C8orf17		
C8orf2	AR	spastic paraplegia 18, 611225 (3),
C8orf20		
C8orf35		
C8orf36	AR	seckel syndrome 10, 617253 (3),
C8orf37	AR	retinitis pigmentosa 64, 614500 (3), ; cone-rod dystrophy 16, 614500 (3), ; bardet-biedl syndrome 21, 617406 (3),
C8orf38	AR	mitochondrial complex i deficiency, nuclear type 17, 618239 (3), ; fanconi renotubular syndrome 5, 618913 (3),
C8orf4		
C8orf41	AR	intellectual developmental disorder, 39, 615541 (3),
C8orf42		
C8orf45		
C8orf52	AR	?neurodevelopmental disorder with cerebellar hypoplasia and spasticity, 618572 (3),
C8orf57		
C8orf61	AR	ceroid lipofuscinosis, neuronal, 8, northern epilepsy variant, 610003 (3), ; ceroid lipofuscinosis, neuronal, 8, 600143 (3),
C8orf68		
C8orf72		
C8orf79		
C8orf80		
C8orf9		
C9	AD	c9 deficiency, 613825 (3); {macular degeneration, age-related, 15, susceptibility to}, 615591 (3),
C90RF3	AR	dystonia 31, 619565 (3),
C9orf10		
C9orf101		
C9orf102	AR	bone marrow failure syndrome 2, 615715 (3),
C9orf103		
C9orf105		
C9orf108		
C9orf11		
C9orf111		
C9orf112		
C9orf113		
C9orf114		
C9orf116		
C9orf119		
C9orf12		
C9orf121		
C9orf123		
C9orf125		
C9orf126		
C9orf127		
C9orf13		
C9orf132		
C9orf134		
C9orf136		
C9orf138		
C9orf140		
C9orf142		
C9orf143	AR,AD	manitoba oculotrichoanal syndrome, 248450 (3), ; bifid nose with or without anorectal and renal anomalies, 608980 (3), ; trigonocephaly 2, 614485 (3),
C9orf145	AR,AD	manitoba oculotrichoanal syndrome, 248450 (3), ; bifid nose with or without anorectal and renal anomalies, 608980 (3), ; trigonocephaly 2, 614485 (3),
C9orf15		
C9orf150		
C9orf154	AR,AD	manitoba oculotrichoanal syndrome, 248450 (3), ; bifid nose with or without anorectal and renal anomalies, 608980 (3), ; trigonocephaly 2, 614485 (3),
C9orf155		
C9orf157	AR,AD	ovarian dysgenesis 5, 617690 (3), ; spermatogenic failure 32, 618115 (3),
C9orf164		
C9orf165		
C9orf17		
C9orf18		
C9orf19		
C9orf2		
C9orf24		
C9orf26		
C9orf3	AR	dystonia 31, 619565 (3),
C9orf32		
C9orf34		
C9orf35		
C9orf39		
C9orf4	AR	developmental and epileptic encephalopathy 37, 616981 (3),
C9orf41		
C9orf42		
C9orf46		
C9orf47		
C9orf48		
C9orf5		
C9orf52		
C9orf54		
C9orf6		
C9orf60		
C9orf61		
C9orf64		
C9orf65		
C9orf67		
C9orf7		
C9orf72	AD	frontotemporal dementia and/or amyotrophic lateral sclerosis 1, 105550 (3),
C9orf74		
C9orf75	AR	deafness, 79, 613307 (3),
C9orf76		
C9orf77		
C9orf78		
C9orf8	AR	thrombotic thrombocytopenic purpura, hereditary, 274150 (3),
C9orf80		
C9orf81	AR	cone-rod dystrophy and hearing loss, 617236 (3),
C9orf83		
C9orf84	AR	spermatogenic failure 75, 619949 (3),
C9orf86		
C9orf87	AR	osteogenesis imperfecta, type xiv, 615066 (3),
C9orf88		
C9orf89		
C9orf9		
C9orf90		
C9orf94		
C9orf95		
C9orf96		
C9orf98		
CA-125		
CA-II	AR	osteopetrosis, 3, with renal tubular acidosis, 259730 (3),
CA-RPX		
CA1		
CA10		
CA11		
CA12	AR	hyperchlorhidrosis, isolated, 143860 (3),
CA125		
CA13		
CA14		
Ca15-3	AD	tubulointerstitial kidney disease, 2, 174000 (3),
CA150		
CA2	AR	osteopetrosis, 3, with renal tubular acidosis, 259730 (3),
CA21H	AR	hyperandrogenism, nonclassic type, due to 21-hydroxylase deficiency, 201910 (3), ; adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency, 201910 (3),
CA3		
CA4		
CA44	AD,AR	hematuria, familial benign, 1, 141200 (3), ; alport syndrome 2, 203780 (3),
CA5	AR	hyperammonemia due to carbonic anhydrase va deficiency, 615751 (3),
CA5A	AR	hyperammonemia due to carbonic anhydrase va deficiency, 615751 (3),
CA5B		
CA6		
CA7		
CA8	AR	cerebellar ataxia, impaired intellectual development and dysequilibrium syndrome 3, 613227 (3),
CA9		
CAAF1		
CAB-		
CAB1		
CAB2	AR	hyperphosphatasia with impaired intellectual development syndrome 4, 615716 (3),
CAB39		
CAB39L		
Cab45		
CAB56184	AR	mucolipidosis iii gamma, 252605 (3),
CABC1	AR	coenzyme q10 deficiency, primary, 4, 612016 (3),
CABIN1		
CABLES1		
CABLES2		
CABP		
CABP1		
CABP2	AR	deafness, 93, 614899 (3),
CaBP3		
CABP3		
CABP4	AR	cone-rod synaptic disorder, congenital nonprogressive, 610427 (3),
CABP5		
CABP7		
CABP8		
CABP9K		
CABS1		
CABYR		
CAC	AR	carnitine-acylcarnitine translocase deficiency, 212138 (3),
CAC1		
CaCC		
CaCC2		
CACClnc		
CACD2	AD,AR	macular dystrophy, patterned, 1, 169150 (3), ; choroidal dystrophy, central areolar 2, 613105 (3), ; retinitis punctata albescens, 136880 (3), ; leber congenital amaurosis 18, 608133 (3), digenic , ; macular dystrophy, vitelliform, 3, 608161 (3), ; retinitis pigmentosa 7 and digenic form, 608133 (3), digenic ,
CACFD1		
Cach		
CACH2	AD	timothy syndrome, 601005 (3), ; long qt syndrome 8, 618447 (3), ; neurodevelopmental disorder with hypotonia, language delay, and skeletal defects with or without seizures, 620029 (3), ; brugada syndrome 3, 611875 (3),
CACH3	AD,AR	primary aldosteronism, seizures, and neurologic abnormalities, 615474 (3), ; sinoatrial node dysfunction and deafness, 614896 (3),
CACH6	AD	developmental and epileptic encephalopathy 69, 618285 (3),
CACHD1		
CACN2	AD	timothy syndrome, 601005 (3), ; long qt syndrome 8, 618447 (3), ; neurodevelopmental disorder with hypotonia, language delay, and skeletal defects with or without seizures, 620029 (3), ; brugada syndrome 3, 611875 (3),
CACN4	AD,AR	primary aldosteronism, seizures, and neurologic abnormalities, 615474 (3), ; sinoatrial node dysfunction and deafness, 614896 (3),
CACNA1A	AD	spinocerebellar ataxia 6, 183086 (3), ; episodic ataxia, type 2, 108500 (3), ; developmental and epileptic encephalopathy 42, 617106 (3), ; migraine, familial hemiplegic, 1, with progressive cerebellar ataxia, 141500 (3), ; migraine, familial hemiplegic, 1, 141500 (3),
CACNA1B	AR	neurodevelopmental disorder with seizures and nonepileptic hyperkinetic movements, 618497 (3),
CACNA1C	AD	timothy syndrome, 601005 (3), ; long qt syndrome 8, 618447 (3), ; neurodevelopmental disorder with hypotonia, language delay, and skeletal defects with or without seizures, 620029 (3), ; brugada syndrome 3, 611875 (3),
CACNA1C-IT2	AD	timothy syndrome, 601005 (3), ; long qt syndrome 8, 618447 (3), ; neurodevelopmental disorder with hypotonia, language delay, and skeletal defects with or without seizures, 620029 (3), ; brugada syndrome 3, 611875 (3),
CACNA1D	AD,AR	primary aldosteronism, seizures, and neurologic abnormalities, 615474 (3), ; sinoatrial node dysfunction and deafness, 614896 (3),
CACNA1E	AD	developmental and epileptic encephalopathy 69, 618285 (3),
CACNA1F	XL,XLR	cone-rod dystrophy, 3, 300476 (3), ; night blindness, congenital stationary (incomplete), 2a, 300071 (3), ; aland island eye disease, 300600 (3),
CACNA1G	AD	spinocerebellar ataxia 42, 616795 (3), ; spinocerebellar ataxia 42, early-onset, severe, with neurodevelopmental deficits, 618087 (3),
CACNA1H	AD	{epilepsy, childhood absence, susceptibility to, 6}, 611942 (3); hyperaldosteronism, familial, type iv, 617027 (3), ; {epilepsy, idiopathic generalized, susceptibility to, 6}, 611942 (3)
CACNA1I	AD	neurodevelopmental disorder with speech impairment and with or without seizures, 620114 (3),
CACNA1S	AD,AR	{thyrotoxic periodic paralysis, susceptibility to, 1}, 188580 (3), ; congenital myopathy 18 due to dihydropyridine receptor defect, 620246 (3), ; hypokalemic periodic paralysis, type 1, 170400 (3), ; {malignant hyperthermia susceptibility 5}, 601887 (3),
CACNA2	AR	developmental and epileptic encephalopathy 110, 620149 (3),
CACNA2D1	AR	developmental and epileptic encephalopathy 110, 620149 (3),
CACNA2D2	AR	cerebellar atrophy with seizures and variable developmental delay, 618501 (3),
CACNA2D3		
CACNA2D4	AR	retinal cone dystrophy 4, 610478 (3),
CACNB1		
CACNB2	AD	brugada syndrome 4, 611876 (3),
CACNB3		
CACNB4	AD	{epilepsy, juvenile myoclonic, susceptibility to, 6}, 607682 (3), ; episodic ataxia, type 5, 613855 (3), ; {epilepsy, idiopathic generalized, susceptibility to, 9}, 607682 (3),
CACNG1		
CACNG2	AD	?intellectual developmental disorder, 10, 614256 (3),
CACNG3		
CACNG4		
CACNG5		
CACNG6		
CACNG7		
CACNG8		
CACNL1A1	AD	timothy syndrome, 601005 (3), ; long qt syndrome 8, 618447 (3), ; neurodevelopmental disorder with hypotonia, language delay, and skeletal defects with or without seizures, 620029 (3), ; brugada syndrome 3, 611875 (3),
CACNL1A2	AD,AR	primary aldosteronism, seizures, and neurologic abnormalities, 615474 (3), ; sinoatrial node dysfunction and deafness, 614896 (3),
CACNL1A3	AD,AR	{thyrotoxic periodic paralysis, susceptibility to, 1}, 188580 (3), ; congenital myopathy 18 due to dihydropyridine receptor defect, 620246 (3), ; hypokalemic periodic paralysis, type 1, 170400 (3), ; {malignant hyperthermia susceptibility 5}, 601887 (3),
CACNL1A4	AD	spinocerebellar ataxia 6, 183086 (3), ; episodic ataxia, type 2, 108500 (3), ; developmental and epileptic encephalopathy 42, 617106 (3), ; migraine, familial hemiplegic, 1, with progressive cerebellar ataxia, 141500 (3), ; migraine, familial hemiplegic, 1, 141500 (3),
CACNL1A5	AR	neurodevelopmental disorder with seizures and nonepileptic hyperkinetic movements, 618497 (3),
CACNL1A6	AD	developmental and epileptic encephalopathy 69, 618285 (3),
CACNL2A	AR	developmental and epileptic encephalopathy 110, 620149 (3),
CACNLB1		
CACNLB2	AD	brugada syndrome 4, 611876 (3),
CACNLB3		
CACNLG		
CACNN	AR	neurodevelopmental disorder with seizures and nonepileptic hyperkinetic movements, 618497 (3),
CACP	AR	camptodactyly-arthropathy-coxa vara-pericarditis syndrome, 208250 (3),
CACRC		
CACT	AR	carnitine-acylcarnitine translocase deficiency, 212138 (3),
CACTIN		
CACUL1		
CACY		
CACYBP		
Cad		[blood group, sid system], 615018 (3); sd(a) polyagglutination syndrome, 615018 (3)
CAD	AR	developmental and epileptic encephalopathy 50, 616457 (3),
CAD11	AD,AR	teebi hypertelorism syndrome 2, 619736 (3), ; elsahy-waters syndrome, 211380 (3),
CADASIL	AD	lateral meningocele syndrome, 130720 (3), ; ?myofibromatosis, infantile 2, 615293 (3), ; cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1, 125310 (3),
cadherin		
CADM1		
CADM2		
CADM3	AD	charcot-marie-tooth disease, axonal, type 2ff, 619519 (3),
CADM4		
cADPR1		
cADPR2		
CADPS		
CADPS1		
CADPS2		
CADTK		
CAE	AD	cataract 1, multiple types, 116200 (3),
CAE1	AD	cataract 1, multiple types, 116200 (3),
CAF-1		
CAF1		
CAF1A		
CAF1B		
CAF1P150		
CAF1P60		
CAF40		
CAG3A		
CAG4A	AR	developmental and epileptic encephalopathy 60, 617929 (3),
CAG7A		
CAGA		
CAGB		
CAGC		
CAGE		
CAGE1		
CAGF28		
CAGF29		
CAGF9		
CAGH16		
CAGH1A		
CAGH26	AD	?epilepsy, familial adult myoclonic, 6, 618074 (3),
CAGH3		
CAGH32		
CAGH39	XLR,XLD,XL	intellectual developmental disorder, with or without nystagmus, 300422 (3), ; intellectual developmental disorder and microcephaly with pontine and cerebellar hypoplasia, 300749 (3), ; fg syndrome 4, 300422 (3),
CAGH4		
CAGH44	AD	speech-language disorder-1, 602081 (3),
CAGH45	XLR,XL,XLD	lujan-fryns syndrome, 309520 (3), ; ohdo syndrome, 300895 (3), ; hardikar syndrome, 301068 (3), ; opitz-kaveggia syndrome, 305450 (3),
CAGL114	AD	branchial arch abnormalities, choanal atresia, athelia, hearing loss, and hypothyroidism syndrome, 620186 (3), ; kabuki syndrome 1, 147920 (3),
CAGL237	AD	huntington disease-like 2, 606438 (3),
CAGL85		
CAGLP		
CAGR1	AR	cerebellar, ocular, craniofacial, and genital syndrome, 618479 (3),
CAH1	AR	hyperandrogenism, nonclassic type, due to 21-hydroxylase deficiency, 201910 (3), ; adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency, 201910 (3),
CAHL		
CAHM		
CAII	AR	osteopetrosis, 3, with renal tubular acidosis, 259730 (3),
CAIII		
CAIN	AR	leukemia, t-cell acute lymphoblastic, somatic, 613065 (3); leukemia, acute myeloid, somatic, 601626 (3); {encephalopathy, acute, infection-induced, susceptibility to, 9}, 618426 (3),
CAIV		
CAIX		
cajalin-2		
CAK		
CAK1		
CAKB		
CAL		
CAL1H		
CAL1L		
CAL2		
CALB		
CALB1		
CALB2		
CALB3		
CALBL		
CALC	AR	myopathy with extrapyramidal signs, 615673 (3),
CALC1		
CALC2		
CALCA		
CALCB		
CALCOCO2		
CALCOCO3		
CALCR	AD	{osteoporosis, postmenopausal, susceptibility}, 166710 (3),
CALCRL	AR	?lymphatic malformation 8, 618773 (3),
CALCYON		
CALD1		
CALDAG-GEFI	AR	?bleeding disorder, platelet-type, 18, 615888 (3),
CalDAG-GEFII	AR	immunodeficiency 64, 618534 (3),
CalDAG-GEFIII		
CALHM1		
CALHM2		
CALHM3		
CALHM6		
CALIF		
CALJA	AR	calcification of joints and arteries, 211800 (3),
CALL		
CALLA	AD,AR	?spinocerebellar ataxia 43, 617018 (3), ; charcot-marie-tooth disease, axonal, type 2t, 617017 (3),
CALM		leukemia, acute myeloid, somatic, 601626 (3)
CALM1	AD	ventricular tachycardia, catecholaminergic polymorphic, 4, 614916 (3), ; long qt syndrome 14, 616247 (3),
CALM2	AD	long qt syndrome 15, 616249 (3),
CALM3	AD	long qt syndrome 16, 618782 (3), ; ?ventricular tachycardia, catecholaminergic polymorphic 6, 618782 (3),
Calmbp1	AR	microcephaly 5, primary, 608716 (3),
CALML2	AD	ventricular tachycardia, catecholaminergic polymorphic, 4, 614916 (3), ; long qt syndrome 14, 616247 (3),
CALML3		
CALML5		
CALML6		
CALN	AD	arthrogryposis, cleft palate, craniosynostosis, and impaired intellectual development, 618265 (3), ; developmental and epileptic encephalopathy 91, 617711 (3),
CALN1		
CALNA	AD	arthrogryposis, cleft palate, craniosynostosis, and impaired intellectual development, 618265 (3), ; developmental and epileptic encephalopathy 91, 617711 (3),
CALNA2		
CALNA3		
CALNB		
CALNB1		
Calnuc		
CALP		
CalpM		
CALR		myelofibrosis, somatic, 254450 (3); thrombocythemia, somatic, 187950 (3)
CALR1		myelofibrosis, somatic, 254450 (3); thrombocythemia, somatic, 187950 (3)
CALR3		
CALS	AR	cerebellar ataxia, impaired intellectual development and dysequilibrium syndrome 3, 613227 (3),
CALS-21		
CALS-7		
CALS-C		
CALT		
CALU		
CALY		
CALY3		
CAM	AD	hyperkeratotic cutaneous capillary-venous malformations associated with cerebral capillary malformations, 116860 (3), ; cerebral cavernous malformations-1, 116860 (3), ; cavernous malformations of cns and retina, 116860 (3),
CaM-IP2	AR	spermatogenic failure 51, 619177 (3),
CaM-IP3	AR	spermatogenic failure 84, 620409 (3),
CaM-IP4	AR	spermatogenic failure 33, 618152 (3),
CaM-KIIN		
CAM2	AD	intellectual developmental disorder, 54, 617799 (3),
CAMDI		
CAMEL		
CAMGAP1		
CAMI	AD	ventricular tachycardia, catecholaminergic polymorphic, 4, 614916 (3), ; long qt syndrome 14, 616247 (3),
CAMII	AD	long qt syndrome 15, 616249 (3),
CaMK-GR		
CAMK1		
CaMK1b		
CAMK1D		
CAMK1G		
CAMK2	AD	intellectual developmental disorder, 54, 617799 (3),
CAMK2A	AD,AR	intellectual developmental disorder, 53, 617798 (3), ; ?intellectual developmental disorder, 63, 618095 (3),
CAMK2B	AD	intellectual developmental disorder, 54, 617799 (3),
CAMK2D		
CAMK2G	AD	intellectual developmental disorder, 59, 618522 (3),
CAMK2N1		
CAMK2N2		
CAMK4		
CAMKA	AD,AR	intellectual developmental disorder, 53, 617798 (3), ; ?intellectual developmental disorder, 63, 618095 (3),
CAMKB	AD	intellectual developmental disorder, 54, 617799 (3),
CAMKD		
CAMKG	AD	intellectual developmental disorder, 59, 618522 (3),
CaMKI		
CaMKI-alpha		
CaMKIII		
CaMKIINalpha	AD,AR	intellectual developmental disorder, 53, 617798 (3), ; ?intellectual developmental disorder, 63, 618095 (3),
CaMKIIÎ±	AD,AR	intellectual developmental disorder, 53, 617798 (3), ; ?intellectual developmental disorder, 63, 618095 (3),
CaMKIIÎ²	AD	intellectual developmental disorder, 54, 617799 (3),
CaMKIV		
CAMKK		
CAMKK1		
CAMKK2		
CAMKKA		
CAMKKB		
CAMKMT		
CAMKP		
CaMKP-N		
CaMKPase		
CAMKV		
CAML	AR	?congenital disorder of glycosylation, type iiz, 620201 (3),
CAML1	XLR,XL	masa syndrome, 303350 (3), ; hydrocephalus, congenital, 307000 (3), ; ?corpus callosum, partial agenesis of, 304100 (3),
caMLCK		
CAMLG	AR	?congenital disorder of glycosylation, type iiz, 620201 (3),
CAMOS		
CAMP	AD	neurodevelopmental disorder with hypotonia, impaired language, and dysmorphic features, 616579 (3),
cAMP-GEFI		
cAMP-GEFII		
CAMR	XLD,XL	hsd10 mitochondrial disease, 300438 (3),
CAMRQ2	AR	cerebellar ataxia, impaired intellectual development, and dysquilibrium syndrome 2, 610185 (3), ; hydrocephalus, congenital, 3, with brain anomalies, 617967 (3),
CAMSAP1	AR	cortical dysplasia, complex, with other brain malformations 12, 620316 (3),
CAMSAP1L1		
CAMSAP2		
CAMSAP3		
CAMTA1	AD	cerebellar dysfunction with variable cognitive and behavioral abnormalities, 614756 (3),
CAMTA2		
CAN	AR	leukemia, t-cell acute lymphoblastic, somatic, 613065 (3); leukemia, acute myeloid, somatic, 601626 (3); {encephalopathy, acute, infection-induced, susceptibility to, 9}, 618426 (3),
CAN19		
CAND1		
CAND2		
CanIon	AD,AR	congenital contractures of the limbs and face, hypotonia, and developmental delay, 616266 (3), ; hypotonia, infantile, with psychomotor retardation and characteristic facies 1, 615419 (3),
CANN6		
CANP	AD,AR	poikiloderma, hereditary fibrosing, with tendon contractures, myopathy, and pulmonary fibrosis, 615704 (3), |spastic paraplegia 76, 616907 (3),
CANP3	AR,AD	muscular dystrophy, limb-girdle, 1, 253600 (3), ; muscular dystrophy, limb-girdle, 4, 618129 (3),
CANPL1	AR	spastic paraplegia 76, 616907 (3),
CANPL2		
CANPml		
CANPS		
CANPX		
CANT1	AR	desbuquois dysplasia 1, 251450 (3), ; epiphyseal dysplasia, multiple, 7, 617719 (3),
CANu1		
CANX		
CAP	AR,AR	?deafness, 91, 613453 (3), |congenital myopathy 11, 619967 (3),
CAP-1	AD	{?encephalopathy, acute, infection-induced (herpes-specific), susceptibility to, 5}, 614849 (3),
CAP-23		
CAP-C		
CAP-D2	AR	?microcephaly 21, primary, 617983 (3),
CAP-D3	AR	microcephaly 22, primary, 617984 (3),
CAP-E		
CAP-G		
CAP-G2	AR	khan-khan-katsanis syndrome, 618460 (3),
CAP-H	AR	?microcephaly 23, primary, 617985 (3),
CAP-H2		
CAP-R	AR	cortical dysplasia, complex, with other brain malformations 9, 618174 (3),
CAP-Rf	XL,XLD,XLR	intellectual developmental disorder, syndromic, snijders blok type, 300958 (3),
CAP1		
CAP102	AD	macular dystrophy, patterned, 2, 608970 (3),
CAP18		
CAP2	AR	peeling skin syndrome 5, 617115 (3),
CAP20		
CAP23		
CAP3	AR	ichthyosis, congenital, 11, 602400 (3),
CAP350		
CAP37		
CAP43	AR	charcot-marie-tooth disease, type 4d, 601455 (3),
CAP70		
CAPAM		
CAPER		
CAPERalpha		
CAPG		
CAPH2		
CAPL		
CAPN1	AR	spastic paraplegia 76, 616907 (3),
CAPN10		{diabetes mellitus, noninsulin-dependent 1}, 601283 (3)
CAPN11		
CAPN12		
CAPN13		
CAPN14		
CAPN15	AR	oculogastrointestinal neurodevelopmental syndrome, 619318 (3),
CAPN16		
CAPN2		
CAPN3	AR,AD	muscular dystrophy, limb-girdle, 1, 253600 (3), ; muscular dystrophy, limb-girdle, 4, 618129 (3),
CAPN4		
CAPN5	AD	vitreoretinopathy, neovascular inflammatory, 193235 (3),
CAPN6		
CAPN7		
CAPN8		
CAPN9		
CAPNS1		
CAPNS2		
CAPNX		
CAPON	AR	nephrotic syndrome, type 22, 619155 (3),
CAPPA2		
CAPPA3		
CAPRI		
Caprice		
caprin-1		
caprin-2		
CAPRIN1		
CAPRIN2		
CAPS		
CAPS1		
CAPS2		
CAPSL		
capucin		
CAPZ		
CAPZA1		
CAPZA2		
CAPZA3		
CAPZB		
CapZIP		
CAR	AR,AD	spastic paraplegia 7, 607259 (3),
Car1		
CAR1		
Car2	AR	osteopetrosis, 3, with renal tubular acidosis, 259730 (3),
Car3		
Car4		
Carabin		
CARB		
CARD10	AR	?immunodeficiency 89 and autoimmunity, 619632 (3),
CARD11	AD,AR	b-cell expansion with nfkb and t-cell anergy, 616452 (3), ; immunodeficiency 11b with atopic dermatitis, 617638 (3), ; immunodeficiency 11a, 615206 (3),
CARD12	AD	?familial cold autoinflammatory syndrome 4, 616115 (3), ; autoinflammation with infantile enterocolitis, 616050 (3),
CARD14	AD	psoriasis 2, 602723 (3), ; pityriasis rubra pilaris, 173200 (3),
CARD15	AD,MF	blau syndrome, 186580 (3), ; {yao syndrome}, 617321 (3), ; {inflammatory bowel disease 1, crohn disease}, 266600 (3),
CARD16		
CARD17		
CARD17P		
CARD18		
CARD19		
CARD2	AD	?myoclonus, familial, 1, 614937 (3),
CARD3		
CARD4		
CARD5		
CARD6		
CARD7	AR,AD	{vitiligo-associated multiple autoimmune disease susceptibility 1}, 606579 (3); ?respiratory papillomatosis, juvenile recurrent, congenital, 618803 (3), ; autoinflammation with arthritis and dyskeratosis, 617388 (3), ; palmoplantar carcinoma, multiple self-healing, 615225 (3),
CARD8	AD	?inflammatory bowel disease (crohn disease) 30, 619079 (3),
CARD9	AR	immunodeficiency 103, susceptibility to fungal infection, 212050 (3),
CARDIAK		
Cardif		
CARDINAL	AD	?inflammatory bowel disease (crohn disease) 30, 619079 (3),
CarF		
CARF		
CARHSP1		
CARK	AD	cardiac conduction disease with or without dilated cardiomyopathy, 616117 (3),
CARKD	AR	encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy, 2, 618321 (3),
CARKL	AR	[sedoheptulokinase deficiency], 617213 (3),
CARLo-1		
CARLo-2		
CARLo-5		
CARLo-6		
CARLo-7		
CARM1		
CARMA1	AD,AR	b-cell expansion with nfkb and t-cell anergy, 616452 (3), ; immunodeficiency 11b with atopic dermatitis, 617638 (3), ; immunodeficiency 11a, 615206 (3),
CARMA2	AD	psoriasis 2, 602723 (3), ; pityriasis rubra pilaris, 173200 (3),
CARMA3	AR	?immunodeficiency 89 and autoimmunity, 619632 (3),
CARMEN	AR	{lymphoma, follicular, somatic}, 605027 (3); ?immunodeficiency 37, 616098 (3), ; {sezary syndrome, somatic} (3); {male germ cell tumor, somatic}, 273300 (3); lymphoma, malt, somatic, 137245 (3); {mesothelioma, somatic}, 156240 (3)
CARMIL		
CARMIL1		
CARMIL2	AR	immunodeficiency 58, 618131 (3),
CARMIL3		
CARMQ1	AR	cerebellar hypoplasia, impaired intellectual development, and dysequilibrium syndrome 1, 224050 (3),
CARNMT1		
CARNS1		
CARP	AR	cerebellar ataxia, impaired intellectual development and dysequilibrium syndrome 3, 613227 (3),
CARP-1		
CARP-2		
CARP1		
CARP2		
CARPX		
CARPX1		
CARS	AR	microcephaly, developmental delay, and brittle hair syndrome, 618891 (3),
CARS-Cyp		
CARS1	AR	microcephaly, developmental delay, and brittle hair syndrome, 618891 (3),
CARS2	AR	combined oxidative phosphorylation deficiency 27, 616672 (3),
CART	AR,MF,AD	{?obesity, susceptibility to}, 601665 (3), ,
CART1	AR	frontonasal dysplasia 3, 613456 (3),
CARTPT	AR,MF,AD	{?obesity, susceptibility to}, 601665 (3), ,
CAS		
CAS-L		
CAS2	AR	[skin/hair/eye pigmentation, variation in, 11 (melanesian blond hair)], 612271 (3); albinism, oculocutaneous, type iii, 203290 (3),
CASA		
CASB		
CASC1		
CASC11		
CASC12		
CASC13		
CASC14		
CASC15		
CASC19		
CASC2		
CASC21		
CASC3		
CASC5	AR	microcephaly 4, primary, 604321 (3),
CASC7	AD	lessel-kreienkamp syndrome, 619149 (3),
CASC8		
CASD1		
CASH		
CASIL	AD	lateral meningocele syndrome, 130720 (3), ; ?myofibromatosis, infantile 2, 615293 (3), ; cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1, 125310 (3),
CASK	XLR,XLD,XL	intellectual developmental disorder, with or without nystagmus, 300422 (3), ; intellectual developmental disorder and microcephaly with pontine and cerebellar hypoplasia, 300749 (3), ; fg syndrome 4, 300422 (3),
CASKIN1		
CASKIN2		
CASM		
CASP	AD,AR	global developmental delay with or without impaired intellectual development, 618330 (3), |osteogenesis imperfecta, type vii, 610682 (3),
Casp-8	AD,AR	{breast cancer, protection against}, 114480 (3), somatic mutation, ; ?caspase 8 lymphadenopathy syndrome, 607271 (3), ; hepatocellular carcinoma, somatic, 114550 (3); {lung cancer, protection against}, 211980 (3), somatic mutation,
CASP1		
CASP10	AD	autoimmune lymphoproliferative syndrome, type ii, 603909 (3), ; gastric cancer, somatic, 613659 (3); lymphoma, non-hodgkin, somatic, 605027 (3)
CASP11		
CASP12		{sepsis, susceptibility to} (3)
CASP12P1		{sepsis, susceptibility to} (3)
CASP14	AR	ichthyosis, congenital, 12, 617320 (3),
CASP2		
CASP3		
CASP4		
CASP5		
CASP6		
CASP7		
CASP8	AD,AR	{breast cancer, protection against}, 114480 (3), somatic mutation, ; ?caspase 8 lymphadenopathy syndrome, 607271 (3), ; hepatocellular carcinoma, somatic, 114550 (3); {lung cancer, protection against}, 211980 (3), somatic mutation,
CASP8AP1		
CASP8AP2		
CASP8IP1		
CASP9		
caspase-6		
Casper		
Caspr	AR	lethal congenital contracture syndrome 7, 616286 (3), ; hypomyelinating neuropathy, congenital, 3, 618186 (3),
Caspr2	AR	pitt-hopkins like syndrome 1, 610042 (3), ; {autism susceptibility 15}, 612100 (3)
CASPR3		
CASPR4		
caspr5		
CASQ	AD	myopathy, vacuolar, with casq1 aggregates, 616231 (3),
CASQ1	AD	myopathy, vacuolar, with casq1 aggregates, 616231 (3),
CASQ2	AR	ventricular tachycardia, catecholaminergic polymorphic, 2, 611938 (3),
CASQ2BP1	AR	traboulsi syndrome, 601552 (3),
CASR	AD,AR	hypocalcemia, with bartter syndrome, 601198 (3), ; {epilepsy idiopathic generalized, susceptibility to, 8}, 612899 (3); hyperparathyroidism, neonatal, 239200 (3), ; hypocalcemia, 601198 (3), ; hypocalciuric hypercalcemia, type i, 145980 (3),
CASS1		
CASS2		
CASS3		
CASS4		
CAST	AR	peeling skin with leukonychia, acral punctate keratoses, cheilitis, and knuckle pads, 616295 (3),
CAST1		
CAST2		
castor		
CASTOR1		
CASTOR2		
CASZ1		
CAT		acatalasemia, 614097 (3)
CAT-1		
CAT-2		
CAT-3		
CAT-4		
CaT1	AR	hyperparathyroidism, transient neonatal, 618188 (3),
CAT1	AR	?neurodegeneration with brain iron accumulation 8, 617917 (3),
CaT2		
CAT5	AR	?coenzyme q10 deficiency, primary, 8, 616733 (3),
CAT53		
CATACOMB		
CATB	AR	[skin/hair/eye pigmentation, variation in, 11 (melanesian blond hair)], 612271 (3); albinism, oculocutaneous, type iii, 203290 (3),
CATCH22	AD	tetralogy of fallot, 187500 (3), ; digeorge syndrome, 188400 (3), ; conotruncal anomaly face syndrome, 217095 (3); velocardiofacial syndrome, 192430 (3),
CATF1	AR	neuronopathy, distal hereditary motor, type vi, 604320 (3), ; charcot-marie-tooth disease, axonal, type 2s, 616155 (3),
CATIP	AR	?spermatogenic failure 54, 619379 (3),
CATL1	AD	?spastic paraplegia 73, 616282 (3),
CATR1		
CATS		
CATSF	AR	ceroid lipofuscinosis, neuronal, 13 (kufs type), 615362 (3),
CATSPER	AR	spermatogenic failure 7, 612997 (3),
CATSPER1	AR	spermatogenic failure 7, 612997 (3),
CATSPER2		
CATSPER3		
CATSPER4		
CATSPERB		
CATSPERD		
CATSPERE		
CATSPERG		
CATSPERZ		
CATX-15	AR	neuropathy, hereditary sensory and autonomic, type vi, 614653 (3), ; epidermolysis bullosa simplex 3, localized or generalized intermediate, with bp230 deficiency, 615425 (3),
CATX-8		
CAUXIN		
CAV	AR,AR,AD	hyperammonemia due to carbonic anhydrase va deficiency, 615751 (3), |lipodystrophy, congenital generalized, type 3, 612526 (3), ; pulmonary hypertension, primary, 3, 615343 (3), ; lipodystrophy, familial partial, type 7, 606721 (3),
CAV1	AR,AD	lipodystrophy, congenital generalized, type 3, 612526 (3), ; pulmonary hypertension, primary, 3, 615343 (3), ; lipodystrophy, familial partial, type 7, 606721 (3),
Cav1.1	AD,AR	{thyrotoxic periodic paralysis, susceptibility to, 1}, 188580 (3), ; congenital myopathy 18 due to dihydropyridine receptor defect, 620246 (3), ; hypokalemic periodic paralysis, type 1, 170400 (3), ; {malignant hyperthermia susceptibility 5}, 601887 (3),
Cav1.2	AD	timothy syndrome, 601005 (3), ; long qt syndrome 8, 618447 (3), ; neurodevelopmental disorder with hypotonia, language delay, and skeletal defects with or without seizures, 620029 (3), ; brugada syndrome 3, 611875 (3),
Cav1.3	AD,AR	primary aldosteronism, seizures, and neurologic abnormalities, 615474 (3), ; sinoatrial node dysfunction and deafness, 614896 (3),
Cav1.4	XL,XLR	cone-rod dystrophy, 3, 300476 (3), ; night blindness, congenital stationary (incomplete), 2a, 300071 (3), ; aland island eye disease, 300600 (3),
CAV2		
Cav2.1	AD	spinocerebellar ataxia 6, 183086 (3), ; episodic ataxia, type 2, 108500 (3), ; developmental and epileptic encephalopathy 42, 617106 (3), ; migraine, familial hemiplegic, 1, with progressive cerebellar ataxia, 141500 (3), ; migraine, familial hemiplegic, 1, 141500 (3),
Cav2.2	AR	neurodevelopmental disorder with seizures and nonepileptic hyperkinetic movements, 618497 (3),
Cav2.3	AD	developmental and epileptic encephalopathy 69, 618285 (3),
CAV3	AD	myopathy, distal, tateyama type, 614321 (3), ; creatine phosphokinase, elevated serum, 123320 (3), ; cardiomyopathy, familial hypertrophic, 192600 (3), digenic , ; rippling muscle disease 2, 606072 (3), ; long qt syndrome 9, 611818 (3),
Cav3.1	AD	spinocerebellar ataxia 42, 616795 (3), ; spinocerebellar ataxia 42, early-onset, severe, with neurodevelopmental deficits, 618087 (3),
Cav3.2	AD	{epilepsy, childhood absence, susceptibility to, 6}, 611942 (3); hyperaldosteronism, familial, type iv, 617027 (3), ; {epilepsy, idiopathic generalized, susceptibility to, 6}, 611942 (3)
Cav3.3	AD	neurodevelopmental disorder with speech impairment and with or without seizures, 620114 (3),
CAVA	AR	hyperammonemia due to carbonic anhydrase va deficiency, 615751 (3),
cavin-1	AR	lipodystrophy, congenital generalized, type 4, 613327 (3),
cavin-2		
cavin-3		
cavin-4		
CAVIN1	AR	lipodystrophy, congenital generalized, type 4, 613327 (3),
CAVIN2		
CAVIN3		
CAVIN4		
CAXIII		
CAZIP		
CB-R		
CB1		
CB1A		
CB1K5		
CB2		
CBAP		
CBARA1	AR	myopathy with extrapyramidal signs, 615673 (3),
CBBM	XLR,XL,XL,XLR	blue cone monochromacy, 303700 (3), ; colorblindness, protan, 303900 (3), |colorblindness, deutan, 303800 (3), ; blue cone monochromacy, 303700 (3),
Cbc2		
CBCIP2		
CBCP1		
CBD	XL,XLR	colorblindness, deutan, 303800 (3), ; blue cone monochromacy, 303700 (3),
CBE1		
CBF-A		
CBF-B		
CBF-C		
CBF1	AD	adams-oliver syndrome 3, 614814 (3),
CBF2		
Cbf5	XL,XLR	dyskeratosis congenita, 305000 (3),
CBFA1	AD	metaphyseal dysplasia with maxillary hypoplasia with or without brachydactyly, 156510 (3), ; cleidocranial dysplasia, forme fruste, with brachydactyly, 119600 (3), ; cleidocranial dysplasia, forme fruste, dental anomalies only, 119600 (3), ; cleidocranial dysplasia, 119600 (3),
CBFA2	AD	platelet disorder, familial, with associated myeloid malignancy, 601399 (3), ; leukemia, acute myeloid, 601626 (3), somatic mutation,
CBFA2T1		
CBFA2T2		
CBFA2T3		
CBFA3		
CBFB	AD	cleidocranial dysplasia 2, 620099 (3),
CBG	AR,AD	corticosteroid-binding globulin deficiency, 611489 (3),
CBGL1		
CBL	AD	noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia, 613563 (3), ; ?juvenile myelomonocytic leukemia, 607785 (3), somatic mutation,
CBL-3		
Cbl-b		
CBL-SL		
CBL2	AD	noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia, 613563 (3), ; ?juvenile myelomonocytic leukemia, 607785 (3), somatic mutation,
cblA	AR	methylmalonic aciduria, vitamin b12-responsive, cbla type, 251100 (3),
cblB	AR	methylmalonic aciduria, vitamin b12-responsive, cblb type, 251110 (3),
CBLB		
cblC	AR	methylmalonic aciduria and homocystinuria, cblc type, 277400 (3),
CBLC		
cblD	AR	methylmalonic aciduria, cbld type, variant 2, 277410 (3), ; methylmalonic aciduria and homocystinuria, cbld type, 277410 (3), ; homocystinuria, cbld type, variant 1, 277410 (3),
cblE	AR	homocystinuria-megaloblastic anemia, cbl e type, 236270 (3), ; {neural tube defects, folate-sensitive, susceptibility to}, 601634 (3),
cblF	AR	methylmalonic aciduria and homocystinuria, cblf type, 277380 (3),
cblG	AR	{neural tube defects, folate-sensitive, susceptibility to}, 601634 (3), ; homocystinuria-megaloblastic anemia, cblg complementation type, 250940 (3),
CBLIF	AR	intrinsic factor deficiency, 261000 (3),
CBLL1		
CBLN1		
CBLN2		
CBLN3		
CBLN4		
CBLNL1		
CBP	XLR,XL,AD	blue cone monochromacy, 303700 (3), ; colorblindness, protan, 303900 (3), |menke-hennekam syndrome 1, 618332 (3), ; rubinstein-taybi syndrome 1, 180849 (3),
CBP1	MF,AR	{preterm premature rupture of the membranes, susceptibility to}, 610504 (3), ; osteogenesis imperfecta, type x, 613848 (3),
CBP2	MF,AR	{preterm premature rupture of the membranes, susceptibility to}, 610504 (3), ; osteogenesis imperfecta, type x, 613848 (3),
CBP20		
CBP3		
Cbp6	AR	mitochondrial complex iii deficiency, nuclear type 7, 615824 (3),
CBP80		
CBP86		
CBPIN		
CBPP		
CBR		
CBR1		
CBR3		
CBR4		
CBS	AR	thrombosis, hyperhomocysteinemic, 236200 (3), ; homocystinuria, b6-responsive and nonresponsive types, 236200 (3),
CBS-1		
CBS1		
CBT	AD	colorblindness, tritan, 190900 (3),
CBWD1		
CBWD2		
CBWD3		
CBX		
CBX1		
CBX2	AR	?46xy sex reversal 5, 613080 (3),
CBX3		
CBX4		
CBX5		
CBX6		
CBX7		
CBX8		
Cby		
CBY1		
CBY2		
CC-CKR-2		{hiv infection, susceptibility/resistance to}, 609423 (3)
CC-CKR-3		
CC-CKR-4		
CC-CKR-5		{hiv infection, susceptibility/resistance to}, 609423 (3); {diabetes mellitus, insulin-dependent, 22}, 612522 (3); {hepatitis c virus, resistance to}, 609532 (3); {west nile virus, susceptibility to}, 610379 (3)
Cc1		breast cancer, somatic, 114480 (3)
CC1.3		
CC10		
CC16		
cC1qR		myelofibrosis, somatic, 254450 (3); thrombocythemia, somatic, 187950 (3)
CC28		
CC2D1A	AR	intellectual developmental disorder, 3, 608443 (3),
CC2D2A	AR	coach syndrome 2, 619111 (3), ; retinitis pigmentosa 93, 619845 (3), ; meckel syndrome 6, 612284 (3), ; joubert syndrome 9, 612285 (3),
CC3		
CCA	AD	macular degeneration, early-onset, 616118 (3), ; contractural arachnodactyly, congenital, 121050 (3),
CCA1	AR	sideroblastic anemia with b-cell immunodeficiency, periodic fevers, and developmental delay, 616084 (3), ; retinitis pigmentosa and erythrocytic microcytosis, 616959 (3),
CCA2	AD	cataract 3, multiple types, 601547 (3),
CCAL2	AD	chondrocalcinosis 2, 118600 (3), ; craniometaphyseal dysplasia, 123000 (3),
CCAR1		
CCAR2		
CCAT	AD,AR	[blood group, ii], 110800 (3), ; adult i phenotype without cataract, 110800 (3), ; cataract 13 with adult i phenotype, 116700 (3),
CCAT1		
CCAT2		
CCBE1	AR	hennekam lymphangiectasia-lymphedema syndrome 1, 235510 (3),
CCBL1		
CCBL2		
CCBP1	AR,AD	[blood group, duffy system], 110700 (3), ; [white blood cell count qtl], 611862 (3), ; {malaria, vivax, protection against}, 611162 (3)
CCBP2		
CCC1	AR,AD	kilquist syndrome, 619080 (3), ; delpire-mcneill syndrome, 619083 (3), ; deafness, 78, 619081 (3),
CCC2	AR	bartter syndrome, type 1, 601678 (3),
CCC9		
CCCAP	AR	senior-loken syndrome 7, 613615 (3), ; bardet-biedl syndrome 16, 615993 (3),
CCCP-1		
CCD	AD	metaphyseal dysplasia with maxillary hypoplasia with or without brachydactyly, 156510 (3), ; cleidocranial dysplasia, forme fruste, with brachydactyly, 119600 (3), ; cleidocranial dysplasia, forme fruste, dental anomalies only, 119600 (3), ; cleidocranial dysplasia, 119600 (3),
CCD1	AD	metaphyseal dysplasia with maxillary hypoplasia with or without brachydactyly, 156510 (3), ; cleidocranial dysplasia, forme fruste, with brachydactyly, 119600 (3), ; cleidocranial dysplasia, forme fruste, dental anomalies only, 119600 (3), ; cleidocranial dysplasia, 119600 (3),
CCD41		
CCDC10		
CCDC100	AR	short-rib thoracic dysplasia 13 with or without polydactyly, 616300 (3), ; joubert syndrome 31, 617761 (3),
CCDC101		
CCDC103	AR	ciliary dyskinesia, primary, 17, 614679 (3),
CCDC106		
CCDC108	AR	spermatogenic failure 40, 618664 (3),
CCDC109A		
CCDC11	AR	heterotaxy, visceral, 6, 614779 (3),
CCDC110		
CCDC111	AD	myopia 22, 615420 (3),
CCDC113		
CCDC114	AR	ciliary dyskinesia, primary, 20, 615067 (3),
CCDC115	AR	congenital disorder of glycosylation, type iio, 616828 (3),
CCDC120		
CCDC122		
CCDC123		
CCDC125		
CCDC128	AR	neurodevelopmental disorder with hypotonia, facial dysmorphism, and brain abnormalities, 619383 (3),
CCDC132	AR	neurodevelopmental disorder with microcephaly, seizures, and neonatal cholestasis, 619685 (3),
CCDC133		
CCDC134	AR	osteogenesis imperfecta, type xxii, 619795 (3),
CCDC135		
CCDC136		
CCDC137		
CCDC139		
CCDC14		
CCDC141		
CCDC144A		
CCDC146		
CCDC147	AR	spermatogenic failure 49, 619144 (3),
CCDC151	AR	ciliary dyskinesia, primary, 30, 616037 (3),
CCDC154		
CCDC155		
CCDC157		
CCDC164	AR	spermatogenic failure 80, 620222 (3), ; ciliary dyskinesia, primary, 21, 615294 (3),
CCDC165		
CCDC174	AR	hypotonia, infantile, with psychomotor retardation, 616816 (3),
CCDC183		
CCDC186		
CCDC189		
CCDC19	AR	heterotaxy, visceral, 11, with male infertility, 619608 (3),
CCDC193		
CCDC2	AR	bardet-biedl syndrome 22, 617119 (3), ; spermatogenic failure 58, 619585 (3), ; joubert syndrome 40, 619582 (3),
CCDC21		
CCDC22	XLR,XL	ritscher-schinzel syndrome 2, 300963 (3),
CCDC23	AR	neurodevelopmental disorder with ataxia, hypotonia, and microcephaly, 618569 (3),
CCDC25		
CCDC26		{glioma susceptibility 7}, 613032 (3)
CCDC28A		
CCDC28B	AR	{bardet-biedl syndrome 1, modifier of}, 209900 (3), digenic
CCDC32	AR	cardiofacioneurodevelopmental syndrome, 619123 (3),
CCDC33		
CCDC34	AR	spermatogenic failure 76, 620084 (3),
CCDC35	AR	spermatogenic failure 65, 619712 (3),
CCDC36		
CCDC39	AR	ciliary dyskinesia, primary, 14, 613807 (3),
CCDC40	AR	ciliary dyskinesia, primary, 15, 613808 (3),
CCDC41	AR	nephronophthisis 18, 615862 (3),
CCDC44	AR	mitochondrial complex iv deficiency, nuclear type 8, 619052 (3),
CCDC46	AR	spermatogenic failure 44, 619044 (3),
CCDC47	AR	trichohepatoneurodevelopmental syndrome, 618268 (3),
CCDC5		
CCDC50	AD	?deafness, 44, 607453 (3),
CCDC51		
CCDC52		
CCDC53		
CCDC55	AR	neurodevelopmental disorder with spasticity, seizures, and brain abnormalities, 620001 (3),
CCDC56	AR	?mitochondrial complex iv deficiency, nuclear type 14, 619058 (3),
CCDC59		
CCDC6		
CCDC62	AR	?spermatogenic failure 67, 619803 (3),
CCDC63		
CCDC64		
CCDC64B		
CCDC65	AR	ciliary dyskinesia, primary, 27, 615504 (3),
CCDC66		
CCDC67		
CCDC68		
CCDC69		
CCDC7		
CCDC72		
CCDC73		
CCDC78	AD	?centronuclear myopathy 4, 614807 (3),
CCDC79	AR	spermatogenic failure 60, 619646 (3),
CCDC8	AR	3-m syndrome 3, 614205 (3),
CCDC80		
CCDC82		
CCDC84	AR	?mosaic variegated aneuploidy syndrome 4, 620153 (3),
CCDC85B		
CCDC86		
CCDC88		
CCDC88A	AR	?peho syndrome-like, 617507 (3),
CCDC88B		
CCDC88C	AD,AR	?spinocerebellar ataxia 40, 616053 (3), ; hydrocephalus, congenital, 1, 236600 (3),
CCDC89B		
CCDC90A		
CCDC91		
CCDC96		
CCDC98		
CCDC99		
CCER2		
CCG1	XL,XLR	intellectual developmental disorder, syndromic 33, 300966 (3), ; dystonia-parkinsonism, 314250 (3),
CCG2		
CCGS	XL,XLR	intellectual developmental disorder, syndromic 33, 300966 (3), ; dystonia-parkinsonism, 314250 (3),
CCHCR1		
CCHL	XLD,XL	linear skin defects with multiple congenital anomalies 1, 309801 (3),
CCHL1A1	AD	timothy syndrome, 601005 (3), ; long qt syndrome 8, 618447 (3), ; neurodevelopmental disorder with hypotonia, language delay, and skeletal defects with or without seizures, 620029 (3), ; brugada syndrome 3, 611875 (3),
CCHL1A2	AD,AR	primary aldosteronism, seizures, and neurologic abnormalities, 615474 (3), ; sinoatrial node dysfunction and deafness, 614896 (3),
CCIN		
CCK		
CCK1		
CCK4		
CCKAR		
CCKBR		
CCL1		
CCL11	AD	{asthma, susceptibility to}, 600807 (3), ; {hiv1, resistance to}, 609423 (3)
CCL13		
CCL14		
CCL15		
CCL16		
CCL17		
CCL18		
CCL19		
CCL2	AD	{mycobacterium tuberculosis, susceptibility to}, 607948 (3); {hiv-1, resistance to}, 609423 (3); {coronary artery disease, modifier of} (3); {spina bifida, susceptibility to}, 182940 (3),
CCL20		
CCL21		
CCL22		
CCL23		
CCL24		
CCL25		
CCL26		
CCL27		
CCL28		
CCL3		{hiv infection, resistance to}, 609423 (2)
CCL3L1		{hiv/aids, susceptibility to}, 609423 (3)
CCL3L3		
CCL4		
CCL4L		
CCL4L1		
CCL4L2		
CCL5		{hiv-1 disease, rapid progression of}, 609423 (3); {hiv-1 disease, delayed progression of}, 609423 (3)
CCL7		
CCL8		
Cclp1		
CCM1	AD	hyperkeratotic cutaneous capillary-venous malformations associated with cerebral capillary malformations, 116860 (3), ; cerebral cavernous malformations-1, 116860 (3), ; cavernous malformations of cns and retina, 116860 (3),
CCM2	AD	cerebral cavernous malformations-2, 603284 (3),
CCM3	AD	cerebral cavernous malformations-3, 603285 (3),
CCN1		
CCN2		
CCN3		
CCN4		
CCN5		
CCN6	AR	progressive pseudorheumatoid dysplasia, 208230 (3),
CCNA		
CCNA1		
CCNA2		
CCNB		
CCNB1		
CCNB1IP1		
CCNB2		
CCNB3		
CCNC		
CCNC1	AR	achromatopsia 2, 216900 (3),
CCNCa	AR	achromatopsia 2, 216900 (3),
CCND1	AD	{von hippel-lindau syndrome, modifier of}, 193300 (3), ; {colorectal cancer, susceptibility to}, 114500 (3), somatic mutation, ; {multiple myeloma, susceptibility to}, 254500 (3), somatic mutation
CCND2	AD	megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 3, 615938 (3),
CCND3		
CCNDBP1		
CCNE		
CCNE1		
CCNE2		
CCNF	AD	frontotemporal dementia and/or amyotrophic lateral sclerosis 5, 619141 (3),
CCNG		
CCNG1		
CCNG2		
CCNH		
CCNI		
CCNI1		
CCNI2		
CCNJ		
CCNK	AD	?intellectual developmental disorder with hypertelorism and distinctive facies, 618147 (3),
CCNL1	AD	?deafness, 70, 616968 (3),
CCNL2		
CCNM		
CCNO	AR	ciliary dyskinesia, primary, 29, 615872 (3),
cCNOX		
CCNP		
CCNQ	XLD,XL	star syndrome, 300707 (3),
CCNS		
CCNT		
CCNT1		
CCNT2		
CCNU	AR	ciliary dyskinesia, primary, 29, 615872 (3),
CCNY		
CCO	AR,AD	congenital myopathy 1b, 255320 (3), ; congenital myopathy 1a, with susceptibility to malignant hyperthermia, 117000 (3), ; king-denborough syndrome, 619542 (3), ; {malignant hyperthermia susceptibility 1}, 145600 (3),
CCP-X		
ccp1	AR	congenital disorder of glycosylation, type iio, 616828 (3),
CCP1	AR	neurodegeneration, childhood-onset, with cerebellar atrophy, 618276 (3),
CCP110		
CCP2		
CCP3		
CCP4	AD	corneal dystrophy, fuchs endothelial, 8, 615523 (3),
CCP5	AR	retinitis pigmentosa 75, 617023 (3),
CCP6		
CCPG		
CCPG1		
CCPI		
CCR1		
CCR10		
CCR11		
CCR2		{hiv infection, susceptibility/resistance to}, 609423 (3)
CCR3		
CCR4		
Ccr4a		
Ccr4b		
Ccr4c		
Ccr4d		
Ccr4e		
CCR4L		
CCR5		{hiv infection, susceptibility/resistance to}, 609423 (3); {diabetes mellitus, insulin-dependent, 22}, 612522 (3); {hepatitis c virus, resistance to}, 609532 (3); {west nile virus, susceptibility to}, 610379 (3)
CCR6		
CCR7		
CCR8		
CCR9		
CCRK		
CCRL1		{rapid progression to aids from hiv1 infection}, 609423 (3); {macular degeneration, age-related, 12}, 613784 (3); {coronary artery disease, resistance to}, 607339 (3)
CCRL1AP		
CCRL2		
CCRN4L		
CCS		
CCSAP		
CCSER1		
CCSER2		
CCSP		
CCSP-2		
CCT	AR	proliferative vasculopathy and hydranencephaly-hydrocephaly syndrome, 225790 (3),
CCT-beta		
CCT1		
CCT2		
CCT3		
CCT4		
CCT5	AR	neuropathy, hereditary sensory, with spastic paraplegia, 256840 (3),
CCT6		
CCT6A		
CCT6B		
CCT7		
CCT8		
Ccta		
CCTalpha	AR	spondylometaphyseal dysplasia with cone-rod dystrophy, 608940 (3),
Cctb		
CCTbeta		
Cctd		
Cctg		
Ccth		
Cctq		
Cctz		
Cctz2		
CCX-CKR		
CCXCR1		
CCYC		
CD	AD,MF,AD	blau syndrome, 186580 (3), ; {yao syndrome}, 617321 (3), ; {inflammatory bowel disease 1, crohn disease}, 266600 (3), |immune dysregulation with autoimmunity, immunodeficiency, and lymphoproliferation, 616100 (3), ; {diabetes mellitus, insulin-dependent, 12}, 601388 (3); {celiac disease, susceptibility to, 3}, 609755 (3); {hashimoto thyroiditis}, 140300 (3), ; {systemic lupus erythematosus, susceptibility to}, 152700 (3),
CD-M6PR		
CD-MPR		
CD-RAP		
CD1		
CD10	AD,AR	?spinocerebellar ataxia 43, 617018 (3), ; charcot-marie-tooth disease, axonal, type 2t, 617017 (3),
CD100		
CD101		
CD102		
CD103		
CD104	AR	epidermolysis bullosa, junctional 5b, with pyloric atresia, 226730 (3), ; epidermolysis bullosa, junctional 5a, intermediate, 619816 (3),
CD105	AD	telangiectasia, hereditary hemorrhagic, type 1, 187300 (3),
CD106		
CD107a		
CD107b	XLD,XL	danon disease, 300257 (3),
CD108	AR	?cholestasis, progressive familial intrahepatic, 11, 619874 (3), ; [blood group, john-milton-hagen system], 614745 (3)
CD109		
CD110	AD,AR	myelofibrosis with myeloid metaplasia, somatic, 254450 (3); thrombocythemia 2, 601977 (3), somatic mutation, ; thrombocytopenia, congenital amegakaryocytic, 604498 (3),
CD111	AR	cleft lip/palate-ectodermal dysplasia syndrome, 225060 (3), ; orofacial cleft 7, 225060 (3),
CD112		
CD112R		
CD113		
CD113t-C	AD,AR	methemoglobinemia, beta type, 617971 (3), ; thalassemia-beta, inclusion-body, 603902 (3), ; sickle cell anemia, 603903 (3), ; thalassemia, beta, 613985 (3); delta-beta thalassemia, 141749 (3), ; {malaria, resistance to}, 611162 (3); hereditary persistence of fetal hemoglobin, 141749 (3), ; erythrocytosis, familial, 6, 617980 (3), ; heinz body anemia, 140700 (3),
CD114	AR,AD	neutropenia, severe congenital, 7, 617014 (3), ; ?neutrophilia, hereditary, 162830 (3),
CD115	AR,AD	brain abnormalities, neurodegeneration, and dysosteosclerosis, 618476 (3), ; leukoencephalopathy, diffuse hereditary, with spheroids 1, 221820 (3),
CD116		surfactant metabolism dysfunction, pulmonary, 4, 300770 (3)
CD117	AD	gastrointestinal stromal tumor, familial, 606764 (3), isolated cases, ; mastocytosis, cutaneous, 154800 (3), ; piebaldism, 172800 (3), ; germ cell tumors, somatic, 273300 (3); mastocytosis, systemic, somatic, 154800 (3); leukemia, acute myeloid, somatic, 601626 (3)
CD118	AR	stuve-wiedemann syndrome/schwartz-jampel type 2 syndrome, 601559 (3),
CD119	AR,AD	{h. pylori infection, susceptibility to}, 600263 (3); immunodeficiency 27a, mycobacteriosis, ar, 209950 (3), ; immunodeficiency 27b, mycobacteriosis, ad, 615978 (3), ; {tuberculosis infection, protection against}, 607948 (3); {tuberculosis, susceptibility to}, 607948 (3); {hepatitis b virus infection, susceptibility to}, 610424 (3)
CD11A		
CD11b		
CD11B		
CD11c		
CD11C		
CD11d		
CD120a	AD	{multiple sclerosis, susceptibility to, 5}, 614810 (3); periodic fever, familial, 142680 (3),
CD120b		
CD121A		
CD121b		
CD122	AR	immunodeficiency 63 with lymphoproliferation and autoimmunity, 618495 (3),
CD123		
CD124	AD	{aids, slow progression to}, 609423 (3); {atopy, susceptibility to}, 147050 (3),
CD125		
CD126	AR	[interleukin 6, serum level of, qtl], 614752 (3); hyper-ige recurrent infection syndrome 5, 618944 (3), ; [interleukin-6 receptor, soluble, serum level of, qtl], 614689 (3)
CD127	AR	immunodeficiency 104, severe combined, 608971 (3),
CD129		
CD13		
CD130	AR,AD	stuve-wiedemann syndrome 2, 619751 (3), ; hyper-ige recurrent infection syndrome 4a, 619752 (3), ; ?immunodeficiency 94 with autoinflammation and dysmorphic facies, 619750 (3), ; hyper-ige recurrent infection syndrome 4b, 618523 (3),
CD131	AR	surfactant metabolism dysfunction, pulmonary, 5, 614370 (3),
CD132	XL,XLR	combined immunodeficiency, moderate, 312863 (3), ; severe combined immunodeficiency, 300400 (3),
CD133	AD,AR	macular dystrophy, retinal, 2, 608051 (3), ; retinitis pigmentosa 41, 612095 (3), ; stargardt disease 4, 603786 (3), ; cone-rod dystrophy 12, 612657 (3),
CD134	AR	?immunodeficiency 16, 615593 (3),
CD135		leukemia, acute lymphoblastic, somatic, 613065 (3); leukemia, acute myeloid, reduced survival in, somatic, 601626 (3); leukemia, acute myeloid, somatic, 601626 (3)
CD136	AD	{nasopharyngeal carcinoma, susceptibility to, 3}, 617075 (3),
CD137	AR	immunodeficiency 109 with lymphoproliferation, 620282 (3),
CD137L		
CD138		
CD14		
CD140a		gastrointestinal stromal tumor/gist-plus syndrome, somatic or familial, 175510 (3); hypereosinophilic syndrome, idiopathic, resistant to imatinib, 607685 (3), somatic mutation, isolated cases
CD140b	AD	premature aging syndrome, penttinen type, 601812 (3), ; kosaki overgrowth syndrome, 616592 (3), ; myofibromatosis, infantile, 1, 228550 (3), ; basal ganglia calcification, idiopathic, 4, 615007 (3), ; myeloproliferative disorder with eosinophilia, 131440 (4),
CD141	AD	thrombophilia 12 due to thrombomodulin defect, 614486 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to, 6}, 612926 (3),
CD142		
CD143	AR	{stroke, hemorrhagic}, 614519 (3); renal tubular dysgenesis, 267430 (3), ; {myocardial infarction, susceptibility to} (3); {microvascular complications of diabetes 3}, 612624 (3); [angiotensin i-converting enzyme, benign serum increase] (3); {sars, progression of} (3)
CD144		
CD146		
CD147		[blood group, ok], 111380 (3)
CD148		colon cancer, somatic, 114500 (3)
CD15		
CD150		
CD151	AR	[blood group, raph], 179620 (3); epidermolysis bullosa simplex 7, with nephropathy and deafness, 609057 (3),
CD152	AD	immune dysregulation with autoimmunity, immunodeficiency, and lymphoproliferation, 616100 (3), ; {diabetes mellitus, insulin-dependent, 12}, 601388 (3); {celiac disease, susceptibility to, 3}, 609755 (3); {hashimoto thyroiditis}, 140300 (3), ; {systemic lupus erythematosus, susceptibility to}, 152700 (3),
CD153		
CD154	XL,XLR	immunodeficiency, with hyper-igm, 308230 (3),
CD155		
CD156		
CD156A		
CD156B	AR	?inflammatory skin and bowel disease, neonatal, 1, 614328 (3),
CD156C	AD	{alzheimer disease 18, susceptibility to}, 615590 (3); reticulate acropigmentation of kitamura, 615537 (3),
CD157		
CD158A		
CD158B1		
CD158B2		
CD158C		
CD158D		
CD158E1		{aids, delayed/rapid progression to}, 609423 (3)
CD158e1/2		{aids, delayed/rapid progression to}, 609423 (3)
CD158e2		{aids, delayed/rapid progression to}, 609423 (3)
CD158F		
CD158G		
CD158H		
CD158I		
CD158J		
CD158k		
CD158K		
CD158Z		
CD159a		
CD159c		
CD16	AR	immunodeficiency 20, 615707 (3),
CD160		
CD161		
CD162		
CD163		
CD163B		
CD163L1		
CD164	AD	?deafness, 66, 616969 (3),
CD164L1		
CD166		
CD167		
CD168	AD	{breast cancer, susceptibility to}, 114480 (3), somatic mutation,
CD169		
CD16a	AR	immunodeficiency 20, 615707 (3),
CD16b		
CD170		
CD171	XLR,XL	masa syndrome, 303350 (3), ; hydrocephalus, congenital, 307000 (3), ; ?corpus callosum, partial agenesis of, 304100 (3),
CD172a		
CD172b		
CD172g		
CD174		[blood group, lewis], 618983 (3)
CD177		
CD178	AD	autoimmune lymphoproliferative syndrome, type ib, 601859 (3), ; {lung cancer, susceptibility to}, 211980 (3), somatic mutation,
CD179A		
CD179B	AR	agammaglobulinemia 2, 613500 (3),
CD18	AR	leukocyte adhesion deficiency, 116920 (3),
CD180		
CD181		{aids, slow progression to}, 609423 (3)
CD182	AR	?whim syndrome 2, 619407 (3),
CD183		
CD184	AD	whim syndrome 1, 193670 (3), ; myelokathexis, isolated, 193670 (3),
CD185		
CD186		
CD19	AR	immunodeficiency, common variable, 3, 613493 (3),
CD191		
CD192		{hiv infection, susceptibility/resistance to}, 609423 (3)
CD193		
CD194		
CD195		{hiv infection, susceptibility/resistance to}, 609423 (3); {diabetes mellitus, insulin-dependent, 22}, 612522 (3); {hepatitis c virus, resistance to}, 609532 (3); {west nile virus, susceptibility to}, 610379 (3)
CD196		
CD197		
CD1A		
CD1B		
CD1C		
CD1D		
CD1E		
CD2		
CD20	AR	?immunodeficiency, common variable, 5, 613495 (3),
CD200		
CD200R		
CD200R1		
CD201		
CD202b	AD	venous malformations, multiple cutaneous and mucosal, 600195 (3), ; glaucoma 3, primary congenital, e, 617272 (3),
CD203c		
CD204		barrett esophagus/esophageal adenocarcinoma, 614266 (3)
CD205		
CD206		
CD207		[?birbeck granule deficiency], 613393 (3)
CD208		
CD209		{hiv type 1, susceptibility to}, 609423 (3); {mycobacterium tuberculosis, susceptibility to}, 607948 (3); {dengue fever, protection against}, 614371 (3)
CD209L		
CD20L		
CD20L1		
CD20L2		
CD20L3		
CD20L4		
CD20L5		
CD20L7		
CD21	AR	{systemic lupus erythematosus, susceptibility to, 9}, 610927 (3); ?immunodeficiency, common variable, 7, 614699 (3),
CD210	AR	inflammatory bowel disease 28, early onset, 613148 (3),
CD210a	AR	inflammatory bowel disease 28, early onset, 613148 (3),
CD212	AR	immunodeficiency 30, 614891 (3),
CD213a1		
CD213a2		
CD215		
CD217	AR	immunodeficiency 51, 613953 (3),
CD218a		
CD218b		
CD22		
CD220	AR,AD	rabson-mendenhall syndrome, 262190 (3), ; diabetes mellitus, insulin-resistant, with acanthosis nigricans, 610549 (3); donohue syndrome, 246200 (3), ; hyperinsulinemic hypoglycemia, familial, 5, 609968 (3),
CD221	AR,AD	insulin-like growth factor i, resistance to, 270450 (3),
CD222		hepatocellular carcinoma, somatic, 114550 (3)
CD223		
CD224	AR	?glutathioninuria, 231950 (3),
CD225		
CD226		
CD227	AD	tubulointerstitial kidney disease, 2, 174000 (3),
CD228		
CD229		
CD23		
CD230	AD	spongiform encephalopathy with neuropsychiatric features, 606688 (3), ; gerstmann-straussler disease, 137440 (3), ; huntington disease-like 1, 603218 (3), ; insomnia, fatal familial, 600072 (3), ; {kuru, susceptibility to}, 245300 (3); cerebral amyloid angiopathy, prnp-related, 137440 (3), ; creutzfeldt-jakob disease, 123400 (3),
CD231	XL,XLR	intellectual developmental disorder, 58, 300210 (3),
CD232		
CD233	AD,AR	[blood group, swann], 601550 (3); [blood group, wright], 112050 (3); distal renal tubular acidosis 1, 179800 (3), ; [blood group, waldner], 112010 (3); spherocytosis, type 4, 612653 (3), ; [blood group, froese], 601551 (3); distal renal tubular acidosis 4 with hemolytic anemia, 611590 (3), ; {malaria, resistance to}, 611162 (3); cryohydrocytosis, 185020 (3), ; ovalocytosis, sa type, 166900 (3), ; [blood group, diego], 110500 (3)
CD234	AR,AD	[blood group, duffy system], 110700 (3), ; [white blood cell count qtl], 611862 (3), ; {malaria, vivax, protection against}, 611162 (3)
CD235a		{malaria, resistance to}, 611162 (3); [blood group, mnss system], 111300 (3)
CD235b		[blood group, ss], 111740 (3); {malaria, resistance to}, 611162 (3)
CD236		[blood group, gerbich], 616089 (3); {malaria, resistance to}, 611162 (3)
CD236R		[blood group, gerbich], 616089 (3); {malaria, resistance to}, 611162 (3)
CD238		[blood group, kell], 110900 (3)
CD239	AR	[blood group, lutheran system], 111200 (3); [blood group, auberger system], 111200 (3); [blood group, lutheran null], 247420 (3),
CD23A		
CD24		
CD240CE		rh-null disease, amorph type, 617970 (3)
CD240D		{hemolytic disease of fetus and newborn, rh-induced}, 619462 (3), isolated cases; [blood group, rh system], 111690 (3)
CD241	AD,AR	overhydrated hereditary stomatocytosis, 185000 (3), ; anemia, hemolytic, rh-null, regulator type, 268150 (3),
CD242		[blood group, landsteiner-wiener], 111250 (3)
CD243		{inflammatory bowel disease 13}, 612244 (3); {colchicine resistance}, 120080 (3)
CD244		{rheumatoid arthritis, susceptibility to}, 180300 (3)
CD246		{neuroblastoma, susceptibility to, 3}, 613014 (3)
CD247	AR	?immunodeficiency 25, 610163 (3),
CD248		
CD249		
CD24A		
CD25	AR	immunodeficiency 41 with lymphoproliferation and autoimmunity, 606367 (3), ; {diabetes, mellitus, insulin-dependent, susceptibility to, 10}, 601942 (3)
CD252		{myocardial infarction, susceptibility to}, 608446 (3)
CD253		
CD254	AR	osteopetrosis, 2, 259710 (3),
CD256		
CD257		
CD258		
CD26		
CD261		
CD262	AR	squamous cell carcinoma, head and neck, 275355 (3),
CD263		
CD264		
CD265	AR,AD	osteopetrosis, 7, 612301 (3), ; {paget disease of bone 2, early-onset}, 602080 (3), ; osteolysis, familial expansile, 174810 (3),
CD266		
CD267	AR,AD	immunodeficiency, common variable, 2, 240500 (3), ; immunoglobulin a deficiency 2, 609529 (3)
CD268	AR	immunodeficiency, common variable, 4, 613494 (3),
CD269		
CD27	AR	lymphoproliferative syndrome 2, 615122 (3),
CD27-L	AR	lymphoproliferative syndrome 3, 618261 (3),
CD270		
CD271		
CD272		
CD273		
CD274		
CD275		
CD276		
CD277		
CD278	AR	immunodeficiency, common variable, 1, 607594 (3),
CD279	MF	{multiple sclerosis, disease progression, modifier of}, 126200 (3), ; {systemic lupus erythematosus, susceptibility to, 2}, 605218 (3)
CD27BP		
CD27L	AR	lymphoproliferative syndrome 3, 618261 (3),
CD27LG	AR	lymphoproliferative syndrome 3, 618261 (3),
CD28		
CD280		
CD281		{leprosy, susceptibility to, 5}, 613223 (3); {leprosy, protection against}, 613223 (3)
CD282	AD	{colorectal cancer, susceptibility to}, 114500 (3), somatic mutation, ; {leprosy, susceptibility to}, 246300 (3), ; {mycobacterium tuberculosis, susceptibility to}, 607948 (3)
CD283	AR,AD	{hiv1 infection, resistance to}, 609423 (3); {immunodeficiency 83, susceptibility to viral infections}, 613002 (3),
CD284		
CD286		
CD288	XL	immunodeficiency 98 with autoinflammation, 301078 (3), somatic mosaicism,
CD289		
CD28H		
CD28LG		
CD28LG1		
CD28LG2		
CD29		
CD290		
CD292	AD	polyposis syndrome, hereditary mixed, 2, 610069 (3); polyposis, juvenile intestinal, 174900 (3),
CD294		
CD295	AR	obesity, morbid, due to leptin receptor deficiency, 614963 (3),
CD296		
CD297		[blood group, dombrock], 616060 (3)
CD298		
CD299		
CD2AP		glomerulosclerosis, focal segmental, 3, 607832 (3)
CD2BP1	AD	pyogenic sterile arthritis, pyoderma gangrenosum, and acne, 604416 (3),
CD2BP1L	AD	pyogenic sterile arthritis, pyoderma gangrenosum, and acne, 604416 (3),
CD2BP1S	AD	pyogenic sterile arthritis, pyoderma gangrenosum, and acne, 604416 (3),
CD2BP2		
CD2F-10		
CD3-DELTA	AR	immunodeficiency 19, severe combined, 615617 (3),
CD3-epsilon	AR	immunodeficiency 18, 615615 (3), ; immunodeficiency 18, scid variant, 615615 (3),
CD3-GAMMA	AR	immunodeficiency 17, cd3 gamma deficient, 615607 (3),
CD3-ZETA	AR	?immunodeficiency 25, 610163 (3),
CD30		
CD300A		
CD300C		
CD300D		
CD300E		
CD300f		
CD300H		
CD300LB		
CD300LD		
CD300LE		
CD300LF		
CD300LG		
CD301		
CD302		
CD303		
CD304		
CD305		
CD306		
CD307a		
CD307b		
CD307c		
CD307d		
CD307e		
CD309	AD	{hemangioma, capillary infantile, susceptibility to}, 602089 (3), ; hemangioma, capillary infantile, somatic, 602089 (3)
CD30LG		
CD31		
CD312	AD	vibratory urticaria, 125630 (3),
CD314		
CD315		
CD316		
CD317		
CD318		
CD319		
CD32	AR,AD,AD	{malaria, severe, susceptibility to}, 611162 (3); {pseudomonas aeruginosa, susceptibility to chronic infection by, in cystic fibrosis}, 219700 (3), ; {lupus nephritis, susceptibility to}, 152700 (3), |{systemic lupus erythematosus, susceptibility to}, 152700 (3), ; {malaria, resistance to}, 611162 (3)
CD320	AR	methylmalonic aciduria, transient, due to transcobalamin receptor defect, 613646 (3),
CD321		
CD322	AR	basal ganglia calcification, idiopathic, 8, 618824 (3),
CD324	AD	ovarian cancer, somatic, 167000 (3); blepharocheilodontic syndrome 1, 119580 (3), ; diffuse gastric and lobular breast cancer syndrome with or without cleft lip and/or palate, 137215 (3), ; endometrial carcinoma, somatic, 608089 (3); breast cancer, lobular, somatic, 114480 (3); {prostate cancer, susceptibility to}, 176807 (3), somatic mutation,
CD325	AD,AR	arrhythmogenic right ventricular dysplasia, familial, 14, 618920 (3), ; ?attention deficit-hyperactivity disorder 8, 619957 (3), ; agenesis of corpus callosum, cardiac, ocular, and genital syndrome, 618929 (3),
CD326	AR,AD	diarrhea 5, with tufting enteropathy, congenital, 613217 (3), ; lynch syndrome 8, 613244 (3),
CD327		
CD328		
CD329		
CD32A	AR,AD	{malaria, severe, susceptibility to}, 611162 (3); {pseudomonas aeruginosa, susceptibility to chronic infection by, in cystic fibrosis}, 219700 (3), ; {lupus nephritis, susceptibility to}, 152700 (3),
CD32B	AD	{systemic lupus erythematosus, susceptibility to}, 152700 (3), ; {malaria, resistance to}, 611162 (3)
CD32C		
CD33		
CD331	AD	pfeiffer syndrome, 101600 (3), ; hypogonadotropic hypogonadism 2 with or without anosmia, 147950 (3), ; jackson-weiss syndrome, 123150 (3), ; hartsfield syndrome, 615465 (3), ; trigonocephaly 1, 190440 (3), ; osteoglophonic dysplasia, 166250 (3), ; encephalocraniocutaneous lipomatosis, somatic mosaic, 613001 (3)
CD332	AD	bent bone dysplasia syndrome, 614592 (3), ; ladd syndrome 1, 149730 (3), ; antley-bixler syndrome without genital anomalies or disordered steroidogenesis, 207410 (3), ; scaphocephaly and axenfeld-rieger anomaly (3); jackson-weiss syndrome, 123150 (3), ; gastric cancer, somatic, 613659 (3); craniofacial-skeletal-dermatologic dysplasia, 101600 (3), ; apert syndrome, 101200 (3), ; pfeiffer syndrome, 101600 (3), ; craniosynostosis, nonspecific (3); ?scaphocephaly, maxillary retrusion, and impaired intellectual development, 609579 (3); beare-stevenson cutis gyrata syndrome, 123790 (3), ; crouzon syndrome, 123500 (3), ; saethre-chotzen syndrome, 101400 (3),
CD333	AD,AR	muenke syndrome, 602849 (3), ; saddan, 616482 (3), ; hypochondroplasia, 146000 (3), ; thanatophoric dysplasia, type ii, 187601 (3), ; nevus, epidermal, somatic, 162900 (3); catshl syndrome, 610474 (3), ; thanatophoric dysplasia, type i, 187600 (3), ; spermatocytic seminoma, somatic, 273300 (3); bladder cancer, somatic, 109800 (3); ladd syndrome 2, 620192 (3), ; achondroplasia, 100800 (3), ; cervical cancer, somatic, 603956 (3); colorectal cancer, somatic, 114500 (3); crouzon syndrome with acanthosis nigricans, 612247 (3),
CD334		{cancer progression/metastasis} (3)
CD335		
CD336		
CD337		{malaria, mild, susceptibility to}, 609148 (3)
CD338	AD	[junior blood group system], 614490 (3); [uric acid concentration, serum, qtl1], 138900 (3), ?
CD339	AD	?deafness, congenital heart defects, and posterior embryotoxon, 617992 (3), ; charcot-marie-tooth disease, axonal, type 2hh, 619574 (3), ; alagille syndrome 1, 118450 (3), ; tetralogy of fallot, 187500 (3),
CD33L		
CD33L1		
CD33L2		
CD33L3		
CD34		
CD340	AR	gastric cancer, somatic, 613659 (3); adenocarcinoma of lung, somatic, 211980 (3); ovarian cancer, somatic, 167000 (3); ?visceral neuropathy, familial, 2, 619465 (3), ; glioblastoma, somatic, 137800 (3)
CD344	AD	retinopathy of prematurity, 133780 (3), ; exudative vitreoretinopathy 1, 133780 (3),
CD349		
CD35		[blood group, knops system], 607486 (3); {malaria, severe, resistance to}, 611162 (3)
CD350		
CD351		
CD352		
CD353		
CD354		
CD355		
CD357		
CD358		
CD36	AR	platelet glycoprotein iv deficiency, 608404 (3), ; {coronary heart disease, susceptibility to, 7}, 610938 (3); {malaria, cerebral, susceptibility to}, 611162 (3); {malaria, cerebral, reduced risk of}, 611162 (3)
CD360	AD,AR	[ige, elevated level of], 147050 (3), ; immunodeficiency 56, 615207 (3),
CD361		
CD362		
CD363		
CD365		
CD366	AR	t-cell lymphoma, subcutaneous panniculitis-like, 618398 (3),
CD367		
CD368		
CD369	AR	candidiasis, familial, 4, 613108 (3), ; {aspergillosis, susceptibility to}, 614079 (3)
CD36L1		[high density lipoprotein cholesterol level qtl6], 610762 (3)
CD36L2	AR	epilepsy, progressive myoclonic 4, with or without renal failure, 254900 (3),
CD37		
CD370		
CD371		
CD38		
CD39	AR	spastic paraplegia 64, 615683 (3),
CD39L1		
CD39L2		
CD39L3		
CD39L4		
CD3D	AR	immunodeficiency 19, severe combined, 615617 (3),
CD3DELTA	AR	immunodeficiency 19, severe combined, 615617 (3),
CD3E	AR	immunodeficiency 18, 615615 (3), ; immunodeficiency 18, scid variant, 615615 (3),
CD3EAP		
CD3epsilon	AR	immunodeficiency 18, 615615 (3), ; immunodeficiency 18, scid variant, 615615 (3),
CD3G	AR	immunodeficiency 17, cd3 gamma deficient, 615607 (3),
CD3GAMMA	AR	immunodeficiency 17, cd3 gamma deficient, 615607 (3),
CD3H	AR	?immunodeficiency 25, 610163 (3),
CD3Q	AR	?immunodeficiency 25, 610163 (3),
CD3Z	AR	?immunodeficiency 25, 610163 (3),
CD3ZETA	AR	?immunodeficiency 25, 610163 (3),
CD4	AR	immunodeficiency 79, 619238 (3), ; okt4 epitope deficiency, 613949 (3)
CD40	AR	immunodeficiency with hyper-igm, type 3, 606843 (3),
CD40-L	XL,XLR	immunodeficiency, with hyper-igm, 308230 (3),
CD40bp	AD	{?encephalopathy, acute, infection-induced (herpes-specific), susceptibility to, 5}, 614849 (3),
CD40L	XL,XLR	immunodeficiency, with hyper-igm, 308230 (3),
CD40LG	XL,XLR	immunodeficiency, with hyper-igm, 308230 (3),
CD41	AR,AD	thrombocytopenia, neonatal alloimmune, bak antigen related (3); glanzmann thrombasthenia 1, 273800 (3), ; bleeding disorder, platelet-type, 16, 187800 (3),
CD41B	AR,AD	thrombocytopenia, neonatal alloimmune, bak antigen related (3); glanzmann thrombasthenia 1, 273800 (3), ; bleeding disorder, platelet-type, 16, 187800 (3),
CD42a	AR	bernard-soulier syndrome, type c, 231200 (3),
CD42b	AR,AD	bernard-soulier syndrome, type a1 (), 231200 (3), ; bernard-soulier syndrome, type a2 (), 153670 (3), ; von willebrand disease, platelet-type, 177820 (3), ; {nonarteritic anterior ischemic optic neuropathy, susceptibility to}, 258660 (3),
CD42c	AR	giant platelet disorder, isolated, 231200 (3), ; bernard-soulier syndrome, type b, 231200 (3),
CD42d		
CD43		
CD44		[blood group, indian system], 609027 (3)
CD44R		[blood group, indian system], 609027 (3)
CD45	AR	immunodeficiency 105, severe combined, 619924 (3),
CD45-AP		
CD46	AR,AD	{hemolytic uremic syndrome, atypical, susceptibility to, 2}, 612922 (3),
CD47		
CD48		
CD49a		
CD49B		
CD49c	AR	epidermolysis bullosa, junctional 7, with interstitial lung disease and nephrotic syndrome, 614748 (3),
CD49d		
CD49D		
CD49e		
CD49f	AR	epidermolysis bullosa, junctional 6, with pyloric atresia, 619817 (3),
CD5		
CD50		
CD51		
CD52		
CD53		
CD54		{malaria, cerebral, susceptibility to}, 611162 (3)
CD55	AR	[blood group cromer], 613793 (3), ; complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy, 226300 (3),
CD56		
CD57		
CD58		
CD59	AR	hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy, 612300 (3),
CD5L		
CD6		
CD61	AD,AR	bleeding disorder, platelet-type, 24, 619271 (3); thrombocytopenia, neonatal alloimmune (3); purpura, posttransfusion (3); {myocardial infarction, susceptibility to}, 608446 (3); glanzmann thrombasthenia 2, 619267 (3),
CD62		
CD62E		
CD62L		
CD62P		
CD63		
CD64		[igg receptor i, phagocytic, familial deficiency of] (3)
CD64A		[igg receptor i, phagocytic, familial deficiency of] (3)
CD64b		
CD64c		
CD66a		
CD66b		
CD66c		
CD66d		
CD66e		
CD66f		
CD68		
CD69		
CD7		
CD70	AR	lymphoproliferative syndrome 3, 618261 (3),
CD71	AR	immunodeficiency 46, 616740 (3),
CD72		
CD72b		
CD73	AR	calcification of joints and arteries, 211800 (3),
CD74		
CD79A	AR	agammaglobulinemia 3, 613501 (3),
CD79B	AR	agammaglobulinemia 6, 612692 (3),
CD8	AR	cd8 deficiency, familial, 608957 (3),
CD80		
CD81	AR	immunodeficiency, common variable, 6, 613496 (3),
CD81P3		
CD82		
CD83		
CD84		
CD84-H1		
CD85		
CD85a		
CD85c		
CD85d		
CD85e		
CD85f		
CD85g		
CD85h		
CD85i		
CD85j		
CD85k		
CD86		
CD87		
CD88		
CD89		
CD8A	AR	cd8 deficiency, familial, 608957 (3),
CD8alpha	AR	cd8 deficiency, familial, 608957 (3),
CD8B		
CD8B1		
CD8beta		
CD9		
CD90		
CD91	AR	?keratosis pilaris atrophicans, 604093 (3),
CD92	AR	neurodegeneration, childhood-onset, with ataxia, tremor, optic atrophy, and cognitive decline, 618868 (3),
CD93		
CD94		
CD95	AD	squamous cell carcinoma, burn scar-related, somatic (3); autoimmune lymphoproliferative syndrome, type ia, 601859 (3), ; {autoimmune lymphoproliferative syndrome}, 601859 (3),
CD96	AD	c syndrome, 211750 (3),
CD97		
CD98		
CD98HC		
CD99		
CD99B		
CD99L2		
CD9P-1		
CDA		
CDA-I	AR	dyserythropoietic anemia, congenital, type ia, 224120 (3),
CDA-II	AD,AR	?cowden syndrome 7, 616858 (3), ; dyserythropoietic anemia, congenital, type ii, 224100 (3),
CDA016	AR	{thyroid carcinoma, hurthle cell}, 607464 (3); ?mitochondrial complex i deficiency, nuclear type 28, 618249 (3),
CDA017	AR	albinism, oculocutaneous, type vii, 615179 (3),
CDA03		
CDA06		
CDA08		
CDA09		
CDA1		
CDA11		
CDA2	AR	immunodeficiency with hyper-igm, type 2, 605258 (3),
CDADC1		
CDAI	AR	dyserythropoietic anemia, congenital, type ia, 224120 (3),
CDAII	AD,AR	?cowden syndrome 7, 616858 (3), ; dyserythropoietic anemia, congenital, type ii, 224100 (3),
CDAN1	AR	dyserythropoietic anemia, congenital, type ia, 224120 (3),
CDAN2	AD,AR	?cowden syndrome 7, 616858 (3), ; dyserythropoietic anemia, congenital, type ii, 224100 (3),
CDAR1		
CDB1	AD	corneal dystrophy, avellino type, 607541 (3), ; corneal dystrophy, reis-bucklers type, 608470 (3), ; corneal dystrophy, thiel-behnke type, 602082 (3), ; corneal dystrophy, groenouw type i, 121900 (3), ; corneal dystrophy, epithelial basement membrane, 121820 (3), ; corneal dystrophy, lattice type i, 122200 (3), ; corneal dystrophy, lattice type iiia, 608471 (3),
Cdc1		
CDC10		
CDC123		
cdc14	AR	deafness, 32, with or without immotile sperm, 608653 (3),
CDC14A	AR	deafness, 32, with or without immotile sperm, 608653 (3),
Cdc14A1	AR	deafness, 32, with or without immotile sperm, 608653 (3),
Cdc14A2	AR	deafness, 32, with or without immotile sperm, 608653 (3),
CDC14B		
Cdc14B1		
Cdc14B2		
CDC14B3		
CDC16		
CDC18L	AR	?meier-gorlin syndrome 5, 613805 (3),
cdc19	AD	?deafness, 70, 616968 (3),
CDC2	AD	mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome, 615381 (3), ; {colorectal cancer, susceptibility to, 10}, 612591 (3),
CDC20	AR	oocyte/zygote/embryo maturation arrest 14, 620276 (3),
CDC20A	AR	oocyte/zygote/embryo maturation arrest 14, 620276 (3),
CDC20B		
CDC20C	AD	developmental and epileptic encephalopathy 109, 620145 (3),
CDC21	AR	immunodeficiency 54, 609981 (3),
CDC23		
CDC25		
CDC25A		
CDC25B		
CDC25C		
CDC25L		
CDC26		
CDC27		
CDC28A		
CDC2L	AD	congenital heart defects, dysmorphic facial features, and intellectual developmental disorder, 617360 (3),
CDC2L1		
CDC2L2		
CDC2L3		
CDC2L4		
CDC2L5	AD	congenital heart defects, dysmorphic facial features, and intellectual developmental disorder, 617360 (3),
CDC2L6	AD	developmental and epileptic encephalopathy 87, 618916 (3),
CDC3		
CDC34		
CDC34B		
CDC36	AD	intellectual developmental disorder with nasal speech, dysmorphic facies, and variable skeletal anomalies, 618608 (3),
CDC37		
CDC37B		
CDC37L1		
CDC39	AD	vissers-bodmer syndrome, 619033 (3), ; holoprosencephaly 12, with or without pancreatic agenesis, 618500 (3),
CDC4	AD	developmental delay, hypotonia, and impaired language, 620012 (3),
CDC40	AR	?pontocerebellar hypoplasia, type 15, 619302 (3),
CDC42	AD	takenouchi-kosaki syndrome, 616737 (3),
CDC42BPA		
CDC42BPB	AD	chilton-okur-chung neurodevelopmental syndrome, 619841 (3),
CDC42BPG		
CDC42EP1		
CDC42EP2		
CDC42EP3		
CDC42EP4		
CDC42EP5		
Cdc42GAP		
CDC42GAP		
CDC42Hs	AD	takenouchi-kosaki syndrome, 616737 (3),
CDC42L1		
CDC42SE1		
CDC42SE2		
CDC45	AR	meier-gorlin syndrome 7, 617063 (3),
CDC45L	AR	meier-gorlin syndrome 7, 617063 (3),
CDC45L2	AR	meier-gorlin syndrome 7, 617063 (3),
CDC46	AR	?meier-gorlin syndrome 8, 617564 (3),
CDC47		
CDC48	AD	frontotemporal dementia and/or amyotrophic lateral sclerosis 6, 613954 (3), ; charcot-marie-tooth disease, type 2y, 616687 (3), ; inclusion body myopathy with early-onset paget disease and frontotemporal dementia 1, 167320 (3),
CDC4L	AR	immunodeficiency, common variable, 8, with autoimmunity, 614700 (3),
CDC5		
CDC50A		
CDC50B		
CDC50C		
CDC54	AR	immunodeficiency 54, 609981 (3),
CDC5L		
CDC6	AR	?meier-gorlin syndrome 5, 613805 (3),
CDC68	AD	neurodevelopmental disorder with dysmorphic facies and thin corpus callosum, 619480 (3),
CDC7		
CDC73	AD	hyperparathyroidism, familial primary, 145000 (3), ; parathyroid adenoma with cystic changes, 145001 (3), ; parathyroid carcinoma, 608266 (3); hyperparathyroidism-jaw tumor syndrome, 145001 (3),
CDC7L1		
CDC8	AR	neurodegeneration, childhood-onset, with progressive microcephaly, 619847 (3),
CDC91L1	AR	neurodevelopmental disorder with brain anomalies, seizures, and scoliosis, 618590 (3),
CDCA1		
CDCA2		
CDCA3		
CDCA4		
CDCA5		
CDCA6	AR	?46xy sex reversal 5, 613080 (3),
CDCA7	AR	immunodeficiency-centromeric instability-facial anomalies syndrome 3, 616910 (3),
CDCA7L		
CDCA8		
CDCD2	AD,AR	ventricular fibrillation, familial, 1, 603829 (3); heart block, progressive, type ia, 113900 (3), ; cardiomyopathy, dilated, 1e, 601154 (3), ; heart block, nonprogressive, 113900 (3), ; long qt syndrome 3, 603830 (3), ; sick sinus syndrome 1, 608567 (3), ; brugada syndrome 1, 601144 (3), ; atrial fibrillation, familial, 10, 614022 (3), ; {sudden infant death syndrome, susceptibility to}, 272120 (3),
CDCL1	AD	?deafness, 70, 616968 (3),
CDCP1		
CDCP2		
CDD		
CDEP		
CDF		
CDG-Ij	AR	myasthenic syndrome, congenital, 13, with tubular aggregates, 614750 (3), ; congenital disorder of glycosylation, type ij, 608093 (3),
CDG1	AR	congenital disorder of glycosylation, type ia, 212065 (3),
CDG1a	AR	congenital disorder of glycosylation, type ia, 212065 (3),
CDG1G	AR	congenital disorder of glycosylation, type ig, 607143 (3),
CDG1I	AR	congenital disorder of glycosylation, type ii, 607906 (3), ; myasthenic syndrome, congenital, 14, with tubular aggregates, 616228 (3),
CDG1K	AR	congenital disorder of glycosylation, type ik, 608540 (3),
CDG1N	AR	congenital disorder of glycosylation, type in, 612015 (3),
CDG1P	AR	congenital disorder of glycosylation, type ip, 613661 (3),
CDG1S	XL	developmental and epileptic encephalopathy 36, 300884 (3),
CDGAP	AD	adams-oliver syndrome 1, 100300 (3),
CDGG1	AD	corneal dystrophy, avellino type, 607541 (3), ; corneal dystrophy, reis-bucklers type, 608470 (3), ; corneal dystrophy, thiel-behnke type, 602082 (3), ; corneal dystrophy, groenouw type i, 121900 (3), ; corneal dystrophy, epithelial basement membrane, 121820 (3), ; corneal dystrophy, lattice type i, 122200 (3), ; corneal dystrophy, lattice type iiia, 608471 (3),
CDGIE	AR	congenital disorder of glycosylation, type ie, 608799 (3),
CDGIf	AR	congenital disorder of glycosylation, type if, 609180 (3),
CDGIi	AR	congenital disorder of glycosylation, type ii, 607906 (3), ; myasthenic syndrome, congenital, 14, with tubular aggregates, 616228 (3),
CDGS	AR	congenital disorder of glycosylation, type ia, 212065 (3),
CDGS4	AR	congenital disorder of glycosylation, type id, 601110 (3),
CDH-GAMMA-A5		
CDH1	AD,AD	developmental and epileptic encephalopathy 109, 620145 (3), |ovarian cancer, somatic, 167000 (3); blepharocheilodontic syndrome 1, 119580 (3), ; diffuse gastric and lobular breast cancer syndrome with or without cleft lip and/or palate, 137215 (3), ; endometrial carcinoma, somatic, 608089 (3); breast cancer, lobular, somatic, 114480 (3); {prostate cancer, susceptibility to}, 176807 (3), somatic mutation,
CDH10		
CDH11	AD,AR	teebi hypertelorism syndrome 2, 619736 (3), ; elsahy-waters syndrome, 211380 (3),
CDH11L		
CDH12		
CDH13		
CDH14	AD	intellectual developmental disorder, 3, 612580 (3),
CDH15	AD	intellectual developmental disorder, 3, 612580 (3),
CDH16		
CDH17		
CDH18		
CDH19		
CDH2	AD,AR	arrhythmogenic right ventricular dysplasia, familial, 14, 618920 (3), ; ?attention deficit-hyperactivity disorder 8, 619957 (3), ; agenesis of corpus callosum, cardiac, ocular, and genital syndrome, 618929 (3),
CDH20		
CDH21		
CDH22		
CDH23	AR,AD	usher syndrome, type 1d, 601067 (3), digenic ; {pituitary adenoma 5, multiple types}, 617540 (3), ; usher syndrome, type 1d/f digenic, 601067 (3), digenic ; deafness, 12, 601386 (3),
CDH24		
CDH25	AD,AR	mitral valve prolapse 2, 607829 (3), ; van maldergem syndrome 1, 601390 (3),
CDH26		
CDH27		
CDH28		
CDH3	AR,AD	hypotrichosis, congenital, with juvenile macular dystrophy, 601553 (3), ; ectodermal dysplasia, ectrodactyly, and macular dystrophy, 225280 (3), |intellectual developmental disorder, 3, 612580 (3),
CDH4		
CDH5		
CDH6		
Cdh7		
CDH7		
CDH7L3		
CDH8		
CDH9		
CDHB		
CDHF1		
CDHF10		
CDHF11		
CDHF12	AD	{hirschsprung disease, susceptibility to, 1}, 142623 (3), ; multiple endocrine neoplasia iia, 171400 (3), ; {hirschsprung disease, protection against}, 142623 (3), ; medullary thyroid carcinoma, 155240 (3), ; pheochromocytoma, 171300 (3), ; multiple endocrine neoplasia iib, 162300 (3),
CDHF13	AR	hypotrichosis 6, 607903 (3),
CDHF14	AR	van maldergem syndrome 2, 615546 (3), ; hennekam lymphangiectasia-lymphedema syndrome 2, 616006 (3),
CDHF15		
CDHF2	AR,AD	arrhythmogenic right ventricular dysplasia 11 with mild palmoplantar keratoderma and woolly hair, 610476 (3), ; arrhythmogenic right ventricular dysplasia 11, 610476 (3),
CDHF3	AR	hypotrichosis and recurrent skin vesicles, 613102 (3),
CDHF4	AD,AR	keratosis palmoplantaris striata i, ad, 148700 (3), ; erythroderma, congenital, with palmoplantar keratoderma, hypotrichosis, and hyper ige, 615508 (3),
CDHF5	AR,AD	cardiomyopathy, dilated, 1bb, 612877 (3), ; arrhythmogenic right ventricular dysplasia 10, 610193 (3),
CDHF6	AR	blistering, acantholytic, of oral and laryngeal mucosa, 619226 (3),
CDHF7		
CDHF8	AD	spinocerebellar ataxia 45, 617769 (3),
CDHF9	AD	lymphatic malformation 9, 619319 (3),
CDHH		
CDHJ		
CDHN	AD,AR	arrhythmogenic right ventricular dysplasia, familial, 14, 618920 (3), ; ?attention deficit-hyperactivity disorder 8, 619957 (3), ; agenesis of corpus callosum, cardiac, ocular, and genital syndrome, 618929 (3),
CDHP	AR	hypotrichosis, congenital, with juvenile macular dystrophy, 601553 (3), ; ectodermal dysplasia, ectrodactyly, and macular dystrophy, 225280 (3),
CDHR1	AR	macular dystrophy, retinal, 613660 (3), ; cone-rod dystrophy 15, 613660 (3), ; retinitis pigmentosa 65, 613660 (3),
CDHR10		
CDHR11	AR	van maldergem syndrome 2, 615546 (3), ; hennekam lymphangiectasia-lymphedema syndrome 2, 616006 (3),
CDHR12		
CDHR13		
CDHR14		
CDHR15	AR	usher syndrome, type 1d/f digenic, 601067 (3), digenic ; deafness, 23, 609533 (3), ; usher syndrome, type 1f, 602083 (3),
CDHR16	AD	{hirschsprung disease, susceptibility to, 1}, 142623 (3), ; multiple endocrine neoplasia iia, 171400 (3), ; {hirschsprung disease, protection against}, 142623 (3), ; medullary thyroid carcinoma, 155240 (3), ; pheochromocytoma, 171300 (3), ; multiple endocrine neoplasia iib, 162300 (3),
CDHR2		
CDHR23	AR,AD	usher syndrome, type 1d, 601067 (3), digenic ; {pituitary adenoma 5, multiple types}, 617540 (3), ; usher syndrome, type 1d/f digenic, 601067 (3), digenic ; deafness, 12, 601386 (3),
CDHR3		
CDHR5		
CDHR6	AD,AR	mitral valve prolapse 2, 607829 (3), ; van maldergem syndrome 1, 601390 (3),
CDHR7		
CDHR8		
CDHR9	AD	spinocerebellar ataxia 45, 617769 (3),
CDI1		
CDIN1	AR	dyserythropoietic anemia, congenital, type ib, 615631 (3),
CDIP		
CDIP1		
CDIPT		
CDK1		
CDK10	AR	al kaissi syndrome, 617694 (3),
CDK11	AD	developmental and epileptic encephalopathy 87, 618916 (3),
CDK11-p110		
CDK11-p46		
CDK11-p58		
CDK11A		
CDK11B		
CDK12		
CDK13	AD	congenital heart defects, dysmorphic facial features, and intellectual developmental disorder, 617360 (3),
CDK14		
CDK15		
CDK16		
CDK17		
CDK18		
CDK19	AD	developmental and epileptic encephalopathy 87, 618916 (3),
CDK2		
CDK20		
CDK2AP1		
CDK2AP2		
CDK3		
CDK4	AD	{melanoma, cutaneous malignant, 3}, 609048 (3),
CDK4I	AD	{melanoma and neural system tumor syndrome}, 155755 (3), ; {melanoma, cutaneous malignant, 2}, 155601 (3), ; {melanoma-pancreatic cancer syndrome}, 606719 (3),
CDK5	AR	?lissencephaly 7 with cerebellar hypoplasia, 616342 (3),
CDK5R1		
CDK5R2		
CDK5RAP1		
CDK5RAP2	AR	microcephaly 3, primary, 604804 (3),
CDK5RAP3		
CDK6	AR	?microcephaly 12, primary, 616080 (3),
CDK7		
CDK8	AD	intellectual developmental disorder with hypotonia and behavioral abnormalities, 618748 (3),
CDK9		
CDKAL1		
CDKL1		
CDKL2		
CDKL3		
CDKL5	XLD,XL	developmental and epileptic encephalopathy 2, 300672 (3),
CDKN1		
CDKN1A		
CDKN1B	AD	multiple endocrine neoplasia, type iv, 610755 (3),
CDKN1C	AD,AD	image syndrome, 614732 (3), ; beckwith-wiedemann syndrome, 130650 (3), |wilms tumor 2, 194071 (3), somatic mutation, ; beckwith-wiedemann syndrome, 130650 (3), ; silver-russell syndrome 1, 180860 (3),
CDKN2	AD	{melanoma and neural system tumor syndrome}, 155755 (3), ; {melanoma, cutaneous malignant, 2}, 155601 (3), ; {melanoma-pancreatic cancer syndrome}, 606719 (3),
CDKN2A	AD	{melanoma and neural system tumor syndrome}, 155755 (3), ; {melanoma, cutaneous malignant, 2}, 155601 (3), ; {melanoma-pancreatic cancer syndrome}, 606719 (3),
CDKN2AIP		
CDKN2B		
CDKN2B-AS		
CDKN2B-AS1		
CDKN2BAS		
CDKN2C		
CDKN2D		
CDKN3		
CDKN7		
CDLIV	XL,XLR	intellectual developmental disorder, 9, 309549 (3),
CDM	XLR,XL	deafness, dystonia, and cerebral hypomyelination, 300475 (3),
CDMP1	AR,AD	acromesomelic dysplasia 2a, 200700 (3), ; acromesomelic dysplasia 2b, 228900 (3), ; multiple synostoses syndrome 2, 610017 (3), ; symphalangism, proximal, 1b, 615298 (3), ; brachydactyly, type a2, 112600 (3), ; ?acromesomelic dysplasia 2c, hunter-thompson type, 201250 (3), ; brachydactyly, type c, 113100 (3), ; {osteoarthritis-5}, 612400 (3); brachydactyly, type a1, c, 615072 (3),
cdN		
CDN1		
CDNF		
CDO	AD	holoprosencephaly 11, 614226 (3),
CDO1		
CDON	AD	holoprosencephaly 11, 614226 (3),
CDON1	AD	holoprosencephaly 11, 614226 (3),
CDON2		
CDP	AD	global developmental delay with or without impaired intellectual development, 618330 (3),
CDP/Cut	AD	global developmental delay with or without impaired intellectual development, 618330 (3),
CDP/Cux	AD	global developmental delay with or without impaired intellectual development, 618330 (3),
CDP1	AD	global developmental delay with or without impaired intellectual development, 618330 (3),
CDP138		
CDP2	AD	developmental and epileptic encephalopathy 67, 618141 (3),
CDPD1	AR	corneal endothelial dystrophy, 217700 (3), ; corneal dystrophy, fuchs endothelial, 4, 613268 (3); corneal endothelial dystrophy and perceptive deafness, 217400 (3),
CDPS		
CDPX	XLR,XL	chondrodysplasia punctata, 302950 (3),
CDPX1	XLR,XL	chondrodysplasia punctata, 302950 (3),
CDPX2	XLR,XLD,XL	mend syndrome, 300960 (3), ; chondrodysplasia punctata, 302960 (3),
CDR	AR	{46xy sex reversal 8, modifier of}, 614279 (3),
CDR1		
CDR1-AS		
CDR1as		
CDR1NAT		
CDR2		
CDR34		
CDR62		
CDR62A		
CDRT1		
CDS1	AD	{colorectal cancer, susceptibility to}, 114500 (3), somatic mutation, ; osteosarcoma, somatic, 259500 (3); {breast cancer, susceptibility to}, 114480 (3), somatic mutation, ; {prostate cancer, familial, susceptibility to}, 176807 (3), somatic mutation, ; li-fraumeni syndrome 2, 609265 (3)
CDS2		
CDS3		
CDSIGN		{hiv type 1, susceptibility to}, 609423 (3); {mycobacterium tuberculosis, susceptibility to}, 607948 (3); {dengue fever, protection against}, 614371 (3)
CDSN	AD,AR	hypotrichosis 2, 146520 (3), ; peeling skin syndrome 1, 270300 (3),
CDSP	AR	carnitine deficiency, systemic primary, 212140 (3),
CDT1	AR	meier-gorlin syndrome 4, 613804 (3),
CDT2		
CDT6		
CDV-1R	AR	short-rib thoracic dysplasia 19 with or without polydactyly, 617895 (3),
CDV1	AR	short-rib thoracic dysplasia 19 with or without polydactyly, 617895 (3),
CDV3		
CDw113		
CDw125		
CDw127	AR	immunodeficiency 104, severe combined, 608971 (3),
CDw128a		{aids, slow progression to}, 609423 (3)
CDw136	AD	{nasopharyngeal carcinoma, susceptibility to, 3}, 617075 (3),
CDw197		
CDw198		
CDw199		
CDW210A	AR	inflammatory bowel disease 28, early onset, 613148 (3),
CDW210B	AR	{hepatitis b virus, susceptibility to}, 610424 (3); inflammatory bowel disease 25, early onset, 612567 (3),
CDw217	AR	immunodeficiency 51, 613953 (3),
CDw293	AR,AD	acromesomelic dysplasia 3, 609441 (3), ; brachydactyly, type a2, 112600 (3), ; brachydactyly, type a1, d, 616849 (3),
CDw32	AR,AD	{malaria, severe, susceptibility to}, 611162 (3); {pseudomonas aeruginosa, susceptibility to chronic infection by, in cystic fibrosis}, 219700 (3), ; {lupus nephritis, susceptibility to}, 152700 (3),
CDw44		[blood group, indian system], 609027 (3)
CDW50		
CDW52		
CDw75		
CDW92	AR	neurodegeneration, childhood-onset, with ataxia, tremor, optic atrophy, and cognitive decline, 618868 (3),
CDw93		
CDX1		
CDX2		
CDX3		
CDX4		
CDY1		
CDY1A		
CDY2		
CDY2A		
CDYL		
CDYL1		
CDYL2		
CE-2		
CE5B3		
CEA		
CEACAM1		
CEACAM16	AD,AR	deafness, 4b, 614614 (3), ; deafness, 113, 618410 (3),
CEACAM19		
CEACAM21		
CEACAM3		
CEACAM4		
CEACAM5		
CEACAM6		
CEACAM7		
CEACAM8		
CEAL1		
CEAP1		
CEAR		
CEB		
CEB1		
CEBP	AD	leukemia, acute myeloid, somatic, 601626 (3); ?leukemia, acute myeloid, 601626 (3), somatic mutation,
CEBPA	AD	leukemia, acute myeloid, somatic, 601626 (3); ?leukemia, acute myeloid, 601626 (3), somatic mutation,
CEBPB		
CEBPD		
CEBPE	AR,AD	?immunodeficiency 108 with autoinflammation, 260570 (3), ; specific granule deficiency, 245480 (3),
CEBPG		
CEBPZ		
CECR1	AR	sneddon syndrome, 182410 (3), ; vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome, 615688 (3),
CECR2		
CED	AR,AD	inflammatory bowel disease, immunodeficiency, and encephalopathy, 618213 (3), ; camurati-engelmann disease, 131300 (3), ; {cystic fibrosis lung disease, modifier of}, 219700 (3),
CED-12	AR	vascular malformation, primary intraosseous, 606893 (3),
CED-4		
CED-6		
CED12	AR	vascular malformation, primary intraosseous, 606893 (3),
CED4		
ced5		
CED6		
CEDNIK	AR	cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma syndrome, 609528 (3),
CEE	AR	?congenital disorder of glycosylation, type iiy, 620200 (3),
CEECAM1		
CEF1		
Cegb1		
Cegf1		
CEGF3	AR	short stature, facial dysmorphism, and skeletal anomalies with or without cardiac anomalies, 619184 (3),
CEH	AD	drug metabolism, altered, ces1-related, 618057 (3),
CEI		
CEK	AD	pfeiffer syndrome, 101600 (3), ; hypogonadotropic hypogonadism 2 with or without anosmia, 147950 (3), ; jackson-weiss syndrome, 123150 (3), ; hartsfield syndrome, 615465 (3), ; trigonocephaly 1, 190440 (3), ; osteoglophonic dysplasia, 166250 (3), ; encephalocraniocutaneous lipomatosis, somatic mosaic, 613001 (3)
CEK2	AD,AR	muenke syndrome, 602849 (3), ; saddan, 616482 (3), ; hypochondroplasia, 146000 (3), ; thanatophoric dysplasia, type ii, 187601 (3), ; nevus, epidermal, somatic, 162900 (3); catshl syndrome, 610474 (3), ; thanatophoric dysplasia, type i, 187600 (3), ; spermatocytic seminoma, somatic, 273300 (3); bladder cancer, somatic, 109800 (3); ladd syndrome 2, 620192 (3), ; achondroplasia, 100800 (3), ; cervical cancer, somatic, 603956 (3); colorectal cancer, somatic, 114500 (3); crouzon syndrome with acanthosis nigricans, 612247 (3),
CEK3	AD	bent bone dysplasia syndrome, 614592 (3), ; ladd syndrome 1, 149730 (3), ; antley-bixler syndrome without genital anomalies or disordered steroidogenesis, 207410 (3), ; scaphocephaly and axenfeld-rieger anomaly (3); jackson-weiss syndrome, 123150 (3), ; gastric cancer, somatic, 613659 (3); craniofacial-skeletal-dermatologic dysplasia, 101600 (3), ; apert syndrome, 101200 (3), ; pfeiffer syndrome, 101600 (3), ; craniosynostosis, nonspecific (3); ?scaphocephaly, maxillary retrusion, and impaired intellectual development, 609579 (3); beare-stevenson cutis gyrata syndrome, 123790 (3), ; crouzon syndrome, 123500 (3), ; saethre-chotzen syndrome, 101400 (3),
CEK7		
CEL	AD	maturity-onset diabetes of the young, type viii, 609812 (3),
CELA1		
CELA2A	AD	abdominal obesity-metabolic syndrome 4, 618620 (3),
CELA2B		
CELA3A		
CELA3B		
CELF		
CELF1		
CELF2	AD	developmental and epileptic encephalopathy 97, 619561 (3),
CELF3		
CELF4		
CELF5		
CELF6		
CELIAC1	AR,MF,AR,MF,AD	{celiac disease, susceptibility to}, 212750 (3), |{celiac disease, susceptibility to}, 212750 (3), ; {multiple sclerosis, susceptibility to, 1}, 126200 (3), ; {creutzfeldt-jakob disease, variant, resistance to}, 123400 (3),
CELIAC3	AD	immune dysregulation with autoimmunity, immunodeficiency, and lymphoproliferation, 616100 (3), ; {diabetes mellitus, insulin-dependent, 12}, 601388 (3); {celiac disease, susceptibility to, 3}, 609755 (3); {hashimoto thyroiditis}, 140300 (3), ; {systemic lupus erythematosus, susceptibility to}, 152700 (3),
CELIAC4		{celiac disease, susceptibility to, 4}, 609753 (3)
CELSR1	AD	lymphatic malformation 9, 619319 (3),
CELSR2		
CELSR3		
CELTIX1		
CEM1		
CEM15		
CEMCOX2	AR	mitochondrial complex iv deficiency, nuclear type 6, 615119 (3),
cementoin		
CEMIP		
CEMIP1		
CEMIP2		
CEMP1		
CEN1		
CEN2		
CEN3		
CENATAC	AR	?mosaic variegated aneuploidy syndrome 4, 620153 (3),
CEND1		
CenH3		
CENP-27		
CENP-28		
CENP-29		
CENP-30	AD	developmental and epileptic encephalopathy 100, 619777 (3),
CENP-31	XLR,XL	borjeson-forssman-lehmann syndrome, 301900 (3),
CENP-32		
CENP-33		
CENP-34		
CENP-35		
CENP-36	AD	koolen-de vries syndrome, 610443 (3),
CENP-50		
CENP-A		
CENP-C		
CENP-I		
CENP-K		
CENP-M		
CENP-O		
CENP-P		
CENP-Q		
CENP-S		
CENP-T	AR	?short stature and microcephaly with genital anomalies, 618702 (3),
CENP-U		
CENP-V		
CENP-X		
CENP-Z		
CENPA		
CENPB		
CENPC		
CENPC1		
CENPE	AR	?microcephaly 13, primary, 616051 (3),
CENPF	AR	stromme syndrome, 243605 (3),
CENPH		
CENPI		
CENPJ	AR	microcephaly 6, primary, 608393 (3), ; ?seckel syndrome 4, 613676 (3),
CENPK		
CENPL		
CENPM		
CENPN		
CENPO		
CENPP		
CENPQ		
CENPR		
CENPS		
CENPT	AR	?short stature and microcephaly with genital anomalies, 618702 (3),
CENPU		
CENPV		
CENPW		
CENPX		
CENPZ		
CENTA1		
CENTA2		
CENTB1		
CENTB2		
CENTB3		
CENTB4		
CENTB6		
CENTD1		
CENTD2		
CENTD3		
CENTG1		
CENTG2		
CENTG3		
CEP-68		
CEP1		
CEP104	AR	joubert syndrome 25, 616781 (3), ; intellectual developmental disorder, 77, 619988 (3),
CEP110		
CEP112	AR	spermatogenic failure 44, 619044 (3),
CEP120	AR	short-rib thoracic dysplasia 13 with or without polydactyly, 616300 (3), ; joubert syndrome 31, 617761 (3),
CEP126		
CEP131		
CEP135	AR	microcephaly 8, primary, 614673 (3),
CEP152	AR	microcephaly 9, primary, 614852 (3), ; seckel syndrome 5, 613823 (3),
CEP162		
CEP164	AR	nephronophthisis 15, 614845 (3),
CEP170		
CEP170B		
Cep170R		
CEP19	AR	morbid obesity and spermatogenic failure, 615703 (3),
CEP192		
CEP2	AR	cone-rod dystrophy and hearing loss 2, 618358 (3),
CEP20		
CEP215	AR	microcephaly 3, primary, 604804 (3),
CEP250	AR	cone-rod dystrophy and hearing loss 2, 618358 (3),
CEP27		
CEP290	AR	leber congenital amaurosis 10, 611755 (3); joubert syndrome 5, 610188 (3), ; senior-loken syndrome 6, 610189 (3), ; ?bardet-biedl syndrome 14, 615991 (3), ; meckel syndrome 4, 611134 (3),
CEP295		
CEP3		
CEP350		
CEP4	AR	microcephaly 8, primary, 614673 (3),
CEP41	AR	joubert syndrome 15, 614464 (3),
CEP43		myeloproliferative disorder, 605392 (2)
CEP44		
CEP4L	AR	?spermatogenic failure 26, 617961 (3),
CEP5		
CEP52		
CEP55	AR	multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly, 236500 (3),
CEP57	AR	mosaic variegated aneuploidy syndrome 2, 614114 (3),
CEP63	AR	?seckel syndrome 6, 614728 (3),
CEP68		
CEP70		
CEP72		
CEP78	AR	cone-rod dystrophy and hearing loss, 617236 (3),
CEP83	AR	nephronophthisis 18, 615862 (3),
CEP85		
CEP85L	AD	lissencephaly 10, 618873 (3),
CEP89		
CEP90	AR	joubert syndrome 33, 617767 (3),
CEP97		
CEPR		
CEPT1		
CEPTRL2		
CEPU-1		
cer-d4		
CER1		
CER2		
CERCAM		
Cerd4		
cerebroglycan		
CerIII	AD	?myoclonus, familial, 2, 618364 (3), ; seizures, benign familial infantile, 5, 617080 (3), ; cognitive impairment with or without cerebellar ataxia, 614306 (3), ; developmental and epileptic encephalopathy 13, 614558 (3),
CERK		
CERKL	AR	retinitis pigmentosa 26, 608380 (3),
CERNA2		
Cernunnos		severe combined immunodeficiency with microcephaly, growth retardation, and sensitivity to ionizing radiation, 611291 (3)
CERS1	AR	epilepsy, progressive myoclonic, 8, 616230 (3),
CERS2		
CERS3	AR	ichthyosis, congenital, 9, 615023 (3),
CERS4		
CERS5		
CERS6		
CERT	AD	intellectual developmental disorder, 34, 616351 (3),
CERT1	AD	intellectual developmental disorder, 34, 616351 (3),
CES1	AD	drug metabolism, altered, ces1-related, 618057 (3),
CES1A1	AD	drug metabolism, altered, ces1-related, 618057 (3),
CES1A2	AD	drug metabolism, altered, ces1-related, 618057 (3),
CES2	AD	drug metabolism, altered, ces1-related, 618057 (3),
CES2A1		
CES3		
CES4C1		
CES5		
CES5A		
CES5A1		
CES7		
CESC1		
CESD	AR	wolman disease, 620151 (3), ; cholesteryl ester storage disease, 278000 (3),
CESP-1		
CETN		
CETN1		
CETN2		
CETN3		
CETP	AD	[high density lipoprotein cholesterol level qtl 10], 143470 (3), ; hyperalphalipoproteinemia, 143470 (3),
CEV14	AR	odontochondrodysplasia 1, 184260 (3), ; achondrogenesis, type ia, 200600 (3),
CEZANNE		
CEZANNE2		
CF	AR,AD	cystic fibrosis, 219700 (3), ; sweat chloride elevation without cf (3); congenital bilateral absence of vas deferens, 277180 (3), ; {pancreatitis, hereditary}, 167800 (3), ; {bronchiectasis with or without elevated sweat chloride 1, modifier of}, 211400 (3), ; {hypertrypsinemia, neonatal} (3)
CF2	XLR,XL	immunodeficiency 47, 300972 (3),
CF2R		
CF6		
CFAG		
CFAP106		
CFAP108	AD	intellectual developmental disorder, 21, 615502 (3),
CFAP111	AR	deafness, 63, 611451 (3),
CFAP116	AR	senior-loken syndrome 9, 616629 (3),
CFAP118	AR	short-rib thoracic dysplasia 7 with or without polydactyly, 614091 (3), ; cranioectodermal dysplasia 2, 613610 (3),
CFAP119		
CFAP122		
CFAP124	XL,XLR	spinal muscular atrophy, 2, infantile, 301830 (3), ; vexas syndrome, somatic, 301054 (3)
CFAP126		
CFAP133	AR	short-rib thoracic dysplasia 11 with or without polydactyly, 615633 (3),
CFAP134		
CFAP14		
CFAP156	AR	bardet-biedl syndrome 19, 615996 (3),
CFAP160	AR	deafness, 100, 618422 (3),
CFAP163	AR	short-rib thoracic dysplasia 8 with or without polydactyly, 615503 (3),
CFAP167	AR	short-rib thoracic dysplasia 2 with or without polydactyly, 611263 (3),
CFAP169		
CFAP172	AR	ciliary dyskinesia, primary, 15, 613808 (3),
CFAP178		
CFAP194		
CFAP20		
CFAP200		
CFAP22		
CFAP221		
CFAP23	AR	methylmalonic aciduria, vitamin b12-responsive, cblb type, 251110 (3),
CFAP246		
CFAP247	XLD,XL	developmental and epileptic encephalopathy 2, 300672 (3),
CFAP250	AR	ciliary dyskinesia, primary, 27, 615504 (3),
CFAP251	AR	spermatogenic failure 33, 618152 (3),
CFAP255		
CFAP256	AR	joubert syndrome 25, 616781 (3), ; intellectual developmental disorder, 77, 619988 (3),
CFAP276		
CFAP280		
CFAP286		
CFAP297		
CFAP298	AR	ciliary dyskinesia, primary, 26, 615500 (3),
CFAP300	AR	ciliary dyskinesia, primary, 38, 618063 (3),
CFAP305		
CFAP31	AR	nephronophthisis 3, 604387 (3), ; renal-hepatic-pancreatic dysplasia 1, 208540 (3), ; meckel syndrome 7, 267010 (3),
CFAP37	AR	infantile-onset multisystem neurologic, endocrine, and pancreatic disease, 616263 (3),
CFAP39	XL,XLR	?spinocerebellar ataxia, 1, 302500 (3),
CFAP410	AR	retinal dystrophy with macular staphyloma, 617547 (3), ; spondylometaphyseal dysplasia, axial, 602271 (3),
CFAP418	AR	retinitis pigmentosa 64, 614500 (3), ; cone-rod dystrophy 16, 614500 (3), ; bardet-biedl syndrome 21, 617406 (3),
CFAP43	AD,AR	hydrocephalus, normal pressure, 1, 236690 (3), ; spermatogenic failure 19, 617592 (3),
CFAP44	AR	spermatogenic failure 20, 617593 (3),
CFAP45	AR	heterotaxy, visceral, 11, with male infertility, 619608 (3),
CFAP46		
CFAP47	XL,XLR	spermatogenic failure, 3, 301059 (3),
CFAP48	AR	?anhidrosis, isolated, with normal sweat glands, 106190 (3),
CFAP50		
CFAP52	AR	heterotaxy, visceral, 10, with male infertility, 619607 (3),
CFAP53	AR	heterotaxy, visceral, 6, 614779 (3),
CFAP57		
CFAP58	AR	spermatogenic failure 49, 619144 (3),
CFAP59	AR	ciliary dyskinesia, primary, 14, 613807 (3),
CFAP60	AR,AD	short-rib thoracic dysplasia 4 with or without polydactyly, 613819 (3), ; nephronophthisis 12, 613820 (3),
CFAP61	AR	spermatogenic failure 84, 620409 (3),
CFAP65	AR	spermatogenic failure 40, 618664 (3),
CFAP66	AR	nephronophthisis 13, 614377 (3), ; cranioectodermal dysplasia 4, 614378 (3), ; senior-loken syndrome 8, 616307 (3), ; short-rib thoracic dysplasia 5 with or without polydactyly, 614376 (3), ; ?spermatogenic failure 72, 619867 (3),
CFAP67		
CFAP69	AR	spermatogenic failure 24, 617959 (3),
CFAP70	AR	?spermatogenic failure 41, 618670 (3),
CFAP74	AR	ciliary dyskinesia, primary, 49, without situs inversus, 620197 (3),
CFAP75	AR	?spermatogenic failure 27, 617965 (3),
CFAP78		
CFAP79		
CFAP80	AR	cranioectodermal dysplasia 1, 218330 (3),
CFAP81		
CFAP85	AD	congenital myopathy 15, 620161 (3),
CFAP87	AD	long qt syndrome 4, 600919 (3), ; cardiac arrhythmia, ankyrin-b-related, 600919 (3),
CFAP88		
CFAP89		
CFAP91	AR	spermatogenic failure 51, 619177 (3),
CFAP93		
CFAP94		
CFAP97		
CFAP97D1		
CFB	AR,AD	?complement factor b deficiency, 615561 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to, 4}, 612924 (3), ; {macular degeneration, age-related, 14, reduced risk of}, 615489 (3), digenic
CFC		
CFC1	AD	heterotaxy, visceral, 2, 605376 (3),
CFD	AR	complement factor d deficiency, 613912 (3),
CFD1	AD	bent bone dysplasia syndrome, 614592 (3), ; ladd syndrome 1, 149730 (3), ; antley-bixler syndrome without genital anomalies or disordered steroidogenesis, 207410 (3), ; scaphocephaly and axenfeld-rieger anomaly (3); jackson-weiss syndrome, 123150 (3), ; gastric cancer, somatic, 613659 (3); craniofacial-skeletal-dermatologic dysplasia, 101600 (3), ; apert syndrome, 101200 (3), ; pfeiffer syndrome, 101600 (3), ; craniosynostosis, nonspecific (3); ?scaphocephaly, maxillary retrusion, and impaired intellectual development, 609579 (3); beare-stevenson cutis gyrata syndrome, 123790 (3), ; crouzon syndrome, 123500 (3), ; saethre-chotzen syndrome, 101400 (3),
CFDP1		
CFEOM2	AR	fibrosis of extraocular muscles, congenital, 2, 602078 (3),
CFEOM3	AD	fibrosis of extraocular muscles, congenital, 3a, 600638 (3), ; cortical dysplasia, complex, with other brain malformations 1, 614039 (3),
CFEOM3A	AD	fibrosis of extraocular muscles, congenital, 3a, 600638 (3), ; cortical dysplasia, complex, with other brain malformations 1, 614039 (3),
CFF	XLR,XL	methylmalonic aciduria and homocysteinemia, cblx type, 309541 (3),
CFFM4		
CFH	AD,AR	{macular degeneration, age-related, 4}, 610698 (3), ; basal laminar drusen, 126700 (3), ; complement factor h deficiency, 609814 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to, 1}, 235400 (3),
CFHL	AD,AR	{macular degeneration, age-related, reduced risk of}, 603075 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to}, 235400 (3),
CFHL1	AD,AR	{macular degeneration, age-related, reduced risk of}, 603075 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to}, 235400 (3),
CFHL1P	AD,AR	{macular degeneration, age-related, reduced risk of}, 603075 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to}, 235400 (3),
CFHL2		
CFHL3	AD,AR	{macular degeneration, age-related, reduced risk of}, 603075 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to}, 235400 (3),
CFHL4		
CFHL5	AD	nephropathy due to cfhr5 deficiency, 614809 (3),
CFHR1	AD,AR	{macular degeneration, age-related, reduced risk of}, 603075 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to}, 235400 (3),
CFHR1P	AD,AR	{macular degeneration, age-related, reduced risk of}, 603075 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to}, 235400 (3),
CFHR2		
CFHR3	AD,AR	{macular degeneration, age-related, reduced risk of}, 603075 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to}, 235400 (3),
CFHR4		
CFHR5	AD	nephropathy due to cfhr5 deficiency, 614809 (3),
CFI	AD,AR	{hemolytic uremic syndrome, atypical, susceptibility to, 3}, 612923 (3), ; {macular degeneration, age-related, 13, susceptibility to}, 615439 (3), ; complement factor i deficiency, 610984 (3),
CFIM		
CFIM25		
CFIM68		
CFIM72		
CFL		
CFL1		
CFL2	AR	nemaline myopathy 7, 610687 (3),
CFLAR		
cFLIP		
Cfm1		
Cfm2		
CFNS	XLD,XL	craniofrontonasal dysplasia, 304110 (3),
CFP	XL,XLR	properdin deficiency, 312060 (3),
CFP1		
CFR-1		
CFTR	AR,AD	cystic fibrosis, 219700 (3), ; sweat chloride elevation without cf (3); congenital bilateral absence of vas deferens, 277180 (3), ; {pancreatitis, hereditary}, 167800 (3), ; {bronchiectasis with or without elevated sweat chloride 1, modifier of}, 211400 (3), ; {hypertrypsinemia, neonatal} (3)
CFTR/MRP	AR,AD	cystic fibrosis, 219700 (3), ; sweat chloride elevation without cf (3); congenital bilateral absence of vas deferens, 277180 (3), ; {pancreatitis, hereditary}, 167800 (3), ; {bronchiectasis with or without elevated sweat chloride 1, modifier of}, 211400 (3), ; {hypertrypsinemia, neonatal} (3)
CG		
CG-2		
CG-6	AR	developmental and epileptic encephalopathy 37, 616981 (3),
CG-8		
CG-beta-a		
CG-NAP	AD	?long qt syndrome 11, 611820 (3),
CG003		
CG005		
CG008		
CG1	XL,XLR	hypospadias 2, 300758 (3),
CG12-1		
CG1I		
CG22		
CG4853		
CG7943		
CGA		
CGAS		
CGAT		
CGB		
CGB1		
CGB2		
CGB3		
CGB4	AR	hypogonadotropic hypogonadism 23 with or without anosmia, 228300 (3),
CGB5		
CGB7		
CGB8		
CGBP		
CGD	XL,XLR	immunodeficiency 34, mycobacteriosis, 300645 (3), ; chronic granulomatous disease, 306400 (3),
CGEF2		
CGGBP		
CGGBP1		
CGI-01	AR,AD	{?deafness, 26, modifier of}, 605429 (3),
CGI-03		
CGI-04	AR	myopathy, lactic acidosis, and sideroblastic anemia 2, 613561 (3),
CGI-05		
CGI-07		
CGI-10	AR	coenzyme q10 deficiency, primary, 6, 614650 (3),
CGI-100		
CGI-101		
CGI-102	AR	pontocerebellar hypoplasia, type 1b, 614678 (3),
CGI-106		
CGI-108	AR	?pontocerebellar hypoplasia, type 1f, 619304 (3),
CGI-109		
CGI-11		
CGI-110		
CGI-114		
CGI-115		
CGI-116		
CGI-118		
CGI-119		
CGI-12		
CGI-120		
CGI-121	AR	galloway-mowat syndrome 5, 617731 (3),
CGI-123		
CGI-127		
CGI-128		
CGI-129	AR	mitochondrial pyruvate carrier deficiency, 614741 (3),
CGI-131		
CGI-132	AR	combined oxidative phosphorylation deficiency 2, 610498 (3),
CGI-134		
CGI-135		
CGI-137		
CGI-138	AR	?combined oxidative phosphorylation deficiency 46, 618952 (3),
CGI-139		
CGI-141		
CGI-143		
CGI-145		
CGI-146		
CGI-147	AR	infantile-onset multisystem neurologic, endocrine, and pancreatic disease, 616263 (3),
CGI-149		
CGI-15		
CGI-151	AD	{pancreatic cancer, susceptibility to, 1}, 606856 (3),
CGI-152		
CGI-16		
CGI-18	AR	spinal muscular atrophy with congenital bone fractures 2, 616867 (3), ; barrett esophagus/esophageal adenocarcinoma, 614266 (3)
CGI-19		
CGI-20	AR	?congenital disorder of glycosylation, type iiy, 620200 (3),
CGI-202		
CGI-203	AR	?combined oxidative phosphorylation deficiency 19, 615595 (3),
CGI-204		
CGI-21		
CGI-22		
CGI-25		
CGI-26		
CGI-27		
CGI-28		
CGI-29		
CGI-30	AR	neurodevelopmental disorder with short stature, prominent forehead, and feeding difficulties, 620070 (3),
CGI-32		
CGI-33	AR	multiple mitochondrial dysfunctions syndrome 1, 605711 (3),
CGI-34		
CGI-36		
CGI-37		
CGI-38		
CGI-39	AR	{thyroid carcinoma, hurthle cell}, 607464 (3); ?mitochondrial complex i deficiency, nuclear type 28, 618249 (3),
CGI-40		
CGI-44	AR	sulfide:quinone oxidoreductase deficiency, 619221 (3),
CGI-47	AR	sideroblastic anemia with b-cell immunodeficiency, periodic fevers, and developmental delay, 616084 (3), ; retinitis pigmentosa and erythrocytic microcytosis, 616959 (3),
CGI-48		
CGI-50	AR	?intellectual developmental disorder with short stature and variable skeletal anomalies, 618453 (3),
CGI-51		
CGI-52		
CGI-53	AR	short-rib thoracic dysplasia 16 with or without polydactyly, 617102 (3),
CGI-54		
CGI-55		
CGI-56		
CGI-58	AR	chanarin-dorfman syndrome, 275630 (3),
CGI-59		
CGI-60	AR	short-rib thoracic dysplasia 15 with polydactyly, 617088 (3),
CGI-61		
CGI-63	AR	dystonia, childhood-onset, with optic atrophy and basal ganglia abnormalities, 617282 (3),
CGI-64		
CGI-65	AR	mitochondrial complex i deficiency, nuclear type 11, 618234 (3),
CGI-66		
CGI-67		
CGI-68		
CGI-69		
CGI-70		
CGI-72		
CGI-74		
CGI-75		
CGI-76		
CGI-77	AR	intellectual developmental disorder with dysmorphic facies, seizures, and distal limb anomalies, 617452 (3),
CGI-78		
CGI-80		
CGI-83		
CGI-85	AD	intellectual developmental disorder, 51, 617788 (3),
CGI-87	AR	encephalopathy, progressive, early-onset, with brain atrophy and spasticity, 617669 (3),
CGI-89	XL	intellectual developmental disorder, syndromic, raymond type, 300799 (3),
CGI-90		
CGI-91	AR	combined oxidative phosphorylation deficiency 36, 617950 (3),
CGI-92	AR	coenzyme q10 deficiency, primary, 7, 616276 (3),
CGI-93		
CGI-94		
CGI-95		
CGI-96	AR	?microcephaly 28, primary, 619453 (3),
CGI-97	AR	{aplastic anemia, susceptibility to}, 609135 (3); shwachman-diamond syndrome 1, 260400 (3),
CGI-99		
CGI-PDE	AD	hypertension and brachydactyly syndrome, 112410 (3),
CGI121	AR	galloway-mowat syndrome 5, 617731 (3),
CGIN1		
cGKII	AR	spondylometaphyseal dysplasia, pagnamenta type, 619638 (3), ; acromesomelic dysplasia 4, 619636 (3),
CGL-1		
CGL-2		
CGL1		
CGL4	AR	lipodystrophy, congenital generalized, type 4, 613327 (3),
CGLA		
CGLB		
CGM1		
CGM2		
CGM6		
CGM7		
CGN		
CGNL1		
CGR11		
CGR19		
CGREF1		
CGRP		
CGRP-alpha		
CGRP-II		
CGRP-RCP		
CGRPR	AR	?lymphatic malformation 8, 618773 (3),
CGRRF1		
CGS23		
CGT		
CGTHBA	AD	epilepsy, familial focal, with variable foci 3, 617118 (3),
CH		c4b deficiency, 614379 (3)
ch-TOG		
CH1		
CH25H		
CH2H2-25		
CHA		
CHAC	AR	choreoacanthocytosis, 200150 (3),
CHAC1		
CHAC2		
CHAD		
CHADL		
CHAF1A		
CHAF1B		
CHAK1	AD	{amyotrophic lateral sclerosis-parkinsonism/dementia complex, susceptibility to}, 105500 (3),
CHAK2	AR	hypomagnesemia 1, intestinal, 602014 (3),
CHAMP	AR,AD	?spermatogenic failure 73, 619878 (3), |neurodevelopmental disorder with hypotonia, impaired language, and dysmorphic features, 616579 (3),
CHAMP1	AD	neurodevelopmental disorder with hypotonia, impaired language, and dysmorphic features, 616579 (3),
Chap1	XLD,XL	amyotrophic lateral sclerosis 15, with or without frontotemporal dementia, 300857 (3),
CHAP1/DSK2	XLD,XL	amyotrophic lateral sclerosis 15, with or without frontotemporal dementia, 300857 (3),
chapsyn-110		
CHARAC17		
CHASM		
CHAT	AR	myasthenic syndrome, congenital, 6, presynaptic, 254210 (3),
CHC1		
CHC1L		
CHC22		
CHCHD1		
CHCHD10	AD	?myopathy, isolated mitochondrial, 616209 (3), ; spinal muscular atrophy, jokela type, 615048 (3), ; frontotemporal dementia and/or amyotrophic lateral sclerosis 2, 615911 (3),
CHCHD2	AD	parkinson disease 22, 616710 (3),
CHCHD3		
CHCHD4		
CHCHD5		
CHCHD6		
CHCHD7		
CHCHD8		
CHCM1		
CHCR		
CHD1	AD	pilarowski-bjornsson syndrome, 617682 (3),
CHD1L		
CHD2	AD	developmental and epileptic encephalopathy 94, 615369 (3),
CHD2-42		
CHD2-52		
CHD3	AD	snijders blok-campeau syndrome, 618205 (3),
CHD3IP		
CHD4	AD	sifrim-hitz-weiss syndrome, 617159 (3),
CHD5	AD	parenti-mignot neurodevelopmental syndrome, 619873 (3),
CHD6		
CHD7	AD	hypogonadotropic hypogonadism 5 with or without anosmia, 612370 (3), ; charge syndrome, 214800 (3),
CHD8	AD	intellectual developmental disorder with autism and macrocephaly, 615032 (3),
CHD9		
CHDC1		
CHDC2	XL,XLR	spermatogenic failure, 3, 301059 (3),
CHDR	AR	{46xy sex reversal 8, modifier of}, 614279 (3),
CHE-1		
CHE1	AR	butyrylcholinesterase deficiency, 617936 (3), ; {apnea, postanesthetic, susceptibility to, due to bche deficiency}, 617936 (3),
CHE2	AR	butyrylcholinesterase deficiency, 617936 (3), ; {apnea, postanesthetic, susceptibility to, due to bche deficiency}, 617936 (3),
CHED	AD,AD	congenital heart defects, dysmorphic facial features, and intellectual developmental disorder, 617360 (3), |corneal dystrophy, posterior polymorphous, 1, 122000 (3),
CHED1	AD	corneal dystrophy, posterior polymorphous, 1, 122000 (3),
CHED2	AR	corneal endothelial dystrophy, 217700 (3), ; corneal dystrophy, fuchs endothelial, 4, 613268 (3); corneal endothelial dystrophy and perceptive deafness, 217400 (3),
CHEK1		
CHEK2	AD	{colorectal cancer, susceptibility to}, 114500 (3), somatic mutation, ; osteosarcoma, somatic, 259500 (3); {breast cancer, susceptibility to}, 114480 (3), somatic mutation, ; {prostate cancer, familial, susceptibility to}, 176807 (3), somatic mutation, ; li-fraumeni syndrome 2, 609265 (3)
ChemR13		
ChemR23		
CHERP		
CHES1		
CHET9	AD	imagawa-matsumoto syndrome, 618786 (3),
CHETK	AR	muscular dystrophy, congenital, megaconial type, 602541 (3),
CHF-2		
CHF2		
CHFR		
CHGA		
CHGB		
CHGC		
ChGn	AR	skeletal dysplasia, mild, with joint laxity and advanced bone age, 618870 (3),
CHH	AR	anauxetic dysplasia 1, 607095 (3), ; metaphyseal dysplasia without hypotrichosis, 250460 (3), ; cartilage-hair hypoplasia, 250250 (3),
CHI3	AR	[chitotriosidase deficiency], 614122 (3),
CHI3L1	AD	{asthma-related traits, susceptibility to, 7}, 611960 (3); {schizophrenia, susceptibility to}, 181500 (3),
CHI3L2		
CHIA		
Chibby		
Chibby1		
CHIC1		
CHIC2	AD	{leukemia, acute myeloid}, 601626 (3), somatic mutation,
CHICA		
CHID1		
chif		
CHIF		
chifb		
CHIMP		
CHIP	AD,AR	spinocerebellar ataxia 48, 618093 (3), ; spinocerebellar ataxia, 16, 615768 (3),
CHIP28		[aquaporin-1 deficiency], 110450 (3); [blood group, colton], 110450 (3)
Chisel	XL,XLR,XLD	myopathy, distal, 7, adult-onset, 301075 (3), ; deafness, 4, 300066 (3),
CHIT	AR	[chitotriosidase deficiency], 614122 (3),
CHIT1	AR	[chitotriosidase deficiency], 614122 (3),
CHIT2		
CHIT5		
CHK	AR	neurodevelopmental disorder with microcephaly, movement abnormalities, and seizures, 620023 (3),
CHK1		
CHK2	AD	{colorectal cancer, susceptibility to}, 114500 (3), somatic mutation, ; osteosarcoma, somatic, 259500 (3); {breast cancer, susceptibility to}, 114480 (3), somatic mutation, ; {prostate cancer, familial, susceptibility to}, 176807 (3), somatic mutation, ; li-fraumeni syndrome 2, 609265 (3)
CHKA	AR	neurodevelopmental disorder with microcephaly, movement abnormalities, and seizures, 620023 (3),
CHKB	AR	muscular dystrophy, congenital, megaconial type, 602541 (3),
CHKL	AR	muscular dystrophy, congenital, megaconial type, 602541 (3),
CHL	XL,XLR	megalocornea 1, 309300 (3),
CHL1	AR	warsaw breakage syndrome, 613398 (3),
CHL12		
ChlR1	AR	warsaw breakage syndrome, 613398 (3),
CHM	XL	choroideremia, 303100 (3),
CHM-I		
chm-II		
CHM1		
ChM1L		
chm2		
CHML		
CHMP1	AR	pontocerebellar hypoplasia, type 8, 614961 (3),
CHMP1.5		
CHMP1A	AR	pontocerebellar hypoplasia, type 8, 614961 (3),
CHMP1B		
CHMP2		
CHMP2.5	AD	frontotemporal dementia and/or amyotrophic lateral sclerosis 7, 600795 (3),
CHMP2A		
CHMP2B	AD	frontotemporal dementia and/or amyotrophic lateral sclerosis 7, 600795 (3),
CHMP3		
CHMP4A		
CHMP4B	AD	cataract 31, multiple types, 605387 (3),
CHMP4C		
CHMP5		
CHMP6		
CHMP7		
CHMP8		
CHN	AD	chondrosarcoma, extraskeletal myxoid, 612237 (3)|duane retraction syndrome 2, 604356 (3),
CHN1	AD	duane retraction syndrome 2, 604356 (3),
CHN2		
CHO2	XLR,XLD,XL	mend syndrome, 300960 (3), ; chondrodysplasia punctata, 302960 (3),
CHODL		
CHOP		
CHOP10		
CHORDC1		
CHORDC3		
Chp		
CHP	AR	?spastic ataxia 9, 618438 (3),
CHP-1		
CHP1	AR	?spastic ataxia 9, 618438 (3),
CHP3		
CHPF		
CHPF1		
CHPF2		
CHPPR		
CHPT1		
CHR10SYT		
CHR11SYT		
CHR14SYT		
CHR2SYT		
CHR3SYT		
CHR415SYT		
CHRAC1		
CHRAC15		
CHRAC17		
CHRAC2		
CHRD		
CHRDL1	XL,XLR	megalocornea 1, 309300 (3),
CHRDL2		
CHREBP		
CHRFAM7A		
CHRM1		
CHRM2		
CHRM3	AR	prune belly syndrome, 100100 (3),
CHRM4		
CHRM5		
CHRMQ1	AR	cerebellar hypoplasia, impaired intellectual development, and dysequilibrium syndrome 1, 224050 (3),
CHRNA	AR,AD	myasthenic syndrome, congenital, 1b, fast-channel, 608930 (3), ; myasthenic syndrome, congenital, 1a, slow-channel, 601462 (3), ; multiple pterygium syndrome, lethal type, 253290 (3),
CHRNA1	AR,AD	myasthenic syndrome, congenital, 1b, fast-channel, 608930 (3), ; myasthenic syndrome, congenital, 1a, slow-channel, 601462 (3), ; multiple pterygium syndrome, lethal type, 253290 (3),
CHRNA10		
CHRNA2	AD	epilepsy, nocturnal frontal lobe, type 4, 610353 (3),
CHRNA3	AR	{lung cancer susceptibility 2}, 612052 (3); bladder dysfunction, autonomic, with impaired pupillary reflex and secondary cakut, 191800 (3),
CHRNA4	AD	{nicotine addiction, susceptibility to}, 188890 (3); epilepsy, nocturnal frontal lobe, 1, 600513 (3),
CHRNA5		{nicotine dependence, susceptibility to}, 612052 (3); {lung cancer susceptibility 2}, 612052 (3)
CHRNA6		
CHRNA7		
CHRNA7-DR1		
CHRNA9		
CHRNB	AR,AD	?myasthenic syndrome, congenital, 2c, associated with acetylcholine receptor deficiency, 616314 (3), ; myasthenic syndrome, congenital, 2a, slow-channel, 616313 (3),
CHRNB1	AR,AD	?myasthenic syndrome, congenital, 2c, associated with acetylcholine receptor deficiency, 616314 (3), ; myasthenic syndrome, congenital, 2a, slow-channel, 616313 (3),
CHRNB2		epilepsy, nocturnal frontal lobe, 3, 605375 (3)
CHRNB3		
CHRNB4		
CHRND	AR,AD	?myasthenic syndrome, congenital, 3c, associated with acetylcholine receptor deficiency, 616323 (3), ; multiple pterygium syndrome, lethal type, 253290 (3), ; myasthenic syndrome, congenital, 3b, fast-channel, 616322 (3), ; ?myasthenic syndrome, congenital, 3a, slow-channel, 616321 (3),
CHRNE	AR,AD	myasthenic syndrome, congenital, 4a, slow-channel, 605809 (3), ; myasthenic syndrome, congenital, 4c, associated with acetylcholine receptor deficiency, 608931 (3), ; myasthenic syndrome, congenital, 4b, fast-channel, 616324 (3),
CHRNG	AR	multiple pterygium syndrome, lethal type, 253290 (3), ; escobar syndrome, 265000 (3),
CHRONO		
CHRP		
CHS	AR	chediak-higashi syndrome, 214500 (3),
CHS1	AR,AR	chediak-higashi syndrome, 214500 (3), |cohen syndrome, 216550 (3),
CHST1		
CHST10		
CHST11	AR	?osteochondrodysplasia, brachydactyly, and overlapping malformed digits, 618167 (3),
CHST12		
CHST13		
CHST14	AR	ehlers-danlos syndrome, musculocontractural type 1, 601776 (3),
CHST15		
CHST2		
CHST3	AR	spondyloepiphyseal dysplasia with congenital joint dislocations, 143095 (3),
CHST5		
CHST6	AR	macular corneal dystrophy, 217800 (3),
CHST7		
CHST8	AR	?peeling skin syndrome 3, 616265 (3),
CHST9		
CHSY-2		
ChSy-3		
CHSY1	AR	temtamy preaxial brachydactyly syndrome, 605282 (3),
CHSY2		
CHSY3		
ChT	AD,AR	neuronopathy, distal hereditary motor, type viia, 158580 (3), ; myasthenic syndrome, congenital, 20, presynaptic, 617143 (3),
CHT1	AD,AR	neuronopathy, distal hereditary motor, type viia, 158580 (3), ; myasthenic syndrome, congenital, 20, presynaptic, 617143 (3),
CHTF18		
CHTF4		
CHTF8		
CHTL1	AR	neurodegeneration, childhood-onset, with ataxia, tremor, optic atrophy, and cognitive decline, 618868 (3),
CHTOP		
CHUK	AR	?popliteal pterygium syndrome, bartsocas-papas type 2, 619339 (3), ; ?cocoon syndrome, 613630 (3),
CHURC1		
CHX10	AR	microphthalmia, isolated 2, 610093 (3), ; microphthalmia with coloboma 3, 610092 (3),
CI		
CI-10k		
CI-13kA	AR	mitochondrial complex i deficiency, nuclear type 9, 618232 (3),
CI-13kB		
CI-13KD-B		
CI-15k		
CI-18	AR	mitochondrial complex i deficiency, nuclear type 1, 252010 (3),
CI-20	AR	mitochondrial complex i deficiency, nuclear type 3, 618224 (3),
CI-23k	AR	mitochondrial complex i deficiency, nuclear type 2, 618222 (3),
CI-24k	AR	mitochondrial complex i deficiency, nuclear type 7, 618229 (3),
CI-30	AR	mitochondrial complex i deficiency, nuclear type 8, 618230 (3),
CI-39k	AR	mitochondrial complex i deficiency, nuclear type 26, 618247 (3),
CI-42k	AR	mitochondrial complex i deficiency, nuclear type 22, 618243 (3),
CI-49	AR	mitochondrial complex i deficiency, nuclear type 6, 618228 (3),
CI-51K	AR	mitochondrial complex i deficiency, nuclear type 4, 618225 (3),
CI-75k	AR	mitochondrial complex i deficiency, nuclear type 5, 618226 (3),
CI-9k	AR	?mitochondrial complex iv deficiency, nuclear type 21, 619065 (3),
CI-AGGG		
CI-ASHI	AR	mitochondrial complex i deficiency, nuclear type 32, 618252 (3),
CI-B14	AR	mitochondrial complex i deficiency, nuclear type 33, 618253 (3),
CI-B18	AR	?mitochondrial complex i deficiency, nuclear type 39, 620135 (3),
CI-M6PR		hepatocellular carcinoma, somatic, 114550 (3)
CI-MNLL		
CI-MPR		hepatocellular carcinoma, somatic, 114550 (3)
CI-MWFE	XLR,XL	mitochondrial complex i deficiency, nuclear type 12, 301020 (3),
CI-SGDH		
CIA		
CIA1		
CIA2A		
CIA2B		
CIA30	AR	mitochondrial complex i deficiency, nuclear type 11, 618234 (3),
CIAB1		
CIAE1		
CIAE2		
CIAO1		
CIAO2A		
CIAO2B		
CIAO3		
CIAO4		
CIAO5		
CIAO6		
cIAP1		
cIAP2		
CIAPIN1		
CIART		
CIAS1	AD	cinca syndrome, 607115 (3), ; familial cold inflammatory syndrome 1, 120100 (3), ; keratoendothelitis fugax hereditaria, 148200 (3), ; deafness, 34, with or without inflammation, 617772 (3), ; muckle-wells syndrome, 191900 (3),
CIAT	AD	?myoclonus, familial, 2, 618364 (3), ; seizures, benign familial infantile, 5, 617080 (3), ; cognitive impairment with or without cerebellar ataxia, 614306 (3), ; developmental and epileptic encephalopathy 13, 614558 (3),
CIB	AR	epidermodysplasia verruciformis 3, 618267 (3),
CIB1	AR	epidermodysplasia verruciformis 3, 618267 (3),
CIB2	AR	deafness, 48, 609439 (3), ; usher syndrome, type ij, 614869 (3),
CIB3		
CIB4		
CIBAR1	AR	?polydactyly, postaxial, type a9, 618219 (3),
CIBAR2		
CIBZ		
CIC	AR,AD	combined d-2- and l-2-hydroxyglutaric aciduria, 615182 (3), ; myasthenic syndrome, congenital, 23, presynaptic, 618197 (3), |intellectual developmental disorder, 45, 617600 (3),
CIDE-3	AR	?lipodystrophy, familial partial, type 5, 615238 (3),
CIDE-A		
CIDEA		
CIDEB		
CIDEC	AR	?lipodystrophy, familial partial, type 5, 615238 (3),
CIDX	XL,XLR	combined immunodeficiency, moderate, 312863 (3), ; severe combined immunodeficiency, 300400 (3),
CIF150	AR	intellectual developmental disorder, 40, 615599 (3),
CIG	AD	spondylometaphyseal dysplasia, corner fracture type, 184255 (3), ; glomerulopathy with fibronectin deposits 2, 601894 (3),
CIG-30		
CIG-49		
cig42		
cig5		
CIITA	AR	{rheumatoid arthritis, susceptibility to}, 180300 (3); bare lymphocyte syndrome, type ii, complementation group a, 209920 (3),
CIKS	AR	?candidiasis, familial, 8, 615527 (3), ; {psoriasis susceptibility 13}, 614070 (3)
CILD1	AR	ciliary dyskinesia, primary, 1, with or without situs inversus, 244400 (3),
CILD10	AR	ciliary dyskinesia, primary, 10, 612518 (3),
CILD11	AR	ciliary dyskinesia, primary, 11, 612649 (3),
CILD12	AR	ciliary dyskinesia, primary, 12, 612650 (3),
CILD13	AR	ciliary dyskinesia, primary, 13, 613193 (3),
CILD14	AR	ciliary dyskinesia, primary, 14, 613807 (3),
CILD15	AR	ciliary dyskinesia, primary, 15, 613808 (3),
CILD16	AR	ciliary dyskinesia, primary, 16, 614017 (3),
CILD17	AR	ciliary dyskinesia, primary, 17, 614679 (3),
CILD18	AR	ciliary dyskinesia, primary, 18, 614874 (3),
CILD19	AR	ciliary dyskinesia, primary, 19, 614935 (3),
CILD2	AR	ciliary dyskinesia, primary, 2, 606763 (3),
CILD20	AR	ciliary dyskinesia, primary, 20, 615067 (3),
CILD21	AR	spermatogenic failure 80, 620222 (3), ; ciliary dyskinesia, primary, 21, 615294 (3),
CILD22	AR	ciliary dyskinesia, primary, 22, 615444 (3),
CILD23	AR	ciliary dyskinesia, primary, 23, 615451 (3),
CILD24	AR	ciliary dyskinesia, primary, 24, 615481 (3),
CILD25	AD,AR	{dyslexia, susceptibility to, 1}, 127700 (3), ; ciliary dyskinesia, primary, 25, 615482 (3),
CILD26	AR	ciliary dyskinesia, primary, 26, 615500 (3),
CILD27	AR	ciliary dyskinesia, primary, 27, 615504 (3),
CILD28	AR	ciliary dyskinesia, primary, 28, 615505 (3),
CILD3	AR	ciliary dyskinesia, primary, 3, with or without situs inversus, 608644 (3),
CILD5	AR	ciliary dyskinesia, primary, 5, 608647 (3),
CILD6	AR	?ciliary dyskinesia, primary, 6, 610852 (3),
CILD7	AR	ciliary dyskinesia, primary, 7, with or without situs inversus, 611884 (3),
CILD9	AR	ciliary dyskinesia, primary, 9, with or without situs inversus, 612444 (3),
CILK1	AD,AR	{epilepsy, juvenile myoclonic, susceptibility to, 10}, 617924 (3), ; endocrine-cerebroosteodysplasia, 612651 (3),
CILP		{lumbar disc disease, susceptibility to}, 603932 (3)
CILP1		{lumbar disc disease, susceptibility to}, 603932 (3)
CILP2		
CIMAP1A		
CIMAP2		
CIMAP3		
CIMIP1		
CIMPR		hepatocellular carcinoma, somatic, 114550 (3)
CIN		
CIN85	XLR,XL	?immunodeficiency 61, 300310 (3),
CINAP		
CINC-2a		
CINC-2b		
CINCIN1		
CINP		
CIP	AR	myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis, 620138 (3),
CIP1		
CIP29		
CIP2A		
CIP3	AR	pontocerebellar hypoplasia, type 1c, 616081 (3),
CIP4		
CIP98	AR	deafness, 31, 607084 (3), ; usher syndrome, type 2d, 611383 (3),
Cipar1		
CIPC		
CIPER	AR	{lymphoma, follicular, somatic}, 605027 (3); ?immunodeficiency 37, 616098 (3), ; {sezary syndrome, somatic} (3); {male germ cell tumor, somatic}, 273300 (3); lymphoma, malt, somatic, 137245 (3); {mesothelioma, somatic}, 156240 (3)
Cipp		
CIR	AD	long qt syndrome 13, 613485 (3), ; hyperaldosteronism, familial, type iii, 613677 (3),
CIR1		
CIR2		
CIRBP		
CIRH1A		
CIRHIN		
CIRIP		
CIRL1	AD	developmental delay, behavioral abnormalities, and neuropsychiatric disorders, 620065 (3),
CIRL2		
CIROP	AR	heterotaxy, visceral, 12, 619702 (3),
CIRP		
CIRRIN	AD	atrioventricular septal defect, partial, with heterotaxy syndrome, 606217 (3), ; {atrioventricular septal defect, susceptibility to, 2}, 606217 (3),
ciRS-7		
CIS		{malaria, susceptibility to}, 611162 (3); {bacteremia, susceptibility to}, 614383 (3); {tuberculosis, susceptibility to}, 607948 (3)
CIS-1		{malaria, susceptibility to}, 611162 (3); {bacteremia, susceptibility to}, 614383 (3); {tuberculosis, susceptibility to}, 607948 (3)
CIS2		
CIS3		
CIS4		
CIS6		
CISD1		
CISD2	AR	wolfram syndrome 2, 604928 (3),
CISD3		
CISH		{malaria, susceptibility to}, 611162 (3); {bacteremia, susceptibility to}, 614383 (3); {tuberculosis, susceptibility to}, 607948 (3)
Cish1	AD	autoinflammatory syndrome, familial, with or without immunodeficiency, 619375 (3),
Cish2		
Cish3		
Cish4		
Cish5		
CISH6		
CISS	AR	cold-induced sweating syndrome 1, 272430 (3),
CISS1	AR	cold-induced sweating syndrome 1, 272430 (3),
CISS2	AR	cold-induced sweating syndrome 2, 610313 (3),
CIT	AR	microcephaly 17, primary, 617090 (3),
CIT1		
CITED1		
CITED2	AD	atrial septal defect 8, 614433 (3), ; ventricular septal defect 2, 614431 (3),
CITED4		
CITK	AR	microcephaly 17, primary, 617090 (3),
CITRIN	AR	citrullinemia, type ii, neonatal-onset, 605814 (3), ; citrullinemia, adult-onset type ii, 603471 (3),
CIZ		
CIZ1		
CJD	AD	spongiform encephalopathy with neuropsychiatric features, 606688 (3), ; gerstmann-straussler disease, 137440 (3), ; huntington disease-like 1, 603218 (3), ; insomnia, fatal familial, 600072 (3), ; {kuru, susceptibility to}, 245300 (3); cerebral amyloid angiopathy, prnp-related, 137440 (3), ; creutzfeldt-jakob disease, 123400 (3),
CK-5	AD,AR	epidermolysis bullosa simplex 2a, generalized severe, 619555 (3), ; dowling-degos disease 1, 179850 (3), ; epidermolysis bullosa simplex 2f, with mottled pigmentation, 131960 (3), ; epidermolysis bullosa simplex 2d, generalized, intermediate or severe, 619599 (3), ; epidermolysis bullosa simplex 2b, generalized intermediate, 619588 (3), ; epidermolysis bullosa simplex 2c, localized, 619594 (3), ; epidermolysis bullosa simplex 2e, with migratory circinate erythema, 609352 (3),
CK-7		
CK-8		
CK-9	AD	palmoplantar keratoderma, epidermolytic, 1, 144200 (3),
CK1		
CK10	AD	ichthyosis, annular epidermolytic 1, 607602 (3), ; epidermolytic hyperkeratosis 2, 620150 (3); ?ichthyosis histrix, lambert type, 146600 (3), ; ichthyosis with confetti, 609165 (3),
CK13	AD	white sponge nevus 2, 615785 (3),
CK15		
CK19		
CK1a		
CK1alpha		
CK1g2		
CK1gamma1		
CK20		
CK23		
CK2alpha'		
CK3	AD	meesmann corneal dystrophy 2, 618767 (3),
CK4	AD	white sponge nevus 1, 193900 (3),
CK6C	AD	pachyonychia congenita 3, 615726 (3),
CK6D	AD	pachyonychia congenita 3, 615726 (3),
CK7		
CK8		
CKA-3		
Cka1	AD	okur-chung neurodevelopmental syndrome, 617062 (3),
Cka2	AD	okur-chung neurodevelopmental syndrome, 617062 (3),
CKAP1		
CKAP2		
CKAP2L	AR	filippi syndrome, 272440 (3),
CKAP4		
CKAP5		
CKAPI		
CKB		
Ckb-6		
Ckb-8		
Ckb1	AD	poirier-bienvenu neurodevelopmental syndrome, 618732 (3),
CKb1		
CKb10		
CKb11		
CKb12		
Ckb15		
Ckb2	AD	poirier-bienvenu neurodevelopmental syndrome, 618732 (3),
CKb4		
CKb7		
CKb8		
CKb9		
CKBB		
CKBBP1		
CKBBP2		
CKbetaBP2		
CKI	AR	neurodevelopmental disorder with microcephaly, movement abnormalities, and seizures, 620023 (3),
CKIa		
CKIalpha		
CKID	AD	advanced sleep-phase syndrome, familial, 2, 615224 (3),
CKIdelta	AD	advanced sleep-phase syndrome, familial, 2, 615224 (3),
CKIE		
CKIepsilon		
CKIP-1		
CKLF		
CKLF1		
CKLF3		
CKLF4		
CKLFH		
CKLFH1a		
CKLFSF1		
CKLFSF2		
CKLFSF3		
CKLFSF4		
CKLFSF5		
CKLFSF6		
CKLFSF7		
CKLFSF8		
CKLiK		
CKM		
CKMM		
CKMT		
CKMT1		
CKMT1A		
CKMT1B		
CKMT2		
CKN1	AR	uv-sensitive syndrome 2, 614621 (3), ; cockayne syndrome, type a, 216400 (3),
CKN2	AR,AD	uv-sensitive syndrome 1, 600630 (3), ; cerebrooculofacioskeletal syndrome 1, 214150 (3), ; ?de sanctis-cacchione syndrome, 278800 (3), ; cockayne syndrome, type b, 133540 (3), ; {macular degeneration, age-related, susceptibility to, 5}, 613761 (3); premature ovarian failure 11, 616946 (3), ; {lung cancer, susceptibility to}, 211980 (3), somatic mutation,
CKR-1		{aids, slow progression to}, 609423 (3)
CKR-5		{hiv infection, susceptibility/resistance to}, 609423 (3); {diabetes mellitus, insulin-dependent, 22}, 612522 (3); {hepatitis c virus, resistance to}, 609532 (3); {west nile virus, susceptibility to}, 610379 (3)
CKR-L1		
CKR-L2		
CKR-L3		
CKR2		{hiv infection, susceptibility/resistance to}, 609423 (3)
CKR3		
CKR4		
CKR5		{hiv infection, susceptibility/resistance to}, 609423 (3); {diabetes mellitus, insulin-dependent, 22}, 612522 (3); {hepatitis c virus, resistance to}, 609532 (3); {west nile virus, susceptibility to}, 610379 (3)
CKRX		
CKS1		
CKS1B		
CKS2		
ckshs1		
CKTSF1B1		
CKTSF1B2	AD	tooth agenesis, selective, 9, 617275 (3),
CKTSF1B3		
CL-10	AR	3mc syndrome 3, 248340 (3),
cl-11		{aids, delayed/rapid progression to}, 609423 (3)
CL-11	AR	3mc syndrome 2, 265050 (3),
cl-2		{aids, delayed/rapid progression to}, 609423 (3)
CL-20		
cl-39		
cl-42		
cl-43		
cl-49		
cl-5		
cl-6		
CL-6		
CL-K1	AR	3mc syndrome 2, 265050 (3),
CL-L1	AR	3mc syndrome 3, 248340 (3),
CL-P1		
CL100		
CL2		
CL25022	AR	methylmalonic aciduria, cbld type, variant 2, 277410 (3), ; methylmalonic aciduria and homocystinuria, cbld type, 277410 (3), ; homocystinuria, cbld type, variant 1, 277410 (3),
CL25084		
CL469780		
CL640	AR,AD	{multiple system atrophy, susceptibility to}, 146500 (3), ; coenzyme q10 deficiency, primary, 1, 607426 (3),
CLA-1		[high density lipoprotein cholesterol level qtl6], 610762 (3)
CLA1	AR	[high density lipoprotein cholesterol level qtl6], 610762 (3)|spinocerebellar ataxia, 2, 213200 (3),
CLA2	XL,XLR	?spinocerebellar ataxia, 1, 302500 (3),
CLA20	AR	spastic paraplegia 52, 614067 (3),
CLAMP		
CLAN	AD	?familial cold autoinflammatory syndrome 4, 616115 (3), ; autoinflammation with infantile enterocolitis, 616050 (3),
CLAN1	AD	?familial cold autoinflammatory syndrome 4, 616115 (3), ; autoinflammation with infantile enterocolitis, 616050 (3),
CLANA	AD	?familial cold autoinflammatory syndrome 4, 616115 (3), ; autoinflammation with infantile enterocolitis, 616050 (3),
CLANB	AD	?familial cold autoinflammatory syndrome 4, 616115 (3), ; autoinflammation with infantile enterocolitis, 616050 (3),
CLANC	AD	?familial cold autoinflammatory syndrome 4, 616115 (3), ; autoinflammation with infantile enterocolitis, 616050 (3),
CLAND	AD	?familial cold autoinflammatory syndrome 4, 616115 (3), ; autoinflammation with infantile enterocolitis, 616050 (3),
CLAP	AR	{lymphoma, follicular, somatic}, 605027 (3); ?immunodeficiency 37, 616098 (3), ; {sezary syndrome, somatic} (3); {male germ cell tumor, somatic}, 273300 (3); lymphoma, malt, somatic, 137245 (3); {mesothelioma, somatic}, 156240 (3)
CLAPA1		
CLAPA2		
CLAPB1		
CLAPB2	AR	keratitis-ichthyosis-deafness syndrome, 242150 (3),
CLAPG1	AR,AD	usmani-riazuddin syndrome, 619548 (3); usmani-riazuddin syndrome, 619467 (3),
CLAPM1	AD	intellectual developmental disorder 60 with seizures, 618587 (3),
CLAPM2		
CLAPS1	AR	mednik syndrome, 609313 (3),
CLAPS2	AD	hypocalciuric hypercalcemia, type iii, 600740 (3),
CLAPS3		
CLARP		
CLASP		
CLASP1		
CLASP2		
CLASRP		
CLAST3	AR	?proteasome-associated autoinflammatory syndrome 4, 619183 (3),
Clast4		
Clast5		
CLATP		
CLAX		
CLB		
CLC	AR	cold-induced sweating syndrome 2, 610313 (3),
ClC-1	AR,AD	myotonia congenita, 255700 (3), ; myotonia congenita, 160800 (3), ; myotonia levior, 160800 (3),
ClC-2	AR,AD	leukoencephalopathy with ataxia, 615651 (3), ; hyperaldosteronism, familial, type ii, 605635 (3), ; {epilepsy, juvenile myoclonic, susceptibility to, 8}, 607628 (3), ; {epilepsy, juvenile absence, susceptibility to, 2}, 607628 (3), ; {epilepsy, idiopathic generalized, susceptibility to, 11}, 607628 (3),
ClC-3	AR,AD	neurodevelopmental disorder with seizures and brain abnormalities, 619517 (3), ; neurodevelopmental disorder with hypotonia and brain abnormalities, 619512 (3),
ClC-4	XLD,XL	raynaud-claes syndrome, 300114 (3),
ClC-5	XLR,XL	proteinuria, low molecular weight, with hypercalciuric nephrocalcinosis, 308990 (3), ; hypophosphatemic rickets, 300554 (3), ; dent disease 1, 300009 (3), ; nephrolithiasis, type i, 310468 (3),
ClC-6	AD	neurodegeneration, childhood-onset, hypotonia, respiratory insufficiency and brain imaging abnormalities, 619173 (3),
CLC-6	AD	neurodegeneration, childhood-onset, hypotonia, respiratory insufficiency and brain imaging abnormalities, 619173 (3),
ClC-7	AD,AR	hypopigmentation, organomegaly, and delayed myelination and development, 618541 (3), ; osteopetrosis, 4, 611490 (3), ; osteopetrosis, 2, 166600 (3),
CLC-7	AD,AR	hypopigmentation, organomegaly, and delayed myelination and development, 618541 (3), ; osteopetrosis, 4, 611490 (3), ; osteopetrosis, 2, 166600 (3),
ClC-K1		bartter syndrome, type 4b, digenic, 613090 (3), digenic
ClC-K2	AR	bartter syndrome, type 3, 607364 (3), ; bartter syndrome, type 4b, digenic, 613090 (3), digenic
ClC-Kb	AR	bartter syndrome, type 3, 607364 (3), ; bartter syndrome, type 4b, digenic, 613090 (3), digenic
CLC1	AR,AD	myotonia congenita, 255700 (3), ; myotonia congenita, 160800 (3), ; myotonia levior, 160800 (3),
CLC2	AR,AD	leukoencephalopathy with ataxia, 615651 (3), ; hyperaldosteronism, familial, type ii, 605635 (3), ; {epilepsy, juvenile myoclonic, susceptibility to, 8}, 607628 (3), ; {epilepsy, juvenile absence, susceptibility to, 2}, 607628 (3), ; {epilepsy, idiopathic generalized, susceptibility to, 11}, 607628 (3),
CLC3	AR,AD	neurodevelopmental disorder with seizures and brain abnormalities, 619517 (3), ; neurodevelopmental disorder with hypotonia and brain abnormalities, 619512 (3),
CLC4	XLD,XL	raynaud-claes syndrome, 300114 (3),
CLC5	XLR,XL	proteinuria, low molecular weight, with hypercalciuric nephrocalcinosis, 308990 (3), ; hypophosphatemic rickets, 300554 (3), ; dent disease 1, 300009 (3), ; nephrolithiasis, type i, 310468 (3),
CLC7	AD,AR	hypopigmentation, organomegaly, and delayed myelination and development, 618541 (3), ; osteopetrosis, 4, 611490 (3), ; osteopetrosis, 2, 166600 (3),
CLCA1		
CLCA2		
CLCA3		
CLCA3P		
CLCA4		
CLCC1	AR	retinitis pigmentosa 32, 609913 (3),
CLCF1	AR	cold-induced sweating syndrome 2, 610313 (3),
CLCI		
CLCK1		bartter syndrome, type 4b, digenic, 613090 (3), digenic
CLCKB	AR	bartter syndrome, type 3, 607364 (3), ; bartter syndrome, type 4b, digenic, 613090 (3), digenic
CLCN1	AR,AD	myotonia congenita, 255700 (3), ; myotonia congenita, 160800 (3), ; myotonia levior, 160800 (3),
CLCN2	AR,AD	leukoencephalopathy with ataxia, 615651 (3), ; hyperaldosteronism, familial, type ii, 605635 (3), ; {epilepsy, juvenile myoclonic, susceptibility to, 8}, 607628 (3), ; {epilepsy, juvenile absence, susceptibility to, 2}, 607628 (3), ; {epilepsy, idiopathic generalized, susceptibility to, 11}, 607628 (3),
CLCN3	AR,AD	neurodevelopmental disorder with seizures and brain abnormalities, 619517 (3), ; neurodevelopmental disorder with hypotonia and brain abnormalities, 619512 (3),
CLCN4	XLD,XL	raynaud-claes syndrome, 300114 (3),
CLCN5	XLR,XL	proteinuria, low molecular weight, with hypercalciuric nephrocalcinosis, 308990 (3), ; hypophosphatemic rickets, 300554 (3), ; dent disease 1, 300009 (3), ; nephrolithiasis, type i, 310468 (3),
CLCN6	AD	neurodegeneration, childhood-onset, hypotonia, respiratory insufficiency and brain imaging abnormalities, 619173 (3),
CLCN7	AD,AR	hypopigmentation, organomegaly, and delayed myelination and development, 618541 (3), ; osteopetrosis, 4, 611490 (3), ; osteopetrosis, 2, 166600 (3),
CLCNKA		bartter syndrome, type 4b, digenic, 613090 (3), digenic
CLCNKB	AR	bartter syndrome, type 3, 607364 (3), ; bartter syndrome, type 4b, digenic, 613090 (3), digenic
CLCNL1		
CLCNL2	XL,XLR	?intellectual developmental disorder, syndromic 32, 300886 (3),
CLCP1		
CLCR	AD	{pancreatitis, chronic, susceptibility to}, 167800 (3),
CLCRG1		
CLCRG2		
CLCS		{inflammatory bowel disease 13}, 612244 (3); {colchicine resistance}, 120080 (3)
CLD	AR	diarrhea 1, secretory chloride, congenital, 214700 (3),
CLDN1	AR	ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis, 607626 (3),
CLDN10	AR	helix syndrome, 617671 (3),
CLDN11	AD	leukodystrophy, hypomyelinating, 22, 619328 (3),
CLDN12		
CLDN14	AR	deafness, 29, 614035 (3),
CLDN15		
CLDN16	AR	hypomagnesemia 3, renal, 248250 (3),
CLDN17		
CLDN18		
CLDN19	AR	hypomagnesemia 5, renal, with ocular involvement, 248190 (3),
CLDN2	XLR	?azoospermia, obstructive, with nephrolithiasis, 301060 (3),
CLDN23		
CLDN3		
CLDN4		
CLDN5		
CLDN6		
CLDN7		
CLDN8		
CLDN9	AR	?deafness, 116, 619093 (3),
CLDND1		
CLDNL		
CLE		
CLE7		
CLEC-1		{aspergillosis, susceptibility to}, 614079 (3)
CLEC-2		
CLEC1		{aspergillosis, susceptibility to}, 614079 (3)
CLEC10A		
CLEC11A		
CLEC12A		
CLEC12B		
CLEC13A		
CLEC13B		
CLEC13C		
CLEC13D		
CLEC13DL		
CLEC13E		
CLEC14A		
CLEC15A		
CLEC16A		
CLEC17A		
CLEC18A		
CLEC18B		
CLEC18C		
CLEC1A		{aspergillosis, susceptibility to}, 614079 (3)
CLEC1B		
CLEC2		
CLEC2A		
CLEC2B		
CLEC2C		
CLEC2D		
CLEC3A		
CLEC3B	AD	macular dystrophy, retinal, 4, 619977 (3),
CLEC4A		
CLEC4C		
CLEC4D		
CLEC4E		
CLEC4F		
CLEC4G		
CLEC4H1		
CLEC4H2		
CLEC4J		
CLEC4K		[?birbeck granule deficiency], 613393 (3)
CLEC4L		{hiv type 1, susceptibility to}, 609423 (3); {mycobacterium tuberculosis, susceptibility to}, 607948 (3); {dengue fever, protection against}, 614371 (3)
CLEC4M		
CLEC5A		
CLEC5B		
CLEC5C		
CLEC6A		
CLEC7A	AR	candidiasis, familial, 4, 613108 (3), ; {aspergillosis, susceptibility to}, 614079 (3)
CLEC8A		{myocardial infarction, susceptibility to}, 608446 (3)
CLEC9A		
CLECL1		
CLECL1P		
CLECSF1		
CLECSF10		
CLECSF11		
CLECSF12	AR	candidiasis, familial, 4, 613108 (3), ; {aspergillosis, susceptibility to}, 614079 (3)
CLECSF13		
CLECSF14		
CLECSF2		
CLECSF3		
CLECSF5		
CLECSF6		
CLECSF7		
CLECSF8		
CLECSF9		
CLERC		
CLEVER-1		
CLF	AR	cold-induced sweating syndrome 1, 272430 (3),
CLF-1	AR	cold-induced sweating syndrome 1, 272430 (3),
Clf1		
CLG	AR,AR	copd, rate of decline of lung function in, 606963 (3); {epidermolysis bullosa dystrophica, modifier of}, 226600 (3), |leukodystrophy and acquired microcephaly with or without dystonia, 616763 (3),
CLG01		
CLG1		
CLG3	AD,AR	?spondyloepimetaphyseal dysplasia, missouri type, 602111 (3), ; metaphyseal anadysplasia 1, 602111 (3), ; metaphyseal dysplasia, spahr type, 250400 (3),
CLG4	AR	multicentric osteolysis, nodulosis, and arthropathy, 259600 (3),
CLG4A	AR	multicentric osteolysis, nodulosis, and arthropathy, 259600 (3),
CLG4B	AR	metaphyseal anadysplasia 2, 613073 (3),
CLGI		
CLGN		
CLH22		
CLI		
CLIC1		
CLIC1L		
CLIC2	XL,XLR	?intellectual developmental disorder, syndromic 32, 300886 (3),
CLIC3		
CLIC4		
CLIC4L		
CLIC5	AR	?deafness, 103, 616042 (3),
CLIC6		
CLICKIII		
CLIF		
CLIK1		
CLIK1L		
CLIM1		
CLIM2		
CLIMP-63		
CLINT		
CLINT1		
CLIP	AR,MF,AD	{obesity, early-onset, susceptibility to}, 601665 (3), , ; obesity, adrenal insufficiency, and red hair due to pomc deficiency, 609734 (3),
CLIP-115		
CLIP-170		
CLIP1		
CLIP170		
CLIP2		
CLIP3		
CLIP4		
ClipinC		
CLIPR-59		
CLK-1	AR	?coenzyme q10 deficiency, primary, 8, 616733 (3),
CLK1		
CLK2		
CLK3		
CLK4		
CLL-1		
CLLD6		
CLLD7	AR	retinal dystrophy with or without extraocular anomalies, 617175 (3),
CLLD8		
CLLL7	AR	retinal dystrophy with or without extraocular anomalies, 617175 (3),
CLLL8		
CLLP		
CLLU1		
CLLU1-AS1		
CLLU1OS		
CLM	AR	lissencephaly 5, 615191 (3),
CLM1		
CLM2		
CLM7		
CLM9		
CLMF	AR	immunodeficiency 29, mycobacteriosis, 614890 (3),
CLMF2	AR	immunodeficiency 29, mycobacteriosis, 614890 (3),
CLMN		
CLMP	AR	congenital short bowel syndrome, 615237 (3),
CLN1	AR	ceroid lipofuscinosis, neuronal, 1, 256730 (3),
CLN10	AR	ceroid lipofuscinosis, neuronal, 10, 610127 (3),
CLN11	AD,AR	aphasia, primary progressive, 607485 (3), ; frontotemporal lobar degeneration with ubiquitin-positive inclusions, 607485 (3), ; ceroid lipofuscinosis, neuronal, 11, 614706 (3),
CLN12	AR	spastic paraplegia 78, 617225 (3), ; kufor-rakeb syndrome, 606693 (3),
CLN13	AR	ceroid lipofuscinosis, neuronal, 13 (kufs type), 615362 (3),
CLN14	AR	epilepsy, progressive myoclonic 3, with or without intracellular inclusions, 611726 (3),
CLN2	AR	ceroid lipofuscinosis, neuronal, 2, 204500 (3), ; spinocerebellar ataxia, 7, 609270 (3),
CLN3	AR	ceroid lipofuscinosis, neuronal, 3, 204200 (3),
CLN4	AD	ceroid lipofuscinosis, neuronal, 4 (kufs type), 162350 (3),
CLN5	AR	ceroid lipofuscinosis, neuronal, 5, 256731 (3),
CLN6	AR	ceroid lipofuscinosis, neuronal, 6b (kufs type), 204300 (3), ; ceroid lipofuscinosis, neuronal, 6a, 601780 (3),
CLN7	AR	macular dystrophy with central cone involvement, 616170 (3), ; ceroid lipofuscinosis, neuronal, 7, 610951 (3),
CLN8	AR	ceroid lipofuscinosis, neuronal, 8, northern epilepsy variant, 610003 (3), ; ceroid lipofuscinosis, neuronal, 8, 600143 (3),
CLN80		
CLNK		
CLNMT		
CLNS1A		
CLOCK		
CLOM	AR	lethal congenital contracture syndrome 11, 617194 (3),
CLONE243		
CLONE24922		
Clox	AD	global developmental delay with or without impaired intellectual development, 618330 (3),
CLP	AD	?cardiomyopathy, dilated, 1m, 607482 (3); cardiomyopathy, hypertrophic, 12, 612124 (3),
CLP-1		
CLP-36		
CLP1	AR	pontocerebellar hypoplasia, type 10, 615803 (3),
CLP11		
CLP24		
CLP36		
CLPA	XL	cleft palate with ankyloglossia, 303400 (3), ; ?abruzzo-erickson syndrome, 302905 (3),
CLPB	AD,AR	neutropenia, severe congenital, 9, 619813 (3), ; 3-methylglutaconic aciduria, type viib, 616271 (3), ; 3-methylglutaconic aciduria, type viia, 619835 (3),
CLPED1	AR	cleft lip/palate-ectodermal dysplasia syndrome, 225060 (3), ; orofacial cleft 7, 225060 (3),
CLPH		
CLPP	AR	perrault syndrome 3, 614129 (3),
CLPS		
CLPTM1		
CLPTM1L		
CLPX	AD	?protoporphyria, erythropoietic, 2, 618015 (3),
CLR1.1	AD	cinca syndrome, 607115 (3), ; familial cold inflammatory syndrome 1, 120100 (3), ; keratoendothelitis fugax hereditaria, 148200 (3), ; deafness, 34, with or without inflammation, 617772 (3), ; muckle-wells syndrome, 191900 (3),
CLR11.1		
CLR11.2		
CLR11.3		
CLR11.4		
CLR16.1		
CLR16.2		
CLR16.3	AD,MF	blau syndrome, 186580 (3), ; {yao syndrome}, 617321 (3), ; {inflammatory bowel disease 1, crohn disease}, 266600 (3),
CLR17.1	AR,AD	{vitiligo-associated multiple autoimmune disease susceptibility 1}, 606579 (3); ?respiratory papillomatosis, juvenile recurrent, congenital, 618803 (3), ; autoinflammation with arthritis and dyskeratosis, 617388 (3), ; palmoplantar carcinoma, multiple self-healing, 615225 (3),
CLR19.1		
CLR19.2		
CLR19.3	AD	familial cold autoinflammatory syndrome 2, 611762 (3),
CLR19.4	AR	hydatidiform mole, recurrent, 1, 231090 (3),
CLR19.5		
CLR19.6		
CLR19.7		
CLR19.8	AR	oocyte/zygote/embryo maturation arrest 19, 620333 (3),
CLR19.9	AR	oocyte/zygote/embryo maturation arrest 18, 620332 (3),
CLR2.1	AD	?familial cold autoinflammatory syndrome 4, 616115 (3), ; autoinflammation with infantile enterocolitis, 616050 (3),
CLR7.1		
CLRN1	AR	usher syndrome, type 3a, 276902 (3), ; retinitis pigmentosa 61, 614180 (3)
CLRN2	AR	?deafness, 117, 619174 (3),
CLRN3		
CLRP	XL,XLR	night blindness, congenital stationary (complete), 1a, 310500 (3),
CLS	XL,XLD	intellectual developmental disorder, 19, 300844 (3), ; coffin-lowry syndrome, 303600 (3),
CLS1	AR	combined oxidative phosphorylation deficiency 57, 620167 (3),
CLSP		
CLSPN		
CLSS	AR,AD	?myasthenic syndrome, congenital, 17, 616304 (3), ; sclerosteosis 2, 614305 (3), ; cenani-lenz syndactyly syndrome, 212780 (3),
CLST11240		
CLST11240-15		
CLSTN1		
CLSTN2		
CLSTN3		
CLTA		
CLTB		
CLTC	AD	intellectual developmental disorder, 56, 617854 (3),
CLTCL		
CLTCL1		
CLTCL2	AD	intellectual developmental disorder, 56, 617854 (3),
CLTD		
CLTH		leukemia, acute myeloid, somatic, 601626 (3)
CLTRN		
CLU		
CLU1		
CLU2		
CLUAP1		
CLUH		
CLUL1		
CLVS1		
CLVS2		
CLXN		
CLYBL		
CM-AVM	AD	capillary malformation-arteriovenous malformation 1, 608354 (3), ; basal cell carcinoma, somatic, 605462 (3)
CMA1		
CMAR	AR,AD	spastic paraplegia 7, 607259 (3),
CMAS		
CMBL		
CMC1		
CMC3		
CMC4		
CMD1	AD	campomelic dysplasia with sex reversal, 114290 (3), ; acampomelic campomelic dysplasia, 114290 (3), ; campomelic dysplasia, 114290 (3),
CMD1A	AR,AD	mandibuloacral dysplasia, 248370 (3), ; heart-hand syndrome, slovenian type, 610140 (3), ; cardiomyopathy, dilated, 1a, 115200 (3), ; emery-dreifuss muscular dystrophy 3, 616516 (3), ; restrictive dermopathy 2, 619793 (3); charcot-marie-tooth disease, type 2b1, 605588 (3), ; emery-dreifuss muscular dystrophy 2, 181350 (3), ; hutchinson-gilford progeria, 176670 (3), ; lipodystrophy, familial partial, type 2, 151660 (3), ; muscular dystrophy, congenital, 613205 (3), ; malouf syndrome, 212112 (3),
CMD1C	AD	left ventricular noncompaction 3, 601493 (3), ; cardiomyopathy, hypertrophic, 24, 601493 (3), ; myopathy, myofibrillar, 4, 609452 (3), ; cardiomyopathy, dilated, 1c, with or without lvnc, 601493 (3),
CMD1D	AD	cardiomyopathy, dilated, 1d, 601494 (3), ; cardiomyopathy, hypertrophic, 2, 115195 (3), ; cardiomyopathy, familial restrictive, 3, 612422 (3), ; left ventricular noncompaction 6, 601494 (3),
CMD1E	AD,AR	ventricular fibrillation, familial, 1, 603829 (3); heart block, progressive, type ia, 113900 (3), ; cardiomyopathy, dilated, 1e, 601154 (3), ; heart block, nonprogressive, 113900 (3), ; long qt syndrome 3, 603830 (3), ; sick sinus syndrome 1, 608567 (3), ; brugada syndrome 1, 601144 (3), ; atrial fibrillation, familial, 10, 614022 (3), ; {sudden infant death syndrome, susceptibility to}, 272120 (3),
CMD1G	AR,AD	muscular dystrophy, limb-girdle, 10, 608807 (3), ; cardiomyopathy, familial hypertrophic, 9, 613765 (3), ; congenital myopathy 5 with cardiomyopathy, 611705 (3), ; tibial muscular dystrophy, tardive, 600334 (3), ; cardiomyopathy, dilated, 1g, 604145 (3), ; myopathy, myofibrillar, 9, with early respiratory failure, 603689 (3),
CMD1I	AD,AR	scapuloperoneal syndrome, neurogenic, kaeser type, 181400 (3), ; cardiomyopathy, dilated, 1i, 604765 (3), ; myopathy, myofibrillar, 1, 601419 (3),
CMD1J	AD	?cardiomyopathy, dilated, 1j, 605362 (3), ; deafness, 10, 601316 (3),
CMD1L	AR	cardiomyopathy, dilated, 1l, 606685 (3); muscular dystrophy, limb-girdle, 6, 601287 (3),
CMD1M	AD	?cardiomyopathy, dilated, 1m, 607482 (3); cardiomyopathy, hypertrophic, 12, 612124 (3),
CMD1N	AD,AR	cardiomyopathy, hypertrophic, 25, 607487 (3), ; muscular dystrophy, limb-girdle, 7, 601954 (3),
CMD1O	AD,AR	cardiomyopathy, dilated, 1o, 608569 (3), ; hypertrichotic osteochondrodysplasia (cantu syndrome), 239850 (3), ; ?atrial fibrillation, familial, 12, 614050 (3), ; intellectual disability and myopathy syndrome, 619719 (3),
CMD1P	AD	cardiomyopathy, dilated, 1p, 609909 (3); cardiomyopathy, hypertrophic, 18, 613874 (3),
CMD1R	AD	left ventricular noncompaction 4, 613424 (3), ; cardiomyopathy, hypertrophic, 11, 612098 (3), ; atrial septal defect 5, 612794 (3), ; cardiomyopathy, dilated, 1r, 613424 (3),
CMD1S	AD,AR	laing distal myopathy, 160500 (3), ; cardiomyopathy, hypertrophic, 1, 192600 (3), digenic , ; left ventricular noncompaction 5, 613426 (3), ; cardiomyopathy, dilated, 1s, 613426 (3), ; congenital myopathy 7b, myosin storage, 255160 (3), ; congenital myopathy 7a, myosin storage, 608358 (3),
CMD2A	AR,AD	?cardiomyopathy, dilated, 2a, 611880 (3), ; cardiomyopathy, hypertrophic, 7, 613690 (3), ; cardiomyopathy, familial restrictive, 1, 115210 (3), ; cardiomyopathy, dilated, 1ff, 613286 (3)
CMD3A	XLR,XL	barth syndrome, 302060 (3),
CMDJ	AD	chondrocalcinosis 2, 118600 (3), ; craniometaphyseal dysplasia, 123000 (3),
cmDNA		
CMF608		
CMG-1	AR	bardet-biedl syndrome 22, 617119 (3), ; spermatogenic failure 58, 619585 (3), ; joubert syndrome 40, 619582 (3),
CMG-2	AR	hyaline fibromatosis syndrome, 228600 (3),
cMG1		
CMG1	AR	bardet-biedl syndrome 22, 617119 (3), ; spermatogenic failure 58, 619585 (3), ; joubert syndrome 40, 619582 (3),
CMG2	AR	hyaline fibromatosis syndrome, 228600 (3),
CMH-1		
CMH1	AD,AR	laing distal myopathy, 160500 (3), ; cardiomyopathy, hypertrophic, 1, 192600 (3), digenic , ; left ventricular noncompaction 5, 613426 (3), ; cardiomyopathy, dilated, 1s, 613426 (3), ; congenital myopathy 7b, myosin storage, 255160 (3), ; congenital myopathy 7a, myosin storage, 608358 (3),
CMH10	AD,AR	cardiomyopathy, hypertrophic, 10, 608758 (3), ; myopathy, myofibrillar, 12, infantile-onset, with cardiomyopathy, 619424 (3),
CMH2	AD	cardiomyopathy, dilated, 1d, 601494 (3), ; cardiomyopathy, hypertrophic, 2, 115195 (3), ; cardiomyopathy, familial restrictive, 3, 612422 (3), ; left ventricular noncompaction 6, 601494 (3),
CMH3	AD	left ventricular noncompaction 9, 611878 (3), ; cardiomyopathy, hypertrophic, 3, 115196 (3), ; cardiomyopathy, dilated, 1y, 611878 (3),
CMH4	AR,AD	cardiomyopathy, hypertrophic, 4, 115197 (3), ; cardiomyopathy, dilated, 1mm, 615396 (3), ; left ventricular noncompaction 10, 615396 (3),
CMH6	AD	glycogen storage disease of heart, lethal congenital, 261740 (3), ; wolff-parkinson-white syndrome, 194200 (3), ; cardiomyopathy, hypertrophic 6, 600858 (3),
CMH7	AR,AD	?cardiomyopathy, dilated, 2a, 611880 (3), ; cardiomyopathy, hypertrophic, 7, 613690 (3), ; cardiomyopathy, familial restrictive, 1, 115210 (3), ; cardiomyopathy, dilated, 1ff, 613286 (3)
CMH8	AR,AD	cardiomyopathy, hypertrophic, 8, 608751 (3),
CMH9	AR,AD	muscular dystrophy, limb-girdle, 10, 608807 (3), ; cardiomyopathy, familial hypertrophic, 9, 613765 (3), ; congenital myopathy 5 with cardiomyopathy, 611705 (3), ; tibial muscular dystrophy, tardive, 600334 (3), ; cardiomyopathy, dilated, 1g, 604145 (3), ; myopathy, myofibrillar, 9, with early respiratory failure, 603689 (3),
CMIP		
CMIR		
CMK		
CMKAR1		{aids, slow progression to}, 609423 (3)
CMKAR2	AR	?whim syndrome 2, 619407 (3),
CMKAR3		
CMKBR1		
CMKBR2		{hiv infection, susceptibility/resistance to}, 609423 (3)
CMKBR3		
CMKBR4		
CMKBR5		{hiv infection, susceptibility/resistance to}, 609423 (3); {diabetes mellitus, insulin-dependent, 22}, 612522 (3); {hepatitis c virus, resistance to}, 609532 (3); {west nile virus, susceptibility to}, 610379 (3)
CMKBR6		
CMKBR7		
CMKBR8		
CMKBR9		
CMKBRL1		{rapid progression to aids from hiv1 infection}, 609423 (3); {macular degeneration, age-related, 12}, 613784 (3); {coronary artery disease, resistance to}, 607339 (3)
CMKBRL2		
CMKDR1		{rapid progression to aids from hiv1 infection}, 609423 (3); {macular degeneration, age-related, 12}, 613784 (3); {coronary artery disease, resistance to}, 607339 (3)
CMKLR1		
CMKLR2		
CMKLR2-AS		
CMKOR1	AR	?oculomotor-abducens synkinesis, 619215 (3),
CMKRL1		
CMKRL2		
CML		leukemia, chronic myeloid, philadelphia chromosome positive, somatic, 608232 (4); leukemia, acute lymphocytic, philadelphia chromosome positive, somatic, 613065 (4)
CML2		
CML33	AR	?rajab interstitial lung disease with brain calcifications 2, 619013 (3),
CML66		
CMM2	AD	{melanoma and neural system tumor syndrome}, 155755 (3), ; {melanoma, cutaneous malignant, 2}, 155601 (3), ; {melanoma-pancreatic cancer syndrome}, 606719 (3),
CMOAT	AR	dubin-johnson syndrome, 237500 (3),
cMOAT2		
CMP		
CMP-Sia-Tr	AR	congenital disorder of glycosylation, type iif, 603585 (3),
CMPD1	AD	campomelic dysplasia with sex reversal, 114290 (3), ; acampomelic campomelic dysplasia, 114290 (3), ; campomelic dysplasia, 114290 (3),
CMPD2	AD,AD,AR	cardiomyopathy, dilated, 1d, 601494 (3), ; cardiomyopathy, hypertrophic, 2, 115195 (3), ; cardiomyopathy, familial restrictive, 3, 612422 (3), ; left ventricular noncompaction 6, 601494 (3), |ventricular fibrillation, familial, 1, 603829 (3); heart block, progressive, type ia, 113900 (3), ; cardiomyopathy, dilated, 1e, 601154 (3), ; heart block, nonprogressive, 113900 (3), ; long qt syndrome 3, 603830 (3), ; sick sinus syndrome 1, 608567 (3), ; brugada syndrome 1, 601144 (3), ; atrial fibrillation, familial, 10, 614022 (3), ; {sudden infant death syndrome, susceptibility to}, 272120 (3),
CMPD4	AR,AD	muscular dystrophy, limb-girdle, 10, 608807 (3), ; cardiomyopathy, familial hypertrophic, 9, 613765 (3), ; congenital myopathy 5 with cardiomyopathy, 611705 (3), ; tibial muscular dystrophy, tardive, 600334 (3), ; cardiomyopathy, dilated, 1g, 604145 (3), ; myopathy, myofibrillar, 9, with early respiratory failure, 603689 (3),
CMPK		
CMPK1		
CMPK2		
CMPST	AR	congenital disorder of glycosylation, type iif, 603585 (3),
CMPX1	XL	intellectual developmental disorder, 97, 300803 (3),
Cmr1		
CMRF-35-H9		
CMRF-35A		
CMRF35		
CMRF35A		
CMRF35A4		
CMRF35H		
cMRP	AR	dubin-johnson syndrome, 237500 (3),
CMS		glomerulosclerosis, focal segmental, 3, 607832 (3)
CMS1D	AR	fetal akinesia deformation sequence 2, 618388 (3), ; myasthenic syndrome, congenital, 11, associated with acetylcholine receptor deficiency, 616326 (3),
CMS1E	AR	fetal akinesia deformation sequence 2, 618388 (3), ; myasthenic syndrome, congenital, 11, associated with acetylcholine receptor deficiency, 616326 (3),
CMT1	AD,AR	charcot-marie-tooth disease, type 2i, 607677 (3), ; dejerine-sottas disease, 145900 (3), ; charcot-marie-tooth disease, type 1b, 118200 (3), ; roussy-levy syndrome, 180800 (3), ; charcot-marie-tooth disease, intermediate d, 607791 (3), ; hypomyelinating neuropathy, congenital, 2, 618184 (3), ; charcot-marie-tooth disease, type 2j, 607736 (3),
CMT1A	AD,AR	charcot-marie-tooth disease, type 1a, 118220 (3), ; roussy-levy syndrome, 180800 (3), ; charcot-marie-tooth disease, type 1e, 118300 (3), ; ?neuropathy, inflammatory demyelinating, 139393 (3), ? ; neuropathy, recurrent, with pressure palsies, 162500 (3), ; dejerine-sottas disease, 145900 (3),
CMT1B	AD,AR	charcot-marie-tooth disease, type 2i, 607677 (3), ; dejerine-sottas disease, 145900 (3), ; charcot-marie-tooth disease, type 1b, 118200 (3), ; roussy-levy syndrome, 180800 (3), ; charcot-marie-tooth disease, intermediate d, 607791 (3), ; hypomyelinating neuropathy, congenital, 2, 618184 (3), ; charcot-marie-tooth disease, type 2j, 607736 (3),
CMT1F	AR,AD	charcot-marie-tooth disease, type 1f, 607734 (3), ; charcot-marie-tooth disease, intermediate g, 617882 (3), ; charcot-marie-tooth disease, type 2e, 607684 (3),
CMT2	AD	{neuroblastoma, susceptibility to, 1}, 256700 (3), somatic mutation, ; charcot-marie-tooth disease, type 2a1, 118210 (3),
CMT2A	AD	{neuroblastoma, susceptibility to, 1}, 256700 (3), somatic mutation, ; charcot-marie-tooth disease, type 2a1, 118210 (3),
CMT2A2	AR,AD	lipomatosis, multiple symmetric, with or without peripheral neuropathy, 151800 (3), ; charcot-marie-tooth disease, axonal, type 2a2a, 609260 (3), ; charcot-marie-tooth disease, axonal, type 2a2b, 617087 (3), ; hereditary motor and sensory neuropathy via, 601152 (3),
CMT2B	AD	charcot-marie-tooth disease, type 2b, 600882 (3),
CMT2C	AD	spondylometaphyseal dysplasia, kozlowski type, 184252 (3), ; digital arthropathy-brachydactyly, familial, 606835 (3), ; [sodium serum level qtl 1], 613508 (3); sed, maroteaux type, 184095 (3), ; metatropic dysplasia, 156530 (3), ; scapuloperoneal spinal muscular atrophy, 181405 (3), ; hereditary motor and sensory neuropathy, type iic, 606071 (3), ; ?avascular necrosis of femoral head, primary, 2, 617383 (3), ; neuronopathy, distal hereditary motor, type viii, 600175 (3), ; parastremmatic dwarfism, 168400 (3), ; brachyolmia type 3, 113500 (3),
CMT2D	AD	spinal muscular atrophy, infantile, james type, 619042 (3), ; neuronopathy, distal hereditary motor, type va, 600794 (3), ; charcot-marie-tooth disease, type 2d, 601472 (3),
CMT2E	AR,AD	charcot-marie-tooth disease, type 1f, 607734 (3), ; charcot-marie-tooth disease, intermediate g, 617882 (3), ; charcot-marie-tooth disease, type 2e, 607684 (3),
CMT2F	AD	neuronopathy, distal hereditary motor, type iib, 608634 (3), ; charcot-marie-tooth disease, axonal, type 2f, 606595 (3),
CMT2I	AD,AR	charcot-marie-tooth disease, type 2i, 607677 (3), ; dejerine-sottas disease, 145900 (3), ; charcot-marie-tooth disease, type 1b, 118200 (3), ; roussy-levy syndrome, 180800 (3), ; charcot-marie-tooth disease, intermediate d, 607791 (3), ; hypomyelinating neuropathy, congenital, 2, 618184 (3), ; charcot-marie-tooth disease, type 2j, 607736 (3),
CMT2J	AD,AR	charcot-marie-tooth disease, type 2i, 607677 (3), ; dejerine-sottas disease, 145900 (3), ; charcot-marie-tooth disease, type 1b, 118200 (3), ; roussy-levy syndrome, 180800 (3), ; charcot-marie-tooth disease, intermediate d, 607791 (3), ; hypomyelinating neuropathy, congenital, 2, 618184 (3), ; charcot-marie-tooth disease, type 2j, 607736 (3),
CMT2K	AR,AD	charcot-marie-tooth disease, axonal, with vocal cord paresis, 607706 (3), ; charcot-marie-tooth disease, intermediate, a, 608340 (3), ; charcot-marie-tooth disease, axonal, type 2k, 607831 (3), ; charcot-marie-tooth disease, type 4a, 214400 (3),
CMT2L	AD	neuronopathy, distal hereditary motor, type iia, 158590 (3), ; charcot-marie-tooth disease, axonal, type 2l, 608673 (3),
CMT2M	AD,AR	centronuclear myopathy 1, 160150 (3), ; charcot-marie-tooth disease, axonal type 2m, 606482 (3), ; charcot-marie-tooth disease, intermediate b, 606482 (3), ; lethal congenital contracture syndrome 5, 615368 (3),
CMT2N	AR,AD	developmental and epileptic encephalopathy 29, 616339 (3), ; charcot-marie-tooth disease, axonal, type 2n, 613287 (3), ; ?leukoencephalopathy, hereditary diffuse, with spheroids 2, 619661 (3), ; trichothiodystrophy 8, nonphotosensitive, 619691 (3),
CMT2O	AD	charcot-marie-tooth disease, axonal, type 2o, 614228 (3), ; spinal muscular atrophy, lower extremity-pre 1, ad, 158600 (3), ; cortical dysplasia, complex, with other brain malformations 13, 614563 (3),
CMT2P	AR,AD	charcot-marie-tooth disease, axonal, type 2p, 614436 (3),
CMT2Q	AD,AR	?charcot-marie-tooth disease, axonal, type 2q, 615025 (3), ; alpha-aminoadipic and alpha-ketoadipic aciduria, 204750 (3),
CMT2R	AR	charcot-marie-tooth disease, type 2r, 615490 (3),
CMT2S	AR	neuronopathy, distal hereditary motor, type vi, 604320 (3), ; charcot-marie-tooth disease, axonal, type 2s, 616155 (3),
CMT2T	AR	spinal muscular atrophy, distal, 5, 614881 (3),
CMT2U	AR,AD	spastic paraplegia 70, 620323 (3), ; interstitial lung and liver disease, 615486 (3), ; ?trichothiodystrophy 9, nonphotosensitive, 619692 (3), ; charcot-marie-tooth disease, axonal, type 2u, 616280 (3),
CMT4	AR,AD	charcot-marie-tooth disease, axonal, with vocal cord paresis, 607706 (3), ; charcot-marie-tooth disease, intermediate, a, 608340 (3), ; charcot-marie-tooth disease, axonal, type 2k, 607831 (3), ; charcot-marie-tooth disease, type 4a, 214400 (3),
CMT4A	AR,AD	charcot-marie-tooth disease, axonal, with vocal cord paresis, 607706 (3), ; charcot-marie-tooth disease, intermediate, a, 608340 (3), ; charcot-marie-tooth disease, axonal, type 2k, 607831 (3), ; charcot-marie-tooth disease, type 4a, 214400 (3),
CMT4B	AR	charcot-marie-tooth disease, type 4b1, 601382 (3),
CMT4B2	AR	charcot-marie-tooth disease, type 4b2, 604563 (3),
CMT4C	AR,AD	charcot-marie-tooth disease, type 4c, 601596 (3), ; mononeuropathy of the median nerve, mild, 613353 (3),
CMT4H	AR	charcot-marie-tooth disease, type 4h, 609311 (3),
CMT4J	AR,AD	yunis-varon syndrome, 216340 (3), ; ?polymicrogyria, bilateral temporooccipital, 612691 (3), ; amyotrophic lateral sclerosis 11, 612577 (3), ; charcot-marie-tooth disease, type 4j, 611228 (3),
CMTDI1	AD,AR	centronuclear myopathy 1, 160150 (3), ; charcot-marie-tooth disease, axonal type 2m, 606482 (3), ; charcot-marie-tooth disease, intermediate b, 606482 (3), ; lethal congenital contracture syndrome 5, 615368 (3),
CMTDIB	AD,AR	centronuclear myopathy 1, 160150 (3), ; charcot-marie-tooth disease, axonal type 2m, 606482 (3), ; charcot-marie-tooth disease, intermediate b, 606482 (3), ; lethal congenital contracture syndrome 5, 615368 (3),
CMTM1		
CMTM2		
CMTM3		
CMTM4		
CMTM5		
CMTM6		
CMTM7		
CMTM8		
CMTR1		
CMTR2		
CMTX	XLD,XL	charcot-marie-tooth neuropathy, 1, 302800 (3),
CMTX1	XLD,XL	charcot-marie-tooth neuropathy, 1, 302800 (3),
CMTX4	XLR,XL	combined oxidative phosphorylation deficiency 6, 300816 (3), ; cowchock syndrome, 310490 (3), ; spondyloepimetaphyseal dysplasia, with hypomyelinating leukodystrophy, 300232 (3), ; deafness, 5, 300614 (3),
CMTX5	XLR,XL	arts syndrome, 301835 (3), ; phosphoribosylpyrophosphate synthetase superactivity, 300661 (3), ; charcot-marie-tooth disease, 5, 311070 (3), ; deafness, 1, 304500 (3), ; gout, prps-related, 300661 (3),
CMYA1		
CMYA2		
CMYA3		
CMYA4	AD,AR	?cataract 43, 616279 (3), ; myofibrillar myopathy 11, 619178 (3),
CMYA5		
cMyBP-C	AR,AD	cardiomyopathy, hypertrophic, 4, 115197 (3), ; cardiomyopathy, dilated, 1mm, 615396 (3), ; left ventricular noncompaction 10, 615396 (3),
CN-I		
CN-IA		
CN-IB		
cN-II	AR	spastic paraplegia 45, 613162 (3),
cN-III	AR	anemia, hemolytic, due to umph1 deficiency, 266120 (3),
cN-IIIB		
CN1		
CN1A		
CN2		
CNA1	AD	arthrogryposis, cleft palate, craniosynostosis, and impaired intellectual development, 618265 (3), ; developmental and epileptic encephalopathy 91, 617711 (3),
CNA2	AR	cornea plana 2, 217300 (3),
CNA43	AR	immunodeficiency 80 with or without cardiomyopathy, 619313 (3),
CNAIP		
CNALPTC1		
CNAP1	AR	?microcephaly 21, primary, 617983 (3),
CNB		
CNB1		
CNBP	AD	myotonic dystrophy 2, 602668 (3),
CNBP1	AD	myotonic dystrophy 2, 602668 (3),
CNC1	AD	pigmented nodular adrenocortical disease, primary, 1, 610489 (3), ; acrodysostosis 1, with or without hormone resistance, 101800 (3), ; adrenocortical tumor, somatic (3); carney complex, type 1, 160980 (3), ; myxoma, intracardiac, 255960 (3),
CNCA		
CNCA1		
CNCA2		
CNCG	AR	retinitis pigmentosa 49, 613756 (3),
CNCG1	AR	retinitis pigmentosa 49, 613756 (3),
CNCG2	AR	retinitis pigmentosa 45, 613767 (3),
CNCG3	AR	achromatopsia 2, 216900 (3),
CNCG3L	AR	retinitis pigmentosa 45, 613767 (3),
CNDP1		
CNDP2		
CNEP1R1		
CNF	AR	nephrotic syndrome, type 1, 256300 (3),
CNFN		
CNG1	AR	retinitis pigmentosa 49, 613756 (3),
CNG2		
CNG3	AR	achromatopsia 2, 216900 (3),
CNG5		
CNGA1	AR	retinitis pigmentosa 49, 613756 (3),
CNGA2		
CNGA3	AR	achromatopsia 2, 216900 (3),
CNGA4		
CNGB1	AR	retinitis pigmentosa 45, 613767 (3),
CNGB1B	AR	retinitis pigmentosa 45, 613767 (3),
CNGB2		
CNGB3	AR	achromatopsia 3, 262300 (3),
CNIH		
CNIH-2		
CNIH1		
CNIH2		
CNIH4		
Cnil		
CNIL		
CNK		
CNK1		
CNK2	XL	intellectual developmental disorder, syndromic, houge type, 301008 (3),
CNKSR1		
CNKSR2	XL	intellectual developmental disorder, syndromic, houge type, 301008 (3),
CNKSR3		
CNMD		
CNN1		
CNN2		
CNN3		
CNNM1		
CNNM2	AD,AR	hypomagnesemia 6, renal, 613882 (3), ; hypomagnesemia, seizures, and impaired intellectual development 1, 616418 (3),
CNNM3		
CNNM4	AR	jalili syndrome, 217080 (3),
CNO		
CNOL		
CNOT1	AD	vissers-bodmer syndrome, 619033 (3), ; holoprosencephaly 12, with or without pancreatic agenesis, 618500 (3),
CNOT2	AD	intellectual developmental disorder with nasal speech, dysmorphic facies, and variable skeletal anomalies, 618608 (3),
CNOT2-DT		
CNOT3	AD	intellectual developmental disorder with speech delay, autism, and dysmorphic facies, 618672 (3),
CNOT4		
CNOT6		
CNOT6L		
CNOT7		
CNOT8		
CNOT9		
CNOX		
CNP	AR	?leukodystrophy, hypomyelinating, 20, 619071 (3),
CNPY1		
CNPY2		
CNPY3	AR	developmental and epileptic encephalopathy 60, 617929 (3),
CNPY4		
CNR		
CNR1		
CNR2		
CNR4		
CNR5		
CNR6		
CNR7		
CNR8		
CNRIP1		
CNRN1		
CNRN5		
CNRN6		
CNRN7		
CNRN8		
CNRS2		
CNRS4		
CNRS5		
CNRS6		
CNRS7		
CNRS8		
CNS1		
CNSA1	AD	leukemia, acute myeloid, 601626 (1), somatic mutation,
CNSA2		
CNSA3		
CNST		
CNT-B2		
CNT1	AR	[uridine-cytidineuria], 618477 (3),
CNT2		
CNT3		
CNTD		
CNTD1		
CNTD2		
CNTF		
CNTFR		
CNTLN		
CNTN1	AR	?congenital myopathy 12, 612540 (3),
CNTN2	AR	?epilepsy, myoclonic, familial adult, 5, 615400 (3),
CNTN3		
CNTN4		
CNTN5		
CNTN6		
CNTNAP	AR	lethal congenital contracture syndrome 7, 616286 (3), ; hypomyelinating neuropathy, congenital, 3, 618186 (3),
CNTNAP1	AR	lethal congenital contracture syndrome 7, 616286 (3), ; hypomyelinating neuropathy, congenital, 3, 618186 (3),
CNTNAP2	AR	pitt-hopkins like syndrome 1, 610042 (3), ; {autism susceptibility 15}, 612100 (3)
CNTNAP3		
CNTNAP3A		
CNTNAP4		
CNTNAP5		
CNTRL		
CNTROB		
CNX		
CO		[aquaporin-1 deficiency], 110450 (3); [blood group, colton], 110450 (3)
CO-029		
CO11A1	AR,AD	fibrochondrogenesis 1, 228520 (3), ; stickler syndrome, type ii, 604841 (3), ; marshall syndrome, 154780 (3), ; deafness, 37, 618533 (3), ; {lumbar disc herniation, susceptibility to}, 603932 (3)
CO4	AR	[blood group, rodgers], 614374 (3); c4a deficiency, 614380 (3), |c4b deficiency, 614379 (3)
CO9		
COA1		
COA3	AR	?mitochondrial complex iv deficiency, nuclear type 14, 619058 (3),
COA4		
COA5	AR	?mitochondrial complex iv, deficiency, nuclear type 9, 616500 (3),
COA6	AR	mitochondrial complex iv deficiency, nuclear type 13, 616501 (3),
COA7	AR	spinocerebellar ataxia, with axonal neuropathy 3, 618387 (3),
COA8	AR	mitochondrial complex iv deficiency, nuclear type 17, 619061 (3),
COAA		
COAS1		
COAS3		
COASTER		
COASY	AR	pontocerebellar hypoplasia, type 12, 618266 (3), ; neurodegeneration with brain iron accumulation 6, 615643 (3),
COBL		
COBLL1		
COBRA1		
COCA1	AD,AR	lynch syndrome 1, 120435 (3), ; muir-torre syndrome, 158320 (3), ; mismatch repair cancer syndrome 2, 619096 (3),
COCA2	AD,AR	lynch syndrome 2, 609310 (3); muir-torre syndrome, 158320 (3), ; mismatch repair cancer syndrome 1, 276300 (3),
COCH	AD,AR	deafness, 9, 601369 (3), ; ?deafness, 110, 618094 (3),
COCH-5B2	AD,AR	deafness, 9, 601369 (3), ; ?deafness, 110, 618094 (3),
Coco		
COD	AD	cerebrocostomandibular syndrome, 117650 (3),
COD1	AR,AD,XL,XLR	congenital disorder of glycosylation, type iij, 613489 (3), ; saul-wilson syndrome, 618150 (3), |retinitis pigmentosa, and sinorespiratory infections, with or without deafness, 300455 (3), ; cone-rod dystrophy, 1, 304020 (3), ; retinitis pigmentosa 3, 300029 (3), ; macular degeneration, atrophic, 300834 (3),
COD2	AR	shaheen syndrome, 615328 (3), ; congenital disorder of glycosylation, type iil, 614576 (3),
COD3	AD	cone-rod dystrophy 14, 602093 (3), ; cone dystrophy-3, 602093 (3),
COD4	AR	cone dystrophy 4, 613093 (3),
COD5	XLR,XL,XL,XLR	blue cone monochromacy, 303700 (3), ; colorblindness, protan, 303900 (3), |colorblindness, deutan, 303800 (3), ; blue cone monochromacy, 303700 (3),
COE1		
COE2		
COE3	AD	hypotonia, ataxia, and delayed development syndrome, 617330 (3),
COE4		
COG1	AR	congenital disorder of glycosylation, type iig, 611209 (3),
COG2	AR	?congenital disorder of glycosylation, type iiq, 617395 (3),
COG3		
COG4	AR,AD	congenital disorder of glycosylation, type iij, 613489 (3), ; saul-wilson syndrome, 618150 (3),
COG5	AR	congenital disorder of glycosylation, type iii, 613612 (3),
COG6	AR	shaheen syndrome, 615328 (3), ; congenital disorder of glycosylation, type iil, 614576 (3),
COG7	AR	congenital disorder of glycosylation, type iie, 608779 (3),
COG8		congenital disorder of glycosylation, type iih, 611182 (3)
COH1	AR	cohen syndrome, 216550 (3),
COIL		
COL10A1	AD	metaphyseal chondrodysplasia, schmid type, 156500 (3),
COL11A1	AR,AD	fibrochondrogenesis 1, 228520 (3), ; stickler syndrome, type ii, 604841 (3), ; marshall syndrome, 154780 (3), ; deafness, 37, 618533 (3), ; {lumbar disc herniation, susceptibility to}, 603932 (3)
COL11A2	AD,AR	deafness, 13, 601868 (3), ; otospondylomegaepiphyseal dysplasia, 215150 (3), ; fibrochondrogenesis 2, 614524 (3), ; deafness, 53, 609706 (3), ; otospondylomegaepiphyseal dysplasia, 184840 (3),
COL12A1	AD,AR	bethlem myopathy 2, 616471 (3), ; ?ullrich congenital muscular dystrophy 2, 616470 (3),
COL12A1L	AD,AR	bethlem myopathy 2, 616471 (3), ; ?ullrich congenital muscular dystrophy 2, 616470 (3),
COL13A1	AR	myasthenic syndrome, congenital, 19, 616720 (3),
COL14A1		
COL15A1		
COL16A1		
COL17A1	AD,AR	epithelial recurrent erosion dystrophy, 122400 (3), ; epidermolysis bullosa, junctional 4, intermediate, 619787 (3),
COL18A1	AR,AD	knobloch syndrome, type 1, 267750 (3), ; glaucoma, primary closed-angle, 618880 (3),
COL19A1		
COL1A1	AD	osteogenesis imperfecta, type ii, 166210 (3), ; caffey disease, 114000 (3), ; ehlers-danlos syndrome, arthrochalasia type, 1, 130060 (3), ; osteogenesis imperfecta, type i, 166200 (3), ; {bone mineral density variation qtl, osteoporosis}, 166710 (3), ; combined osteogenesis imperfecta and ehlers-danlos syndrome 1, 619115 (3), ; osteogenesis imperfecta, type iv, 166220 (3), ; osteogenesis imperfecta, type iii, 259420 (3),
COL1A2	AD,AR	osteogenesis imperfecta, type iii, 259420 (3), ; {osteoporosis, postmenopausal}, 166710 (3), ; ehlers-danlos syndrome, arthrochalasia type, 2, 617821 (3), ; combined osteogenesis imperfecta and ehlers-danlos syndrome 2, 619120 (3), ; ehlers-danlos syndrome, cardiac valvular type, 225320 (3), ; osteogenesis imperfecta, type iv, 166220 (3), ; osteogenesis imperfecta, type ii, 166210 (3),
COL1AR		
COL20A1		
COL21A1		
COL22A1		
COL23A1		
COL24A1		
COL25A1	AR	fibrosis of extraocular muscles, congenital, 5, 616219 (3),
COL26A1		
COL27A1	AR	steel syndrome, 615155 (3),
COL28A1		
COL29A1		
COL2A1	AD	?vitreoretinopathy with phalangeal epiphyseal dysplasia, 619248 (3), ; czech dysplasia, 609162 (3), ; achondrogenesis, type ii or hypochondrogenesis, 200610 (3), ; spondyloperipheral dysplasia, 271700 (3), ; smed strudwick type, 184250 (3), ; ?epiphyseal dysplasia, multiple, with myopia and deafness, 132450 (3), ; sed congenita, 183900 (3), ; kniest dysplasia, 156550 (3), ; stickler syndrome, type i, nonsyndromic ocular, 609508 (3), ; osteoarthritis with mild chondrodysplasia, 604864 (3), ; stickler syndrome, type i, 108300 (3), ; platyspondylic skeletal dysplasia, torrance type, 151210 (3), ; spondyloepiphyseal dysplasia, stanescu type, 616583 (3), ; avascular necrosis of the femoral head, 608805 (3), ; legg-calve-perthes disease, 150600 (3),
COL3A1	AD,AR	ehlers-danlos syndrome, vascular type, 130050 (3), ; polymicrogyria with or without vascular-type eds, 618343 (3),
COL4A1	AD	?retinal arteries, tortuosity of, 180000 (3), ; {hemorrhage, intracerebral, susceptibility to}, 614519 (3); angiopathy, hereditary, with nephropathy, aneurysms, and muscle cramps, 611773 (3), ; microangiopathy and leukoencephalopathy, pontine, 618564 (3), ; brain small vessel disease with or without ocular anomalies, 175780 (3),
COL4A2	AD	brain small vessel disease 2, 614483 (3), ; {hemorrhage, intracerebral, susceptibility to}, 614519 (3)
COL4A3	AD,AR	hematuria, benign familial, 2, 620320 (3); alport syndrome 3, 104200 (3), ; alport syndrome 2, 203780 (3),
COL4A3BP	AD	intellectual developmental disorder, 34, 616351 (3),
COL4A4	AD,AR	hematuria, familial benign, 1, 141200 (3), ; alport syndrome 2, 203780 (3),
COL4A5	XL,XLD	alport syndrome 1, 301050 (3),
COL4A6	XL,XLR	?deafness, 6, 300914 (3),
COL5A1	AD	ehlers-danlos syndrome, classic type, 1, 130000 (3), ; fibromuscular dysplasia, multifocal, 619329 (3),
COL5A2	AD	ehlers-danlos syndrome, classic type, 2, 130010 (3),
COL5A3		
COL6A1	AR,AD	bethlem myopathy 1, 158810 (3), ; ullrich congenital muscular dystrophy 1, 254090 (3),
COL6A2	AR,AD	bethlem myopathy 1, 158810 (3), ; ?myosclerosis, congenital, 255600 (3), ; ullrich congenital muscular dystrophy 1, 254090 (3),
COL6A3	AR,AD	ullrich congenital muscular dystrophy 1, 254090 (3), ; dystonia 27, 616411 (3), ; bethlem myopathy 1, 158810 (3),
COL6A4		
COL6A4P		
COL6A4P1		
COL6A4P2		
COL6A5		
COL6A6		
COL7A1	AD,AR	nail disorder, nonsyndromic congenital, 8, 607523 (3), ; epidermolysis bullosa dystrophica, bart type, 132000 (3), ; epidermolysis bullosa dystrophica inversa, 226600 (3), ; epidermolysis bullosa dystrophica, 226600 (3), ; epidermolysis bullosa, pretibial, 131850 (3), ; epidermolysis bullosa dystrophica, 131750 (3), ; transient bullous of the newborn, 131705 (3), ; epidermolysis bullosa pruriginosa, 604129 (3), ; epidermolysis bullosa dystrophica, localisata variant, 226600 (3),
COL8A1		
COL8A2	AD	corneal dystrophy, posterior polymorphous 2, 609140 (3), ; corneal dystrophy, fuchs endothelial, 1, 136800 (3),
COL9A1	AD	stickler syndrome, type iv, 614134 (3); ?epiphyseal dysplasia, multiple, 6, 614135 (3),
COL9A2	AD,AR	epiphyseal dysplasia, multiple, 2, 600204 (3), ; ?stickler syndrome, type v, 614284 (3),
COL9A3	AD,AR	{intervertebral disc disease, susceptibility to}, 603932 (3); epiphyseal dysplasia, multiple, 3, with or without myopathy, 600969 (3), ; stickler syndrome, type vi, 620022 (3),
COLCA1		
COLCA2		
COLEC1	AD	{chronic infections, due to mbl deficiency}, 614372 (3),
COLEC10	AR	3mc syndrome 3, 248340 (3),
COLEC11	AR	3mc syndrome 2, 265050 (3),
COLEC12		
COLEC4	AR,AD	interstitial lung disease 1, 619611 (3),
COLEC5	AD	interstitial lung disease 2, 178500 (3),
COLEC7		
COLGALT1	AR	brain small vessel disease 3, 618360 (3),
COLGALT2		
coll-1	AD	{hypogonadotropic hypogonadism 16 with or without anosmia}, 614897 (3),
coll-2		
coll-4		
coll-5		
COLL6	AR,AD	fibrochondrogenesis 1, 228520 (3), ; stickler syndrome, type ii, 604841 (3), ; marshall syndrome, 154780 (3), ; deafness, 37, 618533 (3), ; {lumbar disc herniation, susceptibility to}, 603932 (3)
COLM	AR	lethal congenital contracture syndrome 11, 617194 (3),
colmedin	AR	lethal congenital contracture syndrome 11, 617194 (3),
COLQ	AR	myasthenic syndrome, congenital, 5, 603034 (3),
COM1	AR	seckel syndrome 2, 606744 (3), ; jawad syndrome, 251255 (3), ; pancreatic carcinoma, somatic (3)
COMMD1		
COMMD10		
COMMD2		
COMMD3		
COMMD4		
COMMD5		
COMMD6		
COMMD7		
COMMD8		
COMMD9		
COMP	AD	pseudoachondroplasia, 177170 (3), ; carpal tunnel syndrome 2, 619161 (3), ; epiphyseal dysplasia, multiple, 1, 132400 (3),
COMT	AD	{schizophrenia, susceptibility to}, 181500 (3), ; {panic disorder, susceptibility to}, 167870 (3), ?
COMT2	AR	deafness, 63, 611451 (3),
Contrin		
Cool-2		
COOL1		
Cool2		
COP		
COP1		
COP9		
COPA	AD	{autoimmune interstitial lung, joint, and kidney disease}, 616414 (3),
COPB	AR	baralle-macken syndrome, 619255 (3),
COPB1	AR	baralle-macken syndrome, 619255 (3),
COPB2	AD,AR	osteoporosis, childhood- or juvenile-onset, with developmental delay, 619884 (3), ; ?microcephaly 19, primary, 617800 (3),
COPD	AD	short stature-micrognathia syndrome, 617164 (3),
COPE		
COPEB		gastric cancer, somatic, 613659 (3); prostate cancer, somatic, 176807 (3)
COPG		
COPG1		
COPG2		
COPG2AS		
COPG2IT1		
COPN4		
COPN5		
COPR1		
COPR2		
COPS1		
COPS2		
COPS3		
COPS4		
COPS5		
COPS6		
COPS7A		
COPS7B		
COPS8		
COPS9		
COPT1	AR	neurodegeneration and seizures due to copper transport defect, 620306 (3),
COPT2		
COPZ		
COPZ1		
COPZ2		
COQ1	AR	coenzyme q10 deficiency, primary, 2, 614651 (3),
COQ11	AR	mitochondrial complex i deficiency, nuclear type 26, 618247 (3),
COQ1A	AR	coenzyme q10 deficiency, primary, 2, 614651 (3),
COQ1B	AR	coenzyme q10 deficiency, primary, 3, 614652 (3),
COQ2	AR,AD	{multiple system atrophy, susceptibility to}, 146500 (3), ; coenzyme q10 deficiency, primary, 1, 607426 (3),
COQ3		
COQ4	AR	coenzyme q10 deficiency, primary, 7, 616276 (3),
COQ5	AR	?coenzyme q10 deficiency, primary, 9, 619028 (3),
COQ6	AR	coenzyme q10 deficiency, primary, 6, 614650 (3),
COQ7	AR	?coenzyme q10 deficiency, primary, 8, 616733 (3),
COQ8	AR,AR	coenzyme q10 deficiency, primary, 4, 612016 (3), |nephrotic syndrome, type 9, 615573 (3),
COQ8A	AR	coenzyme q10 deficiency, primary, 4, 612016 (3),
COQ8B	AR	nephrotic syndrome, type 9, 615573 (3),
COQ9	AR	coenzyme q10 deficiency, primary, 5, 614654 (3),
Corcs		
CORD10	AR	retinitis pigmentosa 35, 610282 (3), ; cone-rod dystrophy 10, 610283 (3),
CORD11	AR,AD	retinitis pigmentosa 95, 620102 (3), ; cone-rod dystrophy 11, 610381 (3), ; ?macular degeneration, age-related, 6, 613757 (3)
CORD12	AD,AR	macular dystrophy, retinal, 2, 608051 (3), ; retinitis pigmentosa 41, 612095 (3), ; stargardt disease 4, 603786 (3), ; cone-rod dystrophy 12, 612657 (3),
CORD13	AR	cone-rod dystrophy 13, 608194 (3), ; leber congenital amaurosis 6, 613826 (3),
CORD14	AD	cone-rod dystrophy 14, 602093 (3), ; cone dystrophy-3, 602093 (3),
CORD15	AR	macular dystrophy, retinal, 613660 (3), ; cone-rod dystrophy 15, 613660 (3), ; retinitis pigmentosa 65, 613660 (3),
CORD16	AR	retinitis pigmentosa 64, 614500 (3), ; cone-rod dystrophy 16, 614500 (3), ; bardet-biedl syndrome 21, 617406 (3),
CORD2	AD	leber congenital amaurosis 7, 613829 (3); cone-rod retinal dystrophy-2, 120970 (3),
CORD3	AR,AD	retinal dystrophy, early-onset severe, 248200 (3), ; retinitis pigmentosa 19, 601718 (3), ; {macular degeneration, age-related, 2}, 153800 (3), ; cone-rod dystrophy 3, 604116 (3), ; fundus flavimaculatus, 248200 (3), ; stargardt disease 1, 248200 (3),
CORD5	AD	cone-rod dystrophy 5, 600977 (3),
CORD6	AR,AD	cone-rod dystrophy 6, 601777 (3), ; ?choroidal dystrophy, central areolar 1, 215500 (3), ; leber congenital amaurosis 1, 204000 (3), ; night blindness, congenital stationary, type 1i, 618555 (3),
CORD7	AD	cone-rod dystrophy 7, 603649 (3),
CORD9	AR	cone-rod dystrophy 9, 612775 (3),
CORDX1	XL,XLR	retinitis pigmentosa, and sinorespiratory infections, with or without deafness, 300455 (3), ; cone-rod dystrophy, 1, 304020 (3), ; retinitis pigmentosa 3, 300029 (3), ; macular degeneration, atrophic, 300834 (3),
CORDX3	XL,XLR	cone-rod dystrophy, 3, 300476 (3), ; night blindness, congenital stationary (incomplete), 2a, 300071 (3), ; aland island eye disease, 300600 (3),
COREST		
CORIN		preeclampsia/eclampsia 5, 614595 (3)
CORK1		
CORL1		
CORL2		
CORO1A	AR	immunodeficiency 8, 615401 (3),
CORO1B		
CORO1C		
CORO2A		
CORO2B		
CORO7		
coronin-1	AR	immunodeficiency 8, 615401 (3),
coronin-2		
coronin-3		
Cors		
Cors-26		
CORS1	AR	joubert syndrome 1, 213300 (3), ; mental retardation, truncal obesity, retinal dystrophy, and micropenis, 610156 (3),
CORS2	AR	joubert syndrome 2, 608091 (3), ; meckel syndrome 2, 603194 (3),
CORS3	AR	joubert syndrome 7, 611560 (3), ; meckel syndrome 5, 611561 (3), ; ?coach syndrome 3, 619113 (3),
CORT		
CORTBP1		{autism susceptibility 17}, 613436 (3)
CORTBP2		
Cos12		
Cos17		
Cos26		
Cos5		
Cos52		
Cos8		
COSMC		tn polyagglutination syndrome, somatic, 300622 (3)
COT		lung cancer, somatic, 211980 (3)
cote1		
COTL1		
COUP-TFI	AD	bosch-boonstra-schaaf optic atrophy syndrome, 615722 (3),
COUP-TFII	AD	46xx sex reversal 5, 618901 (3), ; congenital heart defects, multiple types, 4, 615779 (3),
COUPTF1	AD	bosch-boonstra-schaaf optic atrophy syndrome, 615722 (3),
COUPTF2	AD	46xx sex reversal 5, 618901 (3), ; congenital heart defects, multiple types, 4, 615779 (3),
COUPTFB	AD	46xx sex reversal 5, 618901 (3), ; congenital heart defects, multiple types, 4, 615779 (3),
COVA1		
COX	AR	?mitochondrial complex iv deficiency, nuclear type 15, 619059 (3),
COX1		
COX10	AR	mitochondrial complex iv deficiency, nuclear type 3, 619046 (3),
COX11	AR	mitochondrial complex iv deficiency, nuclear type 23, 620275 (3),
COX11P	AR	mitochondrial complex iv deficiency, nuclear type 23, 620275 (3),
COX14	AR	?mitochondrial complex iv deficiency, nuclear type 10, 619053 (3),
COX15	AR	mitochondrial complex iv deficiency, nuclear type 6, 615119 (3),
COX16	AR	mitochondrial complex iv deficiency, nuclear type 22, 619355 (3),
COX17		
COX18		
COX19		
COX2		
COX20	AR	mitochondrial complex iv deficiency, nuclear type 11, 619054 (3),
COX23		
COX25	AR	?mitochondrial complex iv deficiency, nuclear type 14, 619058 (3),
COX4	AR	mitochondrial complex iv deficiency, nuclear type 16, 619060 (3),
COX4-1	AR	mitochondrial complex iv deficiency, nuclear type 16, 619060 (3),
COX4-2	AR	exocrine pancreatic insufficiency, dyserythropoietic anemia, and calvarial hyperostosis, 612714 (3),
COX4B	AR	exocrine pancreatic insufficiency, dyserythropoietic anemia, and calvarial hyperostosis, 612714 (3),
COX4I1	AR	mitochondrial complex iv deficiency, nuclear type 16, 619060 (3),
COX4I2	AR	exocrine pancreatic insufficiency, dyserythropoietic anemia, and calvarial hyperostosis, 612714 (3),
COX4L2	AR	exocrine pancreatic insufficiency, dyserythropoietic anemia, and calvarial hyperostosis, 612714 (3),
COX4NB		
COX5A	AR	?mitochondrial complex iv deficiency, nuclear type 20, 619064 (3),
COX5B		
COX6A	AR	charcot-marie-tooth disease, intermediate d, 616039 (3),
COX6A1	AR	charcot-marie-tooth disease, intermediate d, 616039 (3),
COX6A2	AR	mitochondrial complex iv deficiency, nuclear type 18, 619062 (3),
COX6AH	AR	mitochondrial complex iv deficiency, nuclear type 18, 619062 (3),
COX6AL	AR	charcot-marie-tooth disease, intermediate d, 616039 (3),
COX6B	AR	mitochondrial complex iv deficiency, nuclear type 7, 619051 (3),
COX6B1	AR	mitochondrial complex iv deficiency, nuclear type 7, 619051 (3),
COX6B2		
COX6C		
COX7A		
COX7A1		
COX7A2		
COX7A2L		
COX7AH		
COX7AL		
COX7AR		
COX7B	XLD	linear skin defects with multiple congenital anomalies 2, 300887 (3),
COX7B2		
COX7C		
COX7RP		
COX8	AR	?mitochondrial complex iv deficiency, nuclear type 15, 619059 (3),
COX8-2	AR	?mitochondrial complex iv deficiency, nuclear type 15, 619059 (3),
COX8-3		
COX8A	AR	?mitochondrial complex iv deficiency, nuclear type 15, 619059 (3),
COX8C		
COX8L	AR	?mitochondrial complex iv deficiency, nuclear type 15, 619059 (3),
COXFA4	AR	?mitochondrial complex iv deficiency, nuclear type 21, 619065 (3),
COXFA4L3		
COXG	AR	mitochondrial complex iv deficiency, nuclear type 7, 619051 (3),
COXIV	AR	mitochondrial complex iv deficiency, nuclear type 16, 619060 (3),
COXIV-1	AR	mitochondrial complex iv deficiency, nuclear type 16, 619060 (3),
COXIV-2	AR	exocrine pancreatic insufficiency, dyserythropoietic anemia, and calvarial hyperostosis, 612714 (3),
COXPD7	AR	spastic paraplegia 55, 615035 (3), ; combined oxidative phosphorylation deficiency 7, 613559 (3),
COXVIa-M	AR	mitochondrial complex iv deficiency, nuclear type 18, 619062 (3),
COXVIAH	AR	mitochondrial complex iv deficiency, nuclear type 18, 619062 (3),
COXVIB2		
COXVIIa-L		
CP	AR	cerebellar ataxia, 604290 (3), ; [hypoceruloplasminemia, hereditary], 604290 (3), ; hemosiderosis, systemic, due to aceruloplasminemia, 604290 (3),
CP-23		
cp107		
CP11		
CP110		
CP115	AR,AD	cataract 33, multiple types, 611391 (3),
CP12		
CP1B	AR	glaucoma 3a, primary open angle, congenital, juvenile, or adult onset, 231300 (3), ; anterior segment dysgenesis 6, multiple subtypes, 617315 (3),
CP2		
CP24	AR	hypercalcemia, infantile, 1, 143880 (3),
CP26		
CP27	AR	cerebrotendinous xanthomatosis, 213700 (3),
CP35	MF	{hypertension, salt-sensitive essential, susceptibility to}, 145500 (3),
CP37		
CP47	AD	cataract 12, multiple types, 611597 (3),
CP49	AD	cataract 12, multiple types, 611597 (3),
CP51		
CP64		
cP7		
CP94	AR,AD	cataract 33, multiple types, 611391 (3),
CPA		
CPA1		
CPA2		
CPA3		
CPA4		
CPA5		
CPA6	AD,AR,AD	{lung cancer, resistance to}, 211980 (3), somatic mutation, ; coumarin resistance, 122700 (3), ; {nicotine addiction, protection from}, 188890 (3)|febrile seizures, familial, 11, 614418 (3), ; epilepsy, familial temporal lobe, 5, 614417 (3),
CPAD		
CPAH	AR,AD	febrile seizures, familial, 11, 614418 (3), ; epilepsy, familial temporal lobe, 5, 614417 (3),
CPAMD1	AR,AD	c3 deficiency, 613779 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to, 5}, 612925 (3), ; {macular degeneration, age-related, 9}, 611378 (3)
CPAMD2	AR	[blood group, rodgers], 614374 (3); c4a deficiency, 614380 (3),
CPAMD3		c4b deficiency, 614379 (3)
CPAMD4	AR,AD	c5 deficiency, 609536 (3), ; [eculizumab, poor response to], 615749 (3),
CPAMD5		
CPAMD6		
CPAMD7		
CPAMD8	AR	anterior segment dysgenesis 8, 617319 (3),
CPAMD9	AD	{otitis media, susceptibility to}, 166760 (3),
CPAN		
CPAP	AR	microcephaly 6, primary, 608393 (3), ; ?seckel syndrome 4, 613676 (3),
CPB-I	AD	{pregnancy loss, recurrent, susceptibility to, 3}, 614391 (3),
CPB1		
CPB2		
CPB6		{efavirenz central nervous system toxicity, susceptibility to}, 614546 (3); efavirenz, poor metabolism of, 614546 (3)
CPBP		gastric cancer, somatic, 613659 (3); prostate cancer, somatic, 176807 (3)
CPC8		{drug metabolism, altered, cyp2c8-related}, 618018 (3)
CPCI		
CPCJ	AR	proguanil poor metabolizer, 609535 (3), ; mephenytoin poor metabolizer, 609535 (3), ; clopidogrel, impaired responsiveness to, 609535 (3), ; omeprazole poor metabolizer, 609535 (3),
CPD	AD	?deafness, 68, 616707 (3),
CPD6	AR	{codeine sensitivity}, 608902 (3), ; {debrisoquine sensitivity}, 608902 (3),
CPE	AR	bdv syndrome, 619326 (3),
CPE-R		
CPE-R2		
CPEB		
CPEB1		
CPEB2		
CPEB3		
CPEB4		
CPETR		
CPETR1		
CPETR2		
CPETRL1		
CPETRL2		
CPETRL3	AR	helix syndrome, 617671 (3),
CPG2	AR,AD	arthrogryposis multiplex congenita 3, myogenic type, 618484 (3), ; emery-dreifuss muscular dystrophy 4, 612998 (3), ; spinocerebellar ataxia, 8, 610743 (3),
cPGES		
CPGL		
CPGL2		
CPHXL		
CPI-17		
CPI17-like		
CPL		
cPLA2	AD	neurodevelopmental disorder with dysmorphic facies, sleep disturbance, and brain abnormalities, 619103 (3),
cPLA2-alpha	AR	gastrointestinal ulceration, recurrent, with dysfunctional platelets, 618372 (3),
cPLA2-beta		
cPLA2-gamma		
cPLA2delta		
CPLANE1	AR	orofaciodigital syndrome vi, 277170 (3), ; joubert syndrome 17, 614615 (3),
CPLANE3	AD	{neural tube defects, susceptibility to}, 182940 (3),
CPLANE4	AR	?orofaciodigital syndrome xvii, 617926 (3), ; ?short-rib thoracic dysplasia 20 with polydactyly, 617925 (3),
CPLANE5	AR	?bardet-biedl syndrome 15, 615992 (3), ; congenital heart defects, hamartomas of tongue, and polysyndactyly, 217085 (3),
CPLX1	AR	developmental and epileptic encephalopathy 63, 617976 (3),
CPLX2		
CPLX3		
CPLX4		
CPM		
CPN1	AD,AR,AR	aldosteronism, glucocorticoid-remediable, 103900 (3), ; adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deficiency, 202010 (3), |carboxypeptidase n deficiency, 212070 (3),
CPN10		
CPN2	AR	hypoaldosteronism, congenital, due to cmo i deficiency, 203400 (3), ; aldosterone to renin ratio raised (3); {low renin hypertension, susceptibility to} (3); hypoaldosteronism, congenital, due to cmo ii deficiency, 610600 (3),
CPN4		
CPN5		
CPNE1		
CPNE2		
CPNE3		
CPNE4		
CPNE5		
CPNE6		
CPNE7		
CPO	AR,AD	coproporphyria, 121300 (3), ; harderoporphyria, 618892 (3),
CPOX	AR,AD	coproporphyria, 121300 (3), ; harderoporphyria, 618892 (3),
CPP32		
CPP32B		
CPPDD	AD	chondrocalcinosis 2, 118600 (3), ; craniometaphyseal dysplasia, 123000 (3),
CPPED1		
CPQ		
Cpr2		
CPR3		
CPR4	AD	?intellectual developmental disorder with hypertelorism and distinctive facies, 618147 (3),
CPR8		
cprk		
CPRP1	AR,AD	lipomatosis, multiple symmetric, with or without peripheral neuropathy, 151800 (3), ; charcot-marie-tooth disease, axonal, type 2a2a, 609260 (3), ; charcot-marie-tooth disease, axonal, type 2a2b, 617087 (3), ; hereditary motor and sensory neuropathy via, 601152 (3),
Cps1		
CPS1	AR,AR	carbamoylphosphate synthetase i deficiency, 237300 (3), ; {pulmonary hypertension, neonatal, susceptibility to}, 615371 (3)|hyperandrogenism, nonclassic type, due to 21-hydroxylase deficiency, 201910 (3), ; adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency, 201910 (3),
Cps25		
CPSB		
CPSD	AR	ceroid lipofuscinosis, neuronal, 10, 610127 (3),
CPSF-73	AR	neurodevelopmental disorder with microcephaly, hypotonia, nystagmus, and seizures, 619876 (3),
CPSF1	AD	myopia 27, 618827 (3),
CPSF100		
CPSF160	AD	myopia 27, 618827 (3),
CPSF2		
CPSF2L		
CPSF3	AR	neurodevelopmental disorder with microcephaly, hypotonia, nystagmus, and seizures, 619876 (3),
CPSF30		
CPSF3L		
CPSF4		
CPSF5		
CPSF6		
CPSF73	AR	neurodevelopmental disorder with microcephaly, hypotonia, nystagmus, and seizures, 619876 (3),
CPSF73L		
CPT1	AR,AD,AR	{encephalopathy, acute, infection-induced, 4, susceptibility to}, 614212 (3), ; cpt ii deficiency, infantile, 600649 (3), ; cpt ii deficiency, lethal neonatal, 608836 (3), ; cpt ii deficiency, myopathic, stress-induced, 255110 (3), |cpt deficiency, hepatic, type ia, 255120 (3),
CPT1-L	AR	cpt deficiency, hepatic, type ia, 255120 (3),
CPT1-M		
CPT1A	AR	cpt deficiency, hepatic, type ia, 255120 (3),
CPT1B		
CPT1C	AD	?spastic paraplegia 73, 616282 (3),
CPT1P	AD	?spastic paraplegia 73, 616282 (3),
CPT2	AR,AD	{encephalopathy, acute, infection-induced, 4, susceptibility to}, 614212 (3), ; cpt ii deficiency, infantile, 600649 (3), ; cpt ii deficiency, lethal neonatal, 608836 (3), ; cpt ii deficiency, myopathic, stress-induced, 255110 (3),
CPT7	AR	17,20-lyase deficiency, isolated, 202110 (3), ; 17-alpha-hydroxylase/17,20-lyase deficiency, 202110 (3),
CPTASE	AR,AD	{encephalopathy, acute, infection-induced, 4, susceptibility to}, 614212 (3), ; cpt ii deficiency, infantile, 600649 (3), ; cpt ii deficiency, lethal neonatal, 608836 (3), ; cpt ii deficiency, myopathic, stress-induced, 255110 (3),
CPTIC	AD	?spastic paraplegia 73, 616282 (3),
CPTP		
CPU		
CPUB1		
CPV1	AD	aromatase deficiency, 613546 (3); aromatase excess syndrome, 139300 (3),
CPVL		
CPX	XL,AR,AD,XLR,XLD,XL	cleft palate with ankyloglossia, 303400 (3), ; ?abruzzo-erickson syndrome, 302905 (3), |coproporphyria, 121300 (3), ; harderoporphyria, 618892 (3), |mend syndrome, 300960 (3), ; chondrodysplasia punctata, 302960 (3),
CPX-1		
CPX-2		
CPX-I	AR	developmental and epileptic encephalopathy 63, 617976 (3),
CPX-III		
CPX-IV		
CPX1		
CPX2		
CPXCR1		
CPXD	XLR,XLD,XL	mend syndrome, 300960 (3), ; chondrodysplasia punctata, 302960 (3),
CPXM		
CPXM1		
CPXM2		
CPZ		
CR	AR,AR,AD	[blood group cromer], 613793 (3), ; complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy, 226300 (3), |ectodermal dysplasia 11b, hypohidrotic/hair/tooth type, 614941 (3), ; ectodermal dysplasia 11a, hypohidrotic/hair/tooth type, 614940 (3),
CR-1		
CR1		[blood group, knops system], 607486 (3); {malaria, severe, resistance to}, 611162 (3)
CR16		
CR1L		
CR2	AR	{systemic lupus erythematosus, susceptibility to, 9}, 610927 (3); ?immunodeficiency, common variable, 7, 614699 (3),
CR3A		
CR53		
CR6		
CRA		
CRABP		
CRABP-I		
CRABP-II		
CRABP1		
CRABP2		
CRABPI		
CRAC1		
CRACC		
CRACC1	AD	{hydrocephalus, congenital, 5, susceptibility to}, 620241 (3),
CRACC2	AD	coffin-siris syndrome 8, 618362 (3),
CRACD		
CRACD1	AD	coffin-siris syndrome 11, 618779 (3),
CRACD2	AR	specific granule deficiency 2, 617475 (3),
CRACD3		
CRACM1	AR,AD	immunodeficiency 9, 612782 (3), ; myopathy, tubular aggregate, 2, 615883 (3),
CRACR2A		
CRACR2B		
CRAD		
CRADD	AR	intellectual developmental disorder, 34, with variant lissencephaly, 614499 (3),
CRAF	AD	cardiomyopathy, dilated, 1nn, 615916 (3), ; noonan syndrome 5, 611553 (3), ; leopard syndrome 2, 611554 (3)
CRAF1	AD	{?encephalopathy, acute, infection-induced (herpes-specific), susceptibility to, 5}, 614849 (3),
CRALBP	AR,AD	bothnia retinal dystrophy, 607475 (3), ; newfoundland rod-cone dystrophy, 607476 (3); retinitis punctata albescens, 136880 (3), ; fundus albipunctatus, 136880 (3),
CRALBPL		
CRAM	AD	ritscher-schinzel syndrome 4, 619435 (3),
CRAM-A		
CRAM-B		
CRAPB	AD	chorioretinal atrophy, progressive bifocal, 600790 (3), ; macular dystrophy 1, north carolina type, 136550 (3),
CRARF	AR	3mc syndrome 1, 257920 (3),
CRAT	AR	?neurodegeneration with brain iron accumulation 8, 617917 (3),
CRB1	AR,AD	leber congenital amaurosis 8, 613835 (3), ; retinitis pigmentosa-12, 600105 (3), ; pigmented paravenous chorioretinal atrophy, 172870 (3),
CRB2	AR	focal segmental glomerulosclerosis 9, 616220 (3), ; ventriculomegaly with cystic kidney disease, 219730 (3),
CRB3		
CRBM	AD	cherubism, 118400 (3),
CRBN	AR	intellectual developmental disorder, 2, 607417 (3),
CRBP		
CRBP-I		
CRBP-III		
CRBP1		
CRBP2		
CRBP3		
CRBPI		
CRBPII		
CRBPIII		
CRBPIV		
CRCP		
CRCT1		
CRD	AD,XL,XLR	leber congenital amaurosis 7, 613829 (3); cone-rod retinal dystrophy-2, 120970 (3), |retinitis pigmentosa, and sinorespiratory infections, with or without deafness, 300455 (3), ; cone-rod dystrophy, 1, 304020 (3), ; retinitis pigmentosa 3, 300029 (3), ; macular degeneration, atrophic, 300834 (3),
CRE-BP1		
CRE-BPA		
Cream1		
CREAP-1		
CREB-2		
CREB-H	AD	hypertriglyceridemia 2, 619324 (3),
CREB1		histiocytoma, angiomatoid fibrous, somatic, 612160 (3)
CREB2		
CREB3		
CREB3L1	AR	osteogenesis imperfecta, type xvi, 616229 (3),
CREB3L2		
CREB3L3	AD	hypertriglyceridemia 2, 619324 (3),
CREB3L4		
CREB4		
CREB5		
CREBBP	AD	menke-hennekam syndrome 1, 618332 (3), ; rubinstein-taybi syndrome 1, 180849 (3),
CREBH	AD	hypertriglyceridemia 2, 619324 (3),
CREBL1		
CREBL2		
CREBRF		
CREBZF		
CREF		
CREG		
CREG1		
CREG2		
CRELD1	AD	atrioventricular septal defect, partial, with heterotaxy syndrome, 606217 (3), ; {atrioventricular septal defect, susceptibility to, 2}, 606217 (3),
CRELD2		
CREM		
CREME9		
CREPT		
CRES		
crescerin	AR	joubert syndrome 37, 619185 (3),
Crescerin-1	AR	joubert syndrome 37, 619185 (3),
CREST		
CRF		
CRF-BP		
CRF-R		
CRF-RB		
CRF1		
CRF2		
CRF2-4	AR	{hepatitis b virus, susceptibility to}, 610424 (3); inflammatory bowel disease 25, early onset, 612567 (3),
CRF2-9		
CRF2-S1		
CRF2/12		
CRF21		
CRFB4	AR	{hepatitis b virus, susceptibility to}, 610424 (3); inflammatory bowel disease 25, early onset, 612567 (3),
CRFBP		
CRFG		
CRG	AD	hypogonadotropic hypogonadism 5 with or without anosmia, 612370 (3), ; charge syndrome, 214800 (3),
crg-10		
crg-2		
CRG-L2	AR	lethal congenital contracture syndrome 11, 617194 (3),
CrGAP		
CRH		
CRH1		
CRHBP		
CRHR		
CRHR1		
CRHR2		
CRHSP-24		
CRI1		
CRI2		
CRIF1		
CRIg		
CRIK	AR	microcephaly 17, primary, 617090 (3),
CRIM1		
CRIM2		
CRIM3	AR	diaphanospondylodysostosis, 608022 (3),
CRIP		
CRIP1		
CRIP1a		
CRIP1b		
CRIP2		
CRIPAK		
CRIPT	AR	short stature with microcephaly and distinctive facies, 615789 (3),
CRIPTO		
Cripto-1		
CRISP-1		
CRISP-2		
CRISP-3		
CRISP1		
CRISP2		
CRISP3		
CRISPLD2		
CRK		
CRK7		
Crkas		
CRKL		
CRKR		
CRKRS		
CRL	AD	?amyloidosis, primary localized cutaneous, 2, 613955 (3),
CRL1		
CRL2		
CRL3	AD	?amyloidosis, primary localized cutaneous, 2, 613955 (3),
CRL4		
CRLF1	AR	cold-induced sweating syndrome 1, 272430 (3),
CRLF2		
CRLF3		
CRLR	AR	?lymphatic malformation 8, 618773 (3),
CRLS1	AR	combined oxidative phosphorylation deficiency 57, 620167 (3),
CRLZ1		
CRM-1		
CRM1		
crml-1		
CRMP-5	AD	ritscher-schinzel syndrome 4, 619435 (3),
CRMP1		
CRMP2		
CRMP3		
CRMP4		
CRMP5	AD	ritscher-schinzel syndrome 4, 619435 (3),
CRN		preeclampsia/eclampsia 5, 614595 (3)
CRNDE		
CRNDEP		
CRNKL1		
CRNN		
CRNR1		
CRNR2		
CRNR4		
CRNR5		
CRNR6		
CRNR7		
CRNR8		
CROC-1		
CROC1		
CROC4		
CROCC		
CROCC1		
CROM	AR	[blood group cromer], 613793 (3), ; complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy, 226300 (3),
CROP		
CROT		
CRP		
CRP1	AR,AD	?immunodeficiency 108 with autoinflammation, 260570 (3), ; specific granule deficiency, 245480 (3),
CRP2		
CRP2BP		
CRP3		
CRPPA	AR	muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 7, 616052 (3), ; muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 7, 614643 (3),
CRR9		
CRRL		
CRS	AD	craniosynostosis 1, 123100 (3), ; robinow-sorauf syndrome, 180750 (3), ; sweeney-cox syndrome, 617746 (3), ; saethre-chotzen syndrome with or without eyelid anomalies, 101400 (3),
CRS1	AD	craniosynostosis 1, 123100 (3), ; robinow-sorauf syndrome, 180750 (3), ; sweeney-cox syndrome, 617746 (3), ; saethre-chotzen syndrome with or without eyelid anomalies, 101400 (3),
CRS2	AD	parietal foramina with cleidocranial dysplasia, 168550 (3), ; craniosynostosis 2, 604757 (3), ; parietal foramina 1, 168500 (3),
CRS3		
CRSP1		
CRSP100		
CRSP130	AR	intellectual developmental disorder, 18, with or without epilepsy, 614249 (3),
CRSP150		
CRSP2		
CRSP200		
CRSP3	AR	intellectual developmental disorder, 18, with or without epilepsy, 614249 (3),
CRSP33		
CRSP34	AR	neurodevelopmental disorder with spasticity, cataracts, and cerebellar hypoplasia, 619286 (3),
CRSP4		
CRSP6	AR	microcephaly, postnatal progressive, with seizures and brain atrophy, 613668 (3),
CRSP7		
CRSP70		
CRSP77	AR	microcephaly, postnatal progressive, with seizures and brain atrophy, 613668 (3),
CRSP8	AR	neurodevelopmental disorder with spasticity, cataracts, and cerebellar hypoplasia, 619286 (3),
CRSP9		
CRT	XLR,XL	cerebral creatine deficiency syndrome 1, 300352 (3), |myelofibrosis, somatic, 254450 (3); thrombocythemia, somatic, 187950 (3)
CRT-1	XLR,XL	cerebral creatine deficiency syndrome 1, 300352 (3),
CRT1	XLR,XL	cerebral creatine deficiency syndrome 1, 300352 (3),
CRT2	AD	cataract 47, juvenile, with microcornea, 612018 (3),
CRTAC1		
CRTAM		
CRTAP	AR	osteogenesis imperfecta, type vii, 610682 (3),
CRTC1		mucoepidermoid salivary gland carcinoma (3)
CRTC2		
CRTC3		
CRTH2		
CRTL1		
CRTM		
CRTR	XLR,XL	cerebral creatine deficiency syndrome 1, 300352 (3),
CRTR1		
CRX	AD	leber congenital amaurosis 7, 613829 (3); cone-rod retinal dystrophy-2, 120970 (3),
CRY-g-A		
CRY1	AD	{delayed sleep phase disorder, susceptibility to}, 614163 (3),
CRY2		
CRYA1	AR,AD	cataract 9, multiple types, 604219 (3),
CRYA2	AR,AD	myopathy, myofibrillar, fatal infantile hypertonic, alpha-b crystallin-related, 613869 (3), ; myopathy, myofibrillar, 2, 608810 (3), ; cataract 16, multiple types, 613763 (3), ; cardiomyopathy, dilated, 1ii, 615184 (3),
CRYAA	AR,AD	cataract 9, multiple types, 604219 (3),
CRYAB	AR,AD	myopathy, myofibrillar, fatal infantile hypertonic, alpha-b crystallin-related, 613869 (3), ; myopathy, myofibrillar, 2, 608810 (3), ; cataract 16, multiple types, 613763 (3), ; cardiomyopathy, dilated, 1ii, 615184 (3),
CRYB1	AD	cataract 10, multiple types, 600881 (3),
CRYB2	AD	cataract 3, multiple types, 601547 (3),
CRYB2A	AD	cataract 3, multiple types, 601547 (3),
CRYB3	AR,AD	cataract 22, 609741 (3),
CRYBA1	AD	cataract 10, multiple types, 600881 (3),
CRYBA2	AD	?cataract 42, 115900 (3),
CRYBA4		cataract 23, 610425 (3)
CRYBB1	AR,AD	cataract 17, multiple types, 611544 (3),
CRYBB2	AD	cataract 3, multiple types, 601547 (3),
CRYBB3	AR,AD	cataract 22, 609741 (3),
CRYBG1		
CRYBG2		
CRYBG3		
CRYBP1		
CRYG1		
CRYG2	AD	cataract 39, multiple types, 615188 (3),
CRYG3	AD	cataract 2, multiple types, 604307 (3),
CRYG4	AD	cataract 4, multiple types, 115700 (3),
CRYG5		
CRYG8	AD	cataract 20, multiple types, 116100 (3),
CRYGA		
CRYGB	AD	cataract 39, multiple types, 615188 (3),
CRYGC	AD	cataract 2, multiple types, 604307 (3),
CRYGD	AD	cataract 4, multiple types, 115700 (3),
CRYGN		
CRYGS	AD	cataract 20, multiple types, 116100 (3),
CRYL1		
CRYM	AD	deafness, 40, 616357 (3),
CRYPTIC	AD	heterotaxy, visceral, 2, 605376 (3),
CRYZ		
CRYZL1		
CS		
CS-1	AD	cardiomyopathy, hypertrophic, 16, 613838 (3),
CS-2		
CS-3		
CS-5		
CS-KMT		
CS1		
CS2		
CS3		
CSA	AR	[placental lactogen deficiency] (1)|uv-sensitive syndrome 2, 614621 (3), ; cockayne syndrome, type a, 216400 (3),
Csa-19		
CSAA		
CSAD		
CSAG1		
CSAG2		
CSAG3		
CSAG3A		
CSAG3B		
CSAGE		
CSAP		
CSB	AR,AD	uv-sensitive syndrome 1, 600630 (3), ; cerebrooculofacioskeletal syndrome 1, 214150 (3), ; ?de sanctis-cacchione syndrome, 278800 (3), ; cockayne syndrome, type b, 133540 (3), ; {macular degeneration, age-related, susceptibility to, 5}, 613761 (3); premature ovarian failure 11, 616946 (3), ; {lung cancer, susceptibility to}, 211980 (3), somatic mutation,
CSBF		
CSBP	AD	au-kline syndrome, 616580 (3),
CSBP1		
CSBP2		
CSC-21K		
CSC1	AR	spastic paraplegia 87, 619966 (3),
CSD		
CSD1	AD	corneal dystrophy, avellino type, 607541 (3), ; corneal dystrophy, reis-bucklers type, 608470 (3), ; corneal dystrophy, thiel-behnke type, 602082 (3), ; corneal dystrophy, groenouw type i, 121900 (3), ; corneal dystrophy, epithelial basement membrane, 121820 (3), ; corneal dystrophy, lattice type i, 122200 (3), ; corneal dystrophy, lattice type iiia, 608471 (3),
CSD2	AD	corneal dystrophy, avellino type, 607541 (3), ; corneal dystrophy, reis-bucklers type, 608470 (3), ; corneal dystrophy, thiel-behnke type, 602082 (3), ; corneal dystrophy, groenouw type i, 121900 (3), ; corneal dystrophy, epithelial basement membrane, 121820 (3), ; corneal dystrophy, lattice type i, 122200 (3), ; corneal dystrophy, lattice type iiia, 608471 (3),
CSD3	AD	corneal dystrophy, avellino type, 607541 (3), ; corneal dystrophy, reis-bucklers type, 608470 (3), ; corneal dystrophy, thiel-behnke type, 602082 (3), ; corneal dystrophy, groenouw type i, 121900 (3), ; corneal dystrophy, epithelial basement membrane, 121820 (3), ; corneal dystrophy, lattice type i, 122200 (3), ; corneal dystrophy, lattice type iiia, 608471 (3),
CSDA		
CSDA1		
CSDA2		
CSDA3		
CSDB		
CSDC1		
CSDC2		
CSDD1		
CSDD2		
CSDE1		
CSDP		
CSDUFD1		
CSE	AR,AD,AR	cystathioninuria, 219500 (3), |dystonia 9, 601042 (3), ; glut1 deficiency syndrome 1, infantile onset, severe, 606777 (3), ; stomatin-deficient cryohydrocytosis with neurologic defects, 608885 (3), ; {epilepsy, idiopathic generalized, susceptibility to, 12}, 614847 (3), ; glut1 deficiency syndrome 2, childhood onset, 612126 (3),
CSE-C		{autoimmune disease, susceptibility to, 6}, 613551 (3)
CSE1		
CSE1L		
CSEN		
CSF1		
CSF1R	AR,AD	brain abnormalities, neurodegeneration, and dysosteosclerosis, 618476 (3), ; leukoencephalopathy, diffuse hereditary, with spheroids 1, 221820 (3),
CSF2		
CSF2R		surfactant metabolism dysfunction, pulmonary, 4, 300770 (3)
CSF2RA		surfactant metabolism dysfunction, pulmonary, 4, 300770 (3)
CSF2RB	AR	surfactant metabolism dysfunction, pulmonary, 5, 614370 (3),
CSF3		
CSF3R	AR,AD	neutropenia, severe congenital, 7, 617014 (3), ; ?neutrophilia, hereditary, 162830 (3),
CSFR	AR,AD	brain abnormalities, neurodegeneration, and dysosteosclerosis, 618476 (3), ; leukoencephalopathy, diffuse hereditary, with spheroids 1, 221820 (3),
CSGalNAcT-1	AR	skeletal dysplasia, mild, with joint laxity and advanced bone age, 618870 (3),
CSGALNACT1	AR	skeletal dysplasia, mild, with joint laxity and advanced bone age, 618870 (3),
CSGALNACT2		
CSGlcA-T		
CSH1		[placental lactogen deficiency] (1)
CSH2		
CSHL1		
cSHMT		
CSHP1		
CSIF		{rheumatoid arthritis, progression of}, 180300 (3); {graft-versus-host disease, protection against}, 614395 (3); {hiv-1, susceptibility to}, 609423 (3)
CSIG		
CSK		
CSKMT		
Csl	XL,XLR,XLD	myopathy, distal, 7, adult-onset, 301075 (3), ; deafness, 4, 300066 (3),
CSL		
CSL4	AR	?pontocerebellar hypoplasia, type 1f, 619304 (3),
Csl4p	AR	?pontocerebellar hypoplasia, type 1f, 619304 (3),
CSM1	AD,AR	scapuloperoneal syndrome, neurogenic, kaeser type, 181400 (3), ; cardiomyopathy, dilated, 1i, 604765 (3), ; myopathy, myofibrillar, 1, 601419 (3),
CSM2	AD,AR	scapuloperoneal syndrome, neurogenic, kaeser type, 181400 (3), ; cardiomyopathy, dilated, 1i, 604765 (3), ; myopathy, myofibrillar, 1, 601419 (3),
CSMD1		
CSMD2		
CSMD3		
CSMF		chondrosarcoma, extraskeletal myxoid, 612237 (3)
CSMT		[placental lactogen deficiency] (1)
CSN1		
CSN10		
CSN1S1		
CSN2		
CSN3		
CSN4		
CSN5		
CSN6		
CSN7A		
CSN7B		
CSN8		
CSNAP		
CSNB1	XL,XLR	night blindness, congenital stationary (complete), 1a, 310500 (3),
CSNB1A	XL,XLR	night blindness, congenital stationary (complete), 1a, 310500 (3),
CSNB1B	AR	night blindness, congenital stationary (complete), 1b, 257270 (3),
CSNB1C	AR	night blindness, congenital stationary (complete), 1c, 613216 (3)
CSNB1D	AR	night blindness, congenital stationary (complete), 1d, 613830 (3),
CSNB1E	AR	night blindness, congenital stationary (complete), 1e, 614565 (3),
CSNB1F	AR	night blindness, congenital stationary (complete), 1f, 615058 (3),
CSNB2	XL,XLR	cone-rod dystrophy, 3, 300476 (3), ; night blindness, congenital stationary (incomplete), 2a, 300071 (3), ; aland island eye disease, 300600 (3),
CSNB2A	XL,XLR	cone-rod dystrophy, 3, 300476 (3), ; night blindness, congenital stationary (incomplete), 2a, 300071 (3), ; aland island eye disease, 300600 (3),
CSNB2B	AR	cone-rod synaptic disorder, congenital nonprogressive, 610427 (3),
CSNB3	AR,AD	retinitis pigmentosa-40, 613801 (3), ; night blindness, congenital stationary, 2, 163500 (3),
CSNB4	XL,XLR	night blindness, congenital stationary (complete), 1a, 310500 (3),
CSNBAD1	AD,AR	night blindness, congenital stationary, 1, 610445 (3), ; retinitis pigmentosa 4, or , 613731 (3), ; retinitis punctata albescens, 136880 (3),
CSNBAD2	AR,AD	retinitis pigmentosa-40, 613801 (3), ; night blindness, congenital stationary, 2, 163500 (3),
CSNBAD3	AD,AR	night blindness, congenital stationary, 3, 610444 (3), ; night blindness, congenital stationary, type 1g, 616389 (3),
CSNBX2	XL,XLR	cone-rod dystrophy, 3, 300476 (3), ; night blindness, congenital stationary (incomplete), 2a, 300071 (3), ; aland island eye disease, 300600 (3),
CSNK1A1		
CSNK1D	AD	advanced sleep-phase syndrome, familial, 2, 615224 (3),
CSNK1E		
CSNK1G1		
CSNK1G2		
CSNK1G3		
CSNK2A1	AD	okur-chung neurodevelopmental syndrome, 617062 (3),
CSNK2A2		
CSNK2B	AD	poirier-bienvenu neurodevelopmental syndrome, 618732 (3),
CSNU1	AR,AD	cystinuria, 220100 (3),
CSNU3	AR,AD	cystinuria, 220100 (3),
CSP-6		
CSP-B		
CSP-beta		
CSP-C		
CSP-gamma		
CSPB		
CSPB1		
CSPG1	AD,AR	?spondyloepiphyseal dysplasia, kimberley type, 608361 (3), ; short stature and advanced bone age, with or without early-onset osteoarthritis and/or osteochondritis dissecans, 165800 (3), ; spondyloepimetaphyseal dysplasia, aggrecan type, 612813 (3),
CSPG2	AD	wagner syndrome 1, 143200 (3),
CSPG3		
CSPG4		
CSPG4A		
CSPG4LYP1		
CSPG4P1		
CSPG4P1Y		
CSPG5		
CSPG6	AD	cornelia de lange syndrome 3, 610759 (3),
CSPG7		
CSPG8		[blood group, indian system], 609027 (3)
CSPGCP	AD,AR	?spondyloepiphyseal dysplasia, kimberley type, 608361 (3), ; short stature and advanced bone age, with or without early-onset osteoarthritis and/or osteochondritis dissecans, 165800 (3), ; spondyloepimetaphyseal dysplasia, aggrecan type, 612813 (3),
CSPP	AR	joubert syndrome 21, 615636 (3),
CSPP-L	AR	joubert syndrome 21, 615636 (3),
CSPP1	AR	joubert syndrome 21, 615636 (3),
CSQ1	AD	myopathy, vacuolar, with casq1 aggregates, 616231 (3),
CSR		
CSR1		
CSRNP1		
CSRNP2		
CSRNP3		
CSRP		
CSRP1		
CSRP2		
CSRP2BP	AR	?mitochondrial complex iv deficiency, nuclear type 19, 619063 (3),
CSRP3	AD	?cardiomyopathy, dilated, 1m, 607482 (3); cardiomyopathy, hypertrophic, 12, 612124 (3),
CSS1	AR	temtamy preaxial brachydactyly syndrome, 605282 (3),
CSS2		
CSS3		
cst		
CST		
CST1		
CST11		
CST2		
CST3	AD	{macular degeneration, age-related, 11}, 611953 (3); cerebral amyloid angiopathy, 105150 (3),
CST4		
CST5		
CST6	AR,AR	?ectodermal dysplasia 15, hypohidrotic/hair type, 618535 (3), |epilepsy, progressive myoclonic 1a (unverricht and lundborg), 254800 (3),
CST7		
CST8		
CST8L		
CST9		
CST9L		
CSTA	AR	peeling skin syndrome 4, 607936 (3),
CSTB	AR	epilepsy, progressive myoclonic 1a (unverricht and lundborg), 254800 (3),
CstF-64		
CstF-64T		
CstF-77		
CSTF1		
CSTF2		
CSTF2T		
CSTF3		
CSTN1		
CSTN2		
CSTN3		
CSTP1		
CSU2		
cSVP	AR	?inflammatory skin and bowel disease, neonatal, 1, 614328 (3),
CSX	AD	hypoplastic left heart syndrome 2, 614435 (3), ; tetralogy of fallot, 187500 (3), ; hypothyroidism, congenital nongoitrous, 5, 225250 (3), ; conotruncal heart malformations, variable, 217095 (3); ventricular septal defect 3, 614432 (3), ; atrial septal defect 7, with or without av conduction defects, 108900 (3),
CSX1	AD	hypoplastic left heart syndrome 2, 614435 (3), ; tetralogy of fallot, 187500 (3), ; hypothyroidism, congenital nongoitrous, 5, 225250 (3), ; conotruncal heart malformations, variable, 217095 (3); ventricular septal defect 3, 614432 (3), ; atrial septal defect 7, with or without av conduction defects, 108900 (3),
CSX2		persistent truncus arteriosus, 217095 (3); conotruncal heart malformations, 217095 (3)
CSX3		
CT	AR	spondylometaphyseal dysplasia with cone-rod dystrophy, 608940 (3),
CT-1		
CT-8		
CT-R	AD	{osteoporosis, postmenopausal, susceptibility}, 166710 (3),
CT1	XLR,XL	cerebral creatine deficiency syndrome 1, 300352 (3),
CT1.1		
CT1.10		
CT1.11		
CT1.12		
CT1.19		
CT1.2		
CT1.26		
CT1.3		
CT1.4		
CT1.5		
CT1.6		
CT1.8		
CT1.9		
CT10		
CT100		
CT101		
CT102		
CT103		
CT104.1		
CT104.2		
CT104.3		
CT104.4		
CT104.5		
CT104.7		
CT106		
CT107		
CT108	AR	deafness, 22, 607039 (3),
CT109	AR	?spermatogenic failure 67, 619803 (3),
CT11.1		
CT11.10		
CT11.2		
CT11.3		
CT11.4		
CT11.6		
CT11.7		
CT11.8		
CT11.9		
CT110		
CT111	AR	multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly, 236500 (3),
CT112		
CT113	AR	spermatogenic failure 23, 617707 (3),
CT114	AR	cortical dysplasia, complex, with other brain malformations 9, 618174 (3),
CT117		
CT118	AD,AR	spinocerebellar ataxia 34, 133190 (3), ; stargardt disease 3, 600110 (3), ; ichthyosis, spastic quadriplegia, and impaired intellectual development, 614457 (3),
CT119		
CT12.1a		
CT12.1b		
CT12.1c		
CT12.1d		
CT12.2		
CT12.3a		
CT12.3b		
CT12.5		
CT120		
CT120.1		
CT120.2		
CT121	XL,XLR	proud syndrome, 300004 (3), ; hydranencephaly with abnormal genitalia, 300215 (3), ; partington syndrome, 309510 (3), ; developmental and epileptic encephalopathy 1, 308350 (3), ; lissencephaly, 2, 300215 (3), ; intellectual developmental disorder, 29, 300419 (3),
CT122	AR	spermatogenic failure 43, 618751 (3),
CT123		
CT124		
CT125		
CT126		
CT127		
CT128		
CT129		
CT13		
CT130		
CT131		
CT132		
CT133		
CT134		
CT135		
CT136		
CT137		
CT139		
CT14		
CT140	AR	ciliary dyskinesia, primary, 28, 615505 (3),
CT141		
CT142		
CT143	AR	?spermatogenic failure 55, 619380 (3),
CT144		
CT145		
CT146		
CT147	AR	oocyte/zygote/embryo maturation arrest 10, 619176 (3),
CT149		
CT15		
CT150		
CT152		
CT153		
CT154		
CT155		
CT156		
CT16.1		
CT16.2		
CT16.3		
CT16.4		
CT16.6		
CT16.7		
CT17		
CT19		
CT2		
CT2.1		
CT2.2		
CT2.3		
CT20		
CT21.1		
CT21.2		
CT22		
CT23		
CT24.1		
CT24.2		
CT25.1a		
CT25.1b		
CT26		
CT27		
CT28		
CT29	AR	microcephaly 4, primary, 604321 (3),
CT3.1		
CT3.2		
CT3.3		
CT3.4		
CT3.5		
CT3.6		
CT30		
CT31	AR	intellectual developmental disorder, 65, 618109 (3),
CT32		
CT33		
CT34		
CT35		
CT36		
CT38		
CT39		
CT4.1		
CT4.2		
CT4.3		
CT4.4		
CT4.5		
CT4.6		
CT4.7		
CT4.8		
CT40		
CT41.1		
CT41.2		
CT42	AR	spermatogenic failure 25, 617960 (3),
CT43		
CT44		
CT45-1		
CT45-2		
CT45-3		
CT45-4		
CT45-5		
CT45-6		
CT45.1		
CT45.2		
CT45.3		
CT45.4		
CT45.5		
CT45.6		
CT45A1		
CT45A2		
CT45A3		
CT45A4		
CT45A5		
CT45A6		
CT46		
CT46.2		
CT47.1		
CT47.10		
CT47.11		
CT47.13		
CT47.2		
CT47.3		
CT47.4		
CT47.5		
CT47.6		
CT47.7		
CT47.8		
CT47.9		
CT47A1		
CT47A10		
CT47A11		
CT47A2		
CT47A3		
CT47A4		
CT47A5		
CT47A6		
CT47A7		
CT47A8		
CT47A9		
CT47B1		
CT48		
CT49		
CT5.1	XL	spermatogenic failure, 5, 301099 (3),
CT5.2a		?sarcoma, synovial, 300813 (3)
CT5.3		
CT5.4		
CT50		
CT51		
CT52		
CT53		
CT54		
CT55	XL	?spermatogenic failure, 7, 301106 (3)
CT56		
CT58		
CT59		
CT6.1		
CT6.2a		
CT6.2b		
CT61		
CT63		
CT65		
CT68		
CT7		
CT7.1		
CT7.2		
CT71		
CT72		
CT73		
CT74		
CT76	AR	?spermatogenic failure 15, 616950 (3), ; ?premature ovarian failure 12, 616947 (3),
CT77		
CT78		
CT79	AR	?spermatogenic failure 26, 617961 (3),
CT8		
CT80		
CT80.1		
CT81		
CT82	AR	spermatogenic failure 82, 620353 (3),
CT83		
CT84		
CT86		
CT87	AR	leber congenital amaurosis 10, 611755 (3); joubert syndrome 5, 610188 (3), ; senior-loken syndrome 6, 610189 (3), ; ?bardet-biedl syndrome 14, 615991 (3), ; meckel syndrome 4, 611134 (3),
CT88		
CT89		
CT9	AR	?spermatogenic failure 21, 617644 (3),
CT90		
CT91		
CT92		
CT93		
CT94.1		
CT94.2		
CT95		
CT96		
CT97		
CT98		
CT99		
CTACK		
CTAG		
CTAG1		
CTAG1A		
CTAG1B		
CTAG2		
CTAG3		
CTAGE		
cTAGE-1		
cTAGE-2		
cTAGE-3		
cTAGE-4		
cTAGE-5A		
cTAGE-5B		
cTAGE-5C		
cTAGE-5D		
CTAGE1		
CTAGE3		
CTAGE3P		
CTAGE4		
CTAGE5		
CTAK		
CTAK1	AR	?visual impairment and progressive phthisis bulbi, 618283 (3),
CTAP3		
CTAPIII		
CTB		
Ctb9		
CTBP1	AD	hypotonia, ataxia, developmental delay, and tooth enamel defect syndrome, 617915 (3),
CTBP2		
CTBS		
CTC-534A2.2		
CTC1	AR	cerebroretinal microangiopathy with calcifications and cysts, 612199 (3),
CTCF	AD	intellectual developmental disorder, 21, 615502 (3),
CTCFL		
CTCL		
CTDNEP1		
CTDP1	AR	congenital cataracts, facial dysmorphism, and neuropathy, 604168 (3),
CTDSP1		
CTDSP2		
CTDSPL		
CTDSPL2		
CTE-1		
CTE-II		
CTEN		
CTES2		
CTES5		
CTES7A		
CTES7B		
CTF		
CTF1		
Ctf18		
CTF2		
CTF4		
CTF5		
CTF8		
CTG-B33		
CTG-B43a		
CTG-B45d		
CTG26		
CTG3a		
CTGF		
CTGF-L		
CTH	AR	cystathioninuria, 219500 (3),
CTHRC1		barrett esophagus/esophageal adenocarcinoma, 614266 (3)
CTIF		
CtIP	AR	seckel syndrome 2, 606744 (3), ; jawad syndrome, 251255 (3), ; pancreatic carcinoma, somatic (3)
CTIP-2	AD	immunodeficiency 49, severe combined, 617237 (3), ; intellectual developmental disorder with dysmorphic facies, speech delay, and t-cell abnormalities, 618092 (3),
CTIP1	AD	dias-logan syndrome, 617101 (3),
CTIP2	AD	immunodeficiency 49, severe combined, 617237 (3), ; intellectual developmental disorder with dysmorphic facies, speech delay, and t-cell abnormalities, 618092 (3),
CTK		
CTL1	AR	neurodegeneration, childhood-onset, with ataxia, tremor, optic atrophy, and cognitive decline, 618868 (3),
CTL2		
CTL3		
CTL4	AD	?deafness, 72, 617606 (3),
CTL5		
CTLA-4	AD	immune dysregulation with autoimmunity, immunodeficiency, and lymphoproliferation, 616100 (3), ; {diabetes mellitus, insulin-dependent, 12}, 601388 (3); {celiac disease, susceptibility to, 3}, 609755 (3); {hashimoto thyroiditis}, 140300 (3), ; {systemic lupus erythematosus, susceptibility to}, 152700 (3),
CTLA1		
CTLA3		
CTLA4	AD	immune dysregulation with autoimmunity, immunodeficiency, and lymphoproliferation, 616100 (3), ; {diabetes mellitus, insulin-dependent, 12}, 601388 (3); {celiac disease, susceptibility to, 3}, 609755 (3); {hashimoto thyroiditis}, 140300 (3), ; {systemic lupus erythematosus, susceptibility to}, 152700 (3),
CTLA8		
CTLN1	AR	citrullinemia, 215700 (3),
CTLN2	AR	citrullinemia, type ii, neonatal-onset, 605814 (3), ; citrullinemia, adult-onset type ii, 603471 (3),
CTM	AD	cataract 5, multiple types, 116800 (3),
CTM-1		
CTMP		
cTNI	AR,AD	?cardiomyopathy, dilated, 2a, 611880 (3), ; cardiomyopathy, hypertrophic, 7, 613690 (3), ; cardiomyopathy, familial restrictive, 1, 115210 (3), ; cardiomyopathy, dilated, 1ff, 613286 (3)
CTNNA1	AD	macular dystrophy, patterned, 2, 608970 (3),
CTNNA2	AR	cortical dysplasia, complex, with other brain malformations 9, 618174 (3),
CTNNA3	AD	arrhythmogenic right ventricular dysplasia, familial, 13, 615616 (3),
CTNNAL1		
CTNNB	AD	exudative vitreoretinopathy 7, 617572 (3), ; pilomatricoma, somatic, 132600 (3); colorectal cancer, somatic, 114500 (3); neurodevelopmental disorder with spastic diplegia and visual defects, 615075 (3), ; medulloblastoma, somatic, 155255 (3); ovarian cancer, somatic, 167000 (3); hepatocellular carcinoma, somatic, 114550 (3)
CTNNB1	AD	exudative vitreoretinopathy 7, 617572 (3), ; pilomatricoma, somatic, 132600 (3); colorectal cancer, somatic, 114500 (3); neurodevelopmental disorder with spastic diplegia and visual defects, 615075 (3), ; medulloblastoma, somatic, 155255 (3); ovarian cancer, somatic, 167000 (3); hepatocellular carcinoma, somatic, 114550 (3)
CTNNBIP1		
CTNNBL1	AR	?immunodeficiency 99 with hypogammaglobulinemia and autoimmune cytopenias, 619846 (3),
CTNND	AD	blepharocheilodontic syndrome 2, 617681 (3),
CTNND1	AD	blepharocheilodontic syndrome 2, 617681 (3),
CTNND2		
CTNNG	AR,AD	naxos disease, 601214 (3), ; ?arrhythmogenic right ventricular dysplasia 12, 611528 (3),
CTNS	AR	cystinosis, nephropathic, 219800 (3), ; cystinosis, ocular nonnephropathic, 219750 (3), ; cystinosis, late-onset juvenile or adolescent nephropathic, 219900 (3), ; cystinosis, atypical nephropathic, 219800 (3),
CTNS-LSB	AR	cystinosis, nephropathic, 219800 (3), ; cystinosis, ocular nonnephropathic, 219750 (3), ; cystinosis, late-onset juvenile or adolescent nephropathic, 219900 (3), ; cystinosis, atypical nephropathic, 219800 (3),
CTP	AR	combined d-2- and l-2-hydroxyglutaric aciduria, 615182 (3), ; myasthenic syndrome, congenital, 23, presynaptic, 618197 (3),
CTp11		
CTPCT	AR	spondylometaphyseal dysplasia with cone-rod dystrophy, 608940 (3),
CTPS	AR	immunodeficiency 24, 615897 (3),
CTPS1	AR	immunodeficiency 24, 615897 (3),
CTPS2		
CTR	AD	{osteoporosis, postmenopausal, susceptibility}, 166710 (3),
ctr1	AR	hypotonia, infantile, with psychomotor retardation, 616816 (3),
CTR1	AR	neurodegeneration and seizures due to copper transport defect, 620306 (3),
CTR2		
CTR9		
CTRB		
CTRB1		
CTRB2		
CTRC	AD	{pancreatitis, chronic, susceptibility to}, 167800 (3),
CTRL		
CTRN2		
CTRP1		
CTRP10		
CTRP11		
CTRP12		
CTRP13		
CTRP14		
CTRP15		
CTRP2		
CTRP3		
CTRP4		
CTRP5	AD	retinal degeneration, late-onset, 605670 (3),
CTRP6		
CTRP8		
CTRP9		
CTRP9B		
CTS	AD	amyloidosis, hereditary, transthyretin-related, 105210 (3), ; carpal tunnel syndrome, familial, 115430 (3), ; [dystransthyretinemic hyperthyroxinemia], 145680 (3),
CTS1	AD	amyloidosis, hereditary, transthyretin-related, 105210 (3), ; carpal tunnel syndrome, familial, 115430 (3), ; [dystransthyretinemic hyperthyroxinemia], 145680 (3),
CTS18.1		
CTS9		
CTSA	AR	galactosialidosis, 256540 (3),
CTSB	AD	keratolytic winter erythema, 148370 (4),
CTSC	AR	periodontitis 1, juvenile, 170650 (3), ; haim-munk syndrome, 245010 (3), ; papillon-lefevre syndrome, 245000 (3),
CTSD	AR	ceroid lipofuscinosis, neuronal, 10, 610127 (3),
CTSE		
CTSF	AR	ceroid lipofuscinosis, neuronal, 13 (kufs type), 615362 (3),
CTSG		
CTSGL1		
CTSGL2		
CTSH		
CTSK	AR	pycnodysostosis, 265800 (3),
CTSL		
CTSL1		
CTSL2		
CTSO	AR	pycnodysostosis, 265800 (3),
CTSO1		
CTSO2	AR	pycnodysostosis, 265800 (3),
CTSS		
CTSU		
CTSV		
CTSW		
CTSX		
CTSZ		
CTTN		
CTTNBP1		{autism susceptibility 17}, 613436 (3)
CTTNBP2		
CTTNBP2NL		
CTTNL		
CTU1		
CTU2	AR	microcephaly, facial dysmorphism, renal agenesis, and ambiguous genitalia syndrome, 618142 (3),
CTX	AR	cerebrotendinous xanthomatosis, 213700 (3),
CTXL		
CTXN1		
CTXN3		
CUBN	AR	[proteinuria, chronic benign], 618884 (3), ; imerslund-grasbeck syndrome 1, 261100 (3),
CUDR		
Cue110		
CUEDC2		
CUG-BP		
CUG2		
CUGBP		
CUGBP1		
CUGBP2	AD	developmental and epileptic encephalopathy 97, 619561 (3),
CUL1		
CUL2		
CUL3	AD	neurodevelopmental disorder with or without autism or seizures, 619239 (3), ; pseudohypoaldosteronism, type iie, 614496 (3),
CUL4A		
CUL4B	XL,XLR	intellectual developmental disorder, syndromic, cabezas type, 300354 (3),
CUL5		
CUL7	AR	3-m syndrome 1, 273750 (3),
CUL9		
CUPID1		
CUPID2		
Cupidin	AD	?deafness, 68, 616707 (3),
Cus1	AD	craniofacial microsomia, 164210 (3),
CUT	AD	global developmental delay with or without impaired intellectual development, 618330 (3),
CUT23		
CUT9		
CUTA		
CUTC		
CUTL1	AD	global developmental delay with or without impaired intellectual development, 618330 (3),
CUTL2	AD	developmental and epileptic encephalopathy 67, 618141 (3),
CUX	AD	global developmental delay with or without impaired intellectual development, 618330 (3),
Cux/CDP	AD	global developmental delay with or without impaired intellectual development, 618330 (3),
CUX1	AD	global developmental delay with or without impaired intellectual development, 618330 (3),
CUX2	AD	developmental and epileptic encephalopathy 67, 618141 (3),
CUZD1		
Cv2	AR	diaphanospondylodysostosis, 608022 (3),
CV2	AD	ritscher-schinzel syndrome 4, 619435 (3),
CVAK104	AR	arthrogryposis multiplex congenita 4, neurogenic, with agenesis of the corpus callosum, 618766 (3),
CVARP		
CVG5	XL,XLR	galloway-mowat syndrome 2, 301006 (3),
cvHSP		
Cwc1		
Cwc14		
Cwc2		
Cwc21		
CWC22		
Cwc24	XL	trichothiodystrophy 5, nonphotosensitive, 300953 (3),
CWC27	AR	retinitis pigmentosa with or without skeletal anomalies, 250410 (3),
CWF19L1	AR	spinocerebellar ataxia, 17, 616127 (3),
CWH41	AR	congenital disorder of glycosylation, type iib, 606056 (3),
CWH43		
CWH43-C		
CWH43-N	AR	hyperphosphatasia with impaired intellectual development syndrome 3, 614207 (3),
CX2		
CX25		
CX26	AD,AR	keratoderma, palmoplantar, with deafness, 148350 (3), ; deafness, 1a, 220290 (3), digenic ; deafness, 3a, 601544 (3), ; hystrix-like ichthyosis with deafness, 602540 (3), ; bart-pumphrey syndrome, 149200 (3), ; keratitis-ichthyosis-deafness syndrome, 148210 (3), ; vohwinkel syndrome, 124500 (3),
CX30	AD,AR	ectodermal dysplasia 2, clouston type, 129500 (3), ; deafness, 3b, 612643 (3), ; deafness, 1b, 612645 (3), ; deafness, digenic gjb2/gjb6, 220290 (3), digenic
Cx30.2		
CX30.2		
CX30.3	AD	erythrokeratodermia variabilis et progressiva 2, 617524 (3),
CX31	AR,AD	deafness, digenic, gjb2/gjb3, 220290 (3), digenic ; deafness, (3); deafness, 2b, 612644 (3), ; erythrokeratodermia variabilis et progressiva 1, 133200 (3), ; deafness, with peripheral neuropathy (3)
CX31.1		
CX31.9		
CX32	XLD,XL	charcot-marie-tooth neuropathy, 1, 302800 (3),
CX36		
CX37		
CX3CL1		
CX3CR1		{rapid progression to aids from hiv1 infection}, 609423 (3); {macular degeneration, age-related, 12}, 613784 (3); {coronary artery disease, resistance to}, 607339 (3)
CX40	AD	atrial fibrillation, familial, 11, 614049 (3), ; atrial standstill, digenic (gja5/scn5a), 108770 (3),
CX40.1		
CX43	AD,AR	erythrokeratodermia variabilis et progressiva 3, 617525 (3), ; craniometaphyseal dysplasia, 218400 (3), ; oculodentodigital dysplasia, 164200 (3), ; palmoplantar keratoderma with congenital alopecia, 104100 (3), ; syndactyly, type iii, 186100 (3), ; oculodentodigital dysplasia, 257850 (3),
CX45		
CX46	AD	cataract 14, multiple types, 601885 (3),
CX46.6	AD,AR	lymphatic malformation 3, 613480 (3), ; ?spastic paraplegia 44, 613206 (3), ; leukodystrophy, hypomyelinating, 2, 608804 (3),
CX47	AD,AR	lymphatic malformation 3, 613480 (3), ; ?spastic paraplegia 44, 613206 (3), ; leukodystrophy, hypomyelinating, 2, 608804 (3),
CX50	AD	cataract 1, multiple types, 116200 (3),
CX58		
CX59		
CX62		
CXADR		
CXC3		
CXC3C		
CXCDC1		
CXCDC2		
CXCL1		
CXCL10		
CXCL11		
CXCL12		{aids, resistance to}, 609423 (3)
CXCL13		
CXCL14		
CXCL16		
CXCL17		
CXCL2		
CXCL3		
CXCL4		
CXCL4L1		
CXCL4V1		
CXCL5		
CXCL6		
CXCL7		
CXCL8		
CXCL9		
CXCLG16		
CXCR1		{aids, slow progression to}, 609423 (3)
CXCR2	AR	?whim syndrome 2, 619407 (3),
CXCR3		
CXCR4	AD	whim syndrome 1, 193670 (3), ; myelokathexis, isolated, 193670 (3),
CXCR5		
CXCR6		
CXCR7	AR	?oculomotor-abducens synkinesis, 619215 (3),
CXorf1	XL	intellectual developmental disorder, 111, 301107 (3),
CXorf10	XLR,XL	shukla-vernon syndrome, 301029 (3),
CXorf11	XL	intellectual developmental disorder, syndromic, raymond type, 300799 (3),
CXorf12		
CXorf13		
CXorf15		
CXorf17		
CXorf2	XL	intellectual developmental disorder, 111, 301107 (3),
CXorf21		
CXorf22	XL,XLR	spermatogenic failure, 3, 301059 (3),
CXorf3	XL,XLR	intellectual developmental disorder, 12, 300957 (3),
CXorf30	XL,XLR	spermatogenic failure, 3, 301059 (3),
CXorf32		
CXorf33		
CXorf35		
CXorf36		
CXorf37	XLR,XL	ritscher-schinzel syndrome 2, 300963 (3),
CXorf4		
CXorf40		
CXorf40A		
CXorf41	XL,XLR	ciliary dyskinesia, primary, 36, 300991 (3),
CXorf43		
CXorf45	XL	developmental and epileptic encephalopathy 36, 300884 (3),
CXorf48	XL	?spermatogenic failure, 7, 301106 (3)
CXorf5	XLR,XL,XLD	simpson-golabi-behmel syndrome, type 2, 300209 (3), ; ?retinitis pigmentosa 23, 300424 (3), ; orofaciodigital syndrome i, 311200 (3), ; joubert syndrome 10, 300804 (3),
CXorf53		
CXorf56	XL	?intellectual developmental disorder, 107, 301013 (3),
CXorf59	XL,XLR	spermatogenic failure, 3, 301059 (3),
CXorf6	XL,XLR	hypospadias 2, 300758 (3),
CXorf61		
CXorf67		
CXorf9	XLR,XL	immunodeficiency 102, 301082 (3),
CXX1		
CXXC1		
CXXC10	AD	intellectual developmental disorder, 68, 619934 (3), ; dystonia 28, childhood-onset, 617284 (3),
CXXC11		
CXXC2		
CXXC3		
CXXC4		
CXXC5		
CXXC6		
CXXC7	AD	wiedemann-steiner syndrome, 605130 (3),
CXXC8		
CXXC9	AD	neuropathy, hereditary sensory, type ie, 614116 (3), ; cerebellar ataxia, deafness, and narcolepsy, 604121 (3),
CXYorf3		
CY6		
CYAR	AD	aromatase deficiency, 613546 (3); aromatase excess syndrome, 139300 (3),
CyaY	AR	friedreich ataxia with retained reflexes, 229300 (3), ; friedreich ataxia, 229300 (3),
CYB5	AR	methemoglobinemia and ambiguous genitalia, 250790 (3),
CYB5-M		
CYB560	AD	paragangliomas 3, 605373 (3), ; paraganglioma and gastric stromal sarcoma, 606864 (3); gastrointestinal stromal tumor, 606764 (3), isolated cases,
CYB561	AR	orthostatic hypotension 2, 618182 (3),
CYB561A1	AR	orthostatic hypotension 2, 618182 (3),
CYB561A2		
CYB561A3		
CYB561D2		
CYB5A	AR	methemoglobinemia and ambiguous genitalia, 250790 (3),
CYB5B		
CYB5R1		
CYB5R2		
CYB5R3	AR	methemoglobinemia, type i, 250800 (3), ; methemoglobinemia, type ii, 250800 (3),
CYB5R4		
CYB5RP		
CYBA	AR	chronic granulomatous disease 4, 233690 (3),
CYBASC3		
CYBB	XL,XLR	immunodeficiency 34, mycobacteriosis, 300645 (3), ; chronic granulomatous disease, 306400 (3),
CYBC1	AR	chronic granulomatous disease 5, 618935 (3),
cybL	AD	paragangliomas 3, 605373 (3), ; paraganglioma and gastric stromal sarcoma, 606864 (3); gastrointestinal stromal tumor, 606764 (3), isolated cases,
CYBR		
CYBRD1		
cybS	AD,AR	paragangliomas 1, with or without deafness, 168000 (3), ; paraganglioma and gastric stromal sarcoma, 606864 (3); mitochondrial complex ii deficiency, nuclear type 3, 619167 (3), ; pheochromocytoma, 171300 (3),
CYC	AD	thrombocytopenia 4, 612004 (3),
CYC1	AR	mitochondrial complex iii deficiency, nuclear type 6, 615453 (3),
CYC4		
CyCAP		
CYCB3		
CycC		
CYCE2		
CycH		
cyclon		
CycM	XLD,XL	star syndrome, 300707 (3),
CYCS	AD	thrombocytopenia 4, 612004 (3),
CYCT1		
CYFIP1		
CYFIP2	AD	developmental and epileptic encephalopathy 65, 618008 (3),
CYGB		
CYGD	AR,AD	cone-rod dystrophy 6, 601777 (3), ; ?choroidal dystrophy, central areolar 1, 215500 (3), ; leber congenital amaurosis 1, 204000 (3), ; night blindness, congenital stationary, type 1i, 618555 (3),
CYGF		
CYHR1		
CYK4	AR,AD	?anemia, congenital dyserythropoietic, type iiib, 619789 (3), |white sponge nevus 1, 193900 (3),
CYK8		
CYLC1		
CYLC2		
CYLD	AD	brooke-spiegler syndrome, 605041 (3), ; cylindromatosis, familial, 132700 (3), ; trichoepithelioma, multiple familial, 1, 601606 (3), ; ?frontotemporal dementia and/or amyotrophic lateral sclerosis 8, 619132 (3),
CYLD1	AD	brooke-spiegler syndrome, 605041 (3), ; cylindromatosis, familial, 132700 (3), ; trichoepithelioma, multiple familial, 1, 601606 (3), ; ?frontotemporal dementia and/or amyotrophic lateral sclerosis 8, 619132 (3),
CYLN1		
CYLN2		
CYorf15A		
CYorf15B		
CYP-20		
CyP-33		
CYP-40		
Cyp-60		
Cyp-D		
CYP-S1	AR	osteogenesis imperfecta, type ix, 259440 (3),
CYP1	AR	vitamin d-dependent rickets, type i, 264700 (3),
CYP11A		adrenal insufficiency, congenital, with 46xy sex reversal, partial or complete, 613743 (3)
CYP11A1		adrenal insufficiency, congenital, with 46xy sex reversal, partial or complete, 613743 (3)
CYP11B	AD,AR,AR	aldosteronism, glucocorticoid-remediable, 103900 (3), ; adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deficiency, 202010 (3), |hypoaldosteronism, congenital, due to cmo i deficiency, 203400 (3), ; aldosterone to renin ratio raised (3); {low renin hypertension, susceptibility to} (3); hypoaldosteronism, congenital, due to cmo ii deficiency, 610600 (3),
CYP11B1	AD,AR	aldosteronism, glucocorticoid-remediable, 103900 (3), ; adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deficiency, 202010 (3),
CYP11B2	AR	hypoaldosteronism, congenital, due to cmo i deficiency, 203400 (3), ; aldosterone to renin ratio raised (3); {low renin hypertension, susceptibility to} (3); hypoaldosteronism, congenital, due to cmo ii deficiency, 610600 (3),
CYP11BL	AR	hypoaldosteronism, congenital, due to cmo i deficiency, 203400 (3), ; aldosterone to renin ratio raised (3); {low renin hypertension, susceptibility to} (3); hypoaldosteronism, congenital, due to cmo ii deficiency, 610600 (3),
CYP12		
CYP17	AR	17,20-lyase deficiency, isolated, 202110 (3), ; 17-alpha-hydroxylase/17,20-lyase deficiency, 202110 (3),
CYP17A1	AR	17,20-lyase deficiency, isolated, 202110 (3), ; 17-alpha-hydroxylase/17,20-lyase deficiency, 202110 (3),
CYP19	AD	aromatase deficiency, 613546 (3); aromatase excess syndrome, 139300 (3),
CYP19A1	AD	aromatase deficiency, 613546 (3); aromatase excess syndrome, 139300 (3),
CYP1A1		
CYP1A2		
CYP1B1	AR	glaucoma 3a, primary open angle, congenital, juvenile, or adult onset, 231300 (3), ; anterior segment dysgenesis 6, multiple subtypes, 617315 (3),
CYP21	AR	hyperandrogenism, nonclassic type, due to 21-hydroxylase deficiency, 201910 (3), ; adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency, 201910 (3),
CYP21A2	AR	hyperandrogenism, nonclassic type, due to 21-hydroxylase deficiency, 201910 (3), ; adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency, 201910 (3),
CYP21B	AR	hyperandrogenism, nonclassic type, due to 21-hydroxylase deficiency, 201910 (3), ; adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency, 201910 (3),
CYP24	AR	hypercalcemia, infantile, 1, 143880 (3),
CYP24A1	AR	hypercalcemia, infantile, 1, 143880 (3),
CYP26		
CYP26A1		
CYP26B1		craniosynostosis with radiohumeral fusions and other skeletal and craniofacial anomalies, 614416 (3)
CYP26C1	AR	focal facial dermal dysplasia 4, 614974 (3),
CYP27	AR	cerebrotendinous xanthomatosis, 213700 (3),
CYP27A1	AR	cerebrotendinous xanthomatosis, 213700 (3),
CYP27B1	AR	vitamin d-dependent rickets, type i, 264700 (3),
CYP2A	AD	{lung cancer, resistance to}, 211980 (3), somatic mutation, ; coumarin resistance, 122700 (3), ; {nicotine addiction, protection from}, 188890 (3)
CYP2A13		
CYP2A3	AD	{lung cancer, resistance to}, 211980 (3), somatic mutation, ; coumarin resistance, 122700 (3), ; {nicotine addiction, protection from}, 188890 (3)
CYP2A6	AD	{lung cancer, resistance to}, 211980 (3), somatic mutation, ; coumarin resistance, 122700 (3), ; {nicotine addiction, protection from}, 188890 (3)
CYP2A7		
CYP2B		{efavirenz central nervous system toxicity, susceptibility to}, 614546 (3); efavirenz, poor metabolism of, 614546 (3)
CYP2B6		{efavirenz central nervous system toxicity, susceptibility to}, 614546 (3); efavirenz, poor metabolism of, 614546 (3)
CYP2C	AR	proguanil poor metabolizer, 609535 (3), ; mephenytoin poor metabolizer, 609535 (3), ; clopidogrel, impaired responsiveness to, 609535 (3), ; omeprazole poor metabolizer, 609535 (3),
CYP2C10	AD	warfarin sensitivity, 122700 (3), ; tolbutamide poor metabolizer (3)
CYP2C17		
CYP2C18		
CYP2C19	AR	proguanil poor metabolizer, 609535 (3), ; mephenytoin poor metabolizer, 609535 (3), ; clopidogrel, impaired responsiveness to, 609535 (3), ; omeprazole poor metabolizer, 609535 (3),
CYP2C8		{drug metabolism, altered, cyp2c8-related}, 618018 (3)
CYP2C9	AD	warfarin sensitivity, 122700 (3), ; tolbutamide poor metabolizer (3)
CYP2D	AR	{codeine sensitivity}, 608902 (3), ; {debrisoquine sensitivity}, 608902 (3),
CYP2D6	AR	{codeine sensitivity}, 608902 (3), ; {debrisoquine sensitivity}, 608902 (3),
CYP2D7AP	AR	{codeine sensitivity}, 608902 (3), ; {debrisoquine sensitivity}, 608902 (3),
CYP2D7BP	AR	{codeine sensitivity}, 608902 (3), ; {debrisoquine sensitivity}, 608902 (3),
CYP2D7P2	AR	{codeine sensitivity}, 608902 (3), ; {debrisoquine sensitivity}, 608902 (3),
CYP2D8P2	AR	{codeine sensitivity}, 608902 (3), ; {debrisoquine sensitivity}, 608902 (3),
CYP2DL1	AR	{codeine sensitivity}, 608902 (3), ; {debrisoquine sensitivity}, 608902 (3),
CYP2E		
CYP2E1		
CYP2F		
CYP2F1		
CYP2G1		
CYP2G1P		
CYP2GP1		
CYP2J2		
CYP2R1	AR	rickets due to defect in vitamin d 25-hydroxylation deficiency, 600081 (3),
CYP2S1		
CYP2U1	AR	spastic paraplegia 56, 615030 (3),
CYP2W1		
CYP39A1		
CYP3A3	AD	vitamin d-dependent rickets, type 3, 619073 (3),
CYP3A4	AD	vitamin d-dependent rickets, type 3, 619073 (3),
CYP3A43		
CYP3A5	MF	{hypertension, salt-sensitive essential, susceptibility to}, 145500 (3),
CYP3A7		
CYP46		
CYP46A1		
CYP4A11		
CYP4A2		
CYP4A20		
CYP4A22		
CYP4AH1	AR	bietti crystalline corneoretinal dystrophy, 210370 (3),
CYP4AII		
CYP4B1		
CYP4F		
CYP4F11		
CYP4F12		
CYP4F2		
CYP4F22	AR	ichthyosis, congenital, 5, 604777 (3),
CYP4F3		
CYP4F8		
CYP4V2	AR	bietti crystalline corneoretinal dystrophy, 210370 (3),
CYP4X1		
CYP4Z1		
CYP5	AR	ghosal hematodiaphyseal syndrome, 231095 (3),
CYP51		
CYP51A1		
CYP5A1	AR	ghosal hematodiaphyseal syndrome, 231095 (3),
CYP7		
CYP7A1		
CYP7B1	AR	spastic paraplegia 5a, 270800 (3), ; bile acid synthesis defect, congenital, 3, 613812 (3),
CYP8A1	MF	hypertension, essential, 145500 (3),
CYP8B1		
CYPA		
CYPB	AR	osteogenesis imperfecta, type ix, 259440 (3),
CYPC		
CypD		
CYPH		
CYPIIB6		{efavirenz central nervous system toxicity, susceptibility to}, 614546 (3); efavirenz, poor metabolism of, 614546 (3)
CYPIN		
CyPJ		
CYPL1	AR	pontocerebellar hypoplasia, type 14, 619301 (3),
CYPOR	AR	antley-bixler syndrome with genital anomalies and disordered steroidogenesis, 201750 (3), ; disordered steroidogenesis due to cytochrome p450 oxidoreductase, 613571 (3)
CYR61		
CYREN		
CYRI		
CYRI-B		
CYRIB		
CYRP		
CYS1		
CysLT(1)		
CysLT(2)		
CysLT1		
CYSLT1R		
CYSLT2R		
CYSLTR1		
CYSLTR2		
CYT19		
CYT4		
CYTH1		
CYTH2		
CYTH3		
CYTH4		
CYTHIP		
CYTIP		
CYTL1		
cytohesin-1		
cytohesin-2		
cytohesin-3		
cytohesin-4		
CYTOR4		
CYTSA	AD	teebi hypertelorism syndrome 1, 145420 (3), ; ?facial clefting, oblique, 1, 600251 (3),
CYTSB		
CYYR1		
CYYR1-AS1		
CZP1	AD	cataract 1, multiple types, 116200 (3),
CZP3	AD	cataract 14, multiple types, 601885 (3),
D-10		
D-AKAP1		
D-AKAP2		
D-DT		
D-PCa-2		
D0S117E		
D0S1430E		
D1	AR	?megacystis-microcolon-intestinal hypoperistalsis syndrome 3, 619362 (3),
D10S105E		
D10S170		
D10S64	AR	?retinitis pigmentosa 66, 615233 (3),
D10S65	AR	?retinitis pigmentosa 66, 615233 (3),
D10S66	AR	?retinitis pigmentosa 66, 615233 (3),
D11LGP2		
D11S2243E		
D11S287E	AD	{von hippel-lindau syndrome, modifier of}, 193300 (3), ; {colorectal cancer, susceptibility to}, 114500 (3), somatic mutation, ; {multiple myeloma, susceptibility to}, 254500 (3), somatic mutation
D11S302E		
D11S366	AR	myasthenic syndrome, congenital, 13, with tubular aggregates, 614750 (3), ; congenital disorder of glycosylation, type ij, 608093 (3),
D11S4365		
D11S4896E	AD,AR	myopathy, tubular aggregate, 1, 160565 (3), ; stormorken syndrome, 185070 (3), ; immunodeficiency 10, 612783 (3),
D11S750		
D11S812E	AD	optic nerve hypoplasia, 165550 (3), ; cataract with late-onset corneal dystrophy, 106210 (3), ; ?coloboma, ocular, 120200 (3), ; ?coloboma of optic nerve, 120430 (3), ; aniridia, 106210 (3), ; anterior segment dysgenesis 5, multiple subtypes, 604229 (3), ; ?morning glory disc anomaly, 120430 (3), ; foveal hypoplasia 1, 136520 (3), ; keratitis, 148190 (3),
D11S813E		
D11S833E	AR	cleft palate, proliferative retinopathy, and developmental delay, 619074 (3),
D12		
D123		
D12S1644		
D12S1889	AD	myoclonus, intractable, neonatal, 617235 (3), ; {amyotrophic lateral sclerosis, susceptibility to, 25}, 617921 (3), ; spastic paraplegia 10, 604187 (3),
D12S1900		
D12S2489E		
D12S370		
D12S53E		
D12S755E	AD	dentatorubral-pallidoluysian atrophy, 125370 (3), ; congenital hypotonia, epilepsy, developmental delay, and digital anomalies, 618494 (3),
D13S1056E		
D13S106E		
D13S327	AR	hyperornithinemia-hyperammonemia-homocitrullinemia syndrome, 238970 (3),
D14S1461E		
D14S46E	AD,AR	retinitis pigmentosa 27, 613750 (3), ; retinal degeneration, clumped pigment type (3)
D15Ertd747e	AR	brown-vialetto-van laere syndrome 2, 614707 (3),
D15F37S1	AR	intellectual developmental disorder, 38, 615516 (3), ; [skin/hair/eye pigmentation 1, blond/brown hair], 227220 (3), ; [skin/hair/eye pigmentation 1, blue/nonblue eyes], 227220 (3),
D15S12	AR	[skin/hair/eye pigmentation 1, blue/nonblue eyes], 227220 (3), ; [skin/hair/eye pigmentation 1, blond/brown hair], 227220 (3), ; albinism, brown oculocutaneous, 203200 (3), ; albinism, oculocutaneous, type ii, 203200 (3),
D15S1518E		
D15S9	AD	precocious puberty, central, 2, 615346 (3),
D15Wsu75e		
D16Ertd36e	AR	congenital disorder of glycosylation, type id, 601110 (3),
D16S2531E		
D16S444E	AD	spondyloepimetaphyseal dysplasia, isidor-toutain type, 618728 (3),
D16S469E		
D17S136E		{hiv-1 disease, rapid progression of}, 609423 (3); {hiv-1 disease, delayed progression of}, 609423 (3)
D17S1718		{hiv/aids, susceptibility to}, 609423 (3)
D17S376		
D17S811E		
D17S978E		
D18S892E	AD	left ventricular noncompaction 1, with or without congenital heart defects, 604169 (3),
D19S1177E		
D19S204		
D19S37		leukemia/lymphoma, b-cell, 3, 109560 (2)
D19S593E		
D1S155E		
D1S166E		
D1S1733E		
D1S181E		
D1S2223E	AR	peroxisome biogenesis disorder 12a (zellweger), 614886 (3),
D1S3362		
D2-2		
D2-40		
D20S101		
D21M16SJHU19e		
D21S2048E		
D21S2056E		
D21S21		
D21S58	AR	{hepatitis b virus, susceptibility to}, 610424 (3); inflammatory bowel disease 25, early onset, 612567 (3),
D21S66	AR	{hepatitis b virus, susceptibility to}, 610424 (3); inflammatory bowel disease 25, early onset, 612567 (3),
D22S11		leukemia, chronic myeloid, philadelphia chromosome positive, somatic, 608232 (4); leukemia, acute lymphocytic, philadelphia chromosome positive, somatic, 613065 (4)
D22S662		leukemia, chronic myeloid, philadelphia chromosome positive, somatic, 608232 (4); leukemia, acute lymphocytic, philadelphia chromosome positive, somatic, 613065 (4)
D22S671		
D22S672	AR	?glutathioninuria, 231950 (3),
D22S673	AD	thrombophilia 10 due to heparin cofactor ii deficiency, 612356 (3),
D22S674	AR	schindler disease, type i, 609241 (3), ; kanzaki disease, 609242 (3), ; schindler disease, type iii, 609241 (3),
D22S675	AR	glucose/galactose malabsorption, 606824 (3),
D22S676	AR	transcobalamin ii deficiency, 275350 (3),
D22S731		
D22S732	AR	?glutathioninuria, 231950 (3),
D22S749		
D22S750	AR	transcobalamin ii deficiency, 275350 (3),
D29		
D2H	AR,AD	cystinuria, 220100 (3),
D2HGD	AR	d-2-hydroxyglutaric aciduria, 600721 (3),
D2HGDH	AR	d-2-hydroxyglutaric aciduria, 600721 (3),
D2LIC	AR	short-rib thoracic dysplasia 15 with polydactyly, 617088 (3),
D2S1471		
D2S1473		
D2S201E	AD	whim syndrome 1, 193670 (3), ; myelokathexis, isolated, 193670 (3),
D2S448	AR	anterior segment dysgenesis 7, with sclerocornea, 269400 (3),
D2S448E	AR	anterior segment dysgenesis 7, with sclerocornea, 269400 (3),
D2S69E		
D3F15S2		
D3S1231E		
D3S1363E		
D3S3191	AD	parkinsonism with polyneuropathy, 619279 (3),
D3S3194	AD	?deafness, 70, 616968 (3),
D3S3195		
D3S48E		
D40	AR	microcephaly 4, primary, 604321 (3),
D4Ertd89e	AR	osteogenesis imperfecta, type xiv, 615066 (3),
D4S114		
D4S234E		
D4S2561E		
D4S90	AR	?polydactyly, postaxial, type a6, 615226 (3),
D4ST-1	AR	ehlers-danlos syndrome, musculocontractural type 1, 601776 (3),
D4ST1	AR	ehlers-danlos syndrome, musculocontractural type 1, 601776 (3),
D52		
D53		
D54		
D55		
D5D		
D5S346		
D6		
D6D		
D6Mm5e	AR	spermatogenic failure 48, 619108 (3),
D6S113E		
D6S114E	AR	bare lymphocyte syndrome, type i, 604571 (3),
D6S204	MF	{psoriasis susceptibility 1}, 177900 (3), ; {hiv-1 viremia, susceptibility to}, 609423 (3)
D6S216E	AR	proteasome-associated autoinflammatory syndrome 1 and digenic forms, 256040 (3),
D6S217E	AR	bare lymphocyte syndrome, type i, due to tap2 deficiency, 604571 (3),
D6S218E		
D6S221E		
D6S222E		
D6S2244E	AR	agammaglobulinemia 9, 619693 (3),
D6S2245E		
D6S229E		
D6S230E		
D6S231E		leukemia, acute nonlymphocytic, 125264 (2)
D6S2650E		
D6S2654E		
D6S45		
D6S46		
D6S49E		
D6S504E	AD	spinocerebellar ataxia 1, 164400 (3),
D6S51E		
D6S52E		
D6S54E		
D6S57		
D6S586E	AD,AR	hypotrichosis 2, 146520 (3), ; peeling skin syndrome 1, 270300 (3),
D6S60		
D6S81E		
D6S82E	AR	spastic paraplegia 86, 619735 (3),
D8		
D8C6		
D8S2298E		
D9S2135		
D9S411E		
D9S46E	AR	leukemia, t-cell acute lymphoblastic, somatic, 613065 (3); leukemia, acute myeloid, somatic, 601626 (3); {encephalopathy, acute, infection-induced, susceptibility to, 9}, 618426 (3),
D9S57E		
DA1	AD	arthrogryposis, distal, type 2b4, 108120 (3), ; arthrogryposis, distal, type 1a, 108120 (3), ; congenital myopathy 23, 609285 (3),
DA2B	AD,AD	arthrogryposis, distal, type 2b1, 601680 (3), |arthrogryposis, distal, type 2b2, 618435 (3),
DA41		
dA59H18.2		
dA59H18.3		
DA9	AD	macular degeneration, early-onset, 616118 (3), ; contractural arachnodactyly, congenital, 121050 (3),
DAAM1		
DAAM2	AR	nephrotic syndrome, type 24, 619263 (3),
DAAO		
DAB1	AD	spinocerebellar ataxia 37, 615945 (3),
DAB2		
DAB2IP		
DABP		
DAC		
DACH		
DACH1		
DACH2		
DACT1	AD	townes-brocks syndrome 2, 617466 (3),
DACT2		
DACT3		
dactylidin		
dactylin		
DAD-R		
DAD1		
DAD1L		
DAD1P1		
DAF	AR	[blood group cromer], 613793 (3), ; complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy, 226300 (3),
DAG	AR	muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 9, 616538 (3), ; muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 9, 613818 (3),
DAG1	AR	muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 9, 616538 (3), ; muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 9, 613818 (3),
DAGA4	AR	muscular dystrophy, limb-girdle, 5, 253700 (3),
DAGD	AR	cardiomyopathy, dilated, 1l, 606685 (3); muscular dystrophy, limb-girdle, 6, 601287 (3),
DAGK		
DAGK1		
DAGK2		
DAGK3		
DAGK4		
DAGK5		
DAGK6	AR	{hemolytic uremic syndrome, atypical, susceptibility to, 7}, 615008 (3), ; nephrotic syndrome, type 7, 615008 (3),
DAGK7		
DAGLA		
DAGLALPHA		
DAGLB		
DAGLBETA		
DAI		
DAK	AR	triokinase and fmn cyclase deficiency syndrome, 618805 (3),
Dakar	AD	?inflammatory bowel disease (crohn disease) 30, 619079 (3),
DAL1		
DALRD1	AR	leukodystrophy, hypomyelinating, 9, 616140 (3),
DALRD2	AR	pontocerebellar hypoplasia, type 6, 611523 (3),
DALRD3	AR	?developmental and epileptic encephalopathy 86, 618910 (3),
DAM1		
DAM10		
DAM6		
DAMAGE		
DAMOX		
DAMS		
DAN	AR,AD	dyskeratosis congenita, 6, 616353 (3), ; pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 4, 616371 (3),
DAN15	AD	coffin-siris syndrome 1, 135900 (3),
DAN16		
DANCE	AR,AD	cutis laxa, type ia, 219100 (3), ; charcot-marie-tooth disease, demyelinating, type 1h, 619764 (3), ; macular degeneration, age-related, 3, 608895 (3), ; neuropathy, hereditary, with or without age-related macular degeneration, 608895 (3), ; ?cutis laxa, 2, 614434 (3),
DANCR		
DAND1		
DAND2		
DAND3	AD	tooth agenesis, selective, 9, 617275 (3),
DAND4		
DAND5		
DAND6	AR,AD	sclerosteosis 1, 269500 (3), ; craniodiaphyseal dysplasia, 122860 (3),
DAND7		
DANGER		
DANT1		
DANT2		
DANTE		
DAO		
DAO2		
DAOA	AD	{schizophrenia}, 181500 (2),
DAOA-AS		
DAOA-AS1		
DAOAAS		
DAP		
DAP-1		
DAP-2		
DAP-3		
DAP-AT	AR	rhizomelic chondrodysplasia punctata, type 2, 222765 (3),
DAP1		
DAP10		
DAP12	AR	polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 1, 221770 (3),
DAP13	AR	mitochondrial complex i deficiency, nuclear type 23, 618244 (3),
DAP3		
DAP4		
DAP5		
DAP6		
DAPAT	AR	rhizomelic chondrodysplasia punctata, type 2, 222765 (3),
DAPIT	AR	mitochondrial complex v (atp synthase) deficiency, nuclear type 6, 618683 (3),
DAPK		
DAPK1		
DAPK2		
DAPK3		
DAPLE	AD,AR	?spinocerebellar ataxia 40, 616053 (3), ; hydrocephalus, congenital, 1, 236600 (3),
DAPP1		
DAPPER	AD	townes-brocks syndrome 2, 617466 (3),
DAPPER1	AD	townes-brocks syndrome 2, 617466 (3),
DAPPER2		
DAPPER3		
DAPR		
DAR	AD	acrokeratosis verruciformis, 101900 (3), ; darier disease, 124200 (3),
DARC	AR,AD	[blood group, duffy system], 110700 (3), ; [white blood cell count qtl], 611862 (3), ; {malaria, vivax, protection against}, 611162 (3)
DARP		
DARPP-32		
DARS	AR	hypomyelination with brainstem and spinal cord involvement and leg spasticity, 615281 (3),
DARS1	AR	hypomyelination with brainstem and spinal cord involvement and leg spasticity, 615281 (3),
DARS2	AR	leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation, 611105 (3),
DASOX		
DASPO		
DasraB		
DAT	AR	parkinsonism-dystonia, infantile, 1, 613135 (3), ; {nicotine dependence, protection against}, 188890 (3)
DAT1	AR	parkinsonism-dystonia, infantile, 1, 613135 (3), ; {nicotine dependence, protection against}, 188890 (3)
DATF1		
DAU1	AR	ciliary dyskinesia, primary, 13, 613193 (3),
DAW1		
DAX1	XLR,XL	adrenal hypoplasia, congenital, 300200 (3), ; 46xy sex reversal 2, dosage-sensitive, 300018 (3),
DAXX		
DAZ		
DAZ1		
DAZ2		
DAZ3		
DAZ4		
DAZAP1		
DAZAP2		
DAZH		{spermatogenic failure, susceptibility to} (3)
DAZL		{spermatogenic failure, susceptibility to} (3)
DAZL1		{spermatogenic failure, susceptibility to} (3)
DAZLA		{spermatogenic failure, susceptibility to} (3)
DB1	AD	?cardiomyopathy, dilated, 1oo, 620247 (3),
DBA	AD	diamond-blackfan anemia 1, 105650 (3),
DBC-1		
DBC1		
DBC2	AD	developmental and epileptic encephalopathy 64, 618004 (3),
DBCCR1		
DBCCR1L		
DBCCR1L1		
DBCCR1L2		
DBCN	XL	subcortical laminal heterotopia, 300067 (3), ; lissencephaly, 300067 (3),
DBE-T		
DBET		
DBF4		
DBF4A		
DBF4B		
DBH	AR	orthostatic hypotension 1, due to dbh deficiency, 223360 (3),
DBI		
DBI-1		
DBK		
DBL		
DBM	AR	orthostatic hypotension 1, due to dbh deficiency, 223360 (3),
DBN1		
DBND	AR	hermansky-pudlak syndrome 7, 614076 (3),
DBNDD1		
DBNDD2		
DBNL		
DBP	AR	d-bifunctional protein deficiency, 261515 (3), ; perrault syndrome 1, 233400 (3),
DBP-5	AD	zttk syndrome, 617140 (3),
DBP-RB		
DBP1		
DBP2	AD	neuromuscular disease and ocular or auditory anomalies with or without seizures, 618733 (3),
Dbp4		
DBP5		
dbpA		
DBPB		
DBR1	AR	{encephalitis, acute, infection (viral)-induced, susceptibility to, 11}, 619441 (3),
DBS	AR	donnai-barrow syndrome, 222448 (3),
DBT	AR	maple syrup urine disease, type ii, 248600 (3),
DBX	XL,XLD,XLR	intellectual developmental disorder, syndromic, snijders blok type, 300958 (3),
DBX1		
DBY		
DC	XL	subcortical laminal heterotopia, 300067 (3), ; lissencephaly, 300067 (3),
DC-CK1		
DC-LAMP		
DC-SIGN		{hiv type 1, susceptibility to}, 609423 (3); {mycobacterium tuberculosis, susceptibility to}, 607948 (3); {dengue fever, protection against}, 614371 (3)
DC-SIGN1		{hiv type 1, susceptibility to}, 609423 (3); {mycobacterium tuberculosis, susceptibility to}, 607948 (3); {dengue fever, protection against}, 614371 (3)
DC-SIGN2		
DC-SIGNR		
DC-STAMP		
DC-UbP		
DC/B-CK		
DC11		
DC12		
DC15		
DC2		
DC3		
DC42	AD	intellectual developmental disorder, 41, 616944 (3), ; pierpont syndrome, 602342 (3),
DC44		
DC47		
DC50		
DC6		
DC7		
DC8		
DCAF1		
DCAF10		
DCAF11		
DCAF12		
DCAF13		
DCAF14	AD	chung-jansen syndrome, 617991 (3),
DCAF15		
DCAF17	AR	woodhouse-sakati syndrome, 241080 (3),
DCAF19		
DCAF2		
DCAF3		
DCAF4		
DCAF4L2		
DCAF5		
DCAF6		
DCAF7		
DCAF8	AD	?giant axonal neuropathy 2, 610100 (3),
DCAF9		
DCAL-2		
DCAL1		
DCAMKL1		
DCAMKL2		
DCAMKL3		
DCANP1		
DCBALD06		
DCBLD2		
DCC	AD,AR	mirror movements 1 and/or agenesis of the corpus callosum, 157600 (3), ; esophageal carcinoma, somatic, 133239 (3); colorectal cancer, somatic, 114500 (3); gaze palsy, familial horizontal, with progressive scoliosis, 2, 617542 (3),
DCC1		
DCCK1		
DCD		
DCD-1		
DCDC1		
DCDC2	AR	nephronophthisis 19, 616217 (3), ; ?deafness, 66, 610212 (3), ; sclerosing cholangitis, neonatal, 617394 (3),
DCDC2A	AR	nephronophthisis 19, 616217 (3), ; ?deafness, 66, 610212 (3), ; sclerosing cholangitis, neonatal, 617394 (3),
DCDC3		
DCDC3A		
DCDC3B		
DCDC3C		
DCDC4A	AR,AD	retinitis pigmentosa 1, 180100 (3),
DCDC4B	AD,AR	occult macular dystrophy, 613587 (3), ; retinitis pigmentosa 88, 618826 (3),
DCDC5		
DCE	AR	desmosterolosis, 602398 (3),
DCHS1	AD,AR	mitral valve prolapse 2, 607829 (3), ; van maldergem syndrome 1, 601390 (3),
DCHS2		
DCHT		
DCI		
Dcip1		
DCIR		
DCK		
DCK2		
DCL-1		
DCLAMP		
DCLK		
DCLK1		
DCLK2		
DCLK3		
DCLRE1A		
DCLRE1B	AR	dyskeratosis congenita, 8, 620133 (3),
DCLRE1C	AR	severe combined immunodeficiency, athabascan type, 602450 (3), ; omenn syndrome, 603554 (3),
DCN	AD	corneal dystrophy, congenital stromal, 610048 (3),
DCNP1		
DCOH	AR	hyperphenylalaninemia, bh4-deficient, d, 264070 (3),
DCOH2		
DCOHM		
DCP1	AR	{stroke, hemorrhagic}, 614519 (3); renal tubular dysgenesis, 267430 (3), ; {myocardial infarction, susceptibility to} (3); {microvascular complications of diabetes 3}, 612624 (3); [angiotensin i-converting enzyme, benign serum increase] (3); {sars, progression of} (3)
DCP1A		
DCP1B		
DCP2		
DCPS	AR	al-raqad syndrome, 616459 (3),
DCR	AR	[pentosuria], 260800 (3),
DcR1		
DcR2		
DCR2		
DcR3		
DCR3		
DCRA		
DCRB		
DCRC	AR	developmental and epileptic encephalopathy 55, 617599 (3),
DCRR1		
DCS-1	AR	al-raqad syndrome, 616459 (3),
DCS1	AR	al-raqad syndrome, 616459 (3),
DCSIGNR		
DCST1		
DCST2		
DCSTAMP		
DCT	AR	oculocutaneous albinism, type viii, 619165 (3),
DCT1	AR	anemia, hypochromic microcytic, with iron overload 1, 206100 (3),
DCTD		
DCTN-22		
DCTN-50		
DCTN1	AD,AR	neuronopathy, distal hereditary motor, type viib, 607641 (3), ; perry syndrome, 168605 (3), ; {amyotrophic lateral sclerosis, susceptibility to}, 105400 (3),
DCTN2		
DCTN3		
DCTN4		
DCTN5		
DCTN6		
DCTPP1		
DCUN1D1		
DCUN1D3		
DCUN1D4		
DCUN1D5		
DCUN1L1		
DCX	XL	subcortical laminal heterotopia, 300067 (3), ; lissencephaly, 300067 (3),
DCXR	AR	[pentosuria], 260800 (3),
DCYTB		
DD	AR	46xy sex reversal 8, 614279 (3),
DD1		
DD132	AD	ventricular tachycardia, catecholaminergic polymorphic, 4, 614916 (3), ; long qt syndrome 14, 616247 (3),
DD2	AR	46xy sex reversal 8, 614279 (3),
DD3		
DD4	AR	{46xy sex reversal 8, modifier of}, 614279 (3),
DD5		
DD96		
DDA3		
DDAH		
DDAH1		
DDAH2		
DDB1	AD	white-kernohan syndrome, 619426 (3),
DDB2	AR	xeroderma pigmentosum, group e, ddb-negative subtype, 278740 (3),
DDB27		
DDBB	AR	xeroderma pigmentosum, group e, ddb-negative subtype, 278740 (3),
DDC	AR	aromatic l-amino acid decarboxylase deficiency, 608643 (3),
DDCT		
DDDD		
DDEF1		
DDEF2		
DDEFL1		
DDF1		
DDH		
DDH1		
DDH2	AR	46xy sex reversal 8, 614279 (3),
DDHD1	AR	spastic paraplegia 28, 609340 (3),
DDHD2	AR	spastic paraplegia 54, 615033 (3),
DDIAS		
DDIT1		
DDIT2		
DDIT3		
DDIT4		
DDIT4L		
DDK1	AR	mitochondrial dna depletion syndrome 11, 615084 (3),
DDN		
DDO		
DDOST	AR	congenital disorder of glycosylation, type ir, 614507 (3),
DDP	XLR,XL	mohr-tranebjaerg syndrome, 304700 (3),
DDP2		
DDPAC	AD,AR,MF	supranuclear palsy, progressive, 601104 (3), ; supranuclear palsy, progressive atypical, 260540 (3), ; dementia, frontotemporal, with or without parkinsonism, 600274 (3), ; {parkinson disease, susceptibility to}, 168600 (3), ; pick disease, 172700 (3),
DDR1		
DDR2	AD,AR	warburg-cinotti syndrome, 618175 (3), ; spondylometaepiphyseal dysplasia, short limb-hand type, 271665 (3),
DDR3		
DDRGK1	AR	spondyloepimetaphyseal dysplasia, shohat type, 602557 (3),
DDT		
DDVit-1		
DDVIT1		
DDX		
DDX1		
DDX10		
DDX11	AR	warsaw breakage syndrome, 613398 (3),
DDX13	AR	trichohepatoenteric syndrome 2, 614602 (3),
DDX14	XL,XLD,XLR	intellectual developmental disorder, syndromic, snijders blok type, 300958 (3),
DDX15		
DDX16	AD	neuromuscular disease and ocular or auditory anomalies with or without seizures, 618733 (3),
DDX17		
DDX18		
DDX19		
DDX19B		
DDX20		
DDX21		
DDX23		
DDX24		
DDX25		
DDX26		
DDX26A		
DDX27		
DDX28		
DDX29		
DDX2A		
DDX2B		
DDX3	XL,XLD,XLR	intellectual developmental disorder, syndromic, snijders blok type, 300958 (3),
DDX30	AD	neurodevelopmental disorder with variable motor and speech impairment, 617804 (3),
DDX31		
DDX32		
DDX33		
DDX34		
DDX36		
DDX37	AR,AD	neurodevelopmental disorder with brain anomalies and with or without vertebral or cardiac anomalies, 618731 (3), ; 46xy sex reversal 11, 273250 (3),
DDX38	AR	retinitis pigmentosa 84, 618220 (3),
DDX39		
DDX39A		
DDX39B		
DDX3X	XL,XLD,XLR	intellectual developmental disorder, syndromic, snijders blok type, 300958 (3),
DDX3Y		
DDX4		
DDX40		
DDX41	AD	{myeloproliferative/lymphoproliferative neoplasms, familial (multiple types), susceptibility to}, 616871 (3),
DDX42		
DDX43		
DDX46		
DDX47		
DDX48	AR	robin sequence with cleft mandible and limb anomalies, 268305 (3),
DDX5		
DDX50		
DDX52		
DDX53		
DDX54		
DDX55		
DDX56		
DDX58	AD	singleton-merten syndrome 2, 616298 (3),
DDX59	AR	orofaciodigital syndrome v, 174300 (3),
DDX6	AD	intellectual developmental disorder with impaired language and dysmorphic facies, 618653 (3),
DDX60		
DDX60L		
DDX8		
DDX9		
DDXBP1		
DDXL		
DE-epi2		
DEADC1		
DEAF1	AD,AR	vulto-van silfout-de vries syndrome, 615828 (3), ; neurodevelopmental disorder with hypotonia, impaired expressive language, and with or without seizures, 617171 (3),
DEANR1		
DEAR1		
DEBT91		
DEC-205		
DEC1		
DEC2	AD	[short sleep, familial natural, 1], 612975 (3),
DECR		
DECR1		
DECR2		
DECTIN-1	AR	candidiasis, familial, 4, 613108 (3), ; {aspergillosis, susceptibility to}, 614079 (3)
dectin-2		
Dectin-3		
DED		
DEDAF		
DEDD		
DEDD1		
DEDD2		
DEEPEST		
DEF		
DEF-3		
DEF1		
DEF3		
DEF4		
DEF5		
DEF6	AR	immunodeficiency 87 and autoimmunity, 619573 (3),
DEFA1		
DEFA2		
DEFA3		
DEFA4		
DEFA5		
DEFA6		
DEFB-1		
DEFB-14		
DEFB-18		
DEFB-19		
DEFB-2		
DEFB-20		
DEFB-21		
DEFB-22		
DEFB-23		
DEFB-26		
DEFB1		
DEFB101		
DEFB102		
DEFB103B		
DEFB114		
DEFB118		
DEFB119		
DEFB120		
DEFB121		
DEFB122		
DEFB122P		
DEFB123		
DEFB126		
DEFB2		
DEFB4		
DEFB4A		
DEFCAP	AR,AD	{vitiligo-associated multiple autoimmune disease susceptibility 1}, 606579 (3); ?respiratory papillomatosis, juvenile recurrent, congenital, 618803 (3), ; autoinflammation with arthritis and dyskeratosis, 617388 (3), ; palmoplantar carcinoma, multiple self-healing, 615225 (3),
DEFT		
DEG1	AR	neurodevelopmental disorder with microcephaly and gray sclerae, 617051 (3),
DEGA		
DEGS-1	AR	leukodystrophy, hypomyelinating, 18, 618404 (3),
DEGS1	AR	leukodystrophy, hypomyelinating, 18, 618404 (3),
DEGS2		
DEHAL1	AR	thyroid dyshormonogenesis 4, 274800 (3),
DEIN		
DEK		leukemia, acute nonlymphocytic, 125264 (2)
DEL1		
DELE		
DELE1		
DELEC1		
DelGEF		
DELGIP		
DELGIP1		
DELTA	AD	gabriele-de vries syndrome, 617557 (3),
Delta1		
DEM1		
DEME-6		
DEN1		
DENN	AR	neurodevelopmental disorder with dysmorphic facies, impaired speech and hypotonia, 619005 (3), ; deeah syndrome, 619004 (3),
DENND11		
DENND1A		
DENND1B		
DENND1C		
DENND2A		
DENND2B		
DENND2D		
DENND3		
DENND4A		
DENND4B		
DENND5A	AR	developmental and epileptic encephalopathy 49, 617281 (3),
DENND5B		
DENND7A	AR	charcot-marie-tooth disease, type 4b3, 615284 (3),
DENND7B	AR	charcot-marie-tooth disease, type 4b2, 604563 (3),
DENND8A		
DENND8B	AD	birt-hogg-dube syndrome, 135150 (3), ; colorectal cancer, somatic, 114500 (3); pneumothorax, primary spontaneous, 173600 (3), ; renal carcinoma, chromophobe, somatic, 144700 (3)
DENND9	AD	frontotemporal dementia and/or amyotrophic lateral sclerosis 1, 105550 (3),
DENNL72	AD	frontotemporal dementia and/or amyotrophic lateral sclerosis 1, 105550 (3),
DENR		
densin-180		
Dent-2	XLR,XL	dent disease 2, 300555 (3), ; lowe syndrome, 309000 (3),
DENTS	XLR,XL	proteinuria, low molecular weight, with hypercalciuric nephrocalcinosis, 308990 (3), ; hypophosphatemic rickets, 300554 (3), ; dent disease 1, 300009 (3), ; nephrolithiasis, type i, 310468 (3),
DENTT		
DEOC		
DEP.2		
DEP.5	AD	epilepsy, familial focal, with variable foci 1, 604364 (3),
DEP.6		
DEP.8		
DEP1		colon cancer, somatic, 114500 (3)
DEPC-1		
DEPDC1		
DEPDC1A		
DEPDC1B		
DEPDC2		
DEPDC5	AD	epilepsy, familial focal, with variable foci 1, 604364 (3),
DEPDC6		
DEPDC7		
DEPP		
DEPP1		
DEPTOR		
DER-1		
DER1		
DER12		
DER3		
DER4		
DER7	AR	congenital disorder of glycosylation, type iib, 606056 (3),
DERA		
DERL1		
DERL2		
DERL3		
derlin-1		
derlin-2		
derlin-3		
Dermo-1	AD,AR	ablepharon-macrostomia syndrome, 200110 (3), ; barber-say syndrome, 209885 (3), ; focal facial dermal dysplasia 3, setleis type, 227260 (3),
DERMO1	AD,AR	ablepharon-macrostomia syndrome, 200110 (3), ; barber-say syndrome, 209885 (3), ; focal facial dermal dysplasia 3, setleis type, 227260 (3),
DERP11		
DERP13	AR	glutaric aciduria iii, 231690 (3),
DERP2		
DERP5		
DERP6		
DERP7		
DERP9		
DES	AD,AR	scapuloperoneal syndrome, neurogenic, kaeser type, 181400 (3), ; cardiomyopathy, dilated, 1i, 604765 (3), ; myopathy, myofibrillar, 1, 601419 (3),
Des-1	AR	leukodystrophy, hypomyelinating, 18, 618404 (3),
DES1	AR	leukodystrophy, hypomyelinating, 18, 618404 (3),
DES2		
DES6		
DESC1		
DESI-1		
DESI-2		
DESI1		
DESI2		
desnutrin	AR	neutral lipid storage disease with myopathy, 610717 (3),
DESP4	AR	microcephaly, congenital cataract, and psoriasiform dermatitis, 616834 (3),
DESR1		
DET1		
DEUP1		
DEXI		
DEXRAS1		
DF	AR	complement factor d deficiency, 613912 (3),
DF5L		
DFCP1		
DFF-40		
DFF-45		
DFF1		
DFF40		
DFF45		
DFFA		
DFFB		
DFFRX	XL,XLR,XLD	intellectual developmental disorder, 99, 300919 (3), ; intellectual developmental disorder, 99, syndromic, female-restricted, 300968 (3),
DFFRY	YL	spermatogenic failure, 2, 415000 (3),
DFN1	XLR,XL	mohr-tranebjaerg syndrome, 304700 (3),
DFN2	XLR,XL	arts syndrome, 301835 (3), ; phosphoribosylpyrophosphate synthetase superactivity, 300661 (3), ; charcot-marie-tooth disease, 5, 311070 (3), ; deafness, 1, 304500 (3), ; gout, prps-related, 300661 (3),
DFN3	XL,XLR	deafness, 2, 304400 (3),
DFN6	XL,XLR,XLD	myopathy, distal, 7, adult-onset, 301075 (3), ; deafness, 4, 300066 (3),
DFNA1	AD,AR	deafness, 1, with or without thrombocytopenia, 124900 (3), ; seizures, cortical blindness, microcephaly syndrome, 616632 (3),
DFNA10	AD	?cardiomyopathy, dilated, 1j, 605362 (3), ; deafness, 10, 601316 (3),
DFNA11	AR,AD	deafness, 2, 600060 (3), ; usher syndrome, type 1b, 276900 (3), ; deafness, 11, 601317 (3),
DFNA12	AD,AR	deafness, 8/12, 601543 (3), ; deafness, 21, 603629 (3),
DFNA13	AD,AR	deafness, 13, 601868 (3), ; otospondylomegaepiphyseal dysplasia, 215150 (3), ; fibrochondrogenesis 2, 614524 (3), ; deafness, 53, 609706 (3), ; otospondylomegaepiphyseal dysplasia, 184840 (3),
DFNA14	AD,AR	deafness, 6/14/38, 600965 (3), ; ?cataract 41, 116400 (3), ; wolfram-like syndrome, 614296 (3), ; {diabetes mellitus, noninsulin-dependent, association with}, 125853 (3), ; wolfram syndrome 1, 222300 (3),
DFNA15	AD	deafness, 15, 602459 (3),
DFNA17	AD	macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss, 155100 (3), ; deafness, 17, 603622 (3),
DFNA2	AD,AR,AD	deafness, 2a, 600101 (3), |deafness, digenic, gjb2/gjb3, 220290 (3), digenic ; deafness, (3); deafness, 2b, 612644 (3), ; erythrokeratodermia variabilis et progressiva 1, 133200 (3), ; deafness, with peripheral neuropathy (3)
DFNA20	AD	deafness, 20/26, 604717 (3), ; baraitser-winter syndrome 2, 614583 (3),
DFNA22	AD,AR	deafness, 22, with hypertrophic cardiomyopathy, 606346 (3), ; deafness, 22, 606346 (3), ; deafness, 37, 607821 (3),
DFNA23	AD	deafness, 23, 605192 (3), ; branchiootic syndrome 3, 608389 (3),
DFNA25	AD	deafness, 25, 605583 (3),
DFNA26	AD	deafness, 20/26, 604717 (3), ; baraitser-winter syndrome 2, 614583 (3),
DFNA27	AD	deafness, 27, 612431 (3), ; {wilms tumor 6, susceptibility to}, 616806 (3), ; fibromatosis, gingival, 5, 617626 (3),
DFNA28	AD,AR	deafness, 28, 608641 (3), ; ectodermal dysplasia/short stature syndrome, 616029 (3), ; corneal dystrophy, posterior polymorphous, 4, 618031 (3),
DFNA3	AD,AR,AD,AR	ectodermal dysplasia 2, clouston type, 129500 (3), ; deafness, 3b, 612643 (3), ; deafness, 1b, 612645 (3), ; deafness, digenic gjb2/gjb6, 220290 (3), digenic |keratoderma, palmoplantar, with deafness, 148350 (3), ; deafness, 1a, 220290 (3), digenic ; deafness, 3a, 601544 (3), ; hystrix-like ichthyosis with deafness, 602540 (3), ; bart-pumphrey syndrome, 149200 (3), ; keratitis-ichthyosis-deafness syndrome, 148210 (3), ; vohwinkel syndrome, 124500 (3),
DFNA31	AD,AR	deafness, 9, 601369 (3), ; ?deafness, 110, 618094 (3),
DFNA34	AD	cinca syndrome, 607115 (3), ; familial cold inflammatory syndrome 1, 120100 (3), ; keratoendothelitis fugax hereditaria, 148200 (3), ; deafness, 34, with or without inflammation, 617772 (3), ; muckle-wells syndrome, 191900 (3),
DFNA36	AD,AR	deafness, 36, 606705 (3), ; deafness, 7, 600974 (3),
DFNA37	AR,AD	fibrochondrogenesis 1, 228520 (3), ; stickler syndrome, type ii, 604841 (3), ; marshall syndrome, 154780 (3), ; deafness, 37, 618533 (3), ; {lumbar disc herniation, susceptibility to}, 603932 (3)
DFNA38	AD,AR	deafness, 6/14/38, 600965 (3), ; ?cataract 41, 116400 (3), ; wolfram-like syndrome, 614296 (3), ; {diabetes mellitus, noninsulin-dependent, association with}, 125853 (3), ; wolfram syndrome 1, 222300 (3),
DFNA39	AD	dentinogenesis imperfecta, shields type iii, 125500 (3), ; dentinogenesis imperfecta, shields type ii, 125490 (3), ; dentin dysplasia, type ii, 125420 (3), ; deafness, 39, with dentinogenesis, 605594 (3),
DFNA4	AD	?peripheral neuropathy, myopathy, hoarseness, and hearing loss, 614369 (3), ; deafness, 4a, 600652 (3),
DFNA40	AD	deafness, 40, 616357 (3),
DFNA41	AD	deafness, 41, 608224 (3),
DFNA42	AD	deafness, 15, 602459 (3),
DFNA44	AD	?deafness, 44, 607453 (3),
DFNA48		
DFNA4B	AD,AR	deafness, 4b, 614614 (3), ; deafness, 113, 618410 (3),
DFNA5	AD	deafness, 5, 600994 (3),
DFNA50	AD	deafness, 50, 613074 (3),
DFNA51	AR	hypercholanemia, familial 1, 607748 (3), ; cholestasis, progressive familial intrahepatic 4, 615878 (3),
DFNA52	AD	deafness, 15, 602459 (3),
DFNA56	AD	deafness, 56, 615629 (3),
DFNA6	AD,AR	deafness, 6/14/38, 600965 (3), ; ?cataract 41, 116400 (3), ; wolfram-like syndrome, 614296 (3), ; {diabetes mellitus, noninsulin-dependent, association with}, 125853 (3), ; wolfram syndrome 1, 222300 (3),
DFNA64	AD	deafness, 64, 614152 (3),
DFNA65	AR,AD	deafness, 86, 614617 (3), ; epilepsy, rolandic, with paroxysmal exercise-induce dystonia and writer's cramp, 608105 (3), ; myoclonic epilepsy, infantile, familial, 605021 (3), ; deafness, 65, 616044 (3), ; developmental and epileptic encephalopathy 16, 615338 (3), ; doors syndrome, 220500 (3),
DFNA66	AD	?deafness, 66, 616969 (3),
DFNA67	AD	deafness, 67, 616340 (3),
DFNA68	AD	?deafness, 68, 616707 (3),
DFNA69	AD,AR	hyperpigmentation with or without hypopigmentation, 145250 (3), ; waardenburg syndrome, type 2f, 619947 (3), ; deafness, 69, unilateral or asymmetric, 616697 (3), ; [skin/hair/eye pigmentation 7, blond/brown hair], 611664 (3)
DFNA70	AD	?deafness, 70, 616968 (3),
DFNA71	AR,AD	developmental and epileptic encephalopathy 81, 618663 (3), ; ?deafness, 71, 617605 (3), ; ?polyendocrine-polyneuropathy syndrome, 616113 (3),
DFNA72	AD	?deafness, 72, 617606 (3),
DFNA8	AD,AR	deafness, 8/12, 601543 (3), ; deafness, 21, 603629 (3),
DFNA9	AD,AR	deafness, 9, 601369 (3), ; ?deafness, 110, 618094 (3),
DFNB1	AD,AR	keratoderma, palmoplantar, with deafness, 148350 (3), ; deafness, 1a, 220290 (3), digenic ; deafness, 3a, 601544 (3), ; hystrix-like ichthyosis with deafness, 602540 (3), ; bart-pumphrey syndrome, 149200 (3), ; keratitis-ichthyosis-deafness syndrome, 148210 (3), ; vohwinkel syndrome, 124500 (3),
DFNB10	AR	deafness, 8/10, 601072 (3),
DFNB100	AR	deafness, 100, 618422 (3),
DFNB101	AR	?deafness, 101, 615837 (3),
DFNB102	AR	?deafness, 103, 616042 (3),
DFNB105	AR	deafness, 32, with or without immotile sperm, 608653 (3),
DFNB11	AD,AR	deafness, 36, 606705 (3), ; deafness, 7, 600974 (3),
DFNB117	AR	?deafness, 117, 619174 (3),
DFNB12	AR,AD	usher syndrome, type 1d, 601067 (3), digenic ; {pituitary adenoma 5, multiple types}, 617540 (3), ; usher syndrome, type 1d/f digenic, 601067 (3), digenic ; deafness, 12, 601386 (3),
DFNB15	AR	deafness, 15, 601869 (3),
DFNB16	AR	deafness, 16, 603720 (3),
DFNB18	AR	usher syndrome, type 1c, 276904 (3), ; deafness, 18a, 602092 (3),
DFNB2	AR,AD	deafness, 2, 600060 (3), ; usher syndrome, type 1b, 276900 (3), ; deafness, 11, 601317 (3),
DFNB21	AD,AR	deafness, 8/12, 601543 (3), ; deafness, 21, 603629 (3),
DFNB22	AR	deafness, 22, 607039 (3),
DFNB23	AR	usher syndrome, type 1d/f digenic, 601067 (3), digenic ; deafness, 23, 609533 (3), ; usher syndrome, type 1f, 602083 (3),
DFNB24	AR	deafness, 24, 611022 (3),
DFNB25	AR	deafness, 25, 613285 (3),
DFNB26	AR	?deafness, 26, 605428 (3),
DFNB28	AR	deafness, 28, 609823 (3),
DFNB29	AR	deafness, 29, 614035 (3),
DFNB3	AR	deafness, 3, 600316 (3),
DFNB30	AR	deafness, 30, 607101 (3),
DFNB31	AR	deafness, 31, 607084 (3), ; usher syndrome, type 2d, 611383 (3),
DFNB32	AR	deafness, 32, with or without immotile sperm, 608653 (3),
DFNB35	AR	deafness, 35, 608565 (3),
DFNB36	AD,AR	deafness, neurosensory, without vestibular involvement, 609006 (3), ; deafness, 36, 609006 (3), ; ?usher syndrome, type 1m, 618632 (3),
DFNB37	AD,AR	deafness, 22, with hypertrophic cardiomyopathy, 606346 (3), ; deafness, 22, 606346 (3), ; deafness, 37, 607821 (3),
DFNB39	AR	deafness, 39, 608265 (3),
DFNB4	AR	deafness, 4, with enlarged vestibular aqueduct, 600791 (3), ; pendred syndrome, 274600 (3),
DFNB42	AR	deafness, 42, 609646 (3),
DFNB44	AR	?deafness, 44, 610154 (3),
DFNB48	AR	deafness, 48, 609439 (3), ; usher syndrome, type ij, 614869 (3),
DFNB49	AR	deafness, 49, 610153 (3),
DFNB53	AD,AR	deafness, 13, 601868 (3), ; otospondylomegaepiphyseal dysplasia, 215150 (3), ; fibrochondrogenesis 2, 614524 (3), ; deafness, 53, 609706 (3), ; otospondylomegaepiphyseal dysplasia, 184840 (3),
DFNB57	AR	deafness, 57, 618003 (3), ; {retinal disease in usher syndrome type iia, modifier of}, 276901 (3), ; usher syndrome, type iic, gpr98/pdzd7 digenic, 605472 (3), digenic
DFNB59	AR	deafness, 59, 610220 (3),
DFNB6	AR,AR	auditory neuropathy, 1, 601071 (3), ; deafness, 9, 601071 (3), |deafness, 6, 600971 (3),
DFNB60		{rheumatoid arthritis, susceptibility to}, 180300 (3)
DFNB61	AR	?deafness, 61, 613865 (3),
DFNB63	AR	deafness, 63, 611451 (3),
DFNB66	AR	nephronophthisis 19, 616217 (3), ; ?deafness, 66, 610212 (3), ; sclerosing cholangitis, neonatal, 617394 (3),
DFNB67	AR	deafness, 67, 610265 (3),
DFNB68	AR	deafness, 68, 610419 (3),
DFNB7	AD,AR	deafness, 36, 606705 (3), ; deafness, 7, 600974 (3),
DFNB70	AD,AR	spinocerebellar ataxia 25, 608703 (3), ; deafness, 70, with or without adult-onset neurodegeneration, 614934 (3), ; combined oxidative phosphorylation deficiency 13, 614932 (3),
DFNB72	AR	deafness, 15, 601869 (3),
DFNB73	AR	sensorineural deafness with mild renal dysfunction, 602522 (3), ; bartter syndrome, type 4a, 602522 (3),
DFNB74	AR	deafness, 74, 613718 (3),
DFNB76	AR	deafness, 76, 615540 (3),
DFNB77	AR	deafness, 77, 613079 (3),
DFNB79	AR	deafness, 79, 613307 (3),
DFNB8	AR	deafness, 8/10, 601072 (3),
DFNB82	AR	chudley-mccullough syndrome, 604213 (3),
DFNB84	AD,AR	deafness, 73, 617663 (3), ; deafness, 84a, 613391 (3),
DFNB86	AR,AD	deafness, 86, 614617 (3), ; epilepsy, rolandic, with paroxysmal exercise-induce dystonia and writer's cramp, 608105 (3), ; myoclonic epilepsy, infantile, familial, 605021 (3), ; deafness, 65, 616044 (3), ; developmental and epileptic encephalopathy 16, 615338 (3), ; doors syndrome, 220500 (3),
DFNB88	AR,AD	?deafness, 88, 615429 (3), ; ?deafness, 81, 619500 (3),
DFNB89	AR	deafness, 89, 613916 (3), ; leukoencephalopathy, progressive, infantile-onset, with or without deafness, 619147 (3), ; ?charcot-marie-tooth disease, intermediate, b, 613641 (3), ; deafness, congenital, and adult-onset progressive leukoencephalopathy, 619196 (3),
DFNB9	AR	auditory neuropathy, 1, 601071 (3), ; deafness, 9, 601071 (3),
DFNB91	AR	?deafness, 91, 613453 (3),
DFNB93	AR	deafness, 93, 614899 (3),
DFNB94	AR	combined oxidative phosphorylation deficiency 24, 616239 (3), ; ?deafness, 94, 618434 (3),
DFNB95	AR	deafness, 15, 601869 (3),
DFNB97	AD,AR	renal cell carcinoma, papillary, 1, familial and somatic, 605074 (3); ?arthrogryposis, distal, type 11, 620019 (3), ; hepatocellular carcinoma, childhood type, somatic, 114550 (3); {osteofibrous dysplasia, susceptibility to}, 607278 (3), ; ?deafness, 97, 616705 (3),
DFNB98	AR	tooth agenesis, selective, 10, 620173 (3), ; ?deafness, 98, 614861 (3), ; ectodermal dysplasia 14, hair/tooth type with or without hypohidrosis, 618180 (3),
DFNB99	AR	deafness, 99, 618481 (3),
DFNM1	AR,AD	{?deafness, 26, modifier of}, 605429 (3),
DFNX1	XLR,XL	arts syndrome, 301835 (3), ; phosphoribosylpyrophosphate synthetase superactivity, 300661 (3), ; charcot-marie-tooth disease, 5, 311070 (3), ; deafness, 1, 304500 (3), ; gout, prps-related, 300661 (3),
DFNX2	XL,XLR	deafness, 2, 304400 (3),
DFNX4	XL,XLR,XLD	myopathy, distal, 7, adult-onset, 301075 (3), ; deafness, 4, 300066 (3),
DFNX5	XLR,XL	combined oxidative phosphorylation deficiency 6, 300816 (3), ; cowchock syndrome, 310490 (3), ; spondyloepimetaphyseal dysplasia, with hypomyelinating leukodystrophy, 300232 (3), ; deafness, 5, 300614 (3),
DFS70		
Dfy	AR,AD	[blood group, duffy system], 110700 (3), ; [white blood cell count qtl], 611862 (3), ; {malaria, vivax, protection against}, 611162 (3)
DG6		
DGAT	AR	diarrhea 7, protein-losing enteropathy type, 615863 (3),
DGAT1	AR	diarrhea 7, protein-losing enteropathy type, 615863 (3),
DGAT2		
DGAT2L		
DGAT2L1		
DGAT2L2		
DGAT2L3		
DGAT2L4		
DGAT2L5		
DGAT2L6		
DGCR1		
DGCR10		
DGCR13		
DGCR14		
DGCR2		
DGCR5		
DGCR6		
DGCR6L		
DGCR8		
DGCR9		
DGCRK6		
DGI1	AD	dentinogenesis imperfecta, shields type iii, 125500 (3), ; dentinogenesis imperfecta, shields type ii, 125490 (3), ; dentin dysplasia, type ii, 125420 (3), ; deafness, 39, with dentinogenesis, 605594 (3),
dGK	AR	portal hypertension, noncirrhotic, 1, 617068 (3), ; progressive external ophthalmoplegia with mitochondrial dna deletions, 4, 617070 (3), ; mitochondrial dna depletion syndrome 3 (hepatocerebral type), 251880 (3),
DGK	AR	{hemolytic uremic syndrome, atypical, susceptibility to, 7}, 615008 (3), ; nephrotic syndrome, type 7, 615008 (3),
DGK-alpha		
DGK-BETA		
DGK-IOTA		
DGK-ZETA		
DGKA		
DGKB		
DGKD		
DGKdelta		
DGKE	AR	{hemolytic uremic syndrome, atypical, susceptibility to, 7}, 615008 (3), ; nephrotic syndrome, type 7, 615008 (3),
DGKeta		
DGKG		
DGKH		
DGKI		
DGKK		
DGKQ		
DGKZ		
DGPT	AR	myasthenic syndrome, congenital, 13, with tubular aggregates, 614750 (3), ; congenital disorder of glycosylation, type ij, 608093 (3),
DGS-A		
DGS-B		
DGS-C		
DGS-H		
DGSI		
DGSX	XLR,XL	wilms tumor, somatic, 194070 (3); simpson-golabi-behmel syndrome, type 1, 312870 (3),
dgt3		
dgt5		
dgt6		
DGU	AR	immunodeficiency with hyper igm, type 5, 608106 (3),
DGUOK	AR	portal hypertension, noncirrhotic, 1, 617068 (3), ; progressive external ophthalmoplegia with mitochondrial dna deletions, 4, 617070 (3), ; mitochondrial dna depletion syndrome 3 (hepatocerebral type), 251880 (3),
dHand		
DHAPAT	AR	rhizomelic chondrodysplasia punctata, type 2, 222765 (3),
DHC1	AD	charcot-marie-tooth disease, axonal, type 2o, 614228 (3), ; spinal muscular atrophy, lower extremity-pre 1, ad, 158600 (3), ; cortical dysplasia, complex, with other brain malformations 13, 614563 (3),
DHC1b	AR	short-rib thoracic dysplasia 3 with or without polydactyly, 613091 (3), digenic
DHC2	AR	short-rib thoracic dysplasia 3 with or without polydactyly, 613091 (3), digenic
DHC3		
DHCD1	AR	spermatogenic failure 65, 619712 (3),
DHCR14A		
DHCR14B	AD,AR	pelger-huet anomaly, 169400 (3), ; ?reynolds syndrome, 613471 (3), ; rhizomelic skeletal dysplasia with or without pelger-huet anomaly, 618019 (3), ; greenberg skeletal dysplasia, 215140 (3),
DHCR24	AR	desmosterolosis, 602398 (3),
DHCR7	AR	smith-lemli-opitz syndrome, 270400 (3),
DHDDS	AD,AR	developmental delay and seizures with or without movement abnormalities, 617836 (3), ; ?congenital disorder of glycosylation, type 1bb, 613861 (3), ; retinitis pigmentosa 59, 613861 (3),
DHDH		
DHDPS1		
DHDPS2	AR	hyperoxaluria, primary, type iii, 613616 (3),
DHDPSL	AR	hyperoxaluria, primary, type iii, 613616 (3),
DHEA-ST		
DHFR	AR	megaloblastic anemia due to dihydrofolate reductase deficiency, 613839 (3),
DHFR1	AR	megaloblastic anemia due to dihydrofolate reductase deficiency, 613839 (3),
DHFR2		
DHFRL1		
DHFRP4		
DHH	AR	46xy gonadal dysgenesis with minifascicular neuropathy, 607080 (3), ; 46xy sex reversal 7, 233420 (3),
DHHC15		
DHHC2		
DHHC20		
DHHC21		
DHHC3		
DHHC5		
DHHC7		
DHHC8		
DHHC9	XL	intellectual developmental disorder, syndromic, raymond type, 300799 (3),
DHLAG		
DHLP1		
DHODH	AR	miller syndrome, 263750 (3),
DHOF	XLD,XL	focal dermal hypoplasia, 305600 (3),
DHPase	AR	dihydropyrimidinuria, 222748 (3),
DHPDHase	AR	dihydropyrimidine dehydrogenase deficiency, 274270 (3), ; 5-fluorouracil toxicity, 274270 (3),
DHPR	AR	hyperphenylalaninemia, bh4-deficient, c, 261630 (3),
DHPRP2		
DHPS	AR	neurodevelopmental disorder with seizures and speech and walking impairment, 618480 (3),
DHQU		{breast cancer, poor survival after chemotherapy for} (3); {leukemia, post-chemotherapy, susceptibility to} (3); {benzene toxicity, susceptibility to} (3)
DHQV	AD	{?breast cancer susceptibility}, 114480 (1), somatic mutation,
Dhr1	AR,AD	neurodevelopmental disorder with brain anomalies and with or without vertebral or cardiac anomalies, 618731 (3), ; 46xy sex reversal 11, 273250 (3),
Dhr2		
DHRC		
DHRD	AD	doyne honeycomb degeneration of retina, 126600 (3),
DHRS1		
DHRS10		
DHRS11		
DHRS12		
DHRS13		
DHRS2		
DHRS3		
DHRS4		
DHRS4-AS1		
DHRS4L1		
DHRS4L2		
DHRS5X		
DHRS5Y		
DHRS7		
DHRS7B		
DHRS7C		
DHRS8		
DHRS9		
DHRSX		
DHRSXY		
DHRSY		
DHSR	AR	erythrokeratodermia variabilis et progressiva 4, 617526 (3),
DHTKD1	AD,AR	?charcot-marie-tooth disease, axonal, type 2q, 615025 (3), ; alpha-aminoadipic and alpha-ketoadipic aciduria, 204750 (3),
DHTR	XLR,AD,XL	androgen insensitivity, partial, with or without breast cancer, 312300 (3), ; {prostate cancer, susceptibility to}, 176807 (3), somatic mutation, ; androgen insensitivity, 300068 (3), ; spinal and bulbar muscular atrophy of kennedy, 313200 (3), ; hypospadias 1, 300633 (3),
DHX15		
DHX16	AD	neuromuscular disease and ocular or auditory anomalies with or without seizures, 618733 (3),
DHX29		
DHX30	AD	neurodevelopmental disorder with variable motor and speech impairment, 617804 (3),
DHX32		
DHX33		
DHX34		
DHX36		
DHX37	AR,AD	neurodevelopmental disorder with brain anomalies and with or without vertebral or cardiac anomalies, 618731 (3), ; 46xy sex reversal 11, 273250 (3),
DHX38	AR	retinitis pigmentosa 84, 618220 (3),
DHX40		
DHX58		
DHX8		
DHX9		
DI	AD,AR	[blood group, swann], 601550 (3); [blood group, wright], 112050 (3); distal renal tubular acidosis 1, 179800 (3), ; [blood group, waldner], 112010 (3); spherocytosis, type 4, 612653 (3), ; [blood group, froese], 601551 (3); distal renal tubular acidosis 4 with hemolytic anemia, 611590 (3), ; {malaria, resistance to}, 611162 (3); cryohydrocytosis, 185020 (3), ; ovalocytosis, sa type, 166900 (3), ; [blood group, diego], 110500 (3)
DI-CMTB	AD,AR	centronuclear myopathy 1, 160150 (3), ; charcot-marie-tooth disease, axonal type 2m, 606482 (3), ; charcot-marie-tooth disease, intermediate b, 606482 (3), ; lethal congenital contracture syndrome 5, 615368 (3),
Di-Ras1		
Di-Ras2		
DIA	XLD,XL	?premature ovarian failure 2a, 300511 (3),
DIA1	AR	methemoglobinemia, type i, 250800 (3), ; methemoglobinemia, type ii, 250800 (3),
DIA1R		
DIA2	XLD,XL	?premature ovarian failure 2a, 300511 (3),
DIA4		{breast cancer, poor survival after chemotherapy for} (3); {leukemia, post-chemotherapy, susceptibility to} (3); {benzene toxicity, susceptibility to} (3)
DIA6	AD	{?breast cancer susceptibility}, 114480 (1), somatic mutation,
DIABLO	AD	deafness, 64, 614152 (3),
DIABLO-S	AD	deafness, 64, 614152 (3),
DIAPH1	AD,AR	deafness, 1, with or without thrombocytopenia, 124900 (3), ; seizures, cortical blindness, microcephaly syndrome, 616632 (3),
DIAPH2	XLD,XL	?premature ovarian failure 2a, 300511 (3),
DIAPH2-AS1		
DIAPH3	AD	auditory neuropathy, 1, 609129 (3),
DIB1	AR	burn-mckeown syndrome, 608572 (3),
DIBD1	AR	gillessen-kaesbach-nishimura syndrome, 263210 (3), ; congenital disorder of glycosylation, type il, 608776 (3),
DIC	AR	?mitochondrial dna depletion syndrome 19, 618972 (3),
DIC1	AR	ciliary dyskinesia, primary, 1, with or without situs inversus, 244400 (3),
DIC2	AR	ciliary dyskinesia, primary, 9, with or without situs inversus, 612444 (3),
DIC3		
DIC4		
DIC5	AR	short-rib thoracic dysplasia 11 with or without polydactyly, 615633 (3),
DIC6	AR	short-rib thoracic dysplasia 8 with or without polydactyly, 615503 (3),
DIC74	AR	neurodevelopmental disorder with microcephaly and structural brain anomalies, 618492 (3),
DICE1		
Dicer	AD	pleuropulmonary blastoma, 601200 (3), ; goiter, multinodular 1, with or without sertoli-leydig cell tumors, 138800 (3), ; glow syndrome, somatic mosaic, 618272 (3); rhabdomyosarcoma, embryonal, 2, 180295 (3)
DICER1	AD	pleuropulmonary blastoma, 601200 (3), ; goiter, multinodular 1, with or without sertoli-leydig cell tumors, 138800 (3), ; glow syndrome, somatic mosaic, 618272 (3); rhabdomyosarcoma, embryonal, 2, 180295 (3)
DIDMOAD	AD,AR	deafness, 6/14/38, 600965 (3), ; ?cataract 41, 116400 (3), ; wolfram-like syndrome, 614296 (3), ; {diabetes mellitus, noninsulin-dependent, association with}, 125853 (3), ; wolfram syndrome 1, 222300 (3),
DIDO1		
DIE2		
Dies1		
Diet1		
DIETER	XL,XLR	immunodysregulation, polyendocrinopathy, and enteropathy, 304790 (3),
DIEXF		
DIF	AD	{migraine without aura, susceptibility to}, 157300 (3), ; {dementia, vascular, susceptibility to} (3); {asthma, susceptibility to}, 600807 (3), ; {septic shock, susceptibility to} (3); {malaria, cerebral, susceptibility to}, 611162 (3)
DIF-2		
DIF-3		
DIF3		
DIFF33		
DIFF48	AD,AR	deafness, 21, 607017 (3), ; ?deafness, 104, 616515 (3),
DIFF6		
Dig2		
DIIIc		{hemolytic disease of fetus and newborn, rh-induced}, 619462 (3), isolated cases; [blood group, rh system], 111690 (3)
DIK	AR	chand syndrome, 214350 (3), ; popliteal pterygium syndrome, bartsocas-papas type 1, 263650 (3),
DIL-2		
DIL1		
DILA1		
DILC		
DIM1	AR	burn-mckeown syndrome, 608572 (3),
Dim2		
DIMT1		
DIMT1L		
DINB1		
DINE	AR	arthrogryposis, distal, type 5d, 615065 (3),
DING	AD	luo-schoch-yamamoto syndrome, 619460 (3),
DINP		
DIO-1		
DIO1	AD	thyroid hormone metabolism, abnormal, 2, 619855 (3),
DIO2		
DIO3		
DIO3-AS1		
DIO3OS		
DIORA-1		
DIP		
DIP-1	AD	left ventricular noncompaction 7, 615092 (3),
DIP1		
DIP1/2		
DIP13B		
Dip2		
DIP2		
DIP2A		
DIP2B	AD	intellectual developmental disorder, fra12a type, 136630 (3),
DIP2C		
DIPA		
DIPAS		
DIPB	AD	?aniridia 3, 617142 (3),
DIPK1A		
DIPK1B		
DIPK1C		
DIPK2A		
DIPK2B		
DIPLA1		
DIPP		
DIPP2		
DIPP2alpha		
DIPP2beta		
DIPP3a		
DIPP3b		
DIR	XLR,XL	diabetes insipidus, nephrogenic, 1, 304800 (3), ; nephrogenic syndrome of inappropriate antidiuresis, 300539 (3),
DIR1		
DIR3	XLR,XL	diabetes insipidus, nephrogenic, 1, 304800 (3), ; nephrogenic syndrome of inappropriate antidiuresis, 300539 (3),
DIRAS1		
DIRAS2		
DIRAS3		
DIRC1		
DIRC2		
DIRC3		
DIRS1		
DIS3		
DIS3L		
DIS3L1		
DIS3L2	AR	perlman syndrome, 267000 (3),
dis3p		
DISC1		{schizophrenia 9, susceptibility to}, 604906 (3)
DISC1-AS1	AD	schizophrenia, 181500 (2),
DISC1OS	AD	schizophrenia, 181500 (2),
DISC2	AD	schizophrenia, 181500 (2),
DISP1		
DISP2		
DISP3		
DISPA		
DISPB		
Dist1		
Diva		
DIVA		
DIWS		
DIXDC1		
Dixin		
DJ-1	AR	parkinson disease 7, early-onset, 606324 (3),
dj-2		
DJ1	AR	parkinson disease 7, early-onset, 606324 (3),
DJ10		
dJ1000K24.1		
dJ1002M8.1	AR	intellectual developmental disorder, 73, 619717 (3),
dJ1002M8.3	AR	spermatogenic failure 84, 620409 (3),
dJ1005F21.2		
dJ1009E24.1		
dJ1009E24.2		
dJ1018A4.2	AR	retinitis pigmentosa 25, 602772 (3),
dJ1018D12.3		
dJ101A2.2	AR	galloway-mowat syndrome 4, 617730 (3),
dJ1024C24.1		
dJ1028D15.1	AR	short-rib thoracic dysplasia 16 with or without polydactyly, 617102 (3),
dJ1039K5		
DJ1042K10.2		
dJ1043E3.1		
dJ1049G11.4		
dJ1056H1.1		
dJ1057B20.2		
dJ1061C18.1.1		
dJ1068F16.2	AD	?myasthenic syndrome, congenital, 18, 616330 (3),
dJ1068H6.4		
dJ1085F17.3		
dJ108K11.3		
dJ1099D15.3		
dJ1103G7.3		
dJ1103G7.6		
dJ1103G7.7		
dJ1108D11.2		
dJ1112F19.1	AD	?ivic syndrome, 147750 (3), ; duane-radial ray syndrome, 607323 (3),
dJ1118M15.2		
dJ1119D9.3		
dJ111C20.1	AR	ciliary dyskinesia, primary, 32, 616481 (3),
dJ1121G12.1		
dJ1161H23.1		
dJ1167H4.1		
dJ1181N3.1		
dJ1184F4.2		
dJ1184F4.4		
dJ1187M17.3	AR	spondyloepimetaphyseal dysplasia, shohat type, 602557 (3),
dJ121G13.4		
dJ127C7.3		
dJ130H16.5		
dJ132F21.1		
dJ137F1.4		
dJ138B7.3		
dJ139D8.5		
dJ139D8.6	AD	cone-rod dystrophy 14, 602093 (3), ; cone dystrophy-3, 602093 (3),
dJ142L7.2		
dJ149A16.7		
DJ159A19.3	AD	xia-gibbs syndrome, 615829 (3),
dJ160A22.1		
dJ160A22.3		
DJ167A19.1		
dJ171N11.1		
dJ185D5.1		
dJ186O1.1		
dJ187J11.3		
dJ188D3.1		
dJ18C9.2		
dJ193B12.9		
dJ195P10.2	AR	spermatogenic failure 57, 619528 (3),
dJ202D23.2		
dJ20C7.3		
dJ20C7.4		
dJ20C7.5	AR	3-m syndrome 1, 273750 (3),
dJ20N2.1		
dJ20N2.5		
dJ211D12.4		
dJ211D12.5		
dJ221C16.1	AD	tessadori-bicknell-van haaften neurodevelopmental syndrome 1, 619758 (3),
dJ222E13.1		
dJ223E5.2		
dJ225E12.1		
dJ230I3.1		
dJ236A3.1	AR	combined oxidative phosphorylation deficiency 14, 614946 (3), ; spastic paraplegia 77, 617046 (3),
dJ237I15.1	AR	?spondylocostal dysostosis 6, 616566 (3),
dJ238O23.1		
dJ238O23.3		
dJ248E1.1		
dJ249I4.1	AR,AD	yunis-varon syndrome, 216340 (3), ; ?polymicrogyria, bilateral temporooccipital, 612691 (3), ; amyotrophic lateral sclerosis 11, 612577 (3), ; charcot-marie-tooth disease, type 4j, 611228 (3),
dJ257A7.2	AD	developmental and epileptic encephalopathy 70, 618298 (3),
dJ257A7.3	AR	macrocephaly/megalencephaly syndrome, 248000 (3),
dJ259A10.1		
dJ261G23.1		
dJ265C24.3		
dJ266L20.3	AD	?periventricular nodular heterotopia 6, 615544 (3),
dJ272L16.1		
dJ281H8.1		
dJ281H8.4		{diabetes mellitus, insulin-dependent, 5}, 600320 (3)
dJ288M22.3		
dJ298J15.2		
dJ29K1.2		
dJ303A1.3	AR	hermansky-pudlak syndrome 11, 619172 (3),
dJ303F19.1	AR	retinitis pigmentosa 25, 602772 (3),
dJ310J6.1		
dJ310O13.1		
dJ310O13.3		
dJ322A24.1		
dJ322G13.2	AR	joint laxity, short stature, and myopia, 617662 (3),
dJ322G13.6		
dJ322I12.1		
dJ323M4.1	AD,AR	dyschromatosis universalis hereditaria 1, 127500 (3), ; ?cancer, alopecia, pigment dyscrasia, onychodystrophy, and keratoderma, 618373 (3),
dJ324O17.1		
dJ327J16	AR	?mirror movements 3, 616059 (3),
DJ328E19.C1.1		
dJ329L24.3	AR	ovarian dysgenesis 4, 616185 (3),
dJ330M21.3		
dJ337H4.3		
dJ337O18.4		
dJ337O18.6		
dJ337O18.7		
dJ337O18.8		
dJ349A12.1		
dJ34B21.2		
dJ34B21.3		
dJ351K20.1		
dJ351K20.2		
dJ366N23.1		
dJ366N23.2		
dJ37E16.5		
dJ382I10.6	AR	pontocerebellar hypoplasia, type 6, 611523 (3),
dJ383J4.3		
dJ388M5.4		
dJ391O22.4		
dJ392M17.3		
dJ393D12.2		
dJ39B17.2		
dJ3J17.2		
dJ400N23		
DJ402G11.6	AR	microcephaly and chorioretinopathy, 1, 251270 (3),
DJ402G11.8	AR	?spermatogenic failure 73, 619878 (3),
dJ402H5.1		
dJ402H5.2		
dJ408K24.1		
dJ40E16.7	AD	cortical dysplasia, complex, with other brain malformations 5, 615763 (3),
dJ412I7.1	AR	ciliary dyskinesia, primary, 11, 612649 (3),
dJ413H6.1		
dJ417I1.1		
dJ417M14.2	AR	retinitis pigmentosa 62, 614181 (3),
dJ421H19.2		
dJ422F24.1	AR	thyroid dyshormonogenesis 4, 274800 (3),
dJ423B22.5	AR	?spermatogenic failure 83, 620354 (3),
dJ434O11.1		
dJ442L6.3		
dJ447F3.4		
dJ453C12.4		
dJ453C12.5		
dJ453H5.1		
dJ45H2.2	AR,AD	arthrogryposis multiplex congenita 3, myogenic type, 618484 (3), ; emery-dreifuss muscular dystrophy 4, 612998 (3), ; spinocerebellar ataxia, 8, 610743 (3),
dJ461P17.2		
dJ461P17.6		
DJ462O23.2		
DJ465N24.2.1		
dJ467N11.1		
dJ468K18.4	AR	inflammatory poikiloderma with hair abnormalities and acral keratoses, 620199 (3),
dJ469A13.2		
dJ473B4		
dJ473J16.2		
dJ475N16.4		
dJ482C21.1	AD,AR	marbach-rustad progeroid syndrome, 619322 (3), ; cataract 46, juvenile-onset, 212500 (3),
dJ483K16.1	AD	spinocerebellar ataxia 38, 615957 (3),
dJ486I3.2		
dJ486L4.2		
dJ494G10.1		
dJ496H19.1	AR,AD	erythrokeratodermia variabilis et progressiva 7, 619209 (3), ; olmsted syndrome 2, 619208 (3),
dJ501N12.1		
DJ501N12.8		
dJ506G2.1	XL,XLR	intellectual developmental disorder, 12, 300957 (3),
dJ50J22.1	AR	ichthyosis, congenital, 10, 615024 (3),
dJ510O8.8	AR	deafness, 67, 610265 (3),
dJ522B19.2		
dJ523E19.1		
dJ534B8.3		
dJ543J19.4	AD	macrothrombocytopenia, isolated, 1, 613112 (3),
dJ545L17.2		
dJ548G19.1		
dJ54B20.2		
dJ54B20.3		
dJ553F4.3	AR	hyper-ige recurrent infection syndrome 3, 618282 (3),
dJ553F4.4	AD	cataract 31, multiple types, 605387 (3),
dJ55C23.6		
dJ568C11.3		
dJ579F20.2		
dJ579N16.1		
dJ583P15.3		
dJ583P15.4		
dJ585I14.2	AR	suleiman-el-hattab syndrome, 618950 (3),
dJ591C20.1		
dJ601O1.1		
dJ616B8.3		
dJ620E11.1		
dJ620E11.4		
dJ622L5.7		
dJ62D2.1		
dJ631M13.5		
dJ63G5.3		
dJ63M2.4		
dJ63M2.5		
DJ646B12.2		
dJ676J13.1		
dJ677H15.3		
dJ680N4.3	AD	hypogonadotropic hypogonadism 3 with or without anosmia, 244200 (3),
dJ686C3.3		
dJ686N3.1		
dJ68L15.3	AR	mitochondrial pyruvate carrier deficiency, 614741 (3),
dJ694B14.3		
dJ697K14.1		
dJ69E11.3		
dJ70A9.1		
dJ717M23.1		
dJ718J7.3		
dJ726C3.1	AR	spermatogenic failure 16, 617187 (3),
dJ726C3.2		
dJ726C3.4		
dJ726C3.5		
dJ734P14.3	AD	spinocerebellar ataxia 35, 613908 (3),
dJ737E23.1		
dJ738P15.3		
dJ742J24.1		
dJ744I24.2		
dj747L4.1	AR	adrenocorticotropic hormone deficiency, 201400 (3),
dJ756G23.3		
dJ756N5.1		
dJ756N5.2		
dJ75N13.1	XL	intellectual developmental disorder, 97, 300803 (3),
dJ760C5.1	AR,AD	cystic fibrosis, 219700 (3), ; sweat chloride elevation without cf (3); congenital bilateral absence of vas deferens, 277180 (3), ; {pancreatitis, hereditary}, 167800 (3), ; {bronchiectasis with or without elevated sweat chloride 1, modifier of}, 211400 (3), ; {hypertrypsinemia, neonatal} (3)
dJ776F14.1		
dJ776P7.1	AR	spinocerebellar ataxia, 27, 618369 (3),
dJ779E11.1		
dJ781B1.1		
dJ781B1.3		
dJ794I6.2	AR	corneal endothelial dystrophy, 217700 (3), ; corneal dystrophy, fuchs endothelial, 4, 613268 (3); corneal endothelial dystrophy and perceptive deafness, 217400 (3),
dJ794I6.3	AR	[inosine triphosphatase deficiency], 613850 (3); developmental and epileptic encephalopathy 35, 616647 (3),
dJ796I17.1		
DJ79P11.1		
dJ800J21.2		
dJ805C22.1		
dJ80N2.1		
dJ824F16.3	AR	anonychia congenita, 206800 (3),
dJ831C21.1		
dJ831C21.2		
dJ831D17.1		
dJ836N17.2		
dJ842G6.1	AR	mitochondrial complex i deficiency, nuclear type 16, 618238 (3),
dJ84N20.1		
dJ850E9.2		
dJ852M4.2	AR	warburg micro syndrome 4, 615663 (3),
dJ857M17.1.2		
dJ857M17.2	AR	exocrine pancreatic insufficiency, dyserythropoietic anemia, and calvarial hyperostosis, 612714 (3),
dJ858B16.2	AR	liberfarb syndrome, 618889 (3),
dJ86C11.1		
dJ873F21.1		
dJ881L22.2	AR	siddiqi syndrome, 618635 (3),
dJ885A10.1		
DJ885L7.4.1	AD,AR	{intervertebral disc disease, susceptibility to}, 603932 (3); epiphyseal dysplasia, multiple, 3, with or without myopathy, 600969 (3), ; stickler syndrome, type vi, 620022 (3),
dJ885L7.8		
dJ908M14.2		
DJ90G24.4		
dJ914P20.3		
dJ93H18.5		
dJ94G16.2		
dJ955L16.1	AR	mitchell-riley syndrome, 615710 (3),
dJ95L4.1		
dJ964F7.1		
dJ965G21.2	AR	polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract, 612674 (3),
dJ967N21.5	AR	?premature ovarian failure 10, 612885 (3),
dJ967N21.6	AR	combined oxidative phosphorylation deficiency 57, 620167 (3),
dJ971B4.1		
DJ971N18.2		
dJ97D16.4		
dJ994E9.2		
dJ998H6.1		
DJBP		
DJS	AR	dubin-johnson syndrome, 237500 (3),
DK1	AR	congenital disorder of glycosylation, type im, 610768 (3),
DKC	XL,XLR	dyskeratosis congenita, 305000 (3),
DKC1	XL,XLR	dyskeratosis congenita, 305000 (3),
DKELCHL		
DKFZp313A0139		
DKFZp313B211		
DKFZp313B2333	AR	ventricular tachycardia, catecholaminergic polymorphic, 3, 614021 (3),
DKFZp313D0829	AR	ventricular tachycardia, catecholaminergic polymorphic, 3, 614021 (3),
DKFZp313G1735	AR	mucopolysaccharidosis, type x, 619698 (3),
DKFZp313H0531	AR	short stature, amelogenesis imperfecta, and skeletal dysplasia with scoliosis, 618363 (3),
DKFZp313H0817	AR	?combined oxidative phosphorylation deficiency 50, 619025 (3),
DKFZp313I2429	AR	neurodevelopmental disorder with microcephaly, seizures, and neonatal cholestasis, 619685 (3),
DKFZp313J1114		
DKFZp313L0718	AD	amyloidosis, finnish type, 105120 (3),
DKFZp313M0720	AR	scott syndrome, 262890 (3),
DKFZp313O1132		
DKFZP434A0225		
DKFZP434A043		
DKFZp434A1022		
DKFZP434A1114		
DKFZp434A128	AR	ciliary dyskinesia, primary, 14, 613807 (3),
DKFZP434A1315		
DKFZP434A139	AD	smith-magenis syndrome, 182290 (3), isolated cases,
DKFZp434A1520		
DKFZp434A1721		
DKFZp434A2417	AR	retinal dystrophy with leukodystrophy, 618863 (3),
DKFZP434B0335		
DKFZp434B0417		
DKFZP434B044		
DKFZp434B0717	AR	?spermatogenic failure 73, 619878 (3),
DKFZP434B103		
DKFZp434B1231		
DKFZp434B1272		
DKFZP434B131	AR	neurodevelopmental disorder with microcephaly, cataracts, and renal abnormalities, 617913 (3),
DKFZp434B1517		
DKFZP434B168		
DKFZP434B172		
DKFZP434B1727		
DKFZP434B187	AR	immunodeficiency 23, 615816 (3),
DKFZP434B194		
DKFZp434B195		
DKFZP434B205		
DKFZp434B217		
DKFZp434B227		
DKFZp434B2411		
DKFZP434C013	AD,AR	dyskeratosis congenita, 4, 615190 (3), ; dyskeratosis congenita, 5, 615190 (3), ; pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 3, 616373 (3),
DKFZp434C0328		
DKFZp434C1013		
DKFZP434C128		
DKFZP434C131		
DKFZp434C1372	AR	holoprosencephaly 14, 619895 (3),
DKFZP434C171		
DKFZp434C1714		
DKFZP434C1715		
DKFZp434C1826		
DKFZp434C211		
DKFZP434C212		
DKFZp434C2322	AR	thrombotic thrombocytopenic purpura, hereditary, 274150 (3),
DKFZP434C245	AR	short stature, onychodysplasia, facial dysmorphism, and hypotrichosis, 614813 (3),
DKFZp434D0215		
DKFZP434D0412		
DKFZp434D0513	AR	ciliary dyskinesia, primary, 5, 608647 (3),
DKFZp434D0917		
DKFZp434D0935	AR	?arthrogryposis, perthes disease, and upward gaze palsy, 614262 (3), ; nevus comedonicus, somatic, 617025 (3); lethal congenital contracture syndrome 10, 617022 (3),
DKFZP434D1335		
DKFZP434D146		
DKFZp434D166		
DKFZP434D174	AR	neurodevelopmental disorder with microcephaly, cataracts, and renal abnormalities, 617913 (3),
DKFZp434D1812		
DKFZP434D2111		
DKFZP434D222		
DKFZp434D229	AR	intellectual developmental disorder, 75, with neuropsychiatric features and variant lissencephaly, 619827 (3),
DKFZP434D245	AR	martsolf syndrome 1, 212720 (3), ; warburg micro syndrome 2, 614225 (3),
DKFZp434E0211		
DKFZP434E0321		
DKFZp434E0519		combined oxidative phosphorylation deficiency 56, 620139 (3)
DKFZp434E098		
DKFZp434E202	AR	cortical malformations, occipital, 614115 (3),
DKFZP434E2135		
DKFZp434E2216		
DKFZp434E2220	AD	?pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 5, 618674 (3),
DKFZp434E229		
DKFZP434E2318		
DKFZP434F0318		
DKFZp434F054		
DKFZP434F076		
DKFZP434F1017		
DKFZP434F124	AR	senior-loken syndrome 9, 616629 (3),
DKFZP434F162		
DKFZp434F1728		
DKFZp434F195	AR	cortical dysplasia, complex, with other brain malformations 12, 620316 (3),
DKFZP434F2021	AR	anauxetic dysplasia 3, 618853 (3),
DKFZp434F2322	AR	amelogenesis imperfecta, type ig (enamel-renal syndrome), 204690 (3),
DKFZP434F2429		
DKFZP434G032		
DKFZp434G0420		
DKFZp434G0625PRO34003		
DKFZP434G099	AR	smith-mccort dysplasia 2, 615222 (3),
DKFZP434G1411		
DKFZP434G145	AR	microcephaly, short stature, and polymicrogyria with seizures, 614833 (3),
DKFZP434G156		
DKFZP434G2226		
DKFZP434G232	AR	ichthyosis, congenital, 4b (harlequin), 242500 (3), ; ichthyosis, congenital, 4a, 601277 (3),
DKFZp434g247		
DKFZP434H0115	AR	ciliary dyskinesia, primary, 35, 617092 (3),
DKFZP434H0350		
DKFZp434H055		
DKFZP434H0820		
DKFZp434H204		
DKFZp434H2111	AD	{parkinson disease 8}, 607060 (3),
DKFZp434H2114		
DKFZp434H2226	AD	developmental delay with variable neurologic and brain abnormalities, 619694 (3),
DKFZP434H2235	AD	emery-dreifuss muscular dystrophy 5, 612999 (3),
DKFZp434H247		
DKFZp434I036		
DKFZP434I0428		
DKFZP434I092		
DKFZp434I099		
DKFZP434I114		
DKFZP434I116		
DKFZp434I1930		
DKFZP434I2117	AR	cone-rod dystrophy 22, 619531 (3),
DKFZP434I216		
DKFZP434I225		
DKFZP434J046	AR	microcephaly 2, primary, with or without cortical malformations, 604317 (3),
DKFZp434J0617		
DKFZp434J0911		
DKFZp434J1111	AD	singleton-merten syndrome 2, 616298 (3),
DKFZP434J154	AR	?intellectual developmental disorder with short stature and variable skeletal anomalies, 618453 (3),
DKFZP434J2031		
DKFZP434J212		
DKFZP434J214		
DKFZp434K0322		
DKFZp434K0410		
DKFZP434K0427		
DKFZP434K046	AR	coenzyme q10 deficiency, primary, 5, 614654 (3),
DKFZp434K0512	AR	basel-vanagait-smirin-yosef syndrome, 616449 (3),
DKFZp434K0521		
DKFZp434K0614		
DKFZp434K0621		
DKFZP434K091		
DKFZp434K0920		
DKFZp434K098		
DKFZp434K1115		
DKFZp434K114		
DKFZp434K1210		
DKFZP434K1421	AR	neurodevelopmental disorder with spasticity, seizures, and brain abnormalities, 620001 (3),
DKFZP434K151		
DKFZP434K156	AR	spermatogenic failure 84, 620409 (3),
DKFZp434K1635		
DKFZp434K171		
DKFZP434K1772	AR	ectopia lentis et pupillae, 225200 (3), ; ectopia lentis, isolated, 225100 (3),
DKFZp434K1815		
DKFZP434K2235	AD	witteveen-kolk syndrome, 613406 (3),
DKFZP434L0117		
DKFZP434L057	AD	developmental delay, impaired speech, and behavioral abnormalities, with or without seizures, 619964 (3),
DKFZp434L0718		
DKFZP434L1021		
DKFZp434L1050		
DKFZp434L121		
DKFZp434L1319	AD	cornelia de lange syndrome 1, 122470 (3),
DKFZp434L134		
DKFZP434L1435	AR	combined oxidative phosphorylation deficiency 20, 615917 (3),
DKFZp434L243		
DKFZP434M035	AR	microcephaly, short stature, and limb abnormalities, 617604 (3), ; microcephaly-micromelia syndrome, 251230 (3),
DKFZp434M1317		
DKFZp434M1411		
DKFZp434M1414		
DKFZP434M154		
DKFZP434M1735		
DKFZP434M183		
DKFZp434M222	AR	hyperphosphatasia with impaired intellectual development syndrome 2, 614749 (3),
DKFZP434N043		
DKFZp434N0510		
DKFZp434N061		
DKFZp434N0615		
DKFZp434N0735	AR	spinocerebellar ataxia, 31, 619422 (3),
DKFZp434N074		
DKFZp434N0820	AR	?spermatogenic failure 30, 618110 (3),
DKFZp434N1212		
DKFZP434N1235		
DKFZp434N127	AR	?spermatogenic failure 14, 615842 (3),
DKFZp434N1415		
DKFZp434N1418		
DKFZP434N1511		
DKFZP434N1526		
DKFZP434N178	AR	cortical dysplasia, complex, with other brain malformations 11, 620156 (3),
DKFZP434N1817		
DKFZP434N185		
DKFZP434N1923		
DKFZp434O0527	AR	spermatogenic failure 40, 618664 (3),
DKFZp434O0827		
DKFZP434O125		
DKFZp434O1427		
DKFZp434O192		
DKFZp434P0111	AR	spastic paraplegia 87, 619966 (3),
DKFZP434P0316	AR	spermatogenic failure 35, 618341 (3),
DKFZp434P0531		
DKFZp434P0630		
DKFZp434P0714	AR	spermatogenic failure 38, 618433 (3),
DKFZp434P0735		
DKFZp434P086		
DKFZP434P106	AR	polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract, 612674 (3),
DKFZp434P117		
DKFZp434P1514		
DKFZP434P1735	AR	ciliary dyskinesia, primary, 23, 615451 (3),
DKFZP434P1750		
DKFZp434P2235		
DKFZP43N024		
DKFZp451A175		
DKFZp451C205		
DKFZp451D042		
DKFZp451G223		
DKFZp451I2418		
DKFZp451J0118		
DKFZp451J1719		
DKFZp451L235		
DKFZp547A023		
DKFZp547B0714		
DKFZp547B2013		
DKFZp547C176		
DKFZp547D065	AR	raine syndrome, 259775 (3),
DKFZp547D155		
DKFZp547D2210		
DKFZp547E052		
DKFZP547E1010		
DKFZp547E1912		
DKFZP547E2110		
DKFZp547F072		
DKFZp547F162		
DKFZp547H074		
DKFZp547H236		
DKFZp547I1315	AD	developmental and epileptic encephalopathy 94, 615369 (3),
DKFZp547J036		
DKFZp547J144		
DKFZp547J199	AD	convulsions, familial infantile, with paroxysmal choreoathetosis, 602066 (3), ; seizures, benign familial infantile, 2, 605751 (3), ; episodic kinesigenic dyskinesia 1, 128200 (3),
DKFZp547L134	AR	striatonigral degeneration, infantile, 271930 (3),
DKFZp547M109		
DKFZp547M2010		
DKFZp547M236	AR	hypermanganesemia with dystonia 1, 613280 (3),
DKFZP547N043	AR	ruijs-aalfs syndrome, 616200 (3),
DKFZp547O146	AD	macrocephaly, neurodevelopmental delay, lymphoid hyperplasia, and persistent fetal hemoglobin, 619769 (3),
DKFZp547P055		
DKFZp547P234		
DKFZP564A022	AD,AR	ataxia, sensory, 1, 608984 (3), ; spastic paraplegia 85, 619686 (3),
DKFZP564A033	AR	short-rib thoracic dysplasia 15 with polydactyly, 617088 (3),
DKFZP564A063		
DKFZp564A1164		
DKFZp564A122		
DKFZp564A186		
DKFZp564B0482		
DKFZp564B0769		
DKFZP564B1023	AR	orofaciodigital syndrome v, 174300 (3),
DKFZP564B116		
DKFZP564B1162		
DKFZP564B167		
DKFZp564B176		
DKFZp564C0469		
DKFZP564C1278	AR	combined oxidative phosphorylation deficiency 40, 618835 (3),
DKFZp564C1664		
DKFZP564C186		
DKFZP564C1940		
DKFZp564D0372		
DKFZP564D0478	AR	neurodevelopmental disorder with motor and speech delay and behavioral abnormalities, 619470 (3),
DKFZP564D116	AR	joubert syndrome 18, 614815 (3), ; orofaciodigital syndrome iv, 258860 (3),
DKFZP564D166	AD	intellectual developmental disorder with autistic features and language delay, with or without seizures, 618906 (3),
DKFZp564D177		
DKFZP564D1864		
DKFZp564D206		
DKFZp564E153		
DKFZP564F0923	AR	neurodevelopmental disorder and structural brain anomalies with or without seizures and spasticity, 618890 (3),
DKFZP564F1123	AR	dysostosis multiplex, ain-naz type, 619345 (3),
DKFZp564G013		
DKFZp564G072		
DKFZP564G092		
DKFZP564G202		
DKFZp564H0764		
DKFZP564I0422		
DKFZP564I052		
DKFZP564I122	AR	methylmalonic aciduria and homocystinuria, cblc type, 277400 (3),
DKFZp564I1922		
DKFZP564J0123	AR	mitochondrial complex i deficiency, nuclear type 18, 618240 (3),
DKFZP564J0863	AD	neuropathy, hereditary sensory, type if, 615632 (3),
DKFZP564J157		
DKFZp564K0322	AR	3-m syndrome 3, 614205 (3),
DKFZp564K0822		
DKFZP564K112	AR	alazami syndrome, 615071 (3),
DKFZp564K142	XL,XLR	immunodeficiency, with magnesium defect, epstein-barr virus infection and neoplasia, 300853 (3), ; congenital disorder of glycosylation, type icc, 301031 (3),
DKFZP564K1964	AD	nanophthalmos 4, 615972 (3),
DKFZp564K2464		
DKFZP564K247		
DKFZP564L0562		
DKFZP564L0862		
DKFZP564L0864		
DKFZp564L2123		
DKFZp564L2423	AD,AR	?intellectual developmental disorder, 69, 617863 (3); ?intellectual developmental disorder, 52, 616887 (3),
DKFZP564M082		
DKFZP564M112		
DKFZp564M1178		
DKFZp564M173		
DKFZP564M182		
DKFZp564M1863		
DKFZP564M2423		
DKFZp564N1362	AD	paroxysmal nonkinesigenic dyskinesia 1, 118800 (3),
DKFZP564O0463		
DKFZP564O0823		
DKFZP564O092		
DKFZP564O123	AD	frontotemporal dementia and/or amyotrophic lateral sclerosis 7, 600795 (3),
DKFZp564O176		
DKFZp564O1863		
DKFZp564O2082		
DKFZP564O243		
DKFZP564P1916		
DKFZp566B023		
DKFZP566B0846		
DKFZP566B133		
DKFZp566B1346		
DKFZP566B183	AR	developmental and epileptic encephalopathy 21, 615833 (3),
DKFZP566C134		
DKFZp566C243		
DKFZP566D1346		
DKFZP566D193		
DKFZp566D234		
DKFZp566E104		
DKFZP566E144		
DKFZP566E164		
DKFZP566F084		
DKFZp566F123	AD	primrose syndrome, 259050 (3),
DKFZp566F164		
DKFZP566F2124		
DKFZp566F223	AD	cortical dysplasia, complex, with other brain malformations 7, 610031 (3),
DKFZP566G1424		
DKFZP566G223		
DKFZP566H073		
DKFZp566I1024		
DKFZP566J2046		
DKFZP566K023		
DKFZP566K0524		
DKFZP566K1924		
DKFZP566M1046		
DKFZp566M114	AR	short stature, amelogenesis imperfecta, and skeletal dysplasia with scoliosis, 618363 (3),
DKFZP566N034	AD	leukodystrophy, hypomyelinating, 25, 620243 (3),
DKFZp566O084		
DKFZP566O1646		
DKFZp570I0164		
DKFZp572C163		
DKFZP586A0522		
DKFZp586B0217		
DKFZp586B0621	AD	retinal degeneration, late-onset, 605670 (3),
DKFZP586B0923	AR	goldberg-shprintzen megacolon syndrome, 609460 (3),
DKFZp586B1222		
DKFZP586B1621	AR	triokinase and fmn cyclase deficiency syndrome, 618805 (3),
DKFZP586B2022		
DKFZp586C1223		
DKFZP586C1324		
DKFZP586C1522		
DKFZp586C1620		
DKFZP586C1622		
DKFZp586C1924	AR	optic atrophy 7, 612989 (3),
DKFZp586D0623		
DKFZp586D0624	AR	hypercholesterolemia, familial, 4, 603813 (3),
DKFZP586D0823		
DKFZp586D0824		
DKFZP586D0919		
DKFZp586D1519		
DKFZp586D1822		
DKFZp586D211	AD,AR	{glioma susceptibility 9}, 616568 (3), ; ?cerebroretinal microangiopathy with calcifications and cysts 3, 620368 (3), ; {melanoma, cutaneous malignant, susceptibility to, 10}, 615848 (3), ; ?pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 8, 620367 (3),
DKFZp586D2223		
DKFZP586E0820		
DKFZp586E1422		
DKFZP586E1519	AR,AD	congenital disorder of glycosylation, type iij, 613489 (3), ; saul-wilson syndrome, 618150 (3),
DKFZp586E2023		
DKFZP586F0422		
DKFZp586F1018		
DKFZp586F1023		
DKFZP586F1318		
DKFZP586F1524		
DKFZp586G0123	AD	fontaine progeroid syndrome, 612289 (3),
DKFZP586G0522	AR	?candidiasis, familial, 8, 615527 (3), ; {psoriasis susceptibility 13}, 614070 (3)
DKFZp586G1122		
DKFZp586G1123		
DKFZP586G1517		
DKFZp586G1722		
DKFZP586G1822		
DKFZp586G1919	AD	arrhythmogenic right ventricular dysplasia 5, 604400 (3), ; auditory neuropathy, 3, 619832 (3), ; emery-dreifuss muscular dystrophy 7, ad, 614302 (3),
DKFZp586H0523		
DKFZp586H0723		
DKFZp586H1322		
DKFZp586I021	AD	cardiac, facial, and digital anomalies with developmental delay, 618164 (3),
DKFZP586I0418		
DKFZp586I1419		
DKFZP586J0119		leukoencephalopathy with vanishing white matter 4, with or without ovarian failure, 620314 (3)
DKFZp586J0523		
DKFZp586J0619	AR	neurodevelopmental disorder with cataracts, poor growth, and dysmorphic facies, 618571 (3),
DKFZP586J0917		
DKFZp586K0617		
DKFZp586K0717		
DKFZP586K0919		
DKFZP586L0724		
DKFZP586L2024		
DKFZP586M0122	AD	acrofacial dysostosis, cincinnati type, 616462 (3),
DKFZP586M1120		
DKFZp586M121		neuronopathy, distal hereditary motor, type x, 620080 (3)
DKFZp586M1819		
DKFZP586O0120		
DKFZp586O0223		
DKFZP586O1422	AD	?epilepsy, familial adult myoclonic, 7, 618075 (3),
DKFZP586O1624		
DKFZp586O1822	AR,AD	{vitiligo-associated multiple autoimmune disease susceptibility 1}, 606579 (3); ?respiratory papillomatosis, juvenile recurrent, congenital, 618803 (3), ; autoinflammation with arthritis and dyskeratosis, 617388 (3), ; palmoplantar carcinoma, multiple self-healing, 615225 (3),
DKFZP586P0123	AR	orofaciodigital syndrome xiv, 615948 (3),
DKFZp586P1522		
DKFZp586P2219		
DKFZP586P2220		
DKFZp666A212		
DKFZp666G166		
DKFZp666G247		
DKFZp666K071	AR	?combined oxidative phosphorylation deficiency 51, 619057 (3),
DKFZp666P1710		
DKFZp667A205		
DKFZp667B0210	AD	hypotonia, ataxia, and delayed development syndrome, 617330 (3),
DKFZp667B1218		
DKFZP667C165		
DKFZp667F074	AR	neurodevelopmental disorder with hypotonia, neonatal respiratory insufficiency, and thermodysregulation, 618797 (3),
DKFZp667G2110		
DKFZp667I133		
DKFZp667M1322		
DKFZp667N1320		
DKFZp667O0311		
DKFZP686A01247		
DKFZp686A04236		
DKFZp686A06115		
DKFZP686A10121		
DKFZp686A17109		
DKFZp686A1775		
DKFZp686B0797		
DKFZp686B1036		
DKFZp686B15167	AR	spastic ataxia, charlevoix-saguenay type, 270550 (3),
DKFZp686C0433		
DKFZp686C06101	AD	hypotrichosis 12, 615885 (3),
DKFZp686C0818		
DKFZp686C1178	AR	deafness, 74, 613718 (3),
DKFZp686C12170		
DKFZp686C132		
DKFZP686C2281		
DKFZp686D0972		
DKFZp686D143		
DKFZp686E01200	AD	developmental and epileptic encephalopathy 94, 615369 (3),
DKFZp686E10109		
DKFZp686F0372	AR	polydactyly, postaxial, type a10, 618498 (3),
DKFZp686F22190	AR	?abnormal hair, joint laxity, and developmental delay, 261990 (3),
DKFZp686F2227	AR	?spinocerebellar ataxia, 22, 616948 (3),
DKFZp686G052	AD	coffin-siris syndrome 6, 617808 (3),
DKFZp686G0786		
DKFZp686G12159		
DKFZp686G13268		
DKFZp686G16228		
DKFZp686H18209		
DKFZp686I0110		
DKFZp686I14213	AD	brain small vessel disease 2, 614483 (3), ; {hemorrhage, intracerebral, susceptibility to}, 614519 (3)
DKFZp686I1842		
DKFZp686J07229		
DKFZp686J0796	AR	spermatogenic failure 65, 619712 (3),
DKFZp686J0811	AR	fraser syndrome 2, 617666 (3), ; cryptophthalmos, unilateral or bilateral, isolated, 123570 (3),
DKFZp686K16132		
DKFZp686K19184	AR	netherton syndrome, 256500 (3),
DKFZp686L0365		
DKFZp686L09111		
DKFZp686L1814		
DKFZp686L20145		
DKFZp686L2452		
DKFZp686M05161		
DKFZp686M0843		
DKFZp686M16108	AR,AD	manitoba oculotrichoanal syndrome, 248450 (3), ; bifid nose with or without anorectal and renal anomalies, 608980 (3), ; trigonocephaly 2, 614485 (3),
DKFZp686M18236		
DKFZp686M2086		
DKFZp686M22243		
DKFZp686N0351		
DKFZp686N1651		
DKFZp686O0290		
DKFZp686O0457		
DKFZp686O24166		
DKFZp686P02188	AR	?intellectual developmental disorder with short stature and variable skeletal anomalies, 618453 (3),
DKFZp686P0288		
DKFZp686P0776		esophageal carcinoma, somatic, 133239 (3)
DKFZp686P11128		
DKFZp686P15184		
DKFZp686P24239		
DKFZp727A071	AR	developmental and epileptic encephalopathy 75, 618437 (3),
DKFZP727C091	AD	koolen-de vries syndrome, 610443 (3),
DKFZP727G051		
DKFZP727I051		
DKFZP727M111		
DKFZP727M231		
DKFZp761A052	XL,XLR	multiple congenital anomalies-neurodevelopmental syndrome, 301056 (3),
DKFZp761A0620		
DKFZp761A078	AR	microcephaly 14, primary, 616402 (3),
DKFZP761B039		
DKFZp761B128		
DKFZp761B1514		
DKFZp761C07121		
DKFZp761C121		
DKFZp761C169		
DKFZP761C241		
DKFZp761D0223		
DKFZp761D0712		
DKFZP761D081		
DKFZp761D112		
DKFZp761D221		
DKFZp761E198		
DKFZp761F0118		
DKFZp761F222		
DKFZp761G058	AR	?maple syrup urine disease, mild variant, 615135 (3),
DKFZp761G122		
DKFZP761G1923		
DKFZp761G2113		
DKFZp761H039		
DKFZp761H0421		
DKFZp761H079	AR	joubert syndrome 8, 612291 (3),
DKFZP761H171	AD	hypomagnesemia 7, renal, with or without dilated cardiomyopathy, 620152 (3),
DKFZP761H1710		
DKFZp761H172		
DKFZp761H221		
DKFZp761I1011		
DKFZP761I141		
DKFZP761I172		
DKFZp761I2123		
DKFZp761I2124		
DKFZp761J1324		
DKFZp761J139		
DKFZP761J17121		
DKFZp761K1021		
DKFZp761K1423		
DKFZp761K2222		
DKFZP761L0424		
DKFZp761L1518	AR	ciliary dyskinesia, primary, 39, 618254 (3),
DKFZp761M0212		
DKFZp761M0423		
DKFZP761M1511		
DKFZp761N0624		
DKFZp761N1114		
DKFZp761O0113		
DKFZp761P0423		
DKFZp761P0710	AR,AD	usher syndrome, type 2c, 605472 (3), digenic ; usher syndrome, type 2c, gpr98/pdzd7 digenic, 605472 (3), digenic ; ?febrile seizures, familial, 4, 604352 (3),
DKFZp761P1010		
DKFZp761P1121	AR	metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration, 616878 (3),
DKFZp762A152		
DKFZp762A2013		
DKFZp762A217		
DKFZp762A227		
DKFZp762A2316		
DKFZp762B245		
DKFZp762C143		
DKFZp762C186		
DKFZP762D096	AR,AD	neurodegeneration with brain iron accumulation 4, 614298 (3), ; ?spastic paraplegia 43, 615043 (3),
DKFZp762E1112		
DKFZp762E1312		
DKFZp762F1811		
DKFZp762F2011		
DKFZp762G094	AR	myopathy, myofibrillar, 8, 617258 (3),
DKFZp762G199		
DKFZp762H1311	AR	joubert syndrome 15, 614464 (3),
DKFZp762I194	AR	bardet-biedl syndrome 5, 615983 (3),
DKFZp762K054	AR	spastic paraplegia 46, 614409 (3),
DKFZp762K137		
DKFZp762K2015	AD	basan syndrome, 129200 (3), ; huriez syndrome, 181600 (3), ; adermatoglyphia, 136000 (3),
DKFZP762K2015	AD	basan syndrome, 129200 (3), ; huriez syndrome, 181600 (3), ; adermatoglyphia, 136000 (3),
DKFZp762K222		
DKFZp762L1111		
DKFZP762M115	AD,AR	?charcot-marie-tooth disease, axonal, type 2q, 615025 (3), ; alpha-aminoadipic and alpha-ketoadipic aciduria, 204750 (3),
DKFZp762M126		
DKFZP762M186		
DKFZP762N2316	AD	weiss-kruszka syndrome, 618619 (3),
DKFZp762O076		
DKFZp779C0666		{diabetes mellitus, noninsulin-dependent, 5}, 616087 (3)
DKFZp779D216		
DKFZp779E2460		
DKFZp779F115	AR	finca syndrome, 618278 (3),
DKFZp779G1236	AR	?pontocerebellar hypoplasia, type 3, 608027 (3),
DKFZp779J0927		
DKFZp779L1558		
DKFZp779M2348	AD	arthrogryposis, distal, type 2b2, 618435 (3),
DKFZp779O2438	AR	short stature, amelogenesis imperfecta, and skeletal dysplasia with scoliosis, 618363 (3),
DKFZp781A10161		
DKFZp781B0869	AD	colorectal cancer, somatic, 114500 (3); oligodontia-colorectal cancer syndrome, 608615 (3),
DKFZp781B1548		
DKFZp781D015		
DKFZp781D0314		
DKFZp781D1727	AD	developmental and epileptic encephalopathy 94, 615369 (3),
DKFZp781E1243		
DKFZp781E17107		
DKFZp781E2374		
DKFZp781H0392	AD	sessile serrated polyposis cancer syndrome, 617108 (3),
DKFZp781I1117		
DKFZp781I1119		
DKFZp781I12161		
DKFZp781M2411		
DKFZp781O2362		
DKK-1		
DKK1		
DKK2		
DKK3		
DKK4		
DKKL1		
DL	AD,AR	[hair morphology 1, hair thickness], 612630 (3); ectodermal dysplasia 10a, hypohidrotic/hair/nail type, 129490 (3), ; ectodermal dysplasia 10b, hypohidrotic/hair/tooth type, 224900 (3),
DLAD		
DLAT	AR	pyruvate dehydrogenase e2 deficiency, 245348 (3),
DLB1		
DLB2		
DLC-1		colorectal cancer, somatic, 114500 (3)
DLC1		colorectal cancer, somatic, 114500 (3)
Dlc2		
DLC2		
DLC8		
DLD	AR	dihydrolipoamide dehydrogenase deficiency, 246900 (3),
DLDBP	AR	lacticacidemia due to pdx1 deficiency, 245349 (3),
DLDH	AR	dihydrolipoamide dehydrogenase deficiency, 246900 (3),
DLEC		
DLEC1		
DLEU1		
DLEU2		
DLEU5		
DLEU7		
DLEU8	AR	aicardi-goutieres syndrome 2, 610181 (3),
DLG1		
DLG2		
DLG3	XL,XLR	intellectual developmental disorder, 90, 300850 (3),
DLG4	AD	intellectual developmental disorder, 62, 618793 (3),
DLG5		
DLG6		
DLG7		
DLGAP1		
DLGAP2		
DLGAP3		
DLGAP4		
DLGAP5		
DLGH1		
DLK		
DLK1		
DLL1	AD	neurodevelopmental disorder with nonspecific brain abnormalities and with or without seizures, 618709 (3),
DLL3	AR	spondylocostal dysostosis 1, 277300 (3),
DLL4	AD	adams-oliver syndrome 6, 616589 (3),
DLM-1		
DLM1		
DLNB11		
DLNB13		
DLNB14	AR	?mosaic variegated aneuploidy syndrome 4, 620153 (3),
DLP		
DLP12		
DLP3		
DLST	AD	paragangliomas 7, 618475 (3),
DLTA	AR	pyruvate dehydrogenase e2 deficiency, 245348 (3),
DLTS	AD	paragangliomas 7, 618475 (3),
DLX1		
DLX2		
DLX3	AD	trichodontoosseous syndrome, 190320 (3), ; amelogenesis imperfecta, type iv, 104510 (3),
DLX4	AD	?orofacial cleft 15, 616788 (3),
DLX5	AD,AR	split-hand/foot malformation 1, 183600 (3), ; ?split-hand/foot malformation 1 with sensorineural hearing loss, 220600 (3),
DLX6		
DLX7	AD	?orofacial cleft 15, 616788 (3),
DLX8	AD	?orofacial cleft 15, 616788 (3),
DLX9	AD	?orofacial cleft 15, 616788 (3),
DLXIN-1		
DM	AD	myotonic dystrophy 1, 160900 (3),
DM1	AD	myotonic dystrophy 1, 160900 (3),
DM1PK	AD	myotonic dystrophy 1, 160900 (3),
DM2	AD	myotonic dystrophy 2, 602668 (3),
DM4E3		
DMAC1		
DMAC2		
DMAC2L		
DMAHP		branchiootorenal syndrome 2, 610896 (3)
DMAP1		
DMBT1		
DMBX1		
DMC	AR	smith-mccort dysplasia, 607326 (3), ; dyggve-melchior-clausen disease, 223800 (3),
DMC1	AR	developmental and epileptic encephalopathy 105 with hypopituitarism, 619983 (3),
DMD	XLR,XL	becker muscular dystrophy, 300376 (3), ; cardiomyopathy, dilated, 3b, 302045 (3), ; duchenne muscular dystrophy, 310200 (3),
DMDA	AR	muscular dystrophy, limb-girdle, 5, 253700 (3),
DMDA1	AR	muscular dystrophy, limb-girdle, 5, 253700 (3),
DMDA2	AR	muscular dystrophy, limb-girdle, 3, 608099 (3),
DMDL		
DMGDH	AR	dimethylglycine dehydrogenase deficiency, 605850 (3),
DMGDHL1	AR	[sarcosinemia], 268900 (3),
DMK	AD	myotonic dystrophy 1, 160900 (3),
DMKN		
DMN		
DMP1	AR	hypophosphatemic rickets, ar, 241520 (3),
DMP3	AD	dentinogenesis imperfecta, shields type iii, 125500 (3), ; dentinogenesis imperfecta, shields type ii, 125490 (3), ; dentin dysplasia, type ii, 125420 (3), ; deafness, 39, with dentinogenesis, 605594 (3),
DMP4	AR	raine syndrome, 259775 (3),
DMPK	AD	myotonic dystrophy 1, 160900 (3),
DMPK2		
DMR		
DMR-N9		
DMRT1		
DMRT2		
DMRT3		
DMRTA1		
DMRTA2		
DMRTA3		
DMRTB1		
DMRTC1		
DMRTC2		
DMT		
DMT-1	AR	anemia, hypochromic microcytic, with iron overload 1, 206100 (3),
DMT1	AR	anemia, hypochromic microcytic, with iron overload 1, 206100 (3),
DMTF		
DMTF1		
DMTN		
DMWD		
DMXL1		
DMXL2	AR,AD	developmental and epileptic encephalopathy 81, 618663 (3), ; ?deafness, 71, 617605 (3), ; ?polyendocrine-polyneuropathy syndrome, 616113 (3),
DN-7		
DN7		
DNA-PKC	AR	immunodeficiency 26, with or without neurologic abnormalities, 615966 (3),
DNA-PKcs	AR	immunodeficiency 26, with or without neurologic abnormalities, 615966 (3),
DNA2	AR,AD	?seckel syndrome 8, 615807 (3), ; progressive external ophthalmoplegia with mitochondrial dna deletions, 6, 615156 (3),
DNA2L	AR,AD	?seckel syndrome 8, 615807 (3), ; progressive external ophthalmoplegia with mitochondrial dna deletions, 6, 615156 (3),
DNA43	AR	immunodeficiency 80 with or without cardiomyopathy, 619313 (3),
DNAAF1	AR	ciliary dyskinesia, primary, 13, 613193 (3),
DNAAF10		
DNAAF11	AR	ciliary dyskinesia, primary, 19, 614935 (3),
DNAAF12	AR	ciliary dyskinesia, primary, 39, 618254 (3),
DNAAF13	AR	ciliary dyskinesia, primary, 28, 615505 (3),
DNAAF14		
DNAAF16	AR	ciliary dyskinesia, primary, 26, 615500 (3),
DNAAF17	AR	ciliary dyskinesia, primary, 38, 618063 (3),
DNAAF18		
DNAAF2	AR	ciliary dyskinesia, primary, 10, 612518 (3),
DNAAF3	AR	ciliary dyskinesia, primary, 2, 606763 (3),
DNAAF4	AD,AR	{dyslexia, susceptibility to, 1}, 127700 (3), ; ciliary dyskinesia, primary, 25, 615482 (3),
DNAAF5	AR	ciliary dyskinesia, primary, 18, 614874 (3),
DNAAF6	XL,XLR	ciliary dyskinesia, primary, 36, 300991 (3),
DNAAF7	AR	ciliary dyskinesia, primary, 22, 615444 (3),
DNAAF9		
DNABF		
dNaCh		
DNAH1	AR	spermatogenic failure 18, 617576 (3), ; ciliary dyskinesia, primary, 37, 617577 (3),
DNAH10	AR	spermatogenic failure 56, 619515 (3),
DNAH11	AR	ciliary dyskinesia, primary, 7, with or without situs inversus, 611884 (3),
DNAH12		
DNAH12L		
DNAH14		
DNAH17	AR	spermatogenic failure 39, 618643 (3),
DNAH17L	AR	ciliary dyskinesia, primary, 40, 618300 (3),
DNAH2	AR	spermatogenic failure 45, 619094 (3),
DNAH3		
DNAH5	AR	ciliary dyskinesia, primary, 3, with or without situs inversus, 608644 (3),
DNAH6		
DNAH7	AR	ciliary dyskinesia, primary, 50, 620356 (3),
DNAH7L		
DNAH8	AR	spermatogenic failure 46, 619095 (3),
DNAH9	AR	ciliary dyskinesia, primary, 40, 618300 (3),
DNAHBL	AR	ciliary dyskinesia, primary, 7, with or without situs inversus, 611884 (3),
DNAHC1	AR	spermatogenic failure 18, 617576 (3), ; ciliary dyskinesia, primary, 37, 617577 (3),
Dnahc11	AR	ciliary dyskinesia, primary, 7, with or without situs inversus, 611884 (3),
DNAHC11	AR	ciliary dyskinesia, primary, 7, with or without situs inversus, 611884 (3),
Dnahc14		
Dnahc3		
Dnahc3b		
Dnahc5	AR	ciliary dyskinesia, primary, 3, with or without situs inversus, 608644 (3),
Dnahc6		
Dnahc9	AR	ciliary dyskinesia, primary, 40, 618300 (3),
DNAHL1	AR	spermatogenic failure 39, 618643 (3),
DNAI1	AR	ciliary dyskinesia, primary, 1, with or without situs inversus, 244400 (3),
DNAI2	AR	ciliary dyskinesia, primary, 9, with or without situs inversus, 612444 (3),
DNAI3		
DNAI4		
DNAI7		
DNAI8	AR	?ciliary dyskinesia, primary, 6, 610852 (3),
DNAJ		
DNAJA1		
DNAJA2		
DNAJA3		
DNAJA5	AR	bone marrow failure syndrome 3, 617052 (3),
DNAJB1		
DNAJB11	AD	polycystic kidney disease 6 with or without polycystic liver disease, 618061 (3),
DNAJB12		
DNAJB13	AR	ciliary dyskinesia, primary, 34, 617091 (3),
DNAJB14		
DNAJB2	AR	spinal muscular atrophy, distal, 5, 614881 (3),
DNAJB4	AR	congenital myopathy 21 with early respiratory failure, 620326 (3),
DNAJB5		
DNAJB6	AD	muscular dystrophy, limb-girdle, 1, 603511 (3),
DNAJB7		
DNAJB8		
DNAJB9		
DNAJC1		
DNAJC10		
DNAJC11		
DNAJC12	AR	hyperphenylalaninemia, mild, non-bh4-deficient, 617384 (3),
DNAJC13		
DNAJC14		
DNAJC15		
DNAJC16		
DNAJC17		
DNAJC19	AR	3-methylglutaconic aciduria, type v, 610198 (3),
DNAJC2		
DNAJC20	AR	?anemia, sideroblastic, 5, 619523 (3),
DNAJC21	AR	bone marrow failure syndrome 3, 617052 (3),
DNAJC23	AD	polycystic liver disease 2, 617004 (3),
DNAJC24		
DNAJC26		
DNAJC27		
DNAJC29	AR	spastic ataxia, charlevoix-saguenay type, 270550 (3),
DNAJC3	AR	ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus, 616192 (3),
DNAJC30	AR	leber hereditary optic neuropathy, 619382 (3),
DNAJC4		
DNAJC5	AD	ceroid lipofuscinosis, neuronal, 4 (kufs type), 162350 (3),
DNAJC5A	AD	ceroid lipofuscinosis, neuronal, 4 (kufs type), 162350 (3),
DNAJC5B		
DNAJC5G		
DNAJC6	AR	parkinson disease 19a, juvenile-onset, 615528 (3), ; parkinson disease 19b, early-onset, 615528 (3),
DNAJC7		
DNAJC9		
DNAJD1		
DNAJL1		
DNAL1	AR,AR	ciliary dyskinesia, primary, 16, 614017 (3), |ciliary dyskinesia, primary, 40, 618300 (3),
DNAL4	AR	?mirror movements 3, 616059 (3),
DNALI1	AR	?spermatogenic failure 83, 620354 (3),
DNAM-1		
DNAM1		
DNAPK	AR	immunodeficiency 26, with or without neurologic abnormalities, 615966 (3),
DNAPKc	AR	immunodeficiency 26, with or without neurologic abnormalities, 615966 (3),
DNAPTP6		
DNAS1L1		
DNAS1L2		
DNAS1L3	AR	systemic lupus erythematosus 16, 614420 (3),
DNASE1	AD	{systemic lupus erythematosus, susceptibility to}, 152700 (3),
DNASE1L1		
DNASE1L2		
DNASE1L3	AR	systemic lupus erythematosus 16, 614420 (3),
DNASE2	AR	autoinflammatory-pancytopenia syndrome, 619858 (3),
DNASE2B		
DNASEX		
DNB1	AD	neurodevelopmental disorder with or without anomalies of the brain, eye, or heart, 616975 (3),
DNB5	AR	intellectual developmental disorder with neuropsychiatric features, 617532 (3),
DNC	AR	microcephaly, amish type, 607196 (3), ; thiamine metabolism dysfunction syndrome 4 (progressive polyneuropathy type), 613710 (3),
DNCH1	AD	charcot-marie-tooth disease, axonal, type 2o, 614228 (3), ; spinal muscular atrophy, lower extremity-pre 1, ad, 158600 (3), ; cortical dysplasia, complex, with other brain malformations 13, 614563 (3),
DNCH2	AR	short-rib thoracic dysplasia 3 with or without polydactyly, 613091 (3), digenic
Dnchc1	AD	charcot-marie-tooth disease, axonal, type 2o, 614228 (3), ; spinal muscular atrophy, lower extremity-pre 1, ad, 158600 (3), ; cortical dysplasia, complex, with other brain malformations 13, 614563 (3),
DNCI1		
DNCI2	AR	neurodevelopmental disorder with microcephaly and structural brain anomalies, 618492 (3),
DNCIC1		
DNCL	AD	charcot-marie-tooth disease, axonal, type 2o, 614228 (3), ; spinal muscular atrophy, lower extremity-pre 1, ad, 158600 (3), ; cortical dysplasia, complex, with other brain malformations 13, 614563 (3),
DNCL1		
DNCL1B		
DNCL2A		
DNCL2B		
DNCLI1		
DNCLI2		
DNCM		
DND1		
DNECL	AD	charcot-marie-tooth disease, axonal, type 2o, 614228 (3), ; spinal muscular atrophy, lower extremity-pre 1, ad, 158600 (3), ; cortical dysplasia, complex, with other brain malformations 13, 614563 (3),
DNEL2	AR	spermatogenic failure 39, 618643 (3),
DNER		
DNF15S2		
DNGR-1		
DNHBL	AR	ciliary dyskinesia, primary, 7, with or without situs inversus, 611884 (3),
DNHD1	AR	spermatogenic failure 65, 619712 (3),
DNHD1L	AR	spermatogenic failure 65, 619712 (3),
DNHD2		
DNHD3	AR	spermatogenic failure 45, 619094 (3),
DNHL1		
DNJ3		
DNL	AR	autoinflammatory-pancytopenia syndrome, 619858 (3),
DNL1	AD	{systemic lupus erythematosus, susceptibility to}, 152700 (3),
DNL1L		
DNL2	AR	autoinflammatory-pancytopenia syndrome, 619858 (3),
DNLC2A		
DNLC2B		
DNM	AR,AD	developmental and epileptic encephalopathy 31b, 620352 (3), ; developmental and epileptic encephalopathy 31a, 616346 (3),
DNM1	AR,AD	developmental and epileptic encephalopathy 31b, 620352 (3), ; developmental and epileptic encephalopathy 31a, 616346 (3),
DNM1L	AD,AR	optic atrophy 5, 610708 (3), ; encephalopathy, lethal, due to defective mitochondrial peroxisomal fission 1, 614388 (3),
DNM2	AD,AR	centronuclear myopathy 1, 160150 (3), ; charcot-marie-tooth disease, axonal type 2m, 606482 (3), ; charcot-marie-tooth disease, intermediate b, 606482 (3), ; lethal congenital contracture syndrome 5, 615368 (3),
DNM3		
DNMAP1		
DNMBP	AR	cataract 48, 618415 (3),
DNMT	AD	neuropathy, hereditary sensory, type ie, 614116 (3), ; cerebellar ataxia, deafness, and narcolepsy, 604121 (3),
DNMT1	AD	neuropathy, hereditary sensory, type ie, 614116 (3), ; cerebellar ataxia, deafness, and narcolepsy, 604121 (3),
DNMT2		
DNMT3A	AD	tatton-brown-rahman syndrome, 615879 (3), ; acute myeloid leukemia, somatic, 601626 (3); heyn-sproul-jackson syndrome, 618724 (3),
DNMT3B	AR	immunodeficiency-centromeric instability-facial anomalies syndrome 1, 242860 (3), ; facioscapulohumeral muscular dystrophy 4, digenic, 619478 (3), digenic
DNMT3L		
DNMTAP1		
DNPEP		
DNPH1		
DNPI		
DNPK1	AR	immunodeficiency 26, with or without neurologic abnormalities, 615966 (3),
dNT-1		
DNT-1		
dNT-2		
DNT1		
dNT2		
DNTNP		
DNTT		
DNTTIP1		
DNTTIP2		
DNZ1		
DO		[blood group, dombrock], 616060 (3)
DOA1	AR	neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies, 617527 (3),
Dob1		
doc-1		
DOC-1		
DOC-1R		
DOC-2		
DOC1		
DOC2A		
DOC2B		
DOC2BL		
DOC4	AD	essential tremor, hereditary, 5, 616736 (3),
DOC6	AR	nephrotic syndrome, type 21, 618594 (3),
DOCK1		
DOCK10		
DOCK11		
DOCK180		
DOCK2	AR	immunodeficiency 40, 616433 (3),
DOCK3	AR	neurodevelopmental disorder with impaired intellectual development, hypotonia, and ataxia, 618292 (3),
DOCK4		
DOCK5		
DOCK6	AR	adams-oliver syndrome 2, 614219 (3),
DOCK7	AR	developmental and epileptic encephalopathy 23, 615859 (3),
DOCK8	AR	hyper-ige recurrent infection syndrome, 243700 (3),
DOCK9		
dod		
DOG1	AR	?intestinal dysmotility syndrome, 620045 (3),
DOHH	AR	neurodevelopmental disorder with microcephaly, cerebral atrophy, and visual impairment, 620066 (3),
Dok-2		
Dok-7	AR	fetal akinesia deformation sequence 3, 618389 (3), ; myasthenic syndrome, congenital, 10, 254300 (3),
DOK1		[blood group, dombrock], 616060 (3)
DOK2		
DOK3		
DOK4		
DOK5		
DOK5L		
DOK6		
DOK7	AR	fetal akinesia deformation sequence 3, 618389 (3), ; myasthenic syndrome, congenital, 10, 254300 (3),
DOLK	AR	congenital disorder of glycosylation, type im, 610768 (3),
DOLPP1		
DOM	AD	waardenburg syndrome, type 4c, 613266 (3), ; pcwh syndrome, 609136 (3), ; waardenburg syndrome, type 2e, with or without neurologic involvement, 611584 (3),
DOM3Z		
DOMO1	AD	developmental delay, hypotonia, musculoskeletal defects, and behavioral abnormalities, 619595 (3), ; floating-harbor syndrome, 136140 (3),
Don-1		
DONG1		
DONSON	AR	microcephaly, short stature, and limb abnormalities, 617604 (3), ; microcephaly-micromelia syndrome, 251230 (3),
DOP1A		
DOP1B		
DOPEY1		
DOPEY2		
DOPPEL		
DOR		
DOR1		congenital disorder of glycosylation, type iih, 611182 (3)
DORA		
DORC1		
dorfin		
DORZ1		
DOT1		
DOT1L		
Dot3		
DOWN16	AD,AR	{macular degeneration, age-related, reduced risk of}, 603075 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to}, 235400 (3),
DP		{asthma, susceptibility to, 1}, 607277 (3)
Dp-1		
Dp-2		
DP1		{asthma, susceptibility to, 1}, 607277 (3)
DP103		
DP1L1	AR	retinitis pigmentosa 77, 617304 (3),
DP2	AD	colorectal cancer, somatic, 114500 (3); brain tumor-polyposis syndrome 2, 175100 (3), ; desmoid disease, hereditary, 135290 (3), ; adenoma, periampullary, somatic, 175100 (3); hepatoblastoma, somatic, 114550 (3); gastric cancer, somatic, 613659 (3); gastric adenocarcinoma and proximal polyposis of the stomach, 619182 (3), ; gardner syndrome, 175100 (3), ; adenomatous polyposis coli, 175100 (3),
DP2.5	AD	colorectal cancer, somatic, 114500 (3); brain tumor-polyposis syndrome 2, 175100 (3), ; desmoid disease, hereditary, 135290 (3), ; adenoma, periampullary, somatic, 175100 (3); hepatoblastoma, somatic, 114550 (3); gastric cancer, somatic, 613659 (3); gastric adenocarcinoma and proximal polyposis of the stomach, 619182 (3), ; gardner syndrome, 175100 (3), ; adenomatous polyposis coli, 175100 (3),
DP3	AD,AR,AD	colorectal cancer, somatic, 114500 (3); brain tumor-polyposis syndrome 2, 175100 (3), ; desmoid disease, hereditary, 135290 (3), ; adenoma, periampullary, somatic, 175100 (3); hepatoblastoma, somatic, 114550 (3); gastric cancer, somatic, 613659 (3); gastric adenocarcinoma and proximal polyposis of the stomach, 619182 (3), ; gardner syndrome, 175100 (3), ; adenomatous polyposis coli, 175100 (3), |naxos disease, 601214 (3), ; ?arrhythmogenic right ventricular dysplasia 12, 611528 (3),
DP5		
DP58		
DP8		
DP97		
DPAGT	AR	myasthenic syndrome, congenital, 13, with tubular aggregates, 614750 (3), ; congenital disorder of glycosylation, type ij, 608093 (3),
DPAGT1	AR	myasthenic syndrome, congenital, 13, with tubular aggregates, 614750 (3), ; congenital disorder of glycosylation, type ij, 608093 (3),
DPAGT2	AR	myasthenic syndrome, congenital, 13, with tubular aggregates, 614750 (3), ; congenital disorder of glycosylation, type ij, 608093 (3),
Dpb11		
DPC4	AD	pancreatic cancer, somatic, 260350 (3); myhre syndrome, 139210 (3), ; polyposis, juvenile intestinal, 174900 (3), ; juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome, 175050 (3),
DPCD		
DPCK	AR	pontocerebellar hypoplasia, type 12, 618266 (3), ; neurodegeneration with brain iron accumulation 6, 615643 (3),
DPCR1		
DPD	AR	dihydropyrimidine dehydrogenase deficiency, 274270 (3), ; 5-fluorouracil toxicity, 274270 (3),
DPD1	AR,AD	inflammatory bowel disease, immunodeficiency, and encephalopathy, 618213 (3), ; camurati-engelmann disease, 131300 (3), ; {cystic fibrosis lung disease, modifier of}, 219700 (3),
DPDE1		
DPDE2		
DPDE3	AD	acrodysostosis 2, with or without hormone resistance, 614613 (3),
DPDE4		
DPE2		
DPEP1		
DPEP2		
DPEP3		
DPF1		
DPF2	AD	coffin-siris syndrome 7, 618027 (3),
DPF3		
DPH1	AR	developmental delay with short stature, dysmorphic facial features, and sparse hair, 616901 (3),
DPH2	AR	developmental delay with short stature, dysmorphic facial features, and sparse hair 2, 620062 (3),
DPH2L	AR	developmental delay with short stature, dysmorphic facial features, and sparse hair, 616901 (3),
DPH2L1	AR	developmental delay with short stature, dysmorphic facial features, and sparse hair, 616901 (3),
DPH2L2	AR	developmental delay with short stature, dysmorphic facial features, and sparse hair 2, 620062 (3),
DPH3		
DPH3A		
DPH4		
DPH5	AR	neurodevelopmental disorder with short stature, prominent forehead, and feeding difficulties, 620070 (3),
DPH6		
DPH7		
DPI	AD,AR	arrhythmogenic right ventricular dysplasia 8, 607450 (3), ; epidermolysis bullosa, lethal acantholytic, 609638 (3), ; keratosis palmoplantaris striata ii, 612908 (3), ; dilated cardiomyopathy with woolly hair, keratoderma, and tooth agenesis, 615821 (3), ; cardiomyopathy, dilated, with woolly hair and keratoderma, 605676 (3),
DPII	AD,AR	arrhythmogenic right ventricular dysplasia 8, 607450 (3), ; epidermolysis bullosa, lethal acantholytic, 609638 (3), ; keratosis palmoplantaris striata ii, 612908 (3), ; dilated cardiomyopathy with woolly hair, keratoderma, and tooth agenesis, 615821 (3), ; cardiomyopathy, dilated, with woolly hair and keratoderma, 605676 (3),
DPIII	AR,AD	naxos disease, 601214 (3), ; ?arrhythmogenic right ventricular dysplasia 12, 611528 (3),
DPK		
DPL		
DPL1	AD	intellectual developmental disorder, 33, 616311 (3), ; {ventricular fibrillation, paroxysmal familial, 2}, 612956 (3),
DPL11	AR	ciliary dyskinesia, primary, 7, with or without situs inversus, 611884 (3),
DPL2		
DPM1	AR	congenital disorder of glycosylation, type ie, 608799 (3),
DPM2	AR	congenital disorder of glycosylation, type iu, 615042 (3),
DPM3	AR	?muscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type b, 15, 618992 (3), ; muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 15, 612937 (3),
DPP1	AR	periodontitis 1, juvenile, 170650 (3), ; haim-munk syndrome, 245010 (3), ; papillon-lefevre syndrome, 245000 (3),
DPP10		
DPP2		
DPP3		
DPP4		
DPP6	AD	intellectual developmental disorder, 33, 616311 (3), ; {ventricular fibrillation, paroxysmal familial, 2}, 612956 (3),
DPP7		
DPP8		
DPP9	AR	hatipoglu immunodeficiency syndrome, 620331 (3),
DPPA2		
DPPA3		
DPPA4		
DPPA5		
DPPII		
DPPIV		
DPPL1		
DPPT-L		
DPPX	AD	intellectual developmental disorder, 33, 616311 (3), ; {ventricular fibrillation, paroxysmal familial, 2}, 612956 (3),
DPPY		
DPRP1		
DPRP3		
DPRX		
DPT		
DPY19L1		
DPY19L2	AR	spermatogenic failure 9, 613958 (3),
DPY19L3		
DPY19L4		
DPY30		
DPY30D1		
DPYD	AR	dihydropyrimidine dehydrogenase deficiency, 274270 (3), ; 5-fluorouracil toxicity, 274270 (3),
DPYS	AR	dihydropyrimidinuria, 222748 (3),
DPYSL1		
DPYSL2		
DPYSL3		
DPYSL4		
DPYSL5	AD	ritscher-schinzel syndrome 4, 619435 (3),
DPZF	AD	primrose syndrome, 259050 (3),
DQ1		
DQ2	AR,AD	{dystonia-1, modifier of} (3); arthrogryposis multiplex congenita 5, 618947 (3), ; dystonia-1, torsion, 128100 (3),
DR-nm23		
DR1		
DR11	AR,AD	intellectual developmental disorder, 78, 620237 (3), ; hypogonadotropic hypogonadism 14 with or without anosmia, 614858 (3),
DR3		
DR3LG		
DR4		
DR5	AR	squamous cell carcinoma, head and neck, 275355 (3),
DR6		
DRA	AR	diarrhea 1, secretory chloride, congenital, 214700 (3),
DRABA2	AR	neurodevelopmental disorder with hypotonia, microcephaly, and seizures, 618862 (3),
DRADA	AD,AR	dyschromatosis symmetrica hereditaria, 127400 (3), ; aicardi-goutieres syndrome 6, 615010 (3),
DRADA2	AR	neurodevelopmental disorder with hypotonia, microcephaly, and seizures, 618862 (3),
DRAG1		
DRAGON		
DRAGOU14		breast cancer, somatic, 114480 (3)
DRAIC		
DRAK1		
DRAK2		
DRAL		
DRAM		
DRAM1		
DRAM2	AR	cone-rod dystrophy 21, 616502 (3),
DRAM3		
DRAP		
DRAP1		
DRASIC		
DRAXIN		
DRB1		
DRBP76		
DRC1	AR	spermatogenic failure 80, 620222 (3), ; ciliary dyskinesia, primary, 21, 615294 (3),
DRC2	AR	ciliary dyskinesia, primary, 27, 615504 (3),
DRC3		
DRC4	AR	ciliary dyskinesia, primary, 33, 616726 (3),
DRC5		
DRC6		
DRC7		
DRC8		
DRC9		
DRCC1		
DRCTNNB1A	AR	leukodystrophy, hypomyelinating, 5, 610532 (3),
DRD1		
DRD1B	AD	{blepharospasm, primary benign}, 606798 (3), ; {attention deficit-hyperactivity disorder, susceptibility to}, 143465 (3),
DRD1IP		
DRD1L2	AD	{blepharospasm, primary benign}, 606798 (3), ; {attention deficit-hyperactivity disorder, susceptibility to}, 143465 (3),
DRD2		
DRD3	AD	{essential tremor, hereditary, 1}, 190300 (3), ; {schizophrenia, susceptibility to}, 181500 (3),
DRD4	AD	{attention deficit-hyperactivity disorder}, 143465 (3), ; autonomic nervous system dysfunction (3)
DRD5	AD	{blepharospasm, primary benign}, 606798 (3), ; {attention deficit-hyperactivity disorder, susceptibility to}, 143465 (3),
DRE1	AR,AD	cardiomyopathy, familial hypertrophic, 29, with polyglucosan bodies, 620236 (3), ; epidermolysis bullosa simplex 6, generalized intermediate, with or without cardiomyopathy, 617294 (3),
DREAM		
DREF		
DRES-17	AR	neurodevelopmental disorder with microcephaly, hypotonia, and variable brain anomalies, 617481 (3),
DRES9		
DRES93		
DREV1		
DRF1		
DRF3	AD	auditory neuropathy, 1, 609129 (3),
DRG1	AR	charcot-marie-tooth disease, type 4d, 601455 (3),
DRG11		
DRG2		
DRGX		
DRIL1		
DRIL2		
DRIM		
DRIP100		
DRIP130	AR	intellectual developmental disorder, 18, with or without epilepsy, 614249 (3),
DRIP230		
DRIP36		
DRIP78		
DRIP80	AR	microcephaly, postnatal progressive, with seizures and brain atrophy, 613668 (3),
DRIP92		
DRLM		
DRM		
DRN3	AD,AR	vasculopathy, retinal, with cerebral leukoencephalopathy and systemic manifestations, 192315 (3), ; aicardi-goutieres syndrome 1, and , 225750 (3), ; {systemic lupus erythematosus, susceptibility to}, 152700 (3), ; chilblain lupus, 610448 (3),
DRO1		
DROER		
DROSHA		
DRP		
DRP-1		
DRP-2		
DRP-3		
DRP-4		
DRP1	AD,AR	optic atrophy 5, 610708 (3), ; encephalopathy, lethal, due to defective mitochondrial peroxisomal fission 1, 614388 (3),
DRP2		
DRP3	AD	left ventricular noncompaction 1, with or without congenital heart defects, 604169 (3),
DRPLA	AD	dentatorubral-pallidoluysian atrophy, 125370 (3), ; congenital hypotonia, epilepsy, developmental delay, and digital anomalies, 618494 (3),
DRR1		
DRRF		
DRS1		
DRT	AR	?bleeding disorder, platelet-type, 22, 618462 (3), ; {prostate cancer/brain cancer susceptibility, somatic}, 603688 (3)
DRTF1		
DRV1		
DRV2		
DRY-6		
DRY12		
DS	AD,AR	developmental delay and seizures with or without movement abnormalities, 617836 (3), ; ?congenital disorder of glycosylation, type 1bb, 613861 (3), ; retinitis pigmentosa 59, 613861 (3),
DS-1		
DS-Epi1	AR	ehlers-danlos syndrome, musculocontractural type 2, 615539 (3),
DSAEC		
DSC	AR	hypotrichosis and recurrent skin vesicles, 613102 (3),
DSC1	AR	hypotrichosis and recurrent skin vesicles, 613102 (3),
DSC2	AR,AD,AR	arrhythmogenic right ventricular dysplasia 11 with mild palmoplantar keratoderma and woolly hair, 610476 (3), ; arrhythmogenic right ventricular dysplasia 11, 610476 (3), |hypotrichosis and recurrent skin vesicles, 613102 (3),
DSC3	AR,AD,AR	arrhythmogenic right ventricular dysplasia 11 with mild palmoplantar keratoderma and woolly hair, 610476 (3), ; arrhythmogenic right ventricular dysplasia 11, 610476 (3), |hypotrichosis and recurrent skin vesicles, 613102 (3),
DSC4	AR	hypotrichosis and recurrent skin vesicles, 613102 (3),
DSC54		
DSC92		
DSCAM		
DSCAML1		
DSCC1		
DSCR1		
DSCR1L1		
DSCR1L2		
DSCR2		
DSCR3		
DSCR4		
DSCR5	AR	developmental and epileptic encephalopathy 55, 617599 (3),
DSCR6		
DSCR8		
DSE	AR	ehlers-danlos syndrome, musculocontractural type 2, 615539 (3),
DSEL		
DSEP		
DSEPI	AR	ehlers-danlos syndrome, musculocontractural type 2, 615539 (3),
DSG	AD,AR	keratosis palmoplantaris striata i, ad, 148700 (3), ; erythroderma, congenital, with palmoplantar keratoderma, hypotrichosis, and hyper ige, 615508 (3),
DSG1	AD,AR	keratosis palmoplantaris striata i, ad, 148700 (3), ; erythroderma, congenital, with palmoplantar keratoderma, hypotrichosis, and hyper ige, 615508 (3),
DSG2	AR,AD	cardiomyopathy, dilated, 1bb, 612877 (3), ; arrhythmogenic right ventricular dysplasia 10, 610193 (3),
DSG3	AR	blistering, acantholytic, of oral and laryngeal mucosa, 619226 (3),
DSG4	AR	hypotrichosis 6, 607903 (3),
DSHP	XL,XLR	lymphoproliferative syndrome, 1, 308240 (3),
DSI	AD	cole-carpenter syndrome 1, 112240 (3),
DSIPI		
Dsk2	XLD,XL	amyotrophic lateral sclerosis 15, with or without frontotemporal dementia, 300857 (3),
DSK2		
DSMAV	AD	spinal muscular atrophy, infantile, james type, 619042 (3), ; neuronopathy, distal hereditary motor, type va, 600794 (3), ; charcot-marie-tooth disease, type 2d, 601472 (3),
DSN1		
DSP	AD,AR	arrhythmogenic right ventricular dysplasia 8, 607450 (3), ; epidermolysis bullosa, lethal acantholytic, 609638 (3), ; keratosis palmoplantaris striata ii, 612908 (3), ; dilated cardiomyopathy with woolly hair, keratoderma, and tooth agenesis, 615821 (3), ; cardiomyopathy, dilated, with woolly hair and keratoderma, 605676 (3),
DSPA1	AD	osteogenesis imperfecta, type v, 610967 (3),
DSPA2a		
DSPA2b		{influenza, severe, susceptibility to}, 614680 (3)
DSPA2c		
DSPA3		
DSPB1		
DSPB2		
DSPB3	AD	convulsions, familial infantile, with paroxysmal choreoathetosis, 602066 (3), ; seizures, benign familial infantile, 2, 605751 (3), ; episodic kinesigenic dyskinesia 1, 128200 (3),
DSPC1		
DSPC2		
DSPC3		
DSPD1		
DSPG1	XL,XLR	meester-loeys syndrome, 300989 (3), ; spondyloepimetaphyseal dysplasia, 300106 (3),
DSPG2	AD	corneal dystrophy, congenital stromal, 610048 (3),
DSPG3		
DSPP	AD	dentinogenesis imperfecta, shields type iii, 125500 (3), ; dentinogenesis imperfecta, shields type ii, 125490 (3), ; dentin dysplasia, type ii, 125420 (3), ; deafness, 39, with dentinogenesis, 605594 (3),
DSRC	AR	developmental and epileptic encephalopathy 55, 617599 (3),
DSS	XLR,XL	adrenal hypoplasia, congenital, 300200 (3), ; 46xy sex reversal 2, dosage-sensitive, 300018 (3),
DSS1		
DST	AR	neuropathy, hereditary sensory and autonomic, type vi, 614653 (3), ; epidermolysis bullosa simplex 3, localized or generalized intermediate, with bp230 deficiency, 615425 (3),
DSTN		
DSTYK	AD,AR	congenital anomalies of kidney and urinary tract 1, 610805 (3), ; spastic paraplegia 23, 270750 (3),
DSU		
DT1P1A10	XLR,XL	?diamond-blackfan anemia 14 with mandibulofacial dysostosis, 300946 (3),
DT1P1A7		
DT1P1B11		
DTD	AR	{breast cancer, poor survival after chemotherapy for} (3); {leukemia, post-chemotherapy, susceptibility to} (3); {benzene toxicity, susceptibility to} (3)|epiphyseal dysplasia, multiple, 4, 226900 (3), ; de la chapelle dysplasia, 256050 (3), ; diastrophic dysplasia, 222600 (3), ; diastrophic dysplasia, broad bone-platyspondylic variant, 222600 (3), ; achondrogenesis ib, 600972 (3), ; atelosteogenesis, type ii, 256050 (3),
DTD1		
DTDST	AR	epiphyseal dysplasia, multiple, 4, 226900 (3), ; de la chapelle dysplasia, 256050 (3), ; diastrophic dysplasia, 222600 (3), ; diastrophic dysplasia, broad bone-platyspondylic variant, 222600 (3), ; achondrogenesis ib, 600972 (3), ; atelosteogenesis, type ii, 256050 (3),
DTE		
DTFT5783		
DTHD1		
Dtk		
DTL		
DTN	AD	left ventricular noncompaction 1, with or without congenital heart defects, 604169 (3),
DTN-1	AD	left ventricular noncompaction 1, with or without congenital heart defects, 604169 (3),
DTN-2	AD	left ventricular noncompaction 1, with or without congenital heart defects, 604169 (3),
DTN-3	AD	left ventricular noncompaction 1, with or without congenital heart defects, 604169 (3),
DTNA	AD	left ventricular noncompaction 1, with or without congenital heart defects, 604169 (3),
DTNB		
DTNBP1	AR	hermansky-pudlak syndrome 7, 614076 (3),
dtr		
DTR		{diphtheria, susceptibility to} (1)
Dtrp1		
DTS		{diphtheria, susceptibility to} (1)
DTX1		
DTX2		
DTX3		
DTX3L		
DTX4		
DTYMK	AR	neurodegeneration, childhood-onset, with progressive microcephaly, 619847 (3),
DUB3		
DUBA	XL,XLR	multiple congenital anomalies-neurodevelopmental syndrome, 301056 (3),
DUBA2		
DUBA3		
DUBA4		
DUBA5	AR	intellectual developmental disorder with dysmorphic facies, seizures, and distal limb anomalies, 617452 (3),
DUBA6		
DUBA7		
DUBA8		
DUBR		
dudlin-2	AD	?anemia, hypochromic microcytic, with iron overload 2, 615234 (3),
DUEB		
DUET		
DULLARD		
duo		
DUOX1		
DUOX2	AR	thyroid dyshormonogenesis 6, 607200 (3),
DUOXA1		
DUOXA2	AR	thyroid dyshormonogenesis 5, 274900 (3),
DUP	AR,AR	familial adenomatous polyposis 4, 617100 (3), ; endometrial carcinoma, somatic, 608089 (3)|meier-gorlin syndrome 4, 613804 (3),
DUPD1		
DUPLIN	AD	intellectual developmental disorder with autism and macrocephaly, 615032 (3),
DURS2	AD	duane retraction syndrome 2, 604356 (3),
DUS2		
DUS2L		
DUSP1		
DUSP10		
DUSP11		
DUSP12		
DUSP13		
DUSP13B		
DUSP14		
DUSP15		
DUSP16		
DUSP17		
DUSP18		
DUSP19		
DUSP2		
DUSP20		
DUSP21		
DUSP22		
DUSP23		
DUSP24		
DUSP25		
DUSP26		
DUSP27		
DUSP29		
DUSP3		
DUSP4		
DUSP5		
DUSP6	AD	hypogonadotropic hypogonadism 19 with or without anosmia, 615269 (3),
DUSP7		
DUSP8		
DUSP9		
DustyPK	AD,AR	congenital anomalies of kidney and urinary tract 1, 610805 (3), ; spastic paraplegia 23, 270750 (3),
DUT	AR	bone marrow failure and diabetes mellitus syndrome, 620044 (3),
dUTPase	AR	bone marrow failure and diabetes mellitus syndrome, 620044 (3),
DUTT1	AD,AR	pituitary hormone deficiency, combined or isolated, 8, 620303 (3), ; neurooculorenal syndrome, 620305 (3), ; ?nystagmus 8, congenital, 257400 (3),
DUX2		
DUX4		
DUX4L30		
DUX4L8		
DUX4L9		
DUXA		
DUXB		
DVC1	AR	ruijs-aalfs syndrome, 616200 (3),
DVL-22		
DVL1	AD	robinow syndrome, 2, 616331 (3),
DVL1L1		
DVL1P1		
DVL2		
DVL3	AD	robinow syndrome, 3, 616894 (3),
DVLP	AD,AR	optic atrophy 5, 610708 (3), ; encephalopathy, lethal, due to defective mitochondrial peroxisomal fission 1, 614388 (3),
DVS27		
DVWA		
DWF-1	AR,AD	ellis-van creveld syndrome, 225500 (3), ; ?weyers acrofacial dysostosis, 193530 (3),
Dwfc		
DWORF		
DXF34		
DXF68S1E		
DXO		
DXP4		
DXS1089		x-inactivation, familial skewed, 300087 (3)
DXS1179E		
DXS1253E	XL,XLR	thrombophilia 13, due to factor viii defect, 301071 (3); hemophilia a, 306700 (3),
DXS1272E	XL,XLR	intellectual developmental disorder, syndromic, claes-jensen type, 300534 (3),
DXS128	XL	allan-herndon-dudley syndrome, 300523 (3),
DXS1283E		
DXS128E	XL	allan-herndon-dudley syndrome, 300523 (3),
DXS1357E	XLR,XL	deafness, dystonia, and cerebral hypomyelination, 300475 (3),
DXS142	XLR,XL	becker muscular dystrophy, 300376 (3), ; cardiomyopathy, dilated, 3b, 302045 (3), ; duchenne muscular dystrophy, 310200 (3),
DXS164	XLR,XL	becker muscular dystrophy, 300376 (3), ; cardiomyopathy, dilated, 3b, 302045 (3), ; duchenne muscular dystrophy, 310200 (3),
DXS1692E	XL,XLR	intellectual developmental disorder, 58, 300210 (3),
DXS206	XLR,XL	becker muscular dystrophy, 300376 (3), ; cardiomyopathy, dilated, 3b, 302045 (3), ; duchenne muscular dystrophy, 310200 (3),
DXS230	XLR,XL	becker muscular dystrophy, 300376 (3), ; cardiomyopathy, dilated, 3b, 302045 (3), ; duchenne muscular dystrophy, 310200 (3),
DXS239	XLR,XL	becker muscular dystrophy, 300376 (3), ; cardiomyopathy, dilated, 3b, 302045 (3), ; duchenne muscular dystrophy, 310200 (3),
DXS253E		
DXS254E		
DXS268	XLR,XL	becker muscular dystrophy, 300376 (3), ; cardiomyopathy, dilated, 3b, 302045 (3), ; duchenne muscular dystrophy, 310200 (3),
DXS269	XLR,XL	becker muscular dystrophy, 300376 (3), ; cardiomyopathy, dilated, 3b, 302045 (3), ; duchenne muscular dystrophy, 310200 (3),
DXS270	XLR,XL	becker muscular dystrophy, 300376 (3), ; cardiomyopathy, dilated, 3b, 302045 (3), ; duchenne muscular dystrophy, 310200 (3),
DXS272	XLR,XL	becker muscular dystrophy, 300376 (3), ; cardiomyopathy, dilated, 3b, 302045 (3), ; duchenne muscular dystrophy, 310200 (3),
DXS306		
DXS399E		x-inactivation, familial skewed, 300087 (3)
DXS423E	XLD,XL	cornelia de lange syndrome 2, 300590 (3), ; developmental and epileptic encephalopathy 85, with or without midline brain defects, 301044 (3),
DXS522E		
DXS540	XL	choroideremia, 303100 (3),
DXS552E		
DXS560S		
DXS648	XL,XLR	{autism, susceptibility to, 5}, 300847 (3); intellectual developmental disorder, syndromic 35, 300998 (3),
DXS648E	XL,XLR	{autism, susceptibility to, 5}, 300847 (3); intellectual developmental disorder, syndromic 35, 300998 (3),
DXS6673E		
DXS6984E		
DXS707	XL,XLD,XLR	microphthalmia, syndromic 1, 309800 (3), ; ogden syndrome, 300855 (3),
DXS741		
DXS8237E	XLR,XL	tarp syndrome, 311900 (3),
DXS9822		
DXS9878E		
DXS9879E	XL,XLR	galloway-mowat syndrome 2, 301006 (3),
DXS9928E	XL,XLR	intellectual developmental disorder, syndromic, armfield type, 300261 (3),
DXS9951E	XL,XLR	galloway-mowat syndrome 2, 301006 (3),
DXYS155E		
DYDC1		
dyf-13	AR	biliary, renal, neurologic, and skeletal syndrome, 619534 (3),
DYF-2	AR	nephronophthisis 13, 614377 (3), ; cranioectodermal dysplasia 4, 614378 (3), ; senior-loken syndrome 8, 616307 (3), ; short-rib thoracic dysplasia 5 with or without polydactyly, 614376 (3), ; ?spermatogenic failure 72, 619867 (3),
DYF13	AR	biliary, renal, neurologic, and skeletal syndrome, 619534 (3),
DYH1B	AR	short-rib thoracic dysplasia 3 with or without polydactyly, 613091 (3), digenic
DYH9	AR	ciliary dyskinesia, primary, 40, 618300 (3),
DYM	AR	smith-mccort dysplasia, 607326 (3), ; dyggve-melchior-clausen disease, 223800 (3),
DYMPLE	AD,AR	optic atrophy 5, 610708 (3), ; encephalopathy, lethal, due to defective mitochondrial peroxisomal fission 1, 614388 (3),
DYN2	AD,AR	centronuclear myopathy 1, 160150 (3), ; charcot-marie-tooth disease, axonal type 2m, 606482 (3), ; charcot-marie-tooth disease, intermediate b, 606482 (3), ; lethal congenital contracture syndrome 5, 615368 (3),
Dyn4		
DYNAP		
DYNC1H1	AD	charcot-marie-tooth disease, axonal, type 2o, 614228 (3), ; spinal muscular atrophy, lower extremity-pre 1, ad, 158600 (3), ; cortical dysplasia, complex, with other brain malformations 13, 614563 (3),
DYNC1I1		
DYNC1I2	AR	neurodevelopmental disorder with microcephaly and structural brain anomalies, 618492 (3),
DYNC1LI1		
DYNC1LI2		
DYNC2H1	AR	short-rib thoracic dysplasia 3 with or without polydactyly, 613091 (3), digenic
DYNC2I1	AR	short-rib thoracic dysplasia 8 with or without polydactyly, 615503 (3),
DYNC2I2	AR	short-rib thoracic dysplasia 11 with or without polydactyly, 615633 (3),
DYNC2LI1	AR	short-rib thoracic dysplasia 15 with polydactyly, 617088 (3),
DYNII	AD,AR	centronuclear myopathy 1, 160150 (3), ; charcot-marie-tooth disease, axonal type 2m, 606482 (3), ; charcot-marie-tooth disease, intermediate b, 606482 (3), ; lethal congenital contracture syndrome 5, 615368 (3),
DYNLL1		
DYNLL1-AS1		
DYNLL2		
DYNLRB1		
DYNLRB2		
DYNLT1		
DYNLT2		
DYNLT2B	AR	short-rib thoracic dysplasia 17 with or without polydactyly, 617405 (3),
DYNLT3		
DYNLT4		
DYNLT5		
DYRK	AD	intellectual developmental disorder, 7, 614104 (3),
DYRK1	AD	intellectual developmental disorder, 7, 614104 (3),
DYRK1A	AD	intellectual developmental disorder, 7, 614104 (3),
DYRK1AP3		
DYRK1B	AD	abdominal obesity-metabolic syndrome 3, 615812 (3),
DYRK2		
DYRK3		
DYRK4		
DYRK6		
DYS	AR,AD	{medulloblastoma}, 155255 (3), somatic mutation, ; dysautonomia, familial, 223900 (3),
Dysbindin	AR	hermansky-pudlak syndrome 7, 614076 (3),
DYSF	AR	muscular dystrophy, limb-girdle, 2, 253601 (3), ; miyoshi muscular dystrophy 1, 254130 (3), ; myopathy, distal, with anterior tibial onset, 606768 (3),
dyskerin	XL,XLR	dyskeratosis congenita, 305000 (3),
DYT1	AR,AD	{dystonia-1, modifier of} (3); arthrogryposis multiplex congenita 5, 618947 (3), ; dystonia-1, torsion, 128100 (3),
DYT10	AD	convulsions, familial infantile, with paroxysmal choreoathetosis, 602066 (3), ; seizures, benign familial infantile, 2, 605751 (3), ; episodic kinesigenic dyskinesia 1, 128200 (3),
DYT11	AD	dystonia-11, myoclonic, 159900 (3),
DYT12	AD	alternating hemiplegia of childhood 2, 614820 (3), ; dystonia-12, 128235 (3), ; capos syndrome, 601338 (3), ; developmental and epileptic encephalopathy 99, 619606 (3),
DYT14	AR,AD	dystonia, dopa-responsive, 128230 (3), ; hyperphenylalaninemia, bh4-deficient, b, 233910 (3),
DYT16	AR	dystonia 16, 612067 (3),
DYT18	AD,AR	dystonia 9, 601042 (3), ; glut1 deficiency syndrome 1, infantile onset, severe, 606777 (3), ; stomatin-deficient cryohydrocytosis with neurologic defects, 608885 (3), ; {epilepsy, idiopathic generalized, susceptibility to, 12}, 614847 (3), ; glut1 deficiency syndrome 2, childhood onset, 612126 (3),
DYT2	AR	dystonia 2, torsion, 224500 (3),
DYT23	AD	dystonia 24, 615034 (3),
DYT3	XL,XLR	intellectual developmental disorder, syndromic 33, 300966 (3), ; dystonia-parkinsonism, 314250 (3),
DYT3/TAF1	XL,XLR	intellectual developmental disorder, syndromic 33, 300966 (3), ; dystonia-parkinsonism, 314250 (3),
DYT4	AD	dystonia 4, torsion, 128101 (3), ; leukodystrophy, hypomyelinating, 6, 612438 (3),
DYT5	AR,AD	dystonia, dopa-responsive, 128230 (3), ; hyperphenylalaninemia, bh4-deficient, b, 233910 (3),
DYT5a	AR,AD	dystonia, dopa-responsive, 128230 (3), ; hyperphenylalaninemia, bh4-deficient, b, 233910 (3),
DYT5b	AR	segawa syndrome, 605407 (3),
DYT6	AD	dystonia 6, torsion, 602629 (3),
DYT8	AD	paroxysmal nonkinesigenic dyskinesia 1, 118800 (3),
DYT9	AD,AR	dystonia 9, 601042 (3), ; glut1 deficiency syndrome 1, infantile onset, severe, 606777 (3), ; stomatin-deficient cryohydrocytosis with neurologic defects, 608885 (3), ; {epilepsy, idiopathic generalized, susceptibility to, 12}, 614847 (3), ; glut1 deficiency syndrome 2, childhood onset, 612126 (3),
DYTN		
DYX1C1	AD,AR	{dyslexia, susceptibility to, 1}, 127700 (3), ; ciliary dyskinesia, primary, 25, 615482 (3),
DZIP	AR,AD	spermatogenic failure 47, 619102 (3), ; ?mitral valve prolapse 3, 610840 (3),
DZIP1	AR,AD	spermatogenic failure 47, 619102 (3), ; ?mitral valve prolapse 3, 610840 (3),
DZIP1L	AR	polycystic kidney disease 5, 617610 (3),
DZIP2	AR	polycystic kidney disease 5, 617610 (3),
DZIP3		
E-FABP		
E-LOX	AR	ichthyosis, congenital, 3, 606545 (3),
E-MAP-115		
E(spl)		
E1	AR	butyrylcholinesterase deficiency, 617936 (3), ; {apnea, postanesthetic, susceptibility to, due to bche deficiency}, 617936 (3),
E1-7		
E12		
E14		
E16		
E1A-F		
E1AF		
E1alpha	XLD,XL	pyruvate dehydrogenase e1-alpha deficiency, 312170 (3),
E1b		
E1B-AP5		
E1BAP5		
E1beta	AR	pyruvate dehydrogenase e1-beta deficiency, 614111 (3),
E1c		
E1k	AR	oxoglutarate dehydrogenase deficiency, 203740 (3),
E2	AR	pyruvate dehydrogenase e2 deficiency, 245348 (3),
E2-1		
E2-2	AD	pitt-hopkins syndrome, 610954 (3), ; corneal dystrophy, fuchs endothelial, 3, 613267 (3),
E2-230K		
E2-CDC34		
E2-EPF		
E2(17)KB1		
E25		
E25A		
E25B	AD	?retinal dystrophy with inner retinal dysfunction and ganglion cell abnormalities, 616079 (3), ; dementia, familial british, 176500 (3), ; dementia, familial danish, 117300 (3),
E2A	AR,AD	agammaglobulinemia 8b, 619824 (3), ; agammaglobulinemia 8a, 616941 (3),
E2BP-1		
E2F-2		
E2F-4		
E2F-6		
E2F-like		
E2F1		
E2F2		
E2F3		
E2F4		
E2F5		
E2F6		
E2F7		
E2F8		
E2IG1	AD	neuronopathy, distal hereditary motor, type iia, 158590 (3), ; charcot-marie-tooth disease, axonal, type 2l, 608673 (3),
E2IG2		
E2IG3		
E2IG4		
E2IG5		
E3	AR	dihydrolipoamide dehydrogenase deficiency, 246900 (3),
E3-16	AD	?retinal dystrophy with inner retinal dysfunction and ganglion cell abnormalities, 616079 (3), ; dementia, familial british, 176500 (3), ; dementia, familial danish, 117300 (3),
E3-2		
E3-3	AR	mitochondrial complex i deficiency, nuclear type 18, 618240 (3),
E3B1		
E3BP	AR	lacticacidemia due to pdx1 deficiency, 245349 (3),
E3KARP		
E4	AR	neurodevelopmental disorder with hypotonia and gross motor and seech delay, 619639 (3),
E46L	AD	spinocerebellar ataxia 10, 603516 (3),
E47	AR,AD	agammaglobulinemia 8b, 619824 (3), ; agammaglobulinemia 8a, 616941 (3),
E48		
E4BP4		
E4F		
E4F1		
E4TF1-47		
E4TF1-60		
E4TF1A		
E5-1	AD	alzheimer disease-4, 606889 (3), ; cardiomyopathy, dilated, 1v, 613697 (3),
E6-AP	AD	angelman syndrome, 105830 (3),
E6BP		
E6TP1		
EA2	AD	spinocerebellar ataxia 6, 183086 (3), ; episodic ataxia, type 2, 108500 (3), ; developmental and epileptic encephalopathy 42, 617106 (3), ; migraine, familial hemiplegic, 1, with progressive cerebellar ataxia, 141500 (3), ; migraine, familial hemiplegic, 1, 141500 (3),
EA6	AD	episodic ataxia, type 6, 612656 (3),
EAA4	AD,AR	neurodevelopmental disorder with impaired language and ataxia and with or without seizures, 619580 (3), ; intellectual developmental disorder, 6, 611092 (3),
EAAC1	AR	dicarboxylic aminoaciduria, 222730 (3), ; {?schizophrenia susceptibility 18}, 615232 (3)
EAAT1	AD	episodic ataxia, type 6, 612656 (3),
EAAT2	AD	developmental and epileptic encephalopathy 41, 617105 (3),
EAAT3	AR	dicarboxylic aminoaciduria, 222730 (3), ; {?schizophrenia susceptibility 18}, 615232 (3)
EAAT4		
EAAT5		
EAB1		
EAD	AR	myasthenic syndrome, congenital, 5, 603034 (3),
EAF1		
EAF2		
Eaf3		
Eaf4		
Eaf6		
Eaf7		
eag	AD	zimmermann-laband syndrome 1, 135500 (3), ; temple-baraitser syndrome, 611816 (3),
eag1	AD	zimmermann-laband syndrome 1, 135500 (3), ; temple-baraitser syndrome, 611816 (3),
eag2		
EAOH	AR	ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia, 208920 (3),
EAP		
EAP1	AD	neurodevelopmental disorder with regression, abnormal movements, loss of speech, and seizures, 618088 (3),
EAP2	AR	pontocerebellar hypoplasia, type 1c, 616081 (3),
EAP20		
EAP30		
EAP4		
Eap45		
EAPI		
EAPP		
ear-1		
EAR-1r		
EAR-2		
EAR-3	AD	bosch-boonstra-schaaf optic atrophy syndrome, 615722 (3),
EAR-7.1/EAR-7.2	AD	hypothyroidism, congenital, nongoitrous, 6, 614450 (3),
EAR2		
EARS	AR	leukodystrophy, hypomyelinating, 15, 617951 (3),
EARS2	AR	combined oxidative phosphorylation deficiency 12, 614924 (3),
EAT2		
EB-1		
EB1	AD	symmetric circumferential skin creases, congenital, 2, 616734 (3),
EB11	AD	developmental and epileptic encephalopathy 46, 617162 (3),
EB2	AD	symmetric circumferential skin creases, congenital, 2, 616734 (3),
EB3		
EB6ActI		
EB6ActII		
EB9		
EBAF		
EBAG9		
EBBP		
EBD1	AD,AR	nail disorder, nonsyndromic congenital, 8, 607523 (3), ; epidermolysis bullosa dystrophica, bart type, 132000 (3), ; epidermolysis bullosa dystrophica inversa, 226600 (3), ; epidermolysis bullosa dystrophica, 226600 (3), ; epidermolysis bullosa, pretibial, 131850 (3), ; epidermolysis bullosa dystrophica, 131750 (3), ; transient bullous of the newborn, 131705 (3), ; epidermolysis bullosa pruriginosa, 604129 (3), ; epidermolysis bullosa dystrophica, localisata variant, 226600 (3),
EBDCT	AD,AR	nail disorder, nonsyndromic congenital, 8, 607523 (3), ; epidermolysis bullosa dystrophica, bart type, 132000 (3), ; epidermolysis bullosa dystrophica inversa, 226600 (3), ; epidermolysis bullosa dystrophica, 226600 (3), ; epidermolysis bullosa, pretibial, 131850 (3), ; epidermolysis bullosa dystrophica, 131750 (3), ; transient bullous of the newborn, 131705 (3), ; epidermolysis bullosa pruriginosa, 604129 (3), ; epidermolysis bullosa dystrophica, localisata variant, 226600 (3),
EBF		
EBF1		
EBF2		
EBF3	AD	hypotonia, ataxia, and delayed development syndrome, 617330 (3),
EBF4		
Ebfaz	AR,AD	nephronophthisis 14, 614844 (3), ; joubert syndrome 19, 614844 (3),
EBI	XL	hypothyroidism, congenital, nongoitrous, 8, 301033 (3),
EBI1		
EBI2		
EBI3		
EBI6		
EBLN1		
EBLN2		
EBN	AD,AD	{nicotine addiction, susceptibility to}, 188890 (3); epilepsy, nocturnal frontal lobe, 1, 600513 (3), |developmental and epileptic encephalopathy 7, 613720 (3), ; seizures, benign neonatal, 1, 121200 (3), ; myokymia, 121200 (3),
EBN1	AD,AD	{nicotine addiction, susceptibility to}, 188890 (3); epilepsy, nocturnal frontal lobe, 1, 600513 (3), |developmental and epileptic encephalopathy 7, 613720 (3), ; seizures, benign neonatal, 1, 121200 (3), ; myokymia, 121200 (3),
EBN2	AD	seizures, benign neonatal, 2, 121201 (3),
EBNA1BP2		
EBP	AR,XLR,XLD,XL	gm1-gangliosidosis, type i, 230500 (3), ; gm1-gangliosidosis, type iii, 230650 (3), ; mucopolysaccharidosis type ivb (morquio), 253010 (3), ; gm1-gangliosidosis, type ii, 230600 (3), |mend syndrome, 300960 (3), ; chondrodysplasia punctata, 302960 (3),
EBP-37		
EBP1		
EBP2		
EBP50	AD	nephrolithiasis/osteoporosis, hypophosphatemic, 2, 612287 (3),
EBPL		
EBR1	AD,AR	nail disorder, nonsyndromic congenital, 8, 607523 (3), ; epidermolysis bullosa dystrophica, bart type, 132000 (3), ; epidermolysis bullosa dystrophica inversa, 226600 (3), ; epidermolysis bullosa dystrophica, 226600 (3), ; epidermolysis bullosa, pretibial, 131850 (3), ; epidermolysis bullosa dystrophica, 131750 (3), ; transient bullous of the newborn, 131705 (3), ; epidermolysis bullosa pruriginosa, 604129 (3), ; epidermolysis bullosa dystrophica, localisata variant, 226600 (3),
EBR2	AR	epidermolysis bullosa, junctional 3b, severe, 619786 (3), ; epidermolysis bullosa, junctional 3a, intermediate, 619785 (3),
EBR2A	AR	epidermolysis bullosa, junctional 3b, severe, 619786 (3), ; epidermolysis bullosa, junctional 3a, intermediate, 619785 (3),
EBRP		
EBS1	AR,AD	?epidermolysis bullosa simplex 5d, generalized intermediate, 616487 (3), ; epidermolysis bullosa simplex 5b, with muscular dystrophy, 226670 (3), ; epidermolysis bullosa simplex 5c, with pyloric atresia, 612138 (3), ; epidermolysis bullosa simplex 5a, ogna type, 131950 (3), ; muscular dystrophy, limb-girdle, 17, 613723 (3),
EBS2	AD,AR	epidermolysis bullosa simplex 2a, generalized severe, 619555 (3), ; dowling-degos disease 1, 179850 (3), ; epidermolysis bullosa simplex 2f, with mottled pigmentation, 131960 (3), ; epidermolysis bullosa simplex 2d, generalized, intermediate or severe, 619599 (3), ; epidermolysis bullosa simplex 2b, generalized intermediate, 619588 (3), ; epidermolysis bullosa simplex 2c, localized, 619594 (3), ; epidermolysis bullosa simplex 2e, with migratory circinate erythema, 609352 (3),
EBS3	AR,AD	epidermolysis bullosa simplex 1d, generalized, intermediate or severe, 601001 (3), ; epidermolysis bullosa simplex 1c, localized, 131800 (3), ; dermatopathia pigmentosa reticularis, 125595 (3), ; epidermolysis bullosa simplex 1a, generalized severe, 131760 (3), ; naegeli-franceschetti-jadassohn syndrome, 161000 (3), ; epidermolysis bullosa simplex 1b, generalized intermediate, 131900 (3),
EBS4	AR,AD	epidermolysis bullosa simplex 1d, generalized, intermediate or severe, 601001 (3), ; epidermolysis bullosa simplex 1c, localized, 131800 (3), ; dermatopathia pigmentosa reticularis, 125595 (3), ; epidermolysis bullosa simplex 1a, generalized severe, 131760 (3), ; naegeli-franceschetti-jadassohn syndrome, 161000 (3), ; epidermolysis bullosa simplex 1b, generalized intermediate, 131900 (3),
EBVS	XL,XLR	lymphoproliferative syndrome, 1, 308240 (3),
EC-PTP		
EC-SOD		[superoxide dismutase, elevated extracellular] (3)
EC2		
EC45	AD	diamond-blackfan anemia 12, 615550 (3),
ECAC1		
ECAC2	AR	hyperparathyroidism, transient neonatal, 618188 (3),
ECAT1	AR	hydatidiform mole, recurrent, 2, 614293 (3),
ECD		
ECE	MF,AD	{hypertension, essential, susceptibility to}, 145500 (3), ; ?hirschsprung disease, cardiac defects, and autonomic dysfunction, 613870 (3),
ECE1	MF,AD	{hypertension, essential, susceptibility to}, 145500 (3), ; ?hirschsprung disease, cardiac defects, and autonomic dysfunction, 613870 (3),
ECE2		
ECE3		[blood group, kell], 110900 (3)
ECEL1	AR	arthrogryposis, distal, type 5d, 615065 (3),
ECG2		
ECGF		
ECGF-beta		
ECGF1	AR	mitochondrial dna depletion syndrome 1 (mngie type), 603041 (3),
ECGFA		
ECGFB		
ECH1		
ECHD	AD	?fanconi renotubular syndrome 3, 615605 (3),
ECHDC1		
ECHS1	AR	mitochondrial short-chain enoyl-coa hydratase 1 deficiency, 616277 (3),
ECI1		
ECI2		
ECK	AD	cataract 6, multiple types, 116600 (3),
ECKLG		
ECL		
ECM		
ECM-III		[blood group, indian system], 609027 (3)
ECM1	AR	urbach-wiethe disease, 247100 (3),
ECM2		
ECM29		
ECM39	AR	congenital disorder of glycosylation, type ig, 607143 (3),
ECNOS	MF,AD	{coronary artery spasm 1, susceptibility to} (3); {hypertension, susceptibility to}, 145500 (3), ; {placental abruption} (3); {alzheimer disease, late-onset, susceptibility to}, 104300 (3), ; {hypertension, pregnancy-induced}, 189800 (3), ; {ischemic stroke, susceptibility to}, 601367 (3),
ECONEXIN		
ECop		
ECP		
ECP51		
ECP54		
ECPAS		
ECPN		
ECRAR		
ECRG1		
ECRG2		
ECRG4		
ECS-1		
ECS1		
ECSCR		
ECSIT		
ECSM2		
ECSM3		
ECSM4	AD	aortic valve disease 3, 618496 (3),
ECT1	AD	bent bone dysplasia syndrome, 614592 (3), ; ladd syndrome 1, 149730 (3), ; antley-bixler syndrome without genital anomalies or disordered steroidogenesis, 207410 (3), ; scaphocephaly and axenfeld-rieger anomaly (3); jackson-weiss syndrome, 123150 (3), ; gastric cancer, somatic, 613659 (3); craniofacial-skeletal-dermatologic dysplasia, 101600 (3), ; apert syndrome, 101200 (3), ; pfeiffer syndrome, 101600 (3), ; craniosynostosis, nonspecific (3); ?scaphocephaly, maxillary retrusion, and impaired intellectual development, 609579 (3); beare-stevenson cutis gyrata syndrome, 123790 (3), ; crouzon syndrome, 123500 (3), ; saethre-chotzen syndrome, 101400 (3),
ECT2		
ECTACC		
ED1	XL,XLD,XLR	tooth agenesis, selective, 1, 313500 (3), ; ectodermal dysplasia 1, hypohidrotic, 305100 (3),
ED1-A1	XL,XLD,XLR	tooth agenesis, selective, 1, 313500 (3), ; ectodermal dysplasia 1, hypohidrotic, 305100 (3),
ED1-A2	XL,XLD,XLR	tooth agenesis, selective, 1, 313500 (3), ; ectodermal dysplasia 1, hypohidrotic, 305100 (3),
ED1R	AD,AR	[hair morphology 1, hair thickness], 612630 (3); ectodermal dysplasia 10a, hypohidrotic/hair/nail type, 129490 (3), ; ectodermal dysplasia 10b, hypohidrotic/hair/tooth type, 224900 (3),
ED2	AD,AR	ectodermal dysplasia 2, clouston type, 129500 (3), ; deafness, 3b, 612643 (3), ; deafness, 1b, 612645 (3), ; deafness, digenic gjb2/gjb6, 220290 (3), digenic
ED3	AD,AR	[hair morphology 1, hair thickness], 612630 (3); ectodermal dysplasia 10a, hypohidrotic/hair/nail type, 129490 (3), ; ectodermal dysplasia 10b, hypohidrotic/hair/tooth type, 224900 (3),
ED4	AR	cleft lip/palate-ectodermal dysplasia syndrome, 225060 (3), ; orofacial cleft 7, 225060 (3),
ED5	AD,AR	[hair morphology 1, hair thickness], 612630 (3); ectodermal dysplasia 10a, hypohidrotic/hair/nail type, 129490 (3), ; ectodermal dysplasia 10b, hypohidrotic/hair/tooth type, 224900 (3),
EDA	XL,XLD,XLR	tooth agenesis, selective, 1, 313500 (3), ; ectodermal dysplasia 1, hypohidrotic, 305100 (3),
EDA-A1	XL,XLD,XLR	tooth agenesis, selective, 1, 313500 (3), ; ectodermal dysplasia 1, hypohidrotic, 305100 (3),
EDA-A2	XL,XLD,XLR	tooth agenesis, selective, 1, 313500 (3), ; ectodermal dysplasia 1, hypohidrotic, 305100 (3),
EDA-A2R		
EDA1	XL,XLD,XLR	tooth agenesis, selective, 1, 313500 (3), ; ectodermal dysplasia 1, hypohidrotic, 305100 (3),
EDA1R	AD,AR	[hair morphology 1, hair thickness], 612630 (3); ectodermal dysplasia 10a, hypohidrotic/hair/nail type, 129490 (3), ; ectodermal dysplasia 10b, hypohidrotic/hair/tooth type, 224900 (3),
EDA2	XL,XLD,XLR	tooth agenesis, selective, 1, 313500 (3), ; ectodermal dysplasia 1, hypohidrotic, 305100 (3),
EDA2R		
EDA3	AD,AR	[hair morphology 1, hair thickness], 612630 (3); ectodermal dysplasia 10a, hypohidrotic/hair/nail type, 129490 (3), ; ectodermal dysplasia 10b, hypohidrotic/hair/tooth type, 224900 (3),
EDAA2R		
EDAF-1		
EDAG		
EDAR	AD,AR	[hair morphology 1, hair thickness], 612630 (3); ectodermal dysplasia 10a, hypohidrotic/hair/nail type, 129490 (3), ; ectodermal dysplasia 10b, hypohidrotic/hair/tooth type, 224900 (3),
EDARADD	AR,AD	ectodermal dysplasia 11b, hypohidrotic/hair/tooth type, 614941 (3), ; ectodermal dysplasia 11a, hypohidrotic/hair/tooth type, 614940 (3),
EDB		
EDC1		
EDC3	AR	?intellectual developmental disorder, 50, 616460 (3),
EDC4		
EDD		
EDD1		
EDDM1	AR	niemann-pick disease, type c2, 607625 (3),
EDDM12		
EDDM2B		
EDDM3A		
EDDM3B		
EDDM4		
EDDM5		
EDDM6	XL	congenital bilateral absence of vas deferens, 300985 (3),
EDDM9		
EDDR1		
EDEM		
EDEM1		
EDEM2		
EDEM3	AR	congenital disorder of glycosylation, type iiv, 619493 (3),
EDEN-BP		
EDF		
EDF-1		
EDF1		
edg-1		
edg-2		
EDG-2		
EDG-3		
EDG-4		
Edg-7		
Edg-8		
EDG1		
EDG2		
EDG3		
EDG4		
EDG5	AR	deafness, 68, 610419 (3),
EDG6		
EDG7		
EDG8		
EDH	AD,AR	ectodermal dysplasia 2, clouston type, 129500 (3), ; deafness, 3b, 612643 (3), ; deafness, 1b, 612645 (3), ; deafness, digenic gjb2/gjb6, 220290 (3), digenic
EDH17B2		
EDHB17		
EDIL1		
EDIL3		
EDJ	AD	polycystic kidney disease 6 with or without polycystic liver disease, 618061 (3),
EDL		
EDM1	AD	pseudoachondroplasia, 177170 (3), ; carpal tunnel syndrome 2, 619161 (3), ; epiphyseal dysplasia, multiple, 1, 132400 (3),
EDM2	AD,AR	epiphyseal dysplasia, multiple, 2, 600204 (3), ; ?stickler syndrome, type v, 614284 (3),
EDM3	AD,AR	{intervertebral disc disease, susceptibility to}, 603932 (3); epiphyseal dysplasia, multiple, 3, with or without myopathy, 600969 (3), ; stickler syndrome, type vi, 620022 (3),
EDM4	AR	?hypersulfaturia, 620372 (3), ; ?nephrolithiasis, calcium oxalate, 1, 167030 (3),
EDM5	AD,AR	{osteoarthritis susceptibility 2}, 140600 (3), ; spondyloepimetaphyseal dysplasia, borochowitz-cormier-daire type, 608728 (3), ; epiphyseal dysplasia, multiple, 5, 607078 (3),
EDN		
EDN1	AD,AR	{high density lipoprotein cholesterol level qtl 7} (3); question mark ears, isolated, 612798 (3), ; auriculocondylar syndrome 3, 615706 (3),
EDN2		
EDN3	AR,AD	waardenburg syndrome, type 4b, 613265 (3), ; {hirschsprung disease, susceptibility to, 4}, 613712 (3),
EDNRA	AD	{migraine, resistance to}, 157300 (3), ; mandibulofacial dysostosis with alopecia, 616367 (3),
EDNRB	AD,AR	{hirschsprung disease, susceptibility to, 2}, 600155 (3), ; ?abcd syndrome, 600501 (3), ; waardenburg syndrome, type 4a, 277580 (3),
EDNRBL		
EDP1		
EDPF-1		
EDPF1		
EDR1	AR	?microcephaly 11, primary, 615414 (3),
EDR2		
EDR3		
EDRF		
EDS4A	AD,AR	ehlers-danlos syndrome, vascular type, 130050 (3), ; polymicrogyria with or without vascular-type eds, 618343 (3),
EDTB		
EE1A1		
EEA1		
EEC3	AD	premature ovarian failure 21, 620311 (3), ; ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3, 604292 (3), ; hay-wells syndrome, 106260 (3), ; split-hand/foot malformation 4, 605289 (3), ; orofacial cleft 8, 618149 (3); rapp-hodgkin syndrome, 129400 (3), ; adult syndrome, 103285 (3), ; limb-mammary syndrome, 603543 (3),
EED	AD	cohen-gibson syndrome, 617561 (3),
EEF-2	AD	?spinocerebellar ataxia 26, 609306 (3),
eEF-2K		
EEF1A		
EEF1A1		
EEF1A2	AD	developmental and epileptic encephalopathy 33, 616409 (3), ; intellectual developmental disorder, 38, 616393 (3),
EEF1A2BP1		
EEF1AKMT1		
EEF1AKMT2		
EEF1AKMT3		
EEF1AKNMT	AR,AD	{?deafness, 26, modifier of}, 605429 (3),
EEF1AL	AD	developmental and epileptic encephalopathy 33, 616409 (3), ; intellectual developmental disorder, 38, 616393 (3),
EEF1B2		
EEF1D		
EEF1E1		
EEF1G		
EEF2	AD	?spinocerebellar ataxia 26, 609306 (3),
EEF2K		
EEF2KMT		
EEFSEC		
Eeg1		
EEG1		
Eeig1		
EEIG1		
EEK		
EEN	AD	leukemia, acute myeloid, 601626 (1), somatic mutation,
EEN-B1		
EEN-B2		
EEPD1		
EEYORE		
EF-1a		
EF-1D		
EF-C		
EF-G2mt	AR	combined oxidative phosphorylation deficiency 39, 618397 (3),
EF-TS	AR	combined oxidative phosphorylation deficiency 3, 610505 (3),
EF-Tsmt	AR	combined oxidative phosphorylation deficiency 3, 610505 (3),
EF-TuMT	AR	combined oxidative phosphorylation deficiency 4, 610678 (3),
EF1A		
EF1A1		
EF1ABP		
EF1alpha1		
EF1G		
EF2	AD	?spinocerebellar ataxia 26, 609306 (3),
EF7		
EFA6		
EFA6A		
EFA6B		
EFA6D		
EFA6R		
EFCAB1		
EFCAB14		
EFCAB2		
EFCAB3		
EFCAB4A		
EFCAB4B		
EFCAB6		
EFCAB7		
EFCAB9		
EFCBP2		
EFCBP3		
EFE	XLR,XL	barth syndrome, 302060 (3),
EFE2	XLR,XL	barth syndrome, 302060 (3),
EFEMP1	AD	doyne honeycomb degeneration of retina, 126600 (3),
EFEMP2	AR	cutis laxa, type ib, 614437 (3),
eferin		
EFG2	AR	combined oxidative phosphorylation deficiency 39, 618397 (3),
EFGM	AR	combined oxidative phosphorylation deficiency 1, 609060 (3),
EFHA1		
EFHA2		
EFHA3	AR	myopathy with extrapyramidal signs, 615673 (3),
EFHC1	AD	{epilepsy, juvenile absence, susceptibility to, 1}, 607631 (3), ; {myoclonic epilepsy, juvenile, susceptibility to, 1}, 254770 (3),
EFHC2		
EFHD1		
EFHD2		
EFL1	AR	shwachman-diamond syndrome 2, 617941 (3),
EFM3		
Efm4		
EFMR	XL	developmental and epileptic encephalopathy 9, 300088 (3),
EFNA1		
EFNA2		
EFNA3		
EFNA4		
EFNA5		
EFNB1	XLD,XL	craniofrontonasal dysplasia, 304110 (3),
EFNB2		
EFNB3		
EFO1		
EFO2	AR	juberg-hayward syndrome, 216100 (3), ; roberts-sc phocomelia syndrome, 268300 (3),
EFP		
EFP1		
EFR3A		
EFR3B		
EFS		
EFS1		
EFS2		
EFSEC		
EFTR-2		
EFTu	AR	combined oxidative phosphorylation deficiency 4, 610678 (3),
EFTU	AR	combined oxidative phosphorylation deficiency 4, 610678 (3),
EFTUD1	AR	shwachman-diamond syndrome 2, 617941 (3),
EFTUD2	AD	mandibulofacial dysostosis, guion-almeida type, 610536 (3),
EG		
EG-VEGF		
EG1		
Eg5	AD	microcephaly with or without chorioretinopathy, lymphedema, or mental retardation, 152950 (3),
EGF	AR	?hypomagnesemia 4, renal, 611718 (3),
EGF1	AR	combined oxidative phosphorylation deficiency 1, 609060 (3),
EGFL1		
EGFL10	AR	retinitis pigmentosa 25, 602772 (3),
EGFL11	AR	retinitis pigmentosa 25, 602772 (3),
EGFL2		
EGFL3		
EGFL4	AR	carpenter syndrome 2, 614976 (3),
EGFL5		
EGFL6		
EGFL6L		
EGFL7		
EGFL8		
EGFLAM		
EGFR	AR,AD	?inflammatory skin and bowel disease, neonatal, 2, 616069 (3), ; nonsmall cell lung cancer, response to tyrosine kinase inhibitor in, 211980 (3), somatic mutation, ; adenocarcinoma of lung, response to tyrosine kinase inhibitor in, 211980 (3), somatic mutation, ; {nonsmall cell lung cancer, susceptibility to}, 211980 (3), somatic mutation,
EGFR-RS		
EGLN1	AD	erythrocytosis, familial, 3, 609820 (3), ; [hemoglobin, high altitude adaptation], 609070 (3),
EGLN2		
EGLN3		
EGLN4	AR	hypotonia, hypoventilation, impaired intellectual development, dysautonomia, epilepsy, and eye abnormalities, 618493 (3),
EGO		
EGOT		
EGP-1	AR	corneal dystrophy, gelatinous drop-like, 204870 (3),
EGP-2	AR,AD	diarrhea 5, with tufting enteropathy, congenital, 613217 (3), ; lynch syndrome 8, 613244 (3),
EGP34	AR,AD	diarrhea 5, with tufting enteropathy, congenital, 613217 (3), ; lynch syndrome 8, 613244 (3),
EGP40	AR,AD	diarrhea 5, with tufting enteropathy, congenital, 613217 (3), ; lynch syndrome 8, 613244 (3),
EGR1		
EGR2	AR,AD	dejerine-sottas disease, 145900 (3), ; charcot-marie-tooth disease, type 1d, 607678 (3), ; hypomyelinating neuropathy, congenital, 1, 605253 (3),
EGR3		
EGR4		
EGRA		
EGVEGF		
EH4		
eHand		
EHB21		
EHB3	AR	?pontocerebellar hypoplasia, type 15, 619302 (3),
EHBP1		{prostate cancer, hereditary, 12}, 611868 (3)
EHBP1L1		
EHD1		
EHD2		
EHD3		
EHD4		
EHF		
EHHADH	AD	?fanconi renotubular syndrome 3, 615605 (3),
EHK1	AD,AR	ichthyosis, annular epidermolytic 2, 620148 (3), ; palmoplantar keratoderma, nonepidermolytic, 600962 (3), ; epidermolytic hyperkeratosis 1, 113800 (3), ; palmoplantar keratoderma, epidermolytic, 2, 620411 (3); keratosis palmoplantaris striata iii, 607654 (3); ichthyosis histrix, curth-macklin type, 146590 (3),
Ehk1-L		
EHM2		
EHMT1	AD	kleefstra syndrome 1, 610253 (3),
EHMT1-IT1	AD	kleefstra syndrome 1, 610253 (3),
EHMT2		
EHOC-1	AR	neurodevelopmental disorder with microcephaly, short stature, and speech delay, 620027 (3),
EHOC-17		
EHZF		
EI		
EI24		
EID-1		
EID-2		
EID-3		
EID1		
EID2		
EID2B		
EID3		
EIEE1	XL,XLR	proud syndrome, 300004 (3), ; hydranencephaly with abnormal genitalia, 300215 (3), ; partington syndrome, 309510 (3), ; developmental and epileptic encephalopathy 1, 308350 (3), ; lissencephaly, 2, 300215 (3), ; intellectual developmental disorder, 29, 300419 (3),
EIEE2	XLD,XL	developmental and epileptic encephalopathy 2, 300672 (3),
EIEE3	AR	developmental and epileptic encephalopathy 3, 609304 (3),
EIEE9	XL	developmental and epileptic encephalopathy 9, 300088 (3),
EIF-1		
eIF-1A		
EIF-2A		
EIF-2alpha		
EIF-2B	AR	leukoencephalopathy with vanishing white matter 1, with or without ovarian failure, 603896 (3), |leukoencephalopathy with vanishing white matter 3, with or without ovarian failure, 620313 (3)|leukoencephalopathy with vanishing white matter 4, with or without ovarian failure, 620314 (3)|leukoencephalopathy with vanishing white matter 5, with or without ovarian failure, 620315 (3)
EIF-2Balpha	AR	leukoencephalopathy with vanishing white matter 1, with or without ovarian failure, 603896 (3),
EIF-2Bbeta		leukoencephalopathy with vanishing white matter 2, with or without ovarian failure, 620312 (3)
EIF-4A		
eIF-4C		
EIF-5A	AD	faundes-banka syndrome, 619376 (3),
EIF1		
EIF1A		
EIF1AD		
EIF1AX		
EIF1AY		
EIF2	XLR,XL	mehmo syndrome, 300148 (3),
EIF2A		
EIF2AK1	AD	?leukoencephalopathy, motor delay, spasticity, and dysarthria syndrome, 618878 (3),
EIF2AK2	AD,AR	leukoencephalopathy, developmental delay, and episodic neurologic regression syndrome, 618877 (3), ; dystonia 33, 619687 (3),
EIF2AK3	AR	wolcott-rallison syndrome, 226980 (3),
EIF2AK4	AR	pulmonary venoocclusive disease 2, 234810 (3),
EIF2B	AR	leukoencephalopathy with vanishing white matter 1, with or without ovarian failure, 603896 (3), |leukoencephalopathy with vanishing white matter 2, with or without ovarian failure, 620312 (3)|leukoencephalopathy with vanishing white matter 4, with or without ovarian failure, 620314 (3)
EIF2B1	AR	leukoencephalopathy with vanishing white matter 1, with or without ovarian failure, 603896 (3),
EIF2B2		leukoencephalopathy with vanishing white matter 2, with or without ovarian failure, 620312 (3)
EIF2B3		leukoencephalopathy with vanishing white matter 3, with or without ovarian failure, 620313 (3)
EIF2B4		leukoencephalopathy with vanishing white matter 4, with or without ovarian failure, 620314 (3)
EIF2B5		leukoencephalopathy with vanishing white matter 5, with or without ovarian failure, 620315 (3)
EIF2BA	AR	leukoencephalopathy with vanishing white matter 1, with or without ovarian failure, 603896 (3),
EIF2Balpha	AR	leukoencephalopathy with vanishing white matter 1, with or without ovarian failure, 603896 (3),
EIF2Bbeta		leukoencephalopathy with vanishing white matter 2, with or without ovarian failure, 620312 (3)
EIF2Bdelta		leukoencephalopathy with vanishing white matter 4, with or without ovarian failure, 620314 (3)
EIF2Bepsilon		leukoencephalopathy with vanishing white matter 5, with or without ovarian failure, 620315 (3)
EIF2beta		
EIF2Bgamma		leukoencephalopathy with vanishing white matter 3, with or without ovarian failure, 620313 (3)
EIF2C1	AD	neurodevelopmental disorder with language delay and behavioral abnormalities, with or without seizures, 620292 (3),
EIF2C2	AD	lessel-kreienkamp syndrome, 619149 (3),
EIF2C3		
EIF2C4		
EIF2D		
EIF2G	XLR,XL	mehmo syndrome, 300148 (3),
EIF2gamma	XLR,XL	mehmo syndrome, 300148 (3),
EIF2S1		
EIF2S2		
EIF2S3	XLR,XL	mehmo syndrome, 300148 (3),
EIF3		
eIF3-alpha		
eIF3-beta		
eIF3-delta		
eIF3-epsilon	AR	intellectual developmental disorder, 67, 618295 (3),
eIF3-gamma		
eIF3-p110		
eIF3-p170		
eIF3-p35		
eIF3-p36		
eIF3-p40		
eIF3-p44		
eIF3-p47	AR	intellectual developmental disorder, 67, 618295 (3),
eIF3-p48		
eIF3-p66		
eIF3-theta		
eIF3-zeta		
EIF3A		
EIF3B		
EIF3C		
EIF3D		
EIF3E		
EIF3EIP		
EIF3F	AR	intellectual developmental disorder, 67, 618295 (3),
EIF3G		
EIF3H		
EIF3I		
EIF3J		
EIF3K		
EIF3L		
EIF3M		
EIF3S1		
EIF3S10		
EIF3S11		
EIF3S12		
EIF3S2		
EIF3S3		
EIF3S4		
EIF3S5	AR	intellectual developmental disorder, 67, 618295 (3),
EIF3S6		
EIF3S6IP		
EIF3S7		
EIF3S8		
EIF3S9		
EIF4A		
EIF4A1		
EIF4A2		
EIF4A3	AR	robin sequence with cleft mandible and limb anomalies, 268305 (3),
EIF4AIII	AR	robin sequence with cleft mandible and limb anomalies, 268305 (3),
EIF4B		
EIF4C		
EIF4E		{autism, susceptibility to, 19}, 615091 (3)
EIF4E1		{autism, susceptibility to, 19}, 615091 (3)
EIF4E2		
EIF4E3		
EIF4EBP1		
EIF4EBP2		
EIF4EBP3		
EIF4EL1		{autism, susceptibility to, 19}, 615091 (3)
EIF4EL3		
EIF4ENIF1		
EIF4F	AD	{autism, susceptibility to, 19}, 615091 (3)|{parkinson disease 18}, 614251 (3),
EIF4G	AD	{parkinson disease 18}, 614251 (3),
EIF4G1	AD	{parkinson disease 18}, 614251 (3),
EIF4G2		
EIF4G3		
eIF4GII		
EIF4GL		
EIF4H		
EIF5		
EIF5A	AD	faundes-banka syndrome, 619376 (3),
EIF5A1	AD	faundes-banka syndrome, 619376 (3),
EIF5A2		
EIF5B		
EIF6		
EIG121		
EIG121L		
EIPR-1		
EIPR1		
EJ16	AR	hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy, 612300 (3),
EJ30	AR	hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy, 612300 (3),
EJM	AD	{epilepsy, juvenile absence, susceptibility to, 1}, 607631 (3), ; {myoclonic epilepsy, juvenile, susceptibility to, 1}, 254770 (3),
EJM1	AD	{epilepsy, juvenile absence, susceptibility to, 1}, 607631 (3), ; {myoclonic epilepsy, juvenile, susceptibility to, 1}, 254770 (3),
EJM4	AD	{epilepsy, juvenile myoclonic, susceptibility to, 6}, 607682 (3), ; episodic ataxia, type 5, 613855 (3), ; {epilepsy, idiopathic generalized, susceptibility to, 9}, 607682 (3),
EJM5	AD	{epilepsy, juvenile myoclonic, susceptibility to, 5}, 611136 (3); developmental and epileptic encephalopathy 19, 615744 (3), ; {epilepsy, childhood absence, susceptibility to, 4}, 611136 (3)
EJM6	AR,AD	leukoencephalopathy with ataxia, 615651 (3), ; hyperaldosteronism, familial, type ii, 605635 (3), ; {epilepsy, juvenile myoclonic, susceptibility to, 8}, 607628 (3), ; {epilepsy, juvenile absence, susceptibility to, 2}, 607628 (3), ; {epilepsy, idiopathic generalized, susceptibility to, 11}, 607628 (3),
EKD1	AD	convulsions, familial infantile, with paroxysmal choreoathetosis, 602066 (3), ; seizures, benign familial infantile, 2, 605751 (3), ; episodic kinesigenic dyskinesia 1, 128200 (3),
EKI		
EKI1		
EKI2		
EKLF	AD	blood group--lutheran inhibitor, 111150 (3); dyserythropoietic anemia, congenital, type iv, 613673 (3), ; [hereditary persistence of fetal hemoglobin], 613566 (3)
EKN1	AD,AR	{dyslexia, susceptibility to, 1}, 127700 (3), ; ciliary dyskinesia, primary, 25, 615482 (3),
EKV	AR,AD	deafness, digenic, gjb2/gjb3, 220290 (3), digenic ; deafness, (3); deafness, 2b, 612644 (3), ; erythrokeratodermia variabilis et progressiva 1, 133200 (3), ; deafness, with peripheral neuropathy (3)
EKV3	AR	mednik syndrome, 609313 (3),
EL1	AR,AD	elliptocytosis-1, 611804 (3),
eL13	AD	spondyloepimetaphyseal dysplasia, isidor-toutain type, 618728 (3),
eL14		
eL15	AD	diamond-blackfan anemia 12, 615550 (3),
eL18	AD	?diamond-blackfan anemia 18, 618310 (3),
eL19		
EL2	AR,AD	spherocytosis, type 3, 270970 (3), ; elliptocytosis-2, 130600 (3), ; pyropoikilocytosis, 266140 (3),
eL20		
eL21	AD	hypotrichosis 12, 615885 (3),
eL24		
eL27	AD	?diamond-blackfan anemia 16, 617408 (3),
eL28		
eL29		
eL30		
eL31		
EL32	AR	hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy, 612300 (3),
eL33	AD	diamond-blackfan anemia 5, 612528 (3),
eL34		
eL36		
eL37		
eL38		
eL39		
eL41		
eL42		
eL6		
eL8		
ELA		
ELA1		
ELA2	AD	neutropenia, cyclic, 162800 (3), ; neutropenia, severe congenital 1, 202700 (3),
ELA2A	AD	abdominal obesity-metabolic syndrome 4, 618620 (3),
ELA2B		
ELA3		
ELA3A		
ELA3B		
ELA4	AD	{pancreatitis, chronic, susceptibility to}, 167800 (3),
ELAC1		
ELAC2	AR	{prostate cancer, hereditary, 2, susceptibility to}, 614731 (3); combined oxidative phosphorylation deficiency 17, 615440 (3),
ELAFIN		
ELAM		
ELAM1		
ELANE	AD	neutropenia, cyclic, 162800 (3), ; neutropenia, severe congenital 1, 202700 (3),
ELANH2		
ELAPOR1		
ELAPOR2		
ELAVL1		
ELAVL2		
ELAVL3		
ELAVL4		
ELC		
ELD/OSA1	AD	coffin-siris syndrome 1, 135900 (3),
ELDR		
ELE1		
ELF-1		
ELF1		
ELF2		
ELF3		
ELF4	XL,XLR	autoinflammatory syndrome, familial, behcet-like 2, 301074 (3),
ELF5		
ELFN1		
ELFN2		
ELFR	XL,XLR	autoinflammatory syndrome, familial, behcet-like 2, 301074 (3),
ELFT		
ELG		
ELG1		
Elk-L	XLD,XL	craniofrontonasal dysplasia, 304110 (3),
elk1		
ELK1		
elk2		
elk3		
ELK3		
ELK4		
ELKS		
ELKSL		
ELL		
ELL1		
ELL2		
ELL3		
ELLP3030	AR	seizures, early-onset, with neurodegeneration and brain calcification, 618875 (3),
ELMO-1		
ELMO-2	AR	vascular malformation, primary intraosseous, 606893 (3),
ELMO-3		
ELMO1		
ELMO2	AR	vascular malformation, primary intraosseous, 606893 (3),
ELMO3		
ELMOD1		
ELMOD2		
ELMOD3	AR,AD	?deafness, 88, 615429 (3), ; ?deafness, 81, 619500 (3),
ELN	AD	cutis laxa, 123700 (3), ; supravalvar aortic stenosis, 185500 (3),
ELNR1	AR	gm1-gangliosidosis, type i, 230500 (3), ; gm1-gangliosidosis, type iii, 230650 (3), ; mucopolysaccharidosis type ivb (morquio), 253010 (3), ; gm1-gangliosidosis, type ii, 230600 (3),
ELOA		
EloA-BP1		
ELOA1		
ELOA2		
ELOB		
ELOC		
ELOF1		
ELOVL1	AR,AD	ichthyotic keratoderma, spasticity, hypomyelination, and dysmorphic facies, 618527 (3),
ELOVL2		
ELOVL3		
ELOVL4	AD,AR	spinocerebellar ataxia 34, 133190 (3), ; stargardt disease 3, 600110 (3), ; ichthyosis, spastic quadriplegia, and impaired intellectual development, 614457 (3),
ELOVL5	AD	spinocerebellar ataxia 38, 615957 (3),
ELOVL6		
ELOVL7		
eLOX3	AR	ichthyosis, congenital, 3, 606545 (3),
ELP	AD	46xx sex reversal 4, 617480 (3), ; premature ovarian failure 7, 612964 (3), ; 46xy sex reversal 3, 612965 (3), ; adrenocortical insufficiency, 612964 (3), ; spermatogenic failure 8, 613957 (3),
ELP-1	AR	osteogenesis imperfecta, type xxi, 619131 (3),
ELP1	AR,AD	{medulloblastoma}, 155255 (3), somatic mutation, ; dysautonomia, familial, 223900 (3),
ELP120		
ELP2	AR	intellectual developmental disorder, 58, 617270 (3),
ELP3		
ELP4	AD	?aniridia 2, 617141 (3),
ELP5		
ELP6		
ELP70		
ELP79	AR	band heterotopia, 600348 (3),
ELP95		
ELSPBP1		
ELSPBP2		
ELTD1		
ELYS		
Em:AB014085.3		
Em:AB023049.7		
Em:AB023051.5		
Em:AB023056.3		
Em:AC004181.3		
Em:AC005383.4		
Em:AC012044.3		
Em:AC019205.2		
Em:AC019205.8		
Em:AC022392.3	AR	spinal muscular atrophy with congenital bone fractures 2, 616867 (3), ; barrett esophagus/esophageal adenocarcinoma, 614266 (3)
Em:AC022536.4		
Em:AC024597.2		
Em:AC060234.3		
Em:AC068892.1		
Em:AC068896.4		
Em:AF129756.17		
Em:AF134726.3		
Em:AL662879.1		
EM9	AR	xeroderma pigmentosum, group d, 278730 (3), ; trichothiodystrophy 1, photosensitive, 601675 (3), ; ?cerebrooculofacioskeletal syndrome 2, 610756 (3),
EMA	AR,AD	glutaric acidemia iia, 231680 (3), |tubulointerstitial kidney disease, 2, 174000 (3),
EMAP	AR	band heterotopia, 600348 (3),
EMAP-2	AR	leukodystrophy, hypomyelinating, 3, 260600 (3),
EMAP2		
EMAPII	AR	leukodystrophy, hypomyelinating, 3, 260600 (3),
EMAPL	AR	band heterotopia, 600348 (3),
emb		
EMB		
EMC1	AR	cerebellar atrophy, visual impairment, and psychomotor retardation, 616875 (3),
EMC10	AR	neurodevelopmental disorder with dysmorphic facies and variable seizures, 619264 (3),
EMC19		
EMC2		
EMC3		
EMC4		
EMC5		
EMC6		
EMC8		
EMCN		
EMD	XL,XLR	emery-dreifuss muscular dystrophy 1, 310300 (3),
eMDCII		
EME1		
EME2		
EMG1	AR	bowen-conradi syndrome, 211180 (3),
EMI1		
EMI5		
EMI6		
EMID1		
EMID2		
EMILIN		neuronopathy, distal hereditary motor, type x, 620080 (3)
EMILIN1		neuronopathy, distal hereditary motor, type x, 620080 (3)
EMILIN2		
EMILIN3		
EMILIN4		
EMILIN5		
EMK1		
EML1	AR	band heterotopia, 600348 (3),
EML2		
EML3		
EML4		
EML5		
EMMPRIN		[blood group, ok], 111380 (3)
EMP		
EMP1		
EMP2	AR	nephrotic syndrome, type 10, 615861 (3),
EMP3		
EMPB3	AD,AR	[blood group, swann], 601550 (3); [blood group, wright], 112050 (3); distal renal tubular acidosis 1, 179800 (3), ; [blood group, waldner], 112010 (3); spherocytosis, type 4, 612653 (3), ; [blood group, froese], 601551 (3); distal renal tubular acidosis 4 with hemolytic anemia, 611590 (3), ; {malaria, resistance to}, 611162 (3); cryohydrocytosis, 185020 (3), ; ovalocytosis, sa type, 166900 (3), ; [blood group, diego], 110500 (3)
EMPRIN		[blood group, ok], 111380 (3)
EMR1		
EMR2	AD	vibratory urticaria, 125630 (3),
EMR3		
EMR4		
EMR4P		
EMRE		
EMS		
EMS1		
EMSLR		
EMSP	AR	amelogenesis imperfecta, type iia1, 204700 (3),
EMSP1	AR	amelogenesis imperfecta, type iia1, 204700 (3),
EMSY		
EMT	AR	lymphoproliferative syndrome 1, 613011 (3),
EMTB		macrocytic anemia, refractory, due to 5q deletion, somatic, 153550 (3)
EMU1		
Emu2		
EMX1		
EMX2		schizencephaly, 269160 (3)
EMX2-AS1		
EMX2OS		
eN	AR	calcification of joints and arteries, 211800 (3),
EN-7	AD,AR	immunodeficiency 73a with defective neutrophil chemotaxix and leukocytosis, 608203 (3), ; ?immunodeficiency 73c with defective neutrophil chemotaxis and hypogammaglobulinemia, 618987 (3), ; immunodeficiency 73b with defective neutrophil chemotaxis and lymphopenia, 618986 (3),
EN1	AR	?endove syndrome, limb-brain type, 619218 (3),
EN2		
ENA-78		
ENaCalpha	AR,AD	pseudohypoaldosteronism, type ib1, 264350 (3), ; ?liddle syndrome 3, 618126 (3), ; bronchiectasis with or without elevated sweat chloride 2, 613021 (3),
ENaCbeta	AD,AR	bronchiectasis with or without elevated sweat chloride 1, 211400 (3), ; pseudohypoaldosteronism, type ib2, 620125 (3), ; liddle syndrome 1, 177200 (3),
ENaCdelta		
ENaCgamma	AD,AR	bronchiectasis with or without elevated sweat chloride 3, 613071 (3), ; pseudohypoaldosteronism, type ib3, 620126 (3), ; liddle syndrome 2, 618114 (3),
ENAH		
ENAM	AR,AD	amelogenesis imperfecta, type ic, 204650 (3), ; amelogenesis imperfecta, type ib, 104500 (3),
enaptin	AR,AD	arthrogryposis multiplex congenita 3, myogenic type, 618484 (3), ; emery-dreifuss muscular dystrophy 4, 612998 (3), ; spinocerebellar ataxia, 8, 610743 (3),
ENB1	AD	developmental and epileptic encephalopathy 7, 613720 (3), ; seizures, benign neonatal, 1, 121200 (3), ; myokymia, 121200 (3),
ENC-1		
ENC-2		
ENC1		
ENC2		
encephalopsin		
END	AD	telangiectasia, hereditary hemorrhagic, type 1, 187300 (3),
ENDAP	AR	immunodeficiency due to defect in mapbp-interacting protein, 610798 (3),
Ende		
ENDO180		
ENDOD1		
ENDOG		
ENDOGL1		
ENDOGL2		
endoglycan		
EndoGlyx-1		
endometase		
EndoPDI		
ENDOU		
ENDOV		
ENG	AD	telangiectasia, hereditary hemorrhagic, type 1, 187300 (3),
ENGASE		
ENGL		
ENGL-a		
ENGL-b		
Enh		
ENHO		
ENIGMA		
ENKUR		
enkurin		
ENL		
ENO1		
ENO1-IT1		
ENO1L1		
ENO2		
ENO3	AR	glycogen storage disease xiii, 612932 (3),
ENO4		
eNOS	MF,AD	{coronary artery spasm 1, susceptibility to} (3); {hypertension, susceptibility to}, 145500 (3), ; {placental abruption} (3); {alzheimer disease, late-onset, susceptibility to}, 104300 (3), ; {hypertension, pregnancy-induced}, 189800 (3), ; {ischemic stroke, susceptibility to}, 601367 (3),
ENOSF1		
ENOVIN		
ENOX		
ENOX1		
ENOX2		
Enp1		
ENPEP		
ENPP1	AR,MF,AD	{obesity, susceptibility to}, 601665 (3), , ; hypophosphatemic rickets, 2, 613312 (3), ; {diabetes mellitus, non-insulin-dependent, susceptibility to}, 125853 (3), ; arterial calcification, generalized, of infancy, 1, 208000 (3), ; cole disease, 615522 (3),
ENPP2		
ENPP3		
ENPP4		
ENPP5		
ENPP6		
ENPP7		
ENRAGE		
ENSA		
ENSAL		
ENST00000518376		
eNT	AR	calcification of joints and arteries, 211800 (3),
ENT1		
ENT2		
ENT3	AR	histiocytosis-lymphadenopathy plus syndrome, 602782 (3),
ENT4		
entactin		
ENTH		
ENTK	AR	enterokinase deficiency, 226200 (3),
ENTPD1	AR	spastic paraplegia 64, 615683 (3),
ENTPD2		
ENTPD3		
ENTPD4		
ENTPD5		
ENTPD6		
ENTPD7		
ENTPD8		
ENTR1		
ENTREP		
ENTREP1		
ENTREP2		
ENTREP3		
envFRD		
envK2		
envR		
envW		
Enx		
ENX-1	AD	weaver syndrome, 277590 (3),
ENX2	AD	{pregnancy loss, recurrent, susceptibility to, 3}, 614391 (3),
ENY2		
EOAHA	AR	ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia, 208920 (3),
EOGT	AR	adams-oliver syndrome 4, 615297 (3),
EOLA1		
EOMES		
Eos		
EOS		
eotaxin	AD	{asthma, susceptibility to}, 600807 (3), ; {hiv1, resistance to}, 609423 (3)
eotaxin-2		
eotaxin-3		
EP	AD,AR	{microvascular complications of diabetes 2}, 612623 (3); erythrocytosis, familial, 5, 617907 (3), ; ?diamond-blackfan anemia-like, 617911 (3),
Ep-CAM	AR,AD	diarrhea 5, with tufting enteropathy, congenital, 613217 (3), ; lynch syndrome 8, 613244 (3),
EP1		
EP2	AR	{asthma, aspirin-induced, susceptibility to}, 208550 (3),
EP2C		
EP2D		
EP3		
EP300	AD	menke-hennekam syndrome 2, 618333 (3), ; colorectal cancer, somatic, 114500 (3); rubinstein-taybi syndrome 2, 613684 (3),
EP4		
EP400		
EP58		
EPAC		
EPAS1	AD	erythrocytosis, familial, 4, 611783 (3),
EPB3	AD,AR	[blood group, swann], 601550 (3); [blood group, wright], 112050 (3); distal renal tubular acidosis 1, 179800 (3), ; [blood group, waldner], 112010 (3); spherocytosis, type 4, 612653 (3), ; [blood group, froese], 601551 (3); distal renal tubular acidosis 4 with hemolytic anemia, 611590 (3), ; {malaria, resistance to}, 611162 (3); cryohydrocytosis, 185020 (3), ; ovalocytosis, sa type, 166900 (3), ; [blood group, diego], 110500 (3)
EPB3L1	AR	?osteopetrosis, 9, 620366 (3),
EPB41	AR,AD	elliptocytosis-1, 611804 (3),
EPB41L1	AD	?intellectual developmental disorder, 11, 614257 (3),
EPB41L2		
EPB41L3		
EPB41L4A		
EPB41L4B		
EPB41L4O		
EPB41L5		
EPB42		spherocytosis, type 5, 612690 (3)
EPB49		
EPB7		
Epb7.2l		
EPB72		
EPC-1	AR	osteogenesis imperfecta, type vi, 613982 (3),
EPC1		
EPC2		
EPCAM	AR,AD	diarrhea 5, with tufting enteropathy, congenital, 613217 (3), ; lynch syndrome 8, 613244 (3),
EPCR		
EPD	AR	epilepsy, pyridoxine-dependent, 266100 (3),
EPD1	AD	pseudoachondroplasia, 177170 (3), ; carpal tunnel syndrome 2, 619161 (3), ; epiphyseal dysplasia, multiple, 1, 132400 (3),
Epdd1		
EPDR		
EPDR1		
EPF		
Epfn	AD	amelogenesis imperfecta, type ik, 620104 (3),
EPG		
EPG3		
EPG4		
EPG5	AR	vici syndrome, 242840 (3),
EPGN		
EPH		
EPHA1		
EPHA10	AD	?deafness, 88, 620283 (3),
EPHA2	AD	cataract 6, multiple types, 116600 (3),
EPHA3		
EPHA4		
EPHA5		
EPHA6		
EPHA7		
EPHA8		
EPHB1		
EPHB2	AR	?bleeding disorder, platelet-type, 22, 618462 (3), ; {prostate cancer/brain cancer susceptibility, somatic}, 603688 (3)
EPHB3		
EPHB4	AD	capillary malformation-arteriovenous malformation 2, 618196 (3), ; lymphatic malformation 7, 617300 (3),
EPHB6		
EPHD-2		
EPHT		
EPHT1		
EPHT2		
EPHT3	AR	?bleeding disorder, platelet-type, 22, 618462 (3), ; {prostate cancer/brain cancer susceptibility, somatic}, 603688 (3)
EPHX		
EPHX1		
EPHX2	AR,AD	{hypercholesterolemia, familial, due to ldlr defect, modifier of}, 143890 (3),
EPHX3		
EPHX4		
EPHXRP		
EPI		
EPI64		
EPI64B		
EPI64C		
EPIL		
epiligrin	AR	epidermolysis bullosa, junctional 2a, intermediate, 619783 (3), ; epidermolysis bullosa, junctional 2c, laryngoonychocutaneous, 245660 (3), ; epidermolysis bullosa, junctional 2b, severe, 619784 (3),
EPILYSIN		
EPIM		
EPIPL1		
EPITEMPIN	AD	epilepsy, familial temporal lobe, 1, 600512 (3),
EPK2		
Epl1		
EPLA847		
EPLG1		
EPLG2	XLD,XL	craniofrontonasal dysplasia, 304110 (3),
EPLG3		
EPLG4		
EPLG5		
EPLG6		
EPLG7		
EPLG8		
EPLIN		[low density lipoprotein cholesterol level qtl 8], 618079 (3)
EPM		
EPM1	AR	epilepsy, progressive myoclonic 1a (unverricht and lundborg), 254800 (3),
EPM1B	AR	epilepsy, progressive myoclonic 1b, 612437 (3),
EPM2A	AR	epilepsy, progressive myoclonic 2a (lafora), 254780 (3),
EPM2AIP1		
EPM2B	AR	epilepsy, progressive myoclonic 2b (lafora), 254780 (3),
EPM3	AR	epilepsy, progressive myoclonic 3, with or without intracellular inclusions, 611726 (3),
EpMAN		
EPMR	AR	ceroid lipofuscinosis, neuronal, 8, northern epilepsy variant, 610003 (3), ; ceroid lipofuscinosis, neuronal, 8, 600143 (3),
EPN1		
EPN2		
EPN3		
EPNR		
EPO	AR,AD,AR	[eosinophil peroxidase deficiency], 261500 (3), |{microvascular complications of diabetes 2}, 612623 (3); erythrocytosis, familial, 5, 617907 (3), ; ?diamond-blackfan anemia-like, 617911 (3),
EPO-R	AD	[erythrocytosis, familial, 1], 133100 (3),
Epoc-1		
EPOP		
EPOR	AD	[erythrocytosis, familial, 1], 133100 (3),
EPP	AR	[eosinophil peroxidase deficiency], 261500 (3),
EPPB9	AR	?meckel syndrome 9, 614209 (3), ; joubert syndrome 27, 617120 (3),
EPPIN		
EPPIN1		
EPPIN2		
EPPIN3		
EPPK	AD	palmoplantar keratoderma, epidermolytic, 1, 144200 (3),
EPPK1		
EPR-1		
EPR1		
EPRS	AR	leukodystrophy, hypomyelinating, 15, 617951 (3),
EPRS1	AR	leukodystrophy, hypomyelinating, 15, 617951 (3),
EPS15		
EPS15L1		
eps15R		
EPS8	AR	?deafness, 102, 615974 (3),
EPS8L1		
EPS8L2	AR	deafness 106, 617637 (3),
EPS8L3	AD	?hypotrichosis 5, 612841 (3),
epsilon-COP		
EPSTI1		
EPSTS	AD	macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss, 155100 (3), ; deafness, 17, 603622 (3),
EPT	AD	epilepsy, familial temporal lobe, 1, 600512 (3),
EPT1	AR	spastic paraplegia 81, 618768 (3),
EPVE6AP	AD	angelman syndrome, 105830 (3),
EPVH		
EPX	AR	[eosinophil peroxidase deficiency], 261500 (3),
EPX-PEN	AR	[eosinophil peroxidase deficiency], 261500 (3),
EPYC		
EQTN		
equatorin		
ER		
ER-alpha	AD,AR	breast cancer, somatic, 114480 (3); {migraine, susceptibility to}, 157300 (3), ; estrogen resistance, 615363 (3), ; {myocardial infarction, susceptibility to}, 608446 (3)
ER-beta	AD	?ovarian dysgenesis 8, 618187 (3),
ER71		
ER81		
Era	AD,AR	breast cancer, somatic, 114480 (3); {migraine, susceptibility to}, 157300 (3), ; estrogen resistance, 615363 (3), ; {myocardial infarction, susceptibility to}, 608446 (3)
ERAAP1		
ERAB	XLD,XL	hsd10 mitochondrial disease, 300438 (3),
ERAF		
ERAL1	AR	perrault syndrome 6, 617565 (3),
ERAP1		
ERAP140		
ERAP2		
ERAP75	AR	?spermatogenic failure 67, 619803 (3),
ERAS		
Erb	AD	?ovarian dysgenesis 8, 618187 (3),
ERBA	AD	hypothyroidism, congenital, nongoitrous, 6, 614450 (3),
ERBA-BETA	AR,AD	thyroid hormone resistance, 274300 (3), ; thyroid hormone resistance, 188570 (3), ; thyroid hormone resistance, selective pituitary, 145650 (3),
ERBA1	AD	hypothyroidism, congenital, nongoitrous, 6, 614450 (3),
ERBA2	AR,AD	thyroid hormone resistance, 274300 (3), ; thyroid hormone resistance, 188570 (3), ; thyroid hormone resistance, selective pituitary, 145650 (3),
ERBA2L	AD	cole-carpenter syndrome 1, 112240 (3),
ERBAL2		
ERBAL3	AD	bosch-boonstra-schaaf optic atrophy syndrome, 615722 (3),
ERBB	AR,AD	?inflammatory skin and bowel disease, neonatal, 2, 616069 (3), ; nonsmall cell lung cancer, response to tyrosine kinase inhibitor in, 211980 (3), somatic mutation, ; adenocarcinoma of lung, response to tyrosine kinase inhibitor in, 211980 (3), somatic mutation, ; {nonsmall cell lung cancer, susceptibility to}, 211980 (3), somatic mutation,
ERBB1	AR,AD	?inflammatory skin and bowel disease, neonatal, 2, 616069 (3), ; nonsmall cell lung cancer, response to tyrosine kinase inhibitor in, 211980 (3), somatic mutation, ; adenocarcinoma of lung, response to tyrosine kinase inhibitor in, 211980 (3), somatic mutation, ; {nonsmall cell lung cancer, susceptibility to}, 211980 (3), somatic mutation,
ERBB2	AR	gastric cancer, somatic, 613659 (3); adenocarcinoma of lung, somatic, 211980 (3); ovarian cancer, somatic, 167000 (3); ?visceral neuropathy, familial, 2, 619465 (3), ; glioblastoma, somatic, 137800 (3)
ERBB2IP		
ERBB3	AR,AD	?lethal congenital contractural syndrome 2, 607598 (3), ; {?erythroleukemia, familial, susceptibility to}, 133180 (3), ; visceral neuropathy, familial, 1, 243180 (3),
ERBB4	AD	amyotrophic lateral sclerosis 19, 615515 (3),
ERBIN		
ERBP		
ERC-55		
ERC1		
ERC2		
ERC55		
ERCC1	AR	cerebrooculofacioskeletal syndrome 4, 610758 (3),
ERCC2	AR	xeroderma pigmentosum, group d, 278730 (3), ; trichothiodystrophy 1, photosensitive, 601675 (3), ; ?cerebrooculofacioskeletal syndrome 2, 610756 (3),
ERCC3	AR	trichothiodystrophy 2, photosensitive, 616390 (3), ; xeroderma pigmentosum, group b, 610651 (3),
ERCC4	AR	xeroderma pigmentosum, type f/cockayne syndrome, 278760 (3), ; xfe progeroid syndrome, 610965 (3), ; xeroderma pigmentosum, group f, 278760 (3), ; fanconi anemia, complementation group q, 615272 (3),
ERCC5	AR	xeroderma pigmentosum, group g, 278780 (3), ; cerebrooculofacioskeletal syndrome 3, 616570 (3), ; xeroderma pigmentosum, group g/cockayne syndrome, 278780 (3),
ERCC6	AR,AD	uv-sensitive syndrome 1, 600630 (3), ; cerebrooculofacioskeletal syndrome 1, 214150 (3), ; ?de sanctis-cacchione syndrome, 278800 (3), ; cockayne syndrome, type b, 133540 (3), ; {macular degeneration, age-related, susceptibility to, 5}, 613761 (3); premature ovarian failure 11, 616946 (3), ; {lung cancer, susceptibility to}, 211980 (3), somatic mutation,
ERCC6L		
ERCC6L2	AR	bone marrow failure syndrome 2, 615715 (3),
ERCC8	AR	uv-sensitive syndrome 2, 614621 (3), ; cockayne syndrome, type a, 216400 (3),
ERCM2	AR	xeroderma pigmentosum, group g, 278780 (3), ; cerebrooculofacioskeletal syndrome 3, 616570 (3), ; xeroderma pigmentosum, group g/cockayne syndrome, 278780 (3),
ERD2		
ERD2.1		
ERD2.2	AR	osteogenesis imperfecta, type xxi, 619131 (3),
ERDA1		
ERDA4		
ERdj1		
ERdj2	AD	polycystic liver disease 2, 617004 (3),
ERdj3	AD	polycystic kidney disease 6 with or without polycystic liver disease, 618061 (3),
ERdj5		
ERdj6	AR	ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus, 616192 (3),
EREG		
EREG1		
ERF	AD	craniosynostosis 4, 600775 (3), ; chitayat syndrome, 617180 (3),
eRF1		
ERF1		
ERF2	AR	oocyte/zygote/embryo maturation arrest 13, 620154 (3),
eRF3a		
eRF3b		
eRF3c		
ERFAD		
ERFE		
ERFS		
ERG		
ERG-1		
erg-3		
erg1	AD	short qt syndrome 1, 609620 (3); long qt syndrome 2, 613688 (3),
erg2		
ERG25	AR	microcephaly, congenital cataract, and psoriasiform dermatitis, 616834 (3),
ERG28		
erg3		
ERGIC-32	AR	?arthrogryposis multiplex congenita 2, neurogenic type, 208100 (3),
ERGIC-53	AR	combined factor v and viii deficiency, 227300 (3),
ERGIC-53L		
ERGIC-63		
ERGIC1	AR	?arthrogryposis multiplex congenita 2, neurogenic type, 208100 (3),
ERGIC2		
ERGIC3		
ERGIC32	AR	?arthrogryposis multiplex congenita 2, neurogenic type, 208100 (3),
ERGIC53	AR	combined factor v and viii deficiency, 227300 (3),
ERGL		
ERH		
ERI1		
ERI3		
ERIC-1		
ERIC1		
ERICH1-AS1		
ERIH1		
ERIH2		
ERIS	AD,AR	sting-associated vasculopathy, infantile-onset, 615934 (3), |wolfram syndrome 2, 604928 (3),
ERK	AR,AD	?bleeding disorder, platelet-type, 22, 618462 (3), ; {prostate cancer/brain cancer susceptibility, somatic}, 603688 (3)|noonan syndrome 13, 619087 (3),
ERK1		
ERK2	AD	noonan syndrome 13, 619087 (3),
ERK3		
Erk3-related		
Erk4		
ERK5		
ERK6		
ERK7		
ERK8		
ERLEC1		
ERLEC2		
ERLECTIN		
Erlin-1	AR	spastic paraplegia 62, 615681 (3),
Erlin-2	AR	spastic paraplegia 18, 611225 (3),
ERLIN1	AR	spastic paraplegia 62, 615681 (3),
ERLIN2	AR	spastic paraplegia 18, 611225 (3),
ERM		
ERMan1	AR	rafiq syndrome, 614202 (3),
ERManI	AR	rafiq syndrome, 614202 (3),
ERMAP		[blood group, scianna system], 111750 (3); [blood group, radin], 111620 (3)
ERMARD	AD	?periventricular nodular heterotopia 6, 615544 (3),
ERMIN		
ERMN		
ERMP1		
ERN1		
ERN2		
ERO		
ERO1-alpha		
ERO1-L(beta)		
ERO1A		
Ero1alpha		
ERO1B		
Ero1beta		
ERO1L		
ERO1LB		
Eros	AR	chronic granulomatous disease 5, 618935 (3),
ERP		
ERP18		
ERP19		
ERP27		
ERp28		
ERP29		
ERp31		
ERP44		
ERp46		
ERp5		
ERp57		
ERp60		
ERp61		
ERP70		
ERP72		
ERPROT213-21		
ERR		
ERR-10		
ERR-gamma		
ERR1		
ERR10		
ERR2	AR	deafness, 35, 608565 (3),
ERRa		
ERRalpha		
ERRb	AR	deafness, 35, 608565 (3),
ERRbeta	AR	deafness, 35, 608565 (3),
ERRF		
ERRFI1		
ERRg		
ERRLR01		
ERRP	AR,AD	?inflammatory skin and bowel disease, neonatal, 2, 616069 (3), ; nonsmall cell lung cancer, response to tyrosine kinase inhibitor in, 211980 (3), somatic mutation, ; adenocarcinoma of lung, response to tyrosine kinase inhibitor in, 211980 (3), somatic mutation, ; {nonsmall cell lung cancer, susceptibility to}, 211980 (3), somatic mutation,
ERS-24		
ERT		
ERV-R		
ERV1	AR	myopathy, mitochondrial progressive, with congenital cataract and developmental delay, 613076 (3),
ERV29		
ERV3		
ERV3-1		
Erv41		
Erv46		
ERVE-1		
ERVE1		
ERVFRD-1		
ERVFRDE1		
ERVK-4		
ERVK-5		
ERVK-6		
ERVK-7		
ERVK4		
ERVK5		
ERVK6		
ERVK7		
ERVW-1		
ERVWE1		
ERYF1	XL,XLR	leukemia, megakaryoblastic, with or without down syndrome, somatic, 190685 (3); thrombocytopenia, with or without dyserythropoietic anemia, 300367 (3), ; anemia, with/without neutropenia and/or platelet abnormalities, 300835 (3), ; thrombocytopenia with beta-thalassemia, 314050 (3), ; hemolytic anemia due to elevated adenosine deaminase, 301083 (3),
ES/130		
eS1		
ES1		
eS10	AD	diamond-blackfan anemia 9, 613308 (3),
eS12		
eS17	AD	diamond-blackfan anemia 4, 612527 (3),
ES18		
eS19	AD	diamond-blackfan anemia 1, 105650 (3),
ES2		
eS21		
eS24	AD	diamond-blackfan anemia 3, 610629 (3),
eS25		
eS26	AD	diamond-blackfan anemia 10, 613309 (3),
eS27	AD	?diamond-blackfan anemia 17, 617409 (3),
eS28	AD	diamond blackfan anemia 15 with mandibulofacial dysostosis, 606164 (3),
Es2el		
eS30		
eS31		
ES31		
eS4		
eS6		
es64		
eS7	AD	diamond-blackfan anemia 8, 612563 (3),
eS8		
ESA		{coronary artery spasm 2, susceptibility to} (3); {organophosphate poisoning, sensitivity to} (3); {coronary artery disease, susceptibility to} (3); {microvascular complications of diabetes 5}, 612633 (3)
ESA1	AD	neurodevelopmental disorder with dysmorphic facies, sleep disturbance, and brain abnormalities, 619103 (3),
ESA4		
ESAM	AR	neurodevelopmental disorder with intracranial hemorrhage, seizures, and spasticity, 620371 (3),
ESB3		
ESC2		
ESC42		
ESCO1		
ESCO2	AR	juberg-hayward syndrome, 216100 (3), ; roberts-sc phocomelia syndrome, 268300 (3),
ESD		
ESDN		
ESE-1		
ESE3		
ESEJ		
ESEL		
ESET		
ESF1		
Esf2		
ESG		
Esg1		
ESG1		
ESG2		
ESG3		
ESI		
ESkine		
ESL-1		
ESM1		
ESMLC		
ESO1		
ESO2		
ESO3	XL,XLR	galloway-mowat syndrome 2, 301006 (3),
ESP-1		
ESP1		
ESPL1		
ESPN	AD,AR	deafness, neurosensory, without vestibular involvement, 609006 (3), ; deafness, 36, 609006 (3), ; ?usher syndrome, type 1m, 618632 (3),
ESPNL		
ESR	AD,AR	breast cancer, somatic, 114480 (3); {migraine, susceptibility to}, 157300 (3), ; estrogen resistance, 615363 (3), ; {myocardial infarction, susceptibility to}, 608446 (3)
ESR1	AD,AR	breast cancer, somatic, 114480 (3); {migraine, susceptibility to}, 157300 (3), ; estrogen resistance, 615363 (3), ; {myocardial infarction, susceptibility to}, 608446 (3)
ESR2	AD	?ovarian dysgenesis 8, 618187 (3),
ESRG		
ESRL1		
ESRL2	AR	deafness, 35, 608565 (3),
ESRP1	AR	?deafness, 109, 618013 (3),
ESRP2		
ESRRA		
ESRRB	AR	deafness, 35, 608565 (3),
ESRRBL1	AR	?orofaciodigital syndrome xviii, 617927 (3),
ESRRG		
ESS-2		
ESS1	AD	{multiple self-healing squamous epithelioma, susceptibility to}, 132800 (3), ; loeys-dietz syndrome 1, 609192 (3),
ESS2		
ESSS	XLD,XL	linear skin defects with multiple congenital anomalies 3, 300952 (3), ; ?mitochondrial complex i deficiency, nuclear type 30, 301021 (3),
EST		lung cancer, somatic, 211980 (3)
EST01027		
EST111653	AR	surfactant metabolism dysfunction, pulmonary, 3, 610921 (3),
EST122234		
EST123147		
EST133090		
EST140535	XLR,XL	anemia, sideroblastic, with ataxia, 301310 (3),
EST155051		
EST157481	AD	[junior blood group system], 614490 (3); [uric acid concentration, serum, qtl1], 138900 (3), ?
EST170205		
EST182763		
EST1A		
EST1B		
EST1C		
EST2	AD,AR	dyskeratosis congenita, 2, 613989 (3), ; dyskeratosis congenita, 4, 613989 (3), ; pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 1, 614742 (3), ; {melanoma, cutaneous malignant, 9}, 615134 (3), ; {leukemia, acute myeloid}, 601626 (3), somatic mutation,
EST201864		
EST20237		
EST25263		
EST277145		
EST328128		
EST349056	AR,AD	pseudoxanthoma elasticum, 264800 (3), ; arterial calcification, generalized, of infancy, 2, 614473 (3), ; pseudoxanthoma elasticum, forme fruste, 177850 (3),
EST352188	AR	methylmalonic aciduria and homocystinuria, cblj type, 614857 (3),
EST422562		
EST45597	AD	microphthalmia, isolated, with coloboma 7, 614497 (3), ; dyschromatosis universalis hereditaria 3, 615402 (3), ; [blood group, langereis system], 111600 (3); pseudohyperkalemia, familial, 2, due to red cell leak, 609153 (3),
EST640918		
EST698739		
EST90625	AR	?hypertrichosis, congenital generalized, with gingival hyperplasia, 135400 (3),
EST90757		
ESTF		lung cancer, somatic, 211980 (3)
ESX		
ESX1		
ESX1L		
ESXR1		
ESYT1		
ESYT2		
ESYT3		
ET	AR	spastic paraplegia 82, 618770 (3),
ET-A	AD	{migraine, resistance to}, 157300 (3), ; mandibulofacial dysostosis with alopecia, 616367 (3),
ET1	AD,AR	{high density lipoprotein cholesterol level qtl 7} (3); question mark ears, isolated, 612798 (3), ; auriculocondylar syndrome 3, 615706 (3),
ET2		
ET3	AR,AD	waardenburg syndrome, type 4b, 613265 (3), ; {hirschsprung disease, susceptibility to, 4}, 613712 (3),
ETA-1		
ETA-R	AD	{migraine, resistance to}, 157300 (3), ; mandibulofacial dysostosis with alopecia, 616367 (3),
ETAA1		
ETAA16		
ETB	AD,AR	{hirschsprung disease, susceptibility to, 2}, 600155 (3), ; ?abcd syndrome, 600501 (3), ; waardenburg syndrome, type 4a, 277580 (3),
ETBR-LP-2		
ETEA		
ETF		
ETF1		
ETF3A		
ETFA	AR	glutaric acidemia iia, 231680 (3),
ETFB	AR	glutaric acidemia iib, 231680 (3),
ETFBKMT		
ETFDH	AR	glutaric acidemia iic, 231680 (3),
ETFQO	AR	glutaric acidemia iic, 231680 (3),
ETFR-1		
ETHA	AD,AR	erythermalgia, primary, 133020 (3), ; insensitivity to pain, congenital, 243000 (3), ; small fiber neuropathy, 133020 (3), ; paroxysmal extreme pain disorder, 167400 (3), ; neuropathy, hereditary sensory and autonomic, type iid, 243000 (3),
ETHE1	AR	ethylmalonic encephalopathy, 602473 (3),
ETK		
Etk-2		
ETK1		
ETK2		
ETL		
ETL1	AD,AD	basan syndrome, 129200 (3), ; huriez syndrome, 181600 (3), ; adermatoglyphia, 136000 (3), |epilepsy, familial temporal lobe, 1, 600512 (3),
ETL4		
Etle		
ETMOD		
ETNK1		
ETNK2		
ETNPPL		
ETO		
ETO2		
Etohi2		
etoile		
Etr-3	AD	developmental and epileptic encephalopathy 97, 619561 (3),
ETR1	AR	dystonia, childhood-onset, with optic atrophy and basal ganglia abnormalities, 617282 (3),
ETR101		
ETS-1		
ETS1		
ETS2		
ETS7q		
ETV1		
ETV2		
ETV3		
ETV4		
ETV5		
ETV6	AD	thrombocytopenia 5, 616216 (3), ; leukemia, acute myeloid, somatic, 601626 (3)
ETV7		
ETX1		
Eu-HMTase1	AD	kleefstra syndrome 1, 610253 (3),
EU32		
EUROIMAGE686608		
EUROIMAGE783647		
EVA	AR	deafness, 111, 618145 (3),
EVA1	AR	deafness, 111, 618145 (3),
EVA1A		
EVC	AR,AD	ellis-van creveld syndrome, 225500 (3), ; ?weyers acrofacial dysostosis, 193530 (3),
EVC1	AR,AD	ellis-van creveld syndrome, 225500 (3), ; ?weyers acrofacial dysostosis, 193530 (3),
EVC2	AR,AD	ellis-van creveld syndrome, 225500 (3), ; weyers acrofacial dysostosis, 193530 (3),
EVDA		
EVDB		
Eve-1		
EVE1		
EVEC	AR,AD	cutis laxa, type ia, 219100 (3), ; charcot-marie-tooth disease, demyelinating, type 1h, 619764 (3), ; macular degeneration, age-related, 3, 608895 (3), ; neuropathy, hereditary, with or without age-related macular degeneration, 608895 (3), ; ?cutis laxa, 2, 614434 (3),
EVER1	AR	epidermodysplasia verruciformis, 226400 (3),
EVER2	AR	epidermodysplasia verruciformis 2, 618231 (3),
EVG1		
EVI	AR	zaki syndrome, 619648 (3),
EVI1	AD	myelodysplasia syndrome-1 (3)|radioulnar synostosis with amegakaryocytic thrombocytopenia 2, 616738 (3),
EVI2		
EVI27		
EVI2A		
EVI2B		
Evi3		
EVI5		
EVI9	AD	dias-logan syndrome, 617101 (3),
EVIN1	AR	epidermodysplasia verruciformis, 226400 (3),
EVIN2	AR	epidermodysplasia verruciformis 2, 618231 (3),
EVL		
EVN		
EVPK		
EVPL		
EVR1	AD,AR,AD	osteopetrosis, 1, 607634 (3), ; [bone mineral density variability 1], 601884 (3), ; polycystic liver disease 4 with or without kidney cysts, 617875 (3), ; endosteal hyperostosis, 144750 (3), ; osteoporosis-pseudoglioma syndrome, 259770 (3), ; exudative vitreoretinopathy 4, 601813 (3), |retinopathy of prematurity, 133780 (3), ; exudative vitreoretinopathy 1, 133780 (3),
EVR2	XL,XLD,XLR	exudative vitreoretinopathy 2, 305390 (3), ; norrie disease, 310600 (3),
EVR4	AD,AR	osteopetrosis, 1, 607634 (3), ; [bone mineral density variability 1], 601884 (3), ; polycystic liver disease 4 with or without kidney cysts, 617875 (3), ; endosteal hyperostosis, 144750 (3), ; osteoporosis-pseudoglioma syndrome, 259770 (3), ; exudative vitreoretinopathy 4, 601813 (3),
EVT2		
EVX1		
EVX2		
EWG		
EWI-3	AR	?lacrimal duct defect, 149700 (3),
EWI-F		
EWI2		
EWS		neuroepithelioma, 612219 (3); ewing sarcoma, 612219 (3)
EWSAT1		
EWSR1		neuroepithelioma, 612219 (3); ewing sarcoma, 612219 (3)
EWSR2	AR,AD	bleeding disorder, platelet-type, 21, 617443 (3),
EX1		
EX33		
EXD2		
EXDL2		
EXLM1		
EXO1		
EXO5		
EXO70	AR	neurodevelopmental disorder with seizures and brain atrophy, 619072 (3),
Exo70p	AR	neurodevelopmental disorder with seizures and brain atrophy, 619072 (3),
EXO84	AR	?neurodevelopmental disorder with microcephaly, seizures, and brain atrophy, 619076 (3),
Exo84p	AR	?neurodevelopmental disorder with microcephaly, seizures, and brain atrophy, 619076 (3),
EXOC1		
EXOC2	AR	neurodevelopmental disorder with dysmorphic facies and cerebellar hypoplasia, 619306 (3),
EXOC3		
EXOC3L		
EXOC3L1		
EXOC3L2		
EXOC3L3		
EXOC4		
EXOC5		
EXOC6		
EXOC6A		
EXOC6B	AR	spondyloepimetaphyseal dysplasia with joint laxity, type 3, 618395 (3),
EXOC7	AR	neurodevelopmental disorder with seizures and brain atrophy, 619072 (3),
EXOC8	AR	?neurodevelopmental disorder with microcephaly, seizures, and brain atrophy, 619076 (3),
exodus-1		
exodus-2		
exodus-3		
EXOG		
exophilin-1		
exophilin-3	AR	griscelli syndrome, type 3, 609227 (3),
exophilin-4		
exophilin-7		
exophilin-8		
EXOSC1	AR	?pontocerebellar hypoplasia, type 1f, 619304 (3),
EXOSC10		
EXOSC11		
EXOSC2	AR	short stature, hearing loss, retinitis pigmentosa, and distinctive facies, 617763 (3),
EXOSC3	AR	pontocerebellar hypoplasia, type 1b, 614678 (3),
EXOSC4		
EXOSC5	AR	cerebellar ataxia, brain abnormalities, and cardiac conduction defects, 619576 (3),
EXOSC6		
EXOSC7		
EXOSC8	AR	pontocerebellar hypoplasia, type 1c, 616081 (3),
EXOSC9	AR	pontocerebellar hypoplasia, type 1d, 618065 (3),
EXP		
EXP35		
EXP40		
EXP42		
EXP7		
EXPH5	AR	epidermolysis bullosa simplex 4, localized or generalized intermediate, 615028 (3),
EXT1	AD	exostoses, multiple, type 1, 133700 (3), ; chondrosarcoma, 215300 (3), somatic mutation
EXT2	AR,AD	seizures, scoliosis, and macrocephaly syndrome, 616682 (3), ; exostoses, multiple, type 2, 133701 (3),
EXTL		
EXTL1		
EXTL2		
EXTL3	AR	immunoskeletal dysplasia with neurodevelopmental abnormalities, 617425 (3),
EY-CADHERIN		
EYA1	AD	branchiootic syndrome 1, 602588 (3), ; branchiootorenal syndrome 1, with or without cataracts, 113650 (3), ; anterior segment anomalies with or without cataract, 602588 (3), ; ?otofaciocervical syndrome, 166780 (3),
EYA2		
EYA3		
EYA4	AD	?cardiomyopathy, dilated, 1j, 605362 (3), ; deafness, 10, 601316 (3),
EYA4-AS1		
EYCL	AR	[skin/hair/eye pigmentation 1, blue/nonblue eyes], 227220 (3), ; [skin/hair/eye pigmentation 1, blond/brown hair], 227220 (3), ; albinism, brown oculocutaneous, 203200 (3), ; albinism, oculocutaneous, type ii, 203200 (3),
EYCL2	AR	[skin/hair/eye pigmentation 1, blue/nonblue eyes], 227220 (3), ; [skin/hair/eye pigmentation 1, blond/brown hair], 227220 (3), ; albinism, brown oculocutaneous, 203200 (3), ; albinism, oculocutaneous, type ii, 203200 (3),
EYCL3	AR	[skin/hair/eye pigmentation 1, blue/nonblue eyes], 227220 (3), ; [skin/hair/eye pigmentation 1, blond/brown hair], 227220 (3), ; albinism, brown oculocutaneous, 203200 (3), ; albinism, oculocutaneous, type ii, 203200 (3),
EyeLinc1		
EYS	AR	retinitis pigmentosa 25, 602772 (3),
EZF		
EZF2		
EZFIT		
EZH1	AD	weaver syndrome, 277590 (3),
EZH2	AD	weaver syndrome, 277590 (3),
EZHIP		
EZI		
EZNF		
EZR		
F-LAN-1		
F-LANa		
f-spondin		
F-SRC-1		
F-TCF	AR	deafness, 39, 608265 (3),
F10	AR	factor x deficiency, 227600 (3),
F11	AD,AR	factor xi deficiency, 612416 (3); factor xi deficiency, 612416 (3)
F11R		
F12	AD,AR	angioedema, hereditary, 3, 610618 (3), ; factor xii deficiency, 234000 (3),
F13A	AR,AD	factor xiiia deficiency, 613225 (3), ; {myocardial infarction, protection against}, 608446 (3); {venous thrombosis, protection against}, 188050 (3),
F13A1	AR,AD	factor xiiia deficiency, 613225 (3), ; {myocardial infarction, protection against}, 608446 (3); {venous thrombosis, protection against}, 188050 (3),
F13B	AR	factor xiiib deficiency, 613235 (3),
F14150_1	AR	bare lymphocyte syndrome, type ii, complementation group b, 209920 (3),
F18	XL,XLR	hypospadias 2, 300758 (3),
F2	AR,AD,MF	hypoprothrombinemia, 613679 (3), ; {pregnancy loss, recurrent, susceptibility to, 2}, 614390 (3), ; dysprothrombinemia, 613679 (3), ; thrombophilia 1 due to thrombin defect, 188050 (3), ; {stroke, ischemic, susceptibility to}, 601367 (3),
F23149_1		
F23858		
F2771		
F2R		
F2RL1		
F2RL2		
F2RL3		
F3	AR	?congenital myopathy 12, 612540 (3),
F5	AD,AR,MF	thrombophilia 2 due to activated protein c resistance, 188055 (3), ; {pregnancy loss, recurrent, susceptibility to, 1}, 614389 (3), ; {thrombophilia, susceptibility to, due to factor v leiden}, 188055 (3), ; {budd-chiari syndrome}, 600880 (3), ; {stroke, ischemic, susceptibility to}, 601367 (3), ; factor v deficiency, 227400 (3),
F52		
F5F8D	AR	combined factor v and viii deficiency, 227300 (3), |factor v and factor viii, combined deficiency of, 613625 (3)
F7	AR	{myocardial infarction, decreased susceptibility to}, 608446 (3); factor vii deficiency, 227500 (3),
F7175		
F8	XL,XLR	thrombophilia 13, due to factor viii defect, 301071 (3); hemophilia a, 306700 (3),
F8A		
F8A1		
F8C	XL,XLR	thrombophilia 13, due to factor viii defect, 301071 (3); hemophilia a, 306700 (3),
F8VWF	AD,AR	von willebrand disease, type 1, 193400 (3), ; von willebrand disease, types 2a, 2b, 2m, and 2n, 613554 (3), ; von willebrand disease, type 3, 277480 (3),
F9	XLR,XL	{deep venous thrombosis, protection against}, 300807 (3), ; hemophilia b, 306900 (3), ; thrombophilia 8, due to factor ix defect, 300807 (3), ; {warfarin sensitivity}, 301052 (3),
FA	AR	friedreich ataxia with retained reflexes, 229300 (3), ; friedreich ataxia, 229300 (3),
FA-1		
FA-D2	AR	fanconi anemia, complementation group d2, 227646 (3),
FA-H	AR	fanconi anemia, complementation group a, 227650 (3),
FA1		
FA2H	AR	spastic paraplegia 35, 612319 (3),
FA3	AR	fanconi anemia, complementation group c, 227645 (3),
FAA	AR	fanconi anemia, complementation group a, 227650 (3),
FAAH	AR	{drug addiction, susceptibility to}, 606581 (3)|spastic paraplegia 35, 612319 (3),
FAAH-1		{drug addiction, susceptibility to}, 606581 (3)
FAAH-2		
FAAH-OUT		
FAAH1		{drug addiction, susceptibility to}, 606581 (3)
FAAH2		
FAAHP1		
FAAP		
FAAP10		
FAAP100		
FAAP16		
FAAP20		
FAAP24		
FAAP250	AR	?premature ovarian failure 15, 618096 (3), ; spermatogenic failure 28, 618086 (3),
FAAP43	AR	fanconi anemia, complementation group l, 614083 (3),
FAAP95	XLR,XL	fanconi anemia, complementation group b, 300514 (3),
FAAR		
FAB	XLR,XL	fanconi anemia, complementation group b, 300514 (3),
FAB1	AD	corneal fleck dystrophy, 121850 (3),
fabD		
FABGL		
Fabl		
FABP1		
FABP11		
FABP12		
FABP2		
FABP3		
FABP4		
FABP5		
FABP6		
FABP7		
FABP8	AD	charcot-marie-tooth disease, demyelinating, type 1g, 618279 (3),
FAC	AR	fanconi anemia, complementation group c, 227645 (3),
FAC1	AD	neurodevelopmental disorder with dysmorphic facies and distal limb anomalies, 617755 (3),
FACA	AR	fanconi anemia, complementation group a, 227650 (3),
FACC	AR	fanconi anemia, complementation group c, 227645 (3),
FACD	AR,AD,AR	fanconi anemia, complementation group d1, 605724 (3), ; {glioblastoma 3}, 613029 (3), ; {medulloblastoma}, 155255 (3), somatic mutation, ; {prostate cancer}, 176807 (3), somatic mutation, ; {breast-ovarian cancer, familial, 2}, 612555 (3), ; {breast cancer, male, susceptibility to}, 114480 (3), somatic mutation, ; {pancreatic cancer 2}, 613347 (3); wilms tumor, 194070 (3), somatic mutation, |fanconi anemia, complementation group d2, 227646 (3),
FACE	AR	fanconi anemia, complementation group e, 600901 (3),
FACE-1	AR	mandibuloacral dysplasia with type b lipodystrophy, 608612 (3), ; restrictive dermopathy 1, 275210 (3),
FACE-2		
FACE2		
FACL1		
FACL2		
FACL3		
FACL4	XL,XLD	intellectual developmental disorder, 63, 300387 (3),
FACL5	AR	?diarrhea 13, 620357 (3),
FACL6		myelodysplastic syndrome (3); myelogenous leukemia, acute (3)
FACT	AD	neurodevelopmental disorder with dysmorphic facies and thin corpus callosum, 619480 (3),
FACT80		
FACTP140	AD	neurodevelopmental disorder with dysmorphic facies and thin corpus callosum, 619480 (3),
FACVL1		
FACVL2		
FACVL3		
FAD	AR,AD,AR,AD	fanconi anemia, complementation group d1, 605724 (3), ; {glioblastoma 3}, 613029 (3), ; {medulloblastoma}, 155255 (3), somatic mutation, ; {prostate cancer}, 176807 (3), somatic mutation, ; {breast-ovarian cancer, familial, 2}, 612555 (3), ; {breast cancer, male, susceptibility to}, 114480 (3), somatic mutation, ; {pancreatic cancer 2}, 613347 (3); wilms tumor, 194070 (3), somatic mutation, |fanconi anemia, complementation group d2, 227646 (3), |pick disease, 172700 (3), ; alzheimer disease, type 3, with spastic paraparesis and apraxia, 607822 (3), ; dementia, frontotemporal, 600274 (3), ; ?acne inversa, familial, 3, 613737 (3), ; cardiomyopathy, dilated, 1u, 613694 (3), ; alzheimer disease, type 3, with spastic paraparesis and unusual plaques, 607822 (3), ; alzheimer disease, type 3, 607822 (3),
FAD1	AR,AD,AR	fanconi anemia, complementation group d1, 605724 (3), ; {glioblastoma 3}, 613029 (3), ; {medulloblastoma}, 155255 (3), somatic mutation, ; {prostate cancer}, 176807 (3), somatic mutation, ; {breast-ovarian cancer, familial, 2}, 612555 (3), ; {breast cancer, male, susceptibility to}, 114480 (3), somatic mutation, ; {pancreatic cancer 2}, 613347 (3); wilms tumor, 194070 (3), somatic mutation, |lipid storage myopathy due to flavin adenine dinucleotide synthetase deficiency, 255100 (3),
FAD104		
FAD24		
FADD	AR	immunodeficiency 90 with encephalopathy, functional hyposplenia, and hepatic dysfunction, 613759 (3),
FADK		
FADS1		
FADS2		
FADS3		
FADS4	AD	?deafness, 79, 619086 (3),
FADS5		
FADS6		
FADS7	AR	leukodystrophy, hypomyelinating, 18, 618404 (3),
FADS8		
FADSD5		
FADSD6		
FAE	AR	fanconi anemia, complementation group e, 600901 (3),
FAEES3		
FAF	AR,XL,XLR,XLD	fanconi anemia, complementation group f, 603467 (3), |intellectual developmental disorder, 99, 300919 (3), ; intellectual developmental disorder, 99, syndromic, female-restricted, 300968 (3),
FAF1		
FAF2		
FAG	AR	fanconi anemia, complementation group g, 614082 (3),
FAH	AR,AR	fanconi anemia, complementation group a, 227650 (3), |tyrosinemia, type i, 276700 (3),
FAHD1		
FAIM		
FAIM1		
FAIM2		
FAIM3		
FAK		
FAK1		
FAK2		
FAKTS		
Fal1	AR	robin sequence with cleft mandible and limb anomalies, 268305 (3),
FAL1		
FALCOR		
FALDH	AR	sjogren-larsson syndrome, 270200 (3),
FALEC		
FALL-39		
FALL39		
fallotein		
FALP	AR	glucocorticoid deficiency 2, 607398 (3),
FALZ	AD	neurodevelopmental disorder with dysmorphic facies and distal limb anomalies, 617755 (3),
FAM101A		
FAM101B		
FAM102A		
FAM103A1		
FAM105B	AR,AD	autoinflammation, panniculitis, and dermatosis syndrome, 617099 (3), ; {immunodeficiency 107, susceptibility to invasive staphylococcus aureus infection}, 619986 (3),
FAM107A		
FAM108A1		
FAM108B1		
FAM108C1		
FAM109A		
FAM109B		
FAM10A1		
FAM110A		
FAM110B		
FAM110C		
FAM111A	AD	kenny-caffey syndrome, type 2, 127000 (3), ; gracile bone dysplasia, 602361 (3),
FAM111B	AD	poikiloderma, hereditary fibrosing, with tendon contractures, myopathy, and pulmonary fibrosis, 615704 (3),
FAM112B		
FAM115A		
FAM115C		
FAM117C		{glucocorticoid therapy, response to}, 614400 (3)
FAM118B		
FAM119A		
FAM119B		
FAM11A		
FAM120A		
FAM120B		
FAM120C		
FAM121A		
FAM121B		
FAM122A		
FAM123A		
FAM123B	XLD,XL	osteopathia striata with cranial sclerosis, 300373 (3),
FAM124B		
FAM126A	AR	leukodystrophy, hypomyelinating, 5, 610532 (3),
FAM127A		
FAM128A		
FAM128B		
FAM129A		
FAM129B		
FAM129C		
FAM12A		
FAM12B		
FAM130A1		
FAM130A2		
FAM130B		
FAM131B		
FAM132A		
FAM132B		
FAM134B	AR	neuropathy, hereditary sensory and autonomic, type iib, 613115 (3),
FAM134C		
FAM136A		
FAM137A		
FAM137B		
FAM139A		
FAM13A		
FAM13A-AS1		
FAM13A1		
FAM13A1OS		
FAM13AOS		
FAM13B		
FAM13B1		
FAM148A		
FAM148B		
FAM148C		
FAM149B1	AR	joubert syndrome 36, 618763 (3),
FAM14A		
FAM14B		
FAM14C		
FAM14D		
FAM150A		
FAM150B		
FAM152A		
FAM152B		
FAM154A		
FAM155A		
FAM158B		
FAM159A		
FAM159B		
FAM160A2		
FAM160B1		
FAM160B2		
FAM161A	AR	retinitis pigmentosa 28, 606068 (3),
FAM162A		
FAM163A		
FAM167A		
FAM168A		
FAM168B		
FAM169A		
FAM16AX		
FAM170A		
FAM171B		
FAM173A		
FAM173B		
FAM175A		
FAM175B		
FAM176A		
FAM177A1		
FAM178A	AR	atelis syndrome 1, 620184 (3),
FAM179B	AR	joubert syndrome 37, 619185 (3),
FAM184B		
FAM188A		
FAM189A1		
FAM189A2		
FAM189B		
FAM190A		
FAM190B		
FAM192A		
FAM193A		
FAM193B		
FAM195B		
FAM196A		
FAM198A		
FAM19A1		
FAM19A2		
FAM19A3		
FAM19A4		
FAM19A5		
FAM1A		
FAM1B		
FAM200C		
FAM200D		
FAM206A		
FAM208A		
FAM20A	AR	amelogenesis imperfecta, type ig (enamel-renal syndrome), 204690 (3),
FAM20B		
FAM20C	AR	raine syndrome, 259775 (3),
FAM210A		
FAM210B		
FAM212B		
FAM213A		
FAM214A		
FAM214B		
FAM21C		
FAM220A		
FAM22H		
FAM234B		
FAM26A		
FAM26B		
FAM26C		
FAM26F		
FAM29A		
FAM2A		
FAM2C		
FAM30A		
FAM31A		
FAM31B		
FAM31C		
FAM31D		
FAM32A		
FAM33A		
FAM34A		
FAM34A1		
FAM35A		
FAM35A1		
FAM36A	AR	mitochondrial complex iv deficiency, nuclear type 11, 619054 (3),
FAM38A	AR,AD	[er blood group system], 620207 (3), ; lymphatic malformation 6, 616843 (3), ; dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edema, 194380 (3),
FAM38B	AD,AR	arthrogryposis, distal, type 5, 108145 (3), ; arthrogryposis, distal, with impaired proprioception and touch, 617146 (3), ; arthrogryposis, distal, type 3, 114300 (3), ; ?marden-walker syndrome, 248700 (3),
FAM38B2	AD,AR	arthrogryposis, distal, type 5, 108145 (3), ; arthrogryposis, distal, with impaired proprioception and touch, 617146 (3), ; arthrogryposis, distal, type 3, 114300 (3), ; ?marden-walker syndrome, 248700 (3),
FAM39E		
FAM3A		
FAM3B		
FAM3C		
FAM3D		
FAM40A		
FAM40B		
FAM42A	AR	shwachman-diamond syndrome 2, 617941 (3),
FAM44A		
FAM44B		
FAM46A	AR	osteogenesis imperfecta, type xviii, 617952 (3),
FAM46B		
FAM46C		
FAM46D		
FAM47C		
FAM48A		
FAM49B		
FAM4A		
FAM4A1		
FAM4B		
FAM50A	XL,XLR	intellectual developmental disorder, syndromic, armfield type, 300261 (3),
FAM50B		
FAM51A1		
FAM53A		
FAM53B		
FAM53C		
FAM54A2		
FAM55D		
FAM57A		
FAM57B	AR	cone-rod dystrophy 22, 619531 (3),
FAM58A	XLD,XL	star syndrome, 300707 (3),
FAM59A		
FAM59B		
FAM5A		
FAM5B		
FAM5C		
FAM60A		
FAM61A		
FAM62A		
FAM62B		
FAM62C		
FAM63A		
FAM63B		
FAM64A		
FAM65A		
FAM65B	AD,AR	deafness, 21, 607017 (3), ; ?deafness, 104, 616515 (3),
FAM68A		
FAM68C		
FAM69A		
FAM69B		
FAM69C		
FAM6A	AR	perlman syndrome, 267000 (3),
FAM71A		
FAM71B		
FAM71D		
FAM71E1		
FAM71F1		
FAM71F2		
FAM72A		
FAM72B		
FAM72C		
FAM72D		
FAM73A		
FAM73B		
FAM75A4		
FAM75A7		
FAM77A		
FAM77B		
FAM77C		
FAM77D		
FAM79A		
FAM7B1		
FAM7C1		
FAM80A		
FAM80B		
FAM82A		
FAM82A1		
FAM82A2		
FAM82B		
FAM82C		
FAM83D		
FAM83G		
FAM83H	AD	amelogenesis imperfecta, type iiia, 130900 (3),
FAM83H-AS1		
FAM84A		
FAM84B		
FAM86A		
FAM86B1		
FAM86B2		
FAM86C		
FAM86C1		
FAM86C1P		
FAM89B		
FAM8A1		
FAM90A1		
FAM90A10		
FAM90A10P		
FAM90A12		
FAM90A12P		
FAM90A13		
FAM90A13P		
FAM90A14		
FAM90A14P		
FAM90A15		
FAM90A15P		
FAM90A18		
FAM90A18P		
FAM90A19		
FAM90A19P		
FAM90A20		
FAM90A20P		
FAM90A3		
FAM90A3P		
FAM90A5		
FAM90A5P		
FAM90A7		
FAM90A7P		
FAM90A8		
FAM90A8P		
FAM90A9		
FAM90A9P		
FAM92A	AR	?polydactyly, postaxial, type a9, 618219 (3),
FAM92A1	AR	?polydactyly, postaxial, type a9, 618219 (3),
FAM92B		
FAM96A		
FAM96B		
FAM98B		
FAM9A		
FAM9B		
FAM9C		
FAMIN	AR	juvenile arthritis, 618795 (3),
FAN		
FAN1	AR	interstitial nephritis, karyomegalic, 614817 (3),
FANCA	AR	fanconi anemia, complementation group a, 227650 (3),
FANCB	XLR,XL	fanconi anemia, complementation group b, 300514 (3),
FANCC	AR	fanconi anemia, complementation group c, 227645 (3),
FANCD	AR,AD,AR	fanconi anemia, complementation group d1, 605724 (3), ; {glioblastoma 3}, 613029 (3), ; {medulloblastoma}, 155255 (3), somatic mutation, ; {prostate cancer}, 176807 (3), somatic mutation, ; {breast-ovarian cancer, familial, 2}, 612555 (3), ; {breast cancer, male, susceptibility to}, 114480 (3), somatic mutation, ; {pancreatic cancer 2}, 613347 (3); wilms tumor, 194070 (3), somatic mutation, |fanconi anemia, complementation group d2, 227646 (3),
FANCD1	AR,AD	fanconi anemia, complementation group d1, 605724 (3), ; {glioblastoma 3}, 613029 (3), ; {medulloblastoma}, 155255 (3), somatic mutation, ; {prostate cancer}, 176807 (3), somatic mutation, ; {breast-ovarian cancer, familial, 2}, 612555 (3), ; {breast cancer, male, susceptibility to}, 114480 (3), somatic mutation, ; {pancreatic cancer 2}, 613347 (3); wilms tumor, 194070 (3), somatic mutation,
FANCD2	AR	fanconi anemia, complementation group d2, 227646 (3),
FANCE	AR	fanconi anemia, complementation group e, 600901 (3),
FANCF	AR	fanconi anemia, complementation group f, 603467 (3),
FANCG	AR	fanconi anemia, complementation group g, 614082 (3),
FANCH	AR	fanconi anemia, complementation group a, 227650 (3),
FANCI	AR	fanconi anemia, complementation group i, 609053 (3),
FANCJ	AD	fanconi anemia, complementation group j, 609054 (3); {breast cancer, early-onset, susceptibility to}, 114480 (3), somatic mutation,
FANCL	AR	fanconi anemia, complementation group l, 614083 (3),
FANCM	AR	?premature ovarian failure 15, 618096 (3), ; spermatogenic failure 28, 618086 (3),
FANCN	AD	{breast cancer, susceptibility to}, 114480 (3), somatic mutation, ; {pancreatic cancer, susceptibility to, 3}, 613348 (3); fanconi anemia, complementation group n, 610832 (3)
FANCO	AR	{breast-ovarian cancer, familial, susceptibility to, 3}, 613399 (3); fanconi anemia, complementation group o, 613390 (3),
FANCP	AR	fanconi anemia, complementation group p, 613951 (3),
FANCQ	AR	xeroderma pigmentosum, type f/cockayne syndrome, 278760 (3), ; xfe progeroid syndrome, 610965 (3), ; xeroderma pigmentosum, group f, 278760 (3), ; fanconi anemia, complementation group q, 615272 (3),
FANCR	AD	mirror movements 2, 614508 (3), ; {breast cancer, susceptibility to}, 114480 (3), somatic mutation, ; fanconi anemia, complementation group r, 617244 (3),
FANCS	AR,MF,AD	fanconi anemia, complementation group s, 617883 (3), ; {breast-ovarian cancer, familial, 1}, 604370 (3), ; {pancreatic cancer, susceptibility to, 4}, 614320 (3)
FANCT	AR	fanconi anemia, complementation group t, 616435 (3),
FANCU	AR	spermatogenic failure 50, 619145 (3), ; ?premature ovarian failure 17, 619146 (3), ; ?fanconi anemia, complementation group u, 617247 (3),
FANCV	AR	?fanconi anemia, complementation group v, 617243 (3),
FANCW	AR	?fanconi anemia, complementation group w, 617784 (3),
FANK1		
FAP		
FAP108	AD	intellectual developmental disorder, 21, 615502 (3),
FAP116	AR	senior-loken syndrome 9, 616629 (3),
FAP118	AR	short-rib thoracic dysplasia 7 with or without polydactyly, 614091 (3), ; cranioectodermal dysplasia 2, 613610 (3),
FAP133	AR	short-rib thoracic dysplasia 11 with or without polydactyly, 615633 (3),
FAP155		
FAP156	AR	bardet-biedl syndrome 19, 615996 (3),
FAP16		
FAP163	AR	short-rib thoracic dysplasia 8 with or without polydactyly, 615503 (3),
FAP167	AR	short-rib thoracic dysplasia 2 with or without polydactyly, 611263 (3),
FAP172	AR	ciliary dyskinesia, primary, 15, 613808 (3),
FAP178		
FAP194		
FAP216		
FAP22		
FAP221		
FAP250	AR	ciliary dyskinesia, primary, 27, 615504 (3),
FAP286		
FAP297		
FAP305		
FAP418	AR	retinitis pigmentosa 64, 614500 (3), ; cone-rod dystrophy 16, 614500 (3), ; bardet-biedl syndrome 21, 617406 (3),
FAP48	AD	glomuvenous malformations, 138000 (3),
FAP50		
FAP59	AR	ciliary dyskinesia, primary, 14, 613807 (3),
FAP60	AR,AD	short-rib thoracic dysplasia 4 with or without polydactyly, 613819 (3), ; nephronophthisis 12, 613820 (3),
FAP66	AR	nephronophthisis 13, 614377 (3), ; cranioectodermal dysplasia 4, 614378 (3), ; senior-loken syndrome 8, 616307 (3), ; short-rib thoracic dysplasia 5 with or without polydactyly, 614376 (3), ; ?spermatogenic failure 72, 619867 (3),
FAP68	AD	glomuvenous malformations, 138000 (3),
FAP69	AR	spermatogenic failure 24, 617959 (3),
FAP75	AR	?spermatogenic failure 27, 617965 (3),
FAP78		
FAP79		
FAP80	AR	cranioectodermal dysplasia 1, 218330 (3),
FAP81		
FAP85	AD	congenital myopathy 15, 620161 (3),
FAP87	AD	long qt syndrome 4, 600919 (3), ; cardiac arrhythmia, ankyrin-b-related, 600919 (3),
FAP88		
FAP93		
FAPP1		
FAPP2		
FAR1	AR,AD	peroxisomal fatty acyl-coa reductase 1 disorder, 616154 (3), ; cataracts, spastic paraparesis, and speech delay, 619338 (3),
FAR11A		
FAR11B		
FAR2		
FARP1		
FARP2		
FARR	AR	friedreich ataxia with retained reflexes, 229300 (3), ; friedreich ataxia, 229300 (3),
FARS1	AR	combined oxidative phosphorylation deficiency 14, 614946 (3), ; spastic paraplegia 77, 617046 (3),
FARS2	AR	combined oxidative phosphorylation deficiency 14, 614946 (3), ; spastic paraplegia 77, 617046 (3),
FARSA	AR	?rajab interstitial lung disease with brain calcifications 2, 619013 (3),
FARSB	AR	rajab interstitial lung disease with brain calcifications 1, 613658 (3),
FARSL	AR	?rajab interstitial lung disease with brain calcifications 2, 619013 (3),
FARSLA	AR	?rajab interstitial lung disease with brain calcifications 2, 619013 (3),
FARSLB	AR	rajab interstitial lung disease with brain calcifications 1, 613658 (3),
FAS	AD	squamous cell carcinoma, burn scar-related, somatic (3); autoimmune lymphoproliferative syndrome, type ia, 601859 (3), ; {autoimmune lymphoproliferative syndrome}, 601859 (3),
FAS1	AD	squamous cell carcinoma, burn scar-related, somatic (3); autoimmune lymphoproliferative syndrome, type ia, 601859 (3), ; {autoimmune lymphoproliferative syndrome}, 601859 (3),
FasL	AD	autoimmune lymphoproliferative syndrome, type ib, 601859 (3), ; {lung cancer, susceptibility to}, 211980 (3), somatic mutation,
FASLG	AD	autoimmune lymphoproliferative syndrome, type ib, 601859 (3), ; {lung cancer, susceptibility to}, 211980 (3), somatic mutation,
FASN		
FASN2A		
FASN2B	AR	dystonia, childhood-onset, with optic atrophy and basal ganglia abnormalities, 617282 (3),
FASN2C		
FASN2D		
FASP1		
FAST		
FAST1		
FASTK		
FASTKD1		
FASTKD2	AR	combined oxidative phosphorylation deficiency 44, 618855 (3),
FASTKD3		
FASTKD4		
FASTKD5		
FAT	AR	platelet glycoprotein iv deficiency, 608404 (3), ; {coronary heart disease, susceptibility to, 7}, 610938 (3); {malaria, cerebral, susceptibility to}, 611162 (3); {malaria, cerebral, reduced risk of}, 611162 (3)
FAT-J	AR	van maldergem syndrome 2, 615546 (3), ; hennekam lymphangiectasia-lymphedema syndrome 2, 616006 (3),
FAT1		
FAT10		
FAT2	AD	spinocerebellar ataxia 45, 617769 (3),
FAT3		
FAT4	AR	van maldergem syndrome 2, 615546 (3), ; hennekam lymphangiectasia-lymphedema syndrome 2, 616006 (3),
FATE		
FATE1		
FATP		
FATP-4	AR	ichthyosis prematurity syndrome, 608649 (3),
FATP1		
FATP2		
FATP3		
FATP4	AR	ichthyosis prematurity syndrome, 608649 (3),
FATP5		
FATP6		
FATS		
FATZ		
FATZ-2	AD	cardiomyopathy, hypertrophic, 16, 613838 (3),
FATZ-3		
FAU		
FAXDC1	AR	spastic paraplegia 35, 612319 (3),
FAXDC2		
FAXF		
FAYV2820		
FAZF		
FB1		
FB19		
FBA		
FBB18	AR	ciliary dyskinesia, primary, 26, 615500 (3),
FBB5	AR	ciliary dyskinesia, primary, 38, 618063 (3),
FBF-1		
FBF1		
Fbg1		
FBG2		
FBG3		
FBG4		
Fbg5		
FBH	AD	hypocalciuric hypercalcemia, type ii, 145981 (3), ; hypocalcemia, 2, 615361 (3),
FBH1		
FBH2	AD	hypocalciuric hypercalcemia, type ii, 145981 (3), ; hypocalcemia, 2, 615361 (3),
FBH3	AD	hypocalciuric hypercalcemia, type iii, 600740 (3),
FBHOk	AD	hypocalciuric hypercalcemia, type iii, 600740 (3),
FBI-1	AD	macrocephaly, neurodevelopmental delay, lymphoid hyperplasia, and persistent fetal hemoglobin, 619769 (3),
FBL		
FBL1		
Fbl10		
FBL11		
Fbl12		
Fbl13		
Fbl14		
Fbl15		
Fbl16		
Fbl17		
Fbl18		
Fbl19		
Fbl2		
FBL2		
Fbl20		
Fbl21		
Fbl22		
FBL3	AR	intellectual developmental disorder with short stature, facial anomalies, and speech defects, 606220 (3),
FBL3A	AR	intellectual developmental disorder with short stature, facial anomalies, and speech defects, 606220 (3),
FBL3B		
FBL4	AR	mitochondrial dna depletion syndrome 13 (encephalomyopathic type), 615471 (3),
FBL5	AR	mitochondrial dna depletion syndrome 13 (encephalomyopathic type), 615471 (3),
FBL6		
FBL7		
Fbl8		
FBLIM1		
FBLN	AD	synpolydactyly, 3/3'4, associated with metacarpal and metatarsal synostoses, 608180 (4),
FBLN1	AD	synpolydactyly, 3/3'4, associated with metacarpal and metatarsal synostoses, 608180 (4),
FBLN2		
FBLN3	AD	doyne honeycomb degeneration of retina, 126600 (3),
FBLN4	AR	cutis laxa, type ib, 614437 (3),
FBLN5	AR,AD	cutis laxa, type ia, 219100 (3), ; charcot-marie-tooth disease, demyelinating, type 1h, 619764 (3), ; macular degeneration, age-related, 3, 608895 (3), ; neuropathy, hereditary, with or without age-related macular degeneration, 608895 (3), ; ?cutis laxa, 2, 614434 (3),
FBLN6	AD	{macular degeneration, age-related, 1}, 603075 (3),
FBLN7		
FBLP-1		
FBN	AD	geleophysic dysplasia 2, 614185 (3), ; weill-marchesani syndrome 2, 608328 (3), ; ectopia lentis, familial, 129600 (3), ; mass syndrome, 604308 (3), ; marfan lipodystrophy syndrome, 616914 (3), ; acromicric dysplasia, 102370 (3), ; marfan syndrome, 154700 (3), ; stiff skin syndrome, 184900 (3),
FBN1	AD	geleophysic dysplasia 2, 614185 (3), ; weill-marchesani syndrome 2, 608328 (3), ; ectopia lentis, familial, 129600 (3), ; mass syndrome, 604308 (3), ; marfan lipodystrophy syndrome, 616914 (3), ; acromicric dysplasia, 102370 (3), ; marfan syndrome, 154700 (3), ; stiff skin syndrome, 184900 (3),
FBN2	AD	macular degeneration, early-onset, 616118 (3), ; contractural arachnodactyly, congenital, 121050 (3),
FBN3		
FBNL	AD	doyne honeycomb degeneration of retina, 126600 (3),
FBP	AR	fructose-1,6-bisphosphatase deficiency, 229700 (3),
FBP-11		
FBP1	AR	fructose-1,6-bisphosphatase deficiency, 229700 (3),
FBP11		
FBP17		
FBP2	AD	?leukodystrophy, childhood-onset, remitting, 619864 (3),
FBP21		
FBP3		
FBRS		
FBRSL1		
FBRSL2	AD	intellectual developmental disorder, 26, 615834 (3),
FBS		
Fbs1		
FBS1		
FBS2		
Fbw10		
Fbw11	AD	neurodevelopmental, jaw, eye, and digital syndrome, 618914 (3),
Fbw12		
Fbw1b	AD	neurodevelopmental, jaw, eye, and digital syndrome, 618914 (3),
FBW2		
Fbw4		
Fbw5		
FBW6		
FBW7	AD	developmental delay, hypotonia, and impaired language, 620012 (3),
FBW8		
Fbw9		
Fbx	AR	parkinson disease 15, 260300 (3),
FBX1	AD	frontotemporal dementia and/or amyotrophic lateral sclerosis 5, 619141 (3),
FBX10		
FBX11	AD	intellectual developmental disorder with dysmorphic facies and behavioral abnormalities, 618089 (3),
Fbx13		
FBX14	AR	?intellectual developmental disorder, 45, 615979 (3),
FBX15		
FBX16		
Fbx17		
Fbx18		
FBX2		
FBX20		
FBX21		
FBX22		
FBX24		
FBX25		
Fbx27		
Fbx28	AD	developmental and epileptic encephalopathy 100, 619777 (3),
FBX29		
FBX3		
Fbx30		
FBX30	AD	developmental delay, hypotonia, and impaired language, 620012 (3),
Fbx31	AR	?intellectual developmental disorder, 45, 615979 (3),
Fbx32		
Fbx33		
Fbx34		
Fbx36		
Fbx38	AD	neuronopathy, distal hereditary motor, type iid, 615575 (3),
Fbx39		
FBX4		
Fbx40		
Fbx41		
Fbx42		
Fbx43	AR	spermatogenic failure 64, 619696 (3), ; oocyte/zygote/embryo maturation arrest 12, 619697 (3),
Fbx44		
Fbx45		
Fbx46		
FBX5		
FBX6		
Fbx6b		
FBX7	AR	parkinson disease 15, 260300 (3),
FBX8		
FBX9		
FBXL1		
FBXL10		
FBXL11		
FBXL12		
FBXL13		
FBXL14		
FBXL15		
FBXL16		
FBXL17		
FBXL18		
FBXL19		
FBXL2		
FBXL20		
FBXL21		
FBXL21P		
FBXL22		
FBXL3	AR	intellectual developmental disorder with short stature, facial anomalies, and speech defects, 606220 (3),
FBXL3A	AR	intellectual developmental disorder with short stature, facial anomalies, and speech defects, 606220 (3),
FBXL3B		
FBXL3P		
FBXL4	AR	mitochondrial dna depletion syndrome 13 (encephalomyopathic type), 615471 (3),
FBXL5		
FBXL6		
FBXL7		
FBXL8		
FBXO1	AD	frontotemporal dementia and/or amyotrophic lateral sclerosis 5, 619141 (3),
FBXO10		
FBXO11	AD	intellectual developmental disorder with dysmorphic facies and behavioral abnormalities, 618089 (3),
FBXO13		
FBXO14	AR	?intellectual developmental disorder, 45, 615979 (3),
FBXO15		
FBXO16		
FBXO17		
FBXO18		
FBXO2		
FBXO20		
FBXO21		
FBXO22		
FBXO24		
FBXO25		
FBXO26		
FBXO27		
FBXO28	AD	developmental and epileptic encephalopathy 100, 619777 (3),
FBXO29		
FBXO3		
FBXO30		
Fbxo31		
FBXO31	AR	?intellectual developmental disorder, 45, 615979 (3),
FBXO32		
FBXO33		
FBXO34		
FBXO34L		
FBXO35		
FBXO36		
FBXO37		
FBXO38	AD	neuronopathy, distal hereditary motor, type iid, 615575 (3),
FBXO39		
FBXO4		
FBXO40		
FBXO41		
FBXO42		
FBXO43	AR	spermatogenic failure 64, 619696 (3), ; oocyte/zygote/embryo maturation arrest 12, 619697 (3),
FBXO44		
FBXO45		
FBXO46		
FBXO47		
FBXO5		
FBXO50		
FBXO6		
Fbxo6a		
FBXO7	AR	parkinson disease 15, 260300 (3),
FBXO8		
FBXO9		
FBXW10		
FBXW10B		
FBXW10P1		
FBXW11	AD	neurodevelopmental, jaw, eye, and digital syndrome, 618914 (3),
FBXW12		
FBXW1A		
FBXW1B	AD	neurodevelopmental, jaw, eye, and digital syndrome, 618914 (3),
FBXW2		
FBXW4		
FBXW5		
FBXW6	AD	developmental delay, hypotonia, and impaired language, 620012 (3),
FBXW7	AD	developmental delay, hypotonia, and impaired language, 620012 (3),
FBXW8		
FBXW9		
Fc-gamma-RIIa	AR,AD	{malaria, severe, susceptibility to}, 611162 (3); {pseudomonas aeruginosa, susceptibility to chronic infection by, in cystic fibrosis}, 219700 (3), ; {lupus nephritis, susceptibility to}, 152700 (3),
Fc-gamma-RIIc		
FC(GAMMA)BP		
FCA/MR		
Fcalpha/muR		
FcalphaR		
FcalphaRI		
FCAMR		
FCAR		
FCAS	AD	cinca syndrome, 607115 (3), ; familial cold inflammatory syndrome 1, 120100 (3), ; keratoendothelitis fugax hereditaria, 148200 (3), ; deafness, 34, with or without inflammation, 617772 (3), ; muckle-wells syndrome, 191900 (3),
FCC2	AD,AR	lynch syndrome 2, 609310 (3); muir-torre syndrome, 158320 (3), ; mismatch repair cancer syndrome 1, 276300 (3),
FCE1A		
FCE2		
FcepsilonRIalpha		
FcepsilonRIgamma		
FcepsilonRII		
FCER1A		
FCER1B	AD	{atopy, susceptibility to}, 147050 (3),
FCER1G		
FCER2		
FCERIA		
FCErII		
FCG1		[igg receptor i, phagocytic, familial deficiency of] (3)
FCG2	AR,AD,AD	{malaria, severe, susceptibility to}, 611162 (3); {pseudomonas aeruginosa, susceptibility to chronic infection by, in cystic fibrosis}, 219700 (3), ; {lupus nephritis, susceptibility to}, 152700 (3), |{systemic lupus erythematosus, susceptibility to}, 152700 (3), ; {malaria, resistance to}, 611162 (3)
FCG3	AR	immunodeficiency 20, 615707 (3),
FcgammaBP		
FcgammaRI		[igg receptor i, phagocytic, familial deficiency of] (3)
FcgammaRIa		[igg receptor i, phagocytic, familial deficiency of] (3)
FcgammaRIIa	AR,AD	{malaria, severe, susceptibility to}, 611162 (3); {pseudomonas aeruginosa, susceptibility to chronic infection by, in cystic fibrosis}, 219700 (3), ; {lupus nephritis, susceptibility to}, 152700 (3),
FcgammaRIIb	AD	{systemic lupus erythematosus, susceptibility to}, 152700 (3), ; {malaria, resistance to}, 611162 (3)
FcgammaRIIc		
FcgammaRIIIa	AR	immunodeficiency 20, 615707 (3),
FcgammaRIIIb		
FcgammaRn		
FCGBP		
FCGR1		[igg receptor i, phagocytic, familial deficiency of] (3)
FCGR1A		[igg receptor i, phagocytic, familial deficiency of] (3)
FCGR1B		
FCGR1BP		
FCGR1C		
FCGR1CP		
FCGR2	AR,AD,AD	{malaria, severe, susceptibility to}, 611162 (3); {pseudomonas aeruginosa, susceptibility to chronic infection by, in cystic fibrosis}, 219700 (3), ; {lupus nephritis, susceptibility to}, 152700 (3), |{systemic lupus erythematosus, susceptibility to}, 152700 (3), ; {malaria, resistance to}, 611162 (3)
FCGR2A	AR,AD	{malaria, severe, susceptibility to}, 611162 (3); {pseudomonas aeruginosa, susceptibility to chronic infection by, in cystic fibrosis}, 219700 (3), ; {lupus nephritis, susceptibility to}, 152700 (3),
FCGR2A1	AR,AD	{malaria, severe, susceptibility to}, 611162 (3); {pseudomonas aeruginosa, susceptibility to chronic infection by, in cystic fibrosis}, 219700 (3), ; {lupus nephritis, susceptibility to}, 152700 (3),
FCGR2B	AD	{systemic lupus erythematosus, susceptibility to}, 152700 (3), ; {malaria, resistance to}, 611162 (3)
FCGR2C		
FCGR3	AR	immunodeficiency 20, 615707 (3),
FCGR3A	AR	immunodeficiency 20, 615707 (3),
FCGR3B		
FcGRIIB	AD	{systemic lupus erythematosus, susceptibility to}, 152700 (3), ; {malaria, resistance to}, 611162 (3)
FcGRIIIA	AR	immunodeficiency 20, 615707 (3),
FCGRT		
FCHO1	AR	immunodeficiency 76, 619164 (3),
FCHO2		
FCHSD1		
FCHSD2		
FCMD	AR	muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 4, 611588 (3), ; muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 4, 253800 (3), ; cardiomyopathy, dilated, 1x, 611615 (3), ; muscular dystrophy-dystroglycanopathy (congenital without impaired intellectual development), type b, 4, 613152 (3),
FCMR		
FcmuR		
FCN1		
FCN2		
FCN3	AR	immunodeficiency due to ficolin 3 deficiency, 613860 (3),
FCNH	AR	immunodeficiency due to ficolin 3 deficiency, 613860 (3),
FCNL		
FCNM		
FCP1	AR	congenital cataracts, facial dysmorphism, and neuropathy, 604168 (3),
FCRH1		
FCRH2		
FCRH3		
FCRH4		
FCRH5		
FcRH6		
FcRIIIb		
FCRL		
FCRL1		
FCRL2		
FCRL3		
FCRL4		
FCRL5		
FCRL6		
FCRLA		
FCRLb		
FCRLB		
FCRLc1		
FCRLc2		
FCRLd		
FCRLe		
FCRLM1		
FCRLM2		
FCRLX		
FCRLY		
FcRn		
FCSK	AR	congenital disorder of glycosylation with defective fucosylation 2, 618324 (3),
FCT3A		[fucosyltransferase 6 deficiency], 613852 (3)
FCU	AD	cinca syndrome, 607115 (3), ; familial cold inflammatory syndrome 1, 120100 (3), ; keratoendothelitis fugax hereditaria, 148200 (3), ; deafness, 34, with or without inflammation, 617772 (3), ; muckle-wells syndrome, 191900 (3),
FCYT	AR	polycystic kidney disease 4, with or without hepatic disease, 263200 (3),
FDC-SP		
FDCSP		
FDF03		
FDFACT1		
FDFACT2		
FDFT1	AR	squalene synthase deficiency, 618156 (3),
FDG		
FDH		amed syndrome, digenic, 619151 (3), digenic
FDP		
FDPS	AD	porokeratosis 9, multiple types, 616631 (3),
FDX		
FDX1		
FDX1L	AR	mitochondrial myopathy, episodic, with optic atrophy and reversible leukoencephalopathy, 251900 (3),
FDX2	AR	mitochondrial myopathy, episodic, with optic atrophy and reversible leukoencephalopathy, 251900 (3),
FDXR	AR	auditory neuropathy and optic atrophy, 617717 (3),
FE	AR	trichothiodystrophy 6, nonphotosensitive, 616943 (3),
Fe65		
FE65L		
FE65L1		
FE65L2		
FEAT	AR,AD	{?deafness, 26, modifier of}, 605429 (3),
FEB3	AD	developmental and epileptic encephalopathy 6b, non-dravet, 619317 (3), ; migraine, familial hemiplegic, 3, 609634 (3), ; dravet syndrome, 607208 (3), ; febrile seizures, familial, 3a, 604403 (3), ; generalized epilepsy with febrile seizures plus, type 2, 604403 (3),
FEB4	AR,AD	usher syndrome, type 2c, 605472 (3), digenic ; usher syndrome, type 2c, gpr98/pdzd7 digenic, 605472 (3), digenic ; ?febrile seizures, familial, 4, 604352 (3),
FECD	AD	corneal dystrophy, posterior polymorphous 2, 609140 (3), ; corneal dystrophy, fuchs endothelial, 1, 136800 (3),
FECD1	AD	corneal dystrophy, posterior polymorphous 2, 609140 (3), ; corneal dystrophy, fuchs endothelial, 1, 136800 (3),
FECD4	AR	corneal endothelial dystrophy, 217700 (3), ; corneal dystrophy, fuchs endothelial, 4, 613268 (3); corneal endothelial dystrophy and perceptive deafness, 217400 (3),
FECD6	AD	corneal dystrophy, posterior polymorphous, 3, 609141 (3), ; corneal dystrophy, fuchs endothelial, 6, 613270 (3),
FECH	AR	protoporphyria, erythropoietic, 1, 177000 (3),
FEEL-1		
FEEL-2		
FEG-1		
FEL		
FELE-1		
FELL		
FELS	AR	diarrhea 10, protein-losing enteropathy type, 618183 (3),
FEM-2		
FEM1A		
FEM1B		
FEM1C		
FEN-1		
FEN1		
FENDRR		
FENS-1		
FEO	AR,AD	osteopetrosis, 7, 612301 (3), ; {paget disease of bone 2, early-onset}, 602080 (3), ; osteolysis, familial expansile, 174810 (3),
FEOM1	AD	fibrosis of extraocular muscles, congenital, 3b, 135700 (3), ; fibrosis of extraocular muscles, congenital, 1, 135700 (3),
FEOM2	AR	fibrosis of extraocular muscles, congenital, 2, 602078 (3),
FEOM3	AD	fibrosis of extraocular muscles, congenital, 3a, 600638 (3), ; cortical dysplasia, complex, with other brain malformations 1, 614039 (3),
FER		
FER1L1	AR	muscular dystrophy, limb-girdle, 2, 253601 (3), ; miyoshi muscular dystrophy 1, 254130 (3), ; myopathy, distal, with anterior tibial onset, 606768 (3),
FER1L2	AR	auditory neuropathy, 1, 601071 (3), ; deafness, 9, 601071 (3),
FER1L3	AD	?angioedema, hereditary, 7, 619366 (3),
FERD3L		
FERMT1	AR	kindler syndrome, 173650 (3),
FERMT2		
FERMT3	AR	leukocyte adhesion deficiency, type iii, 612840 (3),
FES		
FES1		
FETA	AD,AR	[hereditary persistence of alpha-fetoprotein], 615970 (3), ; alpha-fetoprotein deficiency, 615969 (3),
FETUA	AR	?alopecia-intellectual disability syndrome 1, 203650 (3),
FETUB		
FEV		
FEX		
FEX1		
FEZ1		esophageal squamous cell carcinoma, somatic, 133239 (3)
FEZ2		
FEZF1	AR	hypogonadotropic hypogonadism 22, with or without anosmia, 616030 (3),
FEZF2		
FEZL		
FFA1R		
FFA2R		
FFA3R		
FFAR1		
FFAR2		
FFAR3		
FFAR3L		
FFAR4		{obesity, susceptibility to}, 607514 (3)
FFM	AR,AD	retinal dystrophy, early-onset severe, 248200 (3), ; retinitis pigmentosa 19, 601718 (3), ; {macular degeneration, age-related, 2}, 153800 (3), ; cone-rod dystrophy 3, 604116 (3), ; fundus flavimaculatus, 248200 (3), ; stargardt disease 1, 248200 (3),
FFR	AR	pontocerebellar hypoplasia, type 13, 618606 (3),
FGA	AD,AR	hypodysfibrinogenemia, congenital, 616004 (3); dysfibrinogenemia, congenital, 616004 (3); amyloidosis, familial visceral, 105200 (3), ; afibrinogenemia, congenital, 202400 (3),
FGARAT		
FGB	AR	hypofibrinogenemia, congenital, 202400 (3), ; dysfibrinogenemia, congenital, 616004 (3); afibrinogenemia, congenital, 202400 (3),
FGD1	XL,XLR	intellectual developmental disorder, syndromic 16, 305400 (3), ; aarskog-scott syndrome, 305400 (3),
FGD2		
FGD3		
FGD4	AR	charcot-marie-tooth disease, type 4h, 609311 (3),
FGD5		
FGD6		
FGDY	XL,XLR	intellectual developmental disorder, syndromic 16, 305400 (3), ; aarskog-scott syndrome, 305400 (3),
FGE	AR	multiple sulfatase deficiency, 272200 (3),
FGF-13	AD	hypogonadotropic hypogonadism 20 with or without anosmia, 615270 (3),
FGF-18		
FGF-alpha		
FGF-AS		
FGF1		
FGF10	AD	ladd syndrome 3, 620193 (3); aplasia of lacrimal and salivary glands, 180920 (3),
FGF11		
FGF12	AD	developmental and epileptic encephalopathy 47, 617166 (3),
FGF12B	AD	developmental and epileptic encephalopathy 47, 617166 (3),
FGF13	XLD,XLR,XL	developmental and epileptic encephalopathy 90, 301058 (3), ; intellectual developmental disorder, 110, 301095 (3),
FGF13-AS1		
FGF14	AD	spinocerebellar ataxia 27a, 193003 (3), ; spinocerebellar ataxia 27b, late-onset, 620174 (3),
FGF16	XLR,XL	metacarpal 4-5 fusion, 309630 (3),
FGF17	AD	hypogonadotropic hypogonadism 20 with or without anosmia, 615270 (3),
FGF18		
FGF19		
FGF2	XLD,XLR,XL	developmental and epileptic encephalopathy 90, 301058 (3), ; intellectual developmental disorder, 110, 301095 (3),
FGF20	AR	?renal hypodysplasia/aplasia 2, 615721 (3),
FGF21		
FGF22		
FGF23	AR,AD	tumoral calcinosis, hyperphosphatemic, familial, 2, 617993 (3), ; hypophosphatemic rickets, 193100 (3),
FGF2AS		
FGF3	AR	deafness, congenital with inner ear agenesis, microtia, and microdontia, 610706 (3),
FGF4		
FGF5	AR	trichomegaly, 190330 (3),
FGF6		
FGF7		
FGF8	AD	hypogonadotropic hypogonadism 6 with or without anosmia, 612702 (3),
FGF9	AD	multiple synostoses syndrome 3, 612961 (3),
FGFA		
FGFB		
FGFBP		
FGFBP1		
FGFBP2		
FGFIBP	AR	thauvin-robinet-faivre syndrome, 617107 (3),
FGFR1	AD	pfeiffer syndrome, 101600 (3), ; hypogonadotropic hypogonadism 2 with or without anosmia, 147950 (3), ; jackson-weiss syndrome, 123150 (3), ; hartsfield syndrome, 615465 (3), ; trigonocephaly 1, 190440 (3), ; osteoglophonic dysplasia, 166250 (3), ; encephalocraniocutaneous lipomatosis, somatic mosaic, 613001 (3)
FGFR1OP		myeloproliferative disorder, 605392 (2)
FGFR1OP2		
FGFR2	AD	bent bone dysplasia syndrome, 614592 (3), ; ladd syndrome 1, 149730 (3), ; antley-bixler syndrome without genital anomalies or disordered steroidogenesis, 207410 (3), ; scaphocephaly and axenfeld-rieger anomaly (3); jackson-weiss syndrome, 123150 (3), ; gastric cancer, somatic, 613659 (3); craniofacial-skeletal-dermatologic dysplasia, 101600 (3), ; apert syndrome, 101200 (3), ; pfeiffer syndrome, 101600 (3), ; craniosynostosis, nonspecific (3); ?scaphocephaly, maxillary retrusion, and impaired intellectual development, 609579 (3); beare-stevenson cutis gyrata syndrome, 123790 (3), ; crouzon syndrome, 123500 (3), ; saethre-chotzen syndrome, 101400 (3),
FGFR3	AD,AR	muenke syndrome, 602849 (3), ; saddan, 616482 (3), ; hypochondroplasia, 146000 (3), ; thanatophoric dysplasia, type ii, 187601 (3), ; nevus, epidermal, somatic, 162900 (3); catshl syndrome, 610474 (3), ; thanatophoric dysplasia, type i, 187600 (3), ; spermatocytic seminoma, somatic, 273300 (3); bladder cancer, somatic, 109800 (3); ladd syndrome 2, 620192 (3), ; achondroplasia, 100800 (3), ; cervical cancer, somatic, 603956 (3); colorectal cancer, somatic, 114500 (3); crouzon syndrome with acanthosis nigricans, 612247 (3),
FGFR4		{cancer progression/metastasis} (3)
FGFRL1		
FGG	AR	dysfibrinogenemia, congenital, 616004 (3); hypodysfibrinogenemia, 616004 (3); hypofibrinogenemia, congenital, 202400 (3), ; afibrinogenemia, congenital, 202400 (3),
FGGAP1		
FGGY		
FGIF		
FGL1		
FGL2		
FGR		
FGS1	XLR,XL,XLD	lujan-fryns syndrome, 309520 (3), ; ohdo syndrome, 300895 (3), ; hardikar syndrome, 301068 (3), ; opitz-kaveggia syndrome, 305450 (3),
FGS4	XLR,XLD,XL	intellectual developmental disorder, with or without nystagmus, 300422 (3), ; intellectual developmental disorder and microcephaly with pontine and cerebellar hypoplasia, 300749 (3), ; fg syndrome 4, 300422 (3),
FH	AD,AR	leiomyomatosis and renal cell cancer, 150800 (3), ; fumarase deficiency, 606812 (3),
FH1	AD,AR	larsen syndrome, 150250 (3), ; atelosteogenesis, type i, 108720 (3), ; atelosteogenesis, type iii, 108721 (3), ; spondylocarpotarsal synostosis syndrome, 272460 (3), ; boomerang dysplasia, 112310 (3),
FH3	AD	{low density lipoprotein cholesterol level qtl 1}, 603776 (3), ; hypercholesterolemia, familial, 3, 603776 (3),
FHC	AD,AR,AD	?hemochromatosis, type 5, 615517 (3), |cardiomyopathy, hypertrophic, 4, 115197 (3), ; cardiomyopathy, dilated, 1mm, 615396 (3), ; left ventricular noncompaction 10, 615396 (3),
FHCB1	AR	hypercholesterolemia, familial, 4, 603813 (3),
FHCB2	AR	hypercholesterolemia, familial, 4, 603813 (3),
FHDC1		
FHF1	AD	developmental and epileptic encephalopathy 47, 617166 (3),
FHF2	XLD,XLR,XL	developmental and epileptic encephalopathy 90, 301058 (3), ; intellectual developmental disorder, 110, 301095 (3),
FHF3		
FHF4	AD	spinocerebellar ataxia 27a, 193003 (3), ; spinocerebellar ataxia 27b, late-onset, 620174 (3),
FHH	AD,AR	hypocalcemia, with bartter syndrome, 601198 (3), ; {epilepsy idiopathic generalized, susceptibility to, 8}, 612899 (3); hyperparathyroidism, neonatal, 239200 (3), ; hypocalcemia, 601198 (3), ; hypocalciuric hypercalcemia, type i, 145980 (3),
FHH2	AD	hypocalciuric hypercalcemia, type ii, 145981 (3), ; hypocalcemia, 2, 615361 (3),
FHI	AD,AR	aldosteronism, glucocorticoid-remediable, 103900 (3), ; adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deficiency, 202010 (3),
FHIP		
FHIP1B		
FHIP2A		
FHIP2B		
FHIT		
FHL1	AD,AR,XL,XLR,XLD	{macular degeneration, age-related, 4}, 610698 (3), ; basal laminar drusen, 126700 (3), ; complement factor h deficiency, 609814 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to, 1}, 235400 (3), |myopathy, with postural muscle atrophy, 300696 (3), ; emery-dreifuss muscular dystrophy 6, 300696 (3), ; ?uruguay faciocardiomusculoskeletal syndrome, 300280 (3), ; scapuloperoneal myopathy, 300695 (3), ; reducing body myopathy, 1b, with late childhood or adult onset, 300718 (3), ; reducing body myopathy, 1a, severe, infantile or early childhood onset, 300717 (3),
FHL1B	XL,XLR,XLD	myopathy, with postural muscle atrophy, 300696 (3), ; emery-dreifuss muscular dystrophy 6, 300696 (3), ; ?uruguay faciocardiomusculoskeletal syndrome, 300280 (3), ; scapuloperoneal myopathy, 300695 (3), ; reducing body myopathy, 1b, with late childhood or adult onset, 300718 (3), ; reducing body myopathy, 1a, severe, infantile or early childhood onset, 300717 (3),
FHL2		
FHL3		
FHL5		
FHM	AD	spinocerebellar ataxia 6, 183086 (3), ; episodic ataxia, type 2, 108500 (3), ; developmental and epileptic encephalopathy 42, 617106 (3), ; migraine, familial hemiplegic, 1, with progressive cerebellar ataxia, 141500 (3), ; migraine, familial hemiplegic, 1, 141500 (3),
FHM2	AD,AR	developmental and epileptic encephalopathy 98, 619605 (3), ; fetal akinesia, respiratory insufficiency, microcephaly, polymicrogyria, and dysmorphic facies, 619602 (3), ; alternating hemiplegia of childhood 1, 104290 (3), ; migraine, familial basilar, 602481 (3), ; migraine, familial hemiplegic, 2, 602481 (3),
FHOD1		
FHOD2		
FHOD3	AD	cardiomyopathy, familial hypertrophic, 28, 619402 (3),
FHOS		
FHOS2	AD	cardiomyopathy, familial hypertrophic, 28, 619402 (3),
FHR-3	AD,AR	{macular degeneration, age-related, reduced risk of}, 603075 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to}, 235400 (3),
FHR-4		
FHR-5	AD	nephropathy due to cfhr5 deficiency, 614809 (3),
FHR1	AD,AR	{macular degeneration, age-related, reduced risk of}, 603075 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to}, 235400 (3),
FHR2		
FHR3	AD,AR	{macular degeneration, age-related, reduced risk of}, 603075 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to}, 235400 (3),
FHR4		
FHR5	AD	nephropathy due to cfhr5 deficiency, 614809 (3),
FHX		
FI	AD,AR	{hemolytic uremic syndrome, atypical, susceptibility to, 3}, 612923 (3), ; {macular degeneration, age-related, 13, susceptibility to}, 615439 (3), ; complement factor i deficiency, 610984 (3),
FIAF	AD	plasma triglyceride level qtl, low, 615881 (3),
FIAT		
FIB		
FIB1	AD,AR	mitral valve prolapse 2, 607829 (3), ; van maldergem syndrome 1, 601390 (3),
FIB2		
FIB3		
FIBCD1		
FIBIN		
FIBL-6	AD	{macular degeneration, age-related, 1}, 603075 (3),
FIBL6	AD	{macular degeneration, age-related, 1}, 603075 (3),
FIBP	AR	thauvin-robinet-faivre syndrome, 617107 (3),
fibroglycan		
FIC		
FIC1	AR,AD	cholestasis, progressive familial intrahepatic 1, 211600 (3), ; cholestasis, intrahepatic, of pregnancy, 1, 147480 (3), ; cholestasis, benign recurrent intrahepatic, 243300 (3),
FICCA	AD	convulsions, familial infantile, with paroxysmal choreoathetosis, 602066 (3), ; seizures, benign familial infantile, 2, 605751 (3), ; episodic kinesigenic dyskinesia 1, 128200 (3),
ficolin-2		
FIEL1		
FIG		
FIG1		
FIG4	AR,AD	yunis-varon syndrome, 216340 (3), ; ?polymicrogyria, bilateral temporooccipital, 612691 (3), ; amyotrophic lateral sclerosis 11, 612577 (3), ; charcot-marie-tooth disease, type 4j, 611228 (3),
Figalpha	AD	premature ovarian failure 6, 612310 (3),
FIGF		
FIGLA	AD	premature ovarian failure 6, 612310 (3),
Figlb		
FIGLER1		
FIGLER2		
FIGLER3		
FIGLER4	AR	night blindness, congenital stationary (complete), 1f, 615058 (3),
FIGLER5		
FIGLER6		
FIGLER7		
FIGLER8		
FIGLER9		
FIGN		
FIGNL1		
FIH1		
FIHP	AD	hyperparathyroidism, familial primary, 145000 (3), ; parathyroid adenoma with cystic changes, 145001 (3), ; parathyroid carcinoma, 608266 (3); hyperparathyroidism-jaw tumor syndrome, 145001 (3),
FIL1	AR,AR	?inflammatory bowel disease (infantile ulcerative colitis) 31, 619398 (3), |psoriasis 14, pustular, 614204 (3),
FIL1(DELTA)	AR	psoriasis 14, pustular, 614204 (3),
FIL1(ZETA)	AR	?inflammatory bowel disease (infantile ulcerative colitis) 31, 619398 (3),
FIL1D	AR	psoriasis 14, pustular, 614204 (3),
FIL1E		
FIL1Z	AR	?inflammatory bowel disease (infantile ulcerative colitis) 31, 619398 (3),
filensin	AR,AD	cataract 33, multiple types, 611391 (3),
FilGAP		
FILI-(ETA)		
FILIP		
FILIP1		
FILIP1L		
FILTRIN		
FIM	AD	neurodevelopmental-craniofacial syndrome with variable renal and cardiac abnormalities, 619522 (3),
FIMP		
FINC	AD	spondylometaphyseal dysplasia, corner fracture type, 184255 (3), ; glomerulopathy with fibronectin deposits 2, 601894 (3),
FIND		
FinGER1		
FinGER2		
FinGER3		
FinGER4		
FinGER5	AR	microcephaly, epilepsy, and diabetes syndrome 2, 619278 (3),
FinGER6		
FinGER7		
FinGER8	AR	kaya-barakat-masson syndrome, 619125 (3),
FinGER9		
FIP		
FIP-1		
FIP-2	AD,AR	glaucoma 1, open angle, e, 137760 (3), ; amyotrophic lateral sclerosis 12 with or without frontotemporal dementia, 613435 (3), ; {glaucoma, normal tension, susceptibility to}, 606657 (3)
FIP-3	XLD,XLR,XL	incontinentia pigmenti, 308300 (3), ; ectodermal dysplasia and immunodeficiency 1, 300291 (3), ; immunodeficiency 33, 300636 (3), ; autoinflammatory disease, systemic, 301081 (3),
FIP-82		
FIP1		
FIP1L1		
FIP2	AD,AR	glaucoma 1, open angle, e, 137760 (3), ; amyotrophic lateral sclerosis 12 with or without frontotemporal dementia, 613435 (3), ; {glaucoma, normal tension, susceptibility to}, 606657 (3)
FIP200		breast cancer, somatic, 114480 (3)
FIP3	XLD,XLR,XL	incontinentia pigmenti, 308300 (3), ; ectodermal dysplasia and immunodeficiency 1, 300291 (3), ; immunodeficiency 33, 300636 (3), ; autoinflammatory disease, systemic, 301081 (3),
Fip3p	XLD,XLR,XL	incontinentia pigmenti, 308300 (3), ; ectodermal dysplasia and immunodeficiency 1, 300291 (3), ; immunodeficiency 33, 300636 (3), ; autoinflammatory disease, systemic, 301081 (3),
FIR	AD	verheij syndrome, 615583 (3),
FIRRE		
FIS1		
FISH		
FISP		
FIST3		
FISTC1		
FIT-1		
FIT1		
FIT2	AR	siddiqi syndrome, 618635 (3),
FITM1		
FITM2	AR	siddiqi syndrome, 618635 (3),
FIX	XLR,XL	{deep venous thrombosis, protection against}, 300807 (3), ; hemophilia b, 306900 (3), ; thrombophilia 8, due to factor ix defect, 300807 (3), ; {warfarin sensitivity}, 301052 (3),
FIZ1		
FIZZ2		
FIZZ3	AD	{hypertension, insulin resistance-related, susceptibility to}, 125853 (3), ; {diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3),
FJ222407		
FJ573250		
fJ646B12.2		
FJH1	AR	?mitochondrial dna depletion syndrome 17, 618567 (3),
FJX1		
FKBP-12		
FKBP-13		
FKBP-25		
FKBP1		
FKBP10	AR	osteogenesis imperfecta, type xi, 610968 (3), ; bruck syndrome 1, 259450 (3),
FKBP11		
FKBP12		
FKBP12.6		
FKBP12C		
FKBP13		
FKBP133		
FKBP14	AR	ehlers-danlos syndrome, kyphoscoliotic type, 2, 614557 (3),
FKBP15		
FKBP16	AD	pituitary adenoma 1, multiple types, 102200 (3), somatic mutation, ; pituitary adenoma predisposition, 102200 (3), somatic mutation,
FKBP19		
FKBP1A		
FKBP1B		
FKBP1L		
FKBP2		
FKBP22	AR	ehlers-danlos syndrome, kyphoscoliotic type, 2, 614557 (3),
FKBP23		
FKBP25		
FKBP3		
FKBP36	AR	spermatogenic failure 77, 620103 (3),
FKBP37	AD	pituitary adenoma 1, multiple types, 102200 (3), somatic mutation, ; pituitary adenoma predisposition, 102200 (3), somatic mutation,
FKBP38		
FKBP4		
FKBP5		{major depressive disorder and accelerated response to antidepressant drug treatment}, 608516 (3)
FKBP51		{major depressive disorder and accelerated response to antidepressant drug treatment}, 608516 (3)
FKBP52		
FKBP54		{major depressive disorder and accelerated response to antidepressant drug treatment}, 608516 (3)
FKBP59		
FKBP6	AR,AR	osteogenesis imperfecta, type xi, 610968 (3), ; bruck syndrome 1, 259450 (3), |spermatogenic failure 77, 620103 (3),
FKBP60		
FKBP63		
FKBP65	AR	osteogenesis imperfecta, type xi, 610968 (3), ; bruck syndrome 1, 259450 (3),
FKBP7		
FKBP8		
FKBP9		
FKBPAP	AD	glomuvenous malformations, 138000 (3),
FKBPL		
FKBPr38		
FKH1		rhabdomyosarcoma, alveolar, 268220 (3), somatic mutation
FKH2	AD	rett syndrome, congenital variant, 613454 (3),
FKH5		
FKH6		
FKHL1	AD	rett syndrome, congenital variant, 613454 (3),
FKHL10	AR	enlarged vestibular aqueduct, 600791 (3),
FKHL11		
FKHL12	AR,AD	anterior segment dysgenesis 2, multiple subtypes, 610256 (3), ; {aortic aneurysm, familial thoracic 11, susceptibility to}, 617349 (3), ; cataract 34, multiple types, 612968 (3)
FKHL13	AD	ciliary dyskinesia, primary, 43, 618699 (3),
FKHL14	AD	lymphedema-distichiasis syndrome, 153400 (3), ; lymphedema-distichiasis syndrome with renal disease and diabetes mellitus, 153400 (3),
FKHL15	AR,AD	bamforth-lazarus syndrome, 241850 (3), ; {thyroid cancer, nonmedullary, 4}, 616534 (3),
FKHL16		
FKHL17		
FKHL18		
FKHL2	AD	rett syndrome, congenital variant, 613454 (3),
FKHL20	AD,AR	t-cell lymphopenia, infantile, with or without nail dystrophy, 618806 (3), ; t-cell immunodeficiency, congenital alopecia, and nail dystrophy, 601705 (3),
FKHL3	AD	rett syndrome, congenital variant, 613454 (3),
FKHL4	AD	rett syndrome, congenital variant, 613454 (3),
FKHL5	AD	alveolar capillary dysplasia with misalignment of pulmonary veins, 265380 (3),
FKHL6		
FKHL7	AD	axenfeld-rieger syndrome, type 3, 602482 (3), ; anterior segment dysgenesis 3, multiple subtypes, 601631 (3),
FKHL8		
FKHL9		
FKHR		rhabdomyosarcoma, alveolar, 268220 (3), somatic mutation
FKHRL1		
FKLF		maturity-onset diabetes of the young, type vii, 610508 (3)
FKLF-2		
FKRP	AR	muscular dystrophy-dystroglycanopathy (congenital with or without impaired intellectual development), type b, 5, 606612 (3), ; muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 5, 607155 (3), ; muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 5, 613153 (3),
FKSG14		
FKSG19	AD	paroxysmal nonkinesigenic dyskinesia 1, 118800 (3),
FKSG21		
FKSG24		
FKSG25		
FKSG28		
FKSG30		
FKSG32	AR	neurodevelopmental disorder with microcephaly and gray sclerae, 617051 (3),
FKSG33		
FKSG36		
FKSG4		
FKSG40		
FKSG44		
FKSG75		
FKSG77		
FKSG79		
FKSG80		
FKSG81		
FKSG84		
FKSG86		
FKSG87		
FKSG89		
FKTN	AR	muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 4, 611588 (3), ; muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 4, 253800 (3), ; cardiomyopathy, dilated, 1x, 611615 (3), ; muscular dystrophy-dystroglycanopathy (congenital without impaired intellectual development), type b, 4, 613152 (3),
FKTR	AR	muscular dystrophy-dystroglycanopathy (congenital with or without impaired intellectual development), type b, 5, 606612 (3), ; muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 5, 607155 (3), ; muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 5, 613153 (3),
FL-NCA-3		
FLA10		
FLA17	AR,AD	short-rib thoracic dysplasia 4 with or without polydactyly, 613819 (3), ; nephronophthisis 12, 613820 (3),
FLA3		
FLA8	AD	retinitis pigmentosa 89, 618955 (3),
FLACC1		
FLAD1	AR	lipid storage myopathy due to flavin adenine dinucleotide synthetase deficiency, 255100 (3),
FLAF1		
FLAME		
FLAME-3		
Flamingo1		
FLANa		
FLAP	MF	{stroke, susceptibility to}, 601367 (3),
FLAP-1		
FLASH		
Flattop		
FLB6421		
FLB7527		
FLCN	AD	birt-hogg-dube syndrome, 135150 (3), ; colorectal cancer, somatic, 114500 (3); pneumothorax, primary spontaneous, 173600 (3), ; renal carcinoma, chromophobe, somatic, 144700 (3)
FLDED1		
FLFL1		
FLFL2		
FLG	AR,AD,AD	ichthyosis vulgaris, 146700 (3), ; {dermatitis, atopic, susceptibility to, 2}, 605803 (3)|pfeiffer syndrome, 101600 (3), ; hypogonadotropic hypogonadism 2 with or without anosmia, 147950 (3), ; jackson-weiss syndrome, 123150 (3), ; hartsfield syndrome, 615465 (3), ; trigonocephaly 1, 190440 (3), ; osteoglophonic dysplasia, 166250 (3), ; encephalocraniocutaneous lipomatosis, somatic mosaic, 613001 (3)
FLG-1	AR,AD	ichthyosis vulgaris, 146700 (3), ; {dermatitis, atopic, susceptibility to, 2}, 605803 (3)
FLG1	AR,AD	ichthyosis vulgaris, 146700 (3), ; {dermatitis, atopic, susceptibility to, 2}, 605803 (3)
FLG2	AR	peeling skin syndrome 6, 618084 (3),
FLG3		
FLH1A	XL,XLR,XLD	myopathy, with postural muscle atrophy, 300696 (3), ; emery-dreifuss muscular dystrophy 6, 300696 (3), ; ?uruguay faciocardiomusculoskeletal syndrome, 300280 (3), ; scapuloperoneal myopathy, 300695 (3), ; reducing body myopathy, 1b, with late childhood or adult onset, 300718 (3), ; reducing body myopathy, 1a, severe, infantile or early childhood onset, 300717 (3),
FLH21957		
FLI		
FLI-1	AR,AD	bleeding disorder, platelet-type, 21, 617443 (3),
Fli1		
FLI1	AR,AD	bleeding disorder, platelet-type, 21, 617443 (3),
FLI1-AS1		
FLICE	AD,AR	{breast cancer, protection against}, 114480 (3), somatic mutation, ; ?caspase 8 lymphadenopathy syndrome, 607271 (3), ; hepatocellular carcinoma, somatic, 114550 (3); {lung cancer, protection against}, 211980 (3), somatic mutation,
FLICE-2	AD	autoimmune lymphoproliferative syndrome, type ii, 603909 (3), ; gastric cancer, somatic, 613659 (3); lymphoma, non-hodgkin, somatic, 605027 (3)
FLII		
FLIIAP1		
FLIL		
FLIP		
FLIP1		
FLIPT1		
FLIPT2		
FLJ00004		
FLJ00007		
FLJ00012		
FLJ00018	AR	leukodystrophy and acquired microcephaly with or without dystonia, 616763 (3),
FLJ00023	AR	?combined oxidative phosphorylation deficiency 50, 619025 (3),
FLJ00026	AR	hyper-ige recurrent infection syndrome, 243700 (3),
FLJ00029		
FLJ00030		
FLJ00032		
FLJ00034		
FLJ00038		
FLJ00040		
FLJ00051		
FLJ00052		
FLJ00055		
FLJ00058		
FLJ00065		
FLJ00073		
FLJ00086		
FLJ00089		
FLJ00101	AR	ciliary dyskinesia, primary, 39, 618254 (3),
FLJ00103		
FLJ00115		
FLJ00118	AD	ceroid lipofuscinosis, neuronal, 4 (kufs type), 162350 (3),
FLJ00131		
FLJ00133		
FLJ00135	AR	hyperphosphatasia with impaired intellectual development syndrome 2, 614749 (3),
FLJ00141		
FLJ00151		
FLJ00152	AR	hyper-ige recurrent infection syndrome, 243700 (3),
FLJ00171		
FLJ00173		
FLJ00193		
FLJ00194		
FLJ00199		
FLJ00204		
FLJ00225		
FLJ00237		
FLJ00248		
FLJ00267		
FLJ00274		
FLJ00332		
FLJ00336		
FLJ00337		
FLJ00346	AR	hyper-ige recurrent infection syndrome, 243700 (3),
FLJ00348		
FLJ00354		
FLJ00375		
FLJ00380		
FLJ00382		
FLJ00391		
FLJ10007		
FLJ10024		
FLJ10035		{inflammatory bowel disease (crohn disease) 10}, 611081 (3)
FLJ10036		
FLJ10042		
FLJ10051	AR	intellectual developmental disorder with speech delay and axonal peripheral neuropathy, 619099 (3),
FLJ10052	AD	{melioidosis, susceptibility to}, 615557 (3), ; {systemic lupus erythematosus, susceptibility to, 1}, 601744 (3); {systemic lupus erythematosus, resistance to}, 601744 (3); {legionnaire disease, susceptibility to}, 608556 (3)
FLJ10053		
FLJ10055		
FLJ10057		
FLJ10060	AD	riboflavin deficiency, 615026 (3),
FLJ10063		
FLJ10067		
FLJ10081		
FLJ10094		
FLJ10097		
FLJ10101		
FLJ10103		
FLJ10106		
FLJ10111		
FLJ10116		
FLJ10128		
FLJ10134		
FLJ10140	AR	{deafness, mitochondrial, modifier of}, 580000 (3), mitochondrial; liver failure, transient infantile, 613070 (3),
FLJ10142		
FLJ10143		
FLJ10147	AR	?orofaciodigital syndrome xviii, 617927 (3),
FLJ10154		
FLJ10156		
FLJ10157		
FLJ10159	AR	?impaired intellectual development, anterior maxillary protrusion, and strabismus, 613671 (3),
FLJ10160		
FLJ10177		
FLJ10181		
FLJ10188		
FLJ10193		
FLJ10197	AD	neurodevelopmental disorder with or without early-onset generalized epilepsy, 619157 (3),
FLJ10201	AD	?epilepsy, myoclonic, familial adult, 4, 615127 (3),
FLJ10209	AD	schuurs-hoeijmakers syndrome, 615009 (3),
FLJ10210	AR	?corpus callosum, agenesis of, with facial anomalies and cerebellar ataxia, 616819 (3),
FLJ10211		
FLJ10215	AD	intellectual developmental disorder with autistic features and language delay, with or without seizures, 618906 (3),
FLJ10233		
FLJ10241		
FLJ10242		
FLJ10243		
FLJ10244		
FLJ10251		
FLJ10252		
FLJ10257		
FLJ10260		
FLJ10261	AR	?intestinal dysmotility syndrome, 620045 (3),
FLJ10262		
FLJ10267		
FLJ10276		
FLJ10283		
FLJ10290		
FLJ10292		
FLJ10296		
FLJ10297		
FLJ10300	AR	short-rib thoracic dysplasia 8 with or without polydactyly, 615503 (3),
FLJ10305	AR	striatonigral degeneration, childhood-onset, 617054 (3),
FLJ10307		
FLJ10308		
FLJ10312		
FLJ10316		
FLJ10320		
FLJ10324		
FLJ10326	AR	cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia, 616007 (3),
FLJ10335	AR	fanconi anemia, complementation group l, 614083 (3),
FLJ10337	AD	?agammaglobulinemia 5, 613506 (3),
FLJ10342		
FLJ10343		
FLJ10351		
FLJ10352		
FLJ10355		
FLJ10357		
FLJ10359		
FLJ10369		
FLJ10372		
FLJ10375	AR	spinocerebellar ataxia, 10, 613728 (3),
FLJ10376	AR	ciliary dyskinesia, primary, 23, 615451 (3),
FLJ10377	AR	?alopecia, neurologic defects, and endocrinopathy syndrome, 612079 (3),
FLJ10381	AR	parkinson disease 23, early onset, 616840 (3),
FLJ10385	AR	dyskeratosis congenita, 3, 613988 (3),
FLJ10386		
FLJ10387	AR	developmental and epileptic encephalopathy 18, 615476 (3),
FLJ10388	AR,AD	leukodystrophy, hypomyelinating, 8, with or without oligodontia and/or hypogonadotropic hypogonadism, 614381 (3), ; charcot-marie-tooth disease, demyelinating, type 1i, 619742 (3),
FLJ10390		
FLJ10392	AR	?peho syndrome-like, 617507 (3),
FLJ10404		
FLJ10407		
FLJ10408		
FLJ10415		
FLJ10416		
FLJ10420		
FLJ10422		
FLJ10430		
FLJ10439		
FLJ10441		
FLJ10450		
FLJ10460		
FLJ10462		
FLJ10466	AD	{epilepsy, juvenile absence, susceptibility to, 1}, 607631 (3), ; {myoclonic epilepsy, juvenile, susceptibility to, 1}, 254770 (3),
FLJ10470		
FLJ10477	AD	dystonia 6, torsion, 602629 (3),
FLJ10485		
FLJ10486	AR	?spastic ataxia 4, 613672 (3),
FLJ10488		
FLJ10491		
FLJ10493	AR	osteogenesis imperfecta, type xiv, 615066 (3),
FLJ10494		
FLJ10496	AR	?developmental and epileptic encephalopathy 86, 618910 (3),
FLJ10504	AR,AD	myopathy, mitochondrial, and ataxia, 617675 (3),
FLJ10506	AR,AD	intellectual developmental disorder, 78, 620237 (3), ; hypogonadotropic hypogonadism 14 with or without anosmia, 614858 (3),
FLJ10509		
FLJ10511		
FLJ10512	AR	atelis syndrome 1, 620184 (3),
FLJ10514	AR	leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation, 611105 (3),
FLJ10517	AR	microcephaly 5, primary, 608716 (3),
FLJ10520	AR	?fanconi anemia, complementation group w, 617784 (3),
FLJ10521		
FLJ10523		
FLJ10524		
FLJ10525		
FLJ10530	AR	{prostate cancer, hereditary, 2, susceptibility to}, 614731 (3); combined oxidative phosphorylation deficiency 17, 615440 (3),
FLJ10534		
FLJ10537	AD	deafness, 64, 614152 (3),
FLJ10539	AR	neurodevelopmental disorder with dystonia and seizures, 619922 (3), ; ?dystonia 35, childhood-onset, 619921 (3),
FLJ10540	AR	multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly, 236500 (3),
FLJ10545		
FLJ10546		
FLJ10548		
FLJ10549	AR	microcephaly 5, primary, 608716 (3),
FLJ10559		
FLJ10560		
FLJ10563	AR	ciliary dyskinesia, primary, 10, 612518 (3),
FLJ10564	AR	?pontocerebellar hypoplasia, type 15, 619302 (3),
FLJ10565		
FLJ10567		
FLJ10569		
FLJ10572		
FLJ10575		
FLJ10578		
FLJ10579		
FLJ10581		
FLJ10582		
FLJ10587	AR	alzahrani-kuwahara syndrome, 619268 (3),
FLJ10590		
FLJ10595	AR	?infantile liver failure syndrome 1, 615438 (3),
FLJ10597	AR	leukodystrophy, hypomyelinating, 23, with ataxia, deafness, liver dysfunction, and dilated cardiomyopathy, 619688 (3),
FLJ10599		
FLJ10601	AR,AD	gapo syndrome, 230740 (3), ; {?hemangioma, capillary infantile, susceptibility to}, 602089 (3),
FLJ10604		
FLJ10607		?rhizomelic dysplasia, ain-naz type, 616510 (3)
FLJ10613		
FLJ10616		
FLJ10618	AR	hyperinsulinemic hypoglycemia, familial, 8, 620211 (3),
FLJ10619	AR	spinocerebellar ataxia, 4, 607317 (3),
FLJ10620		
FLJ10628		
FLJ10631	AR	vertebral, cardiac, renal, and limb defects syndrome 3, 618845 (3),
FLJ10633		
FLJ10634		
FLJ10637		
FLJ10640	AR	short stature, brachydactyly, intellectual developmental disability, and seizures, 617157 (3),
FLJ10648		
FLJ10652		
FLJ10656		
FLJ10657		
FLJ10659		
FLJ10661		
FLJ10665		
FLJ10666		
FLJ10667		
FLJ10669		
FLJ10675		
FLJ10686		
FLJ10688		
FLJ10690		
FLJ10694		
FLJ10697		
FLJ10698	AD	charcot-marie-tooth disease, axonal, type 2ff, 619519 (3),
FLJ10701		
FLJ10702		
FLJ10707	AD	intellectual developmental disorder, 23, 615761 (3),
FLJ10709	AR,AD	harel-yoon syndrome, 617183 (3), ; pontocerebellar hypoplasia, hypotonia, and respiratory insufficiency syndrome, neonatal lethal, 618810 (3),
FLJ10713		
FLJ10715	AR	bardet-biedl syndrome 7, 615984 (3),
FLJ10716	AR	retinal dystrophy with or without extraocular anomalies, 617175 (3),
FLJ10718	AR	myopia, high, with cataract and vitreoretinal degeneration, 614292 (3),
FLJ10719	AR	fanconi anemia, complementation group i, 609053 (3),
FLJ10724	AR	nivelon-nivelon-mabille syndrome, 600092 (3),
FLJ10727	XL,XLR	{autism, susceptibility to, 6}, 300872 (3),
FLJ10730	AD	?hypercarotenemia and vitamin a deficiency, 115300 (3),
FLJ10734		
FLJ10737		
FLJ10738		
FLJ10739		
FLJ10741		
FLJ10743		
FLJ10747		
FLJ10748		
FLJ10749		
FLJ10752	AD	{parkinson disease 17}, 614203 (3),
FLJ10759		
FLJ10761		
FLJ10766	AD	developmental and epileptic encephalopathy 100, 619777 (3),
FLJ10767		
FLJ10768		
FLJ10769	AR	encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy, 2, 618321 (3),
FLJ10770		
FLJ10773		
FLJ10774		
FLJ10775		
FLJ10782	AD	?cataract 49, 619593 (3),
FLJ10783		
FLJ10785		
FLJ10788		
FLJ10792		
FLJ10793		
FLJ10796		
FLJ10803		
FLJ10805		
FLJ10808		
FLJ10813		
FLJ10814	AR	?galloway-mowat syndrome 8, 618349 (3), ; nephrotic syndrome, type 18, 618177 (3),
FLJ10815		
FLJ10816	AD	treacher-collins syndrome 4, 618939 (3),
FLJ10817	AR	ciliary dyskinesia, primary, 23, 615451 (3),
FLJ10821		
FLJ10826		
FLJ10830		
FLJ10832		
FLJ10833		
FLJ10842	AR	cataract 38, 614691 (3), ; sengers syndrome, 212350 (3),
FLJ10846		
FLJ10847		
FLJ10849		
FLJ10850		
FLJ10851	AR	yoon-bellen neurodevelopmental syndrome, 619701 (3),
FLJ10852		
FLJ10853		
FLJ10856		
FLJ10857	AD	neurodevelopmental disorder with dysmorphic facies and thin corpus callosum, 619480 (3),
FLJ10858		
FLJ10867	AR	microcephaly 3, primary, 604804 (3),
FLJ10871		
FLJ10873		
FLJ10874		
FLJ10879	AR	intellectual developmental disorder, 58, 617270 (3),
FLJ10881		
FLJ10883		
FLJ10889		
FLJ10890		
FLJ10893		
FLJ10895		
FLJ10898	AD	shashi-pena syndrome, 617190 (3),
FLJ10900		
FLJ10901	AD	{inflammatory bowel disease 29}, 618077 (3),
FLJ10904		
FLJ10907	AR	leukoencephalopathy, cystic, without megalencephaly, 612951 (3),
FLJ10913		
FLJ10914		
FLJ10916		
FLJ10917	AR	{aplastic anemia, susceptibility to}, 609135 (3); shwachman-diamond syndrome 1, 260400 (3),
FLJ10921		
FLJ10925	AR	?microcephaly 25, primary, 618351 (3),
FLJ10928		
FLJ10933		
FLJ10939		
FLJ10941		
FLJ10955		
FLJ10956	AD	{thiopurines, poor metabolism of, 2}, 616903 (3),
FLJ10961		
FLJ10968		
FLJ10970		
FLJ10971		
FLJ10975		
FLJ10979	AR	pontocerebellar hypoplasia, type 2e, 615851 (3),
FLJ10980		
FLJ10983		
FLJ10986		
FLJ10989	AR	combined oxidative phosphorylation deficiency 40, 618835 (3),
FLJ10998	AR	spinocerebellar ataxia, 17, 616127 (3),
FLJ11001		
FLJ11005	AR	congenital disorder of deglycosylation 1, 615273 (3),
FLJ11006		
FLJ11008		
FLJ11011		
FLJ11015		
FLJ11021		
FLJ11026	AR	neurodevelopmental disorder with dysmorphic facies and cerebellar hypoplasia, 619306 (3),
FLJ11029		
FLJ11030		
FLJ11040		
FLJ11045		
FLJ11046	AR	pontocerebellar hypoplasia, type 11, 617695 (3),
FLJ11052		
FLJ11053		
FLJ11058		
FLJ11061	AR	myasthenic syndrome, congenital, 24, presynaptic, 618198 (3),
FLJ11063		
FLJ11071	AD	developmental delay, hypotonia, and impaired language, 620012 (3),
FLJ11088		
FLJ11090	AR	?spinocerebellar ataxia, with axonal neuropathy 1, 607250 (3),
FLJ11100		
FLJ11105		
FLJ11110		
FLJ11112		
FLJ11113	AD	intellectual developmental disorder, 1, 156200 (3),
FLJ11123		
FLJ11128		
FLJ11129		
FLJ11137		
FLJ11142	AR	spermatogenic failure 20, 617593 (3),
FLJ11146		
FLJ11149		
FLJ11151		
FLJ11152	AD	?periventricular nodular heterotopia 6, 615544 (3),
FLJ11155		
FLJ11159		
FLJ11160	AR	histiocytosis-lymphadenopathy plus syndrome, 602782 (3),
FLJ11168		
FLJ11171		
FLJ11175		
FLJ11180		
FLJ11183		
FLJ11186		
FLJ11189		
FLJ11196		
FLJ11200	AD,AR	?hip dysplasia, beukes type, 142669 (3), ; spondyloepimetaphyseal dysplasia, di rocco type, 617974 (3), ; developmental and epileptic encephalopathy 106, 620028 (3),
FLJ11203	AD	cornelia de lange syndrome 1, 122470 (3),
FLJ11207		
FLJ11208		
FLJ11209		
FLJ11210		
FLJ11213		
FLJ11214	AD	neurodevelopmental disorder with variable motor and speech impairment, 617804 (3),
FLJ11215		
FLJ11218		
FLJ11220		
FLJ11222	AR	heterotaxy, visceral, 9, with male infertility, 618948 (3),
FLJ11230		
FLJ11238	AR	?leukodystrophy, progressive, early childhood-onset, 617762 (3),
FLJ11240	AR	methylmalonic aciduria and homocystinuria, cblf type, 277380 (3),
FLJ11249		
FLJ1125		
FLJ11259		
FLJ11264	AR	skeletal dysplasia, mild, with joint laxity and advanced bone age, 618870 (3),
FLJ11265		
FLJ11266		
FLJ11269		?facioscapulohumeral muscular dystrophy 3, digenic, 619477 (3), digenic
FLJ11273	AD	leukodystrophy, hypomyelinating, 16, 617964 (3),
FLJ11274		
FLJ11275		
FLJ11277	AR	immunodeficiency 91 and hyperinflammation, 619644 (3),
FLJ11280		
FLJ11281	AR	neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies, 617527 (3),
FLJ11282		
FLJ11286		
FLJ11294		
FLJ11301		
FLJ11304		
FLJ11305		
FLJ11307		
FLJ11315		
FLJ11316		
FLJ11320	AR	congenital disorder of glycosylation, type iic, 266265 (3),
FLJ11323		
FLJ11328	AD	deafness, 85, 620227 (3),
FLJ11342		
FLJ11350		
FLJ11360	AR	severe combined immunodeficiency, athabascan type, 602450 (3), ; omenn syndrome, 603554 (3),
FLJ11362	XLR,XL	shukla-vernon syndrome, 301029 (3),
FLJ11383		
FLJ11391		
FLJ11413		
FLJ11429		
FLJ11457	AR,AD	short-rib thoracic dysplasia 4 with or without polydactyly, 613819 (3), ; nephronophthisis 12, 613820 (3),
FLJ11467		
FLJ11477		
FLJ11485		
FLJ11500		
FLJ11506	AD	keratoderma, palmoplantar, punctate type ia, 148600 (3),
FLJ11526		
FLJ11535		
FLJ11539		
FLJ11543		
FLJ11560		
FLJ11564		
FLJ11565		
FLJ11577		
FLJ11595		
FLJ11598		
FLJ11601	AR	spinocerebellar ataxia, 28, 618800 (3),
FLJ11608		
FLJ11618		
FLJ11619		
FLJ11656	AR	vascular malformation, primary intraosseous, 606893 (3),
FLJ11665	AD,AR	triphalangeal thumb, type i, 174500 (3), ; syndactyly, type iv, 186200 (3), ; laurin-sandrow syndrome, 135750 (3), ; hypoplastic or aplastic tibia with polydactyly, 188740 (3), ; polydactyly, preaxial type ii, 174500 (3), ; acheiropody, 200500 (3), ; triphalangeal thumb-polysyndactyly syndrome, 190605 (3),
FLJ11712	AR	aicardi-goutieres syndrome 2, 610181 (3),
FLJ11729	AR	harp syndrome, 607236 (3), ; neurodegeneration with brain iron accumulation 1, 234200 (3),
FLJ11730		
FLJ11749		
FLJ11751		
FLJ11752	AR	geroderma osteodysplasticum, 231070 (3),
FLJ11753		
FLJ11767		
FLJ11773		
FLJ11785	AR	infantile liver failure syndrome 3, 618641 (3),
FLJ11790	AD,AR	mitral valve prolapse 2, 607829 (3), ; van maldergem syndrome 1, 601390 (3),
FLJ11795		
FLJ11798		
FLJ11806	AR	intellectual developmental disorder, 56, 617125 (3),
FLJ11807		
FLJ11808	AR	glutaric aciduria iii, 231690 (3),
FLJ11811		
FLJ11824	AD	intellectual developmental disorder with autistic features and language delay, with or without seizures, 618906 (3),
FLJ11830		
FLJ11834		
FLJ11838	AR	cardiomyopathy, dilated, 2c, 618189 (3),
FLJ11848		
FLJ11856	AR	brown-vialetto-van laere syndrome 2, 614707 (3),
FLJ11867		
FLJ11895	AR	steel syndrome, 615155 (3),
FLJ11896		
FLJ11937		
FLJ11979		
FLJ12042		
FLJ12056		
FLJ12082		
FLJ12085		
FLJ12089		
FLJ12116		
FLJ12118	AR	combined oxidative phosphorylation deficiency 27, 616672 (3),
FLJ12150		
FLJ12155	AD	intellectual developmental disorder with hypotonia, impaired speech, and dysmorphic facies, 619556 (3),
FLJ12168		
FLJ12171		
FLJ12178		
FLJ12179		
FLJ12189	AR	combined oxidative phosphorylation deficiency 40, 618835 (3),
FLJ12229	AR	nephrotic syndrome, type 9, 615573 (3),
FLJ12240	AR	?spondyloepimetaphyseal dysplasia, krakow type, 618162 (3),
FLJ12242	AD	dystonia 26, myoclonic, 616398 (3),
FLJ12254		
FLJ12255		
FLJ12270		
FLJ12286	AR	deafness, 119, 619615 (3), ; neurodevelopmental disorder with hearing loss and spasticity, 619616 (3),
FLJ12287	AR	retinitis pigmentosa 35, 610282 (3), ; cone-rod dystrophy 10, 610283 (3),
FLJ12296		
FLJ12298		
FLJ12343		
FLJ12377	AR	neurodevelopmental disorder with dysmorphic features, spasticity, and brain abnormalities, 615802 (3),
FLJ12383		
FLJ12386	AR	nephrotic syndrome, type 21, 618594 (3),
FLJ12387	AR	spastic paraplegia, optic atrophy, and neuropathy, 609541 (3),
FLJ12389		
FLJ12406		
FLJ12407		
FLJ12419		
FLJ12428		
FLJ12433,MGC2654		
FLJ12436		
FLJ12438		
FLJ12439	AR	spinocerebellar ataxia, with axonal neuropathy 3, 618387 (3),
FLJ12443		
FLJ12450		
FLJ12455		
FLJ12457		
FLJ12460	AD,AR	optic atrophy plus syndrome, 125250 (3), ; {glaucoma, normal tension, susceptibility to}, 606657 (3); optic atrophy 1, 165500 (3), ; behr syndrome, 210000 (3), ; ?mitochondrial dna depletion syndrome 14 (encephalocardiomyopathic type), 616896 (3),
FLJ12474		
FLJ12476		
FLJ12484		
FLJ12488		
FLJ12496		
FLJ12505		
FLJ12519		
FLJ12525	XLR,XL	wilson-turner syndrome, 309585 (3),
FLJ12528	AR	combined oxidative phosphorylation deficiency 21, 615918 (3),
FLJ12530	XL,XLR	?intellectual developmental disorder, 100, 300923 (3),
FLJ12539		
FLJ12541	AR	microphthalmia, syndromic 9, 601186 (3), ; microphthalmia, isolated, with coloboma 8, 601186 (3),
FLJ12549	AR	nephrotic syndrome, type 17, 618176 (3),
FLJ12552		
FLJ12560		
FLJ12562		
FLJ12565		
FLJ12568		
FLJ12571	AR	biliary, renal, neurologic, and skeletal syndrome, 619534 (3),
FLJ12577		
FLJ12581		
FLJ12582		
FLJ12584	AR	joubert syndrome 30, 617622 (3),
FLJ12587		
FLJ12592		
FLJ12597	AD	cornelia de lange syndrome 1, 122470 (3),
FLJ12598		
FLJ12604		
FLJ12610		severe combined immunodeficiency with microcephaly, growth retardation, and sensitivity to ionizing radiation, 611291 (3)
FLJ12614	AR	robinow syndrome, 2, 618529 (3),
FLJ12615		
FLJ12618	AR	l-2-hydroxyglutaric aciduria, 236792 (3),
FLJ12627		
FLJ12628		
FLJ12634		
FLJ12643	AR	cone-rod dystrophy and hearing loss, 617236 (3),
FLJ12644		
FLJ12649		
FLJ12650		
FLJ12655	XL,XLR	?intellectual developmental disorder, 100, 300923 (3),
FLJ12660	AR	mitochondrial complex i deficiency, nuclear type 21, 618242 (3),
FLJ12666		
FLJ12668		
FLJ12671		
FLJ12681	AR	lipase deficiency, combined, 246650 (3),
FLJ12684	AR	myopathy with extrapyramidal signs, 615673 (3),
FLJ12688		
FLJ12691		
FLJ12699	AR	neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies, 617527 (3),
FLJ12701	AR	combined oxidative phosphorylation deficiency 16, 615395 (3),
FLJ12709		
FLJ12716	AR	muscular dystrophy, limb-girdle, 18, 615356 (3),
FLJ12729		
FLJ12732		
FLJ12734	AR	multiple mitochondrial dysfunctions syndrome 3, 615330 (3), ; ?spastic paraplegia 74, 616451 (3),
FLJ12735		
FLJ12740		
FLJ12748		
FLJ12750		
FLJ12752		
FLJ12756		
FLJ12758		
FLJ12760		
FLJ12761		
FLJ12765		
FLJ12768		
FLJ12785		
FLJ12787		
FLJ12793		
FLJ12796		
FLJ12806		
FLJ12810	AR	dyskeratosis congenita, 8, 620133 (3),
FLJ12816		
FLJ12820		
FLJ12827	AR,AD	retinitis pigmentosa 72, 616469 (3), ; ?exudative vitreoretinopathy 6, 616468 (3),
FLJ12838		
FLJ12841	AD	?epilepsy, myoclonic, familial adult, 4, 615127 (3),
FLJ12847	AR	microcephaly 1, primary, 251200 (3),
FLJ12851		
FLJ12870		
FLJ12875		
FLJ12876		
FLJ12879	AD	kleefstra syndrome 1, 610253 (3),
FLJ12886	AR	heart and brain malformation syndrome, 616920 (3), ; neurodevelopmental disorder with intention tremor, pyramidal signs, dyspraxia, and ocular anomalies, 619995 (3),
FLJ12888		
FLJ12892		
FLJ12894	AD	intellectual developmental disorder, 41, 616944 (3), ; pierpont syndrome, 602342 (3),
FLJ12899		
FLJ12903		
FLJ12910		
FLJ12929	AD	oculopharyngodistal myopathy 1, 164310 (3),
FLJ12944		
FLJ12957		
FLJ12967		
FLJ12969		
FLJ12972		
FLJ12973		
FLJ12974		
FLJ12975	AR	joubert syndrome 24, 616654 (3), ; ?meckel syndrome 8, 613885 (3),
FLJ12979	AR	?intellectual developmental disorder with short stature and variable skeletal anomalies, 618453 (3),
FLJ12987		
FLJ12993		
FLJ12994	AD	intellectual developmental disorder, 71, with behavioral abnormalities, 620330 (3),
FLJ12998		
FLJ13008		
FLJ13012		
FLJ13018		
FLJ13022		
FLJ13031		
FLJ13036		
FLJ13044	AR	developmental and epileptic encephalopathy 3, 609304 (3),
FLJ13045		
FLJ13046		
FLJ13052		
FLJ13057		
FLJ13058	AD	acces syndrome, 619959 (3),
FLJ13063	AD	acth-independent macronodular adrenal hyperplasia 2, 615954 (3), somatic mutation,
FLJ13070	AD	ceroid lipofuscinosis, neuronal, 4 (kufs type), 162350 (3),
FLJ13081		
FLJ13087		
FLJ13089		
FLJ13092		
FLJ13094	AR	ciliary dyskinesia, primary, 17, 614679 (3),
FLJ13096	AR	woodhouse-sakati syndrome, 241080 (3),
FLJ13102	AD,AR	developmental delay and seizures with or without movement abnormalities, 617836 (3), ; ?congenital disorder of glycosylation, type 1bb, 613861 (3), ; retinitis pigmentosa 59, 613861 (3),
FLJ13110	AD,AR	?neuronopathy, distal hereditary motor, type vb, 614751 (3), ; spastic paraplegia 31, 610250 (3), ; spinal muscular atrophy, distal, 6, 620011 (3),
FLJ13111	AR	?short stature and microcephaly with genital anomalies, 618702 (3),
FLJ13117		
FLJ13119	AR	shwachman-diamond syndrome 2, 617941 (3),
FLJ13130		
FLJ13134		
FLJ13142	AR	?muscular dystrophy, with rigid spine and distal joint contractures, 617072 (3),
FLJ13149		
FLJ13150		
FLJ13152	AD,AR	neutropenia, severe congenital, 9, 619813 (3), ; 3-methylglutaconic aciduria, type viib, 616271 (3), ; 3-methylglutaconic aciduria, type viia, 619835 (3),
FLJ13154	AR	poikiloderma with neutropenia, 604173 (3),
FLJ13158		
FLJ13159		
FLJ13163		
FLJ13164		
FLJ13171		
FLJ13181		
FLJ13187		
FLJ13189		
FLJ13193		
FLJ13194		
FLJ13203		
FLJ13204		
FLJ13219		
FLJ13220	AR	?developmental and epileptic encephalopathy 40, 617065 (3),
FLJ13222		
FLJ13231	AR	orofaciodigital syndrome vi, 277170 (3), ; joubert syndrome 17, 614615 (3),
FLJ13244	AR	myasthenic syndrome, congenital, 24, presynaptic, 618198 (3),
FLJ13253		
FLJ13258		
FLJ13265		
FLJ13273		
FLJ13287		
FLJ13288		
FLJ13291	AR	epilepsy, progressive myoclonic, 12, 619191 (3),
FLJ13297		
FLJ13305	AR	retinitis pigmentosa 28, 606068 (3),
FLJ13308	AD	?epilepsy, myoclonic, familial adult, 4, 615127 (3),
FLJ13311		
FLJ13322		
FLJ13335	AR	cataract 18, 610019 (3),
FLJ13340	AD	intellectual developmental disorder, 50, with behavioral abnormalities, 617787 (3),
FLJ13352	AR	kahrizi syndrome, 612713 (3), ; congenital disorder of glycosylation, type iq, 612379 (3),
FLJ13354	AD	cornelia de lange syndrome 1, 122470 (3),
FLJ13386	AR	?seckel syndrome 6, 614728 (3),
FLJ13391		
FLJ13397		
FLJ13409		
FLJ13421		
FLJ13425	AR	neuropathy, hereditary sensory and autonomic, type vi, 614653 (3), ; epidermolysis bullosa simplex 3, localized or generalized intermediate, with bp230 deficiency, 615425 (3),
FLJ13433		
FLJ13441		
FLJ13447	AR	combined oxidative phosphorylation deficiency 40, 618835 (3),
FLJ13449		
FLJ13450		
FLJ13451		
FLJ13456		
FLJ13465		
FLJ13479	AR	neurodevelopmental disorder with poor growth, large ears, and dysmorphic facies, 620194 (3),
FLJ13502		
FLJ13511		
FLJ13518		
FLJ13529		
FLJ13540		
FLJ13541	AD	neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies, 618659 (3),
FLJ13568		
FLJ13593		
FLJ13599	AD	singleton-merten syndrome 2, 616298 (3),
FLJ13607		
FLJ13612		
FLJ13614		
FLJ13615	AR	leber congenital amaurosis 10, 611755 (3); joubert syndrome 5, 610188 (3), ; senior-loken syndrome 6, 610189 (3), ; ?bardet-biedl syndrome 14, 615991 (3), ; meckel syndrome 4, 611134 (3),
FLJ13621	AR	microcephaly 8, primary, 614673 (3),
FLJ13624		
FLJ13633		
FLJ13639		
FLJ13648	AD	cornelia de lange syndrome 1, 122470 (3),
FLJ13649		
FLJ13660		
FLJ13687	AD	deafness, 80, 619274 (3), ; renal hypodysplasia/aplasia 3, 617805 (3),
FLJ13693		
FLJ13703		
FLJ13705		
FLJ13710	AD	aortic aneurysm, familial thoracic 12, 619825 (3),
FLJ13725		
FLJ13732		
FLJ13758		
FLJ13782	AD,AR	deafness, 28, 608641 (3), ; ectodermal dysplasia/short stature syndrome, 616029 (3), ; corneal dystrophy, posterior polymorphous, 4, 618031 (3),
FLJ13784		
FLJ13787		
FLJ13791		
FLJ13798		
FLJ13824		
FLJ13839	AR	simha syndrome, 619557 (3),
FLJ13840		
FLJ13841		?seborrhea-like dermatitis with psoriasiform elements, 610227 (3)
FLJ13848		
FLJ13852		
FLJ13855		
FLJ13859	AR	ciliary dyskinesia, primary, 45, 618801 (3),
FLJ13861		
FLJ13874		
FLJ13881	AD	?peripheral neuropathy, myopathy, hoarseness, and hearing loss, 614369 (3), ; deafness, 4a, 600652 (3),
FLJ13902		
FLJ13906		
FLJ13910		
FLJ13912		
FLJ13953		
FLJ13954		
FLJ13956		
FLJ13962	AD	neuronopathy, distal hereditary motor, type iid, 615575 (3),
FLJ13975		
FLJ13984		
FLJ13990	AR	combined oxidative phosphorylation deficiency 16, 615395 (3),
FLJ13995	AR	myopathy, lactic acidosis, and sideroblastic anemia 2, 613561 (3),
FLJ13998	AR	dyskeratosis congenita, 8, 620133 (3),
FLJ14000		
FLJ14001		
FLJ14005		
FLJ14006		
FLJ14009	AR	oocyte/zygote/embryo maturation arrest 15, 616814 (3),
FLJ14010	AD	neurodevelopmental disorder with dysmorphic facies and thin corpus callosum, 619480 (3),
FLJ14011		
FLJ14027		mucoepidermoid salivary gland carcinoma (3)
FLJ14038		
FLJ14040	AD	li-ghorgani-weisz-hubshman syndrome, 618974 (3),
FLJ14051		
FLJ14054	AR	boudin-mortier syndrome, 619543 (3),
FLJ14062		
FLJ14075		
FLJ14079		
FLJ14103		
FLJ14127		
FLJ14153		
FLJ14154		
FLJ14178		
FLJ14195		
FLJ14199		
FLJ14203		
FLJ14204	XL,XLR	?intellectual developmental disorder, 100, 300923 (3),
FLJ14213		
FLJ14217	AR	?intellectual developmental disorder with short stature and variable skeletal anomalies, 618453 (3),
FLJ14220		
FLJ14226		
FLJ14251		
FLJ14260		
FLJ14281		
FLJ14295		
FLJ14298		
FLJ14299		
FLJ14303		
FLJ14314	AD	developmental delay with or without intellectual impairment or behavioral abnormalities, 619575 (3),
FLJ14346		
FLJ14360		
FLJ14374		
FLJ14385		
FLJ14390		
FLJ14393		
FLJ14399		
FLJ14400		
FLJ14408		
FLJ14415		
FLJ14428	AR	t-cell lymphoma, subcutaneous panniculitis-like, 618398 (3),
FLJ14431		
FLJ14440		
FLJ14442		
FLJ14445		
FLJ14454		
FLJ14464		
FLJ14466	AR,AD	immunodeficiency 9, 612782 (3), ; myopathy, tubular aggregate, 2, 615883 (3),
FLJ14471		
FLJ14490	AR	neurodevelopmental disorder with progressive microcephaly, spasticity, and brain abnormalities, 616486 (3),
FLJ14491	AD	?deafness, 72, 617606 (3),
FLJ14494		
FLJ14497		
FLJ14502		?roifman-chitayat syndrome, digenic, 613328 (3), digenic
FLJ14511	AR	congenital disorder of glycosylation, type ii, 607906 (3), ; myasthenic syndrome, congenital, 14, with tubular aggregates, 616228 (3),
FLJ14528		
FLJ14541		
FLJ14547		
FLJ14564		
FLJ14566	AR	muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 8, 614830 (3), ; muscular dystrophy-dystroglycanopathy (limb-girdle) type c, 8, 618135 (3),
FLJ14576		
FLJ14578		
FLJ14585		
FLJ14590		
FLJ14594	AR	intellectual developmental disorder, 64, 618103 (3),
FLJ14596		
FLJ14600	AR	hyperekplexia 4, 618011 (3),
FLJ14602	AR	neutropenia, severe congenital, 6, 616022 (3),
FLJ14611		
FLJ14621		
FLJ14623		
FLJ14624		
FLJ14627		
FLJ14639		
FLJ14640		
FLJ14651		
FLJ14662		
FLJ14668		
FLJ14675	AR	dystonia 31, 619565 (3),
FLJ14681		
FLJ14686		
FLJ14688		
FLJ14697		
FLJ14700	AR	combined oxidative phosphorylation deficiency 23, 616198 (3),
FLJ14708		
FLJ14728		
FLJ14733		
FLJ14736	AR	immunodeficiency-centromeric instability-facial anomalies syndrome 3, 616910 (3),
FLJ14743		
FLJ14744	AR	microcephaly, short stature, and impaired glucose metabolism 2, 616817 (3),
FLJ14751		
FLJ14752		
FLJ14753		
FLJ14767		
FLJ14768		
FLJ14771		
FLJ14777		
FLJ14784		
FLJ14797	AR	microcephaly and chorioretinopathy, 3, 616335 (3),
FLJ14810		
FLJ14813		
FLJ14824		
FLJ14840	AR	cholestasis, progressive familial intrahepatic, 9, 619849 (3),
FLJ14846		
FLJ14848	AR	keratoderma-ichthyosis-deafness syndrome, 620009 (3), ; cholestasis, progressive familial intrahepatic, 12, 620010 (3), ; arthrogryposis, renal dysfunction, and cholestasis 1, 208085 (3),
FLJ14867		
FLJ14885		
FLJ14886		
FLJ14888	AR	galloway-mowat syndrome 1, 251300 (3),
FLJ14902		
FLJ14904		
FLJ14909	AR	inflammatory poikiloderma with hair abnormalities and acral keratoses, 620199 (3),
FLJ14917	AR	3-methylglutaconic aciduria with deafness, encephalopathy, and leigh-like syndrome, 614739 (3),
FLJ14920		
FLJ14923	AR	cone-rod dystrophy 20, 615973 (3),
FLJ14927	AR	fraser syndrome 1, 219000 (3),
FLJ14936		
FLJ14937	AR	lethal congenital contracture syndrome 9, 616503 (3),
FLJ14957		
FLJ14966		
FLJ14972		
FLJ14991		
FLJ14993	AR	amelogenesis imperfecta, type iiic, 618386 (3),
FLJ14996		
FLJ16025		
FLJ16030		
FLJ16052		
FLJ16056		
FLJ16057		
FLJ16061		
FLJ16069		
FLJ16103	AD	?deafness, 88, 620283 (3),
FLJ16107	AR	oocyte/zygote/embryo maturation arrest 5, 617996 (3),
FLJ16119		
FLJ16123		
FLJ16165		
FLJ16213		
FLJ16224		
FLJ16237		
FLJ16239	XLD,XL	?chondrodysplasia with platyspondyly, distinctive brachydactyly, hydrocephaly, and microphthalmia, 300863 (3),
FLJ16331		
FLJ16355		
FLJ16363	AR	weill-marchesani 4 syndrome, 613195 (3),
FLJ16517		
FLJ16518		
FLJ16566	AR	neurodevelopmental disorder with hypotonia, facial dysmorphism, and brain abnormalities, 619383 (3),
FLJ16641		
FLJ16665		
FLJ16686		
FLJ16752		
FLJ16786	AR	focal segmental glomerulosclerosis 9, 616220 (3), ; ventriculomegaly with cystic kidney disease, 219730 (3),
FLJ16792		
FLJ16793		
FLJ16806		
FLJ20003		
FLJ20008	AR	pituitary hormone deficiency, combined or isolated, 7, 618160 (3),
FLJ20013		
FLJ20014		
FLJ20015		
FLJ20022		
FLJ20025		
FLJ20027		
FLJ20032	AR	myelodysplastic syndrome, somatic, 614286 (3); immunodeficiency 75, 619126 (3),
FLJ20033		
FLJ20035		
FLJ20036		
FLJ20037	AR	osteogenesis imperfecta, type xviii, 617952 (3),
FLJ20038		
FLJ20040		
FLJ20041	AD	progressive familial heart block, type ib, 604559 (3), ; erythrokeratodermia variabilis et progressiva 6, 618531 (3),
FLJ20043	AD	lower urinary tract obstruction, congenital, 618612 (3),
FLJ20045		
FLJ20047		
FLJ20048		
FLJ20052	AD	fibrosis of extraocular muscles, congenital, 3b, 135700 (3), ; fibrosis of extraocular muscles, congenital, 1, 135700 (3),
FLJ20053		
FLJ20054		
FLJ20055		
FLJ20059	AR,AD	cardiomyopathy, familial hypertrophic, 29, with polyglucosan bodies, 620236 (3), ; epidermolysis bullosa simplex 6, generalized intermediate, with or without cardiomyopathy, 617294 (3),
FLJ20060		
FLJ20061	AR	combined oxidative phosphorylation deficiency 35, 617873 (3),
FLJ20068		
FLJ20069	AR	joubert syndrome 3, 608629 (3),
FLJ20071	AR	smith-mccort dysplasia, 607326 (3), ; dyggve-melchior-clausen disease, 223800 (3),
FLJ20073	AR,AD	tumoral calcinosis, familial, normophosphatemic, 610455 (3), ; monosomy 7 myelodysplasia and leukemia syndrome 2, 619041 (3), ; mirage syndrome, 617053 (3),
FLJ20075		
FLJ20080		
FLJ20089		
FLJ20097	AR	neurodevelopmental disorder with microcephaly, seizures, and neonatal cholestasis, 619685 (3),
FLJ20101	AR	microhydranencephaly, 605013 (3), ; lissencephaly 4 (with microcephaly), 614019 (3),
FLJ20103	AD	deafness, 85, 620227 (3),
FLJ20105		
FLJ20113		
FLJ20116	AR	kindler syndrome, 173650 (3),
FLJ20121		
FLJ20124		
FLJ20126		
FLJ20127		
FLJ20128	AR	hengel-maroofian-schols syndrome, 619641 (3),
FLJ20129	AD	{lumbar disc degeneration}, 603932 (3); {osteoarthritis susceptibility 3}, 607850 (3),
FLJ20132		
FLJ20135		
FLJ20136	AR	parkinson disease 23, early onset, 616840 (3),
FLJ20142	AR	spinocerebellar ataxia, 27, 618369 (3),
FLJ20147	AR	finca syndrome, 618278 (3),
FLJ20150		
FLJ20152	AR	neuropathy, hereditary sensory and autonomic, type iib, 613115 (3),
FLJ20154		
FLJ20157	AR	ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia, 208920 (3),
FLJ20159		
FLJ20160		
FLJ20163		
FLJ20170	AR	ovarian dysgenesis 4, 616185 (3),
FLJ20171	AR	?deafness, 109, 618013 (3),
FLJ20174		
FLJ20177		
FLJ20184		
FLJ20185		
FLJ20185k		
FLJ20188		
FLJ20189		
FLJ20190		
FLJ20199		
FLJ20202		
FLJ20203		
FLJ20207		
FLJ20211		
FLJ20212	AR	suleiman-el-hattab syndrome, 618950 (3),
FLJ20216		
FLJ20217		
FLJ20219		
FLJ20221		
FLJ20222		
FLJ20224		
FLJ20225		
FLJ20226		
FLJ20230		
FLJ20232		
FLJ20241	AR	intellectual developmental disorder, 3, 608443 (3),
FLJ20244	AR	intellectual developmental disorder, 68, 618302 (3),
FLJ20247		
FLJ20251		
FLJ20254		
FLJ20257		
FLJ20258		
FLJ20259	AD	ververi-brady syndrome, 617982 (3),
FLJ20261		
FLJ20262	AR	hypotonia, hypoventilation, impaired intellectual development, dysautonomia, epilepsy, and eye abnormalities, 618493 (3),
FLJ20265	AR	[blood group, emm system], 619812 (3), ; neurodevelopmental disorder with or without hypotonia, seizures, and cerebellar atrophy, 616917 (3),
FLJ20271		
FLJ20273		
FLJ20274	AR	neurodevelopmental disorder with speech delay and variable ocular anomalies, 619989 (3),
FLJ20275		
FLJ20276		
FLJ20277	AR	muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 3, 613157 (3), ; muscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type b, 3, 613151 (3), ; retinitis pigmentosa 76, 617123 (3), ; muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 3, 253280 (3),
FLJ20279		
FLJ20281		
FLJ20283		
FLJ20284		
FLJ20285	XLD,XL	microphthalmia, syndromic 2, 300166 (3),
FLJ20287		
FLJ20288		
FLJ20294		
FLJ20296		
FLJ20297	AR	neurodevelopmental disorder with microcephaly, arthrogryposis, and structural brain anomalies, 618622 (3),
FLJ20298	XL	nephrotic syndrome, type 20, 301028 (3),
FLJ20300		
FLJ20301		
FLJ20302		
FLJ20303	AR	intellectual developmental disorder, 5, 611091 (3),
FLJ20307	AR	simha syndrome, 619557 (3),
FLJ20308		
FLJ20309		
FLJ20311	AR	khan-khan-katsanis syndrome, 618460 (3),
FLJ20315	AD	sessile serrated polyposis cancer syndrome, 617108 (3),
FLJ20318		
FLJ20320		
FLJ20321		
FLJ20323		
FLJ20330		
FLJ20333		
FLJ20335		
FLJ20337		
FLJ20340		
FLJ20342		
FLJ20343	AR	mitochondrial complex iii deficiency, nuclear type 2, 615157 (3),
FLJ20344		
FLJ20345	AR	bardet-biedl syndrome 13, 615990 (3), ; meckel syndrome 1, 249000 (3), ; joubert syndrome 28, 617121 (3),
FLJ20353		
FLJ20354		
FLJ20357	AD	hypogonadotropic hypogonadism 5 with or without anosmia, 612370 (3), ; charge syndrome, 214800 (3),
FLJ20359		
FLJ20361	AD	hypogonadotropic hypogonadism 5 with or without anosmia, 612370 (3), ; charge syndrome, 214800 (3),
FLJ20364		
FLJ20366		
FLJ20370		
FLJ20371	AR	proliferative vasculopathy and hydranencephaly-hydrocephaly syndrome, 225790 (3),
FLJ20374		
FLJ20375	AR	liver disease, severe congenital, 619991 (3),
FLJ20382		
FLJ20383		
FLJ20391		
FLJ20392	AR	structural heart defects and renal anomalies syndrome, 617478 (3),
FLJ20396		
FLJ20397	AR	ciliary dyskinesia, primary, 18, 614874 (3),
FLJ20399		
FLJ20400		
FLJ20401		
FLJ20403		
FLJ20406		
FLJ20408		
FLJ20419		
FLJ20420		
FLJ20421	AR	chondrodysplasia with joint dislocations, gpapp type, 614078 (3),
FLJ20422		
FLJ20424		
FLJ20431		
FLJ20432	AR	combined oxidative phosphorylation deficiency 30, 616974 (3),
FLJ20435		
FLJ20436		
FLJ20442		
FLJ20445		
FLJ20446	AR	neurodegeneration, childhood-onset, stress-induced, with variable ataxia and seizures, 618170 (3),
FLJ20449		
FLJ20450	AR	hyperuricemia, pulmonary hypertension, renal failure, and alkalosis, 613845 (3),
FLJ20451		
FLJ20452		
FLJ20455		
FLJ20456	AD	tenorio syndrome, 616260 (3),
FLJ20457		
FLJ20459	AR	?sudden cardiac failure, alcohol-induced, 617223 (3), ; sudden cardiac failure, infantile, 617222 (3),
FLJ20467	AR	ciliary dyskinesia, primary, 26, 615500 (3),
FLJ20473		
FLJ20476		
FLJ20477	AR	hyperphosphatasia with impaired intellectual development syndrome 1, 239300 (3),
FLJ20479	AR	dyskeratosis congenita, 2, 613987 (3),
FLJ20480		
FLJ20481		
FLJ20484		
FLJ20485	AR	intellectual developmental disorder with abnormal behavior, microcephaly, and short stature, 618342 (3),
FLJ20487	AD	paragangliomas 2, 601650 (3),
FLJ20489		
FLJ20493		
FLJ20495		
FLJ20500		
FLJ20502		
FLJ20503		
FLJ20505		
FLJ20506		
FLJ20507	AD	{pheochromocytoma, susceptibility to}, 171300 (3),
FLJ20508		
FLJ20509		
FLJ20510	AR	oocyte/zygote/embryo maturation arrest 18, 620332 (3),
FLJ20511		
FLJ20512		
FLJ20513		
FLJ20514		
FLJ20515		
FLJ20516		
FLJ20517		
FLJ20522		
FLJ20527	XL	?spermatogenic failure, 7, 301106 (3)
FLJ20530	AR	?neurodevelopmental disorder with cerebellar hypoplasia and spasticity, 618572 (3),
FLJ20531		
FLJ20532		
FLJ20533	AR	mitochondrial complex v (atp synthase) deficiency, nuclear type 2, 614052 (3),
FLJ20534		
FLJ20535	AR	ciliary dyskinesia, primary, 45, 618801 (3),
FLJ20538		
FLJ20539		
FLJ20542		
FLJ20546	AR	spinocerebellar ataxia, 28, 618800 (3),
FLJ20550		
FLJ20551	AR	anemia, sideroblastic, 2, pyridoxine-refractory, 205950 (3),
FLJ20552		
FLJ20555		
FLJ20556		
FLJ20559		
FLJ20561	AR	ceroid lipofuscinosis, neuronal, 6b (kufs type), 204300 (3), ; ceroid lipofuscinosis, neuronal, 6a, 601780 (3),
FLJ20565		
FLJ20568		
FLJ20571		
FLJ20573		
FLJ20574		
FLJ20578		
FLJ20581		
FLJ20585		
FLJ20590		
FLJ20591		
FLJ20602		
FLJ20604		
FLJ20605		
FLJ20607		
FLJ20608		
FLJ20611		
FLJ20612		
FLJ20615		
FLJ20618		
FLJ20623		
FLJ20624		
FLJ20625		
FLJ20627	AR	combined oxidative phosphorylation deficiency 11, 614922 (3),
FLJ20628		
FLJ20631	XL,XLR	?intellectual developmental disorder, 100, 300923 (3),
FLJ20636		
FLJ20637		
FLJ20639		
FLJ20641		
FLJ20643		
FLJ20644	AD,AR	spermatogenic failure 36, 618420 (3), ; myoectodermal gonadal dysgenesis syndrome, 618419 (3),
FLJ20645		
FLJ20651		
FLJ20654		
FLJ20657		
FLJ20665		
FLJ20666		
FLJ20668		
FLJ20683	AR	osteogenesis imperfecta, type xi, 610968 (3), ; bruck syndrome 1, 259450 (3),
FLJ20693		
FLJ20695	AR	peroxisome biogenesis disorder 7b, 614873 (3), ; peroxisome biogenesis disorder 7a (zellweger), 614872 (3),
FLJ20696		
FLJ20701		
FLJ20705	AD	chung-jansen syndrome, 617991 (3),
FLJ20706		
FLJ20707		
FLJ20713		
FLJ20718	AR	diamond-blackfan anemia 21, 620072 (3),
FLJ20719		
FLJ20725		
FLJ20730		
FLJ20731	AR	ehlers-danlos syndrome, kyphoscoliotic type, 2, 614557 (3),
FLJ20733	AR	xanthinuria, type ii, 603592 (3),
FLJ20736		
FLJ20737		
FLJ20746		
FLJ20748		
FLJ20752		
FLJ20753	AR	ciliary dyskinesia, primary, 15, 613808 (3),
FLJ20755		
FLJ20756	AR	neurodevelopmental disorder with microcephaly, arthrogryposis, and structural brain anomalies, 618622 (3),
FLJ20758	AR	?combined oxidative phosphorylation deficiency 51, 619057 (3),
FLJ20764		
FLJ20772		
FLJ20778		
FLJ20783		
FLJ20793		
FLJ20796	AR	mitochondrial complex iii deficiency, nuclear type 8, 615838 (3),
FLJ20798	AD	aortic valve disease 3, 618496 (3),
FLJ20811		
FLJ20822	AR	striatonigral degeneration, infantile, 271930 (3),
FLJ20831	AR	frank-ter haar syndrome, 249420 (3),
FLJ20847		
FLJ20859		
FLJ20871	AR	?lipodystrophy, familial partial, type 5, 615238 (3),
FLJ20896		
FLJ20897		
FLJ20898		
FLJ20920		
FLJ20940		
FLJ20957		
FLJ20958		
FLJ20967		
FLJ20977		
FLJ20980	AD	?ptosis, congenital, 178300 (2),
FLJ20984		
FLJ20992		
FLJ20998		
FLJ21007		
FLJ21016	AD	skraban-deardorff syndrome, 617616 (3),
FLJ21032	AD	?deafness, 79, 619086 (3),
FLJ21034		
FLJ21044	AR	gaze palsy, familial horizontal, with progressive scoliosis, 1, 607313 (3),
FLJ21047		
FLJ21062	AR	spermatogenic failure 24, 617959 (3),
FLJ21065		
FLJ21076		
FLJ21087		
FLJ21099	AD	zttk syndrome, 617140 (3),
FLJ21103		
FLJ21108	AR	?immunodeficiency 99 with hypogammaglobulinemia and autoimmune cytopenias, 619846 (3),
FLJ21127	AR	joubert syndrome 13, 614173 (3),
FLJ21128	AR	?intellectual developmental disorder, 50, 616460 (3),
FLJ21129		
FLJ21135		
FLJ21144		
FLJ21145		
FLJ21148		
FLJ21150		
FLJ21156		
FLJ21159		
FLJ21162		
FLJ21168		
FLJ21195	AD	tooth agenesis, selective, 9, 617275 (3),
FLJ21201		
FLJ21213		
FLJ21219		
FLJ21230		
FLJ21240		
FLJ21255		
FLJ21269		
FLJ21302		
FLJ21313		
FLJ21324	AR	neuropathy, hereditary motor and sensory, type vic, with optic atrophy, 618511 (3),
FLJ21329		
FLJ21347		
FLJ21353		
FLJ21404	AR	alkuraya-kucinskas syndrome, 617822 (3),
FLJ21430		
FLJ21438		
FLJ21439	AR	amyotrophic lateral sclerosis 5, juvenile, 602099 (3), ; charcot-marie-tooth disease, axonal, type 2x, 616668 (3), ; spastic paraplegia 11, 604360 (3),
FLJ21458		
FLJ21474	AD	glass syndrome, 612313 (3),
FLJ21477		
FLJ21489	AR	neuropathy, hereditary sensory and autonomic, type vi, 614653 (3), ; epidermolysis bullosa simplex 3, localized or generalized intermediate, with bp230 deficiency, 615425 (3),
FLJ21511		
FLJ21522	AD	?hypotrichosis 5, 612841 (3),
FLJ21544	AR	netherton syndrome, 256500 (3),
FLJ21558	AR	spinal muscular atrophy with progressive myoclonic epilepsy, 159950 (3), ; farber lipogranulomatosis, 228000 (3),
FLJ21562		
FLJ21579		
FLJ21588		
FLJ21601		
FLJ21609		
FLJ21610		
FLJ21611		
FLJ21613		
FLJ21615		
FLJ21616		
FLJ21661	AR	combined oxidative phosphorylation deficiency 39, 618397 (3),
FLJ21662		
FLJ21667		
FLJ21675		
FLJ21709		
FLJ21736		
FLJ21739		
FLJ21744		
FLJ21759		
FLJ21763		
FLJ21770		
FLJ21776	AR,AD	gapo syndrome, 230740 (3), ; {?hemangioma, capillary infantile, susceptibility to}, 602089 (3),
FLJ21785		
FLJ21786		
FLJ21788	AR	?infantile liver failure syndrome 1, 615438 (3),
FLJ21791		
FLJ21801		
FLJ21802		
FLJ21811		
FLJ21816	AD	{breast cancer, susceptibility to}, 114480 (3), somatic mutation, ; {pancreatic cancer, susceptibility to, 3}, 613348 (3); fanconi anemia, complementation group n, 610832 (3)
FLJ21820		
FLJ21832	AR,AD	mitochondrial dna depletion syndrome 7 (hepatocerebral type), 271245 (3), ; progressive external ophthalmoplegia with mitochondrial dna deletions, 3, 609286 (3), ; perrault syndrome 5, 616138 (3),
FLJ21839	AR	retinitis pigmentosa 75, 617023 (3),
FLJ21841		
FLJ21850		
FLJ21865		
FLJ21868		
FLJ21869		
FLJ21877		
FLJ21879		
FLJ21882	AD,AR	pituitary hormone deficiency, combined or isolated, 8, 620303 (3), ; neurooculorenal syndrome, 620305 (3), ; ?nystagmus 8, congenital, 257400 (3),
FLJ21889		
FLJ21897	AR	noonan syndrome 14, 619745 (3),
FLJ21901		
FLJ21908		
FLJ21915	AD	acrofacial dysostosis, cincinnati type, 616462 (3),
FLJ21916		
FLJ21918		
FLJ21919		
FLJ21921	AD	treacher-collins syndrome 4, 618939 (3),
FLJ21924		
FLJ21925		
FLJ21934		
FLJ21935	AR	deafness 106, 617637 (3),
FLJ21939		
FLJ2194		
FLJ21945		
FLJ21952		
FLJ21959		
FLJ21963		
FLJ21967		
FLJ21972		
FLJ21977	AR,AD	?deafness, 88, 615429 (3), ; ?deafness, 81, 619500 (3),
FLJ21988		
FLJ21992		
FLJ21998		
FLJ22002		
FLJ22004		
FLJ22009		
FLJ22012		
FLJ22021		
FLJ22027		
FLJ22028	AR	myopathy, myofibrillar, 8, 617258 (3),
FLJ22029		
FLJ22031	AR	fraser syndrome 1, 219000 (3),
FLJ22035		
FLJ22036		
FLJ22041	AR	osteogenesis imperfecta, type xi, 610968 (3), ; bruck syndrome 1, 259450 (3),
FLJ22054		
FLJ22055		
FLJ22057		
FLJ22060		
FLJ22097	AR	microcephaly 14, primary, 616402 (3),
FLJ22104		
FLJ22116		
FLJ22125		
FLJ22139		
FLJ22151		
FLJ22153		
FLJ22167	AR	joubert syndrome 20, 614970 (3), ; meckel syndrome 11, 615397 (3),
FLJ22169		
FLJ22170	AR	cerebroretinal microangiopathy with calcifications and cysts, 612199 (3),
FLJ22171	AR	deafness 106, 617637 (3),
FLJ22174		
FLJ22175		
FLJ22187	AR,AD	3-methylglutaconic aciduria, type iii, 258501 (3), ; optic atrophy 3 with cataract, 165300 (3),
FLJ22191		
FLJ22195		
FLJ22196		
FLJ22197	AD	cimdag syndrome, 619273 (3),
FLJ22206	AD	chopra-amiel-gordon syndrome, 619504 (3),
FLJ22215	AR	neuropathy, hereditary motor, with myopathic features, 619216 (3),
FLJ22218		
FLJ22233		
FLJ22246		
FLJ22251		
FLJ22257	AD	{pheochromocytoma, susceptibility to}, 171300 (3),
FLJ22259	AD	brain small vessel disease 2, 614483 (3), ; {hemorrhage, intracerebral, susceptibility to}, 614519 (3)
FLJ22263	AD	sotos syndrome, 117550 (3),
FLJ22267		
FLJ22269		
FLJ22277		
FLJ22282		
FLJ22297	AD	cardiomyopathy, familial hypertrophic, 28, 619402 (3),
FLJ22298		
FLJ22302	AR	lipase deficiency, combined, 246650 (3),
FLJ22315		congenital disorder of glycosylation, type iih, 611182 (3)
FLJ22316		
FLJ22329	AR	brain small vessel disease 3, 618360 (3),
FLJ22341	AD	tylosis with esophageal cancer, 148500 (3),
FLJ22343		
FLJ22344		
FLJ22345		
FLJ22347		
FLJ22349	AR	osteogenesis imperfecta, type xxii, 619795 (3),
FLJ2235		
FLJ22351		
FLJ22353	AR	craniotubular dysplasia, ikegawa type, 619727 (3),
FLJ22354	AR	developmental and epileptic encephalopathy 49, 617281 (3),
FLJ22362		
FLJ22365	AR	carpenter syndrome 2, 614976 (3),
FLJ22369		
FLJ22386	AR	kohlschutter-tonz syndrome, 226750 (3),
FLJ22389		
FLJ22390		
FLJ22402		
FLJ22404		
FLJ22405	AD	{centronuclear myopathy, modifier of}, 160150 (3),
FLJ22407		
FLJ22408		
FLJ22415	AR	congenital short bowel syndrome, 615237 (3),
FLJ22416		
FLJ22418		
FLJ22422	AR	ciliary dyskinesia, primary, 29, 615872 (3),
FLJ22427		
FLJ22439		
FLJ22445	AR	joubert syndrome 15, 614464 (3),
FLJ22450		
FLJ22457		
FLJ22470		
FLJ22489	AR	?cardiomyopathy, dilated, 2b, 614672 (3),
FLJ22490	AR	joubert syndrome 21, 615636 (3),
FLJ22494		
FLJ22501	AR	hermansky-pudlak syndrome 6, 614075 (3),
FLJ22512		
FLJ22519		
FLJ22524		
FLJ22526		
FLJ22531	AR	hydatidiform mole, recurrent, 4, 618432 (3),
FLJ22548		
FLJ22555		
FLJ22557		
FLJ22559	AR	cerebroretinal microangiopathy with calcifications and cysts 2, 617341 (3),
FLJ22561		
FLJ22569		
FLJ22570		
FLJ22573		
FLJ22578		
FLJ22582		
FLJ22583	AR	?nephrotic syndrome, type 19, 618178 (3),
FLJ22588		
FLJ22589		
FLJ22595		
FLJ22597	AR	mitochondrial complex i deficiency, nuclear type 31, 618251 (3),
FLJ22604		
FLJ22609	AR	combined oxidative phosphorylation deficiency 48, 619012 (3),
FLJ22618	AR	?microcephaly 24, primary, 618179 (3),
FLJ22621	AR	bardet-biedl syndrome 22, 617119 (3), ; spermatogenic failure 58, 619585 (3), ; joubert syndrome 40, 619582 (3),
FLJ22622		
FLJ22623		
FLJ22624		
FLJ22625	AR	meckel syndrome 14, 619879 (3),
FLJ22626	XL,XLR	intellectual developmental disorder, syndromic, hackman-di donato type, 301039 (3),
FLJ22628	AR	hypomagnesemia 1, intestinal, 602014 (3),
FLJ22635		
FLJ22637		
FLJ22638		
FLJ22643		
FLJ22644		
FLJ22649		
FLJ22660		
FLJ22661		
FLJ22662		
FLJ22665		
FLJ22670	AD	rosah syndrome, 614979 (3),
FLJ22672		
FLJ22688	AD	{neural tube defects, susceptibility to}, 182940 (3),
FLJ22690		
FLJ22692		
FLJ22693		
FLJ22717	AD	cardiomyopathy, familial hypertrophic, 28, 619402 (3),
FLJ22724		
FLJ22728	AR,AD	peroxisomal fatty acyl-coa reductase 1 disorder, 616154 (3), ; cataracts, spastic paraparesis, and speech delay, 619338 (3),
FLJ22729		
FLJ22746		
FLJ22756		
FLJ22757		
FLJ22761	AR	retinitis pigmentosa 92, 619614 (3),
FLJ22774	AR	deafness and myopia, 221200 (3),
FLJ22778		
FLJ22792	XLR,XL	?premature ovarian failure 2b, 300604 (3),
FLJ22794	AD	kenny-caffey syndrome, type 2, 127000 (3), ; gracile bone dysplasia, 602361 (3),
FLJ22800	AD	{specific language impairment 5}, 615432 (3),
FLJ22833		
FLJ22843		
FLJ22851	AR	dyserythropoietic anemia, congenital, type ib, 615631 (3),
FLJ22865		
FLJ22875		
FLJ22913		
FLJ22943		
FLJ22944	AD,AR	hydrocephalus, normal pressure, 1, 236690 (3), ; spermatogenic failure 19, 617592 (3),
FLJ22965	XL	?intellectual developmental disorder, 107, 301013 (3),
FLJ22967		
FLJ22973	AD	thrombocytopenia, 7, 619130 (3),
FLJ22986		
FLJ22987		
FLJ22993		
FLJ23017		
FLJ23018	XL	developmental and epileptic encephalopathy 36, 300884 (3),
FLJ23024		
FLJ23027		
FLJ23033		
FLJ23047		
FLJ23054	AD	deafness, 85, 620227 (3),
FLJ23071	XL,XLR	intellectual developmental disorder, 106, 300997 (3),
FLJ23091	AR	zaki syndrome, 619648 (3),
FLJ23109		
FLJ23119	AR	osteosclerotic metaphyseal dysplasia, 615198 (3),
FLJ23121		
FLJ23127	AR	nephronophthisis 13, 614377 (3), ; cranioectodermal dysplasia 4, 614378 (3), ; senior-loken syndrome 8, 616307 (3), ; short-rib thoracic dysplasia 5 with or without polydactyly, 614376 (3), ; ?spermatogenic failure 72, 619867 (3),
FLJ23129		
FLJ23132		
FLJ23142		
FLJ23144	AD,AR	arthrogryposis, distal, type 5, 108145 (3), ; arthrogryposis, distal, with impaired proprioception and touch, 617146 (3), ; arthrogryposis, distal, type 3, 114300 (3), ; ?marden-walker syndrome, 248700 (3),
FLJ23153		
FLJ23182		
FLJ23184	AD	luscan-lumish syndrome, 616831 (3), ; intellectual developmental disorder, 70, 620157 (3), ; rabin-pappas syndrome, 620155 (3),
FLJ23186	AR	hypotrichosis 15, 620177 (3),
FLJ23191	AD	hypogonadotropic hypogonadism 25 with anosmia, 618841 (3),
FLJ23201		
FLJ23205	AR	alzahrani-kuwahara syndrome, 619268 (3),
FLJ23209	AR	deafness, 57, 618003 (3), ; {retinal disease in usher syndrome type iia, modifier of}, 276901 (3), ; usher syndrome, type iic, gpr98/pdzd7 digenic, 605472 (3), digenic
FLJ23229		
FLJ23231		
FLJ23236		
FLJ23239		
FLJ23251	AR	?spinocerebellar ataxia, 24, 617133 (3), ; developmental and epileptic encephalopathy 44, 617132 (3),
FLJ23256		
FLJ23263	AR	intellectual developmental disorder, 39, 615541 (3),
FLJ23274		
FLJ23277	AD	deafness, 85, 620227 (3),
FLJ23282		
FLJ23306		
FLJ23309		
FLJ23311		
FLJ23322		
FLJ23323		
FLJ23347		
FLJ23349		
FLJ23356	AR	?muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 12, 616094 (3), ; muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 12, 615249 (3),
FLJ23360		
FLJ23378		
FLJ23384		
FLJ23399		
FLJ23403	AD,AR	arthrogryposis, distal, type 5, 108145 (3), ; arthrogryposis, distal, with impaired proprioception and touch, 617146 (3), ; arthrogryposis, distal, type 3, 114300 (3), ; ?marden-walker syndrome, 248700 (3),
FLJ23404		
FLJ23406		
FLJ23412	AD	porokeratosis 8, disseminated superficial actinic type, 616063 (3),
FLJ23414		
FLJ23419		
FLJ23420		
FLJ23436		
FLJ23440		
FLJ23441	AR	combined oxidative phosphorylation deficiency 24, 616239 (3), ; ?deafness, 94, 618434 (3),
FLJ23443		
FLJ23445		
FLJ23458	AR	?glycosylphosphatidylinositol biosynthesis defect 25, 619985 (3),
FLJ23459		
FLJ23462		
FLJ23467		
FLJ23469		
FLJ23476	AR	galloway-mowat syndrome 10, 619609 (3),
FLJ23480		
FLJ23493		
FLJ23495		
FLJ23500		
FLJ23501		
FLJ23516		
FLJ23518		
FLJ23523		
FLJ23544	XL,XLR	{autism, susceptibility to, 5}, 300847 (3); intellectual developmental disorder, syndromic 35, 300998 (3),
FLJ23548		
FLJ23554		
FLJ23560	AR	bardet-biedl syndrome 10, 615987 (3),
FLJ23563		
FLJ23577	AR	spermatogenic failure 43, 618751 (3),
FLJ23588		
FLJ23590	AR	bardet-biedl syndrome 1, 209900 (3), digenic
FLJ23591		
FLJ23598		
FLJ23608		
FLJ23614		
FLJ23617		
FLJ23637		
FLJ23654		
FLJ23657	AR	amelogenesis imperfecta, type iia4, 614832 (3),
FLJ23658		
FLJ23666		
FLJ23707		
FLJ23713		
FLJ23743		
FLJ23751		
FLJ23793		
FLJ23802		
FLJ23809	AD	?spastic paraplegia 73, 616282 (3),
FLJ23818		
FLJ23825		
FLJ23833	AR	osteogenesis imperfecta, type xi, 610968 (3), ; bruck syndrome 1, 259450 (3),
FLJ23834		
FLJ23842		
FLJ23849		
FLJ23853		
FLJ23861		
FLJ23866		
FLJ23907		
FLJ23984		
FLJ24002		
FLJ25004		
FLJ25012	AR	atelis syndrome 1, 620184 (3),
FLJ25027		
FLJ25045		
FLJ25049	AD	deafness, 64, 614152 (3),
FLJ25059		
FLJ25067		
FLJ25076		
FLJ25082		
FLJ25084	AD	ichthyosis, lamellar, 146750 (3),
FLJ25102		
FLJ25113	AD	lissencephaly 3, 611603 (3),
FLJ25132		
FLJ25138		
FLJ25157		
FLJ25162	AD	preeclampsia/eclampsia 4, 609404 (3),
FLJ25163		
FLJ25169		
FLJ25179	AD	{otitis media, susceptibility to}, 166760 (3),
FLJ25205		
FLJ25211		
FLJ25270		
FLJ25281		
FLJ25286		
FLJ25287	AR	spastic paraplegia 35, 612319 (3),
FLJ25291		
FLJ25304		
FLJ25320		
FLJ25329		
FLJ25330	AR	ciliary dyskinesia, primary, 13, 613193 (3),
FLJ25348		
FLJ25351	AR	?spermatogenic failure 68, 619805 (3),
FLJ25355		
FLJ25357		
FLJ25369		
FLJ25383	AR	retinitis pigmentosa 77, 617304 (3),
FLJ25390		
FLJ25393		
FLJ25404		
FLJ25409		
FLJ25410	AD	spermatogenic failure 10, 614822 (3),
FLJ25415		
FLJ25416		
FLJ25422		
FLJ25424		
FLJ25429		
FLJ25430		
FLJ25436		
FLJ25439		
FLJ25461	AR,AD	manitoba oculotrichoanal syndrome, 248450 (3), ; bifid nose with or without anorectal and renal anomalies, 608980 (3), ; trigonocephaly 2, 614485 (3),
FLJ25471		
FLJ25475		
FLJ25477		
FLJ25480		
FLJ25513	AD	convulsions, familial infantile, with paroxysmal choreoathetosis, 602066 (3), ; seizures, benign familial infantile, 2, 605751 (3), ; episodic kinesigenic dyskinesia 1, 128200 (3),
FLJ25530	AR,AD	megalencephalic leukoencephalopathy with subcortical cysts 2a, 613925 (3), ; megalencephalic leukoencephalopathy with subcortical cysts 2b, remitting, with or without impaired intellectual development, 613926 (3),
FLJ25555		
FLJ25564	AR	ciliary dyskinesia, primary, 18, 614874 (3),
FLJ25593		
FLJ25604		
FLJ25605		
FLJ25609		
FLJ25621	AR	finca syndrome, 618278 (3),
FLJ25690		
FLJ25691		
FLJ25692		
FLJ25709		
FLJ25732		
FLJ25756		
FLJ25765	AR	?spermatogenic failure 41, 618670 (3),
FLJ25776		
FLJ25778		
FLJ25785	AR	ehlers-danlos syndrome, spondylodysplastic type, 3, 612350 (3),
FLJ25791		
FLJ25795		
FLJ25797		
FLJ25811		
FLJ25818		
FLJ25831		
FLJ25832		
FLJ25851		
FLJ25854		
FLJ25918		
FLJ25925		
FLJ25952		
FLJ25954		
FLJ25955		
FLJ25965		
FLJ25967		{myocardial infarction, susceptibility to}, 608446 (3)
FLJ25968		
FLJ25972		
FLJ25987		
FLJ25989		
FLJ26016		
FLJ26072	AR,AD	{multiple system atrophy, susceptibility to}, 146500 (3), ; coenzyme q10 deficiency, primary, 1, 607426 (3),
FLJ26141		
FLJ26145		
FLJ26184		prostate cancer, somatic, 176807 (3)
FLJ26283		
FLJ26450		
FLJ26468	AR	antley-bixler syndrome with genital anomalies and disordered steroidogenesis, 201750 (3), ; disordered steroidogenesis due to cytochrome p450 oxidoreductase, 613571 (3)
FLJ26680		myelofibrosis, somatic, 254450 (3); thrombocythemia, somatic, 187950 (3)
FLJ26957		
FLJ26963		
FLJ26981	AD	angelman syndrome, 105830 (3),
FLJ27047	AD	{asthma, protection against}, 600807 (3),
FLJ27199		
FLJ27265		
FLJ27285		
FLJ27310		
FLJ27352		
FLJ27379		
FLJ27441		
FLJ27450		
FLJ27452		
FLJ27458	AD	hypotrichosis 12, 615885 (3),
FLJ27520	AR	oocyte/zygote/embryo maturation arrest 10, 619176 (3),
FLJ27524	AR	?mitochondrial complex iv, deficiency, nuclear type 9, 616500 (3),
FLJ29027		
FLJ29030		
FLJ30002		
FLJ30006		
FLJ30012		
FLJ30046		
FLJ30047		
FLJ30058		
FLJ30067		
FLJ30131	AR	congenital disorder of glycosylation, type iio, 616828 (3),
FLJ30135		
FLJ30140		
FLJ30165		
FLJ30166		
FLJ30169	AD	amyotrophic lateral sclerosis 22 with or without frontotemporal dementia, 616208 (3),
FLJ30202	AD	developmental and epileptic encephalopathy 54, 617391 (3),
FLJ30213		
FLJ30259		
FLJ30273	AR,AD	leber congenital amaurosis 13, 612712 (3),
FLJ30296	XL,XLR	{autism, susceptibility to, 4}, 300830 (3),
FLJ30320		
FLJ30322		
FLJ30339		
FLJ30380		
FLJ30395		
FLJ30401		
FLJ30469		
FLJ30473		
FLJ30499		
FLJ30508		
FLJ30525		
FLJ30532	AR	deafness, 49, 610153 (3),
FLJ30542		
FLJ30544	AR	trichothiodystrophy 3, photosensitive, 616395 (3),
FLJ30570	AR	microphthalmia, isolated 5, 611040 (3), ; nanophthalmos 2, 609549 (3)
FLJ30574		
FLJ30596	AR	2,4-dienoyl-coa reductase deficiency, 616034 (3),
FLJ30600	AR	retinitis pigmentosa 64, 614500 (3), ; cone-rod dystrophy 16, 614500 (3), ; bardet-biedl syndrome 21, 617406 (3),
FLJ30619	AD	coffin-siris syndrome 6, 617808 (3),
FLJ30627	AR	neuropathy, hereditary sensory and autonomic, type vi, 614653 (3), ; epidermolysis bullosa simplex 3, localized or generalized intermediate, with bp230 deficiency, 615425 (3),
FLJ30634		
FLJ30655		
FLJ30656		
FLJ30668		
FLJ30672	XLD,XLR,XL	developmental and epileptic encephalopathy 90, 301058 (3), ; intellectual developmental disorder, 110, 301095 (3),
FLJ30678		
FLJ30681	AR	hennekam lymphangiectasia-lymphedema syndrome 1, 235510 (3),
FLJ30691	AR	nephronophthisis 3, 604387 (3), ; renal-hepatic-pancreatic dysplasia 1, 208540 (3), ; meckel syndrome 7, 267010 (3),
FLJ30696		
FLJ30726		
FLJ30744	AR	iron-refractory iron deficiency anemia, 206200 (3),
FLJ30829		
FLJ30845	AR	ciliary dyskinesia, primary, 12, 612650 (3),
FLJ30846		
FLJ30866		
FLJ30899		
FLJ3091		
FLJ30927		
FLJ30977		
FLJ30978		
FLJ30992		
FLJ31031		
FLJ31033		
FLJ31034		
FLJ31037		
FLJ31044		
FLJ31051		
FLJ31052		
FLJ31074	AR	hyaline fibromatosis syndrome, 228600 (3),
FLJ31087		
FLJ31092		
FLJ31101		
FLJ31105		
FLJ31106		
FLJ31121		
FLJ31139		
FLJ31153		
FLJ31168		
FLJ31193		
FLJ31196		
FLJ31204		
FLJ31208		
FLJ31213		
FLJ31228	AR	cortical dysplasia, complex, with other brain malformations 12, 620316 (3),
FLJ31235		
FLJ31236		
FLJ31265		
FLJ31268		
FLJ31290	AD	desanto-shinawi syndrome, 616708 (3),
FLJ31295		
FLJ31300	AR	?urocanase deficiency, 276880 (3),
FLJ31318		
FLJ31340		
FLJ31349		
FLJ31364		
FLJ31400		
FLJ31413		
FLJ31424	AD,AR,MF	supranuclear palsy, progressive, 601104 (3), ; supranuclear palsy, progressive atypical, 260540 (3), ; dementia, frontotemporal, with or without parkinsonism, 600274 (3), ; {parkinson disease, susceptibility to}, 168600 (3), ; pick disease, 172700 (3),
FLJ31425		
FLJ31471		
FLJ31474		
FLJ31484		
FLJ31524		
FLJ31529		
FLJ31547		
FLJ31551		
FLJ31564		
FLJ31579		
FLJ31599		
FLJ31606		
FLJ31614		
FLJ31633		
FLJ31638		
FLJ31641	AR,AD	charcot-marie-tooth disease, axonal, type 2p, 614436 (3),
FLJ31644		
FLJ31657		
FLJ31671	AR	ciliary dyskinesia, primary, 18, 614874 (3),
FLJ31695		
FLJ31709		
FLJ31741		
FLJ31762		
FLJ31812		
FLJ31818		
FLJ31823		
FLJ31846		
FLJ31858		
FLJ31884		
FLJ31890		
FLJ31917	AR	noonan syndrome 14, 619745 (3),
FLJ31937	AR	epilepsy, progressive myoclonic 1b, 612437 (3),
FLJ31940	AR	neuropathy, hereditary motor and sensory, type vic, with optic atrophy, 618511 (3),
FLJ31952		
FLJ31966		
FLJ32000		
FLJ32001		
FLJ32009		
FLJ32011		
FLJ32018		
FLJ32021	AR	ciliary dyskinesia, primary, 15, 613808 (3),
FLJ32029	AR	neurodevelopmental disorder with hypotonia, dysmorphic facies, and skin abnormalities, 620191 (3),
FLJ32040	AR,AD	muscular dystrophy, limb-girdle, 10, 608807 (3), ; cardiomyopathy, familial hypertrophic, 9, 613765 (3), ; congenital myopathy 5 with cardiomyopathy, 611705 (3), ; tibial muscular dystrophy, tardive, 600334 (3), ; cardiomyopathy, dilated, 1g, 604145 (3), ; myopathy, myofibrillar, 9, with early respiratory failure, 603689 (3),
FLJ32053		
FLJ32069	AR	epilepsy, progressive myoclonic 3, with or without intracellular inclusions, 611726 (3),
FLJ32082		
FLJ32093		
FLJ32096		
FLJ32099		
FLJ32115		
FLJ32122		
FLJ32126		
FLJ32136		
FLJ32145		
FLJ32147		
FLJ32150		
FLJ32173	AR	?cranioectodermal dysplasia 3, 614099 (3), ; ?retinitis pigmentosa 81, 617871 (3), ; short-rib thoracic dysplasia 18 with polydactyly, 617866 (3),
FLJ32191		
FLJ32197		
FLJ32198		
FLJ32203	AR	?retinitis pigmentosa 58, 613617 (3),
FLJ32206		
FLJ32235	AR	neuropathy, hereditary sensory and autonomic, type vi, 614653 (3), ; epidermolysis bullosa simplex 3, localized or generalized intermediate, with bp230 deficiency, 615425 (3),
FLJ32254		
FLJ32310	AD	corneal dystrophy, fuchs endothelial, 8, 615523 (3),
FLJ32312		
FLJ32332		
FLJ32334		
FLJ32345		
FLJ32349		
FLJ32356		
FLJ32372		
FLJ32384		
FLJ32389		
FLJ32416		
flj32422	AR	short stature, oligodontia, dysmorphic facies, and motor delay, 619234 (3),
FLJ32430		
FLJ32431		
FLJ32440	AR	seckel syndrome 10, 617253 (3),
FLJ32446		
FLJ32449		
FLJ32549		
FLJ32569		
FLJ32580		
FLJ32585		
FLJ32631		
FLJ32635	AR	camptodactyly-arthropathy-coxa vara-pericarditis syndrome, 208250 (3),
FLJ32642	AR	spastic paraplegia 53, 614898 (3),
FLJ32658		
FLJ32660	AR	spermatogenic failure 80, 620222 (3), ; ciliary dyskinesia, primary, 21, 615294 (3),
FLJ32662	AD	spermatogenic failure 11, 615081 (3),
FLJ32666	AR	macrocephaly/megalencephaly syndrome, 248000 (3),
FLJ32670	AR	deafness, 77, 613079 (3),
FLJ32675		
FLJ32685	AR	ciliary dyskinesia, primary, 44, 618781 (3),
FLJ32703		
FLJ32704		
FLJ32724		
FLJ32731	AR	mucopolysaccharidosis type iiic (sanfilippo c), 252930 (3), ; retinitis pigmentosa 73, 616544 (3),
FLJ32743	AR	heterotaxy, visceral, 6, 614779 (3),
FLJ32752	AR	spermatogenic failure 65, 619712 (3),
FLJ32753	AR	ciliary dyskinesia, primary, 24, 615481 (3),
FLJ32762		
FLJ32767		
FLJ32769	AR	weill-marchesani 4 syndrome, 613195 (3),
FLJ32771		
FLJ32779	AR	spermatogenic failure 75, 619949 (3),
FLJ32785		
FLJ32786		
FLJ32787		
FLJ32792		
FLJ32796		
FLJ32798		
FLJ32804		
FLJ32810		
FLJ32813		
FLJ32818		
FLJ32820		
FLJ32821	AR	neurodevelopmental disorder with severe motor impairment, absent language, cerebral hypomyelination, and brain atrophy, 619972 (3),
FLJ32827		
FLJ32828	AR	spermatogenic failure 81, 620277 (3),
FLJ32833		
FLJ32844	AR	polycystic kidney disease 5, 617610 (3),
FLJ32855		
FLJ32864	AR	?spermatogenic failure 27, 617965 (3),
FLJ32865		
FLJ32871		
FLJ32891		
FLJ32897		
FLJ32906		
FLJ32915	AR	hydrolethalus syndrome, 236680 (3),
FLJ32919	AD	spastic paraplegia 33, 610244 (3),
FLJ32920	AR	ciliary dyskinesia, primary, 28, 615505 (3),
FLJ32926	AR	ciliary dyskinesia, primary, 20, 615067 (3),
FLJ32934		
FLJ32938		
FLJ32942		
FLJ32949	AR	spermatogenic failure 9, 613958 (3),
FLJ32954		
FLJ32965		
FLJ33049		
FLJ33064		
FLJ33069		
FLJ33071		
FLJ33126		
FLJ33139		
FLJ33167	AD	myopia 22, 615420 (3),
FLJ33200		
FLJ33207	AR	myopathy, myofibrillar, 7, 617114 (3),
FLJ33215		
FLJ33279		
FLJ33298	AR	microcephaly 2, primary, with or without cortical malformations, 604317 (3),
FLJ33303		
FLJ33312	AR	finca syndrome, 618278 (3),
FLJ33318		
FLJ33340		
FLJ33365		
FLJ33387		
FLJ33496	AR	hypotonia, infantile, with psychomotor retardation and characteristic facies 2, 616801 (3),
FLJ33552		
FLJ33655	AD	?deafness, 88, 620283 (3),
FLJ33659		
FLJ33674		
FLJ33718	AR	fetal akinesia deformation sequence 3, 618389 (3), ; myasthenic syndrome, congenital, 10, 254300 (3),
FLJ33728		
FLJ33768		
FLJ33770	AR	adams-oliver syndrome 4, 615297 (3),
FLJ33777		
FLJ33779		
FLJ33782		
FLJ33806		
FLJ33817	AR	cerebellar ataxia, impaired intellectual development, and dysquilibrium syndrome 2, 610185 (3), ; hydrocephalus, congenital, 3, with brain anomalies, 617967 (3),
FLJ33829	AR	developmental and epileptic encephalopathy 49, 617281 (3),
FLJ33839	AR	hypotonia, infantile, with psychomotor retardation, 616816 (3),
FLJ33841		
FLJ33847		
FLJ33868		
FLJ33876		
FLJ33877		
FLJ33898		
FLJ33903	AD	legius syndrome, 611431 (3),
FLJ33914	AD	zttk syndrome, 617140 (3),
FLJ33924	AR	usher syndrome, type 1g, 606943 (3),
FLJ33930		
FLJ33951		
FLJ33962		
FLJ33970		
FLJ33979		
FLJ33990		
FLJ34027		
FLJ34064	XLR,XL	fanconi anemia, complementation group b, 300514 (3),
FLJ34093		
FLJ34104		
FLJ34109		
FLJ34125		
FLJ34154	AR	neurodevelopmental disorder with seizures, spasticity, and complete or partial agenesis of the corpus callosum, 620250 (3),
FLJ34157		
FLJ34161		
FLJ34198	AR	?spinocerebellar ataxia, 11, 614229 (3),
FLJ34211	AR	ciliary dyskinesia, primary, 17, 614679 (3),
FLJ34221		
FLJ34231		
FLJ34235		
FLJ34238		
FLJ34243		
FLJ34272		
FLJ34278	AD	intellectual developmental disorder, fra12a type, 136630 (3),
FLJ34306		
FLJ34321	AR	xeroderma pigmentosum, group e, ddb-negative subtype, 278740 (3),
FLJ34389		
FLJ34427	AR	intellectual developmental disorder with autism and dysmorphic facies, 620021 (3),
FLJ34443		
FLJ34463		
FLJ34464		
FLJ34497	AR	?spermatogenic failure 55, 619380 (3),
FLJ34500		
FLJ34502	AR	developmental and epileptic encephalopathy 18, 615476 (3),
FLJ34512	AD	?centronuclear myopathy 4, 614807 (3),
FLJ34577		
FLJ34583		
FLJ34599		
FLJ34602		
FLJ34633	AD	?ectodermal dysplasia 12, hypohidrotic/hair/tooth/nail type, 617337 (3),
FLJ34646		
FLJ34658		
FLJ34705	AD	auditory neuropathy, 1, 609129 (3),
FLJ34709		
FLJ34716		
FLJ34743	AR	short stature, facial dysmorphism, and skeletal anomalies with or without cardiac anomalies, 619184 (3),
FLJ34766		
FLJ34780	AR	spermatogenic failure 34, 618153 (3),
FLJ34823		
FLJ34884	AR,AD	autoinflammation, panniculitis, and dermatosis syndrome, 617099 (3), ; {immunodeficiency 107, susceptibility to invasive staphylococcus aureus infection}, 619986 (3),
FLJ34907	AD,AR	arthrogryposis, distal, type 5, 108145 (3), ; arthrogryposis, distal, with impaired proprioception and touch, 617146 (3), ; arthrogryposis, distal, type 3, 114300 (3), ; ?marden-walker syndrome, 248700 (3),
FLJ34922		
FLJ34923		
FLJ34931	AR	retinitis pigmentosa 54, 613428 (3),
FLJ34999		
FLJ35036		
FLJ35093		
FLJ35105		
FLJ35107		
FLJ35119		
FLJ35155		
FLJ35207		
FLJ35220		
FLJ35226		
FLJ35246		
FLJ35258		
FLJ35277		
FLJ35283		
FLJ35301		
FLJ35355		
FLJ35392		
FLJ35411		
FLJ35510		
FLJ35539		
FLJ35564		
FLJ35587		
FLJ35613		{?autism susceptibility 16}, 613410 (3)
FLJ35630	AR	bardet-biedl syndrome 12, 615989 (3),
FLJ35709	AR	spermatogenic failure 65, 619712 (3),
FLJ35713	AR	spermatogenic failure 69, 619826 (3),
FLJ35725		
FLJ35732	AR	ciliary dyskinesia, primary, 27, 615504 (3),
FLJ35740		
FLJ35746		
FLJ35755	AR,AD	hypogonadotropic hypogonadism 18 with or without anosmia, 615267 (3), digenic ,
FLJ35757		
FLJ35767		
FLJ35779		
FLJ35794	AR	riddle syndrome, 611943 (3),
FLJ35808		
FLJ35827		
FLJ35843		
FLJ35848		
FLJ35857	AD	?giant axonal neuropathy 2, 610100 (3),
FLJ35863		
FLJ35880		
FLJ35882		
FLJ35894	AR	spermatogenic failure 60, 619646 (3),
FLJ35906		
FLJ35908	AR	spermatogenic failure 49, 619144 (3),
FLJ35924		
FLJ35936		
FLJ35951		
FLJ35954		
FLJ35961		
FLJ35989		
FLJ36004		
FLJ36006	AD,AR	hydrocephalus, normal pressure, 1, 236690 (3), ; spermatogenic failure 19, 617592 (3),
FLJ36045		
FLJ36070		
FLJ36085		
FLJ36090	AR	short-rib thoracic dysplasia 13 with or without polydactyly, 616300 (3), ; joubert syndrome 31, 617761 (3),
FLJ36112		
FLJ36128		
FLJ36137	AR,AD	?spastic paraplegia 57, 615658 (3), ; hereditary motor and sensory neuropathy, okinawa type, 604484 (3),
FLJ36139	AR	ciliary dyskinesia, primary, 2, 606763 (3),
FLJ36147		
FLJ36155		
FLJ36156		
FLJ36157		
FLJ36160		
FLJ36164	AR	?spermatogenic failure 30, 618110 (3),
FLJ36198		
FLJ36353		
FLJ36370		
FLJ36445	AR	deafness, 76, 615540 (3),
FLJ36483		
FLJ36507		
FLJ36525		
FLJ36550		
FLJ36557		
FLJ36578		
FLJ36600		
FLJ36601	XL,XLR	spermatogenic failure, 3, 301059 (3),
FLJ36664		
FLJ36691		
FLJ36696	AR	nephronophthisis 3, 604387 (3), ; renal-hepatic-pancreatic dysplasia 1, 208540 (3), ; meckel syndrome 7, 267010 (3),
FLJ36748		
FLJ36749		
FLJ36760	AR	premature ovarian failure 9, 615724 (3),
FLJ36860	AR	oocyte/zygote/embryo maturation arrest 10, 619176 (3),
FLJ36866	AR	deafness, 74, 613718 (3),
FLJ36874		
FLJ36878		
FLJ36890		
FLJ36928	AR	nephronophthisis 16, 615382 (3),
FLJ36931		
FLJ36955		
FLJ36974	AR	perlman syndrome, 267000 (3),
FLJ36980		
FLJ36991		
FLJ36999		
FLJ37000	AR	combined oxidative phosphorylation deficiency 42, 618839 (3),
FLJ37034		
FLJ37041		
FLJ37114		
FLJ37118		
FLJ37194		
FLJ37295		{?attention deficit-hyperactivity disorder, susceptibility to, 7}, 613003 (3); {unipolar depression, susceptibility to}, 608516 (3)
FLJ37300		
FLJ37327	XL,XLR	?deafness, 7, 301018 (3),
FLJ37357		
FLJ37416	AR	anemia, hypochromic microcytic, with iron overload 1, 206100 (3),
FLJ37422		
FLJ37433	AR	glycosylphosphatidylinositol biosynthesis defect 11, 616025 (3),
FLJ37440		
FLJ37451		
FLJ37472	AR	hyperoxaluria, primary, type iii, 613616 (3),
FLJ37478	AR	?n-acetylaspartate deficiency, 614063 (3),
FLJ37521		
FLJ37523		
FLJ37528	AR	heterotaxy, visceral, 10, with male infertility, 619607 (3),
FLJ37538		
FLJ37587	AR	?central hypoventilation syndrome, congenital, 2, and autonomic dysfunction, 619482 (3),
FLJ37592		
FLJ37706	AR	bone marrow failure syndrome 2, 615715 (3),
FLJ37767	AR	retinitis pigmentosa 92, 619614 (3),
FLJ37817		
FLJ37856		
FLJ37857		
FLJ37870		
FLJ37871		
FLJ37874		
FLJ37882	AD,AR	{dyslexia, susceptibility to, 1}, 127700 (3), ; ciliary dyskinesia, primary, 25, 615482 (3),
FLJ37886		
FLJ37927		
FLJ37938		
FLJ37953		
FLJ37958		
FLJ37964		
FLJ37965		
FLJ37970		
FLJ37974	AR	ciliary dyskinesia, primary, 11, 612649 (3),
FLJ37978	AD	developmental and epileptic encephalopathy 54, 617391 (3),
FLJ37990	AD	spinocerebellar ataxia 10, 603516 (3),
FLJ37995		
FLJ38008		
FLJ38020		
FLJ38026		
FLJ38076		
FLJ38088		
FLJ38101		
FLJ38116		
FLJ38135		platelet plc beta-2 deficiency (1)
FLJ38144	AR	degcags syndrome, 619488 (3),
FLJ38190		
FLJ38216		
FLJ38242		
FLJ38273	AR	?aicardi-goutieres syndrome 8, 619486 (3),
FLJ38295		
FLJ38426		
FLJ38464	AR	focal segmental glomerulosclerosis 9, 616220 (3), ; ventriculomegaly with cystic kidney disease, 219730 (3),
FLJ38497		
FLJ38499		
FLJ38505		
FLJ38508		
FLJ38511		
FLJ38519		
FLJ38547		
FLJ38559		
FLJ38568	XL,XLR	intellectual developmental disorder, 93, 300659 (3),
FLJ38569		
FLJ38577	AD	sting-associated vasculopathy, infantile-onset, 615934 (3),
FLJ38602	AR	myopathy, distal, 5, 617030 (3),
FLJ38607		
FLJ38613		
FLJ38614	AD	developmental and epileptic encephalopathy 94, 615369 (3),
FLJ38628		
FLJ38636	AD	charcot-marie-tooth disease, type 1c, 601098 (3),
FLJ38663	AR	spastic paraplegia 55, 615035 (3), ; combined oxidative phosphorylation deficiency 7, 613559 (3),
FLJ38678		
FLJ38680	AR	hypophosphatemic rickets with hypercalciuria, 241530 (3),
FLJ38683		
FLJ38708		
FLJ38709		
FLJ38725	AR	juvenile arthritis, 618795 (3),
FLJ38736	AR	amelogenesis imperfecta, type iia3, 613211 (3),
FLJ38755	AR	ichthyosis, congenital, 10, 615024 (3),
FLJ38819		
FLJ38822		
FLJ38838		
FLJ38841	AR	?spermatogenic failure 62, 619673 (3), ; recombination rate qtl 1, 612042 (3)
FLJ38863		
FLJ38866		
FLJ38871		
FLJ38932		
FLJ38944		
FLJ38962		
FLJ38964		
FLJ38968		
FLJ38973	AR	combined oxidative phosphorylation deficiency 53, 619423 (3),
FLJ38975		
FLJ38979	AR	?polydactyly, postaxial, type a9, 618219 (3),
FLJ38991		
FLJ39004		
FLJ39011	AR	premature ovarian failure 9, 615724 (3),
FLJ39019		
FLJ39061		
FLJ39091		
FLJ39106		
FLJ39110		
FLJ39113		
FLJ39116		
FLJ39117		
FLJ39120		
FLJ39137	AR	fetal akinesia deformation sequence 3, 618389 (3), ; myasthenic syndrome, congenital, 10, 254300 (3),
FLJ39155		
FLJ39176		
FLJ39177		
FLJ39203		
FLJ39207	AR	?ondontochondrodysplasia 2 with hearing loss and diabetes, 619269 (3),
FLJ39237		
FLJ39294		
FLJ39352		
FLJ39369		
FLJ39378	AD	oculopharyngodistal myopathy 4, 619790 (3),
FLJ39381	AR	ciliary dyskinesia, primary, 18, 614874 (3),
FLJ39408	AR	congenital disorder of glycosylation with defective fucosylation 2, 618324 (3),
FLJ39417	AR	ceroid lipofuscinosis, neuronal, 8, northern epilepsy variant, 610003 (3), ; ceroid lipofuscinosis, neuronal, 8, 600143 (3),
FLJ39426		
FLJ39458	AD	epilepsy, familial adult myoclonic, 1, 601068 (3),
FLJ39501	AR	ichthyosis, congenital, 5, 604777 (3),
FLJ39502		
FLJ39565		
FLJ39576		
FLJ39577		
FLJ39599		
FLJ39600		
FLJ39626		
FLJ39630		
FLJ39645		
FLJ39737		
FLJ39785		
FLJ39786	AD	coffin-siris syndrome 4, 614609 (3), ; {rhabdoid tumor predisposition syndrome 2}, 613325 (3),
FLJ39787		
FLJ39796		
FLJ39802		
FLJ39822		
FLJ39827	XLD,XL	osteopathia striata with cranial sclerosis, 300373 (3),
FLJ39873		
FLJ39885	AD	ataxia-pancytopenia syndrome, 159550 (3), ; monosomy 7 myelodysplasia and leukemia syndrome 1, 252270 (3), ; spinocerebellar ataxia 49, 619806 (3),
FLJ39957		
FLJ39963		
FLJ40069	AR	ciliary dyskinesia, primary, 2, 606763 (3),
FLJ40081		
FLJ40084		
FLJ40097		
FLJ40121		
FLJ40137		
FLJ40160		
FLJ40162		
FLJ40191		
FLJ40201		
FLJ40217		
FLJ40240	AR	spermatogenic failure 57, 619528 (3),
FLJ40242		
FLJ40292	AD	kleefstra syndrome 1, 610253 (3),
FLJ40321		
FLJ40338		
FLJ40344	AR	?spermatogenic failure 67, 619803 (3),
FLJ40346		
FLJ40362		
FLJ40363		
FLJ40388		
FLJ40409		
FLJ40417		
FLJ40427		
FLJ40442		
FLJ40451		
FLJ40457	AR	spermatogenic failure 39, 618643 (3),
FLJ40511		
FLJ40584		
FLJ40595		
FLJ40597		
FLJ40629	AR	filippi syndrome, 272440 (3),
FLJ40710		
FLJ40722		
FLJ40752		
FLJ40754		[fucosyltransferase 6 deficiency], 613852 (3)
FLJ40864		
FLJ40869		
FLJ40873		
FLJ40906	AR	palmoplantar hyperkeratosis and true hermaphroditism, 610644 (3), ; palmoplantar hyperkeratosis with squamous cell carcinoma of skin and sex reversal, 610644 (3),
FLJ40908		
FLJ40918		
FLJ41131		
FLJ41188		
FLJ41197		
FLJ41287		
FLJ41346		
FLJ41411	XL,XLD	intellectual developmental disorder, 41, 300849 (3),
FLJ41471		
FLJ41559	AR	bardet-biedl syndrome 12, 615989 (3),
FLJ41564		
FLJ41587		
FLJ41618		
FLJ41625		
FLJ41712		
FLJ41725		
FLJ41791		
FLJ41801		
FLJ41841		
FLJ41930		
FLJ41938		
FLJ41960		
FLJ41993		
FLJ42177		
FLJ42195	AR	d-2-hydroxyglutaric aciduria, 600721 (3),
FLJ42280		
FLJ42568		
FLJ42613		
FLJ42622		
FLJ42625		
FLJ42707		
FLJ42735		
FLJ42888	AR	microcephaly 22, primary, 617984 (3),
FLJ42958		
FLJ42984	AR	?intellectual developmental disorder with short stature and variable skeletal anomalies, 618453 (3),
FLJ42993	AR	thrombotic thrombocytopenic purpura, hereditary, 274150 (3),
FLJ43065		
FLJ43070		
FLJ43080		
FLJ43151		
FLJ43208		
FLJ43269	AR	mitochondrial complex iv deficiency, nuclear type 11, 619054 (3),
FLJ43307		
FLJ43328		
FLJ43346	XL	nystagmus, infantile periodic alternating, 310700 (3), ; nystagmus 1, congenital, 310700 (3),
FLJ43370		
FLJ43424		
FLJ43455	AR	developmental and epileptic encephalopathy 49, 617281 (3),
FLJ43547		
FLJ43653		
FLJ43663		
FLJ43692		
FLJ43803		
FLJ43806		
FLJ43808	AR	spermatogenic failure 56, 619515 (3),
FLJ43842		
FLJ43869	AR	striatonigral degeneration, infantile, 271930 (3),
FLJ43884		
FLJ43983		
FLJ44028		
FLJ44037		
FLJ44060		
FLJ44083	AR	oocyte/zygote/embryo maturation arrest 10, 619176 (3),
FLJ44216		
FLJ44259		
FLJ44279		
FLJ44290		
FLJ44299		
FLJ44366		
FLJ44379		
FLJ44520		
FLJ44612		
FLJ44614		
FLJ44618		
FLJ44670		
FLJ44691	AR	night blindness, congenital stationary (complete), 1f, 615058 (3),
FLJ44734	AD	silver-russell syndrome 3, 616489 (3),
FLJ44809	AD	focal cortical dysplasia, type ii, somatic, 607341 (3); smith-kingsmore syndrome, 616638 (3),
FLJ44862		
FLJ44872		
FLJ44882		
FLJ44930		
FLJ44968		
FLJ45049		
FLJ45135		
FLJ45195		
FLJ45235		
FLJ45338		
FLJ45344		
FLJ45455		
FLJ45465		
FLJ45472	AD	alexander disease, 203450 (3),
FLJ45476	AR	ciliary dyskinesia, primary, 49, without situs inversus, 620197 (3),
FLJ45557		
FLJ45612	AD	lissencephaly 9 with complex brainstem malformation, 618325 (3),
FLJ45686		
FLJ45744		bradyopsia 2, 620344 (3)
FLJ45745		
FLJ45748		
FLJ45778		
FLJ45803		
FLJ45829	AD	{parkinson disease 8}, 607060 (3),
FLJ45857		
FLJ45860	AR	mitochondrial complex i deficiency, nuclear type 3, 618224 (3),
FLJ45906		
FLJ45910		
FLJ45975		
FLJ46058		
FLJ46061		
FLJ46072	AD	amelogenesis imperfecta, type iiia, 130900 (3),
FLJ46135		
FLJ46154		
FLJ46184	AR	spermatogenic failure 65, 619712 (3),
FLJ46312		
FLJ46318	AR	cutis laxa, type ic, 613177 (3),
FLJ46346	AR	deafness, 18b, 614945 (3),
FLJ46353		
FLJ46380		
FLJ46512		
FLJ46615		
FLJ46629		
FLJ46675	AR	spermatogenic failure 45, 619094 (3),
FLJ46727		
FLJ46776	AD	lissencephaly 9 with complex brainstem malformation, 618325 (3),
FLJ46828		
FLJ46831		
FLJ46866	AR	neurodevelopmental disorder with central and peripheral motor dysfunction, 618356 (3),
FLJ46880	AR	mitochondrial complex i deficiency, nuclear type 3, 618224 (3),
FLJ46909		
FLJ75407		[placental lactogen deficiency] (1)
FLJ78302		{hiv infection, susceptibility/resistance to}, 609423 (3)
FLJ78649		
FLJ90005		
FLJ90013	AR	osteochondrodysplasia, complex lethal, symoens-barnes-gistelinck type, 616897 (3),
FLJ90018	AR	cutis laxa, type ic, 613177 (3),
FLJ90023		
FLJ90024		
FLJ90037		
FLJ90065		
FLJ90066		
FLJ90097		
FLJ90106	AR	congenital disorder of glycosylation, type ix, 615597 (3),
FLJ90165		
FLJ90191		
FLJ90193		
FLJ90254	AR	deafness, 79, 613307 (3),
FLJ90298		
FLJ90311	AD	{centronuclear myopathy, modifier of}, 160150 (3),
FLJ90327		
FLJ90341		
FLJ90346		
FLJ90349	AR	?anencephaly 2, 619452 (3),
FLJ90360		
FLJ90365		
FLJ90369		
FLJ90391		
FLJ90406		
FLJ90415		
FLJ90431		
FLJ90440		
FLJ90469	AR	chronic granulomatous disease 5, 618935 (3),
FLJ90481		
FLJ90492	AR	lissencephaly 8, 617255 (3),
FLJ90515		
FLJ90517		
FLJ90566		
FLJ90575		
FLJ90579	AR	deafness, 84b, 614944 (3),
FLJ90583		
FLJ90586		
FLJ90593		
FLJ90603		
FLJ90614		
FLJ90634		
FLJ90637		
FLJ90650		
FLJ90661		
FLJ90694		
FLJ90709		
FLJ90724		
FLJ90734		
FLJ90746		
FLJ90759	AD,AR	{intervertebral disc disease, susceptibility to}, 603932 (3); epiphyseal dysplasia, multiple, 3, with or without myopathy, 600969 (3), ; stickler syndrome, type vi, 620022 (3),
FLJ90771		
FLJ90779		
FLJ90806		
FLJ90810		
FLJ90833		
FLJ90837		
FLJ94393		
FLJ97536	AR	netherton syndrome, 256500 (3),
FLJ97596	AR	netherton syndrome, 256500 (3),
FLJ98147	AD,AR	nemaline myopathy 5c, 620389 (3), ; nemaline myopathy 5a, severe infantile, 605355 (3), ; nemaline myopathy 5b, childhood-onset, 620386 (3),
FLJ99794	AR	netherton syndrome, 256500 (3),
FLK1	AD	{hemangioma, capillary infantile, susceptibility to}, 602089 (3), ; hemangioma, capillary infantile, somatic, 602089 (3)
FLK2		leukemia, acute lymphoblastic, somatic, 613065 (3); leukemia, acute myeloid, reduced survival in, somatic, 601626 (3); leukemia, acute myeloid, somatic, 601626 (3)
FLN	XLD,XLR,XL	otopalatodigital syndrome, type ii, 304120 (3), ; intestinal pseudoobstruction, neuronal, 300048 (3), ; cardiac valvular dysplasia, 314400 (3), ; ?fg syndrome 2, 300321 (3), ; melnick-needles syndrome, 309350 (3), ; terminal osseous dysplasia, 300244 (3), ; congenital short bowel syndrome, 300048 (3), ; otopalatodigital syndrome, type i, 311300 (3), ; heterotopia, periventricular, 1, 300049 (3), ; frontometaphyseal dysplasia 1, 305620 (3),
FLN1	XLD,XLR,XL	otopalatodigital syndrome, type ii, 304120 (3), ; intestinal pseudoobstruction, neuronal, 300048 (3), ; cardiac valvular dysplasia, 314400 (3), ; ?fg syndrome 2, 300321 (3), ; melnick-needles syndrome, 309350 (3), ; terminal osseous dysplasia, 300244 (3), ; congenital short bowel syndrome, 300048 (3), ; otopalatodigital syndrome, type i, 311300 (3), ; heterotopia, periventricular, 1, 300049 (3), ; frontometaphyseal dysplasia 1, 305620 (3),
FLN1L	AD,AR	larsen syndrome, 150250 (3), ; atelosteogenesis, type i, 108720 (3), ; atelosteogenesis, type iii, 108721 (3), ; spondylocarpotarsal synostosis syndrome, 272460 (3), ; boomerang dysplasia, 112310 (3),
FLN2	AD	cardiomyopathy, familial hypertrophic, 26, 617047 (3), ; cardiomyopathy, familial restrictive 5, 617047 (3), ; myopathy, distal, 4, 614065 (3), ; myopathy, myofibrillar, 5, 609524 (3),
FLN29		
FLNA	XLD,XLR,XL	otopalatodigital syndrome, type ii, 304120 (3), ; intestinal pseudoobstruction, neuronal, 300048 (3), ; cardiac valvular dysplasia, 314400 (3), ; ?fg syndrome 2, 300321 (3), ; melnick-needles syndrome, 309350 (3), ; terminal osseous dysplasia, 300244 (3), ; congenital short bowel syndrome, 300048 (3), ; otopalatodigital syndrome, type i, 311300 (3), ; heterotopia, periventricular, 1, 300049 (3), ; frontometaphyseal dysplasia 1, 305620 (3),
FLNB	AD,AR	larsen syndrome, 150250 (3), ; atelosteogenesis, type i, 108720 (3), ; atelosteogenesis, type iii, 108721 (3), ; spondylocarpotarsal synostosis syndrome, 272460 (3), ; boomerang dysplasia, 112310 (3),
FLNC	AD	cardiomyopathy, familial hypertrophic, 26, 617047 (3), ; cardiomyopathy, familial restrictive 5, 617047 (3), ; myopathy, distal, 4, 614065 (3), ; myopathy, myofibrillar, 5, 609524 (3),
FLOT1		
FLOT2		
flower		
FLR		
FLR1		
FLRG		
FLRN		
FLRT1		
FLRT2		
FLRT3	AD	hypogonadotropic hypogonadism 21 with anosmia, 615271 (3),
FLS353		
fls485		
FLT		
FLT1		
FLT2	AD	pfeiffer syndrome, 101600 (3), ; hypogonadotropic hypogonadism 2 with or without anosmia, 147950 (3), ; jackson-weiss syndrome, 123150 (3), ; hartsfield syndrome, 615465 (3), ; trigonocephaly 1, 190440 (3), ; osteoglophonic dysplasia, 166250 (3), ; encephalocraniocutaneous lipomatosis, somatic mosaic, 613001 (3)
FLT3		leukemia, acute lymphoblastic, somatic, 613065 (3); leukemia, acute myeloid, reduced survival in, somatic, 601626 (3); leukemia, acute myeloid, somatic, 601626 (3)
FLT3LG		
FLT4	AD	hemangioma, capillary infantile, somatic, 602089 (3); lymphatic malformation 1, 153100 (3), ; congenital heart defects, multiple types, 7, 618780 (3),
Fltp		
FLVCR	AR	ataxia, posterior column, with retinitis pigmentosa, 609033 (3),
FLVCR1	AR	ataxia, posterior column, with retinitis pigmentosa, 609033 (3),
FLVCR1-AS1		
FLVCR1-DT		
FLVCR2	AR	proliferative vasculopathy and hydranencephaly-hydrocephaly syndrome, 225790 (3),
FM-3		
FMC7	AR	?immunodeficiency, common variable, 5, 613495 (3),
FMF	AD,AR	neutrophilic dermatosis, acute febrile, 608068 (3), ; familial mediterranean fever, ar, 249100 (3), ; familial mediterranean fever, ad, 134610 (3),
FMFD1	AR	combined factor v and viii deficiency, 227300 (3),
FMI		
FMI1		
FMI2	AD	lymphatic malformation 9, 619319 (3),
Fmip		
FMLP		
FMLP-R-II		
FMLPX		
FMLPY		
FMN		
FMN1		
FMN2	AR	intellectual developmental disorder, 47, 616193 (3),
FMNL		
FMNL1		
FMNL2		
FMNL3		
FMO1		
FMO2		
FMO3	AR	trimethylaminuria, 602079 (3),
FMO4		
FMO5		
FMOD		
FMOII	AR	trimethylaminuria, 602079 (3),
FMP27		
FMP30		
FMR1	XLD,XL	fragile x tremor/ataxia syndrome, 300623 (3), ; fragile x syndrome, 300624 (3), ; premature ovarian failure 1, 311360 (3),
FMR1-AS		
FMR1-AS1		
FMR1AS		
FMR1L2		
FMR2	XL,XLR	intellectual developmental disorder, 109, 309548 (3),
FMR4		
FMRFAL		
FMRP	XLD,XL	fragile x tremor/ataxia syndrome, 300623 (3), ; fragile x syndrome, 300624 (3), ; premature ovarian failure 1, 311360 (3),
FMS	AR,AD	brain abnormalities, neurodegeneration, and dysosteosclerosis, 618476 (3), ; leukoencephalopathy, diffuse hereditary, with spheroids 1, 221820 (3),
FMT1	AR	combined oxidative phosphorylation deficiency 15, 614947 (3), ; mitochondrial complex i deficiency, nuclear type 27, 618248 (3),
FN1	AD	spondylometaphyseal dysplasia, corner fracture type, 184255 (3), ; glomerulopathy with fibronectin deposits 2, 601894 (3),
FN14		
FN3K		
FN3KL		
FN3KRP		
FN5		
FNBP1		
FNBP1L		
FNBP2		
FNBP3		
FNBP4		
FND	AR	frontonasal dysplasia 1, 136760 (3),
FNDC1		
FNDC2		
FNDC3		
FNDC3A		
FNDC3B		
FNDC4		
FNDC5		
FNDC6		
FNIP1	AR	immunodeficiency 93 and hypertrophic cardiomyopathy, 619705 (3),
FNIP2		
FNIPL		
FNK		
FNRA		
FNRB		
FNTA		
FNTB		
FNZ127		
FOAP-10		
FOAP-13		
FOAP-4		
FOCAD	AR	liver disease, severe congenital, 619991 (3),
FOE		
FOG		
FOG1		
FOG2	AD	diaphragmatic hernia 3, 610187 (3); 46xy sex reversal 9, 616067 (3), ; tetralogy of fallot, 187500 (3),
foigr	AR	muscular dystrophy, limb-girdle, 18, 615356 (3),
Folbp3		
FOLH		
FOLH1		
FOLH1B		
FOLH2		
FOLHP		
FOLR	AR	neurodegeneration due to cerebral folate transport deficiency, 613068 (3),
FOLR1	AR	neurodegeneration due to cerebral folate transport deficiency, 613068 (3),
FOLR2		
FOLR3		
FOLR4		
FOLT	AR	?megaloblastic anemia, folate-responsive, 601775 (3),
FON		
FONG		
FOP		myeloproliferative disorder, 605392 (2)
FOPNL		
FOPV		
FOR	AR	esophageal squamous cell carcinoma, somatic, 133239 (3); developmental and epileptic encephalopathy 28, 616211 (3), ; spinocerebellar ataxia, 12, 614322 (3),
FOR20		
fortilin		
FOS		
FOSB		
FOSL1		
FOSL2		
FOX-1		
FOX-2		
FOX-3		
FOXA1		
FOXA2		
FOXA3		
FOXB1		
FOXB2		
FOXC1	AD	axenfeld-rieger syndrome, type 3, 602482 (3), ; anterior segment dysgenesis 3, multiple subtypes, 601631 (3),
FOXC2	AD	lymphedema-distichiasis syndrome, 153400 (3), ; lymphedema-distichiasis syndrome with renal disease and diabetes mellitus, 153400 (3),
FOXCUT		
FOXD1		
FOXD2		
FOXD3	AD	{autoimmune disease, susceptibility to, 1}, 607836 (3),
FOXD4		
FOXD4a		
FOXD4L1		
FOXD4L2		
FOXD4L3		
FOXD4L4		
FOXD5		
FOXD6		
FOXE1	AR,AD	bamforth-lazarus syndrome, 241850 (3), ; {thyroid cancer, nonmedullary, 4}, 616534 (3),
FOXE2	AR,AD	bamforth-lazarus syndrome, 241850 (3), ; {thyroid cancer, nonmedullary, 4}, 616534 (3),
FOXE3	AR,AD	anterior segment dysgenesis 2, multiple subtypes, 610256 (3), ; {aortic aneurysm, familial thoracic 11, susceptibility to}, 617349 (3), ; cataract 34, multiple types, 612968 (3)
FOXF1	AD	alveolar capillary dysplasia with misalignment of pulmonary veins, 265380 (3),
FOXF1-AS1		
FOXF2		
FOXG1	AD	rett syndrome, congenital variant, 613454 (3),
FOXG1A	AD	rett syndrome, congenital variant, 613454 (3),
FOXG1B	AD	rett syndrome, congenital variant, 613454 (3),
FOXG1C	AD	rett syndrome, congenital variant, 613454 (3),
FOXH1		
FOXI1	AR	enlarged vestibular aqueduct, 600791 (3),
FOXI2		
FOXI3		
FOXJ1	AD	ciliary dyskinesia, primary, 43, 618699 (3),
FOXJ2		
FOXJ3		
FOXK1		
FOXK2		
FOXL1		
FOXL2	AR,AD	blepharophimosis, epicanthus inversus, and ptosis, type 2, 110100 (3), ; blepharophimosis, epicanthus inversus, and ptosis, type 1, 110100 (3), ; premature ovarian failure 3, 608996 (3),
FOXM1		
FOXN1	AD,AR	t-cell lymphopenia, infantile, with or without nail dystrophy, 618806 (3), ; t-cell immunodeficiency, congenital alopecia, and nail dystrophy, 601705 (3),
FOXN2		
FOXN3		
FOXN4		
FOXN5		
FOXN6		
FOXO1		rhabdomyosarcoma, alveolar, 268220 (3), somatic mutation
FOXO1A		rhabdomyosarcoma, alveolar, 268220 (3), somatic mutation
FOXO2		
FOXO3		
FOXO3A		
FOXO4		
FOXO6		
FOXP1	AD	intellectual developmental disorder with language impairment with or without autistic features, 613670 (3),
FOXP2	AD	speech-language disorder-1, 602081 (3),
FOXP3	XL,XLR	immunodysregulation, polyendocrinopathy, and enteropathy, 304790 (3),
FOXP4		
FOXQ1		
FOXR1		
FOXR2		
FOXRED1	AR	mitochondrial complex i deficiency, nuclear type 19, 618241 (3),
FOXRED2		
FOXS1		
FP	AR,AD	cardiomyopathy, dilated, 1gg, 613642 (3), ; mitochondrial complex ii deficiency, nuclear type 1, 252011 (3), ; neurodegeneration with ataxia and late-onset optic atrophy, 619259 (3), ; paragangliomas 5, 614165 (3),
FP17548	AR	neutral lipid storage disease with myopathy, 610717 (3),
FP588		
FPC	AR	polycystic kidney disease 4, with or without hepatic disease, 263200 (3),
FPD1	AD	paroxysmal nonkinesigenic dyskinesia 1, 118800 (3),
FPG1		
FPG2		
FPGS		
FPGT		
FPH2	AD,AR	hyperpigmentation with or without hypopigmentation, 145250 (3), ; waardenburg syndrome, type 2f, 619947 (3), ; deafness, 69, unilateral or asymmetric, 616697 (3), ; [skin/hair/eye pigmentation 7, blond/brown hair], 611664 (3)
FPM315		
FPN	AD	hemochromatosis, type 4, 606069 (3),
FPN1	AD	hemochromatosis, type 4, 606069 (3),
FPP	AD,AR,AD	parietal foramina 2, 609597 (3), ; {craniosynostosis 5, susceptibility to}, 615529 (3), ; frontonasal dysplasia 2, 613451 (3), |parietal foramina with cleidocranial dysplasia, 168550 (3), ; craniosynostosis 2, 604757 (3), ; parietal foramina 1, 168500 (3),
FPPR		
FPR		
FPR1		
FPR2		
FPR2A		
FPR3		
FPRH1		
FPRH2		
FPRL1		
FPRL2		
FPRP		
FPS		
FPTA		
FPTB		
FR	AD,AR	[blood group, swann], 601550 (3); [blood group, wright], 112050 (3); distal renal tubular acidosis 1, 179800 (3), ; [blood group, waldner], 112010 (3); spherocytosis, type 4, 612653 (3), ; [blood group, froese], 601551 (3); distal renal tubular acidosis 4 with hemolytic anemia, 611590 (3), ; {malaria, resistance to}, 611162 (3); cryohydrocytosis, 185020 (3), ; ovalocytosis, sa type, 166900 (3), ; [blood group, diego], 110500 (3)
FR-G		
FRA		
fra-1		
FRA10AC1	AR	neurodevelopmental disorder with growth retardation, dysmorphic facies, and corpus callosum abnormalities, 620113 (3),
FRA2		
FRA3B		
frabin	AR	charcot-marie-tooth disease, type 4h, 609311 (3),
FRABP	AR	charcot-marie-tooth disease, type 4h, 609311 (3),
FRAG1	AR	hyperphosphatasia with impaired intellectual development syndrome 3, 614207 (3),
fragilis4	AD	osteogenesis imperfecta, type v, 610967 (3),
FRAP	AD	focal cortical dysplasia, type ii, somatic, 607341 (3); smith-kingsmore syndrome, 616638 (3),
FRAP1	AD	focal cortical dysplasia, type ii, somatic, 607341 (3); smith-kingsmore syndrome, 616638 (3),
FRAP2	AD	focal cortical dysplasia, type ii, somatic, 607341 (3); smith-kingsmore syndrome, 616638 (3),
FRAS1	AR	fraser syndrome 1, 219000 (3),
FRAT1		
FRAT2		
FRAXA	XLD,XL	fragile x tremor/ataxia syndrome, 300623 (3), ; fragile x syndrome, 300624 (3), ; premature ovarian failure 1, 311360 (3),
FRAXE	XL,XLR	intellectual developmental disorder, 109, 309548 (3),
FRAXF		
FRCL1		
FRCP1		
FRCP2		
FRDA	AR	friedreich ataxia with retained reflexes, 229300 (3), ; friedreich ataxia, 229300 (3),
FRE	MF	{osteoarthritis susceptibility 1}, 165720 (3),
FREAC1	AD	alveolar capillary dysplasia with misalignment of pulmonary veins, 265380 (3),
FREAC10		
FREAC2		
FREAC3	AD	axenfeld-rieger syndrome, type 3, 602482 (3), ; anterior segment dysgenesis 3, multiple subtypes, 601631 (3),
FREAC4		
FREAC5		
FREAC6	AR	enlarged vestibular aqueduct, 600791 (3),
FREAC7		
FREAC8	AR,AD	anterior segment dysgenesis 2, multiple subtypes, 610256 (3), ; {aortic aneurysm, familial thoracic 11, susceptibility to}, 617349 (3), ; cataract 34, multiple types, 612968 (3)
FREAC9		
FREB		
FREB-2		
FREM1	AR,AD	manitoba oculotrichoanal syndrome, 248450 (3), ; bifid nose with or without anorectal and renal anomalies, 608980 (3), ; trigonocephaly 2, 614485 (3),
FREM2	AR	fraser syndrome 2, 617666 (3), ; cryptophthalmos, unilateral or bilateral, isolated, 123570 (3),
FREM3		
FREQ		
Freud-1	AR	intellectual developmental disorder, 3, 608443 (3),
FRG		
FRG1		
FRG1A		
FRG2		
FRG2A		
fring		
fritz	AR	?bardet-biedl syndrome 15, 615992 (3), ; congenital heart defects, hamartomas of tongue, and polysyndactyly, 217085 (3),
FRITZ	MF	{osteoarthritis susceptibility 1}, 165720 (3),
FRK		
FRMD2		
FRMD3		
FRMD4	AR	?corpus callosum, agenesis of, with facial anomalies and cerebellar ataxia, 616819 (3),
FRMD4A	AR	?corpus callosum, agenesis of, with facial anomalies and cerebellar ataxia, 616819 (3),
FRMD4B		
FRMD5	AD	neurodevelopmental disorder with eye movement abnormalities and ataxia, 620094 (3),
FRMD6		
FRMD7	XL	nystagmus, infantile periodic alternating, 310700 (3), ; nystagmus 1, congenital, 310700 (3),
FRMD8		
FRMPD1		
FRMPD2		
FRMPD3		
FRMPD4	XL	intellectual developmental disorder, 104, 300983 (3),
FRODO	AD	townes-brocks syndrome 2, 617466 (3),
FRP		
FRP-1		
FRP-2		
FRP-3	MF	{osteoarthritis susceptibility 1}, 165720 (3),
FRP-4	AR	pyle disease, 265900 (3),
FRP1	AR,AD	seckel syndrome 1, 210600 (3), ; ?cutaneous telangiectasia and cancer syndrome, familial, 614564 (3),
FRP3		
frpHE	AR	pyle disease, 265900 (3),
FRPHE	AR	pyle disease, 265900 (3),
FRRS1		
FRRS1L	AR	developmental and epileptic encephalopathy 37, 616981 (3),
FRRS2	AR	orthostatic hypotension 2, 618182 (3),
FRRS3		
FRS2		
FRS2A		
FRS2alpha		
FRS2B		
FRS2beta		
FRS3		
FRSB	AR	rajab interstitial lung disease with brain calcifications 1, 613658 (3),
fru		
fruitless		
FRY		
FRZB	MF	{osteoarthritis susceptibility 1}, 165720 (3),
FRZB-1	MF	{osteoarthritis susceptibility 1}, 165720 (3),
FRZB-2	AR	pyle disease, 265900 (3),
FRZB-PEN	MF	{osteoarthritis susceptibility 1}, 165720 (3),
FRZB1	MF	{osteoarthritis susceptibility 1}, 165720 (3),
FRÎ±	AR	neurodegeneration due to cerebral folate transport deficiency, 613068 (3),
FRÎ²		
FRÎ³		
FS		
FSA	AR	alkuraya-kucinskas syndrome, 617822 (3),
FSA-1		
FSAP	AD	{?thyroid cancer, nonmedullary, 5}, 616535 (3), ; {venous thromboembolism, susceptibility to}, 188050 (3),
fSAP105		
fSAP113		
fSAP118		
fSAP121		
fSAP152		
fSAP164		
fSAP17		
fSAP23		
fSAP24		
fSAP29		
fSAP33		
fSAP35	AR	beaulieu-boycott-innes syndrome, 613680 (3),
fSAP47		
fSAP57		
fSAP59		
fSAP79		
fSAP94		
fSAPa		
fSAPb		
fSAPc		
FSBP		
Fsc1		
FSCB		
FSCN1		
FSCN2		retinitis pigmentosa 30, 607921 (3)
FSCN3		
FSD1		
FSD1CL		
FSD1L		
FSD1NL		
Fseg		
FSG1		
FSGS1	AD	glomerulosclerosis, focal segmental, 1, 603278 (3),
FSGS2	AD	glomerulosclerosis, focal segmental, 2, 603965 (3),
FSHA		
FSHB	AR	hypogonadotropic hypogonadism 24 without anosmia, 229070 (3),
FSHD2	AD	bosma arhinia microphthalmia syndrome, 603457 (3), ; fascioscapulohumeral muscular dystrophy 2, digenic, 158901 (3), digenic
FSHPRH1		
FSHR	AR,AD	ovarian response to fsh stimulation, 276400 (3), ; ovarian hyperstimulation syndrome, 608115 (3), ; ovarian dysgenesis 1, 233300 (3),
FSHRG1		
FSHRG2		
FSHRG4		
FSHRO	AR,AD	ovarian response to fsh stimulation, 276400 (3), ; ovarian hyperstimulation syndrome, 608115 (3), ; ovarian dysgenesis 1, 233300 (3),
FSIP1		
FSIP2	AR	spermatogenic failure 34, 618153 (3),
FSL1		
fsMyBP-C		
FSP		
FSP-2		
FSP1	AD	spastic paraplegia 3a, 182600 (3), ; neuropathy, hereditary sensory, type id, 613708 (3),
FSP2	AD	spastic paraplegia 4, 182601 (3),
Fsp27	AR	?lipodystrophy, familial partial, type 5, 615238 (3),
FSP95	AR	spermatogenic failure 82, 620353 (3),
FSRP		
FSSV	AD,AD	arthrogryposis, distal, type 2b1, 601680 (3), |arthrogryposis, distal, type 2b2, 618435 (3),
FST		
FSTL1		
FSTL2	AR	retinal arterial macroaneurysm with supravalvular pulmonic stenosis, 614224 (3),
FSTL3		
FSTL5		
fsTnI	AD	arthrogryposis, distal, type 2b1, 601680 (3),
FT1A		[fucosyltransferase 6 deficiency], 613852 (3)
FTCD	AR	glutamate formiminotransferase deficiency, 229100 (3),
FTCDNL1		
FTDCR1B		
FTDP-17	AD,AR,MF	supranuclear palsy, progressive, 601104 (3), ; supranuclear palsy, progressive atypical, 260540 (3), ; dementia, frontotemporal, with or without parkinsonism, 600274 (3), ; {parkinson disease, susceptibility to}, 168600 (3), ; pick disease, 172700 (3),
fTEX		
FTF		
FTH	AD	?hemochromatosis, type 5, 615517 (3),
FTH1	AD	?hemochromatosis, type 5, 615517 (3),
FTHFD		
FTHFSDC1		
FTHL17		
FTHL6	AD	?hemochromatosis, type 5, 615517 (3),
FTL	AD,AR	hyperferritinemia-cataract syndrome, 600886 (3), ; l-ferritin deficiency, and , 615604 (3), ; neurodegeneration with brain iron accumulation 3, 606159 (3),
FTM	AR	joubert syndrome 7, 611560 (3), ; meckel syndrome 5, 611561 (3), ; ?coach syndrome 3, 619113 (3),
FTMT		
FTNB		
FTNS	AD	macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss, 155100 (3), ; deafness, 17, 603622 (3),
FTO	AR	growth retardation, developmental delay, facial dysmorphism, 612938 (3), ; {obesity, susceptibility to, bmiq14}, 612460 (3),
FTP3	XL,XLD	intellectual developmental disorder, syndromic, bain type, 300986 (3),
FTS		
FTSJ1	XL,XLR	intellectual developmental disorder, 9, 309549 (3),
FTSJ2	AR	?mitochondrial dna depletion syndrome 17, 618567 (3),
FTSJ3		
FTSJD1		
FTSJD2		
FTX		
FTZ-F1		
FTZ-F1beta		
FTZ1	AD	46xx sex reversal 4, 617480 (3), ; premature ovarian failure 7, 612964 (3), ; 46xy sex reversal 3, 612965 (3), ; adrenocortical insufficiency, 612964 (3), ; spermatogenic failure 8, 613957 (3),
FTZF1	AD	46xx sex reversal 4, 617480 (3), ; premature ovarian failure 7, 612964 (3), ; 46xy sex reversal 3, 612965 (3), ; adrenocortical insufficiency, 612964 (3), ; spermatogenic failure 8, 613957 (3),
FU	AR	?ciliary dyskinesia, primary, 46, 619436 (3),
Fub1		
Fubi		
FUBP		
FUBP1		
FUBP2		
FUBP3		
FUC-TIV		
Fuc-TIX		
FUC-TV		
FUCA1	AR	fucosidosis, 230000 (3),
FUCA2		
FUCD		
FucM		
FucT-VI		[fucosyltransferase 6 deficiency], 613852 (3)
FUCT1	AR	congenital disorder of glycosylation, type iic, 266265 (3),
FucU		
Fug1		
FUK	AR	congenital disorder of glycosylation with defective fucosylation 2, 618324 (3),
FUN20		
FUNDC1		
FUNDC2		
FUOM		
FUP1		
FUR		
FUR1		
FURIN		
FUS	AD	amyotrophic lateral sclerosis 6, with or without frontotemporal dementia, 608030 (3); essential tremor, hereditary, 4, 614782 (3),
FUS1	AD	amyotrophic lateral sclerosis 6, with or without frontotemporal dementia, 608030 (3); essential tremor, hereditary, 4, 614782 (3),
FUS2		
fusin	AD	whim syndrome 1, 193670 (3), ; myelokathexis, isolated, 193670 (3),
FUSIP1		
FUSIP2		
Fussel-18		
FUSSEL15		
FUSSEL18		
FUT1	AR	[bombay phenotype], 616754 (3),
FUT10		
FUT11		
FUT12	AD	dowling-degos disease 2, 615327 (3),
FUT13		
FUT2	AR	{norwalk virus infection, resistance to} (3); {vitamin b12 plasma level qtl1}, 612542 (3); [bombay phenotype, digenic], 616754 (3),
FUT3		[blood group, lewis], 618983 (3)
FUT4		
FUT5		
FUT6		[fucosyltransferase 6 deficiency], 613852 (3)
FUT7		
FUT8	AR	congenital disorder of glycosylation with defective fucosylation 1, 618005 (3),
FUT9		
FUZ	AD	{neural tube defects, susceptibility to}, 182940 (3),
FVIII	XL,XLR	thrombophilia 13, due to factor viii defect, 301071 (3); hemophilia a, 306700 (3),
FVSY9334	AD	aortic aneurysm, familial thoracic 12, 619825 (3),
FVT1	AR	erythrokeratodermia variabilis et progressiva 4, 617526 (3),
Fwd1		
Fwd2		
FWP007		
FX		
FXC1		
FXI	AD,AR	factor xi deficiency, 612416 (3); factor xi deficiency, 612416 (3)
FXIIIB	AR	factor xiiib deficiency, 613235 (3),
FXN	AR	friedreich ataxia with retained reflexes, 229300 (3), ; friedreich ataxia, 229300 (3),
FXNA		
FXR	AR	cholestasis, progressive familial intrahepatic, 5, 617049 (3),
FXR1	AR	congenital myopathy 9b, proximal, with minicore lesions, 618823 (3), ; ?congenital myopathy 9a with respiratory insufficiency and bone fractures, 618822 (3),
FXR2		
FXY	XLR,XL	opitz gbbb syndrome, 300000 (3),
FXY2	XL,XLR	?intellectual developmental disorder, 101, 300928 (3),
FXYD1		
FXYD2	AD	hypomagnesemia 2, renal, 154020 (3),
FXYD3		
FXYD4		
FXYD5		
FXYD6		
FXYD7		
Fy	AD	{neural tube defects, susceptibility to}, 182940 (3),
FY	AR,AD	[blood group, duffy system], 110700 (3), ; [white blood cell count qtl], 611862 (3), ; {malaria, vivax, protection against}, 611162 (3)
FYB	AR	thrombocytopenia 3, 273900 (3),
FYB-120/130	AR	thrombocytopenia 3, 273900 (3),
FYB1	AR	thrombocytopenia 3, 273900 (3),
FYB2		
FYCO1	AR	cataract 18, 610019 (3),
FYN		
FYTTD1		
FYVE-DSP1		
FZD1		
FZD10		
FZD11	AR	pallister-hall-like syndrome, 241800 (3), ; basal cell carcinoma, somatic, 605462 (3); curry-jones syndrome, somatic mosaic, 601707 (3)
FZD2	AD	omodysplasia 2, 164745 (3),
FZD3		
FZD4	AD	retinopathy of prematurity, 133780 (3), ; exudative vitreoretinopathy 1, 133780 (3),
FZD5		
FZD6	AR	nail disorder, nonsyndromic congenital, 1, 161050 (3),
FZD7		
FZD8		
FZD9		
FzE3		
FZR	AD	developmental and epileptic encephalopathy 109, 620145 (3),
FZR1	AD	developmental and epileptic encephalopathy 109, 620145 (3),
FZR2	AD	developmental and epileptic encephalopathy 109, 620145 (3),
FZRB	MF	{osteoarthritis susceptibility 1}, 165720 (3),
G-ALPHA-o	AD	developmental and epileptic encephalopathy 17, 615473 (3), ; neurodevelopmental disorder with involuntary movements, 617493 (3),
G-ALPHA-q		capillary malformations, congenital, 1, somatic, mosaic, 163000 (3); sturge-weber syndrome, somatic, mosaic, 185300 (3)
G-BBH		
G-CK	AR	raine syndrome, 259775 (3),
G-CSF		
G-CSF-R	AR,AD	neutropenia, severe congenital, 7, 617014 (3), ; ?neutrophilia, hereditary, 162830 (3),
G(gamma)13		
G0S19-1		{hiv infection, resistance to}, 609423 (2)
G0S19-2		{hiv/aids, susceptibility to}, 609423 (3)
G0S2		
G0S24		
G0S3		
G0S30		
G0S8		
G10		
G10D		
G10P1		
G10P2		
G11		
G12-like		
G13		
g16		
G16		
G17	AR	developmental and epileptic encephalopathy 102, 619881 (3),
G17P1		
G18		{malaria, susceptibility to}, 611162 (3); {bacteremia, susceptibility to}, 614383 (3); {tuberculosis, susceptibility to}, 607948 (3)
G18.1a		
G18.1b		
G18.2		
G19P1	AD	polycystic liver disease 1, 174050 (3),
G1L		
G1P1	AD,AR	dyschromatosis symmetrica hereditaria, 127400 (3), ; aicardi-goutieres syndrome 6, 615010 (3),
G1P2	AR	immunodeficiency 38, 616126 (3),
G1P3		
G1RZFP		
G1SYN		
G2		
G22P1		
G25K	AD	takenouchi-kosaki syndrome, 616737 (3),
G2A		
G2AD		
G2AN	AD	polycystic kidney disease 3, 600666 (3),
G2E3		
G2SYN		
G3		
G30		
G344	AR	hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy, 612300 (3),
G3a		
G3BP		
G3BP1		
G3BP2		
G4-1	AD,AR	spermatogenic failure 36, 618420 (3), ; myoectodermal gonadal dysgenesis syndrome, 618419 (3),
G4.5	XLR,XL	barth syndrome, 302060 (3),
G5		
G5b		
G5c		
G5PR	AD,AR	spermatogenic failure 36, 618420 (3), ; myoectodermal gonadal dysgenesis syndrome, 618419 (3),
G6		
G6A		
G6b	AR	?thrombocytopenia, anemia, and myelofibrosis, 617441 (3),
G6b-B	AR	?thrombocytopenia, anemia, and myelofibrosis, 617441 (3),
G6c		
G6D		
G6e		
G6f		
G6PC	AR	glycogen storage disease ia, 232200 (3),
G6PC1	AR	glycogen storage disease ia, 232200 (3),
G6PC2		
G6PC3	AR	dursun syndrome, 612541 (3), ; neutropenia, severe congenital 4, 612541 (3),
G6PD	XL	hemolytic anemia, g6pd deficient (favism), 300908 (3), ; {resistance to malaria due to g6pd deficiency}, 611162 (3)
G6PD1	XL	hemolytic anemia, g6pd deficient (favism), 300908 (3), ; {resistance to malaria due to g6pd deficiency}, 611162 (3)
G6PT	AR,AR,AD	glycogen storage disease ia, 232200 (3), |glycogen storage disease ib, 232220 (3), ; congenital disorder of glycosylation, type iiw, 619525 (3), ; glycogen storage disease ic, 232240 (3),
G6PT1	AR,AD	glycogen storage disease ib, 232220 (3), ; congenital disorder of glycosylation, type iiw, 619525 (3), ; glycogen storage disease ic, 232240 (3),
G6PT2	AR,AD	glycogen storage disease ib, 232220 (3), ; congenital disorder of glycosylation, type iiw, 619525 (3), ; glycogen storage disease ic, 232240 (3),
G6PT3	AR,AD	glycogen storage disease ib, 232220 (3), ; congenital disorder of glycosylation, type iiw, 619525 (3), ; glycogen storage disease ic, 232240 (3),
G7	AR	?premature ovarian failure 13, 617442 (3), ; spermatogenic failure 74, 619937 (3),
G72	AD	{schizophrenia}, 181500 (2),
G7a	AR	combined oxidative phosphorylation deficiency 20, 615917 (3),
G7b		
G7c		
G7P1		
G8		
G9A		
GA		
GA17		
GA2	AR	glutaric acidemia iia, 231680 (3),
GA733-1	AR	corneal dystrophy, gelatinous drop-like, 204870 (3),
GA733-2	AR,AD	diarrhea 5, with tufting enteropathy, congenital, 613217 (3), ; lynch syndrome 8, 613244 (3),
GAA	AR	glycogen storage disease ii, 232300 (3),
GAA1	AR	glycosylphosphatidylinositol biosynthesis defect 15, 617810 (3),
GAAP		
GAB1	AR,AR	?deafness, 26, 605428 (3), |neurodevelopmental disorder with brain anomalies, seizures, and scoliosis, 618590 (3),
GAB2		
GAB3		
GABA-T	AR	gaba-transaminase deficiency, 613163 (3),
GABABL		
GABABR2	AD	{nicotine dependence, protection against}, 188890 (3); {nicotine dependence, susceptibility to}, 188890 (3); developmental and epileptic encephalopathy 59, 617904 (3), ; neurodevelopmental disorder with poor language and loss of hand skills, 617903 (3),
Gababrbp		
GABARAP		
GABARAPL1		
GABARAPL2		
GABAT	AR	gaba-transaminase deficiency, 613163 (3),
GABATHG	AD	myoclonic-atonic epilepsy, 616421 (3),
GABATR	AD	myoclonic-atonic epilepsy, 616421 (3),
GABBR1		
GABBR2	AD	{nicotine dependence, protection against}, 188890 (3); {nicotine dependence, susceptibility to}, 188890 (3); developmental and epileptic encephalopathy 59, 617904 (3), ; neurodevelopmental disorder with poor language and loss of hand skills, 617903 (3),
GABPA		
GABPB		
GABPB1		
GABPB2		
GABRA1	AD	{epilepsy, juvenile myoclonic, susceptibility to, 5}, 611136 (3); developmental and epileptic encephalopathy 19, 615744 (3), ; {epilepsy, childhood absence, susceptibility to, 4}, 611136 (3)
GABRA2	AD,MF	developmental and epileptic encephalopathy 78, 618557 (3), ; {alcohol dependence, susceptibility to}, 103780 (3),
GABRA3	XL	epilepsy, 2, with or without impaired intellectual development and dysmorphic features, 301091 (3),
GABRA4		
GABRA5	AD	developmental and epileptic encephalopathy 79, 618559 (3),
GABRA6		
GABRB1	AD	developmental and epileptic encephalopathy 45, 617153 (3),
GABRB2	AD	developmental and epileptic encephalopathy 92, 617829 (3),
GABRB3	AD	{epilepsy, childhood absence, susceptibility to, 5}, 612269 (3); developmental and epileptic encephalopathy 43, 617113 (3),
GABRD	AD	{epilepsy, idiopathic generalized, 10}, 613060 (3), ; {epilepsy, juvenile myoclonic, susceptibility to}, 613060 (3), ; {generalized epilepsy with febrile seizures plus, type 5, susceptibility to}, 613060 (3),
GABRE		
GABRG1		
GABRG2	AD	developmental and epileptic encephalopathy 74, 618396 (3), ; febrile seizures, familial, 8, 607681 (3), ; generalized epilepsy with febrile seizures plus, type 3, 607681 (3),
GABRG3		
GABRP		
GABRQ		
GABRR1		
GABRR2		
GABRR3		
GAC	AR,AD	global developmental delay, progressive ataxia, and elevated glutamine, 618412 (3), ; ?infantile cataract, skin abnormalities, glutamate excess, and impaired intellectual development, 618339 (3), ; developmental and epileptic encephalopathy 71, 618328 (3),
GAC-1		
GAC1		
GAC63	AR	birk-landau-perez syndrome, 617595 (3),
GACAT2		
GACAT3		
GAD	AR	developmental and epileptic encephalopathy 89, 619124 (3),
GAD1	AR	developmental and epileptic encephalopathy 89, 619124 (3),
GAD2		
GAD65		
GADD153		
GADD33		
GADD34		
GADD45		
GADD45A		
GADD45B		
GADD45BETA		
GADD45G		
GADD45gamma		
GADD45GIP1		
GADL1		
GADS		
GAF1		
GAGE-7		
GAGE-9		
GAGE1		
GAGE10		
GAGE11		
GAGE12A		
GAGE12C		
GAGE12D		
GAGE12E		
GAGE12F		
GAGE12G		
GAGE12H		
GAGE12I		
GAGE12J		
GAGE13		
GAGE2		
GAGE2A		
GAGE2B		
GAGE2C		
GAGE2D		
GAGE2E		
GAGE3		
GAGE4		
GAGE5		
GAGE6		
GAGE7		
GAGE7B		
GAGE8		
GAGEB1		
GAGEC1		
GAGEC2		
GAGED1		
GAGED2		
GAGED3		
GAGED4		
GAGED5		
GAH		
GAIP		
GAJ		
GAK		
GAKIN		
GAL	AD	?epilepsy, familial temporal lobe, 8, 616461 (3),
Gal-10		
GAL-GMAP	AD	?epilepsy, familial temporal lobe, 8, 616461 (3),
GAL3ST1		
GAL3ST2		
GAL3ST3		
GAL3ST4		
GAL4		
GAL7		
GALA	XL	fabry disease, cardiac variant, 301500 (3), ; fabry disease, 301500 (3),
GALC	AR	krabbe disease, 245200 (3),
GALE	AR	galactose epimerase deficiency, 230350 (3),
GALGT	AR	spastic paraplegia 26, 609195 (3),
GALGT2		[blood group, sid system], 615018 (3); sd(a) polyagglutination syndrome, 615018 (3)
GALIG		
GALK	AR	galactokinase deficiency with cataracts, 230200 (3),
GALK1	AR	galactokinase deficiency with cataracts, 230200 (3),
GALK2		
GALM	AR	galactosemia iv, 618881 (3),
GALN	AD	?epilepsy, familial temporal lobe, 8, 616461 (3),
GalN6S	AR	mucopolysaccharidosis iva, 253000 (3),
GALNAC-4-ST2		
GalNAc-T1		
GalNac-T10		
GalNAc-T10		
GalNAc-T11		
GalNAc-T12		{colorectal cancer, susceptibility to, 1}, 608812 (3)
GalNAc-T13		
GalNac-T14		
GalNAc-T16		
GalNAc-T17		
GalNAc-T18		
GalNAc-T19		
GalNAc-T2	AR	congenital disorder of glycosylation, type iit, 618885 (3),
GalNAc-T3	AR	tumoral calcinosis, hyperphosphatemic, familial, 1, 211900 (3),
GalNAc-T4		
GalNAc-T5		
GalNAc-T5L		
GalNAc-T6		
GalNAc-T6L		
GALNAC-T7		
GALNAC-T8		
GALNAC-T9		
GALNAC4S-6ST		
GALNAC4ST-1	AR	?peeling skin syndrome 3, 616265 (3),
GALNAC4ST-2		
GALNAC6S	AR	mucopolysaccharidosis iva, 253000 (3),
GALNACT-2		
GALNACT2		
GALNR		
GALNR1		
GALNR2		
GALNS	AR	mucopolysaccharidosis iva, 253000 (3),
GALNT1		
GALNT10		
GALNT11		
GALNT12		{colorectal cancer, susceptibility to, 1}, 608812 (3)
GALNT13		
GALNT14		
GALNT15		
GALNT16		
GALNT17		
GALNT18		
GALNT2	AR	congenital disorder of glycosylation, type iit, 618885 (3),
GALNT3	AR	tumoral calcinosis, hyperphosphatemic, familial, 1, 211900 (3),
GALNT4		
GALNT5		
GALNT6		
GALNT7		
GALNT8		
GALNT9		
GALNTL1		
GALNTL2		
GALNTL3		
GALNTL4		
GALNTL5		
GALNTL6		
GALP		
GALR1		
GALR2		
GALR3		
GALR4		
GALT	AR	galactosemia, 230400 (3),
galT3		[blood group, p1pk system, p(k) phenotype], 111400 (3); [blood group, globoside system], 615021 (3)
GalT4		
GAM	AR,AD	global developmental delay, progressive ataxia, and elevated glutamine, 618412 (3), ; ?infantile cataract, skin abnormalities, glutamate excess, and impaired intellectual development, 618339 (3), ; developmental and epileptic encephalopathy 71, 618328 (3),
Gamm1		
gamma-BAR		
gamma-BBH		
GAMT	AR	cerebral creatine deficiency syndrome 2, 612736 (3),
GAN	AR	giant axonal neuropathy-1, 256850 (3),
GAN1	AR	giant axonal neuropathy-1, 256850 (3),
GANAB	AD	polycystic kidney disease 3, 600666 (3),
GANC		
GANP	AR	peripheral neuropathy, with or without impaired intellectual development, 618124 (3),
GAP	AD	capillary malformation-arteriovenous malformation 1, 608354 (3), ; basal cell carcinoma, somatic, 605462 (3)
GAP-43		
GAP-B3	AR	epidermolysis bullosa, junctional 7, with interstitial lung disease and nephrotic syndrome, 614748 (3),
GAP1IP4BP		
GAP1M		
GAP43		
GAPCenA		
GAPD		
GAPD2		
GAPDH		
GAPDH-2		
GAPDHS		
GAPDL5		
GAPDS		
GAPIII		
GAPL		
GAPR-1		
GAPVD1		
GAQ		capillary malformations, congenital, 1, somatic, mosaic, 163000 (3); sturge-weber syndrome, somatic, mosaic, 185300 (3)
GAR1	AR	retinitis pigmentosa 45, 613767 (3),
GAR17	AR	?ciliary dyskinesia, primary, 41, 618449 (3),
GAR22		
GAREM		
GAREM1		
GAREM2		
GAREML		
GARG-16		
GARG-39		
GARG-49		
GARI		
GARI-L1		
GARI-L2		
GARI-L3		
GARI-L4		
GARIL5		
GARIN1A		
GARIN1B		
GARIN2		
GARIN3		
GARIN4		
GARIN5A		
GARLH4		
GARNL1	AR	neurodevelopmental disorder with hypotonia, neonatal respiratory insufficiency, and thermodysregulation, 618797 (3),
GARNL4		
GARP	AR,AR	cleft palate, proliferative retinopathy, and developmental delay, 619074 (3), |retinitis pigmentosa 45, 613767 (3),
GARPL1	AR	seizures, early-onset, with neurodegeneration and brain calcification, 618875 (3),
GARRE1		
GARS	AD	spinal muscular atrophy, infantile, james type, 619042 (3), ; neuronopathy, distal hereditary motor, type va, 600794 (3), ; charcot-marie-tooth disease, type 2d, 601472 (3),
GARS-AIRS-GART		
GARS1	AD	spinal muscular atrophy, infantile, james type, 619042 (3), ; neuronopathy, distal hereditary motor, type va, 600794 (3), ; charcot-marie-tooth disease, type 2d, 601472 (3),
GART		
GAS	AR	mucopolysaccharidosis iva, 253000 (3),
GAS1		
GAS11	AR	ciliary dyskinesia, primary, 33, 616726 (3),
GAS2		
GAS2L1		
GAS2L2	AR	?ciliary dyskinesia, primary, 41, 618449 (3),
GAS2L3		
GAS3	AD,AR	charcot-marie-tooth disease, type 1a, 118220 (3), ; roussy-levy syndrome, 180800 (3), ; charcot-marie-tooth disease, type 1e, 118300 (3), ; ?neuropathy, inflammatory demyelinating, 139393 (3), ? ; neuropathy, recurrent, with pressure palsies, 162500 (3), ; dejerine-sottas disease, 145900 (3),
GAS41		
GAS5		
GAS6		
GAS7		
GAS8	AR	ciliary dyskinesia, primary, 33, 616726 (3),
GAS8-AS1		
GAS9		gastrointestinal stromal tumor/gist-plus syndrome, somatic or familial, 175510 (3); hypereosinophilic syndrome, idiopathic, resistant to imatinib, 607685 (3), somatic mutation, isolated cases
GASC1		
GASK1A		
GASP		
GASP1		
GASP10		
GASP2	XL,XLR	?deafness, 7, 301018 (3),
GASP3		
GASP4		
GASP5		
GASP6		
GASP7		
GASP9		
GAST		
GASZ		
GAT		
GAT-1	AD	myoclonic-atonic epilepsy, 616421 (3),
GAT1	AD	myoclonic-atonic epilepsy, 616421 (3),
GAT2		
GAT3		
GatA	AR	combined oxidative phosphorylation deficiency 40, 618835 (3),
GATA	AR	combined oxidative phosphorylation deficiency 40, 618835 (3),
GATA-1	XL,XLR	leukemia, megakaryoblastic, with or without down syndrome, somatic, 190685 (3); thrombocytopenia, with or without dyserythropoietic anemia, 300367 (3), ; anemia, with/without neutropenia and/or platelet abnormalities, 300835 (3), ; thrombocytopenia with beta-thalassemia, 314050 (3), ; hemolytic anemia due to elevated adenosine deaminase, 301083 (3),
GATA1	XL,XLR	leukemia, megakaryoblastic, with or without down syndrome, somatic, 190685 (3); thrombocytopenia, with or without dyserythropoietic anemia, 300367 (3), ; anemia, with/without neutropenia and/or platelet abnormalities, 300835 (3), ; thrombocytopenia with beta-thalassemia, 314050 (3), ; hemolytic anemia due to elevated adenosine deaminase, 301083 (3),
GATA2	AD	{leukemia, acute myeloid, susceptibility to}, 601626 (3), somatic mutation, ; emberger syndrome, 614038 (3), ; immunodeficiency 21, 614172 (3), ; {myelodysplastic syndrome, susceptibility to}, 614286 (3)
GATA3	AD	hypoparathyroidism, sensorineural deafness, and renal dysplasia, 146255 (3),
GATA4	AD	tetralogy of fallot, 187500 (3), ; atrial septal defect 2, 607941 (3), ; ventricular septal defect 1, 614429 (3), ; atrioventricular septal defect 4, 614430 (3), ; ?testicular anomalies with or without congenital heart disease, 615542 (3),
GATA5	AR,AD	congenital heart defects, multiple types, 5, 617912 (3),
GATA6	AD	atrial septal defect 9, 614475 (3), ; persistent truncus arteriosus, 217095 (3); pancreatic agenesis and congenital heart defects, 600001 (3), ; atrioventricular septal defect 5, 614474 (3), ; tetralogy of fallot, 187500 (3),
GATAD1	AR	?cardiomyopathy, dilated, 2b, 614672 (3),
GATAD2A		
GATAD2B	AD	gand syndrome, 615074 (3),
GATAD3		
GATAS	AR,AD	congenital heart defects, multiple types, 5, 617912 (3),
GATB	AR	?combined oxidative phosphorylation deficiency 41, 618838 (3),
GATC	AR	combined oxidative phosphorylation deficiency 42, 618839 (3),
GATD10		
GATD2	AR	parkinson disease 7, early-onset, 606324 (3),
GATD3		
GATD3A		
GATD4	AR	developmental and epileptic encephalopathy 50, 616457 (3),
GATD5A	AR	immunodeficiency 24, 615897 (3),
GATD5B		
GATD6	AR	carbamoylphosphate synthetase i deficiency, 237300 (3), ; {pulmonary hypertension, neonatal, susceptibility to}, 615371 (3)
GATD7		
GATD8		
GATD9A		
GATD9B		
GATE-16		
GATE16		
GATM	AR,AD	cerebral creatine deficiency syndrome 3, 612718 (3), ; fanconi renotubular syndrome 1, 134600 (3),
GATSL1		
GATSL2		
GATSL3		
GAX		
gb110		
GB14		
Gb3S		[blood group, p1pk system, p(2) phenotype], 111400 (3); nor polyagglutination syndrome, 111400 (3); [blood group, p1pk system, p phenotype], 111400 (3)
GB5	AR	language delay and adhd/cognitive impairment with or without cardiac arrhythmia, 617182 (3), ; intellectual developmental disorder with cardiac arrhythmia, 617173 (3),
GBA	AD,AR,MF	{lewy body dementia, susceptibility to}, 127750 (3), ; gaucher disease, type ii, 230900 (3), ; gaucher disease, type iiic, 231005 (3), ; gaucher disease, type iii, 231000 (3), ; gaucher disease, type i, 230800 (3), ; gaucher disease, perinatal lethal, 608013 (3), ; {parkinson disease, late-onset, susceptibility to}, 168600 (3),
GBA1	AD,AR,MF	{lewy body dementia, susceptibility to}, 127750 (3), ; gaucher disease, type ii, 230900 (3), ; gaucher disease, type iiic, 231005 (3), ; gaucher disease, type iii, 231000 (3), ; gaucher disease, type i, 230800 (3), ; gaucher disease, perinatal lethal, 608013 (3), ; {parkinson disease, late-onset, susceptibility to}, 168600 (3),
GBA2	AR	spastic paraplegia 46, 614409 (3),
GBA3		
GBAS		
GBD1	AR,AD	gallbladder disease 1, 600803 (3), ; cholestasis, intrahepatic, of pregnancy, 3, 614972 (3), ; cholestasis, progressive familial intrahepatic 3, 602347 (3),
GBD4	AR	sitosterolemia 1, 210250 (3), ; {gallbladder disease 4}, 611465 (3)
GBDR1		
GBE1	AR	glycogen storage disease iv, 232500 (3), ; polyglucosan body disease, adult form, 263570 (3),
GbetaL		
GBF		gastric cancer, somatic, 613659 (3); prostate cancer, somatic, 176807 (3)
GBF1	AD	charcot-marie-tooth disease, axonal, type 2gg, 606483 (3),
GBGT1		
GBIF		
GBL		
GBP	AR	hellp syndrome, maternal, of pregnancy, 609016 (3), ; lchad deficiency, 609016 (3), ; mitochondrial trifunctional protein deficiency 1, 609015 (3), ; fatty liver, acute, of pregnancy, 609016 (3),
GBP1		
GBP2		
GBP28	AD	adiponectin deficiency, 612556 (3),
GBP3		
GBP4		
GBP4L		
GBP5		
GBP6		
GBP7		
GBPI-1		
GBTS1		
GBX1		
GBX2		
GC		
GC-1	AR	developmental and epileptic encephalopathy 3, 609304 (3),
GC-B	AD,AR	epiphyseal chondrodysplasia, miura type, 615923 (3), ; short stature with nonspecific skeletal abnormalities, 616255 (3), ; acromesomelic dysplasia 1, maroteaux type, 602875 (3),
GC-C	AD,AR	diarrhea 6, 614616 (3), ; meconium ileus, 614665 (3),
GC-F		
GC-GAP		
GC-LRR		
GC-S-beta-1		
GC-SA2		
GC-SA3	AR	moyamoya 6 with achalasia, 615750 (3),
GC-SB2		
GC-SB3		
GC-UNC45	AR	osteootohepatoenteric syndrome, 619377 (3),
GC1	AR	{microvascular complications of diabetes 6}, 612634 (3)|developmental and epileptic encephalopathy 3, 609304 (3),
gC1Q-R	AR	combined oxidative phosphorylation deficiency 33, 617713 (3),
gC1qR	AR	combined oxidative phosphorylation deficiency 33, 617713 (3),
GC36		
GC79	AD	trichorhinophalangeal syndrome, type iii, 190351 (3), ; trichorhinophalangeal syndrome, type i, 190350 (3),
GCA		
GCAF	AR	dysostosis multiplex, ain-naz type, 619345 (3),
GCAP	AD	cone-rod dystrophy 14, 602093 (3), ; cone dystrophy-3, 602093 (3),
GCAP-1	AD	cone-rod dystrophy 14, 602093 (3), ; cone dystrophy-3, 602093 (3),
GCAP-2		retinitis pigmentosa 48, 613827 (3)
GCAP-I	AD	cone-rod dystrophy 14, 602093 (3), ; cone dystrophy-3, 602093 (3),
GCAP-II		retinitis pigmentosa 48, 613827 (3)
GCAP1	AD	cone-rod dystrophy 14, 602093 (3), ; cone dystrophy-3, 602093 (3),
GCAP2		retinitis pigmentosa 48, 613827 (3)
GCAP3		
GCAT		
GCC	AD,AR	diarrhea 6, 614616 (3), ; meconium ileus, 614665 (3),
GCC1		
GCC185		
GCC1P		
GCC2		
GCC88		
GCD	AR	glutaricaciduria, type i, 231670 (3),
GCD10	AR	combined oxidative phosphorylation deficiency 57, 620167 (3),
GCDFP-15		
GCDFP15		
GCDH	AR	glutaricaciduria, type i, 231670 (3),
GCDP		
GCET1		
GCET2		
GCF		
GCF-2		
GCF2		
GCFC		
GCFC1		
GCFC2		
GCFX	AR,AD,AD,AR	short stature, idiopathic familial, 300582 (3); langer mesomelic dysplasia, 249700 (3), pseudo ; leri-weill dyschondrosteosis, 127300 (3), pseudo |short stature, idiopathic familial, 300582 (3); leri-weill dyschondrosteosis, 127300 (3), pseudo ; langer mesomelic dysplasia, 249700 (3), pseudo
GCG		
GCG1		
GCGR	AR	mahvash disease, 619290 (3),
GCH	AR,AD	dystonia, dopa-responsive, 128230 (3), ; hyperphenylalaninemia, bh4-deficient, b, 233910 (3),
GCH1	AR,AD	dystonia, dopa-responsive, 128230 (3), ; hyperphenylalaninemia, bh4-deficient, b, 233910 (3),
GCHFR		
GCIP		
GCK	AD,AR	mody, type ii, 125851 (3), ; diabetes mellitus, permanent neonatal 1, 606176 (3), ; hyperinsulinemic hypoglycemia, familial, 3, 602485 (3), ; diabetes mellitus, noninsulin-dependent, late onset, 125853 (3),
GCKR		[fasting plasma glucose level qtl 5], 613463 (3)
GCL		
GCL1		
GCLC	AR	{myocardial infarction, susceptibility to}, 608446 (3); hemolytic anemia due to gamma-glutamylcysteine synthetase deficiency, 230450 (3),
GCLM		{myocardial infarction, susceptibility to}, 608446 (3)
GClnc1		{microvascular complications of diabetes 6}, 612634 (3)
GCM1		
GCM2	AR,AD	hypoparathyroidism, familial isolated 2, 618883 (3), ; hyperparathyroidism 4, 617343 (3),
GCMA		
GCMB	AR,AD	hypoparathyroidism, familial isolated 2, 618883 (3), ; hyperparathyroidism 4, 617343 (3),
GCN1		
GCN1L		
GCN1L1		
GCN2	AR	pulmonary venoocclusive disease 2, 234810 (3),
GCN5		
GCN5L		
GCN5L1		
GCN5L2		
GCNA	XL	spermatogenic failure, 4, 301077 (3),
GCNF		
GCNF1		
GCNT1		
GCNT2	AD,AR	[blood group, ii], 110800 (3), ; adult i phenotype without cataract, 110800 (3), ; cataract 13 with adult i phenotype, 116700 (3),
GCNT3		
GCNT4		
GCNT5	AD,AR	[blood group, ii], 110800 (3), ; adult i phenotype without cataract, 110800 (3), ; cataract 13 with adult i phenotype, 116700 (3),
GCOM1		
GCOM2		
GCP	XL,XLR	colorblindness, deutan, 303800 (3), ; blue cone monochromacy, 303700 (3),
GCP-1		
GCP-2		
GCP-WD		
GCP16		
GCP170		
GCP2	AR	pachygyria, microcephaly, developmental delay, and dysmorphic facies, with or without seizures, 618737 (3),
GCP3		
GCP372		
GCP4	AR	microcephaly and chorioretinopathy, 3, 616335 (3),
GCP5		
GCP6	AR	microcephaly and chorioretinopathy, 1, 251270 (3),
GCP60		
GCPHLP		
GCPII		
GCPIII		
GCPL1	AR	galloway-mowat syndrome 3, 617729 (3),
GCPS	AD	greig cephalopolysyndactyly syndrome, 175700 (3), ; polydactyly, postaxial, types a1 and b, 174200 (3), ; pallister-hall syndrome, 146510 (3), ; polydactyly, preaxial, type iv, 174700 (3),
GCR2		
GCS	AR	{myocardial infarction, susceptibility to}, 608446 (3); hemolytic anemia due to gamma-glutamylcysteine synthetase deficiency, 230450 (3),
GCS1	AR	congenital disorder of glycosylation, type iib, 606056 (3),
GCS1L		
GCSAM		
GCSF		
GCSFR	AR,AD	neutropenia, severe congenital, 7, 617014 (3), ; ?neutrophilia, hereditary, 162830 (3),
GCSH		multiple mitochondrial dysfunctions syndrome 7, 620423 (3)
GCSL	AR	dihydrolipoamide dehydrogenase deficiency, 246900 (3),
GCSP	AR	glycine encephalopathy1, 605899 (3),
GCST		glycine encephalopathy 2, 620398 (3)
GCT		
GCTG		
GCX-1		
GD		
GdA		
GDA		
GDAP1	AR,AD	charcot-marie-tooth disease, axonal, with vocal cord paresis, 607706 (3), ; charcot-marie-tooth disease, intermediate, a, 608340 (3), ; charcot-marie-tooth disease, axonal, type 2k, 607831 (3), ; charcot-marie-tooth disease, type 4a, 214400 (3),
GDAP2	AR	spinocerebellar ataxia, 27, 618369 (3),
GDCA		
GDCF-2	AD	{mycobacterium tuberculosis, susceptibility to}, 607948 (3); {hiv-1, resistance to}, 609423 (3); {coronary artery disease, modifier of} (3); {spina bifida, susceptibility to}, 182940 (3),
GDD1	AR,AD	muscular dystrophy, limb-girdle, 12, 611307 (3), ; miyoshi muscular dystrophy 3, 613319 (3), ; gnathodiaphyseal dysplasia, 166260 (3),
GDDR		
GDE	AR	glycogen storage disease iiia, 232400 (3), ; glycogen storage disease iiib, 232400 (3),
GDE1		
GDE2		
GDE3		
GDE4		
GDE5		
GDEP		
GdF		
GDF1	AD,AR	congenital heart defects, multiple types, 6, 613854 (3), ; right atrial isomerism (ivemark), 208530 (3),
GDF10		
GDF11	AD	?vertebral hypersegmentation and orofacial anomalies, 619122 (3),
GDF15		
GDF2	AD	telangiectasia, hereditary hemorrhagic, type 5, 615506 (3),
GDF3	AD	klippel-feil syndrome 3, 613702 (3); microphthalmia, isolated, with coloboma 6, 613703 (3), ; microphthalmia, isolated 7, 613704 (3),
GDF5	AR,AD	acromesomelic dysplasia 2a, 200700 (3), ; acromesomelic dysplasia 2b, 228900 (3), ; multiple synostoses syndrome 2, 610017 (3), ; symphalangism, proximal, 1b, 615298 (3), ; brachydactyly, type a2, 112600 (3), ; ?acromesomelic dysplasia 2c, hunter-thompson type, 201250 (3), ; brachydactyly, type c, 113100 (3), ; {osteoarthritis-5}, 612400 (3); brachydactyly, type a1, c, 615072 (3),
GDF6	AD,AR	microphthalmia with coloboma 6, digenic, 613703 (3), ; microphthalmia, isolated 4, 613094 (3); leber congenital amaurosis 17, 615360 (3), ; multiple synostoses syndrome 4, 617898 (3), ; klippel-feil syndrome 1, 118100 (3),
GDF7		
GDF8	AR	?muscle hypertrophy, 614160 (3),
GDF9	AR	?premature ovarian failure 14, 618014 (3),
GDF9B	XL	premature ovarian failure 4, 300510 (3), ; ovarian dysgenesis 2, 300510 (3),
GDH	AR,AR,AD	cortisone reductase deficiency 1, 604931 (3), |developmental and epileptic encephalopathy 84, 618792 (3), |hyperinsulinism-hyperammonemia syndrome, 606762 (3),
GDH1	AD	hyperinsulinism-hyperammonemia syndrome, 606762 (3),
GDI1	XL,XLD	intellectual developmental disorder, 41, 300849 (3),
GDI2		
GDIA1	AR	nephrotic syndrome, type 8, 615244 (3),
GDIA2		
GDID4		
GDIL	XL,XLD	intellectual developmental disorder, 41, 300849 (3),
GDN		
GDNF	AD	{hirschsprung disease, susceptibility to, 3}, 613711 (3),
GDNFR	AR	renal hypodysplasia/aplasia 4, 619887 (3),
GDNFRA	AR	renal hypodysplasia/aplasia 4, 619887 (3),
GDNFRB		
Gdown		
Gdown1		
GDPD1		
GDPD2		
GDPD3		
GDPD5		
GDPD6		
GDPGP1		
GdS		
GDT1	AR	congenital disorder of glycosylation, type iik, 614727 (3),
GDX		
Ge		[blood group, gerbich], 616089 (3); {malaria, resistance to}, 611162 (3)
Ge-1		
gec1		
GEF		
GEF-H1	AR	?neurodevelopmental disorder with midbrain and hindbrain malformations, 617523 (3),
Gef10	AD	?slowed nerve conduction velocity, ad, 608236 (3),
GEF16		
GEF2		
GEF3		
GEF5		
GEF720	AR	spinal muscular atrophy, distal, 4, 611067 (3), ; charcot-marie-tooth disease, intermediate c, 615376 (3),
GEFH1	AR	?neurodevelopmental disorder with midbrain and hindbrain malformations, 617523 (3),
GEFSP2	AD	developmental and epileptic encephalopathy 6b, non-dravet, 619317 (3), ; migraine, familial hemiplegic, 3, 609634 (3), ; dravet syndrome, 607208 (3), ; febrile seizures, familial, 3a, 604403 (3), ; generalized epilepsy with febrile seizures plus, type 2, 604403 (3),
GEFT		
Gem	AD	meier-gorlin syndrome 6, 616835 (3),
GEM		
GEMC1		
GEMIN1	AR,AR	{spinal muscular atrophy, type iii, modifier of}, 253400 (3), |spinal muscular atrophy-2, 253550 (3), ; spinal muscular atrophy-4, 271150 (3), ; spinal muscular atrophy-3, 253400 (3), ; spinal muscular atrophy-1, 253300 (3),
GEMIN2		
GEMIN3		
GEMIN4	AR	neurodevelopmental disorder with microcephaly, cataracts, and renal abnormalities, 617913 (3),
GEMIN5	AR	neurodevelopmental disorder with cerebellar atrophy and motor dysfunction, 619333 (3),
GEMIN6		
GEMIN7		
GEMIN8		
Gen		
GEN1		
GENE-33		
gene59		
Genesis	AD	{autoimmune disease, susceptibility to, 1}, 607836 (3),
GENX-3414		
GENX-3947	AD	dystonia 24, 615034 (3),
gep		
GEP100	AR	intellectual developmental disorder with short stature and behavioral abnormalities, 618687 (3),
GERP	AD	focal segmental glomerulosclerosis and neurodevelopmental syndrome, 619428 (3),
GES		
GET		
GET1		
GET2	AR	?congenital disorder of glycosylation, type iiz, 620201 (3),
GET3	AR	?cardiomyopathy, dilated, 2h, 620203 (3),
GET4	AR	?congenital disorder of glycosylation, type iiy, 620200 (3),
GET5		
GF1	XL,XLR,AD	leukemia, megakaryoblastic, with or without down syndrome, somatic, 190685 (3); thrombocytopenia, with or without dyserythropoietic anemia, 300367 (3), ; anemia, with/without neutropenia and/or platelet abnormalities, 300835 (3), ; thrombocytopenia with beta-thalassemia, 314050 (3), ; hemolytic anemia due to elevated adenosine deaminase, 301083 (3), |noonan syndrome 4, 610733 (3), ; ?fibromatosis, gingival, 1, 135300 (3),
GFA	AR	myasthenia, congenital, 12, with tubular aggregates, 610542 (3),
GFAP	AD	alexander disease, 203450 (3),
GFAT	AR	myasthenia, congenital, 12, with tubular aggregates, 610542 (3),
GFAT1	AR	myasthenia, congenital, 12, with tubular aggregates, 610542 (3),
GFAT2		
GFER	AR	myopathy, mitochondrial progressive, with congenital cataract and developmental delay, 613076 (3),
gfg		
gfg-1		
GFI-1	AD	?neutropenia, nonimmune chronic idiopathic, of adults, 607847 (3), ; neutropenia, severe congenital 2, 613107 (3),
GFI1	AD	?neutropenia, nonimmune chronic idiopathic, of adults, 607847 (3), ; neutropenia, severe congenital 2, 613107 (3),
GFI1A	AD	?neutropenia, nonimmune chronic idiopathic, of adults, 607847 (3), ; neutropenia, severe congenital 2, 613107 (3),
GFI1B	AR,AD	bleeding disorder, platelet-type, 17, 187900 (3),
GFI2		
GFM	AR	combined oxidative phosphorylation deficiency 1, 609060 (3),
GFM1	AR	combined oxidative phosphorylation deficiency 1, 609060 (3),
GFM2	AR	combined oxidative phosphorylation deficiency 39, 618397 (3),
GFND2	AD	spondylometaphyseal dysplasia, corner fracture type, 184255 (3), ; glomerulopathy with fibronectin deposits 2, 601894 (3),
GFOD1		
GFOD2		
GFPP		
GFPT	AR	myasthenia, congenital, 12, with tubular aggregates, 610542 (3),
GFPT1	AR	myasthenia, congenital, 12, with tubular aggregates, 610542 (3),
GFPT2		
GFR		
GFR-ALPHA-1	AR	renal hypodysplasia/aplasia 4, 619887 (3),
GFRa-3		
GFRA1	AR	renal hypodysplasia/aplasia 4, 619887 (3),
GFRA2		
GFRA3		
GFRA4		
GFRAL		
GFRP		
GFRP1		
GFUS		
GFY		
GG2-1		
GGA1		
GGA2		
GGA3		
GGACT		
GGAP1		
Ggc		
GGCT		
GGCX	AR	vitamin k-dependent clotting factors, combined deficiency of, 1, 277450 (3), ; pseudoxanthoma elasticum-like disorder with multiple coagulation factor deficiency, 610842 (3)
GGF		{?schizophrenia, susceptibility to}, 603013 (1)
GGH		
GGN	AR	spermatogenic failure 69, 619826 (3),
GGNBP1		
GGNBP2		
GGPPS1	AR	muscular dystrophy, congenital hearing loss, and ovarian insufficiency syndrome, 619518 (3),
GGPS1	AR	muscular dystrophy, congenital hearing loss, and ovarian insufficiency syndrome, 619518 (3),
GGR	AR	mahvash disease, 619290 (3),
GGT	AR	?glutathioninuria, 231950 (3), |[gamma-glutamyltransferase, familial high serum], 137181 (2)
GGT-REL		
GGT1	AR	?glutathioninuria, 231950 (3),
GGT2		[gamma-glutamyltransferase, familial high serum], 137181 (2)
GGT2P		[gamma-glutamyltransferase, familial high serum], 137181 (2)
GGT5		
GGT6		
GGT7		
GGTA		
GGTA1		
GGTA1P		
GGTB2	AR	combined low ldl and fibrinogen, 620364 (3), ; congenital disorder of glycosylation, type iid, 607091 (3),
GGTI		
GGTL3		
GGTL4		
GGTL5		
GGTLA1		
GGTLA3		
GGTLA4		
GGTLC1		
GGTLC2		
GGTLC3		
GH	AR,AD	kowarski syndrome, 262650 (3), ; growth hormone deficiency, isolated, type ii, 173100 (3), ; growth hormone deficiency, isolated, type ib, 612781 (3); growth hormone deficiency, isolated, type ia, 262400 (3),
GH-N	AR,AD	kowarski syndrome, 262650 (3), ; growth hormone deficiency, isolated, type ii, 173100 (3), ; growth hormone deficiency, isolated, type ib, 612781 (3); growth hormone deficiency, isolated, type ia, 262400 (3),
GH-V		
GH1	AR,AD	kowarski syndrome, 262650 (3), ; growth hormone deficiency, isolated, type ii, 173100 (3), ; growth hormone deficiency, isolated, type ib, 612781 (3); growth hormone deficiency, isolated, type ia, 262400 (3),
GH2		
GHBP	AR,AD	laron dwarfism, 262500 (3), ; increased responsiveness to growth hormone, 604271 (3), ; growth hormone insensitivity, partial, 604271 (3), ; {hypercholesterolemia, familial, modifier of}, 143890 (3),
GHDC		
GHET1		
GHF-1	AR,AD	pituitary hormone deficiency, combined or isolated, 1, 613038 (3),
GHITM		
GHL		
GHN	AR,AD	kowarski syndrome, 262650 (3), ; growth hormone deficiency, isolated, type ii, 173100 (3), ; growth hormone deficiency, isolated, type ib, 612781 (3); growth hormone deficiency, isolated, type ia, 262400 (3),
GHR	AR,AD	laron dwarfism, 262500 (3), ; increased responsiveness to growth hormone, 604271 (3), ; growth hormone insensitivity, partial, 604271 (3), ; {hypercholesterolemia, familial, modifier of}, 143890 (3),
ghrelin	AR,MF,AD	{obesity, susceptibility to}, 601665 (3), ,
GHRF		gigantism due to ghrf hypersecretion (1); ?isolated growth hormone deficiency due to defect in ghrf (1)
GHRH		gigantism due to ghrf hypersecretion (1); ?isolated growth hormone deficiency due to defect in ghrf (1)
GHRHR	AR	growth hormone deficiency, isolated, type iv, 618157 (3),
GHRL	AR,MF,AD	{obesity, susceptibility to}, 601665 (3), ,
GHRL-AS1		
GHRLOS		
GHSR	AR,AD	growth hormone deficiency, isolated partial, 615925 (3),
GHV		
GI24		
giantin		
GIBT	AR	ovarian dysgenesis 7, 618117 (3), ; combined oxidative phosphorylation deficiency 5, 611719 (3),
GID2		
GID2A		
GID3		
GID4		
GID5		
GID7	AD	skraban-deardorff syndrome, 617616 (3),
GID8		
GID9		
GIDE		
Gie1		
Gie2		
GIF	AR	{rheumatoid arthritis, systemic juvenile, susceptibility to}, 604302 (3)|intrinsic factor deficiency, 261000 (3),
GIG	AR	giant axonal neuropathy-1, 256850 (3),
GIG1		
GIG16		
GIG18		{glucocorticoid therapy, response to}, 614400 (3)
GIG2		
GIG3	AR	immunodeficiency 90 with encephalopathy, functional hyposplenia, and hepatic dysfunction, 613759 (3),
GIG33	AD	diamond-blackfan anemia 5, 612528 (3),
GIG39		
GIG8		
GIGYF1		
GIGYF2		{parkinson disease 11}, 607688 (3)
GIIA	AD	polycystic kidney disease 3, 600666 (3),
GIIB	AD	polycystic liver disease 1, 174050 (3),
GIII-SPLA2		
GIL		[blood group gil], 607457 (3)
GILT		
GILZ		
GIMAP1		
GIMAP2		
GIMAP4		
GIMAP5	AR	portal hypertension, noncirrhotic, 2, 619463 (3),
GIMAP6		
GIMAP7		
GIMAP8		
GIMPC		
GINGF	AD	noonan syndrome 4, 610733 (3), ; ?fibromatosis, gingival, 1, 135300 (3),
GINS1	AR	immunodeficiency 55, 617827 (3),
GINS2		
GINS3		
GINS4		
GIOT-1		
GIOT-3		
GIOT-4		
GIP	AD	ventricular tachycardia, idiopathic, 192605 (3), ; pituitary adenoma, acth-secreting, somatic (3)
gIP-10		
GIP130		
GIPC	AD	oculopharyngodistal myopathy 2, 618940 (3),
GIPC1	AD	oculopharyngodistal myopathy 2, 618940 (3),
GIPC2		
GIPC3	AR	deafness, 15, 601869 (3),
GIPIE		
GIPR		
GIRK1		
GIRK2	AD	keppen-lubinsky syndrome, 614098 (3),
GIRK3		
GIRK4	AD	long qt syndrome 13, 613485 (3), ; hyperaldosteronism, familial, type iii, 613677 (3),
GISP		
GIT	AD	cole-carpenter syndrome 1, 112240 (3),
GIT1		
GIT2		
GITA		
GITR		
GIV	AR	?peho syndrome-like, 617507 (3),
GIYD1		
GIYD2		
GJA1	AD,AR	erythrokeratodermia variabilis et progressiva 3, 617525 (3), ; craniometaphyseal dysplasia, 218400 (3), ; oculodentodigital dysplasia, 164200 (3), ; palmoplantar keratoderma with congenital alopecia, 104100 (3), ; syndactyly, type iii, 186100 (3), ; oculodentodigital dysplasia, 257850 (3),
GJA10		
GJA11		
GJA12	AD,AR	lymphatic malformation 3, 613480 (3), ; ?spastic paraplegia 44, 613206 (3), ; leukodystrophy, hypomyelinating, 2, 608804 (3),
GJA3	AD	cataract 14, multiple types, 601885 (3),
GJA4		
GJA5	AD	atrial fibrillation, familial, 11, 614049 (3), ; atrial standstill, digenic (gja5/scn5a), 108770 (3),
GJA7		
GJA8	AD	cataract 1, multiple types, 116200 (3),
GJA9		
GJAL	AD,AR	erythrokeratodermia variabilis et progressiva 3, 617525 (3), ; craniometaphyseal dysplasia, 218400 (3), ; oculodentodigital dysplasia, 164200 (3), ; palmoplantar keratoderma with congenital alopecia, 104100 (3), ; syndactyly, type iii, 186100 (3), ; oculodentodigital dysplasia, 257850 (3),
GJB1	XLD,XL	charcot-marie-tooth neuropathy, 1, 302800 (3),
GJB2	AD,AR	keratoderma, palmoplantar, with deafness, 148350 (3), ; deafness, 1a, 220290 (3), digenic ; deafness, 3a, 601544 (3), ; hystrix-like ichthyosis with deafness, 602540 (3), ; bart-pumphrey syndrome, 149200 (3), ; keratitis-ichthyosis-deafness syndrome, 148210 (3), ; vohwinkel syndrome, 124500 (3),
GJB3	AR,AD	deafness, digenic, gjb2/gjb3, 220290 (3), digenic ; deafness, (3); deafness, 2b, 612644 (3), ; erythrokeratodermia variabilis et progressiva 1, 133200 (3), ; deafness, with peripheral neuropathy (3)
GJB4	AD	erythrokeratodermia variabilis et progressiva 2, 617524 (3),
GJB5		
GJB6	AD,AR	ectodermal dysplasia 2, clouston type, 129500 (3), ; deafness, 3b, 612643 (3), ; deafness, 1b, 612645 (3), ; deafness, digenic gjb2/gjb6, 220290 (3), digenic
GJB7		
GJC1		
GJC2	AD,AR	lymphatic malformation 3, 613480 (3), ; ?spastic paraplegia 44, 613206 (3), ; leukodystrophy, hypomyelinating, 2, 608804 (3),
GJC3		
GJD2		
GJD3		
GJD4		
GJE1		
GK	XLR,XL	glycerol kinase deficiency, 307030 (3),
GK001	AR	trichohepatoneurodevelopmental syndrome, 618268 (3),
GK002	AR	ovarian dysgenesis 7, 618117 (3), ; combined oxidative phosphorylation deficiency 5, 611719 (3),
GK1	XLR,XL	glycerol kinase deficiency, 307030 (3),
GK2		
GKAP		
GKAP1		
GKAP42		
GKD	XLR,XL	glycerol kinase deficiency, 307030 (3),
GKLF		
GKLP	AR	spinocerebellar ataxia, 21, 616719 (3),
GKN1		
GKN2		
GKP2		
GKTA		
GL	AR	osteopetrosis, 5, 259720 (3),
GL004	AR	encephalopathy due to defective mitochondrial and peroxisomal fission 2, 617086 (3),
GL009	AR	neutropenia, severe congenital, 6, 616022 (3),
GL010	AR	mast syndrome, 248900 (3),
GL011		
GL014		
GL50		
GLA	XL	fabry disease, cardiac variant, 301500 (3), ; fabry disease, 301500 (3),
GLAST	AD	episodic ataxia, type 6, 612656 (3),
GLAST-1	AD	episodic ataxia, type 6, 612656 (3),
GLAST1	AD	episodic ataxia, type 6, 612656 (3),
GLB1	AR	gm1-gangliosidosis, type i, 230500 (3), ; gm1-gangliosidosis, type iii, 230650 (3), ; mucopolysaccharidosis type ivb (morquio), 253010 (3), ; gm1-gangliosidosis, type ii, 230600 (3),
GLBA	AR,AD	combined sap deficiency, 611721 (3), ; krabbe disease, atypical, 611722 (3), ; metachromatic leukodystrophy due to sap-b deficiency, 249900 (3), ; gaucher disease, atypical, 610539 (3); {parkinson disease 24, susceptibility to}, 619491 (3),
GLC1A	AD	glaucoma 1a, primary open angle, 137750 (3),
GLC1E	AD,AR	glaucoma 1, open angle, e, 137760 (3), ; amyotrophic lateral sclerosis 12 with or without frontotemporal dementia, 613435 (3), ; {glaucoma, normal tension, susceptibility to}, 606657 (3)
GLC1F	AD	glaucoma 1, open angle, f, 603383 (3),
GLC1G		glaucoma 1, open angle, g, 609887 (3)
GLC1O		glaucoma 1, open angle, 1o, 613100 (3)
GLC3A	AR	glaucoma 3a, primary open angle, congenital, juvenile, or adult onset, 231300 (3), ; anterior segment dysgenesis 6, multiple subtypes, 617315 (3),
GlcAT-I	AR	multiple joint dislocations, short stature, craniofacial dysmorphism, with or without congenital heart defects, 245600 (3),
GlcAT-P		
GlcAT-S		
GLCC1		
GLCCI1		{glucocorticoid therapy, response to}, 614400 (3)
GLCE		
GLCL	AR	{myocardial infarction, susceptibility to}, 608446 (3); hemolytic anemia due to gamma-glutamylcysteine synthetase deficiency, 230450 (3),
GLCLC	AR	{myocardial infarction, susceptibility to}, 608446 (3); hemolytic anemia due to gamma-glutamylcysteine synthetase deficiency, 230450 (3),
GLCLR		{myocardial infarction, susceptibility to}, 608446 (3)
GLCNAC-TI		
GLCT5		
GLD2		
GLDC	AR	glycine encephalopathy1, 605899 (3),
GLDN	AR	lethal congenital contracture syndrome 11, 617194 (3),
GLE1	AR	lethal congenital contracture syndrome 1, 253310 (3), ; congenital arthrogryposis with anterior horn cell disease, 611890 (3),
GLE1L	AR	lethal congenital contracture syndrome 1, 253310 (3), ; congenital arthrogryposis with anterior horn cell disease, 611890 (3),
Gle2		
GLEPP1	AR	nephrotic syndrome, type 6, 614196 (3),
GLG1		
GLI	AR	polydactyly, preaxial i, 174400 (3), ; polydactyly, postaxial, type a8, 618123 (3),
GLI1	AR	polydactyly, preaxial i, 174400 (3), ; polydactyly, postaxial, type a8, 618123 (3),
GLI2	AD	culler-jones syndrome, 615849 (3), ; holoprosencephaly 9, 610829 (3),
GLI3	AD	greig cephalopolysyndactyly syndrome, 175700 (3), ; polydactyly, postaxial, types a1 and b, 174200 (3), ; pallister-hall syndrome, 146510 (3), ; polydactyly, preaxial, type iv, 174700 (3),
GLI4		
GLIALCAM	AR,AD	megalencephalic leukoencephalopathy with subcortical cysts 2a, 613925 (3), ; megalencephalic leukoencephalopathy with subcortical cysts 2b, remitting, with or without impaired intellectual development, 613926 (3),
GLIF		{rheumatoid arthritis, systemic juvenile, susceptibility to}, 604302 (3)
GLIO703		
GliPR		
GLIPR1		
GLIPR1L1		
GLIPR1L2		
GLIPR2		
GLIS1		
GLIS2		nephronophthisis 7, 611498 (3)
GLIS3	AR	diabetes mellitus, neonatal, with congenital hypothyroidism, 610199 (3),
GLK		
GLM-R	AD	?amyloidosis, primary localized cutaneous, 2, 613955 (3),
GLML	AD	glomuvenous malformations, 138000 (3),
GLMN	AD	glomuvenous malformations, 138000 (3),
GLMP		
Glmr	AD	?amyloidosis, primary localized cutaneous, 2, 613955 (3),
GLNN	AD	?epilepsy, familial temporal lobe, 8, 616461 (3),
GLNS	AR	glutamine deficiency, congenital, 610015 (3),
GLO1		
GLO2	AD	[glyoxalase ii deficiency], 614033 (1),
GLOB		[blood group, p1pk system, p(k) phenotype], 111400 (3); [blood group, globoside system], 615021 (3)
GLOD1		
GLOD2	AR	methylmalonyl-coa epimerase deficiency, 251120 (3),
GLOD3	AD,AR	hawkinsinuria, 140350 (3), ; tyrosinemia, type iii, 276710 (3),
GLOXD1	AR	neurodevelopmental disorder with progressive spasticity and brain white matter abnormalities, 619026 (3), ; spastic paraplegia 83, 619027 (3),
GLP	AD	kleefstra syndrome 1, 610253 (3),
GLP-1		
GLP-1R		
GLP1		
GLP1R		
GLP2		
GLP2R		
GLR	XL	intellectual developmental disorder, syndromic, pilorge type, 301076 (3),
GLRA1	AR,AD	hyperekplexia 1, 149400 (3),
GLRA2	XL	intellectual developmental disorder, syndromic, pilorge type, 301076 (3),
GLRA3		
GLRB	AR	hyperekplexia 2, 614619 (3),
GLRX		
GLRX2		
GLRX3		
GLRX4		
GLRX5	AR	anemia, sideroblastic, 3, pyridoxine-refractory, 616860 (3), ; spasticity, childhood-onset, with hyperglycinemia, 616859 (3),
GLS	AR,AD	global developmental delay, progressive ataxia, and elevated glutamine, 618412 (3), ; ?infantile cataract, skin abnormalities, glutamate excess, and impaired intellectual development, 618339 (3), ; developmental and epileptic encephalopathy 71, 618328 (3),
GLS1	AR,AD	global developmental delay, progressive ataxia, and elevated glutamine, 618412 (3), ; ?infantile cataract, skin abnormalities, glutamate excess, and impaired intellectual development, 618339 (3), ; developmental and epileptic encephalopathy 71, 618328 (3),
GLS2		
GLT-1	AD	developmental and epileptic encephalopathy 41, 617105 (3),
GLT1	AD	developmental and epileptic encephalopathy 41, 617105 (3),
GLT25D1	AR	brain small vessel disease 3, 618360 (3),
GLT25D2		
GLT25D3		
GLT28D1	XL	developmental and epileptic encephalopathy 36, 300884 (3),
GLT6D1		
GLT8D1		
GLT8D3		
GLT8D4		
GLTDC1		
GLTP		
GLTPD1		
GLTSCR1	AD	coffin-siris syndrome 12, 619325 (3),
GLTSCR1L		
GLTSCR2		
GluA1	AR,AD	?intellectual developmental disorder, 76, 619931 (3), ; intellectual developmental disorder, 67, 619927 (3),
GluA2	AD	neurodevelopmental disorder with language impairment and behavioral abnormalities, 618917 (3),
GluA3	XL,XLR	intellectual developmental disorder, syndromic, wu type, 300699 (3),
GluA4	AD	neurodevelopmental disorder with or without seizures and gait abnormalities, 617864 (3),
GLUC	AD,AR,MF	{lewy body dementia, susceptibility to}, 127750 (3), ; gaucher disease, type ii, 230900 (3), ; gaucher disease, type iiic, 231005 (3), ; gaucher disease, type iii, 231000 (3), ; gaucher disease, type i, 230800 (3), ; gaucher disease, perinatal lethal, 608013 (3), ; {parkinson disease, late-onset, susceptibility to}, 168600 (3),
GLUD	AD	hyperinsulinism-hyperammonemia syndrome, 606762 (3),
GluD1		
GLUD1	AD	hyperinsulinism-hyperammonemia syndrome, 606762 (3),
GluD2	AR	spinocerebellar ataxia, 18, 616204 (3),
GLUD2	MF,AD	{parkinson disease, age of onset, modifier}, 168600 (3),
GLUDP1	MF,AD	{parkinson disease, age of onset, modifier}, 168600 (3),
GluII	AD	polycystic kidney disease 3, 600666 (3),
GluK1		
GluK2	AD,AR	neurodevelopmental disorder with impaired language and ataxia and with or without seizures, 619580 (3), ; intellectual developmental disorder, 6, 611092 (3),
GluK3		
GluK4		
GluK5		
GLUK6	AD,AR	neurodevelopmental disorder with impaired language and ataxia and with or without seizures, 619580 (3), ; intellectual developmental disorder, 6, 611092 (3),
GLUL	AR	glutamine deficiency, congenital, 610015 (3),
GLULD1		
GluN1	AR,AD	neurodevelopmental disorder with or without hyperkinetic movements and seizures, 617820 (3), ; developmental and epileptic encephalopathy 101, 619814 (3), ; neurodevelopmental disorder with or without hyperkinetic movements and seizures, 614254 (3),
GluN2A	AD	epilepsy, focal, with speech disorder and with or without impaired intellectual development, 245570 (3),
GluN2B	AD	developmental and epileptic encephalopathy 27, 616139 (3), ; intellectual developmental disorder, 6, with or without seizures, 613970 (3),
GluN2C		
GluN2D	AD	developmental and epileptic encephalopathy 46, 617162 (3),
GluN3A		
GluN3B		
Glup		
GLUPRORS	AR	leukodystrophy, hypomyelinating, 15, 617951 (3),
GluR-2	AD	neurodevelopmental disorder with language impairment and behavioral abnormalities, 618917 (3),
GluR-3	XL,XLR	intellectual developmental disorder, syndromic, wu type, 300699 (3),
GluR-4	AD	neurodevelopmental disorder with or without seizures and gait abnormalities, 617864 (3),
GluR-6	AD,AR	neurodevelopmental disorder with impaired language and ataxia and with or without seizures, 619580 (3), ; intellectual developmental disorder, 6, 611092 (3),
GluR-B	AD	neurodevelopmental disorder with language impairment and behavioral abnormalities, 618917 (3),
GluR-C	XL,XLR	intellectual developmental disorder, syndromic, wu type, 300699 (3),
GluR-D	AD	neurodevelopmental disorder with or without seizures and gait abnormalities, 617864 (3),
GluR-delta-2	AR	spinocerebellar ataxia, 18, 616204 (3),
GluR-K2	AD	neurodevelopmental disorder with language impairment and behavioral abnormalities, 618917 (3),
GluR-K3	XL,XLR	intellectual developmental disorder, syndromic, wu type, 300699 (3),
GLUR1	AR,AD	?intellectual developmental disorder, 76, 619931 (3), ; intellectual developmental disorder, 67, 619927 (3),
GLUR2	AD	neurodevelopmental disorder with language impairment and behavioral abnormalities, 618917 (3),
GLUR3	XL,XLR	intellectual developmental disorder, syndromic, wu type, 300699 (3),
GLUR4	AD	neurodevelopmental disorder with or without seizures and gait abnormalities, 617864 (3),
GLUR4C	AD	neurodevelopmental disorder with or without seizures and gait abnormalities, 617864 (3),
GLUR5		
GLUR6	AD,AR	neurodevelopmental disorder with impaired language and ataxia and with or without seizures, 619580 (3), ; intellectual developmental disorder, 6, 611092 (3),
GLUR7	AR	neurodevelopmental disorder with seizures, hypotonia, and brain abnormalities, 618922 (3),
GLUR8		
GLURA	AR,AD	?intellectual developmental disorder, 76, 619931 (3), ; intellectual developmental disorder, 67, 619927 (3),
GLURB	AD	neurodevelopmental disorder with language impairment and behavioral abnormalities, 618917 (3),
GLURC	XL,XLR	intellectual developmental disorder, syndromic, wu type, 300699 (3),
GLURD	AD	neurodevelopmental disorder with or without seizures and gait abnormalities, 617864 (3),
GLURR2		
GLUT	AD,AR	dystonia 9, 601042 (3), ; glut1 deficiency syndrome 1, infantile onset, severe, 606777 (3), ; stomatin-deficient cryohydrocytosis with neurologic defects, 608885 (3), ; {epilepsy, idiopathic generalized, susceptibility to, 12}, 614847 (3), ; glut1 deficiency syndrome 2, childhood onset, 612126 (3),
GLUT-1	AD,AR	dystonia 9, 601042 (3), ; glut1 deficiency syndrome 1, infantile onset, severe, 606777 (3), ; stomatin-deficient cryohydrocytosis with neurologic defects, 608885 (3), ; {epilepsy, idiopathic generalized, susceptibility to, 12}, 614847 (3), ; glut1 deficiency syndrome 2, childhood onset, 612126 (3),
GLUT-10	AR	arterial tortuosity syndrome, 208050 (3),
GLUT-2	AR,AD	fanconi-bickel syndrome, 227810 (3), ; {diabetes mellitus, noninsulin-dependent}, 125853 (3),
GLUT1	AD,AR	dystonia 9, 601042 (3), ; glut1 deficiency syndrome 1, infantile onset, severe, 606777 (3), ; stomatin-deficient cryohydrocytosis with neurologic defects, 608885 (3), ; {epilepsy, idiopathic generalized, susceptibility to, 12}, 614847 (3), ; glut1 deficiency syndrome 2, childhood onset, 612126 (3),
GLUT10	AR	arterial tortuosity syndrome, 208050 (3),
GLUT11		
GLUT12		
GLUT14		
GLUT1CBP	AD	oculopharyngodistal myopathy 2, 618940 (3),
GLUT2	AR,AD	fanconi-bickel syndrome, 227810 (3), ; {diabetes mellitus, noninsulin-dependent}, 125853 (3),
GLUT3		
GLUT4		
GLUT5		
GLUT6		
GLUT7		
GLUT8		
Glut9	AR,AD	{uric acid concentration, serum, qtl 2}, 612076 (3), ; hypouricemia, renal, 2, 612076 (3),
GLUT9		
GLUTX	AR,AD	{uric acid concentration, serum, qtl 2}, 612076 (3), ; hypouricemia, renal, 2, 612076 (3),
GLUTX1		
Glvr-1		
Glvr-2	AD	basal ganglia calcification, idiopathic, 1, 213600 (3),
GLVR1		
GLVR2	AD	basal ganglia calcification, idiopathic, 1, 213600 (3),
GLXII	AD	[glyoxalase ii deficiency], 614033 (1),
GLXR	AR	hyperoxaluria, primary, type ii, 260000 (3),
GLYAT		
GLYATL1		
GLYATL2		
GLYATL3		
GlyBP	AR	joubert syndrome 25, 616781 (3), ; intellectual developmental disorder, 77, 619988 (3),
GLYCTK	AR	d-glyceric aciduria, 220120 (3),
glypican		
GLYR1		
GlyRS	AD	spinal muscular atrophy, infantile, james type, 619042 (3), ; neuronopathy, distal hereditary motor, type va, 600794 (3), ; charcot-marie-tooth disease, type 2d, 601472 (3),
GlyT-1	AR	glycine encephalopathy with normal serum glycine, 617301 (3),
GlyT-2	AR,AD	hyperekplexia 3, 614618 (3),
GLYT1	AR	glycine encephalopathy with normal serum glycine, 617301 (3),
GLYT2	AR,AD	hyperekplexia 3, 614618 (3),
GM	AD	insulin resistance, severe, digenic, 125853 (3),
GM-CSF		
Gm1012		
GM130	AR	developmental delay with hypotonia, myopathy, and brain abnormalities, 620240 (3),
GM2-AP	AR	gm2-gangliosidosis, ab variant, 272750 (3),
GM2A	AR	gm2-gangliosidosis, ab variant, 272750 (3),
GM2AP	AR	gm2-gangliosidosis, ab variant, 272750 (3),
Gm625		
GM632		
Gm638		
Gm83		
GM88		
GMA	AR	spastic paraplegia 75, 616680 (3),
GMAN		
GMAP	AD	?epilepsy, familial temporal lobe, 8, 616461 (3),
GMAP-210	AR	odontochondrodysplasia 1, 184260 (3), ; achondrogenesis, type ia, 200600 (3),
GMAP210	AR	odontochondrodysplasia 1, 184260 (3), ; achondrogenesis, type ia, 200600 (3),
GMCL1		
GMCL1L		
GMCL1P1		
GMCL2		
GMCSF		
GMD		
GMDS		
GMEB1		
GMEB2		
GMF		
GMFB		
GMFG		
GMH1		
GMIP		
GML		
GMNC		
GMNN	AD	meier-gorlin syndrome 6, 616835 (3),
GMP	AR	spastic paraplegia 45, 613162 (3),
GMP-17		
GMP1		?orofacial cleft 10, 613705 (3), isolated cases
GMP140		
GMPPA	AR	alacrima, achalasia, and impaired intellectual development syndrome, 615510 (3),
GMPPB	AR	muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 14, 615352 (3), ; muscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type b, 14, 615351 (3), ; muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 14, 615350 (3),
GMPR		
GMPR1		
GMPR2		
GMPS		
GMRP-1		
GMRP1		
GN-2		
GNA11	AD	hypocalciuric hypercalcemia, type ii, 145981 (3), ; hypocalcemia, 2, 615361 (3),
GNA12		
GNA13		
GNA14		
GNA15		
GNA16		
GNAI1	AD	neurodevelopmental disorder with hypotonia, impaired speech, and behavioral abnormalities, 619854 (3),
GNAI2	AD	ventricular tachycardia, idiopathic, 192605 (3), ; pituitary adenoma, acth-secreting, somatic (3)
GNAI2A		
GNAI2B	AD	ventricular tachycardia, idiopathic, 192605 (3), ; pituitary adenoma, acth-secreting, somatic (3)
GNAI2L		
GNAI2P1		
GNAI3	AD	auriculocondylar syndrome 1, 602483 (3),
GNAL	AD	dystonia 25, 615073 (3),
GNAO1	AD	developmental and epileptic encephalopathy 17, 615473 (3), ; neurodevelopmental disorder with involuntary movements, 617493 (3),
GNAQ		capillary malformations, congenital, 1, somatic, mosaic, 163000 (3); sturge-weber syndrome, somatic, mosaic, 185300 (3)
GNAS	AD	acth-independent macronodular adrenal hyperplasia, 219080 (3), somatic mutation; pituitary adenoma 3, multiple types, somatic, 617686 (3); pseudohypoparathyroidism ic, 612462 (3), ; pseudohypoparathyroidism ia, 103580 (3), ; osseous heteroplasia, progressive, 166350 (3), ; pseudohypoparathyroidism ib, 603233 (3), ; mccune-albright syndrome, somatic, mosaic, 174800 (3); pseudopseudohypoparathyroidism, 612463 (3),
GNAS-AS	AD	pseudohypoparathyroidism, type ib, 603233 (3),
GNAS-AS1	AD	pseudohypoparathyroidism, type ib, 603233 (3),
GNAS1	AD	acth-independent macronodular adrenal hyperplasia, 219080 (3), somatic mutation; pituitary adenoma 3, multiple types, somatic, 617686 (3); pseudohypoparathyroidism ic, 612462 (3), ; pseudohypoparathyroidism ia, 103580 (3), ; osseous heteroplasia, progressive, 166350 (3), ; pseudohypoparathyroidism ib, 603233 (3), ; mccune-albright syndrome, somatic, mosaic, 174800 (3); pseudopseudohypoparathyroidism, 612463 (3),
GNAS1AS	AD	pseudohypoparathyroidism, type ib, 603233 (3),
GNASAS	AD	pseudohypoparathyroidism, type ib, 603233 (3),
GNASXL	AD	acth-independent macronodular adrenal hyperplasia, 219080 (3), somatic mutation; pituitary adenoma 3, multiple types, somatic, 617686 (3); pseudohypoparathyroidism ic, 612462 (3), ; pseudohypoparathyroidism ia, 103580 (3), ; osseous heteroplasia, progressive, 166350 (3), ; pseudohypoparathyroidism ib, 603233 (3), ; mccune-albright syndrome, somatic, mosaic, 174800 (3); pseudopseudohypoparathyroidism, 612463 (3),
GNAT1	AD,AR	night blindness, congenital stationary, 3, 610444 (3), ; night blindness, congenital stationary, type 1g, 616389 (3),
GNAT2		achromatopsia 4, 613856 (3)
GNAT3		
GNAZ		
GNB1	AD	myelodysplastic syndrome, somatic, 614286 (3); leukemia, acute lymphoblastic, somatic, 613065 (3); intellectual developmental disorder, 42, 616973 (3),
GNB1L		
GNB2	AD	neurodevelopmental disorder with hypotonia and dysmorphic facies, 619503 (3), ; ?sick sinus syndrome 4, 619464 (3),
Gnb2-rs1		
GNB2L1		
GNB3	AR,MF	night blindness, congenital stationary, type 1h, 617024 (3), ; {hypertension, essential, susceptibility to}, 145500 (3),
GNB4	AD	charcot-marie-tooth disease, intermediate f, 615185 (3),
GNB5	AR	language delay and adhd/cognitive impairment with or without cardiac arrhythmia, 617182 (3), ; intellectual developmental disorder with cardiac arrhythmia, 617173 (3),
GNE	AD,AR	sialuria, 269921 (3), ; nonaka myopathy, 605820 (3),
Gnefr		
GNG1		
GNG10		
GNG11		
GNG12		
GNG12-AS1		
GNG13		
GNG2		
GNG3		
GNG3LG	AR,AD	lipodystrophy, congenital generalized, type 2, 269700 (3), ; neuropathy, distal hereditary motor, type vc, 619112 (3), ; silver spastic paraplegia syndrome, 270685 (3), ; encephalopathy, progressive, with or without lipodystrophy, 615924 (3),
GNG4		
GNG5		
GNG7		
GNG9		
GNGT1		
GNGT11		
GNGT2		
GNIP		
GNK		
GNL1		
GNL2		
GNL3		
GNL3B		
GNL3L		
GNLY		
GNMT	AR	glycine n-methyltransferase deficiency, 606664 (3),
Gno1		
GNPAT	AR	rhizomelic chondrodysplasia punctata, type 2, 222765 (3),
GNPDA		
GNPDA1		
GNPDA2		
GNPI		
GNPNAT1		?rhizomelic dysplasia, ain-naz type, 616510 (3)
GNPTA	AR	mucolipidosis iii alpha/beta, 252600 (3), ; mucolipidosis ii alpha/beta, 252500 (3),
GNPTAB	AR	mucolipidosis iii alpha/beta, 252600 (3), ; mucolipidosis ii alpha/beta, 252500 (3),
GNPTAG	AR	mucolipidosis iii gamma, 252605 (3),
GNPTG	AR	mucolipidosis iii gamma, 252605 (3),
GNRH	AR	?hypogonadotropic hypogonadism 12 with or without anosmia, 614841 (3),
GNRH1	AR	?hypogonadotropic hypogonadism 12 with or without anosmia, 614841 (3),
GNRH2		
GNRHR	AR	hypogonadotropic hypogonadism 7 without anosmia, 146110 (3),
GNRP		
GNS	AR	mucopolysaccharidosis type iiid, 252940 (3),
GNT-1		
GnT-4a		
GNT-II	AR	congenital disorder of glycosylation, type iia, 212066 (3),
GNT-III		
GnT-Iva		
GnT-Ivb		
GnT-IX		
GNT-V		
GnT-VB		
GNT1	AR,AD	crigler-najjar syndrome, type i, 218800 (3), ; [bilirubin, serum level of, qtl1], 601816 (3); hyperbilirubinemia, familial transient neonatal, 237900 (3), ; crigler-najjar syndrome, type ii, 606785 (3), ; [gilbert syndrome], 143500 (3),
GnT1IP		
GnTI		
GO	AR	geroderma osteodysplasticum, 231070 (3),
GOA		
GOAT		
GOCAP1		
GODZ		
GOK	AD,AR	myopathy, tubular aggregate, 1, 160565 (3), ; stormorken syndrome, 185070 (3), ; immunodeficiency 10, 612783 (3),
GOLG		
GOLGA1		
GOLGA2	AR	developmental delay with hypotonia, myopathy, and brain abnormalities, 620240 (3),
GOLGA2LY1		
GOLGA2P2		
GOLGA2P2Y		
GOLGA3		
GOLGA3AP1		
GOLGA4		
GOLGA5		
GOLGA6		
GOLGA6A		
GOLGA7		
GOLGA7A		
GOLGA7B		
GOLGA8A		
GOLGA8B		
GOLGB1		
golgin-160		
golgin-240		
GOLGIN-67		
golgin-84		
golgin-95	AR	developmental delay with hypotonia, myopathy, and brain abnormalities, 620240 (3),
golgin-97		
golgin104		
GOLIATH		
GOLIM1		
GOLIM2		
GOLIM3		
GOLIM4		
GOLIM5		
GOLIM6	AD	global developmental delay with or without impaired intellectual development, 618330 (3),
GOLIM7		
GOLM1		
GOLPH1		
GOLPH2		
GOLPH3		
GOLPH3L		
GOLPH4		
GOLPH5		
GOLPH6		
GOLSYN		
GOLT1B		
GOLTC1	AR	congenital disorder of glycosylation, type iii, 613612 (3),
gomafu		{myocardial infarction, susceptibility to}, 608446 (3)
GON-1		
GON-10		
GON-2	AD	?cataract 50 with or without glaucoma, 620253 (3); neurodevelopmental disorder with hypotonia, dysmorphic facies, and skeletal anomalies, with or without seizures, 620224 (3),
GON-4		
GON4		
GON4L		
GON7	AR	galloway-mowat syndrome 9, 619603 (3),
GONDA1		
Goofy		
Gop-1		
GOPC		
GOPC1		
GOPP1		
GORAB	AR	geroderma osteodysplasticum, 231070 (3),
GORASP1		
GORASP2		
GOS-28		
GOS28		
GOS3		
GOSB		
GOSR1		
GOSR2	AR	epilepsy, progressive myoclonic 6, 614018 (3), ; muscular dystrophy, congenital, with or without seizures, 620166 (3),
GOT1		aspartate aminotransferase, serum level of, qtl1, 614419 (3)
GOT2	AR	developmental and epileptic encephalopathy 82, 618721 (3),
GOV		
GOX		
GOX1		
GP		
GP-1		
Gp-340		
GP-83		
gp100		
GP110		
gp115		neuronopathy, distal hereditary motor, type x, 620080 (3)
GP130	AR,AR,AD	mitochondrial complex iv deficiency, nuclear type 5, (french-canadian), 220111 (3), |stuve-wiedemann syndrome 2, 619751 (3), ; hyper-ige recurrent infection syndrome 4a, 619752 (3), ; ?immunodeficiency 94 with autoinflammation and dysmorphic facies, 619750 (3), ; hyper-ige recurrent infection syndrome 4b, 618523 (3),
gp130RB13-6		
gp135		
GP135	AR	?congenital myopathy 12, 612540 (3),
GP147	AR,AD	macular dystrophy, vitelliform, 4, 616151 (3), ; retinitis pigmentosa 91, 153870 (3),
gp150		
gp160		
GP170		{inflammatory bowel disease 13}, 612244 (3); {colchicine resistance}, 120080 (3)
GP180	AR	immunodeficiency 105, severe combined, 619924 (3),
GP1B	AR,AD	bernard-soulier syndrome, type a1 (), 231200 (3), ; bernard-soulier syndrome, type a2 (), 153670 (3), ; von willebrand disease, platelet-type, 177820 (3), ; {nonarteritic anterior ischemic optic neuropathy, susceptibility to}, 258660 (3),
GP1BA	AR,AD	bernard-soulier syndrome, type a1 (), 231200 (3), ; bernard-soulier syndrome, type a2 (), 153670 (3), ; von willebrand disease, platelet-type, 177820 (3), ; {nonarteritic anterior ischemic optic neuropathy, susceptibility to}, 258660 (3),
GP1BB	AR	giant platelet disorder, isolated, 231200 (3), ; bernard-soulier syndrome, type b, 231200 (3),
GP2		
Gp200		
GP210		
gp250		
gp280	AR	[proteinuria, chronic benign], 618884 (3), ; imerslund-grasbeck syndrome 1, 261100 (3),
GP2B	AR,AD	thrombocytopenia, neonatal alloimmune, bak antigen related (3); glanzmann thrombasthenia 1, 273800 (3), ; bleeding disorder, platelet-type, 16, 187800 (3),
gp330	AR	donnai-barrow syndrome, 222448 (3),
gp34		{myocardial infarction, susceptibility to}, 608446 (3)
GP340		
GP36B		
Gp38		
gp39	XL,XLR	immunodeficiency, with hyper-igm, 308230 (3),
GP39	AD	{asthma-related traits, susceptibility to, 7}, 611960 (3); {schizophrenia, susceptibility to}, 181500 (3),
GP3A	AD,AR	bleeding disorder, platelet-type, 24, 619271 (3); thrombocytopenia, neonatal alloimmune (3); purpura, posttransfusion (3); {myocardial infarction, susceptibility to}, 608446 (3); glanzmann thrombasthenia 2, 619267 (3),
GP3B	AR	platelet glycoprotein iv deficiency, 608404 (3), ; {coronary heart disease, susceptibility to, 7}, 610938 (3); {malaria, cerebral, susceptibility to}, 611162 (3); {malaria, cerebral, reduced risk of}, 611162 (3)
GP3ST		
GP4	AR	platelet glycoprotein iv deficiency, 608404 (3), ; {coronary heart disease, susceptibility to, 7}, 610938 (3); {malaria, cerebral, susceptibility to}, 611162 (3); {malaria, cerebral, reduced risk of}, 611162 (3)
GP40		
GP5		
GP55		
gp58	AR	combined factor v and viii deficiency, 227300 (3),
GP6	AR	bleeding disorder, platelet-type, 11, 614201 (3),
Gp63		
GP65		
gp68	AR	diarrhea 10, protein-losing enteropathy type, 618183 (3),
GP73		
GP75	AR	[skin/hair/eye pigmentation, variation in, 11 (melanesian blond hair)], 612271 (3); albinism, oculocutaneous, type iii, 203290 (3),
gp78	AR	spastic paraplegia 89, 620379 (3),
gp80	AR	[interleukin 6, serum level of, qtl], 614752 (3); hyper-ige recurrent infection syndrome 5, 618944 (3), ; [interleukin-6 receptor, soluble, serum level of, qtl], 614689 (3)
GP9	AR	bernard-soulier syndrome, type c, 231200 (3),
gp90		
GP91-2		
GP91-3		
GP91-PHOX	XL,XLR	immunodeficiency 34, mycobacteriosis, 300645 (3), ; chronic granulomatous disease, 306400 (3),
Gp95	AD	[low density lipoprotein cholesterol level qtl6], 613589 (3),
GP96		
GPA		{malaria, resistance to}, 611162 (3); [blood group, mnss system], 111300 (3)
GPA1		
GPA2		
GPA33		
GPA34		
GPAA1	AR	glycosylphosphatidylinositol biosynthesis defect 15, 617810 (3),
GPAM		
GPANK1		
gPAPP	AR	chondrodysplasia with joint dislocations, gpapp type, 614078 (3),
GPAT		
GPAT1		
GPAT2		
GPAT3		
GPAT4		
GPATC2		
GPATC3		
GPATC5		
GPATC6		
GPATC7		
GPATC8		
GPATC9	XLR,XL	tarp syndrome, 311900 (3),
GPATCH10		
GPATCH2		
GPATCH3		
GPATCH5		
GPATCH6		
GPATCH7		
GPATCH8		
GPATCH9	XLR,XL	tarp syndrome, 311900 (3),
GPB		[blood group, ss], 111740 (3); {malaria, resistance to}, 611162 (3)
GPB5		
GPBAR1		
GPBP	AD	intellectual developmental disorder, 34, 616351 (3),
GPBP1		
GPC		[blood group, gerbich], 616089 (3); {malaria, resistance to}, 611162 (3)
GPC-R		
GPC1		
GPC2		
GPC3	XLR,XL	wilms tumor, somatic, 194070 (3); simpson-golabi-behmel syndrome, type 1, 312870 (3),
GPC4	XLR,XL	keipert syndrome, 301026 (3),
GPC5		
GPC6	AR	omodysplasia 1, 258315 (3),
GPCPD1		
GPCR		
GPCR-Br		
GPCR105		
Gpcr13	AR	deafness, 68, 610419 (3),
GPCR135		
GPCR142		
GPCR19		
GPCR2		
GPCR21		
Gpcr26		
GPCR41	AR	brown-vialetto-van laere syndrome 2, 614707 (3),
GPCR42	AD	riboflavin deficiency, 615026 (3),
GPCR97		
GPD	AR,AD	[blood group, duffy system], 110700 (3), ; [white blood cell count qtl], 611862 (3), ; {malaria, vivax, protection against}, 611162 (3)
GPD1	AR	hypertriglyceridemia, transient infantile, 614480 (3),
GPD1L	AD	brugada syndrome 2, 611777 (3),
GPD2	AD	{type 2 diabetes mellitus, susceptibility to}, 125853 (3),
GPE		
GPE1BP		
GPER		
GPER1		
GPHa		
GPHA1		
GPHA2		
GPHB5		
GPHN	AR	molybdenum cofactor deficiency c, 615501 (3),
GPI	AR	hemolytic anemia, nonspherocytic, due to glucose phosphate isomerase deficiency, 613470 (3),
GPI-80		
GPI-H	AR	glycosylphosphatidylinositol biosynthesis defect 17, 618010 (3),
GPI-HBP1	AR	hyperlipoproteinemia, type 1d, 615947 (3),
GPI-MT-I	AR	glycosylphosphatidylinositol deficiency, 610293 (3),
GPI-MT-II	AR	hyperphosphatasia with impaired intellectual development syndrome 1, 239300 (3),
GPI-MT-III	AR	developmental and epileptic encephalopathy 80, 618580 (3),
GPI-MT-IV		
GPI1	AR	multiple congenital anomalies-hypotonia-seizures syndrome 4, 618548 (3),
GPI2	AR	glycosylphosphatidylinositol biosynthesis defect 16, 617816 (3),
GPI3	XLR,XL	paroxysmal nocturnal hemoglobinuria, somatic, 300818 (3); multiple congenital anomalies-hypotonia-seizures syndrome 2, 300868 (3), ; neurodevelopmental disorder with epilepsy and hemochromatosis, 301072 (3)
GPI7	AR	[blood group, emm system], 619812 (3), ; neurodevelopmental disorder with or without hypotonia, seizures, and cerebellar atrophy, 616917 (3),
GPI8	AR	neurodevelopmental disorder with hypotonia and cerebellar atrophy, with or without seizures, 618879 (3),
GPIa		
GPIa*		
GPIAP1		
GPIbalpha	AR,AD	bernard-soulier syndrome, type a1 (), 231200 (3), ; bernard-soulier syndrome, type a2 (), 153670 (3), ; von willebrand disease, platelet-type, 177820 (3), ; {nonarteritic anterior ischemic optic neuropathy, susceptibility to}, 258660 (3),
GPIbbeta	AR	giant platelet disorder, isolated, 231200 (3), ; bernard-soulier syndrome, type b, 231200 (3),
GPIG4		
GPIHBP1	AR	hyperlipoproteinemia, type 1d, 615947 (3),
GPIIA		
GPIIb	AR,AD	thrombocytopenia, neonatal alloimmune, bak antigen related (3); glanzmann thrombasthenia 1, 273800 (3), ; bleeding disorder, platelet-type, 16, 187800 (3),
GPIIIa	AD,AR	bleeding disorder, platelet-type, 24, 619271 (3); thrombocytopenia, neonatal alloimmune (3); purpura, posttransfusion (3); {myocardial infarction, susceptibility to}, 608446 (3); glanzmann thrombasthenia 2, 619267 (3),
GPIIIB	AR	platelet glycoprotein iv deficiency, 608404 (3), ; {coronary heart disease, susceptibility to, 7}, 610938 (3); {malaria, cerebral, susceptibility to}, 611162 (3); {malaria, cerebral, reduced risk of}, 611162 (3)
GPIM		
GPIP4		
GPIV	AR	platelet glycoprotein iv deficiency, 608404 (3), ; {coronary heart disease, susceptibility to, 7}, 610938 (3); {malaria, cerebral, susceptibility to}, 611162 (3); {malaria, cerebral, reduced risk of}, 611162 (3)
GPIX	AR	bernard-soulier syndrome, type c, 231200 (3),
GPKOW		
GPL115		
GPLD1		
GPM6		
GPM6A		
GPM6B		
GPM6C	XLR,XL	pelizaeus-merzbacher disease, 312080 (3), ; spastic paraplegia 2, 312920 (3),
GPN1		
Gpnat1		?rhizomelic dysplasia, ain-naz type, 616510 (3)
GPNMB	AR	amyloidosis, primary localized cutaneous, 3, 617920 (3),
GPP130		
GPP34		
GPP34R		
GPR-9-6		
GPR-CY4		
GPR-CY6		
GPR1		
GPR1-AS		
GPR1-AS1		
GPR10		
GPR100		
GPR101	XL	pituitary adenoma 2, gh-secreting, 300943 (3),
GPR102		
GPR103		
GPR104		
GPR105		
GPR106		
GPR107		
GPR108		
GPR109A		
GPR109B		
GPR11		
GPR110		
GPR112		
GPR114		
GPR115		
GPR119		
GPR12		
GPR120		{obesity, susceptibility to}, 607514 (3)
GPR123		
GPR124		
GPR125		
GPR126	AR	lethal congenital contracture syndrome 9, 616503 (3),
GPR127		
GPR128		
GPR129		{obesity, susceptibility to}, 607514 (3)
GPR13		{rapid progression to aids from hiv1 infection}, 609423 (3); {macular degeneration, age-related, 12}, 613784 (3); {coronary artery disease, resistance to}, 607339 (3)
GPR131		
GPR132		
GPR133		
GPR135		
GPR136		
GPR137B		
GPR139		
GPR14		
GPR140		
GPR141		
GPR142		
GPR143	XL,XLR	ocular albinism, type i, nettleship-falls type, 300500 (3), ; nystagmus 6, congenital, 300814 (3),
GPR145		
GPR147		
GPR15		
GPR151		
GPR153		
GPR154		{asthma, susceptibility to, 2}, 608584 (3)
GPR156		
GPR158		
GPR158L1	AR	night blindness, congenital stationary (complete), 1e, 614565 (3),
GPR159	AR	?oculomotor-abducens synkinesis, 619215 (3),
GPR15L		
GPR15LG		
GPR16		
GPR161	AR,AD	{medulloblastoma predisposition syndrome}, 155255 (3), somatic mutation,
GPR164		
GPR167		
GPR168		
GPR169		
GPR17		
GPR170		
GPR171		
GPR172A	AR	brown-vialetto-van laere syndrome 2, 614707 (3),
GPR172B	AD	riboflavin deficiency, 615026 (3),
GPR173		
GPR174		
GPR175		
GPR176		
GPR177	AR	zaki syndrome, 619648 (3),
GPR178		
GPR179	AR	night blindness, congenital stationary (complete), 1e, 614565 (3),
GPR18		
GPR180		
GPR182		
GPR183		
GPR19		
GPR1AS		
GPR2		
GPR20		
GPR21		
GPR22		
GPR23		
GPR24		
GPR25		
GPR26		
GPR27		
GPR28		
GPR29		
GPR3		
GPR30		
GPR31		
GPR32		
GPR33		
GPR34		
GPR35		
GPR37		
GPR37L1		
GPR38		
GPR39		
GPR4		
GPR40		
GPR41		
GPR41L		
GPR42		
GPR42P		
GPR43		
GPR44		
GPR45		
GPR48	AD	delayed puberty, self-limited, 619613 (3), ; {bone mineral density, low, susceptibility to}, 615311 (3),
GPR49		
GPR5		
GPR50		
GPR51	AD	{nicotine dependence, protection against}, 188890 (3); {nicotine dependence, susceptibility to}, 188890 (3); developmental and epileptic encephalopathy 59, 617904 (3), ; neurodevelopmental disorder with poor language and loss of hand skills, 617903 (3),
GPR52		
GPR54	AR,AD	hypogonadotropic hypogonadism 8 with or without anosmia, 614837 (3), ; ?precocious puberty, central, 1, 176400 (3),
GPR55		
GPR56	AR	polymicrogyria, bilateral frontoparietal, 606854 (3), ; polymicrogyria, bilateral perisylvian, 615752 (3)
GPR58		
GPR59		
GPR6		
GPR60		
GPR61		
GPR62		
GPR63		
GPR64	XL	congenital bilateral absence of vas deferens, 300985 (3),
GPR65		
GPR66		
GPR67		
GPR68	AR	amelogenesis imperfecta, hypomaturation type, iia6, 617217 (3),
GPR69A		
GPR69B		
GPR7		
GPR70		
GPR71		
GPR72		
GPR73		
GPR73a		
GPR73b	AD	hypogonadotropic hypogonadism 3 with or without anosmia, 244200 (3),
GPR73L1	AD	hypogonadotropic hypogonadism 3 with or without anosmia, 244200 (3),
GPR74		
GPR75		
GPR77		
GPR78		
GPR8		
GPR80	AD	nephrolithiasis, calcium oxalate, 2, with nephrocalcinosis, 620374 (3),
GPR81		
GPR82		
GPR83		
GPR84		
GPR85		
GPR86		
GPR87		
GPR88	AR	?chorea, childhood-onset, with psychomotor retardation, 616939 (3),
GPR89		
GPR89A		
GPR89B		
GPR89C		
GPR9		
GPR91		
GPR92		
GPR93		
GPR94		
GPR95		
GPR97		
GPR98	AR,AD	usher syndrome, type 2c, 605472 (3), digenic ; usher syndrome, type 2c, gpr98/pdzd7 digenic, 605472 (3), digenic ; ?febrile seizures, familial, 4, 604352 (3),
GPR99	AD	nephrolithiasis, calcium oxalate, 2, with nephrocalcinosis, 620374 (3),
GPRA		{asthma, susceptibility to, 2}, 608584 (3)
GPRASP1		
GPRASP2	XL,XLR	?deafness, 7, 301018 (3),
GPRASP3		
GPRC1A	AR,AD	spinocerebellar ataxia, 13, 614831 (3), ; spinocerebellar ataxia 44, 617691 (3),
GPRC1B		
GPRC1C		
GPRC1D		
GPRC1E		
GPRC1F	AR	night blindness, congenital stationary (complete), 1b, 257270 (3),
GPRC1G	AR	neurodevelopmental disorder with seizures, hypotonia, and brain abnormalities, 618922 (3),
GPRC1H		
GPRC2A	AD,AR	hypocalcemia, with bartter syndrome, 601198 (3), ; {epilepsy idiopathic generalized, susceptibility to, 8}, 612899 (3); hyperparathyroidism, neonatal, 239200 (3), ; hypocalcemia, 601198 (3), ; hypocalciuric hypercalcemia, type i, 145980 (3),
GPRC3A		
GPRC3B	AD	{nicotine dependence, protection against}, 188890 (3); {nicotine dependence, susceptibility to}, 188890 (3); developmental and epileptic encephalopathy 59, 617904 (3), ; neurodevelopmental disorder with poor language and loss of hand skills, 617903 (3),
GPRC5A		
GPRC5B		
GPRC5C		
GPRC5D		
GPRC6A		
GPRg2	AD	hypogonadotropic hypogonadism 3 with or without anosmia, 244200 (3),
GPRIN1		
GPRIN2		
GPRIN3		
GPRK1		oguchi disease-2, 613411 (3)
GPRK2L		
GPRK4		
GPRK5		
GPRK6		
GPRK7		
GPRv53		
GPS1		
GPS2		
GPSA	AD	acth-independent macronodular adrenal hyperplasia, 219080 (3), somatic mutation; pituitary adenoma 3, multiple types, somatic, 617686 (3); pseudohypoparathyroidism ic, 612462 (3), ; pseudohypoparathyroidism ia, 103580 (3), ; osseous heteroplasia, progressive, 166350 (3), ; pseudohypoparathyroidism ib, 603233 (3), ; mccune-albright syndrome, somatic, mosaic, 174800 (3); pseudopseudohypoparathyroidism, 612463 (3),
GPSM1		
GPSM2	AR	chudley-mccullough syndrome, 604213 (3),
GPSM3		
GPSM4		
GPSN2	AR	intellectual developmental disorder, 14, 614020 (3),
GPSN2L	AR	ventricular tachycardia, catecholaminergic polymorphic, 3, 614021 (3),
GPSTAF50		
GPT	AR	myasthenic syndrome, congenital, 13, with tubular aggregates, 614750 (3), ; congenital disorder of glycosylation, type ij, 608093 (3),
GPT1		
GPT2	AR	neurodevelopmental disorder with microcephaly and spastic paraplegia, 616281 (3),
GPVI	AR	bleeding disorder, platelet-type, 11, 614201 (3),
GPX1	AR	hemolytic anemia due to glutathione peroxidase deficiency, 614164 (1),
GPX2		
GPX3		
GPX4	AR	spondylometaphyseal dysplasia, sedaghatian type, 250220 (3),
GPX5		
GPX6		
GPX7		
GPX8		
GPXP3		
GR	AD	glucocorticoid resistance, 615962 (3),
GR6		
GRAF		leukemia, juvenile myelomonocytic, somatic, 607785 (3)
GRAF2		
GRAF3		
GRAIL		
GRAL		
GRAMD1A		
GRAMD1B		
GRAMD1C		
GRAMD2		
GRAMD2A		
GRAMD2B		
GRAMD3		
GRAMD4		
GRAMD5		
GRAMD6	AR	deafness, 107, 617639 (3),
GRAMD7		
GRAMD8B	XL	nephrotic syndrome, type 20, 301028 (3),
GRAMD9		
GRAMD9B		
GRAN2		
GRAP	AR	deafness, 114, 618456 (3),
GRAP2		
GRASP		
GRASP-1		
GRASP1		
GRASP55		
GRASP65		
GRB1	AD,AR	immunodeficiency 36, 616005 (3), ; ?agammaglobulinemia 7, 615214 (3), ; short syndrome, 269880 (3),
GRB10		
GRB14		
GRB2		
GRB7		
GRBLG		
GrbX		
Grc3		
GRCB		
GRCC10	AR	temtamy syndrome, 218340 (3),
Grcc2f	AR	bowen-conradi syndrome, 211180 (3),
GRCC8		
GRCC9		
Grd19		
GRDN	AR	?peho syndrome-like, 617507 (3),
GREAT		
GREB1		
GREB1L	AD	deafness, 80, 619274 (3), ; renal hypodysplasia/aplasia 3, 617805 (3),
GREM1		
GREM2	AD	tooth agenesis, selective, 9, 617275 (3),
GREM3		
gremlin		
GRF-1		
GRF1		
GRF2		
Grf40		
GRF55		
GRG1		
GRG2		
GRG3		
GRG4		
GRG5		
GRG6	AR	oocyte/zygote/embryo maturation arrest 15, 616814 (3),
GRH	AR	?hypogonadotropic hypogonadism 12 with or without anosmia, 614841 (3),
GRHL1		
GRHL2	AD,AR	deafness, 28, 608641 (3), ; ectodermal dysplasia/short stature syndrome, 616029 (3), ; corneal dystrophy, posterior polymorphous, 4, 618031 (3),
GRHL3	AD	van der woude syndrome 2, 606713 (3),
GRHPR	AR	hyperoxaluria, primary, type ii, 260000 (3),
GRHR	AR	hypogonadotropic hypogonadism 7 without anosmia, 146110 (3),
GRIA1	AR,AD	?intellectual developmental disorder, 76, 619931 (3), ; intellectual developmental disorder, 67, 619927 (3),
GRIA2	AD	neurodevelopmental disorder with language impairment and behavioral abnormalities, 618917 (3),
GRIA3	XL,XLR	intellectual developmental disorder, syndromic, wu type, 300699 (3),
GRIA4	AD	neurodevelopmental disorder with or without seizures and gait abnormalities, 617864 (3),
GRID1		
GRID2	AR	spinocerebellar ataxia, 18, 616204 (3),
GRID2IP		
GRIF-1		
GRIFIN		
GRIK		
GRIK1		
GRIK2	AD,AR	neurodevelopmental disorder with impaired language and ataxia and with or without seizures, 619580 (3), ; intellectual developmental disorder, 6, 611092 (3),
GRIK3		
GRIK4		
GRIK5		
GRIM-12		
GRIM-19	AR	{thyroid carcinoma, hurthle cell}, 607464 (3); ?mitochondrial complex i deficiency, nuclear type 28, 618249 (3),
GRIM19	AR	{thyroid carcinoma, hurthle cell}, 607464 (3); ?mitochondrial complex i deficiency, nuclear type 28, 618249 (3),
GRIN1	AR,AD	neurodevelopmental disorder with or without hyperkinetic movements and seizures, 617820 (3), ; developmental and epileptic encephalopathy 101, 619814 (3), ; neurodevelopmental disorder with or without hyperkinetic movements and seizures, 614254 (3),
GRIN2A	AD	epilepsy, focal, with speech disorder and with or without impaired intellectual development, 245570 (3),
GRIN2B	AD	developmental and epileptic encephalopathy 27, 616139 (3), ; intellectual developmental disorder, 6, with or without seizures, 613970 (3),
GRIN2C		
GRIN2D	AD	developmental and epileptic encephalopathy 46, 617162 (3),
GRIN3		
GRIN3A		
GRIN3B		
GRINA		
GRINL1A		
GRINL1B		
GRIP1	AR	fraser syndrome 3, 617667 (3),
GRIPAP1		
GRIPE	AR	neurodevelopmental disorder with hypotonia, neonatal respiratory insufficiency, and thermodysregulation, 618797 (3),
GRIT		
GRK1		oguchi disease-2, 613411 (3)
GRK2		
GRK3		
GRK4		
GRK5		
GRK6		
GRK7		
GRL	AD	glucocorticoid resistance, 615962 (3),
GRLF1		
GRM1	AR,AD	spinocerebellar ataxia, 13, 614831 (3), ; spinocerebellar ataxia 44, 617691 (3),
GRM2		
GRM3		
GRM4		
GRM5		
GRM6	AR	night blindness, congenital stationary (complete), 1b, 257270 (3),
GRM7	AR	neurodevelopmental disorder with seizures, hypotonia, and brain abnormalities, 618922 (3),
GRM8		
GRMP		
GRN	AD,AR	aphasia, primary progressive, 607485 (3), ; frontotemporal lobar degeneration with ubiquitin-positive inclusions, 607485 (3), ; ceroid lipofuscinosis, neuronal, 11, 614706 (3),
GRO1		
GRO2		
GRO3		
GROa		
GROb		
GroEL	AD,AR	spastic paraplegia 13, 605280 (3), ; leukodystrophy, hypomyelinating, 4, 612233 (3),
GroES		
GROg		
GROS1	AR	osteogenesis imperfecta, type viii, 610915 (3),
GRP		
GRP1		
GRP17		
Grp170	AR	?immunodeficiency 59 and hypoglycemia, 233600 (3),
GRP3		
GRP57		
GRP58		
GRP75	AR,AD	even-plus syndrome, 616854 (3), ; anemia, sideroblastic, 4, 182170 (3),
GRP78		
GRP94		
GrpE		
GRPEL1		
GRPEL2		
GRPP		
GRPR		
GRS		
GRS2		
GRSF1		
GRSP1		
GRTH	AR,AD	thyroid hormone resistance, 274300 (3), ; thyroid hormone resistance, 188570 (3), ; thyroid hormone resistance, selective pituitary, 145650 (3),
GRWD		
GRWD1		
GRX		
GRX1		
GRX2		
GRX3		
GRX4		
GRX5	AR	anemia, sideroblastic, 3, pyridoxine-refractory, 616860 (3), ; spasticity, childhood-onset, with hyperglycinemia, 616859 (3),
GRXCR1	AR	deafness, 25, 613285 (3),
GRXCR2	AR	?deafness, 101, 615837 (3),
gry	AR	muscular dystrophy, limb-girdle, 18, 615356 (3),
GRY-RBP		
GS-X	AD	?deafness, 77, 618915 (3),
GS1	AR	griscelli syndrome, type 1, 214450 (3),
gs114	AR	short-rib thoracic dysplasia 9 with or without polydactyly, 266920 (3), ; retinitis pigmentosa 80, 617781 (3),
GS15		
GS2	AR	griscelli syndrome, type 2, 607624 (3),
GS27	AR	epilepsy, progressive myoclonic 6, 614018 (3), ; muscular dystrophy, congenital, with or without seizures, 620166 (3),
GS28		
GS2L		
GS3	AR	bone marrow failure syndrome 3, 617052 (3),
GS3686		
GS3876		
GS3955		
GSA7	AR	spinocerebellar ataxia, 31, 619422 (3),
GSAP		
GSAS	AD,AR	spastic paraplegia 9a, 601162 (3), ; cutis laxa, type iiia, 219150 (3), ; spastic paraplegia 9b, 616586 (3), ; cutis laxa, 3, 616603 (3),
GSBS	AR,AD	{hypercholesterolemia, susceptibility to}, 143890 (3),
GSC	AR	short stature, auditory canal atresia, mandibular hypoplasia, skeletal abnormalities, 602471 (3),
GSC1	AR	short stature, auditory canal atresia, mandibular hypoplasia, skeletal abnormalities, 602471 (3),
GSC2		
GSCL		
GSD1a	AR	glycogen storage disease ia, 232200 (3),
GSD1b	AR,AD	glycogen storage disease ib, 232220 (3), ; congenital disorder of glycosylation, type iiw, 619525 (3), ; glycogen storage disease ic, 232240 (3),
GSD1c	AR,AD	glycogen storage disease ib, 232220 (3), ; congenital disorder of glycosylation, type iiw, 619525 (3), ; glycogen storage disease ic, 232240 (3),
GSD1d	AR,AD	glycogen storage disease ib, 232220 (3), ; congenital disorder of glycosylation, type iiw, 619525 (3), ; glycogen storage disease ic, 232240 (3),
GSD5	AR	mcardle disease, 232600 (3),
GSD6	AR	glycogen storage disease vi, 232700 (3),
GSDM		
GSDM1		
GSDMA		
GSDMB		
GSDMC		
GSDMD		
GSDMDC1		
GSDME	AD	deafness, 5, 600994 (3),
GSDML		
GSE	AD	immune dysregulation with autoimmunity, immunodeficiency, and lymphoproliferation, 616100 (3), ; {diabetes mellitus, insulin-dependent, 12}, 601388 (3); {celiac disease, susceptibility to, 3}, 609755 (3); {hashimoto thyroiditis}, 140300 (3), ; {systemic lupus erythematosus, susceptibility to}, 152700 (3),
GSE1		
GSF	AD,AR	{diabetes mellitus, type ii, susceptibility to}, 125853 (3), ; pancreatic agenesis 1, 260370 (3), ; mody, type iv, 606392 (3)
GSG1		
GSG1L		
GSG2		
Gsg3		
Gsh-1		
GSH1		
Gsh2	AR	diencephalic-mesencephalic junction dysplasia syndrome 2, 618646 (3),
Gsh4	AD	pituitary hormone deficiency, combined, 4, 262700 (3),
GSHPX-GI		
GSK3A		
GSK3B		
GSKIP		
GSL	AR	galactosialidosis, 256540 (3),
GSN	AD	amyloidosis, finnish type, 105120 (3),
GSNOR		amed syndrome, digenic, 619151 (3), digenic
Gsp1		
GSPT1		
GSPT2		
GSR	AR	hemolytic anemia due to glutathione reductase deficiency, 618660 (3),
GSS	AR,AD	hemolytic anemia due to glutathione synthetase deficiency, 231900 (3), ; glutathione synthetase deficiency, 266130 (3), |spongiform encephalopathy with neuropsychiatric features, 606688 (3), ; gerstmann-straussler disease, 137440 (3), ; huntington disease-like 1, 603218 (3), ; insomnia, fatal familial, 600072 (3), ; {kuru, susceptibility to}, 245300 (3); cerebral amyloid angiopathy, prnp-related, 137440 (3), ; creutzfeldt-jakob disease, 123400 (3),
GST-III		
GST1		
GST12		
GST13		
GST2		
GST3		
GST4		
GST5		
GSTA1		
GSTA2		
GSTA3		
GSTA4		
GSTA5		
GSTCD		
GSTK1		
GSTM1		
GSTM2		
GSTM3		
GSTM3TV2		
GSTM4		
GSTM5		
GSTO1		
GSTO2		
GSTP		
GSTP1		
GSTS		
GSTS1		
GSTS1-1		
GSTT1		
GSTT2		
GSTTLp28		
GSTZ1	AR	[maleylacetoacetate isomerase deficiency], 617596 (3),
GSTZ1-1	AR	[maleylacetoacetate isomerase deficiency], 617596 (3),
GSX1		
GSX2	AR	diencephalic-mesencephalic junction dysplasia syndrome 2, 618646 (3),
GSY	AR	glycogen storage disease 0, muscle, 611556 (3),
GT1	AD	?atrial fibrillation, familial, 18, 617280 (3),
GT198	AR	ovarian dysgenesis 3, 614324 (3),
GT24		
GT335		
GT650		
GTAR	AD	chopra-amiel-gordon syndrome, 619504 (3),
GTBP	AD,AR	lynch syndrome 5, 614350 (3), ; mismatch repair cancer syndrome 3, 619097 (3), ; {endometrial cancer, familial}, 608089 (3), somatic mutation,
GTC90	AR	congenital disorder of glycosylation, type iii, 613612 (3),
GTDC1		
GTDC2	AR	muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 8, 614830 (3), ; muscular dystrophy-dystroglycanopathy (limb-girdle) type c, 8, 618135 (3),
GTF2A1		
GTF2A1L		
GTF2A2		
GTF2B		
GTF2D1	AD,MF	spinocerebellar ataxia 17, 607136 (3), ; {parkinson disease, susceptibility to}, 168600 (3),
GTF2E1		
GTF2E2	AR	trichothiodystrophy 6, nonphotosensitive, 616943 (3),
GTF2F1		
GTF2F2		
GTF2H1		
GTF2H2		
GTF2H3		
GTF2H4		
GTF2H5	AR	trichothiodystrophy 3, photosensitive, 616395 (3),
GTF2I		
GTF2IRD1		
GTF2IRD2		
GTF2IRD2A		
GTF2IRD2B		
GTF2S		
GTF3		
GTF3A		
GTF3B	AR	cerebellofaciodental syndrome, 616202 (3),
GTF3C1		
GTF3C2		
GTF3C3		
GTF3C4		
GTF3C5		
GTF3C6		
GTK		
GTL2		
GTL3		
GTPBG3	AR	combined oxidative phosphorylation deficiency 23, 616198 (3),
GTPBP1		
GTPBP10		
GTPBP2	AR	jaberi-elahi syndrome, 617988 (3),
GTPBP3	AR	combined oxidative phosphorylation deficiency 23, 616198 (3),
GTPBP4		
GTPBP5		
GTPBP6		
GTPBP9		
GTPCH1	AR,AD	dystonia, dopa-responsive, 128230 (3), ; hyperphenylalaninemia, bh4-deficient, b, 233910 (3),
GTR2		
GTRAP3-18		
GTRAP48		
GTSE-1		
GTSE1		
GTSF1		
GTT1	AD	epilepsy, familial adult myoclonic, 2, 607876 (3),
GTX	AR	spastic ataxia 8, with hypomyelinating leukodystrophy, 617560 (3),
Gu-alpha		
GU/RH-II		
GU2		
GUB		
GUC1A2		
GUC1A3	AR	moyamoya 6 with achalasia, 615750 (3),
GUC1A4	AR,AD	cone-rod dystrophy 6, 601777 (3), ; ?choroidal dystrophy, central areolar 1, 215500 (3), ; leber congenital amaurosis 1, 204000 (3), ; night blindness, congenital stationary, type 1i, 618555 (3),
GUC1B3		
GUC2C	AD,AR	diarrhea 6, 614616 (3), ; meconium ileus, 614665 (3),
GUC2D	AR,AD	cone-rod dystrophy 6, 601777 (3), ; ?choroidal dystrophy, central areolar 1, 215500 (3), ; leber congenital amaurosis 1, 204000 (3), ; night blindness, congenital stationary, type 1i, 618555 (3),
GUC2DL		
GUCA	AD	cone-rod dystrophy 14, 602093 (3), ; cone dystrophy-3, 602093 (3),
GUCA1	AD	cone-rod dystrophy 14, 602093 (3), ; cone dystrophy-3, 602093 (3),
GUCA1A	AD	cone-rod dystrophy 14, 602093 (3), ; cone dystrophy-3, 602093 (3),
GUCA1B		retinitis pigmentosa 48, 613827 (3)
GUCA1C		
GUCA2		
GUCA2A		
GUCA2B		
GUCD1		
GUCY1A1	AR	moyamoya 6 with achalasia, 615750 (3),
GUCY1A2		
GUCY1A3	AR	moyamoya 6 with achalasia, 615750 (3),
GUCY1B1		
GUCY1B2		
GUCY1B3		
GUCY2A		
GUCY2B	AR,AD,AR	boudin-mortier syndrome, 619543 (3), |epiphyseal chondrodysplasia, miura type, 615923 (3), ; short stature with nonspecific skeletal abnormalities, 616255 (3), ; acromesomelic dysplasia 1, maroteaux type, 602875 (3),
GUCY2C	AD,AR	diarrhea 6, 614616 (3), ; meconium ileus, 614665 (3),
GUCY2D	AR,AD	cone-rod dystrophy 6, 601777 (3), ; ?choroidal dystrophy, central areolar 1, 215500 (3), ; leber congenital amaurosis 1, 204000 (3), ; night blindness, congenital stationary, type 1i, 618555 (3),
GUCY2F		
GUD	AD	mesothelioma, somatic, 156240 (3); meacham syndrome, 608978 (3), ; frasier syndrome, 136680 (3), somatic mutation, ; nephrotic syndrome, type 4, 256370 (3), ; denys-drash syndrome, 194080 (3), somatic mutation, ; wilms tumor, type 1, 194070 (3), somatic mutation,
gudu	AR	ciliary dyskinesia, primary, 23, 615451 (3),
GUF1	AR	?developmental and epileptic encephalopathy 40, 617065 (3),
GUK1		
GULP		
GULP1		
Gup		
Gup1		
GUP1		
GUP2	AR	nivelon-nivelon-mabille syndrome, 600092 (3),
GURDB		
GUSB	AR	mucopolysaccharidosis vii, 253220 (3),
gustducin		
GVM	AD	glomuvenous malformations, 138000 (3),
GW112		
GW182	AD	?epilepsy, familial adult myoclonic, 6, 618074 (3),
Gwl		
Gwt1	AR	glycosylphosphatidylinositol biosynthesis defect 11, 616025 (3),
GXK1		
GXP1	XL,XLR	spinal muscular atrophy, 2, infantile, 301830 (3), ; vexas syndrome, somatic, 301054 (3)
GXPLA2		
GXVPLA2		
GXYLT1		
GXYLT2		
Gy1		
GY2		
GYF1		
GYF2		{parkinson disease 11}, 607688 (3)
GYG	AR	?glycogen storage disease xv, 613507 (3), ; polyglucosan body myopathy 2, 616199 (3),
GYG1	AR	?glycogen storage disease xv, 613507 (3), ; polyglucosan body myopathy 2, 616199 (3),
GYG2		
GYLTL1B		
GYPA		{malaria, resistance to}, 611162 (3); [blood group, mnss system], 111300 (3)
GYPB		[blood group, ss], 111740 (3); {malaria, resistance to}, 611162 (3)
GYPC		[blood group, gerbich], 616089 (3); {malaria, resistance to}, 611162 (3)
GYPD		[blood group, gerbich], 616089 (3); {malaria, resistance to}, 611162 (3)
GYPE		
GYS	AR	glycogen storage disease 0, muscle, 611556 (3),
GYS1	AR	glycogen storage disease 0, muscle, 611556 (3),
GYS2	AR	glycogen storage disease 0, liver, 240600 (3),
GZF1	AR	joint laxity, short stature, and myopia, 617662 (3),
GZMA		
GZMB		
GZMH		
GZMK		
GZMM		
H	AR	[bombay phenotype], 616754 (3),
H_DJ0042M02.9	AR	lynch syndrome 4, 614337 (3); mismatch repair cancer syndrome 4, 619101 (3),
H_DJ0584D14.12		
H_DJ0747G18.14		
H_GS165L15.1		
H_NH0132A01.6		
H_NH0514P08.8		
H_NH0549I23.2		
H_NH0792N18.3		
H_NH1244M04.5	AR	?congenital disorder of glycosylation, type iiy, 620200 (3),
H_RG012D21.9		
H_RG271G13.9		
H_RG318M05.3		
H_TD2522F11.8		
H-2RIIBP		
H-B		
h-BCS	AR	gracile syndrome, 603358 (3), ; mitochondrial complex iii deficiency, nuclear type 1, 124000 (3), ; bjornstad syndrome, 262000 (3),
H-CAD		
H-CAM		[blood group, indian system], 609027 (3)
h-CD		
h-cGAS		
h-eag	AD	zimmermann-laband syndrome 1, 135500 (3), ; temple-baraitser syndrome, 611816 (3),
H-EAG2		
H-FABP		
H-GRF55		
H-K-ATPase		
H-l(3)mbt-l		
h-Mover		
h-mtRPOL	AR,AD	combined oxidative phosphorylation deficiency 55, 619743 (3),
h-neu		
H-PAST		
H-PGDS		
H-PIP	AD	pyogenic sterile arthritis, pyoderma gangrenosum, and acne, 604416 (3),
H-plk		
H-PLK		
H-PRUNE	AR	neurodevelopmental disorder with microcephaly, hypotonia, and variable brain anomalies, 617481 (3),
H-ray		
H-REV107		
H-REV107-1		
H-Sema-L	AR	?cholestasis, progressive familial intrahepatic, 11, 619874 (3), ; [blood group, john-milton-hagen system], 614745 (3)
H-twist	AD	craniosynostosis 1, 123100 (3), ; robinow-sorauf syndrome, 180750 (3), ; sweeney-cox syndrome, 617746 (3), ; saethre-chotzen syndrome with or without eyelid anomalies, 101400 (3),
h-vps45	AR	neutropenia, severe congenital, 5, 615285 (3),
H-YPT3	AD	neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter, 617807 (3),
H1	AR	neutropenia, severe congenital, 5, 615285 (3),
H1-0		
H1-1		
H1-10		
H1-2		
H1-3		
H1-4	AD	rahman syndrome, 617537 (3),
H1-5		
H1-6		
H1-7		
H1-9		
H1-9P		
H1.0		
H1.1		
H1.2		
H1.3		
H1.4	AD	rahman syndrome, 617537 (3),
H1.9		
H105e3	XLR,XLD,XL	ck syndrome, 300831 (3), ; child syndrome, 308050 (3),
H10BH		
H11	AD	neuronopathy, distal hereditary motor, type iia, 158590 (3), ; charcot-marie-tooth disease, axonal, type 2l, 608673 (3),
H12.3		
H13		
H17	AR	mitochondrial complex i deficiency, nuclear type 19, 618241 (3),
H174		
H19		
H1a		
H1b		
H1c		
H1d		
H1e	AD	rahman syndrome, 617537 (3),
H1F0		
H1F1		
H1F2		
H1F3		
H1F4	AD	rahman syndrome, 617537 (3),
H1F5		
H1FNT		
H1FT		
H1FV		
H1FX		
H1P		
H1RNA		
H1s-1		
H1s-2		
H1s-3		
H1s-4	AD	rahman syndrome, 617537 (3),
H1t		
H1T2		
H1X		
H2	AD	pfeiffer syndrome, 101600 (3), ; hypogonadotropic hypogonadism 2 with or without anosmia, 147950 (3), ; jackson-weiss syndrome, 123150 (3), ; hartsfield syndrome, 615465 (3), ; trigonocephaly 1, 190440 (3), ; osteoglophonic dysplasia, 166250 (3), ; encephalocraniocutaneous lipomatosis, somatic mosaic, 613001 (3)
h2-35		
H2-ALPHA	AD,AD	amyotrophic lateral sclerosis 22 with or without frontotemporal dementia, 616208 (3), |keratoconus 9, 617928 (3),
H2-Bf	AR,AD	?complement factor b deficiency, 615561 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to, 4}, 612924 (3), ; {macular degeneration, age-related, 14, reduced risk of}, 615489 (3), digenic
H2-KE2		
H2-KE4	AR	agammaglobulinemia 9, 619693 (3),
H2-KE6		
H218	AR	deafness, 68, 610419 (3),
H2A		
H2A.1		
H2A.1b		
H2A.2		
H2A.3		
H2A.B.1		
H2A.B.2		
H2A.Z		
H2A/a		
H2A/c		
H2A/d		
H2A/E		
H2A/g		
H2A/i		
H2A/m		
H2A/n		
H2A/p		
H2A/q		
H2A/S		
H2AB1		
H2AB2		
H2AB3		
H2AC1		
H2AC11		
H2AC12		
H2AC13		
H2AC14		
H2AC15		
H2AC16		
H2AC17		
H2AC18		
H2AC20		
H2AC21		
H2AC25		
H2AC4		
H2AC6		
H2AC7		
H2AC8		
H2AFA		
H2AFALii		
H2AFB		
H2AFB1		
H2AFB2		
H2AFB3		
H2AFC		
H2AFD		
H2AFE		
H2AFG		
H2AFI		
H2AFL		
H2AFM		
H2AFN		
H2AFO		
H2AFP		
H2AFQ		
H2AFR		
H2AFV		
H2AFX		
H2AFY		
H2AFY2		
H2AFZ		
H2AV		
H2AW		
H2AX		
H2AZ		
H2AZ1		
H2AZ2		
H2B		
H2B-GL105		
H2B.1		
H2B.1A		
H2B.2		
H2B.h		
H2B/a		
H2B/b		
H2B/c		
H2B/d		
H2B/e		
H2B/f		
H2B/g		
H2B/h		
H2B/j		
H2B/k		
H2B/l		
H2B/n		
H2B/q		
H2B/r		
H2BC1		
H2BC10		
H2BC11		
H2BC12		
H2BC13		
H2BC14		
H2BC15		
H2BC17		
H2BC21		
H2BC26		
H2BC3		
H2BC4		
H2BC5		
H2BC6		
H2BC7		
H2BC8		
H2BC9		
H2BE		
H2BFA		
H2BFAiii		
H2BFB		
H2BFC		
H2BFD		
H2BFE		
H2BFF		
H2BFG		
H2BFH		
H2BFJ		
H2BFK		
H2BFL		
H2BFN		
H2BFQ		
H2BFR		
H2BFT		
H2BFU		
H2BFWT		
H2BU1		
H2BW1		
H2P		
H2RSP		
H3	AD	pfeiffer syndrome, 101600 (3), ; hypogonadotropic hypogonadism 2 with or without anosmia, 147950 (3), ; jackson-weiss syndrome, 123150 (3), ; hartsfield syndrome, 615465 (3), ; trigonocephaly 1, 190440 (3), ; osteoglophonic dysplasia, 166250 (3), ; encephalocraniocutaneous lipomatosis, somatic mosaic, 613001 (3)
H3-3A	AD	bryant-li-bhoj neurodevelopmental syndrome 1, 619720 (3),
H3-3B	AD	bryant-li-bhoj neurodevelopmental syndrome 2, 619721 (3),
H3-4		
H3-5		
H3.1		
H3.2		
H3.3A	AD	bryant-li-bhoj neurodevelopmental syndrome 1, 619720 (3),
H3.3B	AD	bryant-li-bhoj neurodevelopmental syndrome 2, 619721 (3),
H3.3C		
H3.4		
H3.5		
H3.f		
H3/A		
H3/b		
H3/c		
H3/d		
H3/f		
H3/g		
H3/h		
H3/i		
H3/j		
H3/k		
H3/l		
H3/m		
H3/M		
H326	AD	?giant axonal neuropathy 2, 610100 (3),
H36-1	AD,AR	{macular degeneration, age-related, reduced risk of}, 603075 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to}, 235400 (3),
H36-2	AD,AR	{macular degeneration, age-related, reduced risk of}, 603075 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to}, 235400 (3),
H37		
H3C1		
H3C10		
H3C11		
H3C12		
H3C14		
H3C16		
H3C2		
H3C3		
H3C4		
H3C6		
H3C7		
H3C8		
H3F1K		
H3F2		
H3F3	AD	bryant-li-bhoj neurodevelopmental syndrome 1, 619720 (3),
H3F3A	AD	bryant-li-bhoj neurodevelopmental syndrome 1, 619720 (3),
H3F3B	AD	bryant-li-bhoj neurodevelopmental syndrome 2, 619721 (3),
H3F3C		
H3FA		
H3FB		
H3FC		
H3FD		
H3FF		
H3FH		
H3FI		
H3FJ		
H3FK		
H3FL		
H3FM		
H3FT		
H3P		
H3t		
H4	AD	pfeiffer syndrome, 101600 (3), ; hypogonadotropic hypogonadism 2 with or without anosmia, 147950 (3), ; jackson-weiss syndrome, 123150 (3), ; hartsfield syndrome, 615465 (3), ; trigonocephaly 1, 190440 (3), ; osteoglophonic dysplasia, 166250 (3), ; encephalocraniocutaneous lipomatosis, somatic mosaic, 613001 (3)
H4-16		
H4.k		
H4/b		
H4/c		
H4/d		
H4/e	AD	?tessadori-bicknell-van haaften neurodevelopmental syndrome 2, 619759 (3),
H4/g	AD	tessadori-bicknell-van haaften neurodevelopmental syndrome 1, 619758 (3),
H4/h		
H4/I		
H4/j	AD	tessadori-bicknell-van haaften neurodevelopmental syndrome 3, 619950 (3),
H4/k		
H4/l		
H4/m	AD	tessadori-bicknell-van haaften neurodevelopmental syndrome 4, 619951 (3),
H4/n		
H41		
h461		
H4C1		
H4C11	AD	?tessadori-bicknell-van haaften neurodevelopmental syndrome 2, 619759 (3),
H4C12		
H4C13		
H4C14		
H4C16		
H4C2		
H4C3	AD	tessadori-bicknell-van haaften neurodevelopmental syndrome 1, 619758 (3),
H4C4		
H4C5	AD	tessadori-bicknell-van haaften neurodevelopmental syndrome 3, 619950 (3),
H4C6		
H4C7		
H4C8		
H4C9	AD	tessadori-bicknell-van haaften neurodevelopmental syndrome 4, 619951 (3),
H4F2		
H4F2iii		
H4F2iv	AD	?tessadori-bicknell-van haaften neurodevelopmental syndrome 2, 619759 (3),
H4F5		
H4F5rel		
H4FA		
H4FB		
H4FC		
H4FD		
H4FE	AD	?tessadori-bicknell-van haaften neurodevelopmental syndrome 2, 619759 (3),
H4FG	AD	tessadori-bicknell-van haaften neurodevelopmental syndrome 1, 619758 (3),
H4FH		
H4FI		
H4FJ	AD	tessadori-bicknell-van haaften neurodevelopmental syndrome 3, 619950 (3),
H4FK		
H4FL		
H4FM	AD	tessadori-bicknell-van haaften neurodevelopmental syndrome 4, 619951 (3),
H4FN		
H4P		
H4R		
H5	AD	pfeiffer syndrome, 101600 (3), ; hypogonadotropic hypogonadism 2 with or without anosmia, 147950 (3), ; jackson-weiss syndrome, 123150 (3), ; hartsfield syndrome, 615465 (3), ; trigonocephaly 1, 190440 (3), ; osteoglophonic dysplasia, 166250 (3), ; encephalocraniocutaneous lipomatosis, somatic mosaic, 613001 (3)
H6	AR	oculoauricular syndrome, 612109 (3),
H6PD	AR	cortisone reductase deficiency 1, 604931 (3),
H6PDH	AR	cortisone reductase deficiency 1, 604931 (3),
H731		
H7365		
H7AP1		
H9		
H91620p	AD	glycogen storage disease of heart, lethal congenital, 261740 (3), ; wolff-parkinson-white syndrome, 194200 (3), ; cardiomyopathy, hypertrophic 6, 600858 (3),
H963		
Ha-1		
HA-1		
Ha-2		
HA-2		
HA-3		
Ha-3I		
Ha-3II		
Ha-4		
Ha-5		
HA-8		
HA1756		
HA6116	AD	neurodevelopmental disorder with central hypotonia and dysmorphic facies, 619797 (3),
HAAH	AR	traboulsi syndrome, 601552 (3),
HAAO	AR	vertebral, cardiac, renal, and limb defects syndrome 1, 617660 (3),
HAAP		
hABH		
HABON		
HABP	AD	{?thyroid cancer, nonmedullary, 5}, 616535 (3), ; {venous thromboembolism, susceptibility to}, 188050 (3),
HABP1	AR	combined oxidative phosphorylation deficiency 33, 617713 (3),
HABP2	AD	{?thyroid cancer, nonmedullary, 5}, 616535 (3), ; {venous thromboembolism, susceptibility to}, 188050 (3),
HABP4		
HABP4L		
HAC-1	AD	febrile seizures, familial, 2, 602477 (3), ; {epilepsy, idiopathic generalized, susceptibility to, 17}, 602477 (3), ; generalized epilepsy with febrile seizures plus, type 11, 602477 (3),
HAC-2	AD	developmental and epileptic encephalopathy 24, 615871 (3), ; generalized epilepsy with febrile seizures plus, type 10, 618482 (3),
HAC1		
hACC1	AR	acetyl-coa carboxylase deficiency, 613933 (1),
HACC275		
HACD1	AR	congenital myopathy 11, 619967 (3),
HACD2		
HACD3		
HACD4		
HACE1	AR	spastic paraplegia and psychomotor retardation with or without seizures, 616756 (3),
hACF1		
HACL1		
HACL1L		
HACS1		
HACS2	XLR,XL	immunodeficiency 102, 301082 (3),
hACTE-III		
hADA1		
hADA2		
hADA3		
HADH	AR	hyperinsulinemic hypoglycemia, familial, 4, 609975 (3), ; 3-hydroxyacyl-coa dehydrogenase deficiency, 231530 (3),
HADH1	AR	hyperinsulinemic hypoglycemia, familial, 4, 609975 (3), ; 3-hydroxyacyl-coa dehydrogenase deficiency, 231530 (3),
HADH2	XLD,XL	hsd10 mitochondrial disease, 300438 (3),
HADHA	AR	hellp syndrome, maternal, of pregnancy, 609016 (3), ; lchad deficiency, 609016 (3), ; mitochondrial trifunctional protein deficiency 1, 609015 (3), ; fatty liver, acute, of pregnancy, 609016 (3),
HADHB		mitochondrial trifunctional protein deficiency 2, 620300 (3)
HADHSC	AR	hyperinsulinemic hypoglycemia, familial, 4, 609975 (3), ; 3-hydroxyacyl-coa dehydrogenase deficiency, 231530 (3),
HAE1	AR,AD	angioedema, hereditary, 1 and 2, 106100 (3), ; complement component 4, partial deficiency of, 120790 (3),
HAE2	AR,AD	angioedema, hereditary, 1 and 2, 106100 (3), ; complement component 4, partial deficiency of, 120790 (3),
haemojuvelin	AR	hemochromatosis, type 2a, 602390 (3),
HAF		
hAG-1		
HAG-2	AR	respiratory infections, recurrent, and failure to thrive with or without diarrhea, 620233 (3),
hAG-3		
HAG3		
HAGE		
HAGH	AD	[glyoxalase ii deficiency], 614033 (1),
HAGH1	AD	[glyoxalase ii deficiency], 614033 (1),
HAGLR		
hAGO1	AD	neurodevelopmental disorder with language delay and behavioral abnormalities, with or without seizures, 620292 (3),
hAGO2	AD	lessel-kreienkamp syndrome, 619149 (3),
hAGO3		
hAGO4		
HAH1		
hAha1		
HAI	AR	ichthyosis, congenital, 11, 602400 (3),
HAI-1		
HAI-2	AR	diarrhea 3, secretory sodium, congenital, syndromic, 270420 (3),
HAI2	AR	diarrhea 3, secretory sodium, congenital, syndromic, 270420 (3),
HAIK1		
HAK		
HAK005771		
HAK6		
HAKA1	AR	immunodeficiency due to ficolin 3 deficiency, 613860 (3),
HAKAI		
hAKAP82		
HAKRA	AR	{46xy sex reversal 8, modifier of}, 614279 (3),
HAKRB		
HAKRC		
HAKRD	AR	46xy sex reversal 8, 614279 (3),
HAL	AR,AD	[histidinemia], 235800 (3),
hALP		
hALPG2	AR	congenital disorder of glycosylation, type ii, 607906 (3), ; myasthenic syndrome, congenital, 14, with tubular aggregates, 616228 (3),
HALR	AD	kleefstra syndrome 2, 617768 (3),
hamartin	AD	focal cortical dysplasia, type ii, somatic, 607341 (3); tuberous sclerosis-1, 191100 (3), ; lymphangioleiomyomatosis, 606690 (3)
HAMLET		
HAMP	AR	hemochromatosis, type 2b, 613313 (3),
HAN11		
HAND1		
HAND2		
HAND2-AS1		
hang	AR	degcags syndrome, 619488 (3),
HANK	AD	chondrocalcinosis 2, 118600 (3), ; craniometaphyseal dysplasia, 123000 (3),
HANP1		
HAO1		
HAO2		
HAOX2		
HAP	AR,AD	microphthalmia, syndromic 12, 615524 (3),
hAP-2g		
HAP1		
HAP2		
HAP3		
HAP95		
hAPG5	AR	?spinocerebellar ataxia, 25, 617584 (3),
HAPIP		
HAPLN1		
HAPLN2		
HAPLN4		
hAPN		
HAPO	AR	camptodactyly-arthropathy-coxa vara-pericarditis syndrome, 208250 (3),
haponin		
HAPRIN	AR	?anencephaly 1, 206500 (3),
hAQP4		
HAR1A		
HAR1B		
HAR1F		
HAR1R		
HARBI1		
HARC		
hARD2		
HARE		
HARI		
harmonin	AR	usher syndrome, type 1c, 276904 (3), ; deafness, 18a, 602092 (3),
HARP	AR,AR	harp syndrome, 607236 (3), ; neurodegeneration with brain iron accumulation 1, 234200 (3), |schimke immunoosseous dysplasia, 242900 (3),
HARP11		
HARS	AD,AR	charcot-marie-tooth disease, axonal, type 2w, 616625 (3), ; usher syndrome type 3b, 614504 (3),
HARS1	AD,AR	charcot-marie-tooth disease, axonal, type 2w, 616625 (3), ; usher syndrome type 3b, 614504 (3),
HARS2	AR	perrault syndrome 2, 614926 (3),
HARSL	AR	perrault syndrome 2, 614926 (3),
HARSR	AR	perrault syndrome 2, 614926 (3),
HAS		
Has1		
HAS1		
HAS2		
HAS2-AS		
HAS2-AS1		
HAS2AS		
HAS3		
HASF		
HASH1		
HASH2		
HASH3		
HASH4		
hASNase1		
HASNT		
HASPIN		
HASPP28		
HAST4		
HAT		
HAT1		
HAT1R	MF,AR	{hypertension, essential}, 145500 (3), ; renal tubular dysgenesis, 267430 (3),
HAT4		
HATH1	AD	?deafness, 89, 620284 (3),
HATH6		
HATL1		
hAtNOS1		
hATP1	AD,AR	mitochondrial complex v (atp synthase) deficiency, nuclear type 4a, 620358 (3), ; ?combined oxidative phosphorylation deficiency 22, 616045 (3), ; ?mitochondrial complex v (atp synthase) deficiency, nuclear type 4b, encephalopathic type, 615228 (3),
HATPL		
HAUS1		
HAUS2		
HAUS3		
HAUS4		
HAUS5		
HAUS6		
HAUS7		
HAUS8		
HAUSP	AD	hao-fountain syndrome, 616863 (3),
HAVCR		
HAVCR-1		
HAVCR1		
HAVCR2	AR	t-cell lymphoma, subcutaneous panniculitis-like, 618398 (3),
HAX-1	AR	neutropenia, severe congenital 3, 610738 (3),
HAX1	AR	neutropenia, severe congenital 3, 610738 (3),
Hb-1	AD	monilethrix, 158000 (3),
HB-1		
HB-1Y		
Hb-2		
Hb-3	AD,AR	monilethrix, 158000 (3), ; erythrokeratodermia variabilis et progressiva 5, 617756 (3),
Hb-4		
Hb-5	AR	ectodermal dysplasia 4, hair/nail type, 602032 (3),
HB1	AD,AR	ventricular fibrillation, familial, 1, 603829 (3); heart block, progressive, type ia, 113900 (3), ; cardiomyopathy, dilated, 1e, 601154 (3), ; heart block, nonprogressive, 113900 (3), ; long qt syndrome 3, 603830 (3), ; sick sinus syndrome 1, 608567 (3), ; brugada syndrome 1, 601144 (3), ; atrial fibrillation, familial, 10, 614022 (3), ; {sudden infant death syndrome, susceptibility to}, 272120 (3),
HB15		
HB16		
hB1F		
hB1F-2		
HB2	AD,AR	ventricular fibrillation, familial, 1, 603829 (3); heart block, progressive, type ia, 113900 (3), ; cardiomyopathy, dilated, 1e, 601154 (3), ; heart block, nonprogressive, 113900 (3), ; long qt syndrome 3, 603830 (3), ; sick sinus syndrome 1, 608567 (3), ; brugada syndrome 1, 601144 (3), ; atrial fibrillation, familial, 10, 614022 (3), ; {sudden infant death syndrome, susceptibility to}, 272120 (3),
HB24		
HB2A		
Hb2E		
HB5		
Hb6	AD	monilethrix, 158000 (3),
HB6		
HB9	AD	currarino syndrome, 176450 (3),
HBA-T2	AD	heinz body anemia, 140700 (3), ; thalassemia, alpha-, 604131 (3); erythrocytosis, familial, 7, 617981 (3), ; hemoglobin h disease, deletional and nondeletional, 613978 (3)
HBA-T3	AD	hemoglobin h disease, nondeletional, 613978 (3); thalassemias, alpha-, 604131 (3); heinz body anemias, alpha-, 140700 (3), ; methemoglobinemia, alpha type, 617973 (3), ; erythrocytosis, familial, 7, 617981 (3),
HBA1	AD	hemoglobin h disease, nondeletional, 613978 (3); thalassemias, alpha-, 604131 (3); heinz body anemias, alpha-, 140700 (3), ; methemoglobinemia, alpha type, 617973 (3), ; erythrocytosis, familial, 7, 617981 (3),
HBA2	AD	heinz body anemia, 140700 (3), ; thalassemia, alpha-, 604131 (3); erythrocytosis, familial, 7, 617981 (3), ; hemoglobin h disease, deletional and nondeletional, 613978 (3)
HBAC1		
HBAC2		
hBACH		
HBAP2		
HBB	AD,AR	methemoglobinemia, beta type, 617971 (3), ; thalassemia-beta, inclusion-body, 603902 (3), ; sickle cell anemia, 603903 (3), ; thalassemia, beta, 613985 (3); delta-beta thalassemia, 141749 (3), ; {malaria, resistance to}, 611162 (3); hereditary persistence of fetal hemoglobin, 141749 (3), ; erythrocytosis, familial, 6, 617980 (3), ; heinz body anemia, 140700 (3),
HBBD	AD,AR	ventricular fibrillation, familial, 1, 603829 (3); heart block, progressive, type ia, 113900 (3), ; cardiomyopathy, dilated, 1e, 601154 (3), ; heart block, nonprogressive, 113900 (3), ; long qt syndrome 3, 603830 (3), ; sick sinus syndrome 1, 608567 (3), ; brugada syndrome 1, 601144 (3), ; atrial fibrillation, familial, 10, 614022 (3), ; {sudden infant death syndrome, susceptibility to}, 272120 (3),
HBD		thalassemia due to hb lepore (3); thalassemia, delta- (3)
HBD-1		
HBD-2		
HBD1		
HBE		
HBE1		
HBEBP1		
HBEBP2	AR	d-glyceric aciduria, 220120 (3),
HBEBP4	AR	d-glyceric aciduria, 220120 (3),
HBEGF		{diphtheria, susceptibility to} (1)
hbet1		
Hbeta58		
HBF-3	AD	rett syndrome, congenital variant, 613454 (3),
HBFQTL5	AD	dias-logan syndrome, 617101 (3),
HBG-T1	AD	fetal hemoglobin quantitative trait locus 1, 141749 (3), ; cyanosis, transient neonatal, 613977 (3),
HBG-T2	AD	fetal hemoglobin quantitative trait locus 1, 141749 (3),
hBG1		
HBG1	AD	fetal hemoglobin quantitative trait locus 1, 141749 (3),
HBG2	AD	fetal hemoglobin quantitative trait locus 1, 141749 (3), ; cyanosis, transient neonatal, 613977 (3),
HBGF-3	AR	deafness, congenital with inner ear agenesis, microtia, and microdontia, 610706 (3),
HBGF-4		
HBGF1		
HBGF8		
HBGT	AD	developmental and epileptic encephalopathy 41, 617105 (3),
HBI-6		
HBI-61		
HBII-276		
HBII-276HG		
HBII-52-1		
HBII-85-1		
HBK		
HBK2		
HBLD1	AR	multiple mitochondrial dysfunctions syndrome 4, 616370 (3),
HBLD2	AR	multiple mitochondrial dysfunctions syndrome 5, 617613 (3),
HBM	AD,AR	osteopetrosis, 1, 607634 (3), ; [bone mineral density variability 1], 601884 (3), ; polycystic liver disease 4 with or without kidney cysts, 617875 (3), ; endosteal hyperostosis, 144750 (3), ; osteoporosis-pseudoglioma syndrome, 259770 (3), ; exudative vitreoretinopathy 4, 601813 (3),
hBNaC1		
hBNaC2		
HBNF		
HBO1		
HBOA		
Hbp		
HBP		
HBP1		
HBP17		
HBP44	AR	myopia 23, 615431 (3),
HBPA1		
HBQ		
HBQ1		
hBR-STL-1		
hBRE1		
hBRF	AR	cerebellofaciodental syndrome, 616202 (3),
hBRM	AD	nicolaides-baraitser syndrome, 601358 (3), ; blepharophimosis-impaired intellectual development syndrome, 619293 (3),
HBS1		
HBS1L		
HBSCI	AD,AD	developmental and epileptic encephalopathy 6b, non-dravet, 619317 (3), ; migraine, familial hemiplegic, 3, 609634 (3), ; dravet syndrome, 607208 (3), ; febrile seizures, familial, 3a, 604403 (3), ; generalized epilepsy with febrile seizures plus, type 2, 604403 (3), |seizures, benign familial infantile, 3, 607745 (3), ; developmental and epileptic encephalopathy 11, 613721 (3), ; episodic ataxia, type 9, 618924 (3),
HBSCII	AD	seizures, benign familial infantile, 3, 607745 (3), ; developmental and epileptic encephalopathy 11, 613721 (3), ; episodic ataxia, type 9, 618924 (3),
hBSSP-4		
hBUB1	AR	colorectal cancer with chromosomal instability, somatic, 114500 (3); microcephaly 30, primary, 620183 (3),
HBVES	AR	muscular dystrophy, limb-girdle, 25, 616812 (3),
HBXAP		
HBXIP		
HBZ		
HBZ-T1		
HBZ1		
Hc	AD	intellectual developmental disorder, 56, 617854 (3),
HC-II	AD	thrombophilia 10 due to heparin cofactor ii deficiency, 612356 (3),
HC/HCC		
HC10-II		
HC11	AD	{mycobacterium tuberculosis, susceptibility to}, 607948 (3); {hiv-1, resistance to}, 609423 (3); {coronary artery disease, modifier of} (3); {spina bifida, susceptibility to}, 182940 (3),
HC14		
HC2	AD	thrombophilia 10 due to heparin cofactor ii deficiency, 612356 (3),
HC3		
HC5	AR	?neurodevelopmental disorder with microcephaly, hypotonia, and absent language, 620038 (3),
HC56	AR	neurodevelopmental disorder with microcephaly, cataracts, and renal abnormalities, 617913 (3),
HC7-I		
HC8		
HC9		
HC90		
HCA1		
HCA10	XLR,XL	bartter syndrome, type 5, antenatal, transient, 300971 (3),
HCA112		
HCA127	XLR,XLD,XL	wieacker-wolff syndrome, 314580 (3), ; wieacker-wolff syndrome, female-restricted, 301041 (3),
HCA2	AD	{hypercalciuria, absorptive, susceptibility to}, 143870 (3),
HCA3		
HCA4	AR	lung disease, immunodeficiency, and chromosome breakage syndrome, 617241 (3),
HCA519		
HCA557b		
HCA587		
HCA59		
HCA661		
HCA67		
HCA88		
hCAF1		
hCaf1z	AR	pontocerebellar hypoplasia, type 7, 614969 (3),
HCAK1	AR	kappa light chain deficiency, 614102 (3),
Hcam3	AD	?deafness, 74, 618140 (3),
hCAP		
HCAP	AD	cornelia de lange syndrome 3, 610759 (3),
hCAP-1A		
hCAP-C		
hCAP-D2	AR	?microcephaly 21, primary, 617983 (3),
hCAP-D3	AR	microcephaly 22, primary, 617984 (3),
hCAP-E		
hCAP-G		
hCAP-G2	AR	khan-khan-katsanis syndrome, 618460 (3),
hCAP-H	AR	?microcephaly 23, primary, 617985 (3),
hCAP-H2		
HCAP1	AR	neurodevelopmental disorder with microcephaly, cataracts, and renal abnormalities, 617913 (3),
HCAR1		
HCAR2		
HCAR3		
HCaRG		
HCAT1		
HCAT2		
HCAT3		
HCBP1		
HCBP6		
HCC	AR	leukodystrophy, hypomyelinating, 5, 610532 (3),
Hcc-1		
HCC-1		
Hcc-2		
HCC-2		
HCC-3		
HCC-4		
HCC1		
HCC8		
HCCA2	AR	grange syndrome, 602531 (3),
HCCA3	AR	?proteasome-associated autoinflammatory syndrome 4, 619183 (3),
HCCAT1		
HCCAT2		
HCCAT5		
HCCDR1		
HCCR		
HCCR-1		
HCCR-2		
HCCR1		
HCCR2		
HCCRBP-3		
HCCS	XLD,XL	linear skin defects with multiple congenital anomalies 1, 309801 (3),
HCCS1	AR	pontocerebellar hypoplasia, type 2e, 615851 (3),
hCD40L	XL,XLR	immunodeficiency, with hyper-igm, 308230 (3),
hCD48		
hCD84		
hCDC14B		
hCdc21	AR	immunodeficiency 54, 609981 (3),
hCDC5		
HCDCREL-1		
hCDCREL-2		
HCDH	AD	developmental and epileptic encephalopathy 109, 620145 (3),
HCDH1	AD	developmental and epileptic encephalopathy 109, 620145 (3),
HCDI		
HCE		
HCE1		
HCELL		[blood group, indian system], 609027 (3)
hCERK		
HCERN3		
HCF-1	XLR,XL	methylmalonic aciduria and homocysteinemia, cblx type, 309541 (3),
HCF-2		
HCF1	XLR,XL	methylmalonic aciduria and homocysteinemia, cblx type, 309541 (3),
HCF2	AD	thrombophilia 10 due to heparin cofactor ii deficiency, 612356 (3),
HCFC1	XLR,XL	methylmalonic aciduria and homocysteinemia, cblx type, 309541 (3),
HCFC1R1		
HCFC2		
HCG		
hCG_1645727	AD	nemaline myopathy 6, 609273 (3),
hCG_1745121	AR	muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 7, 616052 (3), ; muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 7, 614643 (3),
hCG_40738	AR,AD	beck-fahrner syndrome, 618798 (3),
HCG-1		
HCG-V		
hCG1		
HCG1		
HCG12		
HCG22		
HCG8		
HCG9		
hCGBP		
HCGI		
HcGIP1		
HCGIX		
HCGIX-4		
HCGIX4		
HCGV		
HCGVIII		
HCGVIII-1		
HCHOLA3	AD	{low density lipoprotein cholesterol level qtl 1}, 603776 (3), ; hypercholesterolemia, familial, 3, 603776 (3),
hCHT	AD,AR	neuronopathy, distal hereditary motor, type viia, 158580 (3), ; myasthenic syndrome, congenital, 20, presynaptic, 617143 (3),
hCIC-K2	XLR,XL	proteinuria, low molecular weight, with hypercalciuric nephrocalcinosis, 308990 (3), ; hypophosphatemic rickets, 300554 (3), ; dent disease 1, 300009 (3), ; nephrolithiasis, type i, 310468 (3),
hCIT	AD,AR	developmental delay and seizures with or without movement abnormalities, 617836 (3), ; ?congenital disorder of glycosylation, type 1bb, 613861 (3), ; retinitis pigmentosa 59, 613861 (3),
hCIT529I10		
HCK	AD	autoinflammation with pulmonary and cutaneous vasculitis, 620296 (3),
HCKID	AD	advanced sleep-phase syndrome, familial, 2, 615224 (3),
HCKIE		
hcKrox		
hClC-K2	XLR,XL	proteinuria, low molecular weight, with hypercalciuric nephrocalcinosis, 308990 (3), ; hypophosphatemic rickets, 300554 (3), ; dent disease 1, 300009 (3), ; nephrolithiasis, type i, 310468 (3),
hClC-Ka		bartter syndrome, type 4b, digenic, 613090 (3), digenic
hClC-Kb	AR	bartter syndrome, type 3, 607364 (3), ; bartter syndrome, type 4b, digenic, 613090 (3), digenic
hCLE1		
HCLG1		
hCLIM1		
hCLK2	AR	you-hoover-fong syndrome, 616954 (3),
HCLP-1		
hClp1	AR	pontocerebellar hypoplasia, type 10, 615803 (3),
hCLP46	AD,AR	dowling-degos disease 4, 615696 (3), ; muscular dystrophy, limb-girdle, 21, 617232 (3),
HCLS1		
HCLSBP1	AR	neutropenia, severe congenital 3, 610738 (3),
HCM1228		
Hcml1		
Hcml2		
Hcml3	AR	?n-acetylaspartate deficiency, 614063 (3),
HCMOGT-1		
HCN		
HCN1	AD	developmental and epileptic encephalopathy 24, 615871 (3), ; generalized epilepsy with febrile seizures plus, type 10, 618482 (3),
HCN2	AD	febrile seizures, familial, 2, 602477 (3), ; {epilepsy, idiopathic generalized, susceptibility to, 17}, 602477 (3), ; generalized epilepsy with febrile seizures plus, type 11, 602477 (3),
HCN3		
HCN4	AD	sick sinus syndrome 2, 163800 (3), ; {epilepsy, idiopathic generalized, susceptibility to, 18}, 619521 (3), ; brugada syndrome 8, 613123 (3)
HCNGP		
HCNP		
HCNT2		
HCNTF		
hCOA3	AR	?mitochondrial complex iv deficiency, nuclear type 14, 619058 (3),
HCORO1	AR	immunodeficiency 8, 615401 (3),
HCP	AR,AD	coproporphyria, 121300 (3), ; harderoporphyria, 618892 (3),
hcp-1	AR	stromme syndrome, 243605 (3),
hcp-4		
hcp-6	AR	microcephaly 22, primary, 617984 (3),
HCP1	AR	folate malabsorption, hereditary, 229050 (3),
HCP5		
hCPE-R		
HCPH		
HCR	AD	?leukoencephalopathy, motor delay, spasticity, and dysarthria syndrome, 618878 (3),
HCR2	AR	[pentosuria], 260800 (3),
hCRBP1		
hCREM-2		
HCRN		
HCRNN4		
HCRP1	AR	spastic paraplegia 53, 614898 (3),
HCRT	AD	?narcolepsy 1, 161400 (3),
HCRTR1		
HCRTR2		
HCS	AR,AD	holocarboxylase synthetase deficiency, 253270 (3), |thrombocytopenia 4, 612004 (3),
hCS-A		[placental lactogen deficiency] (1)
hCS-B		
hCS-L		
HCSA	AR	neuronopathy, distal hereditary motor, type vi, 604320 (3), ; charcot-marie-tooth disease, axonal, type 2s, 616155 (3),
hCsl4p	AR	?pontocerebellar hypoplasia, type 1f, 619304 (3),
hCST	AR	congenital disorder of glycosylation, type iif, 603585 (3),
HCST		
hCTR1	AR	neurodegeneration and seizures due to copper transport defect, 620306 (3),
hCTR2		
hCyP3		
HD	AR,AD	lopes-maciel-rodan syndrome, 617435 (3), ; huntington disease, 143100 (3),
HD-5		
HD-6		
HD-PTP	AR	neurodevelopmental disorder and structural brain anomalies with or without seizures and spasticity, 618890 (3),
HD-VDAC3		
HD-ZNF1		
HD1		
HD21		?sarcoma, synovial, 300813 (3)
HD3		
HD4	AD	neurodevelopmental disorder with central hypotonia and dysmorphic facies, 619797 (3),
HD4ST	AR	ehlers-danlos syndrome, musculocontractural type 1, 601776 (3),
hD52		
hD53		
hD54		
HD6	XLD,XL	?chondrodysplasia with platyspondyly, distinctive brachydactyly, hydrocephaly, and microphthalmia, 300863 (3),
HD7		
HDAC		
HDAC-4	AD	neurodevelopmental disorder with central hypotonia and dysmorphic facies, 619797 (3),
HDAC-A	AD	neurodevelopmental disorder with central hypotonia and dysmorphic facies, 619797 (3),
HDAC1		
HDAC10		
HDAC11		
HDAC2		
HDAC3		
HDAC4	AD	neurodevelopmental disorder with central hypotonia and dysmorphic facies, 619797 (3),
HDAC5		
HDAC6	XLD,XL	?chondrodysplasia with platyspondyly, distinctive brachydactyly, hydrocephaly, and microphthalmia, 300863 (3),
HDAC7		
HDAC7A		
HDAC7B		
HDAC8	XLD,XL	cornelia de lange syndrome 5, 300882 (3),
HDAC9		
HDACA	AD	neurodevelopmental disorder with central hypotonia and dysmorphic facies, 619797 (3),
HDACL1	XLD,XL	cornelia de lange syndrome 5, 300882 (3),
HDB		
hDBP		
HDBP1		
HDBP2		
HDC	AD	{gilles de la tourette syndrome, susceptibility to}, 137580 (3),
hDC-SIGN		{hiv type 1, susceptibility to}, 609423 (3); {mycobacterium tuberculosis, susceptibility to}, 607948 (3); {dengue fever, protection against}, 614371 (3)
hDCC1		
hDCIR		
HDCL		
HDCMA18P	AR	alazami syndrome, 615071 (3),
HDCMB47P		
HDCMC04P	AD	o'donnell-luria-rodan syndrome, 618512 (3),
HDCMP		
HDDC1	AD,AR	?chilblain lupus 2, 614415 (3), ; aicardi-goutieres syndrome 5, 612952 (3),
hDectin-1	AR	candidiasis, familial, 4, 613108 (3), ; {aspergillosis, susceptibility to}, 614079 (3)
hDECTIN-2		
HDEL		
HDGF		
HDGFL2		
HDGFL3		
Hdgfrp2		
Hdgfrp3		
hDGKzeta		
HDH-VIII		
hdhc11	AR	short-rib thoracic dysplasia 3 with or without polydactyly, 613091 (3), digenic
hdhc3		
HDHC7	AR	spermatogenic failure 18, 617576 (3), ; ciliary dyskinesia, primary, 37, 617577 (3),
hdhc9	AR	spermatogenic failure 46, 619095 (3),
HDHD1		
HDHD1A		
HDHD2B		
HDHD4		
hDIA1	AD,AR	deafness, 1, with or without thrombocytopenia, 124900 (3), ; seizures, cortical blindness, microcephaly syndrome, 616632 (3),
hDIP		
hDIPP3alpha		
hDIPP3beta		
hdj-2		
HDJ3		
HDL2	AD	huntington disease-like 2, 606438 (3),
HDLBP		
hdlc1		
HDLDT1	AR,AD	tangier disease, 205400 (3), ; hdl deficiency, familial, 1, 604091 (3),
hdlg		
HDM2	AD,AR	{accelerated tumor formation, susceptibility to}, 614401 (3), ; ?lessel-kubisch syndrome, 618681 (3),
hDMP1		
HDMX	AD	?bone marrow failure syndrome 6, 618849 (3),
HDPR1	AD	townes-brocks syndrome 2, 617466 (3),
HDPY-30		
HDR	AD	hypoparathyroidism, sensorineural deafness, and renal dysplasia, 146255 (3),
hDREF		
hDrn1	AR	spinocerebellar ataxia, 17, 616127 (3),
HDS	AD,AR	developmental delay and seizures with or without movement abnormalities, 617836 (3), ; ?congenital disorder of glycosylation, type 1bb, 613861 (3), ; retinitis pigmentosa 59, 613861 (3),
HDSG1		
HDX		
hDx-1		
HDYNIV	AD,AR	optic atrophy 5, 610708 (3), ; encephalopathy, lethal, due to defective mitochondrial peroxisomal fission 1, 614388 (3),
HE		
HE1	AR	niemann-pick disease, type c2, 607625 (3),
HE12		
HE2		
HE3-ALPHA		
HE3-BETA		
HE4		
HE5		
HE6	XL	congenital bilateral absence of vas deferens, 300985 (3),
HE9		
HEA125	AR,AD	diarrhea 5, with tufting enteropathy, congenital, 613217 (3), ; lynch syndrome 8, 613244 (3),
hEAAC1	AR	dicarboxylic aminoaciduria, 222730 (3), ; {?schizophrenia susceptibility 18}, 615232 (3)
HEAB	AR	pontocerebellar hypoplasia, type 10, 615803 (3),
hEAG	AD	zimmermann-laband syndrome 1, 135500 (3), ; temple-baraitser syndrome, 611816 (3),
hEAG2		
HEATR1		
HEATR2	AR	ciliary dyskinesia, primary, 18, 614874 (3),
HEATR3	AR	diamond-blackfan anemia 21, 620072 (3),
HEATR5B		
HEB	AD,AR	craniosynostosis 3, 615314 (3), ; hypogonadotropic hypogonadism 26 with or without anosmia, 619718 (3),
HEBO	AR	bone marrow failure syndrome 2, 615715 (3),
HEBP		
HEBP1		
HEBP2		
HEC		
HEC1		
HECA		
HECL		
HECTD1		
HECTD3		
HECTD4	AR	neurodevelopmental disorder with seizures, spasticity, and complete or partial agenesis of the corpus callosum, 620250 (3),
HECW1		
HECW2	AD	neurodevelopmental disorder with hypotonia, seizures, and absent language, 617268 (3),
Hed		
HED	AD,AR,XL,XLD,XLR	ectodermal dysplasia 2, clouston type, 129500 (3), ; deafness, 3b, 612643 (3), ; deafness, 1b, 612645 (3), ; deafness, digenic gjb2/gjb6, 220290 (3), digenic |tooth agenesis, selective, 1, 313500 (3), ; ectodermal dysplasia 1, hypohidrotic, 305100 (3),
HEDJ	AD	polycystic kidney disease 6 with or without polycystic liver disease, 618061 (3),
HEDLS		
hEDTP	AD	{centronuclear myopathy, modifier of}, 160150 (3),
HEED	AD	cohen-gibson syndrome, 617561 (3),
HEEE9341		
HEF1		
HEFL		
HEFS		
HEG		
HEG1		
HEGFL		{diphtheria, susceptibility to} (1)
HEI-C		
HEI10		
HEIH		
HEIR-1		
HEK		
Hek11		
Hek2		
Hek3		
HEK4		
Hek5	AR	?bleeding disorder, platelet-type, 22, 618462 (3), ; {prostate cancer/brain cancer susceptibility, somatic}, 603688 (3)
Hek6		
Hek7		
Hek8		
HEL-N1		
HEL2		
Hel308		
HELAD1		
HELB		
HELG		
HELIC1		
HELIC2	AD	retinitis pigmentosa 33, 610359 (3),
Helios		
HELLPAR		
HELLS	AR	immunodeficiency-centromeric instability-facial anomalies syndrome 4, 616911 (3),
HELO1	AD	spinocerebellar ataxia 38, 615957 (3),
HELQ		
HELSNF1	AD	intellectual developmental disorder with autism and macrocephaly, 615032 (3),
HELT		
HELZ		
HELZ2		
HEM1	AR	immunodeficiency 72 with autoinflammation, 618982 (3),
HEM2		
HEM45		
HEMA	XL,XLR	thrombophilia 13, due to factor viii defect, 301071 (3); hemophilia a, 306700 (3),
HEMCAM		
HEMGN		
HEMHC	AD,AR	contractures, pterygia, and spondylocarpostarsal fusion syndrome 1a, 178110 (3), ; contractures, pterygia, and spondylocarpotarsal fusion syndrome 1b, 618469 (3), ; arthrogryposis, distal, type 2b3 (sheldon-hall), 618436 (3), ; arthrogryposis, distal, type 2a (freeman-sheldon), 193700 (3),
HEMK1		
HEMK2		
hemojuvelin	AR	hemochromatosis, type 2a, 602390 (3),
HEMPAS	AD,AR	?cowden syndrome 7, 616858 (3), ; dyserythropoietic anemia, congenital, type ii, 224100 (3),
hEmu1		
HEN1		
HEN2	AR	?hypogonadotropic hypogonadism 27 without anosmia, 619755 (3),
HENMT1		
hENT3	AR	histiocytosis-lymphadenopathy plus syndrome, 602782 (3),
HEP		
HEP-COP	AD	{autoimmune interstitial lung, joint, and kidney disease}, 616414 (3),
HEP-NOS		{malaria, resistance to}, 611162 (3)
HEP27		
HEPACAM	AR,AD	megalencephalic leukoencephalopathy with subcortical cysts 2a, 613925 (3), ; megalencephalic leukoencephalopathy with subcortical cysts 2b, remitting, with or without impaired intellectual development, 613926 (3),
HEPACAM2		
HEPC	AR	hemochromatosis, type 2b, 613313 (3),
hEPG5	AR	vici syndrome, 242840 (3),
HEPH		
HEPHL1	AR	?abnormal hair, joint laxity, and developmental delay, 261990 (3),
HEPIS		
HEPL		
HEPN1		
Hepp		
Hepp1		
HEPR		
HEPTP		
HER-2	AR	gastric cancer, somatic, 613659 (3); adenocarcinoma of lung, somatic, 211980 (3); ovarian cancer, somatic, 167000 (3); ?visceral neuropathy, familial, 2, 619465 (3), ; glioblastoma, somatic, 137800 (3)
HER2	AR	gastric cancer, somatic, 613659 (3); adenocarcinoma of lung, somatic, 211980 (3); ovarian cancer, somatic, 167000 (3); ?visceral neuropathy, familial, 2, 619465 (3), ; glioblastoma, somatic, 137800 (3)
HER3	AR,AD	?lethal congenital contractural syndrome 2, 607598 (3), ; {?erythroleukemia, familial, susceptibility to}, 133180 (3), ; visceral neuropathy, familial, 1, 243180 (3),
HER4	AD	amyotrophic lateral sclerosis 19, 615515 (3),
HERA-B	AR	perrault syndrome 6, 617565 (3),
HERC1	AR	macrocephaly, dysmorphic facies, and psychomotor retardation, 617011 (3),
HERC2	AR	intellectual developmental disorder, 38, 615516 (3), ; [skin/hair/eye pigmentation 1, blond/brown hair], 227220 (3), ; [skin/hair/eye pigmentation 1, blue/nonblue eyes], 227220 (3),
HERC3		
HERC4		
HERC5		
HERC6		
HERF1		
HERG	AD	short qt syndrome 1, 609620 (3); long qt syndrome 2, 613688 (3),
HERG2		
HERG3		
HERMES		
Hermes-1		[blood group, indian system], 609027 (3)
HERNA	AD	pleuropulmonary blastoma, 601200 (3), ; goiter, multinodular 1, with or without sertoli-leydig cell tumors, 138800 (3), ; glow syndrome, somatic mosaic, 618272 (3); rhabdomyosarcoma, embryonal, 2, 180295 (3)
HERP		
HERP1		
HERP2		
HERPUD1		
HERV-7q		
HERV-E1		
HERV-FRD		
HERV-K(C7)		
HERV-K(HML-2.HOM)		
HERV-K(I)		
HERV-K(II)		
HERV-K(III)		
HERV-K102		
HERV-K108		
HERV-R		
HERV-W		
HERV-W-ENV		
HERV-W/FRD		
HERV1	AR	myopathy, mitochondrial progressive, with congenital cataract and developmental delay, 613076 (3),
HERVE1		
HERVW		
hES		
HES-1		
HES1		
HES18		
HES2		
HES3		
HES4		
HES5		
HES6		
HES7	AR	spondylocostal dysostosis 4, 613686 (3),
HESL		
HESP		
HESPINTOR		
HESR-1		
HESR1		
HESR2		
HESR3		
HESRG		
hEST2	AD,AR	dyskeratosis congenita, 2, 613989 (3), ; dyskeratosis congenita, 4, 613989 (3), ; pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 1, 614742 (3), ; {melanoma, cutaneous malignant, 9}, 615134 (3), ; {leukemia, acute myeloid}, 601626 (3), somatic mutation,
HESX1	AR,AD	pituitary hormone deficiency, combined, 5, 182230 (3), ; septooptic dysplasia, 182230 (3), ; growth hormone deficiency with pituitary anomalies, 182230 (3),
HET		
hET-AR	AD	{migraine, resistance to}, 157300 (3), ; mandibulofacial dysostosis with alopecia, 616367 (3),
hET(B)R-LP		
HETER1		
HEX		
HEX1		
HEXA	AR	[hex a pseudodeficiency], 272800 (3), ; gm2-gangliosidosis, several forms, 272800 (3), ; tay-sachs disease, 272800 (3),
HEXB	AR	sandhoff disease, infantile, juvenile, and adult forms, 268800 (3),
HEXD		
HEXDC		
HEXIM1		
HEXIM2		
hExoI		
HEY1		
HEY2		
HEY3		
HEYL		
HF	AD,AR	{macular degeneration, age-related, 4}, 610698 (3), ; basal laminar drusen, 126700 (3), ; complement factor h deficiency, 609814 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to, 1}, 235400 (3),
HF.10		
HF.12		
HF.16		
HF.18		
HF1	AD,AR	{macular degeneration, age-related, 4}, 610698 (3), ; basal laminar drusen, 126700 (3), ; complement factor h deficiency, 609814 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to, 1}, 235400 (3),
HF10		
HF1B		
HF2	AD,AR	{macular degeneration, age-related, 4}, 610698 (3), ; basal laminar drusen, 126700 (3), ; complement factor h deficiency, 609814 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to, 1}, 235400 (3),
hFACVL1		
hFAF1		
HFAF1s		
HFARP	AD	plasma triglyceride level qtl, low, 615881 (3),
HFAT2	AD	spinocerebellar ataxia 45, 617769 (3),
HFB1-GDNF	AD	{hirschsprung disease, susceptibility to, 3}, 613711 (3),
HFB30		
HFC1	XLR,XL	methylmalonic aciduria and homocysteinemia, cblx type, 309541 (3),
hFcRII-C		
HFE	AD,AR	{porphyria variegata, susceptibility to}, 176200 (3), ; {microvascular complications of diabetes 7}, 612635 (3); hemochromatosis, 235200 (3), ; {alzheimer disease, susceptibility to}, 104300 (3), ; [transferrin serum level qtl2], 614193 (3); {porphyria cutanea tarda, susceptibility to}, 176100 (3),
HFE1	AD,AR	{porphyria variegata, susceptibility to}, 176200 (3), ; {microvascular complications of diabetes 7}, 612635 (3); hemochromatosis, 235200 (3), ; {alzheimer disease, susceptibility to}, 104300 (3), ; [transferrin serum level qtl2], 614193 (3); {porphyria cutanea tarda, susceptibility to}, 176100 (3),
HFE2	AR	hemochromatosis, type 2a, 602390 (3),
HFE2A	AR	hemochromatosis, type 2a, 602390 (3),
HFE2B	AR	hemochromatosis, type 2b, 613313 (3),
HFE3	AR	hemochromatosis, type 3, 604250 (3),
HFE4	AD	hemochromatosis, type 4, 606069 (3),
HFH-11		
HFH-4	AD	ciliary dyskinesia, primary, 43, 618699 (3),
HFH1		
HFH2	AD	{autoimmune disease, susceptibility to, 1}, 607836 (3),
HFH4	AD	ciliary dyskinesia, primary, 43, 618699 (3),
HFI1		
hFip1		
hFIZ	MF	{osteoarthritis susceptibility 1}, 165720 (3),
HFK1	AD	rett syndrome, congenital variant, 613454 (3),
HFK2	AD	rett syndrome, congenital variant, 613454 (3),
HFK3	AD	rett syndrome, congenital variant, 613454 (3),
hFKBP65	AR	osteogenesis imperfecta, type xi, 610968 (3), ; bruck syndrome 1, 259450 (3),
HFKH-5		
hFKH1B	AD	intellectual developmental disorder with language impairment with or without autistic features, 613670 (3),
HFKH4	AR,AD	bamforth-lazarus syndrome, 241850 (3), ; {thyroid cancer, nonmedullary, 4}, 616534 (3),
hfl-B5		
HFL-EDDG1		
HFL1	AD,AR	{macular degeneration, age-related, reduced risk of}, 603075 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to}, 235400 (3),
HFL2	AD,AR	{macular degeneration, age-related, reduced risk of}, 603075 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to}, 235400 (3),
HFL3		
hFLEG1		
HFM1	AR	premature ovarian failure 9, 615724 (3),
HFMI1		
HFMI2	AD	lymphatic malformation 9, 619319 (3),
hFOG-2	AD	diaphragmatic hernia 3, 610187 (3); 46xy sex reversal 9, 616067 (3), ; tetralogy of fallot, 187500 (3),
hFPG1		
hFPG2		
HFREP-1		
hFrtz	AR	?bardet-biedl syndrome 15, 615992 (3), ; congenital heart defects, hamartomas of tongue, and polysyndactyly, 217085 (3),
HFSP		
HFTC	AR	tumoral calcinosis, hyperphosphatemic, familial, 1, 211900 (3),
HFZ20		
HFZ5		
Hfz6	AR	nail disorder, nonsyndromic congenital, 1, 161050 (3),
hg105		
HG20	AD	{nicotine dependence, protection against}, 188890 (3); {nicotine dependence, susceptibility to}, 188890 (3); developmental and epileptic encephalopathy 59, 617904 (3), ; neurodevelopmental disorder with poor language and loss of hand skills, 617903 (3),
hg27		
hG28K		
HG38		
hGAA1	AR	glycosylphosphatidylinositol biosynthesis defect 15, 617810 (3),
HGAL		
hGAT-1	AD	myoclonic-atonic epilepsy, 616421 (3),
HGB		
hGB1a		
hGCMa		
hGCMb	AR,AD	hypoparathyroidism, familial isolated 2, 618883 (3), ; hyperparathyroidism 4, 617343 (3),
hGCP2	AR	pachygyria, microcephaly, developmental delay, and dysmorphic facies, with or without seizures, 618737 (3),
HGD	AR	alkaptonuria, 203500 (3),
hGDH1	AD	hyperinsulinism-hyperammonemia syndrome, 606762 (3),
HGF	AD,AR,MF,AR,AD	{type 2 diabetes mellitus}, 125853 (3), ; {rheumatoid arthritis, systemic juvenile}, 604302 (3); {intracranial hemorrhage in brain cerebrovascular malformations, susceptibility to}, 108010 (3), somatic mutation; {type 1 diabetes mellitus}, 222100 (3), ; {crohn disease-associated growth failure}, 266600 (3), ; {kaposi sarcoma, susceptibility to}, 148000 (3), |deafness, 39, 608265 (3), |noonan syndrome 4, 610733 (3), ; ?fibromatosis, gingival, 1, 135300 (3),
HGFA		
HGFAC		
HGFAL	AD	{?thyroid cancer, nonmedullary, 5}, 616535 (3), ; {venous thromboembolism, susceptibility to}, 188050 (3),
HGFAP		
HGFB	AR	deafness, 39, 608265 (3),
HGFIN	AR	amyloidosis, primary localized cutaneous, 3, 617920 (3),
HGFL		
HGFR	AD,AR	renal cell carcinoma, papillary, 1, familial and somatic, 605074 (3); ?arthrogryposis, distal, type 11, 620019 (3), ; hepatocellular carcinoma, childhood type, somatic, 114550 (3); {osteofibrous dysplasia, susceptibility to}, 607278 (3), ; ?deafness, 97, 616705 (3),
hGH-N	AR,AD	kowarski syndrome, 262650 (3), ; growth hormone deficiency, isolated, type ii, 173100 (3), ; growth hormone deficiency, isolated, type ib, 612781 (3); growth hormone deficiency, isolated, type ia, 262400 (3),
hGH-V		
hGITRL		
HGK		
HGL		{?schizophrenia, susceptibility to}, 603013 (1)
hGLE1	AR	lethal congenital contracture syndrome 1, 253310 (3), ; congenital arthrogryposis with anterior horn cell disease, 611890 (3),
HGNAT	AR	mucopolysaccharidosis type iiic (sanfilippo c), 252930 (3), ; retinitis pigmentosa 73, 616544 (3),
HGNT-IV-H		
hGntK		
HGO	AR	alkaptonuria, 203500 (3),
hGPCR2		
hGPCR36		
hGPI1	AR	multiple congenital anomalies-hypotonia-seizures syndrome 4, 618548 (3),
hGPI8	AR	neurodevelopmental disorder with hypotonia and cerebellar atrophy, with or without seizures, 618879 (3),
HGPPS	AR	gaze palsy, familial horizontal, with progressive scoliosis, 1, 607313 (3),
HGPRT	XLR,XL	hyperuricemia, hrpt-related, 300323 (3), ; lesch-nyhan syndrome, 300322 (3),
HGPS	AR,AR,AR,AD	gaze palsy, familial horizontal, with progressive scoliosis, 1, 607313 (3), |mandibuloacral dysplasia with type b lipodystrophy, 608612 (3), ; restrictive dermopathy 1, 275210 (3), |mandibuloacral dysplasia, 248370 (3), ; heart-hand syndrome, slovenian type, 610140 (3), ; cardiomyopathy, dilated, 1a, 115200 (3), ; emery-dreifuss muscular dystrophy 3, 616516 (3), ; restrictive dermopathy 2, 619793 (3); charcot-marie-tooth disease, type 2b1, 605588 (3), ; emery-dreifuss muscular dystrophy 2, 181350 (3), ; hutchinson-gilford progeria, 176670 (3), ; lipodystrophy, familial partial, type 2, 151660 (3), ; muscular dystrophy, congenital, 613205 (3), ; malouf syndrome, 212112 (3),
HGR74		
HGRG8		
HGS		
HGSNAT	AR	mucopolysaccharidosis type iiic (sanfilippo c), 252930 (3), ; retinitis pigmentosa 73, 616544 (3),
HGT.1		
HH1	AD,AR	ventricular fibrillation, familial, 1, 603829 (3); heart block, progressive, type ia, 113900 (3), ; cardiomyopathy, dilated, 1e, 601154 (3), ; heart block, nonprogressive, 113900 (3), ; long qt syndrome 3, 603830 (3), ; sick sinus syndrome 1, 608567 (3), ; brugada syndrome 1, 601144 (3), ; atrial fibrillation, familial, 10, 614022 (3), ; {sudden infant death syndrome, susceptibility to}, 272120 (3),
HH114	AR	dyserythropoietic anemia, congenital, type ib, 615631 (3),
HH14	AR,AD	intellectual developmental disorder, 78, 620237 (3), ; hypogonadotropic hypogonadism 14 with or without anosmia, 614858 (3),
HH4R		
HHARI		
HHARP	AR	schimke immunoosseous dysplasia, 242900 (3),
HHAT	AR	nivelon-nivelon-mabille syndrome, 600092 (3),
HHATL		
HHC	AD,AR	hypocalcemia, with bartter syndrome, 601198 (3), ; {epilepsy idiopathic generalized, susceptibility to, 8}, 612899 (3); hyperparathyroidism, neonatal, 239200 (3), ; hypocalcemia, 601198 (3), ; hypocalciuric hypercalcemia, type i, 145980 (3),
HHC1	AD,AR	hypocalcemia, with bartter syndrome, 601198 (3), ; {epilepsy idiopathic generalized, susceptibility to, 8}, 612899 (3); hyperparathyroidism, neonatal, 239200 (3), ; hypocalcemia, 601198 (3), ; hypocalciuric hypercalcemia, type i, 145980 (3),
HHC2	AD	hypocalciuric hypercalcemia, type ii, 145981 (3), ; hypocalcemia, 2, 615361 (3),
HHC3	AD	hypocalciuric hypercalcemia, type iii, 600740 (3),
hHCP-6	AR	microcephaly 22, primary, 617984 (3),
HHCPA78		
hHDC		
HHEX		
HHF1	AR,AD	diabetes mellitus, permanent neonatal 3, with or without neurologic features, 618857 (3), ; diabetes mellitus, transient neonatal 2, 610374 (3); diabetes mellitus, noninsulin-dependent, 125853 (3), ; hypoglycemia of infancy, leucine-sensitive, 240800 (3), ; hyperinsulinemic hypoglycemia, familial, 1, 256450 (3),
HHG	AR,AD	leydig cell adenoma, somatic, with precocious puberty, 176410 (3); leydig cell hypoplasia with pseudohermaphroditism, 238320 (3), ; leydig cell hypoplasia with hypergonadotropic hypogonadism, 238320 (3), ; luteinizing hormone resistance, female, 238320 (3), ; precocious puberty, male, 176410 (3),
HHG-3	AR	46xy gonadal dysgenesis with minifascicular neuropathy, 607080 (3), ; 46xy sex reversal 7, 233420 (3),
HHG1	AD	microphthalmia with coloboma 5, 611638 (3), ; schizencephaly, 269160 (3); single median maxillary central incisor, 147250 (3), ; holoprosencephaly 3, 142945 (3),
HHG2	AR,AD	acrocapitofemoral dysplasia, 607778 (3), ; brachydactyly, type a1, 112500 (3),
HHGP		
HHH	AR	hyperornithinemia-hyperammonemia-homocitrullinemia syndrome, 238970 (3),
HHIP		
HHIPL2		
HHL		
HHLA1		
HHLA2		
HHLA3		
hHLP1		
HHM	AD	brachydactyly, type e2, 613382 (3),
HHMJG		
hhNMC	AR	renal tubular acidosis, proximal, with ocular abnormalities, 604278 (3),
hHR21	AD,AR	cornelia de lange syndrome 4, 614701 (3), ; ?mungan syndrome, 611376 (3),
HHR23A		
HHR23B		
hHR54	AD	{breast cancer, invasive ductal}, 114480 (3), somatic mutation, ; adenocarcinoma, colonic, somatic (3); lymphoma, non-hodgkin, somatic, 605027 (3)
HHR6A	XL,XLR	intellectual developmental disorder, syndromic, nascimento type, 300860 (3),
HHR6B		
HHRF-1	AR	neurodevelopmental disorder with microcephaly, cataracts, and renal abnormalities, 617913 (3),
hHRG-1		
hHRI	AD	?leukoencephalopathy, motor delay, spasticity, and dysarthria syndrome, 618878 (3),
HHS	AR	tumoral calcinosis, hyperphosphatemic, familial, 1, 211900 (3),
HHT	AD	telangiectasia, hereditary hemorrhagic, type 2, 600376 (3),
HHT1	AD	telangiectasia, hereditary hemorrhagic, type 1, 187300 (3),
HHT2	AD	telangiectasia, hereditary hemorrhagic, type 2, 600376 (3),
HHYLTK		
HHZ150		
HHZ168		
HHZ181		
HI	AR,AD	diabetes mellitus, permanent neonatal 3, with or without neurologic features, 618857 (3), ; diabetes mellitus, transient neonatal 2, 610374 (3); diabetes mellitus, noninsulin-dependent, 125853 (3), ; hypoglycemia of infancy, leucine-sensitive, 240800 (3), ; hyperinsulinemic hypoglycemia, familial, 1, 256450 (3),
HI-LNC25		
HI-LNC75		
HI-LNC78		
HI-LNC80		
HI30		
HI95		
hIAN6		
hiap-1		
hiap-2		
HIAT1		
HIATL1		
HIBADH		
HIBCH	AR	3-hydroxyisobutryl-coa hydrolase deficiency, 250620 (3),
HIBDL		
HIC	AR	lymphatic malformation 12, 620014 (3),
Hic-5		
HIC-5		
HIC1		
HIC2		
HICE1		
HID-1	AR	developmental and epileptic encephalopathy 105 with hypopituitarism, 619983 (3),
HID1	AR	developmental and epileptic encephalopathy 105 with hypopituitarism, 619983 (3),
hIes2		
HIF-1	AD	luscan-lumish syndrome, 616831 (3), ; intellectual developmental disorder, 70, 620157 (3), ; rabin-pappas syndrome, 620155 (3),
HIF-1alpha		
HIF-1beta		
HIF1		
HIF1A		
HIF1A-AS1		
HIF1A-AS2		
HIF1AN		
HIF2A	AD	erythrocytosis, familial, 4, 611783 (3),
HIF3A		
HIFPH1		
HIFPH2	AD	erythrocytosis, familial, 3, 609820 (3), ; [hemoglobin, high altitude adaptation], 609070 (3),
HIFPH3		
HIFPH4	AR	hypotonia, hypoventilation, impaired intellectual development, dysautonomia, epilepsy, and eye abnormalities, 618493 (3),
HIG-2		
HIG1		
HIG2		
HIGD1A		
HIGD1B		
hIGFBP-1		
hiGIRK2	AD	keppen-lubinsky syndrome, 614098 (3),
HIGM1	XL,XLR,XL,XLR	immunodeficiency, with hyper-igm, 308230 (3), |immunodeficiency, with hyper-igm, 308230 (3),
HIGM2	AR	immunodeficiency with hyper-igm, type 2, 605258 (3),
HIGM4	AR	immunodeficiency with hyper igm, type 5, 608106 (3),
HIgR	AR	cleft lip/palate-ectodermal dysplasia syndrome, 225060 (3), ; orofacial cleft 7, 225060 (3),
hIk-1	AD	immunodeficiency, common variable, 13, 616873 (3),
hIKCa1	AD	dehydrated hereditary stomatocytosis 2, 616689 (3),
HIKESHI	AR	leukodystrophy, hypomyelinating, 13, 616881 (3),
HIL-10R	AR	inflammatory bowel disease 28, early onset, 613148 (3),
hIL-17R	AR	immunodeficiency 51, 613953 (3),
HILAP		
HILDA		
HILI		
hILP	XL,XLR	lymphoproliferative syndrome, 2, 300635 (3),
HILPDA		
HILS1		
HIMAP1		
HIMAP2		
HIMAP3	AR	portal hypertension, noncirrhotic, 2, 619463 (3),
HIMAP4		
HIMTP		
HIN-1		
HIN1		
HINAC		
HiNF-P		
HINFP		
hINO80		
HINT	AR	neuromyotonia and axonal neuropathy, 137200 (3),
HINT-5	AR	al-raqad syndrome, 616459 (3),
HINT1	AR	neuromyotonia and axonal neuropathy, 137200 (3),
HINT2		
HINT3		
HINT4		
HINT5	AR	al-raqad syndrome, 616459 (3),
hIntL		
HIOMT		
HIOMTY		
HIP		
HIP-55		
HIP1		
HIP10		
HIP116A		
HIP12		
HIP14		
HIP14L		
HIP1R		
HIP2		
HIP3		
HIP4	AR	thrombosis, hyperhomocysteinemic, 236200 (3), ; homocystinuria, b6-responsive and nonresponsive types, 236200 (3),
HIP5		
HIP6		
HIP7	AD,AR	glaucoma 1, open angle, e, 137760 (3), ; amyotrophic lateral sclerosis 12 with or without frontotemporal dementia, 613435 (3), ; {glaucoma, normal tension, susceptibility to}, 606657 (3)
HIP8		
HIP9		
HIPI3	AD	luo-schoch-yamamoto syndrome, 619460 (3),
HIPK1		
HIPK2		
HIPK3		
HIPK4		
HIPPI	AR	?orofaciodigital syndrome xviii, 617927 (3),
HIPSTR		
HIR		
HIRA		
HIRIP3		
HIRIP4		
HIRIP5	AR	multiple mitochondrial dysfunctions syndrome 1, 605711 (3),
hIRK1		
hIRK2		
HIRS-1	AD	{type 2 diabetes mellitus, susceptibility to}, 125853 (3), ; {coronary artery disease, susceptibility to} (3)
HIS	AR,AD	[histidinemia], 235800 (3),
HIS-1		
HIS1		
HIS2		
hIscA	AR	multiple mitochondrial dysfunctions syndrome 5, 617613 (3),
hIscA1	AR	multiple mitochondrial dysfunctions syndrome 5, 617613 (3),
HISPPD1	AR	deafness, 100, 618422 (3),
HISPPD2A		
HisRS	AD,AR	charcot-marie-tooth disease, axonal, type 2w, 616625 (3), ; usher syndrome type 3b, 614504 (3),
HIST1H1A		
HIST1H1B		
HIST1H1C		
HIST1H1D		
HIST1H1E	AD	rahman syndrome, 617537 (3),
HIST1H1T		
HIST1H2AA		
HIST1H2AB		
HIST1H2AC		
HIST1H2AD		
HIST1H2AE		
HIST1H2AG		
HIST1H2AH		
HIST1H2AI		
HIST1H2AJ		
HIST1H2AK		
HIST1H2AL		
HIST1H2AM		
HIST1H2BA		
HIST1H2BB		
HIST1H2BC		
HIST1H2BD		
HIST1H2BE		
HIST1H2BF		
HIST1H2BG		
HIST1H2BH		
HIST1H2BI		
HIST1H2BJ		
HIST1H2BK		
HIST1H2BL		
HIST1H2BM		
HIST1H2BN		
HIST1H2BO		
HIST1H3A		
HIST1H3B		
HIST1H3C		
HIST1H3D		
HIST1H3E		
HIST1H3F		
HIST1H3G		
HIST1H3H		
HIST1H3I		
HIST1H3J		
HIST1H4A		
HIST1H4B		
HIST1H4C	AD	tessadori-bicknell-van haaften neurodevelopmental syndrome 1, 619758 (3),
HIST1H4D		
HIST1H4E	AD	tessadori-bicknell-van haaften neurodevelopmental syndrome 3, 619950 (3),
HIST1H4F		
HIST1H4G		
HIST1H4H		
HIST1H4I	AD	tessadori-bicknell-van haaften neurodevelopmental syndrome 4, 619951 (3),
HIST1H4J	AD	?tessadori-bicknell-van haaften neurodevelopmental syndrome 2, 619759 (3),
HIST1H4K		
HIST1H4L		
HIST2H2AA		
HIST2H2AA3		
HIST2H2AB		
HIST2H2AC		
HIST2H2BE		
HIST2H3C		
HIST2H4		
HIST2H4A		
HIST3H2A		
HIST3H2BB		
HIST3H3		
HIST4H4		
hISWI		
HIT-4		
HIT-40		
Hit1	AR	peho syndrome, 260565 (3),
HITF		
HIV-EP2	AD	intellectual developmental disorder, 43, 616977 (3),
HIVE1		
HIVEN86A	AR	immunodeficiency 92, 619652 (3),
HIVEP1		
HIVEP2	AD	intellectual developmental disorder, 43, 616977 (3),
HIVEP3		
HIWI		
HIWI2		
HIWI3		
HJ1	AD	?deafness, congenital heart defects, and posterior embryotoxon, 617992 (3), ; charcot-marie-tooth disease, axonal, type 2hh, 619574 (3), ; alagille syndrome 1, 118450 (3), ; tetralogy of fallot, 187500 (3),
hJAL		
hJT		
hJumpy	AD	{centronuclear myopathy, modifier of}, 160150 (3),
HJURP		
HJV	AR	hemochromatosis, type 2a, 602390 (3),
HK	AR,AD	[kininogen deficiency], 228960 (3), ; angioedema, hereditary, 6, 619363 (3), ; [high molecular weight kininogen deficiency], 228960 (3),
HK-1		
HK1	AR,AD,AR	microcephaly, cataracts, impaired intellectual development, and dystonia with abnormal striatum, 618284 (3), |retinitis pigmentosa 79, 617460 (3), ; neuropathy, hereditary motor and sensory, russe type, 605285 (3), ; neurodevelopmental disorder with visual defects and brain anomalies, 618547 (3), ; hemolytic anemia due to hexokinase deficiency, 235700 (3),
HK2	AD,AD	atrial fibrillation, familial, 7, 612240 (3), |cortical dysplasia, complex, with other brain malformations 3, 615411 (3),
HK3		
HK33	AR	peroxisome biogenesis disorder 12a (zellweger), 614886 (3),
HK4	AD,AD,AR	developmental and epileptic encephalopathy 32, 616366 (3), |mody, type ii, 125851 (3), ; diabetes mellitus, permanent neonatal 1, 606176 (3), ; hyperinsulinemic hypoglycemia, familial, 3, 602485 (3), ; diabetes mellitus, noninsulin-dependent, late onset, 125853 (3),
HKB3	AR	?osteopetrosis, 9, 620366 (3),
hKCa4	AD	dehydrated hereditary stomatocytosis 2, 616689 (3),
hKCC2	AD,AR	{epilepsy, idiopathic generalized, susceptibility to, 14}, 616685 (3), ; developmental and epileptic encephalopathy 34, 616645 (3),
HKDC1	AR	retinitis pigmentosa 92, 619614 (3),
HKE1.5		
HKE2		
HKE3		
HKE4	AR	agammaglobulinemia 9, 619693 (3),
HKE5	AD,AR	deafness, 13, 601868 (3), ; otospondylomegaepiphyseal dysplasia, 215150 (3), ; fibrochondrogenesis 2, 614524 (3), ; deafness, 53, 609706 (3), ; otospondylomegaepiphyseal dysplasia, 184840 (3),
HKE6		
hkf-1		
hKFC-B	AD	developmental delay with or without intellectual impairment or behavioral abnormalities, 619575 (3),
hKFC-C		
HKIB9		
HKL1		
hKLC1B		
hKLC1G		
hKLC1J		
hKLC1N		
hKLC1P		
hKLC1R		
hKLC1S		
HKLP2	AR	?braddock-carey syndrome 2, 619981 (3),
HKMT1188		
hKNL-1	AR	microcephaly 4, primary, 604321 (3),
hKNL-3		
Hkp1		
HKR-T1		
HKR1		
HKr18		
HKR2		
HKR3		
HKR4		
HkRP1	AR	?peho syndrome-like, 617507 (3),
HkRP2	AD,AR	?spinocerebellar ataxia 40, 616053 (3), ; hydrocephalus, congenital, 1, 236600 (3),
HkRP3		
HKSHIIIC		
HKSP	AD	microcephaly with or without chorioretinopathy, lymphedema, or mental retardation, 152950 (3),
hKvb3		
HKvbeta2.1		
HKvbeta2.2		
hKvBeta3		
HL	AD,AR,AR	{diabetes mellitus, noninsulin-dependent}, 125853 (3), ; hepatic lipase deficiency, 614025 (3), ; [high density lipoprotein cholesterol level qtl 12], 612797 (3)|hmg-coa lyase deficiency, 246450 (3),
HL-1		
HL-11	AR	spermatogenic failure 18, 617576 (3), ; ciliary dyskinesia, primary, 37, 617577 (3),
HL-18		
HL-19		
HL-2		
HL-20	AR	ciliary dyskinesia, primary, 40, 618300 (3),
HL-3	AD	charcot-marie-tooth disease, axonal, type 2o, 614228 (3), ; spinal muscular atrophy, lower extremity-pre 1, ad, 158600 (3), ; cortical dysplasia, complex, with other brain malformations 13, 614563 (3),
HL1	AR	ciliary dyskinesia, primary, 3, with or without situs inversus, 608644 (3),
HL11	AR	spermatogenic failure 18, 617576 (3), ; ciliary dyskinesia, primary, 37, 617577 (3),
HL14		{myocardial infarction, susceptibility to}, 608446 (3)
HL18		
HL20	AR	ciliary dyskinesia, primary, 40, 618300 (3),
HL9		
HLA-A		{hypersensitivity syndrome, carbamazepine-induced, susceptibility to}, 608579 (3)
HLA-B	MF	{synovitis, chronic, susceptibility to} (3); {abacavir hypersensitivity, susceptibility to} (3); {spondyloarthropathy, susceptibility to, 1}, 106300 (3), ; {stevens-johnson syndrome, susceptibility to}, 608579 (3); {drug-induced liver injury due to flucloxacillin} (3); {toxic epidermal necrolysis, susceptibility to}, 608579 (3)
HLA-C	MF	{psoriasis susceptibility 1}, 177900 (3), ; {hiv-1 viremia, susceptibility to}, 609423 (3)
HLA-D0-alpha		
HLA-DMA		
HLA-DMB		
HLA-DNA		
HLA-DOA		
HLA-DOB		
HLA-DP1A		
HLA-DP1B		{beryllium disease, chronic, susceptibility to} (3)
HLA-DPA1		
HLA-DPB1		{beryllium disease, chronic, susceptibility to} (3)
HLA-DQA	AR,MF	{celiac disease, susceptibility to}, 212750 (3),
HLA-DQA1	AR,MF	{celiac disease, susceptibility to}, 212750 (3),
HLA-DQA2		
HLA-DQB	AR,MF,AD	{celiac disease, susceptibility to}, 212750 (3), ; {multiple sclerosis, susceptibility to, 1}, 126200 (3), ; {creutzfeldt-jakob disease, variant, resistance to}, 123400 (3),
HLA-DQB1	AR,MF,AD	{celiac disease, susceptibility to}, 212750 (3), ; {multiple sclerosis, susceptibility to, 1}, 126200 (3), ; {creutzfeldt-jakob disease, variant, resistance to}, 123400 (3),
HLA-DQB2		
HLA-DR1B	MF,AD	{multiple sclerosis, susceptibility to, 1}, 126200 (3), ; {sarcoidosis, susceptibility to, 1}, 181000 (3),
HLA-DR3B		
HLA-DRA		
HLA-DRA1		
HLA-DRB1	MF,AD	{multiple sclerosis, susceptibility to, 1}, 126200 (3), ; {sarcoidosis, susceptibility to, 1}, 181000 (3),
HLA-DRB3		
HLA-DRB5		
HLA-DXA		
HLA-DXB		
HLA-DZA		
HLA-E		
HLA-F		
HLA-G	AD	{asthma, susceptibility to}, 600807 (2),
HLA-H	AD,AR	{porphyria variegata, susceptibility to}, 176200 (3), ; {microvascular complications of diabetes 7}, 612635 (3); hemochromatosis, 235200 (3), ; {alzheimer disease, susceptibility to}, 104300 (3), ; [transferrin serum level qtl2], 614193 (3); {porphyria cutanea tarda, susceptibility to}, 176100 (3),
HLA-ISO		
HLA-JY3	MF	{psoriasis susceptibility 1}, 177900 (3), ; {hiv-1 viremia, susceptibility to}, 609423 (3)
HLAL		
HLALS		
HLAR698		
HLC-1	AR	mitochondrial complex i deficiency, nuclear type 36, 619170 (3),
HLC-10		
HLC14-06-P	AR	[inosine triphosphatase deficiency], 613850 (3); developmental and epileptic encephalopathy 35, 616647 (3),
HLC3		
HLC4		
hLCB1	AD	amyotrophic lateral sclerosis 27, juvenile, 620285 (3), ; neuropathy, hereditary sensory and autonomic, type ia, 162400 (3),
hLCB2a	AD	neuropathy, hereditary sensory and autonomic, type ic, 613640 (3),
hLCB2b		
Hlcd	AR,AD	immunodeficiency 95, 619773 (3), ; aicardi-goutieres syndrome 7, 615846 (3), ; singleton-merten syndrome 1, 182250 (3),
HLCS	AR	holocarboxylase synthetase deficiency, 253270 (3),
HLDA2		
HLE	AD	neutropenia, cyclic, 162800 (3), ; neutropenia, severe congenital 1, 202700 (3),
HLF	AD	erythrocytosis, familial, 4, 611783 (3),
HLF2		
HLF4	AD,AR	{macular degeneration, age-related, reduced risk of}, 603075 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to}, 235400 (3),
hLGA		
HLGP85	AR	epilepsy, progressive myoclonic 4, with or without renal failure, 254900 (3),
hLHB	AR	hypogonadotropic hypogonadism 23 with or without anosmia, 228300 (3),
hLHRc		
hLhx2		
hLHX6		
hLig1	AR	immunodeficiency 96, 619774 (3),
HLJ1	AR	congenital myopathy 21 with early respiratory failure, 620326 (3),
HLK3		
hLLP		
HLN		
HLNX	XL	intellectual developmental disorder, 300495 (3), ; {autism susceptibility, 2}, 300495 (3),
hLON	AR	codas syndrome, 600373 (3),
HLP	AR	trichohepatoenteric syndrome 2, 614602 (3),
HLP2	XL,XLD,XLR	intellectual developmental disorder, syndromic, snijders blok type, 300958 (3),
HLP3	AD	microphthalmia with coloboma 5, 611638 (3), ; schizencephaly, 269160 (3); single median maxillary central incisor, 147250 (3), ; holoprosencephaly 3, 142945 (3),
HLP4		
HLPR		
HLR1		
HLR2	AD	intellectual developmental disorder with impaired language and dysmorphic facies, 618653 (3),
HLRC1	AR	neurodevelopmental disorder with microcephaly, cerebral atrophy, and visual impairment, 620066 (3),
hLRp105		
HLS2	AD	thrombophilia 10 due to heparin cofactor ii deficiency, 612356 (3),
HLS5		
HLTF		
HLTF1		
hLuc7A		
hLuc7B1		
hLuc7B2		
HLUGP		
HLUGP4		
HLX		
HLX1		
HLXB9	AD	currarino syndrome, 176450 (3),
hly9		
HM-CRF		
HM1.24		
HM13		
HM18		
HM31		
HM43		
HM63		
HM74		
HM74A		
HM89	AD	whim syndrome 1, 193670 (3), ; myelokathexis, isolated, 193670 (3),
hMafA	AD	insulinomatosis and diabetes mellitus, 147630 (3),
hMafF		
hMAP126		
Hmat-Xa		
HMAT1	AR	congenital disorder of glycosylation, type ik, 608540 (3),
HMB-45		
HMB45		
hMBOA-7	AR	intellectual developmental disorder, 57, 617188 (3),
HMBOX1		
HMBS	AD	porphyria, acute intermittent, nonerythroid variant, 176000 (3), ; porphyria, acute intermittent, 176000 (3),
hMCD	AR	malonyl-coa decarboxylase deficiency, 248360 (3),
HMCES		
HMCN1	AD	{macular degeneration, age-related, 1}, 603075 (3),
HMCS	AR	xanthinuria, type ii, 603592 (3),
HME		
HMFN0320	AR	?urocanase deficiency, 276880 (3),
HMFN0672		
HMFN0839		
HMFT1638		
HMG1		
HMG14		
HMG17		
HMG1L2		
HMG2		
HMG20A		
HMG20B		
HMG2A	XL	?microphthalmia, syndromic 13, 300915 (3),
HMG2L1		
HMG3		
HMG4	XL	?microphthalmia, syndromic 13, 300915 (3),
HMGA1	AD	{type 2 diabetes mellitus, susceptibility to}, 125853 (3),
HMGA1L4		
HMGA2	AD	silver-russell syndrome 5, 618908 (3),
HMGB1		
HMGB2		
HMGB3	XL	?microphthalmia, syndromic 13, 300915 (3),
HMGB4		
HMGCL	AR	hmg-coa lyase deficiency, 246450 (3),
HMGCLL1		
HMGCR	AR	muscular dystrophy, limb-girdle, 28, 620375 (3), ; [statins, response to], 620410 (3); [low density lipoprotein cholesterol level qtl 3], 620410 (3)
HMGCS		
HMGCS1		
HMGCS2	AR	hmg-coa synthase-2 deficiency, 605911 (3),
hMGE		
HMGIC	AD	silver-russell syndrome 5, 618908 (3),
HMGIY	AD	{type 2 diabetes mellitus, susceptibility to}, 125853 (3),
HMGIYL4		
HMGN1		
HMGN2		
HMGN2P46		
HMGN3		
HMGN5		
HMGX1		
HMGX2		
HMGX3		
HMGXB1		
HMGXB2		
HMGXB3		
HMGXB4		
HMHA1		
HMHB1		
hMI-ER1		
HMIC		
hMIS12		
hMis18alpha		
hMIS18beta		
HMIT		
HML		
HML2		
HMlincRNA717		
HMMH		renal cell carcinoma, clear cell, somatic, 144700 (3)
HMMR	AD	{breast cancer, susceptibility to}, 114480 (3), somatic mutation,
hMMS19		
HMN6	AR	neuronopathy, distal hereditary motor, type vi, 604320 (3), ; charcot-marie-tooth disease, axonal, type 2s, 616155 (3),
hMOF	AD	li-ghorgani-weisz-hubshman syndrome, 618974 (3),
HMOX1	AR	heme oxygenase-1 deficiency, 614034 (3), ; {pulmonary disease, chronic obstructive, susceptibility to}, 606963 (3)
HMOX2		
HMP		
hMP1	AR	spinocerebellar ataxia, 30, 619405 (3),
HMP19		
HMP70		
HMPS		
HMR		
HMRF1L		
HMRP-2B		
HMSD		
hMsd1		
HMSE	AD	drug metabolism, altered, ces1-related, 618057 (3),
HMSE1	AD	drug metabolism, altered, ces1-related, 618057 (3),
hMSL1		
HMSNIA	AD,AR	charcot-marie-tooth disease, type 1a, 118220 (3), ; roussy-levy syndrome, 180800 (3), ; charcot-marie-tooth disease, type 1e, 118300 (3), ; ?neuropathy, inflammatory demyelinating, 139393 (3), ? ; neuropathy, recurrent, with pressure palsies, 162500 (3), ; dejerine-sottas disease, 145900 (3),
HMSNIB	AD,AR	charcot-marie-tooth disease, type 2i, 607677 (3), ; dejerine-sottas disease, 145900 (3), ; charcot-marie-tooth disease, type 1b, 118200 (3), ; roussy-levy syndrome, 180800 (3), ; charcot-marie-tooth disease, intermediate d, 607791 (3), ; hypomyelinating neuropathy, congenital, 2, 618184 (3), ; charcot-marie-tooth disease, type 2j, 607736 (3),
HMSNII	AD	{neuroblastoma, susceptibility to, 1}, 256700 (3), somatic mutation, ; charcot-marie-tooth disease, type 2a1, 118210 (3),
HMT-1	AR	congenital disorder of glycosylation, type ik, 608540 (3),
hMtr3p		
HMUDG		
hmunc13		
hmw		
HMW-MAA		
HMWK	AR,AD	[kininogen deficiency], 228960 (3), ; angioedema, hereditary, 6, 619363 (3), ; [high molecular weight kininogen deficiency], 228960 (3),
HMX1	AR	oculoauricular syndrome, 612109 (3),
HMX2		
HMX3		
hN-CoR		
HN1		
HN1A		
HN1L		
HN3	AR	?proteasome-associated autoinflammatory syndrome 3 and digenic forms, 617591 (3),
HNA2A		
hNaa60		
hNab50		
hNB-2		
HNBC1	AR	renal tubular acidosis, proximal, with ocular abnormalities, 604278 (3),
HNE	AD	neutropenia, cyclic, 162800 (3), ; neutropenia, severe congenital 1, 202700 (3),
hNedd5		
hNEI3		
HNF-3		
HNF-6		
HNF1	AD,AR	hepatic adenoma, somatic, 142330 (3); diabetes mellitus, insulin-dependent, 20, 612520 (3); {diabetes mellitus, noninsulin-dependent, 2}, 125853 (3), ; mody, type iii, 600496 (3), ; {diabetes mellitus, insulin-dependent}, 222100 (3), ; renal cell carcinoma, 144700 (3)
HNF1A	AD,AR	hepatic adenoma, somatic, 142330 (3); diabetes mellitus, insulin-dependent, 20, 612520 (3); {diabetes mellitus, noninsulin-dependent, 2}, 125853 (3), ; mody, type iii, 600496 (3), ; {diabetes mellitus, insulin-dependent}, 222100 (3), ; renal cell carcinoma, 144700 (3)
HNF1B	AD	type 2 diabetes mellitus, 125853 (3), ; renal cysts and diabetes syndrome, 137920 (3), ; {renal cell carcinoma}, 144700 (3)
HNF1beta	AD	type 2 diabetes mellitus, 125853 (3), ; renal cysts and diabetes syndrome, 137920 (3), ; {renal cell carcinoma}, 144700 (3)
HNF1LA		
HNF1Î±	AD,AR	hepatic adenoma, somatic, 142330 (3); diabetes mellitus, insulin-dependent, 20, 612520 (3); {diabetes mellitus, noninsulin-dependent, 2}, 125853 (3), ; mody, type iii, 600496 (3), ; {diabetes mellitus, insulin-dependent}, 222100 (3), ; renal cell carcinoma, 144700 (3)
HNF1Î²	AD	type 2 diabetes mellitus, 125853 (3), ; renal cysts and diabetes syndrome, 137920 (3), ; {renal cell carcinoma}, 144700 (3)
HNF3A		
HNF3B		
HNF3G		
HNF4	AD	fanconi renotubular syndrome 4, with maturity-onset diabetes of the young, 616026 (3), ; {diabetes mellitus, noninsulin-dependent}, 125853 (3), ; mody, type i, 125850 (3),
HNF4A	AD	fanconi renotubular syndrome 4, with maturity-onset diabetes of the young, 616026 (3), ; {diabetes mellitus, noninsulin-dependent}, 125853 (3), ; mody, type i, 125850 (3),
HNF4G		
HNF6		
HNF6A		
hNIFK		
hnifU	AR	myopathy with lactic acidosis, hereditary, 255125 (3),
HNK-1		
HNK-1ST		
hNKR-P1A		
HNL3	XL	{autism susceptibility, 1}, 300425 (3),
HNLF		
HNMT	AR,AD	intellectual developmental disorder, 51, 616739 (3), ; {asthma, susceptibility to}, 600807 (3),
hNOA1		
HNOEL-iso		
HNP		
HNP-1		
HNP-3		
HNP36		
HNPCC	AD,AR,AD,AR	lynch syndrome 1, 120435 (3), ; muir-torre syndrome, 158320 (3), ; mismatch repair cancer syndrome 2, 619096 (3), |lynch syndrome 2, 609310 (3); muir-torre syndrome, 158320 (3), ; mismatch repair cancer syndrome 1, 276300 (3),
HNPCC1	AD,AR	lynch syndrome 1, 120435 (3), ; muir-torre syndrome, 158320 (3), ; mismatch repair cancer syndrome 2, 619096 (3),
HNPCC2	AD,AR	lynch syndrome 2, 609310 (3); muir-torre syndrome, 158320 (3), ; mismatch repair cancer syndrome 1, 276300 (3),
HNPCC4	AR	lynch syndrome 4, 614337 (3); mismatch repair cancer syndrome 4, 619101 (3),
HNPP	AD,AR	charcot-marie-tooth disease, type 1a, 118220 (3), ; roussy-levy syndrome, 180800 (3), ; charcot-marie-tooth disease, type 1e, 118300 (3), ; ?neuropathy, inflammatory demyelinating, 139393 (3), ? ; neuropathy, recurrent, with pressure palsies, 162500 (3), ; dejerine-sottas disease, 145900 (3),
HNRBP2		
hNRD1		
hNRD2		
HNRGW		
hnRNP-A1	AD	?inclusion body myopathy with early-onset paget disease without frontotemporal dementia 3, 615424 (3), ; amyotrophic lateral sclerosis 20, 615426 (3),
hnRNP-E1		
hnRNP-E2		
hnRNP-G	XL,XLR	?intellectual developmental disorder, syndromic 11, shashi type, 300238 (3),
HNRNP-I		
hnRNP-P2	AD	amyotrophic lateral sclerosis 6, with or without frontotemporal dementia, 608030 (3); essential tremor, hereditary, 4, 614782 (3),
hnRNP-Q		
hnRNP-R	AD	neurodevelopmental disorder with dysmorphic facies and skeletal and brain abnormalities, 620073 (3),
hnRNP-X		
HNRNPA0		
HNRNPA1	AD	?inclusion body myopathy with early-onset paget disease without frontotemporal dementia 3, 615424 (3), ; amyotrophic lateral sclerosis 20, 615426 (3),
HNRNPA2B1	AD	?inclusion body myopathy with early-onset paget disease with or without frontotemporal dementia 2, 615422 (3),
HNRNPA3		
HNRNPAB		
HNRNPC		
HNRNPD		
HNRNPDL	AD	muscular dystrophy, limb-girdle, 3, 609115 (3),
HNRNPE2		
HNRNPF		
HNRNPG	XL,XLR	?intellectual developmental disorder, syndromic 11, shashi type, 300238 (3),
HNRNPG-T		
hnRNPH	AD	neurodevelopmental disorder with craniofacial dysmorphism and skeletal defects, 620083 (3),
hnRNPH'	XL,XLD	intellectual developmental disorder, syndromic, bain type, 300986 (3),
HNRNPH1	AD	neurodevelopmental disorder with craniofacial dysmorphism and skeletal defects, 620083 (3),
HNRNPH2	XL,XLD	intellectual developmental disorder, syndromic, bain type, 300986 (3),
HNRNPH3		
HNRNPK	AD	au-kline syndrome, 616580 (3),
HNRNPL		
HNRNPLL		
HNRNPM		
HNRNPM4		
HNRNPP2	AD	amyotrophic lateral sclerosis 6, with or without frontotemporal dementia, 608030 (3); essential tremor, hereditary, 4, 614782 (3),
HNRNPQ		
HNRNPR	AD	neurodevelopmental disorder with dysmorphic facies and skeletal and brain abnormalities, 620073 (3),
HNRNPU	AD	developmental and epileptic encephalopathy 54, 617391 (3),
HNRNPU-AS1	AD	developmental and epileptic encephalopathy 54, 617391 (3),
HNRNPUL1		
HNRPA0		
HNRPA1	AD	?inclusion body myopathy with early-onset paget disease without frontotemporal dementia 3, 615424 (3), ; amyotrophic lateral sclerosis 20, 615426 (3),
HNRPA2B1	AD	?inclusion body myopathy with early-onset paget disease with or without frontotemporal dementia 2, 615422 (3),
HNRPA3		
HNRPAB		
HNRPC		
HNRPCL2		
HNRPCL3		
HNRPD		
HNRPDL	AD	muscular dystrophy, limb-girdle, 3, 609115 (3),
HNRPE1		
HNRPE2		
HNRPF		
HNRPGT		
HNRPH'	XL,XLD	intellectual developmental disorder, syndromic, bain type, 300986 (3),
HNRPH1	AD	neurodevelopmental disorder with craniofacial dysmorphism and skeletal defects, 620083 (3),
HNRPH2	XL,XLD	intellectual developmental disorder, syndromic, bain type, 300986 (3),
HNRPH3		
HNRPI		
HNRPK	AD	au-kline syndrome, 616580 (3),
HNRPL		
HNRPLL		
HNRPM		
HNRPM4		
HNRPQ1		
HNRPR	AD	neurodevelopmental disorder with dysmorphic facies and skeletal and brain abnormalities, 620073 (3),
HNRPU	AD	developmental and epileptic encephalopathy 54, 617391 (3),
HNRPUL1		
HNRPX		
HNSPC	AD	developmental and epileptic encephalopathy 7, 613720 (3), ; seizures, benign neonatal, 1, 121200 (3), ; myokymia, 121200 (3),
HNT		
HNUP153		
HO-1	AR	heme oxygenase-1 deficiency, 614034 (3), ; {pulmonary disease, chronic obstructive, susceptibility to}, 606963 (3)
HO-2		
HO3	AR	perrault syndrome 2, 614926 (3),
HO57	AD	zimmermann-laband syndrome 2, 616455 (3), ; deafness, congenital, with onychodystrophy, 124480 (3),
HOA	AD,AR	{osteoarthritis susceptibility 2}, 140600 (3), ; spondyloepimetaphyseal dysplasia, borochowitz-cormier-daire type, 608728 (3), ; epiphyseal dysplasia, multiple, 5, 607078 (3),
hOAT5		
hOAZ	AR,AD	nephronophthisis 14, 614844 (3), ; joubert syndrome 19, 614844 (3),
Hob		
Hobit		
hOBPIIa		
hOBPIIb		
HOC3F		
HOFNH30		
HOGA	AR	gyrate atrophy of choroid and retina with or without ornithinemia, 258870 (3),
HOGA1	AR	hyperoxaluria, primary, type iii, 613616 (3),
HOGG1		renal cell carcinoma, clear cell, somatic, 144700 (3)
HOIL1	AR	polyglucosan body myopathy 1 with or without immunodeficiency, 615895 (3),
HOIP		
HoJ-1		
HOK-2		
HOKPP	AD,AR	?brugada syndrome 6, 613119 (3)|{thyrotoxic periodic paralysis, susceptibility to, 1}, 188580 (3), ; congenital myopathy 18 due to dihydropyridine receptor defect, 620246 (3), ; hypokalemic periodic paralysis, type 1, 170400 (3), ; {malignant hyperthermia susceptibility 5}, 601887 (3),
HOM-MEL-40		?sarcoma, synovial, 300813 (3)
HOM-TES-103		
HOM-TES-14		
HOM-TES-85		
HOMER-1B		
HOMER-2	AD	?deafness, 68, 616707 (3),
HOMER-2A	AD	?deafness, 68, 616707 (3),
HOMER-2B	AD	?deafness, 68, 616707 (3),
HOMER-3		
HOMER1		
HOMER2	AD	?deafness, 68, 616707 (3),
HOMER3		
HOMEZ		
HOMG	AR	hypomagnesemia 1, intestinal, 602014 (3),
HOMG2	AD	hypomagnesemia 2, renal, 154020 (3),
HOMG3	AR	hypomagnesemia 3, renal, 248250 (3),
HOMT1A		
HOOK1		
HOOK2		
HOOK3		
HOP		
Hop2	AR	ovarian dysgenesis 3, 614324 (3),
HOPA	XLR,XL,XLD	lujan-fryns syndrome, 309520 (3), ; ohdo syndrome, 300895 (3), ; hardikar syndrome, 301068 (3), ; opitz-kaveggia syndrome, 305450 (3),
HOPS	AR,AD	odontohypophosphatasia, 146300 (3), ; hypophosphatasia, infantile, 241500 (3), ; hypophosphatasia, childhood, 241510 (3), ; hypophosphatasia, adult, 146300 (3),
HOPX		
HORK3	AR	bleeding disorder, platelet-type, 8, 609821 (3),
HORMAD1		
HORMAD2		
Hos	AD	neurodevelopmental, jaw, eye, and digital syndrome, 618914 (3),
HOS	AD	holt-oram syndrome, 142900 (3),
HOST2		
HOT1		
HOT7T175	AR,AD	hypogonadotropic hypogonadism 8 with or without anosmia, 614837 (3), ; ?precocious puberty, central, 1, 176400 (3),
HOTAIR		
HOTTIP		
HOTTL		
HOVO1		
HOVO2	AD	corneal dystrophy, posterior polymorphous, 1, 122000 (3),
HOVO3		
HOX1	AR,AD,AD	bosley-salih-alorainy syndrome, 601536 (3), ; athabaskan brainstem dysgenesis syndrome, 601536 (3), |hand-foot-uterus syndrome, 140000 (3), ; ?guttmacher syndrome, 176305 (3), |radioulnar synostosis with amegakaryocytic thrombocytopenia 1, 605432 (3),
HOX10	AR	microphthalmia, isolated 2, 610093 (3), ; microphthalmia with coloboma 3, 610092 (3),
HOX11		
HOX11L-PEN		
HOX11L1		
HOX11L2		
HOX12		
HOX1A		
HOX1B		
HOX1C		
HOX1D		
HOX1E		
HOX1F	AR	bosley-salih-alorainy syndrome, 601536 (3), ; athabaskan brainstem dysgenesis syndrome, 601536 (3),
HOX1G		
HOX1H		
HOX1I	AD	radioulnar synostosis with amegakaryocytic thrombocytopenia 1, 605432 (3),
HOX1J	AD	hand-foot-uterus syndrome, 140000 (3), ; ?guttmacher syndrome, 176305 (3),
HOX1K	AR,AD	microtia with or without hearing impairment (ad), 612290 (3), ; ?microtia, hearing impairment, and cleft palate (ar), 612290 (3),
HOX2	AR	facial paresis, hereditary congenital, 3, 614744 (3),
HOX2A		
HOX2B		
HOX2C		
HOX2D		
HOX2E		
HOX2F		
HOX2G		
HOX2H		
HOX2I	AR	facial paresis, hereditary congenital, 3, 614744 (3),
HOX3	AR	ectodermal dysplasia 9, hair/nail type, 614931 (3),
HOX3A		
HOX3B		
HOX3C		
HOX3D		
HOX3E		
HOX3F		
HOX3G	AR	ectodermal dysplasia 9, hair/nail type, 614931 (3),
HOX3H		
HOX3I		
HOX4	AD	vertical talus, congenital, 192950 (3), ; charcot-marie-tooth disease, foot deformity of, 192950 (3),
HOX4A		
HOX4B		
HOX4C		
HOX4D	AD	vertical talus, congenital, 192950 (3), ; charcot-marie-tooth disease, foot deformity of, 192950 (3),
HOX4E		
HOX4F		
HOX4G		
HOX4H		
HOX4I	AD	syndactyly, type v, 186300 (3), ; synpolydactyly 1, 186000 (3), ; brachydactyly, type e, 113300 (3), ; brachydactyly, type d, 113200 (3), ; ?brachydactyly-syndactyly syndrome, 610713 (3)
HOX7	AD	tooth agenesis, selective, 1, with or without orofacial cleft, 106600 (3), ; ectodermal dysplasia 3, witkop type, 189500 (3), ; orofacial cleft 5, 608874 (3),
HOX8	AD	parietal foramina with cleidocranial dysplasia, 168550 (3), ; craniosynostosis 2, 604757 (3), ; parietal foramina 1, 168500 (3),
HOXA-AS2		
HOXA-AS3		
HOXA-AS5		
HOXA-AS6		
HOXA1	AR	bosley-salih-alorainy syndrome, 601536 (3), ; athabaskan brainstem dysgenesis syndrome, 601536 (3),
HOXA10		
HOXA11	AD	radioulnar synostosis with amegakaryocytic thrombocytopenia 1, 605432 (3),
HOXA11-AS		
HOXA11-AS1		
HOXA11AS		
HOXA11S		
HOXA13	AD	hand-foot-uterus syndrome, 140000 (3), ; ?guttmacher syndrome, 176305 (3),
HOXA13-AS1		
HOXA2	AR,AD	microtia with or without hearing impairment (ad), 612290 (3), ; ?microtia, hearing impairment, and cleft palate (ar), 612290 (3),
HOXA3		
HOXA3as		
HOXA4		
HOXA5		
HOXA6		
HOXA6as		
HOXA7		
HOXA9		
HOXB-AS1		
HOXB-AS5		
HOXB1	AR	facial paresis, hereditary congenital, 3, 614744 (3),
HOXB13		{prostate cancer, hereditary, 9}, 610997 (3)
HOXB13-AS1		
HOXB2		
HOXB3		
HOXB4		
HOXB5		
HOXB6		
HOXB7		
HOXB8		
HOXB9		
HOXC-AS4		
HOXC10		
HOXC11		
HOXC11-AS1		
HOXC12		
HOXC13	AR	ectodermal dysplasia 9, hair/nail type, 614931 (3),
HOXC4		
HOXC5		
HOXC6		
HOXC8		
HOXC9		
HOXD-AS1		
HOXD1		
HOXD10	AD	vertical talus, congenital, 192950 (3), ; charcot-marie-tooth disease, foot deformity of, 192950 (3),
HOXD11		
HOXD12		
HOXD13	AD	syndactyly, type v, 186300 (3), ; synpolydactyly 1, 186000 (3), ; brachydactyly, type e, 113300 (3), ; brachydactyly, type d, 113200 (3), ; ?brachydactyly-syndactyly syndrome, 610713 (3)
HOXD3		
HOXD4		
HOXD8		
HOXD9		
HOXHB9	AD	currarino syndrome, 176450 (3),
HP		[anhaptoglobinemia], 614081 (3); [hypohaptoglobinemia], 614081 (3)|colorectal cancer, somatic, 114500 (3)
HP-4		
HP1		
HP1-ALPHA		
HP1-BETA		
HP1-BP74		
HP1.A		
HP10085		
HP10122	AR	craniofacial dysmorphism, skeletal anomalies, and impaired intellectual development 1, 213980 (3),
HP10328		
HP10347		
HP10390		
HP10433		
HP10481	AR	muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 10, 615041 (3),
HP1BP3		
HP1Hs-alpha		
HP1Hs-beta		
HP1Hs-gamma		
hp28	AR	?spermatogenic failure 83, 620354 (3),
HP40		
HP43.8KD		
hP47		
hp51CN		
HP55	AD,AR	progressive external ophthalmoplegia with mitochondrial dna deletions, 4, 610131 (3), ; ?mitochondrial dna depletion syndrome 16 (hepatic type), 618528 (3), ; ?mitochondrial dna depletion syndrome 16b (neuroophthalmic type), 619425 (3),
HP58	AR	ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus, 616192 (3),
Hp95	AR	?microcephaly 29, primary, 620047 (3),
HPA		
HPA-5		
HPA2	AR	urofacial syndrome 1, 236730 (3),
HPAD10		
HPAFP	AD,AR	[hereditary persistence of alpha-fetoprotein], 615970 (3), ; alpha-fetoprotein deficiency, 615969 (3),
hPAK3	XL,XLR	intellectual developmental disorder, 30, 300558 (3),
hPAN2		
hPANX2		
HPAO		
HPAP	AR	spondyloenchondrodysplasia with immune dysregulation, 607944 (3),
hPAP21		
hPARP-3		
HPAST1		
HPBRII-4		
HPBRII-7		
HPC-1		
hPC2		
HPC2	AR	{prostate cancer, hereditary, 2, susceptibility to}, 614731 (3); combined oxidative phosphorylation deficiency 17, 615440 (3),
HPC3		
HPCA	AR,AD	dystonia 2, torsion, 224500 (3), |spinocerebellar ataxia 6, 183086 (3), ; episodic ataxia, type 2, 108500 (3), ; developmental and epileptic encephalopathy 42, 617106 (3), ; migraine, familial hemiplegic, 1, with progressive cerebellar ataxia, 141500 (3), ; migraine, familial hemiplegic, 1, 141500 (3),
HPCAL1		
HPCAL3		
HPCAL4		
hPCFT	AR	folate malabsorption, hereditary, 229050 (3),
HPCL		
HPCN1	AD	atrial fibrillation, familial, 7, 612240 (3),
HPCN2	AR	microcephaly, cataracts, impaired intellectual development, and dystonia with abnormal striatum, 618284 (3),
HPCN3		
hPCPNI	AR	ehlers-danlos syndrome, dermatosparaxis type, 225410 (3),
HPD	AD,AR	hawkinsinuria, 140350 (3), ; tyrosinemia, type iii, 276710 (3),
HPDL	AR	neurodevelopmental disorder with progressive spasticity and brain white matter abnormalities, 619026 (3), ; spastic paraplegia 83, 619027 (3),
HPDR	XLD,XL	hypophosphatemic rickets, 307800 (3),
HPDR1	XLD,XL	hypophosphatemic rickets, 307800 (3),
HPE2	AD	schizencephaly, 269160 (3); holoprosencephaly 2, 157170 (3),
HPE3	AD	microphthalmia with coloboma 5, 611638 (3), ; schizencephaly, 269160 (3); single median maxillary central incisor, 147250 (3), ; holoprosencephaly 3, 142945 (3),
HPE4	AD	holoprosencephaly 4, 142946 (3),
HPE5	AD	holoprosencephaly 5, 609637 (3),
HPE9	AD	culler-jones syndrome, 615849 (3), ; holoprosencephaly 9, 610829 (3),
hPeas		
hPEBP4		
HPECT1		
HPEPT1		
HPF1		
HPF12		
HPF2		
HPF3		
HPF34		
HPF4		
HPF7		
HPF9		
HPGD	AR	?digital clubbing, isolated congenital, 119900 (3), ; hypertrophic osteoarthropathy, primary, 1, 259100 (3), ; cranioosteoarthropathy, 259100 (3),
HPGDS		
HPH1	AR	?microcephaly 11, primary, 615414 (3),
HPH2		
HPH3		
HPIP		
hPIP1		
HPK1		
HPLH2	AR	hemophagocytic lymphohistiocytosis, familial, 2, 603553 (3), ; aplastic anemia, 609135 (3); lymphoma, non-hodgkin, 605027 (3)
HPM1		
hPMC2		
HPN		
hPN3	AD	episodic pain syndrome, familial, 2, 615551 (3),
HPO1	AR	myopathy, mitochondrial progressive, with congenital cataract and developmental delay, 613076 (3),
HPO2	AR	myopathy, mitochondrial progressive, with congenital cataract and developmental delay, 613076 (3),
hPOC5		
hPot1	AD,AR	{glioma susceptibility 9}, 616568 (3), ; ?cerebroretinal microangiopathy with calcifications and cysts 3, 620368 (3), ; {melanoma, cutaneous malignant, susceptibility to, 10}, 615848 (3), ; ?pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 8, 620367 (3),
HPP1		
hPPAR		
HPR		
HPR1	AD	?deafness, 86, 620280 (3),
HPR2	AR	urofacial syndrome 1, 236730 (3),
HPR6.6		
HPRG	AD	thrombophilia 11 due to hrg deficiency, 613116 (3),
HPRN		
hPrp16	AR	retinitis pigmentosa 84, 618220 (3),
hPrp18		
hPrp3	AD	retinitis pigmentosa 18, 601414 (3),
hPrp31	AD	retinitis pigmentosa 11, 600138 (3),
HPRP4	AD	retinitis pigmentosa 70, 615922 (3),
HPRP4P	AD	retinitis pigmentosa 70, 615922 (3),
hPrp6	AD	retinitis pigmentosa 60, 613983 (3),
hPrp8	AD	retinitis pigmentosa 13, 600059 (3),
HPRP8BP		
HPRT	XLR,XL	hyperuricemia, hrpt-related, 300323 (3), ; lesch-nyhan syndrome, 300322 (3),
HPRT1	XLR,XL	hyperuricemia, hrpt-related, 300323 (3), ; lesch-nyhan syndrome, 300322 (3),
HPS	AR	hermansky-pudlak syndrome 1, 203300 (3),
HPS1	AR	hermansky-pudlak syndrome 1, 203300 (3),
HPS2	AR	hermansky-pudlak syndrome 2, 608233 (3),
HPS3	AR	hermansky-pudlak syndrome 3, 614072 (3),
HPS4	AR	hermansky-pudlak syndrome 4, 614073 (3),
HPS5	AR	hermansky-pudlak syndrome 5, 614074 (3),
HPS6	AR	hermansky-pudlak syndrome 6, 614075 (3),
HPS7	AR	hermansky-pudlak syndrome 7, 614076 (3),
HPS8	AR	hermansky-pudlak syndrome 8, 614077 (3),
HPS9	AR	?hermansky-pudlak syndrome 9, 614171 (3),
HPSE		
HPSE1		
HPSE2	AR	urofacial syndrome 1, 236730 (3),
hPSO4		
HPT-1		
HPTA	AR	deafness, 39, 608265 (3),
hPTMP	AR	?maple syrup urine disease, mild variant, 615135 (3),
HPTP		
hPTP-J		
HPTPA		
HPTPeta		colon cancer, somatic, 114500 (3)
hPTR3		
HPTTG		
hPUF-A		
HPV6AI1		
HPVE6A	AD	angelman syndrome, 105830 (3),
HPX		
HPX42B		
HPX6	AR	?central hypoventilation syndrome, congenital, 3, 619483 (3),
HPXEL		
HQ0256		
HR	AR	atrichia with papular lesions, 209500 (3), ; alopecia universalis, 203655 (3),
hR-PTPu		
HR23B		
HR6A	XL,XLR	intellectual developmental disorder, syndromic, nascimento type, 300860 (3),
HRAD1		
hRad50	AR	nijmegen breakage syndrome-like disorder, 613078 (3),
hRAD54	AD	{breast cancer, invasive ductal}, 114480 (3), somatic mutation, ; adenocarcinoma, colonic, somatic (3); lymphoma, non-hodgkin, somatic, 605027 (3)
HRAS	AD	bladder cancer, somatic, 109800 (3); thyroid carcinoma, follicular, somatic, 188470 (3); congenital myopathy with excess of muscle spindles, 218040 (3), ; nevus sebaceous or woolly hair nevus, somatic, 162900 (3); schimmelpenning-feuerstein-mims syndrome, somatic mosaic, 163200 (3); spitz nevus or nevus spilus, somatic, 137550 (3); costello syndrome, 218040 (3),
HRAS1	AD	bladder cancer, somatic, 109800 (3); thyroid carcinoma, follicular, somatic, 188470 (3); congenital myopathy with excess of muscle spindles, 218040 (3), ; nevus sebaceous or woolly hair nevus, somatic, 162900 (3); schimmelpenning-feuerstein-mims syndrome, somatic mosaic, 163200 (3); spitz nevus or nevus spilus, somatic, 137550 (3); costello syndrome, 218040 (3),
HRAS2		
HRASLS		
HRASLS1		
HRASLS2		
HRASLS3		
HRASLS4		
HRASLS5		
HRASP		
HRB		
HRB2		
HRBL		
HRBP14.4		
HRC		
HRC1		
HRCA1		renal cell carcinoma, 144700 (3)
hRCE1		
HRD	AR	kenny-caffey syndrome, type 1, 244460 (3), ; hypoparathyroidism-retardation-dysmorphism syndrome, 241410 (3), ; encephalopathy, progressive, with amyotrophy and optic atrophy, 617207 (3),
HRD1		
Hrd3		
hREC2		
hRECK		
hRED1	AR	neurodevelopmental disorder with hypotonia, microcephaly, and seizures, 618862 (3),
hRED2		
HREP		
HRES-1		
HRES-1/p28		
HRES-1/RAB4		
HRES1		
hRev		
HREV107		
HREV107-3		
HRF20	AR	hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy, 612300 (3),
hRFC	AR	?megaloblastic anemia, folate-responsive, 601775 (3),
hRFT1	AD	riboflavin deficiency, 615026 (3),
hRFT2	AR	?fazio-londe disease, 211500 (3), ; brown-vialetto-van laere syndrome 1, 211530 (3),
hRFT3	AR	brown-vialetto-van laere syndrome 2, 614707 (3),
HRG	AD	{?schizophrenia, susceptibility to}, 603013 (1)|thrombophilia 11 due to hrg deficiency, 613116 (3),
HRG1		
HRG2		
HRG22		
HRG4	AD	cone-rod dystrophy 24, 620342 (3), ; ?immunodeficiency 13, 615518 (3),
HRGP	AD	thrombophilia 11 due to hrg deficiency, 613116 (3),
HRH-J8		
HRH1		
HRH2		
HRH3		
HRH4		
hrhAMR		
HRI	AD	?leukoencephalopathy, motor delay, spasticity, and dysarthria syndrome, 618878 (3),
HRIHFB2091	AD	{schizophrenia 19, susceptibility to}, 617629 (3),
HRIHFB2115	AD	acces syndrome, 619959 (3),
HRIHFB2122	AR	deafness, 28, 609823 (3),
HRIHFB2206		
HRIHFB2216		
HRIHFB2255		
HRIHFB2436		
HRINS	AR,AD	diabetes mellitus, permanent neonatal 3, with or without neurologic features, 618857 (3), ; diabetes mellitus, transient neonatal 2, 610374 (3); diabetes mellitus, noninsulin-dependent, 125853 (3), ; hypoglycemia of infancy, leucine-sensitive, 240800 (3), ; hyperinsulinemic hypoglycemia, familial, 1, 256450 (3),
hRIP		
hRIT1-alpha	AD	immunodeficiency 49, severe combined, 617237 (3), ; intellectual developmental disorder with dysmorphic facies, speech delay, and t-cell abnormalities, 618092 (3),
HRK		
HRK1		
hRL14		
HRLP5		
HRLRRP		
Hrmp1	AD	osteogenesis imperfecta, type v, 610967 (3),
HRMT1L1		
HRMT1L2		
HRMT1L3		
HRMT1L4		
HRMT1L5		
HRMT1L6		
HRNBP1		
HRNBP2		
HRNBP3		
HRNR		
HRNT1	XL,XLR	intellectual developmental disorder, 106, 300997 (3),
HROB		
HRP-3		
HRP-L30-iso		
HRP1		
HRP2		
HRPAP20	AR	mitochondrial complex i deficiency, nuclear type 15, 618237 (3),
hRPB14		
hRPB14.5		
hRPB19		
hRPB25		
hRPB7.6		
hRPC.1050_D_4		
hRPC155	AR	wiedemann-rautenstrauch syndrome, 264090 (3), ; leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism, 607694 (3),
HRPT1	AD	hyperparathyroidism, familial primary, 145000 (3), ; parathyroid adenoma with cystic changes, 145001 (3), ; parathyroid carcinoma, 608266 (3); hyperparathyroidism-jaw tumor syndrome, 145001 (3),
HRPT2	AD	hyperparathyroidism, familial primary, 145000 (3), ; parathyroid adenoma with cystic changes, 145001 (3), ; parathyroid carcinoma, 608266 (3); hyperparathyroidism-jaw tumor syndrome, 145001 (3),
HRR-1	AR	cholestasis, progressive familial intrahepatic, 5, 617049 (3),
HRR1	AR	cholestasis, progressive familial intrahepatic, 5, 617049 (3),
hRrp-40	AR	pontocerebellar hypoplasia, type 1b, 614678 (3),
hRrp40p	AR	pontocerebellar hypoplasia, type 1b, 614678 (3),
hRrp41p		
hRrp42p		
hRrp46p	AR	cerebellar ataxia, brain abnormalities, and cardiac conduction defects, 619576 (3),
hRrp4p	AR	short stature, hearing loss, retinitis pigmentosa, and distinctive facies, 617763 (3),
Hrs		
HRS		
HRSP12		
HRT-1		
hRUL138		
HRURF	AD	hypotrichosis 4, 146550 (3),
HRVP1		
HRX	AD	wiedemann-steiner syndrome, 605130 (3),
HRX2	AD	intellectual developmental disorder, 68, 619934 (3), ; dystonia 28, childhood-onset, 617284 (3),
HRY		
HS		
HS-40	AD	epilepsy, familial focal, with variable foci 3, 617118 (3),
Hs.22998	AR	pitt-hopkins-like syndrome 2, 614325 (3), ; {schizophrenia, susceptibility to, 17}, 614332 (3)
Hs.37288		
Hs.46638		
Hs.54452	AD	immunodeficiency, common variable, 13, 616873 (3),
Hs.6454	AD	oculopharyngodistal myopathy 2, 618940 (3),
Hs.6719	AR	gracile syndrome, 603358 (3), ; mitochondrial complex iii deficiency, nuclear type 1, 124000 (3), ; bjornstad syndrome, 262000 (3),
Hs.76067	AD	neuronopathy, distal hereditary motor, type iib, 608634 (3), ; charcot-marie-tooth disease, axonal, type 2f, 606595 (3),
Hs.78846		
Hs.8004		
Hs.84084		
Hs.84359		
Hs.89862		
HS1	AD	developmental and epileptic encephalopathy 33, 616409 (3), ; intellectual developmental disorder, 38, 616393 (3),
HS1-BP3,FLJ14249		
HS126B42		
HS1BP1	AR	neutropenia, severe congenital 3, 610738 (3),
HS1BP3		
HS24/P52		
HS2ST1	AR	neurofacioskeletal syndrome with or without renal agenesis, 619194 (3),
HS3ST1		
HS3ST2		
HS3ST3A1		
HS3ST3B1		
HS3ST4		
HS3ST5	AD	?angioedema, hereditary, 8, 619367 (3),
HS3ST6	AD	?angioedema, hereditary, 8, 619367 (3),
hs6M1-12		
HS6ST	AD	{hypogonadotropic hypogonadism 15 with or without anosmia}, 614880 (3),
HS6ST-2	XLR,XL	?paganini-miozzo syndrome, 301025 (3),
HS6ST1	AD	{hypogonadotropic hypogonadism 15 with or without anosmia}, 614880 (3),
HS6ST2	XLR,XL	?paganini-miozzo syndrome, 301025 (3),
HS6ST3		
hsa-let-7a-1		
hsa-let-7a-2		
hsa-let-7a-3		
hsa-let-7b		
hsa-let-7c		
hsa-let-7d		
hsa-let-7e		
hsa-let-7f-1		
hsa-let-7f-2		
hsa-let-7g		
hsa-let-7i		
hsa-lnc-31		
hsa-mir-1-1		
hsa-mir-1-2		
hsa-mir-100		
hsa-mir-101-1		
hsa-mir-101-2		
hsa-mir-103-1		
hsa-mir-103-2		
hsa-mir-103a-1		
hsa-mir-103a-2		
hsa-mir-105-1		
hsa-mir-105-2		
hsa-mir-106a		
hsa-mir-106b		
hsa-mir-107		
hsa-mir-10a		
hsa-mir-10b		
hsa-mir-122		
hsa-mir-1224		
hsa-mir-1225		
hsa-mir-122a		
hsa-mir-1231		
hsa-mir-124-1		
hsa-mir-124a-1		
hsa-mir-1258		
hsa-mir-125a		
hsa-mir-125b-1		
hsa-mir-125b-2		
hsa-mir-126		
hsa-mir-1260b		
hsa-mir-127		
hsa-mir-128-1		
hsa-mir-128-2		
hsa-mir-128a		
hsa-mir-128b		
hsa-mir-1292		
hsa-mir-130a		
hsa-mir-130b		
hsa-mir-132		
hsa-mir-133a-1		
hsa-mir-133a-2		
hsa-mir-133b		
hsa-mir-134		
hsa-mir-135b		
hsa-mir-136		
hsa-mir-137		
hsa-mir-138-1		
hsa-mir-138-2		
hsa-mir-139		
hsa-mir-140	AD	spondyloepiphyseal dysplasia, nishimura type, 618618 (3),
hsa-mir-141		
hsa-mir-142		
hsa-mir-143		
hsa-mir-144		
hsa-mir-145		
hsa-mir-146		
hsa-mir-146a		
hsa-mir-146b		
hsa-mir-148		
hsa-mir-148a		
hsa-mir-148b		
hsa-mir-149		
hsa-mir-150		
hsa-mir-151		
hsa-mir-152		
hsa-mir-155		
hsa-mir-15a		
hsa-mir-15b		
hsa-mir-16-1		
hsa-mir-17		
hsa-mir-18		
hsa-mir-181a		
hsa-mir-181b-1		
hsa-mir-181b-2		
hsa-mir-181c		
hsa-mir-182		
hsa-mir-183		
hsa-mir-184	AD	edict syndrome, 614303 (3),
hsa-mir-185		
hsa-mir-187		
hsa-mir-18a		
hsa-mir-190		
hsa-mir-1909		
hsa-mir-191		
hsa-mir-1915		
hsa-mir-192		
hsa-mir-193		
hsa-mir-193a		
hsa-mir-193b		
hsa-mir-194-1		
hsa-mir-194-2		
hsa-mir-195		
hsa-mir-196-1		
hsa-mir-196-2		
hsa-mir-196a-1		
hsa-mir-196a-2		
hsa-mir-196b		
hsa-mir-197		
hsa-mir-199a-1		
hsa-mir-199a-2		
hsa-mir-199b		
hsa-mir-19a		
hsa-mir-19b-1		
hsa-mir-19b-2		
hsa-mir-20		
hsa-mir-200a		
hsa-mir-200b		
hsa-mir-200c		
hsa-mir-203		
hsa-mir-204	AD	?retinal dystrophy and iris coloboma with or without cataract, 616722 (3),
hsa-mir-205		
hsa-mir-206		
hsa-mir-208		
hsa-mir-208a		
hsa-mir-208b		
hsa-mir-20a		
hsa-mir-20b		
hsa-mir-21		
hsa-mir-210		
hsa-mir-211		
hsa-mir-212		
hsa-mir-213		
hsa-mir-214		
hsa-mir-215		
hsa-mir-216		
hsa-mir-216a		
hsa-mir-217		
hsa-mir-218-1		
hsa-mir-218-2		
hsa-mir-219-1		
hsa-mir-22		
hsa-mir-221		
hsa-mir-222		
hsa-mir-223		
hsa-mir-224		
hsa-mir-23a		
hsa-mir-23b		
hsa-mir-24-1		
hsa-mir-24-2		
hsa-mir-25		
hsa-mir-26a-1		
hsa-mir-26a-2		
hsa-mir-26b		
hsa-mir-27a		
hsa-mir-27b		
hsa-mir-28		
hsa-mir-2861	AR,AD	[bone mineral density qtl 15], 613418 (3),
hsa-mir-29		
hsa-mir-296		
hsa-mir-297		
hsa-mir-298		
hsa-mir-29a		
hsa-mir-29b-1		
hsa-mir-29b-2		
hsa-mir-29c		
hsa-mir-301		
hsa-mir-301a		
hsa-mir-302		
hsa-mir-302a		
hsa-mir-302b		
hsa-mir-302c		
hsa-mir-302d		
hsa-mir-30a		
hsa-mir-30b		
hsa-mir-30c-1		
hsa-mir-30d		
hsa-mir-30e		
hsa-mir-31		
hsa-mir-3120		
hsa-mir-32		
hsa-mir-320		
hsa-mir-326		
hsa-mir-328		
hsa-mir-33		
hsa-mir-335		
hsa-mir-338		
hsa-mir-339		
hsa-mir-33a		
hsa-mir-33b		
hsa-mir-346		
hsa-mir-34a		
hsa-mir-34b		
hsa-mir-34c		
hsa-mir-365-1		
hsa-mir-367		
hsa-mir-368		
hsa-mir-369		
hsa-mir-370		
hsa-mir-371		
hsa-mir-372		
hsa-mir-373		
hsa-mir-375		
hsa-mir-376a		
hsa-mir-376a-1		
hsa-mir-376a-2		
hsa-mir-376b		
hsa-mir-376c		
hsa-mir-378		
hsa-mir-379		
hsa-mir-380		
hsa-mir-409		
hsa-mir-410		
hsa-mir-424		
hsa-mir-4271		
hsa-mir-4276		
hsa-mir-429		
hsa-mir-431		
hsa-mir-433		
hsa-mir-4449		
hsa-mir-448		
hsa-mir-449		
hsa-mir-449a		
hsa-mir-449b		
hsa-mir-451		
hsa-mir-485		
hsa-mir-487b		
hsa-mir-489		
hsa-mir-490		
hsa-mir-492		
hsa-mir-494		
hsa-mir-495		
hsa-mir-497		
hsa-mir-499		
hsa-mir-502		
hsa-mir-503		
hsa-mir-505		
hsa-mir-506		
hsa-mir-508		
hsa-mir-509		
hsa-mir-509-1		
hsa-mir-509-3		
hsa-mir-510		
hsa-mir-519d		
hsa-mir-520c		
hsa-mir-520g		
hsa-mir-520h		
hsa-mir-532		
hsa-mir-551a		
hsa-mir-558		
hsa-mir-570		
hsa-mir-574		
hsa-mir-590		
hsa-mir-610		
hsa-mir-616		
hsa-mir-648		
hsa-mir-650		
hsa-mir-656		
hsa-mir-659		
hsa-mir-661		
hsa-mir-671		
hsa-mir-675		
hsa-mir-7-1		
hsa-mir-718		
hsa-mir-766		
hsa-mir-802		
hsa-mir-873		
hsa-mir-874		
hsa-mir-877		
hsa-mir-886		
hsa-mir-887		
hsa-mir-9-1		
hsa-mir-9-2		
hsa-mir-9-3		
hsa-mir-92-1		
hsa-mir-92-2		
hsa-mir-92a-1		
hsa-mir-92a-2		
hsa-mir-93		
hsa-mir-95		
hsa-mir-96	AD	deafness, 50, 613074 (3),
hsa-mir-98		
hsa-mir-99a		
hsa-mir-99b		
HSA011372		
HSA011916		
HSA238520	AR	?deafness, 112, 618257 (3),
HSA238982		
HSA242976		
HSA243396	AD	atrial fibrillation, familial, 16, 613120 (3), ; brugada syndrome 7, 613120 (3),
HSA250303		
HSA269537	AR	?osteochondrodysplasia, brachydactyly, and overlapping malformed digits, 618167 (3),
HSA271784	XL,XLR	?intellectual developmental disorder, 100, 300923 (3),
HSA272268		
HSA275986		
HSA277276		
HSA277841		
HSA404617		
HSA6591		
HSA9761		
HSA9947	AR	spastic paraplegia 78, 617225 (3), ; kufor-rakeb syndrome, 606693 (3),
hSac2		
hSac3	AR,AD	yunis-varon syndrome, 216340 (3), ; ?polymicrogyria, bilateral temporooccipital, 612691 (3), ; amyotrophic lateral sclerosis 11, 612577 (3), ; charcot-marie-tooth disease, type 4j, 611228 (3),
Hsadhc3		
Hsal1	AD	townes-brocks syndrome 1, 107480 (3), ; townes-brocks branchiootorenal-like syndrome, 107480 (3),
Hsal2	AR	?coloboma, ocular, 216820 (3),
HSAN1	AD	amyotrophic lateral sclerosis 27, juvenile, 620285 (3), ; neuropathy, hereditary sensory and autonomic, type ia, 162400 (3),
HSAN2	AR,AD	neuropathy, hereditary sensory and autonomic, type ii, 201300 (3), ; pseudohypoaldosteronism, type iic, 614492 (3),
HSAS	XLR,XL	masa syndrome, 303350 (3), ; hydrocephalus, congenital, 307000 (3), ; ?corpus callosum, partial agenesis of, 304100 (3),
HSAS1	XLR,XL	masa syndrome, 303350 (3), ; hydrocephalus, congenital, 307000 (3), ; ?corpus callosum, partial agenesis of, 304100 (3),
hsBG		
HSBLMHC1	AD	{sarcoidosis, susceptibility to, 2}, 612387 (3),
hSBP	AR	extraoral halitosis due to mto deficiency, 618148 (3),
HSBP1		
HSC	AR	[bombay phenotype], 616754 (3),
HSC20	AR	?anemia, sideroblastic, 5, 619523 (3),
HSC3		
Hsc40		
HSC70		
HSC71		
HSCARG		
HSCB	AR	?anemia, sideroblastic, 5, 619523 (3),
HSCBCIP1		
HSCD5	AD	?deafness, 79, 619086 (3),
HsCdc7		
HSCO	AR	ethylmalonic encephalopathy, 602473 (3),
HSCR	AD,AR	{hirschsprung disease, susceptibility to, 2}, 600155 (3), ; ?abcd syndrome, 600501 (3), ; waardenburg syndrome, type 4a, 277580 (3),
HSCR1	AD	{hirschsprung disease, susceptibility to, 1}, 142623 (3), ; multiple endocrine neoplasia iia, 171400 (3), ; {hirschsprung disease, protection against}, 142623 (3), ; medullary thyroid carcinoma, 155240 (3), ; pheochromocytoma, 171300 (3), ; multiple endocrine neoplasia iib, 162300 (3),
HSCR2	AD,AR	{hirschsprung disease, susceptibility to, 2}, 600155 (3), ; ?abcd syndrome, 600501 (3), ; waardenburg syndrome, type 4a, 277580 (3),
HSCRISP1D		
HSCRISP1G		
hsCSC1	AR	spastic paraplegia 87, 619966 (3),
HSD-1		
HSD-3.8	AR	ciliary dyskinesia, primary, 28, 615505 (3),
HSD-PLA2		
HSD11	AD	cortisone reductase deficiency 2, 614662 (3),
HSD11B	AD	cortisone reductase deficiency 2, 614662 (3),
HSD11B1	AD	cortisone reductase deficiency 2, 614662 (3),
HSD11B2	AR	apparent mineralocorticoid excess, 218030 (3),
HSD14	AR	dystonia 16, 612067 (3),
HSD15		
HSD17		
HSD17B1		
HSD17B10	XLD,XL	hsd10 mitochondrial disease, 300438 (3),
HSD17B11		
HSD17B12		
HSD17B13	AD	{fatty liver disease, protection from}, 620116 (3),
HSD17B14		
HSD17B2		
HSD17B3	AR	pseudohermaphroditism, male, with gynecomastia, 264300 (3),
HSD17B4	AR	d-bifunctional protein deficiency, 261515 (3), ; perrault syndrome 1, 233400 (3),
HSD17B5		
HSD17B6		
HSD17B7		
HSD17B8		
HSD17B9	AR,AD	fundus albipunctatus, 136880 (3),
HSD2		
HSD3	AR	leber congenital amaurosis 3, 604232 (3), ; retinitis pigmentosa 94, variable age at onset, 604232 (3),
HSD3B		
HSD3B1		
HSD3B2	AR	adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency, 201810 (3),
HSD3B7	AR	bile acid synthesis defect, congenital, 1, 607765 (3),
HSD5		
HSD6		
HSD7		
HSDB3		
HSDL1		
HSE		
HSE1		
Hsema-I	AD	{hypogonadotropic hypogonadism 16 with or without anosmia}, 614897 (3),
HSEPI		
HSER	AD,AR	diarrhea 6, 614616 (3), ; meconium ileus, 614665 (3),
HSET		
HSF	AD,AR,MF	{type 2 diabetes mellitus}, 125853 (3), ; {rheumatoid arthritis, systemic juvenile}, 604302 (3); {intracranial hemorrhage in brain cerebrovascular malformations, susceptibility to}, 108010 (3), somatic mutation; {type 1 diabetes mellitus}, 222100 (3), ; {crohn disease-associated growth failure}, 266600 (3), ; {kaposi sarcoma, susceptibility to}, 148000 (3),
hSF-1	AD	46xx sex reversal 4, 617480 (3), ; premature ovarian failure 7, 612964 (3), ; 46xy sex reversal 3, 612965 (3), ; adrenocortical insufficiency, 612964 (3), ; spermatogenic failure 8, 613957 (3),
HSF-27		
HSF1		
HSF2		
HSF2BP	AR	premature ovarian failure 19, 619245 (3),
HSF2L		
HSF4	AD	cataract 5, multiple types, 116800 (3),
HSFY		
HSFY1		
HSGA	AR	?alopecia-intellectual disability syndrome 1, 203650 (3),
hSGT		
hSGT1		
hSGT2	AR	neurodevelopmental disorder with seizures, microcephaly, and brain abnormalities, 620024 (3),
hSgt2p	AR	neurodevelopmental disorder with seizures, microcephaly, and brain abnormalities, 620024 (3),
HSH	AR	hypomagnesemia 1, intestinal, 602014 (3),
Hsh155		myelodysplastic syndrome, somatic, 614286 (3)
HSH2		
HSH2D		
Hsh49	AD	acrofacial dysostosis 1, nager type, 154400 (3),
HSHIN1		
HSHIN6		
hSHIPPO		
hShisa		
hShisa3		
hShisa4		
hShisa5		
HSI		
hSIAH1	AD	buratti-harel syndrome, 619314 (3),
HSJ001348		
HSJ1	AR	spinal muscular atrophy, distal, 5, 614881 (3),
HSJ2		
hSK1		
Hsk1		
hSK2	AD	?dystonia 34, myoclonic, 619724 (3), ; neurodevelopmental disorder with or without variable movement or behavioral abnormalities, 619725 (3),
hSK3	AD	zimmermann-laband syndrome 3, 618658 (3),
hSK4	AD	dehydrated hereditary stomatocytosis 2, 616689 (3),
HSKM-B		
HSL	AR	lipodystrophy, familial partial, type 6, 615980 (3),
HSL1	AR	al-raqad syndrome, 616459 (3),
hSLAP		
hSLE1	MF	{multiple sclerosis, disease progression, modifier of}, 126200 (3), ; {systemic lupus erythematosus, susceptibility to, 2}, 605218 (3)
hslo-beta	AD	{hypertension, diastolic, resistance to}, 608622 (3),
HSM1	AR	neurodevelopmental disorder with dysmorphic facies and variable seizures, 619264 (3),
HsMAD1	AR	prostate cancer, somatic, 176807 (3); mosaic variegated aneuploidy syndrome 7 with inflammation and tumor predisposition, 620189 (3), ; lymphoma, b-cell, somatic (3)
HSMAD2		
hSmaug1		
hSmaug2		
HSMDPKIN		
HSMNP1		
HsMOT2		
hSMP-1		
hSMP3		
HSMPP8		
HSMRPS14	AR	?combined oxidative phosphorylation deficiency 38, 618378 (3),
HSMU1B		
HSN1	AD	amyotrophic lateral sclerosis 27, juvenile, 620285 (3), ; neuropathy, hereditary sensory and autonomic, type ia, 162400 (3),
HSN2	AR,AD	neuropathy, hereditary sensory and autonomic, type ii, 201300 (3), ; pseudohypoaldosteronism, type iic, 614492 (3),
hsNDC80		
hSNF2a	AD	nicolaides-baraitser syndrome, 601358 (3), ; blepharophimosis-impaired intellectual development syndrome, 619293 (3),
hSNF2b	AD	coffin-siris syndrome 4, 614609 (3), ; {rhabdoid tumor predisposition syndrome 2}, 613325 (3),
hSNF2H		
hSNF2L		
HSNFRK		
hSNFS	AD	rhabdoid tumors, somatic, 609322 (3); {schwannomatosis-1, susceptibility to}, 162091 (3), ; coffin-siris syndrome 3, 614608 (3), ; {rhabdoid tumor predisposition syndrome 1}, 609322 (3),
HSNIK		
hSNM1		
hSNU23		
HSOlf1		
HSORC1	AR	meier-gorlin syndrome 1, 224690 (3),
HsORC4	AR	meier-gorlin syndrome 2, 613800 (3),
HSP10		
HSP105A		
HSP105B		
HSP12A	AR	?immunodeficiency 59 and hypoglycemia, 233600 (3),
Hsp20		
HSP22	AD	neuronopathy, distal hereditary motor, type iia, 158590 (3), ; charcot-marie-tooth disease, axonal, type 2l, 608673 (3),
Hsp25	AD	neuronopathy, distal hereditary motor, type iib, 608634 (3), ; charcot-marie-tooth disease, axonal, type 2f, 606595 (3),
HSP27	AD	neuronopathy, distal hereditary motor, type iib, 608634 (3), ; charcot-marie-tooth disease, axonal, type 2f, 606595 (3),
HSP28	AD	neuronopathy, distal hereditary motor, type iib, 608634 (3), ; charcot-marie-tooth disease, axonal, type 2f, 606595 (3),
Hsp40		
HSP47	MF,AR	{preterm premature rupture of the membranes, susceptibility to}, 610504 (3), ; osteogenesis imperfecta, type x, 613848 (3),
hSP56	AR	extraoral halitosis due to mto deficiency, 618148 (3),
HSP60	AD,AR	spastic paraplegia 13, 605280 (3), ; leukodystrophy, hypomyelinating, 4, 612233 (3),
HSP70-1		
HSP70-2		
HSP70-4		
HSP70-HOM		
HSP70B		
HSP70B'		
HSP70L1		
HSP73		
HSP75		
Hsp89		
Hsp90		
HSP90AA1		
HSP90AA2		
HSP90AA2P		
HSP90AB1		
HSP90ALPHA		
HSP90B1		
HSP90L		
HSP90N		
HSPA-KMT		
HSPA1		
HSPA10		
HSPA12A		
HSPA12B		
HSPA13		
HSPA14		
HSPA1A		
HSPA1B		
HSPA1L		
HSPA2		
HSPA4		
HSPA4L		
HSPA5		
HSPA5BP1		
HSPA6		
HSPA7		
HSPA8		
HSPA9	AR,AD	even-plus syndrome, 616854 (3), ; anemia, sideroblastic, 4, 182170 (3),
HSPA9B	AR,AD	even-plus syndrome, 616854 (3), ; anemia, sideroblastic, 4, 182170 (3),
HSPABP1		
HSPABP2	AD,AR	spinocerebellar ataxia 48, 618093 (3), ; spinocerebellar ataxia, 16, 615768 (3),
hSpagh		
HSPB1	AD	neuronopathy, distal hereditary motor, type iib, 608634 (3), ; charcot-marie-tooth disease, axonal, type 2f, 606595 (3),
HSPB10		
HSPB2		
HSPB3	AD	?neuronopathy, distal hereditary motor, type iic, 613376 (3),
HSPB4	AR,AD	cataract 9, multiple types, 604219 (3),
HSPB5	AR,AD	myopathy, myofibrillar, fatal infantile hypertonic, alpha-b crystallin-related, 613869 (3), ; myopathy, myofibrillar, 2, 608810 (3), ; cataract 16, multiple types, 613763 (3), ; cardiomyopathy, dilated, 1ii, 615184 (3),
HSPB6		
HSPB7		
HSPB8	AD	neuronopathy, distal hereditary motor, type iia, 158590 (3), ; charcot-marie-tooth disease, axonal, type 2l, 608673 (3),
HSPB9		
HSPBAP1		
HSPBP1		
HSPC		
HSPC001		
HSPC007	AR	?combined oxidative phosphorylation deficiency 47, 618958 (3),
HSPC009	AR	?mitochondrial complex iv deficiency, nuclear type 14, 619058 (3),
HSPC011		
HSPC013		
HSPC014	AD,AR	proteasome-associated autoinflammatory syndrome 2, 618048 (3), ; keratosis linearis with ichthyosis congenita and sclerosing keratoderma, 601952 (3),
HSPC015	AR	al-raqad syndrome, 616459 (3),
HSPC016		
HSPC018		
HSPC019	AR	osteopetrosis, 5, 259720 (3),
HSPC020		
HSPC021		
HSPC025		
HSPC028		
HSPC029		
HSPC031		
HSPC033		
HSPC038		
HSPC041		
HSPC042		
HSPC043		
HSPC046		
HSPC049		
HSPC051		
HSPC052		
HSPC053		
HSPC055		
HSPC056		
HSPC060		
HSPC062		
HSPC064		
HSPC065		
HSPC068	AD	immunodeficiency 70, 618969 (3),
HSPC070		
HSPC071		
HSPC097		
HSPC099		
HSPC1		
hSpc105	AR	microcephaly 4, primary, 604321 (3),
HSPC105		
HSPC108		
HSPC109		
HSPC111		
HSPC116		
HSPC117		
HSPC120		
HSPC121		
HSPC122		
HSPC125	AR	mitochondrial complex i deficiency, nuclear type 15, 618237 (3),
HSPC126		
HSPC127		
HSPC128		
HSPC129		
HSPC130		
HSPC132		
HSPC133	AR	intellectual developmental disorder, 72, 618665 (3),
HSPC134		
HSPC136		
HSPC138	AR	leukodystrophy, hypomyelinating, 13, 616881 (3),
HSPC139	AR	short stature with microcephaly and distinctive facies, 615789 (3),
HSPC141		
HSPC142		
HSPC145		
HSPC150	AR	fanconi anemia, complementation group t, 616435 (3),
HSPC152		
HSPC153		
HSPC154		
HSPC155	AR	neurodevelopmental disorder with spasticity and poor growth, 618076 (3),
HSPC156		
HSPC158		
HSPC159		
HSPC160		
HSPC163		
HSPC165		
HSPC166		
HSPC167		
HSPC170		
HSPC176	AR	encephalopathy, progressive, early-onset, with episodic rhabdomyolysis, 618331 (3),
HSPC177		
HSPC179	AR	leukodystrophy, hypomyelinating, 13, 616881 (3),
HSPC182		
HSPC183		
HSPC185		
HSPC187		
HSPC190		
HSPC192	AR	?infantile liver failure syndrome 1, 615438 (3),
HSPC194		
HSPC195		
HSPC196	AR	joubert syndrome 16, 614465 (3),
HSPC2		
HSPC203	AR	mitochondrial complex iv deficiency, nuclear type 22, 619355 (3),
HSPC204		
HSPC213		
HSPC214		
HSPC215	AD	intellectual developmental disorder with language impairment with or without autistic features, 613670 (3),
HSPC220		
HSPC224		
HSPC226		
HSPC228		
HSPC230		
HSPC236		
HSPC238		
HSPC240		
HSPC241		
HSPC242		
HSPC244	AR	joubert syndrome 2, 608091 (3), ; meckel syndrome 2, 603194 (3),
HSPC251		
HSPC252		
HSPC262		
HSPC264	AR	galloway-mowat syndrome 1, 251300 (3),
HSPC274		
HSPC276		
HSPC282		
HSPC283		
HSPC289		
HSPC296	AR	neurodegeneration with developmental delay, early respiratory failure, myoclonic seizures, and brain abnormalities, 620327 (3),
HSPC299		
HSPC300		
HSPC302	AR	hypotonia, infantile, with psychomotor retardation and characteristic facies 3, 616900 (3),
HSPC327		
HSPC329	AR	?combined oxidative phosphorylation deficiency 46, 618952 (3),
HSPC335		
HSPCA		
HSPCAL3		
HSPCB		
HsPCFT	AR	folate malabsorption, hereditary, 229050 (3),
HSPD1	AD,AR	spastic paraplegia 13, 605280 (3), ; leukodystrophy, hypomyelinating, 4, 612233 (3),
hSPE-39	AR	arthrogryposis, renal dysfunction, and cholestasis 2, 613404 (3),
HSPE1		
HSPF1		
HSPF2		
HSPF3	AR	spinal muscular atrophy, distal, 5, 614881 (3),
HSPF4		
HSPG		
HSPG1		
HSPG2	AR	dyssegmental dysplasia, silverman-handmaker type, 224410 (3), ; schwartz-jampel syndrome, type 1, 255800 (3),
HSPH1		
HSPH2		
HSPH3		
HSpin1		
hSpindly		
HSPK36		
HSPL27	AD	?neuronopathy, distal hereditary motor, type iic, 613376 (3),
HSPOX1		
HSPOX2	AD,AR	{schizophrenia, susceptibility to, 4}, 600850 (3), ; hyperprolinemia, type i, 239500 (3),
hSPRY1		
hSPRY2	AD	{?iga nephropathy, susceptibility to, 3}, 616818 (3),
HSPRY3		
HSPX153		
HSR1		
HsRad51	AD	mirror movements 2, 614508 (3), ; {breast cancer, susceptibility to}, 114480 (3), somatic mutation, ; fanconi anemia, complementation group r, 617244 (3),
HSRBC		
HSRG1		
HSRNASEB		
HSRNASPH		
hSRP1	AD	spastic paraplegia 88, 620106 (3),
hsRPB10b		
hsRPB5		
hsRPB7		
HSRTSBETA		
HSS	AR,AR,AR	harp syndrome, 607236 (3), ; neurodegeneration with brain iron accumulation 1, 234200 (3), |mucopolysaccharidosis type iiia (sanfilippo a), 252900 (3), |myopathy, mitochondrial progressive, with congenital cataract and developmental delay, 613076 (3),
HSS1	AR	neurodevelopmental disorder with dysmorphic facies and variable seizures, 619264 (3),
HSSB	AD	pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 6, 619767 (3),
hSSB1		
hSSB2		
hSSBIP1		
HSSG1		
HSST	AR	intellectual developmental disorder, 46, 616116 (3),
HSST2	AR	ichthyosis, congenital, 14, 617571 (3),
HSST3		
HsSWEET1		
HsSwt1		
HST		
HST-1		
HsT1031		
HsT1192		
HsT1196		
HsT1201		
HsT1235		
HsT1341		[blood group, kidd], 111000 (3)
HsT1361		
HsT1461		
HsT1601	AD	?facial palsy, congenital, with ptosis and velopharyngeal dysfunction, 617732 (3),
HsT161	AR	burn-mckeown syndrome, 608572 (3),
HsT16328		
HsT16821		
HsT16908		
HsT16930	AD	mirror movements 2, 614508 (3), ; {breast cancer, susceptibility to}, 114480 (3), somatic mutation, ; fanconi anemia, complementation group r, 617244 (3),
HsT16933		
HsT16992		
HsT17016		
HsT17025		
HsT1707	AR	?proteasome-associated autoinflammatory syndrome 4, 619183 (3),
HsT17083		
HsT17089		
HsT17153		
HsT17226		
HsT17250		
HsT17266	AD,AR	craniosynostosis 3, 615314 (3), ; hypogonadotropic hypogonadism 26 with or without anosmia, 619718 (3),
HsT17287		
HsT17299		
HsT17379		
HsT17391	AR	?muscular dystrophy, congenital, davignon-chauveau type, 617066 (3), ; spinal muscular atrophy with congenital bone fractures 1, 616866 (3),
HsT17412	AR	night blindness, congenital stationary (complete), 1d, 613830 (3),
HsT17432	AD	aortic valve disease 2, 614823 (3), ; {radioulnar synostosis, nonsyndromic}, 179300 (3), ; {craniosynostosis 7, susceptibility to}, 617439 (3),
HsT17436	AD	loeys-dietz syndrome 3, 613795 (3),
HsT17454		
HsT17512		
HsT17534		
HsT17563		
HsT17706		
HsT17725		
HsT18361	AD	cleft palate, cardiac defects, and mental retardation, 600987 (3),
HsT18564		
HsT18676	AR	griscelli syndrome, type 2, 607624 (3),
HsT18717	AD	{alzheimer disease 18, susceptibility to}, 615590 (3); reticulate acropigmentation of kitamura, 615537 (3),
HsT18745		
HsT18816	AR	hyperchlorhidrosis, isolated, 143860 (3),
HsT18872		{lumbar disc disease, susceptibility to}, 603932 (3)
HsT18880		
HsT18960	AR	ceroid lipofuscinosis, neuronal, 6b (kufs type), 204300 (3), ; ceroid lipofuscinosis, neuronal, 6a, 601780 (3),
HsT18964		
HsT18976		
HsT19268	AR	neurodevelopmental disorder with microcephaly, epilepsy, and hypomyelination, 618367 (3),
HsT19289		
HsT19294	AR	shwachman-diamond syndrome 2, 617941 (3),
HsT19360		
HsT19371		
HsT19447	AD	?premature ovarian failure 16, 618723 (3),
HsT19550		
HsT19662		
HsT19680		
HsT19690		
HsT19888		
HsT2298		
HsT2308		
HsT2329		
HsT2456		
HsT2563		
HsT2591		
HsT2645		
HsT2651	AD	amyloidosis, hereditary, transthyretin-related, 105210 (3), ; carpal tunnel syndrome, familial, 115430 (3), ; [dystransthyretinemic hyperthyroxinemia], 145680 (3),
HsT2706		
HsT287		
HsT3101		
HsT3226		
HsT3308		
HsT41028		
HsT422		dyskeratosis congenita, digenic, 620040 (3), digenic
HsT441		
HsT661		
HsT748	AD,AR	arthrogryposis, distal, type 5, 108145 (3), ; arthrogryposis, distal, with impaired proprioception and touch, 617146 (3), ; arthrogryposis, distal, type 3, 114300 (3), ; ?marden-walker syndrome, 248700 (3),
HsT771	AD,AR	arthrogryposis, distal, type 5, 108145 (3), ; arthrogryposis, distal, with impaired proprioception and touch, 617146 (3), ; arthrogryposis, distal, type 3, 114300 (3), ; ?marden-walker syndrome, 248700 (3),
HsT832		
HsT885		
HSTE14		
HSTF1		
HSTP		
HsTRAD		{breast-ovarian cancer, familial, susceptibility to, 4}, 614291 (3)
HSU15552		
HSU24186		
HSU37139		
HSU47926		
HSU52521		
HSU79253		
HSU79266		
HSU79303		
HSU84971		
hSulf-1		
HSULF-2		
HSXIAPAF1		
HSY3RR	AD	whim syndrome 1, 193670 (3), ; myelokathexis, isolated, 193670 (3),
hSyn		
hsyn10		
hsyn16	AD	pseudohypoparathyroidism, type ib, 603233 (3),
HSZ75190		{myocardial infarction, susceptibility to}, 608446 (3)
HT-BETA	AD	global developmental delay, absent or hypoplastic corpus callosum, and dysmorphic facies, 617260 (3),
HT002		
Ht006		
HT007	AR	mitochondrial complex i deficiency, nuclear type 29, 618250 (3),
HT008		
HT009		
HT012		
HT013	AR	retinitis pigmentosa 69, 615780 (3),
HT014		
HT015		
HT018		
HT019	AR	spinocerebellar ataxia, 21, 616719 (3),
HT036		
HT1DA		
HT29-IGFBP		
HT2A	AR	?bardet-biedl syndrome 11, 615988 (3), ; muscular dystrophy, limb-girdle, 8, 254110 (3),
hT2R55		
Ht31		
hT41		
HTA		
hTAFII68		chondrosarcoma, extraskeletal myxoid, 612237 (1)
hTAK1		
htAKR		
hTAOK1	AD	developmental delay with or without intellectual impairment or behavioral abnormalities, 619575 (3),
HTATIP	AD	neurodevelopmental disorder with dysmorphic facies, sleep disturbance, and brain abnormalities, 619103 (3),
HTATIP1	AD	neurodevelopmental disorder with dysmorphic facies, sleep disturbance, and brain abnormalities, 619103 (3),
HTATIP2		
HTATSF1		
hTC-1		
HTCD37	AR	neurodevelopmental disorder with microcephaly, hypotonia, and variable brain anomalies, 617481 (3),
hTDAG8		
hTE		
HTEX-6		
HTEX4		
HTF1		
HTF10		
HTF4	AD,AR	craniosynostosis 3, 615314 (3), ; hypogonadotropic hypogonadism 26 with or without anosmia, 619718 (3),
HTF6		
HTF9		
HTF9A		
HTF9C		
hTg737		
HTGL	AD,AR	{diabetes mellitus, noninsulin-dependent}, 125853 (3), ; hepatic lipase deficiency, 614025 (3), ; [high density lipoprotein cholesterol level qtl 12], 612797 (3)
HTGR1		
hTHG1	AR	spinocerebellar ataxia, 28, 618800 (3),
hTHTR2	AR	thiamine metabolism dysfunction syndrome 2 (biotin- or thiamine-responsive encephalopathy type 2), 607483 (3),
hTid-1		
hTIF1		
hTIM	AD	?advance sleep phase syndrome, familial, 4, 620015 (3),
HTK	AD	capillary malformation-arteriovenous malformation 2, 618196 (3), ; lymphatic malformation 7, 617300 (3),
Htk-L		
HTKL		
HTL		
HTLF		
hTLR8	XL	immunodeficiency 98 with autoinflammation, 301078 (3), somatic mosaicism,
HTLVR	AD,AR	dystonia 9, 601042 (3), ; glut1 deficiency syndrome 1, infantile onset, severe, 606777 (3), ; stomatin-deficient cryohydrocytosis with neurologic defects, 608885 (3), ; {epilepsy, idiopathic generalized, susceptibility to, 12}, 614847 (3), ; glut1 deficiency syndrome 2, childhood onset, 612126 (3),
HTM4		
HTMP10		
HTN1		
HTN3		
hToll		
HTOM34P		
HTP1		
HTPAP		
HTPK1	AR	thiamine metabolism dysfunction syndrome 5 (episodic encephalopathy type), 614458 (3),
HTPZP2		
hTR	AD	pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 2, 614743 (3), ; dyskeratosis congenita, 1, 127550 (3),
HTR1A	AD	periodic fever, menstrual cycle dependent, 614674 (3),
HTR1B		
HTR1C		
HTR1D		
HTR1D2		
HTR1E		
HTR1EL		
HTR1F		
HTR2	MF,AD	{alcohol dependence, susceptibility to}, 103780 (3), ; {anorexia nervosa, susceptibility to}, 606788 (3); {major depressive disorder, response to citalopram therapy in}, 608516 (3); {seasonal affective disorder, susceptibility to}, 608516 (3); {obsessive-compulsive disorder, susceptibility to}, 164230 (3), ; {schizophrenia, susceptibility to}, 181500 (3),
HTR2A	MF,AD	{alcohol dependence, susceptibility to}, 103780 (3), ; {anorexia nervosa, susceptibility to}, 606788 (3); {major depressive disorder, response to citalopram therapy in}, 608516 (3); {seasonal affective disorder, susceptibility to}, 608516 (3); {obsessive-compulsive disorder, susceptibility to}, 164230 (3), ; {schizophrenia, susceptibility to}, 181500 (3),
HTR2B		
HTR2C		
HTR3		
HTR3A		
HTR3B		
HTR3C		
HTR3D		
HTR3E		
HTR4		
HTR5A		
HTR6		
HTR7		
HtrA	AR,AD	{macular degeneration, age-related, neovascular type}, 610149 (3); {macular degeneration, age-related, 7}, 610149 (3); carasil syndrome, 600142 (3), ; cerebral arteriopathy, with subcortical infarcts and leukoencephalopathy, type 2, 616779 (3),
htra-2-alpha		
HTRA1	AR,AD	{macular degeneration, age-related, neovascular type}, 610149 (3); {macular degeneration, age-related, 7}, 610149 (3); carasil syndrome, 600142 (3), ; cerebral arteriopathy, with subcortical infarcts and leukoencephalopathy, type 2, 616779 (3),
HTRA2	AR	{parkinson disease 13}, 610297 (3); 3-methylglutaconic aciduria, type viii, 617248 (3),
Htra2-beta		
HTRA3	AD	vitreoretinopathy, neovascular inflammatory, 193235 (3),
HTRA4		
HTRG		
HTRL		
hTrm112		
hTRM9L		
HTRP		
HTRP-1		
HTRP4		
HTRX	AD	wiedemann-steiner syndrome, 605130 (3),
HTRX1	AD	wiedemann-steiner syndrome, 605130 (3),
HTS1		
HTSP1		
HTT	AD,AR,AD,AR,AD	{obsessive-compulsive disorder}, 164230 (3), ; {anxiety-related personality traits}, 607834 (3)|lopes-maciel-rodan syndrome, 617435 (3), ; huntington disease, 143100 (3), |lopes-maciel-rodan syndrome, 617435 (3), ; huntington disease, 143100 (3),
HTX	XL,XLR	congenital heart defects, nonsyndromic, 1, 306955 (3), ; heterotaxy, visceral, 1, 306955 (3), ; vacterl association, 314390 (3),
HTX1	XL,XLR	congenital heart defects, nonsyndromic, 1, 306955 (3), ; heterotaxy, visceral, 1, 306955 (3), ; vacterl association, 314390 (3),
HTX2	AD	heterotaxy, visceral, 2, 605376 (3),
HU-1		
HU-2		
HU-3	XL,XLD	intellectual developmental disorder, 19, 300844 (3), ; coffin-lowry syndrome, 303600 (3),
HU-K4	AD	?spinocerebellar ataxia 46, 617770 (3),
HU-K5		
HU-PP-1		
Hua		
huASH1	AD	intellectual developmental disorder, 52, 617796 (3),
HuB		
HUB1		
hUba3		
hUbc12		
HUBCEP52		
HUBSPECV		
HUC		
huCdc7		
HuCds1	AD	{colorectal cancer, susceptibility to}, 114500 (3), somatic mutation, ; osteosarcoma, somatic, 259500 (3); {breast cancer, susceptibility to}, 114480 (3), somatic mutation, ; {prostate cancer, familial, susceptibility to}, 176807 (3), somatic mutation, ; li-fraumeni syndrome 2, 609265 (3)
HUCEP-15		
hucep-6	AD	kury-isidor syndrome, 619762 (3), ; tumor predisposition syndrome 1, 614327 (3), ; {uveal melanoma, susceptibility to, 2}, 606661 (3),
hucep-7		
HUCEP11		
HUCL		
HUD		
HUEL	AR	birk-landau-perez syndrome, 617595 (3),
HuEMAP	AR	band heterotopia, 600348 (3),
HuEMAP-2		
HuF2		
HUFI-1		
HUFI-2		
Hug	AR	orofaciodigital syndrome vi, 277170 (3), ; joubert syndrome 17, 614615 (3),
HUG-BR2		
HUGL		
HUGL-1		
Hugl-2		
HUGT1		
HUGT2		
huH1		
huInd1	AR	mitochondrial complex i deficiency, nuclear type 21, 618242 (3),
hUIP4		
HUK1	AD	episodic ataxia/myokymia syndrome, 160120 (3),
HULC		
HUM2DD		
hum70t		
HUMAGCGB		
HUMARA	XLR,AD,XL	androgen insensitivity, partial, with or without breast cancer, 312300 (3), ; {prostate cancer, susceptibility to}, 176807 (3), somatic mutation, ; androgen insensitivity, 300068 (3), ; spinal and bulbar muscular atrophy of kennedy, 313200 (3), ; hypospadias 1, 300633 (3),
HUMARP		
HUMAUANTIG		
HUMAZUR		
humb5R2		
HUMBTFB		
HUMCYT2A		
HUMGT198A	AR	ovarian dysgenesis 3, 614324 (3),
HUMHOXY1		
Humig		
HUMINAE		
humL7-1		
HUMMAT1H		
HUMMLC2B	AR,AD	arthrogryposis, distal, type 1c, 619110 (3),
HUMMR		
HUMNPIIY20		
humNRDR		
HUMORF13		
HUMORF5		
HumORF8		pituitary adenoma 4, acth-secreting, somatic, 219090 (3)
HUMORFA01		
hUMP1	AR	anemia, hemolytic, due to umph1 deficiency, 266120 (3),
HUMPCP		
HUMPMKI	AD	porokeratosis 1, multiple types, 175800 (3),
HUMRPL29		
humS6PKh1		
HUMZD58C02	AR	van den ende-gupta syndrome, 600920 (3),
hUNC-24		
hUNC18	AR,AD	developmental and epileptic encephalopathy 4, 612164 (3),
Hunc18b	AR	hemophagocytic lymphohistiocytosis, familial, 5, with or without microvillus inclusion disease, 613101 (3),
HuncM-IC	AR	glomerulosclerosis, focal segmental, 6, 614131 (3),
HUNK		
HUNK1		
HUNKI		
Hup1	AR	congenital myopathy 19, 618578 (3), ; rhabdomyosarcoma 2, alveolar, 268220 (3), somatic mutation
HUP2	AD,AR	craniofacial-deafness-hand syndrome, 122880 (3), ; waardenburg syndrome, type 3, 148820 (3), ; waardenburg syndrome, type 1, 193500 (3), ; rhabdomyosarcoma 2, alveolar, 268220 (3), somatic mutation
HuPAR-1	AR	brown-vialetto-van laere syndrome 2, 614707 (3),
HUPF1		
HUPF3A		
HUPF3B	XL,XLR	intellectual developmental disorder, syndromic 14, 300676 (3),
HuR		
HUR		
HUR1		
HUR7		
hURAT1	AR	hypouricemia, renal, 220150 (3),
HURP		
HUS	AD,AR	{macular degeneration, age-related, 4}, 610698 (3), ; basal laminar drusen, 126700 (3), ; complement factor h deficiency, 609814 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to, 1}, 235400 (3),
HUS1		
HUS1B		
HUSI		
HUSI-I		
HUSI-II	AR	?spermatogenic failure 29, 618091 (3),
HUSPECV		
HUSSY-18		
HUSSY-29		
HUT2		
HUTCH-1		[blood group, indian system], 609027 (3)
HUTCH-I		[blood group, indian system], 609027 (3)
HUVISL1		
HUWE1	XL	intellectual developmental disorder, syndromic, turner type, 309590 (3),
Hv1		
hv7-3		
hVAP-33		
HVCN1		
HVEA		
HVEB		
HVEC	AR	cleft lip/palate-ectodermal dysplasia syndrome, 225060 (3), ; orofacial cleft 7, 225060 (3),
HVED		
HVEM		
HVEM-L		
hvg-1		
hvg-2		
hvg-3		
hvg-5		
HVG1		
HVG2		
HVG3		
HVH-5		
HVH1		
HVH2		
HVH3		
hVps34		
HVR1		
HVSL1	AR	poikiloderma with neutropenia, 604173 (3),
HVSP41	AR	spinocerebellar ataxia, 29, 619389 (3),
hWNT5A	AD	robinow syndrome, 1, 180700 (3),
HXB	AD	deafness, 56, 615629 (3),
HXBL	AR,AD	ehlers-danlos syndrome, classic-like, 1, 606408 (3), ; vesicoureteral reflux 8, 615963 (3),
HXC-26	XL,XLR	intellectual developmental disorder, syndromic, armfield type, 300261 (3),
HXCP2		
HXMA		
Hxt		
HY		
hY1		
hY3		
hY4		
hY5		
HYA		
HYA22		
hYAK3-2		
HYAL-1	AR	mucopolysaccharidosis type ix, 601492 (3),
HYAL1	AR	mucopolysaccharidosis type ix, 601492 (3),
HYAL2		
HYAL3		
HYAL4		
HYAL5		
HYBID		
HYCC1	AR	leukodystrophy, hypomyelinating, 5, 610532 (3),
hyccin	AR	leukodystrophy, hypomyelinating, 5, 610532 (3),
HYD		
HYD1	AD	tooth agenesis, selective, 1, with or without orofacial cleft, 106600 (3), ; ectodermal dysplasia 3, witkop type, 189500 (3), ; orofacial cleft 5, 608874 (3),
HYDIN	AR	ciliary dyskinesia, primary, 5, 608647 (3),
HYDIN2		
HYDINP1		
HYI		
hYjeF_N2-15q23	AR	?intellectual developmental disorder, 50, 616460 (3),
hYjeF_N3-19p13.11		
HYKK		
HYKPP	AD,AR	paramyotonia congenita, 168300 (3), ; hyperkalemic periodic paralysis, 170500 (3), ; congenital myopathy 22b, severe fetal, 620369 (3), ; hypokalemic periodic paralysis, type 2, 613345 (3), ; myotonia congenita, atypical, acetazolamide-responsive, 608390 (3), ; myasthenic syndrome, congenital, 16, 614198 (3), ; congenital myopathy 22a, classic, 620351 (3),
HYL		
HYLS1	AR	hydrolethalus syndrome, 236680 (3),
HYLTK		
HYMAI		
HYOU1	AR	?immunodeficiency 59 and hypoglycemia, 233600 (3),
HYP	XLD,XL	hypophosphatemic rickets, 307800 (3),
HYP1	XLD,XL	hypophosphatemic rickets, 307800 (3),
hYP38334	XLR,XL	spondyloepiphyseal dysplasia tarda, 313400 (3),
HYPA		
HYPB	AD	luscan-lumish syndrome, 616831 (3), ; intellectual developmental disorder, 70, 620157 (3), ; rabin-pappas syndrome, 620155 (3),
HYPD		
HYPERION	AD	?long qt syndrome 11, 611820 (3),
HYPF		
HYPG		
HYPH		
HYPJ		
HYPK		
HYPL	AD,AR	glaucoma 1, open angle, e, 137760 (3), ; amyotrophic lateral sclerosis 12 with or without frontotemporal dementia, 613435 (3), ; {glaucoma, normal tension, susceptibility to}, 606657 (3)
hypoPP	AD,AR	{thyrotoxic periodic paralysis, susceptibility to, 1}, 188580 (3), ; congenital myopathy 18 due to dihydropyridine receptor defect, 620246 (3), ; hypokalemic periodic paralysis, type 1, 170400 (3), ; {malignant hyperthermia susceptibility 5}, 601887 (3),
HYPP	AD,AR	paramyotonia congenita, 168300 (3), ; hyperkalemic periodic paralysis, 170500 (3), ; congenital myopathy 22b, severe fetal, 620369 (3), ; hypokalemic periodic paralysis, type 2, 613345 (3), ; myotonia congenita, atypical, acetazolamide-responsive, 608390 (3), ; myasthenic syndrome, congenital, 16, 614198 (3), ; congenital myopathy 22a, classic, 620351 (3),
HYRC	AR	immunodeficiency 26, with or without neurologic abnormalities, 615966 (3),
HYRC1	AR	immunodeficiency 26, with or without neurologic abnormalities, 615966 (3),
hYSAH1		
HYST1046		
Hzf		
HZF-16		
HZF-2		
HZF-3	AD	intellectual developmental disorder with language impairment and early-onset dopa-responsive dystonia-parkinsonism, 619911 (3),
HZF1		
HZF12		
HZF16		
HZF2		
HZF22		
HZF3		
HZF4		
HZF5		
HZF6		
HZF8		
HZF9		
HZFP100		
HZFw1		
hZG16		
hZIMP10	AD	neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies, 618659 (3),
hZIMP7		
hZNF1		
hZNF2		
hZR14		
Hzyg		
I-1		
I-15P		
I-309		
I-4		
I-BABP		
I-BALB		
I-BAP		
I-FABP		
I-FLICE		
I-GLCNAC-6-ST		
I-mfa		
I-Rel	AR	immunodeficiency 92, 619652 (3),
I-TAC		
I-TRAF		
I1PP2A		
IA-1		
IA-2		
IA-2beta		
IA-6		
IA1		
IA4		
IAN1		
IAN12		
IAN2		
IAN4L1	AR	portal hypertension, noncirrhotic, 2, 619463 (3),
IAN5	AR	portal hypertension, noncirrhotic, 2, 619463 (3),
IAN6		
IAN7		
IAN9		
IAP	XL,XLR	immunodeficiency, with magnesium defect, epstein-barr virus infection and neoplasia, 300853 (3), ; congenital disorder of glycosylation, type icc, 301031 (3),
IAPP		
IARS	AR	growth retardation, impaired intellectual development, hypotonia, and hepatopathy, 617093 (3),
IARS1	AR	growth retardation, impaired intellectual development, hypotonia, and hepatopathy, 617093 (3),
IARS2	AR	cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia, 616007 (3),
IASPP		
IATIH		
IATIL		
IB1	AD	{diabetes mellitus, noninsulin-dependent}, 125853 (3),
IB1099	AD	epilepsy, familial temporal lobe, 1, 600512 (3),
IB2		
IB291		
Ib772	XL	intellectual developmental disorder, syndromic, turner type, 309590 (3),
IBA1		
IBA57	AR	multiple mitochondrial dysfunctions syndrome 3, 615330 (3), ; ?spastic paraplegia 74, 616451 (3),
IBAT	AR	?bile acid malabsorption, primary, 1, 613291 (3),
IBD1	AD,MF	blau syndrome, 186580 (3), ; {yao syndrome}, 617321 (3), ; {inflammatory bowel disease 1, crohn disease}, 266600 (3),
IBD2		
IBM2	AD,AR	sialuria, 269921 (3), ; nonaka myopathy, 605820 (3),
IBM3	AR,AD	congenital myopathy 6 with ophthalmoplegia, 605637 (3),
IBMPFD	AD	frontotemporal dementia and/or amyotrophic lateral sclerosis 6, 613954 (3), ; charcot-marie-tooth disease, type 2y, 616687 (3), ; inclusion body myopathy with early-onset paget disease and frontotemporal dementia 1, 167320 (3),
IBP	AR	immunodeficiency 87 and autoimmunity, 619573 (3),
IBP1	XLR,XL	?corpus callosum, agenesis of, with impaired intellectual development, ocular coloboma and micrognathia, 300472 (3),
IBP160		
IBP2		
IBP3		
IBP4		
IBRDC1		
IBRDC2		
IBRDC3		
IBSN	AR	striatonigral degeneration, infantile, 271930 (3),
IBSP		
IBTK		
IC53		
ICA1		
ICA12		
ICA512		
ICA69		
ICAAR		
ICAD		
ICAM-R		
ICAM1		{malaria, cerebral, susceptibility to}, 611162 (3)
ICAM2		
ICAM3		
ICAM4		[blood group, landsteiner-wiener], 111250 (3)
ICAM5		
ICAP-1A		
ICAP-1alpha		
ICAP-1B		
ICAP1		
ICAP1A		
ICAP1B		
ICAp69		
ICAT		
Icb-1		
ICB-1		
ICBP90		
ICCA	AD	convulsions, familial infantile, with paroxysmal choreoathetosis, 602066 (3), ; seizures, benign familial infantile, 2, 605751 (3), ; episodic kinesigenic dyskinesia 1, 128200 (3),
ICCD	AD,AR	ventricular fibrillation, familial, 1, 603829 (3); heart block, progressive, type ia, 113900 (3), ; cardiomyopathy, dilated, 1e, 601154 (3), ; heart block, nonprogressive, 113900 (3), ; long qt syndrome 3, 603830 (3), ; sick sinus syndrome 1, 608567 (3), ; brugada syndrome 1, 601144 (3), ; atrial fibrillation, familial, 10, 614022 (3), ; {sudden infant death syndrome, susceptibility to}, 272120 (3),
iCE		
ICE		
ICE-LAP3		
ICE-LAP6		
ICE(rel)II		
ICE(rel)III		
ICE1		
ICE2		
ICEBERG		
ICERE-1	AD	deafness, 5, 600994 (3),
ICF45	AR	spinocerebellar ataxia, 28, 618800 (3),
ICH-2		
ICH1		
ICHYN	AR	ichthyosis, congenital, 6, 612281 (3),
ICIL-1RA	AR	{gastric cancer risk after h. pylori infection}, 613659 (3); {microvascular complications of diabetes 4}, 612628 (3); interleukin 1 receptor antagonist deficiency, 612852 (3),
ICIS		
ICK	AD,AR	{epilepsy, juvenile myoclonic, susceptibility to, 10}, 617924 (3), ; endocrine-cerebroosteodysplasia, 612651 (3),
ICln		
ICMT		
ICOS	AR	immunodeficiency, common variable, 1, 607594 (3),
ICOS-L		
ICOSL		
ICOSLG		
ICP22BP		
ICP55	AR	nephronophthisis-like nephropathy 1, 613159 (3),
ICR1	AD	wilms tumor 2, 194071 (3), somatic mutation, ; beckwith-wiedemann syndrome, 130650 (3), ; silver-russell syndrome 1, 180860 (3),
ICR2	AR	ichthyosis, congenital, 1, 242300 (3),
ICR2B	AR	ichthyosis, congenital, 4b (harlequin), 242500 (3), ; ichthyosis, congenital, 4a, 601277 (3),
ICSBP	AD,AR	immunodeficiency 32a, mycobacteriosis, 614893 (3), ; immunodeficiency 32b, monocyte and dendritic cell deficiency, 226990 (3),
ICSBP1	AD,AR	immunodeficiency 32a, mycobacteriosis, 614893 (3), ; immunodeficiency 32b, monocyte and dendritic cell deficiency, 226990 (3),
ICT1		
ID1		
ID2		
ID2S	XLR,XL	mucopolysaccharidosis ii, 309900 (3),
ID3		
ID4		
IDAS	AR	ciliary dyskinesia, primary, 42, 618695 (3),
IDAX		
IDD	AD,AR	{intervertebral disc disease, susceptibility to}, 603932 (3); epiphyseal dysplasia, multiple, 3, with or without myopathy, 600969 (3), ; stickler syndrome, type vi, 620022 (3),
IDDM1	AR,MF,AD,AD,AR	{celiac disease, susceptibility to}, 212750 (3), ; {multiple sclerosis, susceptibility to, 1}, 126200 (3), ; {creutzfeldt-jakob disease, variant, resistance to}, 123400 (3), |diabetes mellitus, insulin-dependent, 2, 125852 (3), ; maturity-onset diabetes of the young, type 10, 613370 (3), ; hyperproinsulinemia, 616214 (3), ; diabetes mellitus, permanent neonatal 4, 618858 (3),
IDDM10	AR	immunodeficiency 41 with lymphoproliferation and autoimmunity, 606367 (3), ; {diabetes, mellitus, insulin-dependent, susceptibility to, 10}, 601942 (3)
IDDM12	AD	immune dysregulation with autoimmunity, immunodeficiency, and lymphoproliferation, 616100 (3), ; {diabetes mellitus, insulin-dependent, 12}, 601388 (3); {celiac disease, susceptibility to, 3}, 609755 (3); {hashimoto thyroiditis}, 140300 (3), ; {systemic lupus erythematosus, susceptibility to}, 152700 (3),
IDDM19	AR,AD	immunodeficiency 95, 619773 (3), ; aicardi-goutieres syndrome 7, 615846 (3), ; singleton-merten syndrome 1, 182250 (3),
IDDM2	AD,AR	diabetes mellitus, insulin-dependent, 2, 125852 (3), ; maturity-onset diabetes of the young, type 10, 613370 (3), ; hyperproinsulinemia, 616214 (3), ; diabetes mellitus, permanent neonatal 4, 618858 (3),
IDDM20		thrombocythemia, somatic, 187950 (3); myelofibrosis, somatic, 254450 (3); erythrocytosis, somatic, 133100 (3)
IDDM21		
IDDM22		{hiv infection, susceptibility/resistance to}, 609423 (3); {diabetes mellitus, insulin-dependent, 22}, 612522 (3); {hepatitis c virus, resistance to}, 609532 (3); {west nile virus, susceptibility to}, 610379 (3)
IDDM5		{diabetes mellitus, insulin-dependent, 5}, 600320 (3)
IDE		
IDGFL	AR	sneddon syndrome, 182410 (3), ; vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome, 615688 (3),
IDH-2		d-2-hydroxyglutaric aciduria 2, 613657 (3)
IDH1		{glioma, susceptibility to, somatic}, 137800 (3)
IDH2		d-2-hydroxyglutaric aciduria 2, 613657 (3)
IDH3A	AR	retinitis pigmentosa 90, 619007 (3),
IDH3B	AR	retinitis pigmentosa 46, 612572 (3),
IDH3G		
IDH3GL		
IDI1		
IDI2		
IDI2-AS		
IDI2-AS1		
IDN3	AD	cornelia de lange syndrome 1, 122470 (3),
IDNK		
IDO		
IDO1		
IDO2		
IDOL		
IDS	XLR,XL	mucopolysaccharidosis ii, 309900 (3),
IDUA	AR	mucopolysaccharidosis is, 607016 (3), ; mucopolysaccharidosis ih/s, 607015 (3), ; mucopolysaccharidosis ih, 607014 (3),
IDX-1	AD,AR	{diabetes mellitus, type ii, susceptibility to}, 125853 (3), ; pancreatic agenesis 1, 260370 (3), ; mody, type iv, 606392 (3)
IEF-SSP-9502		
IEGF		
IER1		
IER2		
IER3		
IER3IP1	AR	microcephaly, epilepsy, and diabetes syndrome, 614231 (3),
IER5		
IES2		
IEX-1		
IEX-1L		
IF	AD,AR,AR	{hemolytic uremic syndrome, atypical, susceptibility to, 3}, 612923 (3), ; {macular degeneration, age-related, 13, susceptibility to}, 615439 (3), ; complement factor i deficiency, 610984 (3), |intrinsic factor deficiency, 261000 (3),
IF-2mt		
IF-3mt		
IF2		
IF3(mt)		
IF4e		
IFB		
IFC-1	AR	?megaloblastic anemia, folate-responsive, 601775 (3),
IFCR	AR	[proteinuria, chronic benign], 618884 (3), ; imerslund-grasbeck syndrome 1, 261100 (3),
IFEX9	AR	growth retardation, developmental delay, facial dysmorphism, 612938 (3), ; {obesity, susceptibility to, bmiq14}, 612460 (3),
IFF		
IFFO		
IFFO1		
IFGP1		
IFGP3		
IFGP6		
IFI-30		
IFI-4	AD	immunodeficiency 100 with pulmonary alveolar proteinosis and hypogammaglobulinemia, 618042 (3),
IFI-54		
IFI-6-16		
IFI-78K		
IFI1		{mycobacterium tuberculosis, protection against}, 607948 (3); {inflammatory bowel disease (crohn disease) 19}, 612278 (3)
IFI10		
IFI15	AR	immunodeficiency 38, 616126 (3),
IFI16		
IFI17		
IFI27		
IFI27L1		
IFI27L2		
IFI30		
IFI35		
IFI4	AD,AR	dyschromatosis symmetrica hereditaria, 127400 (3), ; aicardi-goutieres syndrome 6, 615010 (3),
IFI41	AR	{mycobacterium tuberculosis, susceptibility to}, 607948 (3); hepatic venoocclusive disease with immunodeficiency, 235550 (3),
IFI44		
IFI44L		
IFI5111		
IFI53	AR,AD	neurodevelopmental disorder with microcephaly and speech delay, with or without brain abnormalities, 620317 (3), ; neuronopathy, distal hereditary motor, type ix, 617721 (3),
IFI54		
IFI56		
IFI6		
IFI60		
IFI616		
IFI75	AR	{mycobacterium tuberculosis, susceptibility to}, 607948 (3); hepatic venoocclusive disease with immunodeficiency, 235550 (3),
IFIH1	AR,AD	immunodeficiency 95, 619773 (3), ; aicardi-goutieres syndrome 7, 615846 (3), ; singleton-merten syndrome 1, 182250 (3),
IFIT1		
IFIT2		
IFIT3		
IFIT4		
IFIT5		
IFITM1		
IFITM10		
IFITM2		
IFITM3		{influenza, severe, susceptibility to}, 614680 (3)
IFITM5	AD	osteogenesis imperfecta, type v, 610967 (3),
IFITMD1	AD	convulsions, familial infantile, with paroxysmal choreoathetosis, 602066 (3), ; seizures, benign familial infantile, 2, 605751 (3), ; episodic kinesigenic dyskinesia 1, 128200 (3),
IFITMD2		
IFITMD3		
IFITMD4		
IFITMD5		
IFITMD6		
IFITMD7		
IFIX		
IFL		interferon, alpha, deficiency (1)
IFLTD1		
IFMH	AR	intrinsic factor deficiency, 261000 (3),
IFN		interferon, alpha, deficiency (1)
IFN-ALPHA		interferon, alpha, deficiency (1)
IFN-alpha4a		
IFN-alphaA		
IFN-alphaB		
IFN-alphaC		
IFN-alphaD		interferon, alpha, deficiency (1)
IFN-alphaG		
IFN-alphaH		
IFN-alphaI		
IFN-alphaJ		
IFN-alphaK		
IFN-alphaO		
IFNA		
IFNA-J		
IFNA@		interferon, alpha, deficiency (1)
IFNA1		interferon, alpha, deficiency (1)
IFNA10		
IFNA13		interferon, alpha, deficiency (1)
IFNA14		
IFNA16		
IFNA17		
IFNA2		
IFNA21		
IFNA4		
IFNA5		
IFNA6		
IFNA7		
IFNA8		
IFNABR	AR	{hepatitis b virus, susceptibility to}, 610424 (3); immunodeficiency 45, 616669 (3),
IFNAI1		
IFNAN		
IFNAR	AR	immunodeficiency 106, susceptibility to viral infections, 619935 (3),
IFNAR1	AR	immunodeficiency 106, susceptibility to viral infections, 619935 (3),
IFNAR2	AR	{hepatitis b virus, susceptibility to}, 610424 (3); immunodeficiency 45, 616669 (3),
IFNB		
IFNB1		
IFNB2	AD,AR,MF	{type 2 diabetes mellitus}, 125853 (3), ; {rheumatoid arthritis, systemic juvenile}, 604302 (3); {intracranial hemorrhage in brain cerebrovascular malformations, susceptibility to}, 108010 (3), somatic mutation; {type 1 diabetes mellitus}, 222100 (3), ; {crohn disease-associated growth failure}, 266600 (3), ; {kaposi sarcoma, susceptibility to}, 148000 (3),
IFNE		
IFNE1		
IFNG	AD,AR	{hepatitis c virus, response to therapy of}, 609532 (3); {tsc2 angiomyolipomas, renal, modifier of}, 613254 (3), ; {aplastic anemia}, 609135 (3); ?immunodeficiency 69, mycobacteriosis, 618963 (3), ; {tuberculosis, protection against}, 607948 (3); {aids, rapid progression to}, 609423 (3)
IFNGIP1		
IFNGR	AR,AD	{h. pylori infection, susceptibility to}, 600263 (3); immunodeficiency 27a, mycobacteriosis, ar, 209950 (3), ; immunodeficiency 27b, mycobacteriosis, ad, 615978 (3), ; {tuberculosis infection, protection against}, 607948 (3); {tuberculosis, susceptibility to}, 607948 (3); {hepatitis b virus infection, susceptibility to}, 610424 (3)
IFNGR1	AR,AD	{h. pylori infection, susceptibility to}, 600263 (3); immunodeficiency 27a, mycobacteriosis, ar, 209950 (3), ; immunodeficiency 27b, mycobacteriosis, ad, 615978 (3), ; {tuberculosis infection, protection against}, 607948 (3); {tuberculosis, susceptibility to}, 607948 (3); {hepatitis b virus infection, susceptibility to}, 610424 (3)
IFNGR2	AR	immunodeficiency 28, mycobacteriosis, 614889 (3),
IFNGT1	AR	immunodeficiency 28, mycobacteriosis, 614889 (3),
IFNK		
IFNL1		
IFNL2		
IFNL3		{hepatitis c virus infection, response to therapy of}, 609532 (3)
IFNL4		
IFNLR		
IFNLR1		
IFNR		
IFNRP		
IFNW1		
IFP35		
IFP53	AR,AD	neurodevelopmental disorder with microcephaly and speech delay, with or without brain abnormalities, 620317 (3), ; neuronopathy, distal hereditary motor, type ix, 617721 (3),
IFPS	AR	peeling skin syndrome 6, 618084 (3),
IFRC	AR	immunodeficiency 106, susceptibility to viral infections, 619935 (3),
IFRD1		
IFRD2		
IFRG15		
IFRG28		
IFT121	AR	short-rib thoracic dysplasia 7 with or without polydactyly, 614091 (3), ; cranioectodermal dysplasia 2, 613610 (3),
IFT122	AR	cranioectodermal dysplasia 1, 218330 (3),
IFT139	AR,AD	short-rib thoracic dysplasia 4 with or without polydactyly, 613819 (3), ; nephronophthisis 12, 613820 (3),
IFT139A	AR	spermatogenic failure 37, 618429 (3),
IFT139B	AR,AD	short-rib thoracic dysplasia 4 with or without polydactyly, 613819 (3), ; nephronophthisis 12, 613820 (3),
IFT140	AR	short-rib thoracic dysplasia 9 with or without polydactyly, 266920 (3), ; retinitis pigmentosa 80, 617781 (3),
IFT144	AR	nephronophthisis 13, 614377 (3), ; cranioectodermal dysplasia 4, 614378 (3), ; senior-loken syndrome 8, 616307 (3), ; short-rib thoracic dysplasia 5 with or without polydactyly, 614376 (3), ; ?spermatogenic failure 72, 619867 (3),
IFT172	AR	retinitis pigmentosa 71, 616394 (3), ; bardet-biedl syndrome 20, 619471 (3), ; short-rib thoracic dysplasia 10 with or without polydactyly, 615630 (3),
IFT20		
IFT27	AR	bardet-biedl syndrome 19, 615996 (3),
IFT38		
IFT43	AR	?cranioectodermal dysplasia 3, 614099 (3), ; ?retinitis pigmentosa 81, 617871 (3), ; short-rib thoracic dysplasia 18 with polydactyly, 617866 (3),
IFT52	AR	short-rib thoracic dysplasia 16 with or without polydactyly, 617102 (3),
IFT54	AR	senior-loken syndrome 9, 616629 (3),
IFT56	AR	biliary, renal, neurologic, and skeletal syndrome, 619534 (3),
IFT57	AR	?orofaciodigital syndrome xviii, 617927 (3),
IFT74	AR	bardet-biedl syndrome 22, 617119 (3), ; spermatogenic failure 58, 619585 (3), ; joubert syndrome 40, 619582 (3),
IFT80	AR	short-rib thoracic dysplasia 2 with or without polydactyly, 611263 (3),
IFT81	AR	short-rib thoracic dysplasia 19 with or without polydactyly, 617895 (3),
IFT88		
IFTA1	AR	short-rib thoracic dysplasia 7 with or without polydactyly, 614091 (3), ; cranioectodermal dysplasia 2, 613610 (3),
IFTAP		
Ig-alpha	AR	agammaglobulinemia 3, 613501 (3),
Ig-beta	AR	agammaglobulinemia 6, 612692 (3),
IG/EBP-1		
IG20	AR	neurodevelopmental disorder with dysmorphic facies, impaired speech and hypotonia, 619005 (3), ; deeah syndrome, 619004 (3),
IGA	AR	agammaglobulinemia 3, 613501 (3),
IGAAD	AD	intellectual developmental disorder, 58, 618106 (3),
IGAD2	AR,AD	immunodeficiency, common variable, 2, 240500 (3), ; immunoglobulin a deficiency 2, 609529 (3)
IGAlpha	AR	agammaglobulinemia 3, 613501 (3),
iGAT	AR	muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 13, 615287 (3),
IGB	AR	agammaglobulinemia 6, 612692 (3),
IGB3S		
Igbeta	AR	agammaglobulinemia 6, 612692 (3),
IGBF		{prostate cancer, hereditary, 13}, 611928 (3)
IGBP1	XLR,XL	?corpus callosum, agenesis of, with impaired intellectual development, ocular coloboma and micrognathia, 300472 (3),
IGBS3S		
IGCD1	XLR,XL	hypothyroidism, central, and testicular enlargement, 300888 (3),
IGCJ		
IGDA	AD	axenfeld-rieger syndrome, type 3, 602482 (3), ; anterior segment dysgenesis 3, multiple subtypes, 601631 (3),
IGDC1	XLR,XL	hypothyroidism, central, and testicular enlargement, 300888 (3),
IGDCC1	AD,AR	mirror movements 1 and/or agenesis of the corpus callosum, 157600 (3), ; esophageal carcinoma, somatic, 133239 (3); colorectal cancer, somatic, 114500 (3); gaze palsy, familial horizontal, with progressive scoliosis, 2, 617542 (3),
IGDCC2		
IGDCC3		
IGDCC4		
IGDCC5		
IGDS	AD	ring dermoid of cornea, 180550 (3), ; axenfeld-rieger syndrome, type 1, 180500 (3), ; anterior segment dysgenesis 4, 137600 (3),
IGER	AD	{atopy, susceptibility to}, 147050 (3),
IGF	AR	growth retardation with deafness and mental retardation due to igf1 deficiency, 608747 (3),
IGF-BP25		
IGF-I	AR	growth retardation with deafness and mental retardation due to igf1 deficiency, 608747 (3),
IGF-II	AD	silver-russell syndrome 3, 616489 (3),
IGF1	AR	growth retardation with deafness and mental retardation due to igf1 deficiency, 608747 (3),
IGF1A	AR	growth retardation with deafness and mental retardation due to igf1 deficiency, 608747 (3),
IGF1R	AR,AD	insulin-like growth factor i, resistance to, 270450 (3),
IGF1R-AS		
IGF2	AD	silver-russell syndrome 3, 616489 (3),
IGF2-AS		
IGF2-AS1		
IGF2AS		
IGF2BP1		
IGF2BP2	AD	{diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3),
IGF2BP3		
IGF2R		hepatocellular carcinoma, somatic, 114550 (3)
IGF2R-AS1		
IGF2RAS		
IGFALS	AR	acid-labile subunit, deficiency of, 615961 (3),
IGFBP-3R	AR	?keratosis pilaris atrophicans, 604093 (3),
IGFBP-4		
IGFBP-4ase		
IGFBP-7	AR	retinal arterial macroaneurysm with supravalvular pulmonic stenosis, 614224 (3),
IGFBP1		
IGFBP10		
IGFBP2		
IGFBP3		
IGFBP3R1	AR	?keratosis pilaris atrophicans, 604093 (3),
IGFBP4		
IGFBP5		
IGFBP5-protease	AR,AD	{macular degeneration, age-related, neovascular type}, 610149 (3); {macular degeneration, age-related, 7}, 610149 (3); carasil syndrome, 600142 (3), ; cerebral arteriopathy, with subcortical infarcts and leukoencephalopathy, type 2, 616779 (3),
IGFBP6		
IGFBP7	AR	retinal arterial macroaneurysm with supravalvular pulmonic stenosis, 614224 (3),
IGFBP8		
IGFBP9		
IGFBPL1		
IGFI	AR	growth retardation with deafness and mental retardation due to igf1 deficiency, 608747 (3),
IGFIR	AR,AD	insulin-like growth factor i, resistance to, 270450 (3),
IGFL1		
IGFL2		
IGFL3		
IGFL4		
IGFLR1		
IGFN1		
IGFP2		
IGFR	AR,AD	insulin-like growth factor i, resistance to, 270450 (3),
IGFR2	AR,AD	{malaria, severe, susceptibility to}, 611162 (3); {pseudomonas aeruginosa, susceptibility to chronic infection by, in cystic fibrosis}, 219700 (3), ; {lupus nephritis, susceptibility to}, 152700 (3),
IGH		
IGH@		
IGHA1		
IGHA2		
IGHD		
IGHD3-3		
IGHD33		
IGHDY1		
IGHE		
IGHG1		
IGHG2		igg2 deficiency, selective (3)
IGHG3		
IGHG4		
IGHM	AR	agammaglobulinemia 1, 601495 (3),
IGHMBP2	AR	neuronopathy, distal hereditary motor, type vi, 604320 (3), ; charcot-marie-tooth disease, axonal, type 2s, 616155 (3),
IGHV3-23		
IGIF		
IGJ		
IGKC	AR	kappa light chain deficiency, 614102 (3),
IGKDE		
IGKDEL		
IGKJ		
IGKJ@		
IGKJRB	AD	adams-oliver syndrome 3, 614814 (3),
IGKJRB1	AD	adams-oliver syndrome 3, 614814 (3),
IGKV		
IGKV@		
IGKV1		
IGKV1@		
IGKV1/OR2-108		
IGKV1OR2-108		
IGKV1OR2108		
IGKV2		
IGKV2@		
IGKV3		
IGKV3@		
IGL5	AR	agammaglobulinemia 2, 613500 (3),
IGLC		
IGLC1		
IGLJ		
IGLJ@		
IGLL	AR	agammaglobulinemia 2, 613500 (3),
IGLL1	AR	agammaglobulinemia 2, 613500 (3),
IGLON1		ovarian cancer, somatic, 167000 (3)
IGLON2		
IGLON3		
IGLON4		
IGLON5		
iGluR3	XL,XLR	intellectual developmental disorder, syndromic, wu type, 300699 (3),
IGLV		
IGLV@		
IGnT	AR	muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 13, 615287 (3),
IGNT	AD,AR	[blood group, ii], 110800 (3), ; adult i phenotype without cataract, 110800 (3), ; cataract 13 with adult i phenotype, 116700 (3),
IGO1		
IGPR-1		
IGRP		
IGSF1	XLR,XL	hypothyroidism, central, and testicular enlargement, 300888 (3),
IGSF10		
IGSF11		
IGSF12		
Igsf13		
IGSF13		
IGSF16		
IGSF2		
IGSF3	AR	?lacrimal duct defect, 149700 (3),
IGSF4		
IGSF4A		
IGSF4B	AD	charcot-marie-tooth disease, axonal, type 2ff, 619519 (3),
IGSF4C		
IGSF4D		
IGSF5		
IGSF6		
IGSF8		
IGSF9		
IGSF9A		
IGSF9B		
IGVPB	AR	agammaglobulinemia 2, 613500 (3),
IHABP4		
IHG-1	AR	spinocerebellar ataxia, 28, 618800 (3),
IHG1	AD	axenfeld-rieger syndrome, type 3, 602482 (3), ; anterior segment dysgenesis 3, multiple subtypes, 601631 (3),
IHG2	AD	ring dermoid of cornea, 180550 (3), ; axenfeld-rieger syndrome, type 1, 180500 (3), ; anterior segment dysgenesis 4, 137600 (3),
IHH	AR,AD	acrocapitofemoral dysplasia, 607778 (3), ; brachydactyly, type a1, 112500 (3),
IHO1		
Ihog	AD	holoprosencephaly 11, 614226 (3),
IHPK1		
IHPK2		
IHPK3		
IHRP		
II	AD,AR	[blood group, ii], 110800 (3), ; adult i phenotype without cataract, 110800 (3), ; cataract 13 with adult i phenotype, 116700 (3),
IIIG9		
IIp45		
IIS		
IK	AD	dehydrated hereditary stomatocytosis 2, 616689 (3),
ik3-2		
IK8		
IKAP	AR,AD	{medulloblastoma}, 155255 (3), somatic mutation, ; dysautonomia, familial, 223900 (3),
IkappaBalpha	AD	ectodermal dysplasia and immunodeficiency 2, 612132 (3),
IkappaBNS		
IKAROS	AD	immunodeficiency, common variable, 13, 616873 (3),
IKBA	AD	ectodermal dysplasia and immunodeficiency 2, 612132 (3),
IKBB		
IKBE		
IKBIP		
IkBKA	AR	?popliteal pterygium syndrome, bartsocas-papas type 2, 619339 (3), ; ?cocoon syndrome, 613630 (3),
IKBKAP	AR,AD	{medulloblastoma}, 155255 (3), somatic mutation, ; dysautonomia, familial, 223900 (3),
IKBKB	AR,AD	immunodeficiency 15b, 615592 (3), ; immunodeficiency 15a, 618204 (3),
IKBKBBP	AR	intellectual developmental disorder, 13, 613192 (3),
IKBKE		
IKBKG	XLD,XLR,XL	incontinentia pigmenti, 308300 (3), ; ectodermal dysplasia and immunodeficiency 1, 300291 (3), ; immunodeficiency 33, 300636 (3), ; autoinflammatory disease, systemic, 301081 (3),
IKBL		{rheumatoid arthritis, susceptibility to}, 180300 (3)
IkBNS		
IKBR	AR	spondyloepimetaphyseal dysplasia, sponastrime type, 271510 (3),
IKEPP		
IKI3	AR,AD	{medulloblastoma}, 155255 (3), somatic mutation, ; dysautonomia, familial, 223900 (3),
IKIP		
IKK-alpha	AR	?popliteal pterygium syndrome, bartsocas-papas type 2, 619339 (3), ; ?cocoon syndrome, 613630 (3),
IKK-beta	AR,AD	immunodeficiency 15b, 615592 (3), ; immunodeficiency 15a, 618204 (3),
IKK-gamma	XLD,XLR,XL	incontinentia pigmenti, 308300 (3), ; ectodermal dysplasia and immunodeficiency 1, 300291 (3), ; immunodeficiency 33, 300636 (3), ; autoinflammatory disease, systemic, 301081 (3),
IKK-i		
IKK1	AR	?popliteal pterygium syndrome, bartsocas-papas type 2, 619339 (3), ; ?cocoon syndrome, 613630 (3),
IKK2	AR,AD	immunodeficiency 15b, 615592 (3), ; immunodeficiency 15a, 618204 (3),
IKKA	AR	?popliteal pterygium syndrome, bartsocas-papas type 2, 619339 (3), ; ?cocoon syndrome, 613630 (3),
IKKAP1	XLD,XLR,XL	incontinentia pigmenti, 308300 (3), ; ectodermal dysplasia and immunodeficiency 1, 300291 (3), ; immunodeficiency 33, 300636 (3), ; autoinflammatory disease, systemic, 301081 (3),
IKKB	AR,AD	immunodeficiency 15b, 615592 (3), ; immunodeficiency 15a, 618204 (3),
IKKE		
IKKG	XLD,XLR,XL	incontinentia pigmenti, 308300 (3), ; ectodermal dysplasia and immunodeficiency 1, 300291 (3), ; immunodeficiency 33, 300636 (3), ; autoinflammatory disease, systemic, 301081 (3),
IKLF		
IKZF1	AD	immunodeficiency, common variable, 13, 616873 (3),
IKZF2		
IKZF3	AD	?immunodeficiency 84, 619437 (3),
IKZF4		
IKZF5	AD	thrombocytopenia, 7, 619130 (3),
IL-10		{rheumatoid arthritis, progression of}, 180300 (3); {graft-versus-host disease, protection against}, 614395 (3); {hiv-1, susceptibility to}, 609423 (3)
IL-10C		
IL-10R2	AR	{hepatitis b virus, susceptibility to}, 610424 (3); inflammatory bowel disease 25, early onset, 612567 (3),
IL-11		
IL-12A		
IL-12B	AR	immunodeficiency 29, mycobacteriosis, 614890 (3),
IL-13	AD	{asthma, susceptibility to}, 600807 (3), ; {allergic rhinitis, susceptibility to}, 607154 (3)
IL-13R		
IL-13Ra		
IL-15		
IL-15RA		
IL-16		
IL-17		
IL-17A		
IL-17B		
IL-17C		
IL-17D		
IL-17E		
IL-17F	AD	?candidiasis, familial, 6, 613956 (3)
IL-17RA	AR	immunodeficiency 51, 613953 (3),
IL-17RD	AR,AD	hypogonadotropic hypogonadism 18 with or without anosmia, 615267 (3), digenic ,
IL-18		
IL-19		
IL-1A		
IL-1B		{gastric cancer risk after h. pylori infection}, 613659 (3)
IL-1F10		
IL-1F5	AR	psoriasis 14, pustular, 614204 (3),
IL-1F6		
IL-1F7	AR	?inflammatory bowel disease (infantile ulcerative colitis) 31, 619398 (3),
IL-1F8		
IL-1F9		
IL-1g		
IL-1H1		
IL-1H2		
IL-1H4	AR	?inflammatory bowel disease (infantile ulcerative colitis) 31, 619398 (3),
IL-1HY2		
IL-1R8		
IL-1R9		
IL-1Ra	AR	[interleukin 6, serum level of, qtl], 614752 (3); hyper-ige recurrent infection syndrome 5, 618944 (3), ; [interleukin-6 receptor, soluble, serum level of, qtl], 614689 (3)
IL-1RAcP		
IL-1RAcPIP		
IL-1RN	AR	{gastric cancer risk after h. pylori infection}, 613659 (3); {microvascular complications of diabetes 4}, 612628 (3); interleukin 1 receptor antagonist deficiency, 612852 (3),
IL-1RP1	AR	?inflammatory bowel disease (infantile ulcerative colitis) 31, 619398 (3),
IL-1RP2		
IL-1Rrp		
IL-2		
IL-20		
IL-20R1		
IL-20R2		
IL-21	AR	?immunodeficiency, common variable, 11, 615767 (3),
IL-22		
IL-22BP		
IL-23		
IL-23A		
IL-23R		{inflammatory bowel disease 17, protection against}, 612261 (3); {psoriasis, protection against}, 605606 (3)
IL-24		
IL-25		
IL-26		
IL-27		
IL-27A		
IL-27R		
IL-28A		
IL-28B		{hepatitis c virus infection, response to therapy of}, 609532 (3)
IL-28R1		
IL-29		
IL-3		
IL-31		
IL-31RA	AD	?amyloidosis, primary localized cutaneous, 2, 613955 (3),
IL-34		
IL-36R		
IL-4		
IL-4-STAT		
IL-5		
IL-6	AD,AR,MF	{type 2 diabetes mellitus}, 125853 (3), ; {rheumatoid arthritis, systemic juvenile}, 604302 (3); {intracranial hemorrhage in brain cerebrovascular malformations, susceptibility to}, 108010 (3), somatic mutation; {type 1 diabetes mellitus}, 222100 (3), ; {crohn disease-associated growth failure}, 266600 (3), ; {kaposi sarcoma, susceptibility to}, 148000 (3),
IL-6R	AR	[interleukin 6, serum level of, qtl], 614752 (3); hyper-ige recurrent infection syndrome 5, 618944 (3), ; [interleukin-6 receptor, soluble, serum level of, qtl], 614689 (3)
IL-6RB	AR,AD	stuve-wiedemann syndrome 2, 619751 (3), ; hyper-ige recurrent infection syndrome 4a, 619752 (3), ; ?immunodeficiency 94 with autoinflammation and dysmorphic facies, 619750 (3), ; hyper-ige recurrent infection syndrome 4b, 618523 (3),
IL-7	AR	{?epidermodysplasia verruciformis, susceptibility to, 5}, 618309 (3),
IL-7Ralpha	AR	immunodeficiency 104, severe combined, 608971 (3),
IL-8		
IL-9		
IL-D110		
IL-TIF		
il-TMP		
IL1		
IL1-ALPHA		
IL1-BETA		{gastric cancer risk after h. pylori infection}, 613659 (3)
IL1-ETA		
IL1-theta		
IL1(EPSILON)		
IL10		{rheumatoid arthritis, progression of}, 180300 (3); {graft-versus-host disease, protection against}, 614395 (3); {hiv-1, susceptibility to}, 609423 (3)
IL10A		{rheumatoid arthritis, progression of}, 180300 (3); {graft-versus-host disease, protection against}, 614395 (3); {hiv-1, susceptibility to}, 609423 (3)
IL10B		
IL10D		
IL10R	AR	inflammatory bowel disease 28, early onset, 613148 (3),
IL10RA	AR	inflammatory bowel disease 28, early onset, 613148 (3),
IL10RB	AR	{hepatitis b virus, susceptibility to}, 610424 (3); inflammatory bowel disease 25, early onset, 612567 (3),
IL11		
IL11RA	AR	craniosynostosis and dental anomalies, 614188 (3),
IL12A		
IL12B	AR	immunodeficiency 29, mycobacteriosis, 614890 (3),
IL12RB	AR	immunodeficiency 30, 614891 (3),
IL12RB1	AR	immunodeficiency 30, 614891 (3),
IL12RB2		
IL13	AD	{asthma, susceptibility to}, 600807 (3), ; {allergic rhinitis, susceptibility to}, 607154 (3)
IL13BP		
IL13RA1		
IL13RA2		
IL15		
IL15RA		
IL15RB	AR	immunodeficiency 63 with lymphoproliferation and autoimmunity, 618495 (3),
IL16		
IL17		
IL17-RL	AR	candidiasis, familial, 9, 616445 (3),
IL17A		
IL17B		
IL17BR		
IL17C		
IL17D		
IL17E		
IL17F	AD	?candidiasis, familial, 6, 613956 (3)
IL17R	AR	immunodeficiency 51, 613953 (3),
IL17RA	AR	immunodeficiency 51, 613953 (3),
IL17RB		
IL17RC	AR	candidiasis, familial, 9, 616445 (3),
IL17RD	AR,AD	hypogonadotropic hypogonadism 18 with or without anosmia, 615267 (3), digenic ,
IL17RE		
IL17REL		
IL17RH1		
IL17RLM	AR,AD	hypogonadotropic hypogonadism 18 with or without anosmia, 615267 (3), digenic ,
IL18		
IL18BP	AR	{?hepatitis, fulminant viral, susceptibility to}, 618549 (3),
IL18BPa	AR	{?hepatitis, fulminant viral, susceptibility to}, 618549 (3),
IL18R1		
IL18RAP		
IL19		
IL1A		
IL1B		{gastric cancer risk after h. pylori infection}, 613659 (3)
IL1BC		
IL1E		
IL1F1		
IL1F10		
IL1F11		
IL1F2		{gastric cancer risk after h. pylori infection}, 613659 (3)
IL1F3	AR	{gastric cancer risk after h. pylori infection}, 613659 (3); {microvascular complications of diabetes 4}, 612628 (3); interleukin 1 receptor antagonist deficiency, 612852 (3),
IL1F4		
IL1F5	AR	psoriasis 14, pustular, 614204 (3),
IL1F6		
IL1F7	AR	?inflammatory bowel disease (infantile ulcerative colitis) 31, 619398 (3),
IL1F8		
IL1F9		
IL1H1		
IL1H2		
IL1HY1	AR	psoriasis 14, pustular, 614204 (3),
IL1L1	AR	psoriasis 14, pustular, 614204 (3),
IL1R		
IL1R-rp2		
IL1R1		
IL1R2		
IL1R3		
IL1R8	XL,XLR	intellectual developmental disorder, 21, 300143 (3),
IL1R9		
IL1RA	AR	{gastric cancer risk after h. pylori infection}, 613659 (3); {microvascular complications of diabetes 4}, 612628 (3); interleukin 1 receptor antagonist deficiency, 612852 (3),
IL1RAP		
IL1RAPL	XL,XLR	intellectual developmental disorder, 21, 300143 (3),
IL1RAPL-2		
IL1RAPL1	XL,XLR	intellectual developmental disorder, 21, 300143 (3),
IL1RAPL2		
IL1RB		
IL1RL1		
Il1rl1l		
IL1RL1LG		
IL1RL2		
IL1RN	AR	{gastric cancer risk after h. pylori infection}, 613659 (3); {microvascular complications of diabetes 4}, 612628 (3); interleukin 1 receptor antagonist deficiency, 612852 (3),
IL1RP3	AR	psoriasis 14, pustular, 614204 (3),
IL1RRP		
IL1RRP2		
IL2		
IL20		
IL20RA		
IL20RB		
IL21	AR	?immunodeficiency, common variable, 11, 615767 (3),
IL21R	AD,AR	[ige, elevated level of], 147050 (3), ; immunodeficiency 56, 615207 (3),
IL22		
IL22R		
IL22RA1		
IL22RA2		
IL23A		
IL23P19		
IL23R		{inflammatory bowel disease 17, protection against}, 612261 (3); {psoriasis, protection against}, 605606 (3)
IL24		
IL25		
IL26		
IL27		
IL27A		
IL27B		
IL27p28		
IL27RA		
IL27w		
IL28A		
IL28B		{hepatitis c virus infection, response to therapy of}, 609532 (3)
IL28C		{hepatitis c virus infection, response to therapy of}, 609532 (3)
IL28RA		
IL29		
IL2R	AR	immunodeficiency 41 with lymphoproliferation and autoimmunity, 606367 (3), ; {diabetes, mellitus, insulin-dependent, susceptibility to, 10}, 601942 (3)
IL2RA	AR	immunodeficiency 41 with lymphoproliferation and autoimmunity, 606367 (3), ; {diabetes, mellitus, insulin-dependent, susceptibility to, 10}, 601942 (3)
IL2RB	AR	immunodeficiency 63 with lymphoproliferation and autoimmunity, 618495 (3),
IL2RG	XL,XLR	combined immunodeficiency, moderate, 312863 (3), ; severe combined immunodeficiency, 300400 (3),
IL3		
IL30		
IL31		
IL31RA	AD	?amyloidosis, primary localized cutaneous, 2, 613955 (3),
IL32		
IL33		
IL33R		
IL34		
IL35B		
IL36A		
IL36B		
IL36G		
IL36RA	AR	psoriasis 14, pustular, 614204 (3),
IL36RN	AR	psoriasis 14, pustular, 614204 (3),
IL37	AR	?inflammatory bowel disease (infantile ulcerative colitis) 31, 619398 (3),
IL3BP1		
IL3RA		
IL3RB	AR	surfactant metabolism dysfunction, pulmonary, 5, 614370 (3),
IL4		
IL4I1		
IL4R	AD	{aids, slow progression to}, 609423 (3); {atopy, susceptibility to}, 147050 (3),
IL5		
IL5R		
IL5RA		
IL5RB	AR	surfactant metabolism dysfunction, pulmonary, 5, 614370 (3),
IL6	AD,AR,MF	{type 2 diabetes mellitus}, 125853 (3), ; {rheumatoid arthritis, systemic juvenile}, 604302 (3); {intracranial hemorrhage in brain cerebrovascular malformations, susceptibility to}, 108010 (3), somatic mutation; {type 1 diabetes mellitus}, 222100 (3), ; {crohn disease-associated growth failure}, 266600 (3), ; {kaposi sarcoma, susceptibility to}, 148000 (3),
IL6DBP		
IL6R	AR	[interleukin 6, serum level of, qtl], 614752 (3); hyper-ige recurrent infection syndrome 5, 618944 (3), ; [interleukin-6 receptor, soluble, serum level of, qtl], 614689 (3)
IL6RA	AR	[interleukin 6, serum level of, qtl], 614752 (3); hyper-ige recurrent infection syndrome 5, 618944 (3), ; [interleukin-6 receptor, soluble, serum level of, qtl], 614689 (3)
IL6ST	AR,AD	stuve-wiedemann syndrome 2, 619751 (3), ; hyper-ige recurrent infection syndrome 4a, 619752 (3), ; ?immunodeficiency 94 with autoinflammation and dysmorphic facies, 619750 (3), ; hyper-ige recurrent infection syndrome 4b, 618523 (3),
IL6ST2		
IL7	AR	{?epidermodysplasia verruciformis, susceptibility to, 5}, 618309 (3),
IL7R	AR	immunodeficiency 104, severe combined, 608971 (3),
IL7RA	AR	immunodeficiency 104, severe combined, 608971 (3),
IL7Ralpha	AR	immunodeficiency 104, severe combined, 608971 (3),
IL8		
IL8RA		{aids, slow progression to}, 609423 (3)
IL8RB	AR	?whim syndrome 2, 619407 (3),
IL9		
IL9R		
ILA	AR	immunodeficiency 109 with lymphoproliferation, 620282 (3),
ILBP		
ILBP3		
ILC		
ILDR1	AR	deafness, 42, 609646 (3),
ILDR2		
ILDR3		
ILEI		
ILF		
ILF1		
ILF2		
ILF3		
ILF3L		
ILK		
ILKAP		
ILLBP		
ILP-1	XL,XLR	lymphoproliferative syndrome, 2, 300635 (3),
ILPIP		
ILPIPA		
ILRS	AR	growth retardation, impaired intellectual development, hypotonia, and hepatopathy, 617093 (3),
ILRUN		
ILT1		
ILT11		
ILT2		
ILT3		
ILT4		
ILT5		
ILT6		
ILT7		
ILTIF		
ILV1		
ILV2H		
ILVASC	AR	ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis, 607626 (3),
ILVBL		
ILWEQ		
IMAC		
IMAGE:4827585		
IMAGE:4839025		
IMAGE:4942737	AR	raine syndrome, 259775 (3),
IMAGE:5164497		
IMAGE50150		
IMAGE5767589		
IMAP1		
IMAP2		
IMAP38		
IMAP4		
IMB1		
IMB3		
IMD1	XL,XLR	agammaglobulinemia, 1, 300755 (3), ; isolated growth hormone deficiency, type iii, with agammaglobulinemia, 307200 (3),
IMD2	XLR,XL	wiskott-aldrich syndrome, 301000 (3), ; neutropenia, severe congenital, 300299 (3), ; thrombocytopenia, intermittent, 313900 (3), ; thrombocytopenia, 313900 (3),
IMD3	XL,XLR	immunodeficiency, with hyper-igm, 308230 (3),
IMD4	XL,XLR	combined immunodeficiency, moderate, 312863 (3), ; severe combined immunodeficiency, 300400 (3),
IMD5	XL,XLR	lymphoproliferative syndrome, 1, 308240 (3),
IMINO		
IMMP1		
IMMP1L		
IMMP2L		
IMMP2L-IT1		
IMMT		
IMOGN38		
IMP		
IMP-1		
IMP-2	AD	{diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3),
IMP-3		
IMP1		
IMP13		
IMP2		
IMP3	AR	immunodeficiency 86, mycobacteriosis, 619549 (3),
IMP4		
IMP5		
Imp7		
IMP8	AR	viss syndrome, 619472 (3),
IMPA	AR	intellectual developmental disorder, 59, 617323 (3),
IMPA1	AR	intellectual developmental disorder, 59, 617323 (3),
IMPA2		
IMPA3	AR	chondrodysplasia with joint dislocations, gpapp type, 614078 (3),
IMPACT		
IMPAD1	AR	chondrodysplasia with joint dislocations, gpapp type, 614078 (3),
IMPAS		
IMPCHASE	AR	aica-ribosiduria due to atic deficiency, 608688 (3),
IMPDH1	AD	retinitis pigmentosa 10, 180105 (3), ; leber congenital amaurosis 11, 613837 (3),
IMPDH2		[impdh2 enzyme activity, variation in], 617995 (3)
IMPG1	AR,AD	macular dystrophy, vitelliform, 4, 616151 (3), ; retinitis pigmentosa 91, 153870 (3),
IMPG2	AR,AD	retinitis pigmentosa 56, 613581 (3), ; macular dystrophy, vitelliform, 5, 616152 (3),
Impnb		
IMPT1		breast cancer, somatic, 114480 (3); lung cancer, somatic, 211980 (3); rhabdomyosarcoma, somatic, 268210 (3)
IMUP		
IMUP-1		
IMUP-2		
IMYPNO		
IN		[blood group, indian system], 609027 (3)
INA		
INAC		
INADL		
INAG1		
INAM		
INAP		
iNAT		
INAVA	AD	{inflammatory bowel disease 29}, 618077 (3),
INCA		
INCA1		
INCENP		
INCL	AR	ceroid lipofuscinosis, neuronal, 1, 256730 (3),
IND1	AR	mitochondrial complex i deficiency, nuclear type 21, 618242 (3),
INDO		
INDOL1		
INDY	AR	developmental and epileptic encephalopathy 25, with amelogenesis imperfecta, 615905 (3),
INE1		
INE2		
INF	AR	intrinsic factor deficiency, 261000 (3),
INF1		
INF2	AD	glomerulosclerosis, focal segmental, 5, 613237 (3); charcot-marie-tooth disease, intermediate e, 614455 (3),
ING1		squamous cell carcinoma, head and neck, somatic, 275355 (3)
ING1-like		
ING1L		
ING2		
ING3		
ING4		
ING5		
INGX		
INHA		
INHBA		
INHBB		
INHBC		
INHBE		
INHBP	XLR,XL	hypothyroidism, central, and testicular enlargement, 300888 (3),
Inhibitor-1-like		
INI		
INI-1	AD	rhabdoid tumors, somatic, 609322 (3); {schwannomatosis-1, susceptibility to}, 162091 (3), ; coffin-siris syndrome 3, 614608 (3), ; {rhabdoid tumor predisposition syndrome 1}, 609322 (3),
Ini1	AD	rhabdoid tumors, somatic, 609322 (3); {schwannomatosis-1, susceptibility to}, 162091 (3), ; coffin-siris syndrome 3, 614608 (3), ; {rhabdoid tumor predisposition syndrome 1}, 609322 (3),
INIP		
INK4	AD	{melanoma and neural system tumor syndrome}, 155755 (3), ; {melanoma, cutaneous malignant, 2}, 155601 (3), ; {melanoma-pancreatic cancer syndrome}, 606719 (3),
INK4a	AD	{melanoma and neural system tumor syndrome}, 155755 (3), ; {melanoma, cutaneous malignant, 2}, 155601 (3), ; {melanoma-pancreatic cancer syndrome}, 606719 (3),
INK4B		
INK4C		
INK4D		
INKA2		
INM01		
INM02	AR	neurodevelopmental disorder with dysmorphic facies and variable seizures, 619264 (3),
INMT		
Ino1		
INO80		
INO80A		
INO80B		
INO80D		
INO80F		
INO80G		
INO80H		
INO80J		
INO80K		
INO80M		
INO80N		
INO80Q		
INO80R		
INO80S	AD	gabriele-de vries syndrome, 617557 (3),
INOC1		
iNOS		{malaria, resistance to}, 611162 (3)
INOS		
INP10		
INPE5792		
INPP1		
INPP4		
INPP4A		
INPP4B		
INPP5		
INPP5A		
INPP5B		
INPP5D		
INPP5E	AR,AR	joubert syndrome 1, 213300 (3), ; mental retardation, truncal obesity, retinal dystrophy, and micropenis, 610156 (3), |spinocerebellar ataxia, 2, 213200 (3),
INPP5F		
INPP5G	AR	parkinson disease 20, early-onset, 615530 (3), ; developmental and epileptic encephalopathy 53, 617389 (3),
INPP5H		
INPP5J		
INPP5K	AR	muscular dystrophy, congenital, with cataracts and intellectual disability, 617404 (3),
INPPL1	AR	opsismodysplasia, 258480 (3),
INrf2		
INS	AD,AR	diabetes mellitus, insulin-dependent, 2, 125852 (3), ; maturity-onset diabetes of the young, type 10, 613370 (3), ; hyperproinsulinemia, 616214 (3), ; diabetes mellitus, permanent neonatal 4, 618858 (3),
INS-1		
INSC		
INSIG1		
INSIG2		
INSL3	AD	cryptorchidism, 219050 (3),
INSL3R		
INSL4		
INSL5		
INSL6		
INSM1		
INSM2		
Insp3r1	AR,AD	gillespie syndrome, 206700 (3), ; spinocerebellar ataxia 29, congenital nonprogressive, 117360 (3), ; spinocerebellar ataxia 15, 606658 (3),
INSP5K2		
INSP6K3		
INSR	AR,AD	rabson-mendenhall syndrome, 262190 (3), ; diabetes mellitus, insulin-resistant, with acanthosis nigricans, 610549 (3); donohue syndrome, 246200 (3), ; hyperinsulinemic hypoglycemia, familial, 5, 609968 (3),
INSRR		
INSSA1		
INSYN1		
INSYN2		
INSYN2A		
INT1	AD,AR,AR	{osteoporosis, early-onset, susceptibility to, }, 615221 (3), ; osteogenesis imperfecta, type xv, 615220 (3), |neurodevelopmental disorder with cataracts, poor growth, and dysmorphic facies, 618571 (3),
INT10		
INT11		
INT12		
INT1L1		
INT2	AR	deafness, congenital with inner ear agenesis, microtia, and microdontia, 610706 (3),
INT3		
INT4	AR	?tetra-amelia syndrome 1, 273395 (3),
INT5		
INT6		
INT7		
INT8	AR	?neurodevelopmental disorder with cerebellar hypoplasia and spasticity, 618572 (3),
INTS1	AR	neurodevelopmental disorder with cataracts, poor growth, and dysmorphic facies, 618571 (3),
INTS10		
INTS11		
INTS12		
INTS13		
INTS2		
INTS3		
INTS4		
INTS5		
INTS6		
INTS7		
INTS8	AR	?neurodevelopmental disorder with cerebellar hypoplasia and spasticity, 618572 (3),
INTS9		
INTU	AR	?orofaciodigital syndrome xvii, 617926 (3), ; ?short-rib thoracic dysplasia 20 with polydactyly, 617925 (3),
INVS	AR	nephronophthisis 2, infantile, 602088 (3),
IOP1		
IOP2		
IOPPP		
IOSCA	AR,AD	mitochondrial dna depletion syndrome 7 (hepatocerebral type), 271245 (3), ; progressive external ophthalmoplegia with mitochondrial dna deletions, 3, 609286 (3), ; perrault syndrome 5, 616138 (3),
IOTA		{myocardial infarction, susceptibility to}, 608446 (3)
IP		
IP-10		
IP-30		
IP-9		
IP1	XLD,XLR,XL	incontinentia pigmenti, 308300 (3), ; ectodermal dysplasia and immunodeficiency 1, 300291 (3), ; immunodeficiency 33, 300636 (3), ; autoinflammatory disease, systemic, 301081 (3),
IP10-R		
IP2	XLD,XLR,XL	incontinentia pigmenti, 308300 (3), ; ectodermal dysplasia and immunodeficiency 1, 300291 (3), ; immunodeficiency 33, 300636 (3), ; autoinflammatory disease, systemic, 301081 (3),
IP3-3KA		
IP3-3KB		
IP3-3KC		
IP30		
IP3KA		
IP3KB		
IP3KC		
IP3R1	AR,AD	gillespie syndrome, 206700 (3), ; spinocerebellar ataxia 29, congenital nonprogressive, 117360 (3), ; spinocerebellar ataxia 15, 606658 (3),
IP3R2	AR	?anhidrosis, isolated, with normal sweat glands, 106190 (3),
IP3R3	AD,AR	charcot-marie-tooth disease, demyelinating, type 1j, 620111 (3), ; {diabetes, type 1, susceptibility to}, 222100 (2),
IP5K		
IP6K1		
IP6K2		
IP6K3		
IP90		
iPABP		
ipaf	AD	?familial cold autoinflammatory syndrome 4, 616115 (3), ; autoinflammation with infantile enterocolitis, 616050 (3),
IPAS		
IPCA-1		
IPCA-2		
IPCA-5		
IPCA-6		
IPCA-7		
IPCA-8		
IPCEF1		
IPEX	XL,XLR	immunodysregulation, polyendocrinopathy, and enteropathy, 304790 (3),
IPF1	AD,AR	{diabetes mellitus, type ii, susceptibility to}, 125853 (3), ; pancreatic agenesis 1, 260370 (3), ; mody, type iv, 606392 (3)
Ipi1		
Ipi3		
IPIA-ALPHA		
IPIP27A		
IPIP27B		
IPK1		
IPL		
IPL1		
iPLA1Ã		
iPLA1alpha	AR	spastic paraplegia 28, 609340 (3),
iPLA1beta		
iPLA1gamma	AR	spastic paraplegia 54, 615033 (3),
iPLA2	AR	parkinson disease 14, 612953 (3), ; neurodegeneration with brain iron accumulation 2b, 610217 (3), ; infantile neuroaxonal dystrophy 1, 256600 (3),
IPLA2-2	AR	?mitochondrial myopathy with lactic acidosis, 251950 (3),
iPLA2beta	AR	parkinson disease 14, 612953 (3), ; neurodegeneration with brain iron accumulation 2b, 610217 (3), ; infantile neuroaxonal dystrophy 1, 256600 (3),
iPLA2delta	AR	spastic paraplegia 39, 612020 (3), ; oliver-mcfarlane syndrome, 275400 (3), ; ?laurence-moon syndrome, 245800 (3), ; boucher-neuhauser syndrome, 215470 (3),
iPLA2epsilon		
iPLA2eta		
IPLA2G	AR	?mitochondrial myopathy with lactic acidosis, 251950 (3),
iPLA2gamma	AR	?mitochondrial myopathy with lactic acidosis, 251950 (3),
iPLA2zeta	AR	neutral lipid storage disease with myopathy, 610717 (3),
IPM150	AR,AD	macular dystrophy, vitelliform, 4, 616151 (3), ; retinitis pigmentosa 91, 153870 (3),
IPM200	AR,AD	retinitis pigmentosa 56, 613581 (3), ; macular dystrophy, vitelliform, 5, 616152 (3),
IPMK		
IPO1		
IPO11		
IPO12	AD	muscular dystrophy, limb-girdle, 2, 608423 (3),
IPO13		
IPO2		
IPO3	AD	intellectual developmental disorder with hypotonia, impaired speech, and dysmorphic facies, 619556 (3),
IPO5		
IPO7		
IPO8	AR	viss syndrome, 619472 (3),
IPOA	AR,AD	spastic tetraplegia and axial hypotonia, progressive, 618598 (3), ; amyotrophic lateral sclerosis 1, 105400 (3),
IPOA1		
IPOA3		
IPOA4	AD	spastic paraplegia 88, 620106 (3),
IPOA5		
IPOA6		
IPOA7		
IPOA8	AR	oocyte/zygote/embryo maturation arrest 17, 620319 (3),
IPOB		{microvascular complications of diabetes 6}, 612634 (3)
IPP		
IPP2		
IPP2A2	AD	intellectual developmental disorder, 58, 618106 (3),
IPPI2		
IPPK		
IPS		
IPS-1		
IPS1		
IPT	AR	combined oxidative phosphorylation deficiency 35, 617873 (3),
IPW		
IQ-ArfGEF	XL,XLD	intellectual developmental disorder, 1, 309530 (3),
IQANK1		
IQCB1	AR	senior-loken syndrome 5, 609254 (3),
IQCE	AR	polydactyly, postaxial, type a7, 617642 (3),
IQCG		
IQCH		
IQCJ		
IQCN	AR	spermatogenic failure 78, 620170 (3),
IQGAP1		
IQGAP2		
IQSEC1	AR	intellectual developmental disorder with short stature and behavioral abnormalities, 618687 (3),
IQSEC2	XL,XLD	intellectual developmental disorder, 1, 309530 (3),
IQSEC3		
IQWD1		
IR10		
IR20		
IR2155535		
IRA1	AD	intellectual developmental disorder, 41, 616944 (3), ; pierpont syndrome, 602342 (3),
IRAG		
IRAG1		
IRAG2		
IRAIN		
IRAK		
IRAK-M		{asthma susceptibility 5}, 611064 (3)
IRAK1		
IRAK1BP1		
IRAK2		
IRAK3		{asthma susceptibility 5}, 611064 (3)
IRAK4	AR	immunodeficiency 67, 607676 (3),
IRAP	AR	{gastric cancer risk after h. pylori infection}, 613659 (3); {microvascular complications of diabetes 4}, 612628 (3); interleukin 1 receptor antagonist deficiency, 612852 (3),
IRAS		
IRAV		
IRBIT		
IRBIT2		
IRBP	AR	?retinitis pigmentosa 66, 615233 (3),
IRC1		
IRC2		
IRE1		
IRE1b		
IRE1P		
IREB1		
IREB2	AR	neurodegeneration, early-onset, with choreoathetoid movements and microcytic anemia, 618451 (3),
IREBP		
IREG1	AD	hemochromatosis, type 4, 606069 (3),
IREM1		
IREM2		
IRF		
IRF-2BP1		
IRF-2BP2	AD	?immunodeficiency, common variable, 14, 617765 (3),
IRF-5		{inflammatory bowel disease 14}, 612245 (3); {systemic lupus erythematosus, susceptibility to, 10}, 612251 (3)
IRF-8	AD,AR	immunodeficiency 32a, mycobacteriosis, 614893 (3), ; immunodeficiency 32b, monocyte and dendritic cell deficiency, 226990 (3),
IRF1		nonsmall cell lung cancer, somatic, 211980 (3); myelodysplastic syndrome, preleukemic (3); gastric cancer, somatic, 613659 (3); myelogenous leukemia, acute (3)
IRF2		
IRF2BP1		
IRF2BP2	AD	?immunodeficiency, common variable, 14, 617765 (3),
IRF2BPL	AD	neurodevelopmental disorder with regression, abnormal movements, loss of speech, and seizures, 618088 (3),
IRF3	AD	{encephalopathy, acute, infection-induced (herpes-specific), susceptibility to, 7}, 616532 (3),
IRF4		[skin/hair/eye pigmentation, variation in, 8], 611724 (3)
IRF5		{inflammatory bowel disease 14}, 612245 (3); {systemic lupus erythematosus, susceptibility to, 10}, 612251 (3)
IRF6	AD	{orofacial cleft 6}, 608864 (3), ; popliteal pterygium syndrome 1, 119500 (3), ; van der woude syndrome 1, 119300 (3),
IRF7	AR	?immunodeficiency 39, 616345 (3),
IRF8	AD,AR	immunodeficiency 32a, mycobacteriosis, 614893 (3), ; immunodeficiency 32b, monocyte and dendritic cell deficiency, 226990 (3),
IRF9	AR	immunodeficiency 65, susceptibility to viral infections, 618648 (3),
IRG1		
IRG2		
IRGM		{mycobacterium tuberculosis, protection against}, 607948 (3); {inflammatory bowel disease (crohn disease) 19}, 612278 (3)
IRGM1		{mycobacterium tuberculosis, protection against}, 607948 (3); {inflammatory bowel disease (crohn disease) 19}, 612278 (3)
iRhom1		
iRhom2	AD	tylosis with esophageal cancer, 148500 (3),
IRID1	AD	axenfeld-rieger syndrome, type 3, 602482 (3), ; anterior segment dysgenesis 3, multiple subtypes, 601631 (3),
IRID2	AD	ring dermoid of cornea, 180550 (3), ; axenfeld-rieger syndrome, type 1, 180500 (3), ; anterior segment dysgenesis 4, 137600 (3),
IRIP	AR	galloway-mowat syndrome 10, 619609 (3),
IRIZIO		
IRK1	AD	atrial fibrillation, familial, 9, 613980 (3), ; andersen syndrome, 170390 (3), ; short qt syndrome 3, 609622 (3)
IRK2		
IRK3		
IRK4		
IRKK		
IRLB		
Irm		
IRP		
IRP1		
IRP2	AR	neurodegeneration, early-onset, with choreoathetoid movements and microcytic anemia, 618451 (3),
Irp60		
IRR		
IRS-4	XLR,XL	hypothyroidism, congenital, nongoitrous, 9, 301035 (3),
IRS1	AD	{type 2 diabetes mellitus, susceptibility to}, 125853 (3), ; {coronary artery disease, susceptibility to} (3)
IRS2	AD	{diabetes mellitus, noninsulin-dependent}, 125853 (3),
IRS4	XLR,XL	hypothyroidism, congenital, nongoitrous, 9, 301035 (3),
IRSp53		
IRT-1		
IRT1		
IRTA1		
IRTA2		
IRTA3		
IRTA4		
IRTA5		
IRTKS		
IRX-1		
IRX-2a	AR	hamamy syndrome, 611174 (3),
IRX-3		
IRX-5		
IRX1		
IRX2		
IRX2-DT		
IRX2NB		
IRX3		
IRX4		
IRX5	AR	hamamy syndrome, 611174 (3),
IRX6		
IRX7		
IRXL1		
IRZ		
IS1-RNPL		
ISA1	AR	multiple mitochondrial dysfunctions syndrome 5, 617613 (3),
ISA2	AR	multiple mitochondrial dysfunctions syndrome 4, 616370 (3),
ISBT	AR	?bile acid malabsorption, primary, 1, 613291 (3),
ISC1		
ISCA1	AR	multiple mitochondrial dysfunctions syndrome 5, 617613 (3),
ISCA2	AR	multiple mitochondrial dysfunctions syndrome 4, 616370 (3),
IscS	AR	combined oxidative phosphorylation deficiency 52, 619386 (3),
ISCU	AR	myopathy with lactic acidosis, hereditary, 255125 (3),
ISD11	AR	?combined oxidative phosphorylation deficiency 19, 615595 (3),
ISG-54		
ISG-54K		
ISG12		
ISG15	AR	immunodeficiency 38, 616126 (3),
ISG20		
ISG20L1		
ISG20L2		
ISG56		
ISG60		
ISG95		
ISGF-3	AD,AR	immunodeficiency 31c, chronic mucocutaneous candidiasis, 614162 (3), ; immunodeficiency 31a, mycobacteriosis, 614892 (3), ; immunodeficiency 31b, mycobacterial and viral infections, 613796 (3),
ISGF3G	AR	immunodeficiency 65, susceptibility to viral infections, 618648 (3),
IsK	AR,AD	jervell and lange-nielsen syndrome 2, 612347 (3), ; long qt syndrome 5, 613695 (3),
Isl-1		
ISL1		
ISL2		
ISLET1		
ISLR		
ISLR2		
ISM1		
ISM2		
ISO1		
ISOC2		
IsoT		
IsoT-3		
IspD	AR	muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 7, 616052 (3), ; muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 7, 614643 (3),
ISPD	AR	muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 7, 616052 (3), ; muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 7, 614643 (3),
ISSD	AR	salla disease, 604369 (3), ; sialic acid storage disorder, infantile, 269920 (3),
ISSX	XL,XLR	proud syndrome, 300004 (3), ; hydranencephaly with abnormal genitalia, 300215 (3), ; partington syndrome, 309510 (3), ; developmental and epileptic encephalopathy 1, 308350 (3), ; lissencephaly, 2, 300215 (3), ; intellectual developmental disorder, 29, 300419 (3),
IST1		
ISU2	AR	myopathy with lactic acidosis, hereditary, 255125 (3),
ISWI		
ISX		
ISY1		
ISYNA1		
IT1		
IT10C3		
IT15	AR,AD	lopes-maciel-rodan syndrome, 617435 (3), ; huntington disease, 143100 (3),
ITAF45		
iTAP		
ITBA1		
ITBA2	XL,XLR	galloway-mowat syndrome 2, 301006 (3),
ITBA4		
ITCH	AR	autoimmune disease, multisystem, with facial dysmorphism, 613385 (3),
ITF		
ITF1	AR,AD	agammaglobulinemia 8b, 619824 (3), ; agammaglobulinemia 8a, 616941 (3),
ITF2	AD	pitt-hopkins syndrome, 610954 (3), ; corneal dystrophy, fuchs endothelial, 3, 613267 (3),
ITFG1		
ITFG2		
ITGA1		
ITGA10		
ITGA11		
ITGA2		
ITGA2B	AR,AD	thrombocytopenia, neonatal alloimmune, bak antigen related (3); glanzmann thrombasthenia 1, 273800 (3), ; bleeding disorder, platelet-type, 16, 187800 (3),
ITGA3	AR	epidermolysis bullosa, junctional 7, with interstitial lung disease and nephrotic syndrome, 614748 (3),
ITGA4		
ITGA4L		
ITGA5		
ITGA6	AR	epidermolysis bullosa, junctional 6, with pyloric atresia, 619817 (3),
ITGA6A	AR	epidermolysis bullosa, junctional 6, with pyloric atresia, 619817 (3),
ITGA6B	AR	epidermolysis bullosa, junctional 6, with pyloric atresia, 619817 (3),
ITGA7	AR	muscular dystrophy, congenital, due to itga7 deficiency, 613204 (3),
ITGA8	AR	renal hypodysplasia/aplasia 1, 191830 (3),
ITGA9		
ITGAD		
ITGAE		
ITGAL		
ITGAM		
ITGAV		
ITGAX		
ITGB1		
ITGB1BP1		
ITGB1BP2		
ITGB1BP3		
ITGB2	AR	leukocyte adhesion deficiency, 116920 (3),
ITGB3	AD,AR	bleeding disorder, platelet-type, 24, 619271 (3); thrombocytopenia, neonatal alloimmune (3); purpura, posttransfusion (3); {myocardial infarction, susceptibility to}, 608446 (3); glanzmann thrombasthenia 2, 619267 (3),
ITGB3BP		
ITGB4	AR	epidermolysis bullosa, junctional 5b, with pyloric atresia, 226730 (3), ; epidermolysis bullosa, junctional 5a, intermediate, 619816 (3),
ITGB4BP		
ITGB5		
ITGB6	AR	amelogenesis imperfecta, type ih, 616221 (3),
ITGB7		
ITGB8		
ITGBL1		
ITI		
ITIH		
ITIH1		
ITIH2		
ITIH3		
ITIH4		
ITIH5		
ITIHL1		
ITIL		
ITILC		
ITK	AR	lymphoproliferative syndrome 1, 613011 (3),
ITLN		
ITLN1		
ITLN2		
ITM		breast cancer, somatic, 114480 (3); lung cancer, somatic, 211980 (3); rhabdomyosarcoma, somatic, 268210 (3)
ITM1	AD,AR	congenital disorder of glycosylation, type iw, 619714 (3), ; congenital disorder of glycosylation, type iw, 615596 (3),
ITM2A		
ITM2B	AD	?retinal dystrophy with inner retinal dysfunction and ganglion cell abnormalities, 616079 (3), ; dementia, familial british, 176500 (3), ; dementia, familial danish, 117300 (3),
ITM2C		
ITM3		
ITPA	AR	[inosine triphosphatase deficiency], 613850 (3); developmental and epileptic encephalopathy 35, 616647 (3),
ITPK1		
ITPKA		
ITPKB		
ITPKC		
ITPR1	AR,AD	gillespie syndrome, 206700 (3), ; spinocerebellar ataxia 29, congenital nonprogressive, 117360 (3), ; spinocerebellar ataxia 15, 606658 (3),
ITPR2	AR	?anhidrosis, isolated, with normal sweat glands, 106190 (3),
ITPR3	AD,AR	charcot-marie-tooth disease, demyelinating, type 1j, 620111 (3), ; {diabetes, type 1, susceptibility to}, 222100 (2),
ITPRID2		
ITPRID3		
ITPRIP		
ITR		
ITSN		
ITSN1		
ITSN2		
IUF-1	AD,AR	{diabetes mellitus, type ii, susceptibility to}, 125853 (3), ; pancreatic agenesis 1, 260370 (3), ; mody, type iv, 606392 (3)
IVD	AR	isovaleric acidemia, 243500 (3),
IVDH	AR	isovaleric acidemia, 243500 (3),
IVF	AD,AR	ventricular fibrillation, familial, 1, 603829 (3); heart block, progressive, type ia, 113900 (3), ; cardiomyopathy, dilated, 1e, 601154 (3), ; heart block, nonprogressive, 113900 (3), ; long qt syndrome 3, 603830 (3), ; sick sinus syndrome 1, 608567 (3), ; brugada syndrome 1, 601144 (3), ; atrial fibrillation, familial, 10, 614022 (3), ; {sudden infant death syndrome, susceptibility to}, 272120 (3),
IVL		
IVNS1ABP	AD	immunodeficiency 70, 618969 (3),
Iwr1	AR	epilepsy, progressive myoclonic, 12, 619191 (3),
IXL		
IYD	AR	thyroid dyshormonogenesis 4, 274800 (3),
IZP6		
IZUMO		
IZUMO1		
IZUMO1R		
IZUMO2		
IZUMO3		
IZUMO4		
J6B7	AR	wrinkly skin syndrome, 278250 (3), ; cutis laxa, type iia, 219200 (3),
JAB	AD	autoinflammatory syndrome, familial, with or without immunodeficiency, 619375 (3),
JAB1		
Jac1	AR	?anemia, sideroblastic, 5, 619523 (3),
JACOP		
JADE-1		
JADE-2		
JADE-3		
JADE1		
JADE2		
JADE3		
JAG1	AD	?deafness, congenital heart defects, and posterior embryotoxon, 617992 (3), ; charcot-marie-tooth disease, axonal, type 2hh, 619574 (3), ; alagille syndrome 1, 118450 (3), ; tetralogy of fallot, 187500 (3),
JAG2	AR	muscular dystrophy, limb-girdle, 27, 619566 (3),
JAGL1	AD	?deafness, congenital heart defects, and posterior embryotoxon, 617992 (3), ; charcot-marie-tooth disease, axonal, type 2hh, 619574 (3), ; alagille syndrome 1, 118450 (3), ; tetralogy of fallot, 187500 (3),
JAGN1	AR	neutropenia, severe congenital, 6, 616022 (3),
JAK-3	AR	scid, t-negative/b-positive type, 600802 (3),
JAK1	AD	autoinflammation, immune dysregulation, and eosinophilia, 618999 (3),
JAK1A	AD	autoinflammation, immune dysregulation, and eosinophilia, 618999 (3),
JAK1B	AD	autoinflammation, immune dysregulation, and eosinophilia, 618999 (3),
JAK2	AD	{budd-chiari syndrome, somatic}, 600880 (3); myelofibrosis, somatic, 254450 (3); erythrocytosis, somatic, 133100 (3); leukemia, acute myeloid, somatic, 601626 (3); thrombocythemia 3, 614521 (3), somatic mutation, ; polycythemia vera, somatic, 263300 (3)
JAK3	AR	scid, t-negative/b-positive type, 600802 (3),
JAK3_HUMAN	AR	scid, t-negative/b-positive type, 600802 (3),
JAKL	AR	scid, t-negative/b-positive type, 600802 (3),
JAKMIP1		
JAKMIP2		
JAKMIP3		
JAM-1		
JAM-2	AR	basal ganglia calcification, idiopathic, 8, 618824 (3),
JAM-3	AR	hemorrhagic destruction of the brain, subependymal calcification, and cataracts, 613730 (3),
JAM-A		
JAM-B	AR	basal ganglia calcification, idiopathic, 8, 618824 (3),
JAM-C	AR	hemorrhagic destruction of the brain, subependymal calcification, and cataracts, 613730 (3),
JAM1		
JAM2	AR	basal ganglia calcification, idiopathic, 8, 618824 (3),
JAM3	AR	hemorrhagic destruction of the brain, subependymal calcification, and cataracts, 613730 (3),
JAM4		
JAMA		
JAMB	AR	basal ganglia calcification, idiopathic, 8, 618824 (3),
JAMC	AR	hemorrhagic destruction of the brain, subependymal calcification, and cataracts, 613730 (3),
JAMIP1		
JAMIP2		
JAML		
JAMP		
JAP3		
JARID1A		
JARID1B	AR	intellectual developmental disorder, 65, 618109 (3),
JARID1C	XL,XLR	intellectual developmental disorder, syndromic, claes-jensen type, 300534 (3),
JARID1D		
JARID2	AD	developmental delay with variable intellectual disability and dysmorphic facies, 620098 (3),
JAW1		
JAW1L		
JAZ		
JAZF1		
JBTS1	AR	joubert syndrome 1, 213300 (3), ; mental retardation, truncal obesity, retinal dystrophy, and micropenis, 610156 (3),
JBTS10	XLR,XL,XLD	simpson-golabi-behmel syndrome, type 2, 300209 (3), ; ?retinitis pigmentosa 23, 300424 (3), ; orofaciodigital syndrome i, 311200 (3), ; joubert syndrome 10, 300804 (3),
JBTS11	AR,AD	short-rib thoracic dysplasia 4 with or without polydactyly, 613819 (3), ; nephronophthisis 12, 613820 (3),
JBTS12	AR	joubert syndrome 12, 200990 (3), ; acrocallosal syndrome, 200990 (3), ; ?hydrolethalus syndrome 2, 614120 (3), ; ?al-gazali-bakalinova syndrome, 607131 (3),
JBTS13	AR	joubert syndrome 13, 614173 (3),
JBTS14	AR	joubert syndrome 14, 614424 (3),
JBTS15	AR	joubert syndrome 15, 614464 (3),
JBTS16	AR	joubert syndrome 16, 614465 (3),
JBTS17	AR	orofaciodigital syndrome vi, 277170 (3), ; joubert syndrome 17, 614615 (3),
JBTS18	AR	joubert syndrome 18, 614815 (3), ; orofaciodigital syndrome iv, 258860 (3),
JBTS19	AR,AD	nephronophthisis 14, 614844 (3), ; joubert syndrome 19, 614844 (3),
JBTS2	AR	joubert syndrome 2, 608091 (3), ; meckel syndrome 2, 603194 (3),
JBTS20	AR	joubert syndrome 20, 614970 (3), ; meckel syndrome 11, 615397 (3),
JBTS21	AR	joubert syndrome 21, 615636 (3),
JBTS22	AR	joubert syndrome 22, 615665 (3),
JBTS23	AR	short-rib thoracic dysplasia 14 with polydactyly, 616546 (3), ; joubert syndrome 23, 616490 (3),
JBTS24	AR	joubert syndrome 24, 616654 (3), ; ?meckel syndrome 8, 613885 (3),
JBTS25	AR	joubert syndrome 25, 616781 (3), ; intellectual developmental disorder, 77, 619988 (3),
JBTS26	AR	joubert syndrome 26, 616784 (3),
JBTS29	AR	orofaciodigital syndrome xvi, 617563 (3), ; meckel syndrome 13, 617562 (3), ; ?joubert syndrome 29, 617562 (3),
JBTS3	AR	joubert syndrome 3, 608629 (3),
JBTS4	AR	joubert syndrome 4, 609583 (3), ; nephronophthisis 1, juvenile, 256100 (3), ; senior-loken syndrome-1, 266900 (3),
JBTS5	AR	leber congenital amaurosis 10, 611755 (3); joubert syndrome 5, 610188 (3), ; senior-loken syndrome 6, 610189 (3), ; ?bardet-biedl syndrome 14, 615991 (3), ; meckel syndrome 4, 611134 (3),
JBTS6	AR	nephronophthisis 11, 613550 (3), ; {bardet-biedl syndrome 14, modifier of}, 615991 (3), ; joubert syndrome 6, 610688 (3), ; meckel syndrome 3, 607361 (3), ; ?rhyns syndrome, 602152 (3), ; coach syndrome 1, 216360 (3),
JBTS7	AR	joubert syndrome 7, 611560 (3), ; meckel syndrome 5, 611561 (3), ; ?coach syndrome 3, 619113 (3),
JBTS8	AR	joubert syndrome 8, 612291 (3),
JBTS9	AR	coach syndrome 2, 619111 (3), ; retinitis pigmentosa 93, 619845 (3), ; meckel syndrome 6, 612284 (3), ; joubert syndrome 9, 612285 (3),
JC8.6		
JCAD		
JCAM		
JCAP	AR	camptodactyly-arthropathy-coxa vara-pericarditis syndrome, 208250 (3),
JCG6		
JCH		
JCHAIN		
JCL-1	XLR,XL	bartter syndrome, type 5, antenatal, transient, 300971 (3),
JCLN		
JCLN1		
JCTN	AR	traboulsi syndrome, 601552 (3),
JDD1		
jdf2	AR	intellectual developmental disorder, 38, 615516 (3), ; [skin/hair/eye pigmentation 1, blond/brown hair], 227220 (3), ; [skin/hair/eye pigmentation 1, blue/nonblue eyes], 227220 (3),
JDP1	AR	hyperphenylalaninemia, mild, non-bh4-deficient, 617384 (3),
JDP2		
JEAP		
JEDI		
JEM-1		
jerky		
JFC1		
JFP11	AR	lipase deficiency, combined, 246650 (3),
JFP7		
JFY1		
JH	AR	hemochromatosis, type 2a, 602390 (3),
JH8		
JHDM1A		
JHDM1B		
JHDM1C		
JHDM1D		
JHDM1E		
JHDM1F	XL,XLR	intellectual developmental disorder, syndromic, siderius type, 300263 (3),
JHDM3A		
JHMD2A		
JHY		
JIK		
JIP-1	AD	{diabetes mellitus, noninsulin-dependent}, 125853 (3),
JIP1	AD	{diabetes mellitus, noninsulin-dependent}, 125853 (3),
JIP2		
JIP3	AD	neurodevelopmental disorder with or without variable brain abnormalities, 618443 (3),
JIP4		
JJAZ1	AD	imagawa-matsumoto syndrome, 618786 (3),
JJJ1	AR	bone marrow failure syndrome 3, 617052 (3),
JJJ3		
JK		[blood group, kidd], 111000 (3)
JK1	AR	neuropathy, hereditary sensory and autonomic, type iib, 613115 (3),
JKAMP		
JKAP		
JKTBP	AD	muscular dystrophy, limb-girdle, 3, 609115 (3),
JLNS1	AD,AR	short qt syndrome 2, 609621 (3), ; atrial fibrillation, familial, 3, 607554 (3), ; long qt syndrome 1, 192500 (3), ; {long qt syndrome 1, acquired, susceptibility to}, 192500 (3), ; jervell and lange-nielsen syndrome, 220400 (3),
JLNS2	AR,AD	jervell and lange-nielsen syndrome 2, 612347 (3), ; long qt syndrome 5, 613695 (3),
JLP		
JM1	XLR,XL	ritscher-schinzel syndrome 2, 300963 (3),
JM11		
JM2	XL,XLR	immunodysregulation, polyendocrinopathy, and enteropathy, 304790 (3),
JM21	XLD,XL	?chondrodysplasia with platyspondyly, distinctive brachydactyly, hydrocephaly, and microphthalmia, 300863 (3),
JM23	XL,XLR	intellectual developmental disorder, 9, 309549 (3),
JM24		
JM3		
JM4		
JM5	XLD,XL	neurodegeneration with brain iron accumulation 5, 300894 (3),
JM8	XL,XLR	cone-rod dystrophy, 3, 300476 (3), ; night blindness, congenital stationary (incomplete), 2a, 300071 (3), ; aland island eye disease, 300600 (3),
JMC8	XL,XLR	cone-rod dystrophy, 3, 300476 (3), ; night blindness, congenital stationary (incomplete), 2a, 300071 (3), ; aland island eye disease, 300600 (3),
JMJ	AD	developmental delay with variable intellectual disability and dysmorphic facies, 620098 (3),
JMJD1		
JMJD10		
JMJD1A		
JMJD1B	AD	diets-jongmans syndrome, 618846 (3),
JMJD1C		
JMJD2		
JMJD2A		
JMJD2B	AD	intellectual developmental disorder, 65, 619320 (3),
JMJD2C		
JMJD2D		
JMJD2E		
JMJD3	AD	neurodevelopmental disorder with coarse facies and mild distal skeletal abnormalities, 618505 (3),
JMJD5		
JMJD6		
JMJD9		
JMS	XLD,XL,XLR	alpha-thalassemia/mental retardation syndrome, 301040 (3), ; alpha-thalassemia myelodysplasia syndrome, somatic, 300448 (3); intellectual disability-hypotonic facies syndrome, 309580 (3),
JMY		
JN		
JNCL	AR	ceroid lipofuscinosis, neuronal, 3, 204200 (3),
JNK		
JNK1		
JNK2		
JNK3		
JNKK1		
Jnkk2		
JOAG1	AD	glaucoma 1a, primary open angle, 137750 (3),
JOS	AD	machado-joseph disease, 109150 (3),
JOSD1		
JOSD2		
JOSD3		
JP-1	AD,AR	?charcot-marie-tooth disease, axonal, type 2k, 607831 (3),
JP-2	AR,AD	cardiomyopathy, dilated, 2e, 619492 (3), ; cardiomyopathy, hypertrophic, 17, 613873 (3),
JP-3	AD	huntington disease-like 2, 606438 (3),
JP-45		
JP3	AD	huntington disease-like 2, 606438 (3),
JPH1	AD,AR	?charcot-marie-tooth disease, axonal, type 2k, 607831 (3),
JPH2	AR,AD	cardiomyopathy, dilated, 2e, 619492 (3), ; cardiomyopathy, hypertrophic, 17, 613873 (3),
JPH3	AD	huntington disease-like 2, 606438 (3),
JPH4		
JPHL1		
JPO1	AR	immunodeficiency-centromeric instability-facial anomalies syndrome 3, 616910 (3),
JPO2		
JPT1		
JPT2		
JPX		
JRK		
JRKL		
JS-2		
JSAP1	AD	neurodevelopmental disorder with or without variable brain abnormalities, 618443 (3),
JSP1		
JSRP1		
JSX	AR	[skin/hair/eye pigmentation 4, fair/dark skin], 113750 (3), ; albinism, oculocutaneous, type vi, 113750 (3),
JTB		
JTK1	AR	immunodeficiency 35, 611521 (3),
JTK10	AD	{budd-chiari syndrome, somatic}, 600880 (3); myelofibrosis, somatic, 254450 (3); erythrocytosis, somatic, 133100 (3); leukemia, acute myeloid, somatic, 601626 (3); thrombocythemia 3, 614521 (3), somatic mutation, ; polycythemia vera, somatic, 263300 (3)
JTK11		
JTK12	AD	premature aging syndrome, penttinen type, 601812 (3), ; kosaki overgrowth syndrome, 616592 (3), ; myofibromatosis, infantile, 1, 228550 (3), ; basal ganglia calcification, idiopathic, 4, 615007 (3), ; myeloproliferative disorder with eosinophilia, 131440 (4),
JTK13	AR,AD	insulin-like growth factor i, resistance to, 270450 (3),
JTK14	AD	lymphatic malformation 11, 619401 (3),
JTK2		{cancer progression/metastasis} (3)
JTK3	AD	autoinflammation, immune dysregulation, and eosinophilia, 618999 (3),
JTK4	AD,AR	muenke syndrome, 602849 (3), ; saddan, 616482 (3), ; hypochondroplasia, 146000 (3), ; thanatophoric dysplasia, type ii, 187601 (3), ; nevus, epidermal, somatic, 162900 (3); catshl syndrome, 610474 (3), ; thanatophoric dysplasia, type i, 187600 (3), ; spermatocytic seminoma, somatic, 273300 (3); bladder cancer, somatic, 109800 (3); ladd syndrome 2, 620192 (3), ; achondroplasia, 100800 (3), ; cervical cancer, somatic, 603956 (3); colorectal cancer, somatic, 114500 (3); crouzon syndrome with acanthosis nigricans, 612247 (3),
JTK5		
JTK5A		
JTK7	AD	leukemia, philadelphia chromosome-positive, resistant to imatinib, 608232 (3), somatic mutation; congenital heart defects and skeletal malformations syndrome, 617602 (3),
JTK8	AD	autoinflammatory disease, systemic, with vasculitis, 620376 (3),
JTK9	AD	autoinflammation with pulmonary and cutaneous vasculitis, 620296 (3),
JTV-1	AR	leukodystrophy, hypomyelinating, 17, 618006 (3),
JTV1	AR	leukodystrophy, hypomyelinating, 17, 618006 (3),
JUB		
JULF2		
JUN		
JUNB		
JUND		
JUNDM1		
JUNDM2		
JUNO		
JUP	AR,AD	naxos disease, 601214 (3), ; ?arrhythmogenic right ventricular dysplasia 12, 611528 (3),
JV15-2	AD	loeys-dietz syndrome 3, 613795 (3),
JV18-1	AD	loeys-dietz syndrome 6, 619656 (3), ; congenital heart defects, multiple types, 8, with or without heterotaxy, 619657 (3),
JV4-1		
JV5-1		
JWA		
JWS	AD	bent bone dysplasia syndrome, 614592 (3), ; ladd syndrome 1, 149730 (3), ; antley-bixler syndrome without genital anomalies or disordered steroidogenesis, 207410 (3), ; scaphocephaly and axenfeld-rieger anomaly (3); jackson-weiss syndrome, 123150 (3), ; gastric cancer, somatic, 613659 (3); craniofacial-skeletal-dermatologic dysplasia, 101600 (3), ; apert syndrome, 101200 (3), ; pfeiffer syndrome, 101600 (3), ; craniosynostosis, nonspecific (3); ?scaphocephaly, maxillary retrusion, and impaired intellectual development, 609579 (3); beare-stevenson cutis gyrata syndrome, 123790 (3), ; crouzon syndrome, 123500 (3), ; saethre-chotzen syndrome, 101400 (3),
K-ALPHA-1		
K-CAP	AR	anterior segment dysgenesis 8, 617319 (3),
K-FGF		
K-glypican	XLR,XL	keipert syndrome, 301026 (3),
K-H		
K-Ras4B	AD	gastric cancer, somatic, 613659 (3); oculoectodermal syndrome, somatic, 600268 (3); breast cancer, somatic, 114480 (3); noonan syndrome 3, 609942 (3), ; ras-associated autoimmune leukoproliferative disorder, 614470 (3), ; arteriovenous malformation of the brain, somatic, 108010 (3); lung cancer, somatic, 211980 (3); pancreatic carcinoma, somatic, 260350 (3); leukemia, acute myeloid, somatic, 601626 (3); schimmelpenning-feuerstein-mims syndrome, somatic mosaic, 163200 (3); cardiofaciocutaneous syndrome 2, 615278 (3), ; bladder cancer, somatic, 109800 (3)
K-REV		
K-SAM	AD	bent bone dysplasia syndrome, 614592 (3), ; ladd syndrome 1, 149730 (3), ; antley-bixler syndrome without genital anomalies or disordered steroidogenesis, 207410 (3), ; scaphocephaly and axenfeld-rieger anomaly (3); jackson-weiss syndrome, 123150 (3), ; gastric cancer, somatic, 613659 (3); craniofacial-skeletal-dermatologic dysplasia, 101600 (3), ; apert syndrome, 101200 (3), ; pfeiffer syndrome, 101600 (3), ; craniosynostosis, nonspecific (3); ?scaphocephaly, maxillary retrusion, and impaired intellectual development, 609579 (3); beare-stevenson cutis gyrata syndrome, 123790 (3), ; crouzon syndrome, 123500 (3), ; saethre-chotzen syndrome, 101400 (3),
K10	AD	ichthyosis, annular epidermolytic 1, 607602 (3), ; epidermolytic hyperkeratosis 2, 620150 (3); ?ichthyosis histrix, lambert type, 146600 (3), ; ichthyosis with confetti, 609165 (3),
K100		
K12	AD	meesmann corneal dystrophy 1, 122100 (3),
K12H4.8-LIKE	AD	pleuropulmonary blastoma, 601200 (3), ; goiter, multinodular 1, with or without sertoli-leydig cell tumors, 138800 (3), ; glow syndrome, somatic mosaic, 618272 (3); rhabdomyosarcoma, embryonal, 2, 180295 (3)
K13	AD	white sponge nevus 2, 615785 (3),
K15		
K19		
K1CO		
K1CS		
K20		
K23		
K2C7		
K2C8		
K2p1.1		
K2p10.1		
K2p12.1		
K2p13.1		
K2p15.1		
K2p16.1		
K2p17.1		
K2p18.1	AD	{migraine, with or without aura, susceptibility to, 13}, 613656 (3),
K2p2.1		
K2p3.1	AD	pulmonary hypertension, primary, 4, 615344 (3),
K2p4.1	AD	facial dysmorphism, hypertrichosis, epilepsy, intellectual/developmental delay, and gingival overgrowth syndrome, 618381 (3),
K2p5.1		
K2p6.1		
K2p7.1		
K2p9.1		birk-barel syndrome, 612292 (3)
K3	AD	meesmann corneal dystrophy 2, 618767 (3),
K35	AD	intellectual developmental disorder with hypotonia and behavioral abnormalities, 618748 (3),
K4	AD	white sponge nevus 1, 193900 (3),
k5-5		
K5B		
K60		
K6C	AD	pachyonychia congenita 3, 615726 (3),
K6D	AD	pachyonychia congenita 3, 615726 (3),
K6HF		{pseudofolliculitis barbae, susceptibility to}, 612318 (3)
K6irs		
K6IRS1	AD	?hypotrichosis 13, 615896 (3),
K6IRS2		
K6IRS3		
K6IRS4	AD,AR	woolly hair, 194300 (3), ; ?hypotrichosis 3, 613981 (3), ; ?ectodermal dysplasia 7, hair/nail type, 614929 (3),
K6L		
K7		
K8		
K9	AD	palmoplantar keratoderma, epidermolytic, 1, 144200 (3),
KA1		
KA2		
KA35		
KA36		
KA6		
KAAG1		
KAB		
KACL		
KAE1	AR	galloway-mowat syndrome 3, 617729 (3),
KAF	AD,AR	{hemolytic uremic syndrome, atypical, susceptibility to, 3}, 612923 (3), ; {macular degeneration, age-related, 13, susceptibility to}, 615439 (3), ; complement factor i deficiency, 610984 (3),
KAI1		
KAIA1777		
KAIA2779		
kaiso		
KAISO		
KAISO-L1		
KAL	XLR,XL	hypogonadotropic hypogonadism 1 with or without anosmia (kallmann syndrome 1), 308700 (3),
KAL1	XLR,XL	hypogonadotropic hypogonadism 1 with or without anosmia (kallmann syndrome 1), 308700 (3),
KAL2	AD	pfeiffer syndrome, 101600 (3), ; hypogonadotropic hypogonadism 2 with or without anosmia, 147950 (3), ; jackson-weiss syndrome, 123150 (3), ; hartsfield syndrome, 615465 (3), ; trigonocephaly 1, 190440 (3), ; osteoglophonic dysplasia, 166250 (3), ; encephalocraniocutaneous lipomatosis, somatic mosaic, 613001 (3)
KAL3	AD	hypogonadotropic hypogonadism 3 with or without anosmia, 244200 (3),
KAL4	AD	hypogonadotropic hypogonadism 4 with or without anosmia, 610628 (3),
KALI		
KALIb		
KALIG-1	XLR,XL	hypogonadotropic hypogonadism 1 with or without anosmia (kallmann syndrome 1), 308700 (3),
kalinin-105kDa	AR	epidermolysis bullosa, junctional 3b, severe, 619786 (3), ; epidermolysis bullosa, junctional 3a, intermediate, 619785 (3),
kalinin-140kDa	AR,AD	epidermolysis bullosa, junctional 1b, severe, 226700 (3), ; epidermolysis bullosa, junctional 1a, intermediate, 226650 (3), ; amelogenesis imperfecta, type ia, 104530 (3),
kalinin-165kDa	AR	epidermolysis bullosa, junctional 2a, intermediate, 619783 (3), ; epidermolysis bullosa, junctional 2c, laryngoonychocutaneous, 245660 (3), ; epidermolysis bullosa, junctional 2b, severe, 619784 (3),
Kalirin		
KALNC2		
KALRN		
kanadaptin		
KANK		cerebral palsy, spastic quadriplegic, 2, 612900 (3)
KANK1		cerebral palsy, spastic quadriplegic, 2, 612900 (3)
KANK2	AR	nephrotic syndrome, type 16, 617783 (3), ; palmoplantar keratoderma and woolly hair, 616099 (3),
KANK3		
KANK4		
KANSL1	AD	koolen-de vries syndrome, 610443 (3),
KANSL1L		
KANSL2		
KANSL3		
KANTR		
KAP		
KAP-1		
KAP1		
KAP1.1		
KAP1.1A		
KAP1.1B		
KAP1.3		
KAP1.4		
KAP1.5		
KAP10		
KAP11.1		
KAP13.1		
KAP24.1		
KAP3		
kappa-200		
kappaB-Ras1		
kappaB-Ras2		
KAR		
KARAP	AR	polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 1, 221770 (3),
KARCA1		
KARP-1		
KARS	AR	deafness, 89, 613916 (3), ; leukoencephalopathy, progressive, infantile-onset, with or without deafness, 619147 (3), ; ?charcot-marie-tooth disease, intermediate, b, 613641 (3), ; deafness, congenital, and adult-onset progressive leukoencephalopathy, 619196 (3),
KARS1	AR	deafness, 89, 613916 (3), ; leukoencephalopathy, progressive, infantile-onset, with or without deafness, 619147 (3), ; ?charcot-marie-tooth disease, intermediate, b, 613641 (3), ; deafness, congenital, and adult-onset progressive leukoencephalopathy, 619196 (3),
KARS2	AR	deafness, 89, 613916 (3), ; leukoencephalopathy, progressive, infantile-onset, with or without deafness, 619147 (3), ; ?charcot-marie-tooth disease, intermediate, b, 613641 (3), ; deafness, congenital, and adult-onset progressive leukoencephalopathy, 619196 (3),
KASH5		
KAT		
KAT1		
KAT12		
KAT13A		
KAT13B		
KAT13C		
KAT13D		
KAT14		
KAT2		
KAT2A		
KAT2B		
KAT3		
KAT3A	AD	menke-hennekam syndrome 1, 618332 (3), ; rubinstein-taybi syndrome 1, 180849 (3),
KAT3B	AD	menke-hennekam syndrome 2, 618333 (3), ; colorectal cancer, somatic, 114500 (3); rubinstein-taybi syndrome 2, 613684 (3),
KAT4	AR,XL,XLR	developmental and epileptic encephalopathy 82, 618721 (3), |intellectual developmental disorder, syndromic 33, 300966 (3), ; dystonia-parkinsonism, 314250 (3),
KAT5	AD	neurodevelopmental disorder with dysmorphic facies, sleep disturbance, and brain abnormalities, 619103 (3),
KAT6A	AD	arboleda-tham syndrome, 616268 (3),
KAT6B	AD	sbbyss syndrome, 603736 (3), ; genitopatellar syndrome, 606170 (3),
KAT7		
KAT8	AD	li-ghorgani-weisz-hubshman syndrome, 618974 (3),
KAT9		
KATI		
KATII		
KATIII		
KATIV	AR	developmental and epileptic encephalopathy 82, 618721 (3),
KATNA1		
KATNAL1		
KATNAL2		
KATNB1	AR	lissencephaly 6, with microcephaly, 616212 (3),
KATNBL1		
KATNIP	AR	joubert syndrome 26, 616784 (3),
KATP1	AD	long qt syndrome 13, 613485 (3), ; hyperaldosteronism, familial, type iii, 613677 (3),
KATP2	AD	keppen-lubinsky syndrome, 614098 (3),
KAZALD1		
KAZN		
KAZRIN		
KB20		
KBF1	AD	immunodeficiency, common variable, 12, 616576 (3),
KBF2	AD	adams-oliver syndrome 3, 614814 (3),
KBL		
KBP	AR	goldberg-shprintzen megacolon syndrome, 609460 (3),
KBP-1		
KBP1		
KBRAS1		
KBRAS2		
KBTBD1		
KBTBD10	AR	nemaline myopathy 9, 615731 (3),
KBTBD11		
KBTBD13	AD	nemaline myopathy 6, 609273 (3),
KBTBD14		
KBTBD2		
KBTBD4		
KBTBD5	AR	nemaline myopathy 8, 615348 (3),
KBTBD6		
KBTBD7		
KBTBD8		
KCa1.1	AD,AR	{epilepsy, idiopathic generalized, susceptibility to, 16}, 618596 (3), ; paroxysmal nonkinesigenic dyskinesia, 3, with or without generalized epilepsy, 609446 (3), ; cerebellar atrophy, developmental delay, and seizures, 617643 (3), ; liang-wang syndrome, 618729 (3),
KCa2.1		
KCa2.2	AD	?dystonia 34, myoclonic, 619724 (3), ; neurodevelopmental disorder with or without variable movement or behavioral abnormalities, 619725 (3),
KCa2.3	AD	zimmermann-laband syndrome 3, 618658 (3),
KCa3.1	AD	dehydrated hereditary stomatocytosis 2, 616689 (3),
KCa4.1	AD	developmental and epileptic encephalopathy 14, 614959 (3), ; epilepsy nocturnal frontal lobe, 5, 615005 (3),
KCa4.2	AD	developmental and epileptic encephalopathy 57, 617771 (3),
KCa5.1	AR	spermatogenic failure 79, 620196 (3),
KCASH1		
KCASH2		
KCASH3		
KCC1		
KCC2	AD,AR	{epilepsy, idiopathic generalized, susceptibility to, 14}, 616685 (3), ; developmental and epileptic encephalopathy 34, 616645 (3),
KCC3	AR,AD	agenesis of the corpus callosum with peripheral neuropathy, 218000 (3), ; charcot-marie-tooth disease, axonal, type 2ii, 620068 (3),
KCC3A	AR,AD	agenesis of the corpus callosum with peripheral neuropathy, 218000 (3), ; charcot-marie-tooth disease, axonal, type 2ii, 620068 (3),
KCC3B	AR,AD	agenesis of the corpus callosum with peripheral neuropathy, 218000 (3), ; charcot-marie-tooth disease, axonal, type 2ii, 620068 (3),
KCC4		
KCCR13L		
KCHIP1		
KCHIP2		
KCHIP3		
KCHIP4		
KCIP-1		
KCLR		
KCMF1		
KCNA1	AD	episodic ataxia/myokymia syndrome, 160120 (3),
KCNA10		
KCNA11	AD	developmental and epileptic encephalopathy 7, 613720 (3), ; seizures, benign neonatal, 1, 121200 (3), ; myokymia, 121200 (3),
KCNA1B		
KCNA2	AD	developmental and epileptic encephalopathy 32, 616366 (3),
KCNA2B		
KCNA3		
KCNA3B		
KCNA4	AR	microcephaly, cataracts, impaired intellectual development, and dystonia with abnormal striatum, 618284 (3),
KCNA4L	AR	microcephaly, cataracts, impaired intellectual development, and dystonia with abnormal striatum, 618284 (3),
KCNA5	AD	atrial fibrillation, familial, 7, 612240 (3),
KCNA6		
KCNA7		
KCNA8	AD,AR	short qt syndrome 2, 609621 (3), ; atrial fibrillation, familial, 3, 607554 (3), ; long qt syndrome 1, 192500 (3), ; {long qt syndrome 1, acquired, susceptibility to}, 192500 (3), ; jervell and lange-nielsen syndrome, 220400 (3),
KCNA9	AD,AR	short qt syndrome 2, 609621 (3), ; atrial fibrillation, familial, 3, 607554 (3), ; long qt syndrome 1, 192500 (3), ; {long qt syndrome 1, acquired, susceptibility to}, 192500 (3), ; jervell and lange-nielsen syndrome, 220400 (3),
KCNAB1		
KCNAB2		
KCNAB3		
KCNB1	AD	developmental and epileptic encephalopathy 26, 616056 (3),
KCNB2		
KCNC1	AD	epilepsy, progressive myoclonic 7, 616187 (3),
KCNC2	AD	developmental and epileptic encephalopathy 103, 619913 (3),
KCNC3	AD	spinocerebellar ataxia 13, 605259 (3),
KCNC4		
KCND1		
KCND2		
KCND3	AD	spinocerebellar ataxia 19, 607346 (3), ; brugada syndrome 9, 616399 (3),
KCNE1	AR,AD	jervell and lange-nielsen syndrome 2, 612347 (3), ; long qt syndrome 5, 613695 (3),
KCNE1L		
KCNE2	AD	long qt syndrome 6, 613693 (3), ; atrial fibrillation, familial, 4, 611493 (3)
KCNE3		?brugada syndrome 6, 613119 (3)
KCNE4		
KCNE5		
KCNF		
KCNF1		
KCNF2		
KCNG		
KCNG1		
KCNG2		
KCNG3		
KCNG4		
KCNH1	AD	zimmermann-laband syndrome 1, 135500 (3), ; temple-baraitser syndrome, 611816 (3),
KCNH2	AD	short qt syndrome 1, 609620 (3); long qt syndrome 2, 613688 (3),
KCNH3		
KCNH4		
KCNH5		
KCNH6		
KCNH7		
KCNH8		
KCNIP1		
KCNIP2		
KCNIP3		
KCNIP4		
KCNJ1	AR	bartter syndrome, type 2, 241200 (3),
KCNJ10	AR	enlarged vestibular aqueduct, digenic, 600791 (3), ; sesame syndrome, 612780 (3),
KCNJ11	AD,AR	diabetes, permanent neonatal 2, with or without neurologic features, 618856 (3), ; {diabetes mellitus, type 2, susceptibility to}, 125853 (3), ; maturity-onset diabetes of the young, type 13, 616329 (3), ; diabetes mellitus, transient neonatal 3, 610582 (3), ; hyperinsulinemic hypoglycemia, familial, 2, 601820 (3),
KCNJ12		
KCNJ13	AD,AR	snowflake vitreoretinal degeneration, 193230 (3), ; leber congenital amaurosis 16, 614186 (3),
KCNJ14		
KCNJ15		
KCNJ16	AR	hypokalemic tubulopathy and deafness, 619406 (3),
KCNJ18	AD	{thyrotoxic periodic paralysis, susceptibility to, 2}, 613239 (3),
KCNJ2	AD	atrial fibrillation, familial, 9, 613980 (3), ; andersen syndrome, 170390 (3), ; short qt syndrome 3, 609622 (3)
KCNJ3		
KCNJ4		
KCNJ5	AD	long qt syndrome 13, 613485 (3), ; hyperaldosteronism, familial, type iii, 613677 (3),
KCNJ6	AD	keppen-lubinsky syndrome, 614098 (3),
KCNJ7	AD	keppen-lubinsky syndrome, 614098 (3),
KCNJ8		
KCNJ9		
KCNJN1		
KCNK1		
KCNK10		
KCNK11		
KCNK12		
KCNK13		
KCNK14		
KCNK15		
KCNK16		
KCNK17		
KCNK18	AD	{migraine, with or without aura, susceptibility to, 13}, 613656 (3),
KCNK2		
KCNK3	AD	pulmonary hypertension, primary, 4, 615344 (3),
KCNK4	AD	facial dysmorphism, hypertrichosis, epilepsy, intellectual/developmental delay, and gingival overgrowth syndrome, 618381 (3),
KCNK5		
KCNK6		
KCNK7		
KCNK9		birk-barel syndrome, 612292 (3)
KCNMA1	AD,AR	{epilepsy, idiopathic generalized, susceptibility to, 16}, 618596 (3), ; paroxysmal nonkinesigenic dyskinesia, 3, with or without generalized epilepsy, 609446 (3), ; cerebellar atrophy, developmental delay, and seizures, 617643 (3), ; liang-wang syndrome, 618729 (3),
Kcnma3	AR	spermatogenic failure 79, 620196 (3),
KCNMB1	AD	{hypertension, diastolic, resistance to}, 608622 (3),
KCNMB2		
KCNMB3		
KCNMB4		
KCNMBL		
KCNMC1	AR	spermatogenic failure 79, 620196 (3),
KCNN1		
KCNN2	AD	?dystonia 34, myoclonic, 619724 (3), ; neurodevelopmental disorder with or without variable movement or behavioral abnormalities, 619725 (3),
KCNN3	AD	zimmermann-laband syndrome 3, 618658 (3),
KCNN4	AD	dehydrated hereditary stomatocytosis 2, 616689 (3),
KCNQ1	AD,AR	short qt syndrome 2, 609621 (3), ; atrial fibrillation, familial, 3, 607554 (3), ; long qt syndrome 1, 192500 (3), ; {long qt syndrome 1, acquired, susceptibility to}, 192500 (3), ; jervell and lange-nielsen syndrome, 220400 (3),
KCNQ1-AS2	AD	beckwith-wiedemann syndrome, 130650 (3),
KCNQ1DN		
KCNQ1OT1	AD	beckwith-wiedemann syndrome, 130650 (3),
KCNQ2	AD	developmental and epileptic encephalopathy 7, 613720 (3), ; seizures, benign neonatal, 1, 121200 (3), ; myokymia, 121200 (3),
KCNQ3	AD	seizures, benign neonatal, 2, 121201 (3),
KCNQ4	AD	deafness, 2a, 600101 (3),
KCNQ5	AD	intellectual developmental disorder, 46, 617601 (3),
KCNRG		
KCNS1		
KCNS2		
KCNS3		
KCNT1	AD	developmental and epileptic encephalopathy 14, 614959 (3), ; epilepsy nocturnal frontal lobe, 5, 615005 (3),
KCNT2	AD	developmental and epileptic encephalopathy 57, 617771 (3),
KCNU1	AR	spermatogenic failure 79, 620196 (3),
KCNV1		
KCNV2	AR	retinal cone dystrophy 3b, 610356 (3),
KCP		
KCP1	AR,AD	erythrokeratodermia variabilis et progressiva 7, 619209 (3), ; olmsted syndrome 2, 619208 (3),
KCP2		
KCP3		
KCR1	AD	{long qt syndrome, acquired, reduced susceptibility to}, 613688 (3),
KCS	AR	kenny-caffey syndrome, type 1, 244460 (3), ; hypoparathyroidism-retardation-dysmorphism syndrome, 241410 (3), ; encephalopathy, progressive, with amyotrophy and optic atrophy, 617207 (3),
KCS1	AR	kenny-caffey syndrome, type 1, 244460 (3), ; hypoparathyroidism-retardation-dysmorphism syndrome, 241410 (3), ; encephalopathy, progressive, with amyotrophy and optic atrophy, 617207 (3),
KCT3		
KCTD1	AD	scalp-ear-nipple syndrome, 181270 (3),
KCTD10		
KCTD11		
KCTD12		
KCTD13		
KCTD15		
KCTD16		
KCTD17	AD	dystonia 26, myoclonic, 616398 (3),
KCTD19		
KCTD2		
KCTD20		
KCTD21		
KCTD3		
KCTD5		
KCTD6		
KCTD7	AR	epilepsy, progressive myoclonic 3, with or without intracellular inclusions, 611726 (3),
KCTD8		
KCTD9		
KD93		
KDAC1		
KDAC2		
KDAC3		
KDAC8	XLD,XL	cornelia de lange syndrome 5, 300882 (3),
Kdap		
KDAP		
KDELC1		
KDELC2		
KDELCL1	AD,AR	dowling-degos disease 4, 615696 (3), ; muscular dystrophy, limb-girdle, 21, 617232 (3),
KDELR1		
KDELR2	AR	osteogenesis imperfecta, type xxi, 619131 (3),
KDELR3		
KDF1	AD	?ectodermal dysplasia 12, hypohidrotic/hair/tooth/nail type, 617337 (3),
KDM1	AD	cleft palate, psychomotor retardation, and distinctive facial features, 616728 (3),
KDM1A	AD	cleft palate, psychomotor retardation, and distinctive facial features, 616728 (3),
KDM1B		
KDM2A		
KDM2B		
KDM3A		
KDM3B	AD	diets-jongmans syndrome, 618846 (3),
KDM3C		
KDM4A		
KDM4B	AD	intellectual developmental disorder, 65, 619320 (3),
KDM4C		
KDM4D		
KDM4DL		
KDM4E		
KDM5A		
KDM5B	AR	intellectual developmental disorder, 65, 618109 (3),
KDM5C	XL,XLR	intellectual developmental disorder, syndromic, claes-jensen type, 300534 (3),
KDM5D		
KDM5E		
KDM6A	XLD,XL	kabuki syndrome 2, 300867 (3),
KDM6AL		
KDM6B	AD	neurodevelopmental disorder with coarse facies and mild distal skeletal abnormalities, 618505 (3),
KDM6C		
KDM7A		
KDM7B	XL,XLR	intellectual developmental disorder, syndromic, siderius type, 300263 (3),
KDM7C		
KDM8		
KDR	AD	{hemangioma, capillary infantile, susceptibility to}, 602089 (3), ; hemangioma, capillary infantile, somatic, 602089 (3)
KDSR	AR	erythrokeratodermia variabilis et progressiva 4, 617526 (3),
KE-2		
KE-3		
KE04	AR	spastic paraplegia 62, 615681 (3),
KE05		
KE1.5		
KE3		
KE4	AR	agammaglobulinemia 9, 619693 (3),
KE6		
KEAP1		
Kec		
KEL		[blood group, kell], 110900 (3)
KELCHL		
KEN	AR	microcephalic osteodysplastic primordial dwarfism, type ii, 210720 (3),
KENAE		
KEPI		
KERA	AR	cornea plana 2, 217300 (3),
KET	AD	premature ovarian failure 21, 620311 (3), ; ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3, 604292 (3), ; hay-wells syndrome, 106260 (3), ; split-hand/foot malformation 4, 605289 (3), ; orofacial cleft 8, 618149 (3); rapp-hodgkin syndrome, 129400 (3), ; adult syndrome, 103285 (3), ; limb-mammary syndrome, 603543 (3),
KF1		
KFABP		
KFGF		
KFS	AD,AR	microphthalmia with coloboma 6, digenic, 613703 (3), ; microphthalmia, isolated 4, 613094 (3); leber congenital amaurosis 17, 615360 (3), ; multiple synostoses syndrome 4, 617898 (3), ; klippel-feil syndrome 1, 118100 (3),
KFS1	AD,AR	microphthalmia with coloboma 6, digenic, 613703 (3), ; microphthalmia, isolated 4, 613094 (3); leber congenital amaurosis 17, 615360 (3), ; multiple synostoses syndrome 4, 617898 (3), ; klippel-feil syndrome 1, 118100 (3),
KFSD	XL,XLR	keratosis follicularis spinulosa decalvans, 308800 (3), ; osteogenesis imperfecta, type xix, 301014 (3), ; ifap syndrome with or without bresheck syndrome, 308205 (3), ; ?olmsted syndrome, 300918 (3),
KFYI		
KG19		
KG1T		
KGA	AR,AD	global developmental delay, progressive ataxia, and elevated glutamine, 618412 (3), ; ?infantile cataract, skin abnormalities, glutamate excess, and impaired intellectual development, 618339 (3), ; developmental and epileptic encephalopathy 71, 618328 (3),
KGD1	AR	oxoglutarate dehydrogenase deficiency, 203740 (3),
KGD2	AD	paragangliomas 7, 618475 (3),
KGF		
KGFR	AD	bent bone dysplasia syndrome, 614592 (3), ; ladd syndrome 1, 149730 (3), ; antley-bixler syndrome without genital anomalies or disordered steroidogenesis, 207410 (3), ; scaphocephaly and axenfeld-rieger anomaly (3); jackson-weiss syndrome, 123150 (3), ; gastric cancer, somatic, 613659 (3); craniofacial-skeletal-dermatologic dysplasia, 101600 (3), ; apert syndrome, 101200 (3), ; pfeiffer syndrome, 101600 (3), ; craniosynostosis, nonspecific (3); ?scaphocephaly, maxillary retrusion, and impaired intellectual development, 609579 (3); beare-stevenson cutis gyrata syndrome, 123790 (3), ; crouzon syndrome, 123500 (3), ; saethre-chotzen syndrome, 101400 (3),
kH1		
kH2		
KHCHP		
KHDC1		
KHDC2		
KHDC3L	AR	hydatidiform mole, recurrent, 2, 614293 (3),
KHDC4		
KHDRBS1		
KHDRBS2		
KHDRBS3		
KHK	AR	?[fructosuria, essential], 229800 (3),
KHL4		
KHLHX		
KHNYN		
KHRBP1		
KHS		
KHS1		
KHSRP		
Ki		
KI-1		
Ki-67		
KIAA-iso		
KIAA0001		
KIAA0003	AD	?angioedema, hereditary, 5, 619361 (3),
KIAA0004		
KIAA0005		
KIAA0006		
KIAA0007		
KIAA0008		
KIAA0009		
KIAA0010	AR	neurodevelopmental disorder with absent speech and movement and behavioral abnormalities, 620270 (3),
KIAA0011		
KIAA0012		{leprosy, susceptibility to, 5}, 613223 (3); {leprosy, protection against}, 613223 (3)
KIAA0013		
KIAA0014		
KIAA0015		
KIAA0016		
KIAA0017		
KIAA0018	AR	desmosterolosis, 602398 (3),
KIAA0019		
KIAA0020		
KIAA0021	AR	cone-rod dystrophy 9, 612775 (3),
KIAA0022		
KIAA0024	AD	lenz-majewski hyperostotic dwarfism, 151050 (3),
KIAA0025		
KIAA0026		
KIAA0027	AR	megalencephalic leukoencephalopathy with subcortical cysts 1, 604004 (3),
KIAA0028	AR	perrault syndrome 4, 615300 (3), ; hydrops, lactic acidosis, and sideroblastic anemia, 617021 (3),
KIAA0029		
KIAA0030	AD	?deafness, 70, 616968 (3),
KIAA0032		
KIAA0033		
KIAA0035		
KIAA0036	AR	senior-loken syndrome 5, 609254 (3),
KIAA0037		
KIAA0038		
KIAA0039		
KIAA0040		
KIAA0041		
KIAA0042	AR	microcephaly 20, primary, 617914 (3), ; ?meckel syndrome 12, 616258 (3),
KIAA0043		
KIAA0045	AD	intellectual developmental disorder, 49, 617752 (3),
KIAA0046	AD	neurodegeneration, childhood-onset, hypotonia, respiratory insufficiency and brain imaging abnormalities, 619173 (3),
KIAA0047	AR	pontocerebellar hypoplasia, type 8, 614961 (3),
KIAA0048		
KIAA0049		
KIAA0050		
KIAA0051		
KIAA0052		
KIAA0053		
KIAA0054		
KIAA0055		pituitary adenoma 4, acth-secreting, somatic, 219090 (3)
KIAA0056	AR	microcephaly 22, primary, 617984 (3),
KIAA0057		
KIAA0058		
KIAA0060		
KIAA0062	AD,AR	?hyperostosis cranalis interna, 144755 (3), ; hypermanganesemia with dystonia 2, 617013 (3),
KIAA0063		
KIAA0064		
KIAA0065		
KIAA0066	AR	martsolf syndrome 2, 619420 (3), ; warburg micro syndrome 1, 600118 (3),
KIAA0067		
KIAA0068		
KIAA0069	AR	?spastic paraplegia 61, 615685 (3),
KIAA0071		
KIAA0072		
KIAA0073		
KIAA0076	AR	3-m syndrome 1, 273750 (3),
KIAA0077		
KIAA0078	AD,AR	cornelia de lange syndrome 4, 614701 (3), ; ?mungan syndrome, 611376 (3),
KIAA0079		
KIAA0080		
KIAA0081	AR	osteogenesis imperfecta, type xx, 618644 (3),
KIAA0082		
KIAA0083	AR,AD	?seckel syndrome 8, 615807 (3), ; progressive external ophthalmoplegia with mitochondrial dna deletions, 6, 615156 (3),
KIAA0084		
KIAA0086		
KIAA0088	AD	polycystic kidney disease 3, 600666 (3),
KIAA0089	AD	brugada syndrome 2, 611777 (3),
KIAA0090	AR	cerebellar atrophy, visual impairment, and psychomotor retardation, 616875 (3),
KIAA0091	AR	?spondyloepiphyseal dysplasia, kondo-fu type, 618392 (3),
KIAA0092	AR	mosaic variegated aneuploidy syndrome 2, 614114 (3),
KIAA0093		
KIAA0094		
KIAA0095	AR	nephrotic syndrome, type 12, 616892 (3),
KIAA0096		
KIAA0097		
KIAA0098	AR	neuropathy, hereditary sensory, with spastic paraplegia, 256840 (3),
KIAA0099	AD	spinocerebellar ataxia 47, 617931 (3),
KIAA0100		
KIAA0101		
KIAA0102		
KIAA0103		
KIAA0104		
KIAA0105		
KIAA0106		
KIAA0107		
KIAA0108		
KIAA0110		
KIAA0111	AR	robin sequence with cleft mandible and limb anomalies, 268305 (3),
KIAA0112		
KIAA0113		
KIAA0114		
KIAA0115	AR	congenital disorder of glycosylation, type ir, 614507 (3),
KIAA0116		
KIAA0117		
KIAA0118		
KIAA0119		
KIAA0120		
KIAA0121		
KIAA0122	XLR,XL	tarp syndrome, 311900 (3),
KIAA0123	AR	spinocerebellar ataxia, 2, 213200 (3),
KIAA0124		
KIAA0125		
KIAA0126	AR	neurodevelopmental disorder with hypotonia and gross motor and seech delay, 619639 (3),
KIAA0127		
KIAA0128		
KIAA0129		
KIAA0130		
KIAA0131		
KIAA0132		
KIAA0133		
KIAA0134		
KIAA0135		
KIAA0136		
KIAA0137		
KIAA0138		
KIAA0139		
KIAA0140		
KIAA0141		
KIAA0142		
KIAA0143		
KIAA0144		
KIAA0145		
KIAA0146	AR	ovarian dysgenesis 9, 619665 (3),
KIAA0147		
KIAA0148		
KIAA0149		
KIAA0150		
KIAA0151		
KIAA0152		
KIAA0153		
KIAA0154		
KIAA0155		
KIAA0156		
KIAA0157		
KIAA0158		
KIAA0159	AR	?microcephaly 21, primary, 617983 (3),
KIAA0160	AD	imagawa-matsumoto syndrome, 618786 (3),
KIAA0161		
KIAA0162		
KIAA0163		
KIAA0164		
KIAA0165		
KIAA0166		
KIAA0168		
KIAA0169	AR	sandestig-stefanova syndrome, 618804 (3),
KIAA0170		
KIAA0171		
KIAA0172		cerebral palsy, spastic quadriplegic, 2, 612900 (3)
KIAA0173		
KIAA0174		
KIAA0175		
KIAA0176		
KIAA0178	XLD,XL	cornelia de lange syndrome 2, 300590 (3), ; developmental and epileptic encephalopathy 85, with or without midline brain defects, 301044 (3),
KIAA0179		
KIAA0180	AD	dowling-degos disease 2, 615327 (3),
KIAA0181		
KIAA0182		
KIAA0183		
KIAA0184		
KIAA0185		
KIAA0186	AR	immunodeficiency 55, 617827 (3),
KIAA0187	AD	?aplasia cutis congenita, nonsyndromic, 107600 (3),
KIAA0188	AR	myoglobinuria, acute recurrent, 268200 (3),
KIAA0189		
KIAA0190		
KIAA0191		
KIAA0192	XLR,XL,XLD	lujan-fryns syndrome, 309520 (3), ; ohdo syndrome, 300895 (3), ; hardikar syndrome, 301068 (3), ; opitz-kaveggia syndrome, 305450 (3),
KIAA0193		
KIAA0194		
KIAA0195	AR	intellectual developmental disorder with cardiac defects and dysmorphic facies, 618316 (3),
KIAA0196	AR,AD	ritscher-schinzel syndrome 1, 220210 (3), ; spastic paraplegia 8, 603563 (3),
KIAA0197	AR	?nephrotic syndrome, type 19, 618178 (3),
KIAA0199		
KIAA0200		
KIAA0201		
KIAA0202		
KIAA0203		breast cancer, somatic, 114480 (3)
KIAA0204		
KIAA0205		
KIAA0206		
KIAA0208	AD	robinow syndrome, 3, 616894 (3),
KIAA0209	AR	immunodeficiency 40, 616433 (3),
KIAA0210		
KIAA0211		
KIAA0212		
KIAA0213		
KIAA0214	AR,AD	lipomatosis, multiple symmetric, with or without peripheral neuropathy, 151800 (3), ; charcot-marie-tooth disease, axonal, type 2a2a, 609260 (3), ; charcot-marie-tooth disease, axonal, type 2a2b, 617087 (3), ; hereditary motor and sensory neuropathy via, 601152 (3),
KIAA0215		
KIAA0216		
KIAA0217		
KIAA0218		
KIAA0219		
KIAA0220		
KIAA0221		
KIAA0222		
KIAA0223		
KIAA0224	AR	retinitis pigmentosa 84, 618220 (3),
KIAA0225	AR	?nephrotic syndrome, type 13, 616893 (3),
KIAA0226	AR	spinocerebellar ataxia, 15, 615705 (3),
KIAA0226L		
KIAA0227		
KIAA0228		
KIAA0229		
KIAA0230	AR	anterior segment dysgenesis 7, with sclerocornea, 269400 (3),
KIAA0231		
KIAA0232		
KIAA0233	AR,AD	[er blood group system], 620207 (3), ; lymphatic malformation 6, 616843 (3), ; dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edema, 194380 (3),
KIAA0234		
KIAA0235		
KIAA0236	AR	neurodevelopmental disorder with impaired speech and hyperkinetic movements, 618425 (3),
KIAA0237		
KIAA0238		
KIAA0239		
KIAA0240		
KIAA0241		
KIAA0242		
KIAA0243	AD	focal cortical dysplasia, type ii, somatic, 607341 (3); tuberous sclerosis-1, 191100 (3), ; lymphangioleiomyomatosis, 606690 (3)
KIAA0245		
KIAA0246		
KIAA0247		
KIAA0248	AD	charcot-marie-tooth disease, axonal, type 2gg, 606483 (3),
KIAA0249		majeed syndrome, 609628 (3)
KIAA0250		
KIAA0251		
KIAA0252		
KIAA0253	AD	acne inversa, familial, 1, 142690 (3),
KIAA0255		
KIAA0256		
KIAA0257		
KIAA0258		
KIAA0259		
KIAA0260	AR	schneckenbecken dysplasia, 269250 (3),
KIAA0261		
KIAA0262		
KIAA0263		
KIAA0264		
KIAA0265		
KIAA0266	AR	congenital disorder of glycosylation, type ip, 613661 (3),
KIAA0267	XL	intellectual developmental disorder, syndromic, christianson type, 300243 (3),
KIAA0268	AR	?ondontochondrodysplasia 2 with hearing loss and diabetes, 619269 (3),
KIAA0269	AD	neurodevelopmental disorder with absent language and variable seizures, 618707 (3),
KIAA0270		
KIAA0271		
KIAA0272	AD	kury-isidor syndrome, 619762 (3), ; tumor predisposition syndrome 1, 614327 (3), ; {uveal melanoma, susceptibility to, 2}, 606661 (3),
KIAA0273		
KIAA0274	AR,AD	yunis-varon syndrome, 216340 (3), ; ?polymicrogyria, bilateral temporooccipital, 612691 (3), ; amyotrophic lateral sclerosis 11, 612577 (3), ; charcot-marie-tooth disease, type 4j, 611228 (3),
KIAA0275		
KIAA0276		
KIAA0277		
KIAA0278		
KIAA0279		
KIAA0280		
KIAA0280L		
KIAA0281		
KIAA0283		
KIAA0284		
KIAA0285		
KIAA0286		
KIAA0287		
KIAA0288	AD	neurodevelopmental disorder with central hypotonia and dysmorphic facies, 619797 (3),
KIAA0290	AR	immunodeficiency 76, 619164 (3),
KIAA0291		
KIAA0293	AD	developmental and epileptic encephalopathy 67, 618141 (3),
KIAA0294	AD	?slowed nerve conduction velocity, ad, 608236 (3),
KIAA0295		
KIAA0296		
KIAA0298		
KIAA0299	AR	neurodevelopmental disorder with impaired intellectual development, hypotonia, and ataxia, 618292 (3),
KIAA0300		
KIAA0301		
KIAA0303		
KIAA0304	AD	intellectual developmental disorder, 68, 619934 (3), ; dystonia 28, childhood-onset, 617284 (3),
KIAA0305		
KIAA0306	AD	intellectual developmental disorder, 45, 617600 (3),
KIAA0307	AR	?webb-dattani syndrome, 615926 (3),
KIAA0308		
KIAA0309	AD	developmental delay, hypotonia, musculoskeletal defects, and behavioral abnormalities, 619595 (3), ; floating-harbor syndrome, 136140 (3),
KIAA0310		
KIAA0311		
KIAA0312	XL	intellectual developmental disorder, syndromic, turner type, 309590 (3),
KIAA0313	AD	?epilepsy, familial adult myoclonic, 7, 618075 (3),
KIAA0314		
KIAA0315		
KIAA0316	XL	intellectual developmental disorder, 104, 300983 (3),
KIAA0317		
KIAA0318		
KIAA0319		
KIAA0319L		
KIAA0320		
KIAA0321	AR	spastic paraplegia 15, 270700 (3),
KIAA0322		
KIAA0323		
KIAA0324		
KIAA0326		
KIAA0327		
KIAA0328	AR	alstrom syndrome, 203800 (3),
KIAA0329	AR	neuropathy, hereditary sensory and autonomic, type ix, with developmental delay, 615031 (3),
KIAA0330		
KIAA0331		
KIAA0333		
KIAA0334		
KIAA0335		
KIAA0336		
KIAA0337		
KIAA0338	AD	?intellectual developmental disorder, 11, 614257 (3),
KIAA0339	AD	epilepsy, early-onset, with or without developmental delay, 618832 (3), ; neurodevelopmental disorder with speech impairment and dysmorphic facies, 619056 (3),
KIAA0340	AD	cone-rod dystrophy 7, 603649 (3),
KIAA0342		
KIAA0343	AR	neurodevelopmental disorder with neuromuscular and skeletal abnormalities, 619833 (3),
KIAA0345		
KIAA0346	AD	neurodevelopmental disorder with coarse facies and mild distal skeletal abnormalities, 618505 (3),
KIAA0347	AD	?advanced sleep phase syndrome, familial, 1, 604348 (3),
KIAA0349		
KIAA0350		
KIAA0351		
KIAA0352		
KIAA0353		
KIAA0354		
KIAA0355		
KIAA0356	AR,AD	?osteopetrosis, 6, 611497 (3), ; osteopetrosis, 3, 618107 (3),
KIAA0357	AR	ciliary dyskinesia, primary, 40, 618300 (3),
KIAA0358	AR	neurodevelopmental disorder with dysmorphic facies, impaired speech and hypotonia, 619005 (3), ; deeah syndrome, 619004 (3),
KIAA0359	AD	retinitis pigmentosa 89, 618955 (3),
KIAA0360	AR	?coloboma, ocular, 216820 (3),
KIAA0361		
KIAA0362		
KIAA0363		
KIAA0364	XLR,XL	hypothyroidism, central, and testicular enlargement, 300888 (3),
KIAA0365		
KIAA0366	AR	hennekam lymphangiectasia-lymphedema syndrome 3, 618154 (3),
KIAA0367		
KIAA0368		
KIAA0369		
KIAA0370		
KIAA0371		
KIAA0372	AR	trichohepatoenteric syndrome 1, 222470 (3),
KIAA0373	AR	leber congenital amaurosis 10, 611755 (3); joubert syndrome 5, 610188 (3), ; senior-loken syndrome 6, 610189 (3), ; ?bardet-biedl syndrome 14, 615991 (3), ; meckel syndrome 4, 611134 (3),
KIAA0375	AR	intellectual developmental disorder, 61, 617773 (3),
KIAA0376	AD	teebi hypertelorism syndrome 1, 145420 (3), ; ?facial clefting, oblique, 1, 600251 (3),
KIAA0377		
KIAA0378		
KIAA0379		
KIAA0380		
KIAA0381	AR	nephrotic syndrome, type 24, 619263 (3),
KIAA0382		
KIAA0384	AD	blepharocheilodontic syndrome 2, 617681 (3),
KIAA0385		
KIAA0386	AD,AR	deafness, 21, 607017 (3), ; ?deafness, 104, 616515 (3),
KIAA0387		
KIAA0388		
KIAA0389	AD,AR	deafness, 22, with hypertrophic cardiomyopathy, 606346 (3), ; deafness, 22, 606346 (3), ; deafness, 37, 607821 (3),
KIAA0390		
KIAA0391	AR	combined oxidative phosphorylation deficiency 54, 619737 (3),
KIAA0392		
KIAA0394		
KIAA0395		
KIAA0397		
KIAA0399		
KIAA0400		
KIAA0402	AR	microcephalic osteodysplastic primordial dwarfism, type ii, 210720 (3),
KIAA0403		
KIAA0404		
KIAA0406		
KIAA0407		
KIAA0408		
KIAA0409		
KIAA0410		
KIAA0411		
KIAA0412		
KIAA0414		
KIAA0415	AR	spastic paraplegia 48, 613647 (3),
KIAA0416		
KIAA0417		
KIAA0418		
KIAA0419		
KIAA0420		
KIAA0421		
KIAA0423	AR	joubert syndrome 37, 619185 (3),
KIAA0424	XL	developmental and epileptic encephalopathy 8, 300607 (3),
KIAA0425		
KIAA0426		
KIAA0427		
KIAA0428		
KIAA0429		
KIAA0430		
KIAA0431		
KIAA0433	AR	deafness, 100, 618422 (3),
KIAA0435		
KIAA0436	AR	myasthenic syndrome, congenital, 22, 616224 (3),
KIAA0437	AD	schinzel-giedion midface retraction syndrome, 269150 (3), ; intellectual developmental disorder, 29, 616078 (3),
KIAA0438		
KIAA0439	AD	periventricular nodular heterotopia 7, 617201 (3),
KIAA0440		
KIAA0441	AR	immunodeficiency-centromeric instability-facial anomalies syndrome 2, 614069 (3),
KIAA0442	AD	intellectual developmental disorder, 26, 615834 (3),
KIAA0446		
KIAA0448	AR	neurofacioskeletal syndrome with or without renal agenesis, 619194 (3),
KIAA0449		
KIAA0450		
KIAA0451		
KIAA0452		
KIAA0453	AR	spinocerebellar ataxia, 4, 607317 (3),
KIAA0454		
KIAA0455		
KIAA0456		
KIAA0458	AD	neurodevelopmental disorder with or without anomalies of the brain, eye, or heart, 616975 (3),
KIAA0459		
KIAA0460		
KIAA0461	AD	white-sutton syndrome, 616364 (3),
KIAA0462		
KIAA0463		
KIAA0464	AR	nephrotic syndrome, type 22, 619155 (3),
KIAA0465	AD	lissencephaly 9 with complex brainstem malformation, 618325 (3),
KIAA0467	AR	developmental and epileptic encephalopathy 18, 615476 (3),
KIAA0469		
KIAA0470		
KIAA0471		
KIAA0472	AD,AR	congenital anomalies of kidney and urinary tract 1, 610805 (3), ; spastic paraplegia 23, 270750 (3),
KIAA0473	AR	parkinson disease 19a, juvenile-onset, 615528 (3), ; parkinson disease 19b, early-onset, 615528 (3),
KIAA0474		
KIAA0475		
KIAA0476		
KIAA0477		
KIAA0478		
KIAA0479		
KIAA0480		
KIAA0483	AD	developmental and epileptic encephalopathy 100, 619777 (3),
KIAA0487		
KIAA0488		
KIAA0491		
KIAA0494		
KIAA0496		
KIAA0500		
KIAA0507		
KIAA0512		
KIAA0513		
KIAA0514		
KIAA0515		
KIAA0516		
KIAA0517	AR	charcot-marie-tooth disease, type 2r, 615490 (3),
KIAA0518		
KIAA0521	AR	retinitis pigmentosa 78, 617433 (3),
KIAA0522	XL,XLD	intellectual developmental disorder, 1, 309530 (3),
KIAA0523		
KIAA0524		
KIAA0525		
KIAA0526	AD	neuropathy, hereditary sensory and autonomic, type ic, 613640 (3),
KIAA0527		
KIAA0528		
KIAA0529		
KIAA0530	AD	intellectual developmental disorder, 64, 619188 (3),
KIAA0534		
KIAA0535		
KIAA0536		
KIAA0537		
KIAA0538		
KIAA0539		
KIAA0540	AR	gray platelet syndrome, 139090 (3),
KIAA0541		
KIAA0542		
KIAA0543		
KIAA0544		
KIAA0545	AR	?cataract 45, 616851 (3),
KIAA0547		
KIAA0549		
KIAA0550		
KIAA0551	AR	intellectual developmental disorder, 54, 617028 (3),
KIAA0552		
KIAA0553		
KIAA0554		
KIAA0555		
KIAA0556	AR	joubert syndrome 26, 616784 (3),
KIAA0558	AR	cerebellar atrophy with seizures and variable developmental delay, 618501 (3),
KIAA0559	AR	?pontocerebellar hypoplasia, type 3, 608027 (3),
KIAA0560		
KIAA0561	AD	developmental and epileptic encephalopathy 108, 620115 (3),
KIAA0562	AR	joubert syndrome 25, 616781 (3), ; intellectual developmental disorder, 77, 619988 (3),
KIAA0563		
KIAA0564	AD	?retinitis pigmentosa 97, 620422 (3),
KIAA0565		
KIAA0566		
KIAA0567	AD,AR	optic atrophy plus syndrome, 125250 (3), ; {glaucoma, normal tension, susceptibility to}, 606657 (3); optic atrophy 1, 165500 (3), ; behr syndrome, 210000 (3), ; ?mitochondrial dna depletion syndrome 14 (encephalocardiomyopathic type), 616896 (3),
KIAA0569	AD	mowat-wilson syndrome, 235730 (3),
KIAA0570		
KIAA0571		
KIAA0572	AR	peripheral neuropathy, with or without impaired intellectual development, 618124 (3),
KIAA0573		
KIAA0574		
KIAA0575		
KIAA0576		
KIAA0578	AR	pitt-hopkins-like syndrome 2, 614325 (3), ; {schizophrenia, susceptibility to, 17}, 614332 (3)
KIAA0581	AR	developmental and epileptic encephalopathy 12, 613722 (3),
KIAA0582		
KIAA0583		
KIAA0584		
KIAA0585		
KIAA0586	AR	short-rib thoracic dysplasia 14 with polydactyly, 616546 (3), ; joubert syndrome 23, 616490 (3),
KIAA0588		
KIAA0589	AR	lethal congenital contractural syndrome 3, 611369 (3),
KIAA0590	AR	short-rib thoracic dysplasia 9 with or without polydactyly, 266920 (3), ; retinitis pigmentosa 80, 617781 (3),
KIAA0591	AD	{neuroblastoma, susceptibility to, 1}, 256700 (3), somatic mutation, ; charcot-marie-tooth disease, type 2a1, 118210 (3),
KIAA0592		
KIAA0593	AD	intellectual developmental disorder, 61, 618009 (3),
KIAA0594	AR	atelis syndrome 2, 620185 (3),
KIAA0595		
KIAA0596	AR	nephronophthisis 20, 617271 (3),
KIAA0598		
KIAA0599		
KIAA0600		
KIAA0601	AD	cleft palate, psychomotor retardation, and distinctive facial features, 616728 (3),
KIAA0602	AD	developmental and epileptic encephalopathy 66, 618067 (3),
KIAA0603		{diabetes mellitus, noninsulin-dependent, 5}, 616087 (3)
KIAA0604		
KIAA0605	AR	geleophysic dysplasia 1, 231050 (3),
KIAA0606		
KIAA0608		
KIAA0609	AR	muscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type b, 6, 608840 (3), ; muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 6, 613154 (3),
KIAA0610	AR	troyer syndrome, 275900 (3),
KIAA0611	AR	neurodevelopmental disorder with poor growth and behavioral abnormalities, 620242 (3),
KIAA0612		
KIAA0613	AD	left ventricular noncompaction 3, 601493 (3), ; cardiomyopathy, hypertrophic, 24, 601493 (3), ; myopathy, myofibrillar, 4, 609452 (3), ; cardiomyopathy, dilated, 1c, with or without lvnc, 601493 (3),
KIAA0614	AR	neurodevelopmental disorder with seizures, spasticity, and complete or partial agenesis of the corpus callosum, 620250 (3),
KIAA0616		mucoepidermoid salivary gland carcinoma (3)
KIAA0618		
KIAA0620	AR	congenital heart defects, multiple types, 9, 620294 (3),
KIAA0621		leukemia, juvenile myelomonocytic, somatic, 607785 (3)
KIAA0622		
KIAA0623		
KIAA0625	AR,AD	spinocerebellar ataxia, with axonal neuropathy 2, 606002 (3), ; amyotrophic lateral sclerosis 4, juvenile, 602433 (3),
KIAA0626		
KIAA0627		
KIAA0629		
KIAA0630		
KIAA0631		
KIAA0632		
KIAA0633		
KIAA0634		
KIAA0635	AR	microcephaly 8, primary, 614673 (3),
KIAA0637		
KIAA0638		
KIAA0639		
KIAA0640		
KIAA0641		
KIAA0642		{parkinson disease 11}, 607688 (3)
KIAA0643		
KIAA0644		
KIAA0645	AD	epilepsy, familial focal, with variable foci 1, 604364 (3),
KIAA0646		
KIAA0647		
KIAA0648		
KIAA0649		
KIAA0650	AD	bosma arhinia microphthalmia syndrome, 603457 (3), ; fascioscapulohumeral muscular dystrophy 2, digenic, 158901 (3), digenic
KIAA0651	AR	?neurodevelopmental disorder with midbrain and hindbrain malformations, 617523 (3),
KIAA0652		
KIAA0653		
KIAA0654		
KIAA0655		
KIAA0656		
KIAA0657	AR	3-m syndrome 2, 612921 (3),
KIAA0659		
KIAA0660		
KIAA0661		
KIAA0662		
KIAA0663		
KIAA0664		
KIAA0665		
KIAA0666		
KIAA0667		
KIAA0669		
KIAA0670		
KIAA0671		
KIAA0672		
KIAA0673	AR	senior-loken syndrome 4, 606996 (3), ; nephronophthisis 4, 606966 (3),
KIAA0674		
KIAA0676		
KIAA0677		
KIAA0678		
KIAA0680		
KIAA0681		
KIAA0682		
KIAA0683	AR	you-hoover-fong syndrome, 616954 (3),
KIAA0684		
KIAA0685		
KIAA0686	AR,AD	usher syndrome, type 2c, 605472 (3), digenic ; usher syndrome, type 2c, gpr98/pdzd7 digenic, 605472 (3), digenic ; ?febrile seizures, familial, 4, 604352 (3),
KIAA0688		
KIAA0689		
KIAA0690		
KIAA0691	AD	intellectual developmental disorder with speech delay, autism, and dysmorphic facies, 618672 (3),
KIAA0692	AR	microcephaly 16, primary, 616681 (3),
KIAA0693		
KIAA0694		
KIAA0696	AD	neurodevelopmental, jaw, eye, and digital syndrome, 618914 (3),
KIAA0697	AD	chopra-amiel-gordon syndrome, 619504 (3),
KIAA0698		
KIAA0699	AD	spinal muscular atrophy, lower extremity-pre, 2b, 618291 (3), ; spinal muscular atrophy, lower extremity-pre, 2a, 615290 (3),
KIAA0700	AD	witteveen-kolk syndrome, 613406 (3),
KIAA0701		
KIAA0702	AR	night blindness, congenital stationary (complete), 1d, 613830 (3),
KIAA0703		
KIAA0704		
KIAA0705	AR	nephrotic syndrome, type 15, 617609 (3),
KIAA0707		
KIAA0708		
KIAA0709		
KIAA0710		
KIAA0711		
KIAA0712		
KIAA0713		
KIAA0714		
KIAA0715		
KIAA0716		
KIAA0717	AD	developmental and epileptic encephalopathy 64, 618004 (3),
KIAA0718		
KIAA0719		
KIAA0720	AR	spinal muscular atrophy, distal, 4, 611067 (3), ; charcot-marie-tooth disease, intermediate c, 615376 (3),
KIAA0721		
KIAA0723	AD	amyotrophic lateral sclerosis 21, 606070 (3),
KIAA0724		
KIAA0725	AR	spastic paraplegia 54, 615033 (3),
KIAA0726		
KIAA0727		
KIAA0728	AR	neuropathy, hereditary sensory and autonomic, type vi, 614653 (3), ; epidermolysis bullosa simplex 3, localized or generalized intermediate, with bp230 deficiency, 615425 (3),
KIAA0729		
KIAA0730	AR	spastic ataxia, charlevoix-saguenay type, 270550 (3),
KIAA0731		
KIAA0732		
KIAA0733	AD	congenital heart defects, nonsyndromic, 2, 614980 (3),
KIAA0734		
KIAA0735		
KIAA0736		
KIAA0737		
KIAA0738		
KIAA0740		
KIAA0741		
KIAA0742		
KIAA0743		
KIAA0744		
KIAA0745		
KIAA0746		
KIAA0747		
KIAA0748		
KIAA0749		
KIAA0750		
KIAA0751	AR	cone-rod synaptic disorder syndrome, congenital nonprogressive, 618970 (3),
KIAA0753	AR	?orofaciodigital syndrome xv, 617127 (3), ; ?joubert syndrome 38, 619476 (3), ; short-rib thoracic dysplasia 21 without polydactyly, 619479 (3),
KIAA0754	AD	lissencephaly 9 with complex brainstem malformation, 618325 (3),
KIAA0755	AR	cole-carpenter syndrome 2, 616294 (3),
KIAA0756	AR	neurodevelopmental disorder with central and peripheral motor dysfunction, 618356 (3),
KIAA0757		
KIAA0759		
KIAA0759L		
KIAA0760	AR,AD	nephronophthisis 14, 614844 (3), ; joubert syndrome 19, 614844 (3),
KIAA0762		
KIAA0763	AR	intellectual developmental disorder with short stature and behavioral abnormalities, 618687 (3),
KIAA0764		
KIAA0765	AD	{schizophrenia 19, susceptibility to}, 617629 (3),
KIAA0766		
KIAA0767		
KIAA0768		
KIAA0769		
KIAA0770		
KIAA0771		
KIAA0772	AD	deafness, 67, 616340 (3),
KIAA0773		
KIAA0774		
KIAA0775		
KIAA0776		
KIAA0777		
KIAA0779		
KIAA0780		
KIAA0781		
KIAA0783		
KIAA0784	AD	helsmoortel-van der aa syndrome, 615873 (3),
KIAA0785		
KIAA0786		
KIAA0787		
KIAA0788	AD	retinitis pigmentosa 33, 610359 (3),
KIAA0789		
KIAA0790	AD,AR	dyschromatosis universalis hereditaria 1, 127500 (3), ; ?cancer, alopecia, pigment dyscrasia, onychodystrophy, and keratoderma, 618373 (3),
KIAA0791	AR	?atrial fibrillation 15, 615770 (3),
KIAA0792	AD	leukodystrophy, hypomyelinating, 19, transient infantile, 618688 (3),
KIAA0793		
KIAA0794		
KIAA0795		
KIAA0796	AR,AD	arthrogryposis multiplex congenita 3, myogenic type, 618484 (3), ; emery-dreifuss muscular dystrophy 4, 612998 (3), ; spinocerebellar ataxia, 8, 610743 (3),
KIAA0797		
KIAA0799		
KIAA0800		
KIAA0801		
KIAA0802		
KIAA0803	AD	?long qt syndrome 11, 611820 (3),
KIAA0804		
KIAA0805		
KIAA0806	AR	urofacial syndrome 2, 615112 (3),
KIAA0807		
KIAA0808		
KIAA0809		
KIAA0810		
KIAA0819		
KIAA0820		
KIAA0821	AD	developmental delay, behavioral abnormalities, and neuropsychiatric disorders, 620065 (3),
KIAA0822		
KIAA0823		
KIAA0824		
KIAA0825	AR	polydactyly, postaxial, type a10, 618498 (3),
KIAA0827		
KIAA0828		
KIAA0829		
KIAA0830		
KIAA0831		
KIAA0833	AD	cerebellar dysfunction with variable cognitive and behavioral abnormalities, 614756 (3),
KIAA0836		
KIAA0837		myelodysplastic syndrome (3); myelogenous leukemia, acute (3)
KIAA0838	AR,AD	global developmental delay, progressive ataxia, and elevated glutamine, 618412 (3), ; ?infantile cataract, skin abnormalities, glutamate excess, and impaired intellectual development, 618339 (3), ; developmental and epileptic encephalopathy 71, 618328 (3),
KIAA0839	AR	martsolf syndrome 1, 212720 (3), ; warburg micro syndrome 2, 614225 (3),
KIAA0840		
KIAA0841		
KIAA0842		
KIAA0843		
KIAA0844		{nephrolithiasis, uric acid, susceptibility to}, 605990 (3)
KIAA0846		
KIAA0847	AD	spinocerebellar ataxia 11, 604432 (3),
KIAA0848		
KIAA0849	AD	brooke-spiegler syndrome, 605041 (3), ; cylindromatosis, familial, 132700 (3), ; trichoepithelioma, multiple familial, 1, 601606 (3), ; ?frontotemporal dementia and/or amyotrophic lateral sclerosis 8, 619132 (3),
KIAA0850	AD	immunodeficiency 70, 618969 (3),
KIAA0851		
KIAA0852	AD	charcot-marie-tooth disease, axonal, type 2z, 616688 (3), ; developmental delay, impaired growth, dysmorphic facies, and axonal neuropathy, 619090 (3),
KIAA0853		
KIAA0854		
KIAA0856	AR,AD	developmental and epileptic encephalopathy 81, 618663 (3), ; ?deafness, 71, 617605 (3), ; ?polyendocrine-polyneuropathy syndrome, 616113 (3),
KIAA0857		
KIAA0858		
KIAA0859	AR,AD	{?deafness, 26, modifier of}, 605429 (3),
KIAA0860		
KIAA0861		
KIAA0862	AD	noonan syndrome-like with loose anagen hair 1, 607721 (3),
KIAA0863		
KIAA0865		
KIAA0867		
KIAA0868	AR	pitt-hopkins like syndrome 1, 610042 (3), ; {autism susceptibility 15}, 612100 (3)
KIAA0869		[memory, enhanced, qtl], 615602 (3)
KIAA0870		
KIAA0871		
KIAA0872		
KIAA0874		
KIAA0875		
KIAA0876	AD	intellectual developmental disorder, 65, 619320 (3),
KIAA0877		
KIAA0878		
KIAA0879		
KIAA0881		
KIAA0882		
KIAA0884	AR	neurodevelopmental disorder with hypotonia, neonatal respiratory insufficiency, and thermodysregulation, 618797 (3),
KIAA0886		
KIAA0887		
KIAA0888		
KIAA0889		
KIAA0890	AD	neurodevelopmental disorder with variable motor and speech impairment, 617804 (3),
KIAA0891		
KIAA0892		
KIAA0893		
KIAA0895		
KIAA0895L		
KIAA0896		
KIAA0898	AR	mulibrey nanism, 253250 (3),
KIAA0899		
KIAA0900		
KIAA0901	XLD,XL	?chondrodysplasia with platyspondyly, distinctive brachydactyly, hydrocephaly, and microphthalmia, 300863 (3),
KIAA0902	XL	intellectual developmental disorder, syndromic, houge type, 301008 (3),
KIAA0903		{prostate cancer, hereditary, 12}, 611868 (3)
KIAA0904		
KIAA0905	AR	?halperin-birk syndrome, 618651 (3),
KIAA0906		
KIAA0907		
KIAA0908		
KIAA0909		
KIAA0911		
KIAA0912	AR	microcephaly 9, primary, 614852 (3), ; seckel syndrome 5, 613823 (3),
KIAA0913		
KIAA0914		
KIAA0915		
KIAA0916		
KIAA0917		
KIAA0918		
KIAA0919	AR	spondyloepimetaphyseal dysplasia with joint laxity, type 3, 618395 (3),
KIAA0922		
KIAA0924		
KIAA0925		
KIAA0926	AR,AD	{vitiligo-associated multiple autoimmune disease susceptibility 1}, 606579 (3); ?respiratory papillomatosis, juvenile recurrent, congenital, 618803 (3), ; autoinflammation with arthritis and dyskeratosis, 617388 (3), ; palmoplantar carcinoma, multiple self-healing, 615225 (3),
KIAA0928	AD	pleuropulmonary blastoma, 601200 (3), ; goiter, multinodular 1, with or without sertoli-leydig cell tumors, 138800 (3), ; glow syndrome, somatic mosaic, 618272 (3); rhabdomyosarcoma, embryonal, 2, 180295 (3)
KIAA0929	AD	radio-tartaglia syndrome, 619312 (3),
KIAA0930		
KIAA0931		
KIAA0933		
KIAA0934		
KIAA0935		
KIAA0936	AD,AR	{epilepsy, juvenile myoclonic, susceptibility to, 10}, 617924 (3), ; endocrine-cerebroosteodysplasia, 612651 (3),
KIAA0937		
KIAA0938		
KIAA0939		
KIAA0940		
KIAA0941		
KIAA0942		
KIAA0943		
KIAA0944	AR	ciliary dyskinesia, primary, 50, 620356 (3),
KIAA0945		
KIAA0946		
KIAA0947		
KIAA0948		
KIAA0949	AR	microcephaly 17, primary, 617090 (3),
KIAA0950		
KIAA0951		
KIAA0952		
KIAA0953		
KIAA0955	AD	?inflammatory bowel disease (crohn disease) 30, 619079 (3),
KIAA0956		
KIAA0957		
KIAA0958		
KIAA0960		
KIAA0961		
KIAA0962		
KIAA0963		
KIAA0964		
KIAA0965		
KIAA0966		
KIAA0967		
KIAA0968	AD,AR	intellectual developmental disorder, 53, 617798 (3), ; ?intellectual developmental disorder, 63, 618095 (3),
KIAA0969		
KIAA0970		
KIAA0971	AR	combined oxidative phosphorylation deficiency 44, 618855 (3),
KIAA0972		
KIAA0973	AD	mega-corpus-callosum syndrome with cerebellar hypoplasia and cortical malformations, 618273 (3),
KIAA0974	AR	joubert syndrome 36, 618763 (3),
KIAA0975		
KIAA0976		
KIAA0977		
KIAA0978	AD	myelodysplastic syndrome, somatic, 614286 (3); bohring-opitz syndrome, 605039 (3),
KIAA0979		
KIAA0980		
KIAA0981	AD	corneal fleck dystrophy, 121850 (3),
KIAA0982	AD	neurooculocardiogenitourinary syndrome, 618652 (3),
KIAA0983		
KIAA0984		
KIAA0985		
KIAA0986	AR	choreoacanthocytosis, 200150 (3),
KIAA0987		
KIAA0990	AR	temtamy preaxial brachydactyly syndrome, 605282 (3),
KIAA0991	AD	amyotrophy, hereditary neuralgic, 162100 (3),
KIAA0992	AD	{pancreatic cancer, susceptibility to, 1}, 606856 (3),
KIAA0993	AD	?microcephaly 18, primary, 617520 (3),
KIAA0994		
KIAA0995		
KIAA0996	AR,AD	spermatogenic failure 47, 619102 (3), ; ?mitral valve prolapse 3, 610840 (3),
KIAA0997		
KIAA0998	AR	cone-rod dystrophy 19, 615860 (3),
KIAA0999	AR	?spondyloepimetaphyseal dysplasia, krakow type, 618162 (3),
KIAA10	AR	neurodevelopmental disorder with absent speech and movement and behavioral abnormalities, 620270 (3),
KIAA1000		
KIAA1001	AR	usher syndrome, type iv, 618144 (3),
KIAA1002		
KIAA1003		
KIAA1004		
KIAA1005	AR	joubert syndrome 7, 611560 (3), ; meckel syndrome 5, 611561 (3), ; ?coach syndrome 3, 619113 (3),
KIAA1006		
KIAA1007	AD	vissers-bodmer syndrome, 619033 (3), ; holoprosencephaly 12, with or without pancreatic agenesis, 618500 (3),
KIAA1008		
KIAA1009		
KIAA1010	AR	cataract 48, 618415 (3),
KIAA1011	AD	emery-dreifuss muscular dystrophy 5, 612999 (3),
KIAA1012		
KIAA1013		
KIAA1014		
KIAA1016		
KIAA1018	AR	interstitial nephritis, karyomegalic, 614817 (3),
KIAA1019	AD	zttk syndrome, 617140 (3),
KIAA1020		
KIAA1021	AD	?auditory neuropathy, 2, 620384 (3), ; ?leukodystrophy, hypomyelinating, 24, 619851 (3), ; deafness, 84, 619810 (3),
KIAA1023	AR	polydactyly, postaxial, type a7, 617642 (3),
KIAA1024		
KIAA1024L	AR	deafness, 120, 620238 (3),
KIAA1025	AD	impaired intellectual development and distinctive facial features with or without cardiac defects, 616789 (3),
KIAA1026		
KIAA1028	AD	developmental and epileptic encephalopathy 87, 618916 (3),
KIAA1029		
KIAA1030		
KIAA1031		
KIAA1032		
KIAA1033	AR	intellectual developmental disorder, 43, 615817 (3),
KIAA1034	AD	glass syndrome, 612313 (3),
KIAA1035	AR	neurodegeneration, childhood-onset, with cerebellar atrophy, 618276 (3),
KIAA1036		
KIAA1037		
KIAA1038		
KIAA1039		
KIAA1040		
KIAA1041		
KIAA1042	AR	developmental and epileptic encephalopathy 68, 618201 (3),
KIAA1043		
KIAA1044		
KIAA1045		
KIAA1046		
KIAA1047		
KIAA1048		
KIAA1049		
KIAA1051		
KIAA1052	AR	nephronophthisis 15, 614845 (3),
KIAA1053		
KIAA1055	AR	neurodevelopmental disorder with seizures and gingival overgrowth, 619323 (3),
KIAA1056	AD	?marsili syndrome, 147430 (3),
KIAA1057		
KIAA1058		
KIAA1059		
KIAA1060		
KIAA1063		
KIAA1064		
KIAA1065		
KIAA1066	AD	neurodevelopmental disorder with or without variable brain abnormalities, 618443 (3),
KIAA1067	AR	neurodevelopmental disorder with seizures and brain atrophy, 619072 (3),
KIAA1068		
KIAA1069	AR	holoprosencephaly 14, 619895 (3),
KIAA1070	AD	{autism, susceptibility to, 20}, 618830 (3),
KIAA1071		
KIAA1072		
KIAA1073	AR	charcot-marie-tooth disease, type 4b1, 601382 (3),
KIAA1074	AD	thrombocytopenia 2, 188000 (3),
KIAA1075		
KIAA1076	AD	intellectual developmental disorder with seizures and language delay, 619000 (3),
KIAA1077		
KIAA1078		
KIAA1079		
KIAA1080		
KIAA1081		
KIAA1082	AD	diets-jongmans syndrome, 618846 (3),
KIAA1083	AD	spastic paraplegia 4, 182601 (3),
KIAA1085		
KIAA1086		
KIAA1087		
KIAA1088	AD,AR	dyskeratosis congenita, 4, 615190 (3), ; dyskeratosis congenita, 5, 615190 (3), ; pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 3, 616373 (3),
KIAA1089		
KIAA1091	AR	developmental and epileptic encephalopathy 49, 617281 (3),
KIAA1092		
KIAA1093	AD	global developmental delay with speech and behavioral abnormalities, 619243 (3),
KIAA1094	AR	congenital disorder of glycosylation, type im, 610768 (3),
KIAA1095		
KIAA1096		
KIAA1097		
KIAA1098		
KIAA1099		
KIAA1100		
KIAA1101		
KIAA1104	AR	spinocerebellar ataxia, 30, 619405 (3),
KIAA1105		
KIAA1106	AD	intellectual developmental disorder, 39, 616521 (3),
KIAA1107		
KIAA1108		
KIAA1109	AR	alkuraya-kucinskas syndrome, 617822 (3),
KIAA1110		
KIAA1111	XL,XLR	intellectual developmental disorder, syndromic, siderius type, 300263 (3),
KIAA1112		
KIAA1113		
KIAA1114		
KIAA1115		
KIAA1116		
KIAA1117		
KIAA1118		
KIAA1119	AR	diarrhea 2, with microvillus atrophy, with or without cholestasis, 251850 (3), ; cholestasis, progressive familial intrahepatic, 10, 619868 (3),
KIAA1121		
KIAA1122	AD	basan syndrome, 129200 (3), ; huriez syndrome, 181600 (3), ; adermatoglyphia, 136000 (3),
KIAA1124	AD	chilton-okur-chung neurodevelopmental syndrome, 619841 (3),
KIAA1125		
KIAA1126		
KIAA1127		
KIAA1128		
KIAA1129	AR,AD	pseudohypoaldosteronism, type iid, 614495 (3),
KIAA1130		
KIAA1131		
KIAA1132		
KIAA1133		
KIAA1134	AR	shaheen syndrome, 615328 (3), ; congenital disorder of glycosylation, type iil, 614576 (3),
KIAA1135		
KIAA1136		
KIAA1137		
KIAA1138		
KIAA1139		
KIAA1140	AR	gastrointestinal defects and immunodeficiency syndrome, 243150 (3),
KIAA1141		
KIAA1145		
KIAA1147		
KIAA1148	AD	intellectual developmental disorder with autistic features and language delay, with or without seizures, 618906 (3),
KIAA1151		
KIAA1154	AR	nephronophthisis 19, 616217 (3), ; ?deafness, 66, 610212 (3), ; sclerosing cholangitis, neonatal, 617394 (3),
KIAA1155		
KIAA1157		
KIAA1160		
KIAA1161	AR	basal ganglia calcification, idiopathic, 7, 618317 (3),
KIAA1162		
KIAA1163		
KIAA1164		
KIAA1165		
KIAA1166	XLR,XLD,XL	wieacker-wolff syndrome, 314580 (3), ; wieacker-wolff syndrome, female-restricted, 301041 (3),
KIAA1167		
KIAA1169		
KIAA1170		
KIAA1171	AR,AD	deafness, 86, 614617 (3), ; epilepsy, rolandic, with paroxysmal exercise-induce dystonia and writer's cramp, 608105 (3), ; myoclonic epilepsy, infantile, familial, 605021 (3), ; deafness, 65, 616044 (3), ; developmental and epileptic encephalopathy 16, 615338 (3), ; doors syndrome, 220500 (3),
KIAA1172		
KIAA1173		
KIAA1174		
KIAA1175	AD	schuurs-hoeijmakers syndrome, 615009 (3),
KIAA1176	AD,AR	{epilepsy, idiopathic generalized, susceptibility to, 14}, 616685 (3), ; developmental and epileptic encephalopathy 34, 616645 (3),
KIAA1180		
KIAA1181	AR	?arthrogryposis multiplex congenita 2, neurogenic type, 208100 (3),
KIAA1182		
KIAA1183		
KIAA1184	AD	paroxysmal nonkinesigenic dyskinesia 1, 118800 (3),
KIAA1185		
KIAA1186		
KIAA1188		
KIAA1189		
KIAA1190		
KIAA1193		
KIAA1194		
KIAA1195		
KIAA1197	AD	?epilepsy, myoclonic, familial adult, 4, 615127 (3),
KIAA1198		
KIAA1199		
KIAA1201		
KIAA1202		
KIAA1203		
KIAA1205	AD	neuroocular syndrome, 619539 (3),
KIAA1207	AD	?angioedema, hereditary, 7, 619366 (3),
KIAA1208	AR	mucolipidosis iii alpha/beta, 252600 (3), ; mucolipidosis ii alpha/beta, 252500 (3),
KIAA1209		
KIAA1210		
KIAA1211		
KIAA1212	AR	?peho syndrome-like, 617507 (3),
KIAA1215	AD	neural tube defects, 182940 (3),
KIAA1217		
KIAA1219		
KIAA1220		
KIAA1221	AD	myopia 21, 614167 (3),
KIAA1222		
KIAA1223		
KIAA1224	AD	neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies, 618659 (3),
KIAA1226		
KIAA1227		
KIAA1228		
KIAA1229		
KIAA1231		
KIAA1232	XL,XLR	intellectual developmental disorder, 90, 300850 (3),
KIAA1233		
KIAA1234		
KIAA1235	AD	coffin-siris syndrome 1, 135900 (3),
KIAA1236	AR	cortical dysplasia, complex, with other brain malformations 11, 620156 (3),
KIAA1237		
KIAA1238		
KIAA1239		
KIAA1240		
KIAA1241	AR	?deafness, 112, 618257 (3),
KIAA1242	AD	developmental and epileptic encephalopathy 109, 620145 (3),
KIAA1244		
KIAA1245		
KIAA1246		
KIAA1247		
KIAA1248		
KIAA1249		
KIAA1251	AD	lissencephaly 9 with complex brainstem malformation, 618325 (3),
KIAA1253		
KIAA1254		
KIAA1255		
KIAA1256		
KIAA1259		
KIAA1260	XL	intellectual developmental disorder, 300495 (3), ; {autism susceptibility, 2}, 300495 (3),
KIAA1263		
KIAA1264		
KIAA1265		
KIAA1266		
KIAA1267	AD	koolen-de vries syndrome, 610443 (3),
KIAA1267L		
KIAA1268		
KIAA1269		
KIAA1270	AR	leukoencephalopathy, progressive, with ovarian failure, 615889 (3), ; combined oxidative phosphorylation deficiency 8, 614096 (3),
KIAA1271		
KIAA1272		
KIAA1273		
KIAA1274		
KIAA1275		
KIAA1276		
KIAA1277		
KIAA1278	AR	?ciliary dyskinesia, primary, 46, 619436 (3),
KIAA1279	AR	goldberg-shprintzen megacolon syndrome, 609460 (3),
KIAA1280		
KIAA1283	AR	anterior segment dysgenesis 8, 617319 (3),
KIAA1284	AR	?orofaciodigital syndrome xvii, 617926 (3), ; ?short-rib thoracic dysplasia 20 with polydactyly, 617925 (3),
KIAA1285		
KIAA1286		
KIAA1287		
KIAA1288		
KIAA1291		
KIAA1292		
KIAA1294	AR	?corpus callosum, agenesis of, with facial anomalies and cerebellar ataxia, 616819 (3),
KIAA1295	AR	frank-ter haar syndrome, 249420 (3),
KIAA1296		
KIAA1297	AR	centronuclear myopathy 5, 615959 (3),
KIAA1298		
KIAA1300		
KIAA1301	AD	neurodevelopmental disorder with hypotonia, seizures, and absent language, 617268 (3),
KIAA1302	AD	essential tremor, hereditary, 5, 616736 (3),
KIAA1303		
KIAA1304	AD	{thyroid cancer, nonmedullary, 2}, 188470 (3), somatic mutation,
KIAA1305		
KIAA1306		
KIAA1307		
KIAA1309		
KIAA1310		
KIAA1311		
KIAA1312		
KIAA1313	XL	developmental and epileptic encephalopathy 9, 300088 (3),
KIAA1314		
KIAA1315		
KIAA1317		
KIAA1318		
KIAA1319		
KIAA1320	AR	spastic paraplegia and psychomotor retardation with or without seizures, 616756 (3),
KIAA1321		
KIAA1322		
KIAA1323	AD	left ventricular noncompaction 7, 615092 (3),
KIAA1324		
KIAA1324L		
KIAA1327		
KIAA1328		
KIAA1329		
KIAA1330	AR	cardiomyopathy, familial hypertrophic 27, 618052 (3),
KIAA1331		
KIAA1332		
KIAA1333		
KIAA1334		
KIAA1335		
KIAA1336	AR	short-rib thoracic dysplasia 7 with or without polydactyly, 614091 (3), ; cranioectodermal dysplasia 2, 613610 (3),
KIAA1337		
KIAA1338	AR	pulmonary venoocclusive disease 2, 234810 (3),
KIAA1339		
KIAA1340		
KIAA1341		
KIAA1342		
KIAA1344		
KIAA1345	AR	coach syndrome 2, 619111 (3), ; retinitis pigmentosa 93, 619845 (3), ; meckel syndrome 6, 612284 (3), ; joubert syndrome 9, 612285 (3),
KIAA1346		
KIAA1347	AD	hailey-hailey disease, 169600 (3),
KIAA1348		
KIAA1350	AR	cholestasis, progressive familial intrahepatic, 7, with or without hearing loss, 619658 (3),
KIAA1351	AR,AD	intellectual developmental disorder, 78, 620237 (3), ; hypogonadotropic hypogonadism 14 with or without anosmia, 614858 (3),
KIAA1353		
KIAA1354		
KIAA1355		
KIAA1357		
KIAA1358		
KIAA1359		
KIAA1360	AR	arthrogryposis multiplex congenita 4, neurogenic, with agenesis of the corpus callosum, 618766 (3),
KIAA1361	AD	developmental delay with or without intellectual impairment or behavioral abnormalities, 619575 (3),
KIAA1363		
KIAA1365		
KIAA1366		
KIAA1367		
KIAA1368		
KIAA1369	AD	?leukoencephalopathy, motor delay, spasticity, and dysarthria syndrome, 618878 (3),
KIAA1370		
KIAA1371	AR	alkuraya-kucinskas syndrome, 617822 (3),
KIAA1373		
KIAA1374	AR	short-rib thoracic dysplasia 2 with or without polydactyly, 611263 (3),
KIAA1376		
KIAA1377		
KIAA1378		
KIAA1380		
KIAA1381	AR	congenital disorder of glycosylation, type iig, 611209 (3),
KIAA1382		
KIAA1383		
KIAA1384		
KIAA1385	AR	molybdenum cofactor deficiency c, 615501 (3),
KIAA1386		
KIAA1387		
KIAA1389		
KIAA1391		
KIAA1393	AR	peripheral neuropathy with variable spasticity, exercise intolerance, and developmental delay, 616539 (3),
KIAA1394		
KIAA1395	AR	adams-oliver syndrome 2, 614219 (3),
KIAA1396		
KIAA1397		
KIAA1399		
KIAA1400		
KIAA1402		
KIAA1403		
KIAA1404	AR	immunodeficiency 91 and hyperinflammation, 619644 (3),
KIAA1405		
KIAA1406		
KIAA1408		
KIAA1409		
KIAA1414		
KIAA1415		
KIAA1416	AD	hypogonadotropic hypogonadism 5 with or without anosmia, 612370 (3), ; charge syndrome, 214800 (3),
KIAA1418	AR	neurodevelopmental disorder with microcephaly, arthrogryposis, and structural brain anomalies, 618622 (3),
KIAA1419		
KIAA1421	AR	parkinson disease 23, early onset, 616840 (3),
KIAA1422	AD	developmental and epileptic encephalopathy 14, 614959 (3), ; epilepsy nocturnal frontal lobe, 5, 615005 (3),
KIAA1423		
KIAA1424		
KIAA1425		
KIAA1426		
KIAA1427		
KIAA1429		
KIAA1430		
KIAA1431		
KIAA1432	AR	catifa syndrome, 618761 (3),
KIAA1434		
KIAA1435		
KIAA1436		
KIAA1437	AD	?agammaglobulinemia 5, 613506 (3),
KIAA1438	AR	?immunodeficiency 66, 618847 (3),
KIAA1439	AD	brain malformations with or without urinary tract defects, 613735 (3),
KIAA1440	AR	neurodevelopmental disorder with cataracts, poor growth, and dysmorphic facies, 618571 (3),
KIAA1441	AD	paget disease of bone 6, 616833 (3),
KIAA1442		
KIAA1443		
KIAA1444		
KIAA1445		
KIAA1446		
KIAA1447		
KIAA1449		
KIAA1450		
KIAA1453		
KIAA1455	AR	microphthalmia, syndromic 15, 615145 (3), ; ?microphthalmia, isolated, with coloboma 9, 615145 (3),
KIAA1456		
KIAA1458		
KIAA1460	AD	?epilepsy, familial adult myoclonic, 6, 618074 (3),
KIAA1461	AD	intellectual developmental disorder, 1, 156200 (3),
KIAA1462		
KIAA1463	AD	intellectual developmental disorder, fra12a type, 136630 (3),
KIAA1464		
KIAA1465		
KIAA1467		
KIAA1468		
KIAA1471	AR	neurodevelopmental disorder and structural brain anomalies with or without seizures and spasticity, 618890 (3),
KIAA1472		
KIAA1473		
KIAA1474		
KIAA1475		
KIAA1479		
KIAA1480	XL	{autism susceptibility, 1}, 300425 (3),
KIAA1481		
KIAA1483		
KIAA1484		
KIAA1485		{autoimmune thyroid disease, susceptibility to, 3}, 608175 (3)
KIAA1486		
KIAA1486L		
KIAA1487		
KIAA1488		
KIAA1490		
KIAA1494		
KIAA1498		
KIAA1499		
KIAA1500	AR	fraser syndrome 1, 219000 (3),
KIAA1501		
KIAA1503	AR	spermatogenic failure 45, 619094 (3),
KIAA1505		
KIAA1506	AD	kleefstra syndrome 2, 617768 (3),
KIAA1507		
KIAA1509	AD,AR	?spinocerebellar ataxia 40, 616053 (3), ; hydrocephalus, congenital, 1, 236600 (3),
KIAA1510		
KIAA1511		
KIAA1512		
KIAA15131		
KIAA1514		
KIAA1515		
KIAA1516	AR	nephrotic syndrome, type 3, 610725 (3),
KIAA1517	AR,AD	neurodevelopmental disorder with brain anomalies and with or without vertebral or cardiac anomalies, 618731 (3), ; 46xy sex reversal 11, 273250 (3),
KIAA1518	AR	nephrotic syndrome, type 16, 617783 (3), ; palmoplantar keratoderma and woolly hair, 616099 (3),
KIAA1519		
KIAA1521		
KIAA1523		
KIAA1524		
KIAA1527	AD	rosah syndrome, 614979 (3),
KIAA1528		
KIAA1530	AR	uv-sensitive syndrome 3, 614640 (3),
KIAA1531		
KIAA1532		
KIAA1533		
KIAA1534		
KIAA1535		
KIAA1537		
KIAA1538		
KIAA1539		
KIAA1542		
KIAA1543		
KIAA1544	AD	neurodevelopmental disorder with or without early-onset generalized epilepsy, 619157 (3),
KIAA1545		
KIAA1546	AR	myelodysplastic syndrome, somatic, 614286 (3); immunodeficiency 75, 619126 (3),
KIAA1547		
KIAA1548		
KIAA1549	AR	retinitis pigmentosa 86, 618613 (3),
KIAA1549L		
KIAA1550		
KIAA1551		
KIAA1553		
KIAA1554	AR,AD	{moyamoya disease 2, susceptibility to}, 607151 (3),
KIAA1555		
KIAA1556	AR	{rhabdomyolysis, susceptibility to, 1}, 620235 (3),
KIAA1557	AD	coffin-siris syndrome 6, 617808 (3),
KIAA1558		
KIAA1559		
KIAA1560		
KIAA1561		
KIAA1562		
KIAA1564	AD	intellectual developmental disorder with autism and macrocephaly, 615032 (3),
KIAA1567		
KIAA1568	AD	vesicoureteral reflux 2, 610878 (3),
KIAA1569		
KIAA1570	AR	microcephaly 4, primary, 604321 (3),
KIAA1571		
KIAA1573		
KIAA1574		
KIAA1575	XLD,XL	microphthalmia, syndromic 2, 300166 (3),
KIAA1576		
KIAA1577	AD	neurodevelopmental disorder with movement abnormalities, abnormal gait, and autistic features, 617865 (3), ; acromelic frontonasal dysostosis, 603671 (3),
KIAA1579		
KIAA1580		
KIAA1582		
KIAA1585		
KIAA1587		
KIAA1589		
KIAA1592	AR	jalili syndrome, 217080 (3),
KIAA1593		
KIAA1594		
KIAA1595		
KIAA1596	AR	?premature ovarian failure 15, 618096 (3), ; spermatogenic failure 28, 618086 (3),
KIAA1597		
KIAA1598		
KIAA1599		
KIAA1600		
KIAA1601		
KIAA1602		
KIAA1604		
KIAA1605	AR	spastic paraplegia 46, 614409 (3),
KIAA1607		
KIAA1608		
KIAA1609		
KIAA1610		
KIAA1611		
KIAA1612		
KIAA1613	AR	retinitis pigmentosa 68, 615725 (3),
KIAA1616	AD	?cataract 50 with or without glaucoma, 620253 (3); neurodevelopmental disorder with hypotonia, dysmorphic facies, and skeletal anomalies, with or without seizures, 620224 (3),
KIAA1617		
KIAA1618	AR,AD	{moyamoya disease 2, susceptibility to}, 607151 (3),
KIAA1619		
KIAA1620	AR,AD	charcot-marie-tooth disease, type 4f, 614895 (3), ; dejerine-sottas disease, 145900 (3),
KIAA1621		
KIAA1622		
KIAA1623		
KIAA1624		
KIAA1625		
KIAA1626		
KIAA1627		
KIAA1630	AD,AR	?charcot-marie-tooth disease, axonal, type 2q, 615025 (3), ; alpha-aminoadipic and alpha-ketoadipic aciduria, 204750 (3),
KIAA1632	AR	vici syndrome, 242840 (3),
KIAA1635	AD	nizon-isidor syndrome, 618872 (3),
KIAA1636	AD	intellectual developmental disorder with autistic features and language delay, with or without seizures, 618906 (3),
KIAA1638	AR	nephronophthisis 13, 614377 (3), ; cranioectodermal dysplasia 4, 614378 (3), ; senior-loken syndrome 8, 616307 (3), ; short-rib thoracic dysplasia 5 with or without polydactyly, 614376 (3), ; ?spermatogenic failure 72, 619867 (3),
KIAA1639	AR	{rhabdomyolysis, susceptibility to, 1}, 620235 (3),
KIAA1640	AR	ciliary dyskinesia, primary, 15, 613808 (3),
KIAA1642	AR	neurodevelopmental disorder with hypotonia, neuropathy, and deafness, 617519 (3),
KIAA1643		
KIAA1646		
KIAA1649		
KIAA1650	AD	phelan-mcdermid syndrome, 606232 (3), ; {schizophrenia 15}, 613950 (3),
KIAA1655		
KIAA1658		
KIAA1662	AR	deafness, 28, 609823 (3),
KIAA1664		
KIAA1665		
KIAA1666		
KIAA1667	AR	hermansky-pudlak syndrome 4, 614073 (3),
KIAA1668		
KIAA1669	AR	microcephaly and chorioretinopathy, 1, 251270 (3),
KIAA1672		
KIAA1673		
KIAA1675	AD	left ventricular noncompaction 8, 615373 (3), ; cardiomyopathy, dilated, 1ll, 615373 (3),
KIAA1676		
KIAA1677	XL,XLR	intellectual developmental disorder, 103, 300982 (3),
KIAA1680		
KIAA1681		
KIAA1682		
KIAA1683	AR	spermatogenic failure 78, 620170 (3),
KIAA1684		
KIAA1685	AD	shashi-pena syndrome, 617190 (3),
KIAA1686		
KIAA1687		
KIAA1688		
KIAA1689	AR	?deafness, 112, 618257 (3),
KIAA1691		
KIAA1692		
KIAA1693		
KIAA1695	AD	cardiomyopathy, familial hypertrophic, 28, 619402 (3),
KIAA1696	AD	intellectual developmental disorder with behavioral abnormalities and craniofacial dysmorphism with or without seizures, 618725 (3),
KIAA1698		
KIAA1699		
KIAA1700		
KIAA1701		
KIAA1702		
KIAA1703	AR	simha syndrome, 619557 (3),
KIAA1705	AR	spastic paraplegia 28, 609340 (3),
KIAA1706		
KIAA1709		
KIAA1710		
KIAA1711		
KIAA1712		
KIAA1713	AD	bainbridge-ropers syndrome, 615485 (3),
KIAA1714		
KIAA1715	AR	neurodevelopmental disorder with epilepsy and hypoplasia of the corpus callosum, 618090 (3),
KIAA1717		
KIAA1718		
KIAA1721		
KIAA1722		
KIAA1724	AR	spastic paraplegia 81, 618768 (3),
KIAA1725		
KIAA1726		
KIAA1727		
KIAA1728		
KIAA1729		
KIAA1731		
KIAA1732	AD	luscan-lumish syndrome, 616831 (3), ; intellectual developmental disorder, 70, 620157 (3), ; rabin-pappas syndrome, 620155 (3),
KIAA1733	AD	developmental and epileptic encephalopathy 70, 618298 (3),
KIAA1735		
KIAA1736		
KIAA1737		
KIAA1738		
KIAA1740		
KIAA1741		
KIAA1742		
KIAA1743		
KIAA1744		
KIAA1745		
KIAA1746		
KIAA1748		
KIAA1749		
KIAA1750		
KIAA1751	AR	ciliary dyskinesia, primary, 49, without situs inversus, 620197 (3),
KIAA1752	AR	growth retardation, developmental delay, facial dysmorphism, 612938 (3), ; {obesity, susceptibility to, bmiq14}, 612460 (3),
KIAA1753		
KIAA1754		
KIAA1758		
KIAA1759		
KIAA1760		
KIAA1761		
KIAA1762	AD	?marsili syndrome, 147430 (3),
KIAA1763		
KIAA1764		
KIAA1765		
KIAA1766	AR	charcot-marie-tooth disease, type 4b2, 604563 (3),
KIAA1767		
KIAA1768		
KIAA1769		
KIAA1771	AR	developmental and epileptic encephalopathy 23, 615859 (3),
KIAA1772	AD	deafness, 80, 619274 (3), ; renal hypodysplasia/aplasia 3, 617805 (3),
KIAA1773	AD,AR	mitral valve prolapse 2, 607829 (3), ; van maldergem syndrome 1, 601390 (3),
KIAA1775	AR	macular dystrophy, retinal, 613660 (3), ; cone-rod dystrophy 15, 613660 (3), ; retinitis pigmentosa 65, 613660 (3),
KIAA1776		
KIAA1777		
KIAA1778		
KIAA1780	AR	congenital myopathy 10a, severe variant, 614399 (3), ; congenital myopathy 10b, mild variant, 620249 (3),
KIAA1781		
KIAA1784	AR	fanconi anemia, complementation group p, 613951 (3),
KIAA1785		
KIAA1786		
KIAA1787		
KIAA1788	AD,AR	parietal foramina 2, 609597 (3), ; {craniosynostosis 5, susceptibility to}, 615529 (3), ; frontonasal dysplasia 2, 613451 (3),
KIAA1789		
KIAA1790	AR	osteosclerotic metaphyseal dysplasia, 615198 (3),
KIAA1791	AD	congenital heart defects, dysmorphic facial features, and intellectual developmental disorder, 617360 (3),
KIAA1793		
KIAA1794	AR	fanconi anemia, complementation group i, 609053 (3),
KIAA1795		
KIAA1797	AR	liver disease, severe congenital, 619991 (3),
KIAA1798		
KIAA1799		
KIAA1803	AD	weiss-kruszka syndrome, 618619 (3),
KIAA1804		
KIAA1806		
KIAA1808		
KIAA1811		
KIAA1813		
KIAA1814		
KIAA1815		
KIAA1816		
KIAA1817		
KIAA1818		
KIAA1819		mucoepidermoid salivary gland carcinoma (3)
KIAA1820	AD	smith-magenis syndrome, 182290 (3), isolated cases,
KIAA1821		
KIAA1822L		
KIAA1823	XLR,XL	borjeson-forssman-lehmann syndrome, 301900 (3),
KIAA1824		
KIAA1825		
KIAA1827		
KIAA1828		
KIAA1830		
KIAA1831		
KIAA1832		
KIAA1834	AR	vascular malformation, primary intraosseous, 606893 (3),
KIAA1835		
KIAA1837		
KIAA1838		
KIAA1839	AR	pituitary hormone deficiency, combined or isolated, 7, 618160 (3),
KIAA1840	AR	amyotrophic lateral sclerosis 5, juvenile, 602099 (3), ; charcot-marie-tooth disease, axonal, type 2x, 616668 (3), ; spastic paraplegia 11, 604360 (3),
KIAA1841		
KIAA1842		
KIAA1843	AR	hypotonia, infantile, with psychomotor retardation and characteristic facies 2, 616801 (3),
KIAA1847		
KIAA1848		
KIAA1849		
KIAA1850		
KIAA1851	AR	muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 14, 615352 (3), ; muscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type b, 14, 615351 (3), ; muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 14, 615350 (3),
KIAA1852		
KIAA1853		
KIAA1854	XL	intellectual developmental disorder, 111, 301107 (3),
KIAA1855		
KIAA1857	AR	neurodevelopmental disorder with behavioral abnormalities, absent speech, and hypotonia, 618718 (3),
KIAA1858	AR	brittle cornea syndrome 1, 229200 (3),
KIAA1859		
KIAA1860		
KIAA1861	AR	neurodevelopmental disorder with microcephaly, seizures, and neonatal cholestasis, 619685 (3),
KIAA1863		
KIAA1864	AR	ciliary dyskinesia, primary, 5, 608647 (3),
KIAA1865	AD	neurodevelopmental disorder with regression, abnormal movements, loss of speech, and seizures, 618088 (3),
KIAA1866		
KIAA1867		
KIAA1868	AR	joubert syndrome 30, 617622 (3),
KIAA1869		
KIAA1870	AR	steel syndrome, 615155 (3),
KIAA1876	AD	kleefstra syndrome 1, 610253 (3),
KIAA1877		
KIAA1878		
KIAA1879		
KIAA1880		
KIAA1881		
KIAA1882	AR	intellectual developmental disorder, 13, 613192 (3),
KIAA1883		
KIAA1884		
KIAA1885	AR	combined oxidative phosphorylation deficiency 20, 615917 (3),
KIAA1886		
KIAA1887		
KIAA1890		
KIAA1891		
KIAA1892		
KIAA1893		
KIAA1895	AD	kenny-caffey syndrome, type 2, 127000 (3), ; gracile bone dysplasia, 602361 (3),
KIAA1896		
KIAA1898		
KIAA1899		
KIAA1901	AR,AD	short-rib thoracic dysplasia 6 with or without polydactyly, 263520 (3), digenic ; {amyotrophic lateral sclerosis, susceptibility to, 24}, 617892 (3),
KIAA1902		
KIAA1903		
KIAA1904		
KIAA1905		
KIAA1906		
KIAA1910	AD,MF	tourette syndrome, 137580 (3), ; ?trichotillomania, 613229 (3),
KIAA1911		
KIAA1914		
KIAA1915	AR	bone marrow failure syndrome 4, 618116 (3),
KIAA1916		
KIAA1918		
KIAA1919		
KIAA1924		
KIAA1925		
KIAA1926		
KIAA1927		
KIAA1929		
KIAA1931		
KIAA1932		
KIAA1933	AR	short stature, brachydactyly, intellectual developmental disability, and seizures, 617157 (3),
KIAA1934		
KIAA1935		
KIAA1936		
KIAA1938	AD	intellectual developmental disorder, 5, 612621 (3),
KIAA1939		
KIAA1940		
KIAA1941		
KIAA1944		
KIAA1945		
KIAA1946		
KIAA1947		
KIAA1949		
KIAA1950		
KIAA1951	AR	dentici-novelli neurodevelopmental syndrome, 619877 (3),
KIAA1952		
KIAA1954		
KIAA1955		
KIAA1956		
KIAA1957		
KIAA1958		
KIAA1959		
KIAA1960		
KIAA1961	AR	immunodeficiency 93 and hypertrophic cardiomyopathy, 619705 (3),
KIAA1966		
KIAA1967		
KIAA1968		
KIAA1969		
KIAA1970	AR	combined oxidative phosphorylation deficiency 12, 614924 (3),
KIAA1971		
KIAA1972	AR	spondyloepimetaphyseal dysplasia, faden-alkuraya type, 616723 (3),
KIAA1976		
KIAA1977		
KIAA1978		
KIAA1981		
KIAA1983	AR	hennekam lymphangiectasia-lymphedema syndrome 1, 235510 (3),
KIAA1984		
KIAA1985	AR,AD	charcot-marie-tooth disease, type 4c, 601596 (3), ; mononeuropathy of the median nerve, mild, 613353 (3),
KIAA1987	AR	fanconi anemia, complementation group p, 613951 (3),
KIAA1988		
KIAA1989		
KIAA1991		
KIAA1993		
KIAA1996	AR	retinal dystrophy with leukodystrophy, 618863 (3),
KIAA1999		
KIAA2000	AR	nephronophthisis 3, 604387 (3), ; renal-hepatic-pancreatic dysplasia 1, 208540 (3), ; meckel syndrome 7, 267010 (3),
KIAA2002		
KIAA2004	AR,AD	tumoral calcinosis, familial, normophosphatemic, 610455 (3), ; monosomy 7 myelodysplasia and leukemia syndrome 2, 619041 (3), ; mirage syndrome, 617053 (3),
KIAA2005	AD	ataxia-pancytopenia syndrome, 159550 (3), ; monosomy 7 myelodysplasia and leukemia syndrome 1, 252270 (3), ; spinocerebellar ataxia 49, 619806 (3),
KIAA2010		
KIAA2011		
KIAA2015		
KIAA2018		
KIAA2022	XL,XLD	intellectual developmental disorder, 98, 300912 (3),
KIAA2023		
KIAA2024		
KIAA2025		?immune dysregulation and systemic hyperinflammation syndrome, 618998 (3)
KIAA2028		
KIAA2030		
KIAA2031		
KIAA2034	AD	?peripheral neuropathy, myopathy, hoarseness, and hearing loss, 614369 (3), ; deafness, 4a, 600652 (3),
KIAA2038		
KIAA2138		
KIAA3016		
KIAA4091		
KIAA9001		
KIAP		
KIBRA		[memory, enhanced, qtl], 615602 (3)
KICS1	AR	developmental and epileptic encephalopathy 18, 615476 (3),
KICS2		
KICS3		
KICS4	AR	intellectual developmental disorder, 41, 615637 (3),
Kid	AD	spondyloepimetaphyseal dysplasia with joint laxity, type 2, 603546 (3),
KID-1		
KID1		
KID3		
KIDCR	AR	[pentosuria], 260800 (3),
KIDINS220	AD,AR	spastic paraplegia, intellectual disability, nystagmus, and obesity, 617296 (3), ; ventriculomegaly and arthrogryposis, 619501 (3),
KIDLIA	XL,XLD	intellectual developmental disorder, 98, 300912 (3),
KIF10	AR	?microcephaly 13, primary, 616051 (3),
KIF11	AD	microcephaly with or without chorioretinopathy, lymphedema, or mental retardation, 152950 (3),
KIF12	AR	cholestasis, progressive familial intrahepatic, 8, 619662 (3),
KIF13A		
KIF13B		
KIF14	AR	microcephaly 20, primary, 617914 (3), ; ?meckel syndrome 12, 616258 (3),
KIF15	AR	?braddock-carey syndrome 2, 619981 (3),
KIF16A		
KIF16B		
KIF17		
KIF17B		
KIF18A		
KIF18B		
KIF19		
KIF19A		
KIF1A	AD,AR	nescav syndrome, 614255 (3), ; neuropathy, hereditary sensory, type iic, 614213 (3), ; spastic paraplegia 30, 610357 (3), ; spastic paraplegia 30, 610357 (3),
KIF1B	AD	{neuroblastoma, susceptibility to, 1}, 256700 (3), somatic mutation, ; charcot-marie-tooth disease, type 2a1, 118210 (3),
KIF1BP	AR	goldberg-shprintzen megacolon syndrome, 609460 (3),
KIF1C	AR	spastic ataxia 2, 611302 (3),
KIF2	AD	cortical dysplasia, complex, with other brain malformations 3, 615411 (3),
KIF20A	AR	?cardiomyopathy, familial restrictive, 6, 619433 (3),
KIF20B		
KIF21A	AD	fibrosis of extraocular muscles, congenital, 3b, 135700 (3), ; fibrosis of extraocular muscles, congenital, 1, 135700 (3),
KIF21B		
KIF22	AD	spondyloepimetaphyseal dysplasia with joint laxity, type 2, 603546 (3),
KIF23	AD	anemia, congenital dyserythropoietic, type iiia, 105600 (3),
KIF24		
KIF25		
KIF26A	AR	cortical dysplasia, complex, with other brain malformations 11, 620156 (3),
KIF26B		
KIF27		
KIF2A	AD	cortical dysplasia, complex, with other brain malformations 3, 615411 (3),
KIF2B		
KIF2C		
KIF3A		
KIF3B	AD	retinitis pigmentosa 89, 618955 (3),
KIF3C		
KIF3X		
KIF4	XL,XLR	?intellectual developmental disorder, 100, 300923 (3),
KIF4-G1	XL,XLR	?intellectual developmental disorder, 100, 300923 (3),
KIF4A	XL,XLR	?intellectual developmental disorder, 100, 300923 (3),
KIF4B		
KIF5A	AD	myoclonus, intractable, neonatal, 617235 (3), ; {amyotrophic lateral sclerosis, susceptibility to, 25}, 617921 (3), ; spastic paraplegia 10, 604187 (3),
KIF5B		
KIF5C	AD	cortical dysplasia, complex, with other brain malformations 2, 615282 (3),
KIF6		
KIF7	AR	joubert syndrome 12, 200990 (3), ; acrocallosal syndrome, 200990 (3), ; ?hydrolethalus syndrome 2, 614120 (3), ; ?al-gazali-bakalinova syndrome, 607131 (3),
KIF9		
KIFAP3		
KIFBP	AR	goldberg-shprintzen megacolon syndrome, 609460 (3),
KIFC1		
KIFC2		
KIFC3		
KILLER	AR	squamous cell carcinoma, head and neck, 275355 (3),
killin		cowden syndrome 4, 615107 (3)
KILON		
KIM1		
KIN		
KIN17		
kinastrin		?roifman-chitayat syndrome, digenic, 613328 (3), digenic
KIND1	AR	kindler syndrome, 173650 (3),
KIND2		
KIND3	AR	leukocyte adhesion deficiency, type iii, 612840 (3),
KINO		
KIP	AR	epidermodysplasia verruciformis 3, 618267 (3),
KIP1	AD	multiple endocrine neoplasia, type iv, 610755 (3),
KIP2	AR,AD,AD	deafness, 48, 609439 (3), ; usher syndrome, type ij, 614869 (3), |image syndrome, 614732 (3), ; beckwith-wiedemann syndrome, 130650 (3), |wilms tumor 2, 194071 (3), somatic mutation, ; beckwith-wiedemann syndrome, 130650 (3), ; silver-russell syndrome 1, 180860 (3),
KIP3		
KIPP1184	AD	paroxysmal nonkinesigenic dyskinesia 1, 118800 (3),
KIR		{aids, delayed/rapid progression to}, 609423 (3)
Kir1.1	AR	bartter syndrome, type 2, 241200 (3),
Kir1.2	AR	enlarged vestibular aqueduct, digenic, 600791 (3), ; sesame syndrome, 612780 (3),
Kir1.3		
Kir1.4	AD,AR	snowflake vitreoretinal degeneration, 193230 (3), ; leber congenital amaurosis 16, 614186 (3),
Kir2.1	AD	atrial fibrillation, familial, 9, 613980 (3), ; andersen syndrome, 170390 (3), ; short qt syndrome 3, 609622 (3)
Kir2.2		
Kir2.2v		
Kir2.3		
Kir2.4		
KIR2.6	AD	{thyrotoxic periodic paralysis, susceptibility to, 2}, 613239 (3),
KIR2DL1		
KIR2DL2		
KIR2DL3		
KIR2DL4		
KIR2DL5		
KIR2DL5.1		
KIR2DL5.2		
KIR2DL5.3		
KIR2DL5.4		
KIR2DL5A		
KIR2DL5B		
KIR2DS1		
KIR2DS2		
KIR2DS3		
KIR2DS4		
KIR2DS5		
KIR2DS6		
Kir3.1		
Kir3.2	AD	keppen-lubinsky syndrome, 614098 (3),
Kir3.3		
Kir3.4	AD	long qt syndrome 13, 613485 (3), ; hyperaldosteronism, familial, type iii, 613677 (3),
KIR3DL1		{aids, delayed/rapid progression to}, 609423 (3)
KIR3DL2		
KIR3DL3		
KIR3DL7		
KIR3DP1		
KIR3DS2P		
Kir4.1	AR	enlarged vestibular aqueduct, digenic, 600791 (3), ; sesame syndrome, 612780 (3),
Kir4.2		
KIR44		
KIR48		
Kir5.1	AR	hypokalemic tubulopathy and deafness, 619406 (3),
Kir6.1		
Kir6.2	AD,AR	diabetes, permanent neonatal 2, with or without neurologic features, 618856 (3), ; {diabetes mellitus, type 2, susceptibility to}, 125853 (3), ; maturity-onset diabetes of the young, type 13, 616329 (3), ; diabetes mellitus, transient neonatal 3, 610582 (3), ; hyperinsulinemic hypoglycemia, familial, 2, 601820 (3),
Kir7.1	AD,AR	snowflake vitreoretinal degeneration, 193230 (3), ; leber congenital amaurosis 16, 614186 (3),
KIRC1		
KIRRE		
KIRREL	AR	nephrotic syndrome, type 23, 619201 (3),
KIRREL1	AR	nephrotic syndrome, type 23, 619201 (3),
KIRREL2		
KIRREL3		
KIRX		
KIS		
kish		
KISS1	AR	?hypogonadotropic hypogonadism 13 with or without anosmia, 614842 (3),
KISS1R	AR,AD	hypogonadotropic hypogonadism 8 with or without anosmia, 614837 (3), ; ?precocious puberty, central, 1, 176400 (3),
Kist		
KIT	AD	gastrointestinal stromal tumor, familial, 606764 (3), isolated cases, ; mastocytosis, cutaneous, 154800 (3), ; piebaldism, 172800 (3), ; germ cell tumors, somatic, 273300 (3); mastocytosis, systemic, somatic, 154800 (3); leukemia, acute myeloid, somatic, 601626 (3)
Kitl	AD,AR	hyperpigmentation with or without hypopigmentation, 145250 (3), ; waardenburg syndrome, type 2f, 619947 (3), ; deafness, 69, unilateral or asymmetric, 616697 (3), ; [skin/hair/eye pigmentation 7, blond/brown hair], 611664 (3)
KITLG	AD,AR	hyperpigmentation with or without hypopigmentation, 145250 (3), ; waardenburg syndrome, type 2f, 619947 (3), ; deafness, 69, unilateral or asymmetric, 616697 (3), ; [skin/hair/eye pigmentation 7, blond/brown hair], 611664 (3)
KIZ	AR	retinitis pigmentosa 69, 615780 (3),
KK-LC-1		
KKA3		
KKIALRE		
KKIAMRE		
KKLF		
KL	AR	?tumoral calcinosis, hyperphosphatemic, familial, 3, 617994 (3),
KL-1	AD,AR	hyperpigmentation with or without hypopigmentation, 145250 (3), ; waardenburg syndrome, type 2f, 619947 (3), ; deafness, 69, unilateral or asymmetric, 616697 (3), ; [skin/hair/eye pigmentation 7, blond/brown hair], 611664 (3)
KL-6	AD	tubulointerstitial kidney disease, 2, 174000 (3),
KLA	AR	?tumoral calcinosis, hyperphosphatemic, familial, 3, 617994 (3),
KLB		
KLC		
KLC1		
KLC2	AR	spastic paraplegia, optic atrophy, and neuropathy, 609541 (3),
KLC2L		
KLC3		
KLCt		
KLEIP		
kleisin-alpha		
KLF1	AD	blood group--lutheran inhibitor, 111150 (3); dyserythropoietic anemia, congenital, type iv, 613673 (3), ; [hereditary persistence of fetal hemoglobin], 613566 (3)
KLF10		
KLF11		maturity-onset diabetes of the young, type vii, 610508 (3)
KLF12		
KLF13		
KLF14	AD	amelogenesis imperfecta, type ik, 620104 (3),
KLF15		
KLF16		
KLF17		
KLF2		
KLF3		
KLF4		
KLF5		
KLF6		gastric cancer, somatic, 613659 (3); prostate cancer, somatic, 176807 (3)
KLF7		
KLF8		
KLF9		
KLG		
KLHDC1		
KLHDC10		
KLHDC2		
KLHDC3		
KLHDC5		
KLHDC7C		
KLHDC8A		
KLHDC8B	AR	{hodgkin lymphoma, susceptibility to}, 236000 (3),
KLHDC9		
KLHL1		
KLHL10	AD	spermatogenic failure 11, 615081 (3),
KLHL11		
KLHL12		
KLHL13		
KLHL14		
KLHL15	XL,XLR	intellectual developmental disorder, 103, 300982 (3),
KLHL16	AR	giant axonal neuropathy-1, 256850 (3),
KLHL17		
KLHL18		
KLHL19		
KLHL1AS	MF,AD	{parkinson disease, susceptibility to}, 168600 (3), ; spinocerebellar ataxia 8, 608768 (3),
KLHL2		
KLHL20		
KLHL21		
KLHL22		
KLHL24	AR,AD	cardiomyopathy, familial hypertrophic, 29, with polyglucosan bodies, 620236 (3), ; epidermolysis bullosa simplex 6, generalized intermediate, with or without cardiomyopathy, 617294 (3),
KLHL25		
KLHL27		
KLHL3	AR,AD	pseudohypoaldosteronism, type iid, 614495 (3),
KLHL31		
KLHL37		
KLHL39	AD	immunodeficiency 70, 618969 (3),
KLHL4		
KLHL40	AR	nemaline myopathy 8, 615348 (3),
KLHL41	AR	nemaline myopathy 9, 615731 (3),
KLHL42		
KLHL5		
KLHL6	AD,AR	retinitis pigmentosa 42, 612943 (3), ; perching syndrome, 617055 (3),
KLHL7	AD,AR	retinitis pigmentosa 42, 612943 (3), ; perching syndrome, 617055 (3),
KLHL8		
KLHL9		
KLIP		
KLIP1		
KLK-L1	AR	amelogenesis imperfecta, type iia1, 204700 (3),
KLK-L2		
KLK-L3		
KLK-L4		
KLK-L5		
KLK-L6		
KLK1		[kallikrein, decreased urinary activity of], 615953 (3)
KLK10		
KLK11		
KLK12		
KLK13		
KLK14		
KLK15		
KLK2		
KLK3	AR	fletcher factor (prekallikrein) deficiency, 612423 (3),
KLK4	AR	amelogenesis imperfecta, type iia1, 204700 (3),
KLK5		
Klk6		[kallikrein, decreased urinary activity of], 615953 (3)
KLK6		
Klk7		
KLK7		
KLK8		
KLK9		
KLKB1	AR	fletcher factor (prekallikrein) deficiency, 612423 (3),
KLLN		cowden syndrome 4, 615107 (3)
KLP	AD	{neuroblastoma, susceptibility to, 1}, 256700 (3), somatic mutation, ; charcot-marie-tooth disease, type 2a1, 118210 (3),
KLP-11	AD	retinitis pigmentosa 89, 618955 (3),
KLP-2		
KLP-20		
KLPH		
KLR		
KLRA1		
KLRA1P		
KLRAP1		
KLRAQ1	AR	neurodevelopmental disorder with hypotonia, facial dysmorphism, and brain abnormalities, 619383 (3),
KLRB1		
KLRC1		
KLRC2		
KLRC3		
KLRC4		
KLRD1		
KLRF1		
KLRF2		
KLRG1		
KLRK1		
KLrP		
KLS		
KLST		
KM-HN-1		
KMLC	AD	cardiomyopathy, hypertrophic, 1, digenic, 192600 (3), digenic ,
KMO		
KMT1A		
KMT1B		
KMT1C		
KMT1D	AD	kleefstra syndrome 1, 610253 (3),
KMT1E		
KMT1F		
KMT2A	AD	wiedemann-steiner syndrome, 605130 (3),
KMT2B	AD	intellectual developmental disorder, 68, 619934 (3), ; dystonia 28, childhood-onset, 617284 (3),
KMT2C	AD	kleefstra syndrome 2, 617768 (3),
KMT2D	AD	branchial arch abnormalities, choanal atresia, athelia, hearing loss, and hypothyroidism syndrome, 620186 (3), ; kabuki syndrome 1, 147920 (3),
KMT2E	AD	o'donnell-luria-rodan syndrome, 618512 (3),
KMT2F	AD	epilepsy, early-onset, with or without developmental delay, 618832 (3), ; neurodevelopmental disorder with speech impairment and dysmorphic facies, 619056 (3),
KMT2G	AD	intellectual developmental disorder with seizures and language delay, 619000 (3),
KMT2H	AD	intellectual developmental disorder, 52, 617796 (3),
KMT3A	AD	luscan-lumish syndrome, 616831 (3), ; intellectual developmental disorder, 70, 620157 (3), ; rabin-pappas syndrome, 620155 (3),
KMT3B	AD	sotos syndrome, 117550 (3),
KMT3C		
KMT3D		
KMT3E		
KMT3F		
KMT3G	AD	rauch-steindl syndrome, 619695 (3),
KMT4		
KMT5A		
KMT5B	AD	intellectual developmental disorder, 51, 617788 (3),
KMT5C		
KMT6	AD	weaver syndrome, 277590 (3),
KMT6A	AD	weaver syndrome, 277590 (3),
KMT6B		
KMT7		
KMT8		
KMT8A		
KMT8B		
KMT8C	AD	patent ductus arteriosus 3, 617039 (3),
KMT8D	AR	?epilepsy, progressive myoclonic, 10, 616640 (3),
KMT8E	AD	myelodysplasia syndrome-1 (3)|radioulnar synostosis with amegakaryocytic thrombocytopenia 2, 616738 (3),
KMT8F	AD	left ventricular noncompaction 8, 615373 (3), ; cardiomyopathy, dilated, 1ll, 615373 (3),
KMT9		
KN		[blood group, knops system], 607486 (3); {malaria, severe, resistance to}, 611162 (3)
KNBC	AR	renal tubular acidosis, proximal, with ocular abnormalities, 604278 (3),
kNBC1	AR	renal tubular acidosis, proximal, with ocular abnormalities, 604278 (3),
KNCN		
KNDC1		
KNG	AR,AD	[kininogen deficiency], 228960 (3), ; angioedema, hereditary, 6, 619363 (3), ; [high molecular weight kininogen deficiency], 228960 (3),
KNG1	AR,AD	[kininogen deficiency], 228960 (3), ; angioedema, hereditary, 6, 619363 (3), ; [high molecular weight kininogen deficiency], 228960 (3),
KNL1	AR	microcephaly 4, primary, 604321 (3),
KNL2		
KNL3		
KNO	AR,AD	knobloch syndrome, type 1, 267750 (3), ; glaucoma, primary closed-angle, 618880 (3),
KNO1	AR,AD	knobloch syndrome, type 1, 267750 (3), ; glaucoma, primary closed-angle, 618880 (3),
KNP-I		
KNP-Ia		
KNP3		
KNPH		
KNPI		
KNS		
KNS1		
KNS2		
KNS2A		
KNS2B		
KNSL1	AD	microcephaly with or without chorioretinopathy, lymphedema, or mental retardation, 152950 (3),
KNSL2		
KNSL3		
KNSL4	AD	spondyloepimetaphyseal dysplasia with joint laxity, type 2, 603546 (3),
KNSL5	AD	anemia, congenital dyserythropoietic, type iiia, 105600 (3),
KNSL6		
KNSL7	AR	?braddock-carey syndrome 2, 619981 (3),
KNSTRN		?roifman-chitayat syndrome, digenic, 613328 (3), digenic
KNT		
KNTC1		
KNTC1AP		
KNTC2		
KNTC2AP		
KO		
KOG1		
Kop	AR	diarrhea 3, secretory sodium, congenital, syndromic, 270420 (3),
KOR		
KOR-3		
KOS1		
KOX		
KOX-1		
KOX1		
KOX10		
KOX11		
KOX12		
KOX13		
KOX14		
KOX15		
KOX16		
KOX17		
KOX18		
KOX19		
KOX2		
KOX20		
KOX21		
KOX22		
KOX25		
KOX26		
KOX27		
KOX29		
KOX3		
KOX30		
KOX31		
KOX32		
KOX4		
KOX5		
KOX6		
KOX7		
KOX9		
KP78	AR	?visual impairment and progressive phthisis bulbi, 618283 (3),
KPC1		
KPC2		
KPG_010		
KPI-2		
KPI2		
KPL1		
KPL2	AR	spermatogenic failure 43, 618751 (3),
KPNA1		
KPNA2		
KPNA3	AD	spastic paraplegia 88, 620106 (3),
KPNA4		
KPNA5		
KPNA6		
KPNA7	AR	oocyte/zygote/embryo maturation arrest 17, 620319 (3),
KPNB1		
KPNB2		
KPNB2B	AD	intellectual developmental disorder with hypotonia, impaired speech, and dysmorphic facies, 619556 (3),
KPNB3		
KPP	AD	ichthyosis, annular epidermolytic 1, 607602 (3), ; epidermolytic hyperkeratosis 2, 620150 (3); ?ichthyosis histrix, lambert type, 146600 (3), ; ichthyosis with confetti, 609165 (3),
KPPS2	AD,AR	arrhythmogenic right ventricular dysplasia 8, 607450 (3), ; epidermolysis bullosa, lethal acantholytic, 609638 (3), ; keratosis palmoplantaris striata ii, 612908 (3), ; dilated cardiomyopathy with woolly hair, keratoderma, and tooth agenesis, 615821 (3), ; cardiomyopathy, dilated, with woolly hair and keratoderma, 605676 (3),
KPRP		
KPTN	AR	intellectual developmental disorder, 41, 615637 (3),
KR18		
KR19		
KRAG		
KRAP		
KRAS	AD	gastric cancer, somatic, 613659 (3); oculoectodermal syndrome, somatic, 600268 (3); breast cancer, somatic, 114480 (3); noonan syndrome 3, 609942 (3), ; ras-associated autoimmune leukoproliferative disorder, 614470 (3), ; arteriovenous malformation of the brain, somatic, 108010 (3); lung cancer, somatic, 211980 (3); pancreatic carcinoma, somatic, 260350 (3); leukemia, acute myeloid, somatic, 601626 (3); schimmelpenning-feuerstein-mims syndrome, somatic mosaic, 163200 (3); cardiofaciocutaneous syndrome 2, 615278 (3), ; bladder cancer, somatic, 109800 (3)
KRAS1	AD	gastric cancer, somatic, 613659 (3); oculoectodermal syndrome, somatic, 600268 (3); breast cancer, somatic, 114480 (3); noonan syndrome 3, 609942 (3), ; ras-associated autoimmune leukoproliferative disorder, 614470 (3), ; arteriovenous malformation of the brain, somatic, 108010 (3); lung cancer, somatic, 211980 (3); pancreatic carcinoma, somatic, 260350 (3); leukemia, acute myeloid, somatic, 601626 (3); schimmelpenning-feuerstein-mims syndrome, somatic mosaic, 163200 (3); cardiofaciocutaneous syndrome 2, 615278 (3), ; bladder cancer, somatic, 109800 (3)
KRAS2	AD	gastric cancer, somatic, 613659 (3); oculoectodermal syndrome, somatic, 600268 (3); breast cancer, somatic, 114480 (3); noonan syndrome 3, 609942 (3), ; ras-associated autoimmune leukoproliferative disorder, 614470 (3), ; arteriovenous malformation of the brain, somatic, 108010 (3); lung cancer, somatic, 211980 (3); pancreatic carcinoma, somatic, 260350 (3); leukemia, acute myeloid, somatic, 601626 (3); schimmelpenning-feuerstein-mims syndrome, somatic mosaic, 163200 (3); cardiofaciocutaneous syndrome 2, 615278 (3), ; bladder cancer, somatic, 109800 (3)
KRBOX2		
KRBOX3		
KRBOX4		
KRC		
Kre33		
KREMEN	AR	ectodermal dysplasia 13, hair/tooth type, 617392 (3),
KREMEN1	AR	ectodermal dysplasia 13, hair/tooth type, 617392 (3),
KREMEN2		
KREV-1		
KRG-2	AR	warsaw breakage syndrome, 613398 (3),
KRIP6	AR,AD	cardiomyopathy, familial hypertrophic, 29, with polyglucosan bodies, 620236 (3), ; epidermolysis bullosa simplex 6, generalized intermediate, with or without cardiomyopathy, 617294 (3),
KRIT1	AD	hyperkeratotic cutaneous capillary-venous malformations associated with cerebral capillary malformations, 116860 (3), ; cerebral cavernous malformations-1, 116860 (3), ; cavernous malformations of cns and retina, 116860 (3),
KRM1	AR	ectodermal dysplasia 13, hair/tooth type, 617392 (3),
KRM2		
KRML	AD	duane retraction syndrome 3, 617041 (3), ; multicentric carpotarsal osteolysis syndrome, 166300 (3),
KRMP1		
KRN1		
KRN1L		
KROX-24		
KROX20	AR,AD	dejerine-sottas disease, 145900 (3), ; charcot-marie-tooth disease, type 1d, 607678 (3), ; hypomyelinating neuropathy, congenital, 1, 605253 (3),
KRP	AR,AD	megacystis-microcolon-intestinal hypoperistalsis syndrome 1, 249210 (3), ; aortic aneurysm, familial thoracic 7, 613780 (3),
Krp1	AR	nemaline myopathy 9, 615731 (3),
KRR1		
KRS1		
KRS2	AR	t-cell immunodeficiency, recurrent infections, autoimmunity, and cardiac malformations, 614868 (3),
KRT1	AD,AR	ichthyosis, annular epidermolytic 2, 620148 (3), ; palmoplantar keratoderma, nonepidermolytic, 600962 (3), ; epidermolytic hyperkeratosis 1, 113800 (3), ; palmoplantar keratoderma, epidermolytic, 2, 620411 (3); keratosis palmoplantaris striata iii, 607654 (3); ichthyosis histrix, curth-macklin type, 146590 (3),
Krt1-3		
KRT10	AD	ichthyosis, annular epidermolytic 1, 607602 (3), ; epidermolytic hyperkeratosis 2, 620150 (3); ?ichthyosis histrix, lambert type, 146600 (3), ; ichthyosis with confetti, 609165 (3),
KRT12	AD	meesmann corneal dystrophy 1, 122100 (3),
KRT13	AD	white sponge nevus 2, 615785 (3),
KRT14	AR,AD	epidermolysis bullosa simplex 1d, generalized, intermediate or severe, 601001 (3), ; epidermolysis bullosa simplex 1c, localized, 131800 (3), ; dermatopathia pigmentosa reticularis, 125595 (3), ; epidermolysis bullosa simplex 1a, generalized severe, 131760 (3), ; naegeli-franceschetti-jadassohn syndrome, 161000 (3), ; epidermolysis bullosa simplex 1b, generalized intermediate, 131900 (3),
KRT15		
KRT16	AD	palmoplantar keratoderma, nonepidermolytic, focal, 613000 (3), ; pachyonychia congenita 1, 167200 (3),
KRT17	AD	steatocystoma multiplex, 184500 (3), ; pachyonychia congenita 2, 167210 (3),
KRT18	AR	cirrhosis, cryptogenic, 215600 (3), ; {cirrhosis, noncryptogenic, susceptibility to}, 215600 (3),
KRT19		
KRT1A	AD,AR	ichthyosis, annular epidermolytic 2, 620148 (3), ; palmoplantar keratoderma, nonepidermolytic, 600962 (3), ; epidermolytic hyperkeratosis 1, 113800 (3), ; palmoplantar keratoderma, epidermolytic, 2, 620411 (3); keratosis palmoplantaris striata iii, 607654 (3); ichthyosis histrix, curth-macklin type, 146590 (3),
KRT1B		
KRT2	AD	ichthyosis bullosa of siemens, 146800 (3),
KRT20		
KRT23		
KRT24		
KRT25	AR	woolly hair, 3, 616760 (3),
KRT25A	AR	woolly hair, 3, 616760 (3),
KRT25B		
KRT25C		
KRT25D		
KRT26		
KRT27		
KRT28		
KRT2A	AD	ichthyosis bullosa of siemens, 146800 (3),
KRT2B		
KRT2P		
KRT3	AD	meesmann corneal dystrophy 2, 618767 (3),
KRT31		
KRT32		
KRT33A		
KRT33B		
KRT34		
KRT35		
KRT36		
KRT37		
KRT38		
KRT39		
KRT4	AD	white sponge nevus 1, 193900 (3),
KRT40		
KRT5	AD,AR	epidermolysis bullosa simplex 2a, generalized severe, 619555 (3), ; dowling-degos disease 1, 179850 (3), ; epidermolysis bullosa simplex 2f, with mottled pigmentation, 131960 (3), ; epidermolysis bullosa simplex 2d, generalized, intermediate or severe, 619599 (3), ; epidermolysis bullosa simplex 2b, generalized intermediate, 619588 (3), ; epidermolysis bullosa simplex 2c, localized, 619594 (3), ; epidermolysis bullosa simplex 2e, with migratory circinate erythema, 609352 (3),
KRT5A	AD,AR	epidermolysis bullosa simplex 2a, generalized severe, 619555 (3), ; dowling-degos disease 1, 179850 (3), ; epidermolysis bullosa simplex 2f, with mottled pigmentation, 131960 (3), ; epidermolysis bullosa simplex 2d, generalized, intermediate or severe, 619599 (3), ; epidermolysis bullosa simplex 2b, generalized intermediate, 619588 (3), ; epidermolysis bullosa simplex 2c, localized, 619594 (3), ; epidermolysis bullosa simplex 2e, with migratory circinate erythema, 609352 (3),
KRT5C	AD,AR	woolly hair, 194300 (3), ; ?hypotrichosis 3, 613981 (3), ; ?ectodermal dysplasia 7, hair/nail type, 614929 (3),
KRT6		
KRT6A	AD	pachyonychia congenita 3, 615726 (3),
KRT6B	AD	pachyonychia congenita 4, 615728 (3),
KRT6C	AD,AD	pachyonychia congenita 3, 615726 (3), |palmoplantar keratoderma, nonepidermolytic, focal or diffuse, 615735 (3),
KRT6D	AD	pachyonychia congenita 3, 615726 (3),
KRT6E	AD	palmoplantar keratoderma, nonepidermolytic, focal or diffuse, 615735 (3),
KRT6IRS	AD	?hypotrichosis 13, 615896 (3),
KRT6IRS1	AD	?hypotrichosis 13, 615896 (3),
KRT6IRS2		
KRT6IRS3		
KRT6IRS4	AD,AR	woolly hair, 194300 (3), ; ?hypotrichosis 3, 613981 (3), ; ?ectodermal dysplasia 7, hair/nail type, 614929 (3),
KRT6L		
KRT7		
KRT71	AD	?hypotrichosis 13, 615896 (3),
KRT72		
KRT73		
KRT74	AD,AR	woolly hair, 194300 (3), ; ?hypotrichosis 3, 613981 (3), ; ?ectodermal dysplasia 7, hair/nail type, 614929 (3),
KRT75		{pseudofolliculitis barbae, susceptibility to}, 612318 (3)
KRT76		
KRT77		
KRT78		
KRT79		
KRT8		
KRT80		
KRT81	AD	monilethrix, 158000 (3),
KRT82		
KRT83	AD,AR	monilethrix, 158000 (3), ; erythrokeratodermia variabilis et progressiva 5, 617756 (3),
KRT84		
KRT85	AR	ectodermal dysplasia 4, hair/nail type, 602032 (3),
KRT86	AD	monilethrix, 158000 (3),
KRT9	AD	palmoplantar keratoderma, epidermolytic, 1, 144200 (3),
KRTAP1-1		
KRTAP1-3		
KRTAP1-4		
KRTAP1-5		
KRTAP11-1		
KRTAP13-1		
KRTAP24-1		
KRTAP5-1		
KRTAP5-9		
KRTAP5.1		
KRTAP5.9		
KRTCAP1	AR,AD	erythrokeratodermia variabilis et progressiva 7, 619209 (3), ; olmsted syndrome 2, 619208 (3),
KRTCAP2		
KRTCAP3		
KRTDAP		
KRTE	AD	ichthyosis bullosa of siemens, 146800 (3),
KRTHA1		
KRTHA2		
KRTHA3A		
KRTHA3B		
KRTHA4		
KRTHA5		
KRTHA6		
KRTHA7		
KRTHA8		
KRTHB1	AD	monilethrix, 158000 (3),
KRTHB2		
KRTHB3	AD,AR	monilethrix, 158000 (3), ; erythrokeratodermia variabilis et progressiva 5, 617756 (3),
KRTHB4		
KRTHB5	AR	ectodermal dysplasia 4, hair/nail type, 602032 (3),
KRTHB6	AD	monilethrix, 158000 (3),
KRTL1	AD	pachyonychia congenita 4, 615728 (3),
Kryn		
KS	AR,AD	knobloch syndrome, type 1, 267750 (3), ; glaucoma, primary closed-angle, 618880 (3),
KS1		
KS1/4	AR,AD	diarrhea 5, with tufting enteropathy, congenital, 613217 (3), ; lynch syndrome 8, 613244 (3),
KSA	AR,AD	diarrhea 5, with tufting enteropathy, congenital, 613217 (3), ; lynch syndrome 8, 613244 (3),
KSGal6ST		
KSHIVB	AD	spinocerebellar ataxia 19, 607346 (3), ; brugada syndrome 9, 616399 (3),
KSP37		
KSR		
KSR1		
KSR2	XL	intellectual developmental disorder, syndromic, houge type, 301008 (3),
KSRP		
KST		
KST1		
KT3.3		
KTELC1	AD,AR	dowling-degos disease 4, 615696 (3), ; muscular dystrophy, limb-girdle, 21, 617232 (3),
KTGNR	AR	ciliary dyskinesia, primary, 3, with or without situs inversus, 608644 (3),
KTI11		
KTN1		
Kto	XLR,XL,XLD	lujan-fryns syndrome, 309520 (3), ; ohdo syndrome, 300895 (3), ; hardikar syndrome, 301068 (3), ; opitz-kaveggia syndrome, 305450 (3),
KTSR5831		
KTU	AR	ciliary dyskinesia, primary, 10, 612518 (3),
KU-MEL-1	AR	joubert syndrome 30, 617622 (3),
KU70		
KU80		
Ku86		
Kua		
KUB1		
KUB2		
KUB3		
Kub5-Hera		
KUCG1		
Kud		
Kuduk		
KUP		
Kur	AR	ciliary dyskinesia, primary, 26, 615500 (3),
kuz	AD	{alzheimer disease 18, susceptibility to}, 615590 (3); reticulate acropigmentation of kitamura, 615537 (3),
Kv1.1	AD	episodic ataxia/myokymia syndrome, 160120 (3),
Kv1.2	AD	developmental and epileptic encephalopathy 32, 616366 (3),
Kv1.3		
Kv1.4	AR	microcephaly, cataracts, impaired intellectual development, and dystonia with abnormal striatum, 618284 (3),
Kv1.5	AD	atrial fibrillation, familial, 7, 612240 (3),
Kv1.6		
Kv1.7		
Kv1.8		
Kv10.1	AD	zimmermann-laband syndrome 1, 135500 (3), ; temple-baraitser syndrome, 611816 (3),
Kv10.2		
Kv11.1	AD	short qt syndrome 1, 609620 (3); long qt syndrome 2, 613688 (3),
Kv11.2		
Kv11.3		
Kv12.1		
Kv12.2		
Kv12.3		
Kv2.1	AD	developmental and epileptic encephalopathy 26, 616056 (3),
Kv2.2		
Kv3.1	AD	epilepsy, progressive myoclonic 7, 616187 (3),
Kv3.2	AD	developmental and epileptic encephalopathy 103, 619913 (3),
Kv3.3	AD	spinocerebellar ataxia 13, 605259 (3),
Kv3.4		
Kv4.1		
Kv4.2		
Kv4.3	AD	spinocerebellar ataxia 19, 607346 (3), ; brugada syndrome 9, 616399 (3),
Kv5.1		
Kv6.1		
Kv6.2		
Kv6.3		
Kv6.4		
Kv7.1	AD,AR	short qt syndrome 2, 609621 (3), ; atrial fibrillation, familial, 3, 607554 (3), ; long qt syndrome 1, 192500 (3), ; {long qt syndrome 1, acquired, susceptibility to}, 192500 (3), ; jervell and lange-nielsen syndrome, 220400 (3),
Kv7.2	AD	developmental and epileptic encephalopathy 7, 613720 (3), ; seizures, benign neonatal, 1, 121200 (3), ; myokymia, 121200 (3),
Kv7.3	AD	seizures, benign neonatal, 2, 121201 (3),
Kv7.4	AD	deafness, 2a, 600101 (3),
Kv7.5	AD	intellectual developmental disorder, 46, 617601 (3),
Kv8.1		
Kv8.2	AR	retinal cone dystrophy 3b, 610356 (3),
Kv9.1		
Kv9.2		
Kv9.3		
Kvb1.3		
KvDMR1	AD	beckwith-wiedemann syndrome, 130650 (3),
KVLQT1	AD,AR	short qt syndrome 2, 609621 (3), ; atrial fibrillation, familial, 3, 607554 (3), ; long qt syndrome 1, 192500 (3), ; {long qt syndrome 1, acquired, susceptibility to}, 192500 (3), ; jervell and lange-nielsen syndrome, 220400 (3),
KvLQT1-AS	AD	beckwith-wiedemann syndrome, 130650 (3),
Kx	XL	mcleod syndrome with or without chronic granulomatous disease, 300842 (3),
KXD1		
KXDL		
KY	AR	myopathy, myofibrillar, 7, 617114 (3),
KYAT1		
KYAT2		
KYAT3		
KYAT4	AR	developmental and epileptic encephalopathy 82, 618721 (3),
KYNU	AR	?hydroxykynureninuria, 236800 (3), ; vertebral, cardiac, renal, and limb defects syndrome 2, 617661 (3),
KYO-T	XL,XLR,XLD	myopathy, with postural muscle atrophy, 300696 (3), ; emery-dreifuss muscular dystrophy 6, 300696 (3), ; ?uruguay faciocardiomusculoskeletal syndrome, 300280 (3), ; scapuloperoneal myopathy, 300695 (3), ; reducing body myopathy, 1b, with late childhood or adult onset, 300718 (3), ; reducing body myopathy, 1a, severe, infantile or early childhood onset, 300717 (3),
L-CAD		
L-CPT1	AR	cpt deficiency, hepatic, type ia, 255120 (3),
L-FABP		
L-JAK	AR	scid, t-negative/b-positive type, 600802 (3),
L-PGDS		
L-PLASTIN		
L-RAP		
L-SOX5	AD	lamb-shaffer syndrome, 616803 (3),
L-UBC		
l(1)-3Rk	AR	griscelli syndrome, type 3, 609227 (3),
L0R8F8		
L1.2		
L10	XL,XLR	{autism, susceptibility to, 5}, 300847 (3); intellectual developmental disorder, syndromic 35, 300998 (3),
L10A		
L10E		
L10MT		
L11	AD	diamond-blackfan anemia 7, 612562 (3),
L12		
L13	AD	spondyloepimetaphyseal dysplasia, isidor-toutain type, 618728 (3),
L13A		
L13mt		
L14		
L15	AD,AR	diamond-blackfan anemia 12, 615550 (3), |spermatogenic failure 76, 620084 (3),
L15mt		
L17		
L18	AD	?diamond-blackfan anemia 18, 618310 (3),
L18A		
L19	AR	?spondyloepimetaphyseal dysplasia, krakow type, 618162 (3),
L1CAM	XLR,XL	masa syndrome, 303350 (3), ; hydrocephalus, congenital, 307000 (3), ; ?corpus callosum, partial agenesis of, 304100 (3),
L1CAM2		
L1RE1		
L1RE2		
l1Rk3	AR	griscelli syndrome, type 3, 609227 (3),
L2	AR	neurodevelopmental disorder with seizures, microcephaly, and brain abnormalities, 620024 (3),
L21	AD	hypotrichosis 12, 615885 (3),
L22		
L23		
L23A		
L23MRP		
L24		
L26	AD	?diamond-blackfan anemia 11, 614900 (3),
L27	AD	?diamond-blackfan anemia 16, 617408 (3),
L27A		
L28		
L29		
L2DTL		
L2HGDH	AR	l-2-hydroxyglutaric aciduria, 236792 (3),
L3		
L30		
L31		
L32mt		
L34		
L34mt		
L35	AD	?diamond-blackfan anemia 19, 618312 (3),
L35A	AD	diamond-blackfan anemia 5, 612528 (3),
L36		
L36A		
L36mt		
L37		
L37A		
L38		
L39		
L39mt		
L3HYPDH		
L3MBTL		
L3MBTL1		
L3MBTL2		
L3MBTL3		
L3MBTL4		
L4		
L40		
L41		
L49mt		
L5	AD	diamond-blackfan anemia 6, 612561 (3),
L6		
L7		
L7A		
L8		
L9		
La		
LA-PF4		
La/SSB		
LAAT-1		
LAAT1		
laAUF1	AD	muscular dystrophy, limb-girdle, 3, 609115 (3),
LAB		
LAB300	AR	immunodeficiency, common variable, 8, with autoimmunity, 614700 (3),
LABH1		
LABH2		
LABH3		
LACC1	AR	juvenile arthritis, 618795 (3),
LACE1		
LACH1		
LACH2		
LACI		
LACR1		
LACRITIN		
LACRT		
LACS		
LACS1		
LACS2		myelodysplastic syndrome (3); myelogenous leukemia, acute (3)
LACS4	XL,XLD	intellectual developmental disorder, 63, 300387 (3),
LACS5		myelodysplastic syndrome (3); myelogenous leukemia, acute (3)
LACTB		
LACTB2		
LAD	AR	dihydrolipoamide dehydrogenase deficiency, 246900 (3),
LAD1		
LAF4	AD	kinsship syndrome, 619297 (3),
Lag		
LAG-1		
LAG-2		
LAG1	AR	epilepsy, progressive myoclonic, 8, 616230 (3),
LAG2		
LAG3		
LAGE-1		
LAGE-1a		
LAGE-1b		
LAGE1		
LAGE2A		
LAGE2B		
LAGE3	XL,XLR	galloway-mowat syndrome 2, 301006 (3),
LAGY		
LAH	AR	hypotrichosis 6, 607903 (3),
LAIR-1		
LAIR-2		
LAIR1		
LAIR2		
Lak	AD	rosah syndrome, 614979 (3),
LAK		
LAK-1		
LAK-4P	AR	epidermodysplasia verruciformis, 226400 (3),
LAKL		
LAKLG		
LAL	AR	wolman disease, 620151 (3), ; cholesteryl ester storage disease, 278000 (3),
LALBA		
LALP1		
LALP70		
LAM	AD,AD	focal cortical dysplasia, type ii, somatic, 607341 (3); tuberous sclerosis-1, 191100 (3), ; lymphangioleiomyomatosis, 606690 (3)|lymphangioleiomyomatosis, somatic, 606690 (3); ?focal cortical dysplasia, type ii, somatic, 607341 (3); tuberous sclerosis-2, 613254 (3),
LAM-1		
LAM1		
LAMA	AR	poretti-boltshauser syndrome, 615960 (3),
LAMA1	AR	poretti-boltshauser syndrome, 615960 (3),
LAMA2	AR	muscular dystrophy, limb-girdle, 23, 618138 (3), ; muscular dystrophy, congenital, merosin deficient or partially deficient, 607855 (3),
LAMA3	AD,AR	cardiomyopathy, dilated, 1jj, 615235 (3), |epidermolysis bullosa, junctional 2a, intermediate, 619783 (3), ; epidermolysis bullosa, junctional 2c, laryngoonychocutaneous, 245660 (3), ; epidermolysis bullosa, junctional 2b, severe, 619784 (3),
LAMA4	AD	cardiomyopathy, dilated, 1jj, 615235 (3),
LAMA5	AR	nephrotic syndrome, type 26, 620049 (3), ; ?bent bone dysplasia syndrome 2, 620076 (3),
LAMAN	AR	mannosidosis, alpha-, types i and ii, 248500 (3),
LAMB1	AR	lissencephaly 5, 615191 (3),
LAMB2	AR	nephrotic syndrome, type 5, with or without ocular abnormalities, 614199 (3); pierson syndrome, 609049 (3),
LAMB2T	AR	epidermolysis bullosa, junctional 3b, severe, 619786 (3), ; epidermolysis bullosa, junctional 3a, intermediate, 619785 (3),
LAMB3	AR,AD	epidermolysis bullosa, junctional 1b, severe, 226700 (3), ; epidermolysis bullosa, junctional 1a, intermediate, 226650 (3), ; amelogenesis imperfecta, type ia, 104530 (3),
LAMB4		
lambda-CRY		
LAMC1		
LAMC2	AR	epidermolysis bullosa, junctional 3b, severe, 619786 (3), ; epidermolysis bullosa, junctional 3a, intermediate, 619785 (3),
LAMC3	AR	cortical malformations, occipital, 614115 (3),
LAMM	AR	muscular dystrophy, limb-girdle, 23, 618138 (3), ; muscular dystrophy, congenital, merosin deficient or partially deficient, 607855 (3),
LAMNA	AR	epidermolysis bullosa, junctional 2a, intermediate, 619783 (3), ; epidermolysis bullosa, junctional 2c, laryngoonychocutaneous, 245660 (3), ; epidermolysis bullosa, junctional 2b, severe, 619784 (3),
LAMNB1	AR,AD	epidermolysis bullosa, junctional 1b, severe, 226700 (3), ; epidermolysis bullosa, junctional 1a, intermediate, 226650 (3), ; amelogenesis imperfecta, type ia, 104530 (3),
LAMNB2	AR	epidermolysis bullosa, junctional 3b, severe, 619786 (3), ; epidermolysis bullosa, junctional 3a, intermediate, 619785 (3),
LAMP		
LAMP1		
LAMP2	XLD,XL	danon disease, 300257 (3),
LAMP3		
LAMP4		
LAMP5		
LAMR1	AD	asplenia, isolated congenital, 271400 (3),
LAMS	AR	nephrotic syndrome, type 5, with or without ocular abnormalities, 614199 (3); pierson syndrome, 609049 (3),
LAMTOR1		
LAMTOR2	AR	immunodeficiency due to defect in mapbp-interacting protein, 610798 (3),
LAMTOR3		
LAMTOR4		
LAMTOR5		
LAN		
LANCL1		
LANCL2		
Langerin		[?birbeck granule deficiency], 613393 (3)
LANO		
LANP		
LANP-L		
LANPL		
LAP	AR,AR	?lysosomal acid phosphatase deficiency, 200950 (1), |microcephaly 6, primary, 608393 (3), ; ?seckel syndrome 4, 613676 (3),
LAP1	AR,AD	?muscular dystrophy, with rigid spine and distal joint contractures, 617072 (3), |{?encephalopathy, acute, infection-induced (herpes-specific), susceptibility to, 5}, 614849 (3),
LAP18		
LAP1B	AR	?muscular dystrophy, with rigid spine and distal joint contractures, 617072 (3),
LAP1C	AR	?muscular dystrophy, with rigid spine and distal joint contractures, 617072 (3),
LAP2		
LAP3		
LAP70		
LAPEP		
LAPSER1		
LAPTM4		
LAPTM4A		
LAPTM4B		
LAPTM5		
LAR	AR	?breasts and/or nipples, aplasia or hypoplasia of, 2, 616001 (3),
Lar1		
LARC		
LARD		
LARG		
LARGE	AR	muscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type b, 6, 608840 (3), ; muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 6, 613154 (3),
LARGE1	AR	muscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type b, 6, 608840 (3), ; muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 6, 613154 (3),
LARGE2		
LARK		
LARP		
LARP1		
LARP3		
LARP4		
LARP4B		
LARP5		
LARP6		
LARP7	AR	alazami syndrome, 615071 (3),
LARS	AR	?infantile liver failure syndrome 1, 615438 (3),
LARS1	AR	?infantile liver failure syndrome 1, 615438 (3),
LARS2	AR	perrault syndrome 4, 615300 (3), ; hydrops, lactic acidosis, and sideroblastic anemia, 617021 (3),
LAS	AR	hyperglycinemia, lactic acidosis, and seizures, 614462 (3),
Las1	XLR,XL	wilson-turner syndrome, 309585 (3),
LAS1		
LAS1L	XLR,XL	wilson-turner syndrome, 309585 (3),
LAS2		
LAS21	AR	[blood group, emm system], 619812 (3), ; neurodevelopmental disorder with or without hypotonia, seizures, and cerebellar atrophy, 616917 (3),
Lasp-1		
LASP1		
LASP1NB		
LASP2		
LASS1	AR	epilepsy, progressive myoclonic, 8, 616230 (3),
LASS2		
LASS3	AR	ichthyosis, congenital, 9, 615023 (3),
LASS4		
LASS5		
LASS6		
LASTR		
LAT	AR	immunodeficiency 52, 617514 (3),
LAT-2		
LAT1	AR	immunodeficiency 52, 617514 (3),
LAT2		
LAT3		
LATHEO		
LATS1		
LATS2		
LAX		
LAX1		
LAYN		
LAZ3		
LB1		
LBA	AR	immunodeficiency, common variable, 8, with autoimmunity, 614700 (3),
LBA1		
LBC		
LBCL2	AR	?immunodeficiency 62, 618459 (3),
LBH		
LBM180	AR	surfactant metabolism dysfunction, pulmonary, 3, 610921 (3),
LBN	AR,AD	ellis-van creveld syndrome, 225500 (3), ; weyers acrofacial dysostosis, 193530 (3),
LBP		
LBP-1a		
LBP-1C		
LBP-32		
LBP-9		
LBR	AD,AR	pelger-huet anomaly, 169400 (3), ; ?reynolds syndrome, 613471 (3), ; rhizomelic skeletal dysplasia with or without pelger-huet anomaly, 618019 (3), ; greenberg skeletal dysplasia, 215140 (3),
LBX1	AR	?central hypoventilation syndrome, congenital, 3, 619483 (3),
LBX1H	AR	?central hypoventilation syndrome, congenital, 3, 619483 (3),
LBX2		
LBXCOR1		
LC-PTP		
LC20	AR	?megacystis-microcolon-intestinal hypoperistalsis syndrome 4, 619365 (3),
LC27		
LC3		
LC3A		
LC64P		
LC8		
Lca		
LCA	AR,AD,AR	cone-rod dystrophy 6, 601777 (3), ; ?choroidal dystrophy, central areolar 1, 215500 (3), ; leber congenital amaurosis 1, 204000 (3), ; night blindness, congenital stationary, type 1i, 618555 (3), |immunodeficiency 105, severe combined, 619924 (3),
LCA1	AR,AD	cone-rod dystrophy 6, 601777 (3), ; ?choroidal dystrophy, central areolar 1, 215500 (3), ; leber congenital amaurosis 1, 204000 (3), ; night blindness, congenital stationary, type 1i, 618555 (3),
LCA10	AR	leber congenital amaurosis 10, 611755 (3); joubert syndrome 5, 610188 (3), ; senior-loken syndrome 6, 610189 (3), ; ?bardet-biedl syndrome 14, 615991 (3), ; meckel syndrome 4, 611134 (3),
LCA11	AD	retinitis pigmentosa 10, 180105 (3), ; leber congenital amaurosis 11, 613837 (3),
LCA12	AR	leber congenital amaurosis 12, 610612 (3),
LCA13	AR,AD	leber congenital amaurosis 13, 612712 (3),
LCA14	AR	leber congenital amaurosis 14, 613341 (3), ; retinal dystrophy, early-onset severe, 613341 (3), ; retinitis pigmentosa, juvenile, 613341 (3),
LCA15	AR	leber congenital amaurosis 15, 613843 (3), ; retinitis pigmentosa 14, 600132 (3),
LCA16	AD,AR	snowflake vitreoretinal degeneration, 193230 (3), ; leber congenital amaurosis 16, 614186 (3),
LCA2	AR,AD	retinitis pigmentosa 20, 613794 (3), ; retinitis pigmentosa 87 with choroidal involvement, 618697 (3), ; leber congenital amaurosis 2, 204100 (3),
LCA3	AR	leber congenital amaurosis 3, 604232 (3), ; retinitis pigmentosa 94, variable age at onset, 604232 (3),
LCA4	AR,AD	leber congenital amaurosis 4, 604393 (3), ; retinitis pigmentosa, juvenile, 604393 (3), ; cone-rod dystrophy, 604393 (3),
LCA5	AR	leber congenital amaurosis 5, 604537 (3),
LCA6	AR	cone-rod dystrophy 13, 608194 (3), ; leber congenital amaurosis 6, 613826 (3),
LCA7	AD	leber congenital amaurosis 7, 613829 (3); cone-rod retinal dystrophy-2, 120970 (3),
LCA8	AR,AD	leber congenital amaurosis 8, 613835 (3), ; retinitis pigmentosa-12, 600105 (3), ; pigmented paravenous chorioretinal atrophy, 172870 (3),
LCA9	AR	spondyloepiphyseal dysplasia, sensorineural hearing loss, intellectual developmental disorder, and leber congenital amaurosis, 619260 (3), ; leber congenital amaurosis 9, 608553 (3),
LCACD	AR	vlcad deficiency, 201475 (3),
LCAD		
LCAL62		
LCAT	AR	fish-eye disease, 136120 (3), ; norum disease, 245900 (3),
Lcb		
LCB1	AD	amyotrophic lateral sclerosis 27, juvenile, 620285 (3), ; neuropathy, hereditary sensory and autonomic, type ia, 162400 (3),
LCB2	AD	neuropathy, hereditary sensory and autonomic, type ic, 613640 (3),
LCB2A	AD	neuropathy, hereditary sensory and autonomic, type ic, 613640 (3),
LCB2B		
LCC-1		
LCCP		
LCCS1	AR	lethal congenital contracture syndrome 1, 253310 (3), ; congenital arthrogryposis with anterior horn cell disease, 611890 (3),
LCCS2	AR,AD	?lethal congenital contractural syndrome 2, 607598 (3), ; {?erythroleukemia, familial, susceptibility to}, 133180 (3), ; visceral neuropathy, familial, 1, 243180 (3),
LCCS3	AR	lethal congenital contractural syndrome 3, 611369 (3),
LCD1	AD	corneal dystrophy, avellino type, 607541 (3), ; corneal dystrophy, reis-bucklers type, 608470 (3), ; corneal dystrophy, thiel-behnke type, 602082 (3), ; corneal dystrophy, groenouw type i, 121900 (3), ; corneal dystrophy, epithelial basement membrane, 121820 (3), ; corneal dystrophy, lattice type i, 122200 (3), ; corneal dystrophy, lattice type iiia, 608471 (3),
LCE		
LCE1A		
LCE1B		
LCE1C		
LCE1D		
LCE1E		
LCE1F		
LCE2A		
LCE2B		
LCE2C		
LCE2D		
LCE3A		
LCE3B		
LCE3C		
LCE3D		
LCE3E		
LCE4A		
LCE5A		
LCEH	AR	hellp syndrome, maternal, of pregnancy, 609016 (3), ; lchad deficiency, 609016 (3), ; mitochondrial trifunctional protein deficiency 1, 609015 (3), ; fatty liver, acute, of pregnancy, 609016 (3),
LCF		
LCGR	AR,AD	leydig cell adenoma, somatic, with precocious puberty, 176410 (3); leydig cell hypoplasia with pseudohermaphroditism, 238320 (3), ; leydig cell hypoplasia with hypergonadotropic hypogonadism, 238320 (3), ; luteinizing hormone resistance, female, 238320 (3), ; precocious puberty, male, 176410 (3),
LCHAD	AR	hellp syndrome, maternal, of pregnancy, 609016 (3), ; lchad deficiency, 609016 (3), ; mitochondrial trifunctional protein deficiency 1, 609015 (3), ; fatty liver, acute, of pregnancy, 609016 (3),
LCHN		
LCK	AR	?immunodeficiency 22, 615758 (3),
LCK2	AD,AR	{epilepsy, juvenile myoclonic, susceptibility to, 10}, 617924 (3), ; endocrine-cerebroosteodysplasia, 612651 (3),
LCLAT1		
LCMR1		
LCMT1		
LCMT2		
LCN1		
LCN10		
LCN12		
LCN13		
LCN14		
LCN2		
LCN5		
LCN6		
LCN7		
LCN8		
LCN9		
LCOR		
LCORL		
LCP		
LCP1		
LCP2	AR	?immunodeficiency 81, 619374 (3),
LCP5		
LCR-F1		
LCRISP2		
LCRP369		
LCT	AR	lactase deficiency, congenital, 223000 (3),
LCTL		
LCX		
LD	AR	epilepsy, progressive myoclonic 2a (lafora), 254780 (3),
LD5-1		
LD78ALPHA		{hiv infection, resistance to}, 609423 (2)
LD78BETA		{hiv/aids, susceptibility to}, 609423 (3)
LDAF1		
LDAH		
LDB1		
LDB2		
LDB3	AD	left ventricular noncompaction 3, 601493 (3), ; cardiomyopathy, hypertrophic, 24, 601493 (3), ; myopathy, myofibrillar, 4, 609452 (3), ; cardiomyopathy, dilated, 1c, with or without lvnc, 601493 (3),
LDC		
LDE	AR	epilepsy, progressive myoclonic 2a (lafora), 254780 (3),
LDGF		
LDH6A		
LDHA	AR	glycogen storage disease xi, 612933 (3),
LDHAL6A		
LDHB		[lactate dehydrogenase-b deficiency], 614128 (3)
LDHC		
LDHD	AR	d-lactic aciduria with susceptibility to gout, 245450 (3),
LDL-PLA2	AR,AD	platelet-activating factor acetylhydrolase deficiency, 614278 (3), ; {asthma, susceptibility to}, 600807 (3), ; {atopy, susceptibility to}, 147050 (3),
LDLB	AR	congenital disorder of glycosylation, type iig, 611209 (3),
LDLC	AR	?congenital disorder of glycosylation, type iiq, 617395 (3),
LDLCQ2	AR,AD	ldl cholesterol level qtl2, 143890 (3), ; hypercholesterolemia, familial, 1, 143890 (3),
LDLR	AR,AD	ldl cholesterol level qtl2, 143890 (3), ; hypercholesterolemia, familial, 1, 143890 (3),
LDLRAD3		
LDLRAD4		
LDLRAP1	AR	hypercholesterolemia, familial, 4, 603813 (3),
LDM		
LDOC1		
LDP		
LDPL		
LE	AR	[blood group, lewis], 618983 (3)|hermansky-pudlak syndrome 4, 614073 (3),
Le-PAS		
Lea1		
LEAP-1	AR	hemochromatosis, type 2b, 613313 (3),
LEAP-2		
LEAP1	AR	hemochromatosis, type 2b, 613313 (3),
LEAP2		
LEC		
LEC1		
LEC2	AD	developmental delay, behavioral abnormalities, and neuropsychiatric disorders, 620065 (3),
LEC3		
Lec35	AR	congenital disorder of glycosylation, type if, 609180 (3),
LECT		
LECT1		
LECT2		
LEDGF		
LEF1		sebaceous tumors, somatic (3)
LEFTA		
LEFTB		
LEFTY1		
LEFTY2		
LEFTYA		
LEFTYB		
LEI		
LEIF2C1		
LEIF2H		
LEKR1		
LEKTI	AR	netherton syndrome, 256500 (3),
LELA1		
LELP1		
LEM		
LEM2	AD,AR	marbach-rustad progeroid syndrome, 619322 (3), ; cataract 46, juvenile-onset, 212500 (3),
Lem4	AR	microcephaly 16, primary, 616681 (3),
LEMD1		
LEMD2	AD,AR	marbach-rustad progeroid syndrome, 619322 (3), ; cataract 46, juvenile-onset, 212500 (3),
LEMD3	AD	buschke-ollendorff syndrome, 166700 (3), ; osteopoikilosis with or without melorheostosis, 166700 (3),
LEMD4		
LEMD5	XL,XLR	emery-dreifuss muscular dystrophy 1, 310300 (3),
LEMD6		
LEMD7	AR	microcephaly 16, primary, 616681 (3),
LEMP-1		
LENEP		
LENG2	AD	intellectual developmental disorder with speech delay, autism, and dysmorphic facies, 618672 (3),
LENG3		
LENG4	AR	intellectual developmental disorder, 57, 617188 (3),
LENG5	AR	?pontocerebellar hypoplasia type 2c, 612390 (3),
LENG7		
LENG8		
LEO1		
LEP	AR	obesity, morbid, due to leptin deficiency, 614962 (3),
LEP1		
LEP10		
LEP11		
LEP12		
LEP13		
LEP14		
LEP15		
LEP16		
LEP17		
LEP18		
LEP2		
LEP3		
LEP4		
LEP5		
LEP503		
LEP6		
LEP8		
LEP9		
LEPR	AR	obesity, morbid, due to leptin receptor deficiency, 614963 (3),
LEPRE1	AR	osteogenesis imperfecta, type viii, 610915 (3),
LEPRECAN	AR	osteogenesis imperfecta, type viii, 610915 (3),
LEPREL1	AR	myopia, high, with cataract and vitreoretinal degeneration, 614292 (3),
LEPREL2		
LEPREL3	AR	osteogenesis imperfecta, type vii, 610682 (3),
LEPREL4		
LEPROT		
LEPROTL1		
LEREPO4		
LERGU		
LERGU2		
LERK-8		
LERK1		
LERK2	XLD,XL	craniofrontonasal dysplasia, 304110 (3),
LERK3		
LERK4		
LERK5		
LERK6		
LERK7		
LERN1	AR	intellectual developmental disorder, 64, 618103 (3),
LERN2		
LERN3		
LESTR	AD	whim syndrome 1, 193670 (3), ; myelokathexis, isolated, 193670 (3),
LET7EH		
LETAL		
LETKI	AR	netherton syndrome, 256500 (3),
LETM1	AR	neurodegeneration, childhood-onset, with multisystem involvement due to mitochondrial dysfunction, 620089 (3),
LETM2		
LETMD1		
LETS	AD	spondylometaphyseal dysplasia, corner fracture type, 184255 (3), ; glomerulopathy with fibronectin deposits 2, 601894 (3),
LEU-22		
Leu-3	AR	immunodeficiency 79, 619238 (3), ; okt4 epitope deficiency, 613949 (3)
Leu-8		
LEU-9		
LEU1		
LEU2		
Leu5		
LEU7		
LEUPIN		
LEURS	AR	perrault syndrome 4, 615300 (3), ; hydrops, lactic acidosis, and sideroblastic anemia, 617021 (3),
LEUS	AR	?infantile liver failure syndrome 1, 615438 (3),
LEUT		
LEUTX		
LEXM		
LFA-1	AR	leukocyte adhesion deficiency, 116920 (3),
LFA1A		
LFA3		
LFB1	AD,AR	hepatic adenoma, somatic, 142330 (3); diabetes mellitus, insulin-dependent, 20, 612520 (3); {diabetes mellitus, noninsulin-dependent, 2}, 125853 (3), ; mody, type iii, 600496 (3), ; {diabetes mellitus, insulin-dependent}, 222100 (3), ; renal cell carcinoma, 144700 (3)
LFB3	AD	type 2 diabetes mellitus, 125853 (3), ; renal cysts and diabetes syndrome, 137920 (3), ; {renal cell carcinoma}, 144700 (3)
Lfc	AR	?neurodevelopmental disorder with midbrain and hindbrain malformations, 617523 (3),
LFG		
LFG1		
LFG2		
LFG3		
LFG4		
LFHL1	AD,AR	deafness, 1, with or without thrombocytopenia, 124900 (3), ; seizures, cortical blindness, microcephaly syndrome, 616632 (3),
LFNG	AR	spondylocostal dysostosis 3, 609813 (3),
LFP40	AR	?neurodevelopmental disorder with midbrain and hindbrain malformations, 617523 (3),
LFR		
LFS1	AD	{basal cell carcinoma 7}, 614740 (3), ; {adrenocortical carcinoma, pediatric}, 202300 (3), ; hepatocellular carcinoma, somatic, 114550 (3); breast cancer, somatic, 114480 (3); li-fraumeni syndrome, 151623 (3), ; pancreatic cancer, somatic, 260350 (3); nasopharyngeal carcinoma, somatic, 607107 (3); {osteosarcoma}, 259500 (3), somatic mutation; {choroid plexus papilloma}, 260500 (3), ; {colorectal cancer}, 114500 (3), somatic mutation, ; {glioma susceptibility 1}, 137800 (3), somatic mutation, ; bone marrow failure syndrome 5, 618165 (3),
Lft		
LGA		
LGALS1		
LGALS10		
LGALS12		
LGALS13		
LGALS14		
LGALS2		{myocardial infarction, susceptibility to}, 608446 (3)
LGALS3		
LGALS3BP		
LGALS4		
LGALS7		
LGALS7A		
LGALS7B		
LGALS8		
LGALS9		
LGALS9A		
LGALSL		
LGCR	AD,AD	exostoses, multiple, type 1, 133700 (3), ; chondrosarcoma, 215300 (3), somatic mutation|trichorhinophalangeal syndrome, type iii, 190351 (3), ; trichorhinophalangeal syndrome, type i, 190350 (3),
Lgd2	AR	intellectual developmental disorder, 3, 608443 (3),
LGI1	AD	epilepsy, familial temporal lobe, 1, 600512 (3),
LGI2		
LGI3	AR	intellectual developmental disorder with muscle tone abnormalities and distal skeletal defects, 620007 (3),
LGI4	AR	arthrogryposis multiplex congenita 1, neurogenic, with myelin defect, 617468 (3),
LGICZ		
LGICZ1		
Lgl1		
LGL1		
LGMD1	AD	myopathy, myofibrillar, 3, 609200 (3),
LGMD1A	AD	myopathy, myofibrillar, 3, 609200 (3),
LGMD1B	AR,AD	mandibuloacral dysplasia, 248370 (3), ; heart-hand syndrome, slovenian type, 610140 (3), ; cardiomyopathy, dilated, 1a, 115200 (3), ; emery-dreifuss muscular dystrophy 3, 616516 (3), ; restrictive dermopathy 2, 619793 (3); charcot-marie-tooth disease, type 2b1, 605588 (3), ; emery-dreifuss muscular dystrophy 2, 181350 (3), ; hutchinson-gilford progeria, 176670 (3), ; lipodystrophy, familial partial, type 2, 151660 (3), ; muscular dystrophy, congenital, 613205 (3), ; malouf syndrome, 212112 (3),
LGMD1C	AD	myopathy, distal, tateyama type, 614321 (3), ; creatine phosphokinase, elevated serum, 123320 (3), ; cardiomyopathy, familial hypertrophic, 192600 (3), digenic , ; rippling muscle disease 2, 606072 (3), ; long qt syndrome 9, 611818 (3),
LGMD1D	AD	muscular dystrophy, limb-girdle, 1, 603511 (3),
LGMD1F	AD	muscular dystrophy, limb-girdle, 2, 608423 (3),
LGMD1G	AD	muscular dystrophy, limb-girdle, 3, 609115 (3),
LGMD2	AR,AD	muscular dystrophy, limb-girdle, 1, 253600 (3), ; muscular dystrophy, limb-girdle, 4, 618129 (3),
LGMD2A	AR,AD	muscular dystrophy, limb-girdle, 1, 253600 (3), ; muscular dystrophy, limb-girdle, 4, 618129 (3),
LGMD2B	AR	muscular dystrophy, limb-girdle, 2, 253601 (3), ; miyoshi muscular dystrophy 1, 254130 (3), ; myopathy, distal, with anterior tibial onset, 606768 (3),
LGMD2C	AR	muscular dystrophy, limb-girdle, 5, 253700 (3),
LGMD2D	AR	muscular dystrophy, limb-girdle, 3, 608099 (3),
LGMD2E	AR	muscular dystrophy, limb-girdle, 4, 604286 (3),
LGMD2F	AR	cardiomyopathy, dilated, 1l, 606685 (3); muscular dystrophy, limb-girdle, 6, 601287 (3),
LGMD2G	AD,AR	cardiomyopathy, hypertrophic, 25, 607487 (3), ; muscular dystrophy, limb-girdle, 7, 601954 (3),
LGMD2H	AR	?bardet-biedl syndrome 11, 615988 (3), ; muscular dystrophy, limb-girdle, 8, 254110 (3),
LGMD2I	AR	muscular dystrophy-dystroglycanopathy (congenital with or without impaired intellectual development), type b, 5, 606612 (3), ; muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 5, 607155 (3), ; muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 5, 613153 (3),
LGMD2J	AR,AD	muscular dystrophy, limb-girdle, 10, 608807 (3), ; cardiomyopathy, familial hypertrophic, 9, 613765 (3), ; congenital myopathy 5 with cardiomyopathy, 611705 (3), ; tibial muscular dystrophy, tardive, 600334 (3), ; cardiomyopathy, dilated, 1g, 604145 (3), ; myopathy, myofibrillar, 9, with early respiratory failure, 603689 (3),
LGMD2K	AR	muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 1, 236670 (3), ; muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 1, 609308 (3), ; muscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type b, 1, 613155 (3),
LGMD2L	AR,AD	muscular dystrophy, limb-girdle, 12, 611307 (3), ; miyoshi muscular dystrophy 3, 613319 (3), ; gnathodiaphyseal dysplasia, 166260 (3),
LGMD2M	AR	muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 4, 611588 (3), ; muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 4, 253800 (3), ; cardiomyopathy, dilated, 1x, 611615 (3), ; muscular dystrophy-dystroglycanopathy (congenital without impaired intellectual development), type b, 4, 613152 (3),
LGMD2N	AR	muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 2, 613158 (3), ; muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 2, 613150 (3), ; muscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type b, 2, 613156 (3),
LGMD2O	AR	muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 3, 613157 (3), ; muscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type b, 3, 613151 (3), ; retinitis pigmentosa 76, 617123 (3), ; muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 3, 253280 (3),
LGMD2R	AD,AR	scapuloperoneal syndrome, neurogenic, kaeser type, 181400 (3), ; cardiomyopathy, dilated, 1i, 604765 (3), ; myopathy, myofibrillar, 1, 601419 (3),
LGMN		
LGMN1		
LGN	AR	chudley-mccullough syndrome, 604213 (3),
LGP1		
LGP2		
LGR1	AR,AD	ovarian response to fsh stimulation, 276400 (3), ; ovarian hyperstimulation syndrome, 608115 (3), ; ovarian dysgenesis 1, 233300 (3),
LGR2	AR,AD	leydig cell adenoma, somatic, with precocious puberty, 176410 (3); leydig cell hypoplasia with pseudohermaphroditism, 238320 (3), ; leydig cell hypoplasia with hypergonadotropic hypogonadism, 238320 (3), ; luteinizing hormone resistance, female, 238320 (3), ; precocious puberty, male, 176410 (3),
LGR3	AD,AR	hyperthyroidism, familial gestational, 603373 (3), ; hyperthyroidism, nonautoimmune, 609152 (3), ; thyroid adenoma, hyperfunctioning, somatic (3); hypothyroidism, congenital, nongoitrous, 1, 275200 (3), ; thyroid carcinoma with thyrotoxicosis, somatic (3)
LGR4	AD	delayed puberty, self-limited, 619613 (3), ; {bone mineral density, low, susceptibility to}, 615311 (3),
LGR5		
LGR6		
LGR7		
LGR8		
LGS	AD	exostoses, multiple, type 1, 133700 (3), ; chondrosarcoma, 215300 (3), somatic mutation
LGSN		
LGTN		
LH-2		
LH1	AR	ehlers-danlos syndrome, kyphoscoliotic type, 1, 225400 (3),
LH2	AR	bruck syndrome 2, 609220 (3),
LH2D1	AR	deafness, 77, 613079 (3),
LH3	AR	lysyl hydroxylase 3 deficiency, 612394 (3),
LHA		
LHB	AR	hypogonadotropic hypogonadism 23 with or without anosmia, 228300 (3),
LHCGR	AR,AD	leydig cell adenoma, somatic, with precocious puberty, 176410 (3); leydig cell hypoplasia with pseudohermaphroditism, 238320 (3), ; leydig cell hypoplasia with hypergonadotropic hypogonadism, 238320 (3), ; luteinizing hormone resistance, female, 238320 (3), ; precocious puberty, male, 176410 (3),
LHFP		
LHFPL1		
LHFPL2		
LHFPL3		
LHFPL4		
LHFPL5	AR	deafness, 67, 610265 (3),
LHFPL6		
Lhp1		
LHPP		
LHR	AR,AD	leydig cell adenoma, somatic, with precocious puberty, 176410 (3); leydig cell hypoplasia with pseudohermaphroditism, 238320 (3), ; leydig cell hypoplasia with hypergonadotropic hypogonadism, 238320 (3), ; luteinizing hormone resistance, female, 238320 (3), ; precocious puberty, male, 176410 (3),
LHRH	AR	?hypogonadotropic hypogonadism 12 with or without anosmia, 614841 (3),
LHRHR	AR	hypogonadotropic hypogonadism 7 without anosmia, 146110 (3),
LHX1		
LHX2		
LHX3	AR	pituitary hormone deficiency, combined, 3, 221750 (3),
LHX4	AD	pituitary hormone deficiency, combined, 4, 262700 (3),
LHX5		
LHX6		
LHX6.1		
Lhx7		
LHX8		
LHX9		
LI	AR	ichthyosis, congenital, 1, 242300 (3),
LI1	AR	ichthyosis, congenital, 1, 242300 (3),
LI2	AR	ichthyosis, congenital, 4b (harlequin), 242500 (3), ; ichthyosis, congenital, 4a, 601277 (3),
LIAG		
LIAR		
LIAS	AR	hyperglycinemia, lactic acidosis, and seizures, 614462 (3),
LIB		
LIC-2	XLD,XL	amyotrophic lateral sclerosis 15, with or without frontotemporal dementia, 300857 (3),
LIC3	AR	short-rib thoracic dysplasia 15 with polydactyly, 617088 (3),
LIECG2		
LIECG3		
LiESP6		
LIF		
LIFEGUARD		
LIFL-H	AR,AD	cataract 33, multiple types, 611391 (3),
LIFL-L	AD	cataract 12, multiple types, 611597 (3),
LIFR	AR	stuve-wiedemann syndrome/schwartz-jampel type 2 syndrome, 601559 (3),
LIG-1		
LIG1	AR	immunodeficiency 96, 619774 (3),
LIG2	AR	mitochondrial dna depletion syndrome 20 (mngie type), 619780 (3),
LIG3	AR	mitochondrial dna depletion syndrome 20 (mngie type), 619780 (3),
LIG3alpha	AR	mitochondrial dna depletion syndrome 20 (mngie type), 619780 (3),
LIG4	AR	lig4 syndrome, 606593 (3), ; {multiple myeloma, resistance to}, 254500 (3), somatic mutation
LIGHT		
LIGHTR		
LIGI	AR	immunodeficiency 96, 619774 (3),
LILINA		
LILRA1		
LILRA2		
LILRA3		
LILRA4		
LILRA5		
LILRB1		
LILRB2		
LILRB3		
LILRB4		
LILRB5		
LILRB7		
LIM		
LIM-1		
LIM1	AD	cataract 15, multiple types, 615274 (3),
LIM15		
LIM2	AR	cataract 19, multiple types, 615277 (3),
LIMA1		[low density lipoprotein cholesterol level qtl 8], 618079 (3)
LIMAB1		
limatin		
LIMCH1		
LIMCH1A		
LIMD1		
LIME		
LIME1		
LIMK		
LIMK1		
LIMK2		
LIMP-2	AR	epilepsy, progressive myoclonic 4, with or without renal failure, 254900 (3),
LIMPII	AR	epilepsy, progressive myoclonic 4, with or without renal failure, 254900 (3),
LIMS1		
LIMS2	AR	?muscular dystrophy, with cardiomyopathy and triangular tongue, 616827 (3),
LIN-10		
LIN-28		
LIN-41	AD	hydrocephalus, congenital, 4, 618667 (3),
lin-53		
LIN-7-C		
LIN-7A		
LIN-7B		
LIN-7C		
LIN1		
LIN2	XLR,XLD,XL	intellectual developmental disorder, with or without nystagmus, 300422 (3), ; intellectual developmental disorder and microcephaly with pontine and cerebellar hypoplasia, 300749 (3), ; fg syndrome 4, 300422 (3),
LIN28		
LIN28A		
LIN28B		
LIN41	AD	hydrocephalus, congenital, 4, 618667 (3),
LIN54		
LIN7A		
LIN7B		
LIN7C		
LIN9		
linc-Brn1a		
linc-Brn1b		
linc-Enc1		
LINC-HEIH		
LINC-HELLP		
linc-MAF-4		
LINC-MD1		
linc-NeD125		
linc-p21		
LINC-PINT		
linc-POU3F3		
linc-Ppara		
Linc-RAM		
LINC-ROR		
linc-UBC1		
LINC00001		x-inactivation, familial skewed, 300087 (3)
LINC00004		
LINC00008		
LINC00013		
LINC00021		
LINC00022		
LINC00023		
LINC00024		
LINC00035		
LINC00036		
LINC00037		
LINC00044		
LINC00047		
LINC00048		
LINC00054		
LINC00057		
LINC00064		
LINC00065		
LINC00066		{myocardial infarction, susceptibility to}, 608446 (3)
LINC00067		
LINC00071		
LINC00078		
LINC00079		
LINC00080		
LINC00084		
LINC00085		
LINC00096		
LINC00101		
LINC00114		
LINC00121		
LINC00123		
LINC00126		
LINC00127		
LINC00162		
LINC00163		
LINC00178		
LINC00180		
LINC00182		
LINC00183		
LINC00237		
LINC00261		
LINC00263		
LINC00277		
LINC00293		
LINC00294		
LINC00305		
LINC00312		
LINC00340		
LINC00341		
LINC00444	AR	mitochondrial dna depletion syndrome 5 (encephalomyopathic with or without methylmalonic aciduria), 612073 (3),
LINC00461		
LINC00464		
LINC00467		
LINC00468		
LINC00472		
LINC00478		
LINC00505		
LINC00532		
LINC00538		
LINC00568		
LINC00586		
LINC00594		
LINC00598		
LINC00617		
LINC00657		
LINC00663		
LINC00672		
LINC00673		
LINC00848		
LINC00850		
LINC00860		
LINC00873		
LINC00883		
LINC00889	XLD,XLR,XL	developmental and epileptic encephalopathy 90, 301058 (3), ; intellectual developmental disorder, 110, 301095 (3),
LINC00902		
LINC00912		
LINC00913		
LINC00947		
LINC00948		
LINC00950		
LINC00958		
LINC00961		
LINC00974		
LINC00978		
LINC00980	AD	lessel-kreienkamp syndrome, 619149 (3),
LINC00990		
LINC01006		
LINC01018		
LINC01059		
LINC01080		
LINC01081		
LINC01082		
LINC01083		
LINC01092		
LINC01112	AR	developmental and epileptic encephalopathy 110, 620149 (3),
LINC01155		
LINC01156		
LINC01157		
LINC01158		
LINC01159		
LINC01190		
LINC01194		
LINC01200		
LINC01212		
LINC01244		
LINC01245		
LINC01279		
LINC01336		
LINC01370		
LINC01379		
LINC01420		
LINC01458		
LINC01481		
LINC01488		
LINC01565		
LINC02170		
LINC02657		
LINC02747		
Linc1992		
lincFOXF1		
LINCMD1		
Lincr		
lincRNA-NR_024015		
lincRNA-p21		
LincRNA-Pint		
lincRNA-RoR		
lincRNA-ST8SIA3		
lincSCRG1		
LIND		
LINGO1	AR	intellectual developmental disorder, 64, 618103 (3),
LINGO2		
LINGO3		
LINGO4		
LINS	AR	intellectual developmental disorder, 27, 614340 (3),
LINS1	AR	intellectual developmental disorder, 27, 614340 (3),
LIP		
LIP-STYX		
LIP.1		
LIP1	AR	microcephaly 6, primary, 608393 (3), ; ?seckel syndrome 4, 613676 (3),
LIP2		
LIP4		
LIP6		
LIP8		
LIPA	AR	wolman disease, 620151 (3), ; cholesteryl ester storage disease, 278000 (3),
LIPB		
LIPC	AD,AR	{diabetes mellitus, noninsulin-dependent}, 125853 (3), ; hepatic lipase deficiency, 614025 (3), ; [high density lipoprotein cholesterol level qtl 12], 612797 (3)
LIPD	AR,AD	lipoprotein lipase deficiency, 238600 (3), ; [high density lipoprotein cholesterol level qtl 11], 238600 (3), ; combined hyperlipidemia, familial, 144250 (3),
LIPE	AR	lipodystrophy, familial partial, type 6, 615980 (3),
LIPF		
LIPG		
LIPH	AR	hypotrichosis 7, 604379 (3), ; woolly hair, 2 with or without hypotrichosis, 604379 (3),
LIPI		
LIPJ		
LIPK		
LIPL1		
LIPL2		
LIPL3		
LIPL4	AR	ichthyosis, congenital, 8, 613943 (3),
LIPM		
LIPN	AR	ichthyosis, congenital, 8, 613943 (3),
LIPN3L		
LIPO	AD	silver-russell syndrome 5, 618908 (3),
LIPRIN		
LIPT1	AR	lipoyltransferase 1 deficiency, 616299 (3),
LIPT2	AR	encephalopathy, neonatal severe, with lactic acidosis and brain abnormalities, 617668 (3),
LIR		
LIR-1		
LIR-2		
LIR-3		
LIR-4		
LIR-5		
LIR-6		
LIR-7		
LIR-8		
LIR1		
LIR2		
LIR3		
LIR4		
LIR5		
LIR6		
LIR7		
LIR8		
LIR9		
LIRF		
LIS1	AD	subcortical laminar heterotopia, 607432 (3), ; lissencephaly 1, 607432 (3),
LISCH7		
LISTERIN		
LISX	XL	subcortical laminal heterotopia, 300067 (3), ; lissencephaly, 300067 (3),
LIT		
LIT1	AD	beckwith-wiedemann syndrome, 130650 (3),
LITAF	AD	charcot-marie-tooth disease, type 1c, 601098 (3),
LITAFL		
LIV-1		
LIX1		
LJAK	AR	scid, t-negative/b-positive type, 600802 (3),
LK4		
LKAP		
LKB1	AD	melanoma, malignant, somatic, 155600 (3); pancreatic cancer, somatic, 260350 (3); peutz-jeghers syndrome, 175200 (3), ; testicular tumor, somatic, 273300 (3)
LKB1IP		
LKLF		
Lkn-1		
LKP		
LKRSDH	AR	hyperlysinemia, 238700 (3),
LL37		
LL5a		
LL5b		
LL5beta		
LLC1		
LLCDL1		
LLCDL2		
LLCDL3		
LLCFC1		
LLGL		
LLGL1		
LLGL2		
LLGL3		
LLGL4		
LLH	AR	ehlers-danlos syndrome, kyphoscoliotic type, 1, 225400 (3),
LLID-114769		
LLN4		
LLPH		
LLPL		
LLREP3		
LLT1		
LMAN1	AR	combined factor v and viii deficiency, 227300 (3),
LMAN1IP		factor v and factor viii, combined deficiency of, 613625 (3)
LMAN1L		
LMAN2		
LMAN2L	AD,AR	?intellectual developmental disorder, 69, 617863 (3); ?intellectual developmental disorder, 52, 616887 (3),
LMBR1	AD,AR	triphalangeal thumb, type i, 174500 (3), ; syndactyly, type iv, 186200 (3), ; laurin-sandrow syndrome, 135750 (3), ; hypoplastic or aplastic tibia with polydactyly, 188740 (3), ; polydactyly, preaxial type ii, 174500 (3), ; acheiropody, 200500 (3), ; triphalangeal thumb-polysyndactyly syndrome, 190605 (3),
LMBR1L		
LMBR2		
LMBRD1	AR	methylmalonic aciduria and homocystinuria, cblf type, 277380 (3),
LMBRD2	AD	developmental delay with variable neurologic and brain abnormalities, 619694 (3),
LMC		
LMCD1		
LMCD1DN		
LMET1		
LMF1	AR	lipase deficiency, combined, 246650 (3),
LMKB		
LMLN		
LMLN2	AR	heterotaxy, visceral, 12, 619702 (3),
LMN1	AR,AD	mandibuloacral dysplasia, 248370 (3), ; heart-hand syndrome, slovenian type, 610140 (3), ; cardiomyopathy, dilated, 1a, 115200 (3), ; emery-dreifuss muscular dystrophy 3, 616516 (3), ; restrictive dermopathy 2, 619793 (3); charcot-marie-tooth disease, type 2b1, 605588 (3), ; emery-dreifuss muscular dystrophy 2, 181350 (3), ; hutchinson-gilford progeria, 176670 (3), ; lipodystrophy, familial partial, type 2, 151660 (3), ; muscular dystrophy, congenital, 613205 (3), ; malouf syndrome, 212112 (3),
LMN2	AD,AR	microcephaly 27, primary, 619180 (3), ; ?epilepsy, progressive myoclonic, 9, 616540 (3), ; {lipodystrophy, partial, acquired, susceptibility to}, 608709 (3),
LMNA	AR,AD	mandibuloacral dysplasia, 248370 (3), ; heart-hand syndrome, slovenian type, 610140 (3), ; cardiomyopathy, dilated, 1a, 115200 (3), ; emery-dreifuss muscular dystrophy 3, 616516 (3), ; restrictive dermopathy 2, 619793 (3); charcot-marie-tooth disease, type 2b1, 605588 (3), ; emery-dreifuss muscular dystrophy 2, 181350 (3), ; hutchinson-gilford progeria, 176670 (3), ; lipodystrophy, familial partial, type 2, 151660 (3), ; muscular dystrophy, congenital, 613205 (3), ; malouf syndrome, 212112 (3),
LMNB1	AD	leukodystrophy, adult-onset, 169500 (3), ; microcephaly 26, primary, 619179 (3),
LMNB2	AD,AR	microcephaly 27, primary, 619180 (3), ; ?epilepsy, progressive myoclonic, 9, 616540 (3), ; {lipodystrophy, partial, acquired, susceptibility to}, 608709 (3),
LMNL1	AR,AD	mandibuloacral dysplasia, 248370 (3), ; heart-hand syndrome, slovenian type, 610140 (3), ; cardiomyopathy, dilated, 1a, 115200 (3), ; emery-dreifuss muscular dystrophy 3, 616516 (3), ; restrictive dermopathy 2, 619793 (3); charcot-marie-tooth disease, type 2b1, 605588 (3), ; emery-dreifuss muscular dystrophy 2, 181350 (3), ; hutchinson-gilford progeria, 176670 (3), ; lipodystrophy, familial partial, type 2, 151660 (3), ; muscular dystrophy, congenital, 613205 (3), ; malouf syndrome, 212112 (3),
Lmnt1		
Lmnt2	AR	neurodevelopmental disorder with behavioral abnormalities, absent speech, and hypotonia, 618718 (3),
LMNTD1		
LMO1		leukemia, t-cell acute lymphoblastic, 186921 (2)
LMO2		leukemia, acute t-cell, 180385 (2)
LMO3		
LMO4		
LMO5		
LMO6	XLD,XL	{leber hereditary optic neuropathy, modifier of}, 308905 (3),
LMO7		
LMO7B		
LMOD1	AR	?megacystis-microcolon-intestinal hypoperistalsis syndrome 3, 619362 (3),
LMOD2	AR	cardiomyopathy, dilated, 2g, 619897 (3),
LMOD3	AR	nemaline myopathy 10, 616165 (3),
LMP10	AR	proteasome-associated autoinflammatory syndrome 5, 619175 (3),
LMP2	AR	?proteasome-associated autoinflammatory syndrome 3, digenic, 617591 (3),
LMP7	AR	proteasome-associated autoinflammatory syndrome 1 and digenic forms, 256040 (3),
LMPB1		
LMPIP		
LMR1		
LMR2		
LMR3		
LMTK1		
LMTK2		
LMTK3		
LMW-PTP		
LMWPTP		
LMX1	AD	deafness, 7, 601412 (3),
LMX1.1	AD	deafness, 7, 601412 (3),
LMX1A	AD	deafness, 7, 601412 (3),
LMX1B	AD	focal segmental glomerulosclerosis 10, 256020 (3), ; nail-patella syndrome, 161200 (3),
LMYC		
ln	AR	griscelli syndrome, type 3, 609227 (3),
lnc		
Lnc_bc060912		
lnc-ABCA12-8	AD	spondylometaphyseal dysplasia, corner fracture type, 184255 (3), ; glomerulopathy with fibronectin deposits 2, 601894 (3),
lnc-DC		
lnc-IL7R	AR	immunodeficiency 104, severe combined, 608971 (3),
lnc-MGC		
Lnc-Myd88		
Lnc-PCIR		
lnc-PKD2-2-3		
Lnc-PMIF	AD	lissencephaly 9 with complex brainstem malformation, 618325 (3),
lnc-SCA7		
lnc-SOX4-1		
lnc-TNFAIP3		
lnc-UCID		
lnc003875		
lncBCAS1-4_1	AR	hypercalcemia, infantile, 1, 143880 (3),
lncCMPK2		
LNCDC		
Lncenc1		
lncFAL		
lncFOXO1		
LncHIFCAR		
lncMX1-215		
lncMYH7b		
lncND		
lncPSCA		
lncRNA-AC130710		
lncRNA-ANCR		
lncRNA-AWPPH		
lncRNA-BGL3		
lncRNA-CMPK2		
lncRNA-GHET1		
lncRNA-HAL		
lncRNA-HEIH		
lncRNA-LET		
lncRNA-MIAT		{myocardial infarction, susceptibility to}, 608446 (3)
lncRNA-N2		
lncRNA-N3	AR	developmental and epileptic encephalopathy 110, 620149 (3),
lncRNA-PE	AD	myopia 25, 617238 (3),
lncRNA#32		
lncRNA16		
lncTCF7		
lncUSMycN		
LncZBTB39	AR	hypogonadotropic hypogonadism 10 with or without anosmia, 614839 (3),
LncZBTB39-1:2	AR	hypogonadotropic hypogonadism 10 with or without anosmia, 614839 (3),
LNEBL		
LNHR		
LNIR	AR	ectodermal dysplasia-syndactyly syndrome 1, 613573 (3),
LNK		thrombocythemia, somatic, 187950 (3); myelofibrosis, somatic, 254450 (3); erythrocytosis, somatic, 133100 (3)
LNKN-1		
LNOX1		
LNOX2	AR	thyroid dyshormonogenesis 6, 607200 (3),
LNP	AR	neurodevelopmental disorder with epilepsy and hypoplasia of the corpus callosum, 618090 (3),
LNP1	AR	neurodevelopmental disorder with epilepsy and hypoplasia of the corpus callosum, 618090 (3),
LNPEP		
LNPK	AR	neurodevelopmental disorder with epilepsy and hypoplasia of the corpus callosum, 618090 (3),
LNX		
LNX1		
LNX2		
LNX3		
LNX4		
LNX5		
Lobe		
LOC100170841		
LOC100505495		
LOC123688		
LOC124512	AR	intellectual developmental disorder, 44, 615942 (3),
LOC133491		
LOC151194		
LOC196541		
LOC201725		
LOC283174		
LOC283677	AR	oocyte/zygote/embryo maturation arrest 10, 619176 (3),
LOC285194		
LOC285498	AR	?spermatogenic failure 62, 619673 (3), ; recombination rate qtl 1, 612042 (3)
LOC285556		
LOC285636		
LOC338328	AR	hyperlipoproteinemia, type 1d, 615947 (3),
LOC342897		
LOC387715		{macular degeneration, age-related, 8}, 613778 (3)
LOC388135		
LOC389073		
LOC391356		
LOC402665		
LOC440145		
LOC51035		
LOC51149		
LOC51491		
LOC54103		
LOC554202		
LOC57722		
LOC643911		
LOC645323		
LOC645638		
LOC645811		
LOC646329		
LOC653319		
LOC84645		
LOC92154	AD	intellectual developmental disorder with ocular anomalies and distinctive facial features, 620086 (3),
LOC93082		
LOH11CR1I		
LOH11CR2A		
LOH12CR1		
LOH18CR1	AR,AD	osteopetrosis, 7, 612301 (3), ; {paget disease of bone 2, early-onset}, 602080 (3), ; osteolysis, familial expansile, 174810 (3),
LOH19CR1	AD	diamond-blackfan anemia 1, 105650 (3),
LOH1CR12		
LOH3CR2A		
LOK		
LOL	AD	{exfoliation syndrome, susceptibility to}, 177650 (3),
long-IRBIT		
LonHS	AR	codas syndrome, 600373 (3),
LONP		
LONP1	AR	codas syndrome, 600373 (3),
LONP2		
LONPL		
LOR	AD	vohwinkel syndrome with ichthyosis, 604117 (3),
LORD	AD	retinal degeneration, late-onset, 605670 (3),
LORICRIN	AD	vohwinkel syndrome with ichthyosis, 604117 (3),
LORSDH	AR	hyperlysinemia, 238700 (3),
LOST1		
LOT1		
LOX	AD	aortic aneurysm, familial thoracic 10, 617168 (3),
LOX-1		{myocardial infarction, susceptibility to}, 608446 (3)
LOXC		
LOXHD1	AR	deafness, 77, 613079 (3),
LOXL	AD	{exfoliation syndrome, susceptibility to}, 177650 (3),
LOXL1	AD	{exfoliation syndrome, susceptibility to}, 177650 (3),
LOXL1-AS1		
LOXL2		
LOXL3	AR	myopia 28, 619781 (3),
LOXL4		
LP	AD	[lpa deficiency, congenital], 618807 (3), ; {coronary artery disease, susceptibility to}, 618807 (3),
LP-A3		
Lp(a)	AD	[lpa deficiency, congenital], 618807 (3), ; {coronary artery disease, susceptibility to}, 618807 (3),
LP0		
LP1		
LP2		
LP2561		
LP3298	AR	encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy, 2, 618321 (3),
LP3663	AR	?mitochondrial complex v (atp synthase) deficiency, nuclear type 1, 604273 (3),
LPA	AD	[lpa deficiency, congenital], 618807 (3), ; {coronary artery disease, susceptibility to}, 618807 (3),
LPA1		
LPA2		
LPA3		
LPA4		
LPA5		
LPAAT-alpha		
LPAAT-beta	AR	lipodystrophy, congenital generalized, type 1, 608594 (3),
LPAAT-delta		
LPAAT-e		
LPAAT-epsilon		
LPAAT-eta		
LPAAT-gamma		
LPAAT-theta		
LPAAT-zeta		
LPAAT3		
LPAAT4		
LPAL2		
LPAP		
LPAR1		
LPAR2		
LPAR3		
LPAR4		
LPAR5		
LPAR6	AR	hypotrichosis 8, 278150 (3), ; woolly hair, 1, with or without hypotrichosis, 278150 (3),
LPC		
LPC1		
LPC2D		
LPCAT1		
LPCAT2		
LPCAT3		
LPCAT4		
lpd-2		
LPDL		
LPDLR	AR	hypotrichosis 7, 604379 (3), ; woolly hair, 2 with or without hypotrichosis, 604379 (3),
LPEAT1		
LPEAT2		
LPGAT1		
Lpgp		
LPGP1		
LPH	AR,MF,AD	{obesity, early-onset, susceptibility to}, 601665 (3), , ; obesity, adrenal insufficiency, and red hair due to pomc deficiency, 609734 (3),
LPHA		
LPHB		
LPHC		
LPHH1		
LPHN1	AD	developmental delay, behavioral abnormalities, and neuropsychiatric disorders, 620065 (3),
LPHN2		
LPHN3		
LPI	AR	lysinuric protein intolerance, 222700 (3),
LPI-PC1		
LPIAT1	AR	intellectual developmental disorder, 57, 617188 (3),
LPIC	AR	ceroid lipofuscinosis, neuronal, 2, 204500 (3), ; spinocerebellar ataxia, 7, 609270 (3),
LPIN1	AR	myoglobinuria, acute recurrent, 268200 (3),
LPIN2		majeed syndrome, 609628 (3)
LPIN3		
LPIPOX		
LPL	AR,AD	lipoprotein lipase deficiency, 238600 (3), ; [high density lipoprotein cholesterol level qtl 11], 238600 (3), ; combined hyperlipidemia, familial, 144250 (3),
LPL1		
LPLAT	AR	intellectual developmental disorder, 57, 617188 (3),
LPLAT1		
LPLAT10		
LPLAT11	AR	intellectual developmental disorder, 57, 617188 (3),
LPLAT12		
LPLAT13		
LPLAT14		
LPLAT2	AR	lipodystrophy, congenital generalized, type 1, 608594 (3),
LPLAT3		
LPLAT4		
LPLAT5		
LPLAT6		
LPLAT7		
LPLAT8		
LPLAT9		
LPLUNC2		
LPLUNC3		
LPLUNC4		
LPLUNC6		
LPNA3		
LPO		
LPP	AD	lipoma (3); leukemia, acute myeloid, 601626 (3), somatic mutation,
LPP1	AD	neural tube defects, 182940 (3),
LPP2		
LPP3		
LPPM429		
LPPR1		
LPPR2		
LPPR3		
LPPR4		
LPPR5		
Lpr4		
LPRP		
LPS	AD	{orofacial cleft 6}, 608864 (3), ; popliteal pterygium syndrome 1, 119500 (3), ; van der woude syndrome 1, 119300 (3),
LPS1		
LPS2		
LPS3		
LPSB	AR	extraoral halitosis due to mto deficiency, 618148 (3),
LPTL		
LPTN		
LPTS		
LPTS-RP1		
LPTSRP1		
LPXN		
LQFBS-1		
LQK1		
LQT	AD,AR	short qt syndrome 2, 609621 (3), ; atrial fibrillation, familial, 3, 607554 (3), ; long qt syndrome 1, 192500 (3), ; {long qt syndrome 1, acquired, susceptibility to}, 192500 (3), ; jervell and lange-nielsen syndrome, 220400 (3),
LQT1	AD,AR	short qt syndrome 2, 609621 (3), ; atrial fibrillation, familial, 3, 607554 (3), ; long qt syndrome 1, 192500 (3), ; {long qt syndrome 1, acquired, susceptibility to}, 192500 (3), ; jervell and lange-nielsen syndrome, 220400 (3),
LQT10	AD	atrial fibrillation, familial, 17, 611819 (3), ; long qt syndrome 10, 611819 (3),
LQT11	AD	?long qt syndrome 11, 611820 (3),
LQT12	AD	long qt syndrome 12, 612955 (3),
LQT13	AD	long qt syndrome 13, 613485 (3), ; hyperaldosteronism, familial, type iii, 613677 (3),
LQT2	AD	short qt syndrome 1, 609620 (3); long qt syndrome 2, 613688 (3),
LQT3	AD,AR	ventricular fibrillation, familial, 1, 603829 (3); heart block, progressive, type ia, 113900 (3), ; cardiomyopathy, dilated, 1e, 601154 (3), ; heart block, nonprogressive, 113900 (3), ; long qt syndrome 3, 603830 (3), ; sick sinus syndrome 1, 608567 (3), ; brugada syndrome 1, 601144 (3), ; atrial fibrillation, familial, 10, 614022 (3), ; {sudden infant death syndrome, susceptibility to}, 272120 (3),
LQT4	AD	long qt syndrome 4, 600919 (3), ; cardiac arrhythmia, ankyrin-b-related, 600919 (3),
LQT5	AR,AD	jervell and lange-nielsen syndrome 2, 612347 (3), ; long qt syndrome 5, 613695 (3),
LQT6	AD	long qt syndrome 6, 613693 (3), ; atrial fibrillation, familial, 4, 611493 (3)
LQT7	AD	atrial fibrillation, familial, 9, 613980 (3), ; andersen syndrome, 170390 (3), ; short qt syndrome 3, 609622 (3)
LQT8	AD	timothy syndrome, 601005 (3), ; long qt syndrome 8, 618447 (3), ; neurodevelopmental disorder with hypotonia, language delay, and skeletal defects with or without seizures, 620029 (3), ; brugada syndrome 3, 611875 (3),
LQT9	AD	myopathy, distal, tateyama type, 614321 (3), ; creatine phosphokinase, elevated serum, 123320 (3), ; cardiomyopathy, familial hypertrophic, 192600 (3), digenic , ; rippling muscle disease 2, 606072 (3), ; long qt syndrome 9, 611818 (3),
LR11		
LR3	AD,AR	osteopetrosis, 1, 607634 (3), ; [bone mineral density variability 1], 601884 (3), ; polycystic liver disease 4 with or without kidney cysts, 617875 (3), ; endosteal hyperostosis, 144750 (3), ; osteoporosis-pseudoglioma syndrome, 259770 (3), ; exudative vitreoretinopathy 4, 601813 (3),
LR8		
LRAD3		
LRANK1		
LRAP		
LRAP25		
LRAP35a		
LRAP35b		
LRAT	AR	leber congenital amaurosis 14, 613341 (3), ; retinal dystrophy, early-onset severe, 613341 (3), ; retinitis pigmentosa, juvenile, 613341 (3),
LRATD1		
LRATD2		
LRBA	AR	immunodeficiency, common variable, 8, with autoimmunity, 614700 (3),
LRBP	AR,AD	hyper-igd syndrome, 260920 (3), ; porokeratosis 3, multiple types, 175900 (3), ; mevalonic aciduria, 610377 (3),
LRCH1		
LRCH4		
LRDD	AR	intellectual developmental disorder, 75, with neuropsychiatric features and variant lissencephaly, 619827 (3),
LRE1		
LRE2		
LRE4		
LRF	AD	macrocephaly, neurodevelopmental delay, lymphoid hyperplasia, and persistent fetal hemoglobin, 619769 (3),
LRFN1		
LRFN2		
LRFN3		
LRFN4		
LRFN5		
LRG		
LRG-47		{mycobacterium tuberculosis, protection against}, 607948 (3); {inflammatory bowel disease (crohn disease) 19}, 612278 (3)
LRG1		
LRG47		{mycobacterium tuberculosis, protection against}, 607948 (3); {inflammatory bowel disease (crohn disease) 19}, 612278 (3)
LRGUK		
LRH-1		
LRH1		
LRIF1		?facioscapulohumeral muscular dystrophy 3, digenic, 619477 (3), digenic
LRIG1		
LRIG2	AR	urofacial syndrome 2, 615112 (3),
LRIG3		
LRIT1		
LRIT3	AR	night blindness, congenital stationary (complete), 1f, 615058 (3),
LRMDA	AR	albinism, oculocutaneous, type vii, 615179 (3),
LRMP		
LRN		
LRP	AR,AD	?keratosis pilaris atrophicans, 604093 (3), |asplenia, isolated congenital, 271400 (3),
LRP-3		
LRP-4	AR,AD	?myasthenic syndrome, congenital, 17, 616304 (3), ; sclerosteosis 2, 614305 (3), ; cenani-lenz syndactyly syndrome, 212780 (3),
LRP-8		{myocardial infarction, susceptibility to}, 608446 (3)
LRP-DIT		
LRP1	AR	?keratosis pilaris atrophicans, 604093 (3),
LRP10		
LRP12	AD	oculopharyngodistal myopathy 1, 164310 (3),
LRP130	AR	mitochondrial complex iv deficiency, nuclear type 5, (french-canadian), 220111 (3),
LRP15		
LRP16		
LRP1A	AR	?keratosis pilaris atrophicans, 604093 (3),
LRP1B		
LRP2	AR	donnai-barrow syndrome, 222448 (3),
Lrp2bp		
LRP2BP		
LRP3		
Lrp4		preeclampsia/eclampsia 5, 614595 (3)
LRP4	AR,AD	?myasthenic syndrome, congenital, 17, 616304 (3), ; sclerosteosis 2, 614305 (3), ; cenani-lenz syndactyly syndrome, 212780 (3),
LRP5	AD,AR	osteopetrosis, 1, 607634 (3), ; [bone mineral density variability 1], 601884 (3), ; polycystic liver disease 4 with or without kidney cysts, 617875 (3), ; endosteal hyperostosis, 144750 (3), ; osteoporosis-pseudoglioma syndrome, 259770 (3), ; exudative vitreoretinopathy 4, 601813 (3),
LRP6	AD	{coronary artery disease, 2}, 610947 (3), ; tooth agenesis, selective, 7, 616724 (3),
LRP7	AD,AR	osteopetrosis, 1, 607634 (3), ; [bone mineral density variability 1], 601884 (3), ; polycystic liver disease 4 with or without kidney cysts, 617875 (3), ; endosteal hyperostosis, 144750 (3), ; osteoporosis-pseudoglioma syndrome, 259770 (3), ; exudative vitreoretinopathy 4, 601813 (3),
LRP8		{myocardial infarction, susceptibility to}, 608446 (3)
LRP9		
LRPAP1	AR	myopia 23, 615431 (3),
LRPC21		
LRPDIT		
LRPPRC	AR	mitochondrial complex iv deficiency, nuclear type 5, (french-canadian), 220111 (3),
LRPR1		
LRR-1		
LRR1		
LRRC1		
LRRC10		
LRRC10A		
LRRC11		
LRRC12	AD,MF	tourette syndrome, 137580 (3), ; ?trichotillomania, 613229 (3),
LRRC14		
LRRC14A		
LRRC15		
LRRC16		
LRRC16A		
LRRC16B		
LRRC16C	AR	immunodeficiency 58, 618131 (3),
LRRC17		
LRRC18		
LRRC19		
LRRC2		
LRRC21		
LRRC25		
LRRC26		
LRRC3		
LRRC32	AR	cleft palate, proliferative retinopathy, and developmental delay, 619074 (3),
LRRC33	AR	seizures, early-onset, with neurodegeneration and brain calcification, 618875 (3),
LRRC34		
LRRC35		
LRRC37A		
LRRC37A1		
LRRC37A2		
LRRC37A3		
LRRC37B		
LRRC38		
LRRC3B		
LRRC3DN		
LRRC4		
LRRC41		
LRRC44		
LRRC47		
LRRC48		
LRRC4C		
LRRC5		
LRRC50	AR	ciliary dyskinesia, primary, 13, 613193 (3),
LRRC51	AR	deafness, 63, 611451 (3),
LRRC52		
LRRC54		
LRRC55		
LRRC56	AR	ciliary dyskinesia, primary, 39, 618254 (3),
LRRC59		
LRRC6	AR	ciliary dyskinesia, primary, 19, 614935 (3),
LRRC62		
LRRC65		malignant fibrous histiocytoma, 605352 (2)
LRRC67		
LRRC7		
LRRC76	AR	retinal dystrophy with macular staphyloma, 617547 (3), ; spondylometaphyseal dysplasia, axial, 602271 (3),
LRRC8	AD	?agammaglobulinemia 5, 613506 (3),
LRRC8A	AD	?agammaglobulinemia 5, 613506 (3),
LRRC8B		
LRRC8C		
LRRC8D		
LRRC8E		
LRRCC1		
LRRFIP1		
LRRFIP2		
LRRIQ2		
LRRIQ3		
LRRK1	AR	osteosclerotic metaphyseal dysplasia, 615198 (3),
LRRK2	AD	{parkinson disease 8}, 607060 (3),
LRRN1		
LRRN2		
LRRN3		
LRRN4		
LRRN5		
LRRN6A	AR	intellectual developmental disorder, 64, 618103 (3),
LRRN6B		
LRRN6C		
LRRN6D		
LRRTM1		
LRRTM2		
LRRTM3		
LRRTM4		
LRS1	AD,AR	larsen syndrome, 150250 (3), ; atelosteogenesis, type i, 108720 (3), ; atelosteogenesis, type iii, 108721 (3), ; spondylocarpotarsal synostosis syndrome, 272460 (3), ; boomerang dysplasia, 112310 (3),
LRSAM1	AR,AD	charcot-marie-tooth disease, axonal, type 2p, 614436 (3),
LRTOMT	AR	deafness, 63, 611451 (3),
LRTOMT1	AR	deafness, 63, 611451 (3),
LRTOMT2	AR	deafness, 63, 611451 (3),
LRTP	AR	ciliary dyskinesia, primary, 19, 614935 (3),
LRWD1		
LSAMP		
LSAMP-AS3		
LSD	AR	systemic lupus erythematosus 16, 614420 (3),
LSD1	AD	cleft palate, psychomotor retardation, and distinctive facial features, 616728 (3),
LSD2		
LSDA5		
LSDP5		
LSE		{autoimmune disease, susceptibility to, 6}, 613551 (3)
LSECTIN		
LSEL		
LSF		
LSFC	AR	mitochondrial complex iv deficiency, nuclear type 5, (french-canadian), 220111 (3),
LSFR1		
LSFR2		
LSG1		
LSH	AR	{mycobacterium tuberculosis, susceptibility to infection by}, 607948 (3); {buruli ulcer, susceptibility to}, 610446 (3)|immunodeficiency-centromeric instability-facial anomalies syndrome 4, 616911 (3),
LSH-B	AR	hypogonadotropic hypogonadism 23 with or without anosmia, 228300 (3),
LSIGN		
LSINCT5		
LSIRF		[skin/hair/eye pigmentation, variation in, 8], 611724 (3)
Lsk		
LSLCL		
LSM1		
LSM10		
LSM11	AR	?aicardi-goutieres syndrome 8, 619486 (3),
LSM12		
LSM14A		
LSM16	AR	?intellectual developmental disorder, 50, 616460 (3),
LSM2		
LSM3		
LSM4		
LSM5		
LSM6		
LSM7		
LSM8		
LSMD1		
LSN		
LSP1		
LSR		
LSR5		
LSS	AR	hypotrichosis 14, 618275 (3), ; cataract 44, 616509 (3), ; alopecia-intellectual disability syndrome 4, 618840 (3),
LST-1		hyperbilirubinemia, rotor type, digenic, 237450 (3), digenic
lst-2		
LST003		
LST005	AR,AD	myopathy, mitochondrial, and ataxia, 617675 (3),
LST1		
LST3		
Lst8		
LT		{psoriatic arthritis, susceptibility to}, 607507 (3); {myocardial infarction, susceptibility to}, 608446 (3); {leprosy, susceptibility to, 4}, 610988 (3)
LTA		{psoriatic arthritis, susceptibility to}, 607507 (3); {myocardial infarction, susceptibility to}, 608446 (3); {leprosy, susceptibility to, 4}, 610988 (3)
LTA4H		
LTAP	AD	neural tube defects, 182940 (3),
LTB		
LTB4DH		
LTB4H		
LTB4R		
LTB4R1		
LTB4R2		
LTBP-4	AR	cutis laxa, type ic, 613177 (3),
LTBP-4L	AR	cutis laxa, type ic, 613177 (3),
LTBP1	AR	cutis laxa, type iie, 619451 (3),
LTBP2	AR,AD,AR	dental anomalies and short stature, 601216 (3), ; geleophysic dysplasia 3, 617809 (3), |glaucoma 3, primary congenital, d, 613086 (3); microspherophakia and/or megalocornea, with ectopia lentis and with or without secondary glaucoma, 251750 (3), ; ?weill-marchesani syndrome 3, 614819 (3),
LTBP3	AR,AD,AR	dental anomalies and short stature, 601216 (3), ; geleophysic dysplasia 3, 617809 (3), |glaucoma 3, primary congenital, d, 613086 (3); microspherophakia and/or megalocornea, with ectopia lentis and with or without secondary glaucoma, 251750 (3), ; ?weill-marchesani syndrome 3, 614819 (3),
LTBP4	AR	cutis laxa, type ic, 613177 (3),
LTBR		
LTC4S	AR	leukotriene c4 synthase deficiency, 614037 (1),
LTF		
LTg		
LTG19		
LTK		
LTM1		
LTN		
LTN1		
LTO1		
LTRPC1	AR	night blindness, congenital stationary (complete), 1c, 613216 (3)
LTRPC2		
LTRPC3	AD	?cataract 50 with or without glaucoma, 620253 (3); neurodevelopmental disorder with hypotonia, dysmorphic facies, and skeletal anomalies, with or without seizures, 620224 (3),
LTRPC5		
LTRPC7	AD	{amyotrophic lateral sclerosis-parkinsonism/dementia complex, susceptibility to}, 105500 (3),
LTV1	AR	inflammatory poikiloderma with hair abnormalities and acral keratoses, 620199 (3),
LU	AR	[blood group, lutheran system], 111200 (3); [blood group, auberger system], 111200 (3); [blood group, lutheran null], 247420 (3),
LU1		
LU103	AD	{asthma, susceptibility to}, 600807 (3),
LU105		
LUARIS		
Luc7		
LUC7A		
LUC7B1		
LUC7B2		
LUC7L		
LUC7L2		
LUC7L3		
LUCA-1		
LUCA-15		
LuCa-2		
LUCA-3		
LUCA1	AR	mucopolysaccharidosis type ix, 601492 (3),
LUCA14		
LUCA15		
LUCA2		
LUCAIR1		
LUCAT1		
LUCT		
LUGP4		
LULL1		
LULU		
LULU1		
LULU2		
LUM		
LUMA	AD	arrhythmogenic right ventricular dysplasia 5, 604400 (3), ; auditory neuropathy, 3, 619832 (3), ; emery-dreifuss muscular dystrophy 7, ad, 614302 (3),
Luman		
LUN		retinitis pigmentosa 31, 609923 (3)
LUNX		
LURAP1		
LURAP1L		
LUSTR1		
LUSTR2		
LUZP		
LUZP1		
LUZP2		
LUZP4		
LUZP5	AR	khan-khan-katsanis syndrome, 618460 (3),
LUZP6		
LVM	AR	megalencephalic leukoencephalopathy with subcortical cysts 1, 604004 (3),
LVRN		
LW		[blood group, landsteiner-wiener], 111250 (3)
LXA4R		
LXN		
LXNL		
LXR-a		
LXR-b		
LXRa		
LXRb		
Ly-3		
Ly-GDI		
Ly108		
Ly110		
LY117		{malaria, mild, susceptibility to}, 609148 (3)
Ly49		
LY49L		
Ly57	AR	?agammaglobulinemia 4, 613502 (3),
Ly6-D		
LY6-D		
LY6-MT	AR	meleda disease, 248300 (3),
LY64		
LY6D		
LY6DL		
LY6E		
LY6G5B		
LY6G5C		
LY6G6C		
LY6G6D		
LY6G6E		
LY6G6F		
LY6H		
LY6K		
LY6LS	AR	meleda disease, 248300 (3),
Ly74	AR,AD	diarrhea 5, with tufting enteropathy, congenital, 613217 (3), ; lynch syndrome 8, 613244 (3),
LY75		
Ly78		
LY86		
LY9		
LY94		
LY95		
LY96		
LYAAT-1		
Lyam-1		
LYAM1		
LYAR		
LYB2		
LYC1		
LYC3		
LYC4		
LYC5		
LYCAT		
LyF-1	AD	immunodeficiency, common variable, 13, 616873 (3),
LYG2		
LYGA2		
LYGH		
LyGPR		
LYK	AR	lymphoproliferative syndrome 1, 613011 (3),
LYK5	AR	polyhydramnios, megalencephaly, and symptomatic epilepsy, 611087 (3),
LYL1		leukemia, t-cell acute lymphoblastoid, 151440 (2)
LYN	AD	autoinflammatory disease, systemic, with vasculitis, 620376 (3),
LYNAP		
LYNX1		
Lyp	AD,AR	{rheumatoid arthritis, susceptibility to}, 180300 (3); {systemic lupus erythematosus susceptibility to}, 152700 (3), ; {diabetes, type 1, susceptibility to}, 222100 (3),
LYP	XL,XLR	lymphoproliferative syndrome, 1, 308240 (3),
Lyp1	AD,AR	{rheumatoid arthritis, susceptibility to}, 180300 (3); {systemic lupus erythematosus susceptibility to}, 152700 (3), ; {diabetes, type 1, susceptibility to}, 222100 (3),
Lyp2	AD,AR	{rheumatoid arthritis, susceptibility to}, 180300 (3); {systemic lupus erythematosus susceptibility to}, 152700 (3), ; {diabetes, type 1, susceptibility to}, 222100 (3),
LYPD1		
LYPD3		
LYPD5		
LYPD6		
LYPD8		
LYPDC1		
LYPLA1		
LYPLA2		
LYPLA3		
LYPLAL1		
LYRIC		
LYRM1		
LYRM10		
LYRM3	AR	?mitochondrial complex i deficiency, nuclear type 24, 618245 (3),
LYRM4	AR	?combined oxidative phosphorylation deficiency 19, 615595 (3),
LYRM6	AR	mitochondrial complex i deficiency, nuclear type 33, 618253 (3),
LYRM7	AR	mitochondrial complex iii deficiency, nuclear type 8, 615838 (3),
LYRM8	AR	mitochondrial complex ii deficiency, nuclear type 2, 619166 (3),
LYS2		
LYS5		
LYSAL1		
LYSET	AR	dysostosis multiplex, ain-naz type, 619345 (3),
LysoLP		
LysoPAFAT		
LYSP100-A		
LYSP100-B		
LYST	AR	chediak-higashi syndrome, 214500 (3),
LYST2	AD	neurodevelopmental disorder with or without early-onset generalized epilepsy, 619157 (3),
LYT-10	AD	immunodeficiency, common variable, 10, 615577 (3),
LYT3		
LYVE-1		
LYVE1		
LYZ	AD	amyloidosis, renal, 105200 (3),
LYZG		
LYZL2		
LYZL3		
LYZL4		
LYZL5		
LYZL6		
LYZL7		
LZ16	AD	kbg syndrome, 148050 (3),
LZAP		
LZIC		
LZIP		
LZK		
LZK1		
LZP		
LZT-Hs9	AR	ehlers-danlos syndrome, spondylodysplastic type, 3, 612350 (3),
LZTFL1	AR	bardet-biedl syndrome 17, 615994 (3),
LZTR-1	AR,AD	noonan syndrome 2, 605275 (3), ; noonan syndrome 10, 616564 (3), ; {schwannomatosis-2, susceptibility to}, 615670 (3),
LZTR1	AR,AD	noonan syndrome 2, 605275 (3), ; noonan syndrome 10, 616564 (3), ; {schwannomatosis-2, susceptibility to}, 615670 (3),
LZTR2		
LZTS1		esophageal squamous cell carcinoma, somatic, 133239 (3)
LZTS2		
LZTS3		
LZTS4		
M-ABC1		
M-ABC2		
M-BAR		
M-CPT1		
M-CSF		
M-FABP	AD	charcot-marie-tooth disease, demyelinating, type 1g, 618279 (3),
M-RAs	AD	noonan syndrome 11, 618499 (3),
M-RIP		
M-SemaK		
M1		
M11S1		
M12.219		
M130	AD	genitourinary and/or/brain malformation syndrome, 618820 (3),
M160		
M17S1		
M17S2		
M18BP1		
M19	AR	mitochondrial complex iii deficiency, nuclear type 7, 615824 (3),
M1AP	AR	spermatogenic failure 48, 619108 (3),
M1S1	AR	corneal dystrophy, gelatinous drop-like, 204870 (3),
M2BP		
M31		
M33	AR	?46xy sex reversal 5, 613080 (3),
M3S1		
M40	AD	symmetric circumferential skin creases, congenital, 1, 156610 (3), ; cortical dysplasia, complex, with other brain malformations 6, 615771 (3),
M4S1	AR,AD	diarrhea 5, with tufting enteropathy, congenital, 613217 (3), ; lynch syndrome 8, 613244 (3),
M68		
M6A		
M6B		
M6P-R		hepatocellular carcinoma, somatic, 114550 (3)
M6PR		
M6PRBP1		
M6S1	AR,MF,AD	{obesity, susceptibility to}, 601665 (3), , ; hypophosphatemic rickets, 2, 613312 (3), ; {diabetes mellitus, non-insulin-dependent, susceptibility to}, 125853 (3), ; arterial calcification, generalized, of infancy, 1, 208000 (3), ; cole disease, 615522 (3),
M7V1		
M8-9	XL,XLR	intellectual developmental disorder, syndromic, hedera type, 300423 (3), ; ?parkinsonism with spasticity, 300911 (3), ; congenital disorder of glycosylation, type iir, 301045 (3),
M83		
M9		
M9.2		
M96		
MA1		
MA2		
MA3		
MA5		
MAAI	AR	[maleylacetoacetate isomerase deficiency], 617596 (3),
MAAT1		
MAATS1	AR	spermatogenic failure 51, 619177 (3),
MAB21L1	AR	cerebellar, ocular, craniofacial, and genital syndrome, 618479 (3),
MAB21L2	AR,AD	microphthalmia/coloboma and skeletal dysplasia syndrome, 615877 (3),
maba1		
MABC1		
MAC-1	AR	leukocyte adhesion deficiency, 116920 (3),
MAC-2		
MAC-2-BP		
MAC25	AR	retinal arterial macroaneurysm with supravalvular pulmonic stenosis, 614224 (3),
MAC30		
MAC387		
MACAM1		
MACC1		
MACF	AD	lissencephaly 9 with complex brainstem malformation, 618325 (3),
MACF1	AD	lissencephaly 9 with complex brainstem malformation, 618325 (3),
MACF2	AR	neuropathy, hereditary sensory and autonomic, type vi, 614653 (3), ; epidermolysis bullosa simplex 3, localized or generalized intermediate, with bp230 deficiency, 615425 (3),
MacGAP		
MACH	AD,AR	{breast cancer, protection against}, 114480 (3), somatic mutation, ; ?caspase 8 lymphadenopathy syndrome, 607271 (3), ; hepatocellular carcinoma, somatic, 114550 (3); {lung cancer, protection against}, 211980 (3), somatic mutation,
MACIF	AR	hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy, 612300 (3),
MACIR		
MacMARCKS		
MACO1		
MACROD1		
MACROD2		
MACROD3	AR	spinocerebellar ataxia, 27, 618369 (3),
MACROH2A1		
macroH2A1.2		
MACROH2A2		
MACS		
MACS1		
MAD	AR	myopathy due to myoadenylate deaminase deficiency, 615511 (3),
MAD-3	AD	ectodermal dysplasia and immunodeficiency 2, 612132 (3),
MAD1	AR	prostate cancer, somatic, 176807 (3); mosaic variegated aneuploidy syndrome 7 with inflammation and tumor predisposition, 620189 (3), ; lymphoma, b-cell, somatic (3)
MAD1L1	AR	prostate cancer, somatic, 176807 (3); mosaic variegated aneuploidy syndrome 7 with inflammation and tumor predisposition, 620189 (3), ; lymphoma, b-cell, somatic (3)
MAD2		prostate cancer, somatic, 176807 (3); neurofibrosarcoma, somatic (3)
MAD2B	AR	?fanconi anemia, complementation group v, 617243 (3),
MAD2L1		
MAD2L1BP		
MAD2L2	AR	?fanconi anemia, complementation group v, 617243 (3),
MAD3		
MAD3L	AD,AR	colorectal cancer, somatic, 114500 (3); [premature chromatid separation trait], 176430 (3), ; mosaic variegated aneuploidy syndrome 1, 257300 (3),
MAD4		
MAD5		
MAD6		
MAD7		
MADA	AR,AD,AR	mandibuloacral dysplasia, 248370 (3), ; heart-hand syndrome, slovenian type, 610140 (3), ; cardiomyopathy, dilated, 1a, 115200 (3), ; emery-dreifuss muscular dystrophy 3, 616516 (3), ; restrictive dermopathy 2, 619793 (3); charcot-marie-tooth disease, type 2b1, 605588 (3), ; emery-dreifuss muscular dystrophy 2, 181350 (3), ; hutchinson-gilford progeria, 176670 (3), ; lipodystrophy, familial partial, type 2, 151660 (3), ; muscular dystrophy, congenital, 613205 (3), ; malouf syndrome, 212112 (3), |myopathy due to myoadenylate deaminase deficiency, 615511 (3),
MADCAM1		
MADD	AR,AR	glutaric acidemia iia, 231680 (3), |neurodevelopmental disorder with dysmorphic facies, impaired speech and hypotonia, 619005 (3), ; deeah syndrome, 619004 (3),
MADER		
MADH1		
MADH2	AD	loeys-dietz syndrome 6, 619656 (3), ; congenital heart defects, multiple types, 8, with or without heterotaxy, 619657 (3),
MADH3	AD	loeys-dietz syndrome 3, 613795 (3),
MADH4	AD	pancreatic cancer, somatic, 260350 (3); myhre syndrome, 139210 (3), ; polyposis, juvenile intestinal, 174900 (3), ; juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome, 175050 (3),
MADH5		
MADH6	AD,AD	aortic valve disease 2, 614823 (3), ; {radioulnar synostosis, nonsyndromic}, 179300 (3), ; {craniosynostosis 7, susceptibility to}, 617439 (3), |pulmonary hypertension, primary, 2, 615342 (3),
MADH7	AD	{colorectal cancer, susceptibility to, 3}, 612229 (3)|aortic valve disease 2, 614823 (3), ; {radioulnar synostosis, nonsyndromic}, 179300 (3), ; {craniosynostosis 7, susceptibility to}, 617439 (3),
MADH8		{colorectal cancer, susceptibility to, 3}, 612229 (3)
MADH9	AD	pulmonary hypertension, primary, 2, 615342 (3),
MADHIP		
MADM	AD	{alzheimer disease 18, susceptibility to}, 615590 (3); reticulate acropigmentation of kitamura, 615537 (3),
MADP-1		
MADP1		
MADR1		
MADR2	AD	loeys-dietz syndrome 6, 619656 (3), ; congenital heart defects, multiple types, 8, with or without heterotaxy, 619657 (3),
MAEA		
MAEG		
MAEL		
MAF	AD	cataract 21, multiple types, 610202 (3), ; ayme-gripp syndrome, 601088 (3),
MAF1		
MAFA	AD	insulinomatosis and diabetes mellitus, 147630 (3),
MAFA-L		
MAFB	AD	duane retraction syndrome 3, 617041 (3), ; multicentric carpotarsal osteolysis syndrome, 166300 (3),
MAFbx		
MAFF		
MAFG		
MAFK		
MAFTRR		
MAG	AR,AR	spastic paraplegia 75, 616680 (3), |xeroderma pigmentosum, group d, 278730 (3), ; trichothiodystrophy 1, photosensitive, 601675 (3), ; ?cerebrooculofacioskeletal syndrome 2, 610756 (3),
MAG1		
MAGE-11		
MAGE-3b		
MAGE-41		
MAGE-B5		
MAGE-B6		
MAGE-C1		
MAGE-C2		
MAGE-C3		
MAGE-D2	XLR,XL	bartter syndrome, type 5, antenatal, transient, 300971 (3),
MAGE-D3		
MAGE-E1		
MAGE-X2		
MAGE-Xp		
MAGE-XP-2		
MAGE1		
MAGE10		
MAGE11		
MAGE12		
MAGE2		
MAGE3		
MAGE3B		
MAGE4		
MAGE4A		
MAGE4B		
MAGE5		
MAGE6		
MAGE8		
MAGE9		
MAGEA-11		
MAGEA1		
MAGEA10		
MAGEA11		
MAGEA12		
MAGEA2		
MAGEA2A		
MAGEA2B		
MAGEA3		
MAGEA4		
MAGEA5		
MAGEA5P		
MAGEA6		
MAGEA8		
MAGEA9		
MAGEA9B		
MAGEB1		
MAGEB10		
MAGEB16		
MAGEB17		
MAGEB18		
MAGEB2		
MAGEB3		
MAGEB4		
MAGEB5		
MAGEB6		
MAGEB6A		
MAGEC1		
MAGEC2		
MAGEC3		
MAGED	XLR,XL	bartter syndrome, type 5, antenatal, transient, 300971 (3),
MAGED1		
MAGED2	XLR,XL	bartter syndrome, type 5, antenatal, transient, 300971 (3),
MAGED3		
MAGED4		
MAGED4B		
MAGEE1		
MAGEE2		
MAGEF1		
MAGEG1	AR	lung disease, immunodeficiency, and chromosome breakage syndrome, 617241 (3),
MAGEH1		
MAGEL1		
MAGEL2	AD	schaaf-yang syndrome, 615547 (3),
MAGEL3	AR	lung disease, immunodeficiency, and chromosome breakage syndrome, 617241 (3),
MAGI-1		
MAGI-2	AR	nephrotic syndrome, type 15, 617609 (3),
MAGI-3		
MAGI1		
MAGI2	AR	nephrotic syndrome, type 15, 617609 (3),
MAGI2-IT		
MAGI2-IT1		
MAGI2IT		
MAGI3		
magicin		
MAGL		
Magmas	AR	spondylometaphyseal dysplasia, megarbane-dagher-melike type, 613320 (3),
MAGOH		
MAGOH1		
MAGOHA		
MAGOHB		
MAGP		
MAGP-1		
MAGP2	AD	aortic aneurysm, familial thoracic 9, 616166 (3),
MAGT1	XL,XLR	immunodeficiency, with magnesium defect, epstein-barr virus infection and neoplasia, 300853 (3), ; congenital disorder of glycosylation, type icc, 301031 (3),
MagT2	AR	intellectual developmental disorder, 7, 611093 (3),
MAI	AR	[maleylacetoacetate isomerase deficiency], 617596 (3),
MAIL		
MAIP1		
MAIR		
MAJIN		
MAK	AR,AR	cardiomyopathy, familial hypertrophic 27, 618052 (3), |retinitis pigmentosa 62, 614181 (3),
MAK10		
MAK11		
MAK3		
Mak3p		
mAKAP		
Mal		{malaria, protection against}, 611162 (3); {tuberculosis, protection against}, 607948 (3); {bacteremia, protection against}, 614382 (3)
MAL	AR	?immunodeficiency 66, 618847 (3),
MAL2		
MALAT-1		
MALAT1		
MALL		
MALRD1		
MALS-1		
MALS-2		
MALS-3		
MALSU1		
MALT1	AR	immunodeficiency 12, 615468 (3),
MALT2		
MAM	AR	muscular dystrophy, limb-girdle, 5, 253700 (3),
Mam-1		
MAM2		
MAM3		mucoepidermoid salivary gland carcinoma (3)
MAMDC1		
MAMDC2		
MAMDC3		
MAMDC4		
MAML1		
MAML2		mucoepidermoid salivary gland carcinoma (3)
MAML3		
MAMLD1	XL,XLR	hypospadias 2, 300758 (3),
MAMSTR		
MAN1	AD	buschke-ollendorff syndrome, 166700 (3), ; osteopoikilosis with or without melorheostosis, 166700 (3),
MAN1A1		
MAN1A2		
MAN1B		
MAN1B1	AR	rafiq syndrome, 614202 (3),
MAN1C1		
MAN2A1		
MAN2A2		
MAN2B1	AR	mannosidosis, alpha-, types i and ii, 248500 (3),
MAN2B2		
MAN2C1	AR	congenital disorder of deglycosylation 2, 619775 (3),
MANA	AR	congenital disorder of deglycosylation 2, 619775 (3),
MANA-ER	AR	rafiq syndrome, 614202 (3),
MANA1	AR	congenital disorder of deglycosylation 2, 619775 (3),
MANA2		
MANA2X		
MANB	AR	mannosidosis, alpha-, types i and ii, 248500 (3),
MANBA	AR	mannosidosis, beta, 248510 (3),
mandaselin		
MANEA		
MANF		
MANI		
MANSC2		
MAOA	XLR,XL	{antisocial behavior}, 300615 (3), ; brunner syndrome, 300615 (3),
MAOB		
MAP-1	AR	3mc syndrome 1, 257920 (3),
MAP-2	AR	masp2 deficiency, 613791 (3),
MAP10		
MAP11	AR	?microcephaly 25, primary, 618351 (3),
MAP126		
MAP17		
Map19	AR	masp2 deficiency, 613791 (3),
MAP1A		
MAP1ALC3		
MAP1B	AD	?deafness, 83, 619808 (3), ; periventricular nodular heterotopia 9, 618918 (3),
MAP1BLC3		
MAP1D		
MAP1L		
MAP1LC3A		
MAP1LC3B		
MAP1LC3C		
MAP1S		
MAP2		
MAP2A		
MAP2B		
MAP2C		
MAP2K1	AD	cardiofaciocutaneous syndrome 3, 615279 (3), ; melorheostosis, isolated, somatic mosaic, 155950 (3)
MAP2K1IP1		
MAP2K2	AD	cardiofaciocutaneous syndrome 4, 615280 (3),
MAP2K3		
MAP2K4		
MAP2K5		
MAP2K6		
MAP2K7		
MAP3K1	AD	46xy sex reversal 6, 613762 (3),
MAP3K10		
MAP3K11		
MAP3K12		
MAP3K13		
MAP3K14		
MAP3K15		
MAP3K16	AD	developmental delay with or without intellectual impairment or behavioral abnormalities, 619575 (3),
MAP3K17		
MAP3K18		
MAP3K2		
MAP3K20	AR	centronuclear myopathy 6 with fiber-type disproportion, 617760 (3), ; split-foot malformation with mesoaxial polydactyly, 616890 (3),
MAP3K21		
MAP3K3		
MAP3K4		
MAP3K5		
MAP3K6		
MAP3K7	AD	frontometaphyseal dysplasia 2, 617137 (3), ; cardiospondylocarpofacial syndrome, 157800 (3),
MAP3K7CL		
MAP3K7IP1		
MAP3K7IP2	AD	congenital heart defects, nonsyndromic, 2, 614980 (3),
MAP3K7IP3		
MAP3K8		lung cancer, somatic, 211980 (3)
MAP3K9		
MAP4		
Map44	AR	3mc syndrome 1, 257920 (3),
MAP4K1		
MAP4K2		
MAP4K3		
MAP4K4		
MAP4K5		
MAP4K6		
MAP5	AD	?deafness, 83, 619808 (3), ; periventricular nodular heterotopia 9, 618918 (3),
MAP6		
MAP6-N		
MAP6D1		
MAP7		
MAP7D3		
MAP8		
Map80	AR	peripheral neuropathy, with or without impaired intellectual development, 618124 (3),
MAP9		
MAP97		
MAPA		
MAPBP		
MAPBPIP	AR	immunodeficiency due to defect in mapbp-interacting protein, 610798 (3),
MAPE		
MAPJD		
MAPK1	AD	noonan syndrome 13, 619087 (3),
MAPK10		
MAPK11		
MAPK12		
MAPK13		
MAPK14		
MAPK15		
MAPK1IP1L		
MAPK2	AD	noonan syndrome 13, 619087 (3),
MAPK3		
MAPK4		
MAPK6		
MAPK7		
MAPK8		
MAPK8IP1	AD	{diabetes mellitus, noninsulin-dependent}, 125853 (3),
MAPK8IP2		
MAPK8IP3	AD	neurodevelopmental disorder with or without variable brain abnormalities, 618443 (3),
MAPK9		
MAPKAP1		
MAPKAP3	AD	?macular dystrophy, patterned, 3, 617111 (3),
MAPKAPK1		
MAPKAPK2		
MAPKAPK3	AD	?macular dystrophy, patterned, 3, 617111 (3),
MAPKAPK5	AR	neurocardiofaciodigital syndrome, 619869 (3),
MAPKBP1	AR	nephronophthisis 20, 617271 (3),
MAPKK1	AD	cardiofaciocutaneous syndrome 3, 615279 (3), ; melorheostosis, isolated, somatic mosaic, 155950 (3)
MAPKK3		
MAPKK5		
MAPKK6		
MAPKKK1	AD	46xy sex reversal 6, 613762 (3),
MAPKKK3		
MAPKKK4		
MAPKKK5		
MAPKKK6		
MAPKKKK3		
MAPKSP1		
MAPKSP1AP	AR	immunodeficiency due to defect in mapbp-interacting protein, 610798 (3),
MAPL		
MAPM		
mapmodulin		
MAPO1		
MAPO2		
MAPRE1		
MAPRE2	AD	symmetric circumferential skin creases, congenital, 2, 616734 (3),
MAPRE3		
MAPT	AD,AR,MF	supranuclear palsy, progressive, 601104 (3), ; supranuclear palsy, progressive atypical, 260540 (3), ; dementia, frontotemporal, with or without parkinsonism, 600274 (3), ; {parkinson disease, susceptibility to}, 168600 (3), ; pick disease, 172700 (3),
MAPTIT		
MAPTL	AD,AR,MF	supranuclear palsy, progressive, 601104 (3), ; supranuclear palsy, progressive atypical, 260540 (3), ; dementia, frontotemporal, with or without parkinsonism, 600274 (3), ; {parkinson disease, susceptibility to}, 168600 (3), ; pick disease, 172700 (3),
MAQ1		
MAR		nonsmall cell lung cancer, somatic, 211980 (3); myelodysplastic syndrome, preleukemic (3); gastric cancer, somatic, 613659 (3); myelogenous leukemia, acute (3)
Mar1		
Mar2		
Mar7		
Mar8		
MAR8C		
Mar9		
MARC		
MARC1		
MARC2		
MARCH-I		
MARCH-II		
MARCH-III		
MARCH-IV		
MARCH-V		
MARCH-VI	AD	epilepsy, familial adult myoclonic, 3, 613608 (3),
MARCH-VII		
MARCH-VIII		
MARCH-X		
MARCH-XI		
MARCH1		
MARCH10		
MARCH11		
MARCH2		
MARCH3		
MARCH4		
MARCH5		
MARCH6	AD	epilepsy, familial adult myoclonic, 3, 613608 (3),
MARCH7		
MARCH8		
MARCH9		
MARCHF1		
MARCHF10		
MARCHF11		
MARCHF2		
MARCHF3		
MARCHF4		
MARCHF5		
MARCHF6	AD	epilepsy, familial adult myoclonic, 3, 613608 (3),
MARCHF7		
MARCHF8		
MARCHF9		
MARCKS		
MARCKSL1		
MARCO		
MARE	AD	epilepsy, familial focal, with variable foci 3, 617118 (3),
MARF	AR,AD	lipomatosis, multiple symmetric, with or without peripheral neuropathy, 151800 (3), ; charcot-marie-tooth disease, axonal, type 2a2a, 609260 (3), ; charcot-marie-tooth disease, axonal, type 2a2b, 617087 (3), ; hereditary motor and sensory neuropathy via, 601152 (3),
MARF1		
MARK		
MARK1		
MARK2		
MARK3	AR	?visual impairment and progressive phthisis bulbi, 618283 (3),
MARK4		
MARKK	AD	developmental delay with or without intellectual impairment or behavioral abnormalities, 619575 (3),
MARKL1		
MARLIN1		
MARP3		
MARS	AR,AD	spastic paraplegia 70, 620323 (3), ; interstitial lung and liver disease, 615486 (3), ; ?trichothiodystrophy 9, nonphotosensitive, 619692 (3), ; charcot-marie-tooth disease, axonal, type 2u, 616280 (3),
MARS1	AR,AD	spastic paraplegia 70, 620323 (3), ; interstitial lung and liver disease, 615486 (3), ; ?trichothiodystrophy 9, nonphotosensitive, 619692 (3), ; charcot-marie-tooth disease, axonal, type 2u, 616280 (3),
MARS2	AR	?combined oxidative phosphorylation deficiency 25, 616430 (3), ; spastic ataxia 3, 611390 (3),
MART		
MART-1		
MART-2	AR	nivelon-nivelon-mabille syndrome, 600092 (3),
MART1		
Mart2		
MART2	AR	nivelon-nivelon-mabille syndrome, 600092 (3),
Mart7		
Mart8		
Mart9		
MARVELD1		
MARVELD2	AR	deafness, 49, 610153 (3),
MARVELD3		
MAS-L		
MAS1	AR	multiple mitochondrial dysfunctions syndrome 6, 617954 (3),
MAS1L		
MAS2	AR	spinocerebellar ataxia, 2, 213200 (3),
MAS20		
MASA	XLR,XL	masa syndrome, 303350 (3), ; hydrocephalus, congenital, 307000 (3), ; ?corpus callosum, partial agenesis of, 304100 (3),
mascRNA		
MASK		
MASK1		
MASK2	AD	chopra-amiel-gordon syndrome, 619504 (3),
maskin		
MASL1		malignant fibrous histiocytoma, 605352 (2)
MASP	AR	3mc syndrome 1, 257920 (3),
MASP-3	AR	3mc syndrome 1, 257920 (3),
MASP1	AR	3mc syndrome 1, 257920 (3),
MASP1P1	AR	masp2 deficiency, 613791 (3),
MASP2	AR	masp2 deficiency, 613791 (3),
maspin		
MASS	AD	geleophysic dysplasia 2, 614185 (3), ; weill-marchesani syndrome 2, 608328 (3), ; ectopia lentis, familial, 129600 (3), ; mass syndrome, 604308 (3), ; marfan lipodystrophy syndrome, 616914 (3), ; acromicric dysplasia, 102370 (3), ; marfan syndrome, 154700 (3), ; stiff skin syndrome, 184900 (3),
MASS1	AR,AD	usher syndrome, type 2c, 605472 (3), digenic ; usher syndrome, type 2c, gpr98/pdzd7 digenic, 605472 (3), digenic ; ?febrile seizures, familial, 4, 604352 (3),
Mast		
MAST	AR	mast syndrome, 248900 (3),
MAST1	AD	mega-corpus-callosum syndrome with cerebellar hypoplasia and cortical malformations, 618273 (3),
MAST2		
MAST205		
MAST3	AD	developmental and epileptic encephalopathy 108, 620115 (3),
MAST4		
MAST9		
MASTL		
MASTR		
MAT	AD,AR	hypermethioninemia, persistent, due to methionine adenosyltransferase i/iii deficiency, 250850 (3), ; methionine adenosyltransferase deficiency, 250850 (3),
Mat-1	AR	congenital disorder of glycosylation, type ik, 608540 (3),
MAT-8		
MAT-I/III	AD,AR	hypermethioninemia, persistent, due to methionine adenosyltransferase i/iii deficiency, 250850 (3), ; methionine adenosyltransferase deficiency, 250850 (3),
MAT-II		
MAT1		
MAT1A	AD,AR	hypermethioninemia, persistent, due to methionine adenosyltransferase i/iii deficiency, 250850 (3), ; methionine adenosyltransferase deficiency, 250850 (3),
MAT1H		
MAT2A		
MAT2B		
Mat89Bb		
MATA1	AD,AR	hypermethioninemia, persistent, due to methionine adenosyltransferase i/iii deficiency, 250850 (3), ; methionine adenosyltransferase deficiency, 250850 (3),
MATA2		
MATCAP1		
MATCAP2		
MATE1		
MATE2		
MATE2-K		
MATER	AR	oocyte/zygote/embryo maturation arrest 19, 620333 (3),
MATH-1	AD	?deafness, 89, 620284 (3),
Math-2		
MATH-3		
Math1	AD	?deafness, 89, 620284 (3),
Math4A		
Math4B	AR	diarrhea 4, malabsorptive, congenital, 610370 (3),
Math4C		
Math5	AR	persistent hyperplastic primary vitreous, 221900 (3),
MATII		
MATIIbeta		
MATK		
MATN1		
MATN2		
MATN3	AD,AR	{osteoarthritis susceptibility 2}, 140600 (3), ; spondyloepimetaphyseal dysplasia, borochowitz-cormier-daire type, 608728 (3), ; epiphyseal dysplasia, multiple, 5, 607078 (3),
MATN4		
MATP	AR	[skin/hair/eye pigmentation 5, dark/light eyes], 227240 (3), ; [skin/hair/eye pigmentation 5, black/nonblack hair], 227240 (3), ; albinism, oculocutaneous, type iv, 606574 (3), ; [skin/hair/eye pigmentation 5, dark/fair skin], 227240 (3),
MATR1	AD,AR	hypertrophic osteoarthropathy, primary, 167100 (3), ; hypertrophic osteoarthropathy, primary, 2, 614441 (3),
MATR3	AD	amyotrophic lateral sclerosis 21, 606070 (3),
Mats1		
MATT		
mau-2		
MAU2		
MAU2L		
Mauve	AR	chediak-higashi syndrome, 214500 (3),
MAV		
MAVS		
MAWBP		
MAWD		
MAWDBP		
MAX	AD	{pheochromocytoma, susceptibility to}, 171300 (3),
Maxer		
Maxp1		
MAZ		
MAZR		
MB	AD	myopathy, sarcoplasmic body, 620286 (3),
MB-1	AR	agammaglobulinemia 3, 613501 (3),
MB1	AR	agammaglobulinemia 3, 613501 (3),
MB20		
MB21D1		
MB67		
Mba1		
MBAB		
MBC2		
MBC3205		
MBD1		
MBD2		
MBD3		
MBD3L		
MBD3L1		
MBD3L2		
MBD4	AD,AR	{uveal melanoma, susceptibility to, 1}, 606660 (3), ; tumor predisposition syndrome 2, 619975 (3),
MBD5	AD	intellectual developmental disorder, 1, 156200 (3),
MBD6		
MBDIN		
MBI		
MBIP		
MBK1	AD	episodic ataxia/myokymia syndrome, 160120 (3),
MBL	AD	{chronic infections, due to mbl deficiency}, 614372 (3),
MBL2	AD	{chronic infections, due to mbl deficiency}, 614372 (3),
MBLL		
MBLL39		
MBLR		
MBLX39		
MBNL		
MBNL1		
MBNL2		
MBNL3		
MBNT		
MBO2		
MBOAT1		
MBOAT2		
MBOAT3		
MBOAT4		
MBOAT5		
MBOAT7	AR	intellectual developmental disorder, 57, 617188 (3),
MBP	AD	{chronic infections, due to mbl deficiency}, 614372 (3),
MBP-1		
MBP-2	AD	intellectual developmental disorder, 43, 616977 (3),
MBP-C	AD	{chronic infections, due to mbl deficiency}, 614372 (3),
MBP1	AD	{chronic infections, due to mbl deficiency}, 614372 (3),
MBP2		
MBPH		
MBR		
MBRL		
MBS	AD	genitourinary and/or/brain malformation syndrome, 618820 (3),
MBS85		
MBT		
MBTD1		
MBTPS1	AR	?spondyloepiphyseal dysplasia, kondo-fu type, 618392 (3),
MBTPS2	XL,XLR	keratosis follicularis spinulosa decalvans, 308800 (3), ; osteogenesis imperfecta, type xix, 301014 (3), ; ifap syndrome with or without bresheck syndrome, 308205 (3), ; ?olmsted syndrome, 300918 (3),
MBX		
MBXL		
MC1R	AR	[analgesia from kappa-opioid receptor agonist, female-specific], 613098 (3); [skin/hair/eye pigmentation 2, red hair/fair skin], 266300 (3), ; [skin/hair/eye pigmentation 2, blond hair/fair skin], 266300 (3), ; {melanoma, cutaneous malignant, 5}, 613099 (3); {albinism, oculocutaneous, type ii, modifier of}, 203200 (3), ; {uv-induced skin damage}, 266300 (3),
MC2R	AR	glucocorticoid deficiency, due to acth unresponsiveness, 202200 (3),
MC3		{obesity, severe, susceptibility to, bmiq9}, 602025 (3)
MC3R		{obesity, severe, susceptibility to, bmiq9}, 602025 (3)
MC4R	AR,AD	obesity (bmiq20), 618406 (3), ; {obesity, resistance to (bmiq20)}, 618406 (3),
MC56		[blood group, indian system], 609027 (3)
MC5R		
MC7	AD	?aniridia 3, 617142 (3),
MCAD	AR	acyl-coa dehydrogenase, medium chain, deficiency of, 201450 (3),
MCADH	AR	acyl-coa dehydrogenase, medium chain, deficiency of, 201450 (3),
MCAF	AD	{mycobacterium tuberculosis, susceptibility to}, 607948 (3); {hiv-1, resistance to}, 609423 (3); {coronary artery disease, modifier of} (3); {spina bifida, susceptibility to}, 182940 (3),
MCAK		
MCAM		
mCANP		
MCAP		
MCARP		
MCART1		
MCART2		
MCART6		
MCAT		
MCB5	AR	methemoglobinemia and ambiguous genitalia, 250790 (3),
MCC		colorectal cancer, somatic, 114500 (3)
MCC2		
MCCA	AR	3-methylcrotonyl-coa carboxylase 1 deficiency, 210200 (3),
MCCB	AR	3-methylcrotonyl-coa carboxylase 2 deficiency, 210210 (3),
MCCC1	AR	3-methylcrotonyl-coa carboxylase 1 deficiency, 210200 (3),
MCCC2	AR	3-methylcrotonyl-coa carboxylase 2 deficiency, 210210 (3),
MCCCÎ±	AR	3-methylcrotonyl-coa carboxylase 1 deficiency, 210200 (3),
MCCCÎ²	AR	3-methylcrotonyl-coa carboxylase 2 deficiency, 210210 (3),
MCCD1		
MCD	AR,AD	malonyl-coa decarboxylase deficiency, 248360 (3), |tubulointerstitial kidney disease, 2, 174000 (3),
MCD4	AR	multiple congenital anomalies-hypotonia-seizures syndrome 1, 614080 (3),
mCD48		
mCD84		
MCDC1	AR	macular corneal dystrophy, 217800 (3),
MCDR1	AD	chorioretinal atrophy, progressive bifocal, 600790 (3), ; macular dystrophy 1, north carolina type, 136550 (3),
MCDR2	AR,AD,AR	46xy sex reversal 8, 614279 (3), |macular dystrophy, retinal, 2, 608051 (3), ; retinitis pigmentosa 41, 612095 (3), ; stargardt disease 4, 603786 (3), ; cone-rod dystrophy 12, 612657 (3),
MCE	AR	methylmalonyl-coa epimerase deficiency, 251120 (3),
MCEE	AR	methylmalonyl-coa epimerase deficiency, 251120 (3),
MCEF	AD	chops syndrome, 616368 (3),
MCEMP1		
MCF2		
MCF2L		
MCF2L2		
MCF3		
MCFD1	AR	combined factor v and viii deficiency, 227300 (3),
MCFD2		factor v and factor viii, combined deficiency of, 613625 (3)
MCFP		
MCG10		
MCG18		
MCG4		
MCGF		
MCH		
MCH1R		
MCH2		
MCH2R		
MCH3		
MCH4	AD	autoimmune lymphoproliferative syndrome, type ii, 603909 (3), ; gastric cancer, somatic, 613659 (3); lymphoma, non-hodgkin, somatic, 605027 (3)
MCH5	AD,AR	{breast cancer, protection against}, 114480 (3), somatic mutation, ; ?caspase 8 lymphadenopathy syndrome, 607271 (3), ; hepatocellular carcinoma, somatic, 114550 (3); {lung cancer, protection against}, 211980 (3), somatic mutation,
MCH6		
MCHR1		
MCHR2		
MCI	AR	ciliary dyskinesia, primary, 42, 618695 (3),
MCI1		{myocardial infarction, susceptibility to}, 608446 (3)
MCIDAS	AR	ciliary dyskinesia, primary, 42, 618695 (3),
MCIF		
MCIN	AR	ciliary dyskinesia, primary, 42, 618695 (3),
MCJ		
MCKD	AD	tubulointerstitial kidney disease, 2, 174000 (3),
MCKD1	AD	tubulointerstitial kidney disease, 2, 174000 (3),
MCL		
Mcl-1		
MCL1		
MCLC	AR	retinitis pigmentosa 32, 609913 (3),
MCM	AR	methylmalonic aciduria, mut(0) type, 251000 (3),
MCM-BP		
MCM1		
MCM10	AR	immunodeficiency 80 with or without cardiomyopathy, 619313 (3),
MCM2	AD	?deafness, 70, 616968 (3),
MCM3		
MCM3AP	AR	peripheral neuropathy, with or without impaired intellectual development, 618124 (3),
MCM4	AR	immunodeficiency 54, 609981 (3),
MCM5	AR	?meier-gorlin syndrome 8, 617564 (3),
MCM6	AD	lactase persistence/nonpersistence, 223100 (3),
MCM7		
MCM8	AR	?premature ovarian failure 10, 612885 (3),
MCM8IP		
MCM9	AR	ovarian dysgenesis 4, 616185 (3),
MCMBP		
MCMDC1	AR	ovarian dysgenesis 4, 616185 (3),
MCMDC2		
MCMP	AR	cone-rod dystrophy 9, 612775 (3),
MCMPMltna		
MCMT	AD	neuropathy, hereditary sensory, type ie, 614116 (3), ; cerebellar ataxia, deafness, and narcolepsy, 604121 (3),
MCNAA		
MCOLN1	AR	mucolipidosis iv, 252650 (3),
MCOLN2		
MCOLN3		
MCOPCB5	AD	microphthalmia with coloboma 5, 611638 (3), ; schizencephaly, 269160 (3); single median maxillary central incisor, 147250 (3), ; holoprosencephaly 3, 142945 (3),
MCP	AR,AD	{hemolytic uremic syndrome, atypical, susceptibility to, 2}, 612922 (3),
MCP-1	AD	{mycobacterium tuberculosis, susceptibility to}, 607948 (3); {hiv-1, resistance to}, 609423 (3); {coronary artery disease, modifier of} (3); {spina bifida, susceptibility to}, 182940 (3),
MCP-1-R		{hiv infection, susceptibility/resistance to}, 609423 (3)
MCP-2		
MCP-3		
MCP-4		
MCP1	AD	{mycobacterium tuberculosis, susceptibility to}, 607948 (3); {hiv-1, resistance to}, 609423 (3); {coronary artery disease, modifier of} (3); {spina bifida, susceptibility to}, 182940 (3),
MCP3		
MCPH1	AR	microcephaly 1, primary, 251200 (3),
MCPH2	AR	microcephaly 2, primary, with or without cortical malformations, 604317 (3),
MCPH3	AR	microcephaly 3, primary, 604804 (3),
MCPH4	AR	microcephaly 4, primary, 604321 (3),
MCPH5	AR	microcephaly 5, primary, 608716 (3),
MCPH6	AR	microcephaly 6, primary, 608393 (3), ; ?seckel syndrome 4, 613676 (3),
MCPH7	AR	microcephaly 7, primary, 612703 (3),
MCPH9	AR	microcephaly 9, primary, 614852 (3), ; seckel syndrome 5, 613823 (3),
MCPHA	AR	microcephaly, amish type, 607196 (3), ; thiamine metabolism dysfunction syndrome 4 (progressive polyneuropathy type), 613710 (3),
MCPIP1		
MCPIP2		
MCPIP3		
MCPIP4		
MCPR	AR	rothmund-thomson syndrome, type 1, 618625 (3),
MCRIP		
MCRIP1		
MCRS1		
MCRS2		
MCS	XLR,XLD,XL	wieacker-wolff syndrome, 314580 (3), ; wieacker-wolff syndrome, female-restricted, 301041 (3),
MCSC		
MCSF		
MCSP	AR	spondylometaphyseal dysplasia, sedaghatian type, 250220 (3),
MCSPG		
MCT	AD,AR	hyperinsulinemic hypoglycemia, familial, 7, 610021 (3), ; erythrocyte lactate transporter defect, 245340 (3), ; monocarboxylate transporter 1 deficiency, 616095 (3),
MCT-1		
MCT1	AD,AR	hyperinsulinemic hypoglycemia, familial, 7, 610021 (3), ; erythrocyte lactate transporter defect, 245340 (3), ; monocarboxylate transporter 1 deficiency, 616095 (3),
MCT10		
MCT11		
MCT12	AD	cataract 47, juvenile, with microcornea, 612018 (3),
MCT2		
MCT3		
MCT4		
MCT5		
MCT6		
MCT7	XL	allan-herndon-dudley syndrome, 300523 (3),
MCT8	XL	allan-herndon-dudley syndrome, 300523 (3),
MCT9		
MCTP1		
MCTP2		
MCTS1		
MCTS2		
MCTS2P		
MCU		
MCUR1		
MD-1		
MD-2		
Md6		
MDA-5	AR,AD	immunodeficiency 95, 619773 (3), ; aicardi-goutieres syndrome 7, 615846 (3), ; singleton-merten syndrome 1, 182250 (3),
mda-7		
MDA-9		
MDA1		
MDA5	AR,AD	immunodeficiency 95, 619773 (3), ; aicardi-goutieres syndrome 7, 615846 (3), ; singleton-merten syndrome 1, 182250 (3),
MDB		
MDC		
MDC-3.13		
MDC-Lm		
MDC-Ls		
MDC1		
MDC15		
MDC1C	AR	muscular dystrophy-dystroglycanopathy (congenital with or without impaired intellectual development), type b, 5, 606612 (3), ; muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 5, 607155 (3), ; muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 5, 613153 (3),
MDC2	AR	developmental and epileptic encephalopathy 61, 617933 (3),
MDC3		
MDC9	AR	cone-rod dystrophy 9, 612775 (3),
MDCR	AD	subcortical laminar heterotopia, 607432 (3), ; lissencephaly 1, 607432 (3),
MDDX28		
MDEG		
MDF2		
MDFI		
MDFIC	AR	lymphatic malformation 12, 620014 (3),
MDFIC1	AR	lymphatic malformation 12, 620014 (3),
MDG		
MDG1		
MDGA1		
MDGA2		
MDGF		
MDGI		
Mdgt		
MDH1	AR	?developmental and epileptic encephalopathy 88, 618959 (3),
MDH2	AR	developmental and epileptic encephalopathy 51, 617339 (3),
mDia1	AD,AR	deafness, 1, with or without thrombocytopenia, 124900 (3), ; seizures, cortical blindness, microcephaly syndrome, 616632 (3),
mdig		
MDK		
MDL-1		
MDM	AR	meleda disease, 248300 (3),
MDM1		
MDM2	AD,AR	{accelerated tumor formation, susceptibility to}, 614401 (3), ; ?lessel-kubisch syndrome, 618681 (3),
MDM35		
Mdm38	AR	neurodegeneration, childhood-onset, with multisystem involvement due to mitochondrial dysfunction, 620089 (3),
MDM4	AD	?bone marrow failure syndrome 6, 618849 (3),
MDMX	AD	?bone marrow failure syndrome 6, 618849 (3),
mdN		
MDN1		
MDNCF		
MDP77		
MDPK	AD	myotonic dystrophy 1, 160900 (3),
MDR-NF1		
MDR1		{inflammatory bowel disease 13}, 612244 (3); {colchicine resistance}, 120080 (3)
MDR15		
MDR2	AR,AD	gallbladder disease 1, 600803 (3), ; cholestasis, intrahepatic, of pregnancy, 3, 614972 (3), ; cholestasis, progressive familial intrahepatic 3, 602347 (3),
MDR3	AR,AD	gallbladder disease 1, 600803 (3), ; cholestasis, intrahepatic, of pregnancy, 3, 614972 (3), ; cholestasis, progressive familial intrahepatic 3, 602347 (3),
mDRC		
MDRS1	AR	congenital myopathy 3 with rigid spine, 602771 (3),
MDS	AD	subcortical laminar heterotopia, 607432 (3), ; lissencephaly 1, 607432 (3),
MDS003	AR	?proteasome-associated autoinflammatory syndrome 4, 619183 (3),
MDS010	AD,AR	dowling-degos disease 4, 615696 (3), ; muscular dystrophy, limb-girdle, 21, 617232 (3),
MDS015		
MDS018		
MDS019		
MDS023		
MDS026		
MDS027		
MDS028		
MDS029		
MDS030		
MDS031	XL	developmental and epileptic encephalopathy 36, 300884 (3),
MDS032		
MDS1	AD	myelodysplasia syndrome-1 (3)|myelodysplasia syndrome-1 (3)|radioulnar synostosis with amegakaryocytic thrombocytopenia 2, 616738 (3),
MDS1-EVI1	AD	myelodysplasia syndrome-1 (3)|myelodysplasia syndrome-1 (3)|radioulnar synostosis with amegakaryocytic thrombocytopenia 2, 616738 (3),
MDS2		
MDSRP	AD,AR	dowling-degos disease 4, 615696 (3), ; muscular dystrophy, limb-girdle, 21, 617232 (3),
MDT1	AR	?retinal dystrophy, juvenile cataracts, and short stature syndrome, 616108 (3),
MDU1		
MDU2		[blood group, indian system], 609027 (3)
MDU3		[blood group, indian system], 609027 (3)
MDY2		
ME1		
mE10	AR	{lymphoma, follicular, somatic}, 605027 (3); ?immunodeficiency 37, 616098 (3), ; {sezary syndrome, somatic} (3); {male germ cell tumor, somatic}, 273300 (3); lymphoma, malt, somatic, 137245 (3); {mesothelioma, somatic}, 156240 (3)
ME2	AD	lymphatic malformation 9, 619319 (3),
ME20		
ME2GLYDH	AR	dimethylglycine dehydrogenase deficiency, 605850 (3),
ME3		
ME491		
ME6		
MEA		
MEA-2		
MEA1		
MEA5		
MEA6		
MEAF2		
MEAF3		
MEAF4		
MEAF6		
mEAK-7		
MEAK7		
MEAX	XL,XLR	myopathy, with excessive autophagy, 310440 (3),
MEB	AR	muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 3, 613157 (3), ; muscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type b, 3, 613151 (3), ; retinitis pigmentosa 76, 617123 (3), ; muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 3, 253280 (3),
MEC		
MEC-15		
MEC1	AR,AD	seckel syndrome 1, 210600 (3), ; ?cutaneous telangiectasia and cancer syndrome, familial, 614564 (3),
MEC17		
MECL1	AR	proteasome-associated autoinflammatory syndrome 5, 619175 (3),
MECOM	AD	myelodysplasia syndrome-1 (3)|radioulnar synostosis with amegakaryocytic thrombocytopenia 2, 616738 (3),
MECP2	XLD,XLR,XL	rett syndrome, atypical, 312750 (3), ; encephalopathy, neonatal severe, 300673 (3), ; intellectual developmental disorder, syndromic, lubs type, 300260 (3), ; {autism susceptibility, 3}, 300496 (3), ; intellectual developmental disorder, syndromic 13, 300055 (3), ; rett syndrome, 312750 (3), ; rett syndrome, preserved speech variant, 312750 (3),
MECR	AR	dystonia, childhood-onset, with optic atrophy and basal ganglia abnormalities, 617282 (3),
MECT1		mucoepidermoid salivary gland carcinoma (3)
MED	AD,AD,AR,AD,AR,AD	?myoclonus, familial, 2, 618364 (3), ; seizures, benign familial infantile, 5, 617080 (3), ; cognitive impairment with or without cerebellar ataxia, 614306 (3), ; developmental and epileptic encephalopathy 13, 614558 (3), |{intervertebral disc disease, susceptibility to}, 603932 (3); epiphyseal dysplasia, multiple, 3, with or without myopathy, 600969 (3), ; stickler syndrome, type vi, 620022 (3), |epiphyseal dysplasia, multiple, 2, 600204 (3), ; ?stickler syndrome, type v, 614284 (3), |pseudoachondroplasia, 177170 (3), ; carpal tunnel syndrome 2, 619161 (3), ; epiphyseal dysplasia, multiple, 1, 132400 (3),
MED1	AD,AR	{uveal melanoma, susceptibility to, 1}, 606660 (3), ; tumor predisposition syndrome 2, 619975 (3),
MED10		
MED11	AR	neurodegeneration with developmental delay, early respiratory failure, myoclonic seizures, and brain abnormalities, 620327 (3),
MED12	XLR,XL,XLD	lujan-fryns syndrome, 309520 (3), ; ohdo syndrome, 300895 (3), ; hardikar syndrome, 301068 (3), ; opitz-kaveggia syndrome, 305450 (3),
MED12L	AD	nizon-isidor syndrome, 618872 (3),
MED13	AD	intellectual developmental disorder, 61, 618009 (3),
MED13L	AD	impaired intellectual development and distinctive facial features with or without cardiac defects, 616789 (3),
MED14		
MED15		
MED16		
MED17	AR	microcephaly, postnatal progressive, with seizures and brain atrophy, 613668 (3),
MED18		
MED19		
MED2		
MED20		
MED21		
MED22		
MED23	AR	intellectual developmental disorder, 18, with or without epilepsy, 614249 (3),
Med24		
MED24		
MED25	AR	basel-vanagait-smirin-yosef syndrome, 616449 (3),
MED26		
MED27	AR	neurodevelopmental disorder with spasticity, cataracts, and cerebellar hypoplasia, 619286 (3),
MED28		
MED29		
MED3	AR	neurodevelopmental disorder with spasticity, cataracts, and cerebellar hypoplasia, 619286 (3),
MED30		
MED4		
MED5		
MED6		
MED7		
MED8		
MED9		
MEDA-7		
MEF	XL,XLR,AD,AR	autoinflammatory syndrome, familial, behcet-like 2, 301074 (3), |neutrophilic dermatosis, acute febrile, 608068 (3), ; familial mediterranean fever, ar, 249100 (3), ; familial mediterranean fever, ad, 134610 (3),
MEF-2		
MEF2A	AD	{coronary artery disease, 1}, 608320 (3),
MEF2B		
MEF2BNB		
MEF2C	AD	chromosome 5q14.3 deletion syndrome, 613443 (4), ; neurodevelopmental disorder with hypotonia, stereotypic hand movements, and impaired language, 613443 (3),
MEF2D		
MEF3L		
MEFV	AD,AR	neutrophilic dermatosis, acute febrile, 608068 (3), ; familial mediterranean fever, ar, 249100 (3), ; familial mediterranean fever, ad, 134610 (3),
MEG2		
MEG3		
MEG8		
MEGANE		
MEGAP		
MEGF1	AD	spinocerebellar ataxia 45, 617769 (3),
MEGF10	AR	congenital myopathy 10a, severe variant, 614399 (3), ; congenital myopathy 10b, mild variant, 620249 (3),
MEGF11		
MEGF12		
MEGF2		
MEGF3		
MEGF4		
MEGF5		
MEGF6		
MEGF7	AR,AD	?myasthenic syndrome, congenital, 17, 616304 (3), ; sclerosteosis 2, 614305 (3), ; cenani-lenz syndactyly syndrome, 212780 (3),
MEGF8	AR	carpenter syndrome 2, 614976 (3),
MEGF9		
MEGT1		
MEI1	AR	hydatidiform mole, recurrent, 3, 618431 (3),
MEI4		
MEI5		
MEIG1		
MEIKIN		
MEILB2	AR	premature ovarian failure 19, 619245 (3),
MEIOB	AR	?spermatogenic failure 22, 617706 (3),
MEIOC		
MEIOK21		
MEIR5		
MEIS1		
MEIS2	AD	cleft palate, cardiac defects, and mental retardation, 600987 (3),
MEIS3		
Meisetz		
MEK1	AD	cardiofaciocutaneous syndrome 3, 615279 (3), ; melorheostosis, isolated, somatic mosaic, 155950 (3)
MEK2	AD	cardiofaciocutaneous syndrome 4, 615280 (3),
MEK3		
MEK4		
MEK5		
MEK6		
MEKA		
MEKK	AD	46xy sex reversal 6, 613762 (3),
MEKK1	AD	46xy sex reversal 6, 613762 (3),
MEKK10		
MEKK11		
MEKK12		
MEKK13		
MEKK2		
MEKK2B		
MEKK3		
MEKK4		
MEKK5		
MEKK6		
MEKK7	AD	frontometaphyseal dysplasia 2, 617137 (3), ; cardiospondylocarpofacial syndrome, 157800 (3),
MEKK8		lung cancer, somatic, 211980 (3)
MEKK9		
MEL		
MEL-18	AD	turnpenny-fry syndrome, 618371 (3),
MEL-1A-R		
MEL-CSPG		
MEL1	AD	left ventricular noncompaction 8, 615373 (3), ; cardiomyopathy, dilated, 1ll, 615373 (3),
Mel1c		
melanopsin		
MelCAM		
MelG		
MELK		
MELTF		
MEM3	AD	{parkinson disease 17}, 614203 (3),
memA		
MEMD		
MEMO		
MEMO1		
Men		
MEN1	AD	lipoma, somatic (3); angiofibroma, somatic (3); multiple endocrine neoplasia 1, 131100 (3), ; carcinoid tumor of lung (3); adrenal adenoma, somatic (3); parathyroid adenoma, somatic (3)
MEN2A	AD	{hirschsprung disease, susceptibility to, 1}, 142623 (3), ; multiple endocrine neoplasia iia, 171400 (3), ; {hirschsprung disease, protection against}, 142623 (3), ; medullary thyroid carcinoma, 155240 (3), ; pheochromocytoma, 171300 (3), ; multiple endocrine neoplasia iib, 162300 (3),
MEN2B	AD	{hirschsprung disease, susceptibility to, 1}, 142623 (3), ; multiple endocrine neoplasia iia, 171400 (3), ; {hirschsprung disease, protection against}, 142623 (3), ; medullary thyroid carcinoma, 155240 (3), ; pheochromocytoma, 171300 (3), ; multiple endocrine neoplasia iib, 162300 (3),
MENA		
MENepsilon/beta		
MENTHO		
MEOX1	AR	klippel-feil syndrome 2, 214300 (3),
MEOX2		
MEP1A		
MEP1B		
MEP50		
MEPCE		
MEPE		
MEPI		
mer	AR	retinitis pigmentosa 38, 613862 (3),
MER3	AR	premature ovarian failure 9, 615724 (3),
MER5	AR,AD	spinocerebellar ataxia, 32, 619862 (3), ; corneal dystrophy, punctiform and polychromatic pre-descemet, 619871 (3),
MER6		
MERIT40		
merlin	AD	neurofibromatosis, type 2, 101000 (3), ; meningioma, nf2-related, somatic, 607174 (3); schwannomatosis, somatic, 162091 (3)
merlin-1	AD	neurofibromatosis, type 2, 101000 (3), ; meningioma, nf2-related, somatic, 607174 (3); schwannomatosis, somatic, 162091 (3)
MERM1		
MERP-1		
MERP1		
MERTK	AR	retinitis pigmentosa 38, 613862 (3),
MESD	AR	osteogenesis imperfecta, type xx, 618644 (3),
MESDC1		
MESDC2	AR	osteogenesis imperfecta, type xx, 618644 (3),
MESP1		
MESP2	AR	spondylocostal dysostosis 2, 608681 (3),
MESRGP		
MEST		
MEST-AS1		
MEST-IT1		
MESTIT1		
MET	AD,AR	renal cell carcinoma, papillary, 1, familial and somatic, 605074 (3); ?arthrogryposis, distal, type 11, 620019 (3), ; hepatocellular carcinoma, childhood type, somatic, 114550 (3); {osteofibrous dysplasia, susceptibility to}, 607278 (3), ; ?deafness, 97, 616705 (3),
MET1		
MET18		
METAP1		
MetAP1A		
METAP1D		
Metap1l		
METAP2		
METCAM		
METH1		
METH2		
METL		
metnase		
METRN		
METRNL		
MetRS	AR,AD	spastic paraplegia 70, 620323 (3), ; interstitial lung and liver disease, 615486 (3), ; ?trichothiodystrophy 9, nonphotosensitive, 619692 (3), ; charcot-marie-tooth disease, axonal, type 2u, 616280 (3),
METT11D1		
METT5D1		
METTL1		
METTL10		
METTL11A		
METTL12		
METTL13	AR,AD	{?deafness, 26, modifier of}, 605429 (3),
METTL14		
METTL15		
METTL17		
METTL18		
METTL19		
METTL2		
METTL20		
METTL21A		
METTL21B		
METTL21C		
METTL21D		
METTL22		
METTL23	AR	intellectual developmental disorder, 44, 615942 (3),
METTL27		
METTL2A		
METTL2B		
METTL3		
METTL4		
METTL5	AR	intellectual developmental disorder, 72, 618665 (3),
METTL6		
METTL7A		
METTL8		
METTL9		
MEX3A		
MEX3B		
MEX3C		
MEX3D		
Mex67		
MF1		
MF4	XLR,XL	metacarpal 4-5 fusion, 309630 (3),
MFAP1		
MFAP2		
MFAP3		
MFAP3L		
MFAP4		
MFAP5	AD	aortic aneurysm, familial thoracic 9, 616166 (3),
MFAT		
MFE-2	AR	d-bifunctional protein deficiency, 261515 (3), ; perrault syndrome 1, 233400 (3),
MFF	AR	encephalopathy due to defective mitochondrial and peroxisomal fission 2, 617086 (3),
MFG-E8		
MFGE8		
MFH-1	AD	lymphedema-distichiasis syndrome, 153400 (3), ; lymphedema-distichiasis syndrome with renal disease and diabetes mellitus, 153400 (3),
MFHAS1		malignant fibrous histiocytoma, 605352 (2)
MFI2		
MFI7	AR	leukocyte adhesion deficiency, 116920 (3),
MFN1		
MFN2	AR,AD	lipomatosis, multiple symmetric, with or without peripheral neuropathy, 151800 (3), ; charcot-marie-tooth disease, axonal, type 2a2a, 609260 (3), ; charcot-marie-tooth disease, axonal, type 2a2b, 617087 (3), ; hereditary motor and sensory neuropathy via, 601152 (3),
MFNG		
MFR		
MFRN		
MFRN1		
MFRP	AR	microphthalmia, isolated 5, 611040 (3), ; nanophthalmos 2, 609549 (3)
MFS1	AD	geleophysic dysplasia 2, 614185 (3), ; weill-marchesani syndrome 2, 608328 (3), ; ectopia lentis, familial, 129600 (3), ; mass syndrome, 604308 (3), ; marfan lipodystrophy syndrome, 616914 (3), ; acromicric dysplasia, 102370 (3), ; marfan syndrome, 154700 (3), ; stiff skin syndrome, 184900 (3),
MFS2	AD	loeys-dietz syndrome 2, 610168 (3), ; colorectal cancer, hereditary nonpolyposis, type 6, 614331 (3); esophageal cancer, somatic, 133239 (3)
MFSD1		
MFSD10		
MFSD11		
MFSD12		
MFSD14A		
MFSD14B		
MFSD2	AR	neurodevelopmental disorder with progressive microcephaly, spasticity, and brain abnormalities, 616486 (3),
MFSD2A	AR	neurodevelopmental disorder with progressive microcephaly, spasticity, and brain abnormalities, 616486 (3),
MFSD2B		
MFSD3		
MFSD4		
MFSD4A		
MFSD4B		
MFSD5		
MFSD6		
MFSD7		
MFSD7B	AR	ataxia, posterior column, with retinitis pigmentosa, 609033 (3),
MFSD7C	AR	proliferative vasculopathy and hydranencephaly-hydrocephaly syndrome, 225790 (3),
MFSD8	AR	macular dystrophy with central cone involvement, 616170 (3), ; ceroid lipofuscinosis, neuronal, 7, 610951 (3),
MFSD9		
MFTC	AR	?exercise intolerance, riboflavin-responsive, 616839 (3),
MFTL		
MG-160		
MG1	AD	{pulmonary fibrosis, idiopathic, susceptibility to}, 178500 (3),
Mg11	AD,AR	?chilblain lupus 2, 614415 (3), ; aicardi-goutieres syndrome 5, 612952 (3),
MG2	AD	{asthma, protection against}, 600807 (3),
MG50	AR	anterior segment dysgenesis 7, with sclerocornea, 269400 (3),
MG53		
MG61	XLD,XL	focal dermal hypoplasia, 305600 (3),
MGA		
MGA1	AR	[proteinuria, chronic benign], 618884 (3), ; imerslund-grasbeck syndrome 1, 261100 (3),
MGA3	AR,AD	3-methylglutaconic aciduria, type iii, 258501 (3), ; optic atrophy 3 with cataract, 165300 (3),
MGAM		
MGARP		
MGAT		
MGAT1		
MGAT1.2	AR	muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 3, 613157 (3), ; muscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type b, 3, 613151 (3), ; retinitis pigmentosa 76, 617123 (3), ; muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 3, 253280 (3),
MGAT2	AR	congenital disorder of glycosylation, type iia, 212066 (3),
MGAT3		
MGAT4A		
MGAT4B		
MGAT4C		
MGAT4D		
MGAT5		
MGAT5A		
MGAT5B		
MGB1		
MGB2		
MGC-24	AD	?deafness, 66, 616969 (3),
MGC-24v	AD	?deafness, 66, 616969 (3),
MGC:14091		
MGC:39976		
MGC:4834		
MGC:8964	AR	alazami-yuan syndrome, 617126 (3),
MGC1	XL,XLR	megalocornea 1, 309300 (3),
MGC10067		
MGC10084		
MGC1010		
MGC10120		
MGC10170		
MGC10200		
MGC10204		
MGC10233		
MGC10235	AR	intellectual developmental disorder, 71, 618504 (3),
MGC102753		
MGC102762	AR	xeroderma pigmentosum, group d, 278730 (3), ; trichothiodystrophy 1, photosensitive, 601675 (3), ; ?cerebrooculofacioskeletal syndrome 2, 610756 (3),
MGC102768		
MGC102804		
MGC102866		
MGC102953		
MGC10327		
MGC10334		
MGC104174		
MGC104186		
MGC104216		
MGC104230		
MGC104241	AD,AR	nemaline myopathy 5c, 620389 (3), ; nemaline myopathy 5a, severe infantile, 605355 (3), ; nemaline myopathy 5b, childhood-onset, 620386 (3),
MGC104255	AD	faundes-banka syndrome, 619376 (3),
MGC104274	AD	hypotrichosis 12, 615885 (3),
MGC104275	AD	hypotrichosis 12, 615885 (3),
MGC10430	AR	{gastric cancer risk after h. pylori infection}, 613659 (3); {microvascular complications of diabetes 4}, 612628 (3); interleukin 1 receptor antagonist deficiency, 612852 (3),
MGC10433		
MGC10442	AD	maturity-onset diabetes of the young, type 11, 613375 (3),
MGC104475		
MGC104638	AR	glomerulosclerosis, focal segmental, 6, 614131 (3),
MGC104706		
MGC10481		
MGC10485		
MGC104959		
MGC10500		
MGC10511		
MGC105127		
MGC10526		
MGC10527	AR	mitochondrial complex i deficiency, nuclear type 18, 618240 (3),
MGC10540		
MGC10556		
MGC10558		
MGC10561	AR	?46xy sex reversal 5, 613080 (3),
MGC1058		
MGC10599		
MGC10612		
MGC10613		
MGC10630		
MGC10676		
MGC10702		
MGC10744	AR	orofaciodigital syndrome xvi, 617563 (3), ; meckel syndrome 13, 617562 (3), ; ?joubert syndrome 29, 617562 (3),
MGC10753	AD	desanto-shinawi syndrome, 616708 (3),
MGC10765		
MGC10772		
MGC10791		
MGC10796		
MGC10818		
MGC10825		
MGC10831		
MGC10848		
MGC10854		
MGC10870		
MGC10881		
MGC10882		
MGC1090		
MGC10902		
MGC10911		
MGC10922	AR,AD	neurodegeneration with brain iron accumulation 4, 614298 (3), ; ?spastic paraplegia 43, 615043 (3),
MGC10924		
MGC10946		
MGC10963		
MGC10966	AR	leukocyte adhesion deficiency, type iii, 612840 (3),
MGC10974		
MGC10981		
MGC10999		
MGC11061		
MGC11102		
MGC11104		
MGC111064		
MGC111083		
MGC111107	XL,XLR,XLD	myopathy, with postural muscle atrophy, 300696 (3), ; emery-dreifuss muscular dystrophy 6, 300696 (3), ; ?uruguay faciocardiomusculoskeletal syndrome, 300280 (3), ; scapuloperoneal myopathy, 300695 (3), ; reducing body myopathy, 1b, with late childhood or adult onset, 300718 (3), ; reducing body myopathy, 1a, severe, infantile or early childhood onset, 300717 (3),
MGC111130		
MGC11115		
MGC111163		
MGC111193	AR	congenital disorder of glycosylation, type iu, 615042 (3),
MGC111222		
MGC11134		
MGC111371	AD	leukemia, acute myeloid, 601626 (1), somatic mutation,
MGC111373		
MGC11138		
MGC1114		
MGC111488		
MGC111763		bradyopsia 1, 608415 (3)
MGC11251	AR	tooth agenesis, selective, 10, 620173 (3), ; ?deafness, 98, 614861 (3), ; ectodermal dysplasia 14, hair/tooth type with or without hypohidrosis, 618180 (3),
MGC11256		
MGC1126		
MGC11266		
MGC1127		
MGC11271		
MGC11279		
MGC11296		
MGC11308		
MGC11316		
MGC11321		
MGC11324		
MGC11326	AR	dyserythropoietic anemia, congenital, type ib, 615631 (3),
MGC11332		
MGC11335		
MGC11337	AR	steel syndrome, 615155 (3),
MGC11349		
MGC1136		
MGC11386		
MGC1167		
MGC116735		spherocytosis, type 5, 612690 (3)
MGC116737		spherocytosis, type 5, 612690 (3)
MGC116786	AD	{asthma, susceptibility to}, 600807 (3), ; {allergic rhinitis, susceptibility to}, 607154 (3)
MGC116788	AD	{asthma, susceptibility to}, 600807 (3), ; {allergic rhinitis, susceptibility to}, 607154 (3)
MGC116789	AD	{asthma, susceptibility to}, 600807 (3), ; {allergic rhinitis, susceptibility to}, 607154 (3)
MGC117152	AR	holoprosencephaly 14, 619895 (3),
MGC117164	AR	?lacrimal duct defect, 149700 (3),
MGC117216		
MGC117262		
MGC117264		
MGC117291		
MGC117310		
MGC117314	AR	osteogenesis imperfecta, type viii, 610915 (3),
MGC117360		
MGC117373		
MGC117402		
MGC117425		
MGC118754.		
MGC118899	AR	thrombotic thrombocytopenic purpura, hereditary, 274150 (3),
MGC118900	AR	thrombotic thrombocytopenic purpura, hereditary, 274150 (3),
MGC119014		
MGC119016		
MGC119055		?sarcoma, synovial, 300813 (3)
MGC119067		
MGC119068		
MGC119069		
MGC119078	AR	ichthyosis, congenital, 12, 617320 (3),
MGC119079	AR	ichthyosis, congenital, 12, 617320 (3),
MGC119100		
MGC119131		
MGC119143	AR	encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy, 617186 (3),
MGC119144	AR	encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy, 617186 (3),
MGC119145	AR	encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy, 617186 (3),
MGC119199		
MGC119201		
MGC119295		
MGC119312		
MGC119403	AD	neural tube defects, 182940 (3),
MGC119404	AD	neural tube defects, 182940 (3),
MGC119447		
MGC119522	AR	?premature ovarian failure 10, 612885 (3),
MGC119523	AR	?premature ovarian failure 10, 612885 (3),
MGC119818	AD	cryptorchidism, 219050 (3),
MGC119819	AD	cryptorchidism, 219050 (3),
MGC11983		
MGC119832		
MGC119833		
MGC119947		
MGC1203	AR	{bardet-biedl syndrome 1, modifier of}, 209900 (3), digenic
MGC120420		
MGC120442		
MGC120443		
MGC120444		
MGC12197	AR	intellectual developmental disorder, 70, 618402 (3),
MGC12217		
MGC1223		
MGC12290	AR	lipoyltransferase 1 deficiency, 616299 (3),
MGC12301		
MGC12314		
MGC12372	AD	hypomagnesemia 2, renal, 154020 (3),
MGC12435	AR	ciliary dyskinesia, primary, 16, 614017 (3),
MGC12458		
MGC125288		
MGC125289		
MGC12536		
MGC125711		
MGC125712		
MGC125835		
MGC125836		
MGC125854		
MGC125855		
MGC125864	AD	noonan syndrome 8, 615355 (3),
MGC125865	AD	noonan syndrome 8, 615355 (3),
MGC125904	AR	?muscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type b, 15, 618992 (3), ; muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 15, 612937 (3),
MGC125905	AR	?muscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type b, 15, 618992 (3), ; muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 15, 612937 (3),
MGC126058		
MGC126059		
MGC126063		
MGC126064		
MGC126187		
MGC126218	AR	xeroderma pigmentosum, group d, 278730 (3), ; trichothiodystrophy 1, photosensitive, 601675 (3), ; ?cerebrooculofacioskeletal syndrome 2, 610756 (3),
MGC126219	AR	xeroderma pigmentosum, group d, 278730 (3), ; trichothiodystrophy 1, photosensitive, 601675 (3), ; ?cerebrooculofacioskeletal syndrome 2, 610756 (3),
MGC126226		
MGC126227		
MGC126228		
MGC126430	AD	{melioidosis, susceptibility to}, 615557 (3), ; {systemic lupus erythematosus, susceptibility to, 1}, 601744 (3); {systemic lupus erythematosus, resistance to}, 601744 (3); {legionnaire disease, susceptibility to}, 608556 (3)
MGC126431	AD	{melioidosis, susceptibility to}, 615557 (3), ; {systemic lupus erythematosus, susceptibility to, 1}, 601744 (3); {systemic lupus erythematosus, resistance to}, 601744 (3); {legionnaire disease, susceptibility to}, 608556 (3)
MGC126442		
MGC126552		
MGC126554		
MGC126562		
MGC126567		
MGC126569		
MGC126572		
MGC126582	AD	colorectal cancer, somatic, 114500 (3); oligodontia-colorectal cancer syndrome, 608615 (3),
MGC126590		
MGC126592		
MGC126621		
MGC126625		
MGC126664		
MGC126666		
MGC126674		
MGC126676		
MGC12676	AR	centronuclear myopathy 5, 615959 (3),
MGC126774		
MGC126834		
MGC126879		
MGC126880		
MGC126881		
MGC126882		
MGC126884		
MGC1269		
MGC1270		
MGC12815		
MGC12824	AD	smith-magenis syndrome, 182290 (3), isolated cases,
MGC12866	AR	?premature ovarian failure 10, 612885 (3),
MGC12901	AR	cerebellar ataxia, brain abnormalities, and cardiac conduction defects, 619576 (3),
MGC12921		
MGC12928		
MGC12936		
MGC1295		
MGC129526		
MGC129552		
MGC129553		
MGC129621	AR	trehalase deficiency, 612119 (3),
MGC129625		
MGC129647	AR,AD	agammaglobulinemia 8b, 619824 (3), ; agammaglobulinemia 8a, 616941 (3),
MGC129648	AR,AD	agammaglobulinemia 8b, 619824 (3), ; agammaglobulinemia 8a, 616941 (3),
MGC12966		
MGC1297		
MGC12972		
MGC12974		
MGC129793		
MGC12981	AR	congenital disorder of glycosylation, type iio, 616828 (3),
MGC129899		
MGC12992		
MGC129934		
MGC129935		
MGC130008		
MGC130009		
MGC13004		
MGC130048	AR	muscular dystrophy, limb-girdle, 5, 253700 (3),
MGC13007		
MGC13010		
MGC13016		
MGC13024		
MGC13034		
MGC13038		
MGC13040	AR	ciliary dyskinesia, primary, 38, 618063 (3),
MGC13057		
MGC13061		
MGC13090		
MGC13096		
MGC13102		
MGC13130		
MGC13138		
MGC1314		
MGC131524		
MGC131633	AR	?neurodevelopmental disorder with cerebellar hypoplasia and spasticity, 618572 (3),
MGC13168		
MGC13170		
MGC131802		
MGC131831		
MGC131950	AR	?tetra-amelia syndrome 1, 273395 (3),
MGC131980		
MGC132011		
MGC13204		
MGC132456		
MGC13250		
MGC13251	AD	glomerulosclerosis, focal segmental, 5, 613237 (3); charcot-marie-tooth disease, intermediate e, 614455 (3),
MGC132578		
MGC13261		
MGC13272		
MGC13275		
MGC132756		
MGC132758		
MGC133046	AR	enterokinase deficiency, 226200 (3),
MGC133107		
MGC133129		
MGC133236		
MGC133289		
MGC133384		
MGC13378	AR	lipoyltransferase 1 deficiency, 616299 (3),
MGC13379	AR	joubert syndrome 2, 608091 (3), ; meckel syndrome 2, 603194 (3),
MGC13453	AR	intellectual developmental disorder, 7, 611093 (3),
MGC1346		
MGC1348		
MGC134948		
MGC134949		
MGC13687		
MGC138140		
MGC138169		
MGC138173		
MGC138321	AR	?tetra-amelia syndrome 1, 273395 (3),
MGC138323	AR	?tetra-amelia syndrome 1, 273395 (3),
MGC138338		
MGC138344		
MGC138391		
MGC138401		
MGC138502	AD	?intellectual developmental disorder, 10, 614256 (3),
MGC138504	AD	?intellectual developmental disorder, 10, 614256 (3),
MGC138509		
MGC138534		
MGC138549	AD,AR,MF	supranuclear palsy, progressive, 601104 (3), ; supranuclear palsy, progressive atypical, 260540 (3), ; dementia, frontotemporal, with or without parkinsonism, 600274 (3), ; {parkinson disease, susceptibility to}, 168600 (3), ; pick disease, 172700 (3),
MGC138598		
MGC138628	AR	bare lymphocyte syndrome, type ii, complementation group b, 209920 (3),
MGC138724		
MGC138900		
MGC138901		
MGC1405		
MGC14126	AR	morbid obesity and spermatogenic failure, 615703 (3),
MGC14140		
MGC14151		
MGC14156	AR	hyperphosphatasia with impaired intellectual development syndrome 6, 616809 (3),
MGC14161	AD	neurodevelopmental disorder with eye movement abnormalities and ataxia, 620094 (3),
MGC141886		
MGC142200		
MGC142283		
MGC142285		
MGC142288		
MGC14254		
MGC14258		
MGC14274		
MGC14288	AR	?mitochondrial complex iv deficiency, nuclear type 10, 619053 (3),
MGC14326		
MGC14327		
MGC14333		
MGC14352		
MGC14353		
MGC14381		
MGC14386		
MGC14421		
MGC14439		
MGC14452	AR	mitochondrial complex i deficiency, nuclear type 20, 611126 (3),
MGC14480		
MGC14542		
MGC14553		
MGC14575		
MGC14613		
MGC14697	AR	mitochondrial complex v (atp synthase) deficiency, nuclear type 6, 618683 (3),
MGC14751		
MGC14793	AR	?leber congenital amaurosis 19, 618513 (3),
MGC14797	XLR,XL	borjeson-forssman-lehmann syndrome, 301900 (3),
MGC14798		
MGC14799		
MGC14801		
MGC14804		
MGC148044		
MGC14817		
MGC14832		
MGC14833	AR	mitochondrial complex iii deficiency, nuclear type 7, 615824 (3),
MGC14836		
MGC14879	AD	deafness, 85, 620227 (3),
MGC14896		
MGC14921		
MGC149260		
MGC149525		
MGC149526		
MGC14961		
MGC149659		
MGC14967		
MGC149845		
MGC149846		
MGC149868		
MGC14993	AR	pontocerebellar hypoplasia, type 6, 611523 (3),
MGC150517		
MGC150530		
MGC150539		
MGC150689		
MGC15092	AR	?proteasome-associated autoinflammatory syndrome 4, 619183 (3),
MGC15093		
MGC15161	XL	tonne-kalscheuer syndrome, 300978 (3),
MGC15171		
MGC15201		
MGC15204		
MGC15229		
MGC15254		
MGC15364		?sarcoma, synovial, 300813 (3)
MGC15366		
MGC15397		
MGC15419	AR	?intellectual developmental disorder, 45, 615979 (3),
MGC15435		
MGC15436		
MGC15438		
MGC15476		
MGC15482		
MGC15523		
MGC15548		
MGC15563		
MGC15619		
MGC15631	AR,AD	retinitis pigmentosa 95, 620102 (3), ; cone-rod dystrophy 11, 610381 (3), ; ?macular degeneration, age-related, 6, 613757 (3)
MGC15668	AR	neurodevelopmental disorder with progressive spasticity and brain white matter abnormalities, 619026 (3), ; spastic paraplegia 83, 619027 (3),
MGC15677		
MGC15718		
MGC15749		
MGC15754		
MGC15827		
MGC15831		
MGC15873	AR	neuropathy, hereditary motor and sensory, type vic, with optic atrophy, 618511 (3),
MGC15875	AR	[?phosphohydroxylysinuria], 615011 (3),
MGC15913	AR	retinitis pigmentosa 78, 617433 (3),
MGC15959		
MGC16028	AR	?cranioectodermal dysplasia 3, 614099 (3), ; ?retinitis pigmentosa 81, 617871 (3), ; short-rib thoracic dysplasia 18 with polydactyly, 617866 (3),
MGC1603		
MGC161462	AD	white sponge nevus 2, 615785 (3),
MGC16169	AR	hypotonia, infantile, with psychomotor retardation and characteristic facies 3, 616900 (3),
MGC16179		
MGC16202		
MGC16279		
MGC163408		
MGC163426		
MGC163428		
MGC16362		
MGC16372	AR	spermatogenic failure 80, 620222 (3), ; ciliary dyskinesia, primary, 21, 615294 (3),
MGC16435	AD	symmetric circumferential skin creases, congenital, 1, 156610 (3), ; cortical dysplasia, complex, with other brain malformations 6, 615771 (3),
MGC164581		
MGC16471		combined oxidative phosphorylation deficiency 56, 620139 (3)
MGC16491		
MGC16597		
MGC16619		
MGC16638		
MGC1665	AR	proteasome-associated autoinflammatory syndrome 5, 619175 (3),
MGC16664		
MGC1667		
MGC166915	AD	left ventricular noncompaction 8, 615373 (3), ; cardiomyopathy, dilated, 1ll, 615373 (3),
MGC167029	AD	deafness, 56, 615629 (3),
MGC16714	AR	?arthrogryposis, perthes disease, and upward gaze palsy, 614262 (3), ; nevus comedonicus, somatic, 617025 (3); lethal congenital contracture syndrome 10, 617022 (3),
MGC16733		
MGC16796		
MGC16817	AD	?hypotrichosis 5, 612841 (3),
MGC16824	AR	ritscher-schinzel syndrome 3, 619135 (3),
MGC16925	AR	intellectual developmental disorder, 75, with neuropsychiatric features and variant lissencephaly, 619827 (3),
MGC16973		
MGC1708		
MGC17125		
MGC17134		
MGC17150		
MGC17164		{hiv-1 disease, rapid progression of}, 609423 (3); {hiv-1 disease, delayed progression of}, 609423 (3)
MGC17211		
MGC17226		
MGC17303		
MGC17318		
MGC17330		
MGC17332		
MGC17342		
MGC17347		
MGC17403		
MGC17525		
MGC17528		
MGC17544		
MGC17552		
MGC17597		
MGC176705		
MGC17791		
MGC17810		
MGC17918		
MGC17921		
MGC17922		
MGC17973		
MGC17986		
MGC17998	AD	birt-hogg-dube syndrome, 135150 (3), ; colorectal cancer, somatic, 114500 (3); pneumothorax, primary spontaneous, 173600 (3), ; renal carcinoma, chromophobe, somatic, 144700 (3)
MGC18079		
MGC18216	AR,AD	insulin-like growth factor i, resistance to, 270450 (3),
MGC18257	AR	myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis, 620138 (3),
MGC1842		
MGC1892		
MGC1936	AR	neurodevelopmental disorder with facial dysmorphism, absent language, and pseudo-pelger-huet anomaly, 620075 (3),
MGC1947		
MGC19520	AR	mitochondrial complex iii deficiency, nuclear type 2, 615157 (3),
MGC19531		
MGC19535		
MGC19556		
MGC19570		
MGC19604	AR	mitochondrial myopathy, episodic, with optic atrophy and reversible leukoencephalopathy, 251900 (3),
MGC19606		
MGC19636		
MGC19641		
MGC19709		
MGC19722		
MGC19764		
MGC19780	AR	intellectual developmental disorder with epilepsy, behavioral abnormalities, and coarse facies, 619031 (3), ; myopathy, epilepsy, and progressive cerebral atrophy, 619036 (3), ; ?myasthenic syndrome, congenital, 15, without tubular aggregates, 616227 (3),
MGC19879		
MGC19907		
MGC20089		
MGC20134		
MGC20149		
MGC20197		
MGC20204		
MGC2022		
MGC20262		
MGC20339		
MGC20369		
MGC20372		
MGC20400		
MGC20410		
MGC20452		
MGC20461		
MGC20471		
MGC20481	AR	cardiofacioneurodevelopmental syndrome, 619123 (3),
MGC20486	AR	short-rib thoracic dysplasia 11 with or without polydactyly, 615633 (3),
MGC20533		
MGC20553		
MGC20625		
MGC20653		
MGC2068		
MGC20689		
MGC20700		
MGC20702		
MGC20706		
MGC20781		
MGC20785		
MGC20791		
MGC20838		
MGC20887		
MGC20962		
MGC20983	AR	ciliary dyskinesia, primary, 30, 616037 (3),
MGC2101		
MGC21336		
MGC21394		
MGC21416		
MGC21459		
MGC21482		
MGC2155		
MGC21559	AR	congenital disorder of glycosylation, type iu, 615042 (3),
MGC2156		
MGC2157		
MGC21621		
MGC21624		
MGC21636		
MGC21658		
MGC21674		
MGC2181		
MGC2182		
MGC21854		
MGC21874		
MGC21981		
MGC22014	AR,AD	beck-fahrner syndrome, 618798 (3),
MGC2217		
MGC22228		
MGC22429		
MGC22484		
MGC22487		
MGC22531		
MGC22554	AD	{asthma, susceptibility to}, 600807 (3), ; {hiv1, resistance to}, 609423 (3)
MGC22579	AR,AD	thrombophilia 7 due to antithrombin iii deficiency, 613118 (3),
MGC22581	AR	{46xy sex reversal 8, modifier of}, 614279 (3),
MGC22671	AR	muscular dystrophy, limb-girdle, 26, 618848 (3),
MGC22756		{myocardial infarction, susceptibility to}, 608446 (3)
MGC2277		
MGC22773		
MGC22776		
MGC22793		
MGC22825		
MGC22853		
MGC22916	AR	neurodevelopmental disorder with cerebellar atrophy and with or without seizures, 618056 (3), ; rigidity and multifocal seizure syndrome, lethal neonatal, 614498 (3),
MGC22921	XL,XLR	intellectual developmental disorder, 106, 300997 (3),
MGC22960		
MGC2297		
MGC23001		
MGC23008		
MGC23130	AR	?combined oxidative phosphorylation deficiency 49, 619024 (3),
MGC23164		
MGC2317		
MGC23214		
MGC23244		
MGC23280		
MGC2333		{myocardial infarction, susceptibility to}, 608446 (3)
MGC23410		
MGC23427		
MGC23445	AD	birt-hogg-dube syndrome, 135150 (3), ; colorectal cancer, somatic, 114500 (3); pneumothorax, primary spontaneous, 173600 (3), ; renal carcinoma, chromophobe, somatic, 144700 (3)
MGC23778	AR	pontocerebellar hypoplasia, type 6, 611523 (3),
MGC23846		{myocardial infarction, susceptibility to}, 608446 (3)
MGC23885		
MGC23909		
MGC23915		
MGC23920	AD	{?pancreatic cancer, susceptibility to, 5}, 618680 (3),
MGC23937		
MGC23940		
MGC23947		
MGC23980	AD	frontotemporal dementia and/or amyotrophic lateral sclerosis 1, 105550 (3),
MGC24009		
MGC24039		
MGC2404		
MGC24047		
MGC2408		
MGC24116		
MGC24132		
MGC24180		
MGC24381		
MGC24415		
MGC2454		
MGC24556		
MGC24596		
MGC2463		
MGC24652		
MGC24665		
MGC2480	AR	?mitochondrial complex i deficiency, nuclear type 39, 620135 (3),
MGC2485		
MGC2488		
MGC2491		
MGC24932		
MGC2494		
MGC24969		
MGC24974		
MGC24983		
MGC24986		
MGC24995		
MGC25043	AR	short stature, amelogenesis imperfecta, and skeletal dysplasia with scoliosis, 618363 (3),
MGC25062		
MGC25181	AR	d-2-hydroxyglutaric aciduria, 600721 (3),
MGC25497		
MGC2550		
MGC2553		
MGC2555		
MGC2560		
MGC2562	AR	mitochondrial complex iv deficiency, nuclear type 17, 619061 (3),
MGC2574		
MGC2599		
MGC2601		
MGC2603		
MGC26121	AR	perrault syndrome 4, 615300 (3), ; hydrops, lactic acidosis, and sideroblastic anemia, 617021 (3),
MGC26130		
MGC2615		
MGC26158		
MGC2616	AR	combined oxidative phosphorylation deficiency 32, 617664 (3),
MGC26189		
MGC26191		
MGC26194	AD	arrhythmogenic right ventricular dysplasia, familial, 13, 615616 (3),
MGC26226		
MGC26243		
MGC26259		
MGC26312		
MGC2633		
MGC26406		{spermatogenic failure, susceptibility to} (3)
MGC2642		
MGC26438		
MGC26458		bradyopsia 1, 608415 (3)
MGC2647		
MGC2650		
MGC26544	AR,AD	{hemolytic uremic syndrome, atypical, susceptibility to, 2}, 612922 (3),
MGC2655	AR	beaulieu-boycott-innes syndrome, 613680 (3),
MGC2656		
MGC26568		
MGC26577		
MGC26594		
MGC26605		
MGC26610		
MGC26642		
MGC26664		
MGC2668		
MGC26684		
MGC26694	AR	metabolic crises, recurrent, with variable encephalomyopathic features and neurologic regression, 618416 (3),
MGC26703		
MGC26706		
MGC26710		
MGC26719		
MGC26733	AR	?spinocerebellar ataxia, 22, 616948 (3),
MGC26740		
MGC26768		
MGC26778		
MGC26816		
MGC26833		
MGC26846		
MGC26847		
MGC26856		
MGC26949		
MGC2695	AR,AD	neurodevelopmental disorder with brain anomalies and with or without vertebral or cardiac anomalies, 618731 (3), ; 46xy sex reversal 11, 273250 (3),
MGC26954		
MGC26963	AD	calvarial doughnut lesions with bone fragility with or without spondylometaphyseal dysplasia, 126550 (3),
MGC26979	AR	nephronophthisis 11, 613550 (3), ; {bardet-biedl syndrome 14, modifier of}, 615991 (3), ; joubert syndrome 6, 610688 (3), ; meckel syndrome 3, 607361 (3), ; ?rhyns syndrome, 602152 (3), ; coach syndrome 1, 216360 (3),
MGC26988		
MGC26996		
MGC26999		
MGC27016		
MGC27027		
MGC27034	AR	microcephaly, short stature, and impaired glucose metabolism 1, 616033 (3),
MGC27044		
MGC2705		
MGC27076		
MGC27085		
MGC27091	AR	ichthyosis, congenital, 9, 615023 (3),
MGC27131		
MGC2714		
MGC27155		
MGC27170		
MGC27277		
MGC2731		
MGC27385		
MGC2742		
MGC27434		{glioma susceptibility 7}, 613032 (3)
MGC2744		
MGC2745		
MGC2749		
MGC2776	AR	pontocerebellar hypoplasia type 2b, 612389 (3),
MGC2793	AR	congenital myopathy 13, 255995 (3),
MGC2832		
MGC2835		
MGC2840	AR,AD	congenital disorder of glycosylation, type ih, 608104 (3), ; polycystic liver disease 3 with or without kidney cysts, 617874 (3),
MGC2865		
MGC2941		
MGC2948		
MGC29506		
MGC2963		
MGC29633		
MGC29634		
MGC29643		
MGC29667		
MGC29671		
MGC29736	AR	?mitochondrial complex v (atp synthase) deficiency, nuclear type 1, 604273 (3),
MGC29761		
MGC29784		
MGC29802		
MGC29816		
MGC29840	AR	psoriasis 14, pustular, 614204 (3),
MGC29843		
MGC29875		
MGC29949		
MGC29959		
MGC30022		
MGC30052		
MGC30156		
MGC30208		
MGC3032		
MGC3037		
MGC3040		
MGC3067		
MGC3077		
MGC3088	AR	deafness 106, 617637 (3),
MGC3090	AD,AR	?charcot-marie-tooth disease, axonal, type 2q, 615025 (3), ; alpha-aminoadipic and alpha-ketoadipic aciduria, 204750 (3),
MGC3101		
MGC3102		
MGC3103		
MGC3121		
MGC3130		
MGC3133		
MGC3162		
MGC3165		
MGC3169		
MGC3178		
MGC3180	AR	orofaciodigital syndrome xix, 620107 (3),
MGC3184		
MGC31930		
MGC31943	AD	paroxysmal nonkinesigenic dyskinesia 1, 118800 (3),
MGC3195		
MGC31963		
MGC3199		
MGC3200	AR	short stature, oligodontia, dysmorphic facies, and motor delay, 619234 (3),
MGC32020		
MGC32043		
MGC32056		
MGC32065		
MGC3207		
MGC3210		
MGC32104		
MGC3213		
MGC3222	AD	arrhythmogenic right ventricular dysplasia 5, 604400 (3), ; auditory neuropathy, 3, 619832 (3), ; emery-dreifuss muscular dystrophy 7, ad, 614302 (3),
MGC3232		
MGC3234		
MGC3248		
MGC3251		
MGC3262		
MGC32686		
MGC3279	AR	3mc syndrome 2, 265050 (3),
MGC32871		
MGC32921		
MGC3295		
MGC32955		
MGC32995	AD,AR	dowling-degos disease 4, 615696 (3), ; muscular dystrophy, limb-girdle, 21, 617232 (3),
MGC33124		
MGC33144		
MGC33147	AR	leukotriene c4 synthase deficiency, 614037 (1),
MGC33154		
MGC33177		
MGC33196	AR	short-rib thoracic dysplasia 7 with or without polydactyly, 614091 (3), ; cranioectodermal dysplasia 2, 613610 (3),
MGC33202		
MGC33211		
MGC33212	AR	short-rib thoracic dysplasia 17 with or without polydactyly, 617405 (3),
MGC33215		
MGC33302	AR	macular dystrophy with central cone involvement, 616170 (3), ; ceroid lipofuscinosis, neuronal, 7, 610951 (3),
MGC33310	AR	immunodeficiency 54, 609981 (3),
MGC33317		
MGC33329		
MGC33345		
MGC33365		
MGC33369	AR	spermatogenic failure 69, 619826 (3),
MGC33370		
MGC33382		
MGC33397		
MGC33407	AR	spermatogenic failure 53, 619258 (3),
MGC33414		
MGC33424		
MGC33442	AR	mitchell-riley syndrome, 615710 (3),
MGC33446		
MGC33463		
MGC33486	AD	episodic kinesigenic dyskinesia 3, 620245 (3),
MGC33548		
MGC33570		
MGC3358		
MGC33600		
MGC33607		
MGC33614		
MGC33630	AR	spermatogenic failure 33, 618152 (3),
MGC33662	AR	diabetes mellitus, neonatal, with congenital hypothyroidism, 610199 (3),
MGC33727	AD	leukodystrophy, hypomyelinating, 16, 617964 (3),
MGC33822		
MGC33835	AR	deafness, 67, 610265 (3),
MGC33843		
MGC33864		
MGC33884		
MGC33887	AR	spermatogenic failure 44, 619044 (3),
MGC33889		
MGC33901		
MGC33911		
MGC33947		
MGC33951	AR	?spermatogenic failure 59, 619645 (3),
MGC33953		
MGC33965		
MGC33971		
MGC33974		
MGC33977		
MGC3400		
MGC34032		
MGC34095		
MGC34275	AR	?muscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type b, 15, 618992 (3), ; muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 15, 612937 (3),
MGC34287		
MGC34328		{aspergillosis, susceptibility to}, 614079 (3)
MGC34403		
MGC34546		{rheumatoid arthritis, susceptibility to}, 180300 (3)
MGC34554		
MGC34646		
MGC34647		
MGC34680		
MGC34695		
MGC34705	AR	hypercholesterolemia, familial, 4, 603813 (3),
MGC34713	AR	polydactyly, postaxial, type a10, 618498 (3),
MGC34725		
MGC34741		
MGC34749		
MGC34750		
MGC34761		
MGC34763		
MGC34773		
MGC3479		
MGC34799		
MGC34821		
MGC34830		
MGC34831	XL,XLR	spermatogenic failure, 3, 301059 (3),
MGC34837		
MGC34869		
MGC34923		
MGC35010		
MGC35097	AR	{hodgkin lymphoma, susceptibility to}, 236000 (3),
MGC35145	AR	46xy gonadal dysgenesis with minifascicular neuropathy, 607080 (3), ; 46xy sex reversal 7, 233420 (3),
MGC35153	AD	lamb-shaffer syndrome, 616803 (3),
MGC35179		
MGC35182		
MGC35212	AR	?spermatogenic failure 22, 617706 (3),
MGC35227		
MGC35232		
MGC35261	XL,XLR	ciliary dyskinesia, primary, 36, 300991 (3),
MGC35285		
MGC35304	AR	ovarian dysgenesis 4, 616185 (3),
MGC35334	AR,AD	{encephalopathy, acute, infection-induced (herpes-specific), susceptibility to, 6}, 614850 (3),
MGC35338	AR	spermatogenic failure 40, 618664 (3),
MGC35352		
MGC35392		
MGC35423		
MGC35450		
MGC35521		
MGC35555	AR	?humerofemoral hypoplasia with radiotibial ray deficiency, 618022 (3), ; tetraamelia syndrome 2, 618021 (3),
MGC35570	AD	spastic paraplegia 6, 600363 (3),
MGC35575		
MGC3647		
MGC3736		
MGC3740		
MGC3781	AD	white sponge nevus 2, 615785 (3),
MGC3794		
MGC3803		
MGC3837		
MGC3844		
MGC3884		?sarcoma, synovial, 300813 (3)
MGC3925		
MGC39265		
MGC39325		
MGC3936		
MGC39366		
MGC39436		
MGC39488		
MGC39497		
MGC39558	AR	muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies, type a, 11, 615181 (3),
MGC39571		
MGC39581		
MGC39616		
MGC39650		
MGC39655		
MGC39671		
MGC39715		
MGC39724		
MGC39820		
MGC39821		
MGC39830		
MGC39900		
MGC39904		
MGC40042	AR	hydatidiform mole, recurrent, 3, 618431 (3),
MGC40051		
MGC40053		
MGC40107		
MGC40108		
MGC40195		
MGC40204		
MGC40214	AR	mitochondrial complex i deficiency, nuclear type 17, 618239 (3), ; fanconi renotubular syndrome 5, 618913 (3),
MGC4022		
MGC4027	AR	short-rib thoracic dysplasia 19 with or without polydactyly, 617895 (3),
MGC40368		
MGC40411		
MGC40413		
MGC40423	AD	corneal fleck dystrophy, 121850 (3),
MGC40441		
MGC40499		
MGC40555		
MGC40597		
MGC40611		
MGC40612		
MGC4083	AD	?facial palsy, congenital, with ptosis and velopharyngeal dysfunction, 617732 (3),
MGC4090		
MGC4093	AR	?meckel syndrome 10, 614175 (3), ; joubert syndrome 34, 614175 (3),
MGC4104		
MGC4147		
MGC4170	AR	mucolipidosis iii alpha/beta, 252600 (3), ; mucolipidosis ii alpha/beta, 252500 (3),
MGC4171		
MGC4172		
MGC4175		
MGC4189		
MGC41903		
MGC41905		
MGC41930		
MGC42174	AR	perlman syndrome, 267000 (3),
MGC42291		
MGC4248		
MGC42530		
MGC4266		
MGC4267	AR	dentici-novelli neurodevelopmental syndrome, 619877 (3),
MGC4276	AR	multiple mitochondrial dysfunctions syndrome 5, 617613 (3),
MGC4289		
MGC4293	AR	neurodevelopmental disorder with microcephaly, cerebral atrophy, and visual impairment, 620066 (3),
MGC43026		
MGC4309		
MGC4319		
MGC4322	AR,AD	neurodevelopmental disorder with brain anomalies and with or without vertebral or cardiac anomalies, 618731 (3), ; 46xy sex reversal 11, 273250 (3),
MGC43306		
MGC43321	AR	omenn syndrome, 603554 (3), ; severe combined immunodeficiency, b cell-negative, 601457 (3), ; combined cellular and humoral immune defects with granulomas, 233650 (3), ; alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity, 609889 (3)
MGC43399		
MGC4342		
MGC4365		
MGC4368	AR	chronic granulomatous disease 5, 618935 (3),
MGC4386		
MGC4399		
MGC4407		
MGC4415		
MGC4423		
MGC44287		
MGC44294		
MGC44316		
MGC44450	AD	intellectual developmental disorder, 57, 618050 (3),
MGC44669		
MGC44848		
MGC44868		
MGC44880		
MGC44903		
MGC44914		
MGC44947		
MGC45027		
MGC4504		
MGC4505		
MGC45269		
MGC45350		
MGC45411		
MGC45416		
MGC45417		
MGC45419		
MGC45428		
MGC45440		
MGC45441	AR	neurodevelopmental disorder with ataxia, hypotonia, and microcephaly, 618569 (3),
MGC45474		
MGC4549		
MGC45492	AR	finca syndrome, 618278 (3),
MGC4562		
MGC45714	AR	congenital disorder of glycosylation, type iip, 616829 (3),
MGC45771		
MGC45780		
MGC45819		
MGC45840		
MGC45866		
MGC45871		
MGC45873		
MGC45931		
MGC4595		
MGC4606		
MGC4607	AD	cerebral cavernous malformations-2, 603284 (3),
MGC46090	AD,AR	{epilepsy, juvenile myoclonic, susceptibility to, 10}, 617924 (3), ; endocrine-cerebroosteodysplasia, 612651 (3),
MGC46138		
MGC46173		
MGC4618		
MGC46204		
MGC46235		
MGC4631		
MGC46315		
MGC4638		
MGC4642		
MGC46424		
MGC4645		
MGC46502		
MGC4667		
MGC46680		
MGC46715		
MGC4701		
MGC4730		
MGC4758		
MGC4766		
MGC4767	AR	?coenzyme q10 deficiency, primary, 9, 619028 (3),
MGC47721		
MGC47799		
MGC47816		
MGC47890	AR	spinocerebellar ataxia, 10, 613728 (3),
MGC4796		
MGC4810		
MGC4816	AR	?premature ovarian failure 10, 612885 (3),
MGC4825		
MGC4832		
MGC48332		
MGC4840		
MGC4856		
MGC48898		
MGC48915		
MGC48935		
MGC48959		
MGC48972		
MGC4954		
MGC49942		
MGC5016		
MGC50337		
MGC50452		
MGC50559		
MGC5067		
MGC5070		
MGC50789	AR	seizures, early-onset, with neurodegeneration and brain calcification, 618875 (3),
MGC50811	AR	?spermatogenic failure 54, 619379 (3),
MGC50831	AR	deafness, 42, 609646 (3),
MGC50844		
MGC50896		
MGC5097		
MGC51008		
MGC51021		
MGC51029		
MGC51169		
MGC5140		
MGC5149	AR	growth retardation, developmental delay, facial dysmorphism, 612938 (3), ; {obesity, susceptibility to, bmiq14}, 612460 (3),
MGC5178		
MGC51822		
MGC51961		
MGC52010		
MGC52019		
MGC52022		
MGC52057		
MGC52110	AR	?mitochondrial complex iv, deficiency, nuclear type 9, 616500 (3),
MGC52123		
MGC52163		
MGC5228		
MGC5242		
MGC5244		
MGC52498		
MGC5254		
MGC5276		
MGC5297		
MGC5302		
MGC5306		
MGC5309		
MGC5347	AR	deafness, 119, 619615 (3), ; neurodevelopmental disorder with hearing loss and spasticity, 619616 (3),
MGC5350		
MGC5352		
MGC5370	AD,AR	{accelerated tumor formation, susceptibility to}, 614401 (3), ; ?lessel-kubisch syndrome, 618681 (3),
MGC5373		
MGC5395		
MGC54284		
MGC54289	AR	cone-rod dystrophy 21, 616502 (3),
MGC5469		
MGC5487		
MGC5499		
MGC5508		
MGC5528		
MGC5540		
MGC5560		
MGC5585	AR	?microcephaly 24, primary, 618179 (3),
MGC5601		
MGC5627		
MGC57125		
MGC57211		
MGC57297		
MGC57564	AD	spinocerebellar ataxia 14, 605361 (3),
MGC57793		
MGC57827		
MGC57858		
MGC59785		
MGC59868		
MGC60165	AD	myopia 21, 614167 (3),
MGC60291		
MGC61550		
MGC61571		
MGC61598		
MGC61633		
MGC61716		
MGC62094		
MGC64882		
MGC64923		
MGC65027		
MGC7036		
MGC70410	AD	myopia 21, 614167 (3),
MGC70651	AD,AR	?pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 9, 620400 (3), ; ?dyskeratosis congenita, 1, 224230 (3),
MGC70794		
MGC70925	XLR,XL	methylmalonic aciduria and homocysteinemia, cblx type, 309541 (3),
MGC71071		
MGC71150		
MGC71229		
MGC71252	AD	hypotrichosis 12, 615885 (3),
MGC71408		
MGC71744		
MGC71745		
MGC71751		
MGC71803		
MGC71805		
MGC71806		
MGC71859	AR	myasthenic syndrome, congenital, 24, presynaptic, 618198 (3),
MGC71873		
MGC71958		
MGC71973		
MGC71974		
MGC71975		
MGC7199	AD,AR	intellectual developmental disorder, 55, with seizures, 617831 (3), ; ?congenital disorder of glycosylation, type 1aa, 617082 (3),
MGC71993		
MGC71996	AD,AR	hyperferritinemia-cataract syndrome, 600886 (3), ; l-ferritin deficiency, and , 615604 (3), ; neurodegeneration with brain iron accumulation 3, 606159 (3),
MGC71997		
MGC71999		
MGC72007	AD	diamond-blackfan anemia 4, 612527 (3),
MGC72244		
MGC74461		
MGC74642		
MGC74969		
MGC75361		
MGC75490	XLR,XL	hypothyroidism, central, and testicular enlargement, 300888 (3),
MGC7807	AD	cardiac, facial, and digital anomalies with developmental delay, 618164 (3),
MGC78454	AR	spinocerebellar ataxia, 21, 616719 (3),
MGC78537		
MGC78563		
MGC78665		
MGC793	AR	mitochondrial complex i deficiency, nuclear type 37, 619272 (3),
MGC79382		
MGC79384		
MGC79398		
MGC79399		
MGC79402		
MGC800		
MGC8350		
MGC8385		
MGC8386	XLR,XL	bartter syndrome, type 5, antenatal, transient, 300971 (3),
MGC8394		
MGC8407		
MGC841	AR	striatonigral degeneration, infantile, 271930 (3),
MGC8421		
MGC8489		
MGC849		
MGC8530	AR	fetal akinesia deformation sequence 4, 618393 (3),
MGC8570		
MGC858		
MGC861		
MGC8664		
MGC8675		
MGC8685	AD	cortical dysplasia, complex, with other brain malformations 7, 610031 (3),
MGC8688		
MGC87009		{autoimmune disease, susceptibility to, 6}, 613551 (3)
MGC8721		
MGC87276		
MGC87400		
MGC87458	XLD,XL	fragile x tremor/ataxia syndrome, 300623 (3), ; fragile x syndrome, 300624 (3), ; premature ovarian failure 1, 311360 (3),
MGC87870		
MGC87886		
MGC88159		{?amyloidosis, secondary, susceptibility to} (1)
MGC882		
MGC8828	AD	{myeloproliferative/lymphoproliferative neoplasms, familial (multiple types), susceptibility to}, 616871 (3),
MGC88288	AD	precocious puberty, central, 2, 615346 (3),
MGC88387	AR	neurodegeneration with developmental delay, early respiratory failure, myoclonic seizures, and brain abnormalities, 620327 (3),
MGC8850		
MGC88819	AD	diamond-blackfan anemia 9, 613308 (3),
MGC8898		
MGC8902		
MGC8916		
MGC8941		
MGC90319	XL	?microphthalmia, syndromic 13, 300915 (3),
MGC90402		
MGC9042	AD,AR	congenital disorder of glycosylation, type iw, 619714 (3), ; congenital disorder of glycosylation, type iw, 615596 (3),
MGC90512		
MGC9084		
MGC9105	AD	amyotrophic lateral sclerosis 21, 606070 (3),
MGC9201		
MGC9294		
MGC9322		
MGC9326		
MGC9341		
MGC9379		
MGC9414		
MGC9434	AD	{mycobacterium tuberculosis, susceptibility to}, 607948 (3); {hiv-1, resistance to}, 609423 (3); {coronary artery disease, modifier of} (3); {spina bifida, susceptibility to}, 182940 (3),
MGC9454		
MGC9534		
MGC9564	AR	folate malabsorption, hereditary, 229050 (3),
MGC9568		
MGC9629		
MGC9721		
MGC9740		
MGC9753	AR	hyperphosphatasia with impaired intellectual development syndrome 4, 615716 (3),
MGC9850	AR,AD	treacher collins syndrome 2, 613717 (3),
MGC99481		
MGC99547	AD	faundes-banka syndrome, 619376 (3),
MGC99595		
MGC99832		
MGCA		
MGCR	AD	cebalid syndrome, 618774 (3), ; meningioma, 607174 (3),
MGCR1	AD	cebalid syndrome, 618774 (3), ; meningioma, 607174 (3),
MGCR1-PEN	AD	cebalid syndrome, 618774 (3), ; meningioma, 607174 (3),
MgcRabGAP		
MgcRacGAP	AR	?anemia, congenital dyserythropoietic, type iiib, 619789 (3),
MGDF	AD	thrombocythemia 1, 187950 (3),
MGEA		
MGEA11		
MGEA5		
MGEA6		
MGF	AD,AR	hyperpigmentation with or without hypopigmentation, 145250 (3), ; waardenburg syndrome, type 2f, 619947 (3), ; deafness, 69, unilateral or asymmetric, 616697 (3), ; [skin/hair/eye pigmentation 7, blond/brown hair], 611664 (3)
MGL		
Mgl1		
MGLL		
mGlu1	AR,AD	spinocerebellar ataxia, 13, 614831 (3), ; spinocerebellar ataxia 44, 617691 (3),
mGlu2		
mGlu3		
mGlu4		
mGlu5		
mGlu6	AR	night blindness, congenital stationary (complete), 1b, 257270 (3),
mGlu7	AR	neurodevelopmental disorder with seizures, hypotonia, and brain abnormalities, 618922 (3),
mGlu8		
MGLUR1	AR,AD	spinocerebellar ataxia, 13, 614831 (3), ; spinocerebellar ataxia 44, 617691 (3),
MGLUR2		
MGLUR3		
MGLUR4		
MGLUR5		
MGLUR6	AR	night blindness, congenital stationary (complete), 1b, 257270 (3),
MGLUR7	AR	neurodevelopmental disorder with seizures, hypotonia, and brain abnormalities, 618922 (3),
MGLUR8		
MGM1	AD,AR	optic atrophy plus syndrome, 125250 (3), ; {glaucoma, normal tension, susceptibility to}, 606657 (3); optic atrophy 1, 165500 (3), ; behr syndrome, 210000 (3), ; ?mitochondrial dna depletion syndrome 14 (encephalocardiomyopathic type), 616896 (3),
MGME1	AR	mitochondrial dna depletion syndrome 11, 615084 (3),
MGMT		
Mgn		
MGN2		
MGP	AR	keutel syndrome, 245150 (3),
MGR		
MGRN1		
MGSA		
MGSA-a		
MGSA-b		
MGST-I		
MGST-II		
MGST-IV		
MGST1		
MGST1-L1		
MGST1L1		
MGST2		
MGST3		
MgtE	AR	?nephronophthisis-like nephropathy 2, 619468 (3),
mgU12-22/U4-8		
mgU6-53		
MH99	AR,AD	diarrhea 5, with tufting enteropathy, congenital, 613217 (3), ; lynch syndrome 8, 613244 (3),
MHA	AD	macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss, 155100 (3), ; deafness, 17, 603622 (3),
MHAM	AD	{glioma susceptibility 2}, 613028 (3), ; {meningioma}, 607174 (3), ; cowden syndrome 1, 158350 (3), ; lhermitte-duclos disease, 158350 (3), ; prostate cancer, somatic, 176807 (3); macrocephaly/autism syndrome, 605309 (3),
MHBD	XLD,XL	hsd10 mitochondrial disease, 300438 (3),
MHC14		
MHC16	AD	?peripheral neuropathy, myopathy, hoarseness, and hearing loss, 614369 (3), ; deafness, 4a, 600652 (3),
MHC2TA	AR	{rheumatoid arthritis, susceptibility to}, 180300 (3); bare lymphocyte syndrome, type ii, complementation group a, 209920 (3),
MHCBFB	AR	cerebellar ataxia, neuropathy, and vestibular areflexia syndrome, 614575 (3),
MHF1		
MHF2		
MHP	AD	spinocerebellar ataxia 6, 183086 (3), ; episodic ataxia, type 2, 108500 (3), ; developmental and epileptic encephalopathy 42, 617106 (3), ; migraine, familial hemiplegic, 1, with progressive cerebellar ataxia, 141500 (3), ; migraine, familial hemiplegic, 1, 141500 (3),
MHP1	AD	spinocerebellar ataxia 6, 183086 (3), ; episodic ataxia, type 2, 108500 (3), ; developmental and epileptic encephalopathy 42, 617106 (3), ; migraine, familial hemiplegic, 1, with progressive cerebellar ataxia, 141500 (3), ; migraine, familial hemiplegic, 1, 141500 (3),
MHP2	AD,AR	developmental and epileptic encephalopathy 98, 619605 (3), ; fetal akinesia, respiratory insufficiency, microcephaly, polymicrogyria, and dysmorphic facies, 619602 (3), ; alternating hemiplegia of childhood 1, 104290 (3), ; migraine, familial basilar, 602481 (3), ; migraine, familial hemiplegic, 2, 602481 (3),
MHRT		
MHS	AR,AD	congenital myopathy 1b, 255320 (3), ; congenital myopathy 1a, with susceptibility to malignant hyperthermia, 117000 (3), ; king-denborough syndrome, 619542 (3), ; {malignant hyperthermia susceptibility 1}, 145600 (3),
MHS1	AR,AD	congenital myopathy 1b, 255320 (3), ; congenital myopathy 1a, with susceptibility to malignant hyperthermia, 117000 (3), ; king-denborough syndrome, 619542 (3), ; {malignant hyperthermia susceptibility 1}, 145600 (3),
MHS3	AR	developmental and epileptic encephalopathy 110, 620149 (3),
MHS4R2	AR	?orofaciodigital syndrome xviii, 617927 (3),
MHS5	AD,AR	{thyrotoxic periodic paralysis, susceptibility to, 1}, 188580 (3), ; congenital myopathy 18 due to dihydropyridine receptor defect, 620246 (3), ; hypokalemic periodic paralysis, type 1, 170400 (3), ; {malignant hyperthermia susceptibility 5}, 601887 (3),
MI	AD,AR	waardenburg syndrome, type 2a, 193510 (3), ; {melanoma, cutaneous malignant, susceptibility to, 8}, 614456 (3); tietz albinism-deafness syndrome, 103500 (3), ; commad syndrome, 617306 (3),
Mi-2a	AD	snijders blok-campeau syndrome, 618205 (3),
Mi-2b	AD	sifrim-hitz-weiss syndrome, 617159 (3),
MI-ER1		
Mi2-ALPHA	AD	snijders blok-campeau syndrome, 618205 (3),
Mi2-BETA	AD	sifrim-hitz-weiss syndrome, 617159 (3),
MIA		
MIA1		
MIA2		
MIA3	AR	?ondontochondrodysplasia 2 with hearing loss and diabetes, 619269 (3),
MIA40		
MIAL		
MIAL1		
MIAT		{myocardial infarction, susceptibility to}, 608446 (3)
MIB	AD	left ventricular noncompaction 7, 615092 (3),
MIB-1		
MIB1	AD	left ventricular noncompaction 7, 615092 (3),
MIB2		
MIBP		
MIBP1	AD	intellectual developmental disorder, 43, 616977 (3),
MIC-1		
MIC1		
Mic10		
MIC10	AR,AD	{hemolytic uremic syndrome, atypical, susceptibility to, 2}, 612922 (3),
MIC11	AR	hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy, 612300 (3),
MIC12	AR	combined oxidative phosphorylation deficiency 37, 618329 (3),
MIC13	AR	combined oxidative phosphorylation deficiency 37, 618329 (3),
MIC14		
MIC18	AR,AD	diarrhea 5, with tufting enteropathy, congenital, 613217 (3), ; lynch syndrome 8, 613244 (3),
Mic19		
MIC2		
Mic23		
Mic25		
MIC26		
Mic27		
MIC2L1		
MIC2X		
MIC2Y		
MIC3		
MIC4		[blood group, indian system], 609027 (3)
MIC5	XLR,XL	masa syndrome, 303350 (3), ; hydrocephalus, congenital, 307000 (3), ; ?corpus callosum, partial agenesis of, 304100 (3),
Mic60		
MICA		
MICAL		
MICAL-L1		
MICAL1		
MICAL2		
MICAL3		
MICALCL		
MICALL1		
MICB		
MICE	AR	ichthyosis, congenital, 12, 617320 (3),
MICL		
MICOS10		
MICOS13	AR	combined oxidative phosphorylation deficiency 37, 618329 (3),
MICOS19		
MICOS25		
MICOS26		
MICOS27		
MICOS60		
MICS1		
MICU1	AR	myopathy with extrapyramidal signs, 615673 (3),
MICU2		
MICU3		
MID1	XLR,XL	opitz gbbb syndrome, 300000 (3),
MID1IP1		
MID2	XL,XLR	?intellectual developmental disorder, 101, 300928 (3),
MiD49	AR	?combined oxidative phosphorylation deficiency 49, 619024 (3),
MiD51		
MidA		
MIDAS		
MIDN		
Midori	AR	cardiomyopathy, familial hypertrophic 27, 618052 (3),
MIEF1		
MIEF2	AR	?combined oxidative phosphorylation deficiency 49, 619024 (3),
MIEN1		
MIER1		
MIER2		
MIER3		
MIF	AR	{rheumatoid arthritis, systemic juvenile, susceptibility to}, 604302 (3)|persistent mullerian duct syndrome, type i, 261550 (3),
MIF-2		
Mif1		
MIF2		
MIF4GD		
MIFD		
MIFR		
MIFR-1		
MIG		
mig-14	AR	zaki syndrome, 619648 (3),
mig-2		
MIG-6		
MIG12		
MIG13	AR	neurodevelopmental disorder with seizures and speech and walking impairment, 618480 (3),
MIG2		
MIG2B	AR	leukocyte adhesion deficiency, type iii, 612840 (3),
MIG7		
MIGA1		
MIGA2		
migfilin		
MigR		
MIHB		
MIHC		
MIHG1		
MIIP		
MIL1		
MILD1		
Mili		
MILT1	AR	developmental and epileptic encephalopathy 68, 618201 (3),
MILT2		
MIM		
MIM1		
MIMA		
MIMB		
mimecan		
mimitin	AR	mitochondrial complex i deficiency, nuclear type 10, 618233 (3),
MIMP		
MIMT1		
MIN1	AR	hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy, 612300 (3),
MIN2	AR	hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy, 612300 (3),
MIN3	AR	hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy, 612300 (3),
MINA		
MINA53		
MINAR1		
MINAR2	AR	deafness, 120, 620238 (3),
MINCLE		
mINDY	AR	developmental and epileptic encephalopathy 25, with amelogenesis imperfecta, 615905 (3),
MINDY-1		
MINDY1		
MINDY2		
MINDY3		
Miner1	AR	wolfram syndrome 2, 604928 (3),
Miner2		
Minerva		
MINERVA		
MINION	AR	?carey-fineman-ziter syndrome 2, 619941 (3),
minK	AR,AD	jervell and lange-nielsen syndrome 2, 612347 (3), ; long qt syndrome 5, 613695 (3),
MINK		
MINK1		
Minna14		
MINOR		chondrosarcoma, extraskeletal myxoid, 612237 (3)
MINOS1		
MINOS2		
MINOS3		
MINPP1	AD,AR	{thyroid carcinoma, follicular}, 188470 (3), somatic mutation, ; pontocerebellar hypoplasia, type 16, 619527 (3),
MiNT		
MINT	AD	radio-tartaglia syndrome, 619312 (3),
MINT1		
MINT2		
mint3		
MIO		
MIO10		
MIOS		
MIOX		
MIP	AD,AR	cataract 15, multiple types, 615274 (3), |combined oxidative phosphorylation deficiency 31, 617228 (3),
MIP-1-alpha		{hiv infection, resistance to}, 609423 (2)
MIP-1-beta		
MIP-1d		
MIP-2a		
MIP-2A	XLR,XL	spondyloepiphyseal dysplasia tarda, 313400 (3),
MIP-2b		
MIP-2g		
MIP-3		
MIP-3a		
MIP-3b		
MIP-4		
MIP-4a		
MIP-4alpha		
MIP-5		
MIP-T3	AR	senior-loken syndrome 9, 616629 (3),
Mip1		
MIP1		
MIP120		
MIP18		
MIP1aR		
MIP224		
MIPEP	AR	combined oxidative phosphorylation deficiency 31, 617228 (3),
MIPOL1		
MIPP	AD,AR	{thyroid carcinoma, follicular}, 188470 (3), somatic mutation, ; pontocerebellar hypoplasia, type 16, 619527 (3),
MIPT3	AR	senior-loken syndrome 9, 616629 (3),
MIR		
MIR-10		
miR-122		
mir-128-1		
miR-137		
MIR-140	AD	spondyloepiphyseal dysplasia, nishimura type, 618618 (3),
MIR-145		
miR-17-92		
miR-182		
MIR-21		
miR-217		
MIR-27b		
miR-490		
MIR-7		
MIR1		
MIR1-1		
MIR1-2		
MIR10		
MIR100		
MIR100HG		
MIR101-1		
MIR101-2		
MIR103-1		
MIR103-2		
MIR103A1		
MIR103A2		
MIR105-1		
MIR105-2		
MIR106A		
MIR106B		
MIR107		
MIR10A		
MIR10B		
MIR1204HG		
MIR122		
MIR1224		
MIR1225		
MIR1231		
MIR124-1		
MIR1258		
MIR125A		
MIR125B1		
MIR125B2		
MIR126		
MIR1260B		
MIR127		
MIR128-1		
MIR128-2		
MIR1292		
MIR130A		
MIR130B		
MIR132		
MIR133A1		
MIR133A2		
MIR133B		
MIR133BHG		
MIR134		
MIR135B		
MIR136		
MIR137		
MIR138-1		
MIR138-2		
MIR139		
MIR140	AD	spondyloepiphyseal dysplasia, nishimura type, 618618 (3),
MIR141		
MIR142		
MIR143		
MIR144		
MIR145		
MIR146A		
MIR146B		
MIR147BHG		
MIR148A		
MIR148B		
MIR149		
MIR150		
MIR151		
MIR151A		
MIR152		
MIR155		
MIR15A		
MIR15AHG		
MIR15B		
MIR16		
MIR16-1		
MIR17		
MIR17HG		
MIR181A1		
MIR181A2		
MIR181B1		
MIR181B2		
MIR181C		
MIR182		
MIR183		
MIR184	AD	edict syndrome, 614303 (3),
MIR185		
MIR187		
MIR18A		
MIR190		
MIR1909		
MIR190A		
MIR191		
MIR1915		
MIR192		
MIR193A		
MIR193B		
MIR194-1		
MIR194-2		
MIR195		
MIR196A1		
MIR196A2		
MIR196B		
MIR197		
MIR199A1		
MIR199A2		
MIR199B		
MIR19A		
MIR19B1		
MIR19B2		
MIR200A		
MIR200B		
MIR200C		
MIR203		
MIR203A		
MIR204	AD	?retinal dystrophy and iris coloboma with or without cataract, 616722 (3),
MIR205		
MIR206		
MIR208A		
MIR208B		
MIR20A		
MIR20B		
MIR21		
MIR210		
MIR211		
MIR212		
MIR214		
MIR215		
MIR216A		
MIR217		
MIR218-1		
MIR218-2		
MIR219-1		
MIR219A1		
MIR22		
MIR221		
MIR222		
MIR223		
MIR224		
MIR23A		
MIR23B		
MIR24-1		
MIR24-2		
MIR25		
MIR26A1		
MIR26A2		
MIR26B		
MIR27A		
MIR27B		
MIR28		
MIR2861	AR,AD	[bone mineral density qtl 15], 613418 (3),
MIR296		
MIR297		
MIR298		
MIR29A		
MIR29B1		
MIR29B2		
MIR29C		
MIR301A		
MIR302A		
MIR302B		
MIR302C		
MIR302D		
MIR30A		
MIR30B		
MIR30C1		
MIR30D		
MIR30E		
MIR31		
MIR3120		
MIR31HG		
MIR32		
MIR320A		
MIR326		
MIR328		
MIR335		
MIR338		
MIR339		
MIR33A		
MIR33B		
MIR346		
MIR34A		
MIR34B		
MIR34C		
MIR365-1		
MIR365A		
MIR367		
MIR369		
MIR370		
MIR371		
MIR371A		
MIR372		
MIR373		
MIR374AHG		
MIR375		
MIR376A1		
MIR376A2		
MIR376B		
MIR376C		
MIR378		
MIR378A		
MIR379		
MIR380		
MIR409		
MIR410		
MIR424		
MIR4271		
MIR4276		
MIR429		
MIR431		
MIR433		
MIR4435-1HG		
MIR4435-2HG		
MIR4449		
MIR448		
MIR449A		
MIR449B		
MIR451		
MIR451A		
MIR4697HG		
MIR485		
MIR487B		
MIR489		
MIR490		
MIR492		
MIR494		
MIR495		
MIR497		
MIR499		
MIR499A		
MIR502		
MIR503		
MIR505		
MIR506		
MIR508		
MIR509-1		
MIR509-3		
MIR510		
MIR519D		
MIR520C		
MIR520G		
MIR520H		
MIR532		
MIR551A		
MIR558		
MIR570		
MIR574		
MIR590		
MIR610		
MIR616		
MIR648		
MIR650		
MIR656		
MIR659		
MIR661		
MIR671		
MIR675		
MIR675HG		
MIR7-1		
MIR718		
MIR766		
MIR7704HG		
MIR802		
MIR873		
MIR874		
MIR877		
MIR886		
MIR887		
MIR9-1		
MIR9-1HG		
MIR9-2		
MIR9-3		
MIR92A1		
MIR92A2		
MIR93		
MIR95		
MIR96	AD	deafness, 50, 613074 (3),
MIR98		
MIR99A		
MIR99AHG		
MIR99B		
MIRAB13		
MIRH1		
MIRHG1		
MIRK	AD	abdominal obesity-metabolic syndrome 3, 615812 (3),
MIRL	AR	hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy, 612300 (3),
MIRLET7A1		
MIRLET7A2		
MIRLET7A3		
MIRLET7B		
MIRLET7BHG		
MIRLET7C		
MIRLET7D		
MIRLET7E		
MIRLET7F1		
MIRLET7F2		
MIRLET7G		
MIRLET7I		
MIRLET7L		
MIRN1-1		
MIRN1-2		
MIRN100		
MIRN101-1		
MIRN101-2		
MIRN103-1		
MIRN103-2		
MIRN105-1		
MIRN105-2		
MIRN106A		
MIRN106B		
MIRN107		
MIRN10A		
MIRN10B		
MIRN122		
MIRN1224		
MIRN1225		
MIRN122A		
MIRN1231		
MIRN124-1		
MIRN124A1		
MIRN1258		
MIRN125A		
MIRN125B1		
MIRN125B2		
MIRN126		
MIRN127		
MIRN128-1		
MIRN128-2		
MIRN128A		
MIRN128B		
MIRN1292		
MIRN130A		
MIRN130B		
MIRN132		
MIRN133A1		
MIRN133A2		
MIRN133B		
MIRN134		
MIRN135B		
MIRN136		
MIRN137		
MIRN138-1		
MIRN138-2		
MIRN139		
MIRN140	AD	spondyloepiphyseal dysplasia, nishimura type, 618618 (3),
MIRN141		
MIRN142		
MIRN143		
MIRN144		
MIRN145		
MIRN146		
MIRN146A		
MIRN146B		
MIRN148		
MIRN148A		
MIRN148B		
MIRN149		
MIRN150		
MIRN151		
MIRN152		
MIRN155		
MIRN15A		
MIRN15B		
MIRN16-1		
MIRN17		
MIRN18		
MIRN181A		
MIRN181A1		
MIRN181A2		
MIRN181B1		
MIRN181B2		
MIRN181C		
MIRN182		
MIRN183		
MIRN184	AD	edict syndrome, 614303 (3),
MIRN185		
MIRN187		
MIRN18A		
MIRN190		
MIRN1909		
MIRN191		
MIRN1915		
MIRN192		
MIRN193		
MIRN193A		
MIRN193B		
MIRN194-1		
MIRN194-2		
MIRN195		
MIRN196-1		
MIRN196-2		
MIRN196A1		
MIRN196A2		
MIRN196B		
MIRN197		
MIRN199A1		
MIRN199A2		
MIRN199B		
MIRN19A		
MIRN19B1		
MIRN19B2		
MIRN20		
MIRN200A		
MIRN200B		
MIRN200C		
MIRN203		
MIRN204	AD	?retinal dystrophy and iris coloboma with or without cataract, 616722 (3),
MIRN205		
MIRN206		
MIRN208		
MIRN208A		
MIRN208B		
MIRN20A		
MIRN20B		
MIRN21		
MIRN210		
MIRN211		
MIRN212		
MIRN213		
MIRN214		
MIRN215		
MIRN216		
MIRN216A		
MIRN217		
MIRN218-1		
MIRN218-2		
MIRN219-1		
MIRN22		
MIRN221		
MIRN222		
MIRN223		
MIRN224		
MIRN23A		
MIRN23B		
MIRN24-1		
MIRN24-2		
MIRN25		
MIRN26A1		
MIRN26A2		
MIRN26B		
MIRN27A		
MIRN27B		
MIRN28		
MIRN29		
MIRN296		
MIRN297		
MIRN298		
MIRN29A		
MIRN29B1		
MIRN29B2		
MIRN29C		
MIRN301		
MIRN301A		
MIRN302		
MIRN302A		
MIRN302B		
MIRN302C		
MIRN302D		
MIRN30A		
MIRN30B		
MIRN30C1		
MIRN30D		
MIRN30E		
MIRN31		
MIRN32		
MIRN320		
MIRN320A		
MIRN326		
MIRN328		
MIRN33		
MIRN335		
MIRN338		
MIRN339		
MIRN33A		
MIRN33B		
MIRN346		
MIRN34A		
MIRN34B		
MIRN34C		
MIRN365-1		
MIRN367		
MIRN368		
MIRN369		
MIRN370		
MIRN371		
MIRN372		
MIRN373		
MIRN375		
MIRN376A		
MIRN376A1		
MIRN376A2		
MIRN376B		
MIRN376C		
MIRN378		
MIRN379		
MIRN380		
MIRN409		
MIRN410		
MIRN424		
MIRN429		
MIRN431		
MIRN433		
MIRN448		
MIRN449		
MIRN449A		
MIRN449B		
MIRN451		
MIRN485		
MIRN487B		
MIRN489		
MIRN490		
MIRN492		
MIRN494		
MIRN495		
MIRN497		
MIRN499		
MIRN502		
MIRN503		
MIRN505		
MIRN506		
MIRN508		
MIRN509		
MIRN509-1		
MIRN509-3		
MIRN510		
MIRN519D		
MIRN520C		
MIRN520G		
MIRN520H		
MIRN532		
MIRN551A		
MIRN558		
MIRN570		
MIRN574		
MIRN590		
MIRN610		
MIRN616		
MIRN648		
MIRN650		
MIRN656		
MIRN659		
MIRN661		
MIRN671		
MIRN675		
MIRN7-1		
MIRN766		
MIRN802		
MIRN873		
MIRN874		
MIRN877		
MIRN886		
MIRN887		
MIRN9-1		
MIRN9-2		
MIRN9-3		
MIRN92-1		
MIRN92-2		
MIRN92A1		
MIRN92A2		
MIRN93		
MIRN95		
MIRN96	AD	deafness, 50, 613074 (3),
MIRN98		
MIRN99A		
MIRN99B		
MIRNLET7A1		
MIRNLET7A2		
MIRNLET7A3		
MIRNLET7B		
MIRNLET7C		
MIRNLET7D		
MIRNLET7E		
MIRNLET7F1		
MIRNLET7F2		
MIRNLET7G		
MIRNLET7I		
MIRO-1		
MIRO-2		
MIRO1		
MIRO2		
MiRP1	AD	long qt syndrome 6, 613693 (3), ; atrial fibrillation, familial, 4, 611493 (3)
MiRP2		?brugada syndrome 6, 613119 (3)
MiRP3		
MIS	AR	persistent mullerian duct syndrome, type i, 261550 (3),
MIS12		
MIS13		
MIS14		
MIS18A		
MIS18B		
MIS18BP1		
Mis5	AD	lactase persistence/nonpersistence, 223100 (3),
Mis6		
misato	AR,AD	myopathy, mitochondrial, and ataxia, 617675 (3),
MISE		
MISP		
MISP1		
MISR2	AR	persistent mullerian duct syndrome, type ii, 261550 (3),
MISRII	AR	persistent mullerian duct syndrome, type ii, 261550 (3),
MIST		
MIST1		
MISTR1	AR	?mitochondrial complex iv deficiency, nuclear type 21, 619065 (3),
MISTRAV		
Misu	AR	intellectual developmental disorder, 5, 611091 (3),
MIT1	AD	hypogonadotropic hypogonadism 4 with or without anosmia, 610628 (3),
MITA	AD	sting-associated vasculopathy, infantile-onset, 615934 (3),
mitAAT	AR	developmental and epileptic encephalopathy 82, 618721 (3),
MITAP1		
MITF	AD,AR	waardenburg syndrome, type 2a, 193510 (3), ; {melanoma, cutaneous malignant, susceptibility to, 8}, 614456 (3); tietz albinism-deafness syndrome, 103500 (3), ; commad syndrome, 617306 (3),
MITOL		
mitoNEET		
MITOSUR		
MITR		
MITRAC12	AR	?mitochondrial complex iv deficiency, nuclear type 14, 619058 (3),
MITRAC15		
MITRAC7		
MIWC		
Miwi2		
MIX14		
MIX17A	AD	?myopathy, isolated mitochondrial, 616209 (3), ; spinal muscular atrophy, jokela type, 615048 (3), ; frontotemporal dementia and/or amyotrophic lateral sclerosis 2, 615911 (3),
MIX17B	AD	parkinson disease 22, 616710 (3),
MIXL		
MIXL1		
miz		
MIZ	AD	neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies, 618659 (3),
MIZ1		
MIZF		
MIZIP		
MJD	AD	machado-joseph disease, 109150 (3),
MJDL		
MK	AR,AD	hyper-igd syndrome, 260920 (3), ; porokeratosis 3, multiple types, 175900 (3), ; mevalonic aciduria, 610377 (3),
MK-1	AR,AD	diarrhea 5, with tufting enteropathy, congenital, 613217 (3), ; lynch syndrome 8, 613244 (3),
MK-3	AD	?macular dystrophy, patterned, 3, 617111 (3),
MK-STYX		
MK2		
MK2S4		
MK3	AD	?macular dystrophy, patterned, 3, 617111 (3),
MK5	AR	neurocardiofaciodigital syndrome, 619869 (3),
MKBP		
MKI67		
MKI67IP		
MKK3		
MKK4		
MKK6		
MKK7		
MKKS	AR	mckusick-kaufman syndrome, 236700 (3), ; bardet-biedl syndrome 6, 605231 (3),
MKL	AR	?immunodeficiency 66, 618847 (3),
MKL1	AR	?immunodeficiency 66, 618847 (3),
MKL2		
MKLN1		
MKLN1-AS1		
MKLP-1	AD	anemia, congenital dyserythropoietic, type iiia, 105600 (3),
MKLP1	AD	anemia, congenital dyserythropoietic, type iiia, 105600 (3),
MKLP2	AR	?cardiomyopathy, familial restrictive, 6, 619433 (3),
MKNK1		
MKNK2		
MKP-1		
MKP-2		
MKP-3	AD	hypogonadotropic hypogonadism 19 with or without anosmia, 615269 (3),
MKP-4		
MKP-5		
MKP-7		
MKP-L		
MKP-X		
MKP4		
MKP5		
MKP6		
MKP7		
MKPX		
mkr5		
MKRN1		
MKRN2		
MKRN3	AD	precocious puberty, central, 2, 615346 (3),
MKRN3-AS		
MKRN3-AS1		
MKRN3AS		
MKS	AR	bardet-biedl syndrome 13, 615990 (3), ; meckel syndrome 1, 249000 (3), ; joubert syndrome 28, 617121 (3),
MKS1	AR	bardet-biedl syndrome 13, 615990 (3), ; meckel syndrome 1, 249000 (3), ; joubert syndrome 28, 617121 (3),
MKS10	AR	?meckel syndrome 10, 614175 (3), ; joubert syndrome 34, 614175 (3),
MKS11	AR	joubert syndrome 20, 614970 (3), ; meckel syndrome 11, 615397 (3),
MKS13	AR	orofaciodigital syndrome xvi, 617563 (3), ; meckel syndrome 13, 617562 (3), ; ?joubert syndrome 29, 617562 (3),
MKS2	AR	joubert syndrome 2, 608091 (3), ; meckel syndrome 2, 603194 (3),
MKS3	AR	nephronophthisis 11, 613550 (3), ; {bardet-biedl syndrome 14, modifier of}, 615991 (3), ; joubert syndrome 6, 610688 (3), ; meckel syndrome 3, 607361 (3), ; ?rhyns syndrome, 602152 (3), ; coach syndrome 1, 216360 (3),
MKS4	AR	leber congenital amaurosis 10, 611755 (3); joubert syndrome 5, 610188 (3), ; senior-loken syndrome 6, 610189 (3), ; ?bardet-biedl syndrome 14, 615991 (3), ; meckel syndrome 4, 611134 (3),
MKS5	AR	joubert syndrome 7, 611560 (3), ; meckel syndrome 5, 611561 (3), ; ?coach syndrome 3, 619113 (3),
MKS6	AR	coach syndrome 2, 619111 (3), ; retinitis pigmentosa 93, 619845 (3), ; meckel syndrome 6, 612284 (3), ; joubert syndrome 9, 612285 (3),
MKS7	AR	nephronophthisis 3, 604387 (3), ; renal-hepatic-pancreatic dysplasia 1, 208540 (3), ; meckel syndrome 7, 267010 (3),
MKS8	AR	joubert syndrome 24, 616654 (3), ; ?meckel syndrome 8, 613885 (3),
MKS9	AR	?meckel syndrome 9, 614209 (3), ; joubert syndrome 27, 617120 (3),
MKSR-1	AR	?meckel syndrome 9, 614209 (3), ; joubert syndrome 27, 617120 (3),
MKSR-2	AR	?meckel syndrome 10, 614175 (3), ; joubert syndrome 34, 614175 (3),
MKX		
ML-1	AD,AR	?candidiasis, familial, 6, 613956 (3)|?cerebellar ataxia, impaired intellectual development, and dysequilibrium syndrome 4, 615268 (3),
ML-IAP		
ML1	AD	?candidiasis, familial, 6, 613956 (3)
ML4	AR	mucolipidosis iv, 252650 (3),
ML7		
ML8		
MLA1		
MLANA		
MLASA1	AR	myopathy, lactic acidosis, and sideroblastic anemia 1, 600462 (3),
MLAT4	AR	myopia, high, with cataract and vitreoretinal degeneration, 614292 (3),
MLC	AR	megalencephalic leukoencephalopathy with subcortical cysts 1, 604004 (3),
MLC-1	AR	congenital myopathy 14, 618414 (3),
MLC1	AR,AR	congenital myopathy 14, 618414 (3), |megalencephalic leukoencephalopathy with subcortical cysts 1, 604004 (3),
MLC1/3	AR	congenital myopathy 14, 618414 (3),
MLC1F	AR	congenital myopathy 14, 618414 (3),
MLC1SA		
MLC1SB	AR,AD	cardiomyopathy, hypertrophic, 8, 608751 (3),
MLC1SM		
MLC1V	AR,AD	cardiomyopathy, hypertrophic, 8, 608751 (3),
MLC2	AR	?megacystis-microcolon-intestinal hypoperistalsis syndrome 4, 619365 (3),
MLC3F	AR	congenital myopathy 14, 618414 (3),
MLC3NM		
MLCK	AR,AD	megacystis-microcolon-intestinal hypoperistalsis syndrome 1, 249210 (3), ; aortic aneurysm, familial thoracic 7, 613780 (3),
MLCK1	AR,AD	megacystis-microcolon-intestinal hypoperistalsis syndrome 1, 249210 (3), ; aortic aneurysm, familial thoracic 7, 613780 (3),
MLCK108	AR,AD	megacystis-microcolon-intestinal hypoperistalsis syndrome 1, 249210 (3), ; aortic aneurysm, familial thoracic 7, 613780 (3),
MLCK2	AD	cardiomyopathy, hypertrophic, 1, digenic, 192600 (3), digenic ,
MLCK210	AR,AD	megacystis-microcolon-intestinal hypoperistalsis syndrome 1, 249210 (3), ; aortic aneurysm, familial thoracic 7, 613780 (3),
MLD	AR	leukodystrophy, hypomyelinating, 18, 618404 (3),
MLDP		
MLEC		
MLEL1		
mlemp	AR	deafness, 18b, 614945 (3),
MLF1		
MLF1IP		
MLF2		
MLH-1	AD,AR	lynch syndrome 2, 609310 (3); muir-torre syndrome, 158320 (3), ; mismatch repair cancer syndrome 1, 276300 (3),
MLH1	AD,AR	lynch syndrome 2, 609310 (3); muir-torre syndrome, 158320 (3), ; mismatch repair cancer syndrome 1, 276300 (3),
MLH2		
MLH3	AD	{endometrial cancer, susceptibility to}, 608089 (3), somatic mutation, ; colorectal cancer, somatic, 114500 (3); colorectal cancer, hereditary nonpolyposis, type 7, 614385 (3)
MLH4	AR	lynch syndrome 4, 614337 (3); mismatch repair cancer syndrome 4, 619101 (3),
mliap		
MLIP	AR	myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis, 620138 (3),
MLIV	AR	mucolipidosis iv, 252650 (3),
MLK1		
MLK2		
MLK3		
MLK4		
MLK7	AR	centronuclear myopathy 6 with fiber-type disproportion, 617760 (3), ; split-foot malformation with mesoaxial polydactyly, 616890 (3),
MLKL		
MLL	AD	wiedemann-steiner syndrome, 605130 (3),
MLL1	AD	wiedemann-steiner syndrome, 605130 (3),
MLL1A	AD	wiedemann-steiner syndrome, 605130 (3),
MLL1B	AD	intellectual developmental disorder, 68, 619934 (3), ; dystonia 28, childhood-onset, 617284 (3),
MLL2	AD,AD	branchial arch abnormalities, choanal atresia, athelia, hearing loss, and hypothyroidism syndrome, 620186 (3), ; kabuki syndrome 1, 147920 (3), |intellectual developmental disorder, 68, 619934 (3), ; dystonia 28, childhood-onset, 617284 (3),
MLL3	AD	kleefstra syndrome 2, 617768 (3),
MLL4	AD,AD	branchial arch abnormalities, choanal atresia, athelia, hearing loss, and hypothyroidism syndrome, 620186 (3), ; kabuki syndrome 1, 147920 (3), |intellectual developmental disorder, 68, 619934 (3), ; dystonia 28, childhood-onset, 617284 (3),
MLL5	AD	o'donnell-luria-rodan syndrome, 618512 (3),
MLLT1		
MLLT10	AD	leukemia, acute myeloid, 601626 (3), somatic mutation,
MLLT11		
MLLT2		
MLLT2-like	AD	kinsship syndrome, 619297 (3),
MLLT3		
MLLT4		
MLLT5		
MLLT6		
MLLT7		
MLM	AD	{melanoma and neural system tumor syndrome}, 155755 (3), ; {melanoma, cutaneous malignant, 2}, 155601 (3), ; {melanoma-pancreatic cancer syndrome}, 606719 (3),
MLN		
MLN-19	AR	gastric cancer, somatic, 613659 (3); adenocarcinoma of lung, somatic, 211980 (3); ovarian cancer, somatic, 167000 (3); ?visceral neuropathy, familial, 2, 619465 (3), ; glioblastoma, somatic, 137800 (3)
MLN50		
MLN51		
MLN62		
MLN64		
MLNR		
MLP	AD	?cardiomyopathy, dilated, 1m, 607482 (3); cardiomyopathy, hypertrophic, 12, 612124 (3),
MLP1	AR,AD	pseudoxanthoma elasticum, 264800 (3), ; arterial calcification, generalized, of infancy, 2, 614473 (3), ; pseudoxanthoma elasticum, forme fruste, 177850 (3),
MLP2		
MLPH	AR	griscelli syndrome, type 3, 609227 (3),
MLPH1		
MLPH2		
MLQ		
MLR	AD	pseudohypoaldosteronism type i, 177735 (3), ; hypertension, early-onset, with exacerbation in pregnancy, 605115 (3)
MLR1		
MLR2		
MLRQ	AR	?mitochondrial complex iv deficiency, nuclear type 21, 619065 (3),
MLS	XLD,XL	linear skin defects with multiple congenital anomalies 1, 309801 (3),
MLSN1	AR	night blindness, congenital stationary (complete), 1c, 613216 (3)
MLST8		
MLSTD1		
MLSTD2	AR,AD	peroxisomal fatty acyl-coa reductase 1 disorder, 616154 (3), ; cataracts, spastic paraparesis, and speech delay, 619338 (3),
MLT	AR	immunodeficiency 12, 615468 (3),
Mlt1		
MLTFI		{hyperlipidemia, familial combined, susceptibility to}, 602491 (3)
MLTK	AR	centronuclear myopathy 6 with fiber-type disproportion, 617760 (3), ; split-foot malformation with mesoaxial polydactyly, 616890 (3),
MLTKalpha	AR	centronuclear myopathy 6 with fiber-type disproportion, 617760 (3), ; split-foot malformation with mesoaxial polydactyly, 616890 (3),
MLTKbeta	AR	centronuclear myopathy 6 with fiber-type disproportion, 617760 (3), ; split-foot malformation with mesoaxial polydactyly, 616890 (3),
MLTN		
MLTNB		
Mltng	AR	cone-rod dystrophy 9, 612775 (3),
MLVAR	AD	basal ganglia calcification, idiopathic, 1, 213600 (3),
MLX		
MLXIP		
MLXIPL		
mLY9		
MLYCD	AR	malonyl-coa decarboxylase deficiency, 248360 (3),
MLZE		
MM-1		
MM-TRAG		
MM1		
MM130		
MM28		
MM46		
Mm47		
MMA		
MMA-1a		
MMA-1b		
MMAA	AR	methylmalonic aciduria, vitamin b12-responsive, cbla type, 251100 (3),
MMAB	AR	methylmalonic aciduria, vitamin b12-responsive, cblb type, 251110 (3),
MMAC1	AD	{glioma susceptibility 2}, 613028 (3), ; {meningioma}, 607174 (3), ; cowden syndrome 1, 158350 (3), ; lhermitte-duclos disease, 158350 (3), ; prostate cancer, somatic, 176807 (3); macrocephaly/autism syndrome, 605309 (3),
MMACHC	AR	methylmalonic aciduria and homocystinuria, cblc type, 277400 (3),
MMADHC	AR	methylmalonic aciduria, cbld type, variant 2, 277410 (3), ; methylmalonic aciduria and homocystinuria, cbld type, 277410 (3), ; homocystinuria, cbld type, variant 1, 277410 (3),
MMAP		
MMCE	AR	methylmalonyl-coa epimerase deficiency, 251120 (3),
MMD		
MMD2		
MME	AD,AR	?spinocerebellar ataxia 43, 617018 (3), ; charcot-marie-tooth disease, axonal, type 2t, 617017 (3),
MMEL1		
MMEL2		
MMGL		
MMGT1		
Mmip-2		
MMP-25		
MMP-28		
MMP1	AR	copd, rate of decline of lung function in, 606963 (3); {epidermolysis bullosa dystrophica, modifier of}, 226600 (3),
MMP10		
MMP11		
MMP12		
MMP13	AD,AR	?spondyloepimetaphyseal dysplasia, missouri type, 602111 (3), ; metaphyseal anadysplasia 1, 602111 (3), ; metaphyseal dysplasia, spahr type, 250400 (3),
MMP14		?winchester syndrome, 277950 (3)
MMP15		
MMP16		
MMP17		
MMP18	AD	cavitary optic disc anomalies, 611543 (3),
MMP19	AD	cavitary optic disc anomalies, 611543 (3),
MMP2	AR	multicentric osteolysis, nodulosis, and arthropathy, 259600 (3),
MMP20	AR	amelogenesis imperfecta, type iia2, 612529 (3),
MMP21	AR,AR	heterotaxy, visceral, 7, 616749 (3), |heterotaxy, visceral, 7, 616749 (3),
MMP22		
MMP23A		
MMP23B		
MMP24		
MMP25		
MMP26		
MMP27		
MMP28		
MMP3		{coronary heart disease, susceptibility to, 6}, 614466 (3)
MMP7		
MMP8		
MMP9	AR	metaphyseal anadysplasia 2, 613073 (3),
MMPL1		
MMRN		
MMRN1		
MMRN2		
Mmrp19		
MMS19		
MMS19L		
MMS2		
MMS21	AR	seckel syndrome 10, 617253 (3),
MMS22L		
MMS4L		
MMSDH	AR	methylmalonate semialdehyde dehydrogenase deficiency, 614105 (3),
MMSET	AD	rauch-steindl syndrome, 619695 (3),
MMTN	AR	mitochondrial complex i deficiency, nuclear type 10, 618233 (3),
MMTRA1B		
MMUT	AR	methylmalonic aciduria, mut(0) type, 251000 (3),
MN		{malaria, resistance to}, 611162 (3); [blood group, mnss system], 111300 (3)
MN1	AD	cebalid syndrome, 618774 (3), ; meningioma, 607174 (3),
MNAB		
MNADK	AR	2,4-dienoyl-coa reductase deficiency, 616034 (3),
MNAR		
MNAT1		
MNBH	AD	intellectual developmental disorder, 7, 614104 (3),
MND1		
MNDA		
MNEI		
MNF1	AR	mitochondrial complex iii deficiency, nuclear type 7, 615824 (3),
MNG1	AD	pleuropulmonary blastoma, 601200 (3), ; goiter, multinodular 1, with or without sertoli-leydig cell tumors, 138800 (3), ; glow syndrome, somatic mosaic, 618272 (3); rhabdomyosarcoma, embryonal, 2, 180295 (3)
MNGIE	AR	mitochondrial dna depletion syndrome 1 (mngie type), 603041 (3),
MNK	XLR,XL	occipital horn syndrome, 304150 (3), ; spinal muscular atrophy, distal, 3, 300489 (3), ; menkes disease, 309400 (3),
MNK1		
MNK2		
MNLL		
MNPEP		
MNR	AR	?orofaciodigital syndrome xv, 617127 (3), ; ?joubert syndrome 38, 619476 (3), ; short-rib thoracic dysplasia 21 without polydactyly, 619479 (3),
Mnrp41		
MNRR1	AD	parkinson disease 22, 616710 (3),
MNS		[blood group, ss], 111740 (3); {malaria, resistance to}, 611162 (3)|{malaria, resistance to}, 611162 (3); [blood group, mnss system], 111300 (3)
MNS1	AR	heterotaxy, visceral, 9, with male infertility, 618948 (3),
MNSFbeta		
MnSOD		{microvascular complications of diabetes 6}, 612634 (3)
MNT		
MNX	AD	monilethrix, 158000 (3),
MNX1	AD	currarino syndrome, 176450 (3),
MO15		
MO25		
MO2L		
MOAP1		
MOAT-B		
MOAT-C		
MOAT-D		
MOATB		
MOB		
mob-1		
Mob-5		
MOB1		
MOB1A		
MOB1B		
MOB1D		
MOB2		
MOB3		
MOB3B		
MOB4		
MOB4A		
Mob4B		
MOBK1B		
MOBKL1A		
MOBKL1B		
MOBKL2B		
MOBKL3		
MOBP		
MOC-31	AR,AD	diarrhea 5, with tufting enteropathy, congenital, 613217 (3), ; lynch syndrome 8, 613244 (3),
MOC31	AR,AD	diarrhea 5, with tufting enteropathy, congenital, 613217 (3), ; lynch syndrome 8, 613244 (3),
MOCA	AR	neurodevelopmental disorder with impaired intellectual development, hypotonia, and ataxia, 618292 (3),
MOCCI		
MOCO1	AR	molybdenum cofactor deficiency b, 252160 (3),
MOCOD	AR	molybdenum cofactor deficiency a, 252150 (3),
MOCOS	AR	xanthinuria, type ii, 603592 (3),
MOCS1	AR	molybdenum cofactor deficiency a, 252150 (3),
MOCS2	AR	molybdenum cofactor deficiency b, 252160 (3),
MOCS2A	AR	molybdenum cofactor deficiency b, 252160 (3),
MOCS2B	AR	molybdenum cofactor deficiency b, 252160 (3),
MOCS3		
MOD1		
MODY	AD	fanconi renotubular syndrome 4, with maturity-onset diabetes of the young, 616026 (3), ; {diabetes mellitus, noninsulin-dependent}, 125853 (3), ; mody, type i, 125850 (3),
MODY1	AD	fanconi renotubular syndrome 4, with maturity-onset diabetes of the young, 616026 (3), ; {diabetes mellitus, noninsulin-dependent}, 125853 (3), ; mody, type i, 125850 (3),
MODY2	AD,AR	mody, type ii, 125851 (3), ; diabetes mellitus, permanent neonatal 1, 606176 (3), ; hyperinsulinemic hypoglycemia, familial, 3, 602485 (3), ; diabetes mellitus, noninsulin-dependent, late onset, 125853 (3),
MODY3	AD,AR	hepatic adenoma, somatic, 142330 (3); diabetes mellitus, insulin-dependent, 20, 612520 (3); {diabetes mellitus, noninsulin-dependent, 2}, 125853 (3), ; mody, type iii, 600496 (3), ; {diabetes mellitus, insulin-dependent}, 222100 (3), ; renal cell carcinoma, 144700 (3)
MODY4	AD,AR	{diabetes mellitus, type ii, susceptibility to}, 125853 (3), ; pancreatic agenesis 1, 260370 (3), ; mody, type iv, 606392 (3)
MODY5	AD	type 2 diabetes mellitus, 125853 (3), ; renal cysts and diabetes syndrome, 137920 (3), ; {renal cell carcinoma}, 144700 (3)
MODY6	AD	{type 2 diabetes mellitus, susceptibility to}, 125853 (3), ; maturity-onset diabetes of the young 6, 606394 (3)
MODY7		maturity-onset diabetes of the young, type vii, 610508 (3)
MODY8	AD	maturity-onset diabetes of the young, type viii, 609812 (3),
MODY9	AR,AD	{diabetes mellitus, ketosis-prone, susceptibility to}, 612227 (3), ; maturity-onset diabetes of the young, type ix, 612225 (3); diabetes mellitus, type 2, 125853 (3),
MOF	AD	li-ghorgani-weisz-hubshman syndrome, 618974 (3),
MOG	AD	?narcolepsy 7, 614250 (3),
MOG1		
MOGAT1		
MOGAT2		
MOGAT3		
MOGS	AR	congenital disorder of glycosylation, type iib, 606056 (3),
MOK		
MOK2		
MOKA	AD	neuronopathy, distal hereditary motor, type iid, 615575 (3),
mol		
MOLT		
MOM19		
MON1A		
MON1B		
MON2		
Mona		
Monad		
MONAP		
Monarch1	AD	familial cold autoinflammatory syndrome 2, 611762 (3),
MONC		
MONDOA		
MONDOB		
MOP		
MOP-5	AD,AR	?chilblain lupus 2, 614415 (3), ; aicardi-goutieres syndrome 5, 612952 (3),
MOP1		
MOP2	AD	erythrocytosis, familial, 4, 611783 (3),
MOP3		
MOP4		
MOP5		
MOP6		
MOP7		
MOP9		
MOR1		
MORC		
MORC1		
MORC2	AD	charcot-marie-tooth disease, axonal, type 2z, 616688 (3), ; developmental delay, impaired growth, dysmorphic facies, and axonal neuropathy, 619090 (3),
MORC3		
MORC4		
Morf	AD	sbbyss syndrome, 603736 (3), ; genitopatellar syndrome, 606170 (3),
MORF4		
MORF4L1		
MORF4L2		
MORFRG15		
MORG1		
MORN4		
MORN5		
morpheus		
MORRBID		
MORT1	AR	immunodeficiency 90 with encephalopathy, functional hyposplenia, and hepatic dysfunction, 613759 (3),
MOS	AR,AR	oocyte/zygote/embryo maturation arrest 20, 620383 (3), |xanthinuria, type ii, 603592 (3),
Mos2		
MOSC1		
MOSC2		
MOSP		
MOSPD1		
MOSPD2		
MOSPD3		
MOST-1		
mot-2	AR,AD	even-plus syndrome, 616854 (3), ; anemia, sideroblastic, 4, 182170 (3),
MOT1		
MOT17		
MOT25	AR	retinitis pigmentosa 64, 614500 (3), ; cone-rod dystrophy 16, 614500 (3), ; bardet-biedl syndrome 21, 617406 (3),
MOT48		
MOT8		
MOV-34		
MOV10		
MOV10L1	AR	?spermatogenic failure 73, 619878 (3),
MOV34		
MOV34-34KD		
MOX		
MOX1	AR	klippel-feil syndrome 2, 214300 (3),
MOX2		
MOX2R		
MOX44		
MOXD1		
MOZ	AD	arboleda-tham syndrome, 616268 (3),
MOZ2	AD	sbbyss syndrome, 603736 (3), ; genitopatellar syndrome, 606170 (3),
MOZART1		
MOZART2A		
MOZART2B		
MP	AD	noonan syndrome-like disorder with loose anagen hair 2, 617506 (3),
MP1	AR	spinocerebellar ataxia, 30, 619405 (3),
MP100		
MP17	AR	cataract 19, multiple types, 615277 (3),
MP19	AR	cataract 19, multiple types, 615277 (3),
MP2	AD	charcot-marie-tooth disease, demyelinating, type 1g, 618279 (3),
MP25	AD	aortic aneurysm, familial thoracic 9, 616166 (3),
MP26	AD	cataract 15, multiple types, 615274 (3),
MP44		
MP68		
MP70		
mPA-PLA1	AR	hypotrichosis 7, 604379 (3), ; woolly hair, 2 with or without hypotrichosis, 604379 (3),
mPA-PLA1alpha	AR	hypotrichosis 7, 604379 (3), ; woolly hair, 2 with or without hypotrichosis, 604379 (3),
mPA-PLA1beta		
Mpa2		
MPAN	AR,AD	neurodegeneration with brain iron accumulation 4, 614298 (3), ; ?spastic paraplegia 43, 615043 (3),
MPB1		
MPC1	AR	mitochondrial pyruvate carrier deficiency, 614741 (3),
MPC1L		
MPC2		
Mpcl		
MPD	AD	porokeratosis 7, multiple types, 614714 (3),
MPD1	AD,AR	laing distal myopathy, 160500 (3), ; cardiomyopathy, hypertrophic, 1, 192600 (3), digenic , ; left ventricular noncompaction 5, 613426 (3), ; cardiomyopathy, dilated, 1s, 613426 (3), ; congenital myopathy 7b, myosin storage, 255160 (3), ; congenital myopathy 7a, myosin storage, 608358 (3),
MPD2	AD	amyotrophic lateral sclerosis 21, 606070 (3),
MPD6		
MPDS	AR	congenital disorder of glycosylation, type ie, 608799 (3),
MPDU1	AR	congenital disorder of glycosylation, type if, 609180 (3),
MPDZ	AR	hydrocephalus, congenital, 2, with or without brain or eye anomalies, 615219 (3),
MPE16		
MPEG1	AD	immunodeficiency 77, 619223 (3),
MPF		
MPFYVE	AR	cholestasis, progressive familial intrahepatic, 9, 619849 (3),
MPG		
MPG1	AD	immunodeficiency 77, 619223 (3),
MPH1		
MPHOSPH1		
MPHOSPH10		
MPHOSPH11		
MPHOSPH2		
MPHOSPH4		
MPHOSPH6		
MPHOSPH7		
MPHOSPH8		
MPHOSPH9		
MPI	AR	congenital disorder of glycosylation, type ib, 602579 (3),
MPIF-1		
MPIF-2		
MPIF2		
MPIG6B	AR	?thrombocytopenia, anemia, and myelofibrosis, 617441 (3),
MPL	AD,AR	myelofibrosis with myeloid metaplasia, somatic, 254450 (3); thrombocythemia 2, 601977 (3), somatic mutation, ; thrombocytopenia, congenital amegakaryocytic, 604498 (3),
MPLKIP	AR	trichothiodystrophy 4, nonphotosensitive, 234050 (3),
MPLLG	AD	thrombocythemia 1, 187950 (3),
MPMGp800B12492Q3		
MPN		
Mpn1	AR	poikiloderma with neutropenia, 604173 (3),
MPO	AD,AR	{alzheimer disease, susceptibility to}, 104300 (3), ; myeloperoxidase deficiency, 254600 (3), ; {lung cancer, protection against, in smokers} (3)
MPOU		
MPP1		
MPP10		
MPP10P		
MPP11		
MPP2		
MPP3		
MPP4		
MPP4110		
MPP5		
MPP6		
MPP7		
mpp8		
MPP9		
MPPB	AR	multiple mitochondrial dysfunctions syndrome 6, 617954 (3),
MPPE1		
MPPED1		
MPPED2		
MPPP52	AR	multiple mitochondrial dysfunctions syndrome 6, 617954 (3),
MPR1		hepatocellular carcinoma, somatic, 114550 (3)
MPR300		hepatocellular carcinoma, somatic, 114550 (3)
MPRA		
MPRB		
MPRG		
MPRI		hepatocellular carcinoma, somatic, 114550 (3)
MPRIP		
MPRP-1		
MPS-1	AD	?diamond-blackfan anemia 17, 617409 (3),
MPS1	AD,AR	?diamond-blackfan anemia 17, 617409 (3), |mucopolysaccharidosis is, 607016 (3), ; mucopolysaccharidosis ih/s, 607015 (3), ; mucopolysaccharidosis ih, 607014 (3),
MPS1L1		
MPS3A	AR	mucopolysaccharidosis type iiia (sanfilippo a), 252900 (3),
MPSI	AR	mucopolysaccharidosis is, 607016 (3), ; mucopolysaccharidosis ih/s, 607015 (3), ; mucopolysaccharidosis ih, 607014 (3),
MPSK		
MPSL1		
MPST		
MPV17	AR	charcot-marie-tooth disease, axonal, type 2ee, 618400 (3), ; mitochondrial dna depletion syndrome 6 (hepatocerebral type), 256810 (3),
MPV17L		
MPV17L1		
MPV17L2		
MPV17L3		
MPYS	AD	sting-associated vasculopathy, infantile-onset, 615934 (3),
MPZ	AD,AR	charcot-marie-tooth disease, type 2i, 607677 (3), ; dejerine-sottas disease, 145900 (3), ; charcot-marie-tooth disease, type 1b, 118200 (3), ; roussy-levy syndrome, 180800 (3), ; charcot-marie-tooth disease, intermediate d, 607791 (3), ; hypomyelinating neuropathy, congenital, 2, 618184 (3), ; charcot-marie-tooth disease, type 2j, 607736 (3),
MPZL1		
MPZL2	AR	deafness, 111, 618145 (3),
MPZL3		
MR	AD	pseudohypoaldosteronism type i, 177735 (3), ; hypertension, early-onset, with exacerbation in pregnancy, 605115 (3)
MR-1	AD	paroxysmal nonkinesigenic dyskinesia 1, 118800 (3),
MR-1S	AD	paroxysmal nonkinesigenic dyskinesia 1, 118800 (3),
MR-GEF		
MR1		
MR60	AR	combined factor v and viii deficiency, 227300 (3),
MRAP	AR	glucocorticoid deficiency 2, 607398 (3),
MRAP1	AR	glucocorticoid deficiency 2, 607398 (3),
MRAP2	AD	{?obesity, susceptibility to, bmiq18}, 615457 (3),
MRAS	AD	noonan syndrome 11, 618499 (3),
MRB	AD	aortic valve disease 3, 618496 (3),
MRC		
MRC1		
MRC1L1		
MRC2		
MRCAF1	AR	?mitochondrial complex iv deficiency, nuclear type 21, 619065 (3),
MRCCAT1		
MRCK		
MRCKA		
MRCKB	AD	chilton-okur-chung neurodevelopmental syndrome, 619841 (3),
MRCKgamma		
MRCL		
MRCL2		
MRCL3		
Mrd1		
MrDb		
MRDI		
MRDS1		
MRE11	AR	ataxia-telangiectasia-like disorder 1, 604391 (3),
MRE11A	AR	ataxia-telangiectasia-like disorder 1, 604391 (3),
Mrec1.3		
MREG		
MRF	AD	encephalitis/encephalopathy, mild, with reversible myelin vacuolization, 618113 (3), ; cardiac-urogenital syndrome, 618280 (3),
MRF-1		
Mrf1		
MRF2		
MRF4		
MRFAP1		
MRG		
MRG1	AD,AD	atrial septal defect 8, 614433 (3), ; ventricular septal defect 2, 614431 (3), |cleft palate, cardiac defects, and mental retardation, 600987 (3),
MRG15		
MRG15BP		
MRG2		
MRGBP		
mrgD		
mrgE		
mrgF		
mrgG		
MRGPRD		
MRGPRE		
MRGPRF		
MRGPRG		
MRGPRX1		
MRGPRX2		
MRGPRX3		
MRGPRX4		
MRGX		
MRGX1		
MRGX2		
MRGX3		
MRGX4		
MRI		
MRI-2		
MRI1		
MRIT		
MRJ	AD	muscular dystrophy, limb-girdle, 1, 603511 (3),
MRK	AD,AR,AR	{epilepsy, juvenile myoclonic, susceptibility to, 10}, 617924 (3), ; endocrine-cerebroosteodysplasia, 612651 (3), |centronuclear myopathy 6 with fiber-type disproportion, 617760 (3), ; split-foot malformation with mesoaxial polydactyly, 616890 (3),
MRL3	AR	combined oxidative phosphorylation deficiency 9, 614582 (3),
MRLC1	AR	?megacystis-microcolon-intestinal hypoperistalsis syndrome 4, 619365 (3),
MRLC2	AR,AD	arthrogryposis, distal, type 1c, 619110 (3),
MRLN		
MRM1		
MRM2	AR	?mitochondrial dna depletion syndrome 17, 618567 (3),
MRM3		
MRNIP		
MRO		
MRP	AD,AR	?deafness, 77, 618915 (3), |zaki syndrome, 619648 (3),
MRP-1		
MRP-14		
MRP-8		
MRP-L10		
MRP-L14		
MRP-L15		
MRP-L18		
MRP-L2		
MRP-L22		
MRP-L25		
MRP-L26		
MRP-L27		
MRP-L28		
MRP-L3		
MRP-L31		
MRP-L32		
MRP-L36		
MRP-L5		
MRP-L50		
MRP-L7		
MRP-L8		
MRP-S	AR	?combined oxidative phosphorylation deficiency 34, 617872 (3),
MRP-S12	AR	combined oxidative phosphorylation deficiency 32, 617664 (3),
MRP-S13		
MRP-S17		
MRP-S22	AR	ovarian dysgenesis 7, 618117 (3), ; combined oxidative phosphorylation deficiency 5, 611719 (3),
MRP-S23	AR	?combined oxidative phosphorylation deficiency 46, 618952 (3),
MRP-S24		
MRP-S25	AR	?combined oxidative phosphorylation deficiency 50, 619025 (3),
MRP-S26		
MRP-S28	AR	?combined oxidative phosphorylation deficiency 47, 618958 (3),
MRP-S29		
MRP-S36		
MRP-S5		
MRP-S6		
MRP-S9		
MRP1	AD,AR	?deafness, 77, 618915 (3), |familial adenomatous polyposis 4, 617100 (3), ; endometrial carcinoma, somatic, 608089 (3)
MRP14		
MRP2	AR	dubin-johnson syndrome, 237500 (3),
MRP3		
MRP4		
MRP5		
MRP6	AR,AD	pseudoxanthoma elasticum, 264800 (3), ; arterial calcification, generalized, of infancy, 2, 614473 (3), ; pseudoxanthoma elasticum, forme fruste, 177850 (3),
MRP63		
MRP64		
MRP7	AR,AD	cystic fibrosis, 219700 (3), ; sweat chloride elevation without cf (3); congenital bilateral absence of vas deferens, 277180 (3), ; {pancreatitis, hereditary}, 167800 (3), ; {bronchiectasis with or without elevated sweat chloride 1, modifier of}, 211400 (3), ; {hypertrypsinemia, neonatal} (3)
MRP8	AD,AR,AD	[axillary odor, variation in], 117800 (3), ; [earwax, wet/dry], 117800 (3), ; [colostrum secretion, variation in], 117800 (3), |diabetes mellitus, permanent neonatal 3, with or without neurologic features, 618857 (3), ; diabetes mellitus, transient neonatal 2, 610374 (3); diabetes mellitus, noninsulin-dependent, 125853 (3), ; hypoglycemia of infancy, leucine-sensitive, 240800 (3), ; hyperinsulinemic hypoglycemia, familial, 1, 256450 (3),
MRP9		
MRPL1		
MRPL10		
MRPL11		
MRPL12	AR	?combined oxidative phosphorylation deficiency 45, 618951 (3),
MRPL13		
MRPL14		
MRPL15		
MRPL16		
MRPL17		
MRPL18		
MRPL19		
MRPL2		
MRPL20		
MRPL21		
MRPL22		
MRPL23		
MRPL24		
MRPL27		
MRPL28		
MRPL3	AR	combined oxidative phosphorylation deficiency 9, 614582 (3),
MRPL30		
MRPL31		
MRPL32		
MRPL33		
MRPL34		
MRPL35		
MRPL36		
MRPL37		
MRPL38		
MRPL39		
MRPL4		
MRPL40		
MRPL41		
MRPL42		
MRPL43		
MRPL44	AR	combined oxidative phosphorylation deficiency 16, 615395 (3),
MRPL45		
MRPL46		
MRPL47		
MRPL48		
MRPL49		
MRPL50		
MRPL51		
MRPL52		
MRPL53		
MRPL54		
MRPL55		
MRPL56		
MRPL57		
MRPL58		
MRPL7	AR	?combined oxidative phosphorylation deficiency 45, 618951 (3),
MRPL7/L12	AR	?combined oxidative phosphorylation deficiency 45, 618951 (3),
MRPL8		
MRPL9		
MRPP1	AR	combined oxidative phosphorylation deficiency 30, 616974 (3),
MRPP2	XLD,XL	hsd10 mitochondrial disease, 300438 (3),
MRPP3	AR	combined oxidative phosphorylation deficiency 54, 619737 (3),
MRPS10		
MRPS11		
MRPS12		
MRPS14	AR	?combined oxidative phosphorylation deficiency 38, 618378 (3),
MRPS15		
MRPS16	AR	combined oxidative phosphorylation deficiency 2, 610498 (3),
MRPS17		
MRPS18-1		
MRPS18-2		
MRPS18-3		
MRPS18A		
MRPS18AL1	AR	ciliary dyskinesia, primary, 12, 612650 (3),
MRPS18B		
MRPS18C		
MRPS2	AR	combined oxidative phosphorylation deficiency 36, 617950 (3),
MRPS21		
MRPS22	AR	ovarian dysgenesis 7, 618117 (3), ; combined oxidative phosphorylation deficiency 5, 611719 (3),
MRPS23	AR	?combined oxidative phosphorylation deficiency 46, 618952 (3),
MRPS24		
MRPS25	AR	?combined oxidative phosphorylation deficiency 50, 619025 (3),
MRPS26		
MRPS27		
MRPS28	AR	?combined oxidative phosphorylation deficiency 47, 618958 (3),
MRPS29		
MRPS30		
MRPS31		
MRPS32		
MRPS33		
MRPS34	AR	combined oxidative phosphorylation deficiency 32, 617664 (3),
MRPS35	AR	?combined oxidative phosphorylation deficiency 47, 618958 (3),
MRPS36		
MRPS4		
MRPS5		
MRPS6		
MRPS7	AR	?combined oxidative phosphorylation deficiency 34, 617872 (3),
MRPS9		
MRRF		
MRS		
MRS1	AD	oocyte/zygote/embryo maturation arrest 7, 618550 (3),
MRS2		
MRS2L		
MRS3/4		
MRS4L		
MRSR	XL,XLR	intellectual developmental disorder, syndromic, snyder-robinson type, 309583 (3),
MRT1	AR	intellectual developmental disorder, 1, 249500 (3),
MRT12	AR	developmental and epileptic encephalopathy 15, 615006 (3), ; intellectual developmental disorder, 12, 611090 (3),
MRT13	AR	intellectual developmental disorder, 13, 613192 (3),
MRT14	AR	intellectual developmental disorder, 14, 614020 (3),
MRT15	AR	rafiq syndrome, 614202 (3),
MRT17	AR	hyperphosphatasia with impaired intellectual development syndrome 3, 614207 (3),
MRT18	AR	intellectual developmental disorder, 18, with or without epilepsy, 614249 (3),
MRT2	AR	intellectual developmental disorder, 2, 607417 (3),
MRT21	AR	hyperphosphatasia with impaired intellectual development syndrome 3, 614207 (3),
MRT22	AR	intellectual developmental disorder, 7, 611093 (3),
MRT27	AR	intellectual developmental disorder, 27, 614340 (3),
MRT2A	AR	intellectual developmental disorder, 2, 607417 (3),
MRT3	AR	intellectual developmental disorder, 3, 608443 (3),
MRT5	AR	intellectual developmental disorder, 5, 611091 (3),
MRT6	AD,AR	neurodevelopmental disorder with impaired language and ataxia and with or without seizures, 619580 (3), ; intellectual developmental disorder, 6, 611092 (3),
MRT7	AR	intellectual developmental disorder, 7, 611093 (3),
MRTF-A	AR	?immunodeficiency 66, 618847 (3),
MRTF-B		
MRTFA	AR	?immunodeficiency 66, 618847 (3),
MRTFB		
MRUL		
MRVI1		
MRVLDC1		
MRVLDC2	AR	deafness, 49, 610153 (3),
MRVLDC3		
MRX1	XL,XLD	intellectual developmental disorder, 1, 309530 (3),
MRX10	XL,XLR	intellectual developmental disorder, 21, 300143 (3),
MRX100	XL,XLR	?intellectual developmental disorder, 100, 300923 (3),
MRX101	XL,XLR	?intellectual developmental disorder, 101, 300928 (3),
MRX12	XL,XLR	intellectual developmental disorder, 12, 300957 (3),
MRX13	XL,XLR	intellectual developmental disorder, syndromic, claes-jensen type, 300534 (3),
MRX16	XLD,XLR,XL	rett syndrome, atypical, 312750 (3), ; encephalopathy, neonatal severe, 300673 (3), ; intellectual developmental disorder, syndromic, lubs type, 300260 (3), ; {autism susceptibility, 3}, 300496 (3), ; intellectual developmental disorder, syndromic 13, 300055 (3), ; rett syndrome, 312750 (3), ; rett syndrome, preserved speech variant, 312750 (3),
MRX18	XL,XLD	intellectual developmental disorder, 1, 309530 (3),
MRX19	XL,XLD	intellectual developmental disorder, 19, 300844 (3), ; coffin-lowry syndrome, 303600 (3),
MRX2	XLR,XL	renpenning syndrome, 309500 (3),
MRX21	XL,XLR	intellectual developmental disorder, 21, 300143 (3),
MRX22	XL	allan-herndon-dudley syndrome, 300523 (3),
MRX29	XL,XLR	proud syndrome, 300004 (3), ; hydranencephaly with abnormal genitalia, 300215 (3), ; partington syndrome, 309510 (3), ; developmental and epileptic encephalopathy 1, 308350 (3), ; lissencephaly, 2, 300215 (3), ; intellectual developmental disorder, 29, 300419 (3),
MRX3	XLR,XL	methylmalonic aciduria and homocysteinemia, cblx type, 309541 (3),
MRX30	XL,XLR	intellectual developmental disorder, 30, 300558 (3),
MRX32	XL,XLR	proud syndrome, 300004 (3), ; hydranencephaly with abnormal genitalia, 300215 (3), ; partington syndrome, 309510 (3), ; developmental and epileptic encephalopathy 1, 308350 (3), ; lissencephaly, 2, 300215 (3), ; intellectual developmental disorder, 29, 300419 (3),
MRX33	XL,XLR	proud syndrome, 300004 (3), ; hydranencephaly with abnormal genitalia, 300215 (3), ; partington syndrome, 309510 (3), ; developmental and epileptic encephalopathy 1, 308350 (3), ; lissencephaly, 2, 300215 (3), ; intellectual developmental disorder, 29, 300419 (3),
MRX34	XL,XLR	intellectual developmental disorder, 21, 300143 (3),
MRX35	XL,XLR	intellectual developmental disorder, 12, 300957 (3),
MRX36	XL,XLR	proud syndrome, 300004 (3), ; hydranencephaly with abnormal genitalia, 300215 (3), ; partington syndrome, 309510 (3), ; developmental and epileptic encephalopathy 1, 308350 (3), ; lissencephaly, 2, 300215 (3), ; intellectual developmental disorder, 29, 300419 (3),
MRX38	XL,XLR	proud syndrome, 300004 (3), ; hydranencephaly with abnormal genitalia, 300215 (3), ; partington syndrome, 309510 (3), ; developmental and epileptic encephalopathy 1, 308350 (3), ; lissencephaly, 2, 300215 (3), ; intellectual developmental disorder, 29, 300419 (3),
MRX41	XL,XLD	intellectual developmental disorder, 41, 300849 (3),
MRX43	XL,XLR	proud syndrome, 300004 (3), ; hydranencephaly with abnormal genitalia, 300215 (3), ; partington syndrome, 309510 (3), ; developmental and epileptic encephalopathy 1, 308350 (3), ; lissencephaly, 2, 300215 (3), ; intellectual developmental disorder, 29, 300419 (3),
MRX44	XL,XLR	intellectual developmental disorder, 9, 309549 (3),
MRX45		
MRX46		
MRX47	XL,XLR	intellectual developmental disorder, 30, 300558 (3),
MRX48	XL,XLD	intellectual developmental disorder, 41, 300849 (3),
MRX50	XL	epilepsy, 1, with variable learning disabilities and behavior disorders, 300491 (3), ; intellectual developmental disorder, 50, 300115 (3),
MRX52	XLD,XL,XLR	alpha-thalassemia/mental retardation syndrome, 301040 (3), ; alpha-thalassemia myelodysplasia syndrome, somatic, 300448 (3); intellectual disability-hypotonic facies syndrome, 309580 (3),
MRX54	XL,XLR	proud syndrome, 300004 (3), ; hydranencephaly with abnormal genitalia, 300215 (3), ; partington syndrome, 309510 (3), ; developmental and epileptic encephalopathy 1, 308350 (3), ; lissencephaly, 2, 300215 (3), ; intellectual developmental disorder, 29, 300419 (3),
MRX55	XLR,XL	renpenning syndrome, 309500 (3),
MRX58	XL,XLR	intellectual developmental disorder, 58, 300210 (3),
MRX59	XLR,XL	pettigrew syndrome, 304340 (3),
MRX60	XL,XLR	intellectual developmental disorder, syndromic, billuart type, 300486 (3),
MRX62	XL,XLR	intellectual developmental disorder, syndromic 14, 300676 (3),
MRX63	XL,XLD	intellectual developmental disorder, 63, 300387 (3),
MRX65	XL	intellectual developmental disorder, 97, 300803 (3),
MRX68	XL,XLD	intellectual developmental disorder, 63, 300387 (3),
MRX72	XL,XLR	intellectual developmental disorder, 72, 300271 (3), ; waisman syndrome, 311510 (3),
MRX74		
MRX76	XL,XLR	proud syndrome, 300004 (3), ; hydranencephaly with abnormal genitalia, 300215 (3), ; partington syndrome, 309510 (3), ; developmental and epileptic encephalopathy 1, 308350 (3), ; lissencephaly, 2, 300215 (3), ; intellectual developmental disorder, 29, 300419 (3),
MRX78	XL,XLD	intellectual developmental disorder, 1, 309530 (3),
MRX79	XLD,XLR,XL	rett syndrome, atypical, 312750 (3), ; encephalopathy, neonatal severe, 300673 (3), ; intellectual developmental disorder, syndromic, lubs type, 300260 (3), ; {autism susceptibility, 3}, 300496 (3), ; intellectual developmental disorder, syndromic 13, 300055 (3), ; rett syndrome, 312750 (3), ; rett syndrome, preserved speech variant, 312750 (3),
MRX82	XL,XLR	intellectual developmental disorder, syndromic 14, 300676 (3),
MRX85	XLR,XL	becker muscular dystrophy, 300376 (3), ; cardiomyopathy, dilated, 3b, 302045 (3), ; duchenne muscular dystrophy, 310200 (3),
MRX87	XL,XLR	proud syndrome, 300004 (3), ; hydranencephaly with abnormal genitalia, 300215 (3), ; partington syndrome, 309510 (3), ; developmental and epileptic encephalopathy 1, 308350 (3), ; lissencephaly, 2, 300215 (3), ; intellectual developmental disorder, 29, 300419 (3),
MRX88		
MRX89		
MRX9	XL,XLR	intellectual developmental disorder, 9, 309549 (3),
MRX90	XL,XLR	intellectual developmental disorder, 90, 300850 (3),
MRX91		
MRX92		
MRX93	XL,XLR	intellectual developmental disorder, 93, 300659 (3),
MRX94	XL,XLR	intellectual developmental disorder, syndromic, wu type, 300699 (3),
MRX95	XL,XLR	immunodeficiency, with magnesium defect, epstein-barr virus infection and neoplasia, 300853 (3), ; congenital disorder of glycosylation, type icc, 301031 (3),
MRX96	XL,XLR	intellectual developmental disorder, 96, 300802 (3),
MRX97	XL	intellectual developmental disorder, 97, 300803 (3),
MRX98	XL,XLD	intellectual developmental disorder, 98, 300912 (3),
MRX99	XL,XLR,XLD	intellectual developmental disorder, 99, 300919 (3), ; intellectual developmental disorder, 99, syndromic, female-restricted, 300968 (3),
MRXS1	XL,XLR	proud syndrome, 300004 (3), ; hydranencephaly with abnormal genitalia, 300215 (3), ; partington syndrome, 309510 (3), ; developmental and epileptic encephalopathy 1, 308350 (3), ; lissencephaly, 2, 300215 (3), ; intellectual developmental disorder, 29, 300419 (3),
MRXS10	XLD,XL	hsd10 mitochondrial disease, 300438 (3),
MRXS3	XLR,XL	renpenning syndrome, 309500 (3),
MRXS4	XLR,XLD,XL	wieacker-wolff syndrome, 314580 (3), ; wieacker-wolff syndrome, female-restricted, 301041 (3),
MRXS5	XLR,XL	pettigrew syndrome, 304340 (3),
MRXS6	XLD,XL	cornelia de lange syndrome 5, 300882 (3),
MRXS8	XLR,XL	renpenning syndrome, 309500 (3),
MS2		
MS4A1	AR	?immunodeficiency, common variable, 5, 613495 (3),
Ms4a10		
MS4A10		
MS4A12		
MS4A2	AD	{atopy, susceptibility to}, 147050 (3),
MS4A3		
MS4A4		
MS4A4A		
MS4A4E		
MS4A5		
MS4A6		
MS4A6A		
MS4A6E		
MS4A7		
MS4A8		
MS4A8B		
MS4A9		
MS4B1		
MS4B2		
MSAP	AD	diaphyseal medullary stenosis with malignant fibrous histiocytoma, 112250 (3),
MSBP3		
MSC		
MSCP		
MSE1	AR	combined oxidative phosphorylation deficiency 12, 614924 (3),
MSE55		
MSF	AD,AR,AD	amyotrophy, hereditary neuralgic, 162100 (3), |camptodactyly-arthropathy-coxa vara-pericarditis syndrome, 208250 (3), |spondylometaphyseal dysplasia, corner fracture type, 184255 (3), ; glomerulopathy with fibronectin deposits 2, 601894 (3),
MSF1	AD	amyotrophy, hereditary neuralgic, 162100 (3),
MSG1		
MSGN1		
MSH	AR,MF,AD,AD	{obesity, early-onset, susceptibility to}, 601665 (3), , ; obesity, adrenal insufficiency, and red hair due to pomc deficiency, 609734 (3), |parietal foramina with cleidocranial dysplasia, 168550 (3), ; craniosynostosis 2, 604757 (3), ; parietal foramina 1, 168500 (3),
MSH-2	AD,AR	lynch syndrome 1, 120435 (3), ; muir-torre syndrome, 158320 (3), ; mismatch repair cancer syndrome 2, 619096 (3),
MSH-6	AD,AR	lynch syndrome 5, 614350 (3), ; mismatch repair cancer syndrome 3, 619097 (3), ; {endometrial cancer, familial}, 608089 (3), somatic mutation,
MSH-R	AR	[analgesia from kappa-opioid receptor agonist, female-specific], 613098 (3); [skin/hair/eye pigmentation 2, red hair/fair skin], 266300 (3), ; [skin/hair/eye pigmentation 2, blond hair/fair skin], 266300 (3), ; {melanoma, cutaneous malignant, 5}, 613099 (3); {albinism, oculocutaneous, type ii, modifier of}, 203200 (3), ; {uv-induced skin damage}, 266300 (3),
MSH2	AD,AR	lynch syndrome 1, 120435 (3), ; muir-torre syndrome, 158320 (3), ; mismatch repair cancer syndrome 2, 619096 (3),
MSH3	AR	familial adenomatous polyposis 4, 617100 (3), ; endometrial carcinoma, somatic, 608089 (3)
MSH4	AR	premature ovarian failure 20, 619938 (3), ; spermatogenic failure 2, 108420 (3),
MSH5	AR	?premature ovarian failure 13, 617442 (3), ; spermatogenic failure 74, 619937 (3),
MSH6	AD,AR	lynch syndrome 5, 614350 (3), ; mismatch repair cancer syndrome 3, 619097 (3), ; {endometrial cancer, familial}, 608089 (3), somatic mutation,
mSHMT	AR	neurodevelopmental disorder with cardiomyopathy, spasticity, and brain abnormalities, 619121 (3),
MSI1		
MSI2		
msk	AD	developmental and epileptic encephalopathy 30, 616341 (3),
MSK1		
MSK12		
MSK16	AD,AR	?spondyloepiphyseal dysplasia, kimberley type, 608361 (3), ; short stature and advanced bone age, with or without early-onset osteoarthritis and/or osteochondritis dissecans, 165800 (3), ; spondyloepimetaphyseal dysplasia, aggrecan type, 612813 (3),
MSK18	AR	epidermolysis bullosa, junctional 7, with interstitial lung disease and nephrotic syndrome, 614748 (3),
MSK2		
MSK21	AR	hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy, 612300 (3),
MSK8		
MSL-1		
msl-2		
Msl1		
MSL1		
MSL1v1	AD	koolen-de vries syndrome, 610443 (3),
MSL1v2		
MSL2		
MSL2L1		
MSL3	XLD,XL	basilicata-akhtar syndrome, 301032 (3),
MSL3L1	XLD,XL	basilicata-akhtar syndrome, 301032 (3),
MSLN		
mSLO1	AD,AR	{epilepsy, idiopathic generalized, susceptibility to, 16}, 618596 (3), ; paroxysmal nonkinesigenic dyskinesia, 3, with or without generalized epilepsy, 609446 (3), ; cerebellar atrophy, developmental delay, and seizures, 617643 (3), ; liang-wang syndrome, 618729 (3),
MSLR1		
MSMB		{prostate cancer, hereditary, 13}, 611928 (3)
MSMO1	AR	microcephaly, congenital cataract, and psoriasiform dermatitis, 616834 (3),
MSMP		
MSN	XLR	immunodeficiency 50, 300988 (3),
Msp		
MSP		{prostate cancer, hereditary, 13}, 611928 (3)
Msp1	AR	hyperekplexia 4, 618011 (3),
MSP58		
MSPB		{prostate cancer, hereditary, 13}, 611928 (3)
MSPL		
MSPS		
mSR		
MSR1		barrett esophagus/esophageal adenocarcinoma, 614266 (3)
MSRA		
MSRB		
MSRB1		
MSRB2		
MSRB3	AR	deafness, 74, 613718 (3),
MSRL1		
MSS	AR	marinesco-sjogren syndrome, 248800 (3),
MSS1	AR	combined oxidative phosphorylation deficiency 23, 616198 (3),
mss4		
MSS4		
MSS51		
MSSE	AD	{multiple self-healing squamous epithelioma, susceptibility to}, 132800 (3), ; loeys-dietz syndrome 1, 609192 (3),
MSSK1		
MSSP-1		
MSSP-2		
MSSP-3		
MST	AR,AD	myopathy, mitochondrial, and ataxia, 617675 (3),
MST-3		
MST016		
MST017		
MST025		
MST080	AR	mucolipidosis iv, 252650 (3),
MST081		
MST087		
MST093		
MST095		
MST1	AR	t-cell immunodeficiency, recurrent infections, autoimmunity, and cardiac malformations, 614868 (3),
MST107		
MST120		
MST149		
MST158		
MST1R	AD	{nasopharyngeal carcinoma, susceptibility to, 3}, 617075 (3),
MST2		
MST3		
MST3B		
MST4		
MSTD	AD,AR,MF	supranuclear palsy, progressive, 601104 (3), ; supranuclear palsy, progressive atypical, 260540 (3), ; dementia, frontotemporal, with or without parkinsonism, 600274 (3), ; {parkinson disease, susceptibility to}, 168600 (3), ; pick disease, 172700 (3),
MSTN	AR	?muscle hypertrophy, 614160 (3),
MSTO1	AR,AD	myopathy, mitochondrial, and ataxia, 617675 (3),
MSTP002		
MSTP003		
MSTP017		
MSTP028		
MSTP033		
MSTP036		
MSTP080	AR	mucolipidosis iv, 252650 (3),
MSTP087		
MSTP095		
MSTP107		
MSTP120		
MSTP141		
MSTP149		
MSTP150		
MSU	AR	maple syrup urine disease, type ia, 248600 (3),
MSX1	AD	tooth agenesis, selective, 1, with or without orofacial cleft, 106600 (3), ; ectodermal dysplasia 3, witkop type, 189500 (3), ; orofacial cleft 5, 608874 (3),
MSX2	AD	parietal foramina with cleidocranial dysplasia, 168550 (3), ; craniosynostosis 2, 604757 (3), ; parietal foramina 1, 168500 (3),
MSY2		
MT		
MT-1l		
MT-A70		
MT-ACT48		
Mt-GrpE#2		
MT-PK	AD	myotonic dystrophy 1, 160900 (3),
MT-SP1	AR	ichthyosis, congenital, 11, 602400 (3),
MT-SP2		
MT-TRX	AR	?combined oxidative phosphorylation deficiency 29, 616811 (3),
mt-TyrRS	AR	myopathy, lactic acidosis, and sideroblastic anemia 2, 613561 (3),
MT1		
MT1-MMP		?winchester syndrome, 277950 (3)
MT1A		
MT1B		
MT1E		
MT1F		
MT1G		
MT1H		
MT1I		
MT1IP		
MT1J		
MT1JP		
MT1K		
MT1L		
MT1M		
MT1NP		
MT1Q		
MT1R		
MT1S		
MT1X		
MT2	AR	iron-refractory iron deficiency anemia, 206200 (3),
MT2-MMP		
MT2A		
MT3		
MT3-MMP		
MT4		
MT4-MMP		
MT5-MMP		
MT6-MMP		
MT75		
MTA1		
MTA1-L1		
MTA1L1		
MTA2		
MTA3		
MTABC2		
MTABC3	AD	microphthalmia, isolated, with coloboma 7, 614497 (3), ; dyschromatosis universalis hereditaria 3, 615402 (3), ; [blood group, langereis system], 111600 (3); pseudohyperkalemia, familial, 2, due to red cell leak, 609153 (3),
MTAC2D1		
MTACR1	AD	wilms tumor 2, 194071 (3), somatic mutation, ; beckwith-wiedemann syndrome, 130650 (3), ; silver-russell syndrome 1, 180860 (3),
MTAG2		
MTAP	AD	diaphyseal medullary stenosis with malignant fibrous histiocytoma, 112250 (3),
MTAP44		
MTARC1		
MTARC2		
mtAspRS	AR	leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation, 611105 (3),
MTB	AR	khan-khan-katsanis syndrome, 618460 (3),
MTB-ZF		
MTBP		
MTBT1	AD,AR,MF	supranuclear palsy, progressive, 601104 (3), ; supranuclear palsy, progressive atypical, 260540 (3), ; dementia, frontotemporal, with or without parkinsonism, 600274 (3), ; {parkinson disease, susceptibility to}, 168600 (3), ; pick disease, 172700 (3),
MTBT2	AD,AR,MF	supranuclear palsy, progressive, 601104 (3), ; supranuclear palsy, progressive atypical, 260540 (3), ; dementia, frontotemporal, with or without parkinsonism, 600274 (3), ; {parkinson disease, susceptibility to}, 168600 (3), ; pick disease, 172700 (3),
MTC	AR	insensitivity to pain, congenital, with anhidrosis, 256800 (3),
MTC1	AD	{hirschsprung disease, susceptibility to, 1}, 142623 (3), ; multiple endocrine neoplasia iia, 171400 (3), ; {hirschsprung disease, protection against}, 142623 (3), ; medullary thyroid carcinoma, 155240 (3), ; pheochromocytoma, 171300 (3), ; multiple endocrine neoplasia iib, 162300 (3),
MTCBP-1		
MtCCA	AR	sideroblastic anemia with b-cell immunodeficiency, periodic fevers, and developmental delay, 616084 (3), ; retinitis pigmentosa and erythrocytic microcytosis, 616959 (3),
MTCH1		
MTCH2		
MTCL1		
MTCL1-AS1		
MTCP1	XL,XLR	lymphoproliferative syndrome, 1, 308240 (3),
MTCP1NB		
MTD		
MTDH		
MTE		
Mte1		
mtEF-G1	AR	combined oxidative phosphorylation deficiency 1, 609060 (3),
MTERF		
MTERF1		
MTERF2		
MTERF3		
MTERF4		
MTERFD1		
MTERFD2		
MTERFD3		
MtF		
MTf		
MTF		
MTF1		
MTF2		
MTF2L1		
MTF2L2		
mtFDH		
MTFMT	AR	combined oxidative phosphorylation deficiency 15, 614947 (3), ; mitochondrial complex i deficiency, nuclear type 27, 618248 (3),
MTFP1		
MTFR1		
MTG16		
MTG2		
MTG3		
MTG8		
mtGlnRS	AR	combined oxidative phosphorylation deficiency 12, 614924 (3),
MTGMP		
MTGP1	AR	combined oxidative phosphorylation deficiency 23, 616198 (3),
MTGR1		
MTGR2		
MTH1		
MTH2	AD	{thiopurines, poor metabolism of, 2}, 616903 (3),
MTH3		
MTHFC	AR	{neural tube defects, folate-sensitive, susceptibility to}, 601634 (3), ; combined immunodeficiency and megaloblastic anemia with or without hyperhomocysteinemia, 617780 (3),
MTHFD	AR	{neural tube defects, folate-sensitive, susceptibility to}, 601634 (3), ; combined immunodeficiency and megaloblastic anemia with or without hyperhomocysteinemia, 617780 (3),
MTHFD1	AR	{neural tube defects, folate-sensitive, susceptibility to}, 601634 (3), ; combined immunodeficiency and megaloblastic anemia with or without hyperhomocysteinemia, 617780 (3),
MTHFD1L		
MTHFD2		
MTHFD2L		
MTHFR	AR,AD	{vascular disease, susceptibility to} (3); homocystinuria due to mthfr deficiency, 236250 (3), ; {thromboembolism, susceptibility to}, 188050 (3), ; {schizophrenia, susceptibility to}, 181500 (3), ; {neural tube defects, susceptibility to}, 601634 (3),
MTHFS	AR	neurodevelopmental disorder with microcephaly, epilepsy, and hypomyelination, 618367 (3),
MTHFSD		
mthsp75	AR,AD	even-plus syndrome, 616854 (3), ; anemia, sideroblastic, 4, 182170 (3),
MTIF2		
MTIF3		
MTIV		
MTJ1		
MTK1		
MTL5		
MTLC		
mtLeuRS	AR	perrault syndrome 4, 615300 (3), ; hydrops, lactic acidosis, and sideroblastic anemia, 617021 (3),
MTLRP	AR,MF,AD	{obesity, susceptibility to}, 601665 (3), ,
MTLV	AD	doyne honeycomb degeneration of retina, 126600 (3),
MTM1	XL,XLR	myopathy, centronuclear, 310400 (3),
mtMetRS	AR	?combined oxidative phosphorylation deficiency 25, 616430 (3), ; spastic ataxia 3, 611390 (3),
MTMMP2		
MTMR1		
MTMR12		
MTMR13	AR	charcot-marie-tooth disease, type 4b2, 604563 (3),
MTMR14	AD	{centronuclear myopathy, modifier of}, 160150 (3),
MTMR15	AR	interstitial nephritis, karyomegalic, 614817 (3),
MTMR2	AR	charcot-marie-tooth disease, type 4b1, 601382 (3),
MTMR3		
MTMR4		
MTMR5	AR	charcot-marie-tooth disease, type 4b3, 615284 (3),
MTMR6		
MTMR7		
MTMR8		
MTMR9		
Mtn-1		
mtnA		
mtnD		
MTNR1A		
MTNR1B	AD	{diabetes mellitus, type 2, susceptibility to}, 125853 (3),
MTO1	AR	combined oxidative phosphorylation deficiency 10, 614702 (3),
MTO2	AR	{deafness, mitochondrial, modifier of}, 580000 (3), mitochondrial; liver failure, transient infantile, 613070 (3),
MTOR	AD	focal cortical dysplasia, type ii, somatic, 607341 (3); smith-kingsmore syndrome, 616638 (3),
MTP	AR	abetalipoproteinemia, 200100 (3),
MTP1	AD	hemochromatosis, type 4, 606069 (3),
MTP18		
MTPA	AR	hellp syndrome, maternal, of pregnancy, 609016 (3), ; lchad deficiency, 609016 (3), ; mitochondrial trifunctional protein deficiency 1, 609015 (3), ; fatty liver, acute, of pregnancy, 609016 (3),
MTPAP	AR	?spastic ataxia 4, 613672 (3),
MTPB		mitochondrial trifunctional protein deficiency 2, 620300 (3)
mtPheRS	AR	combined oxidative phosphorylation deficiency 14, 614946 (3), ; spastic paraplegia 77, 617046 (3),
MTPN		
MTPNUT		
MTPOLB	AD,AR	progressive external ophthalmoplegia with mitochondrial dna deletions, 4, 610131 (3), ; ?mitochondrial dna depletion syndrome 16 (hepatic type), 618528 (3), ; ?mitochondrial dna depletion syndrome 16b (neuroophthalmic type), 619425 (3),
MTQ1		
MTQ2		
MTR	AR	{neural tube defects, folate-sensitive, susceptibility to}, 601634 (3), ; homocystinuria-megaloblastic anemia, cblg complementation type, 250940 (3),
MTr1		
MTR1		
MTR10A	AD	muscular dystrophy, limb-girdle, 2, 608423 (3),
MTR120		
MTr2		
MTR2		
MTR3		
Mtr3p		
Mtr4		
MTRES1		
MTREX		
mtRF-R	AR	spastic paraplegia 55, 615035 (3), ; combined oxidative phosphorylation deficiency 7, 613559 (3),
MTRF1		
mtRF1a		
MTRF1L		
MTRFR	AR	spastic paraplegia 55, 615035 (3), ; combined oxidative phosphorylation deficiency 7, 613559 (3),
MTRNAP	AR,AD	combined oxidative phosphorylation deficiency 55, 619743 (3),
MTRNR2L1		
Mtrp		
MTRPOL	AR,AD	combined oxidative phosphorylation deficiency 55, 619743 (3),
MTRR	AR	homocystinuria-megaloblastic anemia, cbl e type, 236270 (3), ; {neural tube defects, folate-sensitive, susceptibility to}, 601634 (3),
mtRsfA		
MTS	XLR,XL	mohr-tranebjaerg syndrome, 304700 (3),
MTS1	AD	{melanoma and neural system tumor syndrome}, 155755 (3), ; {melanoma, cutaneous malignant, 2}, 155601 (3), ; {melanoma-pancreatic cancer syndrome}, 606719 (3),
MTS2		
mtSerRS	AR	hyperuricemia, pulmonary hypertension, renal failure, and alkalosis, 613845 (3),
MTSG1		
MTSS1		
MTSS1L	AD	intellectual developmental disorder with ocular anomalies and distinctive facial features, 620086 (3),
MTSS2	AD	intellectual developmental disorder with ocular anomalies and distinctive facial features, 620086 (3),
mtSSB	AD	optic atrophy 13 with retinal and foveal abnormalities, 165510 (3),
mtTFB		
MTTP	AR	abetalipoproteinemia, 200100 (3),
MTTRF1		
mtTrpRS	AR	parkinsonism-dystonia 3, childhood-onset, 619738 (3), ; neurodevelopmental disorder, mitochondrial, with abnormal movements and lactic acidosis, with or without seizures, 617710 (3),
MTU1	AR	{deafness, mitochondrial, modifier of}, 580000 (3), mitochondrial; liver failure, transient infantile, 613070 (3),
MTUS1		
MTUS2		
MTVR1		
MTW1		
MTX		
MTX1		
MTX2	AR	mandibuloacral dysplasia progeroid syndrome, 619127 (3),
MTX3		
MTXN		
MU	AR	hermansky-pudlak syndrome 11, 619172 (3),
MU-4	AR	spastic paraplegia 50, 612936 (3),
MU-ARP2	AR	spastic paraplegia 50, 612936 (3),
MU-PCDH		
MU-RMS-40.16A	AD	?long qt syndrome 11, 611820 (3),
mu1A		
mu2	AD	intellectual developmental disorder 60 with seizures, 618587 (3),
mu5		
MUC-24	AD	?deafness, 66, 616969 (3),
MUC1	AD	tubulointerstitial kidney disease, 2, 174000 (3),
MUC11		
MUC12		
MUC13		
MUC14		
MUC15		
MUC16		
MUC17		
MUC18		
MUC19		
MUC2		
MUC20		
MUC21		
MUC22		
MUC3		
MUC3A		
MUC3B		
MUC4		
MUC5	AD	{pulmonary fibrosis, idiopathic, susceptibility to}, 178500 (3),
MUC5AC		
MUC5B	AD	{pulmonary fibrosis, idiopathic, susceptibility to}, 178500 (3),
MUC6		
MUC7	AD	{asthma, protection against}, 600807 (3),
MUC8		
MUC9		
muCANP	AR	spastic paraplegia 76, 616907 (3),
MUCDHL		
muCL	AR	spastic paraplegia 76, 616907 (3),
MUCL1		
MUCL3		
MuD		
Mud1		
MUDENG		
MUDPNP		
MUF1		
MUK		
MUL	AR	mulibrey nanism, 253250 (3),
MUL1		
MULAN		
MULK	AR	cataract 38, 614691 (3), ; sengers syndrome, 212350 (3),
MULTI-CSF		
MUM1		[skin/hair/eye pigmentation, variation in, 8], 611724 (3)
Mum2		
MUM2		
Munc13-1		
Munc13-2		
Munc13-3		
Munc13-4	AR	hemophagocytic lymphohistiocytosis, familial, 3, 608898 (3),
MUNC18-1	AR,AD	developmental and epileptic encephalopathy 4, 612164 (3),
MUNC18-2	AR	hemophagocytic lymphohistiocytosis, familial, 5, with or without microvillus inclusion disease, 613101 (3),
MUP1	AR	microcephaly, amish type, 607196 (3), ; thiamine metabolism dysfunction syndrome 4 (progressive polyneuropathy type), 613710 (3),
MUPCDH		
MUPP1	AR	hydrocephalus, congenital, 2, with or without brain or eye anomalies, 615219 (3),
MURC		
MURF		
MURF-1		
MURF-2		
MURF-3		
MURR1		
MUS81		
MUSER1		
MUSK	AR	fetal akinesia deformation sequence 1, 208150 (3), ; myasthenic syndrome, congenital, 9, associated with acetylcholine receptor deficiency, 616325 (3),
Mustang		
MUSTN1		
MusTRD1		
MUT	AR	methylmalonic aciduria, mut(0) type, 251000 (3),
MUTED	AR	hermansky-pudlak syndrome 11, 619172 (3),
MUTM		renal cell carcinoma, clear cell, somatic, 144700 (3)
MUTYH	AR	adenomas, multiple colorectal, 608456 (3), ; gastric cancer, somatic, 613659 (3)
MVD	AD	porokeratosis 7, multiple types, 614714 (3),
MVK	AR,AD	hyper-igd syndrome, 260920 (3), ; porokeratosis 3, multiple types, 175900 (3), ; mevalonic aciduria, 610377 (3),
MVP		
Mvp1		
MVP17		
MVti1		
MWFE	XLR,XL	mitochondrial complex i deficiency, nuclear type 12, 301020 (3),
MWS	AD	cinca syndrome, 607115 (3), ; familial cold inflammatory syndrome 1, 120100 (3), ; keratoendothelitis fugax hereditaria, 148200 (3), ; deafness, 34, with or without inflammation, 617772 (3), ; muckle-wells syndrome, 191900 (3),
MX1		
MX2		
MxA		
MXB		
MXD1		
MXD2		prostate cancer, somatic, 176807 (3); neurofibrosarcoma, somatic (3)
MXD3		
MXD4		
MXD5		
MXD6		
MXD7		
MXI		prostate cancer, somatic, 176807 (3); neurofibrosarcoma, somatic (3)
MXI1		prostate cancer, somatic, 176807 (3); neurofibrosarcoma, somatic (3)
Mxi2		
MXR	AD	[junior blood group system], 614490 (3); [uric acid concentration, serum, qtl1], 138900 (3), ?
MXRA1		
MXRA2		
MXRA3	AR	nephrotic syndrome, type 16, 617783 (3), ; palmoplantar keratoderma and woolly hair, 616099 (3),
MXRA4		
MXRA5		
MXRA6		
MXRA8		
MXS1	XL,XLR	intellectual developmental disorder, 58, 300210 (3),
My012		
My013	AR	mitochondrial complex i deficiency, nuclear type 15, 618237 (3),
MY014		
My015		
My016		
My021		
My025		
My031	AR	hermansky-pudlak syndrome 7, 614076 (3),
my036		
MY040		
my042		
my047		
MY050	AD	myoclonus, intractable, neonatal, 617235 (3), ; {amyotrophic lateral sclerosis, susceptibility to, 25}, 617921 (3), ; spastic paraplegia 10, 604187 (3),
MYADM		
Myak		
MYB		{t-cell acute lymphoblastic leukemia} (3)
MYBBP1A		
MYBL1		
MYBL2		
MYBPC1	AD,AR	congenital myopathy 16, 618524 (3), ; lethal congenital contracture syndrome 4, 614915 (3), ; arthrogryposis, distal, type 1b, 614335 (3),
MYBPC2		
MYBPC3	AR,AD	cardiomyopathy, hypertrophic, 4, 115197 (3), ; cardiomyopathy, dilated, 1mm, 615396 (3), ; left ventricular noncompaction 10, 615396 (3),
MYBPCF		
MYBPH		
MYBPHL		
MYC		burkitt lymphoma, somatic, 113970 (3)
MYCBP		
MYCBP2		
MYCBPAP		
MYCC		burkitt lymphoma, somatic, 113970 (3)
MYCD	AD	megabladder, congenital, 618719 (3),
MYCL		
MYCL1		
MYCL1P1		
MYCL2		
MYCLK1		
MYCLP1		
MYCN	AD	feingold syndrome 1, 164280 (3),
MYCN-AS1		
MYCNOS		
MYCNOT	AD	feingold syndrome 1, 164280 (3),
MYCNUN		
MYCNUT		
MYCPBP		
MYCT1		
MYD-1		
MYD118		
MYD88	AR	macroglobulinemia, waldenstrom, somatic, 153600 (3); immunodeficiency 68, 612260 (3),
MYDGF		
MYEF2		
MYEOV		
MYEOV2		
MYETS1		
MYF3	AR	congenital myopathy 17, 618975 (3),
MYF4		
MYF5	AR	ophthalmoplegia, external, with rib and vertebral anomalies, 618155 (3),
MYF6		
MYG		
MYG1		
MYH	AR	adenomas, multiple colorectal, 608456 (3), ; gastric cancer, somatic, 613659 (3)
MYH1		
MYH10		
MYH11	AR,AD	megacystis-microcolon-intestinal hypoperistalsis syndrome 2, 619351 (3), ; aortic aneurysm, familial thoracic 4, 132900 (3), ; visceral myopathy 2, 619350 (3),
MYH12	AR	griscelli syndrome, type 1, 214450 (3),
MYH13		
MYH14	AD	?peripheral neuropathy, myopathy, hoarseness, and hearing loss, 614369 (3), ; deafness, 4a, 600652 (3),
MYH15		
MYH17	AD	?peripheral neuropathy, myopathy, hoarseness, and hearing loss, 614369 (3), ; deafness, 4a, 600652 (3),
MYH2	AR,AD	congenital myopathy 6 with ophthalmoplegia, 605637 (3),
MYH2A	AR,AD	congenital myopathy 6 with ophthalmoplegia, 605637 (3),
MYH2B		
MYH3	AD,AR	contractures, pterygia, and spondylocarpostarsal fusion syndrome 1a, 178110 (3), ; contractures, pterygia, and spondylocarpotarsal fusion syndrome 1b, 618469 (3), ; arthrogryposis, distal, type 2b3 (sheldon-hall), 618436 (3), ; arthrogryposis, distal, type 2a (freeman-sheldon), 193700 (3),
MYH4		
MYH6	AD	{sick sinus syndrome 3}, 614090 (3); atrial septal defect 3, 614089 (3); cardiomyopathy, dilated, 1ee, 613252 (3), ; cardiomyopathy, hypertrophic, 14, 613251 (3),
MYH7	AD,AR	laing distal myopathy, 160500 (3), ; cardiomyopathy, hypertrophic, 1, 192600 (3), digenic , ; left ventricular noncompaction 5, 613426 (3), ; cardiomyopathy, dilated, 1s, 613426 (3), ; congenital myopathy 7b, myosin storage, 255160 (3), ; congenital myopathy 7a, myosin storage, 608358 (3),
MYH7B		
MYH8	AD	carney complex variant, 608837 (3); trismus-pseudocamptodactyly syndrome, 158300 (3),
MYH9	AD	macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss, 155100 (3), ; deafness, 17, 603622 (3),
MYHa		
MYHas8	AR,AD	congenital myopathy 6 with ophthalmoplegia, 605637 (3),
MyHC-2A	AR,AD	congenital myopathy 6 with ophthalmoplegia, 605637 (3),
MyHC-2B		
MyHC-2X/D		
MYHC-EMB	AD,AR	contractures, pterygia, and spondylocarpostarsal fusion syndrome 1a, 178110 (3), ; contractures, pterygia, and spondylocarpotarsal fusion syndrome 1b, 618469 (3), ; arthrogryposis, distal, type 2b3 (sheldon-hall), 618436 (3), ; arthrogryposis, distal, type 2a (freeman-sheldon), 193700 (3),
MyHC-eo		
MyHC-IIa	AR,AD	congenital myopathy 6 with ophthalmoplegia, 605637 (3),
MyHC-IIb		
MyHC-peri	AD	carney complex variant, 608837 (3); trismus-pseudocamptodactyly syndrome, 158300 (3),
MyHC-pn	AD	carney complex variant, 608837 (3); trismus-pseudocamptodactyly syndrome, 158300 (3),
Myheart		
MYHL		
MYHSA1		
MYHSA2	AR,AD	congenital myopathy 6 with ophthalmoplegia, 605637 (3),
MYHSE1	AD,AR	contractures, pterygia, and spondylocarpostarsal fusion syndrome 1a, 178110 (3), ; contractures, pterygia, and spondylocarpotarsal fusion syndrome 1b, 618469 (3), ; arthrogryposis, distal, type 2b3 (sheldon-hall), 618436 (3), ; arthrogryposis, distal, type 2a (freeman-sheldon), 193700 (3),
MYL		leukemia, acute promyelocytic, pml/rara type (3)
MYL1	AR	congenital myopathy 14, 618414 (3),
MYL10		
MYL11	AR,AD	arthrogryposis, distal, type 1c, 619110 (3),
MYL12B		
MYL2	AD,AR	cardiomyopathy, hypertrophic, 10, 608758 (3), ; myopathy, myofibrillar, 12, infantile-onset, with cardiomyopathy, 619424 (3),
MYL2A		
MYL3	AR,AD	cardiomyopathy, hypertrophic, 8, 608751 (3),
MYL4	AD	?atrial fibrillation, familial, 18, 617280 (3),
MYL5		
MYL6		
MYL6B		
MYL7		
MYL9	AR	?megacystis-microcolon-intestinal hypoperistalsis syndrome 4, 619365 (3),
MYLC2A		
MYLC2PL		
MYLE		
MYLIP		
MYLK	AR,AD	megacystis-microcolon-intestinal hypoperistalsis syndrome 1, 249210 (3), ; aortic aneurysm, familial thoracic 7, 613780 (3),
MYLK-L	AR,AD	megacystis-microcolon-intestinal hypoperistalsis syndrome 1, 249210 (3), ; aortic aneurysm, familial thoracic 7, 613780 (3),
MYLK1	AR,AD	megacystis-microcolon-intestinal hypoperistalsis syndrome 1, 249210 (3), ; aortic aneurysm, familial thoracic 7, 613780 (3),
MYLK2	AD	cardiomyopathy, hypertrophic, 1, digenic, 192600 (3), digenic ,
MYLK3		
MYLK5	AR,AD	muscular dystrophy, limb-girdle, 10, 608807 (3), ; cardiomyopathy, familial hypertrophic, 9, 613765 (3), ; congenital myopathy 5 with cardiomyopathy, 611705 (3), ; tibial muscular dystrophy, tardive, 600334 (3), ; cardiomyopathy, dilated, 1g, 604145 (3), ; myopathy, myofibrillar, 9, with early respiratory failure, 603689 (3),
MYLK6	AR	centronuclear myopathy 5, 615959 (3),
MYLPF	AR,AD	arthrogryposis, distal, type 1c, 619110 (3),
MYM	AD	neurodevelopmental-craniofacial syndrome with variable renal and cardiac abnormalities, 619522 (3),
MYMK	AR	carey-fineman-ziter syndrome, 254940 (3),
MYMLR		
MYMX	AR	?carey-fineman-ziter syndrome 2, 619941 (3),
MYMY2	AR,AD	{moyamoya disease 2, susceptibility to}, 607151 (3),
MYNE1	AR,AD	arthrogryposis multiplex congenita 3, myogenic type, 618484 (3), ; emery-dreifuss muscular dystrophy 4, 612998 (3), ; spinocerebellar ataxia, 8, 610743 (3),
mynn		
MYNN		
MYO10		
MYO15	AR	deafness, 3, 600316 (3),
MYO15A	AR	deafness, 3, 600316 (3),
MYO16		
Myo16b		
MYO18A		
MYO18B	AR	klippel-feil syndrome 4, with myopathy and facial dysmorphism, 616549 (3),
MYO19		
MYO1A		
MYO1B		
MYO1C	AR	glomerulosclerosis, focal segmental, 6, 614131 (3),
MYO1D		
MYO1E	AR	glomerulosclerosis, focal segmental, 6, 614131 (3),
MYO1F		
MYO1G		
MYO1H	AR	?central hypoventilation syndrome, congenital, 2, and autonomic dysfunction, 619482 (3),
MYO3A	AR	deafness, 30, 607101 (3),
MYO3B		
MYO5	AR	griscelli syndrome, type 1, 214450 (3),
MYO5A	AR	griscelli syndrome, type 1, 214450 (3),
MYO5B	AR	diarrhea 2, with microvillus atrophy, with or without cholestasis, 251850 (3), ; cholestasis, progressive familial intrahepatic, 10, 619868 (3),
MYO5C		
MYO6	AD,AR	deafness, 22, with hypertrophic cardiomyopathy, 606346 (3), ; deafness, 22, 606346 (3), ; deafness, 37, 607821 (3),
MYO7A	AR,AD	deafness, 2, 600060 (3), ; usher syndrome, type 1b, 276900 (3), ; deafness, 11, 601317 (3),
MYO7B		
MYO9A	AR	myasthenic syndrome, congenital, 24, presynaptic, 618198 (3),
MYO9B		{celiac disease, susceptibility to, 4}, 609753 (3)
MYOC	AD	glaucoma 1a, primary open angle, 137750 (3),
MYOCD	AD	megabladder, congenital, 618719 (3),
MYOD	AR	congenital myopathy 17, 618975 (3),
MYOD1	AR	congenital myopathy 17, 618975 (3),
myodulin		
MYOF	AD	?angioedema, hereditary, 7, 619366 (3),
MYOG		
MYOGEF		
MYOHD1		
MyoIC		
MYOM1		
MYOM2		
MYOM3		
MYOMAKER	AR	carey-fineman-ziter syndrome, 254940 (3),
MYONAP	AD,AR	deafness, 21, 607017 (3), ; ?deafness, 104, 616515 (3),
MYOP	AD,AR	cardiomyopathy, hypertrophic, 22, 615248 (3), ; congenital myopathy 24, 617336 (3), ; cardiomyopathy, familial restrictive, 4, 615248 (3), ; cardiomyopathy, dilated, 1kk, 615248 (3),
MYORG	AR	basal ganglia calcification, idiopathic, 7, 618317 (3),
MYOSLID		
MYOT	AD	myopathy, myofibrillar, 3, 609200 (3),
MYOTROPHIN		
MyoX		
MYOZ		
MYOZ1		
MYOZ2	AD	cardiomyopathy, hypertrophic, 16, 613838 (3),
MYOZ3		
MYOZAP		
MYP	AD	?myoclonus, familial, 1, 614937 (3),
MYP6	AD,AR	myopia 6, 608908 (3), ; mitochondrial complex iv deficiency, nuclear type 2, 604377 (3),
MYPN	AD,AR	cardiomyopathy, hypertrophic, 22, 615248 (3), ; congenital myopathy 24, 617336 (3), ; cardiomyopathy, familial restrictive, 4, 615248 (3), ; cardiomyopathy, dilated, 1kk, 615248 (3),
MYPOP		
MYPT1	AD	genitourinary and/or/brain malformation syndrome, 618820 (3),
MYPT2		
MYPT3		
myr1		
MYR12	AR	griscelli syndrome, type 1, 214450 (3),
myr2		
myr4		
MYR8		
MYRF	AD	encephalitis/encephalopathy, mild, with reversible myelin vacuolization, 618113 (3), ; cardiac-urogenital syndrome, 618280 (3),
MYRIP		
MYRL2	AR	?megacystis-microcolon-intestinal hypoperistalsis syndrome 4, 619365 (3),
MYSB	AD	brugada syndrome 4, 611876 (3),
MYSM1	AR	bone marrow failure syndrome 4, 618116 (3),
MysPDZ		
MYST1	AD	li-ghorgani-weisz-hubshman syndrome, 618974 (3),
MYST2		
MYST3	AD	arboleda-tham syndrome, 616268 (3),
MYST4	AD	sbbyss syndrome, 603736 (3), ; genitopatellar syndrome, 606170 (3),
MYT1		
MYT1L	AD	intellectual developmental disorder, 39, 616521 (3),
MYTI		
MYZAP		
MZB1		
MZF-1		
MZF1		
MZF1B		
MZIP2	AR	spermatogenic failure 75, 619949 (3),
MZIP4	XL,XLR	spermatogenic failure, 2, 309120 (3),
MZM1L	AR	mitochondrial complex iii deficiency, nuclear type 8, 615838 (3),
MZT1		
MZT2A		
MZT2B		
n-chimerin	AD	duane retraction syndrome 2, 604356 (3),
N-CoR		
N-CYM		
N-myc	AD	feingold syndrome 1, 164280 (3),
N-PAC		
N-ras	AD	noonan syndrome 6, 613224 (3), ; ?ras-associated autoimmune lymphoproliferative syndrome type iv, somatic, 614470 (3); melanocytic nevus syndrome, congenital, somatic, 137550 (3); epidermal nevus, somatic, 162900 (3); schimmelpenning-feuerstein-mims syndrome, somatic mosaic, 163200 (3); thyroid carcinoma, follicular, somatic, 188470 (3); neurocutaneous melanosis, somatic, 249400 (3); colorectal cancer, somatic, 114500 (3)
N-SAM	AD	pfeiffer syndrome, 101600 (3), ; hypogonadotropic hypogonadism 2 with or without anosmia, 147950 (3), ; jackson-weiss syndrome, 123150 (3), ; hartsfield syndrome, 615465 (3), ; trigonocephaly 1, 190440 (3), ; osteoglophonic dysplasia, 166250 (3), ; encephalocraniocutaneous lipomatosis, somatic mosaic, 613001 (3)
N-Shc		
N-syndecan	AR,MF,AD	{obesity, association with}, 601665 (3), ,
N-TWIST		
N-WASP		
N/OFQ		
N10		
N14		
N143		
N155	AR	?atrial fibrillation 15, 615770 (3),
N214	AR	leukemia, t-cell acute lymphoblastic, somatic, 613065 (3); leukemia, acute myeloid, somatic, 601626 (3); {encephalopathy, acute, infection-induced, susceptibility to, 9}, 618426 (3),
N27C7-4	AD	?myopathy, isolated mitochondrial, 616209 (3), ; spinal muscular atrophy, jokela type, 615048 (3), ; frontotemporal dementia and/or amyotrophic lateral sclerosis 2, 615911 (3),
N2N		
N33	AR	intellectual developmental disorder, 7, 611093 (3),
n339260		
N4BP1		
N4BP2		
N4BP2L2		
N4BP3		
N4BP4	XLD,XL	amyotrophic lateral sclerosis 15, with or without frontotemporal dementia, 300857 (3),
N4WBP5		
N4wbp5a		
N61		
N6AMT		
N6AMT1		
N6AMT2		
N7-MTase		
N8L		
"NA"	XL	mcleod syndrome with or without chronic granulomatous disease, 300842 (3),
NA14		
NAA10	XL,XLD,XLR	microphthalmia, syndromic 1, 309800 (3), ; ogden syndrome, 300855 (3),
NAA11		
NAA15	AD	intellectual developmental disorder, 50, with behavioral abnormalities, 617787 (3),
NAA16		
NAA20	AR	intellectual developmental disorder, 73, 619717 (3),
NAA25		
NAA30		
NAA35		
NAA38		
NAA40		
NAA50		
NAA60		
NAA80		
NAAA		
NAAGS		
NAAGS-I		
NAAGS-II		
NAALAD1		
NAALAD2		
NAALAdase		
NAALADASE2		
NAALADL1		
NAALADL2		
NAAR1	XL	spermatogenic failure, 4, 301077 (3),
NAB1		
NAB2		
NAB50		
NaBC1	AR	corneal endothelial dystrophy, 217700 (3), ; corneal dystrophy, fuchs endothelial, 4, 613268 (3); corneal endothelial dystrophy and perceptive deafness, 217400 (3),
NABC1		
NABP1		
NABP1-OT1		
NABP2		
NAC	AR,AD,XL	{vitiligo-associated multiple autoimmune disease susceptibility 1}, 606579 (3); ?respiratory papillomatosis, juvenile recurrent, congenital, 618803 (3), ; autoinflammation with arthritis and dyskeratosis, 617388 (3), ; palmoplantar carcinoma, multiple self-healing, 615225 (3), |mcleod syndrome with or without chronic granulomatous disease, 300842 (3),
NAC-1	AD	neurodevelopmental disorder with epilepsy, cataracts, feeding difficulties, and delayed brain myelination, 617393 (3),
NAC1	AD,AD	developmental and epileptic encephalopathy 6b, non-dravet, 619317 (3), ; migraine, familial hemiplegic, 3, 609634 (3), ; dravet syndrome, 607208 (3), ; febrile seizures, familial, 3a, 604403 (3), ; generalized epilepsy with febrile seizures plus, type 2, 604403 (3), |neurodevelopmental disorder with epilepsy, cataracts, feeding difficulties, and delayed brain myelination, 617393 (3),
NACA		
NACA1		
NACA2		
NACAD		
NACAE		
NACAL		
NACB		
NACC1	AD	neurodevelopmental disorder with epilepsy, cataracts, feeding difficulties, and delayed brain myelination, 617393 (3),
NACC2		
NACGT1	AD,AR	[blood group, ii], 110800 (3), ; adult i phenotype without cataract, 110800 (3), ; cataract 13 with adult i phenotype, 116700 (3),
NACGT2		
NaCh6	AD	?myoclonus, familial, 2, 618364 (3), ; seizures, benign familial infantile, 5, 617080 (3), ; cognitive impairment with or without cerebellar ataxia, 614306 (3), ; developmental and epileptic encephalopathy 13, 614558 (3),
NACHRA9		
NACK		
NACP	AD	dementia, lewy body, 127750 (3), ; parkinson disease 1, 168601 (3), ; parkinson disease 4, 605543 (3),
NACSIN		{prostate cancer, hereditary, 12}, 611868 (3)
NACT	AR	developmental and epileptic encephalopathy 25, with amelogenesis imperfecta, 615905 (3),
NaDC-1		
NADC3	AR	leukoencephalopathy, acute reversible, with increased urinary alpha-ketoglutarate, 618384 (3),
NADE		
NADHB14	AR	mitochondrial complex i deficiency, nuclear type 33, 618253 (3),
NADK		
NADK1		
NADK2	AR	2,4-dienoyl-coa reductase deficiency, 616034 (3),
NADKD1	AR	2,4-dienoyl-coa reductase deficiency, 616034 (3),
NADRIN		
NADSYN1	AR	vertebral, cardiac, renal, and limb defects syndrome 3, 618845 (3),
NAE1	AR	neurodevelopmental disorder with dysmorphic facies and ischiopubic hypoplasia, 620210 (3),
NAE2		
NAF		
NAF-1	AR	wolfram syndrome 2, 604928 (3),
NAF1	AD	pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 7, 620365 (3),
NaG		
NAG	AD,AR,AR	?charcot-marie-tooth disease, axonal, type 2v, 616491 (3), ; mucopolysaccharidosis type iiib (sanfilippo b), 252920 (3), |short stature, optic nerve atrophy, and pelger-huet anomaly, 614800 (3), ; infantile liver failure syndrome 2, 616483 (3),
NAG-1		
NAG-2		
NAG-5		
NAG-7		
NAG14		
NAG6		
NAG7		
NAGA	AR	schindler disease, type i, 609241 (3), ; kanzaki disease, 609242 (3), ; schindler disease, type iii, 609241 (3),
NAGCT1	AD,AR	[blood group, ii], 110800 (3), ; adult i phenotype without cataract, 110800 (3), ; cataract 13 with adult i phenotype, 116700 (3),
NAGCT2		
NAGK		
NAGLU	AD,AR	?charcot-marie-tooth disease, axonal, type 2v, 616491 (3), ; mucopolysaccharidosis type iiib (sanfilippo b), 252920 (3),
NAGPA		
NAGR1		
NAGS	AR	n-acetylglutamate synthase deficiency, 237310 (3),
NAGT	AR	glucose/galactose malabsorption, 606824 (3),
NAIC		
NAIF1		
NAIL		{rheumatoid arthritis, susceptibility to}, 180300 (3)
NAIP		
NAK	AD	{encephalopathy, acute, infection-induced (herpes-specific), susceptibility to, 8}, 617900 (3), ; frontotemporal dementia and/or amyotrophic lateral sclerosis 4, 616439 (3),
NAK-1		
NAKAP95		
Naked2		
NALCN	AD,AR	congenital contractures of the limbs and face, hypotonia, and developmental delay, 616266 (3), ; hypotonia, infantile, with psychomotor retardation and characteristic facies 1, 615419 (3),
NALF1		
Nalp-iota		
NALP1	AR,AD	{vitiligo-associated multiple autoimmune disease susceptibility 1}, 606579 (3); ?respiratory papillomatosis, juvenile recurrent, congenital, 618803 (3), ; autoinflammation with arthritis and dyskeratosis, 617388 (3), ; palmoplantar carcinoma, multiple self-healing, 615225 (3),
NALP10		
NALP11		
NALP12	AD	familial cold autoinflammatory syndrome 2, 611762 (3),
NALP13		
NALP14		
NALP2	AR	oocyte/zygote/embryo maturation arrest 18, 620332 (3),
NALP3	AD	cinca syndrome, 607115 (3), ; familial cold inflammatory syndrome 1, 120100 (3), ; keratoendothelitis fugax hereditaria, 148200 (3), ; deafness, 34, with or without inflammation, 617772 (3), ; muckle-wells syndrome, 191900 (3),
NALP4		
NALP5	AR	oocyte/zygote/embryo maturation arrest 19, 620333 (3),
NALP6		
NALP7	AR	hydatidiform mole, recurrent, 1, 231090 (3),
NALP8		
NALP9		
NAMA		
NAMPT		
NAMSD	XLR,XL	combined oxidative phosphorylation deficiency 6, 300816 (3), ; cowchock syndrome, 310490 (3), ; spondyloepimetaphyseal dysplasia, with hypomyelinating leukodystrophy, 300232 (3), ; deafness, 5, 300614 (3),
NaN	AD	episodic pain syndrome, familial, 3, 615552 (3), ; neuropathy, hereditary sensory and autonomic, type vii, 615548 (3),
NANCI		
NANOG		
NANOS1	AD	spermatogenic failure 12, 615413 (3),
NANOS1L		
NANOS2		
NANOS3		
NANP		
NANS	AR	spondyloepimetaphyseal dysplasia, camera-genevieve type, 610442 (3),
NANTA3		
NAP	AR	?immunodeficiency 99 with hypogammaglobulinemia and autoimmune cytopenias, 619846 (3),
NAP-1		
NAP-2		
NAP-2-L1		
NAP-22		
NAP-3		
NAP-X		
Nap1		
NAP1		
NAP125		
NAP1L		
NAP1L1		
NAP1L2		
NAP1L3		
NAP1L4		
NAP1L5		
NAP2		
NAP22		
NAP4		
NAP5		
NAP57	XL,XLR	dyskeratosis congenita, 305000 (3),
NAPA		
NAPB	AR	developmental and epileptic encephalopathy 107, 620033 (3),
NAPE-PLD		
NAPEPLD		
NAPG		
NAPI-1		
NaPi-2b	AR	pulmonary alveolar microlithiasis, 265100 (3),
NaPi-2c	AR	hypophosphatemic rickets with hypercalciuria, 241530 (3),
NAPI-3	AR,AD	?fanconi renotubular syndrome 2, 613388 (3), ; hypercalcemia, infantile, 2, 616963 (3), ; nephrolithiasis/osteoporosis, hypophosphatemic, 1, 612286 (3),
NAPI-3B	AR	pulmonary alveolar microlithiasis, 265100 (3),
NaPi-Cap1		
NaPi-Cap2		
NAPI-IIb	AR	pulmonary alveolar microlithiasis, 265100 (3),
NaPi2b	AR	pulmonary alveolar microlithiasis, 265100 (3),
NAPOR		
NAPOR-2	AD	developmental and epileptic encephalopathy 97, 619561 (3),
NAPRT		
NAPRT1		
NAPSA		
NAPTB	AR	developmental and epileptic encephalopathy 48, 617276 (3),
NAR		
NAR1		
NARC-1	AD	{low density lipoprotein cholesterol level qtl 1}, 603776 (3), ; hypercholesterolemia, familial, 3, 603776 (3),
NARF		
NARFL		
NARG1	AD	intellectual developmental disorder, 50, with behavioral abnormalities, 617787 (3),
NARG1L		
NARG2		
NARR		
NARS	AD,AR	neurodevelopmental disorder with microcephaly, impaired language, epilepsy, and gait abnormalities, 619092 (3), ; neurodevelopmental disorder with microcephaly, impaired language, and gait abnormalities, 619091 (3),
NARS1	AD,AR	neurodevelopmental disorder with microcephaly, impaired language, epilepsy, and gait abnormalities, 619092 (3), ; neurodevelopmental disorder with microcephaly, impaired language, and gait abnormalities, 619091 (3),
NARS2	AR	combined oxidative phosphorylation deficiency 24, 616239 (3), ; ?deafness, 94, 618434 (3),
NAS1		
NASH1		
NaSi-1		
NASP		
NAT		
NAT-1		
NAT1	AD	?orthostatic intolerance, 604715 (3),
NAT10		
NAT11		
NAT12		
NAT13		
NAT15		
NAT16		
NAT2	AR	[acetylation, slow], 243400 (3),
NAT3	AR	intellectual developmental disorder, 73, 619717 (3),
NAT5	AR	intellectual developmental disorder, 73, 619717 (3),
NAT6		
NAT7	AR	n-acetylglutamate synthase deficiency, 237310 (3),
NAT8		
NAT8B		
NAT8BP		
NAT8L	AR	?n-acetylaspartate deficiency, 614063 (3),
NatF		
NATH	AD	intellectual developmental disorder, 50, with behavioral abnormalities, 617787 (3),
NATO3		
NAV1		
Nav1.1	AD	developmental and epileptic encephalopathy 6b, non-dravet, 619317 (3), ; migraine, familial hemiplegic, 3, 609634 (3), ; dravet syndrome, 607208 (3), ; febrile seizures, familial, 3a, 604403 (3), ; generalized epilepsy with febrile seizures plus, type 2, 604403 (3),
Nav1.2	AD	seizures, benign familial infantile, 3, 607745 (3), ; developmental and epileptic encephalopathy 11, 613721 (3), ; episodic ataxia, type 9, 618924 (3),
Nav1.3	AD	epilepsy, familial focal, with variable foci 4, 617935 (3), ; developmental and epileptic encephalopathy 62, 617938 (3),
Nav1.4	AD,AR	paramyotonia congenita, 168300 (3), ; hyperkalemic periodic paralysis, 170500 (3), ; congenital myopathy 22b, severe fetal, 620369 (3), ; hypokalemic periodic paralysis, type 2, 613345 (3), ; myotonia congenita, atypical, acetazolamide-responsive, 608390 (3), ; myasthenic syndrome, congenital, 16, 614198 (3), ; congenital myopathy 22a, classic, 620351 (3),
Nav1.5	AD,AR	ventricular fibrillation, familial, 1, 603829 (3); heart block, progressive, type ia, 113900 (3), ; cardiomyopathy, dilated, 1e, 601154 (3), ; heart block, nonprogressive, 113900 (3), ; long qt syndrome 3, 603830 (3), ; sick sinus syndrome 1, 608567 (3), ; brugada syndrome 1, 601144 (3), ; atrial fibrillation, familial, 10, 614022 (3), ; {sudden infant death syndrome, susceptibility to}, 272120 (3),
Nav1.6	AD	?myoclonus, familial, 2, 618364 (3), ; seizures, benign familial infantile, 5, 617080 (3), ; cognitive impairment with or without cerebellar ataxia, 614306 (3), ; developmental and epileptic encephalopathy 13, 614558 (3),
Nav1.7	AD,AR	erythermalgia, primary, 133020 (3), ; insensitivity to pain, congenital, 243000 (3), ; small fiber neuropathy, 133020 (3), ; paroxysmal extreme pain disorder, 167400 (3), ; neuropathy, hereditary sensory and autonomic, type iid, 243000 (3),
Nav1.8	AD	episodic pain syndrome, familial, 2, 615551 (3),
Nav1.9	AD	episodic pain syndrome, familial, 3, 615552 (3), ; neuropathy, hereditary sensory and autonomic, type vii, 615548 (3),
NAV2		
Nav2.1		
Nav2.2		
NAV3		
NAXD	AR	encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy, 2, 618321 (3),
NAXE	AR	encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy, 617186 (3),
NAZC		
NB		
NB-2		
NB-3		
Nb(III)		
NB1		
NB4S		
NBA1		
Nbak2		
NBAS	AR	short stature, optic nerve atrophy, and pelger-huet anomaly, 614800 (3), ; infantile liver failure syndrome 2, 616483 (3),
NBAT	AR,AD	cystinuria, 220100 (3),
NBAT-1		
NBAT1		
NBC1	AR	renal tubular acidosis, proximal, with ocular abnormalities, 604278 (3),
NBC2	AR	renal tubular acidosis, proximal, with ocular abnormalities, 604278 (3),
NBC3		
NBC4		
NBCCS	AD	basal cell nevus syndrome 1, 109400 (3), ; basal cell carcinoma, somatic, 605462 (3); holoprosencephaly 7, 610828 (3),
NBCe1	AR	renal tubular acidosis, proximal, with ocular abnormalities, 604278 (3),
NBCn2		
NBDY		
NBEA	AD	neurodevelopmental disorder with or without early-onset generalized epilepsy, 619157 (3),
NBEAL1		
NBEAL2	AR	gray platelet syndrome, 139090 (3),
NBEAP1		
NBIA1	AR	harp syndrome, 607236 (3), ; neurodegeneration with brain iron accumulation 1, 234200 (3),
NBIA2	AR	parkinson disease 14, 612953 (3), ; neurodegeneration with brain iron accumulation 2b, 610217 (3), ; infantile neuroaxonal dystrophy 1, 256600 (3),
NBIA3	AD,AR	hyperferritinemia-cataract syndrome, 600886 (3), ; l-ferritin deficiency, and , 615604 (3), ; neurodegeneration with brain iron accumulation 3, 606159 (3),
NBIA4	AR,AD	neurodegeneration with brain iron accumulation 4, 614298 (3), ; ?spastic paraplegia 43, 615043 (3),
NBIA5	XLD,XL	neurodegeneration with brain iron accumulation 5, 300894 (3),
NBK		
NBL1		
NBL4		
NBLA00058		
NBLA00301		
Nbla00650		
Nbla10058		
Nbla10143	AR	immunodeficiency-centromeric instability-facial anomalies syndrome 4, 616911 (3),
Nbla10314		
Nbla10388		
NBN	AR	leukemia, acute lymphoblastic, 613065 (3); aplastic anemia, 609135 (3); nijmegen breakage syndrome, 251260 (3),
NBND3	AR	?osteopetrosis, 9, 620366 (3),
NBP	AR,AD	pontocerebellar hypoplasia, type 12, 618266 (3), ; neurodegeneration with brain iron accumulation 6, 615643 (3), |premature ovarian failure 21, 620311 (3), ; ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3, 604292 (3), ; hay-wells syndrome, 106260 (3), ; split-hand/foot malformation 4, 605289 (3), ; orofacial cleft 8, 618149 (3); rapp-hodgkin syndrome, 129400 (3), ; adult syndrome, 103285 (3), ; limb-mammary syndrome, 603543 (3),
NBP1		
NBP16		
NBP35		
NBPF1		
NBPF10		
NBPF11		
NBPF12		
NBPF14		
NBPF15		
NBPF16		
NBPF19		
NBPF20		
NBPF24		
NBPF3		
NBPF4		
NBPF5		
NBPF5P		
NBPF6		
NBPF7		
NBPF7P		
NBPF8		
NBPF8P		
NBPF9		
NBPhox	AD	{neuroblastoma, susceptibility to, 2}, 613013 (3); neuroblastoma with hirschsprung disease, 613013 (3); central hypoventilation syndrome, congenital, 1, with or without hirschsprung disease, 209880 (3),
NBR		
NBR1		
NBR13	AD	spinocerebellar ataxia 42, 616795 (3), ; spinocerebellar ataxia 42, early-onset, severe, with neurodevelopmental deficits, 618087 (3),
NBR2		
NBS	AR	leukemia, acute lymphoblastic, 613065 (3); aplastic anemia, 609135 (3); nijmegen breakage syndrome, 251260 (3),
NBS1	AR,AR	leukemia, acute lymphoblastic, 613065 (3); aplastic anemia, 609135 (3); nijmegen breakage syndrome, 251260 (3), |oocyte/zygote/embryo maturation arrest 18, 620332 (3),
NC2-alpha		
NC2-BETA		
NC28		
NC2B		
nc886		
NCA		
NCAD	AD,AR	arrhythmogenic right ventricular dysplasia, familial, 14, 618920 (3), ; ?attention deficit-hyperactivity disorder 8, 619957 (3), ; agenesis of corpus callosum, cardiac, ocular, and genital syndrome, 618929 (3),
NCAG1		
NCALD		
NCAM		
NCAM-L1	XLR,XL	masa syndrome, 303350 (3), ; hydrocephalus, congenital, 307000 (3), ; ?corpus callosum, partial agenesis of, 304100 (3),
NCAM1		
NCAM2		
NCAM21		
NCAN		
NCAPD2	AR	?microcephaly 21, primary, 617983 (3),
NCAPD3	AR	microcephaly 22, primary, 617984 (3),
NCAPG		
NCAPG2	AR	khan-khan-katsanis syndrome, 618460 (3),
NCAPH	AR	?microcephaly 23, primary, 617985 (3),
NCAPH1	AR	?microcephaly 23, primary, 617985 (3),
NCAPH2		
NCB2		
NCB5OR		
NCBE		
NCBP		
NCBP1		
NCBP2		
NCBP3		
NCC	AR	gitelman syndrome, 263800 (3),
NCC-1		
NCC-2		
NCC-3		
NCC-4		
NCC27		
NCCP1		
NCCRP-1		
NCCRP1		
NCCT	AR	gitelman syndrome, 263800 (3),
NCDN	AD	neurodevelopmental disorder with infantile epileptic spasms, 619373 (3),
NCDN-1	AD	neurodevelopmental disorder with infantile epileptic spasms, 619373 (3),
NCDN-2	AD	neurodevelopmental disorder with infantile epileptic spasms, 619373 (3),
NCE2		
NCEH		
NCEH1		
NCF1	AR	chronic granulomatous disease 1, 233700 (3),
NCF1A	AR	chronic granulomatous disease 1, 233700 (3),
NCF2	AR	chronic granulomatous disease 2, 233710 (3),
NCF4	AR	chronic granulomatous disease 3, 613960 (3),
NCIE2	AR	chanarin-dorfman syndrome, 275630 (3),
NCK		
NCK1		
NCK2		
Nck5a		
NCK5AI		
NCKalpha		
NCKAP1		
NCKAP1L	AR	immunodeficiency 72 with autoinflammation, 618982 (3),
NCKAP2		
NCKAP3		
NCKAP4		
NCKAP5		
NCKAP5L		
NCKbeta		
NCKIPSD		
NCKX	AR	night blindness, congenital stationary (complete), 1d, 613830 (3),
NCKX1	AR	night blindness, congenital stationary (complete), 1d, 613830 (3),
NCKX2		
NCKX4	AR	[skin/hair/eye pigmentation 6, blond/brown hair], 210750 (3), ; amelogenesis imperfecta, type iia5, 615887 (3), ; [skin/hair/eye pigmentation 6, blue/green eyes], 210750 (3),
NCKX5	AR	[skin/hair/eye pigmentation 4, fair/dark skin], 113750 (3), ; albinism, oculocutaneous, type vi, 113750 (3),
NCKX6		
NCL		
nCL-1	AR,AD	muscular dystrophy, limb-girdle, 1, 253600 (3), ; muscular dystrophy, limb-girdle, 4, 618129 (3),
nCL-2		
nCL-3	AD	vitreoretinopathy, neovascular inflammatory, 193235 (3),
nCL-4		
nclf	AR	ceroid lipofuscinosis, neuronal, 6b (kufs type), 204300 (3), ; ceroid lipofuscinosis, neuronal, 6a, 601780 (3),
NCLN		
NCLX		
NCM		
NCM1		
NCoA-1		
NCoA-2		
NCoA-62		
NCOA1		
NCOA2		
NCOA3		
NCOA4		
NCOA5		
NCOA6		
NCOA6IP		
NCOA7		
NCOAT		
NCOR1		
NCOR2		
NCR1		
NCR2		
NCR3		{malaria, mild, susceptibility to}, 609148 (3)
NCR3LG1		
NCRMS		
ncRNA-a1		
NCRNA00001		x-inactivation, familial skewed, 300087 (3)
NCRNA00002		
NCRNA00003	MF,AD	{parkinson disease, susceptibility to}, 168600 (3), ; spinocerebellar ataxia 8, 608768 (3),
NCRNA00004		
NCRNA00005		
NCRNA00006		
NCRNA00007		
NCRNA00008		
NCRNA00009		
NCRNA00010		
NCRNA00011		
NCRNA00012	AD	beckwith-wiedemann syndrome, 130650 (3),
NCRNA00013		
NCRNA00014		
NCRNA00015	AD	schizophrenia, 181500 (2),
NCRNA00019		
NCRNA00020		
NCRNA00021		
NCRNA00022		
NCRNA00023		
NCRNA00024		
NCRNA00030		
NCRNA00035		
NCRNA00036		
NCRNA00037		
NCRNA00039		
NCRNA00040		
NCRNA00041		
NCRNA00043		
NCRNA00044		
NCRNA00045		
NCRNA00047		
NCRNA00048		
NCRNA00049		
NCRNA00054		
NCRNA00057		
NCRNA00058		
NCRNA00064		
NCRNA00065		
NCRNA00066		{myocardial infarction, susceptibility to}, 608446 (3)
NCRNA00067		
NCRNA00068		
NCRNA00071		
NCRNA00072		
NCRNA00075	AD	pseudohypoparathyroidism, type ib, 603233 (3),
NCRNA00076		
NCRNA00077		
NCRNA00078		
NCRNA00079		
NCRNA00080		
NCRNA00081	AR	?bardet-biedl syndrome 18, 615995 (3),
NCRNA00084		
NCRNA00085		
NCRNA00088		
NCRNA00089		
NCRNA00114		
NCRNA00140		
NCRNA00153	AR	retinitis pigmentosa 69, 615780 (3),
NCRNA00156		
NCRNA00162		
NCRNA00163		
NCRNA00170		
NCRNA00171		
NCRNA00177		
NCRNA00182		
NCRNA00183		
NCRNA00187		
NCRNA00190		
NCRNA00192		
NCRNA00194		
NCRNA00196		
NCRNA00197		
NCRNA00198		
NCRNA00199		
NCRNA00201	AD	developmental and epileptic encephalopathy 54, 617391 (3),
NCRNA00206		
NCRNA00213		
NCRNA00214		
NCRNA00237		
NCRNA00253		
NCRNA00261		
NCRNA00263		
NCRNA00277		
NCRNA00292		
NCRNA00293		
NCRNA00294		
NCRNA00295		
NCRNA00305		
NCRNA00312		
NCRNA00341		
NCS-1		
NCS1		
NCS2	AR	microcephaly, facial dysmorphism, renal agenesis, and ambiguous genitalia syndrome, 618142 (3),
NCS6		
NCSTN	AD	acne inversa, familial, 1, 142690 (3),
NCU-G1		
NCUBE1		
NCUBE2		
NCX		
NCX1		
NCX2		
NCX3		
NCYM		
ND1	AD	immunodeficiency 70, 618969 (3),
NDC1		
NDC80		
NDE	AR	microhydranencephaly, 605013 (3), ; lissencephaly 4 (with microcephaly), 614019 (3),
NDE1	AR	microhydranencephaly, 605013 (3), ; lissencephaly 4 (with microcephaly), 614019 (3),
NDE1L1		
NDE2		
NDEL1		
NDF		{?schizophrenia, susceptibility to}, 603013 (1)
NDFIP1		
NDFIP2		
NDG1		
NDIME		
NDK		
NDN		
NDNF	AD	hypogonadotropic hypogonadism 25 with anosmia, 618841 (3),
NDNL1	AD	schaaf-yang syndrome, 615547 (3),
NDNL2	AR	lung disease, immunodeficiency, and chromosome breakage syndrome, 617241 (3),
NDOR1		
NDP	XL,XLD,XLR	exudative vitreoretinopathy 2, 305390 (3), ; norrie disease, 310600 (3),
NDP52		
NDPKA		
NDPKB		
NDPKC		
NDPKD		
NDPP	AD	?inflammatory bowel disease (crohn disease) 30, 619079 (3),
NDPP1		
NDR		
NDR1	AR	charcot-marie-tooth disease, type 4d, 601455 (3),
NDR2		
NDRF	AD	developmental and epileptic encephalopathy 72, 618374 (3),
NDRG1	AR	charcot-marie-tooth disease, type 4d, 601455 (3),
NDRG2		
NDRG3		
NDRG4		
ndrp	AD	chung-jansen syndrome, 617991 (3),
NDSP		
NDST1	AR	intellectual developmental disorder, 46, 616116 (3),
NDST2		
NDST3		
NDST4		
Ndt80	AD	encephalitis/encephalopathy, mild, with reversible myelin vacuolization, 618113 (3), ; cardiac-urogenital syndrome, 618280 (3),
NDUFA1	XLR,XL	mitochondrial complex i deficiency, nuclear type 12, 301020 (3),
NDUFA10	AR	mitochondrial complex i deficiency, nuclear type 22, 618243 (3),
NDUFA11	AR	mitochondrial complex i deficiency, nuclear type 14, 618236 (3),
NDUFA12	AR	mitochondrial complex i deficiency, nuclear type 23, 618244 (3),
NDUFA12L	AR	mitochondrial complex i deficiency, nuclear type 10, 618233 (3),
NDUFA13	AR	{thyroid carcinoma, hurthle cell}, 607464 (3); ?mitochondrial complex i deficiency, nuclear type 28, 618249 (3),
NDUFA2	AR	mitochondrial complex i deficiency, nuclear type 13, 618235 (3),
NDUFA3		
NDUFA4	AR	?mitochondrial complex iv deficiency, nuclear type 21, 619065 (3),
NDUFA5		
NDUFA6	AR	mitochondrial complex i deficiency, nuclear type 33, 618253 (3),
NDUFA7		
NDUFA8	AR	mitochondrial complex i deficiency, nuclear type 37, 619272 (3),
NDUFA9	AR	mitochondrial complex i deficiency, nuclear type 26, 618247 (3),
NDUFAB1		
NDUFAF1	AR	mitochondrial complex i deficiency, nuclear type 11, 618234 (3),
NDUFAF2	AR	mitochondrial complex i deficiency, nuclear type 10, 618233 (3),
NDUFAF3	AR	mitochondrial complex i deficiency, nuclear type 18, 618240 (3),
NDUFAF4	AR	mitochondrial complex i deficiency, nuclear type 15, 618237 (3),
NDUFAF5	AR	mitochondrial complex i deficiency, nuclear type 16, 618238 (3),
NDUFAF6	AR	mitochondrial complex i deficiency, nuclear type 17, 618239 (3), ; fanconi renotubular syndrome 5, 618913 (3),
NDUFAF7		
NDUFAF8	AR	mitochondrial complex i deficiency, nuclear type 34, 618776 (3),
NDUFB1		
NDUFB10	AR	?mitochondrial complex i deficiency, nuclear type 35, 619003 (3),
NDUFB11	XLD,XL	linear skin defects with multiple congenital anomalies 3, 300952 (3), ; ?mitochondrial complex i deficiency, nuclear type 30, 301021 (3),
NDUFB2		
NDUFB3	AR	mitochondrial complex i deficiency, nuclear type 25, 618246 (3),
NDUFB4		
NDUFB5		
NDUFB6		
NDUFB7	AR	?mitochondrial complex i deficiency, nuclear type 39, 620135 (3),
NDUFB8	AR	mitochondrial complex i deficiency, nuclear type 32, 618252 (3),
NDUFB9	AR	?mitochondrial complex i deficiency, nuclear type 24, 618245 (3),
NDUFC1		
NDUFC2	AR	mitochondrial complex i deficiency, nuclear type 36, 619170 (3),
NDUFS1	AR	mitochondrial complex i deficiency, nuclear type 5, 618226 (3),
NDUFS2	AR	mitochondrial complex i deficiency, nuclear type 6, 618228 (3),
NDUFS2L	AR	mitochondrial complex i deficiency, nuclear type 26, 618247 (3),
NDUFS3	AR	mitochondrial complex i deficiency, nuclear type 8, 618230 (3),
NDUFS4	AR	mitochondrial complex i deficiency, nuclear type 1, 252010 (3),
NDUFS5		
NDUFS6	AR	mitochondrial complex i deficiency, nuclear type 9, 618232 (3),
NDUFS7	AR	mitochondrial complex i deficiency, nuclear type 3, 618224 (3),
NDUFS8	AR	mitochondrial complex i deficiency, nuclear type 2, 618222 (3),
NDUFV1	AR	mitochondrial complex i deficiency, nuclear type 4, 618225 (3),
NDUFV2	AR	mitochondrial complex i deficiency, nuclear type 7, 618229 (3),
NDUFV3		
NE	AD	neutropenia, cyclic, 162800 (3), ; neutropenia, severe congenital 1, 202700 (3),
NE-Dlg	XL,XLR	intellectual developmental disorder, 90, 300850 (3),
NE-NA	AD,AR	erythermalgia, primary, 133020 (3), ; insensitivity to pain, congenital, 243000 (3), ; small fiber neuropathy, 133020 (3), ; paroxysmal extreme pain disorder, 167400 (3), ; neuropathy, hereditary sensory and autonomic, type iid, 243000 (3),
NEAP		
NEAT1		
NEAT2		
NEB	AR	nemaline myopathy 2, 256030 (3), ; arthrogryposis multiplex congenita 6, 619334 (3),
NEB177D	AR	nemaline myopathy 2, 256030 (3), ; arthrogryposis multiplex congenita 6, 619334 (3),
NEBL		
NEC1	AR	{obesity, susceptibility to, bmiq12}, 612362 (3); endocrinopathy due to proprotein convertase 1/3 deficiency, 600955 (3),
NEC2		
NECAB2		
NECAB3		
NECAP1	AR	developmental and epileptic encephalopathy 21, 615833 (3),
NECAP2		
NECC1		
NECC2		
Necl-1	AD	charcot-marie-tooth disease, axonal, type 2ff, 619519 (3),
Necl-2		
Necl-3		
Necl-4		
Necl-5		
NECL1	AD	charcot-marie-tooth disease, axonal, type 2ff, 619519 (3),
NECL2		
NECL3		
NECL5		
Nectin-1	AR	cleft lip/palate-ectodermal dysplasia syndrome, 225060 (3), ; orofacial cleft 7, 225060 (3),
Nectin-2		
nectin-3		
nectin-4	AR	ectodermal dysplasia-syndactyly syndrome 1, 613573 (3),
NECTIN1	AR	cleft lip/palate-ectodermal dysplasia syndrome, 225060 (3), ; orofacial cleft 7, 225060 (3),
NECTIN2		
NECTIN3		
NECTIN4	AR	ectodermal dysplasia-syndactyly syndrome 1, 613573 (3),
Nedd-8		
NEDD1		
NEDD10		
NEDD2		
NEDD3		
NEDD4		
NEDD4-1		
NEDD4-2	AD	periventricular nodular heterotopia 7, 617201 (3),
NEDD4L	AD	periventricular nodular heterotopia 7, 617201 (3),
NEDD5		
NEDD6		
NEDD7		
NEDD8		
NEDD9		
NEDF		
NEDL1		
NEDL2	AD	neurodevelopmental disorder with hypotonia, seizures, and absent language, 617268 (3),
NEDLG	XL,XLR	intellectual developmental disorder, 90, 300850 (3),
NEDP1		
NEEP21		
NEF3		
NEF4	AR,AD	{amyotrophic lateral sclerosis, susceptibility to}, 105400 (3),
NEF5		
NEFA		
NEFH	AD,AR	charcot-marie-tooth disease, axonal, type 2cc, 616924 (3), ; {?amyotrophic lateral sclerosis, susceptibility to}, 105400 (3),
NEFL	AR,AD	charcot-marie-tooth disease, type 1f, 607734 (3), ; charcot-marie-tooth disease, intermediate g, 617882 (3), ; charcot-marie-tooth disease, type 2e, 607684 (3),
NEFM		
NEGF1		
NEGF2		
NEGR1		
NEH2		
NEI1		
NEIL1		
NEIL2		
NEIL3		
NEK1	AR,AD	short-rib thoracic dysplasia 6 with or without polydactyly, 263520 (3), digenic ; {amyotrophic lateral sclerosis, susceptibility to, 24}, 617892 (3),
NEK10	AR	ciliary dyskinesia, primary, 44, 618781 (3),
NEK11		
NEK2	AR	?retinitis pigmentosa 67, 615565 (3),
NEK2A	AR	?retinitis pigmentosa 67, 615565 (3),
NEK3		
NEK4		
NEK5		
NEK6		
NEK7		
Nek8	AR	?arthrogryposis, perthes disease, and upward gaze palsy, 614262 (3), ; nevus comedonicus, somatic, 617025 (3); lethal congenital contracture syndrome 10, 617022 (3),
NEK8	AR	renal-hepatic-pancreatic dysplasia 2, 615415 (3), ; ?nephronophthisis 9, 613824 (3)
NEK9	AR	?arthrogryposis, perthes disease, and upward gaze palsy, 614262 (3), ; nevus comedonicus, somatic, 617025 (3); lethal congenital contracture syndrome 10, 617022 (3),
NELF	AD	hypogonadotropic hypogonadism 9 with or without anosmia, 614838 (3),
NELF-A		
NELF-B		
NELF-C		
NELF-D		
NELF-E		
NELFA		
NELFB		
NELFCD		
NELFE		
NELIN	AD	cardiomyopathy, dilated, 1cc, 613122 (3), ; cardiomyopathy, hypertrophic, 20, 613876 (3),
NELL1		
NELL2		
NEM1	AD,AR	congenital myopathy 4a, 255310 (3), ; congenital myopathy 4b, 609284 (3),
NEM2	AR	nemaline myopathy 2, 256030 (3), ; arthrogryposis multiplex congenita 6, 619334 (3),
NEM3	AR,AD	congenital myopathy 2b, severe infantile, 620265 (3), ; ?myopathy, scapulohumeroperoneal, 616852 (3), ; congenital myopathy 2c, severe infantile, 620278 (3), ; congenital myopathy 2a, typical, 161800 (3),
NEM4	AD	arthrogryposis, distal, type 2b4, 108120 (3), ; arthrogryposis, distal, type 1a, 108120 (3), ; congenital myopathy 23, 609285 (3),
NEM5	AD,AR	nemaline myopathy 5c, 620389 (3), ; nemaline myopathy 5a, severe infantile, 605355 (3), ; nemaline myopathy 5b, childhood-onset, 620386 (3),
NEM6	AD	nemaline myopathy 6, 609273 (3),
NEM7	AR	nemaline myopathy 7, 610687 (3),
NEM8	AR	nemaline myopathy 8, 615348 (3),
NEMF	AR	intellectual developmental disorder with speech delay and axonal peripheral neuropathy, 619099 (3),
NEMO	XLD,XLR,XL	incontinentia pigmenti, 308300 (3), ; ectodermal dysplasia and immunodeficiency 1, 300291 (3), ; immunodeficiency 33, 300636 (3), ; autoinflammatory disease, systemic, 301081 (3),
NEMP1		
NEMP2		
NENA	AD,AR	erythermalgia, primary, 133020 (3), ; insensitivity to pain, congenital, 243000 (3), ; small fiber neuropathy, 133020 (3), ; paroxysmal extreme pain disorder, 167400 (3), ; neuropathy, hereditary sensory and autonomic, type iid, 243000 (3),
NENF		
NEO1		
NEOT2		
NEP	AD,AR	?spinocerebellar ataxia 43, 617018 (3), ; charcot-marie-tooth disease, axonal, type 2t, 617017 (3),
NEP1	AR	bowen-conradi syndrome, 211180 (3),
NEP1-R1		
NEPH1	AR	nephrotic syndrome, type 23, 619201 (3),
NEPH2		
NEPH3		
NEPII		
NEPPK	AD	palmoplantar keratoderma, nonepidermolytic, focal, 613000 (3), ; pachyonychia congenita 1, 167200 (3),
NEPRO	AR	anauxetic dysplasia 3, 618853 (3),
NER		
NER-I		
NERCC	AR	?arthrogryposis, perthes disease, and upward gaze palsy, 614262 (3), ; nevus comedonicus, somatic, 617025 (3); lethal congenital contracture syndrome 10, 617022 (3),
NERCC1	AR	?arthrogryposis, perthes disease, and upward gaze palsy, 614262 (3), ; nevus comedonicus, somatic, 617025 (3); lethal congenital contracture syndrome 10, 617022 (3),
NERF		
NERF-1A		
NERF-1B		
NERF-2		
NERPP-2C		
NES		
NES1		
NESCA		
NESG1	AR	heterotaxy, visceral, 11, with male infertility, 619608 (3),
NESH		
NESHBP		
NESP	AD	acth-independent macronodular adrenal hyperplasia, 219080 (3), somatic mutation; pituitary adenoma 3, multiple types, somatic, 617686 (3); pseudohypoparathyroidism ic, 612462 (3), ; pseudohypoparathyroidism ia, 103580 (3), ; osseous heteroplasia, progressive, 166350 (3), ; pseudohypoparathyroidism ib, 603233 (3), ; mccune-albright syndrome, somatic, mosaic, 174800 (3); pseudopseudohypoparathyroidism, 612463 (3),
NESP-AS	AD	pseudohypoparathyroidism, type ib, 603233 (3),
Nesp1	AR,AD	arthrogryposis multiplex congenita 3, myogenic type, 618484 (3), ; emery-dreifuss muscular dystrophy 4, 612998 (3), ; spinocerebellar ataxia, 8, 610743 (3),
Nesp2	AD	emery-dreifuss muscular dystrophy 5, 612999 (3),
Nesp3		
Nesp4	AR	deafness, 76, 615540 (3),
NESP55	AD	acth-independent macronodular adrenal hyperplasia, 219080 (3), somatic mutation; pituitary adenoma 3, multiple types, somatic, 617686 (3); pseudohypoparathyroidism ic, 612462 (3), ; pseudohypoparathyroidism ia, 103580 (3), ; osseous heteroplasia, progressive, 166350 (3), ; pseudohypoparathyroidism ib, 603233 (3), ; mccune-albright syndrome, somatic, mosaic, 174800 (3); pseudopseudohypoparathyroidism, 612463 (3),
NESPAS	AD	pseudohypoparathyroidism, type ib, 603233 (3),
Nesprin-1	AR,AD	arthrogryposis multiplex congenita 3, myogenic type, 618484 (3), ; emery-dreifuss muscular dystrophy 4, 612998 (3), ; spinocerebellar ataxia, 8, 610743 (3),
Nesprin-2	AD	emery-dreifuss muscular dystrophy 5, 612999 (3),
Nesprin-3		
Nesprin-4	AR	deafness, 76, 615540 (3),
nessy		
NET	AD	?orthostatic intolerance, 604715 (3),
NET-1		
NET-2	AD	exudative vitreoretinopathy 5, 613310 (3),
NET-4		
NET-5		
NET-6		
NET-7		
NET1	AD,AR,AD,AD	?orthostatic intolerance, 604715 (3), |hyperekplexia 3, 614618 (3), |mirror movements 4, 618264 (3),
NET10		
NET12		
NET13	AR	neurodevelopmental disorder with microcephaly, arthrogryposis, and structural brain anomalies, 618622 (3),
NET14		
NET15		
NET16		
NET17	AR	anauxetic dysplasia 3, 618853 (3),
NET18		
NET1A		
NET2		
NET21		
NET22	AD	diets-jongmans syndrome, 618846 (3),
NET23	AD	sting-associated vasculopathy, infantile-onset, 615934 (3),
NET24	AR	?arthrogryposis multiplex congenita 2, neurogenic type, 208100 (3),
NET25	AD,AR	marbach-rustad progeroid syndrome, 619322 (3), ; cataract 46, juvenile-onset, 212500 (3),
NET26		
NET27		
NET28	AR	neurodevelopmental disorder with cataracts, poor growth, and dysmorphic facies, 618571 (3),
NET29		
NET3		
NET30		
NET32	AR	spastic paraplegia 18, 611225 (3),
NET33		
NET34	AD,AR	?hyperostosis cranalis interna, 144755 (3), ; hypermanganesemia with dystonia 2, 617013 (3),
NET35		
NET36		
NET37	AR	basal ganglia calcification, idiopathic, 7, 618317 (3),
NET38	AR	congenital disorder of glycosylation, type ii, 607906 (3), ; myasthenic syndrome, congenital, 14, with tubular aggregates, 616228 (3),
NET39		
NET4	AR	craniotubular dysplasia, ikegawa type, 619727 (3),
NET40		
NET41		
NET42		
NET43		
NET44	AR	developmental and epileptic encephalopathy 3, 609304 (3),
NET45	AR	triokinase and fmn cyclase deficiency syndrome, 618805 (3),
NET46		
NET47		
NET48		
NET49		
NET51		
NET52		
NET53		
NET54	AR	?spermatogenic failure 30, 618110 (3),
NET56		
NET57	AR,AD	{moyamoya disease 2, susceptibility to}, 607151 (3),
NET59		
NET6		
NET60		
NET62		
NET67		
NET7		
NET8		
NET9		
NetG1		
NETO1		
NETO2		
NetrinG1		
NetrinG2	AR	neurodevelopmental disorder with behavioral abnormalities, absent speech, and hypotonia, 618718 (3),
NETS	AR	netherton syndrome, 256500 (3),
NEU	AR,AR	gastric cancer, somatic, 613659 (3); adenocarcinoma of lung, somatic, 211980 (3); ovarian cancer, somatic, 167000 (3); ?visceral neuropathy, familial, 2, 619465 (3), ; glioblastoma, somatic, 137800 (3)|sialidosis, type ii, 256550 (3), ; sialidosis, type i, 256550 (3),
neu-1		
NEU1	AR	sialidosis, type ii, 256550 (3), ; sialidosis, type i, 256550 (3),
NEU2		
NEU3		
NEU4		
Neucrin		
NEUD4		
NeuN		
Neur2		
Neurabin-I		
NEURL		
NEURL1		
NEURL1B		
NEURL2		
NEURL3		
NEURL4		
neuro-d4		
neurocrescin		
NeuroD	AD	{type 2 diabetes mellitus, susceptibility to}, 125853 (3), ; maturity-onset diabetes of the young 6, 606394 (3)
NEUROD	AD	{type 2 diabetes mellitus, susceptibility to}, 125853 (3), ; maturity-onset diabetes of the young 6, 606394 (3)
NEUROD1	AD	{type 2 diabetes mellitus, susceptibility to}, 125853 (3), ; maturity-onset diabetes of the young 6, 606394 (3)
NEUROD2	AD	developmental and epileptic encephalopathy 72, 618374 (3),
NEUROD3		
NEUROD4		
NEUROD6		
Neurodap1		
NEUROG1		
NEUROG2		
NEUROG3	AR	diarrhea 4, malabsorptive, congenital, 610370 (3),
neuropsin		
neurosin		
NEW1CP		
Nex1		
NEX1M		
nexilin	AD	cardiomyopathy, dilated, 1cc, 613122 (3), ; cardiomyopathy, hypertrophic, 20, 613876 (3),
nexin		
NEXMIF	XL,XLD	intellectual developmental disorder, 98, 300912 (3),
NEXN	AD	cardiomyopathy, dilated, 1cc, 613122 (3), ; cardiomyopathy, hypertrophic, 20, 613876 (3),
NEXN-AS1		
Nezha		
NF	AR	neurodevelopmental disorder with central and peripheral motor dysfunction, 618356 (3),
NF-66		
NF-AT5		
NF-ATC		
NF-ATP	AR	?joint contracture, osteochondromas, and b-cell lymphoma, 620232 (3),
NF-E1	AD,XL,XLR	gabriele-de vries syndrome, 617557 (3), |leukemia, megakaryoblastic, with or without down syndrome, somatic, 190685 (3); thrombocytopenia, with or without dyserythropoietic anemia, 300367 (3), ; anemia, with/without neutropenia and/or platelet abnormalities, 300835 (3), ; thrombocytopenia with beta-thalassemia, 314050 (3), ; hemolytic anemia due to elevated adenosine deaminase, 301083 (3),
NF-E2		
NF-E3	AD	46xx sex reversal 5, 618901 (3), ; congenital heart defects, multiple types, 4, 615779 (3),
NF-E4		
NF-H	AD,AR	charcot-marie-tooth disease, axonal, type 2cc, 616924 (3), ; {?amyotrophic lateral sclerosis, susceptibility to}, 105400 (3),
NF-HEV		
NF-I		
NF-IL3A		
NF-IL6-beta		
NF-kappaB	AD	immunodeficiency, common variable, 12, 616576 (3),
NF-kB1	AD	immunodeficiency, common variable, 12, 616576 (3),
NF-kB2	AD	immunodeficiency, common variable, 10, 615577 (3),
NF-M		
NF-YA		
NF-YB		
NF-YC		
NF1	AD	watson syndrome, 193520 (3), ; leukemia, juvenile myelomonocytic, 607785 (3), somatic mutation, ; neurofibromatosis, familial spinal, 162210 (3), ; neurofibromatosis, type 1, 162200 (3), ; neurofibromatosis-noonan syndrome, 601321 (3),
NF110		
NF110b		
NF15S2		
NF1A	AD	marshall-smith syndrome, 602535 (3), ; malan syndrome, 614753 (3),
NF2	AD	neurofibromatosis, type 2, 101000 (3), ; meningioma, nf2-related, somatic, 607174 (3); schwannomatosis, somatic, 162091 (3)
NF45		
NF68	AR,AD	charcot-marie-tooth disease, type 1f, 607734 (3), ; charcot-marie-tooth disease, intermediate g, 617882 (3), ; charcot-marie-tooth disease, type 2e, 607684 (3),
NF90		
NF90a		
NF90c		
NF90ctv		
NFAM1		
NFAR-1		
NFAR-2		
NFAR110		
NFAR90		
NFASC	AR	neurodevelopmental disorder with central and peripheral motor dysfunction, 618356 (3),
NFAT1	AR	?joint contracture, osteochondromas, and b-cell lymphoma, 620232 (3),
NFAT2		
NFAT3		
NFAT4		
NFAT5		
NFATc		
NFATC1		
NFATC2	AR	?joint contracture, osteochondromas, and b-cell lymphoma, 620232 (3),
NFATC2IP		
NFATC3		
NFATC4		
NFATL1		
NFATp	AR	?joint contracture, osteochondromas, and b-cell lymphoma, 620232 (3),
NFATX		
NFATZ		
Nfb42		
NFBD1		
NFBP		
NFE1	XL,XLR	leukemia, megakaryoblastic, with or without down syndrome, somatic, 190685 (3); thrombocytopenia, with or without dyserythropoietic anemia, 300367 (3), ; anemia, with/without neutropenia and/or platelet abnormalities, 300835 (3), ; thrombocytopenia with beta-thalassemia, 314050 (3), ; hemolytic anemia due to elevated adenosine deaminase, 301083 (3),
NFE1B	AD	{leukemia, acute myeloid, susceptibility to}, 601626 (3), somatic mutation, ; emberger syndrome, 614038 (3), ; immunodeficiency 21, 614172 (3), ; {myelodysplastic syndrome, susceptibility to}, 614286 (3)
NFE2		
NFE2L1		
NFE2L2	AD	immunodeficiency, developmental delay, and hypohomocysteinemia, 617744 (3),
NFE2L3		
NFE2U		
NFE4		
NFH	AD,AR	charcot-marie-tooth disease, axonal, type 2cc, 616924 (3), ; {?amyotrophic lateral sclerosis, susceptibility to}, 105400 (3),
NFI		
NFI-L	AD	brain malformations with or without urinary tract defects, 613735 (3),
NFI-RED	AD	macrocephaly, acquired, with impaired intellectual development, 618286 (3),
NFIA	AD	brain malformations with or without urinary tract defects, 613735 (3),
NFIB	AD	macrocephaly, acquired, with impaired intellectual development, 618286 (3),
NFIB2	AD	macrocephaly, acquired, with impaired intellectual development, 618286 (3),
NFIB3	AD	macrocephaly, acquired, with impaired intellectual development, 618286 (3),
NFIC		
NFIL3		
NFIL3A		
NFIL6		
NFIX	AD	marshall-smith syndrome, 602535 (3), ; malan syndrome, 614753 (3),
NFkappaB	AD	immunodeficiency, common variable, 12, 616576 (3),
NFKB-p50	AD	immunodeficiency, common variable, 12, 616576 (3),
NFKB1	AD	immunodeficiency, common variable, 12, 616576 (3),
NFKB2	AD	immunodeficiency, common variable, 10, 615577 (3),
NFKB3	AD	autoinflammatory disease, familial, behcet-like-3, 618287 (3),
NFKBI	AD	ectodermal dysplasia and immunodeficiency 2, 612132 (3),
NFKBIA	AD	ectodermal dysplasia and immunodeficiency 2, 612132 (3),
NFKBIB		
NFKBID		
NFKBIE		
NFKBIKA	AR	?popliteal pterygium syndrome, bartsocas-papas type 2, 619339 (3), ; ?cocoon syndrome, 613630 (3),
NFKBIKB	AR,AD	immunodeficiency 15b, 615592 (3), ; immunodeficiency 15a, 618204 (3),
NFKBIL		{rheumatoid arthritis, susceptibility to}, 180300 (3)
NFKBIL1		{rheumatoid arthritis, susceptibility to}, 180300 (3)
NFKBIL2	AR	spondyloepimetaphyseal dysplasia, sponastrime type, 271510 (3),
NFKBIZ		
NFL	AR,AD	charcot-marie-tooth disease, type 1f, 607734 (3), ; charcot-marie-tooth disease, intermediate g, 617882 (3), ; charcot-marie-tooth disease, type 2e, 607684 (3),
NFM		
NFRKB		
NFS1	AR	combined oxidative phosphorylation deficiency 52, 619386 (3),
NFSK		
NFT2		
NFU1	AR	multiple mitochondrial dysfunctions syndrome 1, 605711 (3),
NFX1		
NFX2		
NFYA		
NFYB		
NFYC		
NG.1		
NG1		
NG2		
NG20		
NG22	AD	?deafness, 72, 617606 (3),
NG24		
NG25		
NG26	AR	spastic paraplegia 86, 619735 (3),
NG3		
NG31	AR	?thrombocytopenia, anemia, and myelofibrosis, 617441 (3),
NG32		
NG33		
NG36/G9a		
NG37		
NG38		
NG5		
NG7		
NGAL		
NGalNAc-T1		
NGALR		
nGAP		
NGB		
NgBR	AD,AR	intellectual developmental disorder, 55, with seizures, 617831 (3), ; ?congenital disorder of glycosylation, type 1aa, 617082 (3),
NGC		
NGD		
NGD2	AR	short-rib thoracic dysplasia 16 with or without polydactyly, 617102 (3),
NGD5	AR	short-rib thoracic dysplasia 16 with or without polydactyly, 617102 (3),
NGDN		
NGEF		
NGEP		
NGF	AR	neuropathy, hereditary sensory and autonomic, type v, 608654 (3),
NGF2		
NGFB	AR	neuropathy, hereditary sensory and autonomic, type v, 608654 (3),
NGFI-A		
NGFI-C		
NGFIB		
NGFR		
NGFRAP1		
NGFRAP1L1		
NGG1		
NGL	AR	gastric cancer, somatic, 613659 (3); adenocarcinoma of lung, somatic, 211980 (3); ovarian cancer, somatic, 167000 (3); ?visceral neuropathy, familial, 2, 619465 (3), ; glioblastoma, somatic, 137800 (3)
NGL-1		
NGL-2		
NGLY1	AR	congenital disorder of deglycosylation 1, 615273 (3),
NGN		
ngn-2		
ngn1		
NGN2		
ngn3	AR	diarrhea 4, malabsorptive, congenital, 610370 (3),
Ngp-1		
NgR2		
NgR3		
NGRH1		
NGRH2		
NGRN		
NGS17	AR	bare lymphocyte syndrome, type i, 604571 (3),
NGX6		
NGX6a		
NHA1		
NHA2		
NHE		
NHE-1	AR	lichtenstein-knorr syndrome, 616291 (3),
NHE-3	AR	diarrhea 8, secretory sodium, congenital, 616868 (3),
NHE-6	XL	intellectual developmental disorder, syndromic, christianson type, 300243 (3),
NHE-7	XL,XLR	intellectual developmental disorder, 108, 301024 (3),
NHE-RF	AD	nephrolithiasis/osteoporosis, hypophosphatemic, 2, 612287 (3),
NHE1	AR	lichtenstein-knorr syndrome, 616291 (3),
NHE2		
NHE3	AR	diarrhea 8, secretory sodium, congenital, 616868 (3),
NHE4		
NHE5		
NHE6	XL	intellectual developmental disorder, syndromic, christianson type, 300243 (3),
NHE7	XL,XLR	intellectual developmental disorder, 108, 301024 (3),
NHE8		
NHE9		{?autism susceptibility 16}, 613410 (3)
NHEDC1		
NHEDC2		
NHEJ1		severe combined immunodeficiency with microcephaly, growth retardation, and sensitivity to ionizing radiation, 611291 (3)
NHERF	AD	nephrolithiasis/osteoporosis, hypophosphatemic, 2, 612287 (3),
NHERF-1	AD	nephrolithiasis/osteoporosis, hypophosphatemic, 2, 612287 (3),
NHERF-2		
NHERF1	AD	nephrolithiasis/osteoporosis, hypophosphatemic, 2, 612287 (3),
NHERF2		
NHERF3		
NHERF4		
NHL	AD,AR	dyskeratosis congenita, 4, 615190 (3), ; dyskeratosis congenita, 5, 615190 (3), ; pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 3, 616373 (3),
NHLH1		
NHLH2	AR	?hypogonadotropic hypogonadism 27 without anosmia, 619755 (3),
NHLRC1	AR	epilepsy, progressive myoclonic 2b (lafora), 254780 (3),
NHLRC2	AR	finca syndrome, 618278 (3),
NHP2	AR	dyskeratosis congenita, 2, 613987 (3),
NHP2L1		
NHS	XL,XLD	cataract 40, 302200 (3), ; nance-horan syndrome, 302350 (3),
NHSL1		
NHSL2		
NIACR1		
NIAM		
NIBAN		
NIBAN1		
NIBAN2		
NIBAN3		
NIBP	AR	intellectual developmental disorder, 13, 613192 (3),
NICAL		
NICALIN		
NICE-1		
NICE-3		
NICE-4		
NICE-5		
nicein-100kDa	AR	epidermolysis bullosa, junctional 3b, severe, 619786 (3), ; epidermolysis bullosa, junctional 3a, intermediate, 619785 (3),
nicein-125kDa	AR,AD	epidermolysis bullosa, junctional 1b, severe, 226700 (3), ; epidermolysis bullosa, junctional 1a, intermediate, 226650 (3), ; amelogenesis imperfecta, type ia, 104530 (3),
nicein-150kDa	AR	epidermolysis bullosa, junctional 2a, intermediate, 619783 (3), ; epidermolysis bullosa, junctional 2c, laryngoonychocutaneous, 245660 (3), ; epidermolysis bullosa, junctional 2b, severe, 619784 (3),
NICN1		
NICOL		
NICOL1		
NID		
NID1		
NID2		
NID67		
NIF		
NIF-1	AR	microcephaly 10, primary, 615095 (3),
NIF3L1		
NIF3L1BP1		
NIFIE14	AR	neurodevelopmental disorder with facial dysmorphism, absent language, and pseudo-pelger-huet anomaly, 620075 (3),
NIFK		
NifS	AR	combined oxidative phosphorylation deficiency 52, 619386 (3),
NifU	AR	multiple mitochondrial dysfunctions syndrome 1, 605711 (3),
NIFUC	AR	multiple mitochondrial dysfunctions syndrome 1, 605711 (3),
NIFUN	AR	myopathy with lactic acidosis, hereditary, 255125 (3),
NIK		
NIL-2-A	AD	corneal dystrophy, posterior polymorphous, 3, 609141 (3), ; corneal dystrophy, fuchs endothelial, 6, 613270 (3),
NIM3		
NIMP	AR	optic atrophy 10 with or without ataxia, impaired intellectual development and seizures, 616732 (3),
NIN	AR	?seckel syndrome 7, 614851 (3),
NIN1		
Nin1p		
nin283		
NINJ1		
NINJ2		
NINL		
Nip	AR	muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 7, 616052 (3), ; muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 7, 614643 (3),
NIP	AD	oculopharyngodistal myopathy 2, 618940 (3),
Nip1		
NIP1		
Nip2		
Nip3		
NIP30		
NIP45		
NIP7		
Nip7-1		
NIPA		
NIPA1	AD	spastic paraplegia 6, 600363 (3),
NIPA2		
NIPA3		
NIPA4	AR	ichthyosis, congenital, 6, 612281 (3),
NIPAL1		
NIPAL3		
NIPAL4	AR	ichthyosis, congenital, 6, 612281 (3),
NIPBL	AD	cornelia de lange syndrome 1, 122470 (3),
NIPP-1		
NIPP1		
NIPSNAP1		
NIPSNAP2		
NIPSNAP3		
NIPSNAP3A		
NIPSNAP3B		
NIPSNAP4		
NIR		
NIR1	AD	cone-rod dystrophy 5, 600977 (3),
NIR2		
NIR3		
NIRF		
NIS	AR	thyroid dyshormonogenesis 1, 274400 (3),
NISCH		
NIT1		
NIT2		
Nix		
NJAC		
NK-1		
NK-p44		
NK-p46		
NK1		
NK10		
NK1R		
NK28		
NK2R		
NK3	AR	hypogonadotropic hypogonadism 10 with or without anosmia, 614839 (3),
NK3R	AR	hypogonadotropic hypogonadism 11 with or without anosmia, 614840 (3),
NK4		
NKAIN1		
NKAIN2		
NKAIN3		
NKAIN3-IT1		
NKAIN4		
NKAP	XL,XLR	intellectual developmental disorder, syndromic, hackman-di donato type, 301039 (3),
nkat1		
nkat2		
nkat2a		
nkat2b		
nkat3		{aids, delayed/rapid progression to}, 609423 (3)
nkat4		
nkat4a		
nkat4b		
nkat5		
nkat6		
nkat7		
nkat8		
nkat9		
NKB	AR	hypogonadotropic hypogonadism 10 with or without anosmia, 614839 (3),
NKB1		{aids, delayed/rapid progression to}, 609423 (3)
NKB1B		{aids, delayed/rapid progression to}, 609423 (3)
NKCC1	AR,AD	kilquist syndrome, 619080 (3), ; delpire-mcneill syndrome, 619083 (3), ; deafness, 78, 619081 (3),
NKCC2	AR	bartter syndrome, type 1, 601678 (3),
NKD1		
NKD2		
NKEFA	AR	methylmalonic aciduria and homocystinuria, cblc type, digenic, 277400 (3),
NKEFB		
NKG2		
NKG2-A		
NKG2-B		
NKG2-C		
NKG2-D		
NKG2-E		
NKG2-F		
NKG2C		
NKG2D		
NKG5		
NKG7		
NKH	AR	glycine encephalopathy 2, 620398 (3)|glycine encephalopathy1, 605899 (3),
NKHC	AD	myoclonus, intractable, neonatal, 617235 (3), ; {amyotrophic lateral sclerosis, susceptibility to, 25}, 617921 (3), ; spastic paraplegia 10, 604187 (3),
NKHC2	AD	cortical dysplasia, complex, with other brain malformations 2, 615282 (3),
NKIAMRE		
NKIR		
NKIRAS1		
NKIRAS2		
NKLAM		
NKNA		
NKNAR		
NKNB	AR	hypogonadotropic hypogonadism 10 with or without anosmia, 614839 (3),
NKp30		{malaria, mild, susceptibility to}, 609148 (3)
NKP46		
NKp65		
NKp80		
NKR	AR	hypogonadotropic hypogonadism 11 with or without anosmia, 614840 (3),
NKR-P1		
NKR-P1A		
NKR2B4		{rheumatoid arthritis, susceptibility to}, 180300 (3)
NKRF		
NKSF	AR	immunodeficiency 29, mycobacteriosis, 614890 (3),
NKSF1		
NKSF2	AR	immunodeficiency 29, mycobacteriosis, 614890 (3),
NKTL	AR	spinocerebellar ataxia, 21, 616719 (3),
NKTR		
NKX1-1		
NKX2-1	AD	chorea, hereditary benign, 118700 (3), ; {thyroid cancer, nonmedullary, 1}, 188550 (3), ; choreoathetosis, hypothyroidism, and neonatal respiratory distress, 610978 (3),
NKX2-2		
NKX2-3		
NKX2-4		
NKX2-5	AD	hypoplastic left heart syndrome 2, 614435 (3), ; tetralogy of fallot, 187500 (3), ; hypothyroidism, congenital nongoitrous, 5, 225250 (3), ; conotruncal heart malformations, variable, 217095 (3); ventricular septal defect 3, 614432 (3), ; atrial septal defect 7, with or without av conduction defects, 108900 (3),
NKX2-6		persistent truncus arteriosus, 217095 (3); conotruncal heart malformations, 217095 (3)
NKX2-8		
Nkx2-9		
NKX2.2		
NKX2.3		
NKX2.4		
NKX2.5	AD	hypoplastic left heart syndrome 2, 614435 (3), ; tetralogy of fallot, 187500 (3), ; hypothyroidism, congenital nongoitrous, 5, 225250 (3), ; conotruncal heart malformations, variable, 217095 (3); ventricular septal defect 3, 614432 (3), ; atrial septal defect 7, with or without av conduction defects, 108900 (3),
NKX2.8		
NKX2A	AD	chorea, hereditary benign, 118700 (3), ; {thyroid cancer, nonmedullary, 1}, 188550 (3), ; choreoathetosis, hypothyroidism, and neonatal respiratory distress, 610978 (3),
NKX2B		
NKX2C		
NKX2D		
NKX2E	AD	hypoplastic left heart syndrome 2, 614435 (3), ; tetralogy of fallot, 187500 (3), ; hypothyroidism, congenital nongoitrous, 5, 225250 (3), ; conotruncal heart malformations, variable, 217095 (3); ventricular septal defect 3, 614432 (3), ; atrial septal defect 7, with or without av conduction defects, 108900 (3),
NKX2H		
NKX3-1		
NKX3-2	AR	spondylo-megaepiphyseal-metaphyseal dysplasia, 613330 (3),
NKX3.1		
NKX3.2	AR	spondylo-megaepiphyseal-metaphyseal dysplasia, 613330 (3),
NKX3A		
NKX3B	AR	spondylo-megaepiphyseal-metaphyseal dysplasia, 613330 (3),
NKX4-1	AD	hypoplastic left heart syndrome 2, 614435 (3), ; tetralogy of fallot, 187500 (3), ; hypothyroidism, congenital nongoitrous, 5, 225250 (3), ; conotruncal heart malformations, variable, 217095 (3); ventricular septal defect 3, 614432 (3), ; atrial septal defect 7, with or without av conduction defects, 108900 (3),
NKX4-2		persistent truncus arteriosus, 217095 (3); conotruncal heart malformations, 217095 (3)
NKX4-3		
NKX5-1		
NKX5-2		
NKX5-3	AR	oculoauricular syndrome, 612109 (3),
NKX6-1		
NKX6-2	AR	spastic ataxia 8, with hypomyelinating leukodystrophy, 617560 (3),
NKX6-3		
Nkx6.1		
NKX6.1	AR	spastic ataxia 8, with hypomyelinating leukodystrophy, 617560 (3),
NKX6A		
NKX6B	AR	spastic ataxia 8, with hypomyelinating leukodystrophy, 617560 (3),
NL1		
NL2	AD	plasma triglyceride level qtl, low, 615881 (3),
NLBP		
NLC1-A		
NLC1-C		
NLC1A		
NLF-1		
NLF1		
NLF2		
NLF3		
NLG1		
NLGN	XL	intellectual developmental disorder, 300495 (3), ; {autism susceptibility, 2}, 300495 (3),
NLGN1	AD	{autism, susceptibility to, 20}, 618830 (3),
NLGN2		
NLGN3	XL	{autism susceptibility, 1}, 300425 (3),
NLGN4	XL	intellectual developmental disorder, 300495 (3), ; {autism susceptibility, 2}, 300495 (3),
NLGN4X	XL	intellectual developmental disorder, 300495 (3), ; {autism susceptibility, 2}, 300495 (3),
NLGN4Y		
NLI		
NLIIF		
NLK	AR	hemolytic anemia, nonspherocytic, due to glucose phosphate isomerase deficiency, 613470 (3),
NLK1	AR	?retinitis pigmentosa 67, 615565 (3),
NLN		
NLP		
NLP_1		
NLRA	AR	{rheumatoid arthritis, susceptibility to}, 180300 (3); bare lymphocyte syndrome, type ii, complementation group a, 209920 (3),
NLRB1		
NLRC1		
NLRC2	AD,MF	blau syndrome, 186580 (3), ; {yao syndrome}, 617321 (3), ; {inflammatory bowel disease 1, crohn disease}, 266600 (3),
NLRC3		
NLRC4	AD	?familial cold autoinflammatory syndrome 4, 616115 (3), ; autoinflammation with infantile enterocolitis, 616050 (3),
NLRC5		
NLRP1	AR,AD	{vitiligo-associated multiple autoimmune disease susceptibility 1}, 606579 (3); ?respiratory papillomatosis, juvenile recurrent, congenital, 618803 (3), ; autoinflammation with arthritis and dyskeratosis, 617388 (3), ; palmoplantar carcinoma, multiple self-healing, 615225 (3),
NLRP10		
NLRP11		
NLRP12	AD	familial cold autoinflammatory syndrome 2, 611762 (3),
NLRP13		
NLRP14		
NLRP2	AR	oocyte/zygote/embryo maturation arrest 18, 620332 (3),
NLRP3	AD	cinca syndrome, 607115 (3), ; familial cold inflammatory syndrome 1, 120100 (3), ; keratoendothelitis fugax hereditaria, 148200 (3), ; deafness, 34, with or without inflammation, 617772 (3), ; muckle-wells syndrome, 191900 (3),
NLRP4		
NLRP5	AR	oocyte/zygote/embryo maturation arrest 19, 620333 (3),
NLRP6		
NLRP7	AR	hydatidiform mole, recurrent, 1, 231090 (3),
NLRP8		
NLRP9		
NLRR3		
NLRR4		
NLRX1		
NLT		
NLVCF		
NLZ1		
Nlz2		
nM15	AD	schaaf-yang syndrome, 615547 (3),
NM23		
NM23-H1		
NM23-H10	XL	retinitis pigmentosa 2, 312600 (3),
NM23-H2		
NM23-H3		
nm23-H4		
nm23-H5	AR	ciliary dyskinesia, primary, 48, without situs inversus, 620032 (3),
NM23-H6		
NM23-H7		
NM23-H8	AR	?ciliary dyskinesia, primary, 6, 610852 (3),
NM23-H9		
NM23H4		
NMA		
NMB	AR	amyloidosis, primary localized cutaneous, 3, 617920 (3),
NMBR		
NMD3		
NMDAR1	AR,AD	neurodevelopmental disorder with or without hyperkinetic movements and seizures, 617820 (3), ; developmental and epileptic encephalopathy 101, 619814 (3), ; neurodevelopmental disorder with or without hyperkinetic movements and seizures, 614254 (3),
NMDAR2A	AD	epilepsy, focal, with speech disorder and with or without impaired intellectual development, 245570 (3),
NMDAR2B	AD	developmental and epileptic encephalopathy 27, 616139 (3), ; intellectual developmental disorder, 6, with or without seizures, 613970 (3),
NMDAR2C		
NMDAR2D	AD	developmental and epileptic encephalopathy 46, 617162 (3),
NMDARA1		
NME1	AR	anauxetic dysplasia 1, 607095 (3), ; metaphyseal dysplasia without hypotrichosis, 250460 (3), ; cartilage-hair hypoplasia, 250250 (3),
NME10	XL	retinitis pigmentosa 2, 312600 (3),
NME2		
NME3		
NME4		
NME5	AR	ciliary dyskinesia, primary, 48, without situs inversus, 620032 (3),
NME6		
NME7		
NME8	AR	?ciliary dyskinesia, primary, 6, 610852 (3),
NME9		
NMES1		
NMHC-II-A	AD	macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss, 155100 (3), ; deafness, 17, 603622 (3),
NMI		
NMIG		
NML		
NMLY6		
NMMHCA	AD	macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss, 155100 (3), ; deafness, 17, 603622 (3),
NMMHCB		
NMNAT	AR	spondyloepiphyseal dysplasia, sensorineural hearing loss, intellectual developmental disorder, and leber congenital amaurosis, 619260 (3), ; leber congenital amaurosis 9, 608553 (3),
NMNAT1	AR	spondyloepiphyseal dysplasia, sensorineural hearing loss, intellectual developmental disorder, and leber congenital amaurosis, 619260 (3), ; leber congenital amaurosis 9, 608553 (3),
NMNAT2		
NMNAT3		
NMO-1		
NMOR1		{breast cancer, poor survival after chemotherapy for} (3); {leukemia, post-chemotherapy, susceptibility to} (3); {benzene toxicity, susceptibility to} (3)
NMOR2	AD	{?breast cancer susceptibility}, 114480 (1), somatic mutation,
NMP200		
NMP238		
NMP35		
NMP4		
NMRAL1		
Nmrk		{rheumatoid arthritis, susceptibility to}, 180300 (3)
NMRK1		
NMRK2		
NMS		
NMT		
NMT1		
NMT2		
NMT55	XL	intellectual developmental disorder, syndromic 34, 300967 (3),
NMU		
NMU1R		
NMU2R		
NMUR1		
NMUR2		
NMYC	AD	feingold syndrome 1, 164280 (3),
NN8-4AG		
Nna1	AR	neurodegeneration, childhood-onset, with cerebellar atrophy, 618276 (3),
NNAT		
NNMT		homocysteine plasma level, 600008 (2)
NNO2	AR	microphthalmia, isolated 5, 611040 (3), ; nanophthalmos 2, 609549 (3)
nNOS		
NNP-1		
Nnp1		
NNT	AR	glucocorticoid deficiency 4, with or without mineralocorticoid deficiency, 614736 (3),
NNT-1	AR	cold-induced sweating syndrome 2, 610313 (3),
NNT1	AR	cold-induced sweating syndrome 2, 610313 (3),
NNX3		
NO145		
NO3		
NO52		
NO55		
NO66		
NOA1		
NOA36		
NOB1		
NOB1P		
NoBody		
NOBOX	AD	premature ovarian failure 5, 611548 (3),
NOBP		
NOC		
Noc2		
NOC2L		
NOC3L		
Noc4		
NOC4		
NOC4L		
NOCIR		
NOCT		
NOD1		
NOD12	AR	hydatidiform mole, recurrent, 1, 231090 (3),
NOD14		
NOD16		
NOD17		
NOD2	AD,MF	blau syndrome, 186580 (3), ; {yao syndrome}, 617321 (3), ; {inflammatory bowel disease 1, crohn disease}, 266600 (3),
NOD27		
NOD3		
NOD5		
NOD6		
NOD8		
NOD9		
NODAL	AD	heterotaxy, visceral, 5, 270100 (3),
NOE1		
NOE2		
NOE3		
NOELIN		
NOEY2		
NOF		
NOF1		
NOG	AD	symphalangism, proximal, 1a, 185800 (3), ; brachydactyly, type b2, 611377 (3), ; stapes ankylosis with broad thumbs and toes, 184460 (3), ; tarsal-carpal coalition syndrome, 186570 (3), ; multiple synostoses syndrome 1, 186500 (3),
NOG1		
Nog2		
NOGO		
NOGOR	AD	{schizophrenia, susceptibility to}, 181500 (3),
NOH-1		
NOH-1L		
NOH1		
NOH61		
NOHLH	AR,AD	ovarian dysgenesis 5, 617690 (3), ; spermatogenic failure 32, 618115 (3),
NOK		
NOL1		
NOL10		
NOL11		
NOL14		
NOL1R		
NOL3	AD	?myoclonus, familial, 1, 614937 (3),
NOL4		
NOL4L		
NOL5A	AD	spinocerebellar ataxia 36, 614153 (3),
NOL6		
NOL7		
NOL8		
NOL9		
NOLA1		
NOLA2	AR	dyskeratosis congenita, 2, 613987 (3),
NOLA3	AD,AR	?pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 9, 620400 (3), ; ?dyskeratosis congenita, 1, 224230 (3),
NOLA4	XL,XLR	dyskeratosis congenita, 305000 (3),
NOLC1		
NOLP		
NOM1		
NOMO		
NOMO1		
NOMO2		
NOMO3		
NONO	XL	intellectual developmental disorder, syndromic 34, 300967 (3),
NOP		
Nop1		
NOP10	AD,AR	?pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 9, 620400 (3), ; ?dyskeratosis congenita, 1, 224230 (3),
NOP10P	AD,AR	?pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 9, 620400 (3), ; ?dyskeratosis congenita, 1, 224230 (3),
NOP120		
Nop132		
NOP14		
NOP16		
NOP17		
NOP2		
NOP27		
NOP30	AD	?myoclonus, familial, 1, 614937 (3),
NOP4	AR	?alopecia, neurologic defects, and endocrinopathy syndrome, 612079 (3),
NOP5		
Nop52		
NOP52		
NOP53		
NOP56	AD	spinocerebellar ataxia 36, 614153 (3),
NOP58		
NOP7		
NOP9		
NOPD1		
NOPE		
NOPP130		
NOPP140		
Nopp34		
NOPr		
NOR-90	AD	neurodegeneration, childhood-onset, with brain atrophy, 617672 (3),
NOR1		chondrosarcoma, extraskeletal myxoid, 612237 (3)
NORAD		
NORE1		
NORE2A		
NORF1		
Nori-2p	AR	galloway-mowat syndrome 4, 617730 (3),
Nori-3		
NORPEG		
norrin	XL,XLD,XLR	exudative vitreoretinopathy 2, 305390 (3), ; norrie disease, 310600 (3),
NOS		{malaria, resistance to}, 611162 (3)
NOS1	AD	spermatogenic failure 12, 615413 (3),
NOS1AP	AR	nephrotic syndrome, type 22, 619155 (3),
NOS2		{malaria, resistance to}, 611162 (3)
NOS2A		{malaria, resistance to}, 611162 (3)
NOS2B		
NOS2P2		
NOS3	MF,AD	{coronary artery spasm 1, susceptibility to} (3); {hypertension, susceptibility to}, 145500 (3), ; {placental abruption} (3); {alzheimer disease, late-onset, susceptibility to}, 104300 (3), ; {hypertension, pregnancy-induced}, 189800 (3), ; {ischemic stroke, susceptibility to}, 601367 (3),
NOS3AS		
NOSIP		
NOSTRIN		
NOT	AD	intellectual developmental disorder with language impairment and early-onset dopa-responsive dystonia-parkinsonism, 619911 (3),
NOT1	AD	vissers-bodmer syndrome, 619033 (3), ; holoprosencephaly 12, with or without pancreatic agenesis, 618500 (3),
NOT1H	AD	vissers-bodmer syndrome, 619033 (3), ; holoprosencephaly 12, with or without pancreatic agenesis, 618500 (3),
NOT2	AD	intellectual developmental disorder with nasal speech, dysmorphic facies, and variable skeletal anomalies, 618608 (3),
NOT2H	AD	intellectual developmental disorder with nasal speech, dysmorphic facies, and variable skeletal anomalies, 618608 (3),
NOT3	AD	intellectual developmental disorder with speech delay, autism, and dysmorphic facies, 618672 (3),
NOT3H	AD	intellectual developmental disorder with speech delay, autism, and dysmorphic facies, 618672 (3),
NOT4		
NOT4H		
Not56	AR	congenital disorder of glycosylation, type id, 601110 (3),
NOT56L	AR	congenital disorder of glycosylation, type id, 601110 (3),
NOTCH1	AD	adams-oliver syndrome 5, 616028 (3), ; aortic valve disease 1, 109730 (3),
NOTCH2	AD	alagille syndrome 2, 610205 (3), ; hajdu-cheney syndrome, 102500 (3),
NOTCH2NL		
NOTCH2NLA		
NOTCH2NLB		
NOTCH2NLC	AD	tremor, hereditary essential, 6, 618866 (3), ; oculopharyngodistal myopathy 3, 619473 (3), ; neuronal intranuclear inclusion disease, 603472 (3),
NOTCH3	AD	lateral meningocele syndrome, 130720 (3), ; ?myofibromatosis, infantile 2, 615293 (3), ; cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1, 125310 (3),
NOTCH4		
Notchl2		
NOTUM		
NOV	XL,XLR,AR	{autism, susceptibility to, 5}, 300847 (3); intellectual developmental disorder, syndromic 35, 300998 (3), |dworschak-punetha neurodevelopmental syndrome, 619955 (3),
NOVA-1		
NOVA-2	AD	neurodevelopmental disorder with or without autistic features and/or structural brain abnormalities, 618859 (3),
NOVA1		
NOVA2	AD	neurodevelopmental disorder with or without autistic features and/or structural brain abnormalities, 618859 (3),
NOVA3	AD	neurodevelopmental disorder with or without autistic features and/or structural brain abnormalities, 618859 (3),
NOX1		
NOX2	XL,XLR	immunodeficiency 34, mycobacteriosis, 300645 (3), ; chronic granulomatous disease, 306400 (3),
NOX3		
NOX4		
NOX5		
NOX5A		
NOX5B		
NOXA		
NOXA1		
NOXA2	AR	chronic granulomatous disease 2, 233710 (3),
NOXEF1		
noxin		
NOXO1		
NOXO2	AR	chronic granulomatous disease 1, 233700 (3),
NP	AR	immunodeficiency due to purine nucleoside phosphorylase deficiency, 613179 (3),
NP-C2	AR	niemann-pick disease, type c2, 607625 (3),
Np15	XLD,XL	linear skin defects with multiple congenital anomalies 3, 300952 (3), ; ?mitochondrial complex i deficiency, nuclear type 30, 301021 (3),
NP17.3	XLD,XL	linear skin defects with multiple congenital anomalies 3, 300952 (3), ; ?mitochondrial complex i deficiency, nuclear type 30, 301021 (3),
NP22		
NP220		
NP25		
np55		
NP60		
np65		
Np95		
NPA1		
NPA2		
NPAL1		
NPAL3		
NPAP1		
NPAP60L		
NPAS1		
NPAS2		
NPAS3		
NPAS4		
NPAT		
NPB		
NPBWR1		
NPBWR2		
NPC1	AR	niemann-pick disease, type c1, 257220 (3), ; niemann-pick disease, type d, 257220 (3),
NPC1L1		[ezetimibe, nonresponse to], 617966 (3); [low density lipoprotein cholesterol level qtl 7], 617966 (3)
NPC2	AR	niemann-pick disease, type c2, 607625 (3),
NPD002	AR	mitochondrial complex i deficiency, nuclear type 20, 611126 (3),
NPD007		
NPDC1		
NPEPPS		
NPFF		
NPFF1R1		
NPFF2		
NPFFR1		
NPFFR2		
NPG	AD,AR	optic atrophy plus syndrome, 125250 (3), ; {glaucoma, normal tension, susceptibility to}, 606657 (3); optic atrophy 1, 165500 (3), ; behr syndrome, 210000 (3), ; ?mitochondrial dna depletion syndrome 14 (encephalocardiomyopathic type), 616896 (3),
NPGPR		
NPGPx		
NPH1	AR	joubert syndrome 4, 609583 (3), ; nephronophthisis 1, juvenile, 256100 (3), ; senior-loken syndrome-1, 266900 (3),
NPH2		
NPH3	AR	nephronophthisis 3, 604387 (3), ; renal-hepatic-pancreatic dysplasia 1, 208540 (3), ; meckel syndrome 7, 267010 (3),
NPH4		
NPHL1	XLR,XL	proteinuria, low molecular weight, with hypercalciuric nephrocalcinosis, 308990 (3), ; hypophosphatemic rickets, 300554 (3), ; dent disease 1, 300009 (3), ; nephrolithiasis, type i, 310468 (3),
NPHL2	XLR,XL	proteinuria, low molecular weight, with hypercalciuric nephrocalcinosis, 308990 (3), ; hypophosphatemic rickets, 300554 (3), ; dent disease 1, 300009 (3), ; nephrolithiasis, type i, 310468 (3),
NPHN	AR	nephrotic syndrome, type 1, 256300 (3),
NPHP1	AR	joubert syndrome 4, 609583 (3), ; nephronophthisis 1, juvenile, 256100 (3), ; senior-loken syndrome-1, 266900 (3),
NPHP10	AR	senior-loken syndrome 7, 613615 (3), ; bardet-biedl syndrome 16, 615993 (3),
NPHP11	AR	nephronophthisis 11, 613550 (3), ; {bardet-biedl syndrome 14, modifier of}, 615991 (3), ; joubert syndrome 6, 610688 (3), ; meckel syndrome 3, 607361 (3), ; ?rhyns syndrome, 602152 (3), ; coach syndrome 1, 216360 (3),
NPHP12	AR,AD	short-rib thoracic dysplasia 4 with or without polydactyly, 613819 (3), ; nephronophthisis 12, 613820 (3),
NPHP13	AR	nephronophthisis 13, 614377 (3), ; cranioectodermal dysplasia 4, 614378 (3), ; senior-loken syndrome 8, 616307 (3), ; short-rib thoracic dysplasia 5 with or without polydactyly, 614376 (3), ; ?spermatogenic failure 72, 619867 (3),
NPHP14	AR,AD	nephronophthisis 14, 614844 (3), ; joubert syndrome 19, 614844 (3),
NPHP15	AR	nephronophthisis 15, 614845 (3),
NPHP16	AR	nephronophthisis 16, 615382 (3),
NPHP17	AR	retinitis pigmentosa 71, 616394 (3), ; bardet-biedl syndrome 20, 619471 (3), ; short-rib thoracic dysplasia 10 with or without polydactyly, 615630 (3),
NPHP18	AR	nephronophthisis 18, 615862 (3),
NPHP19	AR	nephronophthisis 19, 616217 (3), ; ?deafness, 66, 610212 (3), ; sclerosing cholangitis, neonatal, 617394 (3),
NPHP2	AR	nephronophthisis 2, infantile, 602088 (3),
NPHP20	AR	nephronophthisis 20, 617271 (3),
NPHP3	AR	nephronophthisis 3, 604387 (3), ; renal-hepatic-pancreatic dysplasia 1, 208540 (3), ; meckel syndrome 7, 267010 (3),
NPHP4	AR	senior-loken syndrome 4, 606996 (3), ; nephronophthisis 4, 606966 (3),
NPHP5	AR	senior-loken syndrome 5, 609254 (3),
NPHP6	AR	leber congenital amaurosis 10, 611755 (3); joubert syndrome 5, 610188 (3), ; senior-loken syndrome 6, 610189 (3), ; ?bardet-biedl syndrome 14, 615991 (3), ; meckel syndrome 4, 611134 (3),
NPHP7		nephronophthisis 7, 611498 (3)
NPHP8	AR	joubert syndrome 7, 611560 (3), ; meckel syndrome 5, 611561 (3), ; ?coach syndrome 3, 619113 (3),
NPHP9	AR	renal-hepatic-pancreatic dysplasia 2, 615415 (3), ; ?nephronophthisis 9, 613824 (3)
NPHPL1	AR	nephronophthisis-like nephropathy 1, 613159 (3),
NPHS1	AR	nephrotic syndrome, type 1, 256300 (3),
NPHS2	AR	nephrotic syndrome, type 2, 600995 (3),
NPHS24	AR	nephrotic syndrome, type 24, 619263 (3),
NPHS3	AR	nephrotic syndrome, type 3, 610725 (3),
NPHS4	AD	mesothelioma, somatic, 156240 (3); meacham syndrome, 608978 (3), ; frasier syndrome, 136680 (3), somatic mutation, ; nephrotic syndrome, type 4, 256370 (3), ; denys-drash syndrome, 194080 (3), somatic mutation, ; wilms tumor, type 1, 194070 (3), somatic mutation,
NPHS5	AR	nephrotic syndrome, type 5, with or without ocular abnormalities, 614199 (3); pierson syndrome, 609049 (3),
NPHS6	AR	nephrotic syndrome, type 6, 614196 (3),
NPI	AR	ehlers-danlos syndrome, dermatosparaxis type, 225410 (3),
NPI-1		
NPIP		
NPIPA1		
NPIPB3		
NPIPL3		
NPK		
NPL		
NPL1		
NPL2	AR	hyperoxaluria, primary, type iii, 613616 (3),
Npl3		chondrosarcoma, extraskeletal myxoid, 612237 (1)
NPL3		
NPL4		
NPLOC4		
NPM		leukemia, acute myeloid, somatic, 601626 (3)
NPM1		leukemia, acute myeloid, somatic, 601626 (3)
NPM2		
NPM3		
Npn3		
NPNT		
NPP	AR,MF,AD	{obesity, early-onset, susceptibility to}, 601665 (3), , ; obesity, adrenal insufficiency, and red hair due to pomc deficiency, 609734 (3),
npp-20		
NPP4		
NPP7		
NPPA	AR,AD	atrial standstill 2, 615745 (3), ; atrial fibrillation, familial, 6, 612201 (3),
NPPB		
NPPC		
NPPS	AR,MF,AD	{obesity, susceptibility to}, 601665 (3), , ; hypophosphatemic rickets, 2, 613312 (3), ; {diabetes mellitus, non-insulin-dependent, susceptibility to}, 125853 (3), ; arterial calcification, generalized, of infancy, 1, 208000 (3), ; cole disease, 615522 (3),
NPQ		
NPR1		
NPR2	AD,AD,AR	epilepsy, familial focal, with variable foci 2, 617116 (3), |epiphyseal chondrodysplasia, miura type, 615923 (3), ; short stature with nonspecific skeletal abnormalities, 616255 (3), ; acromesomelic dysplasia 1, maroteaux type, 602875 (3),
NPR2L	AD	epilepsy, familial focal, with variable foci 2, 617116 (3),
NPR3	AR,AD	boudin-mortier syndrome, 619543 (3), |epilepsy, familial focal, with variable foci 3, 617118 (3),
NPRA		
NPRAP		
NPRB	AD,AR	epiphyseal chondrodysplasia, miura type, 615923 (3), ; short stature with nonspecific skeletal abnormalities, 616255 (3), ; acromesomelic dysplasia 1, maroteaux type, 602875 (3),
NPRC	AR	boudin-mortier syndrome, 619543 (3),
NPRL2	AD	epilepsy, familial focal, with variable foci 2, 617116 (3),
NPRL3	AD	epilepsy, familial focal, with variable foci 3, 617118 (3),
NPS		
NPS1	AD	focal segmental glomerulosclerosis 10, 256020 (3), ; nail-patella syndrome, 161200 (3),
NPSR1		{asthma, susceptibility to, 2}, 608584 (3)
NPSR1-AS1		
NPT1		
NPT2	AR,AD	?fanconi renotubular syndrome 2, 613388 (3), ; hypercalcemia, infantile, 2, 616963 (3), ; nephrolithiasis/osteoporosis, hypophosphatemic, 1, 612286 (3),
NPT2C	AR	hypophosphatemic rickets with hypercalciuria, 241530 (3),
NPT3		
NPT4	AD	[uric acid concentration, serum, qtl4], 612671 (3), ; {gout susceptibility 4}, 612671 (3),
nPTB		
NPTIIa	AR,AD	?fanconi renotubular syndrome 2, 613388 (3), ; hypercalcemia, infantile, 2, 616963 (3), ; nephrolithiasis/osteoporosis, hypophosphatemic, 1, 612286 (3),
NPTIIb	AR	pulmonary alveolar microlithiasis, 265100 (3),
NPTIIc	AR	hypophosphatemic rickets with hypercalciuria, 241530 (3),
NPTN		
NPTN-IT1		
NPTX1	AD	spinocerebellar ataxia 50, 620158 (3),
NPTX2		
NPTXR		
NPVF		
NPW		
NPWBP	AD	vertebral, cardiac, tracheoesophageal, renal, and limb defects, 619227 (3),
NPY		
NPY1R		
NPY1RL		
NPY2R		
NPY3R	AD	whim syndrome 1, 193670 (3), ; myelokathexis, isolated, 193670 (3),
NPY4R		
NPY5R		
NPY6R		
NPY6RP		
NPYR	AD	whim syndrome 1, 193670 (3), ; myelokathexis, isolated, 193670 (3),
NPYR5		
NPYY3R	AD	whim syndrome 1, 193670 (3), ; myelokathexis, isolated, 193670 (3),
NQO1		{breast cancer, poor survival after chemotherapy for} (3); {leukemia, post-chemotherapy, susceptibility to} (3); {benzene toxicity, susceptibility to} (3)
NQO2	AD	{?breast cancer susceptibility}, 114480 (1), somatic mutation,
NQO3A2		
NR0B1	XLR,XL	adrenal hypoplasia, congenital, 300200 (3), ; 46xy sex reversal 2, dosage-sensitive, 300018 (3),
NR0B2	AR,MF,AD	obesity, mild, early-onset, 601665 (3), ,
NR1		
NR1A1	AD	hypothyroidism, congenital, nongoitrous, 6, 614450 (3),
NR1A2	AR,AD	thyroid hormone resistance, 274300 (3), ; thyroid hormone resistance, 188570 (3), ; thyroid hormone resistance, selective pituitary, 145650 (3),
NR1B1		leukemia, acute promyelocytic, 612376 (1)
NR1B2	AR,AD	microphthalmia, syndromic 12, 615524 (3),
NR1B3		
NR1C1		
NR1C2		
NR1C3	AD,AR,MF	{diabetes, type 2}, 125853 (3), ; insulin resistance, severe, digenic, 604367 (3), ; lipodystrophy, familial partial, type 3, 604367 (3), ; [obesity, resistance to] (3); obesity, severe, 601665 (3), , ; carotid intimal medial thickness 1, 609338 (3)
NR1D1		
NR1D2		
NR1F1	AD	intellectual developmental disorder with or without epilepsy or cerebellar ataxia, 618060 (3),
NR1F2	AD	{epilepsy, idiopathic generalized, susceptibility to, 15}, 618357 (3),
NR1F3	AR	immunodeficiency 42, 616622 (3),
NR1H2		
NR1H3		
NR1H4	AR	cholestasis, progressive familial intrahepatic, 5, 617049 (3),
NR1I1	AR	rickets, vitamin d-resistant, type iia, 277440 (3),
NR1I2		
NR1I3		
NR2A1	AD	fanconi renotubular syndrome 4, with maturity-onset diabetes of the young, 616026 (3), ; {diabetes mellitus, noninsulin-dependent}, 125853 (3), ; mody, type i, 125850 (3),
NR2A2		
NR2B1		
NR2B2		
NR2B3		
NR2C1		
NR2C2		
NR2C2AP		
NR2D	AD	developmental and epileptic encephalopathy 46, 617162 (3),
NR2E1		
NR2E3	AR,AD	retinitis pigmentosa 37, 611131 (3), ; enhanced s-cone syndrome, 268100 (3),
NR2F1	AD	bosch-boonstra-schaaf optic atrophy syndrome, 615722 (3),
NR2F2	AD	46xx sex reversal 5, 618901 (3), ; congenital heart defects, multiple types, 4, 615779 (3),
NR2F6		
NR3A1	AD,AR	breast cancer, somatic, 114480 (3); {migraine, susceptibility to}, 157300 (3), ; estrogen resistance, 615363 (3), ; {myocardial infarction, susceptibility to}, 608446 (3)
NR3A2	AD	?ovarian dysgenesis 8, 618187 (3),
NR3B1		
NR3B2	AR	deafness, 35, 608565 (3),
NR3B3		
NR3C1	AD	glucocorticoid resistance, 615962 (3),
NR3C2	AD	pseudohypoaldosteronism type i, 177735 (3), ; hypertension, early-onset, with exacerbation in pregnancy, 605115 (3)
NR3C3	AR	?progesterone resistance, 264080 (2),
NR3C4	XLR,AD,XL	androgen insensitivity, partial, with or without breast cancer, 312300 (3), ; {prostate cancer, susceptibility to}, 176807 (3), somatic mutation, ; androgen insensitivity, 300068 (3), ; spinal and bulbar muscular atrophy of kennedy, 313200 (3), ; hypospadias 1, 300633 (3),
NR4		
NR4A1		
NR4A2	AD	intellectual developmental disorder with language impairment and early-onset dopa-responsive dystonia-parkinsonism, 619911 (3),
NR4A3		chondrosarcoma, extraskeletal myxoid, 612237 (3)
NR5A1	AD	46xx sex reversal 4, 617480 (3), ; premature ovarian failure 7, 612964 (3), ; 46xy sex reversal 3, 612965 (3), ; adrenocortical insufficiency, 612964 (3), ; spermatogenic failure 8, 613957 (3),
NR5A2		
NR6	AR	cold-induced sweating syndrome 2, 610313 (3),
NR6A1		
NRAC		
NRAGE		
NRAMP		{mycobacterium tuberculosis, susceptibility to infection by}, 607948 (3); {buruli ulcer, susceptibility to}, 610446 (3)
NRAMP1		{mycobacterium tuberculosis, susceptibility to infection by}, 607948 (3); {buruli ulcer, susceptibility to}, 610446 (3)
NRAMP2	AR	anemia, hypochromic microcytic, with iron overload 1, 206100 (3),
Nrap		
NRAP		
NRARP		
NRAS	AD	noonan syndrome 6, 613224 (3), ; ?ras-associated autoimmune lymphoproliferative syndrome type iv, somatic, 614470 (3); melanocytic nevus syndrome, congenital, somatic, 137550 (3); epidermal nevus, somatic, 162900 (3); schimmelpenning-feuerstein-mims syndrome, somatic mosaic, 163200 (3); thyroid carcinoma, follicular, somatic, 188470 (3); neurocutaneous melanosis, somatic, 249400 (3); colorectal cancer, somatic, 114500 (3)
NRAV		
NRB54	XL	intellectual developmental disorder, syndromic 34, 300967 (3),
NRBF1	AR	dystonia, childhood-onset, with optic atrophy and basal ganglia abnormalities, 617282 (3),
NRBF2		
NRBP		
NRBP1		
NRBP2		
NRC		
NRCAM	AR	neurodevelopmental disorder with neuromuscular and skeletal abnormalities, 619833 (3),
NRCAML	AR	neurodevelopmental disorder with central and peripheral motor dysfunction, 618356 (3),
NRD1		
NRDC		
NRDE2		
NRDP1		
NREBP	AD	zttk syndrome, 617140 (3),
NREP		
NRF		
NRF-1		
NRF-2	AD	immunodeficiency, developmental delay, and hypohomocysteinemia, 617744 (3),
NRF1		
NRF2	AD	immunodeficiency, developmental delay, and hypohomocysteinemia, 617744 (3),
NRF2A		
Nrf3		
NRG1		{?schizophrenia, susceptibility to}, 603013 (1)
NRG1-IT2		{?schizophrenia, susceptibility to}, 603013 (1)
NRG2		
NRG3		
NRG4		
NRGN		
NRIF3		
NRIF4		
NRIP1	AD	?congenital anomalies of kidney and urinary tract 3, 618270 (3),
nRip11		
NRIP3		
NRIR		
NRK		
NRK1		
NRK2		
NRL	AD,AR	retinitis pigmentosa 27, 613750 (3), ; retinal degeneration, clumped pigment type (3)
NRL-MAF	AD,AR	retinitis pigmentosa 27, 613750 (3), ; retinal degeneration, clumped pigment type (3)
NRLN1	XL,XLR	megalocornea 1, 309300 (3),
NRM		
NRM29		
NRMT		
NRMT1		
NRN		
NRN1		
NRON		
NRP	AD,AR	glaucoma 1, open angle, e, 137760 (3), ; amyotrophic lateral sclerosis 12 with or without frontotemporal dementia, 613435 (3), ; {glaucoma, normal tension, susceptibility to}, 606657 (3)
NRP1		
NRP2		
NRPB		
NRPS998		
NRROS	AR	seizures, early-onset, with neurodegeneration and brain calcification, 618875 (3),
nrs		
NRSF	AD	deafness, 27, 612431 (3), ; {wilms tumor 6, susceptibility to}, 616806 (3), ; fibromatosis, gingival, 5, 617626 (3),
NRSN1		
NRSN2		
Nrt1		
NRTN		
NRU		
NRX	AR	robinow syndrome, 2, 618529 (3),
NRXN1	AR	pitt-hopkins-like syndrome 2, 614325 (3), ; {schizophrenia, susceptibility to, 17}, 614332 (3)
NRXN2		
NRXN3		
NRXN4	AR,AR	lethal congenital contracture syndrome 7, 616286 (3), ; hypomyelinating neuropathy, congenital, 3, 618186 (3), |pitt-hopkins like syndrome 1, 610042 (3), ; {autism susceptibility 15}, 612100 (3)
NS	AR	netherton syndrome, 256500 (3),
NS-1	AD	immunodeficiency 70, 618969 (3),
NS1	AD	noonan syndrome 1, 163950 (3), ; leopard syndrome 1, 151100 (3), ; metachondromatosis, 156250 (3), ; leukemia, juvenile myelomonocytic, somatic, 607785 (3)
NS1-BP	AD	immunodeficiency 70, 618969 (3),
NS3TP1		
NS3TP2		
NS4ATP2		
NS5ATP1		
NS5ATP9		
Nsa1		
NSA2		
NSAP1		
NSBP1		
NSCL		
NSCL1		
NSCL2	AR,XL,XLR	?hypogonadotropic hypogonadism 27 without anosmia, 619755 (3), |intellectual developmental disorder, syndromic 33, 300966 (3), ; dystonia-parkinsonism, 314250 (3),
NSD	AR	salla disease, 604369 (3), ; sialic acid storage disorder, infantile, 269920 (3),
NSD1	AD	sotos syndrome, 117550 (3),
NSD2	AD	rauch-steindl syndrome, 619695 (3),
NSD3		
NSDAN	AD	auditory neuropathy, 1, 609129 (3),
NSDDR		
NSDHL	XLR,XLD,XL	ck syndrome, 300831 (3), ; child syndrome, 308050 (3),
NSE		
NSE1		
NSE2	AR	seckel syndrome 10, 617253 (3),
NSE3	AR	lung disease, immunodeficiency, and chromosome breakage syndrome, 617241 (3),
NSE4A		
NSE4B		
nSec1	AR,AD	developmental and epileptic encephalopathy 4, 612164 (3),
NSEP-1		
NSEP1		
NSF	AD	developmental and epileptic encephalopathy 96, 619340 (3),
NSFL1C		
NSG1		
NSG2		
NSG3		
NSGPx		
NSHC		
NSHPT	AD,AR	hypocalcemia, with bartter syndrome, 601198 (3), ; {epilepsy idiopathic generalized, susceptibility to, 8}, 612899 (3); hyperparathyroidism, neonatal, 239200 (3), ; hypocalcemia, 601198 (3), ; hypocalciuric hypercalcemia, type i, 145980 (3),
NSL1	AD	koolen-de vries syndrome, 610443 (3),
NSL2		
NSL3		
NSLP1		
NSLP2		
NSMAF		
nSMase		
nSMase-3	AR	neurodevelopmental disorder with microcephaly, arthrogryposis, and structural brain anomalies, 618622 (3),
NSMASE2		
NSMASE3	AR	neurodevelopmental disorder with microcephaly, arthrogryposis, and structural brain anomalies, 618622 (3),
NSMCE1		
NSMCE2	AR	seckel syndrome 10, 617253 (3),
NSMCE3	AR	lung disease, immunodeficiency, and chromosome breakage syndrome, 617241 (3),
NSMCE4A		
NSMCE4B		
NSMF	AD	hypogonadotropic hypogonadism 9 with or without anosmia, 614838 (3),
NSP		
NSP-CL		
NSP1		
NSP2	AD	spastic paraplegia 12, 604805 (3),
NSP3		
NSPC1		
NSPL1	AD	spastic paraplegia 12, 604805 (3),
NSPL2		
NSPLII		
Nsr1		
nSR100		
NSRD1	AD,AR	keratoderma, palmoplantar, with deafness, 148350 (3), ; deafness, 1a, 220290 (3), digenic ; deafness, 3a, 601544 (3), ; hystrix-like ichthyosis with deafness, 602540 (3), ; bart-pumphrey syndrome, 149200 (3), ; keratitis-ichthyosis-deafness syndrome, 148210 (3), ; vohwinkel syndrome, 124500 (3),
NSRD2	AR,AD	deafness, 2, 600060 (3), ; usher syndrome, type 1b, 276900 (3), ; deafness, 11, 601317 (3),
NSRP1	AR	neurodevelopmental disorder with spasticity, seizures, and brain abnormalities, 620001 (3),
NSrp70	AR	neurodevelopmental disorder with spasticity, seizures, and brain abnormalities, 620001 (3),
NST1	AR	intellectual developmental disorder, 46, 616116 (3),
NST2		
NSUN1		
NSUN2	AR	intellectual developmental disorder, 5, 611091 (3),
NSUN3	AR	combined oxidative phosphorylation deficiency 48, 619012 (3),
NSUN4		
NSUN5		
NSUN5A		
NSUN6		
NSUN7		
NSX	XL,XLR	pigmentary disorder, reticulate, with systemic manifestations, 301220 (3), ; van esch-o'driscoll syndrome, 301030 (3),
NT-4/5		glaucoma 1, open angle, 1o, 613100 (3)
NT3	AD	[low density lipoprotein cholesterol level qtl6], 613589 (3),
NT5	AR	calcification of joints and arteries, 211800 (3),
NT5B	AR	spastic paraplegia 45, 613162 (3),
NT5C		
NT5C1A		
NT5C1B		
NT5C2	AR	spastic paraplegia 45, 613162 (3),
NT5C3	AR	anemia, hemolytic, due to umph1 deficiency, 266120 (3),
NT5C3A	AR	anemia, hemolytic, due to umph1 deficiency, 266120 (3),
NT5C3B		
NT5C3L		
NT5DC3		
NT5E	AR	calcification of joints and arteries, 211800 (3),
NT5M		
NTAK		
NTAL		
NTAN1		
NTB-A		
NTBA		
NTC31		
NTC90		
NTCP	AR	hypercholanemia, familial 2, 619256 (3),
NTCP1	AR	hypercholanemia, familial 2, 619256 (3),
NTCP2	AR	?bile acid malabsorption, primary, 1, 613291 (3),
NTE	AR	spastic paraplegia 39, 612020 (3), ; oliver-mcfarlane syndrome, 275400 (3), ; ?laurence-moon syndrome, 245800 (3), ; boucher-neuhauser syndrome, 215470 (3),
NTE-R1		
NTEL1		
NTF2		
NTF3		
NTF4		glaucoma 1, open angle, 1o, 613100 (3)
NTF5		glaucoma 1, open angle, 1o, 613100 (3)
NTF97		
NTG	AD,AR	optic atrophy plus syndrome, 125250 (3), ; {glaucoma, normal tension, susceptibility to}, 606657 (3); optic atrophy 1, 165500 (3), ; behr syndrome, 210000 (3), ; ?mitochondrial dna depletion syndrome 14 (encephalocardiomyopathic type), 616896 (3),
NTH1	AR	familial adenomatous polyposis 3, 616415 (3),
NTHL1	AR	familial adenomatous polyposis 3, 616415 (3),
NTKL	AR	spinocerebellar ataxia, 21, 616719 (3),
NTKL-BP1	AR	geroderma osteodysplasticum, 231070 (3),
NTM		
NTMOD		
NTMT1		
NTN		
NTN1	AD	mirror movements 4, 618264 (3),
NTN1L	AD	mirror movements 4, 618264 (3),
NTN1R1	AD,AR	mirror movements 1 and/or agenesis of the corpus callosum, 157600 (3), ; esophageal carcinoma, somatic, 133239 (3); colorectal cancer, somatic, 114500 (3); gaze palsy, familial horizontal, with progressive scoliosis, 2, 617542 (3),
NTN1R2		
NTN2L		
NTN3		
NTN4		
NTNG1	AR	neurodevelopmental disorder with behavioral abnormalities, absent speech, and hypotonia, 618718 (3),
NTNG2	AR	neurodevelopmental disorder with behavioral abnormalities, absent speech, and hypotonia, 618718 (3),
NTNRA		
NTPBP		
NTPDase-1	AR	spastic paraplegia 64, 615683 (3),
NTPDase-2		
NTPDase-3		
NTPDase-4		
NTPDase-5		
NTPDase-6		
NTPDase-8		
NTPH		{?attention deficit-hyperactivity disorder, susceptibility to, 7}, 613003 (3); {unipolar depression, susceptibility to}, 608516 (3)
NTR		
NTR2		
Ntra		
NTRI		
NTRK1	AR	insensitivity to pain, congenital, with anhidrosis, 256800 (3),
NTRK2	AD	developmental and epileptic encephalopathy 58, 617830 (3), ; obesity, hyperphagia, and developmental delay, 613886 (3),
NTRK3		
NTRK4		
NTRKR1	AR	?deafness, 108, 617654 (3),
NTRKR2	AD,AR	brachydactyly, type b1, 113000 (3), ; robinow syndrome, 268310 (3),
NTRKR3	AD,AR	warburg-cinotti syndrome, 618175 (3), ; spondylometaepiphyseal dysplasia, short limb-hand type, 271665 (3),
NTS		
NTSR1		
NTSR2		
NTT4	AR	intellectual developmental disorder, 48, 616269 (3),
NTT5		
NTT73		
NU		
NUA	AD	emery-dreifuss muscular dystrophy 5, 612999 (3),
NUAK1		
NUAK2	AR	?anencephaly 2, 619452 (3),
NUANCE	AD	emery-dreifuss muscular dystrophy 5, 612999 (3),
NUB1		
NUB1L		
NuBI-1		
NUBP1		
NUBP2		
NUBPL	AR	mitochondrial complex i deficiency, nuclear type 21, 618242 (3),
NUC		
NUC1		
NUC2		
NUCB1		
NUCB2		
NUCII		
NUCKS		
NUCKS1		
NUDC		
NUDCD1		
NUDCD2		
NUDCD3		
NudCL		
NudCL2		
nudE	AR	microhydranencephaly, 605013 (3), ; lissencephaly 4 (with microcephaly), 614019 (3),
NUDEL		
NudF	AD	subcortical laminar heterotopia, 607432 (3), ; lissencephaly 1, 607432 (3),
NUDR	AD,AR	vulto-van silfout-de vries syndrome, 615828 (3), ; neurodevelopmental disorder with hypotonia, impaired expressive language, and with or without seizures, 617171 (3),
NUDT1		
NUDT10		
NUDT11		
NUDT12		
NUDT13		
NUDT14		
NUDT15	AD	{thiopurines, poor metabolism of, 2}, 616903 (3),
NUDT16		
NUDT16L1		
NUDT18		
NUDT2	AR	intellectual developmental disorder with or without peripheral neuropathy, 619844 (3),
NUDT20		
NUDT21		
NUDT3		
NUDT4		
NUDT5		
NUDT6		
NUDT7		
NUDT9		
NUDT9H		
NUDT9L1		
NUF2		
NUF2R		
NUFIP		
NUFIP1		
NUFIP2		
NUFM		
NUFP2		
Nug2		
NUGGC		
Nulp1		
NUMA		leukemia, acute promyelocytic, somatic, 612376 (3)
NUMA1		leukemia, acute promyelocytic, somatic, 612376 (3)
NUMB		
NUMB-R		
NUMBIP		
NUMBL		
NUMBLIKE		
NUMBR		
NUP107	AR	?ovarian dysgenesis 6, 618078 (3), ; galloway-mowat syndrome 7, 618348 (3), ; nephrotic syndrome, type 11, 616730 (3),
NUP133	AR	?galloway-mowat syndrome 8, 618349 (3), ; nephrotic syndrome, type 18, 618177 (3),
NUP153		
NUP155	AR	?atrial fibrillation 15, 615770 (3),
NUP160	AR	?nephrotic syndrome, type 19, 618178 (3),
NUP188	AR	sandestig-stefanova syndrome, 618804 (3),
NUP196		
NUP205	AR	?nephrotic syndrome, type 13, 616893 (3),
NUP210		
NUP214	AR	leukemia, t-cell acute lymphoblastic, somatic, 613065 (3); leukemia, acute myeloid, somatic, 601626 (3); {encephalopathy, acute, infection-induced, susceptibility to, 9}, 618426 (3),
NUP35		
NUP358	AD	{encephalopathy, acute, infection-induced, 3, susceptibility to}, 608033 (3),
NUP37	AR	?microcephaly 24, primary, 618179 (3),
NUP42		
NUP43		
NUP45		
NUP475		
NUP50		
NUP54		
NUP58		
NUP62	AR	striatonigral degeneration, infantile, 271930 (3),
NUP75	AR	nephrotic syndrome, type 17, 618176 (3),
NUP84	AR	?ovarian dysgenesis 6, 618078 (3), ; galloway-mowat syndrome 7, 618348 (3), ; nephrotic syndrome, type 11, 616730 (3),
NUP85	AR	nephrotic syndrome, type 17, 618176 (3),
NUP88	AR	fetal akinesia deformation sequence 4, 618393 (3),
NUP93	AR	nephrotic syndrome, type 12, 616892 (3),
NUP96		
NUP98		
Nup98-96		
Nup98-Nup96		
NUPL1		
NUPL2		
NUPR1		
NUR77		
NURF140		
NURF301	AD	neurodevelopmental disorder with dysmorphic facies and distal limb anomalies, 617755 (3),
NURF55		
NURIT		
NURR1	AD	intellectual developmental disorder with language impairment and early-onset dopa-responsive dystonia-parkinsonism, 619911 (3),
NUS1	AD,AR	intellectual developmental disorder, 55, with seizures, 617831 (3), ; ?congenital disorder of glycosylation, type 1aa, 617082 (3),
NUSAP1		
NUT		
NUT2		
NUTF2		
NUTM1		
NUTM2B-AS1	AD	?oculopharyngeal myopathy with leukoencephalopathy 1, 618637 (3),
NVL		
NVL2		
NWASP		
NWC		
NWD1		
NWD2		
NX17		
NXF		
NXF1		
NXF2		
NXF3		
NXF4		
NXF5		
NXN	AR	robinow syndrome, 2, 618529 (3),
NXNL1		
NXNL2		
NXP2		
NXPE4		
NXPH1		
NXPH2		
NXPH3		
NXPH4		
NXT1		
NXT2		
NY-BR-1		
NY-BR-1.1		
NY-BR-15	AD	lissencephaly 10, 618873 (3),
NY-BR-16	AD	chopra-amiel-gordon syndrome, 619504 (3),
NY-BR-62	AR	?braddock-carey syndrome 2, 619981 (3),
NY-BR-81		
NY-BR-84		
NY-BR-85	AR	chronic atrial and intestinal dysrhythmia, 616201 (3),
NY-BR-96	AR	polyhydramnios, megalencephaly, and symptomatic epilepsy, 611087 (3),
NY-BR-99	AD	retinitis pigmentosa 11, 600138 (3),
NY-CO-1	AR	intellectual developmental disorder with speech delay and axonal peripheral neuropathy, 619099 (3),
NY-CO-10	AR	retinitis pigmentosa with or without skeletal anomalies, 250410 (3),
NY-CO-16		
NY-CO-25		
NY-CO-28		
NY-CO-3		
NY-CO-31		
NY-CO-33	AD	aural atresia, congenital, 607842 (3),
NY-CO-37	AR	usher syndrome, type 1c, 276904 (3), ; deafness, 18a, 602092 (3),
NY-CO-38	AR	usher syndrome, type 1c, 276904 (3), ; deafness, 18a, 602092 (3),
NY-CO-43		
NY-CO-45		
NY-CO-7	AD,AR	spinocerebellar ataxia 48, 618093 (3), ; spinocerebellar ataxia, 16, 615768 (3),
NY-CO-8	AR	senior-loken syndrome 7, 613615 (3), ; bardet-biedl syndrome 16, 615993 (3),
NY-CO-9		
NY-ESO-1		
NY-LU-12		
NY-MEL-1		
NY-REN-2		
NY-REN-21		
NY-REN-24		
NY-REN-25		
NY-REN-28		
NY-REN-34		
NY-REN-37	AR	intellectual developmental disorder, 56, 617125 (3),
NY-REN-41	AR	spermatogenic failure 76, 620084 (3),
NY-REN-43	XL	tonne-kalscheuer syndrome, 300978 (3),
NY-REN-45		
NY-REN-55	AR,AD	short-rib thoracic dysplasia 6 with or without polydactyly, 263520 (3), digenic ; {amyotrophic lateral sclerosis, susceptibility to, 24}, 617892 (3),
NY-REN-57		
NY-REN-58	AR	nephronophthisis 18, 615862 (3),
NY-REN-6		
NY-REN-60		
NY-REN-64	AR	immunodeficiency 67, 607676 (3),
NY-SAR-48		
NY-SAR-79		
NY-SAR-91		
NYAP1		
NYAP2		
NYAP3		
NYD-SP11		
NYD-SP12	AR	?spermatogenic failure 6, 102530 (3),
NYD-SP14	AR	spermatogenic failure 42, 618745 (3),
NYD-SP15		
NYD-SP16		
NYD-SP18		
NYD-SP19	AR	?immunodeficiency 99 with hypogammaglobulinemia and autoimmune cytopenias, 619846 (3),
NYD-SP20		
NYD-SP22		
NYD-SP24		
NYD-SP25		
NYD-SP26		
NYD-SP27	AR	spermatogenic failure 17, 617214 (3),
NYD-SP28	AR	ciliary dyskinesia, primary, 27, 615504 (3),
NYD-SP29		
NYD-SP6		
NYD-sp9		
NYD-TSP1		
NYGGF4		
NYNRIN		
NYREN18		
NYS	XL	nystagmus, infantile periodic alternating, 310700 (3), ; nystagmus 1, congenital, 310700 (3),
NYS1	XL	nystagmus, infantile periodic alternating, 310700 (3), ; nystagmus 1, congenital, 310700 (3),
NYSAR97	XL,XLR	ciliary dyskinesia, primary, 36, 300991 (3),
NYX	XL,XLR	night blindness, congenital stationary (complete), 1a, 310500 (3),
NZF-3		
NZF1	AD	intellectual developmental disorder, 39, 616521 (3),
NZF2		
NZF3		
O-FABP		
O-Fuc-T	AD	dowling-degos disease 2, 615327 (3),
O-FUT	AD	dowling-degos disease 2, 615327 (3),
O-GLCNAC	XL,XLR	intellectual developmental disorder, 106, 300997 (3),
O/E-4		
O3FAR1		{obesity, susceptibility to}, 607514 (3)
OA1	XL,XLR	ocular albinism, type i, nettleship-falls type, 300500 (3), ; nystagmus 6, congenital, 300814 (3),
OA2	XL,XLR	cone-rod dystrophy, 3, 300476 (3), ; night blindness, congenital stationary (incomplete), 2a, 300071 (3), ; aland island eye disease, 300600 (3),
OA3		
OA48-18		
OABP		
OAcGD3S		
OACT1		
OACT2		
OACT3		
OACT4		
OACT5		
OARD1		
OAS1	AD	immunodeficiency 100 with pulmonary alveolar proteinosis and hypogammaglobulinemia, 618042 (3),
OAS2		
OAS3		
OASIS	AR	osteogenesis imperfecta, type xvi, 616229 (3),
OASL		
OASL1		
OAT	AR	gyrate atrophy of choroid and retina with or without ornithinemia, 258870 (3),
OAT1		
OAT10		
OAT2		
OAT3		
OAT4		
OAT4L	AR	hypouricemia, renal, 220150 (3),
OAT5		
Oat6		
OAT6		
OAT7		
OATL1		
OATP		
OATP-A		
OATP-B		
OATP-C		hyperbilirubinemia, rotor type, digenic, 237450 (3), digenic
OATP-D		
OATP-E		
OATP-F		
OATP-H		
OATP-J		
OATP1		
OATP1A2		
OATP1B1		hyperbilirubinemia, rotor type, digenic, 237450 (3), digenic
OATP1B3		hyperbilirubinemia, rotor type, digenic, 237450 (3), digenic
OATP1C1		
OATP2A1	AD,AR	hypertrophic osteoarthropathy, primary, 167100 (3), ; hypertrophic osteoarthropathy, primary, 2, 614441 (3),
OATP2B1		
OATP3A1		
OATP4A1		
OATP4C1		
OATP5A1		
OATP6A1		
OATP8		hyperbilirubinemia, rotor type, digenic, 237450 (3), digenic
OATPRP4		
OATPX		
OATPY		
OAZ	AR,AD	nephronophthisis 14, 614844 (3), ; joubert syndrome 19, 614844 (3),
OAZ1		
OAZ2		
OAZ3		
OAZI		
OAZIN		
OB	AR,AD,AR	obesity, morbid, due to leptin deficiency, 614962 (3), |teebi hypertelorism syndrome 2, 619736 (3), ; elsahy-waters syndrome, 211380 (3),
OB-BP1		
OB-BP2		
OB-RGRP		
OB1		
OBCAM		ovarian cancer, somatic, 167000 (3)
OBDPF		
obestatin	AR,MF,AD	{obesity, susceptibility to}, 601665 (3), ,
OBF		
OBF1		
OBFC1	AR	cerebroretinal microangiopathy with calcifications and cysts 2, 617341 (3),
OBFC2A		
OBFC2B		
ObgH1		
OBGH2		
OBI1		
OBIF		
OBOE	AR	cone-rod synaptic disorder syndrome, congenital nonprogressive, 618970 (3),
OBP		
OBP-1	AD	spondyloepimetaphyseal dysplasia with joint laxity, type 2, 603546 (3),
OBP-2	AD	spondyloepimetaphyseal dysplasia with joint laxity, type 2, 603546 (3),
OBP2A		
OBP2B		
OBPH1		
OBR	AR	obesity, morbid, due to leptin receptor deficiency, 614963 (3),
OBRGRP		
OBS	AR	obesity, morbid, due to leptin deficiency, 614962 (3),
OBSCN	AR	{rhabdomyolysis, susceptibility to, 1}, 620235 (3),
OBSL1	AR	3-m syndrome 2, 612921 (3),
OBTP		
OC-116	AR	osteopetrosis, 1, 259700 (3),
OC-2		
OC116	AR	osteopetrosis, 1, 259700 (3),
OC120		
OC90		
OCA-B		
OCA-T2		
OCA1	AD,AR	[skin/hair/eye pigmentation 3, light/dark/freckling skin], 601800 (3), ; [skin/hair/eye pigmentation 3, blue/green eyes], 601800 (3), ; {melanoma, cutaneous malignant, susceptibility to, 8}, 601800 (3), ; albinism, oculocutaneous, type ib, 606952 (3), ; albinism, oculocutaneous, type ia, 203100 (3),
OCA1A	AD,AR	[skin/hair/eye pigmentation 3, light/dark/freckling skin], 601800 (3), ; [skin/hair/eye pigmentation 3, blue/green eyes], 601800 (3), ; {melanoma, cutaneous malignant, susceptibility to, 8}, 601800 (3), ; albinism, oculocutaneous, type ib, 606952 (3), ; albinism, oculocutaneous, type ia, 203100 (3),
OCA2	AR	[skin/hair/eye pigmentation 1, blue/nonblue eyes], 227220 (3), ; [skin/hair/eye pigmentation 1, blond/brown hair], 227220 (3), ; albinism, brown oculocutaneous, 203200 (3), ; albinism, oculocutaneous, type ii, 203200 (3),
OCA3	AR	[skin/hair/eye pigmentation, variation in, 11 (melanesian blond hair)], 612271 (3); albinism, oculocutaneous, type iii, 203290 (3),
OCA4	AR	[skin/hair/eye pigmentation 5, dark/light eyes], 227240 (3), ; [skin/hair/eye pigmentation 5, black/nonblack hair], 227240 (3), ; albinism, oculocutaneous, type iv, 606574 (3), ; [skin/hair/eye pigmentation 5, dark/fair skin], 227240 (3),
OCA6	AR	[skin/hair/eye pigmentation 4, fair/dark skin], 113750 (3), ; albinism, oculocutaneous, type vi, 113750 (3),
OCA7	AR	albinism, oculocutaneous, type vii, 615179 (3),
OCAIA	AD,AR	[skin/hair/eye pigmentation 3, light/dark/freckling skin], 601800 (3), ; [skin/hair/eye pigmentation 3, blue/green eyes], 601800 (3), ; {melanoma, cutaneous malignant, susceptibility to, 8}, 601800 (3), ; albinism, oculocutaneous, type ib, 606952 (3), ; albinism, oculocutaneous, type ia, 203100 (3),
OCC-1		
OCC1		
OCD1	AD	{obsessive-compulsive disorder}, 164230 (3), ; {anxiety-related personality traits}, 607834 (3)
OCI-5	XLR,XL	wilms tumor, somatic, 194070 (3); simpson-golabi-behmel syndrome, type 1, 312870 (3),
OCIA		
OCIAD1		
OCIAD2		
OCIF	AR	paget disease of bone 5, juvenile-onset, 239000 (3),
OCIL		
OCIM		
OCLN	AR	pseudo-torch syndrome 1, 251290 (3),
OCM		
OCM1		
OCN		
OCNC1		
OCNC2		
OCNCa		
OCNCalpha		
OCNCALPHA		
OCNCb		
OCP-II		
OCP1		
OCP2		
OCRL	XLR,XL	dent disease 2, 300555 (3), ; lowe syndrome, 309000 (3),
OCRL1	XLR,XL	dent disease 2, 300555 (3), ; lowe syndrome, 309000 (3),
OCSYN		
OCT		
OCT-4		
OCT1		
OCT11		
OCT2		
OCT3		
Oct3/4		
Oct4		
OCT6		
OCT7		
OCTD	AD	geleophysic dysplasia 2, 614185 (3), ; weill-marchesani syndrome 2, 608328 (3), ; ectopia lentis, familial, 129600 (3), ; mass syndrome, 604308 (3), ; marfan lipodystrophy syndrome, 616914 (3), ; acromicric dysplasia, 102370 (3), ; marfan syndrome, 154700 (3), ; stiff skin syndrome, 184900 (3),
OCTL1		
OCTL2		
OCTL3		
OCTN1		{rheumatoid arthritis, susceptibility to}, 180300 (3)
OCTN2	AR	carnitine deficiency, systemic primary, 212140 (3),
OCTS2		
OCTS3	AR	familial adenomatous polyposis 3, 616415 (3),
ODA-8S	AD	primrose syndrome, 259050 (3),
ODA10	AR	ciliary dyskinesia, primary, 30, 616037 (3),
ODA16		
ODA5		
ODA7	AR	ciliary dyskinesia, primary, 13, 613193 (3),
ODAD1	AR	ciliary dyskinesia, primary, 20, 615067 (3),
ODAD2	AR	ciliary dyskinesia, primary, 23, 615451 (3),
ODAD3	AR	ciliary dyskinesia, primary, 30, 616037 (3),
ODAD4	AR	ciliary dyskinesia, primary, 35, 617092 (3),
ODAD5		
ODAG	AR	?cardiomyopathy, dilated, 2b, 614672 (3),
ODAM		
ODAPH	AR	amelogenesis imperfecta, type iia4, 614832 (3),
ODC	AR,AD	?mitochondrial dna depletion syndrome 18, 618811 (3), |bachmann-bupp syndrome, 619075 (3),
ODC-p		
ODC1	AR,AD	?mitochondrial dna depletion syndrome 18, 618811 (3), |bachmann-bupp syndrome, 619075 (3),
ODC1L		
ODCp		
ODD	AD,AR	erythrokeratodermia variabilis et progressiva 3, 617525 (3), ; craniometaphyseal dysplasia, 218400 (3), ; oculodentodigital dysplasia, 164200 (3), ; palmoplantar keratoderma with congenital alopecia, 104100 (3), ; syndactyly, type iii, 186100 (3), ; oculodentodigital dysplasia, 257850 (3),
ODDD	AD,AR	erythrokeratodermia variabilis et progressiva 3, 617525 (3), ; craniometaphyseal dysplasia, 218400 (3), ; oculodentodigital dysplasia, 164200 (3), ; palmoplantar keratoderma with congenital alopecia, 104100 (3), ; syndactyly, type iii, 186100 (3), ; oculodentodigital dysplasia, 257850 (3),
ODF	AR	osteopetrosis, 2, 259710 (3),
ODF1		
ODF2		
ODF27		
ODF2L		
ODF3		
ODF4		
ODF5		
ODF6		
ODF84		
ODFPG		
ODFR	AR,AD	osteopetrosis, 7, 612301 (3), ; {paget disease of bone 2, early-onset}, 602080 (3), ; osteolysis, familial expansile, 174810 (3),
ODG1	AR,AD	ovarian response to fsh stimulation, 276400 (3), ; ovarian hyperstimulation syndrome, 608115 (3), ; ovarian dysgenesis 1, 233300 (3),
ODOD	AD,AR	erythrokeratodermia variabilis et progressiva 3, 617525 (3), ; craniometaphyseal dysplasia, 218400 (3), ; oculodentodigital dysplasia, 164200 (3), ; palmoplantar keratoderma with congenital alopecia, 104100 (3), ; syndactyly, type iii, 186100 (3), ; oculodentodigital dysplasia, 257850 (3),
odr-4		
ODR4		
ODT1	XL,XLD,XLR	tooth agenesis, selective, 1, 313500 (3), ; ectodermal dysplasia 1, hypohidrotic, 305100 (3),
ODZ1		
ODZ2		
ODZ3	AR	microphthalmia, syndromic 15, 615145 (3), ; ?microphthalmia, isolated, with coloboma 9, 615145 (3),
ODZ4	AD	essential tremor, hereditary, 5, 616736 (3),
OEATC-1		
OEBT		
OF	AD,AD	agammaglobulinemia 10, 619707 (3), |fanconi anemia, complementation group j, 609054 (3); {breast cancer, early-onset, susceptibility to}, 114480 (3), somatic mutation,
OFC10		?orofacial cleft 10, 613705 (3), isolated cases
OFC5	AD	tooth agenesis, selective, 1, with or without orofacial cleft, 106600 (3), ; ectodermal dysplasia 3, witkop type, 189500 (3), ; orofacial cleft 5, 608874 (3),
OFC6	AD	{orofacial cleft 6}, 608864 (3), ; popliteal pterygium syndrome 1, 119500 (3), ; van der woude syndrome 1, 119300 (3),
OFC7	AR	cleft lip/palate-ectodermal dysplasia syndrome, 225060 (3), ; orofacial cleft 7, 225060 (3),
OFC8	AD	premature ovarian failure 21, 620311 (3), ; ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3, 604292 (3), ; hay-wells syndrome, 106260 (3), ; split-hand/foot malformation 4, 605289 (3), ; orofacial cleft 8, 618149 (3); rapp-hodgkin syndrome, 129400 (3), ; adult syndrome, 103285 (3), ; limb-mammary syndrome, 603543 (3),
OFCC1		
OFD1	XLR,XL,XLD	simpson-golabi-behmel syndrome, type 2, 300209 (3), ; ?retinitis pigmentosa 23, 300424 (3), ; orofaciodigital syndrome i, 311200 (3), ; joubert syndrome 10, 300804 (3),
OFIP	AR	?orofaciodigital syndrome xv, 617127 (3), ; ?joubert syndrome 38, 619476 (3), ; short-rib thoracic dysplasia 21 without polydactyly, 619479 (3),
OFOXD1		
OG12		
OG12X		
OG2	AD	premature ovarian failure 5, 611548 (3),
Og2x	AD	premature ovarian failure 5, 611548 (3),
OG9		
OG9X		
OGA		
OGC	AD	paragangliomas 6, 618464 (3),
OGDC-E1	AR	oxoglutarate dehydrogenase deficiency, 203740 (3),
OGDC-E2	AD	paragangliomas 7, 618475 (3),
OGDC-E3	AR	dihydrolipoamide dehydrogenase deficiency, 246900 (3),
OGDH	AR	oxoglutarate dehydrogenase deficiency, 203740 (3),
OGDH2	AR	oxoglutarate dehydrogenase deficiency, 203740 (3),
OGDHL	AR	yoon-bellen neurodevelopmental syndrome, 619701 (3),
OGFOD1		
OGFR		
OGG1		renal cell carcinoma, clear cell, somatic, 144700 (3)
OGH1		renal cell carcinoma, clear cell, somatic, 144700 (3)
OGN		
OGR1	AR	amelogenesis imperfecta, hypomaturation type, iia6, 617217 (3),
OGT	XL,XLR	intellectual developmental disorder, 106, 300997 (3),
OGT1	XL,XLR	intellectual developmental disorder, 106, 300997 (3),
OI4	AD,AD,AR	osteogenesis imperfecta, type ii, 166210 (3), ; caffey disease, 114000 (3), ; ehlers-danlos syndrome, arthrochalasia type, 1, 130060 (3), ; osteogenesis imperfecta, type i, 166200 (3), ; {bone mineral density variation qtl, osteoporosis}, 166710 (3), ; combined osteogenesis imperfecta and ehlers-danlos syndrome 1, 619115 (3), ; osteogenesis imperfecta, type iv, 166220 (3), ; osteogenesis imperfecta, type iii, 259420 (3), |osteogenesis imperfecta, type iii, 259420 (3), ; {osteoporosis, postmenopausal}, 166710 (3), ; ehlers-danlos syndrome, arthrochalasia type, 2, 617821 (3), ; combined osteogenesis imperfecta and ehlers-danlos syndrome 2, 619120 (3), ; ehlers-danlos syndrome, cardiac valvular type, 225320 (3), ; osteogenesis imperfecta, type iv, 166220 (3), ; osteogenesis imperfecta, type ii, 166210 (3),
OI9	AR	osteogenesis imperfecta, type ix, 259440 (3),
OIAS	AD	immunodeficiency 100 with pulmonary alveolar proteinosis and hypogammaglobulinemia, 618042 (3),
OIASI	AD	immunodeficiency 100 with pulmonary alveolar proteinosis and hypogammaglobulinemia, 618042 (3),
OIF		
OIP1		
OIP106	AR	developmental and epileptic encephalopathy 68, 618201 (3),
OIP2	AR	pontocerebellar hypoplasia, type 1c, 616081 (3),
OIP3		
OIP5		
OIP98		
OIT1		
OIT2		
OIT3		
OK		[blood group, ok], 111380 (3)
OK/SW-cl.114		
OK/SW-cl.4		
OK/SW-cl.56	AD	symmetric circumferential skin creases, congenital, 1, 156610 (3), ; cortical dysplasia, complex, with other brain malformations 6, 615771 (3),
OKB1		
OKL38		
OKS	XLR,XL,XLD	lujan-fryns syndrome, 309520 (3), ; ohdo syndrome, 300895 (3), ; hardikar syndrome, 301068 (3), ; opitz-kaveggia syndrome, 305450 (3),
OL-64		
OL-PCDH		
OLA1		
old-35	AD,AR	spinocerebellar ataxia 25, 608703 (3), ; deafness, 70, with or without adult-onset neurodegeneration, 614934 (3), ; combined oxidative phosphorylation deficiency 13, 614932 (3),
OLD35	AD,AR	spinocerebellar ataxia 25, 608703 (3), ; deafness, 70, with or without adult-onset neurodegeneration, 614934 (3), ; combined oxidative phosphorylation deficiency 13, 614932 (3),
OLF		
OLF1		
OLF3		
OLF44		
OlfA		
OlfC		
OlfD		
OLFM1		
OLFM2		
OLFM3		
OLFM4		
Olfmf		
OLFMF		
OLFML2A		
OLFML3		
OLFR1		
OLIG1		
OLIG2		
OLIG3		
OLIGO2		
OLMALINC		
OLR1		{myocardial infarction, susceptibility to}, 608446 (3)
OMA1		
OMD		
OMG		
OMGP		
OMI	AR	{parkinson disease 13}, 610297 (3); 3-methylglutaconic aciduria, type viii, 617248 (3),
OMP		
OMP85		
OMR	AD,AR	mitochondrial complex v (atp synthase) deficiency, nuclear type 4a, 620358 (3), ; ?combined oxidative phosphorylation deficiency 22, 616045 (3), ; ?mitochondrial complex v (atp synthase) deficiency, nuclear type 4b, encephalopathic type, 615228 (3),
ON	AR	osteogenesis imperfecta, type xvii, 616507 (3),
onco-lncRNA-100		
onco-lncRNA-16		
onco-lncRNA-17		
onco-lncRNA-21		
onco-lncRNA-3		
onco-lncRNA-30		
onco-lncRNA-36		
onco-lncRNA-40		
onco-lncRNA-83		
ONECUT1		
ONECUT2		
ONECUT3		
ONR1		
ONT	AR	osteogenesis imperfecta, type xvii, 616507 (3),
onzin		
OOEP		
OOMA1		
OOR		
OOSP2		
OOSP2A		
OOSP2B		
OOSP2L		
OP-1		
OP-2		
OP18		
OPA1	XLR,XL,XLD,AD,AR	lujan-fryns syndrome, 309520 (3), ; ohdo syndrome, 300895 (3), ; hardikar syndrome, 301068 (3), ; opitz-kaveggia syndrome, 305450 (3), |optic atrophy plus syndrome, 125250 (3), ; {glaucoma, normal tension, susceptibility to}, 606657 (3); optic atrophy 1, 165500 (3), ; behr syndrome, 210000 (3), ; ?mitochondrial dna depletion syndrome 14 (encephalocardiomyopathic type), 616896 (3),
OPA3	AR,AD	3-methylglutaconic aciduria, type iii, 258501 (3), ; optic atrophy 3 with cataract, 165300 (3),
OPA7	AR	optic atrophy 7, 612989 (3),
OPAL1		
OPALIN		
OPCA3	AD	spinocerebellar ataxia 7, 164500 (3),
OPCM		ovarian cancer, somatic, 167000 (3)
OPCML		ovarian cancer, somatic, 167000 (3)
OPD1	XLD,XLR,XL	otopalatodigital syndrome, type ii, 304120 (3), ; intestinal pseudoobstruction, neuronal, 300048 (3), ; cardiac valvular dysplasia, 314400 (3), ; ?fg syndrome 2, 300321 (3), ; melnick-needles syndrome, 309350 (3), ; terminal osseous dysplasia, 300244 (3), ; congenital short bowel syndrome, 300048 (3), ; otopalatodigital syndrome, type i, 311300 (3), ; heterotopia, periventricular, 1, 300049 (3), ; frontometaphyseal dysplasia 1, 305620 (3),
OPD2	XLD,XLR,XL	otopalatodigital syndrome, type ii, 304120 (3), ; intestinal pseudoobstruction, neuronal, 300048 (3), ; cardiac valvular dysplasia, 314400 (3), ; ?fg syndrome 2, 300321 (3), ; melnick-needles syndrome, 309350 (3), ; terminal osseous dysplasia, 300244 (3), ; congenital short bowel syndrome, 300048 (3), ; otopalatodigital syndrome, type i, 311300 (3), ; heterotopia, periventricular, 1, 300049 (3), ; frontometaphyseal dysplasia 1, 305620 (3),
OPDX	AR	lacticacidemia due to pdx1 deficiency, 245349 (3),
OPG	AR	paget disease of bone 5, juvenile-onset, 239000 (3),
OPGL	AR	osteopetrosis, 2, 259710 (3),
OPHN1	XL,XLR	intellectual developmental disorder, syndromic, billuart type, 300486 (3),
OPHN1L		leukemia, juvenile myelomonocytic, somatic, 607785 (3)
OPHN1L1		leukemia, juvenile myelomonocytic, somatic, 607785 (3)
OPHN2	XL,XLD	intellectual developmental disorder, 41, 300849 (3),
OPHN4	XL,XLR	intellectual developmental disorder, 21, 300143 (3),
OPI10	AR	leukodystrophy, hypomyelinating, 13, 616881 (3),
OPLA	AR,AD	5-oxoprolinase deficiency, 260005 (3),
OPLAH	AR,AD	5-oxoprolinase deficiency, 260005 (3),
OPMD	AD	oculopharyngeal muscular dystrophy, 164300 (3),
OPN		
OPN1	XL,XLR	intellectual developmental disorder, syndromic, billuart type, 300486 (3),
OPN1LW	XLR,XL	blue cone monochromacy, 303700 (3), ; colorblindness, protan, 303900 (3),
OPN1MW	XL,XLR	colorblindness, deutan, 303800 (3), ; blue cone monochromacy, 303700 (3),
OPN1MW1	XL,XLR	colorblindness, deutan, 303800 (3), ; blue cone monochromacy, 303700 (3),
OPN1SW	AD	colorblindness, tritan, 190900 (3),
OPN2	AD,AR	night blindness, congenital stationary, 1, 610445 (3), ; retinitis pigmentosa 4, or , 613731 (3), ; retinitis punctata albescens, 136880 (3),
OPN3		
OPN4		
OPN5		
Opo		
OPPG	AD,AR	osteopetrosis, 1, 607634 (3), ; [bone mineral density variability 1], 601884 (3), ; polycystic liver disease 4 with or without kidney cysts, 617875 (3), ; endosteal hyperostosis, 144750 (3), ; osteoporosis-pseudoglioma syndrome, 259770 (3), ; exudative vitreoretinopathy 4, 601813 (3),
OPPO1		
OPRD1		
OPRK		
OPRK1		
OPRL1		
OPRM1		
OPRPN		
OPRS1	AR	?spinal muscular atrophy, distal, 2, 605726 (3), ; ?amyotrophic lateral sclerosis 16, juvenile, 614373 (3),
OPS	AD,AR	osteopetrosis, 1, 607634 (3), ; [bone mineral density variability 1], 601884 (3), ; polycystic liver disease 4 with or without kidney cysts, 617875 (3), ; endosteal hyperostosis, 144750 (3), ; osteoporosis-pseudoglioma syndrome, 259770 (3), ; exudative vitreoretinopathy 4, 601813 (3),
OPT		
OPTA1	AD,AR	osteopetrosis, 1, 607634 (3), ; [bone mineral density variability 1], 601884 (3), ; polycystic liver disease 4 with or without kidney cysts, 617875 (3), ; endosteal hyperostosis, 144750 (3), ; osteoporosis-pseudoglioma syndrome, 259770 (3), ; exudative vitreoretinopathy 4, 601813 (3),
OPTA2	AD,AR	hypopigmentation, organomegaly, and delayed myelination and development, 618541 (3), ; osteopetrosis, 4, 611490 (3), ; osteopetrosis, 2, 166600 (3),
OPTC		
OPTI	AR	?craniofacial dysmorphism, skeletal anomalies, and impaired intellectual development syndrome 2, 616994 (3),
OPTN	AD,AR	glaucoma 1, open angle, e, 137760 (3), ; amyotrophic lateral sclerosis 12 with or without frontotemporal dementia, 613435 (3), ; {glaucoma, normal tension, susceptibility to}, 606657 (3)
OPTX2	AR	optic disc anomalies with retinal and/or macular dystrophy, 212550 (3),
OR10A1		
OR10A5		
OR10J5		
OR11-10		
OR11-403		
OR11-55		
OR11-610		
OR13G1		
OR14-60		
OR14I1		
OR16-36		
OR16-37		
OR16-88		
OR16-89		
OR16-90		
OR17-4		
OR17-6		
OR17-7		
OR19-B		
OR1A1		
OR1A2		
OR1D2		
OR1F1		
OR1F10		
OR1F13P		
OR1F4		
OR1F5		
OR1F6		
OR1F7		
OR1F8		
OR1F9		
OR2D1		
OR2D2		
OR2F1		
OR2F3		
OR2F3P		
OR2F4		
OR2F5		
OR2H2		
OR2J3	AD	[c3hex, ability to smell], 615082 (3),
OR2M7		
OR2W3		
OR2W3P		
OR2W8P		
OR3-145		
OR4C46		
OR4M1		
OR51E1		
OR51E1P		
OR51E2		
OR52A3P		
OR5AN1		
OR5BU1		
OR5BU1P		
OR5F1		
OR5I1		
OR6-6	AD	[c3hex, ability to smell], 615082 (3),
OR6A1		
OR6A2		
OR6A2P		
OR7-139		
OR7-140		
OR7D4		
OR7D4P		
ORAI1	AR,AD	immunodeficiency 9, 612782 (3), ; myopathy, tubular aggregate, 2, 615883 (3),
ORAI2		
ORAI3		
ORAOV1		
ORAOV2	AR	?intestinal dysmotility syndrome, 620045 (3),
ORB3		
ORC1	AR,AR	hyperornithinemia-hyperammonemia-homocitrullinemia syndrome, 238970 (3), |meier-gorlin syndrome 1, 224690 (3),
ORC1L	AR	meier-gorlin syndrome 1, 224690 (3),
ORC2		
ORC2L		
ORC3		
ORC3L		
ORC4	AR	meier-gorlin syndrome 2, 613800 (3),
ORC4L	AR	meier-gorlin syndrome 2, 613800 (3),
Orc4p	AR	meier-gorlin syndrome 2, 613800 (3),
ORC5		
ORC5L		
Orc5p		
ORC5T		
ORC6	AR	meier-gorlin syndrome 3, 613803 (3),
ORC6L	AR	meier-gorlin syndrome 3, 613803 (3),
ORCA		
ORCAM	AD	holoprosencephaly 11, 614226 (3),
ORCTL2		breast cancer, somatic, 114480 (3); lung cancer, somatic, 211980 (3); rhabdomyosarcoma, somatic, 268210 (3)
ORCTL2S		
ORCTL3		
ORCTL4		
OREBP		
ORF	XLR,XL	immunodeficiency 47, 300972 (3),
ORF1	AR	joubert syndrome 3, 608629 (3),
ORF19	AR	glutaric aciduria iii, 231690 (3),
ORF20	AR	trichothiodystrophy 4, nonphotosensitive, 234050 (3),
Orf26		
ORF26	AR	nephronophthisis 13, 614377 (3), ; cranioectodermal dysplasia 4, 614378 (3), ; senior-loken syndrome 8, 616307 (3), ; short-rib thoracic dysplasia 5 with or without polydactyly, 614376 (3), ; ?spermatogenic failure 72, 619867 (3),
Orf3		
ORF34		
Orf4		
ORF9		
ORFX		
ORL1		
ORM	AD,AR	mitochondrial complex v (atp synthase) deficiency, nuclear type 4a, 620358 (3), ; ?combined oxidative phosphorylation deficiency 22, 616045 (3), ; ?mitochondrial complex v (atp synthase) deficiency, nuclear type 4b, encephalopathic type, 615228 (3),
ORM1		
ORM2		
ORMDL1		
ORMDL2		
ORMDL3		
ORNT1	AR	hyperornithinemia-hyperammonemia-homocitrullinemia syndrome, 238970 (3),
ORNT2		
ORP-1		
ORP-11		
ORP-2	AD	deafness, 67, 616340 (3),
ORP-3		
ORP-4		
ORP1	AR,AD	retinitis pigmentosa 1, 180100 (3),
ORP11		
ORP150	AR	?immunodeficiency 59 and hypoglycemia, 233600 (3),
ORP3		
ORP4		
ORP5		
ORP6		
ORP7		
ORP8		
ORW	AD	telangiectasia, hereditary hemorrhagic, type 1, 187300 (3),
ORW1	AD	telangiectasia, hereditary hemorrhagic, type 1, 187300 (3),
ORW2	AD	telangiectasia, hereditary hemorrhagic, type 2, 600376 (3),
ORXR1		
ORXR2		
OS	XLR,XL	opitz gbbb syndrome, 300000 (3),
OS-9		
OS4		
OS9		
OSAP		
OSBP		
OSBP1		
OSBP10		
OSBP2		
OSBP3		
OSBPL1		
OSBPL10		
OSBPL11		
OSBPL1A		
OSBPL1B		
OSBPL2	AD	deafness, 67, 616340 (3),
OSBPL3		
OSBPL5		
OSBPL6		
OSBPL7		
OSBPL8		
OSBPL9		
OSC	AR	hypotrichosis 14, 618275 (3), ; cataract 44, 616509 (3), ; alopecia-intellectual disability syndrome 4, 618840 (3),
OSCAR		
OSCP	AR	mitochondrial complex v (atp synthase) deficiency, nuclear type 7, 620359 (3),
OSCP1		
Oseg6	AR	nephronophthisis 13, 614377 (3), ; cranioectodermal dysplasia 4, 614378 (3), ; senior-loken syndrome 8, 616307 (3), ; short-rib thoracic dysplasia 5 with or without polydactyly, 614376 (3), ; ?spermatogenic failure 72, 619867 (3),
OSF		
OSF-2		
OSGEP	AR	galloway-mowat syndrome 3, 617729 (3),
OSGEP1	AR	galloway-mowat syndrome 3, 617729 (3),
OSGEPL		
OSGEPL1		
OSGIN1		
OSGIN2		
OSIL	AR,AD	neurodegeneration with ataxia, dystonia, and gaze palsy, childhood-onset, 617145 (3), ; frontotemporal dementia and/or amyotrophic lateral sclerosis 3, 616437 (3), ; myopathy, distal, with rimmed vacuoles, 617158 (3), ; paget disease of bone 3, 167250 (3),
OSM	AD	cerebral cavernous malformations-2, 603284 (3),
osm-1	AR	retinitis pigmentosa 71, 616394 (3), ; bardet-biedl syndrome 20, 619471 (3), ; short-rib thoracic dysplasia 10 with or without polydactyly, 615630 (3),
OSM-3		
OSMR	AD	amyloidosis, primary localized cutaneous, 1, 105250 (3),
OSMRB	AD	amyloidosis, primary localized cutaneous, 1, 105250 (3),
OSMRbeta	AD	amyloidosis, primary localized cutaneous, 1, 105250 (3),
OSP	AD	leukodystrophy, hypomyelinating, 22, 619328 (3),
OSP-L	AR	helix syndrome, 617671 (3),
Osp94		
OSR1		
OSR2		
OSRC	AD	small cell cancer of the lung, somatic, 182280 (3); bladder cancer, somatic, 109800 (3); retinoblastoma, trilateral, 180200 (3), somatic mutation, ; osteosarcoma, somatic, 259500 (3); retinoblastoma, 180200 (3), somatic mutation,
OSSA		
OST	AR	congenital disorder of glycosylation, type ir, 614507 (3),
OST1		
OST2		
OST3A	AR	intellectual developmental disorder, 7, 611093 (3),
OST3B	XL,XLR	immunodeficiency, with magnesium defect, epstein-barr virus infection and neoplasia, 300853 (3), ; congenital disorder of glycosylation, type icc, 301031 (3),
OST4		
OST48	AR	congenital disorder of glycosylation, type ir, 614507 (3),
OST718		
OSTalpha	AR	?cholestasis, progressive familial intrahepatic, 6, 619484 (3),
OSTbeta	AR	?bile acid malabsorption, primary, 2, 619481 (3),
OSTC		
osteoadherin		
osterix	AR	osteogenesis imperfecta, type xii, 613849 (3),
OSTF1		
OSTM1	AR	osteopetrosis, 5, 259720 (3),
OSTN		
OSX	AR	osteogenesis imperfecta, type xii, 613849 (3),
OT		
OT-NPI		
OT7T022		
OTAG-12		
OTC	XL	ornithine transcarbamylase deficiency, 311250 (3),
OTC1	XL	ornithine transcarbamylase deficiency, 311250 (3),
OTCase	XL	ornithine transcarbamylase deficiency, 311250 (3),
OTCD	XL	ornithine transcarbamylase deficiency, 311250 (3),
OTDC1		
OTEX		
OTF1		
OTF2		
OTF3		
OTF3C		
OTF3P1		
OTF6		
OTF7		
OTF8	AD	snijders blok-fisher syndrome, 618604 (3),
OTF9	XL,XLR	deafness, 2, 304400 (3),
OTGN	AR	deafness, 18b, 614945 (3),
OTK18		
OTK4		
Otlx2	AD	ring dermoid of cornea, 180550 (3), ; axenfeld-rieger syndrome, type 1, 180500 (3), ; anterior segment dysgenesis 4, 137600 (3),
OTM	AD	leukodystrophy, hypomyelinating, 22, 619328 (3),
OTOA	AR	deafness, 22, 607039 (3),
OTOF	AR	auditory neuropathy, 1, 601071 (3), ; deafness, 9, 601071 (3),
OTOG	AR	deafness, 18b, 614945 (3),
OTOGL	AR	deafness, 84b, 614944 (3),
OTOP1		
OTOP2		
OTOP3		
OTOR		
OTOS		
OTOSP		
OTP		
OTR		
OTRPC4	AD	spondylometaphyseal dysplasia, kozlowski type, 184252 (3), ; digital arthropathy-brachydactyly, familial, 606835 (3), ; [sodium serum level qtl 1], 613508 (3); sed, maroteaux type, 184095 (3), ; metatropic dysplasia, 156530 (3), ; scapuloperoneal spinal muscular atrophy, 181405 (3), ; hereditary motor and sensory neuropathy, type iic, 606071 (3), ; ?avascular necrosis of femoral head, primary, 2, 617383 (3), ; neuronopathy, distal hereditary motor, type viii, 600175 (3), ; parastremmatic dwarfism, 168400 (3), ; brachyolmia type 3, 113500 (3),
OTT		
OTT1		
OTT3		
OTTHUMG00000013337		
OTTHUMG00000019597		
OTTHUMG00000019959		
OTTHUMG00000020980		
OTTHUMG00000021016		
OTTHUMG00000024136		
OTTHUMG00000024137		
OTTHUMG00000024138		
OTTHUMG00000024144		
OTTHUMG00000024145		
OTTHUMG00000024146		
OTTHUMG00000024147		
OTTHUMG00000024148		
OTTHUMG00000024149		
OTTHUMG00000066752		
OTTHUMG00000067390		
OTTHUMP00000017061		
OTTHUMP00000017062		
OTTHUMT00000075032		
OTUB1		
OTUB2		
OTUD1		
OTUD2		
OTUD3		
OTUD4		
OTUD5	XL,XLR	multiple congenital anomalies-neurodevelopmental syndrome, 301056 (3),
OTUD6A		
OTUD6B	AR	intellectual developmental disorder with dysmorphic facies, seizures, and distal limb anomalies, 617452 (3),
OTUD7		
OTUD7A		
OTUD7B		
OTUD7C	AD	autoinflammatory syndrome, familial, behcet-like 1, 616744 (3),
OTULIN	AR,AD	autoinflammation, panniculitis, and dermatosis syndrome, 617099 (3), ; {immunodeficiency 107, susceptibility to invasive staphylococcus aureus infection}, 619986 (3),
OTX1		
OTX2	AD	retinal dystrophy, early-onset, with or without pituitary dysfunction, 610125 (3), ; pituitary hormone deficiency, combined, 6, 613986 (3), ; microphthalmia, syndromic 5, 610125 (3),
OTX3	AD	leber congenital amaurosis 7, 613829 (3); cone-rod retinal dystrophy-2, 120970 (3),
OUT		
OV-1		
ovasin		
ovastacin	AR	?oocyte/zygote/embryo maturation arrest 11, 619643 (3),
OVC10-2		
OVCA1	AR	developmental delay with short stature, dysmorphic facial features, and sparse hair, 616901 (3),
OVCA2		
OVCH2		
OVCOV1		
OVD1A	AR	maple syrup urine disease, type ia, 248600 (3),
OVGP1		
OVOL1		
OVOL2	AD	corneal dystrophy, posterior polymorphous, 1, 122000 (3),
OVOL3		
OVTN		
OX	AD	?narcolepsy 1, 161400 (3),
OX-2		
OX-40L		{myocardial infarction, susceptibility to}, 608446 (3)
OX1R		
OX2R		
OX40	AR	?immunodeficiency 16, 615593 (3),
OXA1		
OXA1L		
OXA1L1		
OXA1L2		
OXCT	AR	succinyl coa:3-oxoacid coa transferase deficiency, 245050 (3),
OXCT1	AR	succinyl coa:3-oxoacid coa transferase deficiency, 245050 (3),
OXCT2		
OXER1		
OXGR1	AD	nephrolithiasis, calcium oxalate, 2, with nephrocalcinosis, 620374 (3),
OXPAT		
OXR1	AR	cerebellar hypoplasia/atrophy, epilepsy, and global developmental delay, 213000 (3),
OXR2		
OXSM		
OXSR1		
OXT		
OXT-NPI		
OXTR		
OY-TES-1		
OZF		
ozrf1		
Ozz		
Ozz-E3		
P	AR	[skin/hair/eye pigmentation 1, blue/nonblue eyes], 227220 (3), ; [skin/hair/eye pigmentation 1, blond/brown hair], 227220 (3), ; albinism, brown oculocutaneous, 203200 (3), ; albinism, oculocutaneous, type ii, 203200 (3),
p-170		{inflammatory bowel disease 13}, 612244 (3); {colchicine resistance}, 120080 (3)
P-450AROM	AD	aromatase deficiency, 613546 (3); aromatase excess syndrome, 139300 (3),
P-450C18	AR	hypoaldosteronism, congenital, due to cmo i deficiency, 203400 (3), ; aldosterone to renin ratio raised (3); {low renin hypertension, susceptibility to} (3); hypoaldosteronism, congenital, due to cmo ii deficiency, 610600 (3),
P-B		
P-CIP1		
P-dlg		
P-gp		{inflammatory bowel disease 13}, 612244 (3); {colchicine resistance}, 120080 (3)
P-LAP		
P-PST		
P-REX1		
P-REX2		
P(k)		[blood group, p1pk system, p(2) phenotype], 111400 (3); nor polyagglutination syndrome, 111400 (3); [blood group, p1pk system, p phenotype], 111400 (3)
P/CAF		
p/CIP		
P0	AD,AR	charcot-marie-tooth disease, type 2i, 607677 (3), ; dejerine-sottas disease, 145900 (3), ; charcot-marie-tooth disease, type 1b, 118200 (3), ; roussy-levy syndrome, 180800 (3), ; charcot-marie-tooth disease, intermediate d, 607791 (3), ; hypomyelinating neuropathy, congenital, 2, 618184 (3), ; charcot-marie-tooth disease, type 2j, 607736 (3),
p0071		
P1	AR	[blood group, p1pk system, p(2) phenotype], 111400 (3); nor polyagglutination syndrome, 111400 (3); [blood group, p1pk system, p phenotype], 111400 (3)|hemophagocytic lymphohistiocytosis, familial, 2, 603553 (3), ; aplastic anemia, 609135 (3); lymphoma, non-hodgkin, 605027 (3)
P1-450		
P1-Cdc21	AR	immunodeficiency 54, 609981 (3),
p10	AR	pontocerebellar hypoplasia, type 1b, 614678 (3),
p100		
p101	AR	ataxia-oculomotor apraxia 3, 615217 (3),
P101-PI3K	AR	ataxia-oculomotor apraxia 3, 615217 (3),
p104		
p105	AD,AD	immunodeficiency, common variable, 10, 615577 (3), |immunodeficiency, common variable, 12, 616576 (3),
P105	AR	spinocerebellar ataxia, 21, 616719 (3),
p107		
p11		
P11		
p110		
p110D	AD,AR	immunodeficiency 14a, 615513 (3), ; immunodeficiency 14b, 619281 (3), ; ?roifman-chitayat syndrome, digenic, 613328 (3), digenic
P112		
P114-RhoGEF	AR	retinitis pigmentosa 78, 617433 (3),
p114RhoGEF	AR	retinitis pigmentosa 78, 617433 (3),
p115		
P115-RHOGEF	AR	?immunodeficiency 62, 618459 (3),
p116Rip		
P117	AR	combined oxidative phosphorylation deficiency 37, 618329 (3),
p12		
p120	AD,AD	blepharocheilodontic syndrome 2, 617681 (3), |capillary malformation-arteriovenous malformation 1, 608354 (3), ; basal cell carcinoma, somatic, 605462 (3)
p120(NOL1)		
p120cas	AD	blepharocheilodontic syndrome 2, 617681 (3),
p120ctn	AD	blepharocheilodontic syndrome 2, 617681 (3),
p120GAP	AD	capillary malformation-arteriovenous malformation 1, 608354 (3), ; basal cell carcinoma, somatic, 605462 (3)
p120RASGAP	AD	capillary malformation-arteriovenous malformation 1, 608354 (3), ; basal cell carcinoma, somatic, 605462 (3)
p122-RhoGAP		colorectal cancer, somatic, 114500 (3)
p125		
p125A		
p125B	AR	spastic paraplegia 54, 615033 (3),
p126		
p12A		
p12B	AR	cerebellar ataxia, brain abnormalities, and cardiac conduction defects, 619576 (3),
p12DOC-1		
p13	AR	?pontocerebellar hypoplasia, type 1f, 619304 (3),
p130	AR	brunet-wagner neurodevelopmental syndrome, 619690 (3),
P130		
P130Cas		
P138		
P138-TOX	AR	thyroid dyshormonogenesis 6, 607200 (3),
P138(TOX)	AR	thyroid dyshormonogenesis 6, 607200 (3),
P13MTCP1		
p14	AD,AR	{melanoma and neural system tumor syndrome}, 155755 (3), ; {melanoma, cutaneous malignant, 2}, 155601 (3), ; {melanoma-pancreatic cancer syndrome}, 606719 (3), |immunodeficiency due to defect in mapbp-interacting protein, 610798 (3),
P14	AR	?immunodeficiency 99 with hypogammaglobulinemia and autoimmune cytopenias, 619846 (3),
P14.5		
p140Cap		
P140SRA-1		
p14ARF	AD	{melanoma and neural system tumor syndrome}, 155755 (3), ; {melanoma, cutaneous malignant, 2}, 155601 (3), ; {melanoma-pancreatic cancer syndrome}, 606719 (3),
P14L	AR	?immunodeficiency 99 with hypogammaglobulinemia and autoimmune cytopenias, 619846 (3),
p15		
P15		
P15-2		
p15(PAF)		
p150	AD	leukemia, philadelphia chromosome-positive, resistant to imatinib, 608232 (3), somatic mutation; congenital heart defects and skeletal malformations syndrome, 617602 (3),
P150		
p150TSP		
p15AS		
p15INK4b		
P15RS		
p16	AD	{melanoma and neural system tumor syndrome}, 155755 (3), ; {melanoma, cutaneous malignant, 2}, 155601 (3), ; {melanoma-pancreatic cancer syndrome}, 606719 (3),
p16-Arc		
P16-INK4A	AD	{melanoma and neural system tumor syndrome}, 155755 (3), ; {melanoma, cutaneous malignant, 2}, 155601 (3), ; {melanoma-pancreatic cancer syndrome}, 606719 (3),
P160		
p160ROCK		
p164-RhoGEF		
p16INK4a	AD	{melanoma and neural system tumor syndrome}, 155755 (3), ; {melanoma, cutaneous malignant, 2}, 155601 (3), ; {melanoma-pancreatic cancer syndrome}, 606719 (3),
p17		
p170	AD	{otitis media, susceptibility to}, 166760 (3),
p18		
P18		
p18-20	AR	hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy, 612300 (3),
p180	XL,XLR	pigmentary disorder, reticulate, with systemic manifestations, 301220 (3), ; van esch-o'driscoll syndrome, 301030 (3),
p185(erbB2)	AR	gastric cancer, somatic, 613659 (3); adenocarcinoma of lung, somatic, 211980 (3); ovarian cancer, somatic, 167000 (3); ?visceral neuropathy, familial, 2, 619465 (3), ; glioblastoma, somatic, 137800 (3)
p19	AD	{melanoma and neural system tumor syndrome}, 155755 (3), ; {melanoma, cutaneous malignant, 2}, 155601 (3), ; {melanoma-pancreatic cancer syndrome}, 606719 (3),
P19		
p190	AR	lethal congenital contracture syndrome 7, 616286 (3), ; hypomyelinating neuropathy, congenital, 3, 618186 (3),
p190-B		
P190A		
p190ARhoGAP		
p190BRhoGAP		
p190RhoGAP		
p190RhoGEF		
p193		
p195		
p19A		
p19Arf	AD	{melanoma and neural system tumor syndrome}, 155755 (3), ; {melanoma, cutaneous malignant, 2}, 155601 (3), ; {melanoma-pancreatic cancer syndrome}, 606719 (3),
p19B		
P1P373C6		
p2		
P2		
p20		
p20-Arc	AD	developmental delay, language impairment, and ocular abnormalities, 620141 (3),
p20-CGGBP		
p200	AD	developmental delay, impaired speech, and behavioral abnormalities, with or without seizures, 619964 (3),
p200a		
p202		
p21	XL,XLD	neurodevelopmental disorder with gait disturbance, dysmorphic facies and behavioral abnormalities, 301094 (3),
P21	XL,XLD	neurodevelopmental disorder with gait disturbance, dysmorphic facies and behavioral abnormalities, 301094 (3),
p21-Arc		
p21-Rac1	AD	intellectual developmental disorder, 48, 617751 (3),
p21cdc42Hs		
p21CIP1		
p21Cip1/Waf1		
p22	AR,AD	?spastic ataxia 9, 618438 (3), |charcot-marie-tooth disease, axonal, type 2o, 614228 (3), ; spinal muscular atrophy, lower extremity-pre 1, ad, 158600 (3), ; cortical dysplasia, complex, with other brain malformations 13, 614563 (3),
p22-PHOX	AR	chronic granulomatous disease 4, 233690 (3),
p220	AD	{parkinson disease 18}, 614251 (3),
p23		
p230		
p235	AD	corneal fleck dystrophy, 121850 (3),
p24	AR	?spastic ataxia 9, 618438 (3),
P24		
P24(DELTA)		
p240		
P24A		
p24a3		
p24alpha3		
p24b1		
p24beta1		
p24d1		
p24delta1		
p24g1		
p24g2		
p24g3		
p24gamma1		
p24gamma2		
p24gamma3		
p24ING1c		squamous cell carcinoma, head and neck, somatic, 275355 (3)
p25		
p250		
p250R	AD	coffin-siris syndrome 1, 135900 (3),
p25alpha		
p25beta		
p25gamma		
P25TI		
p27		
P27		
p27-BWR1B		
P270	AD	coffin-siris syndrome 2, 614607 (3),
p27BBP		
p27K		{myocardial infarction, susceptibility to}, 608446 (3)
P27KIP1	AD	multiple endocrine neoplasia, type iv, 610755 (3),
p27RF-Rho		
p28		
P28	AR	?spermatogenic failure 83, 620354 (3),
p28b		
p28ING5		
p29		
P29		
p29ING4		
P2ECSL		
P2P		
P2P-R		
P2RX1		
P2RX2	AD	deafness, 41, 608224 (3),
P2RX3		
P2RX4		
P2RX5		
P2RX6		
P2RX7		
P2RXL1		
P2RY1		
P2RY10		
P2RY11		
P2RY12	AR	bleeding disorder, platelet-type, 8, 609821 (3),
P2RY13		
P2RY14		
P2RY15	AD	nephrolithiasis, calcium oxalate, 2, with nephrocalcinosis, 620374 (3),
P2RY2		
P2RY4		
P2RY5	AR	hypotrichosis 8, 278150 (3), ; woolly hair, 1, with or without hypotrichosis, 278150 (3),
P2RY6		
P2RY7		
P2RY8		
P2RY9		
P2U		
P2X1		
P2X2	AD	deafness, 41, 608224 (3),
P2X3		
P2X4		
P2X5		
P2X6		
P2X7		
P2XM		
P2Y1		
P2Y10		
P2Y11		
P2Y12	AR	bleeding disorder, platelet-type, 8, 609821 (3),
P2Y13		
P2Y15	AD	nephrolithiasis, calcium oxalate, 2, with nephrocalcinosis, 620374 (3),
P2Y4		
P2Y5	AR	hypotrichosis 8, 278150 (3), ; woolly hair, 1, with or without hypotrichosis, 278150 (3),
P2Y5-LIKE		
P2Y6		
P2Y7		
P2Y8		
P2Y9		
p3		
P3		
P3-450		
p30		
p300	AD	menke-hennekam syndrome 2, 618333 (3), ; colorectal cancer, somatic, 114500 (3); rubinstein-taybi syndrome 2, 613684 (3),
p31		
P31	AR	cutis laxa, type iic, 617402 (3),
P311		
p32	AR,AR	cd8 deficiency, familial, 608957 (3), |combined oxidative phosphorylation deficiency 33, 617713 (3),
p325		
p33		squamous cell carcinoma, head and neck, somatic, 275355 (3)
p33ING1		squamous cell carcinoma, head and neck, somatic, 275355 (3)
p33ING1b		squamous cell carcinoma, head and neck, somatic, 275355 (3)
p33ING2		
p34	AD	keratoderma, palmoplantar, punctate type ia, 148600 (3),
P34		
p34-Arc		
P34H	AR	[pentosuria], 260800 (3),
p35		
P35		
p35-1		
p35-2		
p350	AR	immunodeficiency 26, with or without neurologic abnormalities, 615966 (3),
P35B		
p35nck5a		
p36	AR	anemia, hemolytic, due to umph1 deficiency, 266120 (3),
p37		
P37		
p373c6.1		
P37NB		
p38	AR	leukodystrophy, hypomyelinating, 17, 618006 (3),
p38-2		
p38Beta		
p38delta		
p38gamma		
P38IP		
P39		
p39nck5ai		
P3ECSL		
P3H1	AR	osteogenesis imperfecta, type viii, 610915 (3),
P3H2	AR	myopia, high, with cataract and vitreoretinal degeneration, 614292 (3),
P3H3		
P3H4		
P3H5	AR	osteogenesis imperfecta, type vii, 610682 (3),
p4		
p40	AD,AD	asplenia, isolated congenital, 271400 (3), |premature ovarian failure 21, 620311 (3), ; ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3, 604292 (3), ; hay-wells syndrome, 106260 (3), ; split-hand/foot malformation 4, 605289 (3), ; orofacial cleft 8, 618149 (3); rapp-hodgkin syndrome, 129400 (3), ; adult syndrome, 103285 (3), ; limb-mammary syndrome, 603543 (3),
P40	AR	?neurodevelopmental disorder with midbrain and hindbrain malformations, 617523 (3),
p40-ARC	AR	immunodeficiency 71 with inflammatory disease and congenital thrombocytopenia, 617718 (3),
p40.5		
P400		
p40BBp		
p40phox	AR	chronic granulomatous disease 3, 613960 (3),
p41-ARC	AR	immunodeficiency 71 with inflammatory disease and congenital thrombocytopenia, 617718 (3),
p41mapk	AD	noonan syndrome 13, 619087 (3),
P41NOXA		
P41NOXB		
P41NOXC		
p42		
p42.3		
P42pop		
p43	AR	leukodystrophy, hypomyelinating, 3, 260600 (3),
p44		
p44.5		
p44CTLH		
p44EMLP		
p44erk1		
p44mapk		
p44S10		
p45		
p45/SUG		
P450-14DM		
P450-C		
P450-CC24	AR	hypercalcemia, infantile, 1, 143880 (3),
P450-DB1	AR	{codeine sensitivity}, 608902 (3), ; {debrisoquine sensitivity}, 608902 (3),
P450-HFLA		
P450aldo	AR	hypoaldosteronism, congenital, due to cmo i deficiency, 203400 (3), ; aldosterone to renin ratio raised (3); {low renin hypertension, susceptibility to} (3); hypoaldosteronism, congenital, due to cmo ii deficiency, 610600 (3),
P450c1	AR	vitamin d-dependent rickets, type i, 264700 (3),
P450C11	AD,AR	aldosteronism, glucocorticoid-remediable, 103900 (3), ; adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deficiency, 202010 (3),
P450C17	AR	17,20-lyase deficiency, isolated, 202110 (3), ; 17-alpha-hydroxylase/17,20-lyase deficiency, 202110 (3),
P450c21B	AR	hyperandrogenism, nonclassic type, due to 21-hydroxylase deficiency, 201910 (3), ; adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency, 201910 (3),
P450C2D	AR	{codeine sensitivity}, 608902 (3), ; {debrisoquine sensitivity}, 608902 (3),
P450DX		
P450IIC17		
P450IIC19	AR	proguanil poor metabolizer, 609535 (3), ; mephenytoin poor metabolizer, 609535 (3), ; clopidogrel, impaired responsiveness to, 609535 (3), ; omeprazole poor metabolizer, 609535 (3),
P450IIC9	AD	warfarin sensitivity, 122700 (3), ; tolbutamide poor metabolizer (3)
P450L1		
P450PCN3	MF	{hypertension, salt-sensitive essential, susceptibility to}, 145500 (3),
P450RAI		
P450RAI-2		craniosynostosis with radiohumeral fusions and other skeletal and craniofacial anomalies, 614416 (3)
P450RAI1		
P450SCC		adrenal insufficiency, congenital, with 46xy sex reversal, partial or complete, 613743 (3)
p460	AR	immunodeficiency 26, with or without neurologic abnormalities, 615966 (3),
p47		squamous cell carcinoma, head and neck, somatic, 275355 (3)
P47		
p47ING1a		squamous cell carcinoma, head and neck, somatic, 275355 (3)
p47ING3		
p47phox	AR	chronic granulomatous disease 1, 233700 (3),
p48	AR	pancreatic and cerebellar agenesis, 609069 (3), ; pancreatic agenesis 2, 615935 (3),
P48		
p49		
p49/p100	AD	immunodeficiency, common variable, 10, 615577 (3),
p493F12		
P4H-TM	AR	hypotonia, hypoventilation, impaired intellectual development, dysautonomia, epilepsy, and eye abnormalities, 618493 (3),
P4HA		
P4HA1		
P4HA2	AD	myopia 25, 617238 (3),
P4HA3		
P4HB	AD	cole-carpenter syndrome 1, 112240 (3),
P4Hbeta	AD	cole-carpenter syndrome 1, 112240 (3),
P4HTM	AR	hypotonia, hypoventilation, impaired intellectual development, dysautonomia, epilepsy, and eye abnormalities, 618493 (3),
p5	AR	pontocerebellar hypoplasia, type 1d, 618065 (3),
P5		
P5-1		
P5'N-1	AR	anemia, hemolytic, due to umph1 deficiency, 266120 (3),
p50	AR,AD,AR	immunodeficiency with hyper-igm, type 3, 606843 (3), |immunodeficiency, common variable, 12, 616576 (3), |spinal muscular atrophy with congenital bone fractures 2, 616867 (3), ; barrett esophagus/esophageal adenocarcinoma, 614266 (3)
P50		
P500		
P504S	AR	alpha-methylacyl-coa racemase deficiency, 614307 (3), ; bile acid synthesis defect, congenital, 4, 214950 (3),
P50BP		
P50CDC37		
p50rhoGAP		
p51	AD	premature ovarian failure 21, 620311 (3), ; ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3, 604292 (3), ; hay-wells syndrome, 106260 (3), ; split-hand/foot malformation 4, 605289 (3), ; orofacial cleft 8, 618149 (3); rapp-hodgkin syndrome, 129400 (3), ; adult syndrome, 103285 (3), ; limb-mammary syndrome, 603543 (3),
P51		
P518		
p52	AD	immunodeficiency, common variable, 10, 615577 (3),
P52		
p528	AR	intellectual developmental disorder, 38, 615516 (3), ; [skin/hair/eye pigmentation 1, blond/brown hair], 227220 (3), ; [skin/hair/eye pigmentation 1, blue/nonblue eyes], 227220 (3),
P52rIPK		
p53	AD	{basal cell carcinoma 7}, 614740 (3), ; {adrenocortical carcinoma, pediatric}, 202300 (3), ; hepatocellular carcinoma, somatic, 114550 (3); breast cancer, somatic, 114480 (3); li-fraumeni syndrome, 151623 (3), ; pancreatic cancer, somatic, 260350 (3); nasopharyngeal carcinoma, somatic, 607107 (3); {osteosarcoma}, 259500 (3), somatic mutation; {choroid plexus papilloma}, 260500 (3), ; {colorectal cancer}, 114500 (3), somatic mutation, ; {glioma susceptibility 1}, 137800 (3), somatic mutation, ; bone marrow failure syndrome 5, 618165 (3),
p532	AR	macrocephaly, dysmorphic facies, and psychomotor retardation, 617011 (3),
p53AIP1		
p53BP2-like		
p53CP	AD	premature ovarian failure 21, 620311 (3), ; ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3, 604292 (3), ; hay-wells syndrome, 106260 (3), ; split-hand/foot malformation 4, 605289 (3), ; orofacial cleft 8, 618149 (3); rapp-hodgkin syndrome, 129400 (3), ; adult syndrome, 103285 (3), ; limb-mammary syndrome, 603543 (3),
p53CSV		
P53CSV		
P53DINP1		
P53N		
p53R2	AR,AD	mitochondrial dna depletion syndrome 8b (mngie type), 612075 (3), ; mitochondrial dna depletion syndrome 8a (encephalomyopathic type with renal tubulopathy), 612075 (3), ; rod-cone dystrophy, sensorineural deafness, and fanconi-type renal dysfunction, 268315 (3), ; progressive external ophthalmoplegia with mitochondrial dna deletions, 5, 613077 (3),
p53RDL1		
P53RFP		
P53RRA		
P53TG3		
p54		
P54	XL	{major depressive disorder and accelerated response to antidepressant drug treatment}, 608516 (3)|intellectual developmental disorder, syndromic 34, 300967 (3),
P542		
p54a		
p54bSAPK		
P54NRB	XL	intellectual developmental disorder, syndromic 34, 300967 (3),
p55	AD	stankiewicz-isidor syndrome, 617516 (3),
p55c-fgr		
p55CDC	AR	oocyte/zygote/embryo maturation arrest 14, 620276 (3),
p55T		
p56	AR	?birk-aharoni syndrome, 620071 (3),
P56		
p56dok-2		
p57	AR	immunodeficiency 8, 615401 (3),
P57	AD,AD	image syndrome, 614732 (3), ; beckwith-wiedemann syndrome, 130650 (3), |wilms tumor 2, 194071 (3), somatic mutation, ; beckwith-wiedemann syndrome, 130650 (3), ; silver-russell syndrome 1, 180860 (3),
p58		
P58	AR	ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus, 616192 (3),
p58.1		
p58(IPK)	AR	ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus, 616192 (3),
p58GTA		
P58IPK	AR	ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus, 616192 (3),
p59OASL		
P5C	AR	cutis laxa, type iiib, 614438 (3), ; cutis laxa, type iib, 612940 (3),
P5CDh	AR	hyperprolinemia, type ii, 239510 (3),
P5CR2	AR	leukodystrophy, hypomyelinating, 10, 616420 (3),
P5CS	AD,AR	spastic paraplegia 9a, 601162 (3), ; cutis laxa, type iiia, 219150 (3), ; spastic paraplegia 9b, 616586 (3), ; cutis laxa, 3, 616603 (3),
p6	AR	pontocerebellar hypoplasia, type 1d, 618065 (3),
p60	AR,AD	neurodegeneration with ataxia, dystonia, and gaze palsy, childhood-onset, 617145 (3), ; frontotemporal dementia and/or amyotrophic lateral sclerosis 3, 616437 (3), ; myopathy, distal, with rimmed vacuoles, 617158 (3), ; paget disease of bone 3, 167250 (3),
P60		
p600		
P600	AD	{asthma, susceptibility to}, 600807 (3), ; {allergic rhinitis, susceptibility to}, 607154 (3)
p60TRP		
p619	AR	macrocephaly, dysmorphic facies, and psychomotor retardation, 617011 (3),
p62	AD,AR,AD,AR	{diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3), |neurodegeneration with ataxia, dystonia, and gaze palsy, childhood-onset, 617145 (3), ; frontotemporal dementia and/or amyotrophic lateral sclerosis 3, 616437 (3), ; myopathy, distal, with rimmed vacuoles, 617158 (3), ; paget disease of bone 3, 167250 (3), |striatonigral degeneration, infantile, 271930 (3),
P62	AD	{diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3),
p621		
p62B	AR,AD	neurodegeneration with ataxia, dystonia, and gaze palsy, childhood-onset, 617145 (3), ; frontotemporal dementia and/or amyotrophic lateral sclerosis 3, 616437 (3), ; myopathy, distal, with rimmed vacuoles, 617158 (3), ; paget disease of bone 3, 167250 (3),
p62dok		
p63	AD	premature ovarian failure 21, 620311 (3), ; ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3, 604292 (3), ; hay-wells syndrome, 106260 (3), ; split-hand/foot malformation 4, 605289 (3), ; orofacial cleft 8, 618149 (3); rapp-hodgkin syndrome, 129400 (3), ; adult syndrome, 103285 (3), ; limb-mammary syndrome, 603543 (3),
P63		
p63RhoGEF		
p64	AD,AR	craniosynostosis 3, 615314 (3), ; hypogonadotropic hypogonadism 26 with or without anosmia, 619718 (3),
p64CLCP		
p64H1		
P64H1		
p65	AD	autoinflammatory disease, familial, behcet-like-3, 618287 (3),
P65	AD	baker-gordon syndrome, 618218 (3),
p66		
P66		
p66alpha		
P66beta	AD	gand syndrome, 615074 (3),
p67		
p67phox	AR	chronic granulomatous disease 2, 233710 (3),
p68		
P68		
p7	AR	short stature, hearing loss, retinitis pigmentosa, and distinctive facies, 617763 (3),
P70-BETA		
p70(S6K)-alpha		
P70R	AR	methylmalonic aciduria and homocystinuria, cblj type, 614857 (3),
p70S6Kb		
P71		
P72		
P73	AR	ciliary dyskinesia, primary, 47, and lissencephaly, 619466 (3),
p73H	AD	premature ovarian failure 21, 620311 (3), ; ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3, 604292 (3), ; hay-wells syndrome, 106260 (3), ; split-hand/foot malformation 4, 605289 (3), ; orofacial cleft 8, 618149 (3); rapp-hodgkin syndrome, 129400 (3), ; adult syndrome, 103285 (3), ; limb-mammary syndrome, 603543 (3),
p73L	AD	premature ovarian failure 21, 620311 (3), ; ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3, 604292 (3), ; hay-wells syndrome, 106260 (3), ; split-hand/foot malformation 4, 605289 (3), ; orofacial cleft 8, 618149 (3); rapp-hodgkin syndrome, 129400 (3), ; adult syndrome, 103285 (3), ; limb-mammary syndrome, 603543 (3),
p75	AR,AD	agammaglobulinemia 8b, 619824 (3), ; agammaglobulinemia 8a, 616941 (3),
p75/AIRM1		
p75NTR		
p76		
P76		
P78		
P79PIF		
P7BP2	AD	?retinitis pigmentosa 97, 620422 (3),
p8		
P8		
P80		
p80-coilin		
p82		
p84		
P84	AD	?deafness, 86, 620280 (3),
p85	AD,AR,AD	immunodeficiency 36, 616005 (3), ; ?agammaglobulinemia 7, 615214 (3), ; short syndrome, 269880 (3), |megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 1, 603387 (3),
P85		
p85-ALPHA	AD,AR	immunodeficiency 36, 616005 (3), ; ?agammaglobulinemia 7, 615214 (3), ; short syndrome, 269880 (3),
p85-BETA	AD	megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 1, 603387 (3),
p85alpha	AD,AR	immunodeficiency 36, 616005 (3), ; ?agammaglobulinemia 7, 615214 (3), ; short syndrome, 269880 (3),
P85B	AD	megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 1, 603387 (3),
p85beta	AD	megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 1, 603387 (3),
P85COOL1		
P85SPR		
P87		
p87PIKAP		
P89		
p8MTCP1		
P8MTCP1		
p9	AR	pontocerebellar hypoplasia, type 1c, 616081 (3),
p90	AR	immunodeficiency 46, 616740 (3),
P90		
p90Rsk		
p92	AR	nephrotic syndrome, type 21, 618594 (3),
p94	AR,AD	muscular dystrophy, limb-girdle, 1, 253600 (3), ; muscular dystrophy, limb-girdle, 4, 618129 (3),
P96PIF		
p97	AD,AR	frontotemporal dementia and/or amyotrophic lateral sclerosis 6, 613954 (3), ; charcot-marie-tooth disease, type 2y, 616687 (3), ; inclusion body myopathy with early-onset paget disease and frontotemporal dementia 1, 167320 (3), |neurodevelopmental disorder with microcephaly, cataracts, and renal abnormalities, 617913 (3),
P97		
p97MAPK		
p99		
P9KA		
Pa		
PA	AR	?hermansky-pudlak syndrome 9, 614171 (3), |spherocytosis, type 5, 612690 (3)
PA-FABP		
PA-PLA1	AR	spastic paraplegia 28, 609340 (3),
PA1		
PA2.26		
PA200		
PA26		
PA28-gamma		
PA28alpha		
PA28beta		
PA28G		
PA2G4		
PAAF1		
PAAT		
PAB1		
PAB2	AD	oculopharyngeal muscular dystrophy, 164300 (3),
PABIR1		
PABP1		
PABP2	AD	oculopharyngeal muscular dystrophy, 164300 (3),
PABP3		
PABP5		
PABPC1		
PABPC2		
PABPC3		
PABPC4		
PABPC5		
PABPL1		
PABPL3		
PABPN1	AD	oculopharyngeal muscular dystrophy, 164300 (3),
PAC		
PAC-1		
PAC1		gastric cancer, somatic, 613659 (3); prostate cancer, somatic, 176807 (3)
PAC1R		
pac2	AR	kenny-caffey syndrome, type 1, 244460 (3), ; hypoparathyroidism-retardation-dysmorphism syndrome, 241410 (3), ; encephalopathy, progressive, with amyotrophy and optic atrophy, 617207 (3),
PAC2	AR	?proteasome-associated autoinflammatory syndrome 4, 619183 (3),
PAC3		
PAC4		
PACAP		
PACAPR		
PACC1		
PACE		
PACE-1		
PACE1		
PACE4		
PACER		
PACERR		
PACRG		
PACS1	AD	schuurs-hoeijmakers syndrome, 615009 (3),
PACS1L	AD	developmental and epileptic encephalopathy 66, 618067 (3),
PACS2	AD	developmental and epileptic encephalopathy 66, 618067 (3),
PACSIN1		
PACSIN2		
PACSIN3		
PACT	AR	dystonia 16, 612067 (3),
PAD		
pad1		
PAD1		
PADGEM		
PADI1		
PADI2		
PADI3	AR	uncombable hair syndrome, 191480 (3),
PADI4		
PADI5		
PADI6	AR	oocyte/zygote/embryo maturation arrest 16, 617234 (3),
pADPRT-3		
PAEG		
PAELR		
PAEP		
PAF-1	AR	peroxisome biogenesis disorder 5a (zellweger), 614866 (3), ; peroxisome biogenesis disorder 5b, 614867 (3),
PAF-2	AR,AD	peroxisome biogenesis disorder 4b, 614863 (3), ; peroxisome biogenesis disorder 4a (zellweger), 614862 (3), ; heimler syndrome 2, 616617 (3),
PAF1		
PAF15		
PAF400	AD	?deafness, 75, 618778 (3), ; developmental delay with or without dysmorphic facies and autism, 618454 (3),
PAF49		
PAF65A		
PAFAH	AR,AD,AD	platelet-activating factor acetylhydrolase deficiency, 614278 (3), ; {asthma, susceptibility to}, 600807 (3), ; {atopy, susceptibility to}, 147050 (3), |subcortical laminar heterotopia, 607432 (3), ; lissencephaly 1, 607432 (3),
PAFAH1B1	AD	subcortical laminar heterotopia, 607432 (3), ; lissencephaly 1, 607432 (3),
PAFAH1B2		
PAFAH1B3		
PAFAH2		
PAFR		
PAG		
PAG1		
PAG608		
PAGA	AR	methylmalonic aciduria and homocystinuria, cblc type, digenic, 277400 (3),
PAGE-1		
PAGE-2		
PAGE-3		
PAGE-4		
PAGE-5		
PAGE1		
PAGE2		
PAGE3		
PAGE4		
PAGE5		
PAGM	AR	immunodeficiency 23, 615816 (3),
PAGR1		
PAH	AR	[hyperphenylalaninemia, non-pku mild], 261600 (3), ; phenylketonuria, 261600 (3),
PAHRF		
PAHT		
PAHX	AR	refsum disease, 266500 (3),
PAHX-AP		
PAI	AR,AD	plasminogen activator inhibitor-1 deficiency, 613329 (3), ; {transcription of plasminogen activator inhibitor, modulator of} (3)
PAI-2		
PAI-RBP1		
PAI1	AR,AD	plasminogen activator inhibitor-1 deficiency, 613329 (3), ; {transcription of plasminogen activator inhibitor, modulator of} (3)
PAI2		
PAI3		
PAICS	AR	?phosphoribosylaminoimidazole carboxylase deficiency, 619859 (3),
PAIP1		
PAIP2		
PAIP2A		
PAIP2B		
PAIRBP1		
PAIS	AR	?phosphoribosylaminoimidazole carboxylase deficiency, 619859 (3),
Pak-2		
PAK1	AD	intellectual developmental disorder with macrocephaly, seizures, and speech delay, 618158 (3),
PAK1IP1		
PAK2	AD	?knobloch syndrome 2, 618458 (3),
PAK3	XL,XLR	intellectual developmental disorder, 30, 300558 (3),
PAK4		
PAK5		
PAK6		
PAK65	AD	?knobloch syndrome 2, 618458 (3),
PAK7		
PAKgamma	AD	?knobloch syndrome 2, 618458 (3),
PAL		
PALB	AD	amyloidosis, hereditary, transthyretin-related, 105210 (3), ; carpal tunnel syndrome, familial, 115430 (3), ; [dystransthyretinemic hyperthyroxinemia], 145680 (3),
PALB2	AD	{breast cancer, susceptibility to}, 114480 (3), somatic mutation, ; {pancreatic cancer, susceptibility to, 3}, 613348 (3); fanconi anemia, complementation group n, 610832 (3)
PalBH		
PALD		
PALD1		
PALLD	AD	{pancreatic cancer, susceptibility to, 1}, 606856 (3),
PALM		
PALM1		
PALM2-AKAP2		
PALM2AKAP2		
PALMCOX	AD,AR	mitchell syndrome, 618960 (3), ; peroxisomal acyl-coa oxidase deficiency, 264470 (3),
PALMD		
PALML		
PALP		
PALS	AR	periodontitis 1, juvenile, 170650 (3), ; haim-munk syndrome, 245010 (3), ; papillon-lefevre syndrome, 245000 (3),
PALS1		
PALS2		
PAM		
PAM-1		
PAM14		
PAM16	AR	spondylometaphyseal dysplasia, megarbane-dagher-melike type, 613320 (3),
Pam18	AR	3-methylglutaconic aciduria, type v, 610198 (3),
PAMCI		
PAMM		
PAN1	AR	oocyte/zygote/embryo maturation arrest 18, 620332 (3),
PAN10		
PAN11	AR	oocyte/zygote/embryo maturation arrest 19, 620333 (3),
PAN12		
PAN13		
PAN1B		
PAN2		
PAN3		
PAN4		
PAN5		
PAN6	AD	familial cold autoinflammatory syndrome 2, 611762 (3),
PAN7	AR	hydatidiform mole, recurrent, 1, 231090 (3),
PAN8		
PANCR		
PANDA		
PANDAR		
PANDER		
Pane1		
PANG		
PANK		
PANK1		
PANK1a		
PANK1b		
PANK2	AR	harp syndrome, 607236 (3), ; neurodegeneration with brain iron accumulation 1, 234200 (3),
PANK3		
PANK4	AD	?cataract 49, 619593 (3),
PANP		
PANTR1		
PANX1	AD	oocyte/zygote/embryo maturation arrest 7, 618550 (3),
PANX2		
PANX3		
PAO		
PAOh1		
PAORAC		
PAOX		
PAP		
PAP-1	AD	?retinitis pigmentosa 9, 180104 (3),
PAP-1BP		
PAP-2a		
PAP-2b		
PAP-2c		
PAP-A	AD	greig cephalopolysyndactyly syndrome, 175700 (3), ; polydactyly, postaxial, types a1 and b, 174200 (3), ; pallister-hall syndrome, 146510 (3), ; polydactyly, preaxial, type iv, 174700 (3),
PAP-I	AD	{pregnancy loss, recurrent, susceptibility to, 3}, 614391 (3),
PAP-II		
PAP1		
PAP1B		
PAP2		
PAP21		
PAP2D		
PAP39		
PAP41		
PAP7		
PAPA	AD	greig cephalopolysyndactyly syndrome, 175700 (3), ; polydactyly, postaxial, types a1 and b, 174200 (3), ; pallister-hall syndrome, 146510 (3), ; polydactyly, preaxial, type iv, 174700 (3),
PAPA-1		
PAPA1	AD	greig cephalopolysyndactyly syndrome, 175700 (3), ; polydactyly, postaxial, types a1 and b, 174200 (3), ; pallister-hall syndrome, 146510 (3), ; polydactyly, preaxial, type iv, 174700 (3),
PAPAS	AD	pyogenic sterile arthritis, pyoderma gangrenosum, and acne, 604416 (3),
PAPB	AD	greig cephalopolysyndactyly syndrome, 175700 (3), ; polydactyly, postaxial, types a1 and b, 174200 (3), ; pallister-hall syndrome, 146510 (3), ; polydactyly, preaxial, type iv, 174700 (3),
PAPC		
PAPD1	AR	?spastic ataxia 4, 613672 (3),
PAPD2		
PAPD3		
PAPD4		
PAPD5		
PAPD6		
PAPD7		
PAPK		
PAPL		
PAPL1		
PAPLA1	AR	spastic paraplegia 28, 609340 (3),
PAPLN		
PAPOLA		
PAPOLB		
PAPOLG		
PAPP-A		
PAPP-A2	AR	short stature, dauber-argente type, 619489 (3),
PAPPA		
PAPPA-AS		
PAPPA-AS1		
PAPPA1		
PAPPA2	AR	short stature, dauber-argente type, 619489 (3),
PAPPAS		
PAPPE	AR	short stature, dauber-argente type, 619489 (3),
PAPSS		
PAPSS1		
PAPSS2	AR	brachyolmia 4 with mild epiphyseal and metaphyseal changes, 612847 (3),
PAPST2		
PAPT		
PAQR1		
PAQR10		
PAQR11		
PAQR2		
PAQR3		
PAQR4		
PAQR5		
PAQR6		
PAQR7		
PAQR8		
PAQR9		
PAR		
PAR-1		
PAR-1A	AR	?visual impairment and progressive phthisis bulbi, 618283 (3),
PAR-1B		
PAR-1C		
PAR-1D		
par-4		
PAR-5		
PAR-6		
PAR-6A		
PAR-6B		
PAR-6G		
PAR1	AR	brown-vialetto-van laere syndrome 2, 614707 (3),
PAR14		
PAR17		
Par1b		
PAR2	AD	riboflavin deficiency, 615026 (3),
PAR3		
PAR3beta		
Par3L		
PAR4		
PAR5		
PAR6alpha		
PAR6gamma		
parafibromin	AD	hyperparathyroidism, familial primary, 145000 (3), ; parathyroid adenoma with cystic changes, 145001 (3), ; parathyroid carcinoma, 608266 (3); hyperparathyroidism-jaw tumor syndrome, 145001 (3),
ParaT		
PARAXIS		
PARC		
PARC1	AR	meier-gorlin syndrome 1, 224690 (3),
PARD3		
PARD3A		
PARD3B		
PARD6A		
PARD6B		
PARD6G		
Parf		
PARG		
PARG1		
PARI		
PARIS		
PARIS1		
PARK1	AD	dementia, lewy body, 127750 (3), ; parkinson disease 1, 168601 (3), ; parkinson disease 4, 605543 (3),
PARK11		{parkinson disease 11}, 607688 (3)
PARK13	AR	{parkinson disease 13}, 610297 (3); 3-methylglutaconic aciduria, type viii, 617248 (3),
PARK14	AR	parkinson disease 14, 612953 (3), ; neurodegeneration with brain iron accumulation 2b, 610217 (3), ; infantile neuroaxonal dystrophy 1, 256600 (3),
PARK15	AR	parkinson disease 15, 260300 (3),
PARK17	AD	{parkinson disease 17}, 614203 (3),
PARK18	AD	{parkinson disease 18}, 614251 (3),
PARK19	AR	parkinson disease 19a, juvenile-onset, 615528 (3), ; parkinson disease 19b, early-onset, 615528 (3),
PARK2	AR	adenocarcinoma of lung, somatic, 211980 (3); parkinson disease, juvenile, type 2, 600116 (3), ; ovarian cancer, somatic, 167000 (3)
PARK20	AR	parkinson disease 20, early-onset, 615530 (3), ; developmental and epileptic encephalopathy 53, 617389 (3),
PARK2CRG		
PARK4	AD	dementia, lewy body, 127750 (3), ; parkinson disease 1, 168601 (3), ; parkinson disease 4, 605543 (3),
PARK5	AD,AR	{?parkinson disease 5, susceptibility to}, 613643 (3), ; spastic paraplegia 79a, 620221 (3), ; spastic paraplegia 79b, 615491 (3),
PARK6	AR	parkinson disease 6, early onset, 605909 (3),
PARK7	AR	parkinson disease 7, early-onset, 606324 (3),
PARK8	AD	{parkinson disease 8}, 607060 (3),
PARK9	AR	spastic paraplegia 78, 617225 (3), ; kufor-rakeb syndrome, 606693 (3),
parkin	AR	adenocarcinoma of lung, somatic, 211980 (3); parkinson disease, juvenile, type 2, 600116 (3), ; ovarian cancer, somatic, 167000 (3)
PARL		
PARM1		
PARN	AR,AD	dyskeratosis congenita, 6, 616353 (3), ; pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 4, 616371 (3),
PARP		
PARP-1		
PARP-12		
PARP-5a		
PARP-5b		
PARP-5c		
PARP-7		
PARP1		
PARP10		
PARP11		
PARP12		
PARP13		
PARP14		
PARP15		
PARP16		
PARP2		
PARP3		
PARP4		
PARP5A		
PARP5B		
PARP5C		
PARP6		
PARP7		
PARP9		
PARPBP		
PARS	AR	leukodystrophy, hypomyelinating, 15, 617951 (3),
PARS2	AR	developmental and epileptic encephalopathy 75, 618437 (3),
PART1		
pART14		
pART15		
pART17		
pART5		
pART6		
pART7		
pART8		
PARTICL		
PARTICLE		
PARVA		
PARVB		
PARVG		
PARX		
PAS-2		{malaria, resistance to}, 611162 (3); [blood group, mnss system], 111300 (3)
PAS-3		[blood group, ss], 111740 (3); {malaria, resistance to}, 611162 (3)
Pas1c1		
PASD1		
PASD10		
PASD2	AD	erythrocytosis, familial, 4, 611783 (3),
PASD3		
PASD4		
PASD5		
PASD6		
PASD7		
PASD8		
PASD9		
PASG	AR	immunodeficiency-centromeric instability-facial anomalies syndrome 4, 616911 (3),
pasha		
PASK		
PASKIN		
PASS1		
PAST1		
PAST2		
PAST3		
PAST4		
PAT1		
PAT133		
Pat1a	AR	oocyte/zygote/embryo maturation arrest 4, 617743 (3),
Pat1b		
PAT2	AR,AD	[iminoglycinuria], 242600 (3), digenic ; [hyperglycinuria], 138500 (3),
PAT3		
PAT4		
PATE		
PATE1		
PATJ		
PATL1		
PATL2	AR	oocyte/zygote/embryo maturation arrest 4, 617743 (3),
PATZ		
PATZ1		
PATZ2	AR	immunodeficiency-centromeric instability-facial anomalies syndrome 2, 614069 (3),
Paul		
PAWP		
PAWR		
PAWS1		
PAX-2	AD	glomerulosclerosis, focal segmental, 7, 616002 (3), ; papillorenal syndrome, 120330 (3),
PAX-3	AD,AR	craniofacial-deafness-hand syndrome, 122880 (3), ; waardenburg syndrome, type 3, 148820 (3), ; waardenburg syndrome, type 1, 193500 (3), ; rhabdomyosarcoma 2, alveolar, 268220 (3), somatic mutation
PAX-5		{leukemia, acute lymphoblastic, susceptibility to, 3}, 615545 (3)
PAX-8	AD	hypothyroidism, congenital, due to thyroid dysgenesis or hypoplasia, 218700 (3),
PAX1	AR	otofaciocervical syndrome 2, 615560 (3),
PAX2	AD	glomerulosclerosis, focal segmental, 7, 616002 (3), ; papillorenal syndrome, 120330 (3),
PAX3	AD,AR	craniofacial-deafness-hand syndrome, 122880 (3), ; waardenburg syndrome, type 3, 148820 (3), ; waardenburg syndrome, type 1, 193500 (3), ; rhabdomyosarcoma 2, alveolar, 268220 (3), somatic mutation
PAX4	AR,AD	{diabetes mellitus, ketosis-prone, susceptibility to}, 612227 (3), ; maturity-onset diabetes of the young, type ix, 612225 (3); diabetes mellitus, type 2, 125853 (3),
PAX5		{leukemia, acute lymphoblastic, susceptibility to, 3}, 615545 (3)
PAX6	AD	optic nerve hypoplasia, 165550 (3), ; cataract with late-onset corneal dystrophy, 106210 (3), ; ?coloboma, ocular, 120200 (3), ; ?coloboma of optic nerve, 120430 (3), ; aniridia, 106210 (3), ; anterior segment dysgenesis 5, multiple subtypes, 604229 (3), ; ?morning glory disc anomaly, 120430 (3), ; foveal hypoplasia 1, 136520 (3), ; keratitis, 148190 (3),
PAX7	AR	congenital myopathy 19, 618578 (3), ; rhabdomyosarcoma 2, alveolar, 268220 (3), somatic mutation
PAX8	AD	hypothyroidism, congenital, due to thyroid dysgenesis or hypoplasia, 218700 (3),
PAX9	AD	tooth agenesis, selective, 3, 604625 (3),
PAXB		
PAXBP1		
PAXIP1		
PAXIP1L		
PAXNEB	AD	?aniridia 2, 617141 (3),
PAXX		
PB1		?renal cell carcinoma, clear cell, 144700 (3)
PB39		
Pb99		
PBCGF		
PBCRA	AD	chorioretinal atrophy, progressive bifocal, 600790 (3), ; macular dystrophy 1, north carolina type, 136550 (3),
PBCRA1	AD	chorioretinal atrophy, progressive bifocal, 600790 (3), ; macular dystrophy 1, north carolina type, 136550 (3),
PBDX		[xg blood group system, xg(a-) phenotype], 314700 (3)
PBEF		
PBEF1		
PBF		
PBG1		
PBGD	AD	porphyria, acute intermittent, nonerythroid variant, 176000 (3), ; porphyria, acute intermittent, 176000 (3),
PBGS	AR	porphyria, acute hepatic, 612740 (3), ; {lead poisoning, susceptibility to}, 612740 (3),
PBHNF		
PBI		
PBIP1		
PBK		
PBK1		
PBLD		
PBLT		
PBM1		
PBMUCL1		
PBMUCL2		
PBOV1		
PBP	AR,AD	neurodevelopmental disorder with impaired intellectual development, hypotonia, and ataxia, 618292 (3), |polycystic kidney disease 1, 173900 (3),
PBP74	AR,AD	even-plus syndrome, 616854 (3), ; anemia, sideroblastic, 4, 182170 (3),
PBR		
PBRM1		?renal cell carcinoma, clear cell, 144700 (3)
PBSF		{aids, resistance to}, 609423 (3)
PBT	AD	gastrointestinal stromal tumor, familial, 606764 (3), isolated cases, ; mastocytosis, cutaneous, 154800 (3), ; piebaldism, 172800 (3), ; germ cell tumors, somatic, 273300 (3); mastocytosis, systemic, somatic, 154800 (3); leukemia, acute myeloid, somatic, 601626 (3)
PBX1	AD	congenital anomalies of kidney and urinary tract syndrome with or without hearing loss, abnormal ears, or developmental delay, 617641 (3),
PBX2		
PBX2MHC		
PBX3		
PBX4		
PBXIP1		
PC	AR	pyruvate carboxylase deficiency, 266150 (3),
Pc-1	AD	polycystic kidney disease 1, 173900 (3),
PC-1	AR,MF,AD	{obesity, susceptibility to}, 601665 (3), , ; hypophosphatemic rickets, 2, 613312 (3), ; {diabetes mellitus, non-insulin-dependent, susceptibility to}, 125853 (3), ; arterial calcification, generalized, of infancy, 1, 208000 (3), ; cole disease, 615522 (3),
Pc-2	AD	polycystic kidney disease 2, 613095 (3),
PC-3		
PC-43		
PC-LKC		
PC1	AR	{obesity, susceptibility to, bmiq12}, 612362 (3); endocrinopathy due to proprotein convertase 1/3 deficiency, 600955 (3),
PC1/3	AR	{obesity, susceptibility to, bmiq12}, 612362 (3); endocrinopathy due to proprotein convertase 1/3 deficiency, 600955 (3),
PC2	AD	polycystic kidney disease 2, 613095 (3),
PC3	AR	{obesity, susceptibility to, bmiq12}, 612362 (3); endocrinopathy due to proprotein convertase 1/3 deficiency, 600955 (3),
PC3-96		
PC326		
PC3B	AR	oocyte/zygote/embryo maturation arrest 8, 619009 (3),
PC4		
pc42		
PC43		
PC5		
PC6		
PC7		
PC8		
PCA	AR	ataxia, posterior column, with retinitis pigmentosa, 609033 (3),
PCA1	AR,MF,AD	{obesity, susceptibility to}, 601665 (3), , ; hypophosphatemic rickets, 2, 613312 (3), ; {diabetes mellitus, non-insulin-dependent, susceptibility to}, 125853 (3), ; arterial calcification, generalized, of infancy, 1, 208000 (3), ; cole disease, 615522 (3),
PCA2		
PCA3		
PCA4		
PCAD	AR	hypotrichosis, congenital, with juvenile macular dystrophy, 601553 (3), ; ectodermal dysplasia, ectrodactyly, and macular dystrophy, 225280 (3),
PCAF		
PCAF-b		
PCAN		
PCAN1		
PCANAP1		
PCANAP2		
PCANAP5		
PCANAP5L		
PCANAP6		
PCANAP7		
PCANAP8		
PCAP		
PCARE	AR	retinitis pigmentosa 54, 613428 (3),
PCASP1	AR	immunodeficiency 12, 615468 (3),
PCAT-1		
PCAT1		
PCAT11		
PCAT12		
PCAT18		
PCAT19		
PCAT2		
PCAT29		
PCAT3		
PCAT4		
PCAT8		
PCAT9		
PCB	AR	pyruvate carboxylase deficiency, 266150 (3),
PCBD	AR	hyperphenylalaninemia, bh4-deficient, d, 264070 (3),
PCBD1	AR	hyperphenylalaninemia, bh4-deficient, d, 264070 (3),
PCBD2		
PCBP1		
PCBP2		
PCBP3		
PCBP3-OT1		
PCBP3OT		
PCBP4		
Pcc1	XL,XLR	galloway-mowat syndrome 2, 301006 (3),
PCCA	AR	propionicacidemia, 606054 (3),
PCCB	AR	propionicacidemia, 606054 (3),
PCCMT		
PCCX1		
PCCX2		
PCD	AR,AR,AR,AR	ciliary dyskinesia, primary, 1, with or without situs inversus, 244400 (3), |ciliary dyskinesia, primary, 2, 606763 (3), |ciliary dyskinesia, primary, 3, with or without situs inversus, 608644 (3), |hyperphenylalaninemia, bh4-deficient, d, 264070 (3),
PCDC5RP		
PCDGF	AD,AR	aphasia, primary progressive, 607485 (3), ; frontotemporal lobar degeneration with ubiquitin-positive inclusions, 607485 (3), ; ceroid lipofuscinosis, neuronal, 11, 614706 (3),
PCDH-ALPHA-C2		
PCDH-ALPHA10		
PCDH-ALPHA11		
PCDH-ALPHA12		
PCDH-ALPHA13		
PCDH-ALPHA3		
PCDH-ALPHA4		
PCDH-ALPHA5		
PCDH-ALPHA6		
PCDH-ALPHA9		
PCDH-BETA1		
PCDH-BETA11		
PCDH-BETA12		
PCDH-BETA13		
PCDH-BETA14		
PCDH-BETA15		
PCDH-BETA16		
PCDH-BETA2		
PCDH-BETA3		
PCDH-BETA4		
PCDH-BETA5		
PCDH-BETA6		
PCDH-BETA7		
PCDH-BETA8		
PCDH-BETA9		
PCDH-GAMMA-A1		
PCDH-GAMMA-A10		
PCDH-GAMMA-A11		
PCDH-GAMMA-A12		
PCDH-GAMMA-A2		
PCDH-GAMMA-A3		
PCDH-GAMMA-A4		
PCDH-GAMMA-A5		
PCDH-GAMMA-A6		
PCDH-GAMMA-A7		
PCDH-GAMMA-A8		
PCDH-GAMMA-A9		
PCDH-GAMMA-B1		
PCDH-GAMMA-B2		
PCDH-GAMMA-B3		
PCDH-GAMMA-B4		
PCDH-GAMMA-B5		
PCDH-GAMMA-B6		
PCDH-GAMMA-B7		
PCDH-GAMMA-C3		
PCDH-GAMMA-C4	AR	neurodevelopmental disorder with poor growth and skeletal anomalies, 619880 (3),
PCDH-GAMMA-C5		
PCDH-X		
PCDH1		
PCDH10		
PCDH11		
PCDH11X		
PCDH11Y		
PCDH12	AR	diencephalic-mesencephalic junction dysplasia syndrome 1, 251280 (3),
PCDH13		
PCDH15	AR	usher syndrome, type 1d/f digenic, 601067 (3), digenic ; deafness, 23, 609533 (3), ; usher syndrome, type 1f, 602083 (3),
PCDH16	AD,AR	mitral valve prolapse 2, 607829 (3), ; van maldergem syndrome 1, 601390 (3),
PCDH17		
PCDH18		
PCDH19	XL	developmental and epileptic encephalopathy 9, 300088 (3),
PCDH2		
PCDH20		
PCDH21	AR	macular dystrophy, retinal, 613660 (3), ; cone-rod dystrophy 15, 613660 (3), ; retinitis pigmentosa 65, 613660 (3),
PCDH22		
PCDH23		
PCDH24		
PCDH3H		
PCDH3I		
PCDH3X		
PCDH68		
PCDH68L		
PCDH7		
PCDH8		
PCDH9		
PCDHA1		
PCDHA10		
PCDHA11		
PCDHA12		
PCDHA13		
PCDHA2		
PCDHA3		
PCDHA4		
PCDHA5		
PCDHA6		
PCDHA7		
PCDHA8		
PCDHA9		
PCDHAC1		
PCDHAC2		
PCDHB1		
PCDHB10		
PCDHB11		
PCDHB12		
PCDHB13		
PCDHB14		
PCDHB15		
PCDHB16		
PCDHB2		
PCDHB3		
PCDHB4		
PCDHB5		
PCDHB6		
PCDHB7		
PCDHB8		
PCDHB8a		
PCDHB9		
PCDHGA1		
PCDHGA10		
PCDHGA11		
PCDHGA12		
PCDHGA2		
PCDHGA3		
PCDHGA4		
PCDHGA5		
PCDHGA6		
PCDHGA7		
PCDHGA8		
PCDHGA9		
PCDHGB1		
PCDHGB2		
PCDHGB3		
PCDHGB4		
PCDHGB5		
PCDHGB6		
PCDHGB7		
PCDHGC3		
PCDHGC4	AR	neurodevelopmental disorder with poor growth and skeletal anomalies, 619880 (3),
PCDHGC5		
PCDHJ		
PCDHX		
PCDHY		
PCDP1		
PCEE		
PCF11		
PCFT	AR	folate malabsorption, hereditary, 229050 (3),
PCGEM1		
PCGF1		
PCGF2	AD	turnpenny-fry syndrome, 618371 (3),
PCGF3		
PCGF4		
PCGF5		
PCGF6		
PCH68		
PCHC1	AD	steatocystoma multiplex, 184500 (3), ; pachyonychia congenita 2, 167210 (3),
PCI		
PCID1		
PCID2		
PCIF1		
PCING		
PCINP	AR	ehlers-danlos syndrome, dermatosparaxis type, 225410 (3),
PCK1	AR	phosphoenolpyruvate carboxykinase deficiency, cytosolic, 261680 (3),
PCK2	AR	pepck deficiency, mitochondrial, 261650 (1),
PCL	AD	hemangioma, capillary infantile, somatic, 602089 (3); lymphatic malformation 1, 153100 (3), ; congenital heart defects, multiple types, 7, 618780 (3),
PCL1		
PCL2		
PCL3		
PCLAF		
PCLD	AD	polycystic liver disease 1, 174050 (3),
PCLKC		
PCLN1	AR	hypomagnesemia 3, renal, 248250 (3),
PCLO	AR	?pontocerebellar hypoplasia, type 3, 608027 (3),
PCLP		
PCM1		
PCMF		
PCMT1		
PCMTD1		
PCMTD2		
PCN	AR,AD,AR	?epidermolysis bullosa simplex 5d, generalized intermediate, 616487 (3), ; epidermolysis bullosa simplex 5b, with muscular dystrophy, 226670 (3), ; epidermolysis bullosa simplex 5c, with pyloric atresia, 612138 (3), ; epidermolysis bullosa simplex 5a, ogna type, 131950 (3), ; muscular dystrophy, limb-girdle, 17, 613723 (3), |microcephalic osteodysplastic primordial dwarfism, type ii, 210720 (3),
PCN2	AR	microcephaly, cataracts, impaired intellectual development, and dystonia with abnormal striatum, 618284 (3),
PCN3	MF	{hypertension, salt-sensitive essential, susceptibility to}, 145500 (3),
PCNA	AR	?ataxia-telangiectasia-like disorder 2, 615919 (3),
PCNP		
PCNT	AR	microcephalic osteodysplastic primordial dwarfism, type ii, 210720 (3),
PCNT2	AR	microcephalic osteodysplastic primordial dwarfism, type ii, 210720 (3),
PCNTB	AR	microcephalic osteodysplastic primordial dwarfism, type ii, 210720 (3),
PCNX		
PCNX1		
PCNX2		
PCNX3		
PCNXL1		
PCNXL2		
PCNXL3		
PCOLC	AR	osteogenesis imperfecta, type xiii, 614856 (3),
PCOLCE		
PCOLCE2		
PCOLN3	AR	pontocerebellar hypoplasia, type 8, 614961 (3),
PCOTH		
Pcp		
PCP		
PCP-2		
PCP2		
PCP4		
PCPB		
PCPE		
PCPE1		
PCPE2		
PCPH		
PCPTP1		
PCQAP		
PCSCL		
PCSK1	AR	{obesity, susceptibility to, bmiq12}, 612362 (3); endocrinopathy due to proprotein convertase 1/3 deficiency, 600955 (3),
PCSK1N		
PCSK2		
PCSK3		
PCSK4		
PCSK5		
PCSK6		
PCSK7		
PCSK8	AR	?spondyloepiphyseal dysplasia, kondo-fu type, 618392 (3),
PCSK9	AD	{low density lipoprotein cholesterol level qtl 1}, 603776 (3), ; hypercholesterolemia, familial, 3, 603776 (3),
PCTA-1		
PCTAIRE		
PCTAIRE1		
PCTAIRE2		
PCTAIRE2BP	AR	cataract 36, 613887 (3),
PCTAIRE3		
PCTGAIRE		
PCTK1		
PCTK2		
PCTK3		
PCTP		
PCTP2		
PCTT	AR,AD	tropical calcific pancreatitis, 608189 (3), ; pancreatitis, hereditary, 167800 (3), ; {fibrocalculous pancreatic diabetes, susceptibility to}, 608189 (3),
PCYOX1		
PCYT1	AR	spondylometaphyseal dysplasia with cone-rod dystrophy, 608940 (3),
PCYT1A	AR	spondylometaphyseal dysplasia with cone-rod dystrophy, 608940 (3),
PCYT1B		
PCYT2	AR	spastic paraplegia 82, 618770 (3),
PD-1	MF	{multiple sclerosis, disease progression, modifier of}, 126200 (3), ; {systemic lupus erythematosus, susceptibility to, 2}, 605218 (3)
PD-1H		
PD-IALPHA		
PD-IBETA		
PD-L1		
PD-L2		
PD1	MF,AD	{multiple sclerosis, disease progression, modifier of}, 126200 (3), ; {systemic lupus erythematosus, susceptibility to, 2}, 605218 (3)|dementia, lewy body, 127750 (3), ; parkinson disease 1, 168601 (3), ; parkinson disease 4, 605543 (3),
PD2		
PDA2		
PDAP1		
PDAP2		
PDB2	AR,AD	osteopetrosis, 7, 612301 (3), ; {paget disease of bone 2, early-onset}, 602080 (3), ; osteolysis, familial expansile, 174810 (3),
PDB3	AR,AD	neurodegeneration with ataxia, dystonia, and gaze palsy, childhood-onset, 617145 (3), ; frontotemporal dementia and/or amyotrophic lateral sclerosis 3, 616437 (3), ; myopathy, distal, with rimmed vacuoles, 617158 (3), ; paget disease of bone 3, 167250 (3),
PDC	AD	paroxysmal nonkinesigenic dyskinesia 1, 118800 (3),
PDC-E2	AR	pyruvate dehydrogenase e2 deficiency, 245348 (3),
PDCD1	MF	{multiple sclerosis, disease progression, modifier of}, 126200 (3), ; {systemic lupus erythematosus, susceptibility to, 2}, 605218 (3)
PDCD10	AD	cerebral cavernous malformations-3, 603285 (3),
PDCD11		
PDCD12		
PDCD1LG1		
PDCD1LG2		
PDCD2		
PDCD2L		
PDCD4		
PDCD5		
PDCD6		
PDCD6IP	AR	?microcephaly 29, primary, 620047 (3),
PDCD7		
PDCD8	XLR,XL	combined oxidative phosphorylation deficiency 6, 300816 (3), ; cowchock syndrome, 310490 (3), ; spondyloepimetaphyseal dysplasia, with hypomyelinating leukodystrophy, 300232 (3), ; deafness, 5, 300614 (3),
PDCD9		
PDCL		
PDCL2		
PDCL3		
PDCN	AR	nephrotic syndrome, type 2, 600995 (3),
PDCR		
PDDR	AR	vitamin d-dependent rickets, type i, 264700 (3),
PDE	AR	epilepsy, pyridoxine-dependent, 266100 (3),
PDE10A	AD,AR	striatal degeneration, 616922 (3), ; dyskinesia, limb and orofacial, infantile-onset, 616921 (3),
PDE11A	AD	pigmented nodular adrenocortical disease, primary, 2, 610475 (3),
PDE12		
PDE1A		
PDE1B		
PDE1C	AD	?deafness, 74, 618140 (3),
PDE2A	AR	intellectual developmental disorder with paroxysmal dyskinesia or seizures, 619150 (3),
PDE3A	AD	hypertension and brachydactyly syndrome, 112410 (3),
PDE3B		
PDE4A		
PDE4B		
PDE4C		
PDE4D	AD	acrodysostosis 2, with or without hormone resistance, 614613 (3),
PDE4DIP		
PDE5A		
PDE6A	AR	retinitis pigmentosa 43, 613810 (3),
PDE6B	AR,AD	retinitis pigmentosa-40, 613801 (3), ; night blindness, congenital stationary, 2, 163500 (3),
PDE6C	AR	cone dystrophy 4, 613093 (3),
PDE6D	AR	joubert syndrome 22, 615665 (3),
PDE6G	AR	retinitis pigmentosa 57, 613582 (3),
PDE6H	AR,AD	retinal cone dystrophy 3, 610024 (3), ; achromatopsia 6, 610024 (3),
PDE7A		
PDE7B		
PDE8A		
PDE8B	AD	pigmented nodular adrenocortical disease, primary, 3, 614190 (3); striatal degeneration, 609161 (3),
PDE9A		
PDEA	AR	retinitis pigmentosa 43, 613810 (3),
PDEA2	AR	cone dystrophy 4, 613093 (3),
PDEB	AR,AD	retinitis pigmentosa-40, 613801 (3), ; night blindness, congenital stationary, 2, 163500 (3),
PDEF		
PDEG	AR	retinitis pigmentosa 57, 613582 (3),
PDES1B		
PDF		
PDG	AR	neu-laxova syndrome 1, 256520 (3), ; phosphoglycerate dehydrogenase deficiency, 601815 (3),
PDGB	AR,AD	naxos disease, 601214 (3), ; ?arrhythmogenic right ventricular dysplasia 12, 611528 (3),
PDGF-A		
PDGF1		
PDGFA		
PDGFB	AD	meningioma, sis-related, 607174 (3), ; basal ganglia calcification, idiopathic, 5, 615483 (3), ; dermatofibrosarcoma protuberans, 607907 (3)
PDGFC		
PDGFD		
PDGFR	AD	premature aging syndrome, penttinen type, 601812 (3), ; kosaki overgrowth syndrome, 616592 (3), ; myofibromatosis, infantile, 1, 228550 (3), ; basal ganglia calcification, idiopathic, 4, 615007 (3), ; myeloproliferative disorder with eosinophilia, 131440 (4),
PDGFR1	AD	premature aging syndrome, penttinen type, 601812 (3), ; kosaki overgrowth syndrome, 616592 (3), ; myofibromatosis, infantile, 1, 228550 (3), ; basal ganglia calcification, idiopathic, 4, 615007 (3), ; myeloproliferative disorder with eosinophilia, 131440 (4),
PDGFR2		gastrointestinal stromal tumor/gist-plus syndrome, somatic or familial, 175510 (3); hypereosinophilic syndrome, idiopathic, resistant to imatinib, 607685 (3), somatic mutation, isolated cases
PDGFRA		gastrointestinal stromal tumor/gist-plus syndrome, somatic or familial, 175510 (3); hypereosinophilic syndrome, idiopathic, resistant to imatinib, 607685 (3), somatic mutation, isolated cases
PDGFRB	AD	premature aging syndrome, penttinen type, 601812 (3), ; kosaki overgrowth syndrome, 616592 (3), ; myofibromatosis, infantile, 1, 228550 (3), ; basal ganglia calcification, idiopathic, 4, 615007 (3), ; myeloproliferative disorder with eosinophilia, 131440 (4),
PDGFRL		hepatocellular cancer, somatic, 114550 (3); colorectal cancer, somatic, 114500 (3)
PDH	AR	pyruvate dehydrogenase phosphatase deficiency, 608782 (3),
PDHA	XLD,XL	pyruvate dehydrogenase e1-alpha deficiency, 312170 (3),
PDHA1	XLD,XL	pyruvate dehydrogenase e1-alpha deficiency, 312170 (3),
PDHA2	AR	spermatogenic failure 70, 619828 (3),
PDHAL	AR	spermatogenic failure 70, 619828 (3),
PDHB	AR	pyruvate dehydrogenase e1-beta deficiency, 614111 (3),
PDHE1B	AR	pyruvate dehydrogenase e1-beta deficiency, 614111 (3),
PDHK2		
PDHX	AR	lacticacidemia due to pdx1 deficiency, 245349 (3),
PDI	AD	cole-carpenter syndrome 1, 112240 (3),
PDI-DB		
PDI1		
PDI2		
PDI3	AR	uncombable hair syndrome, 191480 (3),
PDI4		
PDI5		
PDIA1	AD	cole-carpenter syndrome 1, 112240 (3),
PDIA10		
PDIA11		
PDIA12	AR	neurodevelopmental disorder with microcephaly, cortical malformations, and spasticity, 618730 (3),
PDIA13		
PDIA14		
PDIA15		
PDIA16		
PDIA17	AR	respiratory infections, recurrent, and failure to thrive with or without diarrhea, 620233 (3),
PDIA18		
PDIA19		
PDIA2		
PDIA3		
PDIA4		
PDIA5		
PDIA6		
PDIA7		
PDIA8		
PDIA9		
PDIB1	AD	myopathy, vacuolar, with casq1 aggregates, 616231 (3),
PDIB2	AR	ventricular tachycardia, catecholaminergic polymorphic, 2, 611938 (3),
PDIK1L		
PDILT		
PDIP		
PDIP1		
PDIP3		
PDIP38		
PDIP46		
PDIR		
PDJ	AR	adenocarcinoma of lung, somatic, 211980 (3); parkinson disease, juvenile, type 2, 600116 (3), ; ovarian cancer, somatic, 167000 (3)
PDK1		
PDK2		
PDK3	XLD,XL	?charcot-marie-tooth disease, 6, 300905 (3),
PDK4		
PDL1		
PDL2		
PDLIM1		
PDLIM2		
PDLIM3		
PDLIM4	AD	{osteoporosis, susceptibility to}, 166710 (3),
PDLIM5		
PDLIM6	AD	left ventricular noncompaction 3, 601493 (3), ; cardiomyopathy, hypertrophic, 24, 601493 (3), ; myopathy, myofibrillar, 4, 609452 (3), ; cardiomyopathy, dilated, 1c, with or without lvnc, 601493 (3),
PDLIM7		
PDNP1	AR,MF,AD	{obesity, susceptibility to}, 601665 (3), , ; hypophosphatemic rickets, 2, 613312 (3), ; {diabetes mellitus, non-insulin-dependent, susceptibility to}, 125853 (3), ; arterial calcification, generalized, of infancy, 1, 208000 (3), ; cole disease, 615522 (3),
PDNP2		
PDNP3		
PDP	AR	pyruvate dehydrogenase phosphatase deficiency, 608782 (3),
PDP1	AR	pyruvate dehydrogenase phosphatase deficiency, 608782 (3),
pDP1678		
PDP2		
PDP3		
PDPK1		
PDPN		
PDPR		
PDRC2		
PDRG1		
Pdro		
PDS	AR	deafness, 4, with enlarged vestibular aqueduct, 600791 (3), ; pendred syndrome, 274600 (3),
PDS5A		
PDS5B		
PDSS1	AR	coenzyme q10 deficiency, primary, 2, 614651 (3),
PDSS2	AR	coenzyme q10 deficiency, primary, 3, 614652 (3),
PDSW	AR	?mitochondrial complex i deficiency, nuclear type 35, 619003 (3),
PDX		
PDX-1	AD,AR	{diabetes mellitus, type ii, susceptibility to}, 125853 (3), ; pancreatic agenesis 1, 260370 (3), ; mody, type iv, 606392 (3)
PDX1	AD,AR,AR	{diabetes mellitus, type ii, susceptibility to}, 125853 (3), ; pancreatic agenesis 1, 260370 (3), ; mody, type iv, 606392 (3)|lacticacidemia due to pdx1 deficiency, 245349 (3),
PDXDC1		
PDXK	AR	neuropathy, hereditary motor and sensory, type vic, with optic atrophy, 618511 (3),
PDXP		
PDXPO	AR	pyridoxamine 5'-phosphate oxidase deficiency, 610090 (3),
PDYN	AD	spinocerebellar ataxia 23, 610245 (3),
PDZ-73	AR	usher syndrome, type 1c, 276904 (3), ; deafness, 18a, 602092 (3),
PDZ-GEF1	AD	?epilepsy, familial adult myoclonic, 7, 618075 (3),
PDZ-GEF2		
PDZ-RGS3		
PDZ-RHOGEF		
PDZ73	AR	usher syndrome, type 1c, 276904 (3), ; deafness, 18a, 602092 (3),
PDZD1		
PDZD10	XL	intellectual developmental disorder, 104, 300983 (3),
PDZD11		
PDZD2		
PDZD3		
PDZD4		
PDZD5C		
PDZD6	AR	?orofaciodigital syndrome xvii, 617926 (3), ; ?short-rib thoracic dysplasia 20 with polydactyly, 617925 (3),
PDZD7	AR	deafness, 57, 618003 (3), ; {retinal disease in usher syndrome type iia, modifier of}, 276901 (3), ; usher syndrome, type iic, gpr98/pdzd7 digenic, 605472 (3), digenic
PDZD7B	AR	deafness, 31, 607084 (3), ; usher syndrome, type 2d, 611383 (3),
PDZD7C	AR	usher syndrome, type 1c, 276904 (3), ; deafness, 18a, 602092 (3),
PDZD8	AR	intellectual developmental disorder with autism and dysmorphic facies, 620021 (3),
PDZGEF1	AD	?epilepsy, familial adult myoclonic, 7, 618075 (3),
PDZGEF2		
PDZK1		
PDZK10	XL	intellectual developmental disorder, 104, 300983 (3),
PDZK11		
PDZK1IP1		
PDZK2		
PDZK3		
PDZK4		
PDZK5C		
PDZK6	AR	?orofaciodigital syndrome xvii, 617926 (3), ; ?short-rib thoracic dysplasia 20 with polydactyly, 617925 (3),
PDZK7	AR	deafness, 57, 618003 (3), ; {retinal disease in usher syndrome type iia, modifier of}, 276901 (3), ; usher syndrome, type iic, gpr98/pdzd7 digenic, 605472 (3), digenic
PDZK8	AR	intellectual developmental disorder with autism and dysmorphic facies, 620021 (3),
PDZRN1		
PDZRN2		
PDZRN3		
PDZRN4		
PDZRN4L		
PE-1		
PE-2	AD	craniosynostosis 4, 600775 (3), ; chitayat syndrome, 617180 (3),
PE2	AD	craniosynostosis 4, 600775 (3), ; chitayat syndrome, 617180 (3),
PEA-15		
PEA15		
PEA3		
PEAK1		
PEAK2		
PEAK3		
PEAR1		
PEAS		
PEBP		
PEBP1		
PEBP2A1	AD	metaphyseal dysplasia with maxillary hypoplasia with or without brachydactyly, 156510 (3), ; cleidocranial dysplasia, forme fruste, with brachydactyly, 119600 (3), ; cleidocranial dysplasia, forme fruste, dental anomalies only, 119600 (3), ; cleidocranial dysplasia, 119600 (3),
PEBP2A2	AD	platelet disorder, familial, with associated myeloid malignancy, 601399 (3), ; leukemia, acute myeloid, 601626 (3), somatic mutation,
PEBP2A3		
PEBP2aA1	AD	metaphyseal dysplasia with maxillary hypoplasia with or without brachydactyly, 156510 (3), ; cleidocranial dysplasia, forme fruste, with brachydactyly, 119600 (3), ; cleidocranial dysplasia, forme fruste, dental anomalies only, 119600 (3), ; cleidocranial dysplasia, 119600 (3),
PEBP2B	AD	cleidocranial dysplasia 2, 620099 (3),
PEBP4		
PEC-60		
PECAM1		
pecanex		
PECI		
PECR		
PED		
PED-PEA15		
PED/PEA15		
PEDF	AR	osteogenesis imperfecta, type vi, 613982 (3),
PEDS1		
PEF1		
PEF1A		
PEF1B		
PEG1		
PEG10		
PEG11		
PEG3		
Peg5		
PEG8		
Pegasus	AD	thrombocytopenia, 7, 619130 (3),
PEIG-1		
PEK	AR	wolcott-rallison syndrome, 226980 (3),
PEL98		
PELI1		
PELI2		
PELI3		
pelle		
PELO		
PELP1		
PEM	AD	tubulointerstitial kidney disease, 2, 174000 (3),
PEM-2	XL	developmental and epileptic encephalopathy 8, 300607 (3),
PEMP		
PEMPT		
PEMT		
PEMT2		
PEN		
PEN11B		
PEN2	AD	acne inversa, familial, 2, with or without dowling-degos disease, 613736 (3),
PENK		
PENKB	AD	spinocerebellar ataxia 23, 610245 (3),
PENT		
Penumbra		
PEO	AR,AD	mitochondrial dna depletion syndrome 7 (hepatocerebral type), 271245 (3), ; progressive external ophthalmoplegia with mitochondrial dna deletions, 3, 609286 (3), ; perrault syndrome 5, 616138 (3),
PEO1	AR,AD	mitochondrial dna depletion syndrome 7 (hepatocerebral type), 271245 (3), ; progressive external ophthalmoplegia with mitochondrial dna deletions, 3, 609286 (3), ; perrault syndrome 5, 616138 (3),
PEO2	AR,AD	mitochondrial dna depletion syndrome 12b (cardiomyopathic type) ar, 615418 (3), ; progressive external ophthalmoplegia with mitochondrial dna deletions, 2, 609283 (3), ; mitochondrial dna depletion syndrome 12a (cardiomyopathic type) ad, 617184 (3),
PEO3	AR,AD	mitochondrial dna depletion syndrome 12b (cardiomyopathic type) ar, 615418 (3), ; progressive external ophthalmoplegia with mitochondrial dna deletions, 2, 609283 (3), ; mitochondrial dna depletion syndrome 12a (cardiomyopathic type) ad, 617184 (3),
PEP		
PEP-19		
PEP11		
PEP3		
PEP5	AR	?dystonia 32, 619637 (3), ; leukodystrophy, hypomyelinating, 12, 616683 (3),
PEP8A		
Pep8b		
PEPA		
PEPB		
PEPC		
PEPCK	AR	pepck deficiency, mitochondrial, 261650 (1),
PEPCK-C	AR	phosphoenolpyruvate carboxykinase deficiency, cytosolic, 261680 (3),
PEPCK2	AR	pepck deficiency, mitochondrial, 261650 (1),
PEPD	AR	prolidase deficiency, 170100 (3),
PEPE		
PEPN		
PEPP-2		
PEPP1		
PEPP2		
PEPP3		
PEPS		
PEPT1		
PEPT2		
PER		
PER-EC1		
PER1	AR	hyperphosphatasia with impaired intellectual development syndrome 4, 615716 (3),
PER2	AD	?advanced sleep phase syndrome, familial, 1, 604348 (3),
PER3	AD	?advanced sleep phase syndrome, familial, 3, 616882 (3),
PERB11		
PERB11.1		
PERB11.2		
PERC		
PERCC1	AR	diarrhea 11, malabsorptive, congenital, 618662 (3),
PEREC1		
periostin		
PERK	AR	wolcott-rallison syndrome, 226980 (3),
PERLD1	AR	hyperphosphatasia with impaired intellectual development syndrome 4, 615716 (3),
perlecan	AR	dyssegmental dysplasia, silverman-handmaker type, 224410 (3), ; schwartz-jampel syndrome, type 1, 255800 (3),
PERM1		
peropsin		
PERP	AR,AD	erythrokeratodermia variabilis et progressiva 7, 619209 (3), ; olmsted syndrome 2, 619208 (3),
pERp1		
PERQ1		
PERQ2		{parkinson disease 11}, 607688 (3)
PERQ3		{parkinson disease 11}, 607688 (3)
PERRS		bradyopsia 1, 608415 (3)|bradyopsia 2, 620344 (3)
persyn		
PES		
PES1		
PESCRG1		
PESKY		
Pet-1		
PET100	AR	mitochondrial complex iv deficiency, nuclear type 12, 619055 (3),
PET112	AR	?combined oxidative phosphorylation deficiency 41, 618838 (3),
PET112L	AR	?combined oxidative phosphorylation deficiency 41, 618838 (3),
PET117	AR	?mitochondrial complex iv deficiency, nuclear type 19, 619063 (3),
Pet191	AR	?mitochondrial complex iv, deficiency, nuclear type 9, 616500 (3),
PETA-3	AR	[blood group, raph], 179620 (3); epidermolysis bullosa simplex 7, with nephropathy and deafness, 609057 (3),
PEX	XLD,XL	hypophosphatemic rickets, 307800 (3),
PEX1	AR	heimler syndrome 1, 234580 (3), ; peroxisome biogenesis disorder 1b (nald/ird), 601539 (3), ; peroxisome biogenesis disorder 1a (zellweger), 214100 (3),
PEX10	AR	peroxisome biogenesis disorder 6a (zellweger), 614870 (3), ; peroxisome biogenesis disorder 6b, 614871 (3),
PEX11A		
PEX11alpha		
PEX11B	AR	peroxisome biogenesis disorder 14b, 614920 (3),
PEX11beta	AR	peroxisome biogenesis disorder 14b, 614920 (3),
PEX11G		
PEX11gamma		
PEX11Î±		
PEX11Î²	AR	peroxisome biogenesis disorder 14b, 614920 (3),
PEX11Î³		
PEX12	AR	peroxisome biogenesis disorder 3b, 266510 (3), ; peroxisome biogenesis disorder 3a (zellweger), 614859 (3),
PEX13	AR	peroxisome biogenesis disorder 11a (zellweger), 614883 (3), ; peroxisome biogenesis disorder 11b, 614885 (3),
PEX14	AR	peroxisome biogenesis disorder 13a (zellweger), 614887 (3),
PEX16	AR	peroxisome biogenesis disorder 8b, 614877 (3), ; peroxisome biogenesis disorder 8a (zellweger), 614876 (3),
PEX19	AR	peroxisome biogenesis disorder 12a (zellweger), 614886 (3),
PEX2	AR	peroxisome biogenesis disorder 5a (zellweger), 614866 (3), ; peroxisome biogenesis disorder 5b, 614867 (3),
PEX26	AR	peroxisome biogenesis disorder 7b, 614873 (3), ; peroxisome biogenesis disorder 7a (zellweger), 614872 (3),
PEX3	AR	peroxisome biogenesis disorder 10a (zellweger), 614882 (3), ; ?peroxisome biogenesis disorder 10b, 617370 (3),
PEX5	AR	peroxisome biogenesis disorder 2b, 202370 (3), ; peroxisome biogenesis disorder 2a (zellweger), 214110 (3), ; rhizomelic chondrodysplasia punctata, type 5, 616716 (3),
PEX5L		
PEX5R		
PEX6	AR,AD	peroxisome biogenesis disorder 4b, 614863 (3), ; peroxisome biogenesis disorder 4a (zellweger), 614862 (3), ; heimler syndrome 2, 616617 (3),
PEX7	AR	rhizomelic chondrodysplasia punctata, type 1, 215100 (3), ; peroxisome biogenesis disorder 9b, 614879 (3),
PEZ	AR	choanal atresia and lymphedema, 613611 (3),
PF1		
PF13	AR	ciliary dyskinesia, primary, 10, 612518 (3),
PF16		
PF20		
PF22	AR	ciliary dyskinesia, primary, 2, 606763 (3),
PF4		
PF4V1		
PF6	AR	?spermatogenic failure 55, 619380 (3),
Pfa1		
PFAAP2		
PFAAP5		
PFAS		
PFC	XL,XLR	properdin deficiency, 312060 (3),
PFD	AR	complement factor d deficiency, 613912 (3),
PFD1		
PFD3		
PFD4		
PFD5		
PFD6		
PFDN1		
PFDN2		
PFDN3		
PFDN4		
PFDN5		
PFDN6		
PFET1		
PFHB1	AD,AR	ventricular fibrillation, familial, 1, 603829 (3); heart block, progressive, type ia, 113900 (3), ; cardiomyopathy, dilated, 1e, 601154 (3), ; heart block, nonprogressive, 113900 (3), ; long qt syndrome 3, 603830 (3), ; sick sinus syndrome 1, 608567 (3), ; brugada syndrome 1, 601144 (3), ; atrial fibrillation, familial, 10, 614022 (3), ; {sudden infant death syndrome, susceptibility to}, 272120 (3),
PFIC	AR,AD	cholestasis, progressive familial intrahepatic 1, 211600 (3), ; cholestasis, intrahepatic, of pregnancy, 1, 147480 (3), ; cholestasis, benign recurrent intrahepatic, 243300 (3),
PFIC-2	AR	cholestasis, benign recurrent intrahepatic, 2, 605479 (3), ; cholestasis, progressive familial intrahepatic 2, 601847 (3),
PFIC-3	AR,AD	gallbladder disease 1, 600803 (3), ; cholestasis, intrahepatic, of pregnancy, 3, 614972 (3), ; cholestasis, progressive familial intrahepatic 3, 602347 (3),
PFIC1	AR,AD	cholestasis, progressive familial intrahepatic 1, 211600 (3), ; cholestasis, intrahepatic, of pregnancy, 1, 147480 (3), ; cholestasis, benign recurrent intrahepatic, 243300 (3),
PFIC2	AR	cholestasis, benign recurrent intrahepatic, 2, 605479 (3), ; cholestasis, progressive familial intrahepatic 2, 601847 (3),
PFK-1	AR	glycogen storage disease vii, 232800 (3),
PFK-C		
PFKF		
PFKFB1		
PFKFB2		
PFKFB3		
PFKFB4		
PFKL		hemolytic anemia due to phosphofructokinase deficiency (1)
PFKM	AR	glycogen storage disease vii, 232800 (3),
PFKP		
PFKX	AR	glycogen storage disease vii, 232800 (3),
PFM	AD,AR,AD	parietal foramina 2, 609597 (3), ; {craniosynostosis 5, susceptibility to}, 615529 (3), ; frontonasal dysplasia 2, 613451 (3), |parietal foramina with cleidocranial dysplasia, 168550 (3), ; craniosynostosis 2, 604757 (3), ; parietal foramina 1, 168500 (3),
PFM1	AD	parietal foramina with cleidocranial dysplasia, 168550 (3), ; craniosynostosis 2, 604757 (3), ; parietal foramina 1, 168500 (3),
PFM10	AR	pontocerebellar hypoplasia, type 17, 619909 (3), ; cerebellar dysfunction, impaired intellectual development, and hypogonadotropic hypogonadism, 619761 (3),
PFM13	AD	left ventricular noncompaction 8, 615373 (3), ; cardiomyopathy, dilated, 1ll, 615373 (3),
PFM2	AR,AD,AR	brittle cornea syndrome 2, 614170 (3), |parietal foramina 2, 609597 (3), ; {craniosynostosis 5, susceptibility to}, 615529 (3), ; frontonasal dysplasia 2, 613451 (3),
PFM6		
PFM7		
PFM8		
PFM9	AR	neuropathy, hereditary sensory and autonomic, type viii, 616488 (3),
PFN1		amyotrophic lateral sclerosis 18, 614808 (3)
PFN1P2		
PFN2		
PFN3		
PFN4		
PFP	AR	hemophagocytic lymphohistiocytosis, familial, 2, 603553 (3), ; aplastic anemia, 609135 (3); lymphoma, non-hodgkin, 605027 (3)
PFRX		
Pfs2		
PFTAIRE1		
PFTAIRE2		
PFTK1		
PFTK2		
PG	AR,AD	naxos disease, 601214 (3), ; ?arrhythmogenic right ventricular dysplasia 12, 611528 (3),
Pg-Lb		
PG-M	AD	wagner syndrome 1, 143200 (3),
pG2		
PGA1	AR,AD	autoimmune polyendocrinopathy syndrome , type i, with or without reversible metaphyseal dysplasia, 240300 (3),
PGA4		
PGA5		
PGAM-B		
PGAM-M	AR	glycogen storage disease x, 261670 (3),
PGAM1		
PGAM2	AR	glycogen storage disease x, 261670 (3),
PGAM3		
PGAM4		
PGAM5		
PGAMA		
PGAP1	AR	neurodevelopmental disorder with dysmorphic features, spasticity, and brain abnormalities, 615802 (3),
PGAP2	AR	hyperphosphatasia with impaired intellectual development syndrome 3, 614207 (3),
PGAP2IP		
PGAP3	AR	hyperphosphatasia with impaired intellectual development syndrome 4, 615716 (3),
PGAP4		
PGAP5		
PGAP6		
PGAR	AD	plasma triglyceride level qtl, low, 615881 (3),
PGBD5		
PGC		
PGC-1alpha		
PGC1		
PGC1A		
PGC1B		
Pgc7		
PGCC1		
PGCP		
PGD		
PGD2		
PGDH	AR	neu-laxova syndrome 1, 256520 (3), ; phosphoglycerate dehydrogenase deficiency, 601815 (3),
PGDS		
PGEA1		
PGF		
PGFL		
PGFS		
PGFT		
PGGHG		
PGGT1A		
PGGT1B		
PGHS-1		
PGIS	MF	hypertension, essential, 145500 (3),
PGIV	AR	mitochondrial complex i deficiency, nuclear type 37, 619272 (3),
PGK	AD	aortic aneurysm, familial thoracic 8, 615436 (3),
PGK-2		
PGK1	XLR	phosphoglycerate kinase 1 deficiency, 300653 (3),
PGK2		
PGKPS		
PGL	AD,AR	paragangliomas 1, with or without deafness, 168000 (3), ; paraganglioma and gastric stromal sarcoma, 606864 (3); mitochondrial complex ii deficiency, nuclear type 3, 619167 (3), ; pheochromocytoma, 171300 (3),
PGL1	AD,AR	paragangliomas 1, with or without deafness, 168000 (3), ; paraganglioma and gastric stromal sarcoma, 606864 (3); mitochondrial complex ii deficiency, nuclear type 3, 619167 (3), ; pheochromocytoma, 171300 (3),
PGL2	AD	paragangliomas 2, 601650 (3),
PGL3	AD	paragangliomas 3, 605373 (3), ; paraganglioma and gastric stromal sarcoma, 606864 (3); gastrointestinal stromal tumor, 606764 (3), isolated cases,
PGLP		
PGLS		
PGLYRP		
PGLYRP1		
PGLYRP2		
PGLYRP3		
PGLYRP4		
PGLYRPIalpha		
PGLYRPIbeta		
PGLYRPL		
PGM1	AR	congenital disorder of glycosylation, type it, 614921 (3),
PGM2		
PGM2L1	AR	neurodevelopmental disorder with hypotonia, dysmorphic facies, and skin abnormalities, 620191 (3),
PGM3	AR	immunodeficiency 23, 615816 (3),
PGM5		
PGMRP		
PGP		
PGP-1		[blood group, indian system], 609027 (3)
PGP-I		
Pgp1		[blood group, indian system], 609027 (3)
PGP9.5	AD,AR	{?parkinson disease 5, susceptibility to}, 613643 (3), ; spastic paraplegia 79a, 620221 (3), ; spastic paraplegia 79b, 615491 (3),
PGPEP1		
PGPEP2		
PGPI		
PGPL		
PGPR-p117		
PGR	AR	?progesterone resistance, 264080 (2),
PGR1		
PGR13		
PGR14		{asthma, susceptibility to, 2}, 608584 (3)
PGR16		
PGR17		
PGR18		
PGR19		
PGR2		
PGR21		
PGR25		
PGR26		
PGR27		
PGR28		
PGR3		
PGR4		{obesity, susceptibility to}, 607514 (3)
PGR7		
PGRL		
PGRMC1		
PGRMC2		
PGRN	AD,AR	aphasia, primary progressive, 607485 (3), ; frontotemporal lobar degeneration with ubiquitin-positive inclusions, 607485 (3), ; ceroid lipofuscinosis, neuronal, 11, 614706 (3),
PGRP		
PGRP-Ialpha		
PGRP-Ibeta		
PGRP-L		
PGRP-S		
PGRPIA		
PGRPIB		
PGRPL		
PGRPS		
PGS	XLR,XL	pettigrew syndrome, 304340 (3),
PGS1		
PGs3		
PGSF2	XLR,XL	hypothyroidism, central, and testicular enlargement, 300888 (3),
PGT	AD,AR	hypertrophic osteoarthropathy, primary, 167100 (3), ; hypertrophic osteoarthropathy, primary, 2, 614441 (3),
PGY1		{inflammatory bowel disease 13}, 612244 (3); {colchicine resistance}, 120080 (3)|{inflammatory bowel disease 13}, 612244 (3); {colchicine resistance}, 120080 (3)
PGY3	AR,AD	gallbladder disease 1, 600803 (3), ; cholestasis, intrahepatic, of pregnancy, 3, 614972 (3), ; cholestasis, progressive familial intrahepatic 3, 602347 (3),
PGY4	AR	cholestasis, benign recurrent intrahepatic, 2, 605479 (3), ; cholestasis, progressive familial intrahepatic 2, 601847 (3),
PH	AR	[hyperphenylalaninemia, non-pku mild], 261600 (3), ; phenylketonuria, 261600 (3),
PH-20		
PH-30b		
PH-4	AR	hypotonia, hypoventilation, impaired intellectual development, dysautonomia, epilepsy, and eye abnormalities, 618493 (3),
PH1	AR	hyperoxaluria, primary, type 1, 259900 (3),
PH2	AR	hyperoxaluria, primary, type ii, 260000 (3),
pH2A/f		
PH30		
PH4	AR	hypotonia, hypoventilation, impaired intellectual development, dysautonomia, epilepsy, and eye abnormalities, 618493 (3),
PHACS		
PHACTR1	AD	developmental and epileptic encephalopathy 70, 618298 (3),
PHACTR2		
PHACTR3		
PHACTR4		
PHAF2	AR	hengel-maroofian-schols syndrome, 619641 (3),
PHAFIN1		
PHAFIN2		
phakinin	AD	cataract 12, multiple types, 611597 (3),
PHAPI		
PHAPI2		
PHAPII	AD	intellectual developmental disorder, 58, 618106 (3),
pharbin	AR	joubert syndrome 1, 213300 (3), ; mental retardation, truncal obesity, retinal dystrophy, and micropenis, 610156 (3),
PHAS-I		
PHAX		
PHB	AD	{breast cancer, susceptibility to}, 114480 (3), somatic mutation,
PHB1	AD	{breast cancer, susceptibility to}, 114480 (3), somatic mutation,
PHB2		
PHBP	AD	{?thyroid cancer, nonmedullary, 5}, 616535 (3), ; {venous thromboembolism, susceptibility to}, 188050 (3),
PHC	AR	mitochondrial phosphate carrier deficiency, 610773 (3),
PHC1	AR	?microcephaly 11, primary, 615414 (3),
PHC2		
PHC3		
PHCA	AR	?leukodystrophy, progressive, early childhood-onset, 617762 (3),
PHD1		
PHD2	AD	erythrocytosis, familial, 3, 609820 (3), ; [hemoglobin, high altitude adaptation], 609070 (3),
PHD3		
PHD4	AR	hypotonia, hypoventilation, impaired intellectual development, dysautonomia, epilepsy, and eye abnormalities, 618493 (3),
PHE5		
PheHB	AR	rajab interstitial lung disease with brain calcifications 1, 613658 (3),
PHEMX		
PHES		
PHET		
PHETA1		
PHETA2		
PHEX	XLD,XL	hypophosphatemic rickets, 307800 (3),
PHF1		
PHF10		
PHF11		
PHF12		
PHF13		
PHF14		
PHF15		
PHF16		
PHF17		
PHF18		
PHF19		
PHF2		
PHF20		
PHF20L1		
PHF21A	AD	intellectual developmental disorder with behavioral abnormalities and craniofacial dysmorphism with or without seizures, 618725 (3),
PHF21B		
PHF22		
PHF23		
PHF24		
PHF3		
PHF4		
PHF5A		
PHF6	XLR,XL	borjeson-forssman-lehmann syndrome, 301900 (3),
PHF7		
PHF7B		
PHF8	XL,XLR	intellectual developmental disorder, syndromic, siderius type, 300263 (3),
PHF9	AR	fanconi anemia, complementation group l, 614083 (3),
PHGDH	AR	neu-laxova syndrome 1, 256520 (3), ; phosphoglycerate dehydrogenase deficiency, 601815 (3),
PHGPx	AR	spondylometaphyseal dysplasia, sedaghatian type, 250220 (3),
PHHI	AR,AD	diabetes mellitus, permanent neonatal 3, with or without neurologic features, 618857 (3), ; diabetes mellitus, transient neonatal 2, 610374 (3); diabetes mellitus, noninsulin-dependent, 125853 (3), ; hypoglycemia of infancy, leucine-sensitive, 240800 (3), ; hyperinsulinemic hypoglycemia, familial, 1, 256450 (3),
PHI-1		
PHIP	AD	chung-jansen syndrome, 617991 (3),
PHK	XLR,XL	glycogen storage disease, type ixa2, 306000 (3), ; glycogen storage disease, type ixa1, 306000 (3),
PHKA	XLR,XL	muscle glycogenosis, 300559 (3),
PHKA1	XLR,XL	muscle glycogenosis, 300559 (3),
PHKA2	XLR,XL	glycogen storage disease, type ixa2, 306000 (3), ; glycogen storage disease, type ixa1, 306000 (3),
PHKB	AR	phosphorylase kinase deficiency of liver and muscle, 261750 (3),
PHKD	AD,AD,AD	long qt syndrome 15, 616249 (3), |long qt syndrome 16, 618782 (3), ; ?ventricular tachycardia, catecholaminergic polymorphic 6, 618782 (3), |ventricular tachycardia, catecholaminergic polymorphic, 4, 614916 (3), ; long qt syndrome 14, 616247 (3),
PHKD1	AD	ventricular tachycardia, catecholaminergic polymorphic, 4, 614916 (3), ; long qt syndrome 14, 616247 (3),
PHKD2	AD	long qt syndrome 15, 616249 (3),
PHKD3	AD	long qt syndrome 16, 618782 (3), ; ?ventricular tachycardia, catecholaminergic polymorphic 6, 618782 (3),
PHKG		
PHKG1		
PHKG2	AR	glycogen storage disease ixc, 613027 (3),
PHL		leukemia, chronic myeloid, philadelphia chromosome positive, somatic, 608232 (4); leukemia, acute lymphocytic, philadelphia chromosome positive, somatic, 613065 (4)
PHLDA1		
PHLDA2		
PHLDA3		
PHLDB1		
PHLDB2		
PHLL1	AD	{delayed sleep phase disorder, susceptibility to}, 614163 (3),
PhLP		
PHLPP		
PHLPP1		
PHLPP2		
PHLPPL		
PHM		
PHOCN		
PHOG	AR,AD,AD,AR	short stature, idiopathic familial, 300582 (3); langer mesomelic dysplasia, 249700 (3), pseudo ; leri-weill dyschondrosteosis, 127300 (3), pseudo |short stature, idiopathic familial, 300582 (3); leri-weill dyschondrosteosis, 127300 (3), pseudo ; langer mesomelic dysplasia, 249700 (3), pseudo
phogrin		
phosphacan		
phostensin		
PHOX1	AR,AD	agnathia-otocephaly complex, 202650 (3),
PHOX2A	AR	fibrosis of extraocular muscles, congenital, 2, 602078 (3),
PHOX2B	AD	{neuroblastoma, susceptibility to, 2}, 613013 (3); neuroblastoma with hirschsprung disease, 613013 (3); central hypoventilation syndrome, congenital, 1, with or without hirschsprung disease, 209880 (3),
PHP	XL	intellectual developmental disorder, with isolated growth hormone deficiency, 300123 (3); panhypopituitarism, 312000 (3),
PHP1		
PHP14		
PHP32	AR	spinal muscular atrophy with progressive myoclonic epilepsy, 159950 (3), ; farber lipogranulomatosis, 228000 (3),
PHPT1		
PHR1		
PHRBN		
PHRBNL		
PHRET1		
PHRF1		
PHRIP		
PHS	AD	greig cephalopolysyndactyly syndrome, 175700 (3), ; polydactyly, postaxial, types a1 and b, 174200 (3), ; pallister-hall syndrome, 146510 (3), ; polydactyly, preaxial, type iv, 174700 (3),
PHSECRG2		
PHT1		
PHT2		
PHTF		
PHTF1		
PHTF2		
PHYH	AR	refsum disease, 266500 (3),
PHYH1	AR	refsum disease, 266500 (3),
PHYH2		
PHYHD1		
PHYHIP		
PHYKPL	AR	[?phosphohydroxylysinuria], 615011 (3),
pHZ-1		
pHZ-10		
pHZ-12		
pHZ-13		
pHZ-15		
pHZ-17		
pHZ-20		
pHZ-30		
pHZ-32		
PHZ-37		
pHZ-39		
pHZ-44	AR	?polydactyly, postaxial, type a6, 615226 (3),
pHZ-49	AR	neurodevelopmental disorder with impaired speech and hyperkinetic movements, 618425 (3),
pHZ-52	AD	global developmental delay, absent or hypoplastic corpus callosum, and dysmorphic facies, 617260 (3),
pHZ-66		
pHZ-67		
pHZ-92		
pHZ-96		
PI	AR	hemorrhagic diathesis due to antithrombin pittsburgh, 613490 (3), ; emphysema due to aat deficiency, 613490 (3), ; emphysema-cirrhosis, due to aat deficiency, 613490 (3),
PI-PLC		
PI1	AR	hemorrhagic diathesis due to antithrombin pittsburgh, 613490 (3), ; emphysema due to aat deficiency, 613490 (3), ; emphysema-cirrhosis, due to aat deficiency, 613490 (3),
PI10		
PI11		
PI12	AD	encephalopathy, familial, with neuroserpin inclusion bodies, 604218 (3),
PI13		
PI14		
PI15		
PI2		
PI3		
PI31		
PI3K		clove syndrome, somatic, 612918 (3); hepatocellular carcinoma, somatic, 114550 (3); breast cancer, somatic, 114480 (3); cerebral cavernous malformations 4, somatic, 619538 (3); ovarian cancer, somatic, 167000 (3); colorectal cancer, somatic, 114500 (3); macrodactyly, somatic, 155500 (3); clapo syndrome, somatic, 613089 (3); keratosis, seborrheic, somatic, 182000 (3); nevus, epidermal, somatic, 162900 (3); gastric cancer, somatic, 613659 (3); nonsmall cell lung cancer, somatic, 211980 (3); megalencephaly-capillary malformation-polymicrogyria syndrome, somatic, 602501 (3); cowden syndrome 5, 615108 (3)
PI3K-C2alpha	AR	oculoskeletodental syndrome, 618440 (3),
PI3K-C2beta		
PI4		
PI4K-ALPHA	AR	spastic paraplegia 84, 619621 (3), ; gastrointestinal defects and immunodeficiency syndrome 2, 619708 (3), ; polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis, 616531 (3),
PI4K-BETA	AD	deafness, 87, 620281 (3),
pi4K230	AR	spastic paraplegia 84, 619621 (3), ; gastrointestinal defects and immunodeficiency syndrome 2, 619708 (3), ; polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis, 616531 (3),
PI4K2A		
PI4K2B		
pi4K92	AD	deafness, 87, 620281 (3),
PI4KA	AR	spastic paraplegia 84, 619621 (3), ; gastrointestinal defects and immunodeficiency syndrome 2, 619708 (3), ; polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis, 616531 (3),
PI4KB	AD	deafness, 87, 620281 (3),
PI4KII		
PI4KIIB		
PI5		
PI6	AR	?deafness, 91, 613453 (3),
PI7		
PI8	AR	peeling skin syndrome 5, 617115 (3),
PI9		
PIA		
PIANP		
PIAS1		
PIAS2		
PIAS3		
PIAS4		
Piasg		
PIASX-ALPHA		
PIASX-BETA		
PIASY		
PIB5PA		
PIBF	AR	joubert syndrome 33, 617767 (3),
PIBF1	AR	joubert syndrome 33, 617767 (3),
PiC	AR	mitochondrial phosphate carrier deficiency, 610773 (3),
PIC1		?orofacial cleft 10, 613705 (3), isolated cases
PICALM		leukemia, acute myeloid, somatic, 601626 (3)
PICH		
PICK1		
PICOT		
PICSAR		
PICT-1		
PICT1		
PID1		
PIDD	AR	intellectual developmental disorder, 75, with neuropsychiatric features and variant lissencephaly, 619827 (3),
PIDD1	AR	intellectual developmental disorder, 75, with neuropsychiatric features and variant lissencephaly, 619827 (3),
PIDX	XL,XLR	immunodysregulation, polyendocrinopathy, and enteropathy, 304790 (3),
PIERCE1		
PIERCE2		
PIEZO1	AR,AD	[er blood group system], 620207 (3), ; lymphatic malformation 6, 616843 (3), ; dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edema, 194380 (3),
PIEZO2	AD,AR	arthrogryposis, distal, type 5, 108145 (3), ; arthrogryposis, distal, with impaired proprioception and touch, 617146 (3), ; arthrogryposis, distal, type 3, 114300 (3), ; ?marden-walker syndrome, 248700 (3),
PIF		
PIF1		
PIF79		
PIF96		
PIFO		
PIG-A	XLR,XL	paroxysmal nocturnal hemoglobinuria, somatic, 300818 (3); multiple congenital anomalies-hypotonia-seizures syndrome 2, 300868 (3), ; neurodevelopmental disorder with epilepsy and hemochromatosis, 301072 (3)
PIG-B	AR	developmental and epileptic encephalopathy 80, 618580 (3),
PIG-C	AR	glycosylphosphatidylinositol biosynthesis defect 16, 617816 (3),
PIG-F	AR	onychodystrophy, osteodystrophy, impaired intellectual development, and seizures syndrome, 619356 (3),
PIG-K	AR	neurodevelopmental disorder with hypotonia and cerebellar atrophy, with or without seizures, 618879 (3),
PIG-L	AR	chime syndrome, 280000 (3),
PIG-M	AR	glycosylphosphatidylinositol deficiency, 610293 (3),
PIG-N	AR	multiple congenital anomalies-hypotonia-seizures syndrome 1, 614080 (3),
PIG-O	AR	hyperphosphatasia with impaired intellectual development syndrome 2, 614749 (3),
PIG-S	AR	developmental and epileptic encephalopathy 95, 618143 (3),
PIG-T	AD,AR	?paroxysmal nocturnal hemoglobinuria 2, 615399 (3), somatic mutation, ; multiple congenital anomalies-hypotonia-seizures syndrome 3, 615398 (3),
PIG-U	AR	neurodevelopmental disorder with brain anomalies, seizures, and scoliosis, 618590 (3),
PIG-V	AR	hyperphosphatasia with impaired intellectual development syndrome 1, 239300 (3),
PIG-W	AR	glycosylphosphatidylinositol biosynthesis defect 11, 616025 (3),
PIG-X		
PIG-Y	AR	hyperphosphatasia with impaired intellectual development syndrome 6, 616809 (3),
PIG-Z		
PIG1		
PIG10		
PIG11		
PIG12		
PIG15	AD	?hemochromatosis, type 5, 615517 (3),
PIG17		
PIG2	AR	cerebral creatine deficiency syndrome 2, 612736 (3),
PIG20		
PIG27	AR	?mirror movements 3, 616059 (3),
PIG3		
PIG35	AR	osteogenesis imperfecta, type vi, 613982 (3),
PIG38		
PIG4		
PIG5		
PIG54		
PIG6	AD,AR	{schizophrenia, susceptibility to, 4}, 600850 (3), ; hyperprolinemia, type i, 239500 (3),
PIG7	AD	charcot-marie-tooth disease, type 1c, 601098 (3),
PIG8		
PIG9	AR	prostate cancer, somatic, 176807 (3); mosaic variegated aneuploidy syndrome 7 with inflammation and tumor predisposition, 620189 (3), ; lymphoma, b-cell, somatic (3)
PIGA	XLR,XL	paroxysmal nocturnal hemoglobinuria, somatic, 300818 (3); multiple congenital anomalies-hypotonia-seizures syndrome 2, 300868 (3), ; neurodevelopmental disorder with epilepsy and hemochromatosis, 301072 (3)
PIGB	AR	developmental and epileptic encephalopathy 80, 618580 (3),
PIGBOS1		
PIGC	AR	glycosylphosphatidylinositol biosynthesis defect 16, 617816 (3),
PIGEA-14		
PIGEA14		
PIGF	AR	onychodystrophy, osteodystrophy, impaired intellectual development, and seizures syndrome, 619356 (3),
PIGG	AR	[blood group, emm system], 619812 (3), ; neurodevelopmental disorder with or without hypotonia, seizures, and cerebellar atrophy, 616917 (3),
PIGH	AR	glycosylphosphatidylinositol biosynthesis defect 17, 618010 (3),
PIGK	AR	neurodevelopmental disorder with hypotonia and cerebellar atrophy, with or without seizures, 618879 (3),
PIGL	AR	chime syndrome, 280000 (3),
PIGM	AR	glycosylphosphatidylinositol deficiency, 610293 (3),
PIGN	AR	multiple congenital anomalies-hypotonia-seizures syndrome 1, 614080 (3),
PIGO	AR	hyperphosphatasia with impaired intellectual development syndrome 2, 614749 (3),
PIGP	AR	developmental and epileptic encephalopathy 55, 617599 (3),
PIGPC1	AR,AD	erythrokeratodermia variabilis et progressiva 7, 619209 (3), ; olmsted syndrome 2, 619208 (3),
PIGQ	AR	multiple congenital anomalies-hypotonia-seizures syndrome 4, 618548 (3),
PIGR		
PIGS	AR	developmental and epileptic encephalopathy 95, 618143 (3),
PIGT	AD,AR	?paroxysmal nocturnal hemoglobinuria 2, 615399 (3), somatic mutation, ; multiple congenital anomalies-hypotonia-seizures syndrome 3, 615398 (3),
PIGU	AR	neurodevelopmental disorder with brain anomalies, seizures, and scoliosis, 618590 (3),
PIGV	AR	hyperphosphatasia with impaired intellectual development syndrome 1, 239300 (3),
PIGW	AR	glycosylphosphatidylinositol biosynthesis defect 11, 616025 (3),
PIGX		
PIGY	AR	hyperphosphatasia with impaired intellectual development syndrome 6, 616809 (3),
PIGZ		
Pih1		
PIH1D1		
PIH1D3	XL,XLR	ciliary dyskinesia, primary, 36, 300991 (3),
PiHL		
PIK3AP		
PIK3AP1		
PIK3C1		
PIK3C2A	AR	oculoskeletodental syndrome, 618440 (3),
PIK3C2B		
PIK3C2G		
PIK3C3		
PIK3CA		clove syndrome, somatic, 612918 (3); hepatocellular carcinoma, somatic, 114550 (3); breast cancer, somatic, 114480 (3); cerebral cavernous malformations 4, somatic, 619538 (3); ovarian cancer, somatic, 167000 (3); colorectal cancer, somatic, 114500 (3); macrodactyly, somatic, 155500 (3); clapo syndrome, somatic, 613089 (3); keratosis, seborrheic, somatic, 182000 (3); nevus, epidermal, somatic, 162900 (3); gastric cancer, somatic, 613659 (3); nonsmall cell lung cancer, somatic, 211980 (3); megalencephaly-capillary malformation-polymicrogyria syndrome, somatic, 602501 (3); cowden syndrome 5, 615108 (3)
PIK3CB		
PIK3CD	AD,AR	immunodeficiency 14a, 615513 (3), ; immunodeficiency 14b, 619281 (3), ; ?roifman-chitayat syndrome, digenic, 613328 (3), digenic
PIK3CG	AR	immunodeficiency 97 with autoinflammation, 619802 (3),
PIK3IP1		
PIK3R1	AD,AR	immunodeficiency 36, 616005 (3), ; ?agammaglobulinemia 7, 615214 (3), ; short syndrome, 269880 (3),
PIK3R2	AD	megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 1, 603387 (3),
PIK3R3		
PIK3R4		
PIK3R5	AR	ataxia-oculomotor apraxia 3, 615217 (3),
PIK3R6		
PIK42A		
PIK42B		
PIK4CA	AR	spastic paraplegia 84, 619621 (3), ; gastrointestinal defects and immunodeficiency syndrome 2, 619708 (3), ; polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis, 616531 (3),
PIK4CB	AD	deafness, 87, 620281 (3),
PIKA		
PIKFYVE	AD	corneal fleck dystrophy, 121850 (3),
PILAR		
PILB		
PILOT		
PILRA		
PILRB		
PILS-AP		
PILT		
PIM		
PIM1	AR	codas syndrome, 600373 (3),
PIM2		
PIM3		
PIMREG		
PIMT		
PIN		
PIN1		
PIN1L		
PIN1P1		
PIN2		
PIN4		
PINCH		
PINCH-2	AR	?muscular dystrophy, with cardiomyopathy and triangular tongue, 616827 (3),
PINCH1		
PINCH2	AR	?muscular dystrophy, with cardiomyopathy and triangular tongue, 616827 (3),
PINH		
PINK1	AR	parkinson disease 6, early onset, 605909 (3),
pinkbar		
Pins	AR	chudley-mccullough syndrome, 604213 (3),
PINT		
PINT1		
PINT87aa		
PINX1		
PION		
PIP		
Pip1	AR,AD	?dyskeratosis congenita, 7, 616553 (3), ; ?dyskeratosis congenita, 6, 616553 (3),
PIP1		
PIP3-E		
PIP30		
PIP3AP		
PIP4K2A		
PIP4K2B		
PIP4K2C		
PIP4P1		
PIP4P2		
PIP5K	AD	corneal fleck dystrophy, 121850 (3),
PIP5K1A		
PIP5K1B		
PIP5K1C	AR	lethal congenital contractural syndrome 3, 611369 (3),
PIP5K2A		
PIP5K2B		
PIP5K2C		
PIP5K3	AD	corneal fleck dystrophy, 121850 (3),
PIP5Kgamma	AR	lethal congenital contractural syndrome 3, 611369 (3),
PIP5KIIA		
PIP5KIIalpha		
PIP5KIIB		
PIP5KIIbeta		
PIP5KL1		
PIP7S	AR	alazami syndrome, 615071 (3),
PIPOX		
PIPP		
PIPPin		
PIR		
PIR-B		
PIR1		
PIR121	AD	developmental and epileptic encephalopathy 65, 618008 (3),
PIR51		
PIRB		
PIRH2		
PIRT		
PIS		
PIS1		
PISD	AR	liberfarb syndrome, 618889 (3),
PISSLRE	AR	al kaissi syndrome, 617694 (3),
PIST		
PiT-1		
PIT-1	AR,AD	pituitary hormone deficiency, combined or isolated, 1, 613038 (3),
PiT-2	AD	basal ganglia calcification, idiopathic, 1, 213600 (3),
PiT1		
PIT1	AR,AD	pituitary hormone deficiency, combined or isolated, 1, 613038 (3),
PIT2	AD	basal ganglia calcification, idiopathic, 1, 213600 (3),
PITALRE		
pitchfork		
PITHD1		
PITK		
PITPN		
PITPNA		
PITPNB		
PITPNC1		
PITPNM		
PITPNM1		
PITPNM2		
PITPNM3	AD	cone-rod dystrophy 5, 600977 (3),
PITRM1	AR	spinocerebellar ataxia, 30, 619405 (3),
PITSLRE		
PITX1	AD	liebenberg syndrome, 186550 (4), ; clubfoot, congenital, with or without deficiency of long bones and/or mirror-image polydactyly, 119800 (3),
PITX2	AD	ring dermoid of cornea, 180550 (3), ; axenfeld-rieger syndrome, type 1, 180500 (3), ; anterior segment dysgenesis 4, 137600 (3),
PITX3	AR,AD	cataract 11, multiple types, 610623 (3), ; anterior segment dysgenesis 1, multiple subtypes, 107250 (3), ; cataract 11, syndromic, 610623 (3),
PIWI		
PIWIL1		
PIWIL2		
PIWIL3		
PIWIL4		
PIXB		
PJA1		
PJA2		
PJS	AD	melanoma, malignant, somatic, 155600 (3); pancreatic cancer, somatic, 260350 (3); peutz-jeghers syndrome, 175200 (3), ; testicular tumor, somatic, 273300 (3)
PJVK	AR	deafness, 59, 610220 (3),
PK1		
PK1.3		
pk18		
PK2	AD	hypogonadotropic hypogonadism 4 with or without anosmia, 610628 (3),
PK3		
PK428		
PKACa	AD	cushing syndrome, acth-independent adrenal, somatic, 615830 (3); cardioacrofacial dysplasia 1, 619142 (3),
PKACb	AD	cardioacrofacial dysplasia 2, 619143 (3), somatic mosaicism,
PKACg	AR	?bleeding disorder, platelet-type, 19, 616176 (3),
PKAN	AR	harp syndrome, 607236 (3), ; neurodegeneration with brain iron accumulation 1, 234200 (3),
PKB		breast cancer, somatic, 114480 (3); cowden syndrome 6, 615109 (3); colorectal cancer, somatic, 114500 (3); proteus syndrome, somatic, 176920 (3); ovarian cancer, somatic, 167000 (3)
PKBG	AD	megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 2, 615937 (3),
PKBS		
PKBÎ²	AD	diabetes mellitus, type ii, 125853 (3), ; hypoinsulinemic hypoglycemia with hemihypertrophy, 240900 (3),
PKC	AD	convulsions, familial infantile, with paroxysmal choreoathetosis, 602066 (3), ; seizures, benign familial infantile, 2, 605751 (3), ; episodic kinesigenic dyskinesia 1, 128200 (3),
PKC-L	MF	{cerebral infarction, susceptibility to}, 601367 (3),
PKC-mu	AD	congenital heart defects and ectodermal dysplasia, 617364 (3),
PKC12		
PKC2		
PKCA		pituitary tumor, invasive (3)
PKCB		
PKCC	AD	spinocerebellar ataxia 14, 605361 (3),
PKCG	AD	spinocerebellar ataxia 14, 605361 (3),
PKCI		
PKCI-1	AR	neuromyotonia and axonal neuropathy, 137200 (3),
PKCL	MF	{cerebral infarction, susceptibility to}, 601367 (3),
PKCM	AD	congenital heart defects and ectodermal dysplasia, 617364 (3),
PKCSL		
PKCÎ±		pituitary tumor, invasive (3)
PKCÎ²		
PKCÎ³	AD	spinocerebellar ataxia 14, 605361 (3),
PKD	AD	congenital heart defects and ectodermal dysplasia, 617364 (3),
PKD1	AD	polycystic kidney disease 1, 173900 (3),
PKD1L1	AR	heterotaxy, visceral, 8, 617205 (3),
PKD1L2		
PKD1L3		
PKD2	AD	polycystic kidney disease 2, 613095 (3),
PKD2L		
PKD2L1		
PKD2L2		
PKD4	AD	polycystic kidney disease 2, 613095 (3),
PKDCC	AR	rhizomelic limb shortening with dysmorphic features, 618821 (3),
PKDL		
PKDREJ		
PKG	AD	aortic aneurysm, familial thoracic 8, 615436 (3),
PKG1	AD	aortic aneurysm, familial thoracic 8, 615436 (3),
PKG2	AR	spondylometaphyseal dysplasia, pagnamenta type, 619638 (3), ; acromesomelic dysplasia 4, 619636 (3),
PKGB	AR,AD	naxos disease, 601214 (3), ; ?arrhythmogenic right ventricular dysplasia 12, 611528 (3),
PKH	AR	neuropathy, hereditary motor and sensory, type vic, with optic atrophy, 618511 (3),
PKHD1	AR	polycystic kidney disease 4, with or without hepatic disease, 263200 (3),
PKHD1L1		
PKIA		
PKIB		
PKIG		
PKK	AR	chand syndrome, 214350 (3), ; popliteal pterygium syndrome, bartsocas-papas type 1, 263650 (3),
PKL		
PKL12		
PKLR	AD,AR	adenosine triphosphate, elevated, of erythrocytes, 102900 (3), ; pyruvate kinase deficiency, 266200 (3),
PKM		
PKM2		
PKMYT1		
PKN		
PKN1		
PKN2		
PKN3		
PKNbeta		
PKND	AR	pycnodysostosis, 265800 (3),
PKND1	AD	paroxysmal nonkinesigenic dyskinesia 1, 118800 (3),
PKNOX1		
PKNOX2		
PKP1	AR	ectodermal dysplasia/skin fragility syndrome, 604536 (3),
PKP2	AD	arrhythmogenic right ventricular dysplasia 9, 609040 (3),
PKP3		
PKP4		
PKR	AD,AR	leukoencephalopathy, developmental delay, and episodic neurologic regression syndrome, 618877 (3), ; dystonia 33, 619687 (3),
PKR1		
PKR2	AD	hypogonadotropic hypogonadism 3 with or without anosmia, 244200 (3),
PKU-ALPHA	AD	intellectual developmental disorder, 57, 618050 (3),
PKU-BETA		
PKU2	AR	hyperphenylalaninemia, bh4-deficient, c, 261630 (3),
PKX1		
PKY		
PL	AR	?pancreatic lipase deficiency, 614338 (3), |[placental lactogen deficiency] (1)
PL-5283		
PL6		
PLA-1		
PLA/AT1		
PLA1A		
PLA1B	AR	hypotrichosis 7, 604379 (3), ; woolly hair, 2 with or without hypotrichosis, 604379 (3),
PLA1C		
PLA2		
PLA2-R		
PLA2A		
PLA2B	AD	{?colorectal cancer, susceptibility to}, 114500 (3), somatic mutation,
PLA2G10		
PLA2G12		
PLA2G12A		
PLA2G12B		
PLA2G13		
PLA2G15		
PLA2G16		
PLA2G1B		
PLA2G1R		
PLA2G2A	AD	{?colorectal cancer, susceptibility to}, 114500 (3), somatic mutation,
PLA2G2D		
PLA2G2E		
PLA2G2F		
PLA2G3		
PLA2G4	AR	gastrointestinal ulceration, recurrent, with dysfunctional platelets, 618372 (3),
PLA2G4A	AR	gastrointestinal ulceration, recurrent, with dysfunctional platelets, 618372 (3),
PLA2G4B		
PLA2G4C		
PLA2G4D		
PLA2G5	AR	[fleck retina, familial benign], 228980 (3),
PLA2G6	AR	parkinson disease 14, 612953 (3), ; neurodegeneration with brain iron accumulation 2b, 610217 (3), ; infantile neuroaxonal dystrophy 1, 256600 (3),
PLA2G7	AR,AD	platelet-activating factor acetylhydrolase deficiency, 614278 (3), ; {asthma, susceptibility to}, 600807 (3), ; {atopy, susceptibility to}, 147050 (3),
PLA2IR		
PLA2L	AD	{?colorectal cancer, susceptibility to}, 114500 (3), somatic mutation,
PLA2P	AR	neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies, 617527 (3),
PLA2R1		
PLAA	AR	neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies, 617527 (3),
PLAAT-1		
PLAAT-2		
PLAAT-3		
PLAAT-4		
PLAAT-5		
PLAAT1		
PLAAT2		
PLAAT3		
PLAAT4		
PLAAT5		
PLAB		
PLAC-24		
PLAC1		
PLAC1L		
PLAC2		
PLAC3	AR	short stature, dauber-argente type, 619489 (3),
PLAC4		
PLAC6		
PLAC8		
PLAC8L2		
PLAC9		
PLAG1	AD	adenomas, salivary gland pleomorphic, somatic, 181030 (3); silver-russell syndrome 4, 618907 (3),
PLAGL1		
PLAGL2		
PLANH1	AR,AD	plasminogen activator inhibitor-1 deficiency, 613329 (3), ; {transcription of plasminogen activator inhibitor, modulator of} (3)
PLANH2		
PLANH3		
PLAP	AR	neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies, 617527 (3),
PLAP-1	AD	{lumbar disc degeneration}, 603932 (3); {osteoarthritis susceptibility 3}, 607850 (3),
PLAT		
PLAU	AD	quebec platelet disorder, 601709 (3), ; {alzheimer disease, late-onset, susceptibility to}, 104300 (3),
PLAUR		
PLB	AD	cardiomyopathy, dilated, 1p, 609909 (3); cardiomyopathy, hypertrophic, 18, 613874 (3),
PLB1		
PLBD1		
PLBD2		
PLC-eta2		
PLC-I	AR	developmental and epileptic encephalopathy 12, 613722 (3),
PLC-II		
PLC-L		
PLC1		
PLC148		
PLC154	AR	developmental and epileptic encephalopathy 12, 613722 (3),
PLCB1	AR	developmental and epileptic encephalopathy 12, 613722 (3),
PLCB2		platelet plc beta-2 deficiency (1)
PLCB3	AR	spondylometaphyseal dysplasia with corneal dystrophy, 618961 (3),
PLCB3N		
PLCB4	AR,AD	auriculocondylar syndrome 2, 614669 (3),
PLCD1	AR,AD	nail disorder, nonsyndromic congenital, 3, (leukonychia), 151600 (3),
PLCD3		
PLCD4		
PLCE	AR	nephrotic syndrome, type 3, 610725 (3),
PLCE1	AR	nephrotic syndrome, type 3, 610725 (3),
PLCE2		
PLCeta1	AR	holoprosencephaly 14, 619895 (3),
PLCeta2		
PLCG1		
PLCG2	AD	autoinflammation, antibody deficiency, and immune dysregulation syndrome, 614878 (3), ; familial cold autoinflammatory syndrome 3, 614468 (3),
PLCgamma1		
PLCH1	AR	holoprosencephaly 14, 619895 (3),
PLCH2		
PLCL		
PLCL1		
PLCL2		
PLCL3	AR	holoprosencephaly 14, 619895 (3),
PLCL4		
PLCXD1		
PLCXD2		
PLCXD3		
PLCZ1	AR	spermatogenic failure 17, 617214 (3),
PLCzeta	AR	spermatogenic failure 17, 617214 (3),
PLD1	AR,AD	cardiac valvular dysplasia 1, 212093 (3), |polycystic liver disease 1, 174050 (3),
PLD2		
PLD3	AD	?spinocerebellar ataxia 46, 617770 (3),
PLD4		
PLD6		
PLDN	AR	?hermansky-pudlak syndrome 9, 614171 (3),
PLE21		
PLEC	AR,AD	?epidermolysis bullosa simplex 5d, generalized intermediate, 616487 (3), ; epidermolysis bullosa simplex 5b, with muscular dystrophy, 226670 (3), ; epidermolysis bullosa simplex 5c, with pyloric atresia, 612138 (3), ; epidermolysis bullosa simplex 5a, ogna type, 131950 (3), ; muscular dystrophy, limb-girdle, 17, 613723 (3),
PLEC1	AR,AD	?epidermolysis bullosa simplex 5d, generalized intermediate, 616487 (3), ; epidermolysis bullosa simplex 5b, with muscular dystrophy, 226670 (3), ; epidermolysis bullosa simplex 5c, with pyloric atresia, 612138 (3), ; epidermolysis bullosa simplex 5a, ogna type, 131950 (3), ; muscular dystrophy, limb-girdle, 17, 613723 (3),
PLEIAD		
PLEK		
PLEK1		
PLEK2		
PLEKHA1		
PLEKHA2		
PLEKHA3		
PLEKHA4		
PLEKHA5		
PLEKHA6		
PLEKHA7		
PLEKHA8		
PLEKHB1		
PLEKHB2		
PLEKHC1		
PLEKHC2		
PLEKHC3		
PLEKHE1		
PLEKHF1		
PLEKHF2		
PLEKHG1		
PLEKHG2	AR	leukodystrophy and acquired microcephaly with or without dystonia, 616763 (3),
PLEKHG3		
PLEKHG4		
PLEKHG5	AR	spinal muscular atrophy, distal, 4, 611067 (3), ; charcot-marie-tooth disease, intermediate c, 615376 (3),
PLEKHG6		
PLEKHH1L		
PLEKHH2		
PLEKHJ1		
PLEKHK1		
PLEKHM1	AR,AD	?osteopetrosis, 6, 611497 (3), ; osteopetrosis, 3, 618107 (3),
PLEKHM1L		
PLEKHM2		
PLEKHM3		
PLEKHO1		
PLET1		
PLEXB2		
PLEXB3		
PLEXR		
PLG	AR,AD	dysplasminogenemia, 217090 (3), ; angioedema, hereditary, 4, 619360 (3), ; plasminogen deficiency, type i, 217090 (3),
Plg-RKT		
PlGF		
PLGF		
PlGF-2		
PLGL		
PLGLA		
PLGLA1		
PLGLB1		
PLGP2		
PLGRKT		
PLI	AR	alpha-2-plasmin inhibitor deficiency, 262850 (3),
PLIC-1		
PLIC-2	XLD,XL	amyotrophic lateral sclerosis 15, with or without frontotemporal dementia, 300857 (3),
PLIC2	XLD,XL	amyotrophic lateral sclerosis 15, with or without frontotemporal dementia, 300857 (3),
PLIF	AD	?hemochromatosis, type 5, 615517 (3),
PLIN	AD	lipodystrophy, familial partial, type 4, 613877 (3),
PLIN1	AD	lipodystrophy, familial partial, type 4, 613877 (3),
PLIN2		
PLIN3		
PLIN4		
PLIN5		
PLINP-1		
Plinp1		
PLIP	AD	neurodevelopmental disorder with dysmorphic facies, sleep disturbance, and brain abnormalities, 619103 (3),
PLK		
PLK1		
PLK1S1	AR	retinitis pigmentosa 69, 615780 (3),
PLK2		
PLK3		
PLK4	AR	microcephaly and chorioretinopathy, 2, 616171 (3),
PLLP		
PLM		
PLML		
PLN	AD	cardiomyopathy, dilated, 1p, 609909 (3); cardiomyopathy, hypertrophic, 18, 613874 (3),
PLNHR		
PLO-SL	AR	polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 1, 221770 (3),
PLOD	AR	ehlers-danlos syndrome, kyphoscoliotic type, 1, 225400 (3),
PLOD1	AR	ehlers-danlos syndrome, kyphoscoliotic type, 1, 225400 (3),
PLOD2	AR	bruck syndrome 2, 609220 (3),
PLOD3	AR	lysyl hydroxylase 3 deficiency, 612394 (3),
PLOSL	AR	polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 1, 221770 (3),
PLP	AD,XLR,XL	brachydactyly, type e2, 613382 (3), |pelizaeus-merzbacher disease, 312080 (3), ; spastic paraplegia 2, 312920 (3),
PLP1	XLR,XL	pelizaeus-merzbacher disease, 312080 (3), ; spastic paraplegia 2, 312920 (3),
PLP2		
PLPB1		
PLPBP	AR	epilepsy, early-onset, vitamin b6-dependent, 617290 (3),
PLPP1		
PLPP2		
PLPP3		
PLPP5		
PLPP6		
PLPP7		
PLPPR1		
PLPPR2		
PLPPR3		
PLPPR4		
PLPPR5		
PLRG1		
PLRLC		
PLRP1		
PLRP2		
PLS	AR	periodontitis 1, juvenile, 170650 (3), ; haim-munk syndrome, 245010 (3), ; papillon-lefevre syndrome, 245000 (3),
PLS1	AD	deafness, 76, 618787 (3),
PLS2		
PLS3	XLD,XL	bone mineral density qtl18, osteoporosis, 300910 (3),
PLSCR1		
PLSCR2		
PLSCR3		
PLSCR4		
PLSTIRE	AR	?microcephaly 12, primary, 616080 (3),
PLTN	AR,AD	?epidermolysis bullosa simplex 5d, generalized intermediate, 616487 (3), ; epidermolysis bullosa simplex 5b, with muscular dystrophy, 226670 (3), ; epidermolysis bullosa simplex 5c, with pyloric atresia, 612138 (3), ; epidermolysis bullosa simplex 5a, ogna type, 131950 (3), ; muscular dystrophy, limb-girdle, 17, 613723 (3),
PLTP		
PLU-1	AR	intellectual developmental disorder, 65, 618109 (3),
PLUNC		
PLVAP	AR	diarrhea 10, protein-losing enteropathy type, 618183 (3),
PLXDC1		
PLXDC2		
PLXDC2-OT		
PLXN1	AR	dworschak-punetha neurodevelopmental syndrome, 619955 (3),
PLXN2		
Plxn3		
PLXN4		
PLXN5		
PLXN6		
PLXNA1	AR	dworschak-punetha neurodevelopmental syndrome, 619955 (3),
PLXNA2		
PLXNA3		
PLXNA4		
PLXNA4A		
PLXNA4B		
PLXNB1		
PLXNB2		
PLXNB3		
PLXNC1		
PLXND1	AR	congenital heart defects, multiple types, 9, 620294 (3),
PLZF		leukemia, acute promyelocytic, pl2f/rara type (3)
PM		
PM-Scl		
PM/Scl-100		
PM/Scl-75	AR	pontocerebellar hypoplasia, type 1d, 618065 (3),
PM1		
PM20D1		
PM20D2		
PM5		
PMAIP1		
PMAN		
PMBP		
PMCA1	AD	intellectual developmental disorder, 66, 619910 (3),
PMCA2	AD,AR	deafness, 82, 619804 (3), ; {deafness, 12, modifier of}, 601386 (3),
PMCA3	XL,XLR	?spinocerebellar ataxia, 1, 302500 (3),
PMCA4		
PMCH		
PMCHL1		
PMCHL2		
PME	AR	epilepsy, progressive myoclonic 1a (unverricht and lundborg), 254800 (3),
PME-1		
PMEL		
Pmel17		
PMEPA1		
PMES-2		
pMesogenin1		
PMF		
PMF1		
PMFA		
PMFBP1	AR	spermatogenic failure 31, 618112 (3),
PMI	AR	congenital disorder of glycosylation, type ia, 212065 (3),
PMI1	AR	congenital disorder of glycosylation, type ia, 212065 (3),
PMIDP		
PMK	AD	porokeratosis 1, multiple types, 175800 (3),
PMKA	AD	porokeratosis 1, multiple types, 175800 (3),
PML		leukemia, acute promyelocytic, pml/rara type (3)
PML-RAR		
PML1	AR	neurodevelopmental disorder with hypotonia, craniofacial abnormalities, and seizures, 614501 (3),
PMLP		
PMM1		
PMM2	AR	congenital disorder of glycosylation, type ia, 212065 (3),
PMN-E	AD	neutropenia, cyclic, 162800 (3), ; neutropenia, severe congenital 1, 202700 (3),
PMP1	AR	peroxisome biogenesis disorder 12a (zellweger), 614886 (3),
PMP2	AD	charcot-marie-tooth disease, demyelinating, type 1g, 618279 (3),
PMP20		
PMP22	AD,AR	charcot-marie-tooth disease, type 1a, 118220 (3), ; roussy-levy syndrome, 180800 (3), ; charcot-marie-tooth disease, type 1e, 118300 (3), ; ?neuropathy, inflammatory demyelinating, 139393 (3), ? ; neuropathy, recurrent, with pressure palsies, 162500 (3), ; dejerine-sottas disease, 145900 (3),
PMP24		
PMP28		
PMP34		
PMP35	AR	peroxisome biogenesis disorder 5a (zellweger), 614866 (3), ; peroxisome biogenesis disorder 5b, 614867 (3),
PMP69	AR	methylmalonic aciduria and homocystinuria, cblj type, 614857 (3),
PMP70	AR	?bile acid synthesis defect, congenital, 5, 616278 (3),
PMPCA	AR	spinocerebellar ataxia, 2, 213200 (3),
PMPCB	AR	multiple mitochondrial dysfunctions syndrome 6, 617954 (3),
PMPI	AR	peroxisome biogenesis disorder 12a (zellweger), 614886 (3),
PMR1	AD	hailey-hailey disease, 169600 (3),
PMS		
PMS-2	AR	lynch syndrome 4, 614337 (3); mismatch repair cancer syndrome 4, 619101 (3),
PMS1		
PMS2	AR	lynch syndrome 4, 614337 (3); mismatch repair cancer syndrome 4, 619101 (3),
PMS2L1		
PMS2L13		
PMS2L6		
PMS2L7		
PMS2L8		
PMS2P1		
PMS3		
PMS8		
PMSA2		
PMSB1	AR	?neurodevelopmental disorder with microcephaly, hypotonia, and absent language, 620038 (3),
PMSCL1	AR	pontocerebellar hypoplasia, type 1d, 618065 (3),
PMSCL2		
PMSL1		
PMSL2	AR	lynch syndrome 4, 614337 (3); mismatch repair cancer syndrome 4, 619101 (3),
PMSR1		
PMSR2		
PMVK	AD	porokeratosis 1, multiple types, 175800 (3),
PMX1	AR,AD	agnathia-otocephaly complex, 202650 (3),
PMX2		
PMX2A	AR	fibrosis of extraocular muscles, congenital, 2, 602078 (3),
PMX2B	AD	{neuroblastoma, susceptibility to, 2}, 613013 (3); neuroblastoma with hirschsprung disease, 613013 (3); central hypoventilation syndrome, congenital, 1, with or without hirschsprung disease, 209880 (3),
PN		
PN-I	AR	anemia, hemolytic, due to umph1 deficiency, 266120 (3),
PN1	AD,AR	erythermalgia, primary, 133020 (3), ; insensitivity to pain, congenital, 243000 (3), ; small fiber neuropathy, 133020 (3), ; paroxysmal extreme pain disorder, 167400 (3), ; neuropathy, hereditary sensory and autonomic, type iid, 243000 (3),
PN3	AD	episodic pain syndrome, familial, 2, 615551 (3),
PN4	AD	?myoclonus, familial, 2, 618364 (3), ; seizures, benign familial infantile, 5, 617080 (3), ; cognitive impairment with or without cerebellar ataxia, 614306 (3), ; developmental and epileptic encephalopathy 13, 614558 (3),
PN44		{prostate cancer, hereditary, 13}, 611928 (3)
PNAS-11	AR	?craniofacial dysmorphism, skeletal anomalies, and impaired intellectual development syndrome 2, 616994 (3),
PNAS-111		
PNAS-4		
PNAT1	AR	spondyloepiphyseal dysplasia, sensorineural hearing loss, intellectual developmental disorder, and leber congenital amaurosis, 619260 (3), ; leber congenital amaurosis 9, 608553 (3),
PNAT2		
PNAT3		
pNBC	AR	renal tubular acidosis, proximal, with ocular abnormalities, 604278 (3),
PNC1		
PNC2	AR	hyperinsulinemic hypoglycemia, familial, 8, 620211 (3),
PNCK		
PND	AR,AD	atrial standstill 2, 615745 (3), ; atrial fibrillation, familial, 6, 612201 (3),
PNEM		
PNG		
PNG-1	AR	congenital disorder of deglycosylation 1, 615273 (3),
PNG1	AR	congenital disorder of deglycosylation 1, 615273 (3),
PNI		
PNISR		
PNK	AR,AR	?charcot-marie-tooth disease, type 2b2, 605589 (3), ; ataxia-oculomotor apraxia 4, 616267 (3), ; microcephaly, seizures, and developmental delay, 613402 (3), |neuropathy, hereditary motor and sensory, type vic, with optic atrophy, 618511 (3),
PNKD	AD	paroxysmal nonkinesigenic dyskinesia 1, 118800 (3),
PNKP	AR	?charcot-marie-tooth disease, type 2b2, 605589 (3), ; ataxia-oculomotor apraxia 4, 616267 (3), ; microcephaly, seizures, and developmental delay, 613402 (3),
PNLDC1	AR	spermatogenic failure 57, 619528 (3),
PNLIP	AR	?pancreatic lipase deficiency, 614338 (3),
PNLIPRP1		
PNLIPRP2		
PNMA1		
PNMA2		
PNMA3		
PNMA4		
PNMA5		
PNMA6A		
PNMA6C		
PNMA7A		
PNMA8B		
PNMAL2		
PNMT		
PNN		
PNO1		
pNO40		
PNOC		
PNOCR		
pNORF1		
PNP	AR	immunodeficiency due to purine nucleoside phosphorylase deficiency, 613179 (3),
PNPase	AD,AR	spinocerebellar ataxia 25, 608703 (3), ; deafness, 70, with or without adult-onset neurodegeneration, 614934 (3), ; combined oxidative phosphorylation deficiency 13, 614932 (3),
PNPK6288		
PNPLA1	AR	ichthyosis, congenital, 10, 615024 (3),
PNPLA2	AR	neutral lipid storage disease with myopathy, 610717 (3),
PNPLA3		
PNPLA4		
PNPLA5		
PNPLA6	AR	spastic paraplegia 39, 612020 (3), ; oliver-mcfarlane syndrome, 275400 (3), ; ?laurence-moon syndrome, 245800 (3), ; boucher-neuhauser syndrome, 215470 (3),
PNPLA7		
PNPLA8	AR	?mitochondrial myopathy with lactic acidosis, 251950 (3),
PNPLA9	AR	parkinson disease 14, 612953 (3), ; neurodegeneration with brain iron accumulation 2b, 610217 (3), ; infantile neuroaxonal dystrophy 1, 256600 (3),
PNPO	AR	pyridoxamine 5'-phosphate oxidase deficiency, 610090 (3),
PNPT1	AD,AR	spinocerebellar ataxia 25, 608703 (3), ; deafness, 70, with or without adult-onset neurodegeneration, 614934 (3), ; combined oxidative phosphorylation deficiency 13, 614932 (3),
PNQALRE		
PNR	AR,AD	retinitis pigmentosa 37, 611131 (3), ; enhanced s-cone syndrome, 268100 (3),
pNR-2		
PNRC1		
PNRC2		
PNSC1		
PnSP-2		
PNSP1	AD	{asthma, susceptibility to}, 600807 (3),
PNT5	AR	spastic paraplegia 45, 613162 (3),
PNUTL1		
PNUTL2		
Pnutl3		
PNUTL3		
PNUTL4	AD	amyotrophy, hereditary neuralgic, 162100 (3),
PNUTS		
PNX		
PO-GA	AR	cerebellar ataxia, neuropathy, and vestibular areflexia syndrome, 614575 (3),
PO4DB	AD	cole-carpenter syndrome 1, 112240 (3),
PO4HB	AD	cole-carpenter syndrome 1, 112240 (3),
POB1	AR	mulibrey nanism, 253250 (3),
POB16		
POC	AR,MF,AD	{obesity, early-onset, susceptibility to}, 601665 (3), , ; obesity, adrenal insufficiency, and red hair due to pomc deficiency, 609734 (3),
POC10	AR	senior-loken syndrome 4, 606996 (3), ; nephronophthisis 4, 606966 (3),
POC12	AR	bardet-biedl syndrome 13, 615990 (3), ; meckel syndrome 1, 249000 (3), ; joubert syndrome 28, 617121 (3),
POC16		
POC1A	AR	short stature, onychodysplasia, facial dysmorphism, and hypotrichosis, 614813 (3),
POC1B	AR	cone-rod dystrophy 20, 615973 (3),
POC20	XL,XLR	spinal muscular atrophy, 2, infantile, 301830 (3), ; vexas syndrome, somatic, 301054 (3)
POC3	AR	leber congenital amaurosis 10, 611755 (3); joubert syndrome 5, 610188 (3), ; senior-loken syndrome 6, 610189 (3), ; ?bardet-biedl syndrome 14, 615991 (3), ; meckel syndrome 4, 611134 (3),
POC5		
POC7	AD	cone-rod dystrophy 24, 620342 (3), ; ?immunodeficiency 13, 615518 (3),
POC7A	AD	cone-rod dystrophy 24, 620342 (3), ; ?immunodeficiency 13, 615518 (3),
POC9	AD	{epilepsy, juvenile absence, susceptibility to, 1}, 607631 (3), ; {myoclonic epilepsy, juvenile, susceptibility to, 1}, 254770 (3),
POD1		
PODLX2		
PODN		
PODOCAN		
PODXL		
PODXL1		
PODXL2		
POEM		
POF	XLD,XL,XLR,XL,XLD,XL	?premature ovarian failure 2a, 300511 (3), |?premature ovarian failure 2b, 300604 (3), |fragile x tremor/ataxia syndrome, 300623 (3), ; fragile x syndrome, 300624 (3), ; premature ovarian failure 1, 311360 (3),
POF1	XLD,XL	fragile x tremor/ataxia syndrome, 300623 (3), ; fragile x syndrome, 300624 (3), ; premature ovarian failure 1, 311360 (3),
POF1B	XLR,XL	?premature ovarian failure 2b, 300604 (3),
POF2	XLD,XL	?premature ovarian failure 2a, 300511 (3),
POFUT1	AD	dowling-degos disease 2, 615327 (3),
POFUT2		
Pog	AR	fanconi anemia, complementation group l, 614083 (3),
POGK		
POGLUT1	AD,AR	dowling-degos disease 4, 615696 (3), ; muscular dystrophy, limb-girdle, 21, 617232 (3),
POGLUT2		
POGLUT3		
POGZ	AD	white-sutton syndrome, 616364 (3),
POH1		
pokemon	AD	macrocephaly, neurodevelopmental delay, lymphoid hyperplasia, and persistent fetal hemoglobin, 619769 (3),
POL3S		
Pol5		
POLA	XL,XLR	pigmentary disorder, reticulate, with systemic manifestations, 301220 (3), ; van esch-o'driscoll syndrome, 301030 (3),
POLA1	XL,XLR	pigmentary disorder, reticulate, with systemic manifestations, 301220 (3), ; van esch-o'driscoll syndrome, 301030 (3),
POLA2		
POLB		
POLD	AD	mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome, 615381 (3), ; {colorectal cancer, susceptibility to, 10}, 612591 (3),
POLD1	AD	mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome, 615381 (3), ; {colorectal cancer, susceptibility to, 10}, 612591 (3),
POLD2		
POLD3		
POLD4		
POLDIP1		
POLDIP2		
POLDIP3		
POLDS		
POLE	AD,AR	{colorectal cancer, susceptibility to, 12}, 615083 (3), ; fils syndrome, 615139 (3), ; image-i syndrome, 618336 (3),
POLE1	AD,AR	{colorectal cancer, susceptibility to, 12}, 615083 (3), ; fils syndrome, 615139 (3), ; image-i syndrome, 618336 (3),
POLE2		
POLE3		
POLE4		
POLG	AR,AD	mitochondrial ataxia syndrome (includes sando and scae), 607459 (3), ; mitochondrial dna depletion syndrome 4b (mngie type), 613662 (3), ; mitochondrial dna depletion syndrome 4a (alpers type), 203700 (3), ; progressive external ophthalmoplegia, 1, 157640 (3), ; progressive external ophthalmoplegia, 1, 258450 (3),
POLG1	AR,AD	mitochondrial ataxia syndrome (includes sando and scae), 607459 (3), ; mitochondrial dna depletion syndrome 4b (mngie type), 613662 (3), ; mitochondrial dna depletion syndrome 4a (alpers type), 203700 (3), ; progressive external ophthalmoplegia, 1, 157640 (3), ; progressive external ophthalmoplegia, 1, 258450 (3),
POLG2	AD,AR	progressive external ophthalmoplegia with mitochondrial dna deletions, 4, 610131 (3), ; ?mitochondrial dna depletion syndrome 16 (hepatic type), 618528 (3), ; ?mitochondrial dna depletion syndrome 16b (neuroophthalmic type), 619425 (3),
POLGA	AR,AD	mitochondrial ataxia syndrome (includes sando and scae), 607459 (3), ; mitochondrial dna depletion syndrome 4b (mngie type), 613662 (3), ; mitochondrial dna depletion syndrome 4a (alpers type), 203700 (3), ; progressive external ophthalmoplegia, 1, 157640 (3), ; progressive external ophthalmoplegia, 1, 258450 (3),
POLH	AR	xeroderma pigmentosum, variant type, 278750 (3),
POLI		
POLK		
POLL		
POLM		
POLN		
POLQ		
POLR1A	AD	acrofacial dysostosis, cincinnati type, 616462 (3),
POLR1B	AD	treacher-collins syndrome 4, 618939 (3),
POLR1C	AR	leukodystrophy, hypomyelinating, 11, 616494 (3), ; treacher collins syndrome 3, 248390 (3),
POLR1D	AR,AD	treacher collins syndrome 2, 613717 (3),
POLR1F		
POLR1G		
POLR1H		
POLR1HASP		
POLR2	AD	neurodevelopmental disorder with hypotonia and variable intellectual and behavioral abnormalities, 618603 (3),
POLR2A	AD	neurodevelopmental disorder with hypotonia and variable intellectual and behavioral abnormalities, 618603 (3),
POLR2B		
POLR2C		
POLR2D		
POLR2E		
POLR2F		
POLR2G		
POLR2H		
POLR2I		
POLR2J		
POLR2J1		
POLR2J2		
POLR2K		
POLR2L		
POLR2M		
POLR2MP1		
POLR3A	AR	wiedemann-rautenstrauch syndrome, 264090 (3), ; leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism, 607694 (3),
POLR3B	AR,AD	leukodystrophy, hypomyelinating, 8, with or without oligodontia and/or hypogonadotropic hypogonadism, 614381 (3), ; charcot-marie-tooth disease, demyelinating, type 1i, 619742 (3),
POLR3C		
POLR3D		
POLR3E		
POLR3F	AD	?immunodeficiency 101 (varicella zoster virus-specific), 619872 (3),
POLR3G		
POLR3GL	AR	short stature, oligodontia, dysmorphic facies, and motor delay, 619234 (3),
POLR3H		
POLR3I		
POLR3K	AR	leukodystrophy, hypomyelinating, 21, 619310 (3),
POLRA	AD	neurodevelopmental disorder with hypotonia and variable intellectual and behavioral abnormalities, 618603 (3),
POLRMT	AR,AD	combined oxidative phosphorylation deficiency 55, 619743 (3),
POLS		
Poly-PARP		
POLYDOM		
POLZ		
POLZ2	AR	?fanconi anemia, complementation group v, 617243 (3),
POM-ZP3		
POM121		
POM121A		
POM121C		
POM121L5P		
POM210		
Pom33		
POMC	AR,MF,AD	{obesity, early-onset, susceptibility to}, 601665 (3), , ; obesity, adrenal insufficiency, and red hair due to pomc deficiency, 609734 (3),
POMFIL1		
POMFIL2		
POMFIL3		
POMGNT1	AR	muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 3, 613157 (3), ; muscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type b, 3, 613151 (3), ; retinitis pigmentosa 76, 617123 (3), ; muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 3, 253280 (3),
POMGNT2	AR	muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 8, 614830 (3), ; muscular dystrophy-dystroglycanopathy (limb-girdle) type c, 8, 618135 (3),
POMK	AR	?muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 12, 616094 (3), ; muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 12, 615249 (3),
POMP	AR,AD,AR	anemia, hemolytic, due to umph1 deficiency, 266120 (3), |proteasome-associated autoinflammatory syndrome 2, 618048 (3), ; keratosis linearis with ichthyosis congenita and sclerosing keratoderma, 601952 (3),
POMT1	AR	muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 1, 236670 (3), ; muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 1, 609308 (3), ; muscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type b, 1, 613155 (3),
POMT2	AR	muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 2, 613158 (3), ; muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 2, 613150 (3), ; muscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type b, 2, 613156 (3),
POMZP3		
PON		{coronary artery spasm 2, susceptibility to} (3); {organophosphate poisoning, sensitivity to} (3); {coronary artery disease, susceptibility to} (3); {microvascular complications of diabetes 5}, 612633 (3)
PON1		{coronary artery spasm 2, susceptibility to} (3); {organophosphate poisoning, sensitivity to} (3); {coronary artery disease, susceptibility to} (3); {microvascular complications of diabetes 5}, 612633 (3)
PON2		{coronary artery disease, susceptibility to} (3)
PON3		
ponsin		
Pontin52		
POP1	AR,AR	anauxetic dysplasia 2, 617396 (3), |muscular dystrophy, limb-girdle, 25, 616812 (3),
POP101		
POP2		
Pop3		
POP3	AR	muscular dystrophy, limb-girdle, 26, 618848 (3),
POP4		
POP5		
POP7		
POPDC1	AR	muscular dystrophy, limb-girdle, 25, 616812 (3),
POPDC2		
POPDC3	AR	muscular dystrophy, limb-girdle, 26, 618848 (3),
POPX1		
POPX2		
por	XLD,XL	focal dermal hypoplasia, 305600 (3),
POR	AR	antley-bixler syndrome with genital anomalies and disordered steroidogenesis, 201750 (3), ; disordered steroidogenesis due to cytochrome p450 oxidoreductase, 613571 (3)
POR1		
PORC	XLD,XL,AD	focal dermal hypoplasia, 305600 (3), |porphyria, acute intermittent, nonerythroid variant, 176000 (3), ; porphyria, acute intermittent, 176000 (3),
PORCN	XLD,XL	focal dermal hypoplasia, 305600 (3),
PORIMIN		
PORIN		
POSH		
POSH2		
POSHER		
POST		
POSTN		
POT1	AD,AR	{glioma susceptibility 9}, 616568 (3), ; ?cerebroretinal microangiopathy with calcifications and cysts 3, 620368 (3), ; {melanoma, cutaneous malignant, susceptibility to, 10}, 615848 (3), ; ?pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 8, 620367 (3),
POTE		
POTE-14		
POTE-15		
POTE-2		
POTE-21		
POTE-8		
POTE14		
POTE14alpha		
POTE15		
POTE2		
POTE21		
POTE22		
POTE2delta		
POTE2gamma		
POTE8		
POTEA		
POTEB		
POTED		
POTEE		
POTEG		
POTEH		
POTEK		
POTEKP		
POTX	AD	liebenberg syndrome, 186550 (4), ; clubfoot, congenital, with or without deficiency of long bones and/or mirror-image polydactyly, 119800 (3),
POU1F1	AR,AD	pituitary hormone deficiency, combined or isolated, 1, 613038 (3),
POU1F1a	AR,AD	pituitary hormone deficiency, combined or isolated, 1, 613038 (3),
POU2AF1		
POU2AF3		
POU2F1		
POU2F2		
POU2F3		
POU3F1		
POU3F2		
POU3F3	AD	snijders blok-fisher syndrome, 618604 (3),
POU3F4	XL,XLR	deafness, 2, 304400 (3),
POU4F1	AD	ataxia, intention tremor, and hypotonia syndrome, childhood-onset, 619352 (3),
POU4F2		
POU4F3	AD	deafness, 15, 602459 (3),
POU5F1		
POU5F1B		
POU5F1P1		
POU6F1		
POU6F2	AD	{wilms tumor susceptibility-5}, 601583 (3), somatic mutation,
POUF3		
POV1		
POX	AD,AR	{schizophrenia, susceptibility to, 4}, 600850 (3), ; hyperprolinemia, type i, 239500 (3),
PP		
PP-1A		
PP-1B	AD	noonan syndrome-like disorder with loose anagen hair 2, 617506 (3),
pp-GalNAc-T15		
PP1		
PP1030		
PP11		
pp1158	AD	plasma triglyceride level qtl, low, 615881 (3),
PP12		
PP1201		
PP1221		
pp12301		
PP13		
PP13187		
PP13296		
pp13842		
PP14		
PP1425	AD	{colorectal cancer, susceptibility to}, 114500 (3), somatic mutation, ; osteosarcoma, somatic, 259500 (3); {breast cancer, susceptibility to}, 114480 (3), somatic mutation, ; {prostate cancer, familial, susceptibility to}, 176807 (3), somatic mutation, ; li-fraumeni syndrome 2, 609265 (3)
PP1498	AR	hyperphosphatasia with impaired intellectual development syndrome 4, 615716 (3),
PP15		
PP1665		
PP17		
PP1744		
PP19		
PP1A		
PP1alpha		
PP1B	AD	noonan syndrome-like disorder with loose anagen hair 2, 617506 (3),
PP1beta	AD	noonan syndrome-like disorder with loose anagen hair 2, 617506 (3),
PP1bp55		
PP1c	AD	noonan syndrome-like disorder with loose anagen hair 2, 617506 (3),
PP1C		
PP1gamma		
PP2		
PP20	AR	thiamine metabolism dysfunction syndrome 5 (episodic encephalopathy type), 614458 (3),
PP203		
PP2030		
pp21	XL,XLD	neurodevelopmental disorder with gait disturbance, dysmorphic facies and behavioral abnormalities, 301094 (3),
PP2A-Aalpha	AD	intellectual developmental disorder, 36, 616362 (3),
PP2A-Abeta		lung cancer, somatic, 211980 (3)
PP2AA	AD	intellectual developmental disorder, 36, 616362 (3),
PP2Abeta		
PP2AC	AD	neurodevelopmental disorder and language delay with or without structural brain abnormalities, 618354 (3),
PP2Bbeta		
PP2Bgamma		
PP2C-DELTA	AD	breast cancer, somatic, 114480 (3); jansen de vries syndrome, 617450 (3),
PP2CA		
PP2Calpha	AD	neurodevelopmental disorder and language delay with or without structural brain abnormalities, 618354 (3),
PP2CB		
PP2CBETA		
PP2CE		
PP2Ceta		
PP2CG		
PP2Cgamma		
PP2CH		
PP2Ckappa	AR	?maple syrup urine disease, mild variant, 615135 (3),
PP2Cm	AR	?maple syrup urine disease, mild variant, 615135 (3),
PP2Czeta		
PP32		
PP32R1		
PP32R2		
PP3381		
PP3501		
PP3856		
PP4		
PP432		
PP46		
PP4R1		
PP4R3		
PP4R4		
PP5		
PP5395		
PP5656		
PP591	AR	lipid storage myopathy due to flavin adenine dinucleotide synthetase deficiency, 255100 (3),
PP6		
PP6-ARS-A		
PP610		
PP6R3		
pp75		
PP753		
PP838		
pp8875		
pp9012		
PPA1		
PPA2	AR	?sudden cardiac failure, alcohol-induced, 617223 (3), ; sudden cardiac failure, infantile, 617222 (3),
PPAN		
PPAP2A		
PPAP2B		
PPAP2C		
PPAPDC1B		
PPAPDC2		
PPAPDC3		
PPAR		
PPARA		
PPARAGCIÎ±		
PPARAGCIÎ²		
PPARB		
PPARBP		
PPARD		
PPARG	AD,AR,MF	{diabetes, type 2}, 125853 (3), ; insulin resistance, severe, digenic, 604367 (3), ; lipodystrophy, familial partial, type 3, 604367 (3), ; [obesity, resistance to] (3); obesity, severe, 601665 (3), , ; carotid intimal medial thickness 1, 609338 (3)
PPARG1	AD,AR,MF	{diabetes, type 2}, 125853 (3), ; insulin resistance, severe, digenic, 604367 (3), ; lipodystrophy, familial partial, type 3, 604367 (3), ; [obesity, resistance to] (3); obesity, severe, 601665 (3), , ; carotid intimal medial thickness 1, 609338 (3)
PPARG2	AD,AR,MF	{diabetes, type 2}, 125853 (3), ; insulin resistance, severe, digenic, 604367 (3), ; lipodystrophy, familial partial, type 3, 604367 (3), ; [obesity, resistance to] (3); obesity, severe, 601665 (3), , ; carotid intimal medial thickness 1, 609338 (3)
PPARgamma	AD,AR,MF	{diabetes, type 2}, 125853 (3), ; insulin resistance, severe, digenic, 604367 (3), ; lipodystrophy, familial partial, type 3, 604367 (3), ; [obesity, resistance to] (3); obesity, severe, 601665 (3), , ; carotid intimal medial thickness 1, 609338 (3)
PPARGBP		
PPARGC1		
PPARGC1A		
PPARGC1B		
Ppase		
PPAT	AR	pontocerebellar hypoplasia, type 12, 618266 (3), ; neurodegeneration with brain iron accumulation 6, 615643 (3),
PPBP		
PPBPL1		
PPBPL2		
PPBPP1		
PPBPP2		
PPC2BETAX		
PPCD	AD,AD	?craniofacial anomalies and anterior segment dysgenesis syndrome, 614195 (3), ; keratoconus 1, 148300 (3), |corneal dystrophy, posterior polymorphous 2, 609140 (3), ; corneal dystrophy, fuchs endothelial, 1, 136800 (3),
PPCD1	AD	?craniofacial anomalies and anterior segment dysgenesis syndrome, 614195 (3), ; keratoconus 1, 148300 (3),
PPCD2	AD	corneal dystrophy, posterior polymorphous 2, 609140 (3), ; corneal dystrophy, fuchs endothelial, 1, 136800 (3),
PPCD3	AD	corneal dystrophy, posterior polymorphous, 3, 609141 (3), ; corneal dystrophy, fuchs endothelial, 6, 613270 (3),
PPCDC		
PPCS	AR	cardiomyopathy, dilated, 2c, 618189 (3),
PPD	AD,AD,AR	?craniofacial anomalies and anterior segment dysgenesis syndrome, 614195 (3), ; keratoconus 1, 148300 (3), |hawkinsinuria, 140350 (3), ; tyrosinemia, type iii, 276710 (3),
PPDIV	AD	greig cephalopolysyndactyly syndrome, 175700 (3), ; polydactyly, postaxial, types a1 and b, 174200 (3), ; pallister-hall syndrome, 146510 (3), ; polydactyly, preaxial, type iv, 174700 (3),
PPEF		
PPEF1		
PPEF2		
PPFIA1		
PPFIA2		
PPFIA3		
PPFIA4		
PPFIBP1	AR	neurodevelopmental disorder with seizures, microcephaly, and brain abnormalities, 620024 (3),
PPFIBP2		
PPG		
ppGalNAc-T17		
PPGB	AR	galactosialidosis, 256540 (3),
PPH		
PPH1	AD	pulmonary hypertension, familial primary, 1, with or without hht, 178600 (3), ; pulmonary hypertension, primary, fenfluramine or dexfenfluramine-associated, 178600 (3), ; pulmonary venoocclusive disease 1, 265450 (3),
PPHA		
PPHLN1		
PPI5PIV	AR	joubert syndrome 1, 213300 (3), ; mental retardation, truncal obesity, retinal dystrophy, and micropenis, 610156 (3),
PPIA		
PPIAL4E		
PPIase	AR,AR	{major depressive disorder and accelerated response to antidepressant drug treatment}, 608516 (3)|osteogenesis imperfecta, type ix, 259440 (3), |spermatogenic failure 77, 620103 (3),
PPIASE		
PPIB	AR	osteogenesis imperfecta, type ix, 259440 (3),
PPIC		
PPID		
PPIE		
PPIF		
PPIG		
PPIH		
PPIL1	AR	pontocerebellar hypoplasia, type 14, 619301 (3),
PPIL2		
PPIL3		
PPIL4		
PPIL5		
PPIP5K1		
PPIP5K2	AR	deafness, 100, 618422 (3),
PPKS2	AD,AR	arrhythmogenic right ventricular dysplasia 8, 607450 (3), ; epidermolysis bullosa, lethal acantholytic, 609638 (3), ; keratosis palmoplantaris striata ii, 612908 (3), ; dilated cardiomyopathy with woolly hair, keratoderma, and tooth agenesis, 615821 (3), ; cardiomyopathy, dilated, with woolly hair and keratoderma, 605676 (3),
PPL		
PPL13		
PPL7		
PPL8		
PPLA2		
PPM1A		
PPM1B		
PPM1D	AD	breast cancer, somatic, 114480 (3); jansen de vries syndrome, 617450 (3),
PPM1E		
PPM1F		
PPM1G		
PPM1H		
PPM1J		
PPM1K	AR	?maple syrup urine disease, mild variant, 615135 (3),
PPM1L		
PPM1M		
PPM1O		
PPM2		
PPM2A	AR	pyruvate dehydrogenase phosphatase deficiency, 608782 (3),
PPM2B		
PPM2C	AR	pyruvate dehydrogenase phosphatase deficiency, 608782 (3),
PPM2C2		
PPM3A		
PPM3B		
PPME1		
PPMT		
PPMT1		
PPN	XLD,XL	focal dermal hypoplasia, 305600 (3),
PPND	AD,AR,MF	supranuclear palsy, progressive, 601104 (3), ; supranuclear palsy, progressive atypical, 260540 (3), ; dementia, frontotemporal, with or without parkinsonism, 600274 (3), ; {parkinson disease, susceptibility to}, 168600 (3), ; pick disease, 172700 (3),
PPNOC		
PPNPB		
PPO	AD	porphyria variegata, 176200 (3),
PPOL		
PPOX	AD,AD	?narcolepsy 1, 161400 (3), |porphyria variegata, 176200 (3),
PPP1A		
PPP1beta	AD	noonan syndrome-like disorder with loose anagen hair 2, 617506 (3),
PPP1CA		
PPP1CB	AD	noonan syndrome-like disorder with loose anagen hair 2, 617506 (3),
PPP1CC		
PPP1INL		
PPP1R10		
PPP1R100		
PPP1R101		
PPP1R102	AD	?deafness, 83, 619808 (3), ; periventricular nodular heterotopia 9, 618918 (3),
PPP1R103	AD,AR,MF	supranuclear palsy, progressive, 601104 (3), ; supranuclear palsy, progressive atypical, 260540 (3), ; dementia, frontotemporal, with or without parkinsonism, 600274 (3), ; {parkinson disease, susceptibility to}, 168600 (3), ; pick disease, 172700 (3),
PPP1R104		
PPP1R105		
PPP1R106		
PPP1R107		
PPP1R108		
PPP1R109		
PPP1R11		
PPP1R110	AR,AD	charcot-marie-tooth disease, type 1f, 607734 (3), ; charcot-marie-tooth disease, intermediate g, 617882 (3), ; charcot-marie-tooth disease, type 2e, 607684 (3),
PPP1R111	AR	?retinitis pigmentosa 67, 615565 (3),
PPP1R112		
PPP1R113		
PPP1R114	XL	intellectual developmental disorder, syndromic 34, 300967 (3),
PPP1R115	AR	pseudo-torch syndrome 1, 251290 (3),
PPP1R116		
PPP1R117		
PPP1R118		
PPP1R119		
PPP1R120		
PPP1R121		
PPP1R122	AR	glycogen storage disease vii, 232800 (3),
PPP1R123		
PPP1R124		
PPP1R125		
PPP1R126		
PPP1R127		
PPP1R128		
PPP1R129		
PPP1R12A	AD	genitourinary and/or/brain malformation syndrome, 618820 (3),
PPP1R12B		
PPP1R12C		
PPP1R130	AD	small cell cancer of the lung, somatic, 182280 (3); bladder cancer, somatic, 109800 (3); retinoblastoma, trilateral, 180200 (3), somatic mutation, ; osteosarcoma, somatic, 259500 (3); retinoblastoma, 180200 (3), somatic mutation,
PPP1R131		breast cancer, somatic, 114480 (3)
PPP1R132		
PPP1R133		
PPP1R134	AR	joubert syndrome 7, 611560 (3), ; meckel syndrome 5, 611561 (3), ; ?coach syndrome 3, 619113 (3),
PPP1R135	AD	diamond-blackfan anemia 6, 612561 (3),
PPP1R136		
PPP1R137	AR,AD	congenital myopathy 1b, 255320 (3), ; congenital myopathy 1a, with susceptibility to malignant hyperthermia, 117000 (3), ; king-denborough syndrome, 619542 (3), ; {malignant hyperthermia susceptibility 1}, 145600 (3),
PPP1R138	AR	spastic ataxia, charlevoix-saguenay type, 270550 (3),
PPP1R139		
PPP1R13A		
PPP1R13B		
PPP1R13L		
PPP1R140		
PPP1R141	AR,AD	kilquist syndrome, 619080 (3), ; delpire-mcneill syndrome, 619083 (3), ; deafness, 78, 619081 (3),
PPP1R142	AR	retinitis pigmentosa 68, 615725 (3),
PPP1R143	AR	lichtenstein-knorr syndrome, 616291 (3),
PPP1R144	AD	rhabdoid tumors, somatic, 609322 (3); {schwannomatosis-1, susceptibility to}, 162091 (3), ; coffin-siris syndrome 3, 614608 (3), ; {rhabdoid tumor predisposition syndrome 1}, 609322 (3),
PPP1R145		
PPP1R146		
PPP1R147	AD	legius syndrome, 611431 (3),
PPP1R148		
PPP1R149		
PPP1R14A		
PPP1R14B		
PPP1R14C		
PPP1R14D		
PPP1R150		
PPP1R151		
PPP1R153		
PPP1R155		
PPP1R156		
PPP1R157		
PPP1R158		
PPP1R159		
PPP1R15A		
PPP1R15B	AR	microcephaly, short stature, and impaired glucose metabolism 2, 616817 (3),
PPP1R160	AD	lymphangioleiomyomatosis, somatic, 606690 (3); ?focal cortical dysplasia, type ii, somatic, 607341 (3); tuberous sclerosis-2, 613254 (3),
PPP1R161		
PPP1R163	AR	rickets, vitamin d-resistant, type iia, 277440 (3),
PPP1R164		
PPP1R165	AD	vertebral, cardiac, tracheoesophageal, renal, and limb defects, 619227 (3),
PPP1R166	AR	cerebellar ataxia, impaired intellectual development, and dysquilibrium syndrome 2, 610185 (3), ; hydrocephalus, congenital, 3, with brain anomalies, 617967 (3),
PPP1R167	AR,AD	neuropathy, hereditary sensory and autonomic, type ii, 201300 (3), ; pseudohypoaldosteronism, type iic, 614492 (3),
PPP1R168		[memory, enhanced, qtl], 615602 (3)
PPP1R169		
PPP1R16A		
PPP1R16B		
PPP1R17	AR,AD	{hypercholesterolemia, susceptibility to}, 143890 (3),
PPP1R170	AD	developmental and epileptic encephalopathy 56, 617665 (3),
PPP1R171		
PPP1R172		
PPP1R173		
PPP1R174		
PPP1R18		
PPP1R19		
PPP1R1A		
PPP1R1B		
PPP1R1C		
PPP1R2		
PPP1R20	AR	3-m syndrome 3, 614205 (3),
PPP1R21	AR	neurodevelopmental disorder with hypotonia, facial dysmorphism, and brain abnormalities, 619383 (3),
PPP1R22		
PPP1R23		
PPP1R24		
PPP1R25		
PPP1R26		
PPP1R28		
PPP1R29		
PPP1R2A		
PPP1R2C		
PPP1R2P9		
PPP1R3	AD	insulin resistance, severe, digenic, 125853 (3),
PPP1R30		
PPP1R31	AR	ciliary dyskinesia, primary, 5, 608647 (3),
PPP1R32		
PPP1R33		
PPP1R34		
PPP1R35		
PPP1R36		
PPP1R38		
PPP1R39		
PPP1R3A	AD	insulin resistance, severe, digenic, 125853 (3),
PPP1R3B		
PPP1R3C		
PPP1R3D		
PPP1R3E		
PPP1R3F		
PPP1R3G		
PPP1R4		
PPP1R40		
PPP1R41		
PPP1R42		
PPP1R43		
PPP1R44		
PPP1R45	AD	?long qt syndrome 11, 611820 (3),
PPP1R46	AD	colorectal cancer, somatic, 114500 (3); brain tumor-polyposis syndrome 2, 175100 (3), ; desmoid disease, hereditary, 135290 (3), ; adenoma, periampullary, somatic, 175100 (3); hepatoblastoma, somatic, 114550 (3); gastric cancer, somatic, 613659 (3); gastric adenocarcinoma and proximal polyposis of the stomach, 619182 (3), ; gardner syndrome, 175100 (3), ; adenomatous polyposis coli, 175100 (3),
PPP1R47	AD	{colon cancer, susceptibility to}, 114500 (3), somatic mutation,
PPP1R48		
PPP1R49		hepatocellular carcinoma, somatic, 114550 (3); ?caudal duplication anomaly, 607864 (3)
PPP1R5		
PPP1R50		leukemia/lymphoma, b-cell, 2 (3)
PPP1R51		
PPP1R52		
PPP1R53	AR,MF,AD	fanconi anemia, complementation group s, 617883 (3), ; {breast-ovarian cancer, familial, 1}, 604370 (3), ; {pancreatic cancer, susceptibility to, 4}, 614320 (3)
PPP1R54		
PPP1R55	AR	microcephaly 4, primary, 604321 (3),
PPP1R56		
PPP1R57		
PPP1R58		
PPP1R59		
PPP1R6		
PPP1R60		
PPP1R61	AR	?microcephaly 13, primary, 616051 (3),
PPP1R62		
PPP1R63	AD,AR	hypopigmentation, organomegaly, and delayed myelination and development, 618541 (3), ; osteopetrosis, 4, 611490 (3), ; osteopetrosis, 2, 166600 (3),
PPP1R64		
PPP1R65		
PPP1R66		
PPP1R67		
PPP1R68		
PPP1R69		
PPP1R7		
PPP1R70		
PPP1R71		
PPP1R72		
PPP1R73		
PPP1R74		
PPP1R75		
PPP1R76		
PPP1R77		
PPP1R78		
PPP1R79		
PPP1R8		
PPP1R80		
PPP1R81		
PPP1R82	XL,XLR	intellectual developmental disorder, 90, 300850 (3),
PPP1R83	AD,AR	leukoencephalopathy, developmental delay, and episodic neurologic regression syndrome, 618877 (3), ; dystonia 33, 619687 (3),
PPP1R84		
PPP1R85	AR,AD	spinocerebellar ataxia, 13, 614831 (3), ; spinocerebellar ataxia 44, 617691 (3),
PPP1R86		
PPP1R87	AR	neurodevelopmental disorder with seizures, hypotonia, and brain abnormalities, 618922 (3),
PPP1R88	AR	deafness, 25, 613285 (3),
PPP1R89	XLR,XL	methylmalonic aciduria and homocysteinemia, cblx type, 309541 (3),
PPP1R9		
PPP1R90	XLD,XL	?chondrodysplasia with platyspondyly, distinctive brachydactyly, hydrocephaly, and microphthalmia, 300863 (3),
PPP1R91		
PPP1R92	AD	immunodeficiency, common variable, 13, 616873 (3),
PPP1R93	AR,AD	thrombocytopenia, neonatal alloimmune, bak antigen related (3); glanzmann thrombasthenia 1, 273800 (3), ; bleeding disorder, platelet-type, 16, 187800 (3),
PPP1R94	AR,AD	gillespie syndrome, 206700 (3), ; spinocerebellar ataxia 29, congenital nonprogressive, 117360 (3), ; spinocerebellar ataxia 15, 606658 (3),
PPP1R96		
PPP1R97		
PPP1R98	AR	intellectual developmental disorder, 65, 618109 (3),
PPP1R99		
PPP1R9A		
PPP1R9B		
PPP2B	AD	arthrogryposis, cleft palate, craniosynostosis, and impaired intellectual development, 618265 (3), ; developmental and epileptic encephalopathy 91, 617711 (3),
PPP2CA	AD	neurodevelopmental disorder and language delay with or without structural brain abnormalities, 618354 (3),
PPP2CB		
PPP2CZ		
PPP2R1A	AD	intellectual developmental disorder, 36, 616362 (3),
PPP2R1B		lung cancer, somatic, 211980 (3)
PPP2R2A		
PPP2R2B	AD	spinocerebellar ataxia 12, 604326 (3),
PPP2R2C		
PPP2R2D		
PPP2R3		
PPP2R3A		
PPP2R3B		
PPP2R3C	AD,AR	spermatogenic failure 36, 618420 (3), ; myoectodermal gonadal dysgenesis syndrome, 618419 (3),
PPP2R3L		
PPP2R3LY		
PPP2R4		
PPP2R5A		
PPP2R5B		
PPP2R5C		
PPP2R5D	AD	intellectual developmental disorder, 35, 616355 (3),
PPP2R5E		
PPP2R6A		
PPP2R6B		
PPP2R6C		
PPP3CA	AD	arthrogryposis, cleft palate, craniosynostosis, and impaired intellectual development, 618265 (3), ; developmental and epileptic encephalopathy 91, 617711 (3),
PPP3CB		
PPP3CC		
PPP3IN		
PPP3R1		
PPP3R2		
PPP3RL		
PPP4C		
PPP4R1		
PPP4R2		
PPP4R3A		
PPP4R3B		
PPP4R4		
PPP5		
PPP5C		
PPP6C		
PPP6R1		
PPP6R2		
PPP6R3		
PPP7CA		
PPP7CB		
PPPDE1		
PPPDE2		
PPR1		
PPR3		
PPRC1		
PPRibP	XLR,XL	arts syndrome, 301835 (3), ; phosphoribosylpyrophosphate synthetase superactivity, 300661 (3), ; charcot-marie-tooth disease, 5, 311070 (3), ; deafness, 1, 304500 (3), ; gout, prps-related, 300661 (3),
PPT	AR	ceroid lipofuscinosis, neuronal, 1, 256730 (3),
PPT-C		
PPT1	AR	ceroid lipofuscinosis, neuronal, 1, 256730 (3),
PPT2		
pPTB		
Pptc		
PPTC7		
PPWD1		
PPX		
PPY		
PPY2		
PPY2P		
PPYR1		
PQBP1	XLR,XL	renpenning syndrome, 309500 (3),
PQBP2	AR	spastic paraplegia 53, 614898 (3),
PQBP3		
PQBP5		
PQLC2		
PQLC4	AR	cystinosis, nephropathic, 219800 (3), ; cystinosis, ocular nonnephropathic, 219750 (3), ; cystinosis, late-onset juvenile or adolescent nephropathic, 219900 (3), ; cystinosis, atypical nephropathic, 219800 (3),
PQLC5	AR	congenital disorder of glycosylation, type if, 609180 (3),
pqn-47	AD	encephalitis/encephalopathy, mild, with reversible myelin vacuolization, 618113 (3), ; cardiac-urogenital syndrome, 618280 (3),
pqn-68		
Pr		
PR	AR	?progesterone resistance, 264080 (2),
PR-3		
PR-Set7		
PR01238	AR	anemia, sideroblastic, 3, pyridoxine-refractory, 616860 (3), ; spasticity, childhood-onset, with hyperglycinemia, 616859 (3),
PR1		
PR130		
PR22		
PR264		
PR46b	AR	ciliary dyskinesia, primary, 17, 614679 (3),
PR47		
PR48		
PR4H		
PR52		
PR52A		
PR52B	AD	spinocerebellar ataxia 12, 604326 (3),
PR53		
PR55-BETA	AD	spinocerebellar ataxia 12, 604326 (3),
PR55A		
PR55alpha		
PR55G		
PR61A		
PR61B		
PR61G		
PR65A	AD	intellectual developmental disorder, 36, 616362 (3),
PR65B		lung cancer, somatic, 211980 (3)
PR70		
PR72		
PRA		
PRA1		
PRAC		
PRAC1		
PRAC2		
PRAD1	AD	{von hippel-lindau syndrome, modifier of}, 193300 (3), ; {colorectal cancer, susceptibility to}, 114500 (3), somatic mutation, ; {multiple myeloma, susceptibility to}, 254500 (3), somatic mutation
PRADC1		
PRAF1		
PRAF2		
PRAF3		
PRAG1		
PRAGMIN		
PRAJA1		
PRAJA2		
PRAK	AR	neurocardiofaciodigital syndrome, 619869 (3),
PRAM1		
PRAME		
PRANCR		
PRAP		
PRAP1		
PRAS40		
PRAT		
PRAT4B		
PRAX-1		
PRB1		
PRB1L		
PRB1M		
PRB2		
PRB3		
PRB4		
PRC		
PRC1		
PRC17		
PRCA1	AD	prostate cancer 1, 601518 (3),
PRCAN	AR	dyssegmental dysplasia, silverman-handmaker type, 224410 (3), ; schwartz-jampel syndrome, type 1, 255800 (3),
PRCAT47		
PRCC		renal cell carcinoma, papillary, 605074 (3)
PRCD		retinitis pigmentosa 36, 610599 (3)
PRCP		
PRD51		
Prdc	AD	tooth agenesis, selective, 9, 617275 (3),
PRdelta		
PRDI-BF1		
PRDII-BF1		
PRDM1		
PRDM10		
PRDM11		
PRDM12	AR	neuropathy, hereditary sensory and autonomic, type viii, 616488 (3),
PRDM13	AR	pontocerebellar hypoplasia, type 17, 619909 (3), ; cerebellar dysfunction, impaired intellectual development, and hypogonadotropic hypogonadism, 619761 (3),
PRDM14		
PRDM15		
PRDM16	AD	left ventricular noncompaction 8, 615373 (3), ; cardiomyopathy, dilated, 1ll, 615373 (3),
PRDM2		
PRDM3	AD	myelodysplasia syndrome-1 (3)|myelodysplasia syndrome-1 (3)|radioulnar synostosis with amegakaryocytic thrombocytopenia 2, 616738 (3),
PRDM4		
PRDM5	AR	brittle cornea syndrome 2, 614170 (3),
PRDM6	AD	patent ductus arteriosus 3, 617039 (3),
PRDM7		
PRDM8	AR	?epilepsy, progressive myoclonic, 10, 616640 (3),
PRDM9		
PRDX1	AR	methylmalonic aciduria and homocystinuria, cblc type, digenic, 277400 (3),
PRDX2		
PRDX3	AR,AD	spinocerebellar ataxia, 32, 619862 (3), ; corneal dystrophy, punctiform and polychromatic pre-descemet, 619871 (3),
PRDX4		
PRDX5		
PRDX6		
pre-miR-886		
PREB		
PRED12		
PRED22		
PRED28		
PRED31		
PRED44		
PRED5		
PRED6		
PRED66		
PRED71		
PRED74		
PRED77		
PRED78		
PRED79	AR	neuropathy, hereditary motor and sensory, type vic, with optic atrophy, 618511 (3),
Pref-1		
PREI3		
PRELI		
PRELID1		
PRELID3A		
PRELID4A		
PRELID4B		
PRELP		
PreP	AR	spinocerebellar ataxia, 30, 619405 (3),
PREP		
PREP1		
PREPL	AR	myasthenic syndrome, congenital, 22, 616224 (3),
prepro-26RFa		
PRES	AR	?deafness, 61, 613865 (3),
PREX1		
PREX2		
PreY		
PRF-1		
PRF1	AR	hemophagocytic lymphohistiocytosis, familial, 2, 603553 (3), ; aplastic anemia, 609135 (3); lymphoma, non-hodgkin, 605027 (3)
PRG		
PRG-1		
PRG-2		
PRG-3		
PRG-4		
PRG1		
PRG2	AR	anterior segment dysgenesis 7, with sclerocornea, 269400 (3),
PRG3		
PRG4	AR	camptodactyly-arthropathy-coxa vara-pericarditis syndrome, 208250 (3),
PRG5		
PRG6		
PRGP1		
PRGP2		
PRGS		
PRH		
PRH1		
PRH2		
PRHOXNB		
PRHX		
PRIC285		
PRICKLE1	AR	epilepsy, progressive myoclonic 1b, 612437 (3),
PRICKLE2		
PRICKLE3	XLD,XL	{leber hereditary optic neuropathy, modifier of}, 308905 (3),
PRICKLE4		
prIL-16		
PRIM1	AR	primordial dwarfism-immunodeficiency-lipodystrophy syndrome, 620005 (3),
PRIM2		
PRIM2A		
PRIMA		
PRIMA1		
PRIMPOL	AD	myopia 22, 615420 (3),
PRIP	AD	spongiform encephalopathy with neuropsychiatric features, 606688 (3), ; gerstmann-straussler disease, 137440 (3), ; huntington disease-like 1, 603218 (3), ; insomnia, fatal familial, 600072 (3), ; {kuru, susceptibility to}, 245300 (3); cerebral amyloid angiopathy, prnp-related, 137440 (3), ; creutzfeldt-jakob disease, 123400 (3),
PRISM	AD	patent ductus arteriosus 3, 617039 (3),
PRK		
PRK1		
PRK2		
PRKA1		
PRKA10		
PRKA11		
PRKA6		
PRKA9	AD	?long qt syndrome 11, 611820 (3),
PRKAA		
PRKAA1		
PRKAA2		
PRKAB1		
PRKAB2		
PRKACA	AD	cushing syndrome, acth-independent adrenal, somatic, 615830 (3); cardioacrofacial dysplasia 1, 619142 (3),
PRKACB	AD	cardioacrofacial dysplasia 2, 619143 (3), somatic mosaicism,
PRKACG	AR	?bleeding disorder, platelet-type, 19, 616176 (3),
PRKACN1		
PRKACN2		
PRKAG1		
PRKAG2	AD	glycogen storage disease of heart, lethal congenital, 261740 (3), ; wolff-parkinson-white syndrome, 194200 (3), ; cardiomyopathy, hypertrophic 6, 600858 (3),
PRKAG3	AR	[skeletal muscle glycogen content and metabolism qtl], 619030 (3),
PRKAR1	AD	pigmented nodular adrenocortical disease, primary, 1, 610489 (3), ; acrodysostosis 1, with or without hormone resistance, 101800 (3), ; adrenocortical tumor, somatic (3); carney complex, type 1, 160980 (3), ; myxoma, intracardiac, 255960 (3),
PRKAR1A	AD	pigmented nodular adrenocortical disease, primary, 1, 610489 (3), ; acrodysostosis 1, with or without hormone resistance, 101800 (3), ; adrenocortical tumor, somatic (3); carney complex, type 1, 160980 (3), ; myxoma, intracardiac, 255960 (3),
PRKAR1B	AD	marbach-schaaf neurodevelopmental syndrome, 619680 (3),
PRKAR2		
PRKAR2A		
PRKAR2B		
PRKBA		breast cancer, somatic, 114480 (3); cowden syndrome 6, 615109 (3); colorectal cancer, somatic, 114500 (3); proteus syndrome, somatic, 176920 (3); ovarian cancer, somatic, 167000 (3)
PRKBG	AD	megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 2, 615937 (3),
PRKCA		pituitary tumor, invasive (3)
PRKCABP		
PRKCB		
PRKCB1		
PRKCB2		
PRKCBP1		
PRKCBP2		
PRKCD	AR	autoimmune lymphoproliferative syndrome, type iii, 615559 (3),
PRKCDBP		
PRKCE		
PRKCG	AD	spinocerebellar ataxia 14, 605361 (3),
PRKCH	MF	{cerebral infarction, susceptibility to}, 601367 (3),
PRKCI		
PRKCL	MF	{cerebral infarction, susceptibility to}, 601367 (3),
PRKCL1		
PRKCL2		
PRKCM	AD	congenital heart defects and ectodermal dysplasia, 617364 (3),
PRKCN		
PRKCNH1	AR	neuromyotonia and axonal neuropathy, 137200 (3),
PRKCQ		
PRKCSH	AD	polycystic liver disease 1, 174050 (3),
PRKCZ		
PRKD1	AD	congenital heart defects and ectodermal dysplasia, 617364 (3),
PRKD2		
PRKD3		
PRKDC	AR	immunodeficiency 26, with or without neurologic abnormalities, 615966 (3),
PRKE1		
PRKG1	AD	aortic aneurysm, familial thoracic 8, 615436 (3),
PRKG1B	AD	aortic aneurysm, familial thoracic 8, 615436 (3),
PRKG2	AR	spondylometaphyseal dysplasia, pagnamenta type, 619638 (3), ; acromesomelic dysplasia 4, 619636 (3),
PRKGR1B	AD	aortic aneurysm, familial thoracic 8, 615436 (3),
PRKGR2	AR	spondylometaphyseal dysplasia, pagnamenta type, 619638 (3), ; acromesomelic dysplasia 4, 619636 (3),
PRKM1	AD	noonan syndrome 13, 619087 (3),
PRKM10		
PRKM11		
PRKM12		
PRKM13		
PRKM14		
PRKM15		
PRKM2	AD	noonan syndrome 13, 619087 (3),
PRKM3		
PRKM4		
PRKM6		
PRKM7		
PRKM8		
PRKM8IP	AD	{diabetes mellitus, noninsulin-dependent}, 125853 (3),
PRKM8IPL		
PRKM9		
PRKMK1	AD	cardiofaciocutaneous syndrome 3, 615279 (3), ; melorheostosis, isolated, somatic mosaic, 155950 (3)
PRKMK2	AD	cardiofaciocutaneous syndrome 4, 615280 (3),
PRKMK3		
PRKMK4		
PRKMK5		
PRKMK6		
PRKMK7		
PRKN	AR	adenocarcinoma of lung, somatic, 211980 (3); parkinson disease, juvenile, type 2, 600116 (3), ; ovarian cancer, somatic, 167000 (3)
PRKR	AD,AR	leukoencephalopathy, developmental delay, and episodic neurologic regression syndrome, 618877 (3), ; dystonia 33, 619687 (3),
PRKRA	AR	dystonia 16, 612067 (3),
PRKRI	AR	ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus, 616192 (3),
PRKRIP1		
PRKRIR		
PRKWNK1	AR,AD	neuropathy, hereditary sensory and autonomic, type ii, 201300 (3), ; pseudohypoaldosteronism, type iic, 614492 (3),
PRKWNK2		
PRKWNK3		
PRKWNK4	AD	pseudohypoaldosteronism, type iib, 614491 (3),
PRKX		
PRKXP3		
PRKY		
PRKYP		
PRL		
PRL-1		
PRL-2		
PRL-3		
PRL-R		
PRL1		
PRL2		
PRL3		
PRL5		
PRLH		
PRLHR		
PRLP0		
PRLR	AD,AR	multiple fibroadenomas of the breast, 615554 (3), ; hyperprolactinemia, 615555 (3),
PRLTS		hepatocellular cancer, somatic, 114550 (3); colorectal cancer, somatic, 114500 (3)
PRM1		
PRM2		
PrmC		
PRMT1		
PRMT10		
PRMT2		
PRMT3		
PRMT4		
PRMT5		
PRMT6		
PRMT7	AR	short stature, brachydactyly, intellectual developmental disability, and seizures, 617157 (3),
PRMT8		
PRMT9		
PRN		
PRNCR1		
PRND		
PRNP	AD	spongiform encephalopathy with neuropsychiatric features, 606688 (3), ; gerstmann-straussler disease, 137440 (3), ; huntington disease-like 1, 603218 (3), ; insomnia, fatal familial, 600072 (3), ; {kuru, susceptibility to}, 245300 (3); cerebral amyloid angiopathy, prnp-related, 137440 (3), ; creutzfeldt-jakob disease, 123400 (3),
PRNPIP		
PRO0082		
PRO0213		
PRO0310p1		
PRO0899		
PRO0971		
PRO0989		
PRO0992	AR	leukodystrophy, hypomyelinating, 17, 618006 (3),
PRO1	AR,AR,AD	mandibuloacral dysplasia with type b lipodystrophy, 608612 (3), ; restrictive dermopathy 1, 275210 (3), |mandibuloacral dysplasia, 248370 (3), ; heart-hand syndrome, slovenian type, 610140 (3), ; cardiomyopathy, dilated, 1a, 115200 (3), ; emery-dreifuss muscular dystrophy 3, 616516 (3), ; restrictive dermopathy 2, 619793 (3); charcot-marie-tooth disease, type 2b1, 605588 (3), ; emery-dreifuss muscular dystrophy 2, 181350 (3), ; hutchinson-gilford progeria, 176670 (3), ; lipodystrophy, familial partial, type 2, 151660 (3), ; muscular dystrophy, congenital, 613205 (3), ; malouf syndrome, 212112 (3),
PRO1048		
PRO1068		
PRO1073		
PRO1194		
PRO1280	AD,AR	{meningioma, familial, susceptibility to}, 607174 (3), ; joubert syndrome 32, 617757 (3), ; basal cell nevus syndrome 2, 620343 (3); {medulloblastoma}, 155255 (3), somatic mutation,
PRO1385		
PRO1474		
PRO1485		
PRO1488		
PRO1557	AR	atransferrinemia, 209300 (3),
PRO1598	AD,AR	{epilepsy, familial temporal lobe, 7}, 616436 (3), ; lissencephaly 2 (norman-roberts type), 257320 (3),
PRO1659		
PRO1741	AD	desanto-shinawi syndrome, 616708 (3),
PRO1777		
PRO180	AR	cone-rod dystrophy 21, 616502 (3),
PRO1853		
PRO1855		
PRO1873		
PRO1886	AR	joubert syndrome 20, 614970 (3), ; meckel syndrome 11, 615397 (3),
PRO19563	AR	heterotaxy, visceral, 8, 617205 (3),
PRO1957	AD	?atrial fibrillation, familial, 18, 617280 (3),
PRO19651		
PRO1992	AR	pontocerebellar hypoplasia, type 6, 611523 (3),
PRO1996		
PRO1999		
PRO2000		
PRO2015		
PRO2047		
PRO2086	AR	atransferrinemia, 209300 (3),
PRO2194		
PRO2207		
PRO2249	AR	immunodeficiency 80 with or without cardiomyopathy, 619313 (3),
PRO2389		
PRO2435		
PRO2451	AR	specific granule deficiency 2, 617475 (3),
PRO2507	AD	polycystic liver disease 2, 617004 (3),
PRO2521		
PRO2577		
PRO2729		
PRO2730		
PRO28631		
PRO3094		
PRO34005	AD	aortic aneurysm, familial thoracic 12, 619825 (3),
PRO34047		
PRO3567		
PRO4979		
PRO813		
PRO940		
PRO9904		
PROC	AD,AR	thrombophilia 3 due to protein c deficiency, 176860 (3), ; thrombophilia 3 due to protein c deficiency, 612304 (3),
PROCA1		
PROCI		
PROCR		
PRODH	AD,AR	{schizophrenia, susceptibility to, 4}, 600850 (3), ; hyperprolinemia, type i, 239500 (3),
PRODH1	AD,AR	{schizophrenia, susceptibility to, 4}, 600850 (3), ; hyperprolinemia, type i, 239500 (3),
PRODH2	AD,AR	{schizophrenia, susceptibility to, 4}, 600850 (3), ; hyperprolinemia, type i, 239500 (3),
PROHB	AD	cole-carpenter syndrome 1, 112240 (3),
PROK1		
PROK2	AD	hypogonadotropic hypogonadism 4 with or without anosmia, 610628 (3),
PROKR1		
PROKR2	AD	hypogonadotropic hypogonadism 3 with or without anosmia, 244200 (3),
PROL1		
PROL2		
PROL3		
PROL4		
PROL5		
prolargin		
PROM1	AD,AR	macular dystrophy, retinal, 2, 608051 (3), ; retinitis pigmentosa 41, 612095 (3), ; stargardt disease 4, 603786 (3), ; cone-rod dystrophy 12, 612657 (3),
PROM2		
proMBP		
promethin		
PROML1	AD,AR	macular dystrophy, retinal, 2, 608051 (3), ; retinitis pigmentosa 41, 612095 (3), ; stargardt disease 4, 603786 (3), ; cone-rod dystrophy 12, 612657 (3),
PROP1	AR	pituitary hormone deficiency, combined, 2, 262600 (3),
PRORP	AR	combined oxidative phosphorylation deficiency 54, 619737 (3),
PROS	AR,AD	thrombophilia 5 due to protein s deficiency, 614514 (3), ; thrombophilia 5 due to protein s deficiency, 612336 (3),
PROS1	AR,AD	thrombophilia 5 due to protein s deficiency, 614514 (3), ; thrombophilia 5 due to protein s deficiency, 612336 (3),
PROS26	AR	?proteasome-associated autoinflammatory syndrome 3 and digenic forms, 617591 (3),
PROS27		{myocardial infarction, susceptibility to}, 608446 (3)
PROS30		
proSAAS		
ProSAP1		{autism susceptibility 17}, 613436 (3)
prosap2	AD	phelan-mcdermid syndrome, 606232 (3), ; {schizophrenia 15}, 613950 (3),
ProSAPiP1		
ProSAPiP2		
PROSC	AR	epilepsy, early-onset, vitamin b6-dependent, 617290 (3),
prostein		
prostinogen		
PROT		
PROTO-LB		
Protor-1.		
PROTOR-2		
PROTOR1		
proX	AR	lacticacidemia due to pdx1 deficiency, 245349 (3),
PROX1		
PROX1UT		
PROX2		
PROZ		[protein z deficiency], 614024 (3)
PRP	AD	spongiform encephalopathy with neuropsychiatric features, 606688 (3), ; gerstmann-straussler disease, 137440 (3), ; huntington disease-like 1, 603218 (3), ; insomnia, fatal familial, 600072 (3), ; {kuru, susceptibility to}, 245300 (3); cerebral amyloid angiopathy, prnp-related, 137440 (3), ; creutzfeldt-jakob disease, 123400 (3),
PRP-B		
Prp10		myelodysplastic syndrome, somatic, 614286 (3)
Prp11		
Prp16	AR	retinitis pigmentosa 84, 618220 (3),
PRP17	AR	?pontocerebellar hypoplasia, type 15, 619302 (3),
PRP19		
Prp2	AD	neuromuscular disease and ocular or auditory anomalies with or without seizures, 618733 (3),
Prp21		
Prp22		
Prp28		
Prp3	AD	retinitis pigmentosa 18, 601414 (3),
PRP31	AD	retinitis pigmentosa 11, 600138 (3),
Prp38		
Prp4		
PRP4	AD	retinitis pigmentosa 70, 615922 (3),
Prp40		
Prp43		
Prp45		
Prp46		
Prp4B		
PRP4K		
Prp4p	AD	retinitis pigmentosa 70, 615922 (3),
Prp5		
Prp6	AD	retinitis pigmentosa 60, 613983 (3),
Prp8	AD	retinitis pigmentosa 13, 600059 (3),
PRP8BP		
PRP9		
PRPC8	AD	retinitis pigmentosa 13, 600059 (3),
PRPF10		myelodysplastic syndrome, somatic, 614286 (3)
PRPF11		
PRPF16	AR	retinitis pigmentosa 84, 618220 (3),
PRPF17	AR	?pontocerebellar hypoplasia, type 15, 619302 (3),
PRPF18		
PRPF19		
PRPF2	AD	neuromuscular disease and ocular or auditory anomalies with or without seizures, 618733 (3),
PRPF21		
PRPF22		
PRPF28		
PRPF3	AD	retinitis pigmentosa 18, 601414 (3),
PRPF31	AD	retinitis pigmentosa 11, 600138 (3),
PRPF38A		
PRPF39		
PRPF4	AD	retinitis pigmentosa 70, 615922 (3),
PRPF40A		
PRPF43		
PRPF45		
PRPF46		
PRPF4B		
PRPF5		
PRPF6	AD	retinitis pigmentosa 60, 613983 (3),
PRPF8	AD	retinitis pigmentosa 13, 600059 (3),
PRPF8BP		
PRPF9		
PRPH	AR,AD	{amyotrophic lateral sclerosis, susceptibility to}, 105400 (3),
PRPH1	AR,AD	{amyotrophic lateral sclerosis, susceptibility to}, 105400 (3),
PRPH2	AD,AR	macular dystrophy, patterned, 1, 169150 (3), ; choroidal dystrophy, central areolar 2, 613105 (3), ; retinitis punctata albescens, 136880 (3), ; leber congenital amaurosis 18, 608133 (3), digenic , ; macular dystrophy, vitelliform, 3, 608161 (3), ; retinitis pigmentosa 7 and digenic form, 608133 (3), digenic ,
prpk	AR	galloway-mowat syndrome 4, 617730 (3),
PRPL36		
PrPLP		
PrPp43p		
PRPPRB1		
PRPS		{prostate cancer, hereditary, 13}, 611928 (3)
PRPS1	XLR,XL	arts syndrome, 301835 (3), ; phosphoribosylpyrophosphate synthetase superactivity, 300661 (3), ; charcot-marie-tooth disease, 5, 311070 (3), ; deafness, 1, 304500 (3), ; gout, prps-related, 300661 (3),
PRPS1L1		
PRPS2		
PRPS3		
PRPSAP1		
PRPSAP2		
PRPSL		
PRR	AR,XL,XLR	cleft lip/palate-ectodermal dysplasia syndrome, 225060 (3), ; orofacial cleft 7, 225060 (3), |intellectual developmental disorder, syndromic, hedera type, 300423 (3), ; ?parkinsonism with spasticity, 300911 (3), ; congenital disorder of glycosylation, type iir, 301045 (3),
PRR1	AR	cleft lip/palate-ectodermal dysplasia syndrome, 225060 (3), ; orofacial cleft 7, 225060 (3),
PRR11		
PRR12	AD	neuroocular syndrome, 619539 (3),
PRR13		
PRR14		
PRR15		
PRR16		
PRR2		
PRR28		
PRR4	AR	ectodermal dysplasia-syndactyly syndrome 1, 613573 (3),
PRR5		
PRR5L		
PRR6		
PRR7		
PRRC2A		
PRRC2B		
PRRC2C		
PRRDH		
PRRG1		
PRRG2		
PRRG3		
PRRG4		
PrRPR		
PRRT1		
PRRT2	AD	convulsions, familial infantile, with paroxysmal choreoathetosis, 602066 (3), ; seizures, benign familial infantile, 2, 605751 (3), ; episodic kinesigenic dyskinesia 1, 128200 (3),
PRRT3		
PRRT3-AS1		
PRRX1	AR,AD	agnathia-otocephaly complex, 202650 (3),
PRRX2		
PRRXL1		
PRS-I	XLR,XL	arts syndrome, 301835 (3), ; phosphoribosylpyrophosphate synthetase superactivity, 300661 (3), ; charcot-marie-tooth disease, 5, 311070 (3), ; deafness, 1, 304500 (3), ; gout, prps-related, 300661 (3),
PRSC		preeclampsia/eclampsia 5, 614595 (3)
PRSC1		
PRSC2		
PRSM1	AR	pontocerebellar hypoplasia, type 8, 614961 (3),
PRSMG1	AR	galloway-mowat syndrome 3, 617729 (3),
Prsp		
PRSS		
PRSS1	AD	pancreatitis, hereditary, 167800 (3),
PRSS10		
PRSS11	AR,AD	{macular degeneration, age-related, neovascular type}, 610149 (3); {macular degeneration, age-related, 7}, 610149 (3); carasil syndrome, 600142 (3), ; cerebral arteriopathy, with subcortical infarcts and leukoencephalopathy, type 2, 616779 (3),
PRSS12	AR	intellectual developmental disorder, 1, 249500 (3),
PRSS14	AR	ichthyosis, congenital, 11, 602400 (3),
PRSS15	AR	codas syndrome, 600373 (3),
PRSS16		
PRSS17	AR	amelogenesis imperfecta, type iia1, 204700 (3),
PRSS18		
PRSS19		
PRSS2	AD	{pancreatitis, chronic, protection against}, 167800 (3),
PRSS20		
PRSS21		
PRSS22		
PRSS23		
PRSS24		
PRSS25	AR	{parkinson disease 13}, 610297 (3); 3-methylglutaconic aciduria, type viii, 617248 (3),
PRSS26		
PRSS27		
PRSS3		
PRSS31		
PRSS33		
PRSS36		
PRSS4		
PRSS5	AR	3mc syndrome 1, 257920 (3),
PRSS50		
PRSS53		
PRSS55		
PRSS56	AR	microphthalmia, isolated 6, 613517 (3),
PRSS6		
PRSS7	AR	enterokinase deficiency, 226200 (3),
PRSS8		
PRSS9		
PRSSL1		
PRT1		
PRTD-NY2		
PRTD-NY3		
PRTFDC1		
PRTG		
PRTH	AR,AD	thyroid hormone resistance, 274300 (3), ; thyroid hormone resistance, 188570 (3), ; thyroid hormone resistance, selective pituitary, 145650 (3),
PRTN3		
PRTS	XL,XLR	proud syndrome, 300004 (3), ; hydranencephaly with abnormal genitalia, 300215 (3), ; partington syndrome, 309510 (3), ; developmental and epileptic encephalopathy 1, 308350 (3), ; lissencephaly, 2, 300215 (3), ; intellectual developmental disorder, 29, 300419 (3),
PRUNE	AR	neurodevelopmental disorder with microcephaly, hypotonia, and variable brain anomalies, 617481 (3),
PRUNE1	AR	neurodevelopmental disorder with microcephaly, hypotonia, and variable brain anomalies, 617481 (3),
PRUNE2		
PRUNE2-AS1		
PRV1		
PRVTIRB	AR,AD	{encephalopathy, acute, infection-induced (herpes-specific), susceptibility to, 6}, 614850 (3),
PRX	AR,AD	charcot-marie-tooth disease, type 4f, 614895 (3), ; dejerine-sottas disease, 145900 (3),
PRX2		
PRXII		
PRXL2A		
PRXV		
PRY		
PRY1		
PRY2		
Ps		
PS-1	AD	pick disease, 172700 (3), ; alzheimer disease, type 3, with spastic paraparesis and apraxia, 607822 (3), ; dementia, frontotemporal, 600274 (3), ; ?acne inversa, familial, 3, 613737 (3), ; cardiomyopathy, dilated, 1u, 613694 (3), ; alzheimer disease, type 3, with spastic paraparesis and unusual plaques, 607822 (3), ; alzheimer disease, type 3, 607822 (3),
PS-2	AD	alzheimer disease-4, 606889 (3), ; cardiomyopathy, dilated, 1v, 613697 (3),
PS-p68		
ps-PLA1		
PS1	AD	pick disease, 172700 (3), ; alzheimer disease, type 3, with spastic paraparesis and apraxia, 607822 (3), ; dementia, frontotemporal, 600274 (3), ; ?acne inversa, familial, 3, 613737 (3), ; cardiomyopathy, dilated, 1u, 613694 (3), ; alzheimer disease, type 3, with spastic paraparesis and unusual plaques, 607822 (3), ; alzheimer disease, type 3, 607822 (3),
PS1D		
pS2		
PS2	AD	alzheimer disease-4, 606889 (3), ; cardiomyopathy, dilated, 1v, 613697 (3),
PS20		
PS6K		
PSA	AR	neu-laxova syndrome 2, 616038 (3), ; ?phosphoserine aminotransferase deficiency, 610992 (3),
PSACH	AD	pseudoachondroplasia, 177170 (3), ; carpal tunnel syndrome 2, 619161 (3), ; epiphyseal dysplasia, multiple, 1, 132400 (3),
PSAP	AR,AD	combined sap deficiency, 611721 (3), ; krabbe disease, atypical, 611722 (3), ; metachromatic leukodystrophy due to sap-b deficiency, 249900 (3), ; gaucher disease, atypical, 610539 (3); {parkinson disease 24, susceptibility to}, 619491 (3),
PSAP2	AD	phelan-mcdermid syndrome, 606232 (3), ; {schizophrenia 15}, 613950 (3),
PSARL		
PSARL1		
PSAT	AR	neu-laxova syndrome 2, 616038 (3), ; ?phosphoserine aminotransferase deficiency, 610992 (3),
PSAT1	AR	neu-laxova syndrome 2, 616038 (3), ; ?phosphoserine aminotransferase deficiency, 610992 (3),
PSBG1		
PSBG2		
PSBP1		
Psc1		
PSCA		
PSCD1		
PSCD2		
PSCD2L		
PSCD3		
PSCD4		
PSCDBP		
PSCTK1	XL,XLR	agammaglobulinemia, 1, 300755 (3), ; isolated growth hormone deficiency, type iii, with agammaglobulinemia, 307200 (3),
PSCTK2	AR	lymphoproliferative syndrome 1, 613011 (3),
PSCTK3		
PSCTK4		
PSCTK5		
PSD		
PSD-93		
PSD-95	AD	intellectual developmental disorder, 62, 618793 (3),
PSD1		
PSD3		
PSD4		
PSD93		
PSD95	AD	intellectual developmental disorder, 62, 618793 (3),
PSDC	AR	liberfarb syndrome, 618889 (3),
PSE1		
PSEL		
PSEN1	AD	pick disease, 172700 (3), ; alzheimer disease, type 3, with spastic paraparesis and apraxia, 607822 (3), ; dementia, frontotemporal, 600274 (3), ; ?acne inversa, familial, 3, 613737 (3), ; cardiomyopathy, dilated, 1u, 613694 (3), ; alzheimer disease, type 3, with spastic paraparesis and unusual plaques, 607822 (3), ; alzheimer disease, type 3, 607822 (3),
PSEN2	AD	alzheimer disease-4, 606889 (3), ; cardiomyopathy, dilated, 1v, 613697 (3),
PSENEN	AD	acne inversa, familial, 2, with or without dowling-degos disease, 613736 (3),
PSENL3		
pseudo-ICE		
PSEUDO-ICE		
PSF	AR	retinal arterial macroaneurysm with supravalvular pulmonic stenosis, 614224 (3),
PSF1	AR,AR	bare lymphocyte syndrome, type i, 604571 (3), |immunodeficiency 55, 617827 (3),
PSF2	AR	bare lymphocyte syndrome, type i, due to tap2 deficiency, 604571 (3),
PSF3		
PSFL		
PSG		
PSG1		
PSG10		
PSG10P		
PSG11		
PSG12		
PSG13		
PSG14		
PSG2		
PSG3		
PSG4		
PSG5		
PSG6		
PSG7		
PSG8		
PSG9		
PSGGA		
PSGGB		
PSGII		
PSGL-1		
PSGR		
psiMCT-1		
PSIP1		
PSIP2		
psiPTEN		
psiSSX2		
PSK		
PSK-1		
PSK-J3	AD	{melanoma, cutaneous malignant, 3}, 609048 (3),
PSK1		
PSK1-BETA		
PSK2	AD	developmental delay with or without intellectual impairment or behavioral abnormalities, 619575 (3),
PSKH1		
PSKH2		
PSL1		
PSL2	AR	immunodeficiency 86, mycobacteriosis, 619549 (3),
PSL3		
PSL4		
PSM		
PSMA		
PSMA1		
PSMA2		
PSMA3		
PSMA4		
PSMA5		
PSMA6		{myocardial infarction, susceptibility to}, 608446 (3)
PSMA7		
PSMA7L		
PSMA8		
PSMAL		
PSMB1	AR	?neurodevelopmental disorder with microcephaly, hypotonia, and absent language, 620038 (3),
PSMB10	AR	proteasome-associated autoinflammatory syndrome 5, 619175 (3),
PSMB11		
PSMB2		
PSMB3		
PSMB4	AR	?proteasome-associated autoinflammatory syndrome 3 and digenic forms, 617591 (3),
PSMB5		
PSMB5i	AR	proteasome-associated autoinflammatory syndrome 1 and digenic forms, 256040 (3),
PSMB6		
PSMB6i	AR	?proteasome-associated autoinflammatory syndrome 3, digenic, 617591 (3),
PSMB7		
PSMB8	AR	proteasome-associated autoinflammatory syndrome 1 and digenic forms, 256040 (3),
PSMB9	AR	?proteasome-associated autoinflammatory syndrome 3, digenic, 617591 (3),
PSMC1	AR	?birk-aharoni syndrome, 620071 (3),
PSMC2		
PSMC3	AR	?deafness, cataract, impaired intellectual development, and polyneuropathy, 619354 (3),
PSMC3IP	AR	ovarian dysgenesis 3, 614324 (3),
PSMC4		
PSMC5		
PSMC6		
PSMD1		
PSMD10		
PSMD11		
PSMD12	AD	stankiewicz-isidor syndrome, 617516 (3),
PSMD13		
PSMD14		
PSMD15		
PSMD16		
PSMD2		
PSMD3		
PSMD4		
PSMD5		
PSMD6		
PSMD7		
PSMD8		
PSMD8BP1		
PSMD9		
PSME1		
PSME2		
PSME3		
PSME3IP1		
PSME4		
PSMF1		
PSMG1		
PSMG2	AR	?proteasome-associated autoinflammatory syndrome 4, 619183 (3),
PSMG3		
PSMG4		
PSMP		
PSN1	AR	anemia, hemolytic, due to umph1 deficiency, 266120 (3),
PSNL1	AD	pick disease, 172700 (3), ; alzheimer disease, type 3, with spastic paraparesis and apraxia, 607822 (3), ; dementia, frontotemporal, 600274 (3), ; ?acne inversa, familial, 3, 613737 (3), ; cardiomyopathy, dilated, 1u, 613694 (3), ; alzheimer disease, type 3, with spastic paraparesis and unusual plaques, 607822 (3), ; alzheimer disease, type 3, 607822 (3),
PSO2		
PSO4		
PSOR1		
PSORAS1	AD,MF	blau syndrome, 186580 (3), ; {yao syndrome}, 617321 (3), ; {inflammatory bowel disease 1, crohn disease}, 266600 (3),
PSORS1	MF	{psoriasis susceptibility 1}, 177900 (3), ; {hiv-1 viremia, susceptibility to}, 609423 (3)
PSORS12		
PSORS1C1		
PSORS1C2		
PSORS1C3		
PSORS2	AD	psoriasis 2, 602723 (3), ; pityriasis rubra pilaris, 173200 (3),
PSP	AR	{prostate cancer, hereditary, 13}, 611928 (3)|phosphoserine phosphatase deficiency, 614023 (3),
PSP-94		{prostate cancer, hereditary, 13}, 611928 (3)
PSP-C	AD	surfactant metabolism dysfunction, pulmonary, 2, 610913 (3),
PSP1		
PSP24		
PSP24(beta)		
PSP24A		
PSP24B		
PSP57		{prostate cancer, hereditary, 13}, 611928 (3)
PSP94		{prostate cancer, hereditary, 13}, 611928 (3)
PSPC1		
PSPH	AR	phosphoserine phosphatase deficiency, 614023 (3),
PSPHL		
PSPHP1		
PSPN		
PSPS		
PSPS1		
PSPS2		
PSR1		
PSR2		
PSRC1		
PSS1	AD	lenz-majewski hyperostotic dwarfism, 151050 (3),
PSS2		
PSSA	AD	lenz-majewski hyperostotic dwarfism, 151050 (3),
PSSALRE	AR	?lissencephaly 7 with cerebellar hypoplasia, 616342 (3),
PSST	AR	mitochondrial complex i deficiency, nuclear type 3, 618224 (3),
PSST739		
PST		
PST1		
PSTI	AR,AD	tropical calcific pancreatitis, 608189 (3), ; pancreatitis, hereditary, 167800 (3), ; {fibrocalculous pancreatic diabetes, susceptibility to}, 608189 (3),
PSTK		
PSTPIP	AD	pyogenic sterile arthritis, pyoderma gangrenosum, and acne, 604416 (3),
PSTPIP1	AD	pyogenic sterile arthritis, pyoderma gangrenosum, and acne, 604416 (3),
PSTPIP2		
PSTS	AR	amelogenesis imperfecta, type iia1, 204700 (3),
PSY2		
PT-ALPHA		
pt-wd		
pT1		
pT17		
pT49		
pT7		
PTA		
Pta1		
PTA1		
PTAC58		
PTAFR		
PTAR2		
PTAR3		
PTB		
PTB-1		
PTB2		
PTB3		
PTB4		
PTBLP		
PTBP1		
PTBP2		
PTBP3		
PTC	AD,AD	[phenylthiocarbamide tasting], 171200 (3), |{hirschsprung disease, susceptibility to, 1}, 142623 (3), ; multiple endocrine neoplasia iia, 171400 (3), ; {hirschsprung disease, protection against}, 142623 (3), ; medullary thyroid carcinoma, 155240 (3), ; pheochromocytoma, 171300 (3), ; multiple endocrine neoplasia iib, 162300 (3),
PTC1		
PTC3		
PTC4		
PTC7		
PTCD1		
PTCD2		
PTCD3	AR	?combined oxidative phosphorylation deficiency 51, 619057 (3),
PTCH	AD	basal cell nevus syndrome 1, 109400 (3), ; basal cell carcinoma, somatic, 605462 (3); holoprosencephaly 7, 610828 (3),
PTCH1	AD	basal cell nevus syndrome 1, 109400 (3), ; basal cell carcinoma, somatic, 605462 (3); holoprosencephaly 7, 610828 (3),
PTCH2		medulloblastoma, somatic, 155255 (3); basal cell carcinoma, somatic, 605462 (3)
PTCH53		
PTCHD1	XL,XLR	{autism, susceptibility to, 4}, 300830 (3),
PTCHD2		
PTCHD3		
PTCHD4		
PTCRA		
PTCSC		
PTCSC1		
PTCSC3		
PTD001		
PTD002		
PTD004		
PTD007		
PTD008		
PTD009	AR	neurodevelopmental disorder with epilepsy, spasticity, and brain atrophy, 618741 (3),
PTD010		
PTD011		
PTD012		
PTD016		
PTD017		
PTDSR		
PTDSR1		
PTDSS1	AD	lenz-majewski hyperostotic dwarfism, 151050 (3),
PTDSS2		
PTE-2		
PTE-Ib		
PTE1		
PTE2B		
PTEN	AD	{glioma susceptibility 2}, 613028 (3), ; {meningioma}, 607174 (3), ; cowden syndrome 1, 158350 (3), ; lhermitte-duclos disease, 158350 (3), ; prostate cancer, somatic, 176807 (3); macrocephaly/autism syndrome, 605309 (3),
PTEN-rs		
PTEN1	AD	{glioma susceptibility 2}, 613028 (3), ; {meningioma}, 607174 (3), ; cowden syndrome 1, 158350 (3), ; lhermitte-duclos disease, 158350 (3), ; prostate cancer, somatic, 176807 (3); macrocephaly/autism syndrome, 605309 (3),
PTEN2		
PTENP1		
PTENpg1		
PTER		
PTF1-p48	AR	pancreatic and cerebellar agenesis, 609069 (3), ; pancreatic agenesis 2, 615935 (3),
PTF1A	AR	pancreatic and cerebellar agenesis, 609069 (3), ; pancreatic agenesis 2, 615935 (3),
PTFalpha		
PTFbeta		
PTFdelta		
PTFgamma		
PTG		
Ptg-10		{major depressive disorder and accelerated response to antidepressant drug treatment}, 608516 (3)
PTGDR		{asthma, susceptibility to, 1}, 607277 (3)
PTGDR1		{asthma, susceptibility to, 1}, 607277 (3)
PTGDR2		
PTGDS		
PTGER1		
PTGER2	AR	{asthma, aspirin-induced, susceptibility to}, 208550 (3),
PTGER3		
PTGER4		
PTGES		
PTGES2		
PTGES3		
PTGFB		
PTGFR		
PTGFRN		
PTGHS		
PTGIR		
PTGIS	MF	hypertension, essential, 145500 (3),
PTGR1		
PTGR2		
PTGS1		
PTGS2		
PTGS2-AS1		
PTH	AR,AD	hypoparathyroidism, familial isolated 1, 146200 (3),
PTH1	AR,AD	hypoparathyroidism, familial isolated 1, 146200 (3),
PTH1R	AD,AR	metaphyseal chondrodysplasia, murk jansen type, 156400 (3), ; eiken syndrome, 600002 (3), ; failure of tooth eruption, primary, 125350 (3), ; chondrodysplasia, blomstrand type, 215045 (3),
PTH2	AR	infantile-onset multisystem neurologic, endocrine, and pancreatic disease, 616263 (3),
PTH2R		
PTHB1	AR	bardet-biedl syndrome 9, 615986 (3),
PTHLH	AD	brachydactyly, type e2, 613382 (3),
PTHR	AD,AD,AR	brachydactyly, type e2, 613382 (3), |metaphyseal chondrodysplasia, murk jansen type, 156400 (3), ; eiken syndrome, 600002 (3), ; failure of tooth eruption, primary, 125350 (3), ; chondrodysplasia, blomstrand type, 215045 (3),
PTHR1	AD,AR	metaphyseal chondrodysplasia, murk jansen type, 156400 (3), ; eiken syndrome, 600002 (3), ; failure of tooth eruption, primary, 125350 (3), ; chondrodysplasia, blomstrand type, 215045 (3),
PTHR2		
PTHRP	AD	brachydactyly, type e2, 613382 (3),
PTI	AR	?deafness, 91, 613453 (3),
PTIP		
PTK		
PTK1		
PTK2		
PTK2B		
PTK3A		
PTK4		
PTK5		
PTK6		
PTK7		
PTK70		
PTK8	AD	{nasopharyngeal carcinoma, susceptibility to, 3}, 617075 (3),
PTK9		
PTK9L		
PTMA		
PTMS		
PTN		
Ptop	AR,AD	?dyskeratosis congenita, 7, 616553 (3), ; ?dyskeratosis congenita, 6, 616553 (3),
PTOV1		
PTP	AR	mitochondrial phosphate carrier deficiency, 610773 (3),
PTP-1C		
PTP-BAS		
PTP-BL		
ptp-IV1a		
PTP-oc	AR	nephrotic syndrome, type 6, 614196 (3),
PTP-PEST		colon cancer, somatic, 114500 (3)
PTP-SL		
PTP-U2	AR	nephrotic syndrome, type 6, 614196 (3),
PTP18		
PTP1B	AD	{insulin resistance, susceptibility to}, 125853 (3),
PTP1E		
PTP2C	AD	noonan syndrome 1, 163950 (3), ; leopard syndrome 1, 151100 (3), ; metachondromatosis, 156250 (3), ; leukemia, juvenile myelomonocytic, somatic, 607785 (3)
PTP4A		
PTP4A1		
PTP4A2		
PTP4A3		
PTPA		
PTPB		
PTPBR7		
PTPCAAX1		
PTPCAAX2		
PTPD		
PTPD1		
PTPD2	AR	choanal atresia and lymphedema, 613611 (3),
PTPE		
PTPG		
PTPG1		colon cancer, somatic, 114500 (3)
PTPH1		
PTPIP51		
PTPL1		
PTPLA	AR	congenital myopathy 11, 619967 (3),
PTPLAD1		
PTPLAD2		
PTPLB		
PTPMEG		
PTPMT1		
PTPN1	AD	{insulin resistance, susceptibility to}, 125853 (3),
PTPN10		
PTPN11	AD	noonan syndrome 1, 163950 (3), ; leopard syndrome 1, 151100 (3), ; metachondromatosis, 156250 (3), ; leukemia, juvenile myelomonocytic, somatic, 607785 (3)
PTPN12		colon cancer, somatic, 114500 (3)
PTPN13		
PTPN13LY		
PTPN13LY2		
PTPN14	AR	choanal atresia and lymphedema, 613611 (3),
PTPN18		
PTPN2		
PTPN20		
PTPN20A		
PTPN20B		
PTPN21		
PTPN22	AD,AR	{rheumatoid arthritis, susceptibility to}, 180300 (3); {systemic lupus erythematosus susceptibility to}, 152700 (3), ; {diabetes, type 1, susceptibility to}, 222100 (3),
PTPN23	AR	neurodevelopmental disorder and structural brain anomalies with or without seizures and spasticity, 618890 (3),
PTPN3		
PTPN4		
PTPN5		
PTPN6		
PTPN7		
PTPN8	AD,AR	{rheumatoid arthritis, susceptibility to}, 180300 (3); {systemic lupus erythematosus susceptibility to}, 152700 (3), ; {diabetes, type 1, susceptibility to}, 222100 (3),
PTPN9		
PTPNS1		
PTPRA		
PTPRB		
PTPRC	AR	immunodeficiency 105, severe combined, 619924 (3),
PTPRCAP		
PTPRD		
PTPRE		
PTPRF	AR	?breasts and/or nipples, aplasia or hypoplasia of, 2, 616001 (3),
PTPRG		
PTPRH		
PTPRJ		colon cancer, somatic, 114500 (3)
PTPRK		
PTPRL1		
PTPRL10		
PTPRL2		
PTPRM		
PTPRN		
PTPRN2		
PTPRO	AR	nephrotic syndrome, type 6, 614196 (3),
PTPRQ	AD,AR	deafness, 73, 617663 (3), ; deafness, 84a, 613391 (3),
PTPRR		
PTPRS		
PTPRT		
PTPRU		
PTPRZ		
PTPRZ1		
PTPRZ2		
PTPS	AR	hyperphenylalaninemia, bh4-deficient, a, 261640 (3),
PTPSTEP		
PTPT		
PTPU2	AR	nephrotic syndrome, type 6, 614196 (3),
PTPZ		
PTR		
PTR4		
PTRF	AR	lipodystrophy, congenital generalized, type 4, 613327 (3),
PTRH2	AR	infantile-onset multisystem neurologic, endocrine, and pancreatic disease, 616263 (3),
PTRHD1		
PTS	AR	hyperphenylalaninemia, bh4-deficient, a, 261640 (3),
PTS1R	AR	peroxisome biogenesis disorder 2b, 202370 (3), ; peroxisome biogenesis disorder 2a (zellweger), 214110 (3), ; rhizomelic chondrodysplasia punctata, type 5, 616716 (3),
PTS2R	AR	rhizomelic chondrodysplasia punctata, type 1, 215100 (3), ; peroxisome biogenesis disorder 9b, 614879 (3),
PTTG		
PTTG1		
PTTG1IP		
PTTG1IP1		
PTTG2		
PTX1	AD	liebenberg syndrome, 186550 (4), ; clubfoot, congenital, with or without deficiency of long bones and/or mirror-image polydactyly, 119800 (3),
PTX2		{?amyloidosis, secondary, susceptibility to} (1)
PTX3		
PTX4		
PTZ17		
PU.1	AD	agammaglobulinemia 10, 619707 (3),
PUDP		
Puf-A		
PUF6		
PUF60	AD	verheij syndrome, 615583 (3),
PUM	AR,AD	congenital myopathy 17, 618975 (3), |tubulointerstitial kidney disease, 2, 174000 (3),
PUM1	AD	spinocerebellar ataxia 47, 617931 (3),
PUM2		
PUM3		
PUMA		
Puma-g		
PUMAG		
PUMB1		
PUMH1	AD	spinocerebellar ataxia 47, 617931 (3),
PUMH2		
PUMP-1		
PUNC		
punctin-2		
PUNP	AR	immunodeficiency due to purine nucleoside phosphorylase deficiency, 613179 (3),
Pur-1		
PUR-ALPHA	AD	neurodevelopmental disorder with neonatal respiratory insufficiency, hypotonia, and feeding difficulties, 616158 (3),
PUR1	AD	neurodevelopmental disorder with neonatal respiratory insufficiency, hypotonia, and feeding difficulties, 616158 (3),
PURA	AD	neurodevelopmental disorder with neonatal respiratory insufficiency, hypotonia, and feeding difficulties, 616158 (3),
PURALPHA	AD	neurodevelopmental disorder with neonatal respiratory insufficiency, hypotonia, and feeding difficulties, 616158 (3),
PURB		
PURBETA		
PURG		
PURG-A		
PURG-B		
PURH	AR	aica-ribosiduria due to atic deficiency, 608688 (3),
PURL		
PUS1	AR	myopathy, lactic acidosis, and sideroblastic anemia 1, 600462 (3),
PUS10		
PUS3	AR	neurodevelopmental disorder with microcephaly and gray sclerae, 617051 (3),
PUS4		
PUS7	AR	intellectual developmental disorder with abnormal behavior, microcephaly, and short stature, 618342 (3),
PV-1	AR	diarrhea 10, protein-losing enteropathy type, 618183 (3),
PV1	AR	diarrhea 10, protein-losing enteropathy type, 618183 (3),
PVALB	AD	myopathy, sarcoplasmic body, 620286 (3),
PVR		
PVRIG		
PVRL1	AR	cleft lip/palate-ectodermal dysplasia syndrome, 225060 (3), ; orofacial cleft 7, 225060 (3),
PVRL2		
PVRL3		
PVRL4	AR	ectodermal dysplasia-syndactyly syndrome 1, 613573 (3),
PVRR1	AR	cleft lip/palate-ectodermal dysplasia syndrome, 225060 (3), ; orofacial cleft 7, 225060 (3),
PVRR2		
PVRR3		
PVS		
PVT1		
PWAR1		
PWAR5		
PWCR		
Pwdmp	AR	nephronophthisis 13, 614377 (3), ; cranioectodermal dysplasia 4, 614378 (3), ; senior-loken syndrome 8, 616307 (3), ; short-rib thoracic dysplasia 5 with or without polydactyly, 614376 (3), ; ?spermatogenic failure 72, 619867 (3),
PWP1		
PWP2		
PWP2H		
PWRN1		
PWRN2		
PWWP2A		
PX1	AD	oocyte/zygote/embryo maturation arrest 7, 618550 (3),
PX19		
PX2		
Px3		
PXAAA1	AR,AD	peroxisome biogenesis disorder 4b, 614863 (3), ; peroxisome biogenesis disorder 4a (zellweger), 614862 (3), ; heimler syndrome 2, 616617 (3),
PXDN	AR	anterior segment dysgenesis 7, with sclerocornea, 269400 (3),
PXDNL		
PXE	AR,AD	pseudoxanthoma elasticum, 264800 (3), ; arterial calcification, generalized, of infancy, 2, 614473 (3), ; pseudoxanthoma elasticum, forme fruste, 177850 (3),
PXF	AR	peroxisome biogenesis disorder 12a (zellweger), 614886 (3),
PXK		
PXMP1	AR,AR	?bile acid synthesis defect, congenital, 5, 616278 (3), |peroxisome biogenesis disorder 12a (zellweger), 614886 (3),
PXMP1L	AR	methylmalonic aciduria and homocystinuria, cblj type, 614857 (3),
PXMP2		
PXMP3	AR	peroxisome biogenesis disorder 5a (zellweger), 614866 (3), ; peroxisome biogenesis disorder 5b, 614867 (3),
PXMP4		
PXN	AR	anterior segment dysgenesis 7, with sclerocornea, 269400 (3),
PXR		
Pxr1		
PXR1	AR	peroxisome biogenesis disorder 2b, 202370 (3), ; peroxisome biogenesis disorder 2a (zellweger), 214110 (3), ; rhizomelic chondrodysplasia punctata, type 5, 616716 (3),
PXR2		
PXYLP1		
PXYLT1	AR	desbuquois dysplasia 2, 615777 (3), ; {pseudoxanthoma elasticum, modifier of severity of}, 264800 (3),
PXYLT2	AR	{pseudoxanthoma elasticum, modifier of severity of}, 264800 (3), ; spondyloocular syndrome, 605822 (3),
PY160	XLR,XL	hypothyroidism, congenital, nongoitrous, 9, 301035 (3),
PYCARD		
PYCD	AR	pycnodysostosis, 265800 (3),
PYCR1	AR	cutis laxa, type iiib, 614438 (3), ; cutis laxa, type iib, 612940 (3),
PYCR2	AR	leukodystrophy, hypomyelinating, 10, 616420 (3),
PYCR3		
PYCRL		
PYCS	AD,AR	spastic paraplegia 9a, 601162 (3), ; cutis laxa, type iiia, 219150 (3), ; spastic paraplegia 9b, 616586 (3), ; cutis laxa, 3, 616603 (3),
PYDC1		
PYDC2		
PYGB		
PYGL	AR	glycogen storage disease vi, 232700 (3),
PYGM	AR	mcardle disease, 232600 (3),
PYGO1		
PYGO2		
PYHIN1		
PYHIN2		
PYHIN3		
PYHIN4		
PYK	XLR,XL	glycogen storage disease, type ixa2, 306000 (3), ; glycogen storage disease, type ixa1, 306000 (3),
PYK2		
PYM		
PYM1		
Pynod		
PYPAF1	AD	cinca syndrome, 607115 (3), ; familial cold inflammatory syndrome 1, 120100 (3), ; keratoendothelitis fugax hereditaria, 148200 (3), ; deafness, 34, with or without inflammation, 617772 (3), ; muckle-wells syndrome, 191900 (3),
PYPAF2	AR	oocyte/zygote/embryo maturation arrest 18, 620332 (3),
PYPAF3	AR	hydatidiform mole, recurrent, 1, 231090 (3),
PYPAF4		
PYPAF5		
PYPAF6		
PYPAF7	AD	familial cold autoinflammatory syndrome 2, 611762 (3),
PYPAF8	AR	oocyte/zygote/embryo maturation arrest 19, 620333 (3),
PYROXD1	AR	myopathy, myofibrillar, 8, 617258 (3),
PYROXD2		
PYST1	AD	hypogonadotropic hypogonadism 19 with or without anosmia, 615269 (3),
PYST2		
PYURF		
PYY		
PYY1		
PYY2		
PYY4		
PZ		[protein z deficiency], 614024 (3)
PZF		
PZI		
PZP		
PZR		
Q0310		
Q10	AD	lessel-kreienkamp syndrome, 619149 (3),
Q96AV0		
QA79		
QARS	AR,AR	leukodystrophy, hypomyelinating, 15, 617951 (3), |microcephaly, progressive, seizures, and cerebral and cerebellar atrophy, 615760 (3),
QARS1	AR	microcephaly, progressive, seizures, and cerebral and cerebellar atrophy, 615760 (3),
QC		
QCR1	AD	parkinsonism with polyneuropathy, 619279 (3),
QCR10		
QCR2	AR	mitochondrial complex iii deficiency, nuclear type 5, 615160 (3),
QCR6	AR	?mitochondrial complex iii deficiency, nuclear type 11, 620137 (3),
QCR7	AR	mitochondrial complex iii deficiency, nuclear type 3, 615158 (3),
QCR8	AR	mitochondrial complex iii deficiency, nuclear type 4, 615159 (3),
QCR9		
QDPR	AR	hyperphenylalaninemia, bh4-deficient, c, 261630 (3),
QIK		
QIL1	AR	combined oxidative phosphorylation deficiency 37, 618329 (3),
QIN	AD	rett syndrome, congenital variant, 613454 (3),
QIP1		
QIP2		
QK3		
qkf	AD	sbbyss syndrome, 603736 (3), ; genitopatellar syndrome, 606170 (3),
QKI		
QM	XL,XLR	{autism, susceptibility to, 5}, 300847 (3); intellectual developmental disorder, syndromic 35, 300998 (3),
QN1		
QNG1		
QOH-1		
QP-C	AR,AR	mitochondrial complex iii deficiency, nuclear type 3, 615158 (3), |mitochondrial complex iii deficiency, nuclear type 4, 615159 (3),
QPCT		
QPRS	AR	leukodystrophy, hypomyelinating, 15, 617951 (3),
QPRT		
QPRTase		
QR1		{breast cancer, poor survival after chemotherapy for} (3); {leukemia, post-chemotherapy, susceptibility to} (3); {benzene toxicity, susceptibility to} (3)
QR2	AD	{?breast cancer susceptibility}, 114480 (1), somatic mutation,
QRF1	AD	intellectual developmental disorder with language impairment with or without autistic features, 613670 (3),
QRFP		
QRFPR		
Qri7		
QRICH1	AD	ververi-brady syndrome, 617982 (3),
QRICH2	AR	spermatogenic failure 35, 618341 (3),
QRSL1	AR	combined oxidative phosphorylation deficiency 40, 618835 (3),
QSCN6		
QSCN6L1		
QSER1		
QSK	AR	?spondyloepimetaphyseal dysplasia, krakow type, 618162 (3),
QSOX1		
QSOX2		
QTRT1		
querkopf	AD	sbbyss syndrome, 603736 (3), ; genitopatellar syndrome, 606170 (3),
R-CAD		
R-PTP-kappa		
R-Ras		
R-RAS3	AD	noonan syndrome 11, 618499 (3),
R00504		
R1		
R2		
R29124_1		
R33729_1		
R3HDM		
R3HDM1		
R3HDM2		
R3HDM3		
R51H2		
R51H3		{breast-ovarian cancer, familial, susceptibility to, 4}, 614291 (3)
R7BP		
R9AP		bradyopsia 2, 620344 (3)
RA-GEF	AD	?epilepsy, familial adult myoclonic, 7, 618075 (3),
RA-GEF-2		
RA175		
RA410		
RA70		
RAA1		amyotrophic lateral sclerosis 9, 611895 (3)
RAB		
RAB-14		
RAB1		
RAB10		
Rab11-FIP1		
Rab11-FIP2		
Rab11-FIP3		
RAB11-FIP4		
RAB11A		
RAB11B	AD	neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter, 617807 (3),
RAB11BP		
RAB11FIP1		
RAB11FIP2		
RAB11FIP3		
RAB11FIP4		
RAB11FIP5		
RAB12		
RAB13		
RAB14		
RAB15		
RAB15EP		
RAB16		
RAB17		
RAB18	AR	warburg micro syndrome 3, 614222 (3),
RAB1A		
RAB1B		
RAB2		
RAB21		
RAB22A		
Rab22B		
RAB23	AR	carpenter syndrome, 201000 (3),
RAB24		
RAB25		
RAB26		
RAB27	AR	griscelli syndrome, type 2, 607624 (3),
RAB27A	AR	griscelli syndrome, type 2, 607624 (3),
Rab27A-GAPbeta		
RAB27B		
RAB28	AR	cone-rod dystrophy 18, 615374 (3),
RAB29		
RAB2A		
RAB2B		
RAB2L		
RAB3-GAP150	AR	martsolf syndrome 1, 212720 (3), ; warburg micro syndrome 2, 614225 (3),
RAB30		
RAB31		
RAB32		
RAB33A		
RAB33B	AR	smith-mccort dysplasia 2, 615222 (3),
RAB34		
RAB35		
RAB36		
RAB37		
RAB38		
RAB39		
RAB39A		
RAB39B	XL,XLR	intellectual developmental disorder, 72, 300271 (3), ; waisman syndrome, 311510 (3),
RAB3A		
RAB3B		
RAB3C		
RAB3D		
RAB3GAP	AR	martsolf syndrome 2, 619420 (3), ; warburg micro syndrome 1, 600118 (3),
RAB3GAP1	AR	martsolf syndrome 2, 619420 (3), ; warburg micro syndrome 1, 600118 (3),
RAB3GAP130	AR	martsolf syndrome 2, 619420 (3), ; warburg micro syndrome 1, 600118 (3),
RAB3GAP2	AR	martsolf syndrome 1, 212720 (3), ; warburg micro syndrome 2, 614225 (3),
RAB3GEP	AR	neurodevelopmental disorder with dysmorphic facies, impaired speech and hypotonia, 619005 (3), ; deeah syndrome, 619004 (3),
RAB3IP		
RAB3IP2	AD	cone-rod dystrophy 7, 603649 (3),
RAB3IP3	AR	cone-rod synaptic disorder syndrome, congenital nonprogressive, 618970 (3),
RAB4		
RAB40A		
RAB40AL		
RAB40B		
RAB40C		
RAB45		
RAB46		
RAB4A		
RAB4B		
RAB5		
RAB5A		
RAB5B		
RAB5C		
RAB5CL		
RAB5EP		
RAB5IF	AR	?craniofacial dysmorphism, skeletal anomalies, and impaired intellectual development syndrome 2, 616994 (3),
RAB5IFL		
RAB6		
RAB6A		
RAB6B		
RAB6C		
RAB6IP1	AR	developmental and epileptic encephalopathy 49, 617281 (3),
RAB6IP2		
RAB6KIFL	AR	?cardiomyopathy, familial restrictive, 6, 619433 (3),
RAB7	AD	charcot-marie-tooth disease, type 2b, 600882 (3),
RAB7A	AD	charcot-marie-tooth disease, type 2b, 600882 (3),
RAB7L		
RAB7L1		
RAB8		
RAB8A		
RAB8B		
RAB8IP		
RAB8IPL1		
RAB9		
RAB9A		
RAB9B		
RAB9L		
RAB9P40		
RABAC1		
rabaptin-5		
RABEP1		
RABEP2		
RABEPK		
rabex-5		
RABEX5		
RabGAP-5		
RABGAP1		
RABGAP1L		
RABGAP5		
RABGDIA	XL,XLD	intellectual developmental disorder, 41, 300849 (3),
RABGDIB		
RABGEF1		
RABGGTA		
RABGGTB		
RABIF		
RABIN3		
RABIN8		
RABIP4		
RABIP4R		
RabJS		
RABL		
RABL2A		
RABL2B		
RABL3	AD	{?pancreatic cancer, susceptibility to, 5}, 618680 (3),
RABL4	AR	bardet-biedl syndrome 19, 615996 (3),
RABL6		
rabphilin		
RABPT5		
RABR		
RabS10		
RAC		breast cancer, somatic, 114480 (3); cowden syndrome 6, 615109 (3); colorectal cancer, somatic, 114500 (3); proteus syndrome, somatic, 176920 (3); ovarian cancer, somatic, 167000 (3)
Rac-1	AD	intellectual developmental disorder, 48, 617751 (3),
RAC-alpha		breast cancer, somatic, 114480 (3); cowden syndrome 6, 615109 (3); colorectal cancer, somatic, 114500 (3); proteus syndrome, somatic, 176920 (3); ovarian cancer, somatic, 167000 (3)
RAC-gamma	AD	megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 2, 615937 (3),
RAC1	AD	intellectual developmental disorder, 48, 617751 (3),
RAC2	AD,AR	immunodeficiency 73a with defective neutrophil chemotaxix and leukocytosis, 608203 (3), ; ?immunodeficiency 73c with defective neutrophil chemotaxis and hypogammaglobulinemia, 618987 (3), ; immunodeficiency 73b with defective neutrophil chemotaxis and lymphopenia, 618986 (3),
RAC3	AD	neurodevelopmental disorder with structural brain anomalies and dysmorphic facies, 618577 (3),
RACE	AR	alpha-methylacyl-coa racemase deficiency, 614307 (3), ; bile acid synthesis defect, congenital, 4, 214950 (3),
RACGAP1	AR	?anemia, congenital dyserythropoietic, type iiib, 619789 (3),
RACH1		[blood group, kidd], 111000 (3)
RACH2		[blood group, kidd], 111000 (3)
RACK1		
RACK17		
RACK7		
RACO-1		
RACO1		
RAD		
RAD1	AR	xeroderma pigmentosum, type f/cockayne syndrome, 278760 (3), ; xfe progeroid syndrome, 610965 (3), ; xeroderma pigmentosum, group f, 278760 (3), ; fanconi anemia, complementation group q, 615272 (3),
RAD10	AR	cerebrooculofacioskeletal syndrome 4, 610758 (3),
RAD17		
RAD17Sp		
RAD18		
RAD2		
RAD21	AD,AR	cornelia de lange syndrome 4, 614701 (3), ; ?mungan syndrome, 611376 (3),
RAD21L		
RAD21L1		
RAD23A		
RAD23B		
Rad24		
RAD25	AR	trichothiodystrophy 2, photosensitive, 616390 (3), ; xeroderma pigmentosum, group b, 610651 (3),
RAD26	AR,AD	uv-sensitive syndrome 1, 600630 (3), ; cerebrooculofacioskeletal syndrome 1, 214150 (3), ; ?de sanctis-cacchione syndrome, 278800 (3), ; cockayne syndrome, type b, 133540 (3), ; {macular degeneration, age-related, susceptibility to, 5}, 613761 (3); premature ovarian failure 11, 616946 (3), ; {lung cancer, susceptibility to}, 211980 (3), somatic mutation,
RAD26L	AR	bone marrow failure syndrome 2, 615715 (3),
RAD30A	AR	xeroderma pigmentosum, variant type, 278750 (3),
RAD30B		
RAD3D		
RAD3OB		
RAD4	AR	xeroderma pigmentosum, group c, 278720 (3),
RAD50	AR	nijmegen breakage syndrome-like disorder, 613078 (3),
RAD50-2	AR	nijmegen breakage syndrome-like disorder, 613078 (3),
RAD51	AD	mirror movements 2, 614508 (3), ; {breast cancer, susceptibility to}, 114480 (3), somatic mutation, ; fanconi anemia, complementation group r, 617244 (3),
RAD51A	AD	mirror movements 2, 614508 (3), ; {breast cancer, susceptibility to}, 114480 (3), somatic mutation, ; fanconi anemia, complementation group r, 617244 (3),
RAD51AP1		
RAD51B		
RAD51C	AR	{breast-ovarian cancer, familial, susceptibility to, 3}, 613399 (3); fanconi anemia, complementation group o, 613390 (3),
RAD51D		{breast-ovarian cancer, familial, susceptibility to, 4}, 614291 (3)
RAD51L1		
RAD51L2	AR	{breast-ovarian cancer, familial, susceptibility to, 3}, 613399 (3); fanconi anemia, complementation group o, 613390 (3),
RAD51L3		{breast-ovarian cancer, familial, susceptibility to, 4}, 614291 (3)
RAD52		
RAD52B		
RAD53	AD	{colorectal cancer, susceptibility to}, 114500 (3), somatic mutation, ; osteosarcoma, somatic, 259500 (3); {breast cancer, susceptibility to}, 114480 (3), somatic mutation, ; {prostate cancer, familial, susceptibility to}, 176807 (3), somatic mutation, ; li-fraumeni syndrome 2, 609265 (3)
RAD54	XLD,XL,XLR	alpha-thalassemia/mental retardation syndrome, 301040 (3), ; alpha-thalassemia myelodysplasia syndrome, somatic, 300448 (3); intellectual disability-hypotonic facies syndrome, 309580 (3),
RAD54A	AD	{breast cancer, invasive ductal}, 114480 (3), somatic mutation, ; adenocarcinoma, colonic, somatic (3); lymphoma, non-hodgkin, somatic, 605027 (3)
RAD54B		colon cancer, somatic, 114500 (3); lymphoma, non-hodgkin, somatic, 605027 (3)
RAD54L	AD	{breast cancer, invasive ductal}, 114480 (3), somatic mutation, ; adenocarcinoma, colonic, somatic (3); lymphoma, non-hodgkin, somatic, 605027 (3)
RAD54L2		
RAD60		
RAD6A	XL,XLR	intellectual developmental disorder, syndromic, nascimento type, 300860 (3),
RAD6B		
RAD9		
RAD9A		
RAD9B		
RADIL		
radmis	AR	filippi syndrome, 272440 (3),
RAE1		
RAE2		
RAE28	AR	?microcephaly 11, primary, 615414 (3),
RAET1E		
RAET1G		
RAET1H		
RAET1I		
RAET1L		
RAET1N		
Raf-1	AD	cardiomyopathy, dilated, 1nn, 615916 (3), ; noonan syndrome 5, 611553 (3), ; leopard syndrome 2, 611554 (3)
RAF1	AD	cardiomyopathy, dilated, 1nn, 615916 (3), ; noonan syndrome 5, 611553 (3), ; leopard syndrome 2, 611554 (3)
RAF1B		
RAF3		
RAFI63		
RAFT1	AD	focal cortical dysplasia, type ii, somatic, 607341 (3); smith-kingsmore syndrome, 616638 (3),
RAFTK		
Raftlin		
Raftlin-2		
RAG1	AR	omenn syndrome, 603554 (3), ; severe combined immunodeficiency, b cell-negative, 601457 (3), ; combined cellular and humoral immune defects with granulomas, 233650 (3), ; alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity, 609889 (3)
RAG1AP1		
RAG2	AR	severe combined immunodeficiency, b cell-negative, 601457 (3), ; combined cellular and humoral immune defects with granulomas, 233650 (3), ; omenn syndrome, 603554 (3),
RAGA		
RAGE		
RAGE1		
Ragulator1		
Ragulator2	AR	immunodeficiency due to defect in mapbp-interacting protein, 610798 (3),
Ragulator3		
RAH		
RAI		
RAI1	AD	smith-magenis syndrome, 182290 (3), isolated cases,
RAI13		
RAI14		
RAI15		
RAI16		
RAI17	AD	neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies, 618659 (3),
RAI2		
RAI3		
RAIDD	AR	intellectual developmental disorder, 34, with variant lissencephaly, 614499 (3),
RAIG-2		
RAIG-3		
RAIG1		
RAIN		
RAINB1		
RAK		
RAK1		
RAL	AD	hiatt-neu-cooper neurodevelopmental syndrome, 619311 (3),
RAL1B		
RALA	AD	hiatt-neu-cooper neurodevelopmental syndrome, 619311 (3),
RALB		
RALBP1		
RALDH1		
RALDH2	AR	diaphragmatic hernia 4, with cardiovascular defects, 620025 (3),
RALDH3	AR	microphthalmia, isolated 8, 615113 (3),
RALGAPA1	AR	neurodevelopmental disorder with hypotonia, neonatal respiratory insufficiency, and thermodysregulation, 618797 (3),
RALGAPA2		
RalGAPalpha1	AR	neurodevelopmental disorder with hypotonia, neonatal respiratory insufficiency, and thermodysregulation, 618797 (3),
RALGAPB		
RalGAPbeta		
RALGDS		
RalGEF		
RALGEF2		
RALGPS1		
RALGPS1A		
RALGPS2		
RaLP		
RALT		
RALY		
RALYL		
RAM	AR	{glioma susceptibility 7}, 613032 (3)|griscelli syndrome, type 2, 607624 (3),
Ram-1	AD	basal ganglia calcification, idiopathic, 1, 213600 (3),
RAM2		
RAMA1		
RAMA3	AR	spermatogenic failure 76, 620084 (3),
RAMAC		
RAMMET		
RAMP	AD	neurodevelopmental-craniofacial syndrome with variable renal and cardiac abnormalities, 619522 (3),
RAMP1		
RAMP2		
RAMP3		
RAMP4		
RAN		
RANBP1		
RANBP10		
RanBP11		
RANBP13		
RANBP16		
RANBP17		
RANBP2	AD	{encephalopathy, acute, infection-induced, 3, susceptibility to}, 608033 (3),
RANBP20		
RanBP2alpha		
RANBP2L1		
RANBP2L2		
RANBP3		
RANBP3L		
RANBP5		
RANBP7		
RANBP8	AR	viss syndrome, 619472 (3),
RANBP9		
RanBPM		
RANGAP1		
RANGNRF		
RANGRF		
RANK	AR,AD	osteopetrosis, 7, 612301 (3), ; {paget disease of bone 2, early-onset}, 602080 (3), ; osteolysis, familial expansile, 174810 (3),
RANK-5		
RANKL	AR	osteopetrosis, 2, 259710 (3),
RANTES		{hiv-1 disease, rapid progression of}, 609423 (3); {hiv-1 disease, delayed progression of}, 609423 (3)
RAO		
RAP	AR	myopia 23, 615431 (3),
RAP1		
RAP140		
RAP1A		
RAP1B		
RAP1GA1		
RAP1GAP		
RAP1GAP1		
RAP1GAP2		
RAP1GAPII		
RAP1GDS1		lymphocytic leukemia, acute t-cell (3)
RAP1GN1		
RAP2		
RAP250		
RAP2A		
RAP2B		
RAP2C		
RAP2IP		
RAP3	AD	hyperchylomicronemia, late-onset, 144650 (3), ; {hypertriglyceridemia, susceptibility to}, 145750 (3),
RAP30		
RAP55		
RAP55A		
RAP74		
RAP80		
RAPA		
RapGAPalpha2		
RAPGEF1		
RAPGEF2	AD	?epilepsy, familial adult myoclonic, 7, 618075 (3),
RAPGEF3		
RAPGEF4		
RAPGEF5		
RAPGEF6		
RAPH	AR	[blood group, raph], 179620 (3); epidermolysis bullosa simplex 7, with nephropathy and deafness, 609057 (3),
RAPH1		
RAPL		
RAPSN	AR	fetal akinesia deformation sequence 2, 618388 (3), ; myasthenic syndrome, congenital, 11, associated with acetylcholine receptor deficiency, 616326 (3),
RAPT1	AD	focal cortical dysplasia, type ii, somatic, 607341 (3); smith-kingsmore syndrome, 616638 (3),
raptor		
RAR		leukemia, acute promyelocytic, 612376 (1)
Rar-2		
RAR-alpha		leukemia, acute promyelocytic, 612376 (1)
RAR-beta	AR,AD	microphthalmia, syndromic 12, 615524 (3),
RAR-gamma		
RAR2		
RAR2A		
RARA		leukemia, acute promyelocytic, 612376 (1)
RARalpha		leukemia, acute promyelocytic, 612376 (1)
RARB	AR,AD	microphthalmia, syndromic 12, 615524 (3),
RARbeta	AR,AD	microphthalmia, syndromic 12, 615524 (3),
RARC		
RARG		
RARG-1		
RARgamma		
RARL		
RARRES1		
RARRES2		
RARRES3		
RARS	AR	leukodystrophy, hypomyelinating, 9, 616140 (3),
RARS1	AR	leukodystrophy, hypomyelinating, 9, 616140 (3),
RARS2	AR	pontocerebellar hypoplasia, type 6, 611523 (3),
RARSL	AR	pontocerebellar hypoplasia, type 6, 611523 (3),
Ras-GRF2		
RASA	AD	capillary malformation-arteriovenous malformation 1, 608354 (3), ; basal cell carcinoma, somatic, 605462 (3)
RASA1	AD	capillary malformation-arteriovenous malformation 1, 608354 (3), ; basal cell carcinoma, somatic, 605462 (3)
RASA2		
RASA3		
RASA4		
RASA5	AD	intellectual developmental disorder, 5, 612621 (3),
RASAL		
RASAL1		
RASAL2		
RASAL3		
RASD1		
RASD2		
RASEF		
RASGEF1A		
RASGEF1B		
RASGEF2		
RASGRF1		
RASGRF2		
RASGRF3		
RASGRP	AR	immunodeficiency 64, 618534 (3),
RASGRP1	AR	immunodeficiency 64, 618534 (3),
RASGRP2	AR	?bleeding disorder, platelet-type, 18, 615888 (3),
RASGRP3		
RASGRP4		
RASI-1	AD	cavitary optic disc anomalies, 611543 (3),
RASIP1		
RASIP2		
RASL10A		
RASL10B		
RASL11A		
RASL11B		
RASL7A		
RASL7B		
RASL8C		
RASON		
rasp	AR	nivelon-nivelon-mabille syndrome, 600092 (3),
RASSF1		
RASSF10		
RASSF2		
RASSF3		
RASSF4	AR	macrocephaly, alopecia, cutis laxa, and scoliosis, 613075 (3),
RASSF5		
RASSF6		
RASSF7		
RASSF8		
RASSF9		
RAV2	AR	kohlschutter-tonz syndrome, 226750 (3),
RAVER1		
RAVER2		
RAX	AR,AR	dystonia 16, 612067 (3), |microphthalmia, syndromic 16, 611038 (3),
RAX1	AR	microphthalmia, syndromic 16, 611038 (3),
RAX2	AR,AD	retinitis pigmentosa 95, 620102 (3), ; cone-rod dystrophy 11, 610381 (3), ; ?macular degeneration, age-related, 6, 613757 (3)
RAXL1	AR,AD	retinitis pigmentosa 95, 620102 (3), ; cone-rod dystrophy 11, 610381 (3), ; ?macular degeneration, age-related, 6, 613757 (3)
RAXLX		
Ray		
RAY1		
RAYL	AR	bardet-biedl syndrome 19, 615996 (3),
RAZ1		
RB	AD	small cell cancer of the lung, somatic, 182280 (3); bladder cancer, somatic, 109800 (3); retinoblastoma, trilateral, 180200 (3), somatic mutation, ; osteosarcoma, somatic, 259500 (3); retinoblastoma, 180200 (3), somatic mutation,
RB1	AD	small cell cancer of the lung, somatic, 182280 (3); bladder cancer, somatic, 109800 (3); retinoblastoma, trilateral, 180200 (3), somatic mutation, ; osteosarcoma, somatic, 259500 (3); retinoblastoma, 180200 (3), somatic mutation,
RB18A		
RB1CC1		breast cancer, somatic, 114480 (3)
Rb2	AR	brunet-wagner neurodevelopmental syndrome, 619690 (3),
RBAF600		
RBAK		
RBAP2		
RbAp46		
RbAp48		
RBAT	AR,AD	cystinuria, 220100 (3),
RBBP1		
RBBP2		
RBBP2H1A	AR	intellectual developmental disorder, 65, 618109 (3),
RBBP3		
RBBP4		
RBBP5		
RBBP6		
RBBP7		
RBBP8	AR	seckel syndrome 2, 606744 (3), ; jawad syndrome, 251255 (3), ; pancreatic carcinoma, somatic (3)
RBBP9		
RBCC		
RBCC728	AR	?anencephaly 1, 206500 (3),
RBCK1	AR	polyglucosan body myopathy 1 with or without immunodeficiency, 615895 (3),
RBCK2	AR	polyglucosan body myopathy 1 with or without immunodeficiency, 615895 (3),
RBED1	AR,AD	?deafness, 88, 615429 (3), ; ?deafness, 81, 619500 (3),
RBEL1		
RbEST47		
RBFOX1		
RBFOX2		
RBFOX3		
RBIG1	AR	gaze palsy, familial horizontal, with progressive scoliosis, 1, 607313 (3),
RBJ		
RBK1	AD	episodic ataxia/myokymia syndrome, 160120 (3),
RBKIN		
RBKS		
RBL1		
RBL2	AR	brunet-wagner neurodevelopmental syndrome, 619690 (3),
RBM1		
RBM10	XLR,XL	tarp syndrome, 311900 (3),
RBM11		
RBM12	AD	{schizophrenia 19, susceptibility to}, 617629 (3),
RBM14		
RBM15		
RBM15B		
RBM15C	AD	radio-tartaglia syndrome, 619312 (3),
RBM16		
RBM17		
RBM19		
RBM2		
RBM20	AD	cardiomyopathy, dilated, 1dd, 613172 (3),
RBM21		
RBM22		
RBM24		
RBM25		
RBM26		
RBM27		
RBM28	AR	?alopecia, neurologic defects, and endocrinopathy syndrome, 612079 (3),
RBM29	AR,AD	?deafness, 88, 615429 (3), ; ?deafness, 81, 619500 (3),
RBM3		
RBM34		
RBM35A	AR	?deafness, 109, 618013 (3),
RBM35B		
RBM36		
RBM37		
RBM38		
RBM39		
RBM4		
RBM40	AR	pituitary hormone deficiency, combined or isolated, 7, 618160 (3),
RBM42		
RBM45		
RBM46		
RBM47		
RBM4A		
RBM5		
RBM6		
RBM7		
RBM8	AR	thrombocytopenia-absent radius syndrome, 274000 (3),
RBM8A	AR	thrombocytopenia-absent radius syndrome, 274000 (3),
RBM9		
RBMS1		
RBMS2		
RBMS3		
RBMS4		
RBMX	XL,XLR	?intellectual developmental disorder, syndromic 11, shashi type, 300238 (3),
RBMXL2		
RBMY1A1		
RBP		
RBP-1		
RBP-J	AD	adams-oliver syndrome 3, 614814 (3),
RBP-L		
RBP1		
RBP10		
RBP1L1		
RBP2		
RBP3	AR	?retinitis pigmentosa 66, 615233 (3),
RBP4	AD,AR	microphthalmia, isolated, with coloboma 10, 616428 (3), ; retinal dystrophy, iris coloboma, and comedogenic acne syndrome, 615147 (3),
RBP5		
RBP50		
RBP56		chondrosarcoma, extraskeletal myxoid, 612237 (1)
RBP7		
RBP95		
RBPC		
RBPC2		
RBPJ	AD	adams-oliver syndrome 3, 614814 (3),
RBPJK	AD	adams-oliver syndrome 3, 614814 (3),
RBPJL		
RBPMS		
RBPMS2		
RBPSUH	AD	adams-oliver syndrome 3, 614814 (3),
RBPSUHL		
RBQ3		
RBS	AR	juberg-hayward syndrome, 216100 (3), ; roberts-sc phocomelia syndrome, 268300 (3),
rbSec1	AR,AD	developmental and epileptic encephalopathy 4, 612164 (3),
RBSK		
RBSN		
RBSP3		
RBT1		
RBTN1		leukemia, t-cell acute lymphoblastic, 186921 (2)
RBTN2		leukemia, acute t-cell, 180385 (2)
RBTNL1		leukemia, acute t-cell, 180385 (2)
RBTNL2		
RBX1		
RBX2		
RC		
RC-68		
RC-74		
RC1		
RC3	AR,AD	developmental and epileptic encephalopathy 81, 618663 (3), ; ?deafness, 71, 617605 (3), ; ?polyendocrine-polyneuropathy syndrome, 616113 (3),
RC3H1		?immune dysregulation and systemic hyperinflammation syndrome, 618998 (3)
RC3H2		
RC6-1		
RCA1		renal cell carcinoma, 144700 (3)
RCAD		
RCAF1	AR	?craniofacial dysmorphism, skeletal anomalies, and impaired intellectual development syndrome 2, 616994 (3),
Rcal		
RCAN1		
RCAN2		
RCAN3		
RCAS1		
RCBTB1	AR	retinal dystrophy with or without extraocular anomalies, 617175 (3),
RCBTB2		
RCC	AR	?spinocerebellar ataxia, 26, 617633 (3),
RCC1		
RCC2		
RCC4		
RCCD1		
RCCP1		renal cell carcinoma, papillary, 605074 (3)
RCCP2	AD,AR	renal cell carcinoma, papillary, 1, familial and somatic, 605074 (3); ?arthrogryposis, distal, type 11, 620019 (3), ; hepatocellular carcinoma, childhood type, somatic, 114550 (3); {osteofibrous dysplasia, susceptibility to}, 607278 (3), ; ?deafness, 97, 616705 (3),
RCD-8		
Rcd1		
RCD1		
RCD1+		
RCDG1		
RCE1		
RCE1A		
RCE1B		
RCF1A		
RCH1		
RCH2		
RCHY1		
RCK	AD	intellectual developmental disorder with impaired language and dysmorphic facies, 618653 (3),
Rck/p54	AD	intellectual developmental disorder with impaired language and dysmorphic facies, 618653 (3),
rcl		
RCL1		
RCN		
RCN1		
RCN2		
RCN3		
RCNC1	AR	retinitis pigmentosa 49, 613756 (3),
RCNC2	AR	retinitis pigmentosa 45, 613767 (3),
RCNCa	AR	retinitis pigmentosa 49, 613756 (3),
RCNCb	AR	retinitis pigmentosa 45, 613767 (3),
RCOR		
RCoR-1		
RCOR1		
RCOR2		
RCP	XLR,XL	blue cone monochromacy, 303700 (3), ; colorblindness, protan, 303900 (3),
RCP9		
RCS1		
RCSD1		
RCV1		
RCVRN		
RD	AR,AR	[blood group, scianna system], 111750 (3); [blood group, radin], 111620 (3)|refsum disease, 266500 (3), |rhizomelic chondrodysplasia punctata, type 1, 215100 (3), ; peroxisome biogenesis disorder 9b, 614879 (3),
rd1	AR,AD	retinitis pigmentosa-40, 613801 (3), ; night blindness, congenital stationary, 2, 163500 (3),
rd12	AR,AD	retinitis pigmentosa 20, 613794 (3), ; retinitis pigmentosa 87 with choroidal involvement, 618697 (3), ; leber congenital amaurosis 2, 204100 (3),
rd16	AR	leber congenital amaurosis 10, 611755 (3); joubert syndrome 5, 610188 (3), ; senior-loken syndrome 6, 610189 (3), ; ?bardet-biedl syndrome 14, 615991 (3), ; meckel syndrome 4, 611134 (3),
rd2	AD,AR	macular dystrophy, patterned, 1, 169150 (3), ; choroidal dystrophy, central areolar 2, 613105 (3), ; retinitis punctata albescens, 136880 (3), ; leber congenital amaurosis 18, 608133 (3), digenic , ; macular dystrophy, vitelliform, 3, 608161 (3), ; retinitis pigmentosa 7 and digenic form, 608133 (3), digenic ,
RD3	AR	leber congenital amaurosis 12, 610612 (3),
rd5	AR	?retinal dystrophy and obesity, 616188 (3),
rd6	AR	microphthalmia, isolated 5, 611040 (3), ; nanophthalmos 2, 609549 (3)
rd7	AR,AD	retinitis pigmentosa 37, 611131 (3), ; enhanced s-cone syndrome, 268100 (3),
Rd9		
RDA32		
RDBP		
RDC-1	AD	ataxia, intention tremor, and hypotonia syndrome, childhood-onset, 619352 (3),
RDC1	AR	?oculomotor-abducens synkinesis, 619215 (3),
RDC4		
RDC7		
RDC8		
RDCVF		
RdCVF2		
RDGB		
RDGB-BETA		
RDGB1		
RDGB2		
RDGBA1		
RDGBA2		
RDGBA3	AD	cone-rod dystrophy 5, 600977 (3),
RDGBB		
RDGBB1		
RDH-E2		
RDH1	AR,AD	fundus albipunctatus, 136880 (3),
RDH10		
RDH11	AR	?retinal dystrophy, juvenile cataracts, and short stature syndrome, 616108 (3),
RDH12	AR,AD	leber congenital amaurosis 13, 612712 (3),
RDH14		
RDH15		
RDH16		
RDH17		
RDH5	AR,AD	fundus albipunctatus, 136880 (3),
RDH54		colon cancer, somatic, 114500 (3); lymphoma, non-hodgkin, somatic, 605027 (3)
RDH8		
RDHE2		
RDHL		
RDHS	AR	ichthyosis, congenital, 13, 617574 (3),
RDM1		
RDP		
RDRC		
RDRTA2	AR	distal renal tubular acidosis 3, with or without sensorineural hearing loss, 602722 (3),
RDS	AD,AR	macular dystrophy, patterned, 1, 169150 (3), ; choroidal dystrophy, central areolar 2, 613105 (3), ; retinitis punctata albescens, 136880 (3), ; leber congenital amaurosis 18, 608133 (3), digenic , ; macular dystrophy, vitelliform, 3, 608161 (3), ; retinitis pigmentosa 7 and digenic form, 608133 (3), digenic ,
Rds3		
RDT	AD	rhabdoid tumors, somatic, 609322 (3); {schwannomatosis-1, susceptibility to}, 162091 (3), ; coffin-siris syndrome 3, 614608 (3), ; {rhabdoid tumor predisposition syndrome 1}, 609322 (3),
RDX	AR	deafness, 24, 611022 (3),
Rdx12		
RE2	AR,AD	{medulloblastoma predisposition syndrome}, 155255 (3), somatic mutation,
REA		
Rea1		
REC	AR	?premature ovarian failure 10, 612885 (3),
rec.1.3		
REC01035		
REC1		
REC114	AR	oocyte/zygote/embryo maturation arrest 10, 619176 (3),
REC14		
REC1L		
REC2		
REC8		
REC8L1		
Rec8p		
RECA	AD	mirror movements 2, 614508 (3), ; {breast cancer, susceptibility to}, 114480 (3), somatic mutation, ; fanconi anemia, complementation group r, 617244 (3),
RECK		
RecQ1	AR	recon progeroid syndrome, 620370 (3),
RECQ2	AR	bloom syndrome, 210900 (3),
RECQ3	AR	werner syndrome, 277700 (3),
RecQ4	AR	baller-gerold syndrome, 218600 (3), ; rothmund-thomson syndrome, type 2, 268400 (3), ; rapadilino syndrome, 266280 (3),
RecQ5		
RECQL	AR	recon progeroid syndrome, 620370 (3),
RecQL1	AR	recon progeroid syndrome, 620370 (3),
RECQL2	AR	werner syndrome, 277700 (3),
RECQL3	AR	bloom syndrome, 210900 (3),
RECQL4	AR	baller-gerold syndrome, 218600 (3), ; rothmund-thomson syndrome, type 2, 268400 (3), ; rapadilino syndrome, 266280 (3),
RECQL5		
RECS1		
RED		
RED1	AR	neurodevelopmental disorder with hypotonia, microcephaly, and seizures, 618862 (3),
RED2		
REDD-1		
REDD1		
REDD2		
REDK		
REEP1	AD,AR	?neuronopathy, distal hereditary motor, type vb, 614751 (3), ; spastic paraplegia 31, 610250 (3), ; spinal muscular atrophy, distal, 6, 620011 (3),
REEP2	AD,AR	?spastic paraplegia 72, 615625 (3), ; ?spastic paraplegia 72, 615625 (3),
REEP3		
REEP4		
REEP5		
REEP6	AR	retinitis pigmentosa 77, 617304 (3),
REF		
REF-1		
REF1		
RefilinA		
RefilinB		
REG		
REG-GAMMA		
REG-III		
REG-IV		
REG1A		
REG1B		
REG3		
REG3A		
REG3G		
REG4		
REGH		
REGI-BETA		
REGL		
Regnase-1		
REGR	AR	immunoskeletal dysplasia with neurodevelopmental abnormalities, 617425 (3),
REH3P21		
REHF-1		
REIC		
Rek		
REL	AR	immunodeficiency 92, 619652 (3),
REL-B	AR	?immunodeficiency 53, 617585 (3),
RELA	AD	autoinflammatory disease, familial, behcet-like-3, 618287 (3),
RELB	AR	?immunodeficiency 53, 617585 (3),
RELCH		
RELL1		
RELL2		
RELMb		
RELN	AD,AR	{epilepsy, familial temporal lobe, 7}, 616436 (3), ; lissencephaly 2 (norman-roberts type), 257320 (3),
RELP		
RELT	AR	amelogenesis imperfecta, type iiic, 618386 (3),
REM		
REM1		
REM2		
REM3		
REMP		
REN	AR,AD	renal tubular dysgenesis, 267430 (3), ; [hyperproreninemia] (3); tubulointerstitial kidney disease, 4, 613092 (3),
renalase		
RENBP		
RENR	XL,XLR	intellectual developmental disorder, syndromic, hedera type, 300423 (3), ; ?parkinsonism with spasticity, 300911 (3), ; congenital disorder of glycosylation, type iir, 301045 (3),
RENS1	XLR,XL	renpenning syndrome, 309500 (3),
RENT1		
RENT2		
RENT3A		
RENT3B	XL,XLR	intellectual developmental disorder, syndromic 14, 300676 (3),
REP-1	XL	choroideremia, 303100 (3),
REP-2		
REP15		
REP8		
REPA1	AD	pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 6, 619767 (3),
REPA3		
REPIN1		
Repo-Man		
REPRIMO		
Repro-SA-1		
REPS1	AR	?neurodegeneration with brain iron accumulation 7, 617916 (3),
REPS2		
Reptin52		
REQ	AD	coffin-siris syndrome 7, 618027 (3),
RER		
RER1		
RERE	AD	neurodevelopmental disorder with or without anomalies of the brain, eye, or heart, 616975 (3),
RERG		
RES4-22		
RES4-23	AD	cherubism, 118400 (3),
RES4-25		
RES4-26		
RESA1	AR	spinocerebellar ataxia, with axonal neuropathy 3, 618387 (3),
RESF1		
RESP18		
REST	AD	deafness, 27, 612431 (3), ; {wilms tumor 6, susceptibility to}, 616806 (3), ; fibromatosis, gingival, 5, 617626 (3),
RET	AD	{hirschsprung disease, susceptibility to, 1}, 142623 (3), ; multiple endocrine neoplasia iia, 171400 (3), ; {hirschsprung disease, protection against}, 142623 (3), ; medullary thyroid carcinoma, 155240 (3), ; pheochromocytoma, 171300 (3), ; multiple endocrine neoplasia iib, 162300 (3),
ret-II		
RET1	AR	microphthalmia, isolated 2, 610093 (3), ; microphthalmia with coloboma 3, 610092 (3),
RET1L	AR	renal hypodysplasia/aplasia 4, 619887 (3),
RET51	AD	{hirschsprung disease, susceptibility to, 1}, 142623 (3), ; multiple endocrine neoplasia iia, 171400 (3), ; {hirschsprung disease, protection against}, 142623 (3), ; medullary thyroid carcinoma, 155240 (3), ; pheochromocytoma, 171300 (3), ; multiple endocrine neoplasia iib, 162300 (3),
retDSR4		
retGC	AR,AD	cone-rod dystrophy 6, 601777 (3), ; ?choroidal dystrophy, central areolar 1, 215500 (3), ; leber congenital amaurosis 1, 204000 (3), ; night blindness, congenital stationary, type 1i, 618555 (3),
RETGC-1	AR,AD	cone-rod dystrophy 6, 601777 (3), ; ?choroidal dystrophy, central areolar 1, 215500 (3), ; leber congenital amaurosis 1, 204000 (3), ; night blindness, congenital stationary, type 1i, 618555 (3),
RetGC-2		
RETL1	AR	renal hypodysplasia/aplasia 4, 619887 (3),
RETL2		
RETN	AD	{hypertension, insulin resistance-related, susceptibility to}, 125853 (3), ; {diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3),
RETN1	AD	{hypertension, insulin resistance-related, susceptibility to}, 125853 (3), ; {diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3),
RETNLB		
RETREG1	AR	neuropathy, hereditary sensory and autonomic, type iib, 613115 (3),
RETREG3		
RETSAT		
retSDR1		
RetSDR2		
retSDR3		
RETSDR8		
Rev-ErbAalpha		
REV1		
REV1L		
REV3		
REV3L		
REV7	AR	?fanconi anemia, complementation group v, 617243 (3),
REVERBA		
REVERBalpha		
REVERBB		
REVERBbeta		
REX1		
REXO1		
REXO2		
REXO4		
RF-A	AD	pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 6, 619767 (3),
RF1		
RFB30		
RFC	AR	?megaloblastic anemia, folate-responsive, 601775 (3),
RFC1	AR,AR	?megaloblastic anemia, folate-responsive, 601775 (3), |cerebellar ataxia, neuropathy, and vestibular areflexia syndrome, 614575 (3),
RFC140	AR	cerebellar ataxia, neuropathy, and vestibular areflexia syndrome, 614575 (3),
RFC2		
RFC3		
RFC36		
RFC37		
RFC38		
RFC4		
RFC40		
RFC5		
RFFL		
RFG		
rfg5		
RFG7		
RFK		
RFLAT-1		
RFLNA		
RFLNB		
RFNG		
RFP		
RFP2		
RFP2OS		
RFPL1		
RFPL1-AS		
RFPL1-AS1		
RFPL1S		
RFPL2		
RFPL3		
RFPL3-AS		
RFPL3-AS1		
RFPL3S		
RFPL4		
RFPL4A		
RFRP		
RFSN		retinitis pigmentosa 30, 607921 (3)
RFT-1	AR	?megaloblastic anemia, folate-responsive, 601775 (3),
RFT1	AR	congenital disorder of glycosylation, type in, 612015 (3),
RFT2	AR	?fazio-londe disease, 211500 (3), ; brown-vialetto-van laere syndrome 1, 211530 (3),
RFT3	AR	brown-vialetto-van laere syndrome 2, 614707 (3),
RFTN1		
RFTN2		
RFVT1	AD	riboflavin deficiency, 615026 (3),
RFVT2	AR	brown-vialetto-van laere syndrome 2, 614707 (3),
RFVT3	AR	?fazio-londe disease, 211500 (3), ; brown-vialetto-van laere syndrome 1, 211530 (3),
RFWD1	AD	cardiac, facial, and digital anomalies with developmental delay, 618164 (3),
RFWD2		
RFWD3	AR	?fanconi anemia, complementation group w, 617784 (3),
RFX-B	AR	bare lymphocyte syndrome, type ii, complementation group b, 209920 (3),
RFX1		
RFX2		
RFX3		
RFX4		
RFX5	AR	bare lymphocyte syndrome, type ii, complementation group c, 209920 (3), ; bare lymphocyte syndrome, type ii, complementation group e, 209920 (3),
RFX6	AR	mitchell-riley syndrome, 615710 (3),
RFX7	AD	intellectual developmental disorder, 71, with behavioral abnormalities, 620330 (3),
RFXANK	AR	bare lymphocyte syndrome, type ii, complementation group b, 209920 (3),
RFXAP	AR	bare lymphocyte syndrome, type ii, complementation group d, 209920 (3),
RFXDC1	AR	mitchell-riley syndrome, 615710 (3),
RFXDC2	AD	intellectual developmental disorder, 71, with behavioral abnormalities, 620330 (3),
RG	AR	[blood group, rodgers], 614374 (3); c4a deficiency, 614380 (3),
RG083M05.2	AR	?cardiomyopathy, dilated, 2b, 614672 (3),
RG7MT1		
RG9MTD1	AR	combined oxidative phosphorylation deficiency 30, 616974 (3),
RG9MTD2	AR	microcephaly, short stature, and impaired glucose metabolism 1, 616033 (3),
RGAG1		
RGAG2		
RGAG3		
RGC-32		
RGC32		
RGCC		
RGDS		
RGF		
RGI1	AR	cone-rod dystrophy 13, 608194 (3), ; leber congenital amaurosis 6, 613826 (3),
RGL		
RGL1		
RGL2		
RGL3		
RGL4		
RGM		
RGMA		
RGMB		
RGMC	AR	hemochromatosis, type 2a, 602390 (3),
RGN		
RGNEF		
RGP1		
RGP2		
RGP3		
RGP4		
RGP5		
RGP6		
RGPD1		
RGPD2		
RGPD3		
RGPD4		
RGPD5		
RGPD6		
RGPD8		
RGPR		
Rgr		
RGR		retinitis pigmentosa 44, 613769 (3)
RGR1		
RGS	AD	ring dermoid of cornea, 180550 (3), ; axenfeld-rieger syndrome, type 1, 180500 (3), ; anterior segment dysgenesis 4, 137600 (3),
RGS-17		
RGS-PX1		
RGS-PX2	AR	spinocerebellar ataxia, 20, 616354 (3),
RGS-r		
RGS1		
RGS10		
RGS11		
RGS12		
RGS13		
RGS14		
RGS16		
RGS17		
RGS18		
RGS19		
RGS19IP1	AD	oculopharyngodistal myopathy 2, 618940 (3),
RGS2		
RGS20		
RGS21		
RGS22		
RGS3		
RGS4		
RGS5	MF	[blood pressure regulation qtl], 145500 (2),
RGS6		
RGS7		
RGS7BP		
RGS8		
RGS9		bradyopsia 1, 608415 (3)
RGS9BP		bradyopsia 2, 620344 (3)
RGS9L		bradyopsia 1, 608415 (3)
RGSGAIP		
RGSL1		
RGSL2		
RGSZ1		
RGSZ2		
RH		{hemolytic disease of fetus and newborn, rh-induced}, 619462 (3), isolated cases; [blood group, rh system], 111690 (3)|rh-null disease, amorph type, 617970 (3)
RH-II/GU		
RH-II/GuB		
Rh30a		{hemolytic disease of fetus and newborn, rh-induced}, 619462 (3), isolated cases; [blood group, rh system], 111690 (3)
Rh4		{hemolytic disease of fetus and newborn, rh-induced}, 619462 (3), isolated cases; [blood group, rh system], 111690 (3)
RH50A	AD,AR	overhydrated hereditary stomatocytosis, 185000 (3), ; anemia, hemolytic, rh-null, regulator type, 268150 (3),
RHA		
RHAG	AD,AR	overhydrated hereditary stomatocytosis, 185000 (3), ; anemia, hemolytic, rh-null, regulator type, 268150 (3),
RHAMM	AD	{breast cancer, susceptibility to}, 114480 (3), somatic mutation,
RHAU		
RHBDD1		
RHBDD2		
RHBDF1		
RHBDF2	AD	tylosis with esophageal cancer, 148500 (3),
RHBDL		
RHBDL1		
RHBDL2		
RHBDL3		
RHBDL4		
RHBDL5	AD	tylosis with esophageal cancer, 148500 (3),
RHBDL6	AD	tylosis with esophageal cancer, 148500 (3),
RHBDL7		
RHBDS1		
RHBG		
RHCE		rh-null disease, amorph type, 617970 (3)
RHCG		
RHD		{hemolytic disease of fetus and newborn, rh-induced}, 619462 (3), isolated cases; [blood group, rh system], 111690 (3)
RHEB		
RHEB2		
RHEBL1		
RHELP		
Rhes		
RHEX		
RHGK		
RhII		{hemolytic disease of fetus and newborn, rh-induced}, 619462 (3), isolated cases; [blood group, rh system], 111690 (3)
RHINO		
RHNO1		
Rho		
RHO	AD,AR	night blindness, congenital stationary, 1, 610445 (3), ; retinitis pigmentosa 4, or , 613731 (3), ; retinitis punctata albescens, 136880 (3),
Rho12		ectodermal dysplasia with facial dysmorphism and acral, ocular, and brain anomalies, somatic mosaic, 618727 (3)
Rho6		
Rho7		
Rho8		
RHOA		ectodermal dysplasia with facial dysmorphism and acral, ocular, and brain anomalies, somatic mosaic, 618727 (3)
RHOB		
RHOBTB1		
RHOBTB2	AD	developmental and epileptic encephalopathy 64, 618004 (3),
RHOBTB3		
RHOC		
RHOD		
RhoE		
RHOF		
RHOG		
RhoGAP		
RhoGAP2	AD	duane retraction syndrome 2, 604356 (3),
RhoGAP3		
RhoGAP4		
RhoGAP5		
rhoGAPX-1		
RHOGDI	AR	nephrotic syndrome, type 8, 615244 (3),
RHOGDI-3		
RhoGDI2		
RHOH	AR	{?epidermodysplasia verruciformis, susceptibility to, 4}, 618307 (3),
RHOH12		ectodermal dysplasia with facial dysmorphism and acral, ocular, and brain anomalies, somatic mosaic, 618727 (3)
RHOH6		
RhoHP1		
RHOIP3		
RHOJ		
RHOK		oguchi disease-2, 613411 (3)
Rhom-3		
RHOM1		leukemia, t-cell acute lymphoblastic, 186921 (2)
RHOM2		leukemia, acute t-cell, 180385 (2)
RhoN		
RHOQ		
RHOS		
RHOT1		
RHOT2		
RHOU		
RHOV		
RHOXF1		
RHOXF1P1		
RHOXF2		
RhPI		{hemolytic disease of fetus and newborn, rh-induced}, 619462 (3), isolated cases; [blood group, rh system], 111690 (3)
RHPN		
RHPN1		
RHPN2		
RI58		
RIA1	AR	shwachman-diamond syndrome 2, 617941 (3),
RIAM		
Rian		
RIAZ		
RIB72	AD	{epilepsy, juvenile absence, susceptibility to, 1}, 607631 (3), ; {myoclonic epilepsy, juvenile, susceptibility to, 1}, 254770 (3),
RIBA		
RIBB	AD	noonan syndrome 8, 615355 (3),
ribeye		
RIBIIR		
RIC-4	AD	?myasthenic syndrome, congenital, 18, 616330 (3),
RIC1	AR	catifa syndrome, 618761 (3),
RIC3		
RIC4	AD	?myasthenic syndrome, congenital, 18, 616330 (3),
RIC8		
RIC8A		
RIC8B		
RICH-2		
RICH1		
RICH2		
RICK		
RICS		
RICTOR		
RIDA		
RIE2		
RIEG	AD	ring dermoid of cornea, 180550 (3), ; axenfeld-rieger syndrome, type 1, 180500 (3), ; anterior segment dysgenesis 4, 137600 (3),
RIEG1	AD	ring dermoid of cornea, 180550 (3), ; axenfeld-rieger syndrome, type 1, 180500 (3), ; anterior segment dysgenesis 4, 137600 (3),
RIF		
RIF1		?facioscapulohumeral muscular dystrophy 3, digenic, 619477 (3), digenic
RIFF		
rififylin		
RIFK		
RIFL		
RIFLE	AR,AD	charcot-marie-tooth disease, axonal, type 2p, 614436 (3),
RIG		
RIG-1	AD	singleton-merten syndrome 2, 616298 (3),
RIG-E		
RIG-G		
RIG-I	AD	singleton-merten syndrome 2, 616298 (3),
RIG1	AD	singleton-merten syndrome 2, 616298 (3),
RIGB		
RIGI	AD	singleton-merten syndrome 2, 616298 (3),
RIGUI		
RIHFB2157	XLD,XL	amyotrophic lateral sclerosis 15, with or without frontotemporal dementia, 300857 (3),
RIL	AD	{osteoporosis, susceptibility to}, 166710 (3),
RILP	AR	epilepsy, progressive myoclonic 1b, 612437 (3),
RILPL1	AD	oculopharyngodistal myopathy 4, 619790 (3),
RILPL2		
RIM	AD,AR	cone-rod dystrophy 7, 603649 (3), |seckel syndrome 2, 606744 (3), ; jawad syndrome, 251255 (3), ; pancreatic carcinoma, somatic (3)
RIM-BP1		
RIM-BP2		
RIM1	AD	cone-rod dystrophy 7, 603649 (3),
RIM2	AR	cone-rod synaptic disorder syndrome, congenital nonprogressive, 618970 (3),
RIM3		
RIMBP1		
RIMBP2		
RIMBP3		
RIMBP3.1		
RIMBP3A		
RIMBP3B		
RIMBP3C		
RIMKLA		
RIMKLB		
RIMOC1		
RIMS1	AD	cone-rod dystrophy 7, 603649 (3),
RIMS2	AR	cone-rod synaptic disorder syndrome, congenital nonprogressive, 618970 (3),
RIMS3		
RIMS4		
RIN		
RIN1		
RIN2	AR	macrocephaly, alopecia, cutis laxa, and scoliosis, 613075 (3),
RIN3		
RINCK		
RINF		
RING1		
RING10	AR	proteasome-associated autoinflammatory syndrome 1 and digenic forms, 256040 (3),
RING11	AR	bare lymphocyte syndrome, type i, due to tap2 deficiency, 604571 (3),
RING12	AR	?proteasome-associated autoinflammatory syndrome 3, digenic, 617591 (3),
RING1B	AD	luo-schoch-yamamoto syndrome, 619460 (3),
RING2	AD	luo-schoch-yamamoto syndrome, 619460 (3),
RING3		
RING3L		
RING4	AR	bare lymphocyte syndrome, type i, 604571 (3),
RING5	AR	agammaglobulinemia 9, 619693 (3),
RING6		
RING7		
Ringo1		
Ringo2		
Ringo3		
RINN1		
RINN2		
RINN3		
RINT-1	AR	infantile liver failure syndrome 3, 618641 (3),
RINT1	AR	infantile liver failure syndrome 3, 618641 (3),
RINZF		
RIOK1		
RIOK2		
RIOK3		
RIOX1		
RIOX2		
RIP	AR,AD	immunodeficiency 57 with autoinflammation, 618108 (3), ; autoinflammation with episodic fever and lymphadenopathy, 618852 (3),
RIP-1	AR,AD	immunodeficiency 57 with autoinflammation, 618108 (3), ; autoinflammation with episodic fever and lymphadenopathy, 618852 (3),
RIP1	AR,AD,AR	immunodeficiency 57 with autoinflammation, 618108 (3), ; autoinflammation with episodic fever and lymphadenopathy, 618852 (3), |mitochondrial complex iii deficiency, nuclear type 10, 618775 (3),
RIP11		
RIP14	AR	cholestasis, progressive familial intrahepatic, 5, 617049 (3),
RIP140	AD	?congenital anomalies of kidney and urinary tract 3, 618270 (3),
RIP15		
RIP160		
RIP2		
RIP25		
RIP3		
RIP4	AR	chand syndrome, 214350 (3), ; popliteal pterygium syndrome, bartsocas-papas type 1, 263650 (3),
RIP5	AR,AD,AR	?craniofacial dysmorphism, skeletal anomalies, and impaired intellectual development syndrome 2, 616994 (3), |congenital anomalies of kidney and urinary tract 1, 610805 (3), ; spastic paraplegia 23, 270750 (3),
RIP60		
RIPE3b1	AD	insulinomatosis and diabetes mellitus, 147630 (3),
RIPK1	AR,AD	immunodeficiency 57 with autoinflammation, 618108 (3), ; autoinflammation with episodic fever and lymphadenopathy, 618852 (3),
RIPK2		
RIPK3		
RIPK4	AR	chand syndrome, 214350 (3), ; popliteal pterygium syndrome, bartsocas-papas type 1, 263650 (3),
RIPK5	AD,AR	congenital anomalies of kidney and urinary tract 1, 610805 (3), ; spastic paraplegia 23, 270750 (3),
RIPK6	AR	osteosclerotic metaphyseal dysplasia, 615198 (3),
RIPK7	AD	{parkinson disease 8}, 607060 (3),
RIPOR1		
RIPOR2	AD,AR	deafness, 21, 607017 (3), ; ?deafness, 104, 616515 (3),
RIPPLY1		
RIPPLY2	AR	?spondylocostal dysostosis 6, 616566 (3),
RIPPLY3		
RIPx		
RIR		
RIS1	AR	mitochondrial complex iii deficiency, nuclear type 10, 618775 (3),
RIS2	AR	meier-gorlin syndrome 4, 613804 (3),
RISC		
RISP	AR	mitochondrial complex iii deficiency, nuclear type 10, 618775 (3),
RIT	AD	noonan syndrome 8, 615355 (3),
RIT1	AD	noonan syndrome 8, 615355 (3),
RIT2		
RITA		
RIZ		
RIZ1		
RIZ2		
RJD2		
RK		oguchi disease-2, 613411 (3)
RK5		
RKHD1		
RKHD2		
RKHD3		
RKHD4		
RKIP		
RL	AD,AR	{epilepsy, familial temporal lobe, 7}, 616436 (3), ; lissencephaly 2 (norman-roberts type), 257320 (3),
RL14		
Rlb1		
RLBP1	AR,AD	bothnia retinal dystrophy, 607475 (3), ; newfoundland rod-cone dystrophy, 607476 (3); retinitis punctata albescens, 136880 (3), ; fundus albipunctatus, 136880 (3),
RLBP1L1		
RLBP1L2		
RLC		
RLD-1		
RLF	AD	cryptorchidism, 219050 (3),
RLGP		
RLI		
RLI1		
RLIM	XL	tonne-kalscheuer syndrome, 300978 (3),
RLIP76		
RLK		
RLLM1		
RLLV1833		
RLN1		
RLN2		
RLN3		
RLN3R1		
RLN3R2		
RLNL	AD	cryptorchidism, 219050 (3),
RLP49		
RLPK		
RLTPR	AR	immunodeficiency 58, 618131 (3),
RLX1		
RLXH2		
RM1		
RMA1		
RMC1		
RMCH	AR	achromatopsia 3, 262300 (3),
RMD1	AR	combined oxidative phosphorylation deficiency 11, 614922 (3),
RMD11	AD	epilepsy, familial focal, with variable foci 3, 617118 (3),
RMD2		
RMD3		
RMD5		
RMDN1		
RMDN2		
RMDN3		
RME8		
RMI1		
RMI2		
RMLP-R-I		
RMND1	AR	combined oxidative phosphorylation deficiency 11, 614922 (3),
RMND5A		
RMP		
RMRP	AR	anauxetic dysplasia 1, 607095 (3), ; metaphyseal dysplasia without hypotrichosis, 250460 (3), ; cartilage-hair hypoplasia, 250250 (3),
RMRPR	AR	anauxetic dysplasia 1, 607095 (3), ; metaphyseal dysplasia without hypotrichosis, 250460 (3), ; cartilage-hair hypoplasia, 250250 (3),
RMST		
RMTL1		
RN		
RN-tre		
RN3		
RN49018		
RN5S		
RN5S1@		
RN7SK		
RN7SL		
RN7SL1		
RN7SL2		
RN7SL3		
RN7SL631P		
RNAC		
RNAH		
RNAHP		
RNASE1		
RNASE2		
RNASE3		
RNASE3L		
RNASE4		
RNASE5		amyotrophic lateral sclerosis 9, 611895 (3)
RNASE6		
RNASE6PL	AR	leukoencephalopathy, cystic, without megalencephaly, 612951 (3),
RNASE7		
RNASE8		
RNASE9		
RNASEH1	AR	progressive external ophthalmoplegia with mitochondrial dna deletions, 2, 616479 (3),
RNASEH2A	AR	aicardi-goutieres syndrome 4, 610333 (3),
RNASEH2B	AR	aicardi-goutieres syndrome 2, 610181 (3),
RNASEH2C	AR	aicardi-goutieres syndrome 3, 610329 (3),
RNASEHI	AR	aicardi-goutieres syndrome 4, 610333 (3),
RNASEK		
RNaseK6		
RNASEL	AD	prostate cancer 1, 601518 (3),
RNASEL1		
RNASELI		
RNASEN		
RNASEP1		
RNASET2	AR	leukoencephalopathy, cystic, without megalencephaly, 612951 (3),
RNB6		
RNBP		
Rncr2		{myocardial infarction, susceptibility to}, 608446 (3)
RND1		
RND2		
RND3		
RNE1		
RNE2		
RNE3		
RNF		
RNF1		
RNF10		
RNF100		
RNF102		
RNF103		
RNF104		
RNF105		
RNF106		
RNF107		
RNF108	AR	?dystonia 32, 619637 (3), ; leukodystrophy, hypomyelinating, 12, 616683 (3),
RNF109		
RNF11		
RNF110	AD	turnpenny-fry syndrome, 618371 (3),
RNF111		
RNF112		
RNF113	XL	trichothiodystrophy 5, nonphotosensitive, 300953 (3),
RNF113A	XL	trichothiodystrophy 5, nonphotosensitive, 300953 (3),
RNF114		
RNF115		
RNF117		
RNF118	AD	{?encephalopathy, acute, infection-induced (herpes-specific), susceptibility to, 5}, 614849 (3),
RNF119	AD	cardiac, facial, and digital anomalies with developmental delay, 618164 (3),
RNF12	XL	tonne-kalscheuer syndrome, 300978 (3),
RNF120		
RNF123		
RNF125	AD	tenorio syndrome, 616260 (3),
RNF126		
RNF128		
RNF129		
RNF13	AD	developmental and epileptic encephalopathy 73, 618379 (3),
RNF130		
RNF131		
RNF132		
RNF134		
RNF135		
RNF137		
RNF138		
RNF139		renal cell carcinoma, 144700 (3)
RNF14		
RNF140		
RNF141		
RNF142		
RNF143		
RNF144		
RNF144A		
RNF144B		
RNF146		
RNF147		
RNF152		
RNF153		
RNF154		
RNF155		
RNF156		
RNF158		
RNF159		
RNF16		
RNF160		
RNF162		
RNF162A		
RNF162B		
RNF162C	AR	oocyte/zygote/embryo maturation arrest 13, 620154 (3),
RNF163	AD	myotonic dystrophy 2, 602668 (3),
RNF164		
RNF166		
RNF167		
RNF168	AR	riddle syndrome, 611943 (3),
RNF169		
RNF17		
RNF170	AD,AR	ataxia, sensory, 1, 608984 (3), ; spastic paraplegia 85, 619686 (3),
RNF171		
RNF172		
RNF173		
RNF174		
RNF176	AD	epilepsy, familial adult myoclonic, 3, 613608 (3),
RNF177		
RNF178		
RNF179		
RNF18		
RNF180		
RNF181		
RNF184		
RNF185		
RNF186		
RNF187		
RNF188		
RNF189		
RNF19		
RNF190		
RNF193		
RNF194		
RNF195		
RNF196		
RNF197		
RNF198		?immune dysregulation and systemic hyperinflammation syndrome, 618998 (3)
RNF199		
RNF19A		
RNF19B		
RNF2	AD	luo-schoch-yamamoto syndrome, 619460 (3),
RNF20		
RNF200		
RNF201	AR	?fanconi anemia, complementation group w, 617784 (3),
RNF202		
RNF203		
RNF204		
RNF205	AR	fetal akinesia deformation sequence 2, 618388 (3), ; myasthenic syndrome, congenital, 11, associated with acetylcholine receptor deficiency, 616326 (3),
RNF206	AR	seckel syndrome 9, 616777 (3),
RNF207		
RNF208		
RNF21		
RNF210		
RNF212	AR	?spermatogenic failure 62, 619673 (3), ; recombination rate qtl 1, 612042 (3)
RNF213	AR,AD	{moyamoya disease 2, susceptibility to}, 607151 (3),
RNF216	AR	cerebellar ataxia and hypogonadotropic hypogonadism, 212840 (3),
RNF217		
RNF217-AS1		
RNF218		
RNF219		
RNF22		
RNF220	AR	leukodystrophy, hypomyelinating, 23, with ataxia, deafness, liver dysfunction, and dilated cardiomyopathy, 619688 (3),
RNF221		
RNF226		
RNF23		
RNF24		
RNF25		
RNF26		
RNF27	AD	focal segmental glomerulosclerosis and neurodevelopmental syndrome, 619428 (3),
RNF28		
RNF29		
RNF3		
RNF30		
RNF31		
RNF32		
RNF32-DT		
RNF33		
RNF34		
RNF34L		
RNF35		
RNF36		
RNF37		
RNF38		
RNF39		
RNF3A		
RNF4		
RNF40		
RNF41		
RNF43	AD	sessile serrated polyposis cancer syndrome, 617108 (3),
RNF44		
RNF45	AR	spastic paraplegia 89, 620379 (3),
RNF46		
RNF47		
RNF48		
RNF49		
RNF5		
RNF50		
RNF51		
RNF52		
RNF53	AR,MF,AD	fanconi anemia, complementation group s, 617883 (3), ; {breast-ovarian cancer, familial, 1}, 604370 (3), ; {pancreatic cancer, susceptibility to, 4}, 614320 (3)
RNF54	AR	polyglucosan body myopathy 1 with or without immunodeficiency, 615895 (3),
RNF55	AD	noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia, 613563 (3), ; ?juvenile myelomonocytic leukemia, 607785 (3), somatic mutation,
RNF56		
RNF57		
RNF58		
RNF59	XLR,XL	opitz gbbb syndrome, 300000 (3),
RNF6		esophageal carcinoma, somatic, 133239 (3)
RNF60	XL,XLR	?intellectual developmental disorder, 101, 300928 (3),
RNF61		
RNF62		
RNF63	AD	precocious puberty, central, 2, 615346 (3),
RNF66		
RNF67		
RNF67B		
RNF68		
RNF69	AR	peroxisome biogenesis disorder 6a (zellweger), 614870 (3), ; peroxisome biogenesis disorder 6b, 614871 (3),
RNF7		
RNF70		
RNF71		leukemia, acute promyelocytic, pml/rara type (3)
RNF72	AR	peroxisome biogenesis disorder 5a (zellweger), 614866 (3), ; peroxisome biogenesis disorder 5b, 614867 (3),
RNF73		
RNF74	AR	omenn syndrome, 603554 (3), ; severe combined immunodeficiency, b cell-negative, 601457 (3), ; combined cellular and humoral immune defects with granulomas, 233650 (3), ; alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity, 609889 (3)
RNF75		
RNF76		
RNF77		
RNF78		
RNF79		
RNF8		
RNF80		
RNF81		
RNF82		
RNF83		
RNF84		
RNF85		
RNF86	AR	charcot-marie-tooth disease, type 2r, 615490 (3),
RNF88		
RNF89		
RNF9		
RNF90		
RNF91		
RNF92		
RNF94		
RNF95		
RNF96		
RNF97		
RNF98	AR	?anencephaly 1, 206500 (3),
RNF99		
RNFT1		
RNFT2		
RNG105		
RNG140		
RNGTT		
RNH		
RNH1		
RNH2		
RNHIA	AR	aicardi-goutieres syndrome 4, 610333 (3),
RNHL	AR	aicardi-goutieres syndrome 4, 610333 (3),
RNLS		
RNMT		
RNMT1		
RNMTL1		
RNMX	XL,XLR	?intellectual developmental disorder, syndromic 11, shashi type, 300238 (3),
RNNL		
RNO2	AD	familial cold autoinflammatory syndrome 2, 611762 (3),
RNP24		
RNPC1		
RNPC2		
RNPC3	AR	pituitary hormone deficiency, combined or isolated, 7, 618160 (3),
RNPC6		
RNPC7		
RNPEP		
RNPEPL1		
RNPS1		
RNPU1Z		
RNR1	AD	intellectual developmental disorder with language impairment and early-onset dopa-responsive dystonia-parkinsonism, 619911 (3),
RNR2		
RNR3		
RNR4		
RNR5		
RNS1		
RNS2		
RNS3		
RNS4	AD	prostate cancer 1, 601518 (3),
RNS4I		
RNS6		
RNSRP1		
RNSRP2		
RNSRP3		
RNTLS	AR	?infantile liver failure syndrome 1, 615438 (3),
RNTRE		
RNU1-4		
RNU105A		
RNU107		
RNU108		
RNU12	AR	cdags syndrome, 603116 (3), ; ?spinocerebellar ataxia, 33, 620208 (3),
RNU12-1	AR	cdags syndrome, 603116 (3), ; ?spinocerebellar ataxia, 33, 620208 (3),
RNU12P	AR	cdags syndrome, 603116 (3), ; ?spinocerebellar ataxia, 33, 620208 (3),
RNU13		
RNU15A		
RNU17A		
RNU17B		
RNU17C		
RNU17D		
RNU1D2		
RNU1E2		
RNU1F1		
RNU1G1		
RNU1G2		
RNU2-1		
RNU20		
RNU21		
RNU22		
RNU25		
RNU26		
RNU27		
RNU28		
RNU29		
RNU2AF1		
RNU3		
RNU30		
RNU31		
RNU3IP1		
RNU3IP2		
RNU43		
RNU4ATAC	AR	roifman syndrome, 616651 (3), ; lowry-wood syndrome, 226960 (3), ; microcephalic osteodysplastic primordial dwarfism, type i, 210710 (3),
RNU4ATAC1	AR	roifman syndrome, 616651 (3), ; lowry-wood syndrome, 226960 (3), ; microcephalic osteodysplastic primordial dwarfism, type i, 210710 (3),
RNU50		
RNU5A		
RNU5A-1		
RNU5C		
RNU5D		
RNU5D-1		
RNU5E		
RNU5E-1		
RNU5F		
RNU5F-1		
RNU6-1		
RNU6A		
RNU6ATAC		
RNU6ATAC1		
RNU6C		
RNU7	AR	aicardi-goutieres syndrome 9, 619487 (3),
RNU7-1	AR	aicardi-goutieres syndrome 9, 619487 (3),
RNU73		
RNU73A		
RNU82		
RNU83A		
RNU83B		
RNUT1		
RNUXA		
RNX		
RNY1		
RNY3		
RNY4		
RNY5		
RO		myelofibrosis, somatic, 254450 (3); thrombocythemia, somatic, 187950 (3)
RO52		
RO60		
ROAT1		
ROBLD1		
ROBLD2		
ROBLD3	AR	immunodeficiency due to defect in mapbp-interacting protein, 610798 (3),
ROBO1	AD,AR	pituitary hormone deficiency, combined or isolated, 8, 620303 (3), ; neurooculorenal syndrome, 620305 (3), ; ?nystagmus 8, congenital, 257400 (3),
ROBO2	AD	vesicoureteral reflux 2, 610878 (3),
ROBO3	AR	gaze palsy, familial horizontal, with progressive scoliosis, 1, 607313 (3),
ROBO4	AD	aortic valve disease 3, 618496 (3),
RoBPI	AD	verheij syndrome, 615583 (3),
ROC1	AD	noonan syndrome 8, 615355 (3),
ROC2		
ROC22	AR	joubert syndrome 25, 616781 (3), ; intellectual developmental disorder, 77, 619988 (3),
ROCK1		
ROCK2		
ROCO1	AR	osteosclerotic metaphyseal dysplasia, 615198 (3),
ROCO2	AD	{parkinson disease 8}, 607060 (3),
ROD		
ROD1		
RODH		
RODH-4		
RODX	AR	night blindness, congenital stationary (complete), 1d, 613830 (3),
Rog		
ROGD1	AR	kohlschutter-tonz syndrome, 226750 (3),
ROGDI	AR	kohlschutter-tonz syndrome, 226750 (3),
ROK1		
rols	AD	intellectual developmental disorder with autistic features and language delay, with or without seizures, 618906 (3),
ROLSA	AD	intellectual developmental disorder with autistic features and language delay, with or without seizures, 618906 (3),
ROLSB		
ROLT		
ROM	AR,AD	retinitis pigmentosa 7, digenic form, 608133 (3), digenic ,
ROM1	AR,AD	retinitis pigmentosa 7, digenic form, 608133 (3), digenic ,
ROMK1	AR	bartter syndrome, type 2, 241200 (3),
ROMO1		
RON	AD	{nasopharyngeal carcinoma, susceptibility to, 3}, 617075 (3),
RONIN		
RONU	AD,AR	t-cell lymphopenia, infantile, with or without nail dystrophy, 618806 (3), ; t-cell immunodeficiency, congenital alopecia, and nail dystrophy, 601705 (3),
rootletin		
ROPN1		
ROPN1A		
ROPN1L		
ROPP120		
ropporin		
roquin		?immune dysregulation and systemic hyperinflammation syndrome, 618998 (3)
ROR		
ROR-alpha	AD	intellectual developmental disorder with or without epilepsy or cerebellar ataxia, 618060 (3),
ROR-BETA	AD	{epilepsy, idiopathic generalized, susceptibility to, 15}, 618357 (3),
ROR1	AR,AD	?deafness, 108, 617654 (3), |intellectual developmental disorder with or without epilepsy or cerebellar ataxia, 618060 (3),
ROR2	AD,AR,AD	brachydactyly, type b1, 113000 (3), ; robinow syndrome, 268310 (3), |intellectual developmental disorder with or without epilepsy or cerebellar ataxia, 618060 (3),
ROR3	AD	intellectual developmental disorder with or without epilepsy or cerebellar ataxia, 618060 (3),
RORA	AD	intellectual developmental disorder with or without epilepsy or cerebellar ataxia, 618060 (3),
RORa1	AD	intellectual developmental disorder with or without epilepsy or cerebellar ataxia, 618060 (3),
RORalpha	AD	intellectual developmental disorder with or without epilepsy or cerebellar ataxia, 618060 (3),
RORB	AD	{epilepsy, idiopathic generalized, susceptibility to, 15}, 618357 (3),
RORC	AR	immunodeficiency 42, 616622 (3),
RORG	AR	immunodeficiency 42, 616622 (3),
ROS		
ROS-GC	AR,AD	cone-rod dystrophy 6, 601777 (3), ; ?choroidal dystrophy, central areolar 1, 215500 (3), ; leber congenital amaurosis 1, 204000 (3), ; night blindness, congenital stationary, type 1i, 618555 (3),
ROS-GC1	AR,AD	cone-rod dystrophy 6, 601777 (3), ; ?choroidal dystrophy, central areolar 1, 215500 (3), ; leber congenital amaurosis 1, 204000 (3), ; night blindness, congenital stationary, type 1i, 618555 (3),
ROS-GC2		
ROS1		
ROSBIN		
ROX		
RoXaN		
RP-A	AD	pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 6, 619767 (3),
RP-S7	AR	?combined oxidative phosphorylation deficiency 34, 617872 (3),
RP1	AR,AD,AD	retinitis pigmentosa 1, 180100 (3), |symmetric circumferential skin creases, congenital, 2, 616734 (3),
RP1-112K5.2	XLR,XL	?diamond-blackfan anemia 14 with mandibulofacial dysostosis, 300946 (3),
RP1-127C7.4		
RP1-159A19.1	AD	xia-gibbs syndrome, 615829 (3),
RP1-170O19.3		
RP1-286D6.3		
RP1-286D6.4	AR	joubert syndrome 25, 616781 (3), ; intellectual developmental disorder, 77, 619988 (3),
RP1-299I16		
RP1-313L4.2	AD	{hypercalciuria, absorptive, susceptibility to}, 143870 (3),
RP1-93H18.5		
RP10	AD	retinitis pigmentosa 10, 180105 (3), ; leber congenital amaurosis 11, 613837 (3),
RP105		
RP11	AD	retinitis pigmentosa 11, 600138 (3),
RP11-11C5.2		
RP11-13G14		
RP11-145E5.4		
RP11-157D18.1		
RP11-19J3.3		
RP11-265F14.2		
RP11-284N8.3		
RP11-311P8.3		
RP11-312O7.1		
RP11-321G1.1	XL	nephrotic syndrome, type 20, 301028 (3),
RP11-344H11.3	AD	?ectodermal dysplasia 12, hypohidrotic/hair/tooth/nail type, 617337 (3),
RP11-363D14		
RP11-403E24.2	XLD,XL	osteopathia striata with cranial sclerosis, 300373 (3),
RP11-439A17.6		
RP11-46F15.3		
RP11-479E16.1		
RP11-48C7.2		
RP11-506B15.1	AR	developmental and epileptic encephalopathy 18, 615476 (3),
RP11-519K18.1	AD	neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies, 618659 (3),
RP11-529I10.4		
RP11-540D14.5		
RP11-54H19.7		
RP11-54O7.8		
RP11-82K18.3		
RP11-88G17		
RP12	AR,AD	leber congenital amaurosis 8, 613835 (3), ; retinitis pigmentosa-12, 600105 (3), ; pigmented paravenous chorioretinal atrophy, 172870 (3),
RP13	AD	retinitis pigmentosa 13, 600059 (3),
RP13-11B7.1	XL,XLR	spermatogenic failure, 3, 301059 (3),
RP14	AR	leber congenital amaurosis 15, 613843 (3), ; retinitis pigmentosa 14, 600132 (3),
RP15	XL,XLR	retinitis pigmentosa, and sinorespiratory infections, with or without deafness, 300455 (3), ; cone-rod dystrophy, 1, 304020 (3), ; retinitis pigmentosa 3, 300029 (3), ; macular degeneration, atrophic, 300834 (3),
RP17		
RP18	AD	retinitis pigmentosa 18, 601414 (3),
RP19	AR,AD	retinal dystrophy, early-onset severe, 248200 (3), ; retinitis pigmentosa 19, 601718 (3), ; {macular degeneration, age-related, 2}, 153800 (3), ; cone-rod dystrophy 3, 604116 (3), ; fundus flavimaculatus, 248200 (3), ; stargardt disease 1, 248200 (3),
RP1L1	AD,AR	occult macular dystrophy, 613587 (3), ; retinitis pigmentosa 88, 618826 (3),
RP2	XL	retinitis pigmentosa 2, 312600 (3),
RP20	AR,AD	retinitis pigmentosa 20, 613794 (3), ; retinitis pigmentosa 87 with choroidal involvement, 618697 (3), ; leber congenital amaurosis 2, 204100 (3),
RP23	XLR,XL,XLD	simpson-golabi-behmel syndrome, type 2, 300209 (3), ; ?retinitis pigmentosa 23, 300424 (3), ; orofaciodigital syndrome i, 311200 (3), ; joubert syndrome 10, 300804 (3),
RP25	AR	retinitis pigmentosa 25, 602772 (3),
RP26	AR	retinitis pigmentosa 26, 608380 (3),
RP27	AD,AR	retinitis pigmentosa 27, 613750 (3), ; retinal degeneration, clumped pigment type (3)
RP28	AR	retinitis pigmentosa 28, 606068 (3),
RP3	XL,XLR	retinitis pigmentosa, and sinorespiratory infections, with or without deafness, 300455 (3), ; cone-rod dystrophy, 1, 304020 (3), ; retinitis pigmentosa 3, 300029 (3), ; macular degeneration, atrophic, 300834 (3),
RP3-395M20.1		
RP30		retinitis pigmentosa 30, 607921 (3)
RP31		retinitis pigmentosa 31, 609923 (3)
RP33	AD	retinitis pigmentosa 33, 610359 (3),
RP36		retinitis pigmentosa 36, 610599 (3)
RP37	AR,AD	retinitis pigmentosa 37, 611131 (3), ; enhanced s-cone syndrome, 268100 (3),
RP38	AR	retinitis pigmentosa 38, 613862 (3),
RP39	AR	usher syndrome, type 2a, 276901 (3), ; retinitis pigmentosa 39, 613809 (3),
RP4	AD,AR	night blindness, congenital stationary, 1, 610445 (3), ; retinitis pigmentosa 4, or , 613731 (3), ; retinitis punctata albescens, 136880 (3),
RP4-534K7.1		
RP4-622L5		
RP4-622L5.5	AR	{bardet-biedl syndrome 1, modifier of}, 209900 (3), digenic
RP4-678I3		
RP4-758N20.2		
RP4-776P7.2	AR	?spermatogenic failure 55, 619380 (3),
RP4-811H24.7		
RP40	AR,AD	retinitis pigmentosa-40, 613801 (3), ; night blindness, congenital stationary, 2, 163500 (3),
RP41	AD,AR	macular dystrophy, retinal, 2, 608051 (3), ; retinitis pigmentosa 41, 612095 (3), ; stargardt disease 4, 603786 (3), ; cone-rod dystrophy 12, 612657 (3),
RP42	AD,AR	retinitis pigmentosa 42, 612943 (3), ; perching syndrome, 617055 (3),
RP43	AR	retinitis pigmentosa 43, 613810 (3),
RP44		retinitis pigmentosa 44, 613769 (3)
RP45	AR	retinitis pigmentosa 45, 613767 (3),
RP46	AR	retinitis pigmentosa 46, 612572 (3),
RP47	AR,AD	retinitis pigmentosa 47, 613758 (3), ; retinitis pigmentosa 96, 620228 (3), ; oguchi disease-1, 258100 (3),
RP48		retinitis pigmentosa 48, 613827 (3)
RP49	AR	retinitis pigmentosa 49, 613756 (3),
RP5-1056L3.2		
RP5-1070B1.1		
RP5-1100H13.2		
RP5-1180E21.1	AR	cone-rod dystrophy 21, 616502 (3),
RP5-1180E21.2		
RP5-1198E17.5		?immune dysregulation and systemic hyperinflammation syndrome, 618998 (3)
RP5-860F19.3		
RP5-998N21.9		
RP50	AD,AR	macular dystrophy, vitelliform, 2, 153700 (3), ; ?microcornea, rod-cone dystrophy, cataract, and posterior staphyloma 2, 193220 (3), ; retinitis pigmentosa-50, 613194 (3); retinitis pigmentosa, concentric, 613194 (3); vitreoretinochoroidopathy, 193220 (3), ; bestrophinopathy, 611809 (3)
RP51	AR	bardet-biedl syndrome 8, 615985 (3), ; ?retinitis pigmentosa 51, 613464 (3),
RP53	AR,AD	leber congenital amaurosis 13, 612712 (3),
RP54	AR	retinitis pigmentosa 54, 613428 (3),
RP55	AR	retinitis pigmentosa 55, 613575 (3), ; {bardet-biedl syndrome 1, modifier of}, 209900 (3), digenic ; bardet-biedl syndrome 3, 600151 (3),
RP56	AR,AD	retinitis pigmentosa 56, 613581 (3), ; macular dystrophy, vitelliform, 5, 616152 (3),
RP57	AR	retinitis pigmentosa 57, 613582 (3),
RP58	AR,AD	?retinitis pigmentosa 58, 613617 (3), |intellectual developmental disorder, 22, 612337 (3),
RP59	AD,AR	developmental delay and seizures with or without movement abnormalities, 617836 (3), ; ?congenital disorder of glycosylation, type 1bb, 613861 (3), ; retinitis pigmentosa 59, 613861 (3),
RP60	AD	retinitis pigmentosa 60, 613983 (3),
RP61	AR	usher syndrome, type 3a, 276902 (3), ; retinitis pigmentosa 61, 614180 (3)
RP62	AR	retinitis pigmentosa 62, 614181 (3),
RP64	AR	retinitis pigmentosa 64, 614500 (3), ; cone-rod dystrophy 16, 614500 (3), ; bardet-biedl syndrome 21, 617406 (3),
RP65	AR	macular dystrophy, retinal, 613660 (3), ; cone-rod dystrophy 15, 613660 (3), ; retinitis pigmentosa 65, 613660 (3),
RP66	AR,AR	?retinitis pigmentosa 66, 615233 (3), |retinitis pigmentosa with or without situs inversus, 615434 (3),
RP67	AR	?retinitis pigmentosa 67, 615565 (3),
RP7	AD,AR	macular dystrophy, patterned, 1, 169150 (3), ; choroidal dystrophy, central areolar 2, 613105 (3), ; retinitis punctata albescens, 136880 (3), ; leber congenital amaurosis 18, 608133 (3), digenic , ; macular dystrophy, vitelliform, 3, 608161 (3), ; retinitis pigmentosa 7 and digenic form, 608133 (3), digenic ,
RP8		
RP9	AD	?retinitis pigmentosa 9, 180104 (3),
RPA1	AD,AD	acrofacial dysostosis, cincinnati type, 616462 (3), |pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 6, 619767 (3),
RPA12		
RPA135	AD	treacher-collins syndrome 4, 618939 (3),
RPA16	AR,AD	treacher collins syndrome 2, 613717 (3),
RPA190	AD	acrofacial dysostosis, cincinnati type, 616462 (3),
RPA2	AD	treacher-collins syndrome 4, 618939 (3),
RPA3		
RPA34		
RPA39	AR	leukodystrophy, hypomyelinating, 11, 616494 (3), ; treacher collins syndrome 3, 248390 (3),
RPA4		
RPA40	AR	leukodystrophy, hypomyelinating, 11, 616494 (3), ; treacher collins syndrome 3, 248390 (3),
RPA43		
RPA5	AR	leukodystrophy, hypomyelinating, 11, 616494 (3), ; treacher collins syndrome 3, 248390 (3),
RPA70	AD	pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 6, 619767 (3),
RPA9	AR,AD	treacher collins syndrome 2, 613717 (3),
RPABC1		
RPABC5		
RPAC1	AR	leukodystrophy, hypomyelinating, 11, 616494 (3), ; treacher collins syndrome 3, 248390 (3),
RPAC2	AR,AD	treacher collins syndrome 2, 613717 (3),
RPAIN		
RPAP1		
RPAP2		
RPAP3		
RPAP4		
RPB1	AD	neurodevelopmental disorder with hypotonia and variable intellectual and behavioral abnormalities, 618603 (3),
RPB10alpha		
RPB10beta		
RPB11		
RPB11A		
RPB11b1		
RPB11m		
RPB12		
RPB2		
RPB3		
RPB4		
RPB5		
RPB6		
RPB7		
RPB7.6		
RPB8		
RPB9		
RPC		
RPC1	AR	wiedemann-rautenstrauch syndrome, 264090 (3), ; leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism, 607694 (3),
RPC11	AR	leukodystrophy, hypomyelinating, 21, 619310 (3),
RPC155	AR	wiedemann-rautenstrauch syndrome, 264090 (3), ; leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism, 607694 (3),
RPC2	AR,AD	leukodystrophy, hypomyelinating, 8, with or without oligodontia and/or hypogonadotropic hypogonadism, 614381 (3), ; charcot-marie-tooth disease, demyelinating, type 1i, 619742 (3),
RPC3		
RPC32		
RPC39	AD	?immunodeficiency 101 (varicella zoster virus-specific), 619872 (3),
RPC4		
RPC40	AR	leukodystrophy, hypomyelinating, 11, 616494 (3), ; treacher collins syndrome 3, 248390 (3),
RPC5		
RPC6	AD	?immunodeficiency 101 (varicella zoster virus-specific), 619872 (3),
RPC62		
RPC7		
RPC8		
RPCL1		
RPD3	XLD,XL	cornelia de lange syndrome 5, 300882 (3),
RPD3-2		
RPD3L1		
RPE		
RPE65	AR,AD	retinitis pigmentosa 20, 613794 (3), ; retinitis pigmentosa 87 with choroidal involvement, 618697 (3), ; leber congenital amaurosis 2, 204100 (3),
RPEL1	AD	developmental and epileptic encephalopathy 70, 618298 (3),
RPF-1	AD	{wilms tumor susceptibility-5}, 601583 (3), somatic mutation,
RPF1		
RPF2		
RPGR	XL,XLR	retinitis pigmentosa, and sinorespiratory infections, with or without deafness, 300455 (3), ; cone-rod dystrophy, 1, 304020 (3), ; retinitis pigmentosa 3, 300029 (3), ; macular degeneration, atrophic, 300834 (3),
RPGRIP	AR	cone-rod dystrophy 13, 608194 (3), ; leber congenital amaurosis 6, 613826 (3),
RPGRIP1	AR	cone-rod dystrophy 13, 608194 (3), ; leber congenital amaurosis 6, 613826 (3),
RPGRIP1L	AR	joubert syndrome 7, 611560 (3), ; meckel syndrome 5, 611561 (3), ; ?coach syndrome 3, 619113 (3),
RPH11		
RPH3A		
RPH3AL		
RPIA	AR	ribose 5-phosphate isomerase deficiency, 608611 (3),
RPIB9		
RPIP8		
RPIP9		
RPL10	XL,XLR,AD	{autism, susceptibility to, 5}, 300847 (3); intellectual developmental disorder, syndromic 35, 300998 (3), |diamond-blackfan anemia 12, 615550 (3),
RPL10A		
RPL10L	AR	?spermatogenic failure 63, 619689 (3),
RPL11	AD	diamond-blackfan anemia 7, 612562 (3),
RPL12		
RPL13	AD	spondyloepimetaphyseal dysplasia, isidor-toutain type, 618728 (3),
RPL13A		
RPL14		
RPL15	AD	diamond-blackfan anemia 12, 615550 (3),
rpL17		
RPL17		
RPL18	AD	?diamond-blackfan anemia 18, 618310 (3),
RPL18A		
RPL19		
RPL21	AD	hypotrichosis 12, 615885 (3),
RPL22		
rpL23		
RPL23		
RPL23A		
RPL23L		
RPL24		
RPL24L		
RPL26	AD	?diamond-blackfan anemia 11, 614900 (3),
RPL27	AD	?diamond-blackfan anemia 16, 617408 (3),
RPL27A		
RPL28		
RPL29		
RPL29P10		
RPL3		
RPL30		
RPL31		
RPL33L		
RPL34		
RPL35	AD	?diamond-blackfan anemia 19, 618312 (3),
RPL35A	AD	diamond-blackfan anemia 5, 612528 (3),
RPL36		
RPL36A		
RPL36AL		
RPL36AP42		
RPL37		
RPL37A		
RPL38		
RPL39		
RPL39L		
RPL39L1		
RPL39P42		
RPL3L	AR	cardiomyopathy, dilated, 2d, 619371 (3),
RPL4		
RPL40		
RPL41		
RPL44		
RPL5	AD	diamond-blackfan anemia 6, 612561 (3),
RPL6		
RPL7		
RPL7A		
RPL7L1		
RPL8		
RPL9		
RPLP0		
RPLP1		
RPLP2		
RPLY10	AD	diamond-blackfan anemia 12, 615550 (3),
RPMJ		
RPML12	AR	?combined oxidative phosphorylation deficiency 45, 618951 (3),
RPML13		
RPML14		
RPML15		
RPML2		
RPML25		
RPML26		
RPML27		
RPML28		
RPML3	AR	combined oxidative phosphorylation deficiency 9, 614582 (3),
RPML31		
RPML32		
RPML5		
RPML7		
RPML8		
RPMS12		
RPMS13		
RPMS17		
RPMS25	AR	?combined oxidative phosphorylation deficiency 50, 619025 (3),
RPMS6		
RPMS7	AR	?combined oxidative phosphorylation deficiency 34, 617872 (3),
RPMS9		
RPN-II		
Rpn1		
RPN1		
Rpn10		
Rpn11		
Rpn12		
Rpn13		
Rpn14		
Rpn2		
RPN2		
Rpn3		
Rpn4		
Rpn5	AD	stankiewicz-isidor syndrome, 617516 (3),
Rpn6		
Rpn7		
Rpn8		
Rpn9		
RPNII		
Rpo1-2	AD	treacher-collins syndrome 4, 618939 (3),
RPO1-3	AR,AD	treacher collins syndrome 2, 613717 (3),
RPO1-4	AD	acrofacial dysostosis, cincinnati type, 616462 (3),
RPP0		
RPP14		
RPP2		
RPP20		
RPP21		
RPP25		
RPP29		
RPP30		
RPP38		
RPP40		
RPPH1		
RPPH1-1		
RPRD1A		
RPRD1B		
RPRD2		
RPRGL3	AD	{pregnancy loss, recurrent, susceptibility to, 3}, 614391 (3),
RPRM		
RPS10	AD	diamond-blackfan anemia 9, 613308 (3),
RPS11		
RPS12		
RPS13		
RPS14		macrocytic anemia, refractory, due to 5q deletion, somatic, 153550 (3)
RPS15		
RPS15A	AD	?diamond-blackfan anemia 20, 618313 (3),
RPS16		
RPS17	AD	diamond-blackfan anemia 4, 612527 (3),
RPS17L	AD	diamond-blackfan anemia 4, 612527 (3),
RPS17L1	AD	diamond-blackfan anemia 4, 612527 (3),
RPS17L2	AD	diamond-blackfan anemia 4, 612527 (3),
RPS18		
RPS19	AD	diamond-blackfan anemia 1, 105650 (3),
RPS19BP1		
RPS2		
RPS20		
RPS20A		
RPS20B		
RPS20P3		
RPS20P4		
RPS21		
RPS23	AD	brachycephaly, trichomegaly, and developmental delay, 617412 (3),
RPS24	AD	diamond-blackfan anemia 3, 610629 (3),
RPS25		
RPS26	AD	diamond-blackfan anemia 10, 613309 (3),
RPS27	AD	?diamond-blackfan anemia 17, 617409 (3),
RPS27A		
RPS27L		
RPS28	AD	diamond blackfan anemia 15 with mandibulofacial dysostosis, 606164 (3),
RPS29	AD	diamond-blackfan anemia 13, 615909 (3),
RPS3		
RPS30		
RPS3A		
RPS4		
RPS4X		
RPS4Y		
RPS4Y1		
RPS4Y2		
RPS4Y2P		
RPS5		
RPS6		
RPS6KA1		
RPS6KA2		
RPS6KA3	XL,XLD	intellectual developmental disorder, 19, 300844 (3), ; coffin-lowry syndrome, 303600 (3),
RPS6KA4		
RPS6KA5		
RPS6KA6		
RPS6KB1		
RPS6KB2		
RPS6KC1		
RPS7	AD	diamond-blackfan anemia 8, 612563 (3),
RPS8		
RPS9		
RPSA	AD	asplenia, isolated congenital, 271400 (3),
RPSM12		
RPT1		
RPT2	AR	?birk-aharoni syndrome, 620071 (3),
RPT3		
RPT5	AR	?deafness, cataract, impaired intellectual development, and polyneuropathy, 619354 (3),
RPT6		
RPTN		
RPTOR		
RPTPA		
RPTPB		
RPTPG		
RPTPrho		
RPTPU		
RPU1		
RPUSD3		
RPUSD4		
RPX	AR,AD	pituitary hormone deficiency, combined, 5, 182230 (3), ; septooptic dysplasia, 182230 (3), ; growth hormone deficiency with pituitary anomalies, 182230 (3),
RPYL10	AD	diamond-blackfan anemia 12, 615550 (3),
RQC2	AR	intellectual developmental disorder with speech delay and axonal peripheral neuropathy, 619099 (3),
RQCD1		
RRAD		
RRAGA		
RRAGB		
RRAGC		
RRAGD	AD	hypomagnesemia 7, renal, with or without dilated cardiomyopathy, 620152 (3),
RRAS		
RRAS1		
RRAS2	AD	ovarian carcinoma (3); noonan syndrome 12, 618624 (3),
RRAS3	AD	noonan syndrome 11, 618499 (3),
RRB1		
RRB2	AR,AD	microphthalmia, syndromic 12, 615524 (3),
RRBP1		
RREB1		
RRF		
RRG1		
RRH		
RRM1		
RRM2		
RRM2B	AR,AD	mitochondrial dna depletion syndrome 8b (mngie type), 612075 (3), ; mitochondrial dna depletion syndrome 8a (encephalomyopathic type with renal tubulopathy), 612075 (3), ; rod-cone dystrophy, sensorineural deafness, and fanconi-type renal dysfunction, 268315 (3), ; progressive external ophthalmoplegia with mitochondrial dna deletions, 5, 613077 (3),
RRMJ2	AR	?mitochondrial dna depletion syndrome 17, 618567 (3),
RRN3		
RRP		
RRP1		
RRP10		
RRP12		
RRP14		
RRP15		
RRP17		
RRP1A		
RRP1B		
RRP2	AR	anauxetic dysplasia 1, 607095 (3), ; metaphyseal dysplasia without hypotrichosis, 250460 (3), ; cartilage-hair hypoplasia, 250250 (3),
RRP20		
RRP22		
RRP3		
RRP36		
RRP4	AR	short stature, hearing loss, retinitis pigmentosa, and distinctive facies, 617763 (3),
RRP40	AR	pontocerebellar hypoplasia, type 1b, 614678 (3),
Rrp40p	AR	pontocerebellar hypoplasia, type 1b, 614678 (3),
RRP41		
RRP41A		
RRP41B	AR	cerebellar ataxia, brain abnormalities, and cardiac conduction defects, 619576 (3),
Rrp41p		
RRP42		
Rrp42p		
RRP43	AR	pontocerebellar hypoplasia, type 1c, 616081 (3),
Rrp43p	AR	pontocerebellar hypoplasia, type 1c, 616081 (3),
RRP44		
RRP45	AR	pontocerebellar hypoplasia, type 1d, 618065 (3),
Rrp45p	AR	pontocerebellar hypoplasia, type 1d, 618065 (3),
RRP46	AR	cerebellar ataxia, brain abnormalities, and cardiac conduction defects, 619576 (3),
Rrp46p	AR	cerebellar ataxia, brain abnormalities, and cardiac conduction defects, 619576 (3),
Rrp47		
Rrp4p	AR	short stature, hearing loss, retinitis pigmentosa, and distinctive facies, 617763 (3),
RRP5		
RRP6		
Rrp6p		
Rrp7	AR	?microcephaly 28, primary, 619453 (3),
RRP7A	AR	?microcephaly 28, primary, 619453 (3),
RRP8		
RRP9		
RRR1		
RRS1		
RRT2		
RS	XLR,XL,AD	retinoschisis, 312700 (3), |ring dermoid of cornea, 180550 (3), ; axenfeld-rieger syndrome, type 1, 180500 (3), ; anterior segment dysgenesis 4, 137600 (3),
RS1	XLR,XL	retinoschisis, 312700 (3),
RS21C6		
RS447		
Rsa1		
RSAD2		
RSAFD1		
RSBN1		
RSBN1L-AS1		
RSC1A1		
Rsc6p	AD,AR	coffin-siris syndrome 11, 618779 (3), |specific granule deficiency 2, 617475 (3),
rsc786		{leprosy, susceptibility to, 5}, 613223 (3); {leprosy, protection against}, 613223 (3)
Rsc8	AD,AD	{hydrocephalus, congenital, 5, susceptibility to}, 620241 (3), |coffin-siris syndrome 8, 618362 (3),
Rsdr1		
RSE		
RSE1		
RSF-1		
RSF1		
RSHL1		
RSHL2	AR	ciliary dyskinesia, primary, 32, 616481 (3),
RSHL3	AR	ciliary dyskinesia, primary, 11, 612649 (3),
RSK-B		
RSK1		
RSK2	XL,XLD	intellectual developmental disorder, 19, 300844 (3), ; coffin-lowry syndrome, 303600 (3),
RSK3		
RSK4		
RSKL1		
RSL1D1		
RSL24D1		
RSMD1	AR	congenital myopathy 3 with rigid spine, 602771 (3),
RSN		
RSNL1		
RSP-1		
RSP3	AR	ciliary dyskinesia, primary, 32, 616481 (3),
RSP4		
RSP44	AR	ciliary dyskinesia, primary, 24, 615481 (3),
RSP5	AD	periventricular nodular heterotopia 7, 617201 (3),
RSP6		
RSPH1	AR	ciliary dyskinesia, primary, 24, 615481 (3),
RSPH10A	AR	ciliary dyskinesia, primary, 24, 615481 (3),
RSPH11		
RSPH14		
RSPH16A	AR	ciliary dyskinesia, primary, 34, 617091 (3),
RSPH16B		
RSPH22		
RSPH23	AR	ciliary dyskinesia, primary, 48, without situs inversus, 620032 (3),
RSPH3	AR	ciliary dyskinesia, primary, 32, 616481 (3),
RSPH4A	AR	ciliary dyskinesia, primary, 11, 612649 (3),
RSPH4B		
RSPH6A		
RSPH6B	AR	ciliary dyskinesia, primary, 11, 612649 (3),
RSPH9	AR	ciliary dyskinesia, primary, 12, 612650 (3),
RSPO1	AR	palmoplantar hyperkeratosis and true hermaphroditism, 610644 (3), ; palmoplantar hyperkeratosis with squamous cell carcinoma of skin and sex reversal, 610644 (3),
RSPO2	AR	?humerofemoral hypoplasia with radiotibial ray deficiency, 618022 (3), ; tetraamelia syndrome 2, 618021 (3),
RSPO3		
RSPO4	AR	anonychia congenita, 206800 (3),
RSPONDIN	AR	palmoplantar hyperkeratosis and true hermaphroditism, 610644 (3), ; palmoplantar hyperkeratosis with squamous cell carcinoma of skin and sex reversal, 610644 (3),
RSPRY1	AR	spondyloepimetaphyseal dysplasia, faden-alkuraya type, 616723 (3),
RSRC1	AR	intellectual developmental disorder, 70, 618402 (3),
RSRC2		
RSRFC4	AD	{coronary artery disease, 1}, 608320 (3),
RSRFC9	AD	{coronary artery disease, 1}, 608320 (3),
RSRFR2		
RSRP1		
RSS	AR	congenital myopathy 3 with rigid spine, 602771 (3),
RST	AR	hypouricemia, renal, 220150 (3),
RSTI689	AD	?amelogenesis imperfecta, type iiib, 617607 (3),
RSTS	AD	menke-hennekam syndrome 1, 618332 (3), ; rubinstein-taybi syndrome 1, 180849 (3),
RSU1		
RSU2		
RSUME		
RT-LI		
RT7		
RTA1A	AD,AR	[blood group, swann], 601550 (3); [blood group, wright], 112050 (3); distal renal tubular acidosis 1, 179800 (3), ; [blood group, waldner], 112010 (3); spherocytosis, type 4, 612653 (3), ; [blood group, froese], 601551 (3); distal renal tubular acidosis 4 with hemolytic anemia, 611590 (3), ; {malaria, resistance to}, 611162 (3); cryohydrocytosis, 185020 (3), ; ovalocytosis, sa type, 166900 (3), ; [blood group, diego], 110500 (3)
RTA1B	AR	distal renal tubular acidosis 2 with progressive sensorineural hearing loss, 267300 (3),
RTA1C	AR	distal renal tubular acidosis 3, with or without sensorineural hearing loss, 602722 (3),
RTADR	AR	distal renal tubular acidosis 3, with or without sensorineural hearing loss, 602722 (3),
RTBDN		
RTC1		
RTCA		
RTCB		
RTCD1		
RTDR1		
RTEF-1		
RTEL	AD,AR	dyskeratosis congenita, 4, 615190 (3), ; dyskeratosis congenita, 5, 615190 (3), ; pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 3, 616373 (3),
RTEL1	AD,AR	dyskeratosis congenita, 4, 615190 (3), ; dyskeratosis congenita, 5, 615190 (3), ; pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 3, 616373 (3),
RTF	AR	wrinkly skin syndrome, 278250 (3), ; cutis laxa, type iia, 219200 (3),
RTF1		
RTK6		
RTKN		
RTKN-1		
RTKN2		
RTL1		
RTL2		
RTL7		
RTL8C		
RTL9		
RTN1		
RTN2	AD	spastic paraplegia 12, 604805 (3),
RTN3		
RTN3-A1		
RTN4		
RTN4IP1	AR	optic atrophy 10 with or without ataxia, impaired intellectual development and seizures, 616732 (3),
RTN4R	AD	{schizophrenia, susceptibility to}, 181500 (3),
RTN4RL1		
RTN4RL2		
rtp		
RTP	AR	charcot-marie-tooth disease, type 4d, 601455 (3),
RTP1		
RTP2		
RTP3		
RTP4		
RTP801		
Rtp801L		
RTR		
Rtr1		
RTRAF		
rTS		
RTS	AD	menke-hennekam syndrome 1, 618332 (3), ; rubinstein-taybi syndrome 1, 180849 (3),
Rts2		
RTT	XLD,XLR,XL	rett syndrome, atypical, 312750 (3), ; encephalopathy, neonatal severe, 300673 (3), ; intellectual developmental disorder, syndromic, lubs type, 300260 (3), ; {autism susceptibility, 3}, 300496 (3), ; intellectual developmental disorder, syndromic 13, 300055 (3), ; rett syndrome, 312750 (3), ; rett syndrome, preserved speech variant, 312750 (3),
RTTN	AR	microcephaly, short stature, and polymicrogyria with seizures, 614833 (3),
RTVP1		
RU1		
RU2	AR,AR	hermansky-pudlak syndrome 5, 614074 (3), |nephronophthisis 19, 616217 (3), ; ?deafness, 66, 610212 (3), ; sclerosing cholangitis, neonatal, 617394 (3),
RU2AS		
RUBCN	AR	spinocerebellar ataxia, 15, 615705 (3),
RUBCNL		
rubicon	AR	spinocerebellar ataxia, 15, 615705 (3),
RUFY1		
RUFY2		
RUFY3		
Rumi	AD,AR	dowling-degos disease 4, 615696 (3), ; muscular dystrophy, limb-girdle, 21, 617232 (3),
rundataxin	AR	spinocerebellar ataxia, 15, 615705 (3),
RUNDC1		
RUNDC3A		
RUNDC3B		
RUNX1	AD	platelet disorder, familial, with associated myeloid malignancy, 601399 (3), ; leukemia, acute myeloid, 601626 (3), somatic mutation,
RUNX1T1		
RUNX1T3		
RUNX2	AD	metaphyseal dysplasia with maxillary hypoplasia with or without brachydactyly, 156510 (3), ; cleidocranial dysplasia, forme fruste, with brachydactyly, 119600 (3), ; cleidocranial dysplasia, forme fruste, dental anomalies only, 119600 (3), ; cleidocranial dysplasia, 119600 (3),
RUNX3		
RUNXBP2	AD	arboleda-tham syndrome, 616268 (3),
RUSC1		
RUSC2	AR	intellectual developmental disorder, 61, 617773 (3),
RUSC3		
RUTBC1		
RUTBC2		
RUTBC3		
RUVBL1		
RUVBL2		
Rvb1		
RVB1		
Rvb2		
RVB2		
RVDR1		
RVER1		
RVP1		
RVR		
RW1		
RWDD2B		
RWDD3		
RWDD5		
RX	AR	microphthalmia, syndromic 16, 611038 (3),
RXFP1		
RXFP2		
RXFP3		
RXFP4		
RXFPR1		
RXFPR2		
RXFPR3		
RXFPR4		
RXN3		
RXR-alpha		
RXR-beta		
RXR-gamma		
RXRA		
RXRalpha		
RXRB		
RXRbeta		
RXRG		
RXRgamma		
RXYLT1	AR	muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 10, 615041 (3),
RY1		
RYA3		
RYBP		
RYD5		
RyDEN		
RYK		
RYK1		
RYR	AR,AD	congenital myopathy 1b, 255320 (3), ; congenital myopathy 1a, with susceptibility to malignant hyperthermia, 117000 (3), ; king-denborough syndrome, 619542 (3), ; {malignant hyperthermia susceptibility 1}, 145600 (3),
RYR1	AR,AD	congenital myopathy 1b, 255320 (3), ; congenital myopathy 1a, with susceptibility to malignant hyperthermia, 117000 (3), ; king-denborough syndrome, 619542 (3), ; {malignant hyperthermia susceptibility 1}, 145600 (3),
RYR2	AD	ventricular tachycardia, catecholaminergic polymorphic, 1, 604772 (3), ; ventricular arrhythmias due to cardiac ryanodine receptor calcium release deficiency syndrome, 115000 (3),
RYR3	AR	congenital myopathy 20, 620310 (3),
ryudocan		
RZF	AD	developmental and epileptic encephalopathy 73, 618379 (3),
RZPDo834D038D		
RZRA	AD	intellectual developmental disorder with or without epilepsy or cerebellar ataxia, 618060 (3),
RZRB	AD	{epilepsy, idiopathic generalized, susceptibility to, 15}, 618357 (3),
RZRG	AR	immunodeficiency 42, 616622 (3),
S-AKAP84		
S-MAG	AR	spastic paraplegia 75, 616680 (3),
S/G2NA		
S1		
S1-1	XLR,XL	tarp syndrome, 311900 (3),
S1-5	AD	doyne honeycomb degeneration of retina, 126600 (3),
S10	AD,XLR,XL	diamond-blackfan anemia 9, 613308 (3), |masa syndrome, 303350 (3), ; hydrocephalus, congenital, 307000 (3), ; ?corpus callosum, partial agenesis of, 304100 (3),
S100-A8		
S100-A9		
S100-alpha		
S100-zeta		
S100A		
S100A1		
S100A10		
S100A11		
S100A12		
S100A13		
S100A14		
S100A15		
S100A16		
S100a18		
S100A2		
S100A3		
S100A4		
S100A5		
S100A6		
S100A6BP		
S100A7		
S100A7A		
S100A7c		
S100A7f		
S100A7L1		
S100A8		
S100A9		
S100AL		
S100B		
S100beta		
S100C		
S100D		
S100E		
S100F		
S100G		
S100L		
S100P		
S100PBP		
S100PBPR		
S100Z		
S11		
S12		
S13		
S14		macrocytic anemia, refractory, due to 5q deletion, somatic, 153550 (3)
S15		
S152	AR	lymphoproliferative syndrome 2, 615122 (3),
S15A	AD	?diamond-blackfan anemia 20, 618313 (3),
S16		
S164		
S17	AD	diamond-blackfan anemia 4, 612527 (3),
S17AH	AR	17,20-lyase deficiency, isolated, 202110 (3), ; 17-alpha-hydroxylase/17,20-lyase deficiency, 202110 (3),
S18		
S182	AD	pick disease, 172700 (3), ; alzheimer disease, type 3, with spastic paraparesis and apraxia, 607822 (3), ; dementia, frontotemporal, 600274 (3), ; ?acne inversa, familial, 3, 613737 (3), ; cardiomyopathy, dilated, 1u, 613694 (3), ; alzheimer disease, type 3, with spastic paraparesis and unusual plaques, 607822 (3), ; alzheimer disease, type 3, 607822 (3),
S19	AD	diamond-blackfan anemia 1, 105650 (3),
S1P	AR	?spondyloepiphyseal dysplasia, kondo-fu type, 618392 (3),
S1PR1		
S1PR2	AR	deafness, 68, 610419 (3),
S1PR3		
S1PR4		
S1PR5		
S1R		
S2		
S20		
S21		
S23	AD	brachycephaly, trichomegaly, and developmental delay, 617412 (3),
S24	AD	diamond-blackfan anemia 3, 610629 (3),
S25		
S26	AD	diamond-blackfan anemia 10, 613309 (3),
S27	AD	?diamond-blackfan anemia 17, 617409 (3),
S27A		
S28	AD	diamond blackfan anemia 15 with mandibulofacial dysostosis, 606164 (3),
S29	AD	diamond-blackfan anemia 13, 615909 (3),
S2P	XL,XLR	keratosis follicularis spinulosa decalvans, 308800 (3), ; osteogenesis imperfecta, type xix, 301014 (3), ; ifap syndrome with or without bresheck syndrome, 308205 (3), ; ?olmsted syndrome, 300918 (3),
S2V		
S3		
S3-12		
S30		
S3A		
S4	AR	?birk-aharoni syndrome, 620071 (3),
S4D-SRCRB		
S5		
S5.7	AR	immunodeficiency, common variable, 6, 613496 (3),
S52		
S5A		
S5B		
S5D-SRCRB		
S5mt		
S6		
S6K		
S6K1		
S6KB		
S6Kbeta		
S6KÎ²		
S7	AD	diamond-blackfan anemia 8, 612563 (3),
S8		
S863-7		
S9		
S9mt		
SA	AD	{?hypertension, essential} (1)|asplenia, isolated congenital, 271400 (3),
SA-1	AD	intellectual developmental disorder, 47, 617635 (3),
SA-2	XL,XLD,XLR	holoprosencephaly 13, 301043 (3), ; mullegama-klein-martinez syndrome, 301022 (3),
SA1	AD	intellectual developmental disorder, 47, 617635 (3),
SA2	XL,XLD,XLR	holoprosencephaly 13, 301043 (3), ; mullegama-klein-martinez syndrome, 301022 (3),
SA3	AR	spermatogenic failure 61, 619672 (3), ; premature ovarian failure 8, 615723 (3),
SA49P01		
SAA		
SAA1		
SAA2		
SAA4		
SAAS		
SAAT1		
Sab		
SABP		
SAC	AD	{hypercalciuria, absorptive, susceptibility to}, 143870 (3),
SAC1		
SAC2		
SAC3	AR,AR,AD	peripheral neuropathy, with or without impaired intellectual development, 618124 (3), |yunis-varon syndrome, 216340 (3), ; ?polymicrogyria, bilateral temporooccipital, 612691 (3), ; amyotrophic lateral sclerosis 11, 612577 (3), ; charcot-marie-tooth disease, type 4j, 611228 (3),
SAC3D1		
SACI	AD	{hypercalciuria, absorptive, susceptibility to}, 143870 (3),
SACM1L		
SACM2L		
SACS	AR	spastic ataxia, charlevoix-saguenay type, 270550 (3),
Sacy	AD	{hypercalciuria, absorptive, susceptibility to}, 143870 (3),
SAD-A		
SAD-B		
SAD1		
SAE1		
SAE2	AD	acces syndrome, 619959 (3),
SAE3		
SAF-A	AD	developmental and epileptic encephalopathy 54, 617391 (3),
Saf19		
SAF2		
SAFB		
SAFB1		
SAFB2		
SAG	AR,AD	retinitis pigmentosa 47, 613758 (3), ; retinitis pigmentosa 96, 620228 (3), ; oguchi disease-1, 258100 (3),
SAGE		
SAGE1		
SAH		{?hypertension, essential} (1)
SAHH	AR	hypermethioninemia with deficiency of s-adenosylhomocysteine hydrolase, 613752 (3),
SAI1		
Sak	AR	microcephaly and chorioretinopathy, 2, 616171 (3),
SAKAP84		
SAKI	AR	intellectual developmental disorder, 5, 611091 (3),
SAKS1		
SALL1	AD	townes-brocks syndrome 1, 107480 (3), ; townes-brocks branchiootorenal-like syndrome, 107480 (3),
SALL2	AR	?coloboma, ocular, 216820 (3),
SALL3		
SALL4	AD	?ivic syndrome, 147750 (3), ; duane-radial ray syndrome, 607323 (3),
SALM1		
SALM2		
SALM3.		
SALM4		
SALM5		
SALP		
SALPR		
SALSA		
salvador		
SAM50		
Sam68		
SAMC	AR	combined oxidative phosphorylation deficiency 28, 616794 (3),
SAMD1		
SAMD11		
SAMD12	AD	epilepsy, familial adult myoclonic, 1, 601068 (3),
SAMD14		
SAMD2		
SAMD4		
SAMD4A		
SAMD4B		
SAMD6	AR	nephronophthisis 16, 615382 (3),
SAMD8		
SAMD9	AR,AD	tumoral calcinosis, familial, normophosphatemic, 610455 (3), ; monosomy 7 myelodysplasia and leukemia syndrome 2, 619041 (3), ; mirage syndrome, 617053 (3),
SAMD9L	AD	ataxia-pancytopenia syndrome, 159550 (3), ; monosomy 7 myelodysplasia and leukemia syndrome 1, 252270 (3), ; spinocerebellar ataxia 49, 619806 (3),
SAMDC		
SAMHD1	AD,AR	?chilblain lupus 2, 614415 (3), ; aicardi-goutieres syndrome 5, 612952 (3),
SAMM50		
SAMMSON		
SAMP14		
SAMP32		
SAMS	AD,AR	hypermethioninemia, persistent, due to methionine adenosyltransferase i/iii deficiency, 250850 (3), ; methionine adenosyltransferase deficiency, 250850 (3),
SAMS1	AD,AR	hypermethioninemia, persistent, due to methionine adenosyltransferase i/iii deficiency, 250850 (3), ; methionine adenosyltransferase deficiency, 250850 (3),
SAMS2		
SAMSN1		
SAMTOR		
SAMWD1	AR	spastic paraplegia 54, 615033 (3),
San		
SAN1		
SANBR		
Sancho		
SAND1		
SAND2		
SANG	AD	pseudohypoparathyroidism, type ib, 603233 (3),
Sans	AR	usher syndrome, type 1g, 606943 (3),
SAP	XL,XLR	{?amyloidosis, secondary, susceptibility to} (1)|lymphoproliferative syndrome, 1, 308240 (3),
SAP-1		
SAP-102	XL,XLR	intellectual developmental disorder, 90, 300850 (3),
SAP-3	AR	gm2-gangliosidosis, ab variant, 272750 (3),
SAP-90	AD	intellectual developmental disorder, 62, 618793 (3),
SAP-97		
SAP1	AR,AD	combined sap deficiency, 611721 (3), ; krabbe disease, atypical, 611722 (3), ; metachromatic leukodystrophy due to sap-b deficiency, 249900 (3), ; gaucher disease, atypical, 610539 (3); {parkinson disease 24, susceptibility to}, 619491 (3),
SAP102	XL,XLR	intellectual developmental disorder, 90, 300850 (3),
SAP114		
SAP130		
SAP145	AD	craniofacial microsomia, 164210 (3),
SAP14a		
SAP14b		
SAP155		myelodysplastic syndrome, somatic, 614286 (3)
SAP18		
SAP180		
SAP18p		
SAP190		
SAP2	AR,AD	combined sap deficiency, 611721 (3), ; krabbe disease, atypical, 611722 (3), ; metachromatic leukodystrophy due to sap-b deficiency, 249900 (3), ; gaucher disease, atypical, 610539 (3); {parkinson disease 24, susceptibility to}, 619491 (3),
SAP25		
SAP30		
SAP30BP		
SAP30L		
SAP45		
SAP49	AD	acrofacial dysostosis 1, nager type, 154400 (3),
SAP61		
SAP62		
SAP90	AD	intellectual developmental disorder, 62, 618793 (3),
SAP97		
SAPAP1		
SAPAP3		
SAPAP4		
SAPCD2		
SAPK		
SAPK-3		
SAPK1		
SAPK2		
SAPK3		
SAPK4		
SAPKK3		
SAPL		
SAPLa		
SAPS		
SAPS1		
SAPS2		
SAPS3		
SAR		
SAR1		
SAR1A		
SAR1B	AR	chylomicron retention disease, 246700 (3),
Sara		
SARA		
SARA1		
SARA2	AR	chylomicron retention disease, 246700 (3),
SARAF		
SARCC		
SARCOSIN	AR	nemaline myopathy 9, 615731 (3),
SARDH	AR	[sarcosinemia], 268900 (3),
SARG		
SARM		
SARM1		
SARNP		
SARP		
SARP1		
SARP2		
SARP3		
SARS	AR,AR	hyperuricemia, pulmonary hypertension, renal failure, and alkalosis, 613845 (3), |neurodevelopmental disorder with microcephaly, ataxia, and seizures, 617709 (3),
SARS1	AR	neurodevelopmental disorder with microcephaly, ataxia, and seizures, 617709 (3),
SARS2	AR	hyperuricemia, pulmonary hypertension, renal failure, and alkalosis, 613845 (3),
SARSM	AR	hyperuricemia, pulmonary hypertension, renal failure, and alkalosis, 613845 (3),
SART1		
SART2	AR	ehlers-danlos syndrome, musculocontractural type 2, 615539 (3),
SART3		
SAS	AR	spondyloepimetaphyseal dysplasia, camera-genevieve type, 610442 (3),
Sas-4	AR	microcephaly 6, primary, 608393 (3), ; ?seckel syndrome 4, 613676 (3),
SAS-6	AR	microcephaly 14, primary, 616402 (3),
SAS10		
SAS1B	AR	?oocyte/zygote/embryo maturation arrest 11, 619643 (3),
SAS6	AR	microcephaly 14, primary, 616402 (3),
SASH1	AD,AR	dyschromatosis universalis hereditaria 1, 127500 (3), ; ?cancer, alopecia, pigment dyscrasia, onychodystrophy, and keratoderma, 618373 (3),
SASH2		
SASH3	XLR,XL	immunodeficiency 102, 301082 (3),
SASPase	AD	ichthyosis, lamellar, 146750 (3),
SASS4	AR	microcephaly 6, primary, 608393 (3), ; ?seckel syndrome 4, 613676 (3),
SASS6	AR	microcephaly 14, primary, 616402 (3),
SAST	AD	mega-corpus-callosum syndrome with cerebellar hypoplasia and cortical malformations, 618273 (3),
SAT		
SAT-1	AR	?hypersulfaturia, 620372 (3), ; ?nephrolithiasis, calcium oxalate, 1, 167030 (3),
SAT1		
SAT2		
SAT3		
SATB1	AD	kohlschutter-tonz syndrome-like, 619229 (3), ; developmental delay with dysmorphic facies and dental anomalies, 619228 (3),
SATB2	AD	glass syndrome, 612313 (3),
SATT	AR	spastic tetraplegia, thin corpus callosum, and progressive microcephaly, 616657 (3),
SAV1		
SAX2	AR	spastic ataxia 2, 611302 (3),
SAX3	AD,AR	pituitary hormone deficiency, combined or isolated, 8, 620303 (3), ; neurooculorenal syndrome, 620305 (3), ; ?nystagmus 8, congenital, 257400 (3),
SAXO1		
SAXO4		
SAZD		
Sb1		
SB1.8	XLD,XL	cornelia de lange syndrome 2, 300590 (3), ; developmental and epileptic encephalopathy 85, with or without midline brain defects, 301044 (3),
SB138		
SB144		
SB153		
SB52		
SB73		
SBAT1		
SBBI03		
SBBI10		
SBBI22		
SBBI26	AD,AR	retinitis pigmentosa 42, 612943 (3), ; perching syndrome, 617055 (3),
SBBI42		
SBBI54		
SBBI67		
SBBI8		
SBBI88	AD,AR	?chilblain lupus 2, 614415 (3), ; aicardi-goutieres syndrome 5, 612952 (3),
SBBI99		
SBBIZ1		
SBC2		
SBCAD	AR	2-methylbutyrylglycinuria, 610006 (3),
SBDN	AR	neurodevelopmental disorder with epilepsy, spasticity, and brain atrophy, 618741 (3),
SBDS	AR	{aplastic anemia, susceptibility to}, 609135 (3); shwachman-diamond syndrome 1, 260400 (3),
SBEM		
SBF		
SBF1	AR	charcot-marie-tooth disease, type 4b3, 615284 (3),
SBF2	AR	charcot-marie-tooth disease, type 4b2, 604563 (3),
Sbk		
SBK1		
SBK2		
SBLF		
SBMA	XLR,AD,XL	androgen insensitivity, partial, with or without breast cancer, 312300 (3), ; {prostate cancer, susceptibility to}, 176807 (3), somatic mutation, ; androgen insensitivity, 300068 (3), ; spinal and bulbar muscular atrophy of kennedy, 313200 (3), ; hypospadias 1, 300633 (3),
SBNO1		
SBNO2		
SBP-1		
SBP1	AR	carpenter syndrome 2, 614976 (3),
SBP2	AR	thyroid hormone metabolism, abnormal, 1, 609698 (3),
SBSN		
SBZF3		
SC		[blood group, scianna system], 111750 (3); [blood group, radin], 111620 (3)
SC-35		
SC1		
SC2	AR	intellectual developmental disorder, 14, 614020 (3),
SC35		
SC4MOL	AR	microcephaly, congenital cataract, and psoriasiform dermatitis, 616834 (3),
SC5D	AR	lathosterolosis, 607330 (3),
SC5DL	AR	lathosterolosis, 607330 (3),
SC65		
SCA-2		
SCA1	AD	spinocerebellar ataxia 1, 164400 (3),
SCA10	AD	spinocerebellar ataxia 10, 603516 (3),
SCA11	AD	spinocerebellar ataxia 11, 604432 (3),
SCA12	AD	spinocerebellar ataxia 12, 604326 (3),
SCA13	AD	spinocerebellar ataxia 13, 605259 (3),
SCA14	AD	spinocerebellar ataxia 14, 605361 (3),
SCA15	AR,AD	gillespie syndrome, 206700 (3), ; spinocerebellar ataxia 29, congenital nonprogressive, 117360 (3), ; spinocerebellar ataxia 15, 606658 (3),
SCA16	AR,AD	gillespie syndrome, 206700 (3), ; spinocerebellar ataxia 29, congenital nonprogressive, 117360 (3), ; spinocerebellar ataxia 15, 606658 (3),
SCA17	AD,MF	spinocerebellar ataxia 17, 607136 (3), ; {parkinson disease, susceptibility to}, 168600 (3),
SCA19	AD	spinocerebellar ataxia 19, 607346 (3), ; brugada syndrome 9, 616399 (3),
SCA2	AD,MF	{amyotrophic lateral sclerosis, susceptibility to, 13}, 183090 (3), ; spinocerebellar ataxia 2, 183090 (3), ; {parkinson disease, late-onset, susceptibility to}, 168600 (3),
SCA21	AD	spinocerebellar ataxia 21, 607454 (3),
SCA22	AD	spinocerebellar ataxia 19, 607346 (3), ; brugada syndrome 9, 616399 (3),
SCA23	AD	spinocerebellar ataxia 23, 610245 (3),
SCA27	AD	spinocerebellar ataxia 27a, 193003 (3), ; spinocerebellar ataxia 27b, late-onset, 620174 (3),
SCA28	AR,AD	spastic ataxia 5, 614487 (3), ; optic atrophy 12, 618977 (3), ; spinocerebellar ataxia 28, 610246 (3),
SCA29	AR,AD	gillespie syndrome, 206700 (3), ; spinocerebellar ataxia 29, congenital nonprogressive, 117360 (3), ; spinocerebellar ataxia 15, 606658 (3),
SCA3	AD	machado-joseph disease, 109150 (3),
SCA31	AR,AD	mitochondrial dna depletion syndrome 2 (myopathic type), 609560 (3), ; ?progressive external ophthalmoplegia with mitochondrial dna deletions, 3, 617069 (3), |spinocerebellar ataxia 31, 117210 (3),
SCA34	AD,AR	spinocerebellar ataxia 34, 133190 (3), ; stargardt disease 3, 600110 (3), ; ichthyosis, spastic quadriplegia, and impaired intellectual development, 614457 (3),
SCA35	AD	spinocerebellar ataxia 35, 613908 (3),
SCA36	AD	spinocerebellar ataxia 36, 614153 (3),
SCA38	AD	spinocerebellar ataxia 38, 615957 (3),
SCA4		
SCA40	AD,AR	?spinocerebellar ataxia 40, 616053 (3), ; hydrocephalus, congenital, 1, 236600 (3),
SCA5	AD,AR	spinocerebellar ataxia 5, 600224 (3), ; spinocerebellar ataxia, 14, 615386 (3),
SCA6	AD	spinocerebellar ataxia 6, 183086 (3), ; episodic ataxia, type 2, 108500 (3), ; developmental and epileptic encephalopathy 42, 617106 (3), ; migraine, familial hemiplegic, 1, with progressive cerebellar ataxia, 141500 (3), ; migraine, familial hemiplegic, 1, 141500 (3),
SCA7	AD	spinocerebellar ataxia 7, 164500 (3),
SCA8	MF,AD	{parkinson disease, susceptibility to}, 168600 (3), ; spinocerebellar ataxia 8, 608768 (3),
SCAANT1		
SCAD	AR	acyl-coa dehydrogenase, short-chain, deficiency of, 201470 (3),
SCAD-SRL		
SCAF1		
SCAF10		
SCAF11		
SCAF4		
SCAF8		
SCAFI		
SCAI		
SCAL1		
SCAM-1		
SCAMC-1	AD	fontaine progeroid syndrome, 612289 (3),
SCAMC1	AD	fontaine progeroid syndrome, 612289 (3),
SCAMP1		
SCAMP2		
SCAMP3		
SCAMP37		
SCAMP4		
SCAMP5		
SCAN-1	AR	desbuquois dysplasia 1, 251450 (3), ; epiphyseal dysplasia, multiple, 7, 617719 (3),
SCAN1	AR	?spinocerebellar ataxia, with axonal neuropathy 1, 607250 (3),
SCAND1		
SCAND2		
SCAND2P		
SCAND3		
SCAP		
SCAP1		
SCAP2		
SCAPER	AR	intellectual developmental disorder and retinitis pigmentosa, 618195 (3),
SCAR		
SCAR1	AD,AR,AD	neurodevelopmental disorder with absent language and variable seizures, 618707 (3), |spinocerebellar ataxia, with axonal neuropathy 2, 606002 (3), ; amyotrophic lateral sclerosis 4, juvenile, 602433 (3),
SCAR10	AR	spinocerebellar ataxia, 10, 613728 (3),
SCAR2	AR	spinocerebellar ataxia, 2, 213200 (3),
SCAR3		
SCAR5		
SCAR7	AR	ceroid lipofuscinosis, neuronal, 2, 204500 (3), ; spinocerebellar ataxia, 7, 609270 (3),
SCAR8	AR,AD	arthrogryposis multiplex congenita 3, myogenic type, 618484 (3), ; emery-dreifuss muscular dystrophy 4, 612998 (3), ; spinocerebellar ataxia, 8, 610743 (3),
SCAR9	AR	coenzyme q10 deficiency, primary, 4, 612016 (3),
SCARA1		barrett esophagus/esophageal adenocarcinoma, 614266 (3)
SCARA2		
SCARA3		
SCARA4		
SCARA5		
SCARB1		[high density lipoprotein cholesterol level qtl6], 610762 (3)
SCARB2	AR	epilepsy, progressive myoclonic 4, with or without renal failure, 254900 (3),
SCARB3	AR	platelet glycoprotein iv deficiency, 608404 (3), ; {coronary heart disease, susceptibility to, 7}, 610938 (3); {malaria, cerebral, susceptibility to}, 611162 (3); {malaria, cerebral, reduced risk of}, 611162 (3)
SCARD1		
SCARE1		{myocardial infarction, susceptibility to}, 608446 (3)
SCARE2	AR	candidiasis, familial, 4, 613108 (3), ; {aspergillosis, susceptibility to}, 614079 (3)
SCARF1		
SCARF2	AR	van den ende-gupta syndrome, 600920 (3),
SCARH1		
SCARH2		
SCARI1		
SCARI2		
SCARJ1		
SCARMD1	AR	muscular dystrophy, limb-girdle, 3, 608099 (3),
SCARMD2	AR	muscular dystrophy, limb-girdle, 5, 253700 (3),
SCARNA10		
SCARNA12		
SCARNA15		
SCARNA17		
SCARNA18		
SCARNA18A		
SCARNA19	AD	pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 2, 614743 (3), ; dyskeratosis congenita, 1, 127550 (3),
SCARNA5		
SCARNA6		
SCARNA7		
SCARNA8		
SCAT5		
SCAT6		
SCAX1	XL,XLR	?spinocerebellar ataxia, 1, 302500 (3),
SCC		
SCC-112		
SCC-S2		
SCC1	AD,AR	cornelia de lange syndrome 4, 614701 (3), ; ?mungan syndrome, 611376 (3),
Scc2	AD	cornelia de lange syndrome 1, 122470 (3),
SCC3A	AD	intellectual developmental disorder, 47, 617635 (3),
SCC3B	XL,XLD,XLR	holoprosencephaly 13, 301043 (3), ; mullegama-klein-martinez syndrome, 301022 (3),
SCC4		
SCCA-2		
SCCA1		
SCCA2		
SCCD	AD	corneal dystrophy, schnyder type, 121800 (3),
SCCE		
SCCRO		
SCCRO3		
SCD	AR	carnitine deficiency, systemic primary, 212140 (3),
SCD1		
sCD320	AR	methylmalonic aciduria, transient, due to transcobalamin receptor defect, 613646 (3),
SCD4	AD	?deafness, 79, 619086 (3),
SCD5	AD	?deafness, 79, 619086 (3),
SCDGF		
SCDGF-B		
SCDO1	AR	spondylocostal dysostosis 1, 277300 (3),
SCDO2	AR	spondylocostal dysostosis 2, 608681 (3),
SCDO3	AR	spondylocostal dysostosis 3, 609813 (3),
SCDOS		
SCDR9	AD	{fatty liver disease, protection from}, 620116 (3),
SCEH	AR	mitochondrial short-chain enoyl-coa hydratase 1 deficiency, 616277 (3),
SCEL		
SCELL		
SCF	AD,AR	hyperpigmentation with or without hypopigmentation, 145250 (3), ; waardenburg syndrome, type 2f, 619947 (3), ; deafness, 69, unilateral or asymmetric, 616697 (3), ; [skin/hair/eye pigmentation 7, blond/brown hair], 611664 (3)
SCFD1		
SCFR	AD	gastrointestinal stromal tumor, familial, 606764 (3), isolated cases, ; mastocytosis, cutaneous, 154800 (3), ; piebaldism, 172800 (3), ; germ cell tumors, somatic, 273300 (3); mastocytosis, systemic, somatic, 154800 (3); leukemia, acute myeloid, somatic, 601626 (3)
SCG1		
SCG10		
SCG2		
SCG3	AR	muscular dystrophy, limb-girdle, 5, 253700 (3),
SCG5		
SCG6	AD	acth-independent macronodular adrenal hyperplasia, 219080 (3), somatic mutation; pituitary adenoma 3, multiple types, somatic, 617686 (3); pseudohypoparathyroidism ic, 612462 (3), ; pseudohypoparathyroidism ia, 103580 (3), ; osseous heteroplasia, progressive, 166350 (3), ; pseudohypoparathyroidism ib, 603233 (3), ; mccune-albright syndrome, somatic, mosaic, 174800 (3); pseudopseudohypoparathyroidism, 612463 (3),
SCG7		
SCG8		
SCGB1A1		
SCGB1C1		
SCGB1D1		
SCGB1D2		
SCGB1D4		
SCGB2A1		
SCGB2A2		
SCGB2B2		
SCGB3A1		
SCGB3A2	AD	{asthma, susceptibility to}, 600807 (3),
SCGB4A2		
SCGBL		
SCGF		
SCGN		
SCGN10		
SCH	AD	neurofibromatosis, type 2, 101000 (3), ; meningioma, nf2-related, somatic, 607174 (3); schwannomatosis, somatic, 162091 (3)
SCHAD	AR	hyperinsulinemic hypoglycemia, familial, 4, 609975 (3), ; 3-hydroxyacyl-coa dehydrogenase deficiency, 231530 (3),
SCHIP-1		
SCHIP1		
SchLAH		
SCHLAP1		
Schnurri-1		
Schnurri-2	AD	intellectual developmental disorder, 43, 616977 (3),
Schnurri-3		
SCIDA	AR	severe combined immunodeficiency, athabascan type, 602450 (3), ; omenn syndrome, 603554 (3),
SCIDX1	XL,XLR	combined immunodeficiency, moderate, 312863 (3), ; severe combined immunodeficiency, 300400 (3),
SCIMP		
SCIN		
SCIP		
SCIP1		
SCIRP10		
SCK		
SCKL	AR,AD	seckel syndrome 1, 210600 (3), ; ?cutaneous telangiectasia and cancer syndrome, familial, 614564 (3),
SCKL1	AR,AD	seckel syndrome 1, 210600 (3), ; ?cutaneous telangiectasia and cancer syndrome, familial, 614564 (3),
SCKL2	AR	seckel syndrome 2, 606744 (3), ; jawad syndrome, 251255 (3), ; pancreatic carcinoma, somatic (3)
SCKL4	AR,AR	microcephalic osteodysplastic primordial dwarfism, type ii, 210720 (3), |microcephaly 6, primary, 608393 (3), ; ?seckel syndrome 4, 613676 (3),
SCKL5	AR	microcephaly 9, primary, 614852 (3), ; seckel syndrome 5, 613823 (3),
SCL		leukemia, t-cell acute lymphocytic, somatic, 613065 (3)
SCLH	XL	subcortical laminal heterotopia, 300067 (3), ; lissencephaly, 300067 (3),
SCLIP		
SCLT1		
SCLY		
SCM-1		
SCM-1a		
SCM-1b		
SCMH1		
SCML1		
SCML2		
Scml3		
SCN1	AD	developmental and epileptic encephalopathy 6b, non-dravet, 619317 (3), ; migraine, familial hemiplegic, 3, 609634 (3), ; dravet syndrome, 607208 (3), ; febrile seizures, familial, 3a, 604403 (3), ; generalized epilepsy with febrile seizures plus, type 2, 604403 (3),
SCN10A	AD	episodic pain syndrome, familial, 2, 615551 (3),
SCN11A	AD	episodic pain syndrome, familial, 3, 615552 (3), ; neuropathy, hereditary sensory and autonomic, type vii, 615548 (3),
SCN12A	AD	episodic pain syndrome, familial, 3, 615552 (3), ; neuropathy, hereditary sensory and autonomic, type vii, 615548 (3),
SCN1A	AD	developmental and epileptic encephalopathy 6b, non-dravet, 619317 (3), ; migraine, familial hemiplegic, 3, 609634 (3), ; dravet syndrome, 607208 (3), ; febrile seizures, familial, 3a, 604403 (3), ; generalized epilepsy with febrile seizures plus, type 2, 604403 (3),
SCN1B	AD,AR	generalized epilepsy with febrile seizures plus, type 1, 604233 (3), ; developmental and epileptic encephalopathy 52, 617350 (3), ; cardiac conduction defect, nonspecific, 612838 (3); atrial fibrillation, familial, 13, 615377 (3), ; brugada syndrome 5, 612838 (3)
SCN2A	AD	seizures, benign familial infantile, 3, 607745 (3), ; developmental and epileptic encephalopathy 11, 613721 (3), ; episodic ataxia, type 9, 618924 (3),
SCN2A1	AD	seizures, benign familial infantile, 3, 607745 (3), ; developmental and epileptic encephalopathy 11, 613721 (3), ; episodic ataxia, type 9, 618924 (3),
SCN2A2	AD	seizures, benign familial infantile, 3, 607745 (3), ; developmental and epileptic encephalopathy 11, 613721 (3), ; episodic ataxia, type 9, 618924 (3),
SCN2B	AD	atrial fibrillation, familial, 14, 615378 (3),
SCN3A	AD	epilepsy, familial focal, with variable foci 4, 617935 (3), ; developmental and epileptic encephalopathy 62, 617938 (3),
SCN3B	AD	atrial fibrillation, familial, 16, 613120 (3), ; brugada syndrome 7, 613120 (3),
SCN4A	AD,AR	paramyotonia congenita, 168300 (3), ; hyperkalemic periodic paralysis, 170500 (3), ; congenital myopathy 22b, severe fetal, 620369 (3), ; hypokalemic periodic paralysis, type 2, 613345 (3), ; myotonia congenita, atypical, acetazolamide-responsive, 608390 (3), ; myasthenic syndrome, congenital, 16, 614198 (3), ; congenital myopathy 22a, classic, 620351 (3),
SCN4B	AD	atrial fibrillation, familial, 17, 611819 (3), ; long qt syndrome 10, 611819 (3),
SCN5A	AD,AR	ventricular fibrillation, familial, 1, 603829 (3); heart block, progressive, type ia, 113900 (3), ; cardiomyopathy, dilated, 1e, 601154 (3), ; heart block, nonprogressive, 113900 (3), ; long qt syndrome 3, 603830 (3), ; sick sinus syndrome 1, 608567 (3), ; brugada syndrome 1, 601144 (3), ; atrial fibrillation, familial, 10, 614022 (3), ; {sudden infant death syndrome, susceptibility to}, 272120 (3),
SCN6A		
SCN7A		
SCN8A	AD	?myoclonus, familial, 2, 618364 (3), ; seizures, benign familial infantile, 5, 617080 (3), ; cognitive impairment with or without cerebellar ataxia, 614306 (3), ; developmental and epileptic encephalopathy 13, 614558 (3),
SCN9A	AD,AR	erythermalgia, primary, 133020 (3), ; insensitivity to pain, congenital, 243000 (3), ; small fiber neuropathy, 133020 (3), ; paroxysmal extreme pain disorder, 167400 (3), ; neuropathy, hereditary sensory and autonomic, type iid, 243000 (3),
SCNB3	AD	atrial fibrillation, familial, 16, 613120 (3), ; brugada syndrome 7, 613120 (3),
SCNEG	AD,AR	bronchiectasis with or without elevated sweat chloride 3, 613071 (3), ; pseudohypoaldosteronism, type ib3, 620126 (3), ; liddle syndrome 2, 618114 (3),
SCNM1	AR	orofaciodigital syndrome xix, 620107 (3),
SCNN1	AR,AD	pseudohypoaldosteronism, type ib1, 264350 (3), ; ?liddle syndrome 3, 618126 (3), ; bronchiectasis with or without elevated sweat chloride 2, 613021 (3),
SCNN1A	AR,AD	pseudohypoaldosteronism, type ib1, 264350 (3), ; ?liddle syndrome 3, 618126 (3), ; bronchiectasis with or without elevated sweat chloride 2, 613021 (3),
SCNN1B	AD,AR	bronchiectasis with or without elevated sweat chloride 1, 211400 (3), ; pseudohypoaldosteronism, type ib2, 620125 (3), ; liddle syndrome 1, 177200 (3),
SCNN1D		
SCNN1G	AD,AR	bronchiectasis with or without elevated sweat chloride 3, 613071 (3), ; pseudohypoaldosteronism, type ib3, 620126 (3), ; liddle syndrome 2, 618114 (3),
SCO-spondin		
SCO1	AR	mitochondrial complex iv deficiency, nuclear type 4, 619048 (3),
SCO1L	AD,AR	myopia 6, 608908 (3), ; mitochondrial complex iv deficiency, nuclear type 2, 604377 (3),
SCO2	AD,AR	myopia 6, 608908 (3), ; mitochondrial complex iv deficiency, nuclear type 2, 604377 (3),
SCOD1	AR	mitochondrial complex iv deficiency, nuclear type 4, 619048 (3),
SCOP		
SCOT	AR	succinyl coa:3-oxoacid coa transferase deficiency, 245050 (3),
SCOT-T		
SCOTIN		
SCP		
SCP1		
SCP2	AR,AD	?leukoencephalopathy with dystonia and motor neuropathy, 613724 (3), |spermatogenic failure 1, 258150 (3),
SCP3		
SCPEP1		
SCR10		
SCR2		
SCR3		
SCR59		
scra	AD	focal segmental glomerulosclerosis 8, 616032 (3),
SCRA1	AD	currarino syndrome, 176450 (3),
Scraps	AD	focal segmental glomerulosclerosis 8, 616032 (3),
SCRB1		
SCRE		
SCRG-1		
SCRG1		
SCRIB		
SCRL		
SCRN1		
SCRN2		
SCRN3		
SCRO		
SCRT1		
SCS	AD	craniosynostosis 1, 123100 (3), ; robinow-sorauf syndrome, 180750 (3), ; sweeney-cox syndrome, 617746 (3), ; saethre-chotzen syndrome with or without eyelid anomalies, 101400 (3),
SCT		
SCTE		
SCTR		
SCUBE1		
SCUBE2		
SCUBE3	AR	short stature, facial dysmorphism, and skeletal anomalies with or without cardiac anomalies, 619184 (3),
SCURFIN	XL,XLR	immunodysregulation, polyendocrinopathy, and enteropathy, 304790 (3),
SCX		
SCXA		
SCXB		
SCYA1		
SCYA11	AD	{asthma, susceptibility to}, 600807 (3), ; {hiv1, resistance to}, 609423 (3)
SCYA13		
SCYA14		
SCYA15		
SCYA16		
SCYA17		
SCYA18		
SCYA19		
SCYA2	AD	{mycobacterium tuberculosis, susceptibility to}, 607948 (3); {hiv-1, resistance to}, 609423 (3); {coronary artery disease, modifier of} (3); {spina bifida, susceptibility to}, 182940 (3),
SCYA20		
SCYA21		
SCYA22		
SCYA23		
SCYA24		
SCYA25		
SCYA26		
SCYA27		
SCYA28		
SCYA3		{hiv infection, resistance to}, 609423 (2)
SCYA3L		{hiv/aids, susceptibility to}, 609423 (3)
SCYA3L1		{hiv/aids, susceptibility to}, 609423 (3)
SCYA4		
SCYA4L		
SCYA5		{hiv-1 disease, rapid progression of}, 609423 (3); {hiv-1 disease, delayed progression of}, 609423 (3)
SCYA6		
SCYA7		
SCYA8		
SCYAR1		
SCYB1		
SCYB10		
SCYB11		
SCYB12		{aids, resistance to}, 609423 (3)
SCYB13		
SCYB14		
SCYB2		
SCYB3		
SCYB4		
SCYB4V1		
SCYB5		
SCYB6		
SCYB7		
SCYB8		
SCYB9		
SCYB9B		
SCYC1		
SCYC2		
SCYD1		
SCYE1	AR	leukodystrophy, hypomyelinating, 3, 260600 (3),
SCYL1	AR	spinocerebellar ataxia, 21, 616719 (3),
SCYL1BP1	AR	geroderma osteodysplasticum, 231070 (3),
SCYL2	AR	arthrogryposis multiplex congenita 4, neurogenic, with agenesis of the corpus callosum, 618766 (3),
SCYL3		
SCYL4		
SCYLP	AR	osteogenesis imperfecta, type ix, 259440 (3),
Scythe		
SCZD9		
SD	AR	salla disease, 604369 (3), ; sialic acid storage disorder, infantile, 269920 (3),
Sda		[blood group, sid system], 615018 (3); sd(a) polyagglutination syndrome, 615018 (3)
SDAP		
SDBCAG84		
SDC		
SDC1		
SDC2		
SDC3	AR,MF,AD	{obesity, association with}, 601665 (3), ,
SDC4		
SDCBP		
SDCBP1		
SDCBP2		
SDCCAG-10	AR	retinitis pigmentosa with or without skeletal anomalies, 250410 (3),
SDCCAG1	AR	intellectual developmental disorder with speech delay and axonal peripheral neuropathy, 619099 (3),
SDCCAG10	AR	retinitis pigmentosa with or without skeletal anomalies, 250410 (3),
SDCCAG16		
SDCCAG28		
SDCCAG3		
SDCCAG31		
SDCCAG33	AD	aural atresia, congenital, 607842 (3),
SDCCAG43		
SDCCAG7	AD,AR	spinocerebellar ataxia 48, 618093 (3), ; spinocerebellar ataxia, 16, 615768 (3),
SDCCAG8	AR	senior-loken syndrome 7, 613615 (3), ; bardet-biedl syndrome 16, 615993 (3),
SDCT2	AR	leukoencephalopathy, acute reversible, with increased urinary alpha-ketoglutarate, 618384 (3),
SDF-1a		{aids, resistance to}, 609423 (3)
SDF-1b		{aids, resistance to}, 609423 (3)
SDF-5		
SDF1		{aids, resistance to}, 609423 (3)
SDF1A		{aids, resistance to}, 609423 (3)
SDF1B		{aids, resistance to}, 609423 (3)
SDF2		
SDF2L1		
SDF4		
SDFR1		
SDFR2		
SDGF		
SDH	AR,AD,AR	[sarcosinemia], 268900 (3), |paragangliomas 4, 115310 (3), ; mitochondrial complex ii deficiency, nuclear type 4, 619224 (3), ; gastrointestinal stromal tumor, 606764 (3), isolated cases, ; pheochromocytoma, 171300 (3), ; paraganglioma and gastric stromal sarcoma, 606864 (3)
SDH1	AD,AR	paragangliomas 4, 115310 (3), ; mitochondrial complex ii deficiency, nuclear type 4, 619224 (3), ; gastrointestinal stromal tumor, 606764 (3), isolated cases, ; pheochromocytoma, 171300 (3), ; paraganglioma and gastric stromal sarcoma, 606864 (3)
SDH2	AR,AD	cardiomyopathy, dilated, 1gg, 613642 (3), ; mitochondrial complex ii deficiency, nuclear type 1, 252011 (3), ; neurodegeneration with ataxia and late-onset optic atrophy, 619259 (3), ; paragangliomas 5, 614165 (3),
SDH5	AD	paragangliomas 2, 601650 (3),
Sdh7		
Sdh8		
SDHA	AR,AD	cardiomyopathy, dilated, 1gg, 613642 (3), ; mitochondrial complex ii deficiency, nuclear type 1, 252011 (3), ; neurodegeneration with ataxia and late-onset optic atrophy, 619259 (3), ; paragangliomas 5, 614165 (3),
SDHAF1	AR	mitochondrial complex ii deficiency, nuclear type 2, 619166 (3),
SDHAF2	AD	paragangliomas 2, 601650 (3),
SDHAF3		
SDHAF4		
SDHB	AD,AR	paragangliomas 4, 115310 (3), ; mitochondrial complex ii deficiency, nuclear type 4, 619224 (3), ; gastrointestinal stromal tumor, 606764 (3), isolated cases, ; pheochromocytoma, 171300 (3), ; paraganglioma and gastric stromal sarcoma, 606864 (3)
SDHC	AD	paragangliomas 3, 605373 (3), ; paraganglioma and gastric stromal sarcoma, 606864 (3); gastrointestinal stromal tumor, 606764 (3), isolated cases,
SDHD	AD,AR	paragangliomas 1, with or without deafness, 168000 (3), ; paraganglioma and gastric stromal sarcoma, 606864 (3); mitochondrial complex ii deficiency, nuclear type 3, 619167 (3), ; pheochromocytoma, 171300 (3),
SDHF	AR,AD	cardiomyopathy, dilated, 1gg, 613642 (3), ; mitochondrial complex ii deficiency, nuclear type 1, 252011 (3), ; neurodegeneration with ataxia and late-onset optic atrophy, 619259 (3), ; paragangliomas 5, 614165 (3),
SDI1		
SDK1		
SDK2		
SDNSF		factor v and factor viii, combined deficiency of, 613625 (3)
SDO1	AR	{aplastic anemia, susceptibility to}, 609135 (3); shwachman-diamond syndrome 1, 260400 (3),
SDOS		
SDP1		
SDP35		
SDPI		
SDPII		
SDPIII		
SDPR		
SDR		
SDR-O	AR	ichthyosis, congenital, 13, 617574 (3),
SDR-SRL		
SDR1		
SDR10E1	AR,AD	peroxisomal fatty acyl-coa reductase 1 disorder, 616154 (3), ; cataracts, spastic paraparesis, and speech delay, 619338 (3),
SDR10E2		
SDR11E1		
SDR11E2	AR	adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency, 201810 (3),
SDR11E3	AR	bile acid synthesis defect, congenital, 1, 607765 (3),
SDR12C1		
SDR12C2	AR	pseudohermaphroditism, male, with gynecomastia, 264300 (3),
SDR12C3		
SDR16C1		
SDR16C2		
SDR16C3	AD	{fatty liver disease, protection from}, 620116 (3),
SDR16C4		
SDR16C5		
SDR17C1		
SDR18C1		
SDR19C1		
SDR1E1	AR	galactose epimerase deficiency, 230350 (3),
SDR2		
SDR20C1	AR	[pentosuria], 260800 (3),
SDR21C1		
SDR21C2		
SDR22E1	AR	mitochondrial complex i deficiency, nuclear type 26, 618247 (3),
SDR23E1		
SDR24C1		
SDR25C1		
SDR25C2		
SDR25C3		
SDR25C4		
SDR26C1	AD	cortisone reductase deficiency 2, 614662 (3),
SDR27X1		
SDR28C1		
SDR28C2		
SDR29C1		
SDR2E1	AR	catel-manzke syndrome, 616145 (3),
SDR30C1		
SDR31E1	XLR,XLD,XL	ck syndrome, 300831 (3), ; child syndrome, 308050 (3),
SDR32C1		
SDR32C2		
SDR33C1	AR	hyperphenylalaninemia, bh4-deficient, c, 261630 (3),
SDR34C1		
SDR35C1	AR	erythrokeratodermia variabilis et progressiva 4, 617526 (3),
SDR36C1	AR	?digital clubbing, isolated congenital, 119900 (3), ; hypertrophic osteoarthropathy, primary, 1, 259100 (3), ; cranioosteoarthropathy, 259100 (3),
SDR37C1		
SDR38C1	AD,AR	dystonia, dopa-responsive, due to sepiapterin reductase deficiency, 612716 (3), ? ,
SDR39U1		
SDR3E1		
SDR40C1		
SDR41C1	AR	esophageal squamous cell carcinoma, somatic, 133239 (3); developmental and epileptic encephalopathy 28, 616211 (3), ; spinocerebellar ataxia, 12, 614322 (3),
SDR42E1		
SDR43U1		
SDR44U1		
SDR45C1		
SDR46C1		
SDR47C1		
SDR48A1		
SDR4E1		
SDR5C1	XLD,XL	hsd10 mitochondrial disease, 300438 (3),
SDR6E1		
SDR7C1	AR	?retinal dystrophy, juvenile cataracts, and short stature syndrome, 616108 (3),
SDR7C2	AR,AD	leber congenital amaurosis 13, 612712 (3),
SDR7C4		
SDR7C5		
SDR7C6		
SDR8C1	AR	d-bifunctional protein deficiency, 261515 (3), ; perrault syndrome 1, 233400 (3),
SDR9C1		
SDR9C2		
SDR9C3	AR	apparent mineralocorticoid excess, 218030 (3),
SDR9C4		
SDR9C5	AR,AD	fundus albipunctatus, 136880 (3),
SDR9C6		
SDR9C7	AR	ichthyosis, congenital, 13, 617574 (3),
SDR9C8		
SDS	AR	{aplastic anemia, susceptibility to}, 609135 (3); shwachman-diamond syndrome 1, 260400 (3),
sds22		
SDS3		
SDTY3	AD,AR	erythrokeratodermia variabilis et progressiva 3, 617525 (3), ; craniometaphyseal dysplasia, 218400 (3), ; oculodentodigital dysplasia, 164200 (3), ; palmoplantar keratoderma with congenital alopecia, 104100 (3), ; syndactyly, type iii, 186100 (3), ; oculodentodigital dysplasia, 257850 (3),
SDYS	XLR,XL	wilms tumor, somatic, 194070 (3); simpson-golabi-behmel syndrome, type 1, 312870 (3),
SE	AR	{norwalk virus infection, resistance to} (3); {vitamin b12 plasma level qtl1}, 612542 (3); [bombay phenotype, digenic], 616754 (3),
Se2	AR	{norwalk virus infection, resistance to} (3); {vitamin b12 plasma level qtl1}, 612542 (3); [bombay phenotype, digenic], 616754 (3),
se20-10		
SE20-4		
se20-9		
SE57-1		
SE70-2		
se89-1		
SEA	AD	{nasopharyngeal carcinoma, susceptibility to, 3}, 617075 (3),
Sea4		
SEB	AD	schinzel-giedion midface retraction syndrome, 269150 (3), ; intellectual developmental disorder, 29, 616078 (3),
seb4B		
SEB4D		
SEBOX		
SEC10		
SEC10L1		
SEC10P		
SEC11A		
SEC11L1		
SEC12		
SEC13		
SEC13L		
SEC13L1		
SEC13R		
SEC14L		
SEC14L1		
SEC14L2		
SEC14L3		
SEC14L4		
SEC14L5		
Sec15		
SEC15B	AR	spondyloepimetaphyseal dysplasia with joint laxity, type 3, 618395 (3),
SEC15L		
SEC15L1		
SEC15L2	AR	spondyloepimetaphyseal dysplasia with joint laxity, type 3, 618395 (3),
SEC16A		
SEC16B		
Sec16L		
Sec16S		
SEC18	AD	developmental and epileptic encephalopathy 96, 619340 (3),
SEC2	AR	{norwalk virus infection, resistance to} (3); {vitamin b12 plasma level qtl1}, 612542 (3); [bombay phenotype, digenic], 616754 (3),
SEC20		
SEC22A		
SEC22B		
SEC22C		
SEC22L1		
SEC22L2		
SEC22L3		
SEC23A	AR,AD	craniolenticulosutural dysplasia, 607812 (3),
SEC23B	AD,AR	?cowden syndrome 7, 616858 (3), ; dyserythropoietic anemia, congenital, type ii, 224100 (3),
SEC23IP		
SEC24A		
SEC24B		
SEC24C		
SEC24D	AR	cole-carpenter syndrome 2, 616294 (3),
SEC3		
SEC31A	AR	?halperin-birk syndrome, 618651 (3),
SEC31B		
SEC31B-1		
SEC31L1	AR	?halperin-birk syndrome, 618651 (3),
SEC31L2		
SEC34		
SEC3L1		
Sec3p		
SEC4L		
Sec5	AR	neurodevelopmental disorder with dysmorphic facies and cerebellar hypoplasia, 619306 (3),
Sec53		
SEC5L1	AR	neurodevelopmental disorder with dysmorphic facies and cerebellar hypoplasia, 619306 (3),
Sec6		
SEC61A1	AD	tubulointerstitial kidney disease, 5, 617056 (3),
SEC61A2		
SEC61B		
SEC61G		
SEC62		
SEC63	AD	polycystic liver disease 2, 617004 (3),
SEC63D1	AR	premature ovarian failure 9, 615724 (3),
SEC63L	AD	polycystic liver disease 2, 617004 (3),
SEC6L1		
Sec7p-L		
Sec7p-like		
SEC8		
SEC84	AR	?neurodevelopmental disorder with microcephaly, seizures, and brain atrophy, 619076 (3),
SEC8L1		
Sec8p		
SEC9	AD	?myasthenic syndrome, congenital, 18, 616330 (3),
SECISBP2	AR	thyroid hormone metabolism, abnormal, 1, 609698 (3),
SECISBP2L		
SECP43		
SECRET		
SecS	AR	pontocerebellar hypoplasia type 2d, 613811 (3),
SECT		
SECTM1		
securin		
SED1		
SED5		
SEDC	AD	?vitreoretinopathy with phalangeal epiphyseal dysplasia, 619248 (3), ; czech dysplasia, 609162 (3), ; achondrogenesis, type ii or hypochondrogenesis, 200610 (3), ; spondyloperipheral dysplasia, 271700 (3), ; smed strudwick type, 184250 (3), ; ?epiphyseal dysplasia, multiple, with myopia and deafness, 132450 (3), ; sed congenita, 183900 (3), ; kniest dysplasia, 156550 (3), ; stickler syndrome, type i, nonsyndromic ocular, 609508 (3), ; osteoarthritis with mild chondrodysplasia, 604864 (3), ; stickler syndrome, type i, 108300 (3), ; platyspondylic skeletal dysplasia, torrance type, 151210 (3), ; spondyloepiphyseal dysplasia, stanescu type, 616583 (3), ; avascular necrosis of the femoral head, 608805 (3), ; legg-calve-perthes disease, 150600 (3),
SEDL	XLR,XL	spondyloepiphyseal dysplasia tarda, 313400 (3),
SEDT	XLR,XL	spondyloepiphyseal dysplasia tarda, 313400 (3),
SEEEG-1		
SEEK1		
SEF	AR,AD	hypogonadotropic hypogonadism 18 with or without anosmia, 615267 (3), digenic ,
SEF2-1B	AD	pitt-hopkins syndrome, 610954 (3), ; corneal dystrophy, fuchs endothelial, 3, 613267 (3),
SEGN		
sEH	AR,AD	{hypercholesterolemia, familial, due to ldlr defect, modifier of}, 143890 (3),
Seh1		
SEH1A		
SEH1B		
SEH1L		
Sei-2		
SEI1		
seipin	AR,AD	lipodystrophy, congenital generalized, type 2, 269700 (3), ; neuropathy, distal hereditary motor, type vc, 619112 (3), ; silver spastic paraplegia syndrome, 270685 (3), ; encephalopathy, progressive, with or without lipodystrophy, 615924 (3),
sej	AR	{norwalk virus infection, resistance to} (3); {vitamin b12 plasma level qtl1}, 612542 (3); [bombay phenotype, digenic], 616754 (3),
SEL-10	AD	developmental delay, hypotonia, and impaired language, 620012 (3),
SEL10	AD	developmental delay, hypotonia, and impaired language, 620012 (3),
SEL1L		
SEL1L1		
SEL1L2		
SEL1L3		
seladin-1	AR	desmosterolosis, 602398 (3),
SELB		
SELE		
SELENBP1	AR	extraoral halitosis due to mto deficiency, 618148 (3),
SELENOF		
SELENOH		
SELENOI	AR	spastic paraplegia 81, 618768 (3),
SELENOK		
SELENOM		
SELENON	AR	congenital myopathy 3 with rigid spine, 602771 (3),
SELENOO		
SELENOP		
SELENOR		
SELENOS		
SELENOT		
SELENOV		
SELENOW		
SELENOX		
SELENOY		
SELH		
SELI	AR	spastic paraplegia 81, 618768 (3),
SELK		
SELL		
SELM		
SELN	AR	congenital myopathy 3 with rigid spine, 602771 (3),
SELO		
SELP		
SELPLG		
SelR		
SELRC1	AR	spinocerebellar ataxia, with axonal neuropathy 3, 618387 (3),
SELS		
SELT		
SELV		
SELW		
SelX		
SelY		
SELZ	AR	?glucocorticoid deficiency 5, 617825 (3),
SEM-SEMA-Z	AD	epilepsy, progressive myoclonic, 11, 618876 (3),
SEM1		
SemA		
SEMA		
SEMA-VIB	AD	epilepsy, progressive myoclonic, 11, 618876 (3),
Sema-Y		
Sema-Z2		
SEMA1	AD	{hypogonadotropic hypogonadism 16 with or without anosmia}, 614897 (3),
SEMA3A	AD	{hypogonadotropic hypogonadism 16 with or without anosmia}, 614897 (3),
SEMA3B		
SEMA3C		
SEMA3D		
SEMA3E		
SEMA3F		
Sema4		
SEMA4A	AR	retinitis pigmentosa 35, 610282 (3), ; cone-rod dystrophy 10, 610283 (3),
SEMA4B		
SEMA4C		
SEMA4D		
SEMA4F		
SEMA4G		
sema5		
SEMA5A		
SEMA5B		
SEMA6A		
SEMA6A1		
SEMA6B	AD	epilepsy, progressive myoclonic, 11, 618876 (3),
SEMA6C		
SEMA6D		
SEMA7A	AR	?cholestasis, progressive familial intrahepatic, 11, 619874 (3), ; [blood group, john-milton-hagen system], 614745 (3)
SEMAA		
SEMAB	AR	retinitis pigmentosa 35, 610282 (3), ; cone-rod dystrophy 10, 610283 (3),
SEMAC		
SEMACAP3		
Semacl1		
SEMAD	AD	{hypogonadotropic hypogonadism 16 with or without anosmia}, 614897 (3),
SEMAE		
Semaf		
SEMAF		
SEMAG		
SEMAH		
SEMAI		
SEMAJ		
SEMAK		
SEMAL	AR	?cholestasis, progressive familial intrahepatic, 11, 619874 (3), ; [blood group, john-milton-hagen system], 614745 (3)
SEMAM		
SEMAN	AD	epilepsy, progressive myoclonic, 11, 618876 (3),
SEMAQ		
semaV		
SEMAW		
semaZ	AD	epilepsy, progressive myoclonic, 11, 618876 (3),
SemB	AR	retinitis pigmentosa 35, 610282 (3), ; cone-rod dystrophy 10, 610283 (3),
SemC		
SEMCAP	AD	oculopharyngodistal myopathy 2, 618940 (3),
SEMCAP-2		
SEMCAP3		
SemD	AD	{hypogonadotropic hypogonadism 16 with or without anosmia}, 614897 (3),
SemE		
semF		
SemG		
SEMG		
SEMG1		
SEMG2		
SEMP1	AR	ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis, 607626 (3),
SEN		
Sen1	AR,AD	spinocerebellar ataxia, with axonal neuropathy 2, 606002 (3), ; amyotrophic lateral sclerosis 4, juvenile, 602433 (3),
SEN1		
SEN2	AR	pontocerebellar hypoplasia type 2b, 612389 (3),
SEN2L	AR	pontocerebellar hypoplasia type 2b, 612389 (3),
SEN34	AR	?pontocerebellar hypoplasia type 2c, 612390 (3),
SEN34L	AR	?pontocerebellar hypoplasia type 2c, 612390 (3),
SEN4		
SEN54	AR	pontocerebellar hypoplasia type 2a, 277470 (3), ; pontocerebellar hypoplasia type 4, 225753 (3), ; ?pontocerebellar hypoplasia type 5, 610204 (3),
SEN54L	AR	pontocerebellar hypoplasia type 2a, 277470 (3), ; pontocerebellar hypoplasia type 4, 225753 (3), ; ?pontocerebellar hypoplasia type 5, 610204 (3),
SENCR		
SENP1		
SENP2		
SENP3		
SENP5		
SENP6		
SENP7		
SENP8		
SeP		
SEP		
SEP1		
SEP15		
SEP2		
SEP3		
SEP53		
SEPA		
SEPHS1		
SEPHS2		
SEPI	AR	spastic paraplegia 81, 618768 (3),
SEPM		
SEPN1	AR	congenital myopathy 3 with rigid spine, 602771 (3),
SEPP		
SEPP1		
SepR		
SEPS1		
SEPSECS	AR	pontocerebellar hypoplasia type 2d, 613811 (3),
SEPT1		
SEPT10		
SEPT11		
SEPT12	AD	spermatogenic failure 10, 614822 (3),
SEPT13		
SEPT14		
SEPT2		
SEPT3		
SEPT4		
SEPT5		
SEPT6		
SEPT7		
SEPT7A		
SEPT7B		
SEPT7P2		
SEPT8		
SEPT9	AD	amyotrophy, hereditary neuralgic, 162100 (3),
SeptD1	AD	amyotrophy, hereditary neuralgic, 162100 (3),
SEPTIN1		
SEPTIN10		
SEPTIN11		
SEPTIN12	AD	spermatogenic failure 10, 614822 (3),
SEPTIN14		
SEPTIN2		
SEPTIN3		
SEPTIN4		
SEPTIN5		
SEPTIN6		
SEPTIN7		
SEPTIN7P2		
SEPTIN8		
SEPTIN9	AD	amyotrophy, hereditary neuralgic, 162100 (3),
SEPW1		
SEPX1		
Ser-PyrAT	AR	hyperoxaluria, primary, type 1, 259900 (3),
SERA	AR	neu-laxova syndrome 1, 256520 (3), ; phosphoglycerate dehydrogenase deficiency, 601815 (3),
SERAC1	AR	3-methylglutaconic aciduria with deafness, encephalopathy, and leigh-like syndrome, 614739 (3),
SERBP1		
SERBP1L		
SERCA1	AR	brody myopathy, 601003 (3),
SERCA2	AD	acrokeratosis verruciformis, 101900 (3), ; darier disease, 124200 (3),
SERCA3		
SERF1		
SERF1A		
SERF2		
SERGEF		
SERHL		
SERHL2		
SERINC1		
SERINC2		
SERINC3		
SERINC4		
SERINC5		
SERK1		
SERP1		
SERPINA1	AR	hemorrhagic diathesis due to antithrombin pittsburgh, 613490 (3), ; emphysema due to aat deficiency, 613490 (3), ; emphysema-cirrhosis, due to aat deficiency, 613490 (3),
SERPINA10		
SERPINA11		
SERPINA11b		
SERPINA12		
SERPINA3		alpha-1-antichymotrypsin deficiency (3); cerebrovascular disease, occlusive (3)
SERPINA4		
SERPINA5		
SERPINA6	AR,AD	corticosteroid-binding globulin deficiency, 611489 (3),
SERPINA7	XL	[thyroxine-binding globulin qtl], 300932 (3),
SERPINA8	AR,MF	renal tubular dysgenesis, 267430 (3), ; {preeclampsia, susceptibility to} (3); {hypertension, essential, susceptibility to}, 145500 (3),
SERPINA9		
SERPINB1		
SERPINB10		
SERPINB11		
SERPINB12		
SERPINB13		
SERPINB2		
SERPINB3		
SERPINB4		
SERPINB5		
SERPINB6	AR	?deafness, 91, 613453 (3),
SERPINB7	AR	palmoplantar keratoderma, nagashima type, 615598 (3),
SERPINB8	AR	peeling skin syndrome 5, 617115 (3),
SERPINB9		
SERPINC1	AR,AD	thrombophilia 7 due to antithrombin iii deficiency, 613118 (3),
SERPIND1	AD	thrombophilia 10 due to heparin cofactor ii deficiency, 612356 (3),
SERPINE1	AR,AD	plasminogen activator inhibitor-1 deficiency, 613329 (3), ; {transcription of plasminogen activator inhibitor, modulator of} (3)
SERPINE2		
SERPINF1	AR	osteogenesis imperfecta, type vi, 613982 (3),
SERPINF2	AR	alpha-2-plasmin inhibitor deficiency, 262850 (3),
SERPING1	AR,AD	angioedema, hereditary, 1 and 2, 106100 (3), ; complement component 4, partial deficiency of, 120790 (3),
SERPINH1	MF,AR	{preterm premature rupture of the membranes, susceptibility to}, 610504 (3), ; osteogenesis imperfecta, type x, 613848 (3),
SERPINH2	MF,AR	{preterm premature rupture of the membranes, susceptibility to}, 610504 (3), ; osteogenesis imperfecta, type x, 613848 (3),
SERPINI1	AD	encephalopathy, familial, with neuroserpin inclusion bodies, 604218 (3),
SERPINI2		
serrate		
SerRSmt	AR	hyperuricemia, pulmonary hypertension, renal failure, and alkalosis, 613845 (3),
SERS	AR,AR	hyperuricemia, pulmonary hypertension, renal failure, and alkalosis, 613845 (3), |neurodevelopmental disorder with microcephaly, ataxia, and seizures, 617709 (3),
SERT1	AD	{obsessive-compulsive disorder}, 164230 (3), ; {anxiety-related personality traits}, 607834 (3)
SERTAD1		
SERTAD2		
SERTAD3		
SERZ-B		
SERZ1		
SES1	AD	drug metabolism, altered, ces1-related, 618057 (3),
SES2		
SESN1		
SESN2		
SESN3		
SEST1		
SEST2		
SEST3		
SET	AD	intellectual developmental disorder, 58, 618106 (3),
SET07		
Set1	AD	epilepsy, early-onset, with or without developmental delay, 618832 (3), ; neurodevelopmental disorder with speech impairment and dysmorphic facies, 619056 (3),
SET1A	AD	epilepsy, early-onset, with or without developmental delay, 618832 (3), ; neurodevelopmental disorder with speech impairment and dysmorphic facies, 619056 (3),
Set1B	AD	intellectual developmental disorder with seizures and language delay, 619000 (3),
SET7		
SET7/9		
SET8		
Set9		
SETBP1	AD	schinzel-giedion midface retraction syndrome, 269150 (3), ; intellectual developmental disorder, 29, 616078 (3),
SETD1A	AD	epilepsy, early-onset, with or without developmental delay, 618832 (3), ; neurodevelopmental disorder with speech impairment and dysmorphic facies, 619056 (3),
SETD1B	AD	intellectual developmental disorder with seizures and language delay, 619000 (3),
SETD2	AD	luscan-lumish syndrome, 616831 (3), ; intellectual developmental disorder, 70, 620157 (3), ; rabin-pappas syndrome, 620155 (3),
SETD3		
SETD5	AD	intellectual developmental disorder, 23, 615761 (3),
SETD5A	AD	intellectual developmental disorder, 23, 615761 (3),
SETD5B	AD	o'donnell-luria-rodan syndrome, 618512 (3),
SETD6		
SETD7		
SETD8		
SETDB1		
SETDB2		
SETMAR		
SETX	AR,AD	spinocerebellar ataxia, with axonal neuropathy 2, 606002 (3), ; amyotrophic lateral sclerosis 4, juvenile, 602433 (3),
SEX		
SEZ-12		
SEZ17		
SEZ6		
SEZ6L		
SEZ6L1		
SEZ6L2		
SF	AR,AD,AR	deafness, 39, 608265 (3), |hyperpigmentation with or without hypopigmentation, 145250 (3), ; waardenburg syndrome, type 2f, 619947 (3), ; deafness, 69, unilateral or asymmetric, 616697 (3), ; [skin/hair/eye pigmentation 7, blond/brown hair], 611664 (3)
SF-1	AD	46xx sex reversal 4, 617480 (3), ; premature ovarian failure 7, 612964 (3), ; 46xy sex reversal 3, 612965 (3), ; adrenocortical insufficiency, 612964 (3), ; spermatogenic failure 8, 613957 (3),
SF1	AD	46xx sex reversal 4, 617480 (3), ; premature ovarian failure 7, 612964 (3), ; 46xy sex reversal 3, 612965 (3), ; adrenocortical insufficiency, 612964 (3), ; spermatogenic failure 8, 613957 (3),
SF2		
SF20		
SF2000		
SF2001		
SF2p32	AR	combined oxidative phosphorylation deficiency 33, 617713 (3),
SF2p33		
SF3A1		
SF3a120		
SF3A2		
SF3A3		
SF3a60		
SF3a66		
SF3b1	AD	craniofacial microsomia, 164210 (3),
SF3B1		myelodysplastic syndrome, somatic, 614286 (3)
SF3b10		
SF3b125		
SF3b130		
SF3b145	AD	craniofacial microsomia, 164210 (3),
SF3B14a		
SF3b14b		
SF3b155		myelodysplastic syndrome, somatic, 614286 (3)
SF3B2	AD	craniofacial microsomia, 164210 (3),
SF3B3		
SF3B4	AD	acrofacial dysostosis 1, nager type, 154400 (3),
SF3b49	AD	acrofacial dysostosis 1, nager type, 154400 (3),
SF3B5		
SF3B6		
SF3B7		
SF3B8		
SF4		
SFA-1	AR	[blood group, raph], 179620 (3); epidermolysis bullosa simplex 7, with nephropathy and deafness, 609057 (3),
SFA-2		
SFD	AD	sorsby fundus dystrophy, 136900 (3),
SFDalpha		
SFDbeta		
Sfh1p	AD	rhabdoid tumors, somatic, 609322 (3); {schwannomatosis-1, susceptibility to}, 162091 (3), ; coffin-siris syndrome 3, 614608 (3), ; {rhabdoid tumor predisposition syndrome 1}, 609322 (3),
SFI1		
SFL		
SFMBT		
SFMBT1		
SFMBT2		
SFMD	AR	mucopolysaccharidosis type iiia (sanfilippo a), 252900 (3),
SFN		
SFPI1	AD	agammaglobulinemia 10, 619707 (3),
SFPQ		
SFR1		
SFRP1		
SFRP2		
SFRP3	MF	{osteoarthritis susceptibility 1}, 165720 (3),
SFRP4	AR	pyle disease, 265900 (3),
SFRP5		
SFRS1		
SFRS10		
SFRS11		
SFRS12		
SFRS13		
SFRS13A		
SFRS14		
SFRS15		
SFRS16		
SFRS17A		
SFRS18		
SFRS2		
SFRS20		
SFRS21	AR	intellectual developmental disorder, 70, 618402 (3),
SFRS2A		
SFRS2B		
SFRS2IP		
SFRS3		
SFRS4		
SFRS5		
SFRS6		
SFRS7		
SFRS8		
SFRS9		
SFRSK1		
SFRSK2		
SFSWAP		
SFT		
SFTA3		
SFTP1	AR,AD	interstitial lung disease 1, 619611 (3),
SFTP2	AD	surfactant metabolism dysfunction, pulmonary, 2, 610913 (3),
SFTP3	AR	surfactant metabolism dysfunction, pulmonary, 1, 265120 (3),
SFTP4		
SFTPA1	AR,AD	interstitial lung disease 1, 619611 (3),
SFTPA2	AD	interstitial lung disease 2, 178500 (3),
SFTPB	AR	surfactant metabolism dysfunction, pulmonary, 1, 265120 (3),
SFTPC	AD	surfactant metabolism dysfunction, pulmonary, 2, 610913 (3),
SFTPD		
SFTPH		
SFTPJ		
SFX3		
SFXN1		
SFXN2		
SFXN3		
SFXN4	AR	combined oxidative phosphorylation deficiency 18, 615578 (3),
SFXN5		
SG2NA		
SGA56M		
SGA72M		
SGB	XLR,XL	wilms tumor, somatic, 194070 (3); simpson-golabi-behmel syndrome, type 1, 312870 (3),
SGBS	XLR,XL	wilms tumor, somatic, 194070 (3); simpson-golabi-behmel syndrome, type 1, 312870 (3),
SGBS1	XLR,XL	wilms tumor, somatic, 194070 (3); simpson-golabi-behmel syndrome, type 1, 312870 (3),
SGC	AR	muscular dystrophy, limb-girdle, 4, 604286 (3),
SGC32445	AD,AR	?spastic paraplegia 72, 615625 (3), ; ?spastic paraplegia 72, 615625 (3),
SGCA	AR	muscular dystrophy, limb-girdle, 3, 608099 (3),
SGCB	AR	muscular dystrophy, limb-girdle, 4, 604286 (3),
SGCD	AR	cardiomyopathy, dilated, 1l, 606685 (3); muscular dystrophy, limb-girdle, 6, 601287 (3),
SGCE	AD	dystonia-11, myoclonic, 159900 (3),
SGCG	AR	muscular dystrophy, limb-girdle, 5, 253700 (3),
SGCZ		
SGD1		
SGDH		
SGEF		
SGF29		
SGF73	AD	spinocerebellar ataxia 7, 164500 (3),
SgI		
SgII		
SGII		
SgIII		
SGIP1		
SGK		
SGK069		
SGK071		
SGK1		
SgK196	AR	?muscular dystrophy-dystroglycanopathy (limb-girdle), type c, 12, 616094 (3), ; muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 12, 615249 (3),
SGK2		
SgK223		
sgk269		
SGK3		
SgK307	AR	spermatogenic failure 23, 617707 (3),
SgK396		
SgK493	AR	rhizomelic limb shortening with dysmorphic features, 618821 (3),
SgK495		
SGKL		
SGLT-1	AR	glucose/galactose malabsorption, 606824 (3),
SGLT1	AR	glucose/galactose malabsorption, 606824 (3),
SGLT2	AR,AD	renal glucosuria, 233100 (3),
SGLT3		
SGLT4		
SGLT5		
SGLT6		
SGM1	AD,AR	microphthalmia with coloboma 6, digenic, 613703 (3), ; microphthalmia, isolated 4, 613094 (3); leber congenital amaurosis 17, 615360 (3), ; multiple synostoses syndrome 4, 617898 (3), ; klippel-feil syndrome 1, 118100 (3),
SGMS1		
SGMS2	AD	calvarial doughnut lesions with bone fragility with or without spondylometaphyseal dysplasia, 126550 (3),
Sgn1		
SGN3		
SGN4		
SGN5		
SGN8		
SGNE1		
SGNP		
SGO1	AR	chronic atrial and intestinal dysrhythmia, 616201 (3),
SGO2		
SGOL1	AR	chronic atrial and intestinal dysrhythmia, 616201 (3),
SGOL2		
SGOT		aspartate aminotransferase, serum level of, qtl1, 614419 (3)
SGP-2		
sGP130	AR,AD	stuve-wiedemann syndrome 2, 619751 (3), ; hyper-ige recurrent infection syndrome 4a, 619752 (3), ; ?immunodeficiency 94 with autoinflammation and dysmorphic facies, 619750 (3), ; hyper-ige recurrent infection syndrome 4b, 618523 (3),
SGP28		
SGPL1	AR	nephrotic syndrome, type 14, 617575 (3),
SGPP1		
SGPP2		
SGPT		
SGRF		
SGRG		
SGS	AD	geleophysic dysplasia 2, 614185 (3), ; weill-marchesani syndrome 2, 608328 (3), ; ectopia lentis, familial, 129600 (3), ; mass syndrome, 604308 (3), ; marfan lipodystrophy syndrome, 616914 (3), ; acromicric dysplasia, 102370 (3), ; marfan syndrome, 154700 (3), ; stiff skin syndrome, 184900 (3),
SGSH	AR	mucopolysaccharidosis type iiia (sanfilippo a), 252900 (3),
SGSM1		
SGSM2		
SGSM3		
SGT		
SGT1		
SGT2	AR	neurodevelopmental disorder with seizures, microcephaly, and brain abnormalities, 620024 (3),
SGTA		
SgV		
SgVI	AD	acth-independent macronodular adrenal hyperplasia, 219080 (3), somatic mutation; pituitary adenoma 3, multiple types, somatic, 617686 (3); pseudohypoparathyroidism ic, 612462 (3), ; pseudohypoparathyroidism ia, 103580 (3), ; osseous heteroplasia, progressive, 166350 (3), ; pseudohypoparathyroidism ib, 603233 (3), ; mccune-albright syndrome, somatic, mosaic, 174800 (3); pseudopseudohypoparathyroidism, 612463 (3),
SgVII		
SgVIII		
SGY-1		
SH-PTP2	AD	noonan syndrome 1, 163950 (3), ; leopard syndrome 1, 151100 (3), ; metachondromatosis, 156250 (3), ; leukemia, juvenile myelomonocytic, somatic, 607785 (3)
SH120		
SH2A		
SH2B		
SH2B1		
SH2B2		
SH2B3		thrombocythemia, somatic, 187950 (3); myelofibrosis, somatic, 254450 (3); erythrocytosis, somatic, 133100 (3)
SH2BP1		
SH2D1A	XL,XLR	lymphoproliferative syndrome, 1, 308240 (3),
SH2D1B		
SH2D2A		
SH2D3A		
SH2D3B		
SH2D3C		
SH2D4A		
SH3BGR		
SH3BGRL		
SH3BGRL2		
SH3BGRL3		
SH3BP1		
SH3BP2	AD	cherubism, 118400 (3),
SH3BP4		
SH3BP4L		
SH3BP5		
SH3D19		
SH3D1A		
SH3D1B		
SH3D20		
SH3D2A		
SH3D2B	AD	leukemia, acute myeloid, 601626 (1), somatic mutation,
SH3D2C		
SH3D4		
SH3D5		
SH3D6A	AD,AR	dyschromatosis universalis hereditaria 1, 127500 (3), ; ?cancer, alopecia, pigment dyscrasia, onychodystrophy, and keratoderma, 618373 (3),
SH3D6B		
SH3D6C	XLR,XL	immunodeficiency 102, 301082 (3),
SH3GL1	AD	leukemia, acute myeloid, 601626 (1), somatic mutation,
SH3GL2		
SH3GL3		
SH3GLB1		
SH3GLB2		
SH3KBP1	XLR,XL	?immunodeficiency 61, 300310 (3),
SH3MD1		
SH3MD2		
SH3MD3		
SH3MD4		
sh3p12		
SH3P13		
SH3P17		
SH3P18		
SH3P19		
SH3P2		
SH3P20		
SH3P4		
SH3P7		
SH3P8	AD	leukemia, acute myeloid, 601626 (1), somatic mutation,
SH3P9	AR	centronuclear myopathy 2, 255200 (3),
SH3PX1		
SH3PX3		
SH3PXD1A	AR	chronic granulomatous disease 1, 233700 (3),
SH3PXD2A		
SH3PXD2B	AR	frank-ter haar syndrome, 249420 (3),
SH3PXD3A		
SH3PXD3C		
SH3PXD4	AR	chronic granulomatous disease 3, 613960 (3),
SH3PXD5		
SH3RF1		
SH3RF2		
SH3RF3		
SH3TC2	AR,AD	charcot-marie-tooth disease, type 4c, 601596 (3), ; mononeuropathy of the median nerve, mild, 613353 (3),
SH3YL1		
Shadoo		
SHAG1		
SHANK		{autism susceptibility 17}, 613436 (3)
SHANK1		
SHANK2		{autism susceptibility 17}, 613436 (3)
SHANK3	AD	phelan-mcdermid syndrome, 606232 (3), ; {schizophrenia 15}, 613950 (3),
SHAPY	AR	desbuquois dysplasia 1, 251450 (3), ; epiphyseal dysplasia, multiple, 7, 617719 (3),
SHARP	AD	radio-tartaglia syndrome, 619312 (3),
SHARP-1	AD	[short sleep, familial natural, 1], 612975 (3),
SHARP1	AD	[short sleep, familial natural, 1], 612975 (3),
SHARP2		
SHARPIN		
Shati	AR	?n-acetylaspartate deficiency, 614063 (3),
Shax1	AD	cataract 31, multiple types, 605387 (3),
Shax3		
SHB		
SHBG		
SHC		
SHC1		
SHC1P2		
SHC2		
SHC3		
SHC4		
ShcA		
SHCB		
SHCBP1		
SHCBP1L		
SHCC		
SHCD		
SHCL1		
SHD		
SHD1		
SHE		
SHF		
SHFD1		
Shfdg1		
SHFL		
SHFM1		
SHFM3		
SHFM4	AD	premature ovarian failure 21, 620311 (3), ; ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3, 604292 (3), ; hay-wells syndrome, 106260 (3), ; split-hand/foot malformation 4, 605289 (3), ; orofacial cleft 8, 618149 (3); rapp-hodgkin syndrome, 129400 (3), ; adult syndrome, 103285 (3), ; limb-mammary syndrome, 603543 (3),
SHFM6	AD,AR	tooth agenesis, selective, 8, 617073 (3), ; split-hand/foot malformation 6, 225300 (3),
SHGC-10760		
SHH	AD	microphthalmia with coloboma 5, 611638 (3), ; schizencephaly, 269160 (3); single median maxillary central incisor, 147250 (3), ; holoprosencephaly 3, 142945 (3),
SHIP		
SHIP1		
SHIP164		
SHIP2	AR	opsismodysplasia, 258480 (3),
SHIPPO1		
SHISA2		
SHISA3		
SHISA4		
SHISA5		
SHISA6		
SHISA7		
SHISA8		
SHISA9		
SHISAL2A		
SHISAL2B		
SHK	AR	[sedoheptulokinase deficiency], 617213 (3),
SHKBP1		
SHLD1		
SHLD2		
SHLD3		
SHMT	AR	neurodevelopmental disorder with cardiomyopathy, spasticity, and brain abnormalities, 619121 (3),
SHMT1		
SHMT2	AR	neurodevelopmental disorder with cardiomyopathy, spasticity, and brain abnormalities, 619121 (3),
SHN3		
SHOC1	AR	spermatogenic failure 75, 619949 (3),
SHOC2	AD	noonan syndrome-like with loose anagen hair 1, 607721 (3),
shootin-1		
shootin1		
SHOT		
SHOX	AR,AD,AD,AR	short stature, idiopathic familial, 300582 (3); langer mesomelic dysplasia, 249700 (3), pseudo ; leri-weill dyschondrosteosis, 127300 (3), pseudo |short stature, idiopathic familial, 300582 (3); leri-weill dyschondrosteosis, 127300 (3), pseudo ; langer mesomelic dysplasia, 249700 (3), pseudo
SHOX1	AR,AD,AD,AR	short stature, idiopathic familial, 300582 (3); langer mesomelic dysplasia, 249700 (3), pseudo ; leri-weill dyschondrosteosis, 127300 (3), pseudo |short stature, idiopathic familial, 300582 (3); leri-weill dyschondrosteosis, 127300 (3), pseudo ; langer mesomelic dysplasia, 249700 (3), pseudo
SHOX2		
SHOXY	AR,AD,AD,AR	short stature, idiopathic familial, 300582 (3); langer mesomelic dysplasia, 249700 (3), pseudo ; leri-weill dyschondrosteosis, 127300 (3), pseudo |short stature, idiopathic familial, 300582 (3); leri-weill dyschondrosteosis, 127300 (3), pseudo ; langer mesomelic dysplasia, 249700 (3), pseudo
SHP	AR,MF,AD	obesity, mild, early-onset, 601665 (3), ,
SHP-1		
SHP-2	AD	noonan syndrome 1, 163950 (3), ; leopard syndrome 1, 151100 (3), ; metachondromatosis, 156250 (3), ; leukemia, juvenile myelomonocytic, somatic, 607785 (3)
SHP1		
SHP2	AD	noonan syndrome 1, 163950 (3), ; leopard syndrome 1, 151100 (3), ; metachondromatosis, 156250 (3), ; leukemia, juvenile myelomonocytic, somatic, 607785 (3)
SHPK	AR	[sedoheptulokinase deficiency], 617213 (3),
SHPRH		
SHPS-1		
SHPS1		
SHQ1	AR	neurodevelopmental disorder with dystonia and seizures, 619922 (3), ; ?dystonia 35, childhood-onset, 619921 (3),
Shq1p	AR	neurodevelopmental disorder with dystonia and seizures, 619922 (3), ; ?dystonia 35, childhood-onset, 619921 (3),
SHREW-1		
SHREW1		
SHRM		
ShrmL		
SHROOM1		
SHROOM2		
SHROOM3		
SHROOM4		
SHS	XLR,XL	renpenning syndrome, 309500 (3),
SHSF1		
SHTAP		
SHTN1		
SHY1	AR	charcot-marie-tooth disease, type 4k, 616684 (3), ; mitochondrial complex iv deficiency, nuclear type 1, 220110 (3),
SHYC		
SI	AR	sucrase-isomaltase deficiency, congenital, 222900 (3),
Si-1-2		
Si-1-2-19		
SI-CLP		
SIAE		{autoimmune disease, susceptibility to, 6}, 613551 (3)
SIAH1	AD	buratti-harel syndrome, 619314 (3),
SIAH2		
SIAH3		
SIAHBP1	AD	verheij syndrome, 615583 (3),
SIAL2		
SIALIN	AR	salla disease, 604369 (3), ; sialic acid storage disorder, infantile, 269920 (3),
sialoadhesin		
SIASD	AR	salla disease, 604369 (3), ; sialic acid storage disorder, infantile, 269920 (3),
SIAT1		
SIAT10		
SIAT2		
SIAT3C		
SIAT4		
SIAT4A		
SIAT4B		
SIAT4C		
SIAT6	AR	developmental and epileptic encephalopathy 15, 615006 (3), ; intellectual developmental disorder, 12, 611090 (3),
SIAT7		
SIAT7A		
SIAT7B		
SIAT7C		
SIAT7D		
SIAT7E		
SIAT7F		
SIAT8		
SIAT8A		
SIAT8B		
SIAT8C		
SIAT8D		
SIAT8E		
SIAT8F		
SIAT9	AR	salt and pepper developmental regression syndrome, 609056 (3),
SIATFL		
SIATGM3S	AR	salt and pepper developmental regression syndrome, 609056 (3),
SIATL1		
SIC-1	AR,AD	bleeding disorder, platelet-type, 21, 617443 (3),
SID-1		
Sid1669p		
sid2895		
Sid470p	AR	?spastic ataxia 9, 618438 (3),
SID6-1512		
SID6-8061		
SIDS	XLR,XL	mucopolysaccharidosis ii, 309900 (3),
SIDT1		
SIDT2		
SIG13		
SIG81		
SIGIRR		
SIGLEC-1		
SIGLEC-10		
Siglec-12		
SIGLEC-2		
SIGLEC-3		
SIGLEC-4A	AR	spastic paraplegia 75, 616680 (3),
SIGLEC-5		
SIGLEC-6		
SIGLEC-7		
SIGLEC-8		
Siglec-L1		
Siglec-XII		
SIGLEC1		
SIGLEC10		
SIGLEC11		
SIGLEC12		
SIGLEC14		
SIGLEC15		
SIGLEC19P		
SIGLEC2		
SIGLEC3		
SIGLEC4A	AR	spastic paraplegia 75, 616680 (3),
SIGLEC5		
SIGLEC6		
SIGLEC7		
SIGLEC8		
SIGLEC8L		
SIGLEC9		
SIGLECL1		
SIGLECP2		
SIGMA1A	AR	mednik syndrome, 609313 (3),
SIGMA1B	XLR,XL	pettigrew syndrome, 304340 (3),
sigma1C	AD	{psoriasis 15, pustular, susceptibility to}, 616106 (3),
sigma3b		
SIGMAR1	AR	?spinal muscular atrophy, distal, 2, 605726 (3), ; ?amyotrophic lateral sclerosis 16, juvenile, 614373 (3),
SIH002	AD	{pancreatic cancer, susceptibility to, 1}, 606856 (3),
SII		
SIII		
SIIR	XL,XLD	neurodevelopmental disorder with gait disturbance, dysmorphic facies and behavioral abnormalities, 301094 (3),
SIK1	AD	developmental and epileptic encephalopathy 30, 616341 (3),
SIK2		
SIK3	AR	?spondyloepimetaphyseal dysplasia, krakow type, 618162 (3),
SIKE		
SIKE1		
SIL	AR	microcephaly 7, primary, 612703 (3),
sIL-7R	AR	immunodeficiency 104, severe combined, 608971 (3),
SIL1	AR	marinesco-sjogren syndrome, 248800 (3),
SILV		
SIM		
SIM1		
SIM2		
SIMA135		
SIMC1		
Simiate		
SIMP	AR	congenital disorder of glycosylation, type ix, 615597 (3),
SIMPL		
SIMPLE	AD	charcot-marie-tooth disease, type 1c, 601098 (3),
SIMRP7		
SIN		
SIN1		
SIN3A	AD	witteveen-kolk syndrome, 613406 (3),
SIN3B		
Singar1		
SINHCAF		
SIP		
SIP-1	AD	mowat-wilson syndrome, 235730 (3),
SIP1	AD	mowat-wilson syndrome, 235730 (3),
SIP2-28	AR	epidermodysplasia verruciformis 3, 618267 (3),
SIP30		
SIPA1		
SIPA1L1		
SIPA1L2		
SIPA1L3	AR	?cataract 45, 616851 (3),
SIPAR		
SIPL		
SIPL1		
SIPP1	AD	vertebral, cardiac, tracheoesophageal, renal, and limb defects, 619227 (3),
SIR2L		
SIR2L1		
SIR2L3		
SIR2L4		
SIRH1		
SIRH10		
SIRH2		
SIRH5		
SIRH7		
SIRP		
SIRP-ALPHA-1		
SIRP-B2		
SIRP-BETA-1		
SIRPA		
SIRPalpha		
SIRPalpha2		
SIRPB1		
SIRPB2		
SIRPG		
SIRPgamma		
SIRT1		
SIRT2		
SIRT3		
SIRT4		
SIRT5		
SIRT6		
SIRT7		
SIS	AD	meningioma, sis-related, 607174 (3), ; basal ganglia calcification, idiopathic, 5, 615483 (3), ; dermatofibrosarcoma protuberans, 607907 (3)
Sis1		
SISd		{hiv-1 disease, rapid progression of}, 609423 (3); {hiv-1 disease, delayed progression of}, 609423 (3)
SISe		
SISP1		
sit	AR	nivelon-nivelon-mabille syndrome, 600092 (3),
SIT		
SIT1		
SITAC18		
SITPEC		
SIVA		
Siva-1		
Siva-2		
SIVA1		
SIX1	AD	deafness, 23, 605192 (3), ; branchiootic syndrome 3, 608389 (3),
SIX2		
SIX3	AD	schizencephaly, 269160 (3); holoprosencephaly 2, 157170 (3),
SIX4		
SIX5		branchiootorenal syndrome 2, 610896 (3)
SIX6	AR	optic disc anomalies with retinal and/or macular dystrophy, 212550 (3),
SIX6OS1	AR	spermatogenic failure 52, 619202 (3), ; ?premature ovarian failure 18, 619203 (3),
Six9	AR	optic disc anomalies with retinal and/or macular dystrophy, 212550 (3),
SIZN		
SIZN1		
SJS1	AR	dyssegmental dysplasia, silverman-handmaker type, 224410 (3), ; schwartz-jampel syndrome, type 1, 255800 (3),
SK		
SK-12	AR	cleft lip/palate-ectodermal dysplasia syndrome, 225060 (3), ; orofacial cleft 7, 225060 (3),
Sk-Tmod		
SKA1		
SKA2		
SKA3		
SKALP		
SKAP		?roifman-chitayat syndrome, digenic, 613328 (3), digenic
SKAP-HOM		
SKAP1		
SKAP2		
SKAP55		
SKAP55R		
SKAR		
SKB1		
SKB1Hs		
SKCA3	AD	zimmermann-laband syndrome 3, 618658 (3),
SKD1	AD	cimdag syndrome, 619273 (3),
SKD1A	AD	cimdag syndrome, 619273 (3),
SKD1B		
SKD2	AD,AD	cimdag syndrome, 619273 (3), |developmental and epileptic encephalopathy 96, 619340 (3),
SKD3	AD,AR	neutropenia, severe congenital, 9, 619813 (3), ; 3-methylglutaconic aciduria, type viib, 616271 (3), ; 3-methylglutaconic aciduria, type viia, 619835 (3),
skeletrophin		
ski	AR	nivelon-nivelon-mabille syndrome, 600092 (3),
SKI	AD	shprintzen-goldberg syndrome, 182212 (3),
SKI-1	AR	?spondyloepiphyseal dysplasia, kondo-fu type, 618392 (3),
SKI2	AR	trichohepatoenteric syndrome 2, 614602 (3),
SKI2W	AR	trichohepatoenteric syndrome 2, 614602 (3),
SKI3	AR	trichohepatoenteric syndrome 1, 222470 (3),
SKI4	AR	?pontocerebellar hypoplasia, type 1f, 619304 (3),
Ski4p	AR	?pontocerebellar hypoplasia, type 1f, 619304 (3),
SKI6		
Ski6p		
SKI8		
SKIC2	AR	trichohepatoenteric syndrome 2, 614602 (3),
SKIC3	AR	trichohepatoenteric syndrome 1, 222470 (3),
SKIC8		
SKIIP		
SKIL		
skinkine		
SKIP	AR	muscular dystrophy, congenital, with cataracts and intellectual disability, 617404 (3),
SKIP1		
SKIV2	AR	trichohepatoenteric syndrome 2, 614602 (3),
SKIV2L	AR	trichohepatoenteric syndrome 2, 614602 (3),
SKIV2L1	AR	trichohepatoenteric syndrome 2, 614602 (3),
SKIV2L2		
SkM1	AD,AR	paramyotonia congenita, 168300 (3), ; hyperkalemic periodic paralysis, 170500 (3), ; congenital myopathy 22b, severe fetal, 620369 (3), ; hypokalemic periodic paralysis, type 2, 613345 (3), ; myotonia congenita, atypical, acetazolamide-responsive, 608390 (3), ; myasthenic syndrome, congenital, 16, 614198 (3), ; congenital myopathy 22a, classic, 620351 (3),
SKMc15		
skMLCK	AD	cardiomyopathy, hypertrophic, 1, digenic, 192600 (3), digenic ,
Skn	AR	nivelon-nivelon-mabille syndrome, 600092 (3),
Skn-1a		
SKOR1		
SKOR2		
SKP1		
SKP1A		
SKP1B		
SKP1P2		
SKP2		
SKR		
SKR1	AD	fibrodysplasia ossificans progressiva, 135100 (3),
SKR2		pancreatic cancer, somatic, 260350 (3)
SKRP1		
SKRP4		
SKT		
Sky		
SL1		
SL15	AR	congenital disorder of glycosylation, type if, 609180 (3),
SL21		
SLA	AR	pontocerebellar hypoplasia type 2d, 613811 (3),
SLA-p35	AR	pontocerebellar hypoplasia type 2d, 613811 (3),
SLA/LP	AR	pontocerebellar hypoplasia type 2d, 613811 (3),
SLA1		
SLA2		
Slac-2a	AR	griscelli syndrome, type 3, 609227 (3),
SLAC2-B	AR	epidermolysis bullosa simplex 4, localized or generalized intermediate, 615028 (3),
SLAC2-C		
SLAC2C		
SLACK	AD	developmental and epileptic encephalopathy 14, 614959 (3), ; epilepsy nocturnal frontal lobe, 5, 615005 (3),
SLAIN1		
SLAIN2		
SLAM		
SLAMF1		
SLAMF2		
SLAMF3		
SLAMF4		{rheumatoid arthritis, susceptibility to}, 180300 (3)
SLAMF5		
SLAMF6		
SLAMF7		
SLAMF8		
SLAMF9		
SLAP		
SLAP-1		
SLAP-130	AR	thrombocytopenia 3, 273900 (3),
SLAP-2		
SLAP75		
SLAT	AR	immunodeficiency 87 and autoimmunity, 619573 (3),
SLB	AR	retinitis pigmentosa 71, 616394 (3), ; bardet-biedl syndrome 20, 619471 (3), ; short-rib thoracic dysplasia 10 with or without polydactyly, 615630 (3),
SLBP		
SLC		
SLC1		
SLC10A1	AR	hypercholanemia, familial 2, 619256 (3),
SLC10A2	AR	?bile acid malabsorption, primary, 1, 613291 (3),
SLC10A3		
SLC10A4		
SLC10A5		
SLC10A6		
SLC10A7	AR	short stature, amelogenesis imperfecta, and skeletal dysplasia with scoliosis, 618363 (3),
SLC11	AR,AD	?fanconi renotubular syndrome 2, 613388 (3), ; hypercalcemia, infantile, 2, 616963 (3), ; nephrolithiasis/osteoporosis, hypophosphatemic, 1, 612286 (3),
SLC11A1		{mycobacterium tuberculosis, susceptibility to infection by}, 607948 (3); {buruli ulcer, susceptibility to}, 610446 (3)
SLC11A2	AR	anemia, hypochromic microcytic, with iron overload 1, 206100 (3),
SLC11A3	AD	hemochromatosis, type 4, 606069 (3),
SLC12A1	AR	bartter syndrome, type 1, 601678 (3),
SLC12A2	AR,AD	kilquist syndrome, 619080 (3), ; delpire-mcneill syndrome, 619083 (3), ; deafness, 78, 619081 (3),
SLC12A3	AR	gitelman syndrome, 263800 (3),
SLC12A4		
SLC12A5	AD,AR	{epilepsy, idiopathic generalized, susceptibility to, 14}, 616685 (3), ; developmental and epileptic encephalopathy 34, 616645 (3),
SLC12A6	AR,AD	agenesis of the corpus callosum with peripheral neuropathy, 218000 (3), ; charcot-marie-tooth disease, axonal, type 2ii, 620068 (3),
SLC12A7		
SLC12A8		
SLC12A9		
SLC13A1		
SLC13A2		
SLC13A3	AR	leukoencephalopathy, acute reversible, with increased urinary alpha-ketoglutarate, 618384 (3),
SLC13A4		
SLC13A5	AR	developmental and epileptic encephalopathy 25, with amelogenesis imperfecta, 615905 (3),
SLC14A1		[blood group, kidd], 111000 (3)
SLC14A2		
SLC15A1		
SLC15A2		
SLC15A3		
SLC15A4		
SLC15A5		
SLC16A1	AD,AR	hyperinsulinemic hypoglycemia, familial, 7, 610021 (3), ; erythrocyte lactate transporter defect, 245340 (3), ; monocarboxylate transporter 1 deficiency, 616095 (3),
SLC16A10		
SLC16A11		
SLC16A12	AD	cataract 47, juvenile, with microcornea, 612018 (3),
SLC16A2	XL	allan-herndon-dudley syndrome, 300523 (3),
SLC16A3		
SLC16A4		
SLC16A5		
SLC16A6		
SLC16A7		
SLC16A8		
SLC16A9		
SLC17A1		
SLC17A2	AR,AD	?fanconi renotubular syndrome 2, 613388 (3), ; hypercalcemia, infantile, 2, 616963 (3), ; nephrolithiasis/osteoporosis, hypophosphatemic, 1, 612286 (3),
SLC17A3	AD	[uric acid concentration, serum, qtl4], 612671 (3), ; {gout susceptibility 4}, 612671 (3),
SLC17A4		
SLC17A5	AR	salla disease, 604369 (3), ; sialic acid storage disorder, infantile, 269920 (3),
SLC17A6		
SLC17A7		
SLC17A8	AD	deafness, 25, 605583 (3),
SLC17A9	AD	porokeratosis 8, disseminated superficial actinic type, 616063 (3),
SLC18A1		
SLC18A2	AR	?parkinsonism-dystonia, infantile, 2, 618049 (3),
SLC18A3	AR	myasthenic syndrome, congenital, 21, presynaptic, 617239 (3),
SLC18B1		
SLC19A1	AR	?megaloblastic anemia, folate-responsive, 601775 (3),
SLC19A2	AR	thiamine-responsive megaloblastic anemia syndrome, 249270 (3),
SLC19A3	AR	thiamine metabolism dysfunction syndrome 2 (biotin- or thiamine-responsive encephalopathy type 2), 607483 (3),
SLC1A1	AR	dicarboxylic aminoaciduria, 222730 (3), ; {?schizophrenia susceptibility 18}, 615232 (3)
SLC1A2	AD	developmental and epileptic encephalopathy 41, 617105 (3),
SLC1A3	AD	episodic ataxia, type 6, 612656 (3),
SLC1A4	AR	spastic tetraplegia, thin corpus callosum, and progressive microcephaly, 616657 (3),
SLC1A5		
SLC1A6		
SLC1A7		
SLC20A1		
SLC20A2	AD	basal ganglia calcification, idiopathic, 1, 213600 (3),
SLC20A3	AR	combined d-2- and l-2-hydroxyglutaric aciduria, 615182 (3), ; myasthenic syndrome, congenital, 23, presynaptic, 618197 (3),
SLC20A4	AD	paragangliomas 6, 618464 (3),
SLC21A11		
SLC21A12		
SLC21A14		
SLC21A15		
SLC21A2	AD,AR	hypertrophic osteoarthropathy, primary, 167100 (3), ; hypertrophic osteoarthropathy, primary, 2, 614441 (3),
SLC21A20		
SLC21A21		
SLC21A3		
SLC21A6		hyperbilirubinemia, rotor type, digenic, 237450 (3), digenic
SLC21A8		hyperbilirubinemia, rotor type, digenic, 237450 (3), digenic
SLC21A9		
SLC22A1		
SLC22A10		
SLC22A11		
SLC22A12	AR	hypouricemia, renal, 220150 (3),
SLC22A13		
SLC22A14		
SLC22A15		
SLC22A16		
SLC22A17		
SLC22A18		breast cancer, somatic, 114480 (3); lung cancer, somatic, 211980 (3); rhabdomyosarcoma, somatic, 268210 (3)
SLC22A18-AS1		
SLC22A18AS		
SLC22A1L		breast cancer, somatic, 114480 (3); lung cancer, somatic, 211980 (3); rhabdomyosarcoma, somatic, 268210 (3)
SLC22A1LS		
SLC22A2		
SLC22A20		
SLC22A20P		
SLC22A23		
SLC22A24		
SLC22A25		
SLC22A3		
SLC22A4		{rheumatoid arthritis, susceptibility to}, 180300 (3)
SLC22A5	AR	carnitine deficiency, systemic primary, 212140 (3),
SLC22A6		
SLC22A7		
SLC22A8		
SLC22A9		
SLC22B1		
SLC22B2		
SLC22B3		
SLC22B4		
SLC22B5		
SLC23A1		
SLC23A2		
SLC23A3		
SLC24A1	AR	night blindness, congenital stationary (complete), 1d, 613830 (3),
SLC24A2		
SLC24A3		
SLC24A4	AR	[skin/hair/eye pigmentation 6, blond/brown hair], 210750 (3), ; amelogenesis imperfecta, type iia5, 615887 (3), ; [skin/hair/eye pigmentation 6, blue/green eyes], 210750 (3),
SLC24A5	AR	[skin/hair/eye pigmentation 4, fair/dark skin], 113750 (3), ; albinism, oculocutaneous, type vi, 113750 (3),
SLC24A6		
SLC25A1	AR	combined d-2- and l-2-hydroxyglutaric aciduria, 615182 (3), ; myasthenic syndrome, congenital, 23, presynaptic, 618197 (3),
SLC25A10	AR	?mitochondrial dna depletion syndrome 19, 618972 (3),
SLC25A11	AD	paragangliomas 6, 618464 (3),
SLC25A12	AR	developmental and epileptic encephalopathy 39, 612949 (3),
SLC25A13	AR	citrullinemia, type ii, neonatal-onset, 605814 (3), ; citrullinemia, adult-onset type ii, 603471 (3),
SLC25A14		
SLC25A15	AR	hyperornithinemia-hyperammonemia-homocitrullinemia syndrome, 238970 (3),
SLC25A16		
SLC25A17		
SLC25A18		
SLC25A19	AR	microcephaly, amish type, 607196 (3), ; thiamine metabolism dysfunction syndrome 4 (progressive polyneuropathy type), 613710 (3),
SLC25A2		
SLC25A20	AR	carnitine-acylcarnitine translocase deficiency, 212138 (3),
SLC25A21	AR	?mitochondrial dna depletion syndrome 18, 618811 (3),
SLC25A22	AR	developmental and epileptic encephalopathy 3, 609304 (3),
SLC25A23		
SLC25A24	AD	fontaine progeroid syndrome, 612289 (3),
SLC25A25		
SLC25A26	AR	combined oxidative phosphorylation deficiency 28, 616794 (3),
SLC25A27		
SLC25A28		
SLC25A29		
SLC25A3	AR	mitochondrial phosphate carrier deficiency, 610773 (3),
SLC25A30		
SLC25A31		
SLC25A32	AR	?exercise intolerance, riboflavin-responsive, 616839 (3),
SLC25A33		
SLC25A34		
SLC25A35		
SLC25A36	AR	hyperinsulinemic hypoglycemia, familial, 8, 620211 (3),
SLC25A37		
SLC25A38	AR	anemia, sideroblastic, 2, pyridoxine-refractory, 205950 (3),
SLC25A39		
SLC25A4	AR,AD	mitochondrial dna depletion syndrome 12b (cardiomyopathic type) ar, 615418 (3), ; progressive external ophthalmoplegia with mitochondrial dna deletions, 2, 609283 (3), ; mitochondrial dna depletion syndrome 12a (cardiomyopathic type) ad, 617184 (3),
SLC25A40		
SLC25A41		
SLC25A42	AR	metabolic crises, recurrent, with variable encephalomyopathic features and neurologic regression, 618416 (3),
SLC25A43		
SLC25A44		
SLC25A45		
SLC25A46	AR	neuropathy, hereditary motor and sensory, type vib, 616505 (3), ; pontocerebellar hypoplasia, type 1e, 619303 (3),
SLC25A47		
SLC25A48		
SLC25A49		
SLC25A5		
SLC25A50		
SLC25A51		
SLC25A52		
SLC25A53		
SLC25A6		
SLC25A7		
SLC25A8		{obesity, susceptibility to, bmiq4}, 607447 (3)
SLC25A9	AR,MF,AD	{obesity, severe, and type ii diabetes}, 601665 (3), ,
SLC26A1	AR	?hypersulfaturia, 620372 (3), ; ?nephrolithiasis, calcium oxalate, 1, 167030 (3),
SLC26A11		
SLC26A2	AR	epiphyseal dysplasia, multiple, 4, 226900 (3), ; de la chapelle dysplasia, 256050 (3), ; diastrophic dysplasia, 222600 (3), ; diastrophic dysplasia, broad bone-platyspondylic variant, 222600 (3), ; achondrogenesis ib, 600972 (3), ; atelosteogenesis, type ii, 256050 (3),
SLC26A3	AR	diarrhea 1, secretory chloride, congenital, 214700 (3),
SLC26A4	AR	deafness, 4, with enlarged vestibular aqueduct, 600791 (3), ; pendred syndrome, 274600 (3),
SLC26A5	AR	?deafness, 61, 613865 (3),
SLC26A6		
SLC26A7		
SLC26A8	AR,AD	spermatogenic failure 3, 606766 (3),
SLC26A9		
SLC27A1		
SLC27A2		
SLC27A3		
SLC27A4	AR	ichthyosis prematurity syndrome, 608649 (3),
SLC27A5		
SLC27A6		
SLC28A1	AR	[uridine-cytidineuria], 618477 (3),
SLC28A2		
SLC28A3		
SLC29A1		
SLC29A2		
SLC29A3	AR	histiocytosis-lymphadenopathy plus syndrome, 602782 (3),
SLC29A4		
SLC2A1	AD,AR	dystonia 9, 601042 (3), ; glut1 deficiency syndrome 1, infantile onset, severe, 606777 (3), ; stomatin-deficient cryohydrocytosis with neurologic defects, 608885 (3), ; {epilepsy, idiopathic generalized, susceptibility to, 12}, 614847 (3), ; glut1 deficiency syndrome 2, childhood onset, 612126 (3),
SLC2A10	AR	arterial tortuosity syndrome, 208050 (3),
SLC2A11		
SLC2A12		
SLC2A13		
SLC2A14		
SLC2A2	AR,AD	fanconi-bickel syndrome, 227810 (3), ; {diabetes mellitus, noninsulin-dependent}, 125853 (3),
SLC2A3		
SLC2A3P3		
SLC2A4		
SLC2A4RG		
SLC2A5		
SLC2A6		
SLC2A7		
SLC2A8		
SLC2A9	AR,AD	{uric acid concentration, serum, qtl 2}, 612076 (3), ; hypouricemia, renal, 2, 612076 (3),
SLC2C	AD	short qt syndrome 7, 620231 (3),
SLC30A1		
SLC30A10	AR	hypermanganesemia with dystonia 1, 613280 (3),
SLC30A2	AD	zinc deficiency, transient neonatal, 608118 (3),
SLC30A3		
SLC30A4		
SLC30A5		
SLC30A6		
SLC30A7		
SLC30A8	AD	{diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3),
SLC30A9	AR	birk-landau-perez syndrome, 617595 (3),
SLC31A1	AR	neurodegeneration and seizures due to copper transport defect, 620306 (3),
SLC31A2		
SLC32A1		
SLC33A1	AD,AR	spastic paraplegia 42, 612539 (3), ; congenital cataracts, hearing loss, and neurodegeneration, 614482 (3),
SLC33A2		
SLC34A1	AR,AD	?fanconi renotubular syndrome 2, 613388 (3), ; hypercalcemia, infantile, 2, 616963 (3), ; nephrolithiasis/osteoporosis, hypophosphatemic, 1, 612286 (3),
SLC34A2	AR	pulmonary alveolar microlithiasis, 265100 (3),
SLC34A3	AR	hypophosphatemic rickets with hypercalciuria, 241530 (3),
SLC35A1	AR	congenital disorder of glycosylation, type iif, 603585 (3),
SLC35A2	XLD,XL	congenital disorder of glycosylation, type iim, 300896 (3), somatic mosaicism,
SLC35A3	AR	arthrogryposis, impaired intellectual development, and seizures, 615553 (3),
SLC35A4		
SLC35A5		
SLC35B1		
SLC35B2	AR	leukodystrophy, hypomyelinating, 26, with chondrodysplasia, 620269 (3),
SLC35B3		
SLC35B4		
SLC35C1	AR	congenital disorder of glycosylation, type iic, 266265 (3),
SLC35C2		
SLC35D1	AR	schneckenbecken dysplasia, 269250 (3),
SLC35D2		
SLC35D3		
SLC35D4		
SLC35E1		
SLC35E2B		
SLC35E3		
SLC35F1		
SLC35F2		
SLC35F5		
SLC35F6		
SLC35G1		
SLC35G2		
SLC35G5		
SLC35G7		
SLC36A1		
SLC36A2	AR,AD	[iminoglycinuria], 242600 (3), digenic ; [hyperglycinuria], 138500 (3),
SLC36A3		
SLC36A4		
SLC37A1		
SLC37A2		
SLC37A3		
SLC37A4	AR,AD	glycogen storage disease ib, 232220 (3), ; congenital disorder of glycosylation, type iiw, 619525 (3), ; glycogen storage disease ic, 232240 (3),
SLC38A1		
SLC38A10		
SLC38A11		
SLC38A2		
SLC38A3	AR	developmental and epileptic encephalopathy 102, 619881 (3),
SLC38A4		
SLC38A5		
SLC38A6		
SLC38A7		
SLC38A8	AR	foveal hypoplasia 2, with or without optic nerve misrouting and/or anterior segment dysgenesis, 609218 (3),
SLC38A9		
SLC39A1		
SLC39A10		
SLC39A11		
SLC39A12		
SLC39A13	AR	ehlers-danlos syndrome, spondylodysplastic type, 3, 612350 (3),
SLC39A14	AD,AR	?hyperostosis cranalis interna, 144755 (3), ; hypermanganesemia with dystonia 2, 617013 (3),
SLC39A2		
SLC39A3		
SLC39A4	AR	acrodermatitis enteropathica, 201100 (3),
SLC39A5	AD	myopia 24, 615946 (3),
SLC39A6		
SLC39A7	AR	agammaglobulinemia 9, 619693 (3),
SLC39A8	AR	congenital disorder of glycosylation, type iin, 616721 (3),
SLC39A9		
SLC3A1	AR,AD	cystinuria, 220100 (3),
SLC3A2		
SLC40A1	AD	hemochromatosis, type 4, 606069 (3),
SLC41A1	AR	?nephronophthisis-like nephropathy 2, 619468 (3),
SLC41A2		
SLC41A3		
SLC42A1	AD,AR	overhydrated hereditary stomatocytosis, 185000 (3), ; anemia, hemolytic, rh-null, regulator type, 268150 (3),
SLC42A2		
SLC42A3		
SLC43A1		
SLC43A2		
SLC43A3		
SLC44A1	AR	neurodegeneration, childhood-onset, with ataxia, tremor, optic atrophy, and cognitive decline, 618868 (3),
SLC44A2		
SLC44A3		
SLC44A4	AD	?deafness, 72, 617606 (3),
SLC44A5		
SLC45A1	AR	intellectual developmental disorder with neuropsychiatric features, 617532 (3),
SLC45A2	AR	[skin/hair/eye pigmentation 5, dark/light eyes], 227240 (3), ; [skin/hair/eye pigmentation 5, black/nonblack hair], 227240 (3), ; albinism, oculocutaneous, type iv, 606574 (3), ; [skin/hair/eye pigmentation 5, dark/fair skin], 227240 (3),
SLC45A3		
SLC45A4		
SLC46A1	AR	folate malabsorption, hereditary, 229050 (3),
SLC46A2		
SLC46A3		
SLC47A1		
SLC47A2		
SLC48A1		
SLC49A1	AR	ataxia, posterior column, with retinitis pigmentosa, 609033 (3),
SLC49A2	AR	proliferative vasculopathy and hydranencephaly-hydrocephaly syndrome, 225790 (3),
SLC49A3		
SLC49A4		
SLC4A1	AD,AR	[blood group, swann], 601550 (3); [blood group, wright], 112050 (3); distal renal tubular acidosis 1, 179800 (3), ; [blood group, waldner], 112010 (3); spherocytosis, type 4, 612653 (3), ; [blood group, froese], 601551 (3); distal renal tubular acidosis 4 with hemolytic anemia, 611590 (3), ; {malaria, resistance to}, 611162 (3); cryohydrocytosis, 185020 (3), ; ovalocytosis, sa type, 166900 (3), ; [blood group, diego], 110500 (3)
SLC4A10		
SLC4A11	AR	corneal endothelial dystrophy, 217700 (3), ; corneal dystrophy, fuchs endothelial, 4, 613268 (3); corneal endothelial dystrophy and perceptive deafness, 217400 (3),
SLC4A1AP		
SLC4A2	AR	?osteopetrosis, 9, 620366 (3),
SLC4A3	AD	short qt syndrome 7, 620231 (3),
SLC4A4	AR	renal tubular acidosis, proximal, with ocular abnormalities, 604278 (3),
SLC4A5	AR	renal tubular acidosis, proximal, with ocular abnormalities, 604278 (3),
SLC4A6		
SLC4A7		
SLC4A8		
SLC4A9		
SLC50A1		
SLC51A	AR	?cholestasis, progressive familial intrahepatic, 6, 619484 (3),
SLC51B	AR	?bile acid malabsorption, primary, 2, 619481 (3),
SLC52A1	AD	riboflavin deficiency, 615026 (3),
SLC52A2	AR	brown-vialetto-van laere syndrome 2, 614707 (3),
SLC52A3	AR	?fazio-londe disease, 211500 (3), ; brown-vialetto-van laere syndrome 1, 211530 (3),
SLC53A1	AD	basal ganglia calcification, idiopathic, 6, 616413 (3),
SLC54A1	AR	mitochondrial pyruvate carrier deficiency, 614741 (3),
SLC54A2		
SLC54A3		
SLC55A1	AR	neurodegeneration, childhood-onset, with multisystem involvement due to mitochondrial dysfunction, 620089 (3),
SLC55A2		
SLC55A3		
SLC56A1		
SLC56A2		
SLC56A3		
SLC56A4	AR	combined oxidative phosphorylation deficiency 18, 615578 (3),
SLC56A5		
SLC57A1	AD	spastic paraplegia 6, 600363 (3),
SLC57A2		
SLC57A3		
SLC57A5		
SLC57A6	AR	ichthyosis, congenital, 6, 612281 (3),
SLC58A1	XL,XLR	immunodeficiency, with magnesium defect, epstein-barr virus infection and neoplasia, 300853 (3), ; congenital disorder of glycosylation, type icc, 301031 (3),
SLC58A2	AR	intellectual developmental disorder, 7, 611093 (3),
SLC59A1	AR	neurodevelopmental disorder with progressive microcephaly, spasticity, and brain abnormalities, 616486 (3),
SLC59A2		
SLC5A1	AR	glucose/galactose malabsorption, 606824 (3),
SLC5A10		
SLC5A11		
SLC5A12		
SLC5A2	AR,AD	renal glucosuria, 233100 (3),
SLC5A3		
SLC5A4		
SLC5A5	AR	thyroid dyshormonogenesis 1, 274400 (3),
SLC5A6	AR	sodium-dependent multivitamin transporter deficiency, 618973 (3), ; peripheral motor neuropathy, childhood-onset, biotin-responsive, 619903 (3),
SLC5A7	AD,AR	neuronopathy, distal hereditary motor, type viia, 158580 (3), ; myasthenic syndrome, congenital, 20, presynaptic, 617143 (3),
SLC5A8		
SLC5A9		
SLC60A1		
SLC60A2		
SLC61A1		
SLC62A1	AD	chondrocalcinosis 2, 118600 (3), ; craniometaphyseal dysplasia, 123000 (3),
SLC63A1		
SLC63A2	AR	?deafness, 115, 618457 (3),
SLC63A3		
SLC64A1	AR	congenital disorder of glycosylation, type iik, 614727 (3),
SLC65A1	AR	niemann-pick disease, type c1, 257220 (3), ; niemann-pick disease, type d, 257220 (3),
SLC65A2		[ezetimibe, nonresponse to], 617966 (3); [low density lipoprotein cholesterol level qtl 7], 617966 (3)
SLC66A1		
SLC66A4	AR	cystinosis, nephropathic, 219800 (3), ; cystinosis, ocular nonnephropathic, 219750 (3), ; cystinosis, late-onset juvenile or adolescent nephropathic, 219900 (3), ; cystinosis, atypical nephropathic, 219800 (3),
SLC66A5	AR	congenital disorder of glycosylation, type if, 609180 (3),
SLC6A1	AD	myoclonic-atonic epilepsy, 616421 (3),
SLC6A11		
SLC6A12		
SLC6A13		
SLC6A14		
SLC6A15		
SLC6A16		
SLC6A17	AR	intellectual developmental disorder, 48, 616269 (3),
SLC6A18		
SLC6A19	AR	hartnup disorder, 234500 (3),
SLC6A2	AD	?orthostatic intolerance, 604715 (3),
SLC6A20		
SLC6A3	AR	parkinsonism-dystonia, infantile, 1, 613135 (3), ; {nicotine dependence, protection against}, 188890 (3)
SLC6A4	AD	{obsessive-compulsive disorder}, 164230 (3), ; {anxiety-related personality traits}, 607834 (3)
SLC6A5	AD,AR,AD	?orthostatic intolerance, 604715 (3), |hyperekplexia 3, 614618 (3),
SLC6A6	AR	hypotaurinemic retinal degeneration and cardiomyopathy, 145350 (3),
SLC6A7		
SLC6A8	XLR,XL	cerebral creatine deficiency syndrome 1, 300352 (3),
SLC6A9	AR	glycine encephalopathy with normal serum glycine, 617301 (3),
SLC7A1		
SLC7A10		
SLC7A11		
SLC7A13		
SLC7A14	AR	retinitis pigmentosa 68, 615725 (3),
SLC7A2		
SLC7A3		
SLC7A4		
SLC7A5		
SLC7A6		
SLC7A6OS	AR	epilepsy, progressive myoclonic, 12, 619191 (3),
SLC7A7	AR	lysinuric protein intolerance, 222700 (3),
SLC7A8		
SLC7A9	AR,AD	cystinuria, 220100 (3),
SLC8A1		
SLC8A2		
SLC8A3		
SLC8B1		
SLC9A1	AR	lichtenstein-knorr syndrome, 616291 (3),
SLC9A10		
SLC9A11		
SLC9A1BP	AR	?spastic ataxia 9, 618438 (3),
SLC9A2		
SLC9A3	AR	diarrhea 8, secretory sodium, congenital, 616868 (3),
SLC9A3R1	AD	nephrolithiasis/osteoporosis, hypophosphatemic, 2, 612287 (3),
SLC9A3R2		
SLC9A4		
SLC9A5		
SLC9A6	XL	intellectual developmental disorder, syndromic, christianson type, 300243 (3),
SLC9A7	XL,XLR	intellectual developmental disorder, 108, 301024 (3),
SLC9A8		
SLC9A9		{?autism susceptibility 16}, 613410 (3)
SLC9B1		
SLC9B2		
SLC9C1		
SLC9C2		
SLCO1A2		
SLCO1B1		hyperbilirubinemia, rotor type, digenic, 237450 (3), digenic
SLCO1B3		hyperbilirubinemia, rotor type, digenic, 237450 (3), digenic
SLCO1B7		
SLCO1C1		
SLCO2A1	AD,AR	hypertrophic osteoarthropathy, primary, 167100 (3), ; hypertrophic osteoarthropathy, primary, 2, 614441 (3),
SLCO2B1		
SLCO3A1		
SLCO4A1		
SLCO4C1		
SLCO5A1		
SLCO6A1		
SLD	AR	salla disease, 604369 (3), ; sialic acid storage disorder, infantile, 269920 (3),
SLD3		
SLD5		
SLEB1	AD	{melioidosis, susceptibility to}, 615557 (3), ; {systemic lupus erythematosus, susceptibility to, 1}, 601744 (3); {systemic lupus erythematosus, resistance to}, 601744 (3); {legionnaire disease, susceptibility to}, 608556 (3)
SLEB2	MF	{multiple sclerosis, disease progression, modifier of}, 126200 (3), ; {systemic lupus erythematosus, susceptibility to, 2}, 605218 (3)
SLEV1	AR,AD	{vitiligo-associated multiple autoimmune disease susceptibility 1}, 606579 (3); ?respiratory papillomatosis, juvenile recurrent, congenital, 618803 (3), ; autoinflammation with arthritis and dyskeratosis, 617388 (3), ; palmoplantar carcinoma, multiple self-healing, 615225 (3),
SLF	AD,AR	hyperpigmentation with or without hypopigmentation, 145250 (3), ; waardenburg syndrome, type 2f, 619947 (3), ; deafness, 69, unilateral or asymmetric, 616697 (3), ; [skin/hair/eye pigmentation 7, blond/brown hair], 611664 (3)
SLF1		
SLF2	AR	atelis syndrome 1, 620184 (3),
SLFN11		
SLFN12		
SLFN12L		
SLFN13		
SLFN14	AD	bleeding disorder, platelet-type, 20, 616913 (3),
SLFN5		
SLG		
SLG2		
SLI		
SLIC-1		
SLIC1		
SLICK	AD	developmental and epileptic encephalopathy 57, 617771 (3),
SLIL1		
SLIL2		
SLIL3		
slim		
SLIM1	XL,XLR,XLD	myopathy, with postural muscle atrophy, 300696 (3), ; emery-dreifuss muscular dystrophy 6, 300696 (3), ; ?uruguay faciocardiomusculoskeletal syndrome, 300280 (3), ; scapuloperoneal myopathy, 300695 (3), ; reducing body myopathy, 1b, with late childhood or adult onset, 300718 (3), ; reducing body myopathy, 1a, severe, infantile or early childhood onset, 300717 (3),
SLIM2		
SLIM3		
SLIP-GC		
SLIP1		
SLIRP		
Slit-1		
Slit-2		
Slit-3		
SLIT1		
slit2		
SLIT2		
SLIT3		
SLITL1	XL	intellectual developmental disorder, 111, 301107 (3),
SLITL2		
SLITRK1	AD,MF	tourette syndrome, 137580 (3), ; ?trichotillomania, 613229 (3),
SLITRK2	XL	intellectual developmental disorder, 111, 301107 (3),
SLITRK3		
SLITRK4		
SLITRK5		
SLITRK6	AR	deafness and myopia, 221200 (3),
SLK		
SLL0262		
SLLP1		
SLLP2		
SLM-1		
SLM-2		
SLM1		
SLM2		
SLM5	AR	combined oxidative phosphorylation deficiency 24, 616239 (3), ; ?deafness, 94, 618434 (3),
SLMAP		
SLMO1		
SLN		
SLNCR1		
SLO	AD,AR	{epilepsy, idiopathic generalized, susceptibility to, 16}, 618596 (3), ; paroxysmal nonkinesigenic dyskinesia, 3, with or without generalized epilepsy, 609446 (3), ; cerebellar atrophy, developmental delay, and seizures, 617643 (3), ; liang-wang syndrome, 618729 (3),
SLO2.1	AD	developmental and epileptic encephalopathy 57, 617771 (3),
Slo2.2	AD	developmental and epileptic encephalopathy 14, 614959 (3), ; epilepsy nocturnal frontal lobe, 5, 615005 (3),
Slo3	AR	spermatogenic failure 79, 620196 (3),
Slob		
SLOS	AR	smith-lemli-opitz syndrome, 270400 (3),
SLP-1		
SLP-2		
SLP-65	AR	?agammaglobulinemia 4, 613502 (3),
SLP-76	AR	?immunodeficiency 81, 619374 (3),
SLP1		
SLP2		
SLP65	AR	?agammaglobulinemia 4, 613502 (3),
SLP76	AR	?immunodeficiency 81, 619374 (3),
SLPI		
SLRR1A	XL,XLR	meester-loeys syndrome, 300989 (3), ; spondyloepimetaphyseal dysplasia, 300106 (3),
SLRR1B	AD	corneal dystrophy, congenital stromal, 610048 (3),
SLRR1C	AD	{lumbar disc degeneration}, 603932 (3); {osteoarthritis susceptibility 3}, 607850 (3),
SLRR2A		
SLRR2B	AR	cornea plana 2, 217300 (3),
SLRR2C		
SLRR2D		
SLRR2E		
SLRR3A		
SLRR3B		
SLRR4A		
SLRR4B		
SLRR5A		
SLS	AR	sjogren-larsson syndrome, 270200 (3),
SLSN1	AR	joubert syndrome 4, 609583 (3), ; nephronophthisis 1, juvenile, 256100 (3), ; senior-loken syndrome-1, 266900 (3),
SLSN3	AR	nephronophthisis 3, 604387 (3), ; renal-hepatic-pancreatic dysplasia 1, 208540 (3), ; meckel syndrome 7, 267010 (3),
SLSN4	AR	senior-loken syndrome 4, 606996 (3), ; nephronophthisis 4, 606966 (3),
SLSN5	AR	senior-loken syndrome 5, 609254 (3),
SLSN6	AR	leber congenital amaurosis 10, 611755 (3); joubert syndrome 5, 610188 (3), ; senior-loken syndrome 6, 610189 (3), ; ?bardet-biedl syndrome 14, 615991 (3), ; meckel syndrome 4, 611134 (3),
SLSN7	AR	senior-loken syndrome 7, 613615 (3), ; bardet-biedl syndrome 16, 615993 (3),
SLT		
SLT1		
SLU7		
SLUG		
SLUGH		
SLUGH1		
SLUGH2		
SLURP1	AR	meleda disease, 248300 (3),
SLURP2		
slv		
SLX1A		
SLX1B		
SLX2A		
SLX2B		
SLX3		
SLX4	AR	fanconi anemia, complementation group p, 613951 (3),
SLX4IP		
SLX5		
SLY	XLR,XL	immunodeficiency 102, 301082 (3),
SLY1		
SLy2		
sLZIP		
SM-20	AD	erythrocytosis, familial, 3, 609820 (3), ; [hemoglobin, high altitude adaptation], 609070 (3),
Sm-B/B'	AD	cerebrocostomandibular syndrome, 117650 (3),
Sm-Calp		
SM-D		
Sm-D1		
Sm-D2		
Sm-D3		
Sm-E	AD	hypotrichosis 11, 615059 (3),
Sm-F		
Sm-G		
SM-LMOD	AR	?megacystis-microcolon-intestinal hypoperistalsis syndrome 3, 619362 (3),
SM15		
SM22		
SM25H2		
SM2SH2		
SMA	AR	spinal muscular atrophy-2, 253550 (3), ; spinal muscular atrophy-4, 271150 (3), ; spinal muscular atrophy-3, 253400 (3), ; spinal muscular atrophy-1, 253300 (3),
SMA@	AR	spinal muscular atrophy-2, 253550 (3), ; spinal muscular atrophy-4, 271150 (3), ; spinal muscular atrophy-3, 253400 (3), ; spinal muscular atrophy-1, 253300 (3),
SMA1	AR	spinal muscular atrophy-2, 253550 (3), ; spinal muscular atrophy-4, 271150 (3), ; spinal muscular atrophy-3, 253400 (3), ; spinal muscular atrophy-1, 253300 (3),
SMA2	AR	spinal muscular atrophy-2, 253550 (3), ; spinal muscular atrophy-4, 271150 (3), ; spinal muscular atrophy-3, 253400 (3), ; spinal muscular atrophy-1, 253300 (3),
SMA3	AR	spinal muscular atrophy-2, 253550 (3), ; spinal muscular atrophy-4, 271150 (3), ; spinal muscular atrophy-3, 253400 (3), ; spinal muscular atrophy-1, 253300 (3),
SMAC	AD	deafness, 64, 614152 (3),
SMAD1	AD	spinal muscular atrophy, infantile, james type, 619042 (3), ; neuronopathy, distal hereditary motor, type va, 600794 (3), ; charcot-marie-tooth disease, type 2d, 601472 (3),
SMAD2	AD	loeys-dietz syndrome 6, 619656 (3), ; congenital heart defects, multiple types, 8, with or without heterotaxy, 619657 (3),
SMAD3	AD	loeys-dietz syndrome 3, 613795 (3),
SMAD4	AD	pancreatic cancer, somatic, 260350 (3); myhre syndrome, 139210 (3), ; polyposis, juvenile intestinal, 174900 (3), ; juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome, 175050 (3),
SMAD4IP1		
SMAD5		
SMAD5-AS1		
SMAD5OS		
SMAD6	AD	aortic valve disease 2, 614823 (3), ; {radioulnar synostosis, nonsyndromic}, 179300 (3), ; {craniosynostosis 7, susceptibility to}, 617439 (3),
SMAD7		{colorectal cancer, susceptibility to, 3}, 612229 (3)
SMAD8	AD	pulmonary hypertension, primary, 2, 615342 (3),
SMAD8/9	AD	pulmonary hypertension, primary, 2, 615342 (3),
SMAD9	AD	pulmonary hypertension, primary, 2, 615342 (3),
SMADIP		
SMAF1		
smAKAP		
SMAM1		
sMAP	AR	masp2 deficiency, 613791 (3),
SMAP		
SMAP-1	AR	osteootohepatoenteric syndrome, 619377 (3),
SMAP-3		
SMAP-5	AR	microcephaly, epilepsy, and diabetes syndrome 2, 619278 (3),
SMAP-6		
smap-7		
SMAP-8		
SMAP1		
SMAP1L		
SMAP2	AR	dentin dysplasia, type i, with microdontia and misshapen teeth, 125400 (3),
SMAP31		
SMAR1		
SMARBP1		
SMARCA1		
SMARCA2	AD	nicolaides-baraitser syndrome, 601358 (3), ; blepharophimosis-impaired intellectual development syndrome, 619293 (3),
SMARCA3		
SMARCA4	AD	coffin-siris syndrome 4, 614609 (3), ; {rhabdoid tumor predisposition syndrome 2}, 613325 (3),
SMARCA5		
SMARCA6	AR	immunodeficiency-centromeric instability-facial anomalies syndrome 4, 616911 (3),
SMARCAD1	AD	basan syndrome, 129200 (3), ; huriez syndrome, 181600 (3), ; adermatoglyphia, 136000 (3),
SMARCAL1	AR	schimke immunoosseous dysplasia, 242900 (3),
SMARCB1	AD	rhabdoid tumors, somatic, 609322 (3); {schwannomatosis-1, susceptibility to}, 162091 (3), ; coffin-siris syndrome 3, 614608 (3), ; {rhabdoid tumor predisposition syndrome 1}, 609322 (3),
SMARCC1	AD	{hydrocephalus, congenital, 5, susceptibility to}, 620241 (3),
SMARCC2	AD	coffin-siris syndrome 8, 618362 (3),
SMARCD1	AD	coffin-siris syndrome 11, 618779 (3),
SMARCD2	AR	specific granule deficiency 2, 617475 (3),
SMARCD3		
SMARCE1	AD	{meningioma, familial, susceptibility to}, 607174 (3), ; coffin-siris syndrome 5, 616938 (3),
SMARCE1r		
SMARCF1	AD	coffin-siris syndrome 2, 614607 (3),
SMARCF2	AD	coffin-siris syndrome 1, 135900 (3),
SMARCF3	AD	coffin-siris syndrome 6, 617808 (3),
SMARCG1		
SMARCG2	AD	coffin-siris syndrome 7, 618027 (3),
SMARCG3		
SMARCG4		
SMARCH1		?renal cell carcinoma, clear cell, 144700 (3)
SMARCI1		
SMARCI2		
SMARCJ1		
SMARCJ2		
SMARCJ3		
SMARCK1	AD	coffin-siris syndrome 12, 619325 (3),
SMARCK2		
SMARCL1		sarcoma, synovial (1)
SMARCL2		
SMARCM1	AD	dias-logan syndrome, 617101 (3),
SMARCM2	AD	immunodeficiency 49, severe combined, 617237 (3), ; intellectual developmental disorder with dysmorphic facies, speech delay, and t-cell abnormalities, 618092 (3),
SMARCN1		
SMARCN2	AR,AD	developmental and epileptic encephalopathy 76, 618468 (3), ; intellectual developmental disorder with severe speech and ambulation defects, 618470 (3),
SMARD1	AR	neuronopathy, distal hereditary motor, type vi, 604320 (3), ; charcot-marie-tooth disease, axonal, type 2s, 616155 (3),
Smaug		
SMAX1	XLR,AD,XL	androgen insensitivity, partial, with or without breast cancer, 312300 (3), ; {prostate cancer, susceptibility to}, 176807 (3), somatic mutation, ; androgen insensitivity, 300068 (3), ; spinal and bulbar muscular atrophy of kennedy, 313200 (3), ; hypospadias 1, 300633 (3),
SmB/SmB'	AD	cerebrocostomandibular syndrome, 117650 (3),
SMBP		
SMC	AR	smith-mccort dysplasia, 607326 (3), ; dyggve-melchior-clausen disease, 223800 (3),
SMC-CF	AD	{mycobacterium tuberculosis, susceptibility to}, 607948 (3); {hiv-1, resistance to}, 609423 (3); {coronary artery disease, modifier of} (3); {spina bifida, susceptibility to}, 182940 (3),
SMC1A	XLD,XL	cornelia de lange syndrome 2, 300590 (3), ; developmental and epileptic encephalopathy 85, with or without midline brain defects, 301044 (3),
SMC1B		
SMC1L1	XLD,XL	cornelia de lange syndrome 2, 300590 (3), ; developmental and epileptic encephalopathy 85, with or without midline brain defects, 301044 (3),
SMC1L2		
SMC2		
SMC2L1		
SMC3	AD	cornelia de lange syndrome 3, 610759 (3),
SMC3L1	AD	cornelia de lange syndrome 3, 610759 (3),
SMC4		
SMC4L1		
SMC5	AR	atelis syndrome 2, 620185 (3),
SMC5L1	AR	atelis syndrome 2, 620185 (3),
SMC6		
SMC6L1		
Smcb	XLD,XL	cornelia de lange syndrome 2, 300590 (3), ; developmental and epileptic encephalopathy 85, with or without midline brain defects, 301044 (3),
SMCC		
SMCHD1	AD	bosma arhinia microphthalmia syndrome, 603457 (3), ; fascioscapulohumeral muscular dystrophy 2, digenic, 158901 (3), digenic
SMCO4		
SMCP		
SMCP-2		
SMCR	AD	smith-magenis syndrome, 182290 (3), isolated cases,
SMCR7	AR	?combined oxidative phosphorylation deficiency 49, 619024 (3),
SMCR7L		
SMCR8		
SMCT2		
SMCX	XL,XLR	intellectual developmental disorder, syndromic, claes-jensen type, 300534 (3),
SMCY		
SMD3		
SMDP2	AD	surfactant metabolism dysfunction, pulmonary, 2, 610913 (3),
SMDT1		
SMEI	AD	developmental and epileptic encephalopathy 6b, non-dravet, 619317 (3), ; migraine, familial hemiplegic, 3, 609634 (3), ; dravet syndrome, 607208 (3), ; febrile seizures, familial, 3a, 604403 (3), ; generalized epilepsy with febrile seizures plus, type 2, 604403 (3),
SMEK1		
SMEK2		
SMF		
SMG		
smg-10		
smg-2		
smg-3		
SMG-5		
SMG-6		
SMG-7		
SMG1		
SMG5		
SMG6		
SMG7		
SMG8	AR	alzahrani-kuwahara syndrome, 619268 (3),
SMG9	AR	heart and brain malformation syndrome, 616920 (3), ; neurodevelopmental disorder with intention tremor, pyramidal signs, dyspraxia, and ocular anomalies, 619995 (3),
SMGA		
SMGB		
SmgGDS		lymphocytic leukemia, acute t-cell (3)
SMGP21		
SMHC	AR,AD	megacystis-microcolon-intestinal hypoperistalsis syndrome 2, 619351 (3), ; aortic aneurysm, familial thoracic 4, 132900 (3), ; visceral myopathy 2, 619350 (3),
SMHCE	AD,AR	contractures, pterygia, and spondylocarpostarsal fusion syndrome 1a, 178110 (3), ; contractures, pterygia, and spondylocarpotarsal fusion syndrome 1b, 618469 (3), ; arthrogryposis, distal, type 2b3 (sheldon-hall), 618436 (3), ; arthrogryposis, distal, type 2a (freeman-sheldon), 193700 (3),
SMIF		
SMILE	AR	lissencephaly 8, 617255 (3),
SMIM1	AR	[blood group, vel system], 615264 (3),
SMIM20		
SMIM29		
SMIM3		
SMIT		
SMIT1		
SMIT2		
smk-1		
smk1		
SML1		
SmLIM		
SMLMOD	AR	?megacystis-microcolon-intestinal hypoperistalsis syndrome 3, 619362 (3),
SMM1		
SMMCI	AD	microphthalmia with coloboma 5, 611638 (3), ; schizencephaly, 269160 (3); single median maxillary central incisor, 147250 (3), ; holoprosencephaly 3, 142945 (3),
SMMHC	AR,AD	megacystis-microcolon-intestinal hypoperistalsis syndrome 2, 619351 (3), ; aortic aneurysm, familial thoracic 4, 132900 (3), ; visceral myopathy 2, 619350 (3),
smMLCK	AR,AD	megacystis-microcolon-intestinal hypoperistalsis syndrome 1, 249210 (3), ; aortic aneurysm, familial thoracic 7, 613780 (3),
SMMS-1	AR,AD	megacystis-microcolon-intestinal hypoperistalsis syndrome 2, 619351 (3), ; aortic aneurysm, familial thoracic 4, 132900 (3), ; visceral myopathy 2, 619350 (3),
SMN		
SMN1	AR	spinal muscular atrophy-2, 253550 (3), ; spinal muscular atrophy-4, 271150 (3), ; spinal muscular atrophy-3, 253400 (3), ; spinal muscular atrophy-1, 253300 (3),
SMN2	AR	{spinal muscular atrophy, type iii, modifier of}, 253400 (3),
SMNC	AR	{spinal muscular atrophy, type iii, modifier of}, 253400 (3),
SMNDC1		
SMNR		
SMNT	AR	spinal muscular atrophy-2, 253550 (3), ; spinal muscular atrophy-4, 271150 (3), ; spinal muscular atrophy-3, 253400 (3), ; spinal muscular atrophy-1, 253300 (3),
SMO	AR	pallister-hall-like syndrome, 241800 (3), ; basal cell carcinoma, somatic, 605462 (3); curry-jones syndrome, somatic mosaic, 601707 (3)
SMOC1	AR	microphthalmia with limb anomalies, 206920 (3),
SMOC2	AR	dentin dysplasia, type i, with microdontia and misshapen teeth, 125400 (3),
SMOH	AR	pallister-hall-like syndrome, 241800 (3), ; basal cell carcinoma, somatic, 605462 (3); curry-jones syndrome, somatic mosaic, 601707 (3)
SMOX		
smp		
SMP1		
SMP2		
SMP3		
SMP30		
SMPD1	AR	niemann-pick disease, type b, 607616 (3), ; niemann-pick disease, type a, 257200 (3),
SMPD2		
SMPD3		
SMPD4	AR	neurodevelopmental disorder with microcephaly, arthrogryposis, and structural brain anomalies, 618622 (3),
SMPDL3A		
SMPDL3B		
SMPX	XL,XLR,XLD	myopathy, distal, 7, adult-onset, 301075 (3), ; deafness, 4, 300066 (3),
SMR3A		
SMR3B		
SMRP		
SMRP1		
SMRT		
SMRTE		
SMRZ		
SMS	XL,XLR,AD	intellectual developmental disorder, syndromic, snyder-robinson type, 309583 (3), |smith-magenis syndrome, 182290 (3), isolated cases,
SMS1		
SMS2	AD	calvarial doughnut lesions with bone fragility with or without spondylometaphyseal dysplasia, 126550 (3),
SMSr		
SMST		
SMT3A		
SMT3B		
SMT3C		?orofacial cleft 10, 613705 (3), isolated cases
SMT3H1		
SMT3H2		
SMT3H3		?orofacial cleft 10, 613705 (3), isolated cases
SMT3H4		{diabetes mellitus, insulin-dependent, 5}, 600320 (3)
SMT3IP1		
SMT3IP2		
SMTCK		
SMTN		
SMTNL1		
SMU-1		
SMU1		
SMUBP2	AR	neuronopathy, distal hereditary motor, type vi, 604320 (3), ; charcot-marie-tooth disease, axonal, type 2s, 616155 (3),
SMUC		
SMUG1		
SMURF1		
SMURF2		
SMVT	AR	sodium-dependent multivitamin transporter deficiency, 618973 (3), ; peripheral motor neuropathy, childhood-onset, biotin-responsive, 619903 (3),
SMX4		
SMYD1		
SMYD2		
SMYD3		
SMYD4		
SMYD5		
SN		
SN1	AR	developmental and epileptic encephalopathy 102, 619881 (3),
SN2		
SNA		
SNAH		
SNAI1		
SNAI2		
SNAI3		
SNAIL		
SNAIL1		
SNAIL2		
SNAMA		
SNAP	AD	?myasthenic syndrome, congenital, 18, 616330 (3),
SNAP-25	AD	?myasthenic syndrome, congenital, 18, 616330 (3),
SNAP-29	AR	cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma syndrome, 609528 (3),
SNAP-47		
SNAP-BETA	AR	developmental and epileptic encephalopathy 107, 620033 (3),
SNAP1		
SNAP19		
SNAP190		
SNAP23		
SNAP23A		
SNAP23B		
SNAP25	AD	?myasthenic syndrome, congenital, 18, 616330 (3),
SNAP29	AR	cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma syndrome, 609528 (3),
SNAP43		
SNAP45		
SNAP47		
SNAP50		
SNAP91		
SNAPAP		
SNAPB	AR	developmental and epileptic encephalopathy 107, 620033 (3),
SNAPC1		
SNAPC2		
SNAPC3		
SNAPC4		
SNAPC5		
SNAPIN		
SNARK	AR	?anencephaly 2, 619452 (3),
SNAT		
SNAT1		
SNAT10		
SNAT2		
SNAT3	AR	developmental and epileptic encephalopathy 102, 619881 (3),
SNAT4		
SNAT5		
SNAT6		
SNAT7		
SNAT8	AR	foveal hypoplasia 2, with or without optic nerve misrouting and/or anterior segment dysgenesis, 609218 (3),
SNAT9		
SNAX1	AD,AR	ataxia, sensory, 1, 608984 (3), ; spastic paraplegia 85, 619686 (3),
SNC19	AR	ichthyosis, congenital, 11, 602400 (3),
SNC6		
SNCA	AD	dementia, lewy body, 127750 (3), ; parkinson disease 1, 168601 (3), ; parkinson disease 4, 605543 (3),
SNCAIP		
SNCB	AD	dementia, lewy body, 127750 (3),
SNCG		
SND1		
SND3		
SNDI	AR	striatonigral degeneration, infantile, 271930 (3),
SNED1		
Snep		
SNEV		
SNF1LK	AD	developmental and epileptic encephalopathy 30, 616341 (3),
SNF1LK2		
SNF2	AD,AD	coffin-siris syndrome 4, 614609 (3), ; {rhabdoid tumor predisposition syndrome 2}, 613325 (3), |nicolaides-baraitser syndrome, 601358 (3), ; blepharophimosis-impaired intellectual development syndrome, 619293 (3),
SNF2-BETA	AD	coffin-siris syndrome 4, 614609 (3), ; {rhabdoid tumor predisposition syndrome 2}, 613325 (3),
SNF2L		
SNF2L1		
SNF2L2	AD	nicolaides-baraitser syndrome, 601358 (3), ; blepharophimosis-impaired intellectual development syndrome, 619293 (3),
SNF2L3		
SNF2L4	AD	coffin-siris syndrome 4, 614609 (3), ; {rhabdoid tumor predisposition syndrome 2}, 613325 (3),
SNF2LA	AD	nicolaides-baraitser syndrome, 601358 (3), ; blepharophimosis-impaired intellectual development syndrome, 619293 (3),
SNF2LB	AD	coffin-siris syndrome 4, 614609 (3), ; {rhabdoid tumor predisposition syndrome 2}, 613325 (3),
SNF5	AD	rhabdoid tumors, somatic, 609322 (3); {schwannomatosis-1, susceptibility to}, 162091 (3), ; coffin-siris syndrome 3, 614608 (3), ; {rhabdoid tumor predisposition syndrome 1}, 609322 (3),
SNF5L1	AD	rhabdoid tumors, somatic, 609322 (3); {schwannomatosis-1, susceptibility to}, 162091 (3), ; coffin-siris syndrome 3, 614608 (3), ; {rhabdoid tumor predisposition syndrome 1}, 609322 (3),
SNF7-2	AD	cataract 31, multiple types, 605387 (3),
SNF7DC2		
SNF8		
SNFT		
SNHG1		
SNHG11		
SNHG13		
SNHG14		
SNHG2		
SNHG23		
SNHG24		
SNHG3		
SNHG32		
SNHG5		
SNHG6		
SNIP		
SNIP1	AR	neurodevelopmental disorder with hypotonia, craniofacial abnormalities, and seizures, 614501 (3),
SNK		
SNL		
SNM1		
SNM1B	AR	dyskeratosis congenita, 8, 620133 (3),
SNM1C	AR	severe combined immunodeficiency, athabascan type, 602450 (3), ; omenn syndrome, 603554 (3),
SNN		
Sno		
SNO		
SnoA		
SnoN		
SNORA11		
SNORA11A		
SNORA12		
SNORA26		
SNORA2C		
SNORA31	AD	{encephalopathy, acute, infection-induced (herpes-specific), susceptibility to, 10}, 619396 (3),
SNORA31A	AD	{encephalopathy, acute, infection-induced (herpes-specific), susceptibility to, 10}, 619396 (3),
SNORA34		
SNORA3B		
SNORA45		
SNORA45B		
SNORA5C		
SNORA62		
SNORA63		
SNORA63A		
SNORA73A		
SNORA73B		
SNORA74B		
SNORA80EHG		
SNORA81		
SNORD112		
SNORD113-1		
SNORD114-1		
SNORD115-1		
SNORD116-1		
SNORD118	AR	leukoencephalopathy, brain calcifications, and cysts, 614561 (3),
SNORD13		
SNORD139		
SNORD13A		
SNORD15A		
SNORD20		
SNORD21		
SNORD22		
SNORD25		
SNORD26		
SNORD27		
SNORD28		
SNORD28A		
SNORD29		
SNORD30		
SNORD31		
SNORD31A		
SNORD3A		
SNORD43		
SNORD50A		
SNORD50B		
SNORD73A		
SNORD8		
SNORD82		
SNORD83A		
SNORD83B		
SNORD87		
Snp1		
SNPH		
SNPHL		
Snr1	AD	rhabdoid tumors, somatic, 609322 (3); {schwannomatosis-1, susceptibility to}, 162091 (3), ; coffin-siris syndrome 3, 614608 (3), ; {rhabdoid tumor predisposition syndrome 1}, 609322 (3),
SNRK		
snRNP-B	AD	cerebrocostomandibular syndrome, 117650 (3),
SNRNP-N		
SNRNP100		
SNRNP102	AD	retinitis pigmentosa 60, 613983 (3),
SNRNP110		
SNRNP116	AD	mandibulofacial dysostosis, guion-almeida type, 610536 (3),
SNRNP15	AR	burn-mckeown syndrome, 608572 (3),
SNRNP15-5		
SNRNP20		
SNRNP200	AD	retinitis pigmentosa 33, 610359 (3),
SNRNP220	AD	retinitis pigmentosa 13, 600059 (3),
SNRNP27		
SNRNP31		
SNRNP35		
SNRNP40		
SNRNP60	AD	retinitis pigmentosa 70, 615922 (3),
SNRNP61	AD	retinitis pigmentosa 11, 600138 (3),
SNRNP65	AR	pituitary hormone deficiency, combined or isolated, 7, 618160 (3),
SNRNP70		
SNRNP90	AD	retinitis pigmentosa 18, 601414 (3),
Snrp116	AD	mandibulofacial dysostosis, guion-almeida type, 610536 (3),
SNRP70		
SNRPA		
SNRPA1		
SNRPB	AD	cerebrocostomandibular syndrome, 117650 (3),
SNRPB1	AD	cerebrocostomandibular syndrome, 117650 (3),
SNRPB2		
SNRPC		
SNRPD		
SNRPD1		
SNRPD2		
SNRPD3		
SNRPE	AD	hypotrichosis 11, 615059 (3),
SNRPF		
SNRPG		
SNRPN		
SNS	AD	episodic pain syndrome, familial, 2, 615551 (3),
SNS-2	AD	episodic pain syndrome, familial, 3, 615552 (3), ; neuropathy, hereditary sensory and autonomic, type vii, 615548 (3),
SNT-1		
SNT-2		
SNT1	AD	long qt syndrome 12, 612955 (3),
SNT2		
SNT2B1		
SNT2B2		
SNT3		
Snt309		
SNTA1	AD	long qt syndrome 12, 612955 (3),
SNTB1		
SNTB2		
SNTG1		
SNTG2		
SNTL		
SNTN		
Snu114	AD	mandibulofacial dysostosis, guion-almeida type, 610536 (3),
SNU13		
Snu23		
Snu40		
Snu66		
Snu71		
SnuCyp-20		
SNUPN		
SNURF		
SNURF-SNRPN		
SNURPORTIN-1		
Snurportin1		
SNW1		
SNX-L		
SNX1		
SNX10	AR	osteopetrosis, 8, 615085 (3),
SNX11		
SNX12		
SNX13		
SNX14	AR	spinocerebellar ataxia, 20, 616354 (3),
SNX15		
SNX16		
SNX17		
SNX1A		
SNX2		
SNX20		
SNX21		
SNX23		
SNX26		
SNX27		
SNX28		
SNX3		
SNX30		
SNX31		
SNX33		
SNX4		
SNX5		
SNX6		
SNX7		
SNX8		
SNX9		
SOAT		
SOAT1		
SOAT2		
SOB1	AR	spermatogenic failure 82, 620353 (3),
SOBP	AR	?impaired intellectual development, anterior maxillary protrusion, and strabismus, 613671 (3),
SOC		
SOC-2	AD	noonan syndrome-like with loose anagen hair 1, 607721 (3),
SOC2	AD	noonan syndrome-like with loose anagen hair 1, 607721 (3),
SOCI		
SOCS		{malaria, susceptibility to}, 611162 (3); {bacteremia, susceptibility to}, 614383 (3); {tuberculosis, susceptibility to}, 607948 (3)
SOCS-1	AD	autoinflammatory syndrome, familial, with or without immunodeficiency, 619375 (3),
SOCS-2		
SOCS-3		
SOCS-5		
SOCS1	AD	autoinflammatory syndrome, familial, with or without immunodeficiency, 619375 (3),
SOCS2		
SOCS2-AS1		
SOCS3		
SOCS4		
SOCS5		
SOCS6		
SOCS7		
SOD1	AR,AD	spastic tetraplegia and axial hypotonia, progressive, 618598 (3), ; amyotrophic lateral sclerosis 1, 105400 (3),
SOD2		{microvascular complications of diabetes 6}, 612634 (3)
SOD3		[superoxide dismutase, elevated extracellular] (3)
SODD		
Sof1		
SOFAT		
SOGA		
SOGA1		
SOGA2		
SOHLH1	AR,AD	ovarian dysgenesis 5, 617690 (3), ; spermatogenic failure 32, 618115 (3),
SOHLH2		
SOK1		
SOLH	AR	oculogastrointestinal neurodevelopmental syndrome, 619318 (3),
solo		
SOLT		
SOM	AD	van der woude syndrome 2, 606713 (3),
SOM172		
SON	AD	zttk syndrome, 617140 (3),
SONE		
SOP2Hs		
SOP2L		
SORBS1		
SORBS2		
SORBS3		
SORCS		
SORCS1		
SORCS2		
SORCS3		
SORD	AR	sorbitol dehydrogenase deficiency with peripheral neuropathy, 618912 (3),
SORF-1		
SORF-2	AR	cerebellar ataxia, impaired intellectual development, and dysquilibrium syndrome 2, 610185 (3), ; hydrocephalus, congenital, 3, with brain anomalies, 617967 (3),
SORL1		
SorLA		
SorLA-1		
SORT1	AD	[low density lipoprotein cholesterol level qtl6], 613589 (3),
SOS1	AD	noonan syndrome 4, 610733 (3), ; ?fibromatosis, gingival, 1, 135300 (3),
SOS2	AD	noonan syndrome 9, 616559 (3),
SOSS-A		
SOSS-B1		
SOSS-B2		
SOSS-C		
SOST	AR,AD	sclerosteosis 1, 269500 (3), ; craniodiaphyseal dysplasia, 122860 (3),
SOST2	AR,AD	?myasthenic syndrome, congenital, 17, 616304 (3), ; sclerosteosis 2, 614305 (3), ; cenani-lenz syndactyly syndrome, 212780 (3),
SOSTDC1		
SOTV	AR,AD	seizures, scoliosis, and macrocephaly syndrome, 616682 (3), ; exostoses, multiple, type 2, 133701 (3),
SOUL		
SOX-10	AD	waardenburg syndrome, type 4c, 613266 (3), ; pcwh syndrome, 609136 (3), ; waardenburg syndrome, type 2e, with or without neurologic involvement, 611584 (3),
Sox-13		
SOX1		
SOX10	AD	waardenburg syndrome, type 4c, 613266 (3), ; pcwh syndrome, 609136 (3), ; waardenburg syndrome, type 2e, with or without neurologic involvement, 611584 (3),
SOX11	AD	intellectual developmental disorder with microcephaly and with or without ocular malformations or hypogonadotropic hypogonadism, 615866 (3),
SOX12		
SOX13		
SOX14		
SOX15		
SOX17	AD	vesicoureteral reflux 3, 613674 (3),
SOX18	AR,AD	hypotrichosis-lymphedema-telangiectasia syndrome, 607823 (3), ; hypotrichosis-lymphedema-telangiectasia-renal defect syndrome, 137940 (3),
SOX2	AD	optic nerve hypoplasia and abnormalities of the central nervous system, 206900 (3), ; microphthalmia, syndromic 3, 206900 (3),
SOX2-OT		
SOX20		
SOX21		
SOX22		
SOX25		
SOX26		
SOX27		
SOX28		
SOX2OT		
SOX3	XL	intellectual developmental disorder, with isolated growth hormone deficiency, 300123 (3); panhypopituitarism, 312000 (3),
SOX30		
SOX4	AD	coffin-siris syndrome 10, 618506 (3),
SOX5	AD	lamb-shaffer syndrome, 616803 (3),
SOX6	AD	tolchin-le caignec syndrome, 618971 (3),
SOX7		
SOX8		
SOX9	AD	campomelic dysplasia with sex reversal, 114290 (3), ; acampomelic campomelic dysplasia, 114290 (3), ; campomelic dysplasia, 114290 (3),
SOXL		
SOXN		
SP-10		
SP-22	AR,AD	spinocerebellar ataxia, 32, 619862 (3), ; corneal dystrophy, punctiform and polychromatic pre-descemet, 619871 (3),
SP-40		
SP-A	AR,AD	interstitial lung disease 1, 619611 (3),
SP-A1	AR,AD	interstitial lung disease 1, 619611 (3),
SP-A2	AD	interstitial lung disease 2, 178500 (3),
SP-B	AR	surfactant metabolism dysfunction, pulmonary, 1, 265120 (3),
SP-C	AD	surfactant metabolism dysfunction, pulmonary, 2, 610913 (3),
SP-D		
SP-ESP		
SP-H		
SP-II		
SP001LA		
SP1		
SP100		
Sp110	AD,AR	charcot-marie-tooth disease, type 1a, 118220 (3), ; roussy-levy syndrome, 180800 (3), ; charcot-marie-tooth disease, type 1e, 118300 (3), ; ?neuropathy, inflammatory demyelinating, 139393 (3), ? ; neuropathy, recurrent, with pressure palsies, 162500 (3), ; dejerine-sottas disease, 145900 (3),
SP110	AR	{mycobacterium tuberculosis, susceptibility to}, 607948 (3); hepatic venoocclusive disease with immunodeficiency, 235550 (3),
SP140		
SP140L		
SP17		
SP1999	AR	bleeding disorder, platelet-type, 8, 609821 (3),
SP2		
SP260		
SP3		
SP32		
SP329	AD	neuronopathy, distal hereditary motor, type iid, 615575 (3),
SP38	AR	?spermatogenic failure 66, 619799 (3),
SP4		
SP5		
SP6	AD	amelogenesis imperfecta, type ik, 620104 (3),
SP7	AR	osteogenesis imperfecta, type xii, 613849 (3),
SP75	AR	ciliary dyskinesia, primary, 28, 615505 (3),
SP8		
SPA1		
SPA17		
SPAAR		
SPACA1		
SPACA2		
SPACA3		
SPACA4		
SPACA5		
SPACA6		
SPACA6P		
SPACA8		
SPACA9		
SPACDR		
SPACR	AR,AD	macular dystrophy, vitelliform, 4, 616151 (3), ; retinitis pigmentosa 91, 153870 (3),
SPACRCAN	AR,AD	retinitis pigmentosa 56, 613581 (3), ; macular dystrophy, vitelliform, 5, 616152 (3),
SPAF	AR	neurodevelopmental disorder with hearing loss, seizures, and brain abnormalities, 616577 (3),
spag		
SPAG1	AR	ciliary dyskinesia, primary, 28, 615505 (3),
SPAG10		
SPAG11B		
SPAG12		
SPAG13		
SPAG15		
SPAG16		
SPAG17	AR	?spermatogenic failure 55, 619380 (3),
SPAG2		
SPAG3		
SPAG4		
SPAG4L	AR	spermatogenic failure 16, 617187 (3),
SPAG5		
SPAG6		
SPAG7		
SPAG8		
SPAG9		
SPAK		
Spalpha		
SPAM	AR	retinitis pigmentosa 25, 602772 (3),
SPAM1		
SPAN-Xa		
SPAN-Xb		
SPANK-1		
SPANK-2	AD	phelan-mcdermid syndrome, 606232 (3), ; {schizophrenia 15}, 613950 (3),
SPANK-3		{autism susceptibility 17}, 613436 (3)
SPANX		
SPANX-N1		
SPANX-N2		
SPANX-N3		
SPANX-N4		
SPANX-N5		
SPANXA1		
SPANXA2		
SPANXB1		
SPANXB2		
SPANXC		
SPANXD		
SPANXE		
SPANXF1		
SPANXF2		
SPANXN1		
SPANXN2		
SPANXN3		
SPANXN4		
SPANXN5		
SPAP		
SPAP1		
SPAP2		
SPAP2a		
SPAP2b		
SPAP2c		
SPAP2d		
SPAP2e		
SPAR		
SPAR1		
SPAR2		
SPAR3	AR	?cataract 45, 616851 (3),
SPARC	AR	osteogenesis imperfecta, type xvii, 616507 (3),
SPARCL1		
SPART	AR	troyer syndrome, 275900 (3),
Spartan	AR	ruijs-aalfs syndrome, 616200 (3),
SPAS1		
Spasm		
SPAST	AD	spastic paraplegia 4, 182601 (3),
SPAT	AR	hyperoxaluria, primary, type 1, 259900 (3),
SPATA10		
SPATA11		
SPATA12		
SPATA13		
SPATA15		
SPATA16	AR	?spermatogenic failure 6, 102530 (3),
SPATA17		
SPATA18		
SPATA19		
SPATA2		
SPATA20		
SPATA22		
SPATA23		
SPATA25		
SPATA26	AR	spermatogenic failure 51, 619177 (3),
SPATA27	AR,AD	ovarian dysgenesis 5, 617690 (3), ; spermatogenic failure 32, 618115 (3),
SPATA28		
SPATA29		
SPATA3		
SPATA30		
SPATA31A4		
SPATA31A7		
SPATA33		
SPATA34	AR	spermatogenic failure 9, 613958 (3),
SPATA35		
SPATA36		
SPATA37	AR	spermatogenic failure 48, 619108 (3),
SPATA38	AR	hydatidiform mole, recurrent, 3, 618431 (3),
SPATA39		
SPATA4		
SPATA40	AR	heterotaxy, visceral, 9, with male infertility, 618948 (3),
SPATA43		
SPATA44		
SPATA46		
SPATA5	AR	neurodevelopmental disorder with hearing loss, seizures, and brain abnormalities, 616577 (3),
SPATA5L1	AR	deafness, 119, 619615 (3), ; neurodevelopmental disorder with hearing loss and spasticity, 619616 (3),
SPATA6		
SPATA7	AR	leber congenital amaurosis 3, 604232 (3), ; retinitis pigmentosa 94, variable age at onset, 604232 (3),
SPATA8		
SPATA9		
SPATC1		
SPATC1L		
spatial		
SPATS2		
SPATS2L		
SPAX2	AR	spastic ataxia 2, 611302 (3),
SPAX3	AR	?combined oxidative phosphorylation deficiency 25, 616430 (3), ; spastic ataxia 3, 611390 (3),
SPAX4	AR	?spastic ataxia 4, 613672 (3),
SPAX5	AR,AD	spastic ataxia 5, 614487 (3), ; optic atrophy 12, 618977 (3), ; spinocerebellar ataxia 28, 610246 (3),
SPAX6	AR	spastic ataxia, charlevoix-saguenay type, 270550 (3),
SPB1	XL,XLR	intellectual developmental disorder, 9, 309549 (3),
SPBC110		
SPBC24		
SPBC25		
SPBC97	AR	pachygyria, microcephaly, developmental delay, and dysmorphic facies, with or without seizures, 618737 (3),
SPBC98		
SPBP	AD	developmental delay with variable intellectual impairment and behavioral abnormalities, 618430 (3),
SPBPBP		
SPC		
SPC1		
Spc110		
SPC12		
SPC18		
SPC2		
SPC22/23		
SPC24		
SPC25		
SPC3	AR	{obesity, susceptibility to, bmiq12}, 612362 (3); endocrinopathy due to proprotein convertase 1/3 deficiency, 600955 (3),
SPC4		
SPC5		
SPC6		
Spc7	AR	microcephaly 4, primary, 604321 (3),
SPC7		
Spc97p	AR	pachygyria, microcephaly, developmental delay, and dysmorphic facies, with or without seizures, 618737 (3),
Spc98p		
SPCA1	AD	hailey-hailey disease, 169600 (3),
SPCA2		
SPCH1	AD	speech-language disorder-1, 602081 (3),
SPCS1		
SPCS2		
SPCS3		
SPCS4A		
SPD	AD	syndactyly, type v, 186300 (3), ; synpolydactyly 1, 186000 (3), ; brachydactyly, type e, 113300 (3), ; brachydactyly, type d, 113200 (3), ; ?brachydactyly-syndactyly syndrome, 610713 (3)
SPDEF		
SPDL1		
SPDY1		
SPDYA		
SPDYC		
SPDYE		
SPDYE1		
SPDYE2		
SPDYE3		
SPDYE4		
SPE-39	AR	arthrogryposis, renal dysfunction, and cholestasis 2, 613404 (3),
SPE39	AR	arthrogryposis, renal dysfunction, and cholestasis 2, 613404 (3),
SPEC1		
SPEC2		
SPECC1		
SPECC1L	AD	teebi hypertelorism syndrome 1, 145420 (3), ; ?facial clefting, oblique, 1, 600251 (3),
SPEF1		
SPEF1A		
SPEF1B		
SPEF2	AR	spermatogenic failure 43, 618751 (3),
SPEG	AR	centronuclear myopathy 5, 615959 (3),
SPEGalpha	AR	centronuclear myopathy 5, 615959 (3),
SPEGbeta	AR	centronuclear myopathy 5, 615959 (3),
SPEM1		
SPEN	AD	radio-tartaglia syndrome, 619312 (3),
spergen1		
SPERIOLIN		
SPERT		
SPESP1		
spexin		
SPF		
SPF27		
SPF30		
SPF38		
SPF45		
SPFH1	AR	spastic paraplegia 62, 615681 (3),
SPFH2	AR	spastic paraplegia 18, 611225 (3),
SPG	AR	cranioectodermal dysplasia 1, 218330 (3),
SPG1	XLR,XL	masa syndrome, 303350 (3), ; hydrocephalus, congenital, 307000 (3), ; ?corpus callosum, partial agenesis of, 304100 (3),
SPG10	AD	myoclonus, intractable, neonatal, 617235 (3), ; {amyotrophic lateral sclerosis, susceptibility to, 25}, 617921 (3), ; spastic paraplegia 10, 604187 (3),
SPG11	AR	amyotrophic lateral sclerosis 5, juvenile, 602099 (3), ; charcot-marie-tooth disease, axonal, type 2x, 616668 (3), ; spastic paraplegia 11, 604360 (3),
SPG12	AD	spastic paraplegia 12, 604805 (3),
SPG13	AD,AR	spastic paraplegia 13, 605280 (3), ; leukodystrophy, hypomyelinating, 4, 612233 (3),
SPG15	AR	spastic paraplegia 15, 270700 (3),
SPG17	AR,AD	lipodystrophy, congenital generalized, type 2, 269700 (3), ; neuropathy, distal hereditary motor, type vc, 619112 (3), ; silver spastic paraplegia syndrome, 270685 (3), ; encephalopathy, progressive, with or without lipodystrophy, 615924 (3),
SPG18	AR	spastic paraplegia 18, 611225 (3),
SPG2	XLR,XL	pelizaeus-merzbacher disease, 312080 (3), ; spastic paraplegia 2, 312920 (3),
SPG20	AR	troyer syndrome, 275900 (3),
SPG21	AR	mast syndrome, 248900 (3),
SPG23	AD,AR	congenital anomalies of kidney and urinary tract 1, 610805 (3), ; spastic paraplegia 23, 270750 (3),
SPG26	AR	spastic paraplegia 26, 609195 (3),
SPG28	AR	spastic paraplegia 28, 609340 (3),
SPG3	AD	spastic paraplegia 3a, 182600 (3), ; neuropathy, hereditary sensory, type id, 613708 (3),
SPG30	AD,AR	nescav syndrome, 614255 (3), ; neuropathy, hereditary sensory, type iic, 614213 (3), ; spastic paraplegia 30, 610357 (3), ; spastic paraplegia 30, 610357 (3),
SPG31	AD,AR	?neuronopathy, distal hereditary motor, type vb, 614751 (3), ; spastic paraplegia 31, 610250 (3), ; spinal muscular atrophy, distal, 6, 620011 (3),
SPG33	AD	spastic paraplegia 33, 610244 (3),
SPG35	AR	spastic paraplegia 35, 612319 (3),
SPG39	AR	spastic paraplegia 39, 612020 (3), ; oliver-mcfarlane syndrome, 275400 (3), ; ?laurence-moon syndrome, 245800 (3), ; boucher-neuhauser syndrome, 215470 (3),
SPG3A	AD	spastic paraplegia 3a, 182600 (3), ; neuropathy, hereditary sensory, type id, 613708 (3),
SPG4	AD	spastic paraplegia 4, 182601 (3),
SPG42	AD,AR	spastic paraplegia 42, 612539 (3), ; congenital cataracts, hearing loss, and neurodegeneration, 614482 (3),
SPG43	AR,AD	neurodegeneration with brain iron accumulation 4, 614298 (3), ; ?spastic paraplegia 43, 615043 (3),
SPG44	AD,AR	lymphatic malformation 3, 613480 (3), ; ?spastic paraplegia 44, 613206 (3), ; leukodystrophy, hypomyelinating, 2, 608804 (3),
SPG45	AR	spastic paraplegia 45, 613162 (3),
SPG46	AR	spastic paraplegia 46, 614409 (3),
SPG47	AR	spastic paraplegia 47, 614066 (3),
SPG48	AR	spastic paraplegia 48, 613647 (3),
SPG49	AR	spastic paraplegia 56, 615030 (3),
SPG50	AR	spastic paraplegia 50, 612936 (3),
SPG51	AD,AR	stuttering, familial persistent, 1, 184450 (3), ; spastic paraplegia 51, 613744 (3),
SPG52	AR	spastic paraplegia 52, 614067 (3),
SPG53	AR	spastic paraplegia 53, 614898 (3),
SPG54	AR	spastic paraplegia 54, 615033 (3),
SPG55	AR	spastic paraplegia 55, 615035 (3), ; combined oxidative phosphorylation deficiency 7, 613559 (3),
SPG56	AR	spastic paraplegia 56, 615030 (3),
SPG57	AR,AD	?spastic paraplegia 57, 615658 (3), ; hereditary motor and sensory neuropathy, okinawa type, 604484 (3),
SPG58	AR	spastic ataxia 2, 611302 (3),
SPG59		pituitary adenoma 4, acth-secreting, somatic, 219090 (3)
SPG5A	AR	spastic paraplegia 5a, 270800 (3), ; bile acid synthesis defect, congenital, 3, 613812 (3),
SPG5C	AR,AD	spastic paraplegia 7, 607259 (3),
SPG6	AD	spastic paraplegia 6, 600363 (3),
SPG60		
SPG61	AR	?spastic paraplegia 61, 615685 (3),
SPG62	AR	spastic paraplegia 62, 615681 (3),
SPG63	AR	?spastic paraplegia 63, 615686 (3), ; pontocerebellar hypoplasia, type 9, 615809 (3),
SPG64	AR	spastic paraplegia 64, 615683 (3),
SPG65	AR	spastic paraplegia 45, 613162 (3),
SPG66		
SPG67	AR	neurodevelopmental disorder with dysmorphic features, spasticity, and brain abnormalities, 615802 (3),
SPG68		
SPG69	AR	martsolf syndrome 1, 212720 (3), ; warburg micro syndrome 2, 614225 (3),
SPG7	AR,AD	spastic paraplegia 7, 607259 (3),
SPG70	AR,AD	spastic paraplegia 70, 620323 (3), ; interstitial lung and liver disease, 615486 (3), ; ?trichothiodystrophy 9, nonphotosensitive, 619692 (3), ; charcot-marie-tooth disease, axonal, type 2u, 616280 (3),
SPG71		
SPG72	AD,AR	?spastic paraplegia 72, 615625 (3), ; ?spastic paraplegia 72, 615625 (3),
SPG8	AR,AD	ritscher-schinzel syndrome 1, 220210 (3), ; spastic paraplegia 8, 603563 (3),
SPG9	AD,AR	spastic paraplegia 9a, 601162 (3), ; cutis laxa, type iiia, 219150 (3), ; spastic paraplegia 9b, 616586 (3), ; cutis laxa, 3, 616603 (3),
SPGP	AR	cholestasis, benign recurrent intrahepatic, 2, 605479 (3), ; cholestasis, progressive familial intrahepatic 2, 601847 (3),
SPGY		
SPGYLA		{spermatogenic failure, susceptibility to} (3)
SPH1	AR,AD	spherocytosis, type 1, 182900 (3),
SPHK		
SPHK1		
SPHK2		
SPHKAP		
SPI-1	AD	agammaglobulinemia 10, 619707 (3),
SPI-A	AD	agammaglobulinemia 10, 619707 (3),
SPI-B		
SPI-C		
SPI1	AD	agammaglobulinemia 10, 619707 (3),
SPIB		
SPIC		
SPICE		
SPICE1		
SPIDR	AR	ovarian dysgenesis 9, 619665 (3),
SPIN		
SPIN-2		
SPIN1		
SPIN2		
SPIN2A		
SPIN2B		
SPIN90		
SPINK1	AR,AD	tropical calcific pancreatitis, 608189 (3), ; pancreatitis, hereditary, 167800 (3), ; {fibrocalculous pancreatic diabetes, susceptibility to}, 608189 (3),
SPINK13		
SPINK2	AR	?spermatogenic failure 29, 618091 (3),
Spink3	AR,AD	tropical calcific pancreatitis, 608189 (3), ; pancreatitis, hereditary, 167800 (3), ; {fibrocalculous pancreatic diabetes, susceptibility to}, 608189 (3),
SPINK4		
SPINK5	AR	netherton syndrome, 256500 (3),
SPINK5L3		
SPINK6		
SPINK7		
SPINK9		
SPINL		
SPINLW1		
SPINO		
SPINT1		
SPINT2	AR	diarrhea 3, secretory sodium, congenital, syndromic, 270420 (3),
SPINT3		
SPINT4		
spir-1		
spir-2		
SPIRE1		
SPIRE2		
SPK		
SPL	AR	nephrotic syndrome, type 14, 617575 (3),
sPLA2S		
SPLUNC1		
SPMAP2		
SPMIP4		
SPMIP6		
SPMIP8		
SPMIP9		
SPMSY	XL,XLR	intellectual developmental disorder, syndromic, snyder-robinson type, 309583 (3),
Spn		
SPN	AD,AR	vulto-van silfout-de vries syndrome, 615828 (3), ; neurodevelopmental disorder with hypotonia, impaired expressive language, and with or without seizures, 617171 (3),
SPN1		
SPN2		
SPNR		
SPNS1		
SPNS2	AR	?deafness, 115, 618457 (3),
SPNS3		
SPNT1		
SPO		
SPO11		
SPO13		
SPO16		
Spo22	XL,XLR	spermatogenic failure, 2, 309120 (3),
Spo8		
SPOCD1		
SPOCK		
SPOCK1		
SPOCK2		
SPOCK3		
SPOGA2		
SPOGA3		
SPOGA4		
SPON1		
SPON2		
SPOP	AD	nabais sa-de vries syndrome, type 1, 618828 (3), ; nabais sa-de vries syndrome, type 2, 618829 (3),
SPOT14		
SPOUT1		
SPP		
SPP1		
Spp2		
SPP2		
SPP24		
Spp382		
SPPL1		
SPPL2A	AR	immunodeficiency 86, mycobacteriosis, 619549 (3),
SPPL2B		
SPPL2C		
SPPL3		
SPR	AD,AR	dystonia, dopa-responsive, due to sepiapterin reductase deficiency, 612716 (3), ? ,
SPR-1		
SPR-2		
SPR1		
Spred-2	AR	noonan syndrome 14, 619745 (3),
SPRED1	AD	legius syndrome, 611431 (3),
SPRED2	AR	noonan syndrome 14, 619745 (3),
SPRED3		
SPRIGHTLY		
SPRING		
SPRK		
SPRL1A		
SPRL1B		
SPRL2A		
SPRL3A		
SPRL4A		
SPRL5A		
SPRL6A		
SPRL6B		
SPRN		
SPRR1		
SPRR1A		
SPRR1B		
SPRR2A		
SPRR2B		
SPRR2D		
SPRR2E		
SPRR2F		
SPRR2G		
SPRR3		
SPRR4		
SPRTN	AR	ruijs-aalfs syndrome, 616200 (3),
SPRY1		
SPRY2	AD	{?iga nephropathy, susceptibility to, 3}, 616818 (3),
SPRY3		
SPRY4	AD	hypogonadotropic hypogonadism 17 with or without anosmia, 615266 (3),
SPRY4-IT1		
SPRYD2		
SPRYD7		
SpS	XL,XLR	intellectual developmental disorder, syndromic, snyder-robinson type, 309583 (3),
SPS		
SPS1		
SPS2		
SPS2b		
SPSB1		
SPSB2		
SPSB3		
SPSB4		
SPT	AR	hyperoxaluria, primary, type 1, 259900 (3),
SPT16/CDC68	AD	neurodevelopmental disorder with dysmorphic facies and thin corpus callosum, 619480 (3),
SPT20		
SPT3		
SPT3L		
Spt4		
SPT4H		
SPT5		
SPT5H		
SPT6H		
SPT7L		
SPTA1	AR,AD	spherocytosis, type 3, 270970 (3), ; elliptocytosis-2, 130600 (3), ; pyropoikilocytosis, 266140 (3),
SPTAN1	AD	developmental and epileptic encephalopathy 5, 613477 (3),
SPTB	AD	anemia, neonatal hemolytic, fatal or near-fatal, 617948 (3); elliptocytosis-3, 617948 (3); spherocytosis, type 2, 616649 (3),
SPTBN1	AD	developmental delay, impaired speech, and behavioral abnormalities, 619475 (3),
SPTBN2	AD,AR	spinocerebellar ataxia 5, 600224 (3), ; spinocerebellar ataxia, 14, 615386 (3),
SPTBN3	AR	neurodevelopmental disorder with hypotonia, neuropathy, and deafness, 617519 (3),
SPTBN4	AR	neurodevelopmental disorder with hypotonia, neuropathy, and deafness, 617519 (3),
SPTBN5		
SPTI	AD	amyotrophic lateral sclerosis 27, juvenile, 620285 (3), ; neuropathy, hereditary sensory and autonomic, type ia, 162400 (3),
SPTLC1	AD	amyotrophic lateral sclerosis 27, juvenile, 620285 (3), ; neuropathy, hereditary sensory and autonomic, type ia, 162400 (3),
SPTLC2	AD	neuropathy, hereditary sensory and autonomic, type ic, 613640 (3),
SPTLC2L		
SPTLC3		
SPTRX-3		
SPTRX1		
SPTRX2	AR	?ciliary dyskinesia, primary, 6, 610852 (3),
SPTSSA	AD,AR	spastic paraplegia 90a, 620416 (3); ?spastic paraplegia 90b, 620417 (3)
SPTSSB		
SPUF		
SPUVE		
SPX		
SPX1		
SPX2		
SPX3		
SPX4	AR,AD	glycogen storage disease ib, 232220 (3), ; congenital disorder of glycosylation, type iiw, 619525 (3), ; glycogen storage disease ic, 232240 (3),
SPY1		
SPZ1		
spzn		
SQLE		
SQOR	AR	sulfide:quinone oxidoreductase deficiency, 619221 (3),
SQR	AR	sulfide:quinone oxidoreductase deficiency, 619221 (3),
SQRDL	AR	sulfide:quinone oxidoreductase deficiency, 619221 (3),
SQS	AR	squalene synthase deficiency, 618156 (3),
SQSTM1	AR,AD	neurodegeneration with ataxia, dystonia, and gaze palsy, childhood-onset, 617145 (3), ; frontotemporal dementia and/or amyotrophic lateral sclerosis 3, 616437 (3), ; myopathy, distal, with rimmed vacuoles, 617158 (3), ; paget disease of bone 3, 167250 (3),
SQV7L		
SR		
SR-25		
SR-A		barrett esophagus/esophageal adenocarcinoma, 614266 (3)
SR-A1		
SR-A6		
SR-AI		barrett esophagus/esophageal adenocarcinoma, 614266 (3)
SR-AII		barrett esophagus/esophageal adenocarcinoma, 614266 (3)
SR-AIII		barrett esophagus/esophageal adenocarcinoma, 614266 (3)
SR-alpha		
SR-beta		
SR-BI		[high density lipoprotein cholesterol level qtl6], 610762 (3)
SR-BII	AR	epilepsy, progressive myoclonic 4, with or without renal failure, 254900 (3),
SR-BP1	AR	?spinal muscular atrophy, distal, 2, 605726 (3), ; ?amyotrophic lateral sclerosis 16, juvenile, 614373 (3),
SR-F3	AR	congenital myopathy 10a, severe variant, 614399 (3), ; congenital myopathy 10b, mild variant, 620249 (3),
SR-PSOX		
SR140		
SRA		
SRA1	AD	campomelic dysplasia with sex reversal, 114290 (3), ; acampomelic campomelic dysplasia, 114290 (3), ; campomelic dysplasia, 114290 (3),
SRA4		
SRAG		
sRAGE		
Sralpha		
SRAPD1		
SRARP		
SRB1		[high density lipoprotein cholesterol level qtl6], 610762 (3)
SRB2		
SRB4	AR	microcephaly, postnatal progressive, with seizures and brain atrophy, 613668 (3),
SRB5		
SRB6		
SRB7		
SRBC		
SRC	AD	?thrombocytopenia 6, 616937 (3), ; colon cancer, advanced, somatic, 114500 (3)
SRC-3		
SRC1	AD	?thrombocytopenia 6, 616937 (3), ; colon cancer, advanced, somatic, 114500 (3)
SRC2		
SRC3		
SRCAP	AD	developmental delay, hypotonia, musculoskeletal defects, and behavioral abnormalities, 619595 (3), ; floating-harbor syndrome, 136140 (3),
SRCASM		
SRCIN1		
SRCL		
SRCRB-S4D		
SRCRB4D		
SRCyp		
SRD5A1		
SRD5A2	AR	pseudovaginal perineoscrotal hypospadias, 264600 (3),
SRD5A2L	AR	kahrizi syndrome, 612713 (3), ; congenital disorder of glycosylation, type iq, 612379 (3),
SRD5A2L1	AR	kahrizi syndrome, 612713 (3), ; congenital disorder of glycosylation, type iq, 612379 (3),
SRD5A2L2	AR	ventricular tachycardia, catecholaminergic polymorphic, 3, 614021 (3),
SRD5A3	AR	kahrizi syndrome, 612713 (3), ; congenital disorder of glycosylation, type iq, 612379 (3),
SRD5B1	AR	bile acid synthesis defect, congenital, 2, 235555 (3),
SRE-ZBP		
SREB1		
SREB2		
SREB3		
SREBF1	AD	ichthyosis, follicular, with atrichia and photophobia syndrome 2, 619016 (3), ; mucoepithelial dysplasia, hereditary, 158310 (3),
SREBF2		
SREBP-1c	AD	ichthyosis, follicular, with atrichia and photophobia syndrome 2, 619016 (3), ; mucoepithelial dysplasia, hereditary, 158310 (3),
SREBP1	AD	ichthyosis, follicular, with atrichia and photophobia syndrome 2, 619016 (3), ; mucoepithelial dysplasia, hereditary, 158310 (3),
SREBP1a	AD	ichthyosis, follicular, with atrichia and photophobia syndrome 2, 619016 (3), ; mucoepithelial dysplasia, hereditary, 158310 (3),
SREBP2		
SREC		
SREC-II	AR	van den ende-gupta syndrome, 600920 (3),
SREC1		
SREC2	AR	van den ende-gupta syndrome, 600920 (3),
SREK1		
SRF		
SRF-1		
SRF1		
SRFBP1		
SRFP3	MF	{osteoarthritis susceptibility 1}, 165720 (3),
SRG		
SRG1		
SRG3	AD	{hydrocephalus, congenital, 5, susceptibility to}, 620241 (3),
SRG8		
SRGAP1	AD	{thyroid cancer, nonmedullary, 2}, 188470 (3), somatic mutation,
SRGAP2		
SRGAP2A		
SRGAP2B		
SRGAP2C		
SRGAP2D		
SRGAP2P1		
SRGAP2P2		
SRGAP3		
SrGAP4		
SRGN		
SRI		
SRI1	AR,AD	intellectual developmental disorder, 78, 620237 (3), ; hypogonadotropic hypogonadism 14 with or without anosmia, 614858 (3),
SRISNF2L		
SRK	AR	immunodeficiency 48, 269840 (3), ; autoimmune disease, multisystem, infantile-onset, 2, 617006 (3),
SRL		
SRL300		
SRM		
SRM160		
SRm300		
SRML1		
SRMS		
SRN1	AR	nephrotic syndrome, type 2, 600995 (3),
SRO		
SRP		
SRP-alpha		
SRP1		
SRP14		
SRP19		
SRP1alpha		
SRP1gamma	AD	spastic paraplegia 88, 620106 (3),
SRp20		
SRp25		
SRP3		
SRp30a		
SRp30c		
SRp38		
SRP4	AD	spastic paraplegia 88, 620106 (3),
Srp40		
SRP40		
SRP46		
SRP54	AD	neutropenia, severe congenital, 8, 618752 (3),
SRP55		
SRP6		
SRP68		
SRP72	AD	bone marrow failure syndrome 1, 614675 (3),
SRP75		
SRP9		
SRPK1		
SRPK2		
SRPK3		
SRPR		
SRPRA		
SRPRB		
SRPSOX		
SRPUL		?rolandic epilepsy, impaired intellectual development, and speech dyspraxia, 300643 (3)
SRPX		
SRPX1		
SRPX2		?rolandic epilepsy, impaired intellectual development, and speech dyspraxia, 300643 (3)
SRR		
SRR1L		
SRRD		
SRRM1		
SRRM2		
SRRM4		
SRRP129		
SRrp130		
SRrp37		
SRrp40		
SRrp508		
SRrp53	AR	intellectual developmental disorder, 70, 618402 (3),
SRrp86		
SRRT		
SRS	XL,XLR	intellectual developmental disorder, syndromic, snyder-robinson type, 309583 (3),
SRSF1		
SRSF10		
SRSF11		
SRSF2		
SRSF2IP		
SRSF3		
SRSF4		
SRSF5		
SRSF6		
SRSF7		
SRSF8		
SRSF9		
SRX1		
SRXN1		
SRY	YL,XLD,XL	46xy sex reversal 1, 400044 (3), ; 46xx sex reversal 1, 400045 (4),
SRYP	AR	nemaline myopathy 8, 615348 (3),
SS	AR,AD,AD,AR	[blood group, ss], 111740 (3); {malaria, resistance to}, 611162 (3)|short stature, idiopathic familial, 300582 (3); langer mesomelic dysplasia, 249700 (3), pseudo ; leri-weill dyschondrosteosis, 127300 (3), pseudo |short stature, idiopathic familial, 300582 (3); leri-weill dyschondrosteosis, 127300 (3), pseudo ; langer mesomelic dysplasia, 249700 (3), pseudo
SS-56		
SS18		sarcoma, synovial (1)
SS18L1		
SS18L2		
SSA		myelofibrosis, somatic, 254450 (3); thrombocythemia, somatic, 187950 (3)
SSA1		
SSA2		
SSADH	AR	succinic semialdehyde dehydrogenase deficiency, 271980 (3),
SSAT		
SSAT2		
SSAV1		
SSB		
SSB-1		
SSB-2		
SSB-3		
SSB-4		
SSB1		
SSB2		
SSBP	AD	optic atrophy 13 with retinal and foveal abnormalities, 165510 (3),
SSBP1	AD	optic atrophy 13 with retinal and foveal abnormalities, 165510 (3),
SSBP2		
SSBP3		
SSBP4		
Ssc1	AR,AD	ichthyotic keratoderma, spasticity, hypomyelination, and dysmorphic facies, 618527 (3),
SSC1		
Ssc2		
SSC4D		
SSC5D		
SSDH	AR	succinic semialdehyde dehydrogenase deficiency, 271980 (3),
SSDP		
SSDP1		
SSeCKS		
SSF		
SSF1		
SSF2		
SSFA1		
SSFA2		
SSG1		
SSH1		
SSH1L		
SSH2		
SSH3		
SSH3BP1		
SSH3BP2		
SSH3BP3		
SSI-1	AD	autoinflammatory syndrome, familial, with or without immunodeficiency, 619375 (3),
SSI-2		
SSI-3		
SSI2		
SSI4		
SSK1	AD,AR	colorectal cancer, somatic, 114500 (3); [premature chromatid separation trait], 176430 (3), ; mosaic variegated aneuploidy syndrome 1, 257300 (3),
Ssl2	AR	trichothiodystrophy 2, photosensitive, 616390 (3), ; xeroderma pigmentosum, group b, 610651 (3),
ssMyBP-C	AD,AR	congenital myopathy 16, 618524 (3), ; lethal congenital contracture syndrome 4, 614915 (3), ; arthrogryposis, distal, type 1b, 614335 (3),
SSNA1		
SSP29		
SSP3		
SSP411		
SSPN		
SSPO		
SSPOP		
SSR1		
SSR2		
SSR3		
SSR4	XLR,XL	congenital disorder of glycosylation, type iy, 300934 (3),
SSRP1		
Ssrzf1		
SSS1	AD,AR	ventricular fibrillation, familial, 1, 603829 (3); heart block, progressive, type ia, 113900 (3), ; cardiomyopathy, dilated, 1e, 601154 (3), ; heart block, nonprogressive, 113900 (3), ; long qt syndrome 3, 603830 (3), ; sick sinus syndrome 1, 608567 (3), ; brugada syndrome 1, 601144 (3), ; atrial fibrillation, familial, 10, 614022 (3), ; {sudden infant death syndrome, susceptibility to}, 272120 (3),
SSSCA1		
ssSPTa	AD,AR	spastic paraplegia 90a, 620416 (3); ?spastic paraplegia 90b, 620417 (3)
ssSPTb		
SST		
SST1		
SST2		
SST3		
SSTK		
SSTK-IP		
ssTnI		
SSTR1		
SSTR2		
SSTR3		
SSTR4		
SSTR5		
SSTRIP		
ssu-2		
SSU72		
SSUH2		
SSV	AD	meningioma, sis-related, 607174 (3), ; basal ganglia calcification, idiopathic, 5, 615483 (3), ; dermatofibrosarcoma protuberans, 607907 (3)
SSX		?sarcoma, synovial, 300813 (3)
SSX1	XL	spermatogenic failure, 5, 301099 (3),
SSX2		?sarcoma, synovial, 300813 (3)
SSX2IP		
SSX3		
SSX4		
SSX5		
SSX6		
SSX6P		
SSX7		
SSX8		
SSX8P		
SSX9		
SSX9P		
SSXP2		
SSXT		sarcoma, synovial (1)
ST-2		
ST12		gastric cancer, somatic, 613659 (3); prostate cancer, somatic, 176807 (3)
ST13		
ST14	AR	ichthyosis, congenital, 11, 602400 (3),
ST15		
ST16		
ST17		
ST18		
ST19		
ST1B2		
ST1C1		
ST2		
ST2L		
ST2V		
ST38		
ST3GAL1		
ST3GAL2		
ST3GAL3	AR	developmental and epileptic encephalopathy 15, 615006 (3), ; intellectual developmental disorder, 12, 611090 (3),
ST3GAL4		
ST3GAL5	AR	salt and pepper developmental regression syndrome, 609056 (3),
ST3GAL6		
ST3GalA.1		
ST3GalA.2		
ST3GALII		
ST3GalV	AR	salt and pepper developmental regression syndrome, 609056 (3),
ST3GALVI		
ST3O		
ST4		
ST5		
ST6		
ST6GAL1		
ST6GAL2		
St6GalII		
ST6GALNAC1		
ST6GALNAC2		
ST6GALNAC3		
ST6GALNAC4		
ST6GALNAC5		
ST6GALNAC6		
ST6GalNAcI		
ST6GALNACIV		
ST6GalNAcV		
ST6GALNACVI		
ST6GalNAII		
ST7	AD	oculopharyngodistal myopathy 1, 164310 (3),
ST7L		
ST7R		
ST8SIA-II		
ST8SIA1		
ST8SIA2		
ST8SIA3		
ST8SIA4		
ST8SIA5		
ST8SIA6		
STA	XL,XLR	emery-dreifuss muscular dystrophy 1, 310300 (3),
STA3		
STAB-1		
STAB-2		
STAB1		
STAB2		
STAC		
STAC1		
STAC3	AR	congenital myopathy 13, 255995 (3),
STAF		
STAF42		
STAF50		
STAF65		
STAF65gamma		
STAG1	AD	intellectual developmental disorder, 47, 617635 (3),
STAG2	XL,XLD,XLR	holoprosencephaly 13, 301043 (3), ; mullegama-klein-martinez syndrome, 301022 (3),
STAG3	AR	spermatogenic failure 61, 619672 (3), ; premature ovarian failure 8, 615723 (3),
STAI4		
STAM		
STAM1		
STAM2		
STAMBP	AR	microcephaly-capillary malformation syndrome, 614261 (3),
STAMBPL1		
STAMP	AR	cone-rod dystrophy 19, 615860 (3),
STAMP1		
STAMP2		
STAP		
STAP-1		
STAP-2		
STAP1		
STAP2		
STAR	AD,AR,AR	diarrhea 6, 614616 (3), ; meconium ileus, 614665 (3), |lipoid adrenal hyperplasia, 201710 (3),
STARA		
STARD1	AR	lipoid adrenal hyperplasia, 201710 (3),
STARD10		
STARD11	AD	intellectual developmental disorder, 34, 616351 (3),
STARD12		colorectal cancer, somatic, 114500 (3)
STARD13		
STARD14		
STARD15		
STARD2		
STARD3		
STARD3NL		
STARD4		
STARD5		
STARD6		
STARD7	AD	epilepsy, familial adult myoclonic, 2, 607876 (3),
STARD8		
STARD9		
stargazin	AD	?intellectual developmental disorder, 10, 614256 (3),
STARING		
STARS		
STAT		
STAT1	AD,AR	immunodeficiency 31c, chronic mucocutaneous candidiasis, 614162 (3), ; immunodeficiency 31a, mycobacteriosis, 614892 (3), ; immunodeficiency 31b, mycobacterial and viral infections, 613796 (3),
STAT113	AR	pseudo-torch syndrome 3, 618886 (3), ; immunodeficiency 44, 616636 (3),
STAT2	AR	pseudo-torch syndrome 3, 618886 (3), ; immunodeficiency 44, 616636 (3),
STAT3	AD	hyper-ige recurrent infection syndrome, 147060 (3), ; autoimmune disease, multisystem, infantile-onset, 1, 615952 (3),
STAT4		{systemic lupus erythematosus, susceptibility to, 11}, 612253 (3)
STAT5		
STAT5A		
STAT5B	AR,AD	growth hormone insensitivity with immune dysregulation 1, 245590 (3), ; growth hormone insensitivity with immune dysregulation 2, 618985 (3), ; leukemia, acute promyelocytic, somatic, 102578 (3)
STAT6		
STAT91	AD,AR	immunodeficiency 31c, chronic mucocutaneous candidiasis, 614162 (3), ; immunodeficiency 31a, mycobacteriosis, 614892 (3), ; immunodeficiency 31b, mycobacterial and viral infections, 613796 (3),
STATH		
STATI2		
STATI4		
STATIP1	AR	intellectual developmental disorder, 58, 617270 (3),
STAU		
STAU1		
STAU2		
STB1	AD	neural tube defects, 182940 (3),
STB2	AD	{neural tube defects, susceptibility to}, 182940 (3), ; caudal regression syndrome, 600145 (3),
STBD1		
STBM	AD	neural tube defects, 182940 (3),
STBM1	AD	neural tube defects, 182940 (3),
STBP		
STC		
STC-2		
STC1		
STC2		
STCH		
STCP-1		
STD	AR	immunodeficiency 48, 269840 (3), ; autoimmune disease, multisystem, infantile-onset, 2, 617006 (3),
STE		
STE20		
STE24	AR	mandibuloacral dysplasia with type b lipodystrophy, 608612 (3), ; restrictive dermopathy 1, 275210 (3),
Ste24p	AR	mandibuloacral dysplasia with type b lipodystrophy, 608612 (3), ; restrictive dermopathy 1, 275210 (3),
STEAP		
STEAP1		
STEAP2		
STEAP3	AD	?anemia, hypochromic microcytic, with iron overload 2, 615234 (3),
STEAP4		
STEEL		
STEEP1	XL	?intellectual developmental disorder, 107, 301013 (3),
steerin-1		
STEF		
Stella		
STEP		
STEP61		
STEX	AR,AD	spinocerebellar ataxia, with axonal neuropathy 2, 606002 (3), ; amyotrophic lateral sclerosis 4, juvenile, 602433 (3),
STF-1	AD,AR	{diabetes mellitus, type ii, susceptibility to}, 125853 (3), ; pancreatic agenesis 1, 260370 (3), ; mody, type iv, 606392 (3)
STF1	AR	peeling skin syndrome 4, 607936 (3),
STFA	AR	peeling skin syndrome 4, 607936 (3),
STFB	AR	epilepsy, progressive myoclonic 1a (unverricht and lundborg), 254800 (3),
STG		
STGD	AR,AD	retinal dystrophy, early-onset severe, 248200 (3), ; retinitis pigmentosa 19, 601718 (3), ; {macular degeneration, age-related, 2}, 153800 (3), ; cone-rod dystrophy 3, 604116 (3), ; fundus flavimaculatus, 248200 (3), ; stargardt disease 1, 248200 (3),
STGD1	AR,AD	retinal dystrophy, early-onset severe, 248200 (3), ; retinitis pigmentosa 19, 601718 (3), ; {macular degeneration, age-related, 2}, 153800 (3), ; cone-rod dystrophy 3, 604116 (3), ; fundus flavimaculatus, 248200 (3), ; stargardt disease 1, 248200 (3),
STGD2	AD,AR	spinocerebellar ataxia 34, 133190 (3), ; stargardt disease 3, 600110 (3), ; ichthyosis, spastic quadriplegia, and impaired intellectual development, 614457 (3),
STGD3	AD,AR	spinocerebellar ataxia 34, 133190 (3), ; stargardt disease 3, 600110 (3), ; ichthyosis, spastic quadriplegia, and impaired intellectual development, 614457 (3),
STGD4	AD,AR	macular dystrophy, retinal, 2, 608051 (3), ; retinitis pigmentosa 41, 612095 (3), ; stargardt disease 4, 603786 (3), ; cone-rod dystrophy 12, 612657 (3),
STH		
Sth1p	AD	nicolaides-baraitser syndrome, 601358 (3), ; blepharophimosis-impaired intellectual development syndrome, 619293 (3),
STHE	AR,AD	hyperekplexia 1, 149400 (3),
STHM		
STI1		
STI2	AR	spermatogenic failure 37, 618429 (3),
STIL	AR	microcephaly 7, primary, 612703 (3),
STIM1	AD,AR	myopathy, tubular aggregate, 1, 160565 (3), ; stormorken syndrome, 185070 (3), ; immunodeficiency 10, 612783 (3),
STIM2		
STIMATE		
STING	AD	sting-associated vasculopathy, infantile-onset, 615934 (3),
STING1	AD	sting-associated vasculopathy, infantile-onset, 615934 (3),
StIP	AR	intellectual developmental disorder, 58, 617270 (3),
STIP1		
STK1		leukemia, acute lymphoblastic, somatic, 613065 (3); leukemia, acute myeloid, reduced survival in, somatic, 601626 (3); leukemia, acute myeloid, somatic, 601626 (3)
STK10		
STK11	AD	melanoma, malignant, somatic, 155600 (3); pancreatic cancer, somatic, 260350 (3); peutz-jeghers syndrome, 175200 (3), ; testicular tumor, somatic, 273300 (3)
STK11IP		
STK11IP1		
STK12		
STK13	AR	spermatogenic failure 5, 243060 (3),
STK14A		
STK14B		
STK15	AD	{colon cancer, susceptibility to}, 114500 (3), somatic mutation,
STK16		
STK17A		
STK17B		
STK18	AR	microcephaly and chorioretinopathy, 2, 616171 (3),
STK19		
STK2		
STK21	AR	microcephaly 17, primary, 617090 (3),
STK22B		
STK22C		
STK22D		
STK22E		
STK23		
STK24		
STK25		
STK26		
STK29		
STK3		
STK30		
STK31		
STK33		
STK35		
STK36	AR	?ciliary dyskinesia, primary, 46, 619436 (3),
STK37		
STK38		
STK38L		
STK39		
STK4	AR	t-cell immunodeficiency, recurrent infections, autoimmunity, and cardiac malformations, 614868 (3),
STK40		
STK5		
STK6	AD	{colon cancer, susceptibility to}, 114500 (3), somatic mutation,
STK7	AD	{colon cancer, susceptibility to}, 114500 (3), somatic mutation,
STK9	XLD,XL	developmental and epileptic encephalopathy 2, 300672 (3),
STKLD1		
STL		
STL1	AD	?vitreoretinopathy with phalangeal epiphyseal dysplasia, 619248 (3), ; czech dysplasia, 609162 (3), ; achondrogenesis, type ii or hypochondrogenesis, 200610 (3), ; spondyloperipheral dysplasia, 271700 (3), ; smed strudwick type, 184250 (3), ; ?epiphyseal dysplasia, multiple, with myopia and deafness, 132450 (3), ; sed congenita, 183900 (3), ; kniest dysplasia, 156550 (3), ; stickler syndrome, type i, nonsyndromic ocular, 609508 (3), ; osteoarthritis with mild chondrodysplasia, 604864 (3), ; stickler syndrome, type i, 108300 (3), ; platyspondylic skeletal dysplasia, torrance type, 151210 (3), ; spondyloepiphyseal dysplasia, stanescu type, 616583 (3), ; avascular necrosis of the femoral head, 608805 (3), ; legg-calve-perthes disease, 150600 (3),
STL2	AR,AD	fibrochondrogenesis 1, 228520 (3), ; stickler syndrome, type ii, 604841 (3), ; marshall syndrome, 154780 (3), ; deafness, 37, 618533 (3), ; {lumbar disc herniation, susceptibility to}, 603932 (3)
Stlk	AR	polyhydramnios, megalencephaly, and symptomatic epilepsy, 611087 (3),
STLR		
STM		
STM2	AD	alzheimer disease-4, 606889 (3), ; cardiomyopathy, dilated, 1v, 613697 (3),
STM6		
STM7		
STMN1		
STMN2		
STMN3		
STMP		
STMP1		
STMP3	AD	?anemia, hypochromic microcytic, with iron overload 2, 615234 (3),
STMY		{coronary heart disease, susceptibility to, 6}, 614466 (3)
STMY1		{coronary heart disease, susceptibility to, 6}, 614466 (3)
STMY2		
STMY3		
STN	AD	developmental and epileptic encephalopathy 33, 616409 (3), ; intellectual developmental disorder, 38, 616393 (3),
STN1	AR	cerebroretinal microangiopathy with calcifications and cysts 2, 617341 (3),
STN2		
STNB2		
STNL	AD	developmental and epileptic encephalopathy 33, 616409 (3), ; intellectual developmental disorder, 38, 616393 (3),
Stno		
STNT	AD,AR	nemaline myopathy 5c, 620389 (3), ; nemaline myopathy 5a, severe infantile, 605355 (3), ; nemaline myopathy 5b, childhood-onset, 620386 (3),
STO	AD	sotos syndrome, 117550 (3),
Sto1		
STOM		
STOML1		
STOML2		
STOML3		
STON1		
STON2		
stoned-b1		
STOP		
STORP		
STOT		
STOX1	AD	preeclampsia/eclampsia 4, 609404 (3),
STOX2		
STP		
STP1		
STP2		
STPG1		
STR		
STRA13		
STRA6	AR	microphthalmia, syndromic 9, 601186 (3), ; microphthalmia, isolated, with coloboma 8, 601186 (3),
STRA8		
STRAA1		
STRAD	AR	polyhydramnios, megalencephaly, and symptomatic epilepsy, 611087 (3),
STRADA	AR	polyhydramnios, megalencephaly, and symptomatic epilepsy, 611087 (3),
STRADB		
STRAIT11499		
Strap	AR	neurodevelopmental disorder with cerebral atrophy and variable facial dysmorphism, 619244 (3),
STRAP		
STRBP		
STRC	AR	deafness, 16, 603720 (3),
Strep14		
STRIN		
STRIP1		
STRIP2		
STRIT1		
STRL22		
STRL33		
STRN		
STRN1		
STRN3		
STRN4		
STS	XL,XLR	ichthyosis, 308100 (3),
STS-1		
STS-2		
STSL	AR	sitosterolemia 2, 618666 (3),
STT3-A	AD,AR	congenital disorder of glycosylation, type iw, 619714 (3), ; congenital disorder of glycosylation, type iw, 615596 (3),
STT3-B	AR	congenital disorder of glycosylation, type ix, 615597 (3),
STT3A	AD,AR	congenital disorder of glycosylation, type iw, 619714 (3), ; congenital disorder of glycosylation, type iw, 615596 (3),
STT3B	AR	congenital disorder of glycosylation, type ix, 615597 (3),
STUB1	AD,AR	spinocerebellar ataxia 48, 618093 (3), ; spinocerebellar ataxia, 16, 615768 (3),
STUD		
Stv1	AR,AR,AD,AR	distal renal tubular acidosis 3, with or without sensorineural hearing loss, 602722 (3), |neurodevelopmental disorder with epilepsy and brain atrophy, 619971 (3), ; developmental and epileptic encephalopathy 104, 619970 (3), |wrinkly skin syndrome, 278250 (3), ; cutis laxa, type iia, 219200 (3),
Stx		
STX		
STX1		
STX10		
STX11	AR	hemophagocytic lymphohistiocytosis, familial, 4, 603552 (3),
STX12		
STX13		
STX14		
STX16	AD	pseudohypoparathyroidism, type ib, 603233 (3),
STX17		
STX18		
STX1A		
STX1B	AD	generalized epilepsy with febrile seizures plus, type 9, 616172 (3),
STX1B1	AD	generalized epilepsy with febrile seizures plus, type 9, 616172 (3),
STX1B2	AD	generalized epilepsy with febrile seizures plus, type 9, 616172 (3),
STX2		
STX2A		
STX2B		
STX2C		
STX3	AR	retinal dystrophy and microvillus inclusion disease, 619446 (3), ; diarrhea 12, with microvillus atrophy, 619445 (3),
STX3A	AR	retinal dystrophy and microvillus inclusion disease, 619446 (3), ; diarrhea 12, with microvillus atrophy, 619445 (3),
STX4		
STX4A		
STX5		
STX5A		
STX6		
STX7		
STX8		
STXBP1	AR,AD	developmental and epileptic encephalopathy 4, 612164 (3),
STXBP1L2		
STXBP2	AR	hemophagocytic lymphohistiocytosis, familial, 5, with or without microvillus inclusion disease, 613101 (3),
STXBP3		
STXBP4		
STXBP5		
STXBP5L		
STXBP6		
STYK1		
STYX		
STYXL1		
STZ		
Su48		{nephrolithiasis, uric acid, susceptibility to}, 605990 (3)
Sua1		
SUA5	AR	galloway-mowat syndrome 10, 619609 (3),
SUB1		
SUB1.5	AR	?immunodeficiency 62, 618459 (3),
SUCLA2	AR	mitochondrial dna depletion syndrome 5 (encephalomyopathic with or without methylmalonic aciduria), 612073 (3),
SUCLG1	AR	mitochondrial dna depletion syndrome 9 (encephalomyopathic type with methylmalonic aciduria), 245400 (3),
SUCLG2		
SUCNR1		
SUCO		
SUDD		
SUDS3		
SUFU	AD,AR	{meningioma, familial, susceptibility to}, 607174 (3), ; joubert syndrome 32, 617757 (3), ; basal cell nevus syndrome 2, 620343 (3); {medulloblastoma}, 155255 (3), somatic mutation,
SUFUH	AD,AR	{meningioma, familial, susceptibility to}, 607174 (3), ; joubert syndrome 32, 617757 (3), ; basal cell nevus syndrome 2, 620343 (3); {medulloblastoma}, 155255 (3), somatic mutation,
SUFUXL	AD,AR	{meningioma, familial, susceptibility to}, 607174 (3), ; joubert syndrome 32, 617757 (3), ; basal cell nevus syndrome 2, 620343 (3); {medulloblastoma}, 155255 (3), somatic mutation,
SUG-1		
SUG1		
SUGCT	AR	glutaric aciduria iii, 231690 (3),
SUGP1		
SUGP2		
SUGT1		
SUH	AD	adams-oliver syndrome 3, 614814 (3),
SUHL		
SUI1		
SULF-1		
SULF-2		
SULF1		
SULF2		
SULT1A1		
SULT1A2		
SULT1A3		
SULT1A4		
SULT1B1		
SULT1C		
SULT1C1		
SULT1C2		
SULT1C3		
SULT1C4		
SULT1E1		
SULT2A1		
SULT2B1	AR	ichthyosis, congenital, 14, 617571 (3),
SULT4A1		
SULT6B1		
SULTX3		
SUMF1	AR	multiple sulfatase deficiency, 272200 (3),
SUMF2		
SUMO-1		?orofacial cleft 10, 613705 (3), isolated cases
SUMO1		?orofacial cleft 10, 613705 (3), isolated cases
SUMO2		
SUMO3		
SUMO4		{diabetes mellitus, insulin-dependent, 5}, 600320 (3)
SUN-CoR		
SUN1		
SUN2		
SUN3		
SUN4		
SUN5	AR	spermatogenic failure 16, 617187 (3),
SUNC1		
SUNCOR		
SUOX	AR	sulfite oxidase deficiency, 272300 (3),
SUP		
SUP45L1		
SUPT16H	AD	neurodevelopmental disorder with dysmorphic facies and thin corpus callosum, 619480 (3),
SUPT20H		
SUPT3H		
Supt4a		
SUPT4H		
SUPT4H1		
SUPT5H		
SUPT6H		
SUPT7L		
SUPV3L1		
SUR	AR,AD	diabetes mellitus, permanent neonatal 3, with or without neurologic features, 618857 (3), ; diabetes mellitus, transient neonatal 2, 610374 (3); diabetes mellitus, noninsulin-dependent, 125853 (3), ; hypoglycemia of infancy, leucine-sensitive, 240800 (3), ; hyperinsulinemic hypoglycemia, familial, 1, 256450 (3),
SUR-5		
SUR-8	AD	noonan syndrome-like with loose anagen hair 1, 607721 (3),
SUR1	AR,AD	diabetes mellitus, permanent neonatal 3, with or without neurologic features, 618857 (3), ; diabetes mellitus, transient neonatal 2, 610374 (3); diabetes mellitus, noninsulin-dependent, 125853 (3), ; hypoglycemia of infancy, leucine-sensitive, 240800 (3), ; hyperinsulinemic hypoglycemia, familial, 1, 256450 (3),
Sur2	AR	intellectual developmental disorder, 18, with or without epilepsy, 614249 (3),
SUR2	AD,AR	cardiomyopathy, dilated, 1o, 608569 (3), ; hypertrichotic osteochondrodysplasia (cantu syndrome), 239850 (3), ; ?atrial fibrillation, familial, 12, 614050 (3), ; intellectual disability and myopathy syndrome, 619719 (3),
SUR8	AD	noonan syndrome-like with loose anagen hair 1, 607721 (3),
SURB7		
SURF1	AR	charcot-marie-tooth disease, type 4k, 616684 (3), ; mitochondrial complex iv deficiency, nuclear type 1, 220110 (3),
SURF2		
SURF3		
SURF4		
SURF5		
SURF6		
SuRTK106		
survivin		
Sus1		
SUSD2		
SUSD3		
SUSD4		
SUSD5		
SUSD6		
SUSP1		
SUT-1		
SUT1		
SUT2		
SUTAL	AR	hermansky-pudlak syndrome 3, 614072 (3),
SUV3		
SUV39H		
SUV39H1		
SUV39H2		
SUV420H1	AD	intellectual developmental disorder, 51, 617788 (3),
SUV420H2		
SUZ12	AD	imagawa-matsumoto syndrome, 618786 (3),
SV2		
SV2A		
SV2B		
SV2C		
SV31	AD	leukodystrophy, hypomyelinating, 25, 620243 (3),
SVAP1		
SVAP30		
SVAS	AD	cutis laxa, 123700 (3), ; supravalvar aortic stenosis, 185500 (3),
SVAT	AR	?parkinsonism-dystonia, infantile, 2, 618049 (3),
SVBP	AR	neurodevelopmental disorder with ataxia, hypotonia, and microcephaly, 618569 (3),
SVCT1		
SVCT2		
SVCT3		
SVEP1		
SVH		
SVIL	AR	myofibrillar myopathy 10, 619040 (3),
SVMT	AR	?parkinsonism-dystonia, infantile, 2, 618049 (3),
SVOP		
SVOPL		
SVP40	AD	46xx sex reversal 5, 618901 (3), ; congenital heart defects, multiple types, 4, 615779 (3),
SVP44	AD	bosch-boonstra-schaaf optic atrophy syndrome, 615722 (3),
SVP65	AD	baker-gordon syndrome, 618218 (3),
svph1		
svph4		
SVUGP2	AR	developmental and epileptic encephalopathy 83, 618744 (3),
SW	AD,AR	[blood group, swann], 601550 (3); [blood group, wright], 112050 (3); distal renal tubular acidosis 1, 179800 (3), ; [blood group, waldner], 112010 (3); spherocytosis, type 4, 612653 (3), ; [blood group, froese], 601551 (3); distal renal tubular acidosis 4 with hemolytic anemia, 611590 (3), ; {malaria, resistance to}, 611162 (3); cryohydrocytosis, 185020 (3), ; ovalocytosis, sa type, 166900 (3), ; [blood group, diego], 110500 (3)
SWA		
SWAN	AD	{schizophrenia 19, susceptibility to}, 617629 (3),
SWAN-1		
SWAP		
SWAP-70		
SWAP2		
SWAP70		
SWAP70L	AR	immunodeficiency 87 and autoimmunity, 619573 (3),
Swc2		
SWC4		
SWC5		
SWD1		
SWD2		
SWD3		
swd66		x-inactivation, familial skewed, 300087 (3)
SWDS	AR	{aplastic anemia, susceptibility to}, 609135 (3); shwachman-diamond syndrome 1, 260400 (3),
SWEET1		
SWELL1	AD	?agammaglobulinemia 5, 613506 (3),
SWI		
SWI2	AD,AD	coffin-siris syndrome 4, 614609 (3), ; {rhabdoid tumor predisposition syndrome 2}, 613325 (3), |nicolaides-baraitser syndrome, 601358 (3), ; blepharophimosis-impaired intellectual development syndrome, 619293 (3),
SWI5		
SWIP	AR	intellectual developmental disorder, 43, 615817 (3),
SWIP1		
SWM1		
SWP1		
SWR1	AD	developmental delay, hypotonia, musculoskeletal defects, and behavioral abnormalities, 619595 (3), ; floating-harbor syndrome, 136140 (3),
sws	AR	spastic paraplegia 39, 612020 (3), ; oliver-mcfarlane syndrome, 275400 (3), ; ?laurence-moon syndrome, 245800 (3), ; boucher-neuhauser syndrome, 215470 (3),
SWS1	AR	spermatogenic failure 71, 619831 (3), ; ?ovarian dysgenesis 10, 619834 (3),
SWS1AP1		
SWSAP1		
sWSS2608	AD	retinitis pigmentosa 10, 180105 (3), ; leber congenital amaurosis 11, 613837 (3),
swt	AR	ciliary dyskinesia, primary, 13, 613193 (3),
SWT1		
SXR		
SYB1	AR,AD	myasthenic syndrome, congenital, 25, 618323 (3), ; spastic ataxia 1, 108600 (3),
SYB2	AD	neurodevelopmental disorder with hypotonia and autistic features with or without hyperkinetic movements, 618760 (3),
SYBL1		
SYBU		
SYCE1	AR	?spermatogenic failure 15, 616950 (3), ; ?premature ovarian failure 12, 616947 (3),
SYCE1L		
SYCE2		
SYCE3		
SYCL		
SYCN		
SYCP1		
SYCP2	AD	spermatogenic failure 1, 258150 (3),
SYCP2L		
SYCP3	AD	pregnancy loss, recurrent, 4, 270960 (3), ; spermatogenic failure 4, 270960 (3),
syd	AD	neurodevelopmental disorder with or without variable brain abnormalities, 618443 (3),
SYD1		
SYDE1		
SYF1		
SYF2		
SYF3		
SYG1	AD	basal ganglia calcification, idiopathic, 6, 616413 (3),
SYK	AD	immunodeficiency 82 with systemic inflammation, 619381 (3),
SYL		
SYLD		
SYM		
SYM-3A		
SYM-4		
SYM1	AR,AD	charcot-marie-tooth disease, axonal, type 2ee, 618400 (3), ; mitochondrial dna depletion syndrome 6 (hepatocerebral type), 256810 (3), |symphalangism, proximal, 1a, 185800 (3), ; brachydactyly, type b2, 611377 (3), ; stapes ankylosis with broad thumbs and toes, 184460 (3), ; tarsal-carpal coalition syndrome, 186570 (3), ; multiple synostoses syndrome 1, 186500 (3),
SYMPK		
SYN		
SYN-16	AD	pseudohypoparathyroidism, type ib, 603233 (3),
SYN1	XL	epilepsy, 1, with variable learning disabilities and behavior disorders, 300491 (3), ; intellectual developmental disorder, 50, 300115 (3),
SYN10		
SYN16	AD	pseudohypoparathyroidism, type ib, 603233 (3),
SYN2	AD	{schizophrenia, susceptibility to}, 181500 (3),
SYN3		
SYN4		
SYN47		
SYN5		
synamon		
SYNC		
SYNC1		
SYNCAM		
SYNCAM1		
SynCAM2		
SynCAM3	AD	charcot-marie-tooth disease, axonal, type 2ff, 619519 (3),
SynCAM4		
SYNCOILIN		
SYNCRIP		
syncytin-2		
SYND1		
SYND2		
SYND3	AR,MF,AD	{obesity, association with}, 601665 (3), ,
SYND4		
syndecan		
SYNDIG1		
SYNDIG1L		
SYNE-1B	AR,AD	arthrogryposis multiplex congenita 3, myogenic type, 618484 (3), ; emery-dreifuss muscular dystrophy 4, 612998 (3), ; spinocerebellar ataxia, 8, 610743 (3),
SYNE-2	AD	emery-dreifuss muscular dystrophy 5, 612999 (3),
SYNE1	AR,AD	arthrogryposis multiplex congenita 3, myogenic type, 618484 (3), ; emery-dreifuss muscular dystrophy 4, 612998 (3), ; spinocerebellar ataxia, 8, 610743 (3),
SYNE2	AD	emery-dreifuss muscular dystrophy 5, 612999 (3),
SYNE3		
SYNE4	AR	deafness, 76, 615540 (3),
SYNECTIN	AD	oculopharyngodistal myopathy 2, 618940 (3),
synembryn		
synembryn-A		
SYNG		
SYNGAP	AD	intellectual developmental disorder, 5, 612621 (3),
SYNGAP1	AD	intellectual developmental disorder, 5, 612621 (3),
SYNGR1		
SYNGR2		
SYNGR3		
SYNGR4		
SYNII	AD	{schizophrenia, susceptibility to}, 181500 (3),
SYNIIa	AD	{schizophrenia, susceptibility to}, 181500 (3),
SYNIIb	AD	{schizophrenia, susceptibility to}, 181500 (3),
Synip		
SYNJ1	AR	parkinson disease 20, early-onset, 615530 (3), ; developmental and epileptic encephalopathy 53, 617389 (3),
SYNJ2		
SYNJ2BP		
SYNM		
SYNPO		
SYNPO1		
SYNRG		
SYNS1	AD	symphalangism, proximal, 1a, 185800 (3), ; brachydactyly, type b2, 611377 (3), ; stapes ankylosis with broad thumbs and toes, 184460 (3), ; tarsal-carpal coalition syndrome, 186570 (3), ; multiple synostoses syndrome 1, 186500 (3),
SYP	XL,XLR	intellectual developmental disorder, 96, 300802 (3),
SYPH1		
SYPL		
SYPL1		
SYS	AR	hyperuricemia, pulmonary hypertension, renal failure, and alkalosis, 613845 (3),
SYS1		
SYT	AD	baker-gordon syndrome, 618218 (3), |sarcoma, synovial (1)
SYT-VII		
SYT1	AD	baker-gordon syndrome, 618218 (3),
SYT11		
SYT12		
SYT13		
SYT14	AR	?spinocerebellar ataxia, 11, 614229 (3),
SYT14L		
SYT14P1		
SYT15		
SYT16		
SYT2	AD,AR	myasthenic syndrome, congenital, 7a, presynaptic, and distal motor neuropathy, 616040 (3), ; myasthenic syndrome, congenital, 7b, presynaptic, 619461 (3),
SYT3		
SYT4		
SYT5		
SYT6		
SYT7		
SYT8		
SYT9		
SYTDEP		
SYTIP1		
SYTIP2		
SYTL1		
SYTL2		
SYTL4		
sytXIV	AR	?spinocerebellar ataxia, 11, 614229 (3),
SYVN1		
Syx	AR	spinal muscular atrophy, distal, 4, 611067 (3), ; charcot-marie-tooth disease, intermediate c, 615376 (3),
SZF1		
SZP	AR	camptodactyly-arthropathy-coxa vara-pericarditis syndrome, 208250 (3),
SZT2	AR	developmental and epileptic encephalopathy 18, 615476 (3),
SZT2A	AR	developmental and epileptic encephalopathy 18, 615476 (3),
SZT2B	AR	developmental and epileptic encephalopathy 18, 615476 (3),
T	AR,AD	sacral agenesis with vertebral anomalies, 615709 (3), ; {neural tube defects, susceptibility to}, 182940 (3),
T-ALK	AD	pulmonary hypertension, familial primary, 1, with or without hht, 178600 (3), ; pulmonary hypertension, primary, fenfluramine or dexfenfluramine-associated, 178600 (3), ; pulmonary venoocclusive disease 1, 265450 (3),
T-BAM	XL,XLR	immunodeficiency, with hyper-igm, 308230 (3),
T-bet	AR	asthma and nasal polyps, 208550 (3), ; ?immunodeficiency 88, 619630 (3), ; {asthma, aspirin-induced, susceptibility to}, 208550 (3),
T-BTF2P44		
T-cap	AD,AR	cardiomyopathy, hypertrophic, 25, 607487 (3), ; muscular dystrophy, limb-girdle, 7, 601954 (3),
T-plastin	XLD,XL	bone mineral density qtl18, osteoporosis, 300910 (3),
T-SP1		
T-STAR		
T-synthase		
T1	AR,AR,AD	intellectual developmental disorder, 13, 613192 (3), |mitochondrial dna depletion syndrome 12b (cardiomyopathic type) ar, 615418 (3), ; progressive external ophthalmoplegia with mitochondrial dna deletions, 2, 609283 (3), ; mitochondrial dna depletion syndrome 12a (cardiomyopathic type) ad, 617184 (3),
T13	AD	kbg syndrome, 148050 (3),
T1A-2		
T1R1		
T1R2		
T1R3		
T2		
T200	AR	immunodeficiency 105, severe combined, 619924 (3),
T245		
T2BP		
T2R1		
T2R10		
T2R13		
T2R14		
T2R16	MF,AD	{alcohol dependence, susceptibility to}, 103780 (3), ; [beta-glycopyranoside tasting], 617956 (3),
T2R19		
T2R20		
T2R23		
T2R24		
T2R3		
T2R30		
T2R31		
T2R4		
T2R5		
T2R51		
T2R52		
T2R53		
T2R54		
T2R55		
T2R56		
T2R59		
T2R60		
T2R61	AD	[phenylthiocarbamide tasting], 171200 (3),
T2R7		
T2R8		
T2R9		
T3		
T3D	AR	immunodeficiency 19, severe combined, 615617 (3),
T3JAM		
T4	AR	immunodeficiency 79, 619238 (3), ; okt4 epitope deficiency, 613949 (3)
T4-A		
T49		
T4A1		
T54		
T6BP		
TA-GPCR		
TA-KRP		
TA-LRRP		
TA-NFKBH		
TA-PP2C		
TA-WDRP		glaucoma 1, open angle, g, 609887 (3)
TA1		
TA3		
TA4		
TA5		
TAAR1		
TAAR2		
TAAR5		
TAAR6		
TAAR8		
TAAR9		
TAB1		
TAB182		
TAB2	AD	congenital heart defects, nonsyndromic, 2, 614980 (3),
TAB3		
TABP	AD,AR	larsen syndrome, 150250 (3), ; atelosteogenesis, type i, 108720 (3), ; atelosteogenesis, type iii, 108721 (3), ; spondylocarpotarsal synostosis syndrome, 272460 (3), ; boomerang dysplasia, 112310 (3),
TAC1		
TAC1R		
TAC2		
Tac2-N		
TAC2R		
TAC3	AR	hypogonadotropic hypogonadism 10 with or without anosmia, 614839 (3),
TAC3R	AR	hypogonadotropic hypogonadism 11 with or without anosmia, 614840 (3),
TAC4		
TACAN		
TACC1		
TACC2		
TACC3		
Tacc4		
TACE	AR	?inflammatory skin and bowel disease, neonatal, 1, 614328 (3),
TACI	AR,AD	immunodeficiency, common variable, 2, 240500 (3), ; immunoglobulin a deficiency 2, 609529 (3)
TACIP1	AD	long qt syndrome 12, 612955 (3),
TACO1	AR	mitochondrial complex iv deficiency, nuclear type 8, 619052 (3),
TACR1		
TACR2		
TACR3	AR	hypogonadotropic hypogonadism 11 with or without anosmia, 614840 (3),
TACSTD1	AR,AD	diarrhea 5, with tufting enteropathy, congenital, 613217 (3), ; lynch syndrome 8, 613244 (3),
TACSTD2	AR	corneal dystrophy, gelatinous drop-like, 204870 (3),
Tact1		
TACTILE	AD	c syndrome, 211750 (3),
TAD2		
TAD3	AR	neurodevelopmental disorder with brain abnormalities, poor growth, and dysmorphic facies, 615286 (3),
TADA1		
TADA1L		
TADA2A		
TADA2B		
TADA2L		
TADA3		
TADA3L		
TADG14		
TAF-172		
TAF-I	AD	intellectual developmental disorder, 58, 618106 (3),
TAF-IBETA	AD	intellectual developmental disorder, 58, 618106 (3),
TAF(I)41		
TAF(II)170		
TAF(II)43	AR	neurodevelopmental disorder with severe motor impairment, absent language, cerebral hypomyelination, and brain atrophy, 619972 (3),
TAF1	XL,XLR	intellectual developmental disorder, syndromic 33, 300966 (3), ; dystonia-parkinsonism, 314250 (3),
TAF10		
TAF11		
TAF12		
TAF13	AR	intellectual developmental disorder, 60, 617432 (3),
TAF140		
TAF15		chondrosarcoma, extraskeletal myxoid, 612237 (1)
TAF172		
TAF1A		
TAF1B		
TAF1C		
TAF1D		
TAF1L		
TAF2	AR	intellectual developmental disorder, 40, 615599 (3),
TAF2A	XL,XLR	intellectual developmental disorder, syndromic 33, 300966 (3), ; dystonia-parkinsonism, 314250 (3),
TAF2B	AR	intellectual developmental disorder, 40, 615599 (3),
TAF2C		
TAF2C1		
TAF2C2	AR	?spermatogenic failure 13, 615841 (3),
TAF2D		
TAF2E	AR	alazami-yuan syndrome, 617126 (3),
TAF2F		
TAF2G		
TAF2H		
TAF2I		
TAF2J		
TAF2K	AR	intellectual developmental disorder, 60, 617432 (3),
TAF2N		chondrosarcoma, extraskeletal myxoid, 612237 (1)
TAF2Q		
TAF2S		
TAF3		
TAF3B1	AR	?deafness, 112, 618257 (3),
TAF3B2	AR	cerebellofaciodental syndrome, 616202 (3),
TAF3C	AR	cerebellofaciodental syndrome, 616202 (3),
TAF4		
TAF4A		
TAF4B	AR	?spermatogenic failure 13, 615841 (3),
TAF5		
TAF6	AR	alazami-yuan syndrome, 617126 (3),
TAF6L		
TAF7		
TAF7L		
TAF8	AR	neurodevelopmental disorder with severe motor impairment, absent language, cerebral hypomyelination, and brain atrophy, 619972 (3),
TAF9		
TAF9B		
TAF9L		
TAFA-1		
TAFA-2		
TAFA-3		
TAFA-4		
TAFA-5		
TAFA1		
TAFA2		
TAFA3		
TAFA4		
TAFA5		
TAFAZZIN	XLR,XL	barth syndrome, 302060 (3),
TAFF1		
TAFI		
TAFI110		
TAFI48		
TAFI63		
TAFI95		
TAFII100		
TAFII105	AR	?spermatogenic failure 13, 615841 (3),
TAFII130		
TAFII135		
TAFII140		
TAFII150	AR	intellectual developmental disorder, 40, 615599 (3),
TAFII170		
TAFII18	AR	intellectual developmental disorder, 60, 617432 (3),
TAFII20		
TAFII250	XL,XLR	intellectual developmental disorder, syndromic 33, 300966 (3), ; dystonia-parkinsonism, 314250 (3),
TAFII28		
TAFII30		
TAFII31		
TAFII31L		
TAFII32		
TAFII55		
TAFII70	AR	alazami-yuan syndrome, 617126 (3),
TAFII80	AR	alazami-yuan syndrome, 617126 (3),
TAFII85	AR	alazami-yuan syndrome, 617126 (3),
TAFIID32		
TAG		
TAG-1	AR	?epilepsy, myoclonic, familial adult, 5, 615400 (3),
TAG7		
TAGAP		
Tage4		
tagL		
tagL-alpha		
tagl-beta		
TAGL-like		
TAGLN		
TAGLN1		
TAGLN2		
TAGLN3		
Tah1		
TAHCCP1	AR	troyer syndrome, 275900 (3),
TAHCCP2	AD	paroxysmal nonkinesigenic dyskinesia 1, 118800 (3),
TAIF		
TAIFb		
TAIFd		
TAIL1		
TAIP-12		
TAIP-2		
TAIP-3		
TAJ		
TAJ-alpha		
TAK		
TAK1	AD	frontometaphyseal dysplasia 2, 617137 (3), ; cardiospondylocarpofacial syndrome, 157800 (3),
TAK1L		
TAKL		
TAKL-1		
TAKL-2		
TAKL-4		
TAL	AR,AD	charcot-marie-tooth disease, axonal, type 2p, 614436 (3),
TAL1		leukemia, t-cell acute lymphocytic, somatic, 613065 (3)
TAL2		leukemia, t-cell acute lymphocytic, somatic, 613065 (3)
TALDO1	AR	transaldolase deficiency, 606003 (3),
TALI		
TALK-1		
TALK-2		
TALK1		
TALK2		
TALL-1		
TALL1		
TALLA-1	XL,XLR	intellectual developmental disorder, 58, 300210 (3),
Talpid3	AR	short-rib thoracic dysplasia 14 with polydactyly, 616546 (3), ; joubert syndrome 23, 616490 (3),
TAMALIN		
TAMM41		combined oxidative phosphorylation deficiency 56, 620139 (3)
tamo		
Tan1	AR	neurodevelopmental disorder with speech delay and variable ocular anomalies, 619989 (3),
TAN1	AD	adams-oliver syndrome 5, 616028 (3), ; aortic valve disease 1, 109730 (3),
TANC1		
TANC2	AD	intellectual developmental disorder with autistic features and language delay, with or without seizures, 618906 (3),
TANCR		
TANGERIN		
TANGO	AR	?ondontochondrodysplasia 2 with hearing loss and diabetes, 619269 (3),
TANGO1	AR	?ondontochondrodysplasia 2 with hearing loss and diabetes, 619269 (3),
TANGO10B		
TANGO13A		
TANGO13B		
TANGO14	AD,AR	intellectual developmental disorder, 55, with seizures, 617831 (3), ; ?congenital disorder of glycosylation, type 1aa, 617082 (3),
TANGO2	AR	metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration, 616878 (3),
TANGO4		
TANGO5		
TANGO6		
TANGO7		
TANGO9		
TANK		
TANK2		
TAO1	AD	developmental delay with or without intellectual impairment or behavioral abnormalities, 619575 (3),
TAO2		
Tao2beta		
TAOK1	AD	developmental delay with or without intellectual impairment or behavioral abnormalities, 619575 (3),
TAOK2		
TAOK3		
TAOS1		
TAOS2	AR	?intestinal dysmotility syndrome, 620045 (3),
TAP	AD,AR	larsen syndrome, 150250 (3), ; atelosteogenesis, type i, 108720 (3), ; atelosteogenesis, type iii, 108721 (3), ; spondylocarpotarsal synostosis syndrome, 272460 (3), ; boomerang dysplasia, 112310 (3),
TAP1	AR	bare lymphocyte syndrome, type i, 604571 (3),
TAP2	AR	bare lymphocyte syndrome, type i, due to tap2 deficiency, 604571 (3),
TAP20		
TAP26		
TAP3		
TAP68	AR	deafness, 28, 609823 (3),
TAPA	AR	bare lymphocyte syndrome, type i, 604571 (3),
TAPA-1	AR	immunodeficiency, common variable, 6, 613496 (3),
TAPA1	AR	immunodeficiency, common variable, 6, 613496 (3),
TAPBP	AR	bare lymphocyte syndrome, type i, 604571 (3),
TAPBP-R		
TAPBPL		
TAPBPR		
TAPE	AR	intellectual developmental disorder, 3, 608443 (3),
TAPK	AR	spinocerebellar ataxia, 21, 616719 (3),
TAPL-2		
TAPP1		
TAPP2		
Taps	AD	ichthyosis, lamellar, 146750 (3),
TAPT1	AR	osteochondrodysplasia, complex lethal, symoens-barnes-gistelinck type, 616897 (3),
TAQPEP		
TAR1		
TAR3		
TAR5		
Tara	AR	deafness, 28, 609823 (3),
TARBP1		
TARBP2		
TARC		
TARDBP	AD	frontotemporal lobar degeneration, tardbp-related, 612069 (3), ; amyotrophic lateral sclerosis 10, with or without ftd, 612069 (3),
TARG1		
TARID		
TARM1		
TARPP		
TARS	AR	trichothiodystrophy 7, nonphotosensitive, 618546 (3),
TARS1	AR	trichothiodystrophy 7, nonphotosensitive, 618546 (3),
TARS2	AR	combined oxidative phosphorylation deficiency 21, 615918 (3),
TARSH		
TARSL1	AR	combined oxidative phosphorylation deficiency 21, 615918 (3),
TAS1R1		
TAS1R2		
TAS1R3		
TAS2R1		
TAS2R10		
TAS2R13		
TAS2R14		
TAS2R16	MF,AD	{alcohol dependence, susceptibility to}, 103780 (3), ; [beta-glycopyranoside tasting], 617956 (3),
TAS2R19		
TAS2R20		
TAS2R23		
TAS2R3		
TAS2R30		
TAS2R31		
TAS2R38	AD	[phenylthiocarbamide tasting], 171200 (3),
TAS2R4		
TAS2R40		
TAS2R41		
TAS2R42		
TAS2R43		
TAS2R44		
TAS2R45		
TAS2R46		
TAS2R47		
TAS2R48		
TAS2R49		
TAS2R5		
TAS2R50		
TAS2R55		
TAS2R60		
TAS2R7		
TAS2R8		
TAS2R9		
TASK	AD	pulmonary hypertension, primary, 4, 615344 (3),
TASK-1	AD	pulmonary hypertension, primary, 4, 615344 (3),
TASK-2		
TASK-3		birk-barel syndrome, 612292 (3)
TASK-4		
TASK-5		
TASK1	AD	pulmonary hypertension, primary, 4, 615344 (3),
TASK2		
TASK3		birk-barel syndrome, 612292 (3)
TASK4		
TASK5		
TASL		
TASOR		
TASOR1		
Tasp		
TASP		
TASP1	AR	suleiman-el-hattab syndrome, 618950 (3),
TASR1		
TASR2		
TassC		
TASTIN		
TAT	AR	tyrosinemia, type ii, 276600 (3),
TAT-SF1		
TAT1	AR,AD	spermatogenic failure 3, 606766 (3),
TATDN1		
TATDN2		
TATI	AR,AD	tropical calcific pancreatitis, 608189 (3), ; pancreatitis, hereditary, 167800 (3), ; {fibrocalculous pancreatic diabetes, susceptibility to}, 608189 (3),
TATIP	AR	?bardet-biedl syndrome 11, 615988 (3), ; muscular dystrophy, limb-girdle, 8, 254110 (3),
tau	AD,AR,MF	supranuclear palsy, progressive, 601104 (3), ; supranuclear palsy, progressive atypical, 260540 (3), ; dementia, frontotemporal, with or without parkinsonism, 600274 (3), ; {parkinson disease, susceptibility to}, 168600 (3), ; pick disease, 172700 (3),
TAU	AD,AR,MF	supranuclear palsy, progressive, 601104 (3), ; supranuclear palsy, progressive atypical, 260540 (3), ; dementia, frontotemporal, with or without parkinsonism, 600274 (3), ; {parkinson disease, susceptibility to}, 168600 (3), ; pick disease, 172700 (3),
tau-40	AD,AR,MF	supranuclear palsy, progressive, 601104 (3), ; supranuclear palsy, progressive atypical, 260540 (3), ; dementia, frontotemporal, with or without parkinsonism, 600274 (3), ; {parkinson disease, susceptibility to}, 168600 (3), ; pick disease, 172700 (3),
Tau-PHF6	AD,AR,MF	supranuclear palsy, progressive, 601104 (3), ; supranuclear palsy, progressive atypical, 260540 (3), ; dementia, frontotemporal, with or without parkinsonism, 600274 (3), ; {parkinson disease, susceptibility to}, 168600 (3), ; pick disease, 172700 (3),
tauCstF-64		
TAUT	AR	hypotaurinemic retinal degeneration and cardiomyopathy, 145350 (3),
TAX	AR	?epilepsy, myoclonic, familial adult, 5, 615400 (3),
TAX1	AR	?epilepsy, myoclonic, familial adult, 5, 615400 (3),
TAX1BP1		
TAX1BP2	AR	striatonigral degeneration, childhood-onset, 617054 (3),
TAX1BP3		
TAX40		
TAXREB107		
TAXREB67		
TAZ	XLR,XL	barth syndrome, 302060 (3),
TAZ-1	AD	intellectual developmental disorder, 22, 612337 (3),
TAZ1	XLR,XL	barth syndrome, 302060 (3),
TB-5		
TB10		
TB2		
TB3-1		
TB4X		
TB4Y		
TBATA		
TBC		
TBC1		
TBC1D1		
TBC1D10		
TBC1D10A		
TBC1D10B		
TBC1D10C		
TBC1D11		
TBC1D12		
TBC1D13		
TBC1D14		
TBC1D15		
TBC1D16		
TBC1D17		
TBC1D18		
TBC1D2		
TBC1D20	AR	warburg micro syndrome 4, 615663 (3),
TBC1D21		
TBC1D22A		
TBC1D22B		
TBC1D23	AR	pontocerebellar hypoplasia, type 11, 617695 (3),
TBC1D24	AR,AD	deafness, 86, 614617 (3), ; epilepsy, rolandic, with paroxysmal exercise-induce dystonia and writer's cramp, 608105 (3), ; myoclonic epilepsy, infantile, familial, 605021 (3), ; deafness, 65, 616044 (3), ; developmental and epileptic encephalopathy 16, 615338 (3), ; doors syndrome, 220500 (3),
TBC1D25		
TBC1D2A		
TBC1D2B	AR	neurodevelopmental disorder with seizures and gingival overgrowth, 619323 (3),
TBC1D3		
TBC1D30		
TBC1D32		
TBC1D3A		
TBC1D3B		
TBC1D3C		
TBC1D3D		
TBC1D3E		
TBC1D3F		
TBC1D3G		
TBC1D3H		
TBC1D3I		
TBC1D4		{diabetes mellitus, noninsulin-dependent, 5}, 616087 (3)
TBC1D5		
TBC1D7	AR	macrocephaly/megalencephaly syndrome, 248000 (3),
TBC1D8B	XL	nephrotic syndrome, type 20, 301028 (3),
TBC1D9		
TBC1D9B		
TBC7	AR	macrocephaly/megalencephaly syndrome, 248000 (3),
TBCA		
TBCB		
TBCC		
TBCCD1		
TBCCD2	XL	retinitis pigmentosa 2, 312600 (3),
TBCD	AR	encephalopathy, progressive, early-onset, with brain atrophy and thin corpus callosum, 617193 (3),
TBCE	AR	kenny-caffey syndrome, type 1, 244460 (3), ; hypoparathyroidism-retardation-dysmorphism syndrome, 241410 (3), ; encephalopathy, progressive, with amyotrophy and optic atrophy, 617207 (3),
TBCEL		
TBCK	AR	hypotonia, infantile, with psychomotor retardation and characteristic facies 3, 616900 (3),
TBDN100	AD	intellectual developmental disorder, 50, with behavioral abnormalities, 617787 (3),
TBE-1	AR	multicentric osteolysis, nodulosis, and arthropathy, 259600 (3),
TBG	XL	[thyroxine-binding globulin qtl], 300932 (3),
TBK1	AD	{encephalopathy, acute, infection-induced (herpes-specific), susceptibility to, 8}, 617900 (3), ; frontotemporal dementia and/or amyotrophic lateral sclerosis 4, 616439 (3),
TBKBP1		
TBL1	YL,XL	?deafness, 2, 400047 (3), |hypothyroidism, congenital, nongoitrous, 8, 301033 (3),
TBL1X	XL	hypothyroidism, congenital, nongoitrous, 8, 301033 (3),
TBL1XR1	AD	intellectual developmental disorder, 41, 616944 (3), ; pierpont syndrome, 602342 (3),
TBL1Y	YL	?deafness, 2, 400047 (3),
TBL2		
TBL3		
TBLR1	AD	intellectual developmental disorder, 41, 616944 (3), ; pierpont syndrome, 602342 (3),
TBLYM	AR	asthma and nasal polyps, 208550 (3), ; ?immunodeficiency 88, 619630 (3), ; {asthma, aspirin-induced, susceptibility to}, 208550 (3),
TBN	AR	neurodevelopmental disorder with severe motor impairment, absent language, cerebral hypomyelination, and brain atrophy, 619972 (3),
TBP	AD,MF	spinocerebellar ataxia 17, 607136 (3), ; {parkinson disease, susceptibility to}, 168600 (3),
TBP-1	AR	?deafness, cataract, impaired intellectual development, and polyneuropathy, 619354 (3),
TBP-7		
TBP1	AR,AD,MF	?deafness, cataract, impaired intellectual development, and polyneuropathy, 619354 (3), |spinocerebellar ataxia 17, 607136 (3), ; {parkinson disease, susceptibility to}, 168600 (3),
TBP10		
TBP2		
TBP7		
TBPIP	AR	ovarian dysgenesis 3, 614324 (3),
TBPL1		
TBPL2		
TBR-i	AD	{multiple self-healing squamous epithelioma, susceptibility to}, 132800 (3), ; loeys-dietz syndrome 1, 609192 (3),
TBR-ii	AD	loeys-dietz syndrome 2, 610168 (3), ; colorectal cancer, hereditary nonpolyposis, type 6, 614331 (3); esophageal cancer, somatic, 133239 (3)
TBR1	AD	intellectual developmental disorder with autism and speech delay, 606053 (3),
TBR2		
TBRG1		
TBRG4		
TBRI	AD	{multiple self-healing squamous epithelioma, susceptibility to}, 132800 (3), ; loeys-dietz syndrome 1, 609192 (3),
TBRII	AD	loeys-dietz syndrome 2, 610168 (3), ; colorectal cancer, hereditary nonpolyposis, type 6, 614331 (3); esophageal cancer, somatic, 133239 (3)
TBS	AD	townes-brocks syndrome 1, 107480 (3), ; townes-brocks branchiootorenal-like syndrome, 107480 (3),
TBX1	AD	tetralogy of fallot, 187500 (3), ; digeorge syndrome, 188400 (3), ; conotruncal anomaly face syndrome, 217095 (3); velocardiofacial syndrome, 192430 (3),
TBX10		
TBX13		
TBX14	AR	cousin syndrome, 260660 (3),
TBX15	AR	cousin syndrome, 260660 (3),
TBX18	AD	congenital anomalies of kidney and urinary tract 2, 143400 (3),
TBX19	AR	adrenocorticotropic hormone deficiency, 201400 (3),
TBX2	AD	vertebral anomalies and variable endocrine and t-cell dysfunction, 618223 (3),
TBX20		atrial septal defect 4, 611363 (3)
TBX21	AR	asthma and nasal polyps, 208550 (3), ; ?immunodeficiency 88, 619630 (3), ; {asthma, aspirin-induced, susceptibility to}, 208550 (3),
TBX22	XL	cleft palate with ankyloglossia, 303400 (3), ; ?abruzzo-erickson syndrome, 302905 (3),
TBX3	AD	ulnar-mammary syndrome, 181450 (3),
TBX3-ISO	AD	ulnar-mammary syndrome, 181450 (3),
TBX4	AD,AR	ischiocoxopodopatellar syndrome with or without pulmonary arterial hypertension, 147891 (3), ; amelia, posterior, with pelvic and pulmonary hypoplasia syndrome, 601360 (3),
TBX5	AD	holt-oram syndrome, 142900 (3),
TBX6	AR,AD	spondylocostal dysostosis 5, 122600 (3),
TBX7		
TBXA2R	AD	{bleeding disorder, platelet-type, 13, susceptibility to}, 614009 (3),
TBXAS1	AR	ghosal hematodiaphyseal syndrome, 231095 (3),
TBXT	AR,AD	sacral agenesis with vertebral anomalies, 615709 (3), ; {neural tube defects, susceptibility to}, 182940 (3),
TBZF		
TC	AR	[blood group cromer], 613793 (3), ; complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy, 226300 (3),
TC-1		
TC-25	AD	intellectual developmental disorder, 48, 617751 (3),
TC-PTP		
TC1		
TC10		
TC2	AR	transcobalamin ii deficiency, 275350 (3),
TC21	AD	ovarian carcinoma (3); noonan syndrome 12, 618624 (3),
TC2N		
TC4		
TCA3		
TCA4		
TCAB1	AR	dyskeratosis congenita, 3, 613988 (3),
TCAF1		
TCAF2		
TCAG_1951439		
TCAM1		
TCAM1P		
TCAP	AD,AR	cardiomyopathy, hypertrophic, 25, 607487 (3), ; muscular dystrophy, limb-girdle, 7, 601954 (3),
TCBA1		
TCBAP0758	AR	basel-vanagait-smirin-yosef syndrome, 616449 (3),
TCblR	AR	methylmalonic aciduria, transient, due to transcobalamin receptor defect, 613646 (3),
TCBP49		
TCC52		
TCCE518	AD	{specific language impairment 5}, 615432 (3),
TCCR		
TCD	XL	choroideremia, 303100 (3),
TCEA		
TCEA1		
TCEA2		
TCEA3		
TCEAL1	XL,XLD	neurodevelopmental disorder with gait disturbance, dysmorphic facies and behavioral abnormalities, 301094 (3),
TCEAL7		
TCEANC		
TCEANC1		
TCEB1		
TCEB1L		
TCEB2		
TCEB3		
TCEB3A		
TCEB3B		
TCEB3BP1		
TCEB3L		
TCELLPTP		
TCERG1		
TCF-1		
TCF-4	AD	{diabetes mellitus, type 2, susceptibility to}, 125853 (3),
TCF1	AD,AR	hepatic adenoma, somatic, 142330 (3); diabetes mellitus, insulin-dependent, 20, 612520 (3); {diabetes mellitus, noninsulin-dependent, 2}, 125853 (3), ; mody, type iii, 600496 (3), ; {diabetes mellitus, insulin-dependent}, 222100 (3), ; renal cell carcinoma, 144700 (3)
TCF10		sebaceous tumors, somatic (3)
TCF11		
TCF12	AD,AR	craniosynostosis 3, 615314 (3), ; hypogonadotropic hypogonadism 26 with or without anosmia, 619718 (3),
TCF13	AD	sveinsson chorioretinal atrophy, 108985 (3),
TCF13L1		
TCF14	AD	fanconi renotubular syndrome 4, with maturity-onset diabetes of the young, 616026 (3), ; {diabetes mellitus, noninsulin-dependent}, 125853 (3), ; mody, type i, 125850 (3),
TCF15		
TCF16	AR	?popliteal pterygium syndrome, bartsocas-papas type 2, 619339 (3), ; ?cocoon syndrome, 613630 (3),
TCF17		
TCF19		
TCF1ALPHA		sebaceous tumors, somatic (3)
TCF2	AD	type 2 diabetes mellitus, 125853 (3), ; renal cysts and diabetes syndrome, 137920 (3), ; {renal cell carcinoma}, 144700 (3)
TCF20	AD	developmental delay with variable intellectual impairment and behavioral abnormalities, 618430 (3),
TCF21		
TCF23		
TCF25		
TCF3	AR,AD	agammaglobulinemia 8b, 619824 (3), ; agammaglobulinemia 8a, 616941 (3),
TCF4	AD,AD	{diabetes mellitus, type 2, susceptibility to}, 125853 (3), |pitt-hopkins syndrome, 610954 (3), ; corneal dystrophy, fuchs endothelial, 3, 613267 (3),
TCF5		
TCF6	AR	?mitochondrial dna depletion syndrome 15 (hepatocerebral type), 617156 (3),
TCF6L2	AR	?mitochondrial dna depletion syndrome 15 (hepatocerebral type), 617156 (3),
TCF7		
TCF7L1		
TCF7L2	AD	{diabetes mellitus, type 2, susceptibility to}, 125853 (3),
TCF7L3		sebaceous tumors, somatic (3)
TCF8	AD	corneal dystrophy, posterior polymorphous, 3, 609141 (3), ; corneal dystrophy, fuchs endothelial, 6, 613270 (3),
TCF9		
TCFB1		
TCFCOUP1	AD	bosch-boonstra-schaaf optic atrophy syndrome, 615722 (3),
TCFEB		
TCFEC		
TCFL1		
TCFL4		
TCFL5		
TCGAP		
TCGF		
TCHH	AR	?uncombable hair syndrome 3, 617252 (3),
TCHP		
TCI		
TCII-R	AR	methylmalonic aciduria, transient, due to transcobalamin receptor defect, 613646 (3),
TCIM		
TCIRG1	AR	osteopetrosis, 1, 259700 (3),
TCL		
TCL1		leukemia/lymphoma, t-cell, 186960 (2)
TCL1A		leukemia/lymphoma, t-cell, 186960 (2)
TCL1B		leukemia/lymphoma, t-cell, 603769 (2)
TCL1C		
TCL3		
TCL4		leukemia/lymphoma, t-cell, 186860 (2)
TCL5		leukemia, t-cell acute lymphocytic, somatic, 613065 (3)
TCL6		
TCL6e1		
TCN1		
TCN2	AR	transcobalamin ii deficiency, 275350 (3),
TCN2R	AR	methylmalonic aciduria, transient, due to transcobalamin receptor defect, 613646 (3),
TCN3	AR	intrinsic factor deficiency, 261000 (3),
TCOF1	AD	treacher collins syndrome 1, 154500 (3),
TCONS_00006930		
TCONS_00009511-XLOC_004555		
TCONS_00010378		
TCONS_00011636		
TCONS_00014535		
TCONS_00015167		
TCONS_00017086		
TCONS_00020260		
TCONS_00021856		
TCONS_00024492		
TCONS_00024764		
TCONS_00025599		
TCONS_00027846		
TCP1		
TCP10		
TCP10L		
TCP10L3		
TCP11		
TCP110		
TCP11L2		
TCP20		
TCP228		{hiv-1 disease, rapid progression of}, 609423 (3); {hiv-1 disease, delayed progression of}, 609423 (3)
TCPTP		
TCPZ		
TCRBC1		
TCRBC2		
TCRBD1		
TCRBD2		
TCRGC1		
TCRGC2		
TCRIM		
TCRP1		
TCRZ	AR	?immunodeficiency 25, 610163 (3),
TCS	AD	treacher collins syndrome 1, 154500 (3),
TCS1	AD,AR	dyskeratosis congenita, 2, 613989 (3), ; dyskeratosis congenita, 4, 613989 (3), ; pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 1, 614742 (3), ; {melanoma, cutaneous malignant, 9}, 615134 (3), ; {leukemia, acute myeloid}, 601626 (3), somatic mutation,
TCS3	AR	galloway-mowat syndrome 3, 617729 (3),
TCTA		
TCTE1		
TCTE1L		
TCTE3		
TCTE5		
TCTEL1		
Tctex-1		
tctex-6		
TCTEX1		
TCTEX1D1		
TCTEX1D2	AR	short-rib thoracic dysplasia 17 with or without polydactyly, 617405 (3),
TCTEX1D3		
TCTEX1D4		
TCTEX1L		
TCTEX2		
Tctex4		
Tctex5		
TCTN1	AR	joubert syndrome 13, 614173 (3),
TCTN2	AR	joubert syndrome 24, 616654 (3), ; ?meckel syndrome 8, 613885 (3),
TCTN3	AR	joubert syndrome 18, 614815 (3), ; orofaciodigital syndrome iv, 258860 (3),
TCTP		
TCX1		
TD-60		
TD1		
TD26		
TDAG51		
TDAG8		
TDD	AR	46xy sex reversal 8, 614279 (3),
TDD5	AR	charcot-marie-tooth disease, type 4d, 601455 (3),
TDE		
TDE1		
TDE1L		
TDE2		
TDE2L		
TDF	YL,XLD,XL	46xy sex reversal 1, 400044 (3), ; 46xx sex reversal 1, 400045 (4),
TDG		
TDGF1		
TDI		
Tdif1		
TdIF2		
tdl		
TDO	AR	[?hypertryptophanemia], 600627 (3),
TDO2	AR	[?hypertryptophanemia], 600627 (3),
TDP-43	AD	frontotemporal lobar degeneration, tardbp-related, 612069 (3), ; amyotrophic lateral sclerosis 10, with or without ftd, 612069 (3),
TDP1	AR	?spinocerebellar ataxia, with axonal neuropathy 1, 607250 (3),
TDP2	AR	spinocerebellar ataxia, 23, 616949 (3),
TDPGD	AR	catel-manzke syndrome, 616145 (3),
TDPX1		
TDRD1		
TDRD11		
TDRD13	XL	developmental and epileptic encephalopathy 36, 300884 (3),
TDRD14A		
TDRD14B	AD	intellectual developmental disorder, 65, 619320 (3),
TDRD14C		
TDRD16A	AR	spinal muscular atrophy-2, 253550 (3), ; spinal muscular atrophy-4, 271150 (3), ; spinal muscular atrophy-3, 253400 (3), ; spinal muscular atrophy-1, 253300 (3),
TDRD16B	AR	{spinal muscular atrophy, type iii, modifier of}, 253400 (3),
TDRD16C		
TDRD17		
TDRD18	AD,AR	pelger-huet anomaly, 169400 (3), ; ?reynolds syndrome, 613471 (3), ; rhizomelic skeletal dysplasia with or without pelger-huet anomaly, 618019 (3), ; greenberg skeletal dysplasia, 215140 (3),
TDRD19A		
TDRD19B		
TDRD19C		
TDRD2		
TDRD20A		
TDRD20B		
TDRD21		
TDRD22		
TDRD23		
TDRD24		
TDRD25		
TDRD26		
TDRD29		
TDRD3		
TDRD30		
TDRD4		
TDRD5		
TDRD6		
TDRD7	AR	cataract 36, 613887 (3),
TDRD8		
TDRD9	AR	?spermatogenic failure 30, 618110 (3),
TDRG1		
TDRKH		
TDRP		
TDRP1		
TDRP2		
TdT		
TDT		
Tdt-N		
TDU		
TE2	XL,XLD,XLR	microphthalmia, syndromic 1, 309800 (3), ; ogden syndrome, 300855 (3),
TEAD1	AD	sveinsson chorioretinal atrophy, 108985 (3),
TEAD2		
TEAD3		
TEAD4		
TEAD5		
Teap		
TEB1		
TEB2	AR,AD	ovarian dysgenesis 5, 617690 (3), ; spermatogenic failure 32, 618115 (3),
TEB4	AD	epilepsy, familial adult myoclonic, 3, 613608 (3),
TEBG		
TEBP		
TEC		
Tech	AR	spinal muscular atrophy, distal, 4, 611067 (3), ; charcot-marie-tooth disease, intermediate c, 615376 (3),
TECK		
TECPR1		
TECPR2	AR	neuropathy, hereditary sensory and autonomic, type ix, with developmental delay, 615031 (3),
TECR	AR	intellectual developmental disorder, 14, 614020 (3),
TECRL	AR	ventricular tachycardia, catecholaminergic polymorphic, 3, 614021 (3),
TECT1	AR	joubert syndrome 13, 614173 (3),
TECT2	AR	joubert syndrome 24, 616654 (3), ; ?meckel syndrome 8, 613885 (3),
TECT3	AR	joubert syndrome 18, 614815 (3), ; orofaciodigital syndrome iv, 258860 (3),
TECTA	AD,AR	deafness, 8/12, 601543 (3), ; deafness, 21, 603629 (3),
TECTB		
TEDDM1		
TEF		
TEF-1	AD	sveinsson chorioretinal atrophy, 108985 (3),
TEF-3		
TEF-4		
TEF-5		
TEF2	AD	nabais sa-de vries syndrome, type 1, 618828 (3), ; nabais sa-de vries syndrome, type 2, 618829 (3),
TEF3	AR	mulibrey nanism, 253250 (3),
TEF4		
TEFM		
TEFR-1		
TEG-261		
TEG-42		
TEGT		
TEIF	AR	spinocerebellar ataxia, 21, 616719 (3),
TEK	AD	venous malformations, multiple cutaneous and mucosal, 600195 (3), ; glaucoma 3, primary congenital, e, 617272 (3),
TEKT1		
TEKT2		
TEKT2BP2		
TEKT3	AR	spermatogenic failure 81, 620277 (3),
TEKT5		
TEKTB1		
TEL	AD	thrombocytopenia 5, 616216 (3), ; leukemia, acute myeloid, somatic, 601626 (3)
TEL-2		
TEL1	AR,AD	lymphoma, b-cell non-hodgkin, somatic (3); ataxia-telangiectasia, 208900 (3), ; {breast cancer, susceptibility to}, 114480 (3), somatic mutation, ; t-cell prolymphocytic leukemia, somatic (3); lymphoma, mantle cell, somatic (3)
TEL2	AR	you-hoover-fong syndrome, 616954 (3),
TELE	AD,AR	cardiomyopathy, hypertrophic, 25, 607487 (3), ; muscular dystrophy, limb-girdle, 7, 601954 (3),
telethonin	AD,AR	cardiomyopathy, hypertrophic, 25, 607487 (3), ; muscular dystrophy, limb-girdle, 7, 601954 (3),
TELO1	AR,AD	lymphoma, b-cell non-hodgkin, somatic (3); ataxia-telangiectasia, 208900 (3), ; {breast cancer, susceptibility to}, 114480 (3), somatic mutation, ; t-cell prolymphocytic leukemia, somatic (3); lymphoma, mantle cell, somatic (3)
TELO2	AR	you-hoover-fong syndrome, 616954 (3),
Telokin	AR,AD	megacystis-microcolon-intestinal hypoperistalsis syndrome 1, 249210 (3), ; aortic aneurysm, familial thoracic 7, 613780 (3),
TEM		
TEM1		
TEM2		
TEM3		
TEM4		
TEM5		
TEM6		
TEM7		
TEM7R		
TEM8	AR,AD	gapo syndrome, 230740 (3), ; {?hemangioma, capillary infantile, susceptibility to}, 602089 (3),
TEN-M1		
Ten-M2		
Ten-M3	AR	microphthalmia, syndromic 15, 615145 (3), ; ?microphthalmia, isolated, with coloboma 9, 615145 (3),
Ten-M4	AD	essential tremor, hereditary, 5, 616736 (3),
TEN1		
TEN2		
TEN3	AR	microphthalmia, syndromic 15, 615145 (3), ; ?microphthalmia, isolated, with coloboma 9, 615145 (3),
TEN4	AD	essential tremor, hereditary, 5, 616736 (3),
TENB2		
TENC1		
tendin		
TENM1		
TENM2		
TENM3	AR	microphthalmia, syndromic 15, 615145 (3), ; ?microphthalmia, isolated, with coloboma 9, 615145 (3),
TENM4	AD	essential tremor, hereditary, 5, 616736 (3),
Tenr		
TENRL		
TENS1		
TENT1		
TENT2		
TENT3A		
TENT3B		
TENT4A		
TENT4B		
TENT5A	AR	osteogenesis imperfecta, type xviii, 617952 (3),
TENT5B		
TENT5C		
TENT5D		
TENT6	AR	?spastic ataxia 4, 613672 (3),
TEP1	AD	{glioma susceptibility 2}, 613028 (3), ; {meningioma}, 607174 (3), ; cowden syndrome 1, 158350 (3), ; lhermitte-duclos disease, 158350 (3), ; prostate cancer, somatic, 176807 (3); macrocephaly/autism syndrome, 605309 (3),
TEPP		
TER	AR,AD	intellectual developmental disorder, 14, 614020 (3), |pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 2, 614743 (3), ; dyskeratosis congenita, 1, 127550 (3),
TER1		
TERA	AD	frontotemporal dementia and/or amyotrophic lateral sclerosis 6, 613954 (3), ; charcot-marie-tooth disease, type 2y, 616687 (3), ; inclusion body myopathy with early-onset paget disease and frontotemporal dementia 1, 167320 (3),
TERB1	AR	spermatogenic failure 60, 619646 (3),
TERB2	AR	?spermatogenic failure 59, 619645 (3),
TERC	AD	pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 2, 614743 (3), ; dyskeratosis congenita, 1, 127550 (3),
TERE1	AD	corneal dystrophy, schnyder type, 121800 (3),
terf		
TERF1		
TERF2		
TERF2IP		
TERL	AR	ventricular tachycardia, catecholaminergic polymorphic, 3, 614021 (3),
TERP		
TERT	AD,AR	dyskeratosis congenita, 2, 613989 (3), ; dyskeratosis congenita, 4, 613989 (3), ; pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 1, 614742 (3), ; {melanoma, cutaneous malignant, 9}, 615134 (3), ; {leukemia, acute myeloid}, 601626 (3), somatic mutation,
TES		
TES-1		
TES101RP		
Tes3		
TESC		
TESK1		
TESK2		
TESMIN		
TESPA1		
TESS-2		
TEST1		
testican-1		
testican-2		
testican-3		
TESTIN		
TET1		
TET2	AR	myelodysplastic syndrome, somatic, 614286 (3); immunodeficiency 75, 619126 (3),
TET3	AR,AD	beck-fahrner syndrome, 618798 (3),
tetherin		
TETRAN		
TETRASPAN		
TEX1		
TEX10		
TEX101		
TEX11	XL,XLR	spermatogenic failure, 2, 309120 (3),
TEX12		
TEX13A		
TEX13B		
TEX14	AR	spermatogenic failure 23, 617707 (3),
TEX15	AR	spermatogenic failure 25, 617960 (3),
TEX19		
TEX2		
TEX261		
TEX27		
TEX28		
TEX292		
TEX37		
TEX39A		
TEX39B		
TEX39C		
TEX4	AR	?combined oxidative phosphorylation deficiency 43, 618851 (3),
TEX40		
Tex42		
TF	AR	atransferrinemia, 209300 (3),
TF12		
TF1B		
TF1G		
TF2E2	AR	trichothiodystrophy 6, nonphotosensitive, 616943 (3),
TF2F1		
TF2S		
TF34		
TF6	AR,AD	?spastic paraplegia 57, 615658 (3), ; hereditary motor and sensory neuropathy, okinawa type, 604484 (3),
TFAM	AR	?mitochondrial dna depletion syndrome 15 (hepatocerebral type), 617156 (3),
TFAP2	AD	branchiooculofacial syndrome, 113620 (3),
TFAP2A	AD	branchiooculofacial syndrome, 113620 (3),
TFAP2A-AS2		
TFAP2B	AD	patent ductus arteriosus 2, 617035 (3), ; char syndrome, 169100 (3),
TFAP2BL1		
TFAP2C		
TFAP2D		
TFAP2E		
TFAP2G		
TFAP4		
TFAR15	AD	cerebral cavernous malformations-3, 603285 (3),
TFAR19		
TFB1M		
TFB2		
TFB2M		
TFB5	AR	trichothiodystrophy 3, photosensitive, 616395 (3),
TFC5	AR	?deafness, 112, 618257 (3),
TFCOUP1	AD	bosch-boonstra-schaaf optic atrophy syndrome, 615722 (3),
TFCOUP2	AD	46xx sex reversal 5, 618901 (3), ; congenital heart defects, multiple types, 4, 615779 (3),
TFCP2		
TFCP2C		
TFCP2L1		
TFCP2L2		
TFCP2L3	AD,AR	deafness, 28, 608641 (3), ; ectodermal dysplasia/short stature syndrome, 616029 (3), ; corneal dystrophy, posterior polymorphous, 4, 618031 (3),
TFCP2L4	AD	van der woude syndrome 2, 606713 (3),
TFDP1		
TFDP2		
TFDP3		
TFE3	XL	intellectual developmental disorder, syndromic, with pigmentary mosaicism and coarse facies, 301066 (3), ; renal cell carcinoma, papillary, 1, 300854 (3)
TFEA	XL	intellectual developmental disorder, syndromic, with pigmentary mosaicism and coarse facies, 301066 (3), ; renal cell carcinoma, papillary, 1, 300854 (3)
TFEB		
TFEC		
TFECL		
TFF1		
TFF2		
TFF3		
TFG	AR,AD	?spastic paraplegia 57, 615658 (3), ; hereditary motor and sensory neuropathy, okinawa type, 604484 (3),
TFI		
TFII-I		
TFIIA		
TFIIB		
TFIID	AD,MF	spinocerebellar ataxia 17, 607136 (3), ; {parkinson disease, susceptibility to}, 168600 (3),
TFIID-31		
TFIIE-A		
TFIIE-B	AR	trichothiodystrophy 6, nonphotosensitive, 616943 (3),
TFIIF		
TFIIH	AR	trichothiodystrophy 3, photosensitive, 616395 (3),
TFIIIA		
TFIIIA-INTP	AD,AR	glaucoma 1, open angle, e, 137760 (3), ; amyotrophic lateral sclerosis 12 with or without frontotemporal dementia, 613435 (3), ; {glaucoma, normal tension, susceptibility to}, 606657 (3)
TFIIIB150	AR	?deafness, 112, 618257 (3),
TFIIIB50		
TFIIIB90	AR,AR	?deafness, 112, 618257 (3), |cerebellofaciodental syndrome, 616202 (3),
TFIIIC102		
TFIIIC110		
TFiiiC2-102		
TFiiiC2-63		
TFIIIC220		
TFIIIC35		
TFIIIC63		
TFIIIC90		
TFIIICepsilon		
TFIIS		
TFIIS.H		
TFIP11		
TFIZ1		
TFNR	AR	?deafness, 112, 618257 (3),
TFPI		
TFPI-2		
TFPI1		
TFPI2		
TFPT		
TFR1	AR	immunodeficiency 46, 616740 (3),
TFR2	AR	hemochromatosis, type 3, 604250 (3),
TFRC	AR	immunodeficiency 46, 616740 (3),
TFRC2	AR	hemochromatosis, type 3, 604250 (3),
TG	AR	{autoimmune thyroid disease, susceptibility to, 3}, 608175 (3); thyroid dyshormonogenesis 3, 274700 (3),
TG1019		
Tg737		
TGAM77		
TGASE	AR	ichthyosis, congenital, 1, 242300 (3),
TGB		
TGB1		
TGB2		
TGC		
TGC1	XL,XLR	spermatogenic failure, 2, 309120 (3),
TGC3B		
TGD	AR,AD	tangier disease, 205400 (3), ; hdl deficiency, familial, 1, 604091 (3),
TGDS	AR	catel-manzke syndrome, 616145 (3),
TGE	AR	?uncombable hair syndrome 2, 617251 (3),
TGFA		
TGFB	AR,AD	inflammatory bowel disease, immunodeficiency, and encephalopathy, 618213 (3), ; camurati-engelmann disease, 131300 (3), ; {cystic fibrosis lung disease, modifier of}, 219700 (3),
TGFB1	AR,AD	inflammatory bowel disease, immunodeficiency, and encephalopathy, 618213 (3), ; camurati-engelmann disease, 131300 (3), ; {cystic fibrosis lung disease, modifier of}, 219700 (3),
TGFB1I1		
TGFB1I4		
TGFB2	AD	loeys-dietz syndrome 4, 614816 (3),
TGFB3	AD	arrhythmogenic right ventricular dysplasia 1, 107970 (3), ; loeys-dietz syndrome 5, 615582 (3),
TGFB4		
TGFbeta	AR,AD	inflammatory bowel disease, immunodeficiency, and encephalopathy, 618213 (3), ; camurati-engelmann disease, 131300 (3), ; {cystic fibrosis lung disease, modifier of}, 219700 (3),
TGFBI	AD	corneal dystrophy, avellino type, 607541 (3), ; corneal dystrophy, reis-bucklers type, 608470 (3), ; corneal dystrophy, thiel-behnke type, 602082 (3), ; corneal dystrophy, groenouw type i, 121900 (3), ; corneal dystrophy, epithelial basement membrane, 121820 (3), ; corneal dystrophy, lattice type i, 122200 (3), ; corneal dystrophy, lattice type iiia, 608471 (3),
TGFBR1	AD	{multiple self-healing squamous epithelioma, susceptibility to}, 132800 (3), ; loeys-dietz syndrome 1, 609192 (3),
TGFBR2	AD	loeys-dietz syndrome 2, 610168 (3), ; colorectal cancer, hereditary nonpolyposis, type 6, 614331 (3); esophageal cancer, somatic, 133239 (3)
TGFBR3		
TGFBRAP1		
TGIF	AD	{rheumatoid arthritis, progression of}, 180300 (3); {graft-versus-host disease, protection against}, 614395 (3); {hiv-1, susceptibility to}, 609423 (3)|holoprosencephaly 4, 142946 (3),
TGIF1	AD	holoprosencephaly 4, 142946 (3),
TGIF2		
TGIF2LX		
TGIF2LY		
TGK	AR	ichthyosis, congenital, 1, 242300 (3),
TGLN		
TGM1	AR	ichthyosis, congenital, 1, 242300 (3),
TGM2		
TGM3	AR	?uncombable hair syndrome 2, 617251 (3),
TGM3L	AD	spinocerebellar ataxia 35, 613908 (3),
TGM4		
TGM5	AR	peeling skin syndrome 2, 609796 (3),
TGM6	AD	spinocerebellar ataxia 35, 613908 (3),
TGM7		
TGMX	AR	peeling skin syndrome 2, 609796 (3),
TGMZ		
TGN	AR	{autoimmune thyroid disease, susceptibility to, 3}, 608175 (3); thyroid dyshormonogenesis 3, 274700 (3),
TGN38		
TGN46		
TGN48		
TGN51		
TGOLN2		
TGP		
TGR		
TGR5		
TGS		
TGS1		
TGT		
TGT3		
TGX	AR	peeling skin syndrome 2, 609796 (3),
TGY	AD	spinocerebellar ataxia 35, 613908 (3),
TH	AR	segawa syndrome, 605407 (3),
TH1		
TH1L		
TH2B-175		
THADA		
THANK		
THAP0		
THAP1	AD	dystonia 6, torsion, 602629 (3),
THAP10		
THAP11		
THAP12		
THAP2		
THAP3		
THAP4		
THAP5		
THAP6		
THAP7		
THAP8		
THAP9		
THAS	AR	ghosal hematodiaphyseal syndrome, 231095 (3),
THBD	AD	thrombophilia 12 due to thrombomodulin defect, 614486 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to, 6}, 612926 (3),
THBGB1		
THBP1		
THBS		
THBS-1		
THBS1		
THBS2		{lumbar disc herniation, susceptibility to}, 603932 (3)
THBS3		
THBS4		
THBS5	AD	pseudoachondroplasia, 177170 (3), ; carpal tunnel syndrome 2, 619161 (3), ; epiphyseal dysplasia, multiple, 1, 132400 (3),
THC	XLR,XL	wiskott-aldrich syndrome, 301000 (3), ; neutropenia, severe congenital, 300299 (3), ; thrombocytopenia, intermittent, 313900 (3), ; thrombocytopenia, 313900 (3),
THC2	AD	thrombocytopenia 2, 188000 (3),
THC211630		
THCCox	AR	bile acid synthesis defect, congenital, 6, 617308 (3),
THDF1	AR	combined oxidative phosphorylation deficiency 23, 616198 (3),
THEA		
THEAL		
THEG		
THEG1		
THEM1		
THEM2		
THEM4		
THEM5		
THEMIS		
THEMIS1		
THEMIS2		
THES	AR	trichohepatoenteric syndrome 1, 222470 (3),
THEX1		
THG-1		
THG1		
THG1L	AR	spinocerebellar ataxia, 28, 618800 (3),
THH	AR	?uncombable hair syndrome 3, 617252 (3),
THIF		
THIK-1		
THIK-2		
THIK1		
THIK2		
THIL	AR	alpha-methylacetoacetic aciduria, 203750 (3),
Thing1		
Thing2		
THM1	AR,AD	short-rib thoracic dysplasia 4 with or without polydactyly, 613819 (3), ; nephronophthisis 12, 613820 (3),
Thm2	AR	spermatogenic failure 37, 618429 (3),
THNSL1		
THNSL2		
THO1		
THO2	XL,XLR	intellectual developmental disorder, 12, 300957 (3),
THOC1	AD	?deafness, 86, 620280 (3),
THOC2	XL,XLR	intellectual developmental disorder, 12, 300957 (3),
THOC3		
THOC4		
THOC5		
THOC6	AR	beaulieu-boycott-innes syndrome, 613680 (3),
THOC7		
THOP1		
THOR		
THORLNC		
THOX1		
THOX2	AR	thyroid dyshormonogenesis 6, 607200 (3),
THP1	AD	culler-jones syndrome, 615849 (3), ; holoprosencephaly 9, 610829 (3),
THP2	AD	culler-jones syndrome, 615849 (3), ; holoprosencephaly 9, 610829 (3),
THPO	AD	thrombocythemia 1, 187950 (3),
ThPOK		
THPOR	AD,AR	myelofibrosis with myeloid metaplasia, somatic, 254450 (3); thrombocythemia 2, 601977 (3), somatic mutation, ; thrombocytopenia, congenital amegakaryocytic, 604498 (3),
THR1	AR,AD	thyroid hormone resistance, 274300 (3), ; thyroid hormone resistance, 188570 (3), ; thyroid hormone resistance, selective pituitary, 145650 (3),
THRA	AD	hypothyroidism, congenital, nongoitrous, 6, 614450 (3),
THRA1	AD	hypothyroidism, congenital, nongoitrous, 6, 614450 (3),
THRA2	AD	hypothyroidism, congenital, nongoitrous, 6, 614450 (3),
THRA3	AD	hypothyroidism, congenital, nongoitrous, 6, 614450 (3),
THRAL		
THRalpha	AD	hypothyroidism, congenital, nongoitrous, 6, 614450 (3),
THRalpha1	AD	hypothyroidism, congenital, nongoitrous, 6, 614450 (3),
THRalpha2	AD	hypothyroidism, congenital, nongoitrous, 6, 614450 (3),
THRAP1	AD	intellectual developmental disorder, 61, 618009 (3),
THRAP2	AD	impaired intellectual development and distinctive facial features with or without cardiac defects, 616789 (3),
THRAP3		
THRAP4		
THRAP5		
THRAP6		
THRB	AR,AD	thyroid hormone resistance, 274300 (3), ; thyroid hormone resistance, 188570 (3), ; thyroid hormone resistance, selective pituitary, 145650 (3),
THRB1	AR,AD	thyroid hormone resistance, 274300 (3), ; thyroid hormone resistance, 188570 (3), ; thyroid hormone resistance, selective pituitary, 145650 (3),
THRB2	AR,AD	thyroid hormone resistance, 274300 (3), ; thyroid hormone resistance, 188570 (3), ; thyroid hormone resistance, selective pituitary, 145650 (3),
THRbeta	AR,AD	thyroid hormone resistance, 274300 (3), ; thyroid hormone resistance, 188570 (3), ; thyroid hormone resistance, selective pituitary, 145650 (3),
THRbeta1	AR,AD	thyroid hormone resistance, 274300 (3), ; thyroid hormone resistance, 188570 (3), ; thyroid hormone resistance, selective pituitary, 145650 (3),
Thrbeta2	AR,AD	thyroid hormone resistance, 274300 (3), ; thyroid hormone resistance, 188570 (3), ; thyroid hormone resistance, selective pituitary, 145650 (3),
THRIL		
THRM	AD	thrombophilia 12 due to thrombomodulin defect, 614486 (3), ; {hemolytic uremic syndrome, atypical, susceptibility to, 6}, 612926 (3),
THRP		
THRSP		
THRSPL		
THSD1	AD,AR	?aneurysm, intracranial berry, 12, 618734 (3), ; lymphatic malformation 13, 620244 (3),
THSD2		
THSD3		
THSD4	AD	aortic aneurysm, familial thoracic 12, 619825 (3),
THSD7A		
ThT1	AR	thiamine-responsive megaloblastic anemia syndrome, 249270 (3),
THTPA		
THTPASE		
thTr-2	AR	thiamine metabolism dysfunction syndrome 2 (biotin- or thiamine-responsive encephalopathy type 2), 607483 (3),
THTR1	AR	thiamine-responsive megaloblastic anemia syndrome, 249270 (3),
THTR2	AR	thiamine metabolism dysfunction syndrome 2 (biotin- or thiamine-responsive encephalopathy type 2), 607483 (3),
THUMPD1	AR	neurodevelopmental disorder with speech delay and variable ocular anomalies, 619989 (3),
THUMPD2		
THW	AR,AD	erythrokeratodermia variabilis et progressiva 7, 619209 (3), ; olmsted syndrome 2, 619208 (3),
THY1		
THY28		
THYEX3	AD	townes-brocks syndrome 2, 617466 (3),
THYN1		
TI-VAMP		
TIA-1	AR,AD	welander distal myopathy, 604454 (3), ; amyotrophic lateral sclerosis 26 with or without frontotemporal dementia, 619133 (3),
TIA1	AR,AD	welander distal myopathy, 604454 (3), ; amyotrophic lateral sclerosis 26 with or without frontotemporal dementia, 619133 (3),
TIAF1		
TIAL1		
TIAM1	AR	neurodevelopmental disorder with language delay and seizures, 619908 (3),
TIAM2		
TIAR		
TIARP		
TIC		
TIC1		
TICAM-1	AR,AD	{encephalopathy, acute, infection-induced (herpes-specific), susceptibility to, 6}, 614850 (3),
TICAM-2		
TICAM1	AR,AD	{encephalopathy, acute, infection-induced (herpes-specific), susceptibility to, 6}, 614850 (3),
TICAM2		
TICRR		
TID1		
TID3		
TIE	AD	lymphatic malformation 11, 619401 (3),
TIE-2	AD	venous malformations, multiple cutaneous and mucosal, 600195 (3), ; glaucoma 3, primary congenital, e, 617272 (3),
TIE1	AD	lymphatic malformation 11, 619401 (3),
TIE2	AD	venous malformations, multiple cutaneous and mucosal, 600195 (3), ; glaucoma 3, primary congenital, e, 617272 (3),
TIED		
TIEG		
TIEG1		
TIEG2		maturity-onset diabetes of the young, type vii, 610508 (3)
Tieg3		maturity-onset diabetes of the young, type vii, 610508 (3)
Tif		
TIF-IA		
TIF1		
TIF1-beta		
Tif1a		
TIF1A		
TIF1B		
TIF1beta		
TIF1D		
TIF1G		
TIF1GAMMA		
TIF2		
TIF32		
TIFa		
TIFA		
TIFAA		
TIFAB		
Tiff66		
TIFGAMMA		
TIFIL-23		
TIG-1		
TIG1		
TIG2		
TIG3		
TIGAR		
TIGD1		
TIGD2		
TIGD3		
TIGD7		
TIGIRR-1		
TIGIRR-2	XL,XLR	intellectual developmental disorder, 21, 300143 (3),
TIGIT		
TIGM1	AR	polycystic kidney disease 4, with or without hepatic disease, 263200 (3),
TIGR	AD	glaucoma 1a, primary open angle, 137750 (3),
TIH1		
TIH2		
TIKI1		
TIKI2		
TIL3	AD	{melioidosis, susceptibility to}, 615557 (3), ; {systemic lupus erythematosus, susceptibility to, 1}, 601744 (3); {systemic lupus erythematosus, resistance to}, 601744 (3); {legionnaire disease, susceptibility to}, 608556 (3)
TIL4	AD	{colorectal cancer, susceptibility to}, 114500 (3), somatic mutation, ; {leprosy, susceptibility to}, 246300 (3), ; {mycobacterium tuberculosis, susceptibility to}, 607948 (3)
tilB	AR	ciliary dyskinesia, primary, 19, 614935 (3),
TILRR	AR,AD	manitoba oculotrichoanal syndrome, 248450 (3), ; bifid nose with or without anorectal and renal anomalies, 608980 (3), ; trigonocephaly 2, 614485 (3),
TILZ2		
TILZ4a		
TILZ4b		
TILZ4c		
TIM	AD	?advance sleep phase syndrome, familial, 4, 620015 (3),
TIM-1		
Tim-3	AR	t-cell lymphoma, subcutaneous panniculitis-like, 618398 (3),
TIM1	AD	?advance sleep phase syndrome, familial, 4, 620015 (3),
TIM10		
TIM10A		
TIM10B		
Tim13		
Tim14	AR	3-methylglutaconic aciduria, type v, 610198 (3),
Tim16	AR	spondylometaphyseal dysplasia, megarbane-dagher-melike type, 613320 (3),
TIM17		
TIM17A		
TIM21		
TIM22	AR	?combined oxidative phosphorylation deficiency 43, 618851 (3),
TIM23		
TIM29		
TIM3	AR	t-cell lymphoma, subcutaneous panniculitis-like, 618398 (3),
TIM4		
TIM44		
TIM50	AR	3-methylglutaconic aciduria, type ix, 617698 (3),
TIM50L	AR	3-methylglutaconic aciduria, type ix, 617698 (3),
TIM8B		
TIM9A		
Tim9b		
TIMAP		
TIMD1		
TIMD3	AR	t-cell lymphoma, subcutaneous panniculitis-like, 618398 (3),
TIMD4		
TIMELESS	AD	?advance sleep phase syndrome, familial, 4, 620015 (3),
TIMM10		
TIMM10A		
TIMM10B		
TIMM13		
TIMM13B		
TIMM14	AR	3-methylglutaconic aciduria, type v, 610198 (3),
TIMM16	AR	spondylometaphyseal dysplasia, megarbane-dagher-melike type, 613320 (3),
TIMM17A		
TIMM17B		
TIMM21		
TIMM22	AR	?combined oxidative phosphorylation deficiency 43, 618851 (3),
TIMM23		
TIMM29		
TIMM40		
TIMM44		
TIMM50	AR	3-methylglutaconic aciduria, type ix, 617698 (3),
TIMM8A	XLR,XL	mohr-tranebjaerg syndrome, 304700 (3),
TIMM8B		
TIMM9		
TIMMDC1	AR	mitochondrial complex i deficiency, nuclear type 31, 618251 (3),
TIMP		
TIMP1		
TIMP2		
TIMP3	AD	sorsby fundus dystrophy, 136900 (3),
TIMP4		
TIN1		
TIN2	AD	dyskeratosis congenita, 3, 613990 (3), ; revesz syndrome, 268130 (3),
TINAG		
TINAGL1		
TINAGRP		
TINCR		
TINF1		
TINF2	AD	dyskeratosis congenita, 3, 613990 (3), ; revesz syndrome, 268130 (3),
Tino		
TINP1		
Tint1	AR,AD	?dyskeratosis congenita, 7, 616553 (3), ; ?dyskeratosis congenita, 6, 616553 (3),
TINUR	AD	intellectual developmental disorder with language impairment and early-onset dopa-responsive dystonia-parkinsonism, 619911 (3),
TIP		
TIP-1		
TIP-2	AD	oculopharyngodistal myopathy 2, 618940 (3),
TIP-33		
TIP-40		
TIP-43		
TIP110		
TIP120		
TIP120A		
TIP120B		
TIP150		
TIP27		
TIP3	AD	autoinflammatory syndrome, familial, with or without immunodeficiency, 619375 (3),
TIP30		
TIP39		
TIP41		
TIP47		
TIP48		
TIP49		
TIP49a		
TIP49b		
TIP5		
TIP60	AD	neurodevelopmental disorder with dysmorphic facies, sleep disturbance, and brain abnormalities, 619103 (3),
TIPARP		
TIPIN		
TIPRL		
TIPRL1		
TIPUH1		
TIR8		
TIRAP		{malaria, protection against}, 611162 (3); {tuberculosis, protection against}, 607948 (3); {bacteremia, protection against}, 614382 (3)
TIRC7	AR	osteopetrosis, 1, 259700 (3),
TIRP		
TIRR		
TIS11		
TIS11B		
TIS11D	AR	oocyte/zygote/embryo maturation arrest 13, 620154 (3),
TIS21		
TIS7		
TIS8		
Tisp78		
TITF1	AD	chorea, hereditary benign, 118700 (3), ; {thyroid cancer, nonmedullary, 1}, 188550 (3), ; choreoathetosis, hypothyroidism, and neonatal respiratory distress, 610978 (3),
TITF2	AR,AD	bamforth-lazarus syndrome, 241850 (3), ; {thyroid cancer, nonmedullary, 4}, 616534 (3),
TIX1		
TIZ		
TJ6	AR	wrinkly skin syndrome, 278250 (3), ; cutis laxa, type iia, 219200 (3),
TJ6M	AR	wrinkly skin syndrome, 278250 (3), ; cutis laxa, type iia, 219200 (3),
TJ6s	AR	wrinkly skin syndrome, 278250 (3), ; cutis laxa, type iia, 219200 (3),
TJAP1		
TJP1		
TJP2	AR	hypercholanemia, familial 1, 607748 (3), ; cholestasis, progressive familial intrahepatic 4, 615878 (3),
TJP3		
TJP4		
TK1		
TK14	AD	bent bone dysplasia syndrome, 614592 (3), ; ladd syndrome 1, 149730 (3), ; antley-bixler syndrome without genital anomalies or disordered steroidogenesis, 207410 (3), ; scaphocephaly and axenfeld-rieger anomaly (3); jackson-weiss syndrome, 123150 (3), ; gastric cancer, somatic, 613659 (3); craniofacial-skeletal-dermatologic dysplasia, 101600 (3), ; apert syndrome, 101200 (3), ; pfeiffer syndrome, 101600 (3), ; craniosynostosis, nonspecific (3); ?scaphocephaly, maxillary retrusion, and impaired intellectual development, 609579 (3); beare-stevenson cutis gyrata syndrome, 123790 (3), ; crouzon syndrome, 123500 (3), ; saethre-chotzen syndrome, 101400 (3),
TK2	AR	mitochondrial dna depletion syndrome 2 (myopathic type), 609560 (3), ; ?progressive external ophthalmoplegia with mitochondrial dna deletions, 3, 617069 (3),
TK25	AD	bent bone dysplasia syndrome, 614592 (3), ; ladd syndrome 1, 149730 (3), ; antley-bixler syndrome without genital anomalies or disordered steroidogenesis, 207410 (3), ; scaphocephaly and axenfeld-rieger anomaly (3); jackson-weiss syndrome, 123150 (3), ; gastric cancer, somatic, 613659 (3); craniofacial-skeletal-dermatologic dysplasia, 101600 (3), ; apert syndrome, 101200 (3), ; pfeiffer syndrome, 101600 (3), ; craniosynostosis, nonspecific (3); ?scaphocephaly, maxillary retrusion, and impaired intellectual development, 609579 (3); beare-stevenson cutis gyrata syndrome, 123790 (3), ; crouzon syndrome, 123500 (3), ; saethre-chotzen syndrome, 101400 (3),
TKA-1		
TKAL754		
TKFC	AR	triokinase and fmn cyclase deficiency syndrome, 618805 (3),
TKL		
TKR		
TKT	AR,AD,AR	short stature, developmental delay, and congenital heart defects, 617044 (3), |warburg-cinotti syndrome, 618175 (3), ; spondylometaepiphyseal dysplasia, short limb-hand type, 271665 (3),
TKT2		
TKTL1		
TL-PST		
TL1		
TL1A		
TL2		
TL6		
TLA519		
TLAP		
TLC		
TLCD3A		
TLCD3B	AR	cone-rod dystrophy 22, 619531 (3),
TLCD6	AR	ceroid lipofuscinosis, neuronal, 8, northern epilepsy variant, 610003 (3), ; ceroid lipofuscinosis, neuronal, 8, 600143 (3),
TLCN		
TLDC1		
TLDC3	AR	cerebellar hypoplasia/atrophy, epilepsy, and global developmental delay, 213000 (3),
TLDC4		
TLDC5		
TLDC5B		
TLDC6	AR,AD	deafness, 86, 614617 (3), ; epilepsy, rolandic, with paroxysmal exercise-induce dystonia and writer's cramp, 608105 (3), ; myoclonic epilepsy, infantile, familial, 605021 (3), ; deafness, 65, 616044 (3), ; developmental and epileptic encephalopathy 16, 615338 (3), ; doors syndrome, 220500 (3),
TLE-1		
TLE1		
TLE2		
TLE3		
TLE4		
TLE5		
TLE6	AR	oocyte/zygote/embryo maturation arrest 15, 616814 (3),
TLF		
TLH	AR	bruck syndrome 2, 609220 (3),
TLH29		
TLH6	AR	hyperoxaluria, primary, type 1, 259900 (3),
TLIMP		
TLiSA1		
TLK1		
TLK2	AD	intellectual developmental disorder, 57, 618050 (3),
TLL		
TLL1	AD	atrial septal defect 6, 613087 (3),
TLL2		
TLLR		
TLN		
TLN1		
TLN2		
TLNRD1		
TLOC1		
TLP		
TLP1		
TLP19		
TLR-4		
TLR1		{leprosy, susceptibility to, 5}, 613223 (3); {leprosy, protection against}, 613223 (3)
TLR10		
TLR2	AD	{colorectal cancer, susceptibility to}, 114500 (3), somatic mutation, ; {leprosy, susceptibility to}, 246300 (3), ; {mycobacterium tuberculosis, susceptibility to}, 607948 (3)
TLR3	AR,AD	{hiv1 infection, resistance to}, 609423 (3); {immunodeficiency 83, susceptibility to viral infections}, 613002 (3),
TLR4		
TLR5	AD	{melioidosis, susceptibility to}, 615557 (3), ; {systemic lupus erythematosus, susceptibility to, 1}, 601744 (3); {systemic lupus erythematosus, resistance to}, 601744 (3); {legionnaire disease, susceptibility to}, 608556 (3)
TLR6		
TLR7	XL,XLR,XLD	immunodeficiency 74, covid19-related, 301051 (3), ; systemic lupus erythematosus 17, 301080 (3),
TLR8	XL	immunodeficiency 98 with autoinflammation, 301078 (3), somatic mosaicism,
TLR9		
TLS	AD	amyotrophic lateral sclerosis 6, with or without frontotemporal dementia, 608030 (3); essential tremor, hereditary, 4, 614782 (3),
TLSF-a		{aids, resistance to}, 609423 (3)
TLSF-b		{aids, resistance to}, 609423 (3)
TLSP		
TLT1		
TLT2		
TLT3		
TLT4		
TLX	AR,AD	{hemolytic uremic syndrome, atypical, susceptibility to, 2}, 612922 (3),
TLX1		
TLX1NB		
TLX2		
TLX3		
TM-8		
TM-PAP		
TM14		
TM2D1		
TM2D2		
TM2D3		
TM4-A		
TM4-B		
TM4SF1		
TM4SF10		
TM4SF11		
TM4SF12	AD	exudative vitreoretinopathy 5, 613310 (3),
TM4SF13		
TM4SF15		
TM4SF16		
TM4SF2	XL,XLR	intellectual developmental disorder, 58, 300210 (3),
TM4SF20	AD	{specific language impairment 5}, 615432 (3),
TM4SF3		
TM4SF4		
TM4SF5		
TM4SF6		
TM4SF7		
TM4SF8		
TM4SF9		
TM6P1		
TM6SF1		
TM6SF2		
TM7LN1		
TM7LN2	XL	congenital bilateral absence of vas deferens, 300985 (3),
TM7LN3		
TM7LN4	AR	polymicrogyria, bilateral frontoparietal, 606854 (3), ; polymicrogyria, bilateral perisylvian, 615752 (3)
TM7SF1		
TM7SF2		
TM7SF3		
TM7SF4		
TM7XN1	AR	polymicrogyria, bilateral frontoparietal, 606854 (3), ; polymicrogyria, bilateral perisylvian, 615752 (3)
TM9SF1		
TM9SF2		
TM9SF3		
TM9SF4		
TMA24		
TMA7		
TMAP		
TMBIM1		
TMBIM2		
TMBIM3		
TMBIM4		
TMBIM5		
TMBIM6		
TMC	AD,AR	congenital disorder of glycosylation, type iw, 619714 (3), ; congenital disorder of glycosylation, type iw, 615596 (3),
TMC1	AD,AR	deafness, 36, 606705 (3), ; deafness, 7, 600974 (3),
TMC2		
TMC3		
TMC4		
TMC5		
TMC6	AR	epidermodysplasia verruciformis, 226400 (3),
TMC7		
TMC8	AR	epidermodysplasia verruciformis 2, 618231 (3),
TMCC1		
TMCC2		
TMCC3		
TMCC4	AR	craniofacial dysmorphism, skeletal anomalies, and impaired intellectual development 1, 213980 (3),
TMCO1	AR	craniofacial dysmorphism, skeletal anomalies, and impaired intellectual development 1, 213980 (3),
TMCO3		
TMCO7		
TMD	AR,AD	muscular dystrophy, limb-girdle, 10, 608807 (3), ; cardiomyopathy, familial hypertrophic, 9, 613765 (3), ; congenital myopathy 5 with cardiomyopathy, 611705 (3), ; tibial muscular dystrophy, tardive, 600334 (3), ; cardiomyopathy, dilated, 1g, 604145 (3), ; myopathy, myofibrillar, 9, with early respiratory failure, 603689 (3),
tMDCIII		
TMDP		
TMED1		
TMED10		
TMED2		
TMED4		
TMED5		
TMED7		
TMEFF1		
TMEFF2		
TMEM1	AR	neurodevelopmental disorder with microcephaly, short stature, and speech delay, 620027 (3),
TMEM10		
TMEM100		
TMEM102		
TMEM103		
TMEM106B	AD	leukodystrophy, hypomyelinating, 16, 617964 (3),
TMEM107	AR	orofaciodigital syndrome xvi, 617563 (3), ; meckel syndrome 13, 617562 (3), ; ?joubert syndrome 29, 617562 (3),
TMEM108		
TMEM109		
TMEM11		
TMEM110		
TMEM111		
TMEM112	AR	lipase deficiency, combined, 246650 (3),
TMEM112A	AR	lipase deficiency, combined, 246650 (3),
TMEM113		
TMEM114		
TMEM115		
TMEM118		
TMEM119		
TMEM12		
TMEM120A		
TMEM120B		
TMEM122		
TMEM123		
TMEM126A	AR	optic atrophy 7, 612989 (3),
TMEM126B	AR	mitochondrial complex i deficiency, nuclear type 29, 618250 (3),
TMEM127	AD	{pheochromocytoma, susceptibility to}, 171300 (3),
TMEM129		
TMEM13		
TMEM131		
TMEM131L		
TMEM132A		
TMEM132B		
TMEM132D		
TMEM132E	AR	deafness, 99, 618481 (3),
TMEM133		
TMEM135		
TMEM138	AR	joubert syndrome 16, 614465 (3),
TMEM139		
TMEM142A	AR,AD	immunodeficiency 9, 612782 (3), ; myopathy, tubular aggregate, 2, 615883 (3),
TMEM142B		
TMEM142C		
TMEM144		
TMEM146		
TMEM147	AR	neurodevelopmental disorder with facial dysmorphism, absent language, and pseudo-pelger-huet anomaly, 620075 (3),
TMEM149		
TMEM14A		
TMEM14B		
TMEM14C		
TMEM15	AR	congenital disorder of glycosylation, type im, 610768 (3),
TMEM150		
TMEM150A		
TMEM150B		
TMEM150C		
TMEM151	AD	episodic kinesigenic dyskinesia 3, 620245 (3),
TMEM151A	AD	episodic kinesigenic dyskinesia 3, 620245 (3),
TMEM158		
TMEM159		
TMEM160		
TMEM161A		
TMEM163	AD	leukodystrophy, hypomyelinating, 25, 620243 (3),
TMEM165	AR	congenital disorder of glycosylation, type iik, 614727 (3),
TMEM166		
TMEM167		
TMEM167A		
TMEM16A	AR	?intestinal dysmotility syndrome, 620045 (3),
TMEM16B		
TMEM16C	AD	dystonia 24, 615034 (3),
TMEM16D		
TMEM16E	AR,AD	muscular dystrophy, limb-girdle, 12, 611307 (3), ; miyoshi muscular dystrophy 3, 613319 (3), ; gnathodiaphyseal dysplasia, 166260 (3),
TMEM16F	AR	scott syndrome, 262890 (3),
TMEM16G		
TMEM16H		
TMEM16J		
TMEM16K	AR	spinocerebellar ataxia, 10, 613728 (3),
TMEM17		
TMEM173	AD	sting-associated vasculopathy, infantile-onset, 615934 (3),
TMEM174		
TMEM175		
TMEM176A		
TMEM176B		
TMEM18		
TMEM181		
TMEM183B		
TMEM183BP		
TMEM184C		
TMEM185A		
TMEM187		
TMEM188		
TMEM189		
TMEM194		
TMEM194A		
TMEM194B		
TMEM195		
TMEM199	AR	congenital disorder of glycosylation, type iip, 616829 (3),
TMEM2		
TMEM20		
TMEM203		
TMEM204		
TMEM205		
TMEM206		
TMEM207		
TMEM214		
TMEM216	AR	joubert syndrome 2, 608091 (3), ; meckel syndrome 2, 603194 (3),
TMEM218	AR	joubert syndrome 39, 619562 (3),
TMEM219		
TMEM22		
TMEM222	AR	neurodevelopmental disorder with motor and speech delay and behavioral abnormalities, 619470 (3),
TMEM224		
TMEM226	AR	carey-fineman-ziter syndrome, 254940 (3),
TMEM227		
TMEM228		
TMEM229B		
TMEM23		
TMEM230		
TMEM231	AR	joubert syndrome 20, 614970 (3), ; meckel syndrome 11, 615397 (3),
TMEM232		
TMEM233		
TMEM234		
TMEM235		
TMEM237	AR	joubert syndrome 14, 614424 (3),
TMEM24		
TMEM240	AD	spinocerebellar ataxia 21, 607454 (3),
TMEM241		
TMEM243		
TMEM245		
TMEM246		
TMEM24L		
TMEM25		
TMEM251	AR	dysostosis multiplex, ain-naz type, 619345 (3),
TMEM256		
TMEM257	XL	intellectual developmental disorder, 111, 301107 (3),
TMEM258		
TMEM259		
TMEM26		
TMEM260	AR	structural heart defects and renal anomalies syndrome, 617478 (3),
TMEM261		
TMEM266		
TMEM27		
TMEM270		
TMEM2L		
TMEM3		
TMEM30A		
TMEM30B		
TMEM30C		
TMEM30CP		
TMEM31		
TMEM32		
TMEM33		
TMEM34		
TMEM37		
TMEM38A		
TMEM38B	AR	osteogenesis imperfecta, type xiv, 615066 (3),
TMEM4		
TMEM41B		
TMEM43	AD	arrhythmogenic right ventricular dysplasia 5, 604400 (3), ; auditory neuropathy, 3, 619832 (3), ; emery-dreifuss muscular dystrophy 7, ad, 614302 (3),
TMEM45A		
TMEM45C		
TMEM46		
TMEM47		
TMEM48		
TMEM49		
TMEM5	AR	muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 10, 615041 (3),
TMEM50A		
TMEM50B		
TMEM53	AR	craniotubular dysplasia, ikegawa type, 619727 (3),
TMEM55A		
TMEM55B		
TMEM57		
TMEM58		
TMEM59		
TMEM59L		
TMEM6		
TMEM63A	AD	leukodystrophy, hypomyelinating, 19, transient infantile, 618688 (3),
TMEM63B		
TMEM63C	AR	spastic paraplegia 87, 619966 (3),
TMEM65		
TMEM66		
TMEM67	AR	nephronophthisis 11, 613550 (3), ; {bardet-biedl syndrome 14, modifier of}, 615991 (3), ; joubert syndrome 6, 610688 (3), ; meckel syndrome 3, 607361 (3), ; ?rhyns syndrome, 602152 (3), ; coach syndrome 1, 216360 (3),
TMEM7		
TMEM70	AR	mitochondrial complex v (atp synthase) deficiency, nuclear type 2, 614052 (3),
TMEM71		
TMEM74		
TMEM76	AR	mucopolysaccharidosis type iiic (sanfilippo c), 252930 (3), ; retinitis pigmentosa 73, 616544 (3),
TMEM77	AR	cone-rod dystrophy 21, 616502 (3),
TMEM79		
TMEM8		
TMEM80		
TMEM84		
TMEM85		
TMEM86B		
TMEM87B		
TMEM88		
TMEM8A		
TMEM8B		
TMEM8C	AR	carey-fineman-ziter syndrome, 254940 (3),
TMEM9		
TMEM90A		
TMEM90B		
TMEM91		
TMEM92		
TMEM93		
TMEM94	AR	intellectual developmental disorder with cardiac defects and dysmorphic facies, 618316 (3),
TMEM95		
TMEM96		
TMEM97		
TMEM98	AD	nanophthalmos 4, 615972 (3),
TMEM9A		
TMEM9B		
TMEPAI		
TMF		
TMF1		
TMG3		
TMG4		
Tmhs	AR	deafness, 67, 610265 (3),
TMIE	AR	deafness, 6, 600971 (3),
TMIGD2		
TML1		leukemia/lymphoma, t-cell, 603769 (2)
TMLH	XL,XLR	{autism, susceptibility to, 6}, 300872 (3),
TMLHE	XL,XLR	{autism, susceptibility to, 6}, 300872 (3),
TMOD		
TMOD1		
TMOD2		
TMOD3		
TMOD4		
TMP		
TMP10		
TMP21		
TMPIT		
TMPK	AR	neurodegeneration, childhood-onset, with progressive microcephaly, 619847 (3),
TMPO		
TMPRSS1		
TMPRSS10		preeclampsia/eclampsia 5, 614595 (3)
TMPRSS11		
TMPRSS11A		
TMPRSS11D		
TMPRSS11E		
TMPRSS11E2		
TMPRSS13		
TMPRSS14	AR	ichthyosis, congenital, 11, 602400 (3),
TMPRSS15	AR	enterokinase deficiency, 226200 (3),
TMPRSS2		
TMPRSS3	AR	deafness, 8/10, 601072 (3),
TMPRSS4		
TMPRSS5		
TMPRSS6	AR	iron-refractory iron deficiency anemia, 206200 (3),
TMPRSS9		
TMPT27	AR	congenital disorder of glycosylation, type iik, 614727 (3),
TMS		dyskeratosis congenita, digenic, 620040 (3), digenic
TMS-1		
TMS-2		
TMSA		
TMSB10		
TMSB15A		
TMSB15B		
TMSB4		
TMSB4X		
TMSB4Y		
TMSL8		
TMSNB		
TMT		
TMT1A		
TMTC1		
TMTC2		
TMTC3	AR	lissencephaly 8, 617255 (3),
TMTC4		
TMTSP	AD,AR	?aneurysm, intracranial berry, 12, 618734 (3), ; lymphatic malformation 13, 620244 (3),
TMUB1		
TMVCF		
TMX		
TMX1		
TMX2	AR	neurodevelopmental disorder with microcephaly, cortical malformations, and spasticity, 618730 (3),
TMX3		
TMX4		
TN	AD,AD	deafness, 56, 615629 (3), |macular dystrophy, retinal, 4, 619977 (3),
TN-X	AR,AD	ehlers-danlos syndrome, classic-like, 1, 606408 (3), ; vesicoureteral reflux 8, 615963 (3),
TNA	AD	macular dystrophy, retinal, 4, 619977 (3),
TNaC1		
TNALP	AR,AD	odontohypophosphatasia, 146300 (3), ; hypophosphatasia, infantile, 241500 (3), ; hypophosphatasia, childhood, 241510 (3), ; hypophosphatasia, adult, 146300 (3),
TNAP	AR,AD	odontohypophosphatasia, 146300 (3), ; hypophosphatasia, infantile, 241500 (3), ; hypophosphatasia, childhood, 241510 (3), ; hypophosphatasia, adult, 146300 (3),
TNC	AD	deafness, 56, 615629 (3),
TncRNA		
TNDM2	AR,AD	diabetes mellitus, permanent neonatal 3, with or without neurologic features, 618857 (3), ; diabetes mellitus, transient neonatal 2, 610374 (3); diabetes mellitus, noninsulin-dependent, 125853 (3), ; hypoglycemia of infancy, leucine-sensitive, 240800 (3), ; hyperinsulinemic hypoglycemia, familial, 1, 256450 (3),
TNF	AD	{migraine without aura, susceptibility to}, 157300 (3), ; {dementia, vascular, susceptibility to} (3); {asthma, susceptibility to}, 600807 (3), ; {septic shock, susceptibility to} (3); {malaria, cerebral, susceptibility to}, 611162 (3)
TNF-alpha	AD	{migraine without aura, susceptibility to}, 157300 (3), ; {dementia, vascular, susceptibility to} (3); {asthma, susceptibility to}, 600807 (3), ; {septic shock, susceptibility to} (3); {malaria, cerebral, susceptibility to}, 611162 (3)
TNF-R	AD	{multiple sclerosis, susceptibility to, 5}, 614810 (3); periodic fever, familial, 142680 (3),
TNF-R-I	AD	{multiple sclerosis, susceptibility to, 5}, 614810 (3); periodic fever, familial, 142680 (3),
TNF-R-II		
TNF-R-III		
TNF-R55	AD	{multiple sclerosis, susceptibility to, 5}, 614810 (3); periodic fever, familial, 142680 (3),
TNF-R75		
TNFA	AD	{migraine without aura, susceptibility to}, 157300 (3), ; {dementia, vascular, susceptibility to} (3); {asthma, susceptibility to}, 600807 (3), ; {septic shock, susceptibility to} (3); {malaria, cerebral, susceptibility to}, 611162 (3)
TNFAIP1		
TNFAIP2		
TNFAIP3	AD	autoinflammatory syndrome, familial, behcet-like 1, 616744 (3),
TNFAIP4		
TNFAIP5		
TNFAIP6		
TNFAIP8		
TNFAIP8L1		
TNFAIP8L2		
TNFAIP8L3		
TNFAIP9		
TNFAR	AD	{multiple sclerosis, susceptibility to, 5}, 614810 (3); periodic fever, familial, 142680 (3),
TNFB		{psoriatic arthritis, susceptibility to}, 607507 (3); {myocardial infarction, susceptibility to}, 608446 (3); {leprosy, susceptibility to, 4}, 610988 (3)
TNFBR		
TNFC		
TNFCR		
TNFR-RP		
TNFR1	AD	{multiple sclerosis, susceptibility to, 5}, 614810 (3); periodic fever, familial, 142680 (3),
TNFR2		
TNFR2-RP		
TNFR60	AD	{multiple sclerosis, susceptibility to, 5}, 614810 (3); periodic fever, familial, 142680 (3),
TNFR80		
TNFRSF10A		
TNFRSF10B	AR	squamous cell carcinoma, head and neck, 275355 (3),
TNFRSF10C		
TNFRSF10D		
TNFRSF11A	AR,AD	osteopetrosis, 7, 612301 (3), ; {paget disease of bone 2, early-onset}, 602080 (3), ; osteolysis, familial expansile, 174810 (3),
TNFRSF11B	AR	paget disease of bone 5, juvenile-onset, 239000 (3),
TNFRSF12		
TNFRSF12A		
TNFRSF13A		
TNFRSF13B	AR,AD	immunodeficiency, common variable, 2, 240500 (3), ; immunoglobulin a deficiency 2, 609529 (3)
TNFRSF13C	AR	immunodeficiency, common variable, 4, 613494 (3),
TNFRSF14		
TNFRSF16		
TNFRSF17		
TNFRSF18		
TNFRSF19		
TNFRSF19L	AR	amelogenesis imperfecta, type iiic, 618386 (3),
TNFRSF1A	AD	{multiple sclerosis, susceptibility to, 5}, 614810 (3); periodic fever, familial, 142680 (3),
TNFRSF1B		
TNFRSF21		
TNFRSF25		
TNFRSF27		
TNFRSF3		
TNFRSF4	AR	?immunodeficiency 16, 615593 (3),
TNFRSF5	AR	immunodeficiency with hyper-igm, type 3, 606843 (3),
TNFRSF6	AD	squamous cell carcinoma, burn scar-related, somatic (3); autoimmune lymphoproliferative syndrome, type ia, 601859 (3), ; {autoimmune lymphoproliferative syndrome}, 601859 (3),
TNFRSF6B		
TNFRSF7	AR	lymphoproliferative syndrome 2, 615122 (3),
TNFRSF8		
TNFRSF9	AR	immunodeficiency 109 with lymphoproliferation, 620282 (3),
TNFSF1		{psoriatic arthritis, susceptibility to}, 607507 (3); {myocardial infarction, susceptibility to}, 608446 (3); {leprosy, susceptibility to, 4}, 610988 (3)
TNFSF10		
TNFSF11	AR	osteopetrosis, 2, 259710 (3),
TNFSF12		
TNFSF13		
TNFSF13B		
TNFSF14		
TNFSF15		
TNFSF18		
TNFSF2	AD	{migraine without aura, susceptibility to}, 157300 (3), ; {dementia, vascular, susceptibility to} (3); {asthma, susceptibility to}, 600807 (3), ; {septic shock, susceptibility to} (3); {malaria, cerebral, susceptibility to}, 611162 (3)
TNFSF20		
TNFSF3		
TNFSF3L		
TNFSF4		{myocardial infarction, susceptibility to}, 608446 (3)
TNFSF5	XL,XLR	immunodeficiency, with hyper-igm, 308230 (3),
TNFSF5IP1	AR	?proteasome-associated autoinflammatory syndrome 4, 619183 (3),
TNFSF6	AD	autoimmune lymphoproliferative syndrome, type ib, 601859 (3), ; {lung cancer, susceptibility to}, 211980 (3), somatic mutation,
TNFSF7	AR	lymphoproliferative syndrome 3, 618261 (3),
TNFSF8		
TNFSF9		
TNG1		
TNG2		
TNIK	AR	intellectual developmental disorder, 54, 617028 (3),
TNIP1		
TNIP2		
TNIP3		
TNK1		
TNK2		
TNKL		
TNKS		
TNKS1		
TNKS1BP1		
TNKS2		
TNL		
TNM		
TNMD		
TNN		
TNNC	AD	cardiomyopathy, dilated, 1z, 611879 (3); cardiomyopathy, hypertrophic, 13, 613243 (3),
TNNC1	AR,AD,AD	?cardiomyopathy, dilated, 2a, 611880 (3), ; cardiomyopathy, hypertrophic, 7, 613690 (3), ; cardiomyopathy, familial restrictive, 1, 115210 (3), ; cardiomyopathy, dilated, 1ff, 613286 (3)|cardiomyopathy, dilated, 1z, 611879 (3); cardiomyopathy, hypertrophic, 13, 613243 (3),
TNNC2	AD	congenital myopathy 15, 620161 (3),
TNNI1		
TNNI2	AD	arthrogryposis, distal, type 2b1, 601680 (3),
TNNI3	AR,AD	?cardiomyopathy, dilated, 2a, 611880 (3), ; cardiomyopathy, hypertrophic, 7, 613690 (3), ; cardiomyopathy, familial restrictive, 1, 115210 (3), ; cardiomyopathy, dilated, 1ff, 613286 (3)
TNNI3K	AD	cardiac conduction disease with or without dilated cardiomyopathy, 616117 (3),
TNNT1	AD,AR	nemaline myopathy 5c, 620389 (3), ; nemaline myopathy 5a, severe infantile, 605355 (3), ; nemaline myopathy 5b, childhood-onset, 620386 (3),
TNNT2	AD	cardiomyopathy, dilated, 1d, 601494 (3), ; cardiomyopathy, hypertrophic, 2, 115195 (3), ; cardiomyopathy, familial restrictive, 3, 612422 (3), ; left ventricular noncompaction 6, 601494 (3),
TNNT3	AD	arthrogryposis, distal, type 2b2, 618435 (3),
tNOX		
TNP1		
TNP2		
TNPO1		
TNPO2	AD	intellectual developmental disorder with hypotonia, impaired speech, and dysmorphic facies, 619556 (3),
TNPO3	AD	muscular dystrophy, limb-girdle, 2, 608423 (3),
TNR	AR	neurodevelopmental disorder, nonprogressive, with spasticity and transient opisthotonus, 619653 (3),
TNR-CFTR	AR,AD	cystic fibrosis, 219700 (3), ; sweat chloride elevation without cf (3); congenital bilateral absence of vas deferens, 277180 (3), ; {pancreatitis, hereditary}, 167800 (3), ; {bronchiectasis with or without elevated sweat chloride 1, modifier of}, 211400 (3), ; {hypertrypsinemia, neonatal} (3)
TNRC1		
TNRC10	AD	speech-language disorder-1, 602081 (3),
TNRC11	XLR,XL,XLD	lujan-fryns syndrome, 309520 (3), ; ohdo syndrome, 300895 (3), ; hardikar syndrome, 301068 (3), ; opitz-kaveggia syndrome, 305450 (3),
TNRC11L	AD	nizon-isidor syndrome, 618872 (3),
TNRC12		
TNRC13	AD,MF	{amyotrophic lateral sclerosis, susceptibility to, 13}, 183090 (3), ; spinocerebellar ataxia 2, 183090 (3), ; {parkinson disease, late-onset, susceptibility to}, 168600 (3),
TNRC14		
TNRC15		{parkinson disease 11}, 607688 (3)
TNRC16		
TNRC19		
TNRC2		
TNRC20		
TNRC21	AD	branchial arch abnormalities, choanal atresia, athelia, hearing loss, and hypothyroidism syndrome, 620186 (3), ; kabuki syndrome 1, 147920 (3),
TNRC22	AD	huntington disease-like 2, 606438 (3),
TNRC23		
TNRC3		
TNRC4		
TNRC5	AR	developmental and epileptic encephalopathy 60, 617929 (3),
TNRC6	AD	?epilepsy, familial adult myoclonic, 6, 618074 (3),
TNRC6A	AD	?epilepsy, familial adult myoclonic, 6, 618074 (3),
TNRC6B	AD	global developmental delay with speech and behavioral abnormalities, 619243 (3),
TNRC6C		
TNRC6C-AS1	AR	epidermodysplasia verruciformis, 226400 (3),
TNRC7		
TNRC8	XLR,XLD,XL	intellectual developmental disorder, with or without nystagmus, 300422 (3), ; intellectual developmental disorder and microcephaly with pontine and cerebellar hypoplasia, 300749 (3), ; fg syndrome 4, 300422 (3),
TNRC9		
TNS		
TNS1		
TNS2		
TNS3		
TNS4		
TNSALP	AR,AD	odontohypophosphatasia, 146300 (3), ; hypophosphatasia, infantile, 241500 (3), ; hypophosphatasia, childhood, 241510 (3), ; hypophosphatasia, adult, 146300 (3),
TNT	AD,AR	nemaline myopathy 5c, 620389 (3), ; nemaline myopathy 5a, severe infantile, 605355 (3), ; nemaline myopathy 5b, childhood-onset, 620386 (3),
TNTS	AD,AR	nemaline myopathy 5c, 620389 (3), ; nemaline myopathy 5a, severe infantile, 605355 (3), ; nemaline myopathy 5b, childhood-onset, 620386 (3),
TNW		
TNX	AR,AD	ehlers-danlos syndrome, classic-like, 1, 606408 (3), ; vesicoureteral reflux 8, 615963 (3),
TNXB	AR,AD	ehlers-danlos syndrome, classic-like, 1, 606408 (3), ; vesicoureteral reflux 8, 615963 (3),
TNXB1	AR,AD	ehlers-danlos syndrome, classic-like, 1, 606408 (3), ; vesicoureteral reflux 8, 615963 (3),
TNXB2	AR,AD	ehlers-danlos syndrome, classic-like, 1, 606408 (3), ; vesicoureteral reflux 8, 615963 (3),
TNXBS	AR,AD	ehlers-danlos syndrome, classic-like, 1, 606408 (3), ; vesicoureteral reflux 8, 615963 (3),
TOB		
TOB1		
TOB2		
TOB3		
TOB4		
tob55		
TOB55		
TOBL		
TOC	AD	tylosis with esophageal cancer, 148500 (3),
TOCA1		
TOCG	AD	tylosis with esophageal cancer, 148500 (3),
TOE-1	AR	pontocerebellar hypoplasia, type 7, 614969 (3),
TOE1	AR	pontocerebellar hypoplasia, type 7, 614969 (3),
TOF		
TOG		
TOGARAM1	AR	joubert syndrome 37, 619185 (3),
TOGp		
TOK-1		
TOLLIP		
TOM	AD	retinitis pigmentosa 60, 613983 (3),
TOM1	AD	?immunodeficiency 85 and autoimmunity, 619510 (3),
TOM1L1		
TOM1L2		
TOM20		
TOM22		
TOM34		
TOM40		
Tom5		
Tom6		
Tom7		
Tom70		
TOME-1		
TOMM20		
TOMM22		
TOMM34		
TOMM40		
TOMM5		
TOMM6		
TOMM7		
TOMM70		
TOMM70A		
tomosyn		
tomosyn-1		
tomosyn-2		
TONDU		
TONEBP		
TONSL	AR	spondyloepimetaphyseal dysplasia, sponastrime type, 271510 (3),
TOP1		dna topoisomerase i, camptothecin-resistant (3)
TOP1MT		
TOP2		dna topoisomerase ii, resistance to inhibition of, by amsacrine (3)
TOP2A		dna topoisomerase ii, resistance to inhibition of, by amsacrine (3)
TOP2alpha		dna topoisomerase ii, resistance to inhibition of, by amsacrine (3)
TOP2B	AD	b-cell immunodeficiency, distal limb anomalies, and urogenital malformations, 609296 (3),
top2beta	AD	b-cell immunodeficiency, distal limb anomalies, and urogenital malformations, 609296 (3),
TOP2BP1		
TOP3	AR	?progressive external ophthalmoplegia with mitochondrial dna deletions, 5, 618098 (3), ; microcephaly, growth restriction, and increased sister chromatid exchange 2, 618097 (3),
TOP3A	AR	?progressive external ophthalmoplegia with mitochondrial dna deletions, 5, 618098 (3), ; microcephaly, growth restriction, and increased sister chromatid exchange 2, 618097 (3),
TOP3B		
TOP6BL	AR	hydatidiform mole, recurrent, 4, 618432 (3),
TOPAZ1		
TOPBP1		
TOPIIA		dna topoisomerase ii, resistance to inhibition of, by amsacrine (3)
TOPIIB	AD	b-cell immunodeficiency, distal limb anomalies, and urogenital malformations, 609296 (3),
TOPK		
TOPORS		retinitis pigmentosa 31, 609923 (3)
TOPOVIA		
TOPOVIBL	AR	hydatidiform mole, recurrent, 4, 618432 (3),
TOPVIA		
TOR	AR	immunodeficiency 42, 616622 (3),
TOR1A	AR,AD	{dystonia-1, modifier of} (3); arthrogryposis multiplex congenita 5, 618947 (3), ; dystonia-1, torsion, 128100 (3),
TOR1AIP1	AR	?muscular dystrophy, with rigid spine and distal joint contractures, 617072 (3),
TOR1AIP2		
TOR1B		
TOR2A		
TOR3A		
TORC1		mucoepidermoid salivary gland carcinoma (3)
TORC2		
TORP1		
TOSO		
TOT1	AR,AD	{medulloblastoma}, 155255 (3), somatic mutation, ; dysautonomia, familial, 223900 (3),
TOX		
TOX1		
TOX2		
TOX3		
TOX4		
TP		
TP1		
Tp120		
Tp120b		
TP15		
TP2	AD,AR	dyskeratosis congenita, 2, 613989 (3), ; dyskeratosis congenita, 4, 613989 (3), ; pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 1, 614742 (3), ; {melanoma, cutaneous malignant, 9}, 615134 (3), ; {leukemia, acute myeloid}, 601626 (3), somatic mutation,
Tp40		
TP41		
TP53	AD	{basal cell carcinoma 7}, 614740 (3), ; {adrenocortical carcinoma, pediatric}, 202300 (3), ; hepatocellular carcinoma, somatic, 114550 (3); breast cancer, somatic, 114480 (3); li-fraumeni syndrome, 151623 (3), ; pancreatic cancer, somatic, 260350 (3); nasopharyngeal carcinoma, somatic, 607107 (3); {osteosarcoma}, 259500 (3), somatic mutation; {choroid plexus papilloma}, 260500 (3), ; {colorectal cancer}, 114500 (3), somatic mutation, ; {glioma susceptibility 1}, 137800 (3), somatic mutation, ; bone marrow failure syndrome 5, 618165 (3),
TP53AIP1		
TP53AP1		
TP53BP1		
TP53BP2		
TP53BPL		retinitis pigmentosa 31, 609923 (3)
TP53COR1		
TP53CP	AD	premature ovarian failure 21, 620311 (3), ; ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3, 604292 (3), ; hay-wells syndrome, 106260 (3), ; split-hand/foot malformation 4, 605289 (3), ; orofacial cleft 8, 618149 (3); rapp-hodgkin syndrome, 129400 (3), ; adult syndrome, 103285 (3), ; limb-mammary syndrome, 603543 (3),
TP53I1		
TP53I10		
TP53I11		
TP53I12		
TP53I2	AR	cerebral creatine deficiency syndrome 2, 612736 (3),
TP53I3		
TP53I4		
TP53I5		
TP53I6	AD,AR	{schizophrenia, susceptibility to, 4}, 600850 (3), ; hyperprolinemia, type i, 239500 (3),
TP53I7	AD	charcot-marie-tooth disease, type 1c, 601098 (3),
TP53I8		
TP53I9	AR	prostate cancer, somatic, 176807 (3); mosaic variegated aneuploidy syndrome 7 with inflammation and tumor predisposition, 620189 (3), ; lymphoma, b-cell, somatic (3)
TP53INP1		
TP53INP1A		
TP53INP1B		
TP53INP2		
TP53L	AD	premature ovarian failure 21, 620311 (3), ; ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3, 604292 (3), ; hay-wells syndrome, 106260 (3), ; split-hand/foot malformation 4, 605289 (3), ; orofacial cleft 8, 618149 (3); rapp-hodgkin syndrome, 129400 (3), ; adult syndrome, 103285 (3), ; limb-mammary syndrome, 603543 (3),
TP53LC09		
TP53LC12		
TP53LC15		
TP53RK	AR	galloway-mowat syndrome 4, 617730 (3),
TP53TG1		
TP53TG3		
TP53TG3A		
TP53TG5		
Tp55	AR	lymphoproliferative syndrome 2, 615122 (3),
TP63	AD	premature ovarian failure 21, 620311 (3), ; ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3, 604292 (3), ; hay-wells syndrome, 106260 (3), ; split-hand/foot malformation 4, 605289 (3), ; orofacial cleft 8, 618149 (3); rapp-hodgkin syndrome, 129400 (3), ; adult syndrome, 103285 (3), ; limb-mammary syndrome, 603543 (3),
TP73	AR	ciliary dyskinesia, primary, 47, and lissencephaly, 619466 (3),
TP73L	AD	premature ovarian failure 21, 620311 (3), ; ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3, 604292 (3), ; hay-wells syndrome, 106260 (3), ; split-hand/foot malformation 4, 605289 (3), ; orofacial cleft 8, 618149 (3); rapp-hodgkin syndrome, 129400 (3), ; adult syndrome, 103285 (3), ; limb-mammary syndrome, 603543 (3),
TPA018		
TPA1		
tPABP		
TPAR1		{aids, resistance to}, 609423 (3)
TPARL	AR	congenital disorder of glycosylation, type iik, 614727 (3),
TPARM	AR	ciliary dyskinesia, primary, 45, 618801 (3),
TPBG		
TPC	AR	microcephaly, amish type, 607196 (3), ; thiamine metabolism dysfunction syndrome 4 (progressive polyneuropathy type), 613710 (3),
TPC1		
TPC2		[skin/hair/eye pigmentation 10, blond/brown hair], 612267 (3)
TPCN1		
TPCN2		[skin/hair/eye pigmentation 10, blond/brown hair], 612267 (3)
TPD52		
TPD52L1		
TPD52L2		
TPD52L3		
TPD53		
TPD54		
TPD55		
TPEF		
TPGS3		
TPH		
TPH1		
TPH2	AR	[?hypertryptophanemia], 600627 (3), |{?attention deficit-hyperactivity disorder, susceptibility to, 7}, 613003 (3); {unipolar depression, susceptibility to}, 608516 (3)
TPI1	AR	hemolytic anemia due to triosephosphate isomerase deficiency, 615512 (3),
TPIP		
TPIS	AR	ciliary dyskinesia, primary, 28, 615505 (3),
TPIT	AR	adrenocorticotropic hormone deficiency, 201400 (3),
TPK1	AR	thiamine metabolism dysfunction syndrome 5 (episodic encephalopathy type), 614458 (3),
Tpl-2		lung cancer, somatic, 211980 (3)
TPM1	AD	left ventricular noncompaction 9, 611878 (3), ; cardiomyopathy, hypertrophic, 3, 115196 (3), ; cardiomyopathy, dilated, 1y, 611878 (3),
TPM2	AD	arthrogryposis, distal, type 2b4, 108120 (3), ; arthrogryposis, distal, type 1a, 108120 (3), ; congenital myopathy 23, 609285 (3),
TPM3	AD,AR	congenital myopathy 4a, 255310 (3), ; congenital myopathy 4b, 609284 (3),
TPM4		
TpMs		
TPMT	AR	{thiopurines, poor metabolism of, 1}, 610460 (3),
TPN	AR	bare lymphocyte syndrome, type i, 604571 (3),
TPO	AD,AR	thrombocythemia 1, 187950 (3), |thyroid dyshormonogenesis 2a, 274500 (3),
TPO1		
TPOR	AD,AR	myelofibrosis with myeloid metaplasia, somatic, 254450 (3); thrombocythemia 2, 601977 (3), somatic mutation, ; thrombocytopenia, congenital amegakaryocytic, 604498 (3),
TPP-1	AR	ceroid lipofuscinosis, neuronal, 2, 204500 (3), ; spinocerebellar ataxia, 7, 609270 (3),
Tpp1	AR,AD	?dyskeratosis congenita, 7, 616553 (3), ; ?dyskeratosis congenita, 6, 616553 (3),
TPP1	AR	ceroid lipofuscinosis, neuronal, 2, 204500 (3), ; spinocerebellar ataxia, 7, 609270 (3),
TPP2	AR	immunodeficiency 78 with autoimmunity and developmental delay, 619220 (3),
TPPII	AR	immunodeficiency 78 with autoimmunity and developmental delay, 619220 (3),
TPPP		
TPPP/p25		
TPPP1		
TPPP2		
TPPP3		
TPPT	AD	?deafness, 72, 617606 (3),
TPR	AR	?intellectual developmental disorder, 79, 620393 (3),
TPR1		
TPR2		
TPRA1		
TPRA40		
TPRD		
TPRDI		
TPRDII		
TPRDIII		
TPRG1L		
TPRGL		
TPRH		
TPRKB	AR,AR	galloway-mowat syndrome 4, 617730 (3), |galloway-mowat syndrome 5, 617731 (3),
TPRN	AR	deafness, 79, 613307 (3),
TPRT	AR	coenzyme q10 deficiency, primary, 2, 614651 (3),
TPRX1		
TPRX2		
TPRX2P		
TPRX2P1		
TPRX3P		
TPRXL		
TPS1		
TPS2		
TPSAB1		
TPSB1		
TPSB2		
TPSD1		
TPSG1		
TPSN	AR	bare lymphocyte syndrome, type i, 604571 (3),
TPST1		
TPST2		
TPT	AR,AD	coenzyme q10 deficiency, primary, 2, 614651 (3), |microphthalmia with coloboma 5, 611638 (3), ; schizencephaly, 269160 (3); single median maxillary central incisor, 147250 (3), ; holoprosencephaly 3, 142945 (3),
TPT1		
TPTE		
TPTE1		
TPTE2		
TPTPS	AD	microphthalmia with coloboma 5, 611638 (3), ; schizencephaly, 269160 (3); single median maxillary central incisor, 147250 (3), ; holoprosencephaly 3, 142945 (3),
TPX	AR	thyroid dyshormonogenesis 2a, 274500 (3),
TPX1		
TPX2		
TR	AR,AD	?glucocorticoid deficiency 5, 617825 (3), |pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 2, 614743 (3), ; dyskeratosis congenita, 1, 127550 (3),
TR-AP	AD	?deafness, 75, 618778 (3), ; developmental delay with or without dysmorphic facies and autism, 618454 (3),
TR1	AR	paget disease of bone 5, juvenile-onset, 239000 (3),
TR2		
TR2-11		
TR2IT1		
TR2R1		
TR3	AR	?glucocorticoid deficiency 5, 617825 (3),
TR4		
TR6		
TRA-TGC7-1		
Tra1	AD	?deafness, 75, 618778 (3), ; developmental delay with or without dysmorphic facies and autism, 618454 (3),
TRA1		
TRA16		
TRA2.10	AR,AD	{hemolytic uremic syndrome, atypical, susceptibility to, 2}, 612922 (3),
TRA2A		
TRA2B		
TRAAK	AD	facial dysmorphism, hypertrichosis, epilepsy, intellectual/developmental delay, and gingival overgrowth syndrome, 618381 (3),
TRABD2A		
TRABD2B		
TRABID		
TRAC	AR	immunodeficiency 7, tcr-alpha/beta deficient, 615387 (3),
TRAC-1		
TRAC1		
TRAcP	AR	spondyloenchondrodysplasia with immune dysregulation, 607944 (3),
Trad		{breast-ovarian cancer, familial, susceptibility to, 4}, 614291 (3)
TRAD		
TRADD		
TRADE		
TRAF1		
TRAF2		
TRAF3	AD	{?encephalopathy, acute, infection-induced (herpes-specific), susceptibility to, 5}, 614849 (3),
TRAF3IP1	AR	senior-loken syndrome 9, 616629 (3),
TRAF3IP2	AR	?candidiasis, familial, 8, 615527 (3), ; {psoriasis susceptibility 13}, 614070 (3)
TRAF3IP3		
TRAF4		
TRAF4AF1		?roifman-chitayat syndrome, digenic, 613328 (3), digenic
TRAF5		
TRAF6		
TRAF7	AD	cardiac, facial, and digital anomalies with developmental delay, 618164 (3),
TRAFD1		
TRAG		
TRAG3		
TRAIL		
TRAIL-R2	AR	squamous cell carcinoma, head and neck, 275355 (3),
TRAILR-1		
TRAILR1		
TRAILR2	AR	squamous cell carcinoma, head and neck, 275355 (3),
TRAILR3		
TRAILR4		
TRAIP	AR	seckel syndrome 9, 616777 (3),
TRAITS		
TRAK1	AR	developmental and epileptic encephalopathy 68, 618201 (3),
TRAK2		
TRALP	AD	nizon-isidor syndrome, 618872 (3),
TRalpha	AD	hypothyroidism, congenital, nongoitrous, 6, 614450 (3),
TRalpha1	AD	hypothyroidism, congenital, nongoitrous, 6, 614450 (3),
TRalpha2	AD	hypothyroidism, congenital, nongoitrous, 6, 614450 (3),
TRALPUSH	AD	nizon-isidor syndrome, 618872 (3),
TRAM		
TRAM-1		
TRAM1		
TRAM1L1		
TRAM2		
TRAMD1	AR,AD	[iminoglycinuria], 242600 (3), digenic ; [hyperglycinuria], 138500 (3),
TRAMD2		
TRAMD3		
tramdorin	AR,AD	[iminoglycinuria], 242600 (3), digenic ; [hyperglycinuria], 138500 (3),
tramdorin2		
TRAMP		
TRAN		
TRANCE	AR	osteopetrosis, 2, 259710 (3),
TRANCE-R	AR,AD	osteopetrosis, 7, 612301 (3), ; {paget disease of bone 2, early-onset}, 602080 (3), ; osteolysis, familial expansile, 174810 (3),
TRANK1		
Translokin	AR	mosaic variegated aneuploidy syndrome 2, 614114 (3),
TRAP	XL,XLR,AR,AR	immunodeficiency, with hyper-igm, 308230 (3), |spinocerebellar ataxia, 21, 616719 (3), |spondyloenchondrodysplasia with immune dysregulation, 607944 (3),
TRAP-1		
TRAP1		
TRAP100		
TRAP150		
TRAP170		
TRAP2		
TRAP220		
TRAP230	XLR,XL,XLD	lujan-fryns syndrome, 309520 (3), ; ohdo syndrome, 300895 (3), ; hardikar syndrome, 301068 (3), ; opitz-kaveggia syndrome, 305450 (3),
TRAP240	AD	intellectual developmental disorder, 61, 618009 (3),
TRAP240L	AD	impaired intellectual development and distinctive facial features with or without cardiac defects, 616789 (3),
TRAP25		
TRAP3		
TRAP36		
TRAP37	AR	neurodevelopmental disorder with spasticity, cataracts, and cerebellar hypoplasia, 619286 (3),
TRAP80	AR	microcephaly, postnatal progressive, with seizures and brain atrophy, 613668 (3),
TRAP95		
TRAPA		
TRAPB		
TRAPD	XLR,XL	congenital disorder of glycosylation, type iy, 300934 (3),
TRAPG		
TRAPPC1		
TRAPPC10	AR	neurodevelopmental disorder with microcephaly, short stature, and speech delay, 620027 (3),
TRAPPC11	AR	muscular dystrophy, limb-girdle, 18, 615356 (3),
TRAPPC12	AR	encephalopathy, progressive, early-onset, with brain atrophy and spasticity, 617669 (3),
TRAPPC14	AR	?microcephaly 25, primary, 618351 (3),
TRAPPC2	XLR,XL	spondyloepiphyseal dysplasia tarda, 313400 (3),
TRAPPC2L	AR	encephalopathy, progressive, early-onset, with episodic rhabdomyolysis, 618331 (3),
TRAPPC3		
TRAPPC3L		
TRAPPC4	AR	neurodevelopmental disorder with epilepsy, spasticity, and brain atrophy, 618741 (3),
TRAPPC6A		
TRAPPC6B	AR	neurodevelopmental disorder with microcephaly, epilepsy, and brain atrophy, 617862 (3),
TRAPPC8		
TRAPPC9	AR	intellectual developmental disorder, 13, 613192 (3),
TRAR1		
TRAR3		
TRAR4		
TRAR5		
TRARG1		
TRAT1		
TRAX		
TRb	AR,AD	thyroid hormone resistance, 274300 (3), ; thyroid hormone resistance, 188570 (3), ; thyroid hormone resistance, selective pituitary, 145650 (3),
TRB1		
TRB2		
TRB3		
TRB4		
TRB5		
TRB6		
TRB7		
TRBC1		
TRBC2		
TRBD1		
TRBD2		
TRbeta	AR,AD	thyroid hormone resistance, 274300 (3), ; thyroid hormone resistance, 188570 (3), ; thyroid hormone resistance, selective pituitary, 145650 (3),
TRbeta1	AR,AD	thyroid hormone resistance, 274300 (3), ; thyroid hormone resistance, 188570 (3), ; thyroid hormone resistance, selective pituitary, 145650 (3),
TRBF1		
TRBF2		
Trbp		
TRBP		
TRC3	AD	pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 2, 614743 (3), ; dyskeratosis congenita, 1, 127550 (3),
TRC35	AR	?congenital disorder of glycosylation, type iiy, 620200 (3),
TRC40	AR	?cardiomyopathy, dilated, 2h, 620203 (3),
TRC8		renal cell carcinoma, 144700 (3)
TRDC		
TRDMT1		
TRDN	AR	cardiac arrhythmia syndrome, with or without skeletal muscle weakness, 615441 (3),
TRE	AR	trehalase deficiency, 612119 (3),
Tre-2		
TRE-TTC3-1		
TRE17		
Tre2		
TRE2NL		
TREA	AR	trehalase deficiency, 612119 (3),
treacle	AD	treacher collins syndrome 1, 154500 (3),
TREB36		
TREB7		
TREH	AR	trehalase deficiency, 612119 (3),
TREK-1		
TREK-2		
TREK2		
TREM-1		
TREM-2	AR	polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 2, 618193 (3),
TREM1		
TREM2	AR	polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 2, 618193 (3),
Trem2a	AR	polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 2, 618193 (3),
Trem2b	AR	polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 2, 618193 (3),
Trem2c	AR	polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 2, 618193 (3),
Trem4		
TREM5		
TREML1		
TREML2		
TREML3		
TREML3P		
TREML4		
TReP-132		
TRERF1		
TRESK	AD	{migraine, with or without aura, susceptibility to, 13}, 613656 (3),
TRESK-2	AD	{migraine, with or without aura, susceptibility to, 13}, 613656 (3),
TRESK2	AD	{migraine, with or without aura, susceptibility to, 13}, 613656 (3),
Treslin		
TRESMCR		
TREX1	AD,AR	vasculopathy, retinal, with cerebral leukoencephalopathy and systemic manifestations, 192315 (3), ; aicardi-goutieres syndrome 1, and , 225750 (3), ; {systemic lupus erythematosus, susceptibility to}, 152700 (3), ; chilblain lupus, 610448 (3),
TREX2		
TRF		
TRF1		
TRF2		
TRF3		
TRF4		
TRF4-1		
TRF4-2		
TRFP		
TRG-3		
TRG-CCC1-1		
TRG-GCC2-4		
TRG-GCC2-6		
TRG-TCC1-1		
TRG2		
TRG20		
TRG3		
TRGC1		
TRGC2		
TRGC2(2X)		
TRGC2(3X)		
TRH	AR	thyrotropin-releasing hormone deficiency, 275120 (1),
TRH-DE		
Trh1		
Trh4		
TRHDE		
TRHR	AR	hypothyroidism, congenital, nongoitrous, 7, 618573 (3),
TRIAD1		
TRIAD2		
TRIAD3	AR	cerebellar ataxia and hypogonadotropic hypogonadism, 212840 (3),
TRIAP1		
TRIB1		
TRIB2		
TRIB3		
TRIC	AR	deafness, 49, 610153 (3),
TRIC-A		
TRIC-B	AR	osteogenesis imperfecta, type xiv, 615066 (3),
TRIC5		
TRICK2A	AR	squamous cell carcinoma, head and neck, 275355 (3),
TRICKB	AR	squamous cell carcinoma, head and neck, 275355 (3),
TRID		
trident		
Trif		
TRIF	AR,AD	{encephalopathy, acute, infection-induced (herpes-specific), susceptibility to, 6}, 614850 (3),
TRIFIC		
TRIK	AD	{migraine, with or without aura, susceptibility to, 13}, 613656 (3),
TRIL		
TRIM		
TRIM1	XL,XLR	?intellectual developmental disorder, 101, 300928 (3),
TRIM10		
TRIM11		
TRIM13		
TRIM13OS		
TRIM14		
TRIM16		
TRIM17		
TRIM18	XLR,XL	opitz gbbb syndrome, 300000 (3),
TRIM19		leukemia, acute promyelocytic, pml/rara type (3)
TRIM2	AR	charcot-marie-tooth disease, type 2r, 615490 (3),
TRIM20	AD,AR	neutrophilic dermatosis, acute febrile, 608068 (3), ; familial mediterranean fever, ar, 249100 (3), ; familial mediterranean fever, ad, 134610 (3),
TRIM21		
TRIM22		
TRIM23		
TRIM24		
TRIM25		
TRIM26		
TRIM27		
TRIM28		
TRIM29		
TRIM3		
TRIM31		
TRIM32	AR	?bardet-biedl syndrome 11, 615988 (3), ; muscular dystrophy, limb-girdle, 8, 254110 (3),
TRIM33		
TRIM34		
TRIM35		
TRIM36	AR	?anencephaly 1, 206500 (3),
TRIM37	AR	mulibrey nanism, 253250 (3),
TRIM39		
TRIM40		
TRIM41		
TRIM42		
TRIM44	AD	?aniridia 3, 617142 (3),
TRIM45		
TRIM46		
TRIM47		
TRIM49		
TRIM49A		
TRIM5		
TRIM50		
TRIM50A		
TRIM50B		
TRIM50C		
TRIM52		
TRIM52-AS1		
TRIM54		
TRIM55		
TRIM56		
TRIM57		
TRIM59		
TRIM5alpha		
TRIM6		
TRIM60		
TRIM61		
TRIM62		
TRIM63		
TRIM65		
TRIM66		
TRIM67		
TRIM68		
TRIM69		
TRIM7		
TRIM71	AD	hydrocephalus, congenital, 4, 618667 (3),
TRIM72		
TRIM73		
TRIM74		
TRIM76		
TRIM8	AD	focal segmental glomerulosclerosis and neurodevelopmental syndrome, 619428 (3),
TRIM9		
TRIMLESS		
Trimmer	AR	spermatogenic failure 57, 619528 (3),
TRIO	AD	intellectual developmental disorder, 44, with microcephaly, 617061 (3), ; intellectual developmental disorder, 63, with macrocephaly, 618825 (3),
TRIOBP	AR	deafness, 28, 609823 (3),
TrIP		
TRIP	AR	seckel syndrome 9, 616777 (3),
TRIP-1		
TRIP-Br1		
TRIP-Br2		
TRIP1		
TRIP10		
TRIP11	AR	odontochondrodysplasia 1, 184260 (3), ; achondrogenesis, type ia, 200600 (3),
TRIP12	AD	intellectual developmental disorder, 49, 617752 (3),
TRIP13	AR	oocyte/zygote/embryo maturation arrest 9, 619011 (3), ; mosaic variegated aneuploidy syndrome 3, 617598 (3),
TRIP14		
TRIP15		
TRIP2		
Trip230	AR	odontochondrodysplasia 1, 184260 (3), ; achondrogenesis, type ia, 200600 (3),
TRIP3	AR	peho syndrome, 260565 (3),
TRIP4	AR	?muscular dystrophy, congenital, davignon-chauveau type, 617066 (3), ; spinal muscular atrophy with congenital bone fractures 1, 616866 (3),
TRIP5	AD	microcephaly with or without chorioretinopathy, lymphedema, or mental retardation, 152950 (3),
TRIP6		
TRIP7		
TRIP8		
TRIP8b		
TRIP9		
TRIPC	AD	intellectual developmental disorder, 49, 617752 (3),
TRIPIN		
TRISK	AR	cardiac arrhythmia syndrome, with or without skeletal muscle weakness, 615441 (3),
TRIT1	AR	combined oxidative phosphorylation deficiency 35, 617873 (3),
TRK	AD,AR,AR	congenital myopathy 4a, 255310 (3), ; congenital myopathy 4b, 609284 (3), |insensitivity to pain, congenital, with anhidrosis, 256800 (3),
TRK-CTT2-3		
TRK-CTT2-4		
TRK-TTT3-4		
TRK-TTT3-5		
TRK1		
TRK2		
TRKA	AR	insensitivity to pain, congenital, with anhidrosis, 256800 (3),
TRKB	AD	developmental and epileptic encephalopathy 58, 617830 (3), ; obesity, hyperphagia, and developmental delay, 613886 (3),
TRKC		
TRL-AAG2-1		
TRL-AAG2-3		
TRL-TAG1-1		
TRL1		
TRL2		
TRM1	AR	intellectual developmental disorder, 68, 618302 (3),
TRM10	AR	microcephaly, short stature, and impaired glucose metabolism 1, 616033 (3),
TRM112		
Trm12		
TRM2		
TRM3		
TRM4	AR	intellectual developmental disorder, 5, 611091 (3),
TRM44		
TRM5	AR	peripheral neuropathy with variable spasticity, exercise intolerance, and developmental delay, 616539 (3),
TRM7	XL,XLR	intellectual developmental disorder, 9, 309549 (3),
Trm732		
Trm734		
TRM8		
TRM82	AR	galloway-mowat syndrome 6, 618347 (3), ; microcephaly, growth deficiency, seizures, and brain malformations, 618346 (3),
TRM9	AR	intellectual developmental disorder, 71, 618504 (3),
TRM9L		
TRMA	AR	thiamine-responsive megaloblastic anemia syndrome, 249270 (3),
TRMI1		
TRMI2		
TRMT	AR	{deafness, mitochondrial, modifier of}, 580000 (3), mitochondrial; liver failure, transient infantile, 613070 (3),
TRMT1	AR	intellectual developmental disorder, 68, 618302 (3),
TRMT10A	AR	microcephaly, short stature, and impaired glucose metabolism 1, 616033 (3),
TRMT10C	AR	combined oxidative phosphorylation deficiency 30, 616974 (3),
TRMT11-2		
TRMT112		
TRMT12		
TRMT1L		
TRMT2A		
TRMT3		
TRMT44		
TRMT5	AR	peripheral neuropathy with variable spasticity, exercise intolerance, and developmental delay, 616539 (3),
TRMT61B		
TRMT7	XL,XLR	intellectual developmental disorder, 9, 309549 (3),
TRMT8		
TRMT82	AR	galloway-mowat syndrome 6, 618347 (3), ; microcephaly, growth deficiency, seizures, and brain malformations, 618346 (3),
TRMT9A	AR	intellectual developmental disorder, 71, 618504 (3),
TRMT9B		
TRMU	AR	{deafness, mitochondrial, modifier of}, 580000 (3), mitochondrial; liver failure, transient infantile, 613070 (3),
TRN		
TRN-GTT2-7		
TRN-SR	AD	muscular dystrophy, limb-girdle, 2, 608423 (3),
TRN-SR2	AD	muscular dystrophy, limb-girdle, 2, 608423 (3),
TRN2	AD	intellectual developmental disorder with hypotonia, impaired speech, and dysmorphic facies, 619556 (3),
tRNA-Ala-TGC-7-1		
tRNA-Arg-ACG-1-2		
tRNA-Arg-TCG-4-1		
tRNA-Arg-TCT-2-1		
tRNA-Asn-GTT-2-7		
tRNA-Gln-CTG-1-5		
tRNA-Gln-TTG-1-1		
tRNA-Glu-TTC-3-1		
tRNA-Gly-CCC-1-1		
tRNA-Gly-GCC-2-6		
tRNA-Gly-TCC-1-1		
tRNA-iMet-CAT-1-2		
tRNA-iMet-CAT-2-1		
tRNA-Leu-AAG-2-3		
tRNA-Leu-TAG-1-1		
tRNA-Lys-CTT-2-3		
tRNA-Lys-TTT-3-5		
tRNA-Pro-AGG-2-5		
tRNA-Pro-AGG-2-6		
tRNA-Pro-TGG-3-1		
tRNA-SeC-TCA-1-1	AR	thyroid hormone metabolism, abnormal, 3, 620198 (3),
tRNA-Ser-AGA-2-3		
tRNA-Ser-TGA-2-1		
tRNA-Ser-TGA-4-1		
tRNA-Thr-AGT-2-2		
tRNA-Thr-TGT-3-1		
tRNA-Thr-TGT-6-1		
tRNA-Val-AAC-1-1		
tRNA-Val-AAC-1-4		
tRNA-Val-AAC-4-1		
tRNA-Val-AAC-5-1		
tRNA-Val-CAC-1-2		
tRNA-Val-CAC-1-6		
tRNA-Val-CAC-3-1		
tRNA(Sec)	AR	thyroid hormone metabolism, abnormal, 3, 620198 (3),
TRNAA1		
TRNAE1		
TRNAG2		
TRNAG3		
TRNAG37		
TRNAK1		
TRNAK2		
TRNAL1		
TRNAL2		
TRNAM1		
TRNAM2		
TRNAMI1		
TRNAMI2		
TRNAP1		
TRNAP2		
TRNAP3		
TRNAQ1		
TRNAQ2		
TRNAR1		
TRNAR2		
TRNAR3		
TRNAS1		
TRNAS2		
TRNAS3		
TRNAT1		
TRNAT15		
TRNAT2		
TRNAU1	AR	thyroid hormone metabolism, abnormal, 3, 620198 (3),
TRNAU1AP		
TRNAV1		
TRNAV12		
TRNAV17		
TRNAV2		
TRNAV21		
TRNAV24		
TRNAV32		
TRNL		
TRNP		
TRNP1		
TRNR1	AR	renal hypodysplasia/aplasia 4, 619887 (3),
TRNR2		
TRNS		
TRNT1	AR	sideroblastic anemia with b-cell immunodeficiency, periodic fevers, and developmental delay, 616084 (3), ; retinitis pigmentosa and erythrocytic microcytosis, 616959 (3),
TRO		
TROAP		
TROB		
TROB1		
TROB2		
TROP1	AR,AD	diarrhea 5, with tufting enteropathy, congenital, 613217 (3), ; lynch syndrome 8, 613244 (3),
TROP2	AR	corneal dystrophy, gelatinous drop-like, 204870 (3),
TROVE1		
TROVE2		
TROY		
TRP	AR	[skin/hair/eye pigmentation, variation in, 11 (melanesian blond hair)], 612271 (3); albinism, oculocutaneous, type iii, 203290 (3),
TRP-185		
TRP-2	AR	oculocutaneous albinism, type viii, 619165 (3),
TRP-AGG2-3		
TRP-AGG2-4		
TRP-AGG2-5		
TRP-AGG2-6		
TRP-ML2		
TRP-ML3		
TRP-PLIK	AD	{amyotrophic lateral sclerosis-parkinsonism/dementia complex, susceptibility to}, 105500 (3),
TRP-TGG3-1		
TRP-TGG3-5		
TRP1		
TRP12	AD	spondylometaphyseal dysplasia, kozlowski type, 184252 (3), ; digital arthropathy-brachydactyly, familial, 606835 (3), ; [sodium serum level qtl 1], 613508 (3); sed, maroteaux type, 184095 (3), ; metatropic dysplasia, 156530 (3), ; scapuloperoneal spinal muscular atrophy, 181405 (3), ; hereditary motor and sensory neuropathy, type iic, 606071 (3), ; ?avascular necrosis of femoral head, primary, 2, 617383 (3), ; neuronopathy, distal hereditary motor, type viii, 600175 (3), ; parastremmatic dwarfism, 168400 (3), ; brachyolmia type 3, 113500 (3),
TRP14		
TRP2	AR	oculocutaneous albinism, type viii, 619165 (3),
TRP3		
TRP32		
TRP4		
Trp53cor1		
TRP6	AD	glomerulosclerosis, focal segmental, 2, 603965 (3),
TRPA1	AD	?episodic pain syndrome, familial, 1, 615040 (3),
TRPC1		
TRPC3	AD	?spinocerebellar ataxia 41, 616410 (3),
TRPC4		
TRPC4AP		
TRPC5		
TRPC6	AD	glomerulosclerosis, focal segmental, 2, 603965 (3),
TRPC7		
TRPM-2		
TRPM-L1	AR	mucolipidosis iv, 252650 (3),
TRPM1	AR	night blindness, congenital stationary (complete), 1c, 613216 (3)
TRPM2		
TRPM3	AD	?cataract 50 with or without glaucoma, 620253 (3); neurodevelopmental disorder with hypotonia, dysmorphic facies, and skeletal anomalies, with or without seizures, 620224 (3),
TRPM4	AD	progressive familial heart block, type ib, 604559 (3), ; erythrokeratodermia variabilis et progressiva 6, 618531 (3),
TRPM5		
TRPM6	AR	hypomagnesemia 1, intestinal, 602014 (3),
TRPM7	AD	{amyotrophic lateral sclerosis-parkinsonism/dementia complex, susceptibility to}, 105500 (3),
TRPM8		
TRPML1	AR	mucolipidosis iv, 252650 (3),
TRPML2		
TRPML3		
TRPP1	AD	polycystic kidney disease 1, 173900 (3),
TRPP2	AD	polycystic kidney disease 2, 613095 (3),
TRPP3		
TRPP5		
TRPS1	AD	trichorhinophalangeal syndrome, type iii, 190351 (3), ; trichorhinophalangeal syndrome, type i, 190350 (3),
TRPT1		
TRPV1		
TRPV2		
TRPV3	AD	?palmoplantar keratoderma, nonepidermolytic, focal 2, 616400 (3), ; olmsted syndrome 1, 614594 (3),
TRPV4	AD	spondylometaphyseal dysplasia, kozlowski type, 184252 (3), ; digital arthropathy-brachydactyly, familial, 606835 (3), ; [sodium serum level qtl 1], 613508 (3); sed, maroteaux type, 184095 (3), ; metatropic dysplasia, 156530 (3), ; scapuloperoneal spinal muscular atrophy, 181405 (3), ; hereditary motor and sensory neuropathy, type iic, 606071 (3), ; ?avascular necrosis of femoral head, primary, 2, 617383 (3), ; neuronopathy, distal hereditary motor, type viii, 600175 (3), ; parastremmatic dwarfism, 168400 (3), ; brachyolmia type 3, 113500 (3),
TRPV5		
TRPV6	AR	hyperparathyroidism, transient neonatal, 618188 (3),
TRQ-CTG1-2		
TRQ-CTG1-5		
TRQ-TTG1-1		
TRQ1		
TRQ2		
TRR-ACG1-2		
TRR-ACG1-3		
TRR-TCG4-1		
TRR-TCT2-1		
TRR1		
TRR2		
TRR3		
TRRAP	AD	?deafness, 75, 618778 (3), ; developmental delay with or without dysmorphic facies and autism, 618454 (3),
TRRP4AP		
TRS-AGA2-3		
TRS-AGA2-4		
TRS-TGA2-1		
TRS-TGA4-1		
TRS1		
TRS120	AR	intellectual developmental disorder, 13, 613192 (3),
TRS130	AR	neurodevelopmental disorder with microcephaly, short stature, and speech delay, 620027 (3),
TRS2		
TRS20	XLR,XL	spondyloepiphyseal dysplasia tarda, 313400 (3),
TRS23	AR	neurodevelopmental disorder with epilepsy, spasticity, and brain atrophy, 618741 (3),
TRS3		
TRS33		
TRS85		
TRSLN		
TRSP	AR	thyroid hormone metabolism, abnormal, 3, 620198 (3),
TRSPAP1		
TRT	AD,AR	dyskeratosis congenita, 2, 613989 (3), ; dyskeratosis congenita, 4, 613989 (3), ; pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 1, 614742 (3), ; {melanoma, cutaneous malignant, 9}, 615134 (3), ; {leukemia, acute myeloid}, 601626 (3), somatic mutation,
TRT-AGT2-2		
TRT-TGT3-1		
TRT-TGT6-1		
TRT1		
TRT2		
TRU-TCA1-1	AR	thyroid hormone metabolism, abnormal, 3, 620198 (3),
TRUB1		
TRUB2		
TRUNDD		
TRUP		
TRV		
TRV-AAC1-1		
TRV-AAC1-4		
TRV-AAC4-1		
TRV-AAC5-1		
TRV-CAC1-2		
TRV-CAC1-6		
TRV-CAC3-1		
TRV1		
TRV2		
TRX		
TRX-CAT1-2		
TRX-CAT1-3		
TRX-CAT2-1		
TRX1	AD	wiedemann-steiner syndrome, 605130 (3),
TRX2	AD	intellectual developmental disorder, 68, 619934 (3), ; dystonia 28, childhood-onset, 617284 (3),
TRX6		
Trx80		
Trxr1		
TRXR2	AR	?glucocorticoid deficiency 5, 617825 (3),
TRXR3		
TRY1	AD	pancreatitis, hereditary, 167800 (3),
TRY2	AD	{pancreatitis, chronic, protection against}, 167800 (3),
TRY3		
TRY4		
TRYP2		
TS	AR,AD	dyskeratosis congenita, digenic, 620040 (3), digenic |ghosal hematodiaphyseal syndrome, 231095 (3), |timothy syndrome, 601005 (3), ; long qt syndrome 8, 618447 (3), ; neurodevelopmental disorder with hypotonia, language delay, and skeletal defects with or without seizures, 620029 (3), ; brugada syndrome 3, 611875 (3),
TSA		
TSA-1		
TSA1902		
TSA2004		
TSA303		
TSA806		
TSACC		
TSAd		
TSAP6	AD	?anemia, hypochromic microcytic, with iron overload 2, 615234 (3),
TSARG1		
TSARG2		
TSARG4	AR	spermatogenic failure 16, 617187 (3),
TSARG6	AR	ciliary dyskinesia, primary, 34, 617091 (3),
TSARG7		
Tsase		dyskeratosis congenita, digenic, 620040 (3), digenic
TSBF1		
TSBN51		
TSBP		
TSBP1		
TSC	AD,AR	focal cortical dysplasia, type ii, somatic, 607341 (3); tuberous sclerosis-1, 191100 (3), ; lymphangioleiomyomatosis, 606690 (3)|gitelman syndrome, 263800 (3),
TSC-1		
TSC-22R		
TSC-5		
TSC1	AD	focal cortical dysplasia, type ii, somatic, 607341 (3); tuberous sclerosis-1, 191100 (3), ; lymphangioleiomyomatosis, 606690 (3)
TSC2	AD	lymphangioleiomyomatosis, somatic, 606690 (3); ?focal cortical dysplasia, type ii, somatic, 607341 (3); tuberous sclerosis-2, 613254 (3),
TSC21		
TSC22		
TSC22D1		
TSC22D2		
TSC22D3		
TSC22D4		
tsc36		
TSC4	AD	lymphangioleiomyomatosis, somatic, 606690 (3); ?focal cortical dysplasia, type ii, somatic, 607341 (3); tuberous sclerosis-2, 613254 (3),
TSC403		
TSC501		
TSCOT		
TSE1	AD	pigmented nodular adrenocortical disease, primary, 1, 610489 (3), ; acrodysostosis 1, with or without hormone resistance, 101800 (3), ; adrenocortical tumor, somatic (3); carney complex, type 1, 160980 (3), ; myxoma, intracardiac, 255960 (3),
TSEN15	AR	pontocerebellar hypoplasia, type 2f, 617026 (3),
TSEN2	AR	pontocerebellar hypoplasia type 2b, 612389 (3),
TSEN34	AR	?pontocerebellar hypoplasia type 2c, 612390 (3),
TSEN54	AR	pontocerebellar hypoplasia type 2a, 277470 (3), ; pontocerebellar hypoplasia type 4, 225753 (3), ; ?pontocerebellar hypoplasia type 5, 610204 (3),
TSEPA		
TSFM	AR	combined oxidative phosphorylation deficiency 3, 610505 (3),
TSG		
TSG-1		
TSG-14		
TSG-6		
TSG-9		
TSG10		
TSG101		
TSG15		
TSG23		
TSG24	AR	rothmund-thomson syndrome, type 1, 618625 (3),
TSG6		
TSG7		
TSGA		
TSGA10	AR	?spermatogenic failure 26, 617961 (3),
TSGA14	AR	joubert syndrome 15, 614464 (3),
TSGA2	AR	ciliary dyskinesia, primary, 24, 615481 (3),
TSGA3	XL,XLR	spermatogenic failure, 2, 309120 (3),
TSGA5		
TSH1	AD	aural atresia, congenital, 607842 (3),
TSH2		
TSH2B		
TSH3		
TSHA		
TSHB	AR	hypothyroidism, congenital, nongoitrous 4, 275100 (3),
TSHR	AD,AR	hyperthyroidism, familial gestational, 603373 (3), ; hyperthyroidism, nonautoimmune, 609152 (3), ; thyroid adenoma, hyperfunctioning, somatic (3); hypothyroidism, congenital, nongoitrous, 1, 275200 (3), ; thyroid carcinoma with thyrotoxicosis, somatic (3)
TSHZ1	AD	aural atresia, congenital, 607842 (3),
TSHZ2		
TSHZ3		
TSIX		
TSK		
TSKS		
TSKU		
TSLC1		
TSLL1	AD	charcot-marie-tooth disease, axonal, type 2ff, 619519 (3),
TSLL2		
TSLP		
TSLPR		
TSLRP	AR	ciliary dyskinesia, primary, 19, 614935 (3),
TSN		
TSN2		
TSNAX		
TSNAXIP1		
TSP		
TSP-1		
TSP-5	AD	pseudoachondroplasia, 177170 (3), ; carpal tunnel syndrome 2, 619161 (3), ; epiphyseal dysplasia, multiple, 1, 132400 (3),
TSP-EAR	AR	tooth agenesis, selective, 10, 620173 (3), ; ?deafness, 98, 614861 (3), ; ectodermal dysplasia 14, hair/tooth type with or without hypohidrosis, 618180 (3),
TSP-NY	AR	?spermatogenic failure 67, 619803 (3),
TSP1		
TSP10		
TSP2		{lumbar disc herniation, susceptibility to}, 603932 (3)
TSP5	AD	pseudoachondroplasia, 177170 (3), ; carpal tunnel syndrome 2, 619161 (3), ; epiphyseal dysplasia, multiple, 1, 132400 (3),
TSP50		
TSP57	AR	mosaic variegated aneuploidy syndrome 2, 614114 (3),
TSPAN		
TSPAN-1		
TSPAN-2		
TSPAN-3		
TSPAN-4		
Tspan-5		
TSPAN-6		
TSPAN1		
TSPAN12	AD	exudative vitreoretinopathy 5, 613310 (3),
TSPAN13		
TSPAN15		
TSPAN16		
TSPAN18		
TSPAN2		
TSPAN20		
TSPAN21		
TSPAN22	AD,AR	macular dystrophy, patterned, 1, 169150 (3), ; choroidal dystrophy, central areolar 2, 613105 (3), ; retinitis punctata albescens, 136880 (3), ; leber congenital amaurosis 18, 608133 (3), digenic , ; macular dystrophy, vitelliform, 3, 608161 (3), ; retinitis pigmentosa 7 and digenic form, 608133 (3), digenic ,
TSPAN23	AR,AD	retinitis pigmentosa 7, digenic form, 608133 (3), digenic ,
TSPAN24	AR	[blood group, raph], 179620 (3); epidermolysis bullosa simplex 7, with nephropathy and deafness, 609057 (3),
TSPAN25		
TSPAN26		
TSPAN27		
TSPAN28	AR	immunodeficiency, common variable, 6, 613496 (3),
TSPAN29		
TSPAN3		
TSPAN30		
TSPAN31		
TSPAN32		
TSPAN33		
TSPAN4		
TSPAN5		
TSPAN6		
TSPAN7	XL,XLR	intellectual developmental disorder, 58, 300210 (3),
TSPAN8		
TSPAN9		
TSPEAR	AR	tooth agenesis, selective, 10, 620173 (3), ; ?deafness, 98, 614861 (3), ; ectodermal dysplasia 14, hair/tooth type with or without hypohidrosis, 618180 (3),
TSPO		
TSPO1		
TSPO2		
TSPOAP1		
TSPX		
TSPY		
TSPY1		
TSPYL	AR	sudden infant death with dysgenesis of the testes syndrome, 608800 (3),
TSPYL1	AR	sudden infant death with dysgenesis of the testes syndrome, 608800 (3),
TSPYL2		
TSPYL4		
TSPYL5		
TSR1		
TSR2	XLR,XL	?diamond-blackfan anemia 14 with mandibulofacial dysostosis, 300946 (3),
TSR3		
TSRC1	AR	ectopia lentis et pupillae, 225200 (3), ; ectopia lentis, isolated, 225100 (3),
TSSC1		
TSSC2		
TSSC3		
TSSC4		
TSSC5		breast cancer, somatic, 114480 (3); lung cancer, somatic, 211980 (3); rhabdomyosarcoma, somatic, 268210 (3)
TSSC6		
TSSK1		
TSSK1B		
TSSK2		
TSSK3		
TSSK4		
TSSK6		
TSSKS		
TSSN1		{glucocorticoid therapy, response to}, 614400 (3)
TSSP		
TST		
TST1		
TST2		
TSTA1		
TSTA2		
TSTA3		
TSTD1		
TSULF	AR	mucopolysaccharidosis, type x, 619698 (3),
TTBK1		
TTBK2	AD	spinocerebellar ataxia 11, 604432 (3),
TTC-15	AR	encephalopathy, progressive, early-onset, with brain atrophy and spasticity, 617669 (3),
TTC1		
TTC10		
TTC11		
TTC12	AR	ciliary dyskinesia, primary, 45, 618801 (3),
TTC15	AR	encephalopathy, progressive, early-onset, with brain atrophy and spasticity, 617669 (3),
TTC17		
TTC18	AR	?spermatogenic failure 41, 618670 (3),
TTC19	AR	mitochondrial complex iii deficiency, nuclear type 2, 615157 (3),
TTC2		
TTC20	AR	goldberg-shprintzen megacolon syndrome, 609460 (3),
TTC21A	AR	spermatogenic failure 37, 618429 (3),
TTC21B	AR,AD	short-rib thoracic dysplasia 4 with or without polydactyly, 613819 (3), ; nephronophthisis 12, 613820 (3),
TTC23L		
TTC25	AR	ciliary dyskinesia, primary, 35, 617092 (3),
TTC26	AR	biliary, renal, neurologic, and skeletal syndrome, 619534 (3),
TTC28		
TTC29	AR	spermatogenic failure 42, 618745 (3),
TTC3		
TTC35		
TTC37	AR	trichohepatoenteric syndrome 1, 222470 (3),
TTC39A		
TTC39B		
TTC4		
TTC40		
TTC5	AR	neurodevelopmental disorder with cerebral atrophy and variable facial dysmorphism, 619244 (3),
TTC7	AR	gastrointestinal defects and immunodeficiency syndrome, 243150 (3),
TTC7A	AR	gastrointestinal defects and immunodeficiency syndrome, 243150 (3),
TTC7B		
TTC7L1		
TTC8	AR	bardet-biedl syndrome 8, 615985 (3), ; ?retinitis pigmentosa 51, 613464 (3),
TTC9		
TTC9A		
TTCP20		
TTD	AR	trichothiodystrophy 3, photosensitive, 616395 (3),
TTD-A	AR	trichothiodystrophy 3, photosensitive, 616395 (3),
TTDA	AR	trichothiodystrophy 3, photosensitive, 616395 (3),
TTDN1	AR	trichothiodystrophy 4, nonphotosensitive, 234050 (3),
TTF	AR	{?epidermodysplasia verruciformis, susceptibility to, 4}, 618307 (3),
TTF-1	AD	chorea, hereditary benign, 118700 (3), ; {thyroid cancer, nonmedullary, 1}, 188550 (3), ; choreoathetosis, hypothyroidism, and neonatal respiratory distress, 610978 (3),
TTF-2	AR,AD	bamforth-lazarus syndrome, 241850 (3), ; {thyroid cancer, nonmedullary, 4}, 616534 (3),
TTF1	AD	chorea, hereditary benign, 118700 (3), ; {thyroid cancer, nonmedullary, 1}, 188550 (3), ; choreoathetosis, hypothyroidism, and neonatal respiratory distress, 610978 (3),
TTF2		
TTG1		leukemia, t-cell acute lymphoblastic, 186921 (2)
TTG2		leukemia, acute t-cell, 180385 (2)
TTGN2		
TTI1		
TTI2	AR	intellectual developmental disorder, 39, 615541 (3),
TTID	AD	myopathy, myofibrillar, 3, 609200 (3),
TTIM1		
TTK		
TTL		
TTLL1		
TTLL12		
TTLL3		
TTLL4		
TTLL5	AR	cone-rod dystrophy 19, 615860 (3),
TTLL6		
TTLL7		
TTLL8		
TTLL9		
TTMP	AR	hypotrichosis 15, 620177 (3),
TTN	AR,AD	muscular dystrophy, limb-girdle, 10, 608807 (3), ; cardiomyopathy, familial hypertrophic, 9, 613765 (3), ; congenital myopathy 5 with cardiomyopathy, 611705 (3), ; tibial muscular dystrophy, tardive, 600334 (3), ; cardiomyopathy, dilated, 1g, 604145 (3), ; myopathy, myofibrillar, 9, with early respiratory failure, 603689 (3),
TTN1		
TTN2		
TTN3		
TTP	AR	thrombotic thrombocytopenic purpura, hereditary, 274150 (3),
TTPA	AR	ataxia with isolated vitamin e deficiency, 277460 (3),
TTPP2	AD	{thyrotoxic periodic paralysis, susceptibility to, 2}, 613239 (3),
TTR	AD	amyloidosis, hereditary, transthyretin-related, 105210 (3), ; carpal tunnel syndrome, familial, 115430 (3), ; [dystransthyretinemic hyperthyroxinemia], 145680 (3),
TTRAP	AR	spinocerebellar ataxia, 23, 616949 (3),
TTS-2.2	AR	neutral lipid storage disease with myopathy, 610717 (3),
TTTY17		
TTTY17A		
TTTY3		
TTTY3A		
TTTY4		
TTTY4A		
TTTY5		
TTTY6		
TTTY6A		
ttv	AD	exostoses, multiple, type 1, 133700 (3), ; chondrosarcoma, 215300 (3), somatic mutation
TTY3		
TTY4		
TTY5		
TTY6		
TTYH1		
TTYH2		
TTYH3		
TU12		
TU12B1-TY		
TU13		
TU3A		
TUB	AR	?retinal dystrophy and obesity, 616188 (3),
Tuba	AR	cataract 48, 618415 (3),
TUBA1	AD	amyotrophic lateral sclerosis 22 with or without frontotemporal dementia, 616208 (3),
TUBA1A	AD	lissencephaly 3, 611603 (3),
TUBA1B		
TUBA2		
TUBA3	AD	lissencephaly 3, 611603 (3),
TUBA3C		
TUBA3D	AD	keratoconus 9, 617928 (3),
TUBA3E		
TUBA4A	AD	amyotrophic lateral sclerosis 22 with or without frontotemporal dementia, 616208 (3),
TUBA8	AD	macrothrombocytopenia, isolated, 2, 619840 (3),
TUBAL1		
TUBAL2	AD	macrothrombocytopenia, isolated, 2, 619840 (3),
TUBB	AD,AD	cortical dysplasia, complex, with other brain malformations 5, 615763 (3), |symmetric circumferential skin creases, congenital, 1, 156610 (3), ; cortical dysplasia, complex, with other brain malformations 6, 615771 (3),
TUBB1	AD	macrothrombocytopenia, isolated, 1, 613112 (3),
TUBB2	AD	cortical dysplasia, complex, with other brain malformations 5, 615763 (3),
TUBB2A	AD	cortical dysplasia, complex, with other brain malformations 5, 615763 (3),
TUBB2B	AD	cortical dysplasia, complex, with other brain malformations 7, 610031 (3),
TUBB2C	AD	leber congenital amaurosis with early-onset deafness, 617879 (3),
TUBB3	AD	fibrosis of extraocular muscles, congenital, 3a, 600638 (3), ; cortical dysplasia, complex, with other brain malformations 1, 614039 (3),
TUBB4	AD	dystonia 4, torsion, 128101 (3), ; leukodystrophy, hypomyelinating, 6, 612438 (3),
TUBB4A	AD	dystonia 4, torsion, 128101 (3), ; leukodystrophy, hypomyelinating, 6, 612438 (3),
TUBB4B	AD	leber congenital amaurosis with early-onset deafness, 617879 (3),
Tubb5	AD	symmetric circumferential skin creases, congenital, 1, 156610 (3), ; cortical dysplasia, complex, with other brain malformations 6, 615771 (3),
TUBB6	AD	?facial palsy, congenital, with ptosis and velopharyngeal dysfunction, 617732 (3),
TUBB8	AR,AD	oocyte/zygote/embryo maturation arrest 2, 616780 (3),
TUBD		
TUBD1		
TUBE		
TUBE1		
tuberin	AD	lymphangioleiomyomatosis, somatic, 606690 (3); ?focal cortical dysplasia, type ii, somatic, 607341 (3); tuberous sclerosis-2, 613254 (3),
TUBG	AD	cortical dysplasia, complex, with other brain malformations 4, 615412 (3),
TUBG1	AD	cortical dysplasia, complex, with other brain malformations 4, 615412 (3),
TUBG2		
TUBGCP1	AD	cortical dysplasia, complex, with other brain malformations 4, 615412 (3),
TUBGCP2	AR	pachygyria, microcephaly, developmental delay, and dysmorphic facies, with or without seizures, 618737 (3),
TUBGCP3		
TUBGCP4	AR	microcephaly and chorioretinopathy, 3, 616335 (3),
TUBGCP5		
TUBGCP6	AR	microcephaly and chorioretinopathy, 1, 251270 (3),
TUBGCP7		
TUBL		
TUBL1	AR	leber congenital amaurosis 15, 613843 (3), ; retinitis pigmentosa 14, 600132 (3),
TUBL2		
TUBL3	AR	hepatorenocardiac degenerative fibrosis, 619902 (3),
TUCAN	AD	?inflammatory bowel disease (crohn disease) 30, 619079 (3),
TUDOR3		
TUFM	AR	combined oxidative phosphorylation deficiency 4, 610678 (3),
TUFT1	AR	woolly hair-skin fragility syndrome, 620415 (3),
TUG		alveolar soft-part sarcoma, 606243 (3)
TUG1		
TULA		
TULA-2		
TULA2		
Tulip1	AR	neurodevelopmental disorder with hypotonia, neonatal respiratory insufficiency, and thermodysregulation, 618797 (3),
TULP1	AR	leber congenital amaurosis 15, 613843 (3), ; retinitis pigmentosa 14, 600132 (3),
TULP2		
TULP3	AR	hepatorenocardiac degenerative fibrosis, 619902 (3),
TULP4		
TUM1		
TUNA		
TUNAR		
TUNP	AD	au-kline syndrome, 616580 (3),
TUP-1		
TUP1		
TUPLE1		
TUSC1		
TUSC2		
TUSC3	AR	intellectual developmental disorder, 7, 611093 (3),
TUSC4	AD	epilepsy, familial focal, with variable foci 2, 617116 (3),
TUSC5		
TUSC7		
TUSP		
TUT1		
TUT2		
TUT3		
TUT4		
TUT7		
TUTase		
TUTR1		
TUWD12	AR	cone-rod dystrophy 20, 615973 (3),
TWA1		
TWA2		
TWEAK		
TweakR		
Tweek	AR	alkuraya-kucinskas syndrome, 617822 (3),
TWF1		
TWF2		
TWIK-1		
TWIK-2		
TWINKLE	AR,AD	mitochondrial dna depletion syndrome 7 (hepatocerebral type), 271245 (3), ; progressive external ophthalmoplegia with mitochondrial dna deletions, 3, 609286 (3), ; perrault syndrome 5, 616138 (3),
TWINL	AR,AD	mitochondrial dna depletion syndrome 7 (hepatocerebral type), 271245 (3), ; progressive external ophthalmoplegia with mitochondrial dna deletions, 3, 609286 (3), ; perrault syndrome 5, 616138 (3),
TWIST	AD	craniosynostosis 1, 123100 (3), ; robinow-sorauf syndrome, 180750 (3), ; sweeney-cox syndrome, 617746 (3), ; saethre-chotzen syndrome with or without eyelid anomalies, 101400 (3),
TWIST1	AD	craniosynostosis 1, 123100 (3), ; robinow-sorauf syndrome, 180750 (3), ; sweeney-cox syndrome, 617746 (3), ; saethre-chotzen syndrome with or without eyelid anomalies, 101400 (3),
TWIST2	AD,AR	ablepharon-macrostomia syndrome, 200110 (3), ; barber-say syndrome, 209885 (3), ; focal facial dermal dysplasia 3, setleis type, 227260 (3),
TWISTER	XL,XLR	ciliary dyskinesia, primary, 36, 300991 (3),
TWISTNB		
TWNK	AR,AD	mitochondrial dna depletion syndrome 7 (hepatocerebral type), 271245 (3), ; progressive external ophthalmoplegia with mitochondrial dna deletions, 3, 609286 (3), ; perrault syndrome 5, 616138 (3),
TWSG1		
TX		
TXAS	AR	ghosal hematodiaphyseal syndrome, 231095 (3),
TXBP151		
TXBP181	AR	prostate cancer, somatic, 176807 (3); mosaic variegated aneuploidy syndrome 7 with inflammation and tumor predisposition, 620189 (3), ; lymphoma, b-cell, somatic (3)
TXDI1	AD	thyroid hormone metabolism, abnormal, 2, 619855 (3),
TXDI2		
TXDI3		
TXGP1		{myocardial infarction, susceptibility to}, 608446 (3)
TXGP1L	AR	?immunodeficiency 16, 615593 (3),
TXI1		
TXK		
Txl		
TXL-2		
TXLNA		
TXLNB		
TXLNG		
TXLNG2P		
TXLNGX		
TXLNGY		
TXN		
TXN1		
TXN2	AR	?combined oxidative phosphorylation deficiency 29, 616811 (3),
TXNDC		
TXNDC1		
TXNDC10		
TXNDC11		
TXNDC12		
TXNDC13		
TXNDC14	AR	neurodevelopmental disorder with microcephaly, cortical malformations, and spasticity, 618730 (3),
TXNDC15	AR	meckel syndrome 14, 619879 (3),
TXNDC16		
TXNDC17		
TXNDC2		
TXNDC3	AR	?ciliary dyskinesia, primary, 6, 610852 (3),
TXNDC4		
TXNDC5		
TXNDC6		
TXNDC7		
TXNDC8		
TXNDC9		
TXNIP		
TXNL		
TXNL1		
TXNL1CL		
TXNL2		
TXNL4	AR	burn-mckeown syndrome, 608572 (3),
TXNL4A	AR	burn-mckeown syndrome, 608572 (3),
TXNL4B		
TXNL5		
TXNL6		
TXNR		
TXNRD1		
TXNRD2	AR	?glucocorticoid deficiency 5, 617825 (3),
TXNRD3		
TXNRD3IT1		
TXNRD3NB		
TXNRD3NT1		
TXREB		
TXREB1		
TXS	AR	ghosal hematodiaphyseal syndrome, 231095 (3),
TYK1		
TYK2	AR	immunodeficiency 35, 611521 (3),
TYK3		
TYKi		
TYKLM3		
TYKY	AR	mitochondrial complex i deficiency, nuclear type 2, 618222 (3),
TYL		
TYMK	AR	neurodegeneration, childhood-onset, with progressive microcephaly, 619847 (3),
TYMP	AR	mitochondrial dna depletion syndrome 1 (mngie type), 603041 (3),
TYMS		dyskeratosis congenita, digenic, 620040 (3), digenic
TYMSAS		
TYMSTR		
TYP		
TYPE	AR	muscular dystrophy, limb-girdle, 5, 253700 (3),
TYR	AD,AR	[skin/hair/eye pigmentation 3, light/dark/freckling skin], 601800 (3), ; [skin/hair/eye pigmentation 3, blue/green eyes], 601800 (3), ; {melanoma, cutaneous malignant, susceptibility to, 8}, 601800 (3), ; albinism, oculocutaneous, type ib, 606952 (3), ; albinism, oculocutaneous, type ia, 203100 (3),
TYRO1		
TYRO10	AD,AR	warburg-cinotti syndrome, 618175 (3), ; spondylometaepiphyseal dysplasia, short limb-hand type, 271665 (3),
Tyro11	AD	capillary malformation-arteriovenous malformation 2, 618196 (3), ; lymphatic malformation 7, 617300 (3),
Tyro12	AR	retinitis pigmentosa 38, 613862 (3),
TYRO3		
TYRO4		
Tyro5	AR	?bleeding disorder, platelet-type, 22, 618462 (3), ; {prostate cancer/brain cancer susceptibility, somatic}, 603688 (3)
Tyro6		
Tyro7		
TYROBP	AR	polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 1, 221770 (3),
TYRP	AR	[skin/hair/eye pigmentation, variation in, 11 (melanesian blond hair)], 612271 (3); albinism, oculocutaneous, type iii, 203290 (3),
TYRP1	AR	[skin/hair/eye pigmentation, variation in, 11 (melanesian blond hair)], 612271 (3); albinism, oculocutaneous, type iii, 203290 (3),
TYRP2	AR	oculocutaneous albinism, type viii, 619165 (3),
tyrRS	AR,AD	infantile-onset multisystem neurologic, endocrine, and pancreatic disease 2, 619418 (3), ; charcot-marie-tooth disease, intermediate c, 608323 (3),
TYSND1		
TYW1		
TYW1A		
TYW2		
TYW3		
TYW4		
TYW5		
TZAP		
TZFP		
U-II		
U1-70K		
U1-A		
U1-C		
U107		
U108		
U109		
U13		
U15A		
U17A		
U17B		
U17HG		
U17HG-A		
U19		
U19-2		
U1A		
U1B2		
U1D2		
U1E2		
U1F		
U1SNRNPBP		
U2		
U20		
U21		
U21B31	AD	{von hippel-lindau syndrome, modifier of}, 193300 (3), ; {colorectal cancer, susceptibility to}, 114500 (3), somatic mutation, ; {multiple myeloma, susceptibility to}, 254500 (3), somatic mutation
U22		
U25		
U26		
U27		
U28		
U29		
U2A'		
U2AF1		
U2AF1-RS2		
U2AF1L2		
U2AF1L3		
U2AF1L4		
U2AF2		
U2af26		
U2AF35		
U2AF65		
U2AFBP		
U2B		
U2B''		
U2HR	AD	hypotrichosis 4, 146550 (3),
U2SURP		
U3		
U3-55K		
U30		
U31		
U4/U6.U5-27K		
U43		
U4atac	AR	roifman syndrome, 616651 (3), ; lowry-wood syndrome, 226960 (3), ; microcephalic osteodysplastic primordial dwarfism, type i, 210710 (3),
U5-100KD		
U5-102K	AD	retinitis pigmentosa 60, 613983 (3),
U5-116KD	AD	mandibulofacial dysostosis, guion-almeida type, 610536 (3),
U5-15kD	AR	burn-mckeown syndrome, 608572 (3),
U5-200KD	AD	retinitis pigmentosa 33, 610359 (3),
U5-52K		
U50		
U50B		
U50HG		
U5A		
U5B1		
U5DL		
U5DS		
U5E		
U6		
U6-1		
U7.1	AR	aicardi-goutieres syndrome 9, 619487 (3),
U73a		
U8	AR	leukoencephalopathy, brain calcifications, and cysts, 614561 (3),
U82		
U83A		
U83B		
U85		
U87		
U87HG		
U88		
U89		
U90		
U91		
U92		
U99HG		
UACA		
Uae1	AD,AR	sialuria, 269921 (3), ; nonaka myopathy, 605820 (3),
UAN		{nephrolithiasis, uric acid, susceptibility to}, 605990 (3)
UAP1		
Uap56		
UAT	AR	hypouricemia, renal, 220150 (3),
UB1		
UBA1	XL,XLR	spinal muscular atrophy, 2, infantile, 301830 (3), ; vexas syndrome, somatic, 301054 (3)
UBA1B		
UBA2	AD	acces syndrome, 619959 (3),
UBA3		
UBA4		
UBA5	AR	?spinocerebellar ataxia, 24, 617133 (3), ; developmental and epileptic encephalopathy 44, 617132 (3),
UBA52		
UBA6		
UBA7		
Uba80		
UBAC1		
UBADC1		
UBAP	AD	spastic paraplegia 80, 618418 (3),
UBAP1	AD	spastic paraplegia 80, 618418 (3),
UBAP2L		
UBASH3A		
UBASH3B		
UBB		
UBC		
UBC-16		
UBC1		
UBC12		
UBC13		
UBC2	XL,XLR	intellectual developmental disorder, syndromic, nascimento type, 300860 (3),
UBC3		
UBC3B		
UBC4		
UBC4/5		
UBC6		
Ubc6p		
UBC7		
UBC8		
UBC9		
UBCE7IP1	AR	cerebellar ataxia and hypogonadotropic hypogonadism, 212840 (3),
UBCE7IP3	AR	polyglucosan body myopathy 1 with or without immunodeficiency, 615895 (3),
UBCE7IP4		
Ubce7ip5		
UBCEP80		
UBCH		
UbcH-ben		
UBCH10		
UBCH5		
UbcH5A		
UbcH5B		
UbcH5C		
UbcH6		
UBCH7		
UBCH7BP		
UBCH7N3		
UbcH8		
UBCH8		
UbcH9		
UBD		
UBE1	XL,XLR	spinal muscular atrophy, 2, infantile, 301830 (3), ; vexas syndrome, somatic, 301054 (3)
UBE1C		
UBE1DC1	AR	?spinocerebellar ataxia, 24, 617133 (3), ; developmental and epileptic encephalopathy 44, 617132 (3),
UBE1L		
UBE1L2		
UBE1X	XL,XLR	spinal muscular atrophy, 2, infantile, 301830 (3), ; vexas syndrome, somatic, 301054 (3)
UBE2		
UBE2A	XL,XLR	intellectual developmental disorder, syndromic, nascimento type, 300860 (3),
UBE2B		
UBE2C		
UBE2CBP		
UBE2D1		
UBE2D2		
UBE2D3		
UBE2E1		
UBE2E2		
UBE2E3		
UBE2F		
UBE2G		
UBE2G1		
UBE2G2		
UBE2H		
UBE2I		
UBE2J1		
UBE2J2		
UBE2K		
UBE2L1		
UBE2L3		
UBE2L6		
UBE2L7		
UBE2L7P		
UBE2M		
UBE2N		
UBE2O		
UBE2Q		
UBE2Q1		
UBE2Q2		
UBE2QL1		
UBE2R1		
UBE2R2		
UBE2S		
UBE2T	AR	fanconi anemia, complementation group t, 616435 (3),
UBE2V		
UBE2V1		
UBE2V2		
UBE2W		
UBE2Z		
UBE3A	AD	angelman syndrome, 105830 (3),
UBE3A-AS		
UBE3A-AS1		
UBE3A-ATS		
UBE3B	AR	kaufman oculocerebrofacial syndrome, 244450 (3),
UBE3C	AR	neurodevelopmental disorder with absent speech and movement and behavioral abnormalities, 620270 (3),
UBE3D		
UBE4A	AR	neurodevelopmental disorder with hypotonia and gross motor and seech delay, 619639 (3),
UBE4B		
UBEL1		
UBF	AD	neurodegeneration, childhood-onset, with brain atrophy, 617672 (3),
UBF1	AD	neurodegeneration, childhood-onset, with brain atrophy, 617672 (3),
UBF2	AD	neurodegeneration, childhood-onset, with brain atrophy, 617672 (3),
ubi-d4	AD	coffin-siris syndrome 7, 618027 (3),
UBIAD1	AD	corneal dystrophy, schnyder type, 121800 (3),
UBIN		
UBL1		?orofacial cleft 10, 613705 (3), isolated cases
UBL3		
UBL4		
UBL4A		
UBL4B		
UBL5		
UBL7		
UBLCP1		
UBN1		
UBN2		
UBOX1	AD,AR	spinocerebellar ataxia 48, 618093 (3), ; spinocerebellar ataxia, 16, 615768 (3),
UBOX2	AR	neurodevelopmental disorder with hypotonia and gross motor and seech delay, 619639 (3),
UBOX3		
UBOX4		
UBOX5		
UBOX7		
UBP		
Ubp-M		
UBP1		
UBP41		
Ubp6		
UBPO		
UBPY		pituitary adenoma 4, acth-secreting, somatic, 219090 (3)
UBQLN1		
UBQLN2	XLD,XL	amyotrophic lateral sclerosis 15, with or without frontotemporal dementia, 300857 (3),
UBQLN3		
UBQLN4		
UBR1	AR	johanson-blizzard syndrome, 243800 (3),
UBR2		
UBR3		
UBR4		
UBR5		
UBR6	AD	intellectual developmental disorder with dysmorphic facies and behavioral abnormalities, 618089 (3),
UBR7	AR	li-campeau syndrome, 619189 (3),
UBTD1		
UBTD2		
UBTF	AD	neurodegeneration, childhood-onset, with brain atrophy, 617672 (3),
UBTFL1		
UBTOR		
UBX1		
UBXD1		
UBXD10		
UBXD12		
UBXD2		
UBXD3		
UBXD5		
UBXD6		
UBXD7		
UBXD8		
UBXD9		alveolar soft-part sarcoma, 606243 (3)
UBXDC1		
UBXDC2		
UBXN1		
UBXN10		
UBXN11		
UBXN2B		
UBXN2C		
UBXN3A		
UBXN3B		
UBXN4		
UBXN6		
UBXN7		
UBXN8		
UBXN9		alveolar soft-part sarcoma, 606243 (3)
uc.147	AR	immunodeficiency, common variable, 8, with autoimmunity, 614700 (3),
UC28		
UCA1		
UCAT1		
UCC1		
UCCR7.2		
UCE		
Uch-L1	AD,AR	{?parkinson disease 5, susceptibility to}, 613643 (3), ; spastic paraplegia 79a, 620221 (3), ; spastic paraplegia 79b, 615491 (3),
UCH37		
UCHL-1	AD,AR	{?parkinson disease 5, susceptibility to}, 613643 (3), ; spastic paraplegia 79a, 620221 (3), ; spastic paraplegia 79b, 615491 (3),
UCHL1	AD,AR	{?parkinson disease 5, susceptibility to}, 613643 (3), ; spastic paraplegia 79a, 620221 (3), ; spastic paraplegia 79b, 615491 (3),
UCHL2	AD	kury-isidor syndrome, 619762 (3), ; tumor predisposition syndrome 1, 614327 (3), ; {uveal melanoma, susceptibility to, 2}, 606661 (3),
UCHL3		
UCHL5		
UCHL5IP		
UCK-1		
UCK1		
UCK2		
UCKL1		
UCN		
UCN-II		
UCN1		
UCN2		
UCN3		
UCNI		
UCNIII		
UCP		
UCP1		
UCP2		{obesity, susceptibility to, bmiq4}, 607447 (3)
UCP3	AR,MF,AD	{obesity, severe, and type ii diabetes}, 601665 (3), ,
UCP4		
UCP5		
UCRBP	AD	gabriele-de vries syndrome, 617557 (3),
UCRC		
UCRP	AR	immunodeficiency 38, 616126 (3),
UDG	AR	immunodeficiency with hyper igm, type 5, 608106 (3),
UDG2	AR	ciliary dyskinesia, primary, 29, 615872 (3),
UDP-Gal-Tr	XLD,XL	congenital disorder of glycosylation, type iim, 300896 (3), somatic mosaicism,
UDP-GalNAc		
UDP-GlcDH	AR	developmental and epileptic encephalopathy 84, 618792 (3),
UDPase		
UDPGDH	AR	developmental and epileptic encephalopathy 84, 618792 (3),
UDRPASE		
UDRPASE2		
UEF		{hyperlipidemia, familial combined, susceptibility to}, 602491 (3)
UEV-1		
UEV-2		
UEV1A		
UEV2		
UEV3		
UEVLD		
UFBP1	AR	spondyloepimetaphyseal dysplasia, shohat type, 602557 (3),
UFC1	AR	neurodevelopmental disorder with spasticity and poor growth, 618076 (3),
UFD1		
UFD1L		
UFD2	AR	neurodevelopmental disorder with hypotonia and gross motor and seech delay, 619639 (3),
Ufe1		
UFL1		
UFM1	AR	leukodystrophy, hypomyelinating, 14, 617899 (3),
UFO		
UFS	AR	urofacial syndrome 1, 236730 (3),
UFSP		
UFSP1		
UFSP2	AD,AR	?hip dysplasia, beukes type, 142669 (3), ; spondyloepimetaphyseal dysplasia, di rocco type, 617974 (3), ; developmental and epileptic encephalopathy 106, 620028 (3),
UG0581B09		
UGALT	XLD,XL	congenital disorder of glycosylation, type iim, 300896 (3), somatic mosaicism,
UGAT	XLD,XL	congenital disorder of glycosylation, type iim, 300896 (3), somatic mosaicism,
UGB		
UGB2		
UGB3		
UGCG		
UGCGL1		
UGCGL2		
UGD	AR	developmental and epileptic encephalopathy 84, 618792 (3),
UGDH	AR	developmental and epileptic encephalopathy 84, 618792 (3),
UGENE		
UGGT1		
UGGT2		
UGP1	AR	developmental and epileptic encephalopathy 83, 618744 (3),
UGP2	AR	developmental and epileptic encephalopathy 83, 618744 (3),
UGPP		
UGPP1	AR	developmental and epileptic encephalopathy 83, 618744 (3),
UGRP	AR	dursun syndrome, 612541 (3), ; neutropenia, severe congenital 4, 612541 (3),
UGRP1	AD	{asthma, susceptibility to}, 600807 (3),
UGRP2		
UGT	XLD,XL	congenital disorder of glycosylation, type iim, 300896 (3), somatic mosaicism,
UGT1	XLD,XL,AR,AD	congenital disorder of glycosylation, type iim, 300896 (3), somatic mosaicism, |crigler-najjar syndrome, type i, 218800 (3), ; [bilirubin, serum level of, qtl1], 601816 (3); hyperbilirubinemia, familial transient neonatal, 237900 (3), ; crigler-najjar syndrome, type ii, 606785 (3), ; [gilbert syndrome], 143500 (3),
UGT1A	AR,AD	crigler-najjar syndrome, type i, 218800 (3), ; [bilirubin, serum level of, qtl1], 601816 (3); hyperbilirubinemia, familial transient neonatal, 237900 (3), ; crigler-najjar syndrome, type ii, 606785 (3), ; [gilbert syndrome], 143500 (3),
UGT1A1	AR,AD	crigler-najjar syndrome, type i, 218800 (3), ; [bilirubin, serum level of, qtl1], 601816 (3); hyperbilirubinemia, familial transient neonatal, 237900 (3), ; crigler-najjar syndrome, type ii, 606785 (3), ; [gilbert syndrome], 143500 (3),
UGT1A10		
UGT1A3		
UGT1A4		
UGT1A5		
UGT1A6		
UGT1A7		
UGT1A8		
UGT1A9		
UGT1AI		
UGT1C		
UGT1D		
UGT1E		
UGT1F		
UGT1G		
UGT1H		
UGT1J		
UGT2	XLD,XL	congenital disorder of glycosylation, type iim, 300896 (3), somatic mosaicism,
UGT2A1		
UGT2A2		
UGT2A3		
UGT2B10		
UGT2B11		
UGT2B15		
UGT2B17		{bone mineral density qtl 12, osteoporosis}, 612560 (3)
UGT2B28		
UGT2B4		
UGT2B7		
UGT2B8		
UGT2B9		
UGT3A1		
UGT3A2		
UGT8		
UGTL	XLD,XL	congenital disorder of glycosylation, type iim, 300896 (3), somatic mosaicism,
UGTREL1		
UGTrel4	AR	leukodystrophy, hypomyelinating, 26, with chondrodysplasia, 620269 (3),
UGTREL7	AR	schneckenbecken dysplasia, 269250 (3),
UGTrel8		
UHG		
UHMK1		
UHRF1		
UHRF1BP1		
UHRF1BP1L		
UHRF2		
UHX1		
UI		
UIF		
UII		
UIMC1		
UIP1		
UIP5		
UK114		
uKHC		
UKLF		
UKp68	AR	intellectual developmental disorder, 56, 617125 (3),
Ul	AR	neurodevelopmental disorder with epilepsy and hypoplasia of the corpus callosum, 618090 (3),
uL1		
uL10		
uL11		
uL13		
uL14		
uL15		
uL16	XL,XLR	{autism, susceptibility to, 5}, 300847 (3); intellectual developmental disorder, syndromic 35, 300998 (3),
uL18	AD	diamond-blackfan anemia 6, 612561 (3),
uL2		
uL22		
uL23		
uL24	AD	?diamond-blackfan anemia 11, 614900 (3),
uL29	AD	?diamond-blackfan anemia 19, 618312 (3),
uL3		
uL30		
uL4		
uL5	AD	diamond-blackfan anemia 7, 612562 (3),
uL6		
ula-1	AR	neurodevelopmental disorder with dysmorphic facies and ischiopubic hypoplasia, 620210 (3),
ULBP1		
ULBP2		
ULBP3		
ULBP4		
ULBP5		
ULF	AD	intellectual developmental disorder, 49, 617752 (3),
ULG3	AD,AR	[blood group, ii], 110800 (3), ; adult i phenotype without cataract, 110800 (3), ; cataract 13 with adult i phenotype, 116700 (3),
ULG5	AR,AD,AR	leydig cell adenoma, somatic, with precocious puberty, 176410 (3); leydig cell hypoplasia with pseudohermaphroditism, 238320 (3), ; leydig cell hypoplasia with hypergonadotropic hypogonadism, 238320 (3), ; luteinizing hormone resistance, female, 238320 (3), ; precocious puberty, male, 176410 (3), |marinesco-sjogren syndrome, 248800 (3),
ULIP		
ULIP4		
Ulip6	AD	ritscher-schinzel syndrome 4, 619435 (3),
ULK1		
ULK2		
ULK3		
ULK4		
Ulp1		
umat	AD	microphthalmia, isolated, with coloboma 7, 614497 (3), ; dyschromatosis universalis hereditaria 3, 615402 (3), ; [blood group, langereis system], 111600 (3); pseudohyperkalemia, familial, 2, due to red cell leak, 609153 (3),
UMOD	AD	tubulointerstitial kidney disease, 1, 162000 (3),
UMODL1		
UMP-CMPK		
UMP-CMPK2		
UMP1	AD,AR	proteasome-associated autoinflammatory syndrome 2, 618048 (3), ; keratosis linearis with ichthyosis congenita and sclerosing keratoderma, 601952 (3),
UMPH	AR	anemia, hemolytic, due to umph1 deficiency, 266120 (3),
UMPH1	AR	anemia, hemolytic, due to umph1 deficiency, 266120 (3),
UMPH2		
UMPK		
UMPS	AR	orotic aciduria, 258900 (3),
UMS	AD	ulnar-mammary syndrome, 181450 (3),
UMTCK		
UNC-122	AR	lethal congenital contracture syndrome 11, 617194 (3),
UNC-18C		
UNC-31		
UNC-46		
UNC-76		
UNC-80	AR	hypotonia, infantile, with psychomotor retardation and characteristic facies 2, 616801 (3),
UNC104	AD,AR	nescav syndrome, 614255 (3), ; neuropathy, hereditary sensory, type iic, 614213 (3), ; spastic paraplegia 30, 610357 (3), ; spastic paraplegia 30, 610357 (3),
UNC112A	AR	kindler syndrome, 173650 (3),
UNC112B		
UNC112C	AR	leukocyte adhesion deficiency, type iii, 612840 (3),
UNC119	AD	cone-rod dystrophy 24, 620342 (3), ; ?immunodeficiency 13, 615518 (3),
UNC13		
UNC13A		
UNC13B		
UNC13C		
UNC13D	AR	hemophagocytic lymphohistiocytosis, familial, 3, 608898 (3),
Unc13h2		
UNC18	AR,AD	developmental and epileptic encephalopathy 4, 612164 (3),
Unc18-2	AR	hemophagocytic lymphohistiocytosis, familial, 5, with or without microvillus inclusion disease, 613101 (3),
UNC18B	AR	hemophagocytic lymphohistiocytosis, familial, 5, with or without microvillus inclusion disease, 613101 (3),
UNC45	AD,AR	?cataract 43, 616279 (3), ; myofibrillar myopathy 11, 619178 (3),
UNC45A	AR	osteootohepatoenteric syndrome, 619377 (3),
UNC45B	AD,AR	?cataract 43, 616279 (3), ; myofibrillar myopathy 11, 619178 (3),
UNC50		
Unc51.2		
UNC5A		
UNC5B		
UNC5C		
UNC5CL		
UNC5D		
UNC5H1		
UNC5H2		
Unc5h4		
UNC79		
UNC80	AR	hypotonia, infantile, with psychomotor retardation and characteristic facies 2, 616801 (3),
UNC84A		
UNC84B		
UNC89	AR	{rhabdomyolysis, susceptibility to, 1}, 620235 (3),
UNC93	AR	{encephalopathy, acute, infection-induced (herpes-specific), susceptibility to, 1}, 610551 (3),
UNC93A		
UNC93B1	AR	{encephalopathy, acute, infection-induced (herpes-specific), susceptibility to, 1}, 610551 (3),
UNCL		
UND		
UNG	AR	immunodeficiency with hyper igm, type 5, 608106 (3),
UNG1	AR	immunodeficiency with hyper igm, type 5, 608106 (3),
UNG2	AR,AR	ciliary dyskinesia, primary, 29, 615872 (3), |immunodeficiency with hyper igm, type 5, 608106 (3),
UNG3		
UNK		
UNKL		
UNP		
Unph		
UNPH4		
UNQ1833		
UNQ192		
UNQ2430		
UNQ2492		
UNQ2529	AD	oocyte/zygote/embryo maturation arrest 7, 618550 (3),
UNQ26		
UNQ3030	AR	seizures, early-onset, with neurodegeneration and brain calcification, 618875 (3),
UNQ3033		
UNQ3037	AR	multiple sulfatase deficiency, 272200 (3),
UNQ3064		
UNQ429		
UNQ431		
UNQ467		
UNQ470		
UNQ473		
UNQ483		
UNQ501		
UNQ5783		
UNQ5792		
UNQ5804		
UNQ5829		
UNQ6077	AR	?ondontochondrodysplasia 2 with hearing loss and diabetes, 619269 (3),
UNQ6288		
UNQ644		
UNQ645		
UNQ655	AR	?mitochondrial complex iii deficiency, nuclear type 9, 616111 (3),
UNQ676		
UNQ689	AD	?amelogenesis imperfecta, type iiib, 617607 (3),
UNQ698		
UNQ739		
UNQ8193		
UNQ844		
UNQ847		
UNQ933		
UNQ9338		
UNQ9341		
UNQ9356		
UNQ9390		
UNQ9391		
UNQ9433		
UNR		
UNRIP		
UO-44		
UOG1	AR	epilepsy, progressive myoclonic, 8, 616230 (3),
UP		
UP2		
UP50	AR,AD	cutis laxa, type ia, 219100 (3), ; charcot-marie-tooth disease, demyelinating, type 1h, 619764 (3), ; macular degeneration, age-related, 3, 608895 (3), ; neuropathy, hereditary, with or without age-related macular degeneration, 608895 (3), ; ?cutis laxa, 2, 614434 (3),
UPA	AD	quebec platelet disorder, 601709 (3), ; {alzheimer disease, late-onset, susceptibility to}, 104300 (3),
UPAR		
UPASE		
UPASE2		
UPB1	AR	beta-ureidopropionase deficiency, 613161 (3),
UPF1		
UPF2		
UPF3		
UPF3A		
UPF3B	XL,XLR	intellectual developmental disorder, syndromic 14, 300676 (3),
UPF3BP1	XL,XLR	intellectual developmental disorder, syndromic 14, 300676 (3),
UPF3BP2	XL,XLR	intellectual developmental disorder, syndromic 14, 300676 (3),
UPF3BP3	XL,XLR	intellectual developmental disorder, syndromic 14, 300676 (3),
UPF3X	XL,XLR	intellectual developmental disorder, syndromic 14, 300676 (3),
UPH1	AR	cutis laxa, type ib, 614437 (3),
UPII		
UPIIIb		
UPK1		
UPK1A		
UPK1B		
UPK2		
UPK3		
UPK3A		
UPK3B		
UPLC1		
UPP		
UPP1		
UPP2		
UPRT		
UPS	AD	porphyria, acute intermittent, nonerythroid variant, 176000 (3), ; porphyria, acute intermittent, 176000 (3),
UQBP	AR	mitochondrial complex iii deficiency, nuclear type 3, 615158 (3),
UQCC		
UQCC1		
UQCC2	AR	mitochondrial complex iii deficiency, nuclear type 7, 615824 (3),
UQCC3	AR	?mitochondrial complex iii deficiency, nuclear type 9, 616111 (3),
UQCC6		
UQCR		
UQCR1	AD	parkinsonism with polyneuropathy, 619279 (3),
UQCR10		
UQCR11		
UQCR2	AR	mitochondrial complex iii deficiency, nuclear type 5, 615160 (3),
UQCR4	AR	mitochondrial complex iii deficiency, nuclear type 6, 615453 (3),
UQCR5	AR	mitochondrial complex iii deficiency, nuclear type 10, 618775 (3),
UQCR6	AR	mitochondrial complex iii deficiency, nuclear type 3, 615158 (3),
UQCR7	AR	mitochondrial complex iii deficiency, nuclear type 4, 615159 (3),
UQCR8	AR	?mitochondrial complex iii deficiency, nuclear type 11, 620137 (3),
UQCRB	AR	mitochondrial complex iii deficiency, nuclear type 3, 615158 (3),
UQCRC1	AD	parkinsonism with polyneuropathy, 619279 (3),
UQCRC2	AR	mitochondrial complex iii deficiency, nuclear type 5, 615160 (3),
UQCRFS1	AR	mitochondrial complex iii deficiency, nuclear type 10, 618775 (3),
UQCRH	AR	?mitochondrial complex iii deficiency, nuclear type 11, 620137 (3),
UQCRQ	AR	mitochondrial complex iii deficiency, nuclear type 4, 615159 (3),
UQOR13		
UQOR22	AR	?mitochondrial complex i deficiency, nuclear type 24, 618245 (3),
URAD		
URAH		
URAHP		
URAT1	AR	hypouricemia, renal, 220150 (3),
URATv1	AR,AD	{uric acid concentration, serum, qtl 2}, 612076 (3), ; hypouricemia, renal, 2, 612076 (3),
URAX1		
URB		
URB1		
URB2		
URCC	AD	sessile serrated polyposis cancer syndrome, 617108 (3),
UREB1	XL	intellectual developmental disorder, syndromic, turner type, 309590 (3),
URF2		
URG11		
URG4		
URG7	AR,AD	pseudoxanthoma elasticum, 264800 (3), ; arterial calcification, generalized, of infancy, 2, 614473 (3), ; pseudoxanthoma elasticum, forme fruste, 177850 (3),
URGCP		
URH49		
URI		
URI1		
URK	AD	quebec platelet disorder, 601709 (3), ; {alzheimer disease, late-onset, susceptibility to}, 104300 (3),
URK1		
URKL1		
URKR		
URLC9		
URM1		
Urn1		
UROC		
UROC1	AR	?urocanase deficiency, 276880 (3),
UROC28		
UROD	AR,AD	porphyria, hepatoerythropoietic, 176100 (3), ; porphyria cutanea tarda, 176100 (3),
UROS	AR	porphyria, congenital erythropoietic, 263700 (3),
URP		
URP1	AR	kindler syndrome, 173650 (3),
URP2	AR	leukocyte adhesion deficiency, type iii, 612840 (3),
uS10		
uS11		macrocytic anemia, refractory, due to 5q deletion, somatic, 153550 (3)
uS12	AD	brachycephaly, trichomegaly, and developmental delay, 617412 (3),
uS13		
uS14	AD	diamond-blackfan anemia 13, 615909 (3),
uS15		
uS17		
uS19		
uS2	AD	asplenia, isolated congenital, 271400 (3),
uS3		
uS4		
uS5		
uS7		
uS8	AD	?diamond-blackfan anemia 20, 618313 (3),
uS9		
USA-CYP		
USAG1		
USB1	AR	poikiloderma with neutropenia, 604173 (3),
USE1		
USF1		{hyperlipidemia, familial combined, susceptibility to}, 602491 (3)
USF2		
USF3		
USH1B	AR,AD	deafness, 2, 600060 (3), ; usher syndrome, type 1b, 276900 (3), ; deafness, 11, 601317 (3),
USH1C	AR	usher syndrome, type 1c, 276904 (3), ; deafness, 18a, 602092 (3),
USH1D	AR,AD	usher syndrome, type 1d, 601067 (3), digenic ; {pituitary adenoma 5, multiple types}, 617540 (3), ; usher syndrome, type 1d/f digenic, 601067 (3), digenic ; deafness, 12, 601386 (3),
USH1F	AR	usher syndrome, type 1d/f digenic, 601067 (3), digenic ; deafness, 23, 609533 (3), ; usher syndrome, type 1f, 602083 (3),
USH1G	AR	usher syndrome, type 1g, 606943 (3),
USH1J	AR	deafness, 48, 609439 (3), ; usher syndrome, type ij, 614869 (3),
USH2	AR	usher syndrome, type 2a, 276901 (3), ; retinitis pigmentosa 39, 613809 (3),
USH2A	AR	usher syndrome, type 2a, 276901 (3), ; retinitis pigmentosa 39, 613809 (3),
USH2C	AR,AD	usher syndrome, type 2c, 605472 (3), digenic ; usher syndrome, type 2c, gpr98/pdzd7 digenic, 605472 (3), digenic ; ?febrile seizures, familial, 4, 604352 (3),
USH2D	AR	deafness, 31, 607084 (3), ; usher syndrome, type 2d, 611383 (3),
USH3	AR	usher syndrome, type 3a, 276902 (3), ; retinitis pigmentosa 61, 614180 (3)
USH3A	AR	usher syndrome, type 3a, 276902 (3), ; retinitis pigmentosa 61, 614180 (3)
USH3AL1		
USH3B	AD,AR	charcot-marie-tooth disease, axonal, type 2w, 616625 (3), ; usher syndrome type 3b, 614504 (3),
USHBP1		
USMG5	AR	mitochondrial complex v (atp synthase) deficiency, nuclear type 6, 618683 (3),
USO1		
USP1		
USP10		
USP11		
USP12		
USP12L1		
USP13		
USP14		
USP15		
USP16		
USP17		
USP17L2		
USP17L9P		
USP18	AR	pseudo-torch syndrome 2, 617397 (3),
USP19		
USP2		
USP20		
USP21		
USP22		
USP23		
USP24		
USP25		
USP26	XL	spermatogenic failure, 6, 301101 (3),
USP27	XL,XLR	intellectual developmental disorder, 105, 300984 (3),
USP27X	XL,XLR	intellectual developmental disorder, 105, 300984 (3),
USP28		
USP29		
USP3		
USP30		
USP31	AD	deafness, 85, 620227 (3),
USP32		
USP33		
USP34		
USP36		
USP37		
USP38		
USP39		
USP3L		
USP4		
USP40		
USP44		
USP45	AR	?leber congenital amaurosis 19, 618513 (3),
USP46		
USP47		
USP48	AD	deafness, 85, 620227 (3),
USP5		
USP52		
USP53	AR	cholestasis, progressive familial intrahepatic, 7, with or without hearing loss, 619658 (3),
USP6		
USP6NL		
USP6NL-IT1		
USP7	AD	hao-fountain syndrome, 616863 (3),
USP8		pituitary adenoma 4, acth-secreting, somatic, 219090 (3)
USP9X	XL,XLR,XLD	intellectual developmental disorder, 99, 300919 (3), ; intellectual developmental disorder, 99, syndromic, female-restricted, 300968 (3),
USP9Y	YL	spermatogenic failure, 2, 415000 (3),
USPL1		
USPL2	AD	brooke-spiegler syndrome, 605041 (3), ; cylindromatosis, familial, 132700 (3), ; trichoepithelioma, multiple familial, 1, 601606 (3), ; ?frontotemporal dementia and/or amyotrophic lateral sclerosis 8, 619132 (3),
USS2		
UST		
UST3		
UST6		
UT2		
UTA2-1		
UTDP4-1		
UTF1		
UTI		
UTMOD		
UTP1		
UTP10		
UTP11		
UTP11L		
UTP12		
UTP13		
Utp14		
UTP14A		
UTP14C		
UTP15		
UTP17		
UTP18		
UTP19		
UTP2		
UTP20		
UTP21		glaucoma 1, open angle, g, 609887 (3)
UTP22		
UTP25		
UTP3		
UTP30		
UTP4		
UTP5		
UTP7		
UTRN		
UTS2		
UTS2B		
UTS2D		
UTS2R		
UTX	XLD,XL	kabuki syndrome 2, 300867 (3),
UTY		
UV-DDB2	AR	xeroderma pigmentosum, group e, ddb-negative subtype, 278740 (3),
UVO	AD	ovarian cancer, somatic, 167000 (3); blepharocheilodontic syndrome 1, 119580 (3), ; diffuse gastric and lobular breast cancer syndrome with or without cleft lip and/or palate, 137215 (3), ; endometrial carcinoma, somatic, 608089 (3); breast cancer, lobular, somatic, 114480 (3); {prostate cancer, susceptibility to}, 176807 (3), somatic mutation,
uvomorulin	AD	ovarian cancer, somatic, 167000 (3); blepharocheilodontic syndrome 1, 119580 (3), ; diffuse gastric and lobular breast cancer syndrome with or without cleft lip and/or palate, 137215 (3), ; endometrial carcinoma, somatic, 608089 (3); breast cancer, lobular, somatic, 114480 (3); {prostate cancer, susceptibility to}, 176807 (3), somatic mutation,
UVRAG		
UVSSA	AR	uv-sensitive syndrome 3, 614640 (3),
UXS1		
UXT		
V-1		
v-KIND		
V1bR		
V1RL1		
V28		{rapid progression to aids from hiv1 infection}, 609423 (3); {macular degeneration, age-related, 12}, 613784 (3); {coronary artery disease, resistance to}, 607339 (3)
V2R	XLR,XL	diabetes insipidus, nephrogenic, 1, 304800 (3), ; nephrogenic syndrome of inappropriate antidiuresis, 300539 (3),
V7		
V7-3		
V8	AR	?lacrimal duct defect, 149700 (3),
VA68	AR,AD	cutis laxa, type iid, 617403 (3), ; developmental and epileptic encephalopathy 93, 618012 (3),
VAB-9		
VAC-alph	AD	{pregnancy loss, recurrent, susceptibility to, 3}, 614391 (3),
VAC14	AR	striatonigral degeneration, childhood-onset, 617054 (3),
VACAMKL		
VACHT	AR	myasthenic syndrome, congenital, 21, presynaptic, 617239 (3),
VACM-1		
VACVase		
VAKTI	AR	netherton syndrome, 256500 (3),
VAM-1		
VAM6		
VAMAS1	AR,AD	{vitiligo-associated multiple autoimmune disease susceptibility 1}, 606579 (3); ?respiratory papillomatosis, juvenile recurrent, congenital, 618803 (3), ; autoinflammation with arthritis and dyskeratosis, 617388 (3), ; palmoplantar carcinoma, multiple self-healing, 615225 (3),
VAMP-1	AR,AD	myasthenic syndrome, congenital, 25, 618323 (3), ; spastic ataxia 1, 108600 (3),
VAMP-2	AD	neurodevelopmental disorder with hypotonia and autistic features with or without hyperkinetic movements, 618760 (3),
VAMP-7		
VAMP-8		
VAMP1	AR,AD	myasthenic syndrome, congenital, 25, 618323 (3), ; spastic ataxia 1, 108600 (3),
VAMP2	AD	neurodevelopmental disorder with hypotonia and autistic features with or without hyperkinetic movements, 618760 (3),
VAMP3		
VAMP4		
VAMP5		
VAMP7		
VAMP8		
VAN		
VANGL1	AD	{neural tube defects, susceptibility to}, 182940 (3), ; caudal regression syndrome, 600145 (3),
VANGL2	AD	neural tube defects, 182940 (3),
VAP-1		
VAP-A		
VAP-B	AD	spinal muscular atrophy, late-onset, finkel type, 182980 (3), ; amyotrophic lateral sclerosis 8, 608627 (3),
VAP-C	AD	spinal muscular atrophy, late-onset, finkel type, 182980 (3), ; amyotrophic lateral sclerosis 8, 608627 (3),
VAP1		
VAPA		
VAPB	AD	spinal muscular atrophy, late-onset, finkel type, 182980 (3), ; amyotrophic lateral sclerosis 8, 608627 (3),
VARP		
VARS	AR	neurodevelopmental disorder with microcephaly, seizures, and cortical atrophy, 617802 (3),
VARS1	AR	neurodevelopmental disorder with microcephaly, seizures, and cortical atrophy, 617802 (3),
VARS2	AR,AR	combined oxidative phosphorylation deficiency 20, 615917 (3), |neurodevelopmental disorder with microcephaly, seizures, and cortical atrophy, 617802 (3),
VARS2L	AR	combined oxidative phosphorylation deficiency 20, 615917 (3),
VARSL	AR	combined oxidative phosphorylation deficiency 20, 615917 (3),
Vartul		
VASA		
VASAP-60	AD	polycystic liver disease 1, 174050 (3),
VASH1		
VASH2		
VASN		
VASP		
Vaspin		
VAT1		
VAT1L		
VAT2	AR	?parkinsonism-dystonia, infantile, 2, 618049 (3),
VATB	AR,AD	distal renal tubular acidosis 2 with progressive sensorineural hearing loss, 267300 (3), |zimmermann-laband syndrome 2, 616455 (3), ; deafness, congenital, with onychodystrophy, 124480 (3),
VATC		
VATD		
VATF		
VATI		
VATL		
VATPS1	XLR,XL	immunodeficiency 47, 300972 (3),
VATX		
VAULT1		
VAULT2		
VAULT3		
VAULTRC1		
VAULTRC2		
VAULTRC3		
VAV		
VAV1		
VAV2		
VAV3		
VAX1	AR	?microphthalmia, syndromic 11, 614402 (3),
VAX2		
VBCH	AR,AD	sclerosteosis 1, 269500 (3), ; craniodiaphyseal dysplasia, 122860 (3),
VBCH2	AD,AR	osteopetrosis, 1, 607634 (3), ; [bone mineral density variability 1], 601884 (3), ; polycystic liver disease 4 with or without kidney cysts, 617875 (3), ; endosteal hyperostosis, 144750 (3), ; osteoporosis-pseudoglioma syndrome, 259770 (3), ; exudative vitreoretinopathy 4, 601813 (3),
VBP1		
VCA-2	AR	epidermolysis bullosa, junctional 7, with interstitial lung disease and nephrotic syndrome, 614748 (3),
VCAF	XLR,XL	methylmalonic aciduria and homocysteinemia, cblx type, 309541 (3),
VCAM1		
VCAN	AD	wagner syndrome 1, 143200 (3),
VCC1		
VCF	AD	tetralogy of fallot, 187500 (3), ; digeorge syndrome, 188400 (3), ; conotruncal anomaly face syndrome, 217095 (3); velocardiofacial syndrome, 192430 (3),
VCIP135		
VCL	AD	cardiomyopathy, dilated, 1w, 611407 (3); cardiomyopathy, hypertrophic, 15, 613255 (3),
VCP	AD	frontotemporal dementia and/or amyotrophic lateral sclerosis 6, 613954 (3), ; charcot-marie-tooth disease, type 2y, 616687 (3), ; inclusion body myopathy with early-onset paget disease and frontotemporal dementia 1, 167320 (3),
VCP-KMT		
VCPDM	AD	amyotrophic lateral sclerosis 21, 606070 (3),
VCPIP1		
VCPKMT		
VCX		
VCX-10r		
VCX-2r		
VCX-2R		
VCX-8r		
VCX-8R		
VCX-A		
VCX-B1		
VCX-C		
VCX1		
VCX10R		
VCX2		
VCX3		
VCX3A		
VCX3B		
VCY		
VCY1		
VCY1A		
VCY1B		
VCY2		
VCY2A		
VCY2IP1		
VDAC1		
VDAC2		
VDAC3		
VDBP		
VDD1	AR	vitamin d-dependent rickets, type i, 264700 (3),
VDIR	AR,AD	agammaglobulinemia 8b, 619824 (3), ; agammaglobulinemia 8a, 616941 (3),
VDP		
VDR	AR	rickets, vitamin d-resistant, type iia, 277440 (3),
VDRIP		
VDU1		
VDUP1		
VE-JAM	AR	basal ganglia calcification, idiopathic, 8, 618824 (3),
VEAR		
VEGF		{microvascular complications of diabetes 1}, 603933 (3)
VEGF-A		{microvascular complications of diabetes 1}, 603933 (3)
VEGF-C	AD	lymphatic malformation 4, 615907 (3),
VEGF-D		
VEGF165R		
VEGF165R2		
VEGFA		{microvascular complications of diabetes 1}, 603933 (3)
VEGFB		
VEGFC	AD	lymphatic malformation 4, 615907 (3),
VEGFD		
VEGFL		
VEGFR	AD	{hemangioma, capillary infantile, susceptibility to}, 602089 (3), ; hemangioma, capillary infantile, somatic, 602089 (3)
VEGFR-3	AD	hemangioma, capillary infantile, somatic, 602089 (3); lymphatic malformation 1, 153100 (3), ; congenital heart defects, multiple types, 7, 618780 (3),
VEGFR1		
VEGFR2	AD	{hemangioma, capillary infantile, susceptibility to}, 602089 (3), ; hemangioma, capillary infantile, somatic, 602089 (3)
VEGFR3	AD	hemangioma, capillary infantile, somatic, 602089 (3); lymphatic malformation 1, 153100 (3), ; congenital heart defects, multiple types, 7, 618780 (3),
VEGI		
VEGI192A		
VEGP		
Vel	AR	[blood group, vel system], 615264 (3),
VELI1		
VELI2		
VELI3		
VENTX		
VENTX2		
VEPH1		
VERBRAS	AD	ververi-brady syndrome, 617982 (3),
Very-KIND		
Ves-1		
Vesl-2	AD	?deafness, 68, 616707 (3),
VESPR		
VEZF1	AD	?cardiomyopathy, dilated, 1oo, 620247 (3),
VEZT		
VFL1		
VG5Q		
vGAF		
VGAT		
VGCNL1	AD,AR	congenital contractures of the limbs and face, hypotonia, and developmental delay, 616266 (3), ; hypotonia, infantile, with psychomotor retardation and characteristic facies 1, 615419 (3),
VGF		
VGL		
VGL-3		
VGLL1		
VGLL2		
VGLL3		
VGLL4		
VGLUT1		
VGLUT2		
VGLUT3	AD	deafness, 25, 605583 (3),
VGR	AD	{iron overload, susceptibility to}, 620121 (3),
VGR1	AD	{iron overload, susceptibility to}, 620121 (3),
VHL	AR,AD	hemangioblastoma, cerebellar, somatic (3); erythrocytosis, familial, 2, 263400 (3), ; von hippel-lindau syndrome, 193300 (3), ; renal cell carcinoma, somatic, 144700 (3); pheochromocytoma, 171300 (3),
VHL1	AR,AD	hemangioblastoma, cerebellar, somatic (3); erythrocytosis, familial, 2, 263400 (3), ; von hippel-lindau syndrome, 193300 (3), ; renal cell carcinoma, somatic, 144700 (3); pheochromocytoma, 171300 (3),
VHLL		
VHLP		
VHNF1	AD	type 2 diabetes mellitus, 125853 (3), ; renal cysts and diabetes syndrome, 137920 (3), ; {renal cell carcinoma}, 144700 (3)
VHR		
VHX		
VHY		
VIAAT		
VIAF1		
VIB1A		
VIB1B		
VID24		
VID28		
vig1		
VIII	AR	?mitochondrial complex iv deficiency, nuclear type 15, 619059 (3),
VIII-L	AR	?mitochondrial complex iv deficiency, nuclear type 15, 619059 (3),
VIK		
VIK-1		
VIL		
VIL1		
VIL2		
VILIP		
VILIP-1		
VILIP-3		
VILL		
Vilse		
VIM	AD	cataract 30, pulverulent, 116300 (3),
VIM-AS1		
VIMP		
VINC		
vinexin		
VIP	AR	anterior segment dysgenesis 8, 617319 (3),
VIP-21	AD	myopathy, distal, tateyama type, 614321 (3), ; creatine phosphokinase, elevated serum, 123320 (3), ; cardiomyopathy, familial hypertrophic, 192600 (3), digenic , ; rippling muscle disease 2, 606072 (3), ; long qt syndrome 9, 611818 (3),
VIP1		
VIP17		
VIP2	AR	deafness, 100, 618422 (3),
VIP21	AD	myopathy, distal, tateyama type, 614321 (3), ; creatine phosphokinase, elevated serum, 123320 (3), ; cardiomyopathy, familial hypertrophic, 192600 (3), digenic , ; rippling muscle disease 2, 606072 (3), ; long qt syndrome 9, 611818 (3),
VIP32		
VIP36		
VIPAR	AR	arthrogryposis, renal dysfunction, and cholestasis 2, 613404 (3),
VIPAS39	AR	arthrogryposis, renal dysfunction, and cholestasis 2, 613404 (3),
Viperin		
VIPL	AD,AR	?intellectual developmental disorder, 69, 617863 (3); ?intellectual developmental disorder, 52, 616887 (3),
VIPR1		
VIPR2		
VIRMA		
VIS1		
VISA		
Visc		
VISTA		
VIT		
VIT32		
VKCFD1	AR	vitamin k-dependent clotting factors, combined deficiency of, 1, 277450 (3), ; pseudoxanthoma elasticum-like disorder with multiple coagulation factor deficiency, 610842 (3)
VKCFD2	AR,AD	vitamin k-dependent clotting factors, combined deficiency of, 2, 607473 (3), ; warfarin resistance, 122700 (3),
VKGE9338		
VKORC1	AR,AD	vitamin k-dependent clotting factors, combined deficiency of, 2, 607473 (3), ; warfarin resistance, 122700 (3),
VKORC1L1		
VL	AR	megalencephalic leukoencephalopathy with subcortical cysts 1, 604004 (3),
VLA-6	AR	epidermolysis bullosa, junctional 6, with pyloric atresia, 619817 (3),
VLA1		
VLA3a	AR	epidermolysis bullosa, junctional 7, with interstitial lung disease and nephrotic syndrome, 614748 (3),
VLAA2		
VLACS		
VLACSR		
VLC1	AR,AD	cardiomyopathy, hypertrophic, 8, 608751 (3),
VLCAD	AR	vlcad deficiency, 201475 (3),
VLCS		
VLCS-H1		
VLCS-H2		
VLCSH2		
VLDLR	AR	cerebellar hypoplasia, impaired intellectual development, and dysequilibrium syndrome 1, 224050 (3),
VLDLRCH	AR	cerebellar hypoplasia, impaired intellectual development, and dysequilibrium syndrome 1, 224050 (3),
VLGR1	AR,AD	usher syndrome, type 2c, 605472 (3), digenic ; usher syndrome, type 2c, gpr98/pdzd7 digenic, 605472 (3), digenic ; ?febrile seizures, familial, 4, 604352 (3),
Vlk	AR	rhizomelic limb shortening with dysmorphic features, 618821 (3),
VLP		
VLTI465		
Vma1	AR,AD	cutis laxa, type iid, 617403 (3), ; developmental and epileptic encephalopathy 93, 618012 (3),
Vma10		
VMA12	AR	congenital disorder of glycosylation, type iip, 616829 (3),
VMA13		
VMA16		
Vma2	AR,AD	distal renal tubular acidosis 2 with progressive sensorineural hearing loss, 267300 (3), |zimmermann-laband syndrome 2, 616455 (3), ; deafness, congenital, with onychodystrophy, 124480 (3),
VMA21	XL,XLR	myopathy, with excessive autophagy, 310440 (3),
Vma3		
Vma4	AR	cutis laxa, type iic, 617402 (3),
VMA4		
Vma5		
VMA5		
Vma6		
VMA6		
Vma7		
VMA8		
VMAC		
VMAT1		
VMAT2	AR	?parkinsonism-dystonia, infantile, 2, 618049 (3),
VMCM	AD	venous malformations, multiple cutaneous and mucosal, 600195 (3), ; glaucoma 3, primary congenital, e, 617272 (3),
VMCM1	AD	venous malformations, multiple cutaneous and mucosal, 600195 (3), ; glaucoma 3, primary congenital, e, 617272 (3),
VMD2	AD,AR	macular dystrophy, vitelliform, 2, 153700 (3), ; ?microcornea, rod-cone dystrophy, cataract, and posterior staphyloma 2, 193220 (3), ; retinitis pigmentosa-50, 613194 (3); retinitis pigmentosa, concentric, 613194 (3); vitreoretinochoroidopathy, 193220 (3), ; bestrophinopathy, 611809 (3)
VMD2L1		
VMD2L2		
VMD2L3		
VMGLOM	AD	glomuvenous malformations, 138000 (3),
VMP		
VMP1		
Vms1		
VN		
VN1R1		
VNN1		
VNN2		
VNN3		
VNN3P		
VNR19I1		
VNRA		
VNUT	AD	porokeratosis 8, disseminated superficial actinic type, 616063 (3),
VOPP1		
VP	AD	porphyria variegata, 176200 (3),
VPAC1		
VPAC1R		
VPAC2		
VPAC2R		
VPARP		
VPATPD		
VPF		{microvascular complications of diabetes 1}, 603933 (3)
Vph1	AR,AR,AD,AR	distal renal tubular acidosis 3, with or without sensorineural hearing loss, 602722 (3), |neurodevelopmental disorder with epilepsy and brain atrophy, 619971 (3), ; developmental and epileptic encephalopathy 104, 619970 (3), |wrinkly skin syndrome, 278250 (3), ; cutis laxa, type iia, 219200 (3),
VPH2	AR	congenital disorder of glycosylation, type iip, 616829 (3),
VPP1	AR,AD	neurodevelopmental disorder with epilepsy and brain atrophy, 619971 (3), ; developmental and epileptic encephalopathy 104, 619970 (3),
VPP2	AR,AD,AR	cutis laxa, type iid, 617403 (3), ; developmental and epileptic encephalopathy 93, 618012 (3), |distal renal tubular acidosis 3, with or without sensorineural hearing loss, 602722 (3),
VPP3	AR,AD	distal renal tubular acidosis 2 with progressive sensorineural hearing loss, 267300 (3), |zimmermann-laband syndrome 2, 616455 (3), ; deafness, congenital, with onychodystrophy, 124480 (3),
VPR3		
VPRBP		
VpreB		
VPREB1		
VPREB3		
VPS1	AD,AR	optic atrophy 5, 610708 (3), ; encephalopathy, lethal, due to defective mitochondrial peroxisomal fission 1, 614388 (3),
VPS11	AR	?dystonia 32, 619637 (3), ; leukodystrophy, hypomyelinating, 12, 616683 (3),
VPS13A	AR	choreoacanthocytosis, 200150 (3),
VPS13B	AR	cohen syndrome, 216550 (3),
VPS13C	AR	parkinson disease 23, early onset, 616840 (3),
VPS13D	AR	spinocerebellar ataxia, 4, 607317 (3),
VPS15		
VPS16	AD	dystonia 30, 619291 (3),
VPS16B	AR	arthrogryposis, renal dysfunction, and cholestasis 2, 613404 (3),
VPS18		
VPS2		
VPS20		
VPS22		
VPS23		
VPS24		
VPS25		
VPS26		
VPS26A		
VPS26B		
VPS26C		
Vps27		
VPS28		
VPS29		
VPS2A		
VPS2B	AD	frontotemporal dementia and/or amyotrophic lateral sclerosis 7, 600795 (3),
VPS3		
VPS30		
VPS32A		
VPS32B	AD	cataract 31, multiple types, 605387 (3),
VPS32C		
VPS33A	AR	mucopolysaccharidosis-plus syndrome, 617303 (3),
VPS33B	AR	keratoderma-ichthyosis-deafness syndrome, 620009 (3), ; cholestasis, progressive familial intrahepatic, 12, 620010 (3), ; arthrogryposis, renal dysfunction, and cholestasis 1, 208085 (3),
Vps34		
VPS35	AD	{parkinson disease 17}, 614203 (3),
VPS35L	AR	ritscher-schinzel syndrome 3, 619135 (3),
VPS36		
VPS37A	AR	spastic paraplegia 53, 614898 (3),
VPS37B		
VPS37C		
VPS37D		
VPS38		
VPS39		
VPS4	AD	cimdag syndrome, 619273 (3),
VPS4-1	AD	cimdag syndrome, 619273 (3),
VPS4-2		
VPS41	AR	spinocerebellar ataxia, 29, 619389 (3),
VPS45	AR	neutropenia, severe congenital, 5, 615285 (3),
VPS45A	AR	neutropenia, severe congenital, 5, 615285 (3),
VPS45B	AR	neutropenia, severe congenital, 5, 615285 (3),
Vps46A	AR	pontocerebellar hypoplasia, type 8, 614961 (3),
Vps46B		
VPS4A	AD	cimdag syndrome, 619273 (3),
VPS4B		
Vps5		
VPS50	AR	neurodevelopmental disorder with microcephaly, seizures, and neonatal cholestasis, 619685 (3),
VPS51	AR	pontocerebellar hypoplasia, type 13, 618606 (3),
VPS52		
VPS53	AR	pontocerebellar hypoplasia, type 2e, 615851 (3),
VPS54		
VPS54L	AR	neurodevelopmental disorder with microcephaly, seizures, and neonatal cholestasis, 619685 (3),
Vps55		
VPS55		
Vps60		
VPS72		
Vps74		
VPS8		
VPS9D1		
Vpu		
VR-OAC	AD	spondylometaphyseal dysplasia, kozlowski type, 184252 (3), ; digital arthropathy-brachydactyly, familial, 606835 (3), ; [sodium serum level qtl 1], 613508 (3); sed, maroteaux type, 184095 (3), ; metatropic dysplasia, 156530 (3), ; scapuloperoneal spinal muscular atrophy, 181405 (3), ; hereditary motor and sensory neuropathy, type iic, 606071 (3), ; ?avascular necrosis of femoral head, primary, 2, 617383 (3), ; neuronopathy, distal hereditary motor, type viii, 600175 (3), ; parastremmatic dwarfism, 168400 (3), ; brachyolmia type 3, 113500 (3),
VR1		
VR2		
VR20		
VR22	AD	arrhythmogenic right ventricular dysplasia, familial, 13, 615616 (3),
VR3		
VRF		
VRHO		
VRK1	AR	pontocerebellar hypoplasia type 1a, 607596 (3),
VRK2		
VRK3		
VRL		
VRL-1		
VRL-2	AD	spondylometaphyseal dysplasia, kozlowski type, 184252 (3), ; digital arthropathy-brachydactyly, familial, 606835 (3), ; [sodium serum level qtl 1], 613508 (3); sed, maroteaux type, 184095 (3), ; metatropic dysplasia, 156530 (3), ; scapuloperoneal spinal muscular atrophy, 181405 (3), ; hereditary motor and sensory neuropathy, type iic, 606071 (3), ; ?avascular necrosis of femoral head, primary, 2, 617383 (3), ; neuronopathy, distal hereditary motor, type viii, 600175 (3), ; parastremmatic dwarfism, 168400 (3), ; brachyolmia type 3, 113500 (3),
VRL1		
VRL3	AD	?palmoplantar keratoderma, nonepidermolytic, focal 2, 616400 (3), ; olmsted syndrome 1, 614594 (3),
vRNA		
VRNI	AD	vitreoretinopathy, neovascular inflammatory, 193235 (3),
VROAC	AD	spondylometaphyseal dysplasia, kozlowski type, 184252 (3), ; digital arthropathy-brachydactyly, familial, 606835 (3), ; [sodium serum level qtl 1], 613508 (3); sed, maroteaux type, 184095 (3), ; metatropic dysplasia, 156530 (3), ; scapuloperoneal spinal muscular atrophy, 181405 (3), ; hereditary motor and sensory neuropathy, type iic, 606071 (3), ; ?avascular necrosis of femoral head, primary, 2, 617383 (3), ; neuronopathy, distal hereditary motor, type viii, 600175 (3), ; parastremmatic dwarfism, 168400 (3), ; brachyolmia type 3, 113500 (3),
VRP	AD	lymphatic malformation 4, 615907 (3),
VSHK1		
VSIG1		
VSIG10L		
VSIG2		
VSIG3		
VSIG4		
VSIG9		
VSIR		
Vsm-RhoGEF		
VSNL1		
VSOP		
VSTM1		
VSTM2L		
VSTM3		
VSX1	AD	?craniofacial anomalies and anterior segment dysgenesis syndrome, 614195 (3), ; keratoconus 1, 148300 (3),
VSX2	AR	microphthalmia, isolated 2, 610093 (3), ; microphthalmia with coloboma 3, 610092 (3),
VTA1		
VTCN1		
Vti1-rp2		
VTI1A		
VTI1B		
VTI2		
VTN		
VTNR		
VTRNA1-1		
VTRNA1-2		
VTRNA1-3		
vtRNA2		
VTRNA2		
VTRNA2-1		
VTS58635		
VTSIP	AD	ventricular tachycardia, catecholaminergic polymorphic, 1, 604772 (3), ; ventricular arrhythmias due to cardiac ryanodine receptor calcium release deficiency syndrome, 115000 (3),
VWA-1	AR	neuropathy, hereditary motor, with myopathic features, 619216 (3),
VWA1	AR	neuropathy, hereditary motor, with myopathic features, 619216 (3),
VWA2		
VWA3B	AR	?spinocerebellar ataxia, 22, 616948 (3),
VWA4		
VWA5A		
VWA5C		
VWA6		
VWA7		
VWA8	AD	?retinitis pigmentosa 97, 620422 (3),
VWC1		
VWC2		
VWC2L		
VWCD1		
VWCE		
VWF	AD,AR	von willebrand disease, type 1, 193400 (3), ; von willebrand disease, types 2a, 2b, 2m, and 2n, 613554 (3), ; von willebrand disease, type 3, 277480 (3),
vWF-CP	AR	thrombotic thrombocytopenic purpura, hereditary, 274150 (3),
VWFCP	AR	thrombotic thrombocytopenic purpura, hereditary, 274150 (3),
VWS	AD	{orofacial cleft 6}, 608864 (3), ; popliteal pterygium syndrome 1, 119500 (3), ; van der woude syndrome 1, 119300 (3),
VWS1	AD	{orofacial cleft 6}, 608864 (3), ; popliteal pterygium syndrome 1, 119500 (3), ; van der woude syndrome 1, 119300 (3),
vzg-1		
W117m	AR	neurodevelopmental disorder with intracranial hemorrhage, seizures, and spasticity, 620371 (3),
W5C5		
WABS	AR	warsaw breakage syndrome, 613398 (3),
WAC	AD	desanto-shinawi syndrome, 616708 (3),
WAF1		
WAFL		
WAGR	AD,AD	mesothelioma, somatic, 156240 (3); meacham syndrome, 608978 (3), ; frasier syndrome, 136680 (3), somatic mutation, ; nephrotic syndrome, type 4, 256370 (3), ; denys-drash syndrome, 194080 (3), somatic mutation, ; wilms tumor, type 1, 194070 (3), somatic mutation, |optic nerve hypoplasia, 165550 (3), ; cataract with late-onset corneal dystrophy, 106210 (3), ; ?coloboma, ocular, 120200 (3), ; ?coloboma of optic nerve, 120430 (3), ; aniridia, 106210 (3), ; anterior segment dysgenesis 5, multiple subtypes, 604229 (3), ; ?morning glory disc anomaly, 120430 (3), ; foveal hypoplasia 1, 136520 (3), ; keratitis, 148190 (3),
WAIT-1	AD	cohen-gibson syndrome, 617561 (3),
WAKMAR1		
WAKMAR2		
WALp1		
WALp3		
WALp4		
WAML		
WAP1		
WAP2		
WAP3		
WAP4		
WAP5		
WAP7		
WAPAL		
WAPL		
WARBM1	AR	martsolf syndrome 2, 619420 (3), ; warburg micro syndrome 1, 600118 (3),
WARP	AR	neuropathy, hereditary motor, with myopathic features, 619216 (3),
WARS	AR,AD	neurodevelopmental disorder with microcephaly and speech delay, with or without brain abnormalities, 620317 (3), ; neuronopathy, distal hereditary motor, type ix, 617721 (3),
WARS1	AR,AD	neurodevelopmental disorder with microcephaly and speech delay, with or without brain abnormalities, 620317 (3), ; neuronopathy, distal hereditary motor, type ix, 617721 (3),
WARS2	AR	parkinsonism-dystonia 3, childhood-onset, 619738 (3), ; neurodevelopmental disorder, mitochondrial, with abnormal movements and lactic acidosis, with or without seizures, 617710 (3),
WARTS		
WAS	XLR,XL	wiskott-aldrich syndrome, 301000 (3), ; neutropenia, severe congenital, 300299 (3), ; thrombocytopenia, intermittent, 313900 (3), ; thrombocytopenia, 313900 (3),
WASF1	AD	neurodevelopmental disorder with absent language and variable seizures, 618707 (3),
WASF2		
WASF3		
WASH1		
WASHC1		
WASHC2C		
WASHC3		
WASHC4	AR	intellectual developmental disorder, 43, 615817 (3),
WASHC5	AR,AD	ritscher-schinzel syndrome 1, 220210 (3), ; spastic paraplegia 8, 603563 (3),
WASL		
WASLBP		
WASP	XLR,XL	wiskott-aldrich syndrome, 301000 (3), ; neutropenia, severe congenital, 300299 (3), ; thrombocytopenia, intermittent, 313900 (3), ; thrombocytopenia, 313900 (3),
WASPA	XLR,XL	wiskott-aldrich syndrome, 301000 (3), ; neutropenia, severe congenital, 300299 (3), ; thrombocytopenia, intermittent, 313900 (3), ; thrombocytopenia, 313900 (3),
WASPB		
WASPIP	AR	wiskott-aldrich syndrome 2, 614493 (3),
WAVE	AD	neurodevelopmental disorder with absent language and variable seizures, 618707 (3),
WAVE1	AD	neurodevelopmental disorder with absent language and variable seizures, 618707 (3),
WAVE2		
WAVE3		
WBMT		
WBP-1		
WBP-2	AR	deafness, 107, 617639 (3),
WBP1	AR	congenital disorder of glycosylation, type ir, 614507 (3),
WBP11	AD	vertebral, cardiac, tracheoesophageal, renal, and limb defects, 619227 (3),
WBP15		
WBP1L		
WBP1L2		
WBP2	AR	deafness, 107, 617639 (3),
WBP2NL		
WBP3		
WBP4		
WBP7	AD	intellectual developmental disorder, 68, 619934 (3), ; dystonia 28, childhood-onset, 617284 (3),
WBS	AD	cutis laxa, 123700 (3), ; supravalvar aortic stenosis, 185500 (3),
WBSCR1		
WBSCR10		
WBSCR11		
WBSCR12		
WBSCR13		
WBSCR14		
WBSCR15		
WBSCR17		
WBSCR18	AR	leber hereditary optic neuropathy, 619382 (3),
WBSCR19		
WBSCR20		
WBSCR20A		
WBSCR22		
WBSCR24		
WBSCR26		
WBSCR27		
WBSCR28		
WBSCR3		
WBSCR4		
WBSCR5		
WBSCR6		
WBSCR8		
WBSCR9		
WC1		
WCRF180		
WD	AD,AR	[blood group, swann], 601550 (3); [blood group, wright], 112050 (3); distal renal tubular acidosis 1, 179800 (3), ; [blood group, waldner], 112010 (3); spherocytosis, type 4, 612653 (3), ; [blood group, froese], 601551 (3); distal renal tubular acidosis 4 with hemolytic anemia, 611590 (3), ; {malaria, resistance to}, 611162 (3); cryohydrocytosis, 185020 (3), ; ovalocytosis, sa type, 166900 (3), ; [blood group, diego], 110500 (3)
WDC146		
WDCP		
WDF1		
WDFY1		
WDFY2		
WDFY3	AD	?microcephaly 18, primary, 617520 (3),
WDFY4		
WDHD1		
WDPCP	AR	?bardet-biedl syndrome 15, 615992 (3), ; congenital heart defects, hamartomas of tongue, and polysyndactyly, 217085 (3),
WDR1	AR	periodic fever, immunodeficiency, and thrombocytopenia syndrome, 150550 (3),
WDR10	AR	cranioectodermal dysplasia 1, 218330 (3),
WDR10p	AR	cranioectodermal dysplasia 1, 218330 (3),
WDR11	AD,AR,AD	chung-jansen syndrome, 617991 (3), |intellectual developmental disorder, 78, 620237 (3), ; hypogonadotropic hypogonadism 14 with or without anosmia, 614858 (3),
WDR12		
WDR13		
WDR14		
WDR140	AR	cranioectodermal dysplasia 1, 218330 (3),
WDR15	AR,AD	intellectual developmental disorder, 78, 620237 (3), ; hypogonadotropic hypogonadism 14 with or without anosmia, 614858 (3),
WDR16	AR	heterotaxy, visceral, 10, with male infertility, 619607 (3),
WDR17		
WDR18		
WDR19	AR	nephronophthisis 13, 614377 (3), ; cranioectodermal dysplasia 4, 614378 (3), ; senior-loken syndrome 8, 616307 (3), ; short-rib thoracic dysplasia 5 with or without polydactyly, 614376 (3), ; ?spermatogenic failure 72, 619867 (3),
WDR2		
WDR20		
WDR21		
WDR21A		
WDR21C		
WDR22		
WDR23		
WDR24		
WDR25		
WDR26	AD	skraban-deardorff syndrome, 617616 (3),
WDR28		
WDR29		
WDR3		
WDR30		{inflammatory bowel disease (crohn disease) 10}, 611081 (3)
WDR32		
WDR33		
WDR34	AR	short-rib thoracic dysplasia 11 with or without polydactyly, 615633 (3),
WDR35	AR	short-rib thoracic dysplasia 7 with or without polydactyly, 614091 (3), ; cranioectodermal dysplasia 2, 613610 (3),
WDR36		glaucoma 1, open angle, g, 609887 (3)
WDR37	AD	neurooculocardiogenitourinary syndrome, 618652 (3),
WDR39		
WDR4	AR	galloway-mowat syndrome 6, 618347 (3), ; microcephaly, growth deficiency, seizures, and brain malformations, 618346 (3),
WDR40A		
WDR41		
WDR42A	AD	?giant axonal neuropathy 2, 610100 (3),
WDR43		
WDR44		
WDR45	XLD,XL	neurodegeneration with brain iron accumulation 5, 300894 (3),
WDR45B	AR	neurodevelopmental disorder with spastic quadriplegia and brain abnormalities with or without seizures, 617977 (3),
WDR45L	AR	neurodevelopmental disorder with spastic quadriplegia and brain abnormalities with or without seizures, 617977 (3),
WDR46		
WDR47		
WDR48		
WDR5		
WDR50		
WDR51A	AR	short stature, onychodysplasia, facial dysmorphism, and hypotrichosis, 614813 (3),
WDR51B	AR	cone-rod dystrophy 20, 615973 (3),
WDR52	AR	spermatogenic failure 20, 617593 (3),
WDR53		
WDR56	AR	short-rib thoracic dysplasia 2 with or without polydactyly, 611263 (3),
WDR57		
WDR58	AR	beaulieu-boycott-innes syndrome, 613680 (3),
WDR59		
WDR6		
WDR60	AR	short-rib thoracic dysplasia 8 with or without polydactyly, 615503 (3),
WDR61		
WDR62	AR	microcephaly 2, primary, with or without cortical malformations, 604317 (3),
WDR63		
WDR65		
WDR66	AR	spermatogenic failure 33, 618152 (3),
WDR68		
WDR69		
WDR7		
WDR70		
WDR71		
WDR72	AR	amelogenesis imperfecta, type iia3, 613211 (3),
WDR73	AR	galloway-mowat syndrome 1, 251300 (3),
WDR74		
WDR75		
WDR76		
WDR77		
WDR78		
WDR79	AR	dyskeratosis congenita, 3, 613988 (3),
WDR8		
WDR80		
WDR81	AR	cerebellar ataxia, impaired intellectual development, and dysquilibrium syndrome 2, 610185 (3), ; hydrocephalus, congenital, 3, with brain anomalies, 617967 (3),
WDR82		
WDR82A		
WDR83		
WDR83OS		
WDR84		
WDR85		
WDR87		
WDR9		
WDR90		
WDR91		
WDR92		
WDR93		
WDR94		
WDR96	AD,AR	hydrocephalus, normal pressure, 1, 236690 (3), ; spermatogenic failure 19, 617592 (3),
WDR98		
WDRPUH	AR	heterotaxy, visceral, 10, with male infertility, 619607 (3),
WDRX1	XLD,XL	neurodegeneration with brain iron accumulation 5, 300894 (3),
WDSOF1		
WDT2		
WDTC1		
WDTC2	AR	short-rib thoracic dysplasia 9 with or without polydactyly, 266920 (3), ; retinitis pigmentosa 80, 617781 (3),
WEE1		
WEE1A		
WEE1B	AR	oocyte/zygote/embryo maturation arrest 5, 617996 (3),
WEE2	AR	oocyte/zygote/embryo maturation arrest 5, 617996 (3),
WEX5		
WEX9	XL,XLD	neurodevelopmental disorder with gait disturbance, dysmorphic facies and behavioral abnormalities, 301094 (3),
WF-1		
WFDC1		
WFDC12		
WFDC14		
WFDC19	XLR,XL	hypogonadotropic hypogonadism 1 with or without anosmia (kallmann syndrome 1), 308700 (3),
WFDC2		
WFDC20A		
WFDC20B		
WFDC21P		
WFDC4		
WFDC5		
WFDC7		
WFIKKN		
WFIKKN1		
WFIKKN2		
WFIKKNRP		
WFS	AD,AR	deafness, 6/14/38, 600965 (3), ; ?cataract 41, 116400 (3), ; wolfram-like syndrome, 614296 (3), ; {diabetes mellitus, noninsulin-dependent, association with}, 125853 (3), ; wolfram syndrome 1, 222300 (3),
WFS1	AD,AR	deafness, 6/14/38, 600965 (3), ; ?cataract 41, 116400 (3), ; wolfram-like syndrome, 614296 (3), ; {diabetes mellitus, noninsulin-dependent, association with}, 125853 (3), ; wolfram syndrome 1, 222300 (3),
WFS2	AR	wolfram syndrome 2, 604928 (3),
WGAR9166		
WGEF		
WGG1	XLR,XL	?diamond-blackfan anemia 14 with mandibulofacial dysostosis, 300946 (3),
WHAMM		
WHAMM1		
WHAMM2		
WHDC1		
WHIP		
WHISTLE		
WHITE2		
WHN	AD,AR	t-cell lymphopenia, infantile, with or without nail dystrophy, 618806 (3), ; t-cell immunodeficiency, congenital alopecia, and nail dystrophy, 601705 (3),
WHRN	AR	deafness, 31, 607084 (3), ; usher syndrome, type 2d, 611383 (3),
WHSC1	AD	rauch-steindl syndrome, 619695 (3),
WHSC1L1		
WHSC2		
WI-31133		
WIBG		
WICH		
WID		
WIF1		
WIG-1		
WIG1		
willin		
wim	AR	retinitis pigmentosa 71, 616394 (3), ; bardet-biedl syndrome 20, 619471 (3), ; short-rib thoracic dysplasia 10 with or without polydactyly, 615630 (3),
WINS1	AR	intellectual developmental disorder, 27, 614340 (3),
WIP	AR	wiskott-aldrich syndrome 2, 614493 (3),
Wip1	AD	breast cancer, somatic, 114480 (3); jansen de vries syndrome, 617450 (3),
WIPF1	AR	wiskott-aldrich syndrome 2, 614493 (3),
WIPF2		
WIPF3		
WIPI1		
WIPI2	AR	?intellectual developmental disorder with short stature and variable skeletal anomalies, 618453 (3),
WIPI3	AR	neurodevelopmental disorder with spastic quadriplegia and brain abnormalities with or without seizures, 617977 (3),
WIPI4	XLD,XL	neurodegeneration with brain iron accumulation 5, 300894 (3),
WIPI49		
WIRE		
WISH		
WISP-1		
WISP-2		
WISP-3	AR	progressive pseudorheumatoid dysplasia, 208230 (3),
WISP1		
WISP1-OT1		
WISP1-UT1		
WISP2		
WISP3	AR	progressive pseudorheumatoid dysplasia, 208230 (3),
WISp39		
WIT-1		
WIT-2	AD	mesothelioma, somatic, 156240 (3); meacham syndrome, 608978 (3), ; frasier syndrome, 136680 (3), somatic mutation, ; nephrotic syndrome, type 4, 256370 (3), ; denys-drash syndrome, 194080 (3), somatic mutation, ; wilms tumor, type 1, 194070 (3), somatic mutation,
WIT1		
WIZ		
WLS	AR	zaki syndrome, 619648 (3),
WMS	AD	geleophysic dysplasia 2, 614185 (3), ; weill-marchesani syndrome 2, 608328 (3), ; ectopia lentis, familial, 129600 (3), ; mass syndrome, 604308 (3), ; marfan lipodystrophy syndrome, 616914 (3), ; acromicric dysplasia, 102370 (3), ; marfan syndrome, 154700 (3), ; stiff skin syndrome, 184900 (3),
WND	AR	wilson disease, 277900 (3),
WNK1	AR,AD	neuropathy, hereditary sensory and autonomic, type ii, 201300 (3), ; pseudohypoaldosteronism, type iic, 614492 (3),
WNK2		
WNK3		
WNK4	AD	pseudohypoaldosteronism, type iib, 614491 (3),
WNT-12	AD,AR	tooth agenesis, selective, 8, 617073 (3), ; split-hand/foot malformation 6, 225300 (3),
WNT-4	AR,AD	?serkal syndrome, 611812 (3), ; mullerian aplasia and hyperandrogenism, 158330 (3),
Wnt-7a	AR	fuhrmann syndrome, 228930 (3), ; ulna and fibula, absence of, with severe limb deficiency, 276820 (3),
WNT1	AD,AR	{osteoporosis, early-onset, susceptibility to, }, 615221 (3), ; osteogenesis imperfecta, type xv, 615220 (3),
WNT10A	AR,AD	schopf-schulz-passarge syndrome, 224750 (3), ; tooth agenesis, selective, 4, 150400 (3), ; ectodermal dysplasia 16 (odontoonychodermal dysplasia), 257980 (3),
WNT10B	AD,AR	tooth agenesis, selective, 8, 617073 (3), ; split-hand/foot malformation 6, 225300 (3),
WNT11		
WNT13	AR	diarrhea 9, 618168 (3),
WNT14		
WNT14B		
WNT15		
WNT16		
WNT2		
WNT2B	AR	diarrhea 9, 618168 (3),
WNT3	AR	?tetra-amelia syndrome 1, 273395 (3),
WNT3A		
WNT4	AR,AD	?serkal syndrome, 611812 (3), ; mullerian aplasia and hyperandrogenism, 158330 (3),
WNT5A	AD	robinow syndrome, 1, 180700 (3),
WNT5B		
WNT6		
WNT7A	AR	fuhrmann syndrome, 228930 (3), ; ulna and fibula, absence of, with severe limb deficiency, 276820 (3),
WNT7B		
WNT8A		
WNT8B		
WNT8D		
WNT9A		
WNT9B		
WOX1	AR	esophageal squamous cell carcinoma, somatic, 133239 (3); developmental and epileptic encephalopathy 28, 616211 (3), ; spinocerebellar ataxia, 12, 614322 (3),
WP34		
WPWS	AD	glycogen storage disease of heart, lethal congenital, 261740 (3), ; wolff-parkinson-white syndrome, 194200 (3), ; cardiomyopathy, hypertrophic 6, 600858 (3),
WR	AD,AR	[blood group, swann], 601550 (3); [blood group, wright], 112050 (3); distal renal tubular acidosis 1, 179800 (3), ; [blood group, waldner], 112010 (3); spherocytosis, type 4, 612653 (3), ; [blood group, froese], 601551 (3); distal renal tubular acidosis 4 with hemolytic anemia, 611590 (3), ; {malaria, resistance to}, 611162 (3); cryohydrocytosis, 185020 (3), ; ovalocytosis, sa type, 166900 (3), ; [blood group, diego], 110500 (3)
WRAP53	AR	dyskeratosis congenita, 3, 613988 (3),
WRAP73		
WRB		
WRCH-1		
WRCH1		
WRCH2		
WRN	AR	werner syndrome, 277700 (3),
WRNIP1		
WRP		
WS	AD	cutis laxa, 123700 (3), ; supravalvar aortic stenosis, 185500 (3),
WS-3		
WS-betaTRP		
WS-bHLH		
WS1	AD,AR	craniofacial-deafness-hand syndrome, 122880 (3), ; waardenburg syndrome, type 3, 148820 (3), ; waardenburg syndrome, type 1, 193500 (3), ; rhabdomyosarcoma 2, alveolar, 268220 (3), somatic mutation
WS2	AD,AR	waardenburg syndrome, type 2a, 193510 (3), ; {melanoma, cutaneous malignant, susceptibility to, 8}, 614456 (3); tietz albinism-deafness syndrome, 103500 (3), ; commad syndrome, 617306 (3),
WS2A	AD,AR	waardenburg syndrome, type 2a, 193510 (3), ; {melanoma, cutaneous malignant, susceptibility to, 8}, 614456 (3); tietz albinism-deafness syndrome, 103500 (3), ; commad syndrome, 617306 (3),
WS2E	AD	waardenburg syndrome, type 4c, 613266 (3), ; pcwh syndrome, 609136 (3), ; waardenburg syndrome, type 2e, with or without neurologic involvement, 611584 (3),
WS3-10		
WS4	AD	waardenburg syndrome, type 4c, 613266 (3), ; pcwh syndrome, 609136 (3), ; waardenburg syndrome, type 2e, with or without neurologic involvement, 611584 (3),
WS9-14		
WSB1		
WSC4		
WSCD1		
WSCD2		
WSCR1		
WSCR3		
WSCR4		
WSCR5		
WSL-1		
WSL-LR		
WSN	XL,XLR	intellectual developmental disorder, 72, 300271 (3), ; waisman syndrome, 311510 (3),
WSPAR		
WSTF		
WSX-1		
WSX1		
WT-1	AD	mesothelioma, somatic, 156240 (3); meacham syndrome, 608978 (3), ; frasier syndrome, 136680 (3), somatic mutation, ; nephrotic syndrome, type 4, 256370 (3), ; denys-drash syndrome, 194080 (3), somatic mutation, ; wilms tumor, type 1, 194070 (3), somatic mutation,
WT1	AD	mesothelioma, somatic, 156240 (3); meacham syndrome, 608978 (3), ; frasier syndrome, 136680 (3), somatic mutation, ; nephrotic syndrome, type 4, 256370 (3), ; denys-drash syndrome, 194080 (3), somatic mutation, ; wilms tumor, type 1, 194070 (3), somatic mutation,
WT1-AS		
WT1-AS1		
WT1AS		
WT2	AD	wilms tumor 2, 194071 (3), somatic mutation, ; beckwith-wiedemann syndrome, 130650 (3), ; silver-russell syndrome 1, 180860 (3),
WTAP		
WTH3		
WTIP		
WTS	XLD,XL	cornelia de lange syndrome 5, 300882 (3),
WTX	XLD,XL	osteopathia striata with cranial sclerosis, 300373 (3),
WUGSC:H_DJ0747G18.2	AR	mednik syndrome, 609313 (3),
WUGSC:H_DJ525N14.1		
Wuho	AR	galloway-mowat syndrome 6, 618347 (3), ; microcephaly, growth deficiency, seizures, and brain malformations, 618346 (3),
WW45		
WWC1		[memory, enhanced, qtl], 615602 (3)
WWC2		
WWC2-AS1		
WWC3		
WWFQ154	AR	cone-rod dystrophy 21, 616502 (3),
WWOX	AR	esophageal squamous cell carcinoma, somatic, 133239 (3); developmental and epileptic encephalopathy 28, 616211 (3), ; spinocerebellar ataxia, 12, 614322 (3),
WWP1		
WWP2		
WWP3		
Wwp4	AD	desanto-shinawi syndrome, 616708 (3),
WWP4		
WWS	XLR,XLD,XL	wieacker-wolff syndrome, 314580 (3), ; wieacker-wolff syndrome, female-restricted, 301041 (3),
WWTR1		
wyatt		{malaria, protection against}, 611162 (3); {tuberculosis, protection against}, 607948 (3); {bacteremia, protection against}, 614382 (3)
X-kinase		
X104	AR	hypercholanemia, familial 1, 607748 (3), ; cholestasis, progressive familial intrahepatic 4, 615878 (3),
X11		
X11L		
X11L2		
X123		
X17		
X1k	XL	mcleod syndrome with or without chronic granulomatous disease, 300842 (3),
X25	AR	friedreich ataxia with retained reflexes, 229300 (3), ; friedreich ataxia, 229300 (3),
X3	AD	basal ganglia calcification, idiopathic, 6, 616413 (3),
X5L		
X91348		
XAB1		
XAB2		
XACT		
XAF1		
XAG-2	AR	respiratory infections, recurrent, and failure to thrive with or without diarrhea, 620233 (3),
XAGE-1		
XAGE-2		
XAGE-3		
XAGE-5		
XAGE1		
XAGE1A		
XAGE1B		
XAGE1C		
XAGE1D		
XAGE1E		
XAGE2		
XAGE2B		
XAGE3		
XAGE5		
XAP-3	XLR,XL	immunodeficiency 47, 300972 (3),
XAP-4	XL,XLD	intellectual developmental disorder, 41, 300849 (3),
XAP-6		
XAP-7		
XAP101	XL,XLR	dyskeratosis congenita, 305000 (3),
XAP104	XLR,XLD,XL	ck syndrome, 300831 (3), ; child syndrome, 308050 (3),
XAP121	XL,XLR	?intellectual developmental disorder, syndromic 32, 300886 (3),
XAP130	XL,XLR	{autism, susceptibility to, 6}, 300872 (3),
XAP135		
XAP2	AD	pituitary adenoma 1, multiple types, 102200 (3), somatic mutation, ; pituitary adenoma predisposition, 102200 (3), somatic mutation,
XAP3	XLR,XL	immunodeficiency 47, 300972 (3),
XAP4	AR	polyglucosan body myopathy 1 with or without immunodeficiency, 615895 (3),
XAP5	XL,XLR	intellectual developmental disorder, syndromic, armfield type, 300261 (3),
XAP8		
XAPC7		
XAT2		
XB	AR,AD	ehlers-danlos syndrome, classic-like, 1, 606408 (3), ; vesicoureteral reflux 8, 615963 (3),
XB130		
XB51		
XBP1		{major affective disorder-7, susceptibility to}, 612371 (3)
XBP2		{major affective disorder-7, susceptibility to}, 612371 (3)
XBR	AD	deafness, 27, 612431 (3), ; {wilms tumor 6, susceptibility to}, 616806 (3), ; fibromatosis, gingival, 5, 617626 (3),
XBS	AR,AD	ehlers-danlos syndrome, classic-like, 1, 606408 (3), ; vesicoureteral reflux 8, 615963 (3),
XCE	AR	arthrogryposis, distal, type 5d, 615065 (3),
XCL1		
XCL2		
XCR1		
xCT		
XDH	AR	xanthinuria, type i, 278300 (3),
XDRP1		
XE169	XL,XLR	intellectual developmental disorder, syndromic, claes-jensen type, 300534 (3),
XE7		
XE7Y		
XEDAR		
XG		[xg blood group system, xg(a-) phenotype], 314700 (3)
XGALT-1	AR	ehlers-danlos syndrome, spondylodysplastic type, 1, 130070 (3),
XGR		[xg blood group system, xg(a-) phenotype], 314700 (3)
XH2	XLD,XL,XLR	alpha-thalassemia/mental retardation syndrome, 301040 (3), ; alpha-thalassemia myelodysplasia syndrome, somatic, 300448 (3); intellectual disability-hypotonic facies syndrome, 309580 (3),
XHED	XL,XLD,XLR	tooth agenesis, selective, 1, 313500 (3), ; ectodermal dysplasia 1, hypohidrotic, 305100 (3),
XHL	AD	ulnar-mammary syndrome, 181450 (3),
XIAP	XL,XLR	lymphoproliferative syndrome, 2, 300635 (3),
XIAPAF1		
XIB		
Xin		
Xio		
XIP		
Xip1		
XIRP1		
XIRP2		
XIST		x-inactivation, familial skewed, 300087 (3)
XIST-AS1		
XK	XL	mcleod syndrome with or without chronic granulomatous disease, 300842 (3),
XKR1	XL	mcleod syndrome with or without chronic granulomatous disease, 300842 (3),
XKR2		
XKR3		
XKR8		
XKRX		
XKRY		
XKRY1		
XLA	XL,XLR	agammaglobulinemia, 1, 300755 (3), ; isolated growth hormone deficiency, type iii, with agammaglobulinemia, 307200 (3),
XLF		severe combined immunodeficiency with microcephaly, growth retardation, and sensitivity to ionizing radiation, 611291 (3)
XLH	XLD,XL	hypophosphatemic rickets, 307800 (3),
XLHED	XL,XLD,XLR	tooth agenesis, selective, 1, 313500 (3), ; ectodermal dysplasia 1, hypohidrotic, 305100 (3),
XLHSRF-1	AR	spermatogenic failure 18, 617576 (3), ; ciliary dyskinesia, primary, 37, 617577 (3),
XLIS	XL	subcortical laminal heterotopia, 300067 (3), ; lissencephaly, 300067 (3),
XLKD1		
XLP	XL,XLR	lymphoproliferative syndrome, 1, 308240 (3),
XLPD	XL,XLR	lymphoproliferative syndrome, 1, 308240 (3),
XLRH	XLR,XL	proteinuria, low molecular weight, with hypercalciuric nephrocalcinosis, 308990 (3), ; hypophosphatemic rickets, 300554 (3), ; dent disease 1, 300009 (3), ; nephrolithiasis, type i, 310468 (3),
XLRS1	XLR,XL	retinoschisis, 312700 (3),
XLS		
XMEA	XL,XLR	myopathy, with excessive autophagy, 310440 (3),
XMP	AR	nephrotic syndrome, type 10, 615861 (3),
XMPMA	XL,XLR,XLD	myopathy, with postural muscle atrophy, 300696 (3), ; emery-dreifuss muscular dystrophy 6, 300696 (3), ; ?uruguay faciocardiomusculoskeletal syndrome, 300280 (3), ; scapuloperoneal myopathy, 300695 (3), ; reducing body myopathy, 1b, with late childhood or adult onset, 300718 (3), ; reducing body myopathy, 1a, severe, infantile or early childhood onset, 300717 (3),
XNP	XLD,XL,XLR	alpha-thalassemia/mental retardation syndrome, 301040 (3), ; alpha-thalassemia myelodysplasia syndrome, somatic, 300448 (3); intellectual disability-hypotonic facies syndrome, 309580 (3),
XNPEP2		
XO	AR	xanthinuria, type i, 278300 (3),
XOR	AR	xanthinuria, type i, 278300 (3),
XP-V	AR	xeroderma pigmentosum, variant type, 278750 (3),
XP1	AR	xeroderma pigmentosum, group a, 278700 (3),
XP5		
XPA	AR	xeroderma pigmentosum, group a, 278700 (3),
XPAC	AR	xeroderma pigmentosum, group a, 278700 (3),
XPB	AR	trichothiodystrophy 2, photosensitive, 616390 (3), ; xeroderma pigmentosum, group b, 610651 (3),
XPC	AR	xeroderma pigmentosum, group c, 278720 (3),
XPCC	AR	xeroderma pigmentosum, group c, 278720 (3),
XPCT	XL	allan-herndon-dudley syndrome, 300523 (3),
XPD	AR	xeroderma pigmentosum, group d, 278730 (3), ; trichothiodystrophy 1, photosensitive, 601675 (3), ; ?cerebrooculofacioskeletal syndrome 2, 610756 (3),
XPE	AR	xeroderma pigmentosum, group e, ddb-negative subtype, 278740 (3),
XPF	AR	xeroderma pigmentosum, type f/cockayne syndrome, 278760 (3), ; xfe progeroid syndrome, 610965 (3), ; xeroderma pigmentosum, group f, 278760 (3), ; fanconi anemia, complementation group q, 615272 (3),
XPGC	AR	xeroderma pigmentosum, group g, 278780 (3), ; cerebrooculofacioskeletal syndrome 3, 616570 (3), ; xeroderma pigmentosum, group g/cockayne syndrome, 278780 (3),
XPID	XL,XLR	immunodysregulation, polyendocrinopathy, and enteropathy, 304790 (3),
XPLAC		
XPLN		
XPMC2H		
XPN	XL,XLD	intellectual developmental disorder, 98, 300912 (3),
XPNPEP		
XPNPEP1		
XPNPEP2		{angioedema induced by ace inhibitors, susceptibility to}, 300909 (3)
XPNPEP3	AR	nephronophthisis-like nephropathy 1, 613159 (3),
XPNPEPL		
XPNPEPL1		
XPO1		
XPO2		
XPO3		
XPO4		
XPO5		
XPO6		
XPO7		
XPOT		
XPR1	AD	basal ganglia calcification, idiopathic, 6, 616413 (3),
XPVKONA		
XRCC1	AR	?spinocerebellar ataxia, 26, 617633 (3),
XRCC11	AR,AD	fanconi anemia, complementation group d1, 605724 (3), ; {glioblastoma 3}, 613029 (3), ; {medulloblastoma}, 155255 (3), somatic mutation, ; {prostate cancer}, 176807 (3), somatic mutation, ; {breast-ovarian cancer, familial, 2}, 612555 (3), ; {breast cancer, male, susceptibility to}, 114480 (3), somatic mutation, ; {pancreatic cancer 2}, 613347 (3); wilms tumor, 194070 (3), somatic mutation,
XRCC2	AR	spermatogenic failure 50, 619145 (3), ; ?premature ovarian failure 17, 619146 (3), ; ?fanconi anemia, complementation group u, 617247 (3),
XRCC3	AD	{breast cancer, susceptibility to}, 114480 (3), somatic mutation, ; {melanoma, cutaneous malignant, 6}, 613972 (3)
XRCC4	AR	short stature, microcephaly, and endocrine dysfunction, 616541 (3),
XRCC5		
XRCC6		
XRCC6BP1		
XRCC7	AR	immunodeficiency 26, with or without neurologic abnormalities, 615966 (3),
XRCC9	AR	fanconi anemia, complementation group g, 614082 (3),
XRN	XLR,XL	proteinuria, low molecular weight, with hypercalciuric nephrocalcinosis, 308990 (3), ; hypophosphatemic rickets, 300554 (3), ; dent disease 1, 300009 (3), ; nephrolithiasis, type i, 310468 (3),
XRN1		
XRN2		
XRRA1		
XT-I	AR	desbuquois dysplasia 2, 615777 (3), ; {pseudoxanthoma elasticum, modifier of severity of}, 264800 (3),
XT-II	AR	{pseudoxanthoma elasticum, modifier of severity of}, 264800 (3), ; spondyloocular syndrome, 605822 (3),
XT3		
XTES		
XTH2		
XTLL		
XTP1		
XTP2		
XTP3-B		
XTP3TPA		
XTP3TPB		
XTP4		
XTP5		
XTP6		
XTP7		
Xtrp2		
Xtrp3		
XWNT2	AR	diarrhea 9, 618168 (3),
XXYLT1		
XYLB		
XYLT1	AR	desbuquois dysplasia 2, 615777 (3), ; {pseudoxanthoma elasticum, modifier of severity of}, 264800 (3),
XYLT2	AR	{pseudoxanthoma elasticum, modifier of severity of}, 264800 (3), ; spondyloocular syndrome, 605822 (3),
Y		
y+LAT-1	AR	lysinuric protein intolerance, 222700 (3),
y+LAT-2		
Y+LAT1	AR	lysinuric protein intolerance, 222700 (3),
Y14	AR	thrombocytopenia-absent radius syndrome, 274000 (3),
Y4		
YAF1		
YAF2		
YAF9		
YAK1		
Yama		
YAP	AR	grange syndrome, 602531 (3),
YAP-1	AD	coloboma, ocular, with or without hearing impairment, cleft lip/palate, and/or impaired intellectual development, 120433 (3),
YAP1	AD	coloboma, ocular, with or without hearing impairment, cleft lip/palate, and/or impaired intellectual development, 120433 (3),
YAP65	AD	coloboma, ocular, with or without hearing impairment, cleft lip/palate, and/or impaired intellectual development, 120433 (3),
YARP		
YARS	AR,AD	infantile-onset multisystem neurologic, endocrine, and pancreatic disease 2, 619418 (3), ; charcot-marie-tooth disease, intermediate c, 608323 (3),
YARS1	AR,AD	infantile-onset multisystem neurologic, endocrine, and pancreatic disease 2, 619418 (3), ; charcot-marie-tooth disease, intermediate c, 608323 (3),
YARS2	AR	myopathy, lactic acidosis, and sideroblastic anemia 2, 613561 (3),
YB-1		
YB1		
YBEY		
YBL026W		
Ybl1		
YBX1		
YBX2		
YBX3		
YC1		
YCG1		
YCL1		
YCR063W		
YDJC		
YDR378C		
YEA4		
YEAF1		
YEATS1		
YEATS2	AD	?epilepsy, myoclonic, familial adult, 4, 615127 (3),
YEATS3		
YEATS4		
YER112W		
YER146W		
Yes		
YES1		
Yeti		
YF13H12	AR	ethylmalonic encephalopathy, 602473 (3),
YF5	AR	retinal dystrophy with macular staphyloma, 617547 (3), ; spondylometaphyseal dysplasia, axial, 602271 (3),
YG		[xg blood group system, xg(a-) phenotype], 314700 (3)
YGL047W	XL	developmental and epileptic encephalopathy 36, 300884 (3),
Yhc1		
YIF1		
YIF1A		
YIF1B	AR	kaya-barakat-masson syndrome, 619125 (3),
YIF1P		
YIN-YANG-1	AD	gabriele-de vries syndrome, 617557 (3),
Yip2a	AD,AR	?neuronopathy, distal hereditary motor, type vb, 614751 (3), ; spastic paraplegia 31, 610250 (3), ; spinal muscular atrophy, distal, 6, 620011 (3),
Yip2b		
Yip2c		
Yip2d	AD,AR	?spastic paraplegia 72, 615625 (3), ; ?spastic paraplegia 72, 615625 (3),
Yip2e		
Yip2f	AR	retinitis pigmentosa 77, 617304 (3),
YIP3		
Yip6a		
Yip6b		
YIPF1		
YIPF2		
YIPF3		
YIPF4		
YIPF5	AR	microcephaly, epilepsy, and diabetes syndrome 2, 619278 (3),
YIPF6		
YIPF7		
Yiya		
YJDC	AR	?intellectual developmental disorder, 50, 616460 (3),
YJEFN1	AR	encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy, 617186 (3),
YJEFN2	AR	?intellectual developmental disorder, 50, 616460 (3),
YJEFN3		
YJL085W	AR	neurodevelopmental disorder with seizures and brain atrophy, 619072 (3),
YJL124C		
YJR010C-A		
YJR022W		
YJR141W		
YK-40	AD	{asthma-related traits, susceptibility to, 7}, 611960 (3); {schizophrenia, susceptibility to}, 181500 (3),
YKL-39		
YKL086W		
YKL39		
YKL40	AD	{asthma-related traits, susceptibility to, 7}, 611960 (3); {schizophrenia, susceptibility to}, 181500 (3),
YKR087C		
YKT6		
YL-1		
YL1		
YL8		
YLPM1		
YLR066W		
YLR438C		
YME1L	AR	?optic atrophy 11, 617302 (3),
YME1L1	AR	?optic atrophy 11, 617302 (3),
Ymer	AD	?deafness, 44, 607453 (3),
YMO1		
YMP		
YMR292W		
Ynl022cL		
YNL026W		
YNL147W		
Yo		
YOD1		
YOTIAO	AD	?long qt syndrome 11, 611820 (3),
YPEL1		
YPEL2		
YPEL3		
YPEL4		
YPEL5		
YPL207W		
Ypr118w		
YPT1		
YR-23		
yR36GH4.1		
YRDC	AR	galloway-mowat syndrome 10, 619609 (3),
YRRM1		
YRRM2		
YRS	AR,AD	infantile-onset multisystem neurologic, endocrine, and pancreatic disease 2, 619418 (3), ; charcot-marie-tooth disease, intermediate c, 608323 (3),
YRT		
YSA1H		
Ysf3		
YSG2		{autoimmune disease, susceptibility to, 6}, 613551 (3)
YSH1	AR	neurodevelopmental disorder with microcephaly, hypotonia, nystagmus, and seizures, 619876 (3),
YSK1		
YSK2		
YSK3	AR	t-cell immunodeficiency, recurrent infections, autoimmunity, and cardiac malformations, 614868 (3),
Yspl1		
YSPL2		
YSPL3		
YT		[blood group, yt system], 112100 (3)
yt14r		
YT521		
YT521-B		
YTHDC1		
YTHDC2		
YTHDF1		
YTHDF2		
YTHDF3		
YTM1		
YTS	AR,AD	infantile-onset multisystem neurologic, endocrine, and pancreatic disease 2, 619418 (3), ; charcot-marie-tooth disease, intermediate c, 608323 (3),
Yulink		
YVH1		
YVTM2421		
YWHA1		
YWHAA		
YWHAB		
YWHAD		
YWHAE		
YWHAG	AD	developmental and epileptic encephalopathy 56, 617665 (3),
YWHAH		
YWHAQ		
YWHAS		
YWHAZ		
YY1	AD	gabriele-de vries syndrome, 617557 (3),
YY1AP	AR	grange syndrome, 602531 (3),
YY1AP1	AR	grange syndrome, 602531 (3),
YY2		
Z		
Z1971		
Z25		
Z38		
Z39IG		
Z3CXXC1		
Z3CXXC2		
Z3CXXC3		
Z3CXXC4		
Z3CXXC6		
Z3CXXC7		
Za11	AR	?immunodeficiency, common variable, 11, 615767 (3),
ZA20D1		
ZA20D2		
ZA20D3		
ZA2G		
ZABC1		
ZABC2		
ZAC		
ZAC1		
ZACN		
ZACRP4		
ZACRP6		
ZADH1		
ZADH3		
ZADT		
ZAG		
ZAK	AR	centronuclear myopathy 6 with fiber-type disproportion, 617760 (3), ; split-foot malformation with mesoaxial polydactyly, 616890 (3),
ZAKI-4		
ZAN		
ZAN75		
ZAP		
ZAP-70	AR	immunodeficiency 48, 269840 (3), ; autoimmune disease, multisystem, infantile-onset, 2, 617006 (3),
ZAP1		
ZAP128		
ZAP70	AR	immunodeficiency 48, 269840 (3), ; autoimmune disease, multisystem, infantile-onset, 2, 617006 (3),
ZAP75		
ZAPHIR		
ZAQ		
ZAR1		
ZAR1L		
ZAS1		
ZAS2	AD	intellectual developmental disorder, 43, 616977 (3),
ZAS3		
ZASC1		
ZASP	AD	left ventricular noncompaction 3, 601493 (3), ; cardiomyopathy, hypertrophic, 24, 601493 (3), ; myopathy, myofibrillar, 4, 609452 (3), ; cardiomyopathy, dilated, 1c, with or without lvnc, 601493 (3),
ZATT		
ZBED1		
ZBED10P		
ZBED2		
ZBED3		
ZBED4		
ZBED5		
ZBED6		
ZBED6CL		
ZBED7		
ZBED8		
ZBED9		
ZBP-89	AD	global developmental delay, absent or hypoplastic corpus callosum, and dysmorphic facies, 617260 (3),
ZBP-99		
ZBP1		
ZBRK1		
ZBTB1		
ZBTB10		
ZBTB11	AR	intellectual developmental disorder, 69, 618383 (3),
ZBTB14		
ZBTB15		
ZBTB16		leukemia, acute promyelocytic, pl2f/rara type (3)
ZBTB17		
ZBTB18	AD	intellectual developmental disorder, 22, 612337 (3),
ZBTB19		
ZBTB2		
ZBTB20	AD	primrose syndrome, 259050 (3),
ZBTB21		
ZBTB22		
ZBTB22A		
ZBTB22B		
ZBTB23	AR	joint laxity, short stature, and myopia, 617662 (3),
ZBTB24	AR	immunodeficiency-centromeric instability-facial anomalies syndrome 2, 614069 (3),
ZBTB25		
ZBTB26		
ZBTB27		
ZBTB28		
ZBTB29		
ZBTB30		
ZBTB31		
ZBTB32		
ZBTB33		
ZBTB34		
ZBTB35		
ZBTB36		
ZBTB38		
ZBTB39		
ZBTB4		
ZBTB40		
ZBTB40-IT1		
ZBTB42	AR	?lethal congenital contracture syndrome 6, 616248 (3),
ZBTB43		
ZBTB46		
ZBTB47		
ZBTB48		
ZBTB49		
ZBTB5		
ZBTB6		
ZBTB7	AD	macrocephaly, neurodevelopmental delay, lymphoid hyperplasia, and persistent fetal hemoglobin, 619769 (3),
ZBTB7A	AD	macrocephaly, neurodevelopmental delay, lymphoid hyperplasia, and persistent fetal hemoglobin, 619769 (3),
ZBTB7B		
ZBTB7C		
ZBTB8		
ZBTB8A		
ZBTB8OS		
ZC2H2C1		
ZC2H2C2	AD	intellectual developmental disorder, 39, 616521 (3),
ZC2H2C3		
ZC2HC10		
ZC2HC11A		
ZC2HC11B	AD	diaphragmatic hernia 3, 610187 (3); 46xy sex reversal 9, 616067 (3), ; tetralogy of fallot, 187500 (3),
ZC2HC12A	AD	spermatogenic failure 12, 615413 (3),
ZC2HC12B		
ZC2HC12C		
ZC2HC2		
ZC2HC3		
ZC2HC4A		
ZC2HC4B	AD	intellectual developmental disorder, 39, 616521 (3),
ZC2HC5	AR,AD	?muscular dystrophy, congenital, davignon-chauveau type, 617066 (3), ; spinal muscular atrophy with congenital bone fractures 1, 616866 (3), |neurodevelopmental disorder with dysmorphic facies, sleep disturbance, and brain abnormalities, 619103 (3),
ZC2HC6A	AD	arboleda-tham syndrome, 616268 (3),
ZC2HC6B	AD	sbbyss syndrome, 603736 (3), ; genitopatellar syndrome, 606170 (3),
ZC2HC7		
ZC2HC8	AD	li-ghorgani-weisz-hubshman syndrome, 618974 (3),
ZC2HC9	XLD,XLR,XL	incontinentia pigmenti, 308300 (3), ; ectodermal dysplasia and immunodeficiency 1, 300291 (3), ; immunodeficiency 33, 300636 (3), ; autoinflammatory disease, systemic, 301081 (3),
ZC3		
ZC3H1		
ZC3H11A		
ZC3H12A		
ZC3H12B		
ZC3H12C		
ZC3H12D		
ZC3H13		
ZC3H14	AR	intellectual developmental disorder, 56, 617125 (3),
ZC3H15		
ZC3H16		
ZC3H17		
ZC3H19		
ZC3H2		
ZC3H20		
ZC3H22		
ZC3H3		
ZC3H4		
ZC3H5		
ZC3H5L		
ZC3H7		
ZC3H7A		
ZC3H7B		
ZC3H9		
ZC3HAV1		
ZC3HC1		
ZC3HDC1		
ZC3HDC11A		
ZC3HDC2		
ZC3HDC3		
ZC3HDC5		
ZC3HDC5L		
ZC3HDC7		
ZC3HDC9		
ZC4H2	XLR,XLD,XL	wieacker-wolff syndrome, 314580 (3), ; wieacker-wolff syndrome, female-restricted, 301041 (3),
ZCCHC1		
ZCCHC11		
ZCCHC12		
ZCCHC17		
ZCCHC19		
ZCCHC2		
ZCCHC20		
ZCCHC21		
ZCCHC22	AD	myotonic dystrophy 2, 602668 (3),
ZCCHC25		
ZCCHC3		
ZCCHC4		
ZCCHC6		
ZCCHC8	AD	?pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 5, 618674 (3),
ZCCHC9		
ZCCHH1		
ZCD1		
ZCD2	AR	wolfram syndrome 2, 604928 (3),
ZCGPC1		
ZCHY		
ZCRB1		
ZCRB2		
ZCRB3A		
ZCSL2		
ZCSL3		
ZCW1		
ZCW3	AD	charcot-marie-tooth disease, axonal, type 2z, 616688 (3), ; developmental delay, impaired growth, dysmorphic facies, and axonal neuropathy, 619090 (3),
ZCW4		
ZCW5		
ZCW6		
ZCWCC1	AD	charcot-marie-tooth disease, axonal, type 2z, 616688 (3), ; developmental delay, impaired growth, dysmorphic facies, and axonal neuropathy, 619090 (3),
ZCWCC2		
ZCWCC3		
ZCWPW1		
ZCYTO10		
zcyto18		
ZCYTO7		
zcytor1		
ZCYTOR7		
ZD52F10		
ZDBF1		
ZDBF1B		
ZDBF2		
ZDHHC10	XL	intellectual developmental disorder, syndromic, raymond type, 300799 (3),
ZDHHC13		
ZDHHC14		
ZDHHC15		
ZDHHC16		
ZDHHC17		
ZDHHC19		
ZDHHC2		
ZDHHC20		
ZDHHC21		
ZDHHC23		
ZDHHC3		
ZDHHC5		
ZDHHC6		
ZDHHC7		
ZDHHC8		
ZDHHC9	XL	intellectual developmental disorder, syndromic, raymond type, 300799 (3),
ZEB	AD	corneal dystrophy, posterior polymorphous, 3, 609141 (3), ; corneal dystrophy, fuchs endothelial, 6, 613270 (3),
ZEB1	AD	corneal dystrophy, posterior polymorphous, 3, 609141 (3), ; corneal dystrophy, fuchs endothelial, 6, 613270 (3),
ZEB2	AD	mowat-wilson syndrome, 235730 (3),
ZEC		
ZEPPO1		
ZER1		
ZER6		
ZET		
zeta	AR	spastic paraplegia 48, 613647 (3),
ZETA		
ZF		
ZF21		
ZF47		
ZF5128		
ZF87		
Zf9		gastric cancer, somatic, 613659 (3); prostate cancer, somatic, 176807 (3)
ZFAND2A		
ZFAND2B		
ZFAND3		
ZFAND5		
ZFAND5A		
ZFAND5B		
ZFAND6		
ZFAND7	AR	neuronopathy, distal hereditary motor, type vi, 604320 (3), ; charcot-marie-tooth disease, axonal, type 2s, 616155 (3),
ZFAT		{autoimmune thyroid disease, susceptibility to, 3}, 608175 (3)
ZFAT1		{autoimmune thyroid disease, susceptibility to, 3}, 608175 (3)
ZFD25		
ZFEND		
ZFGF5		
ZFH	AD	snijders blok-campeau syndrome, 618205 (3),
ZFH-5	AD	?marsili syndrome, 147430 (3),
ZFH4	AD	?ptosis, congenital, 178300 (2),
Zfhep	AD	corneal dystrophy, posterior polymorphous, 3, 609141 (3), ; corneal dystrophy, fuchs endothelial, 6, 613270 (3),
Zfhx1a	AD	corneal dystrophy, posterior polymorphous, 3, 609141 (3), ; corneal dystrophy, fuchs endothelial, 6, 613270 (3),
ZFHX1B	AD	mowat-wilson syndrome, 235730 (3),
ZFHX2	AD	?marsili syndrome, 147430 (3),
ZFHX2-AS1		
ZFHX3		prostate cancer, somatic, 176807 (3)
ZFHX4	AD	?ptosis, congenital, 178300 (2),
ZFM1		
ZFML		
ZFOC1		
ZFP1		
ZFP103		
Zfp104	AR,AD	nephronophthisis 14, 614844 (3), ; joubert syndrome 19, 614844 (3),
Zfp105		
ZFP112		
Zfp113		
ZFP127	AD	precocious puberty, central, 2, 615346 (3),
Zfp128		
Zfp13		
ZFP14		
ZFP148	AD	global developmental delay, absent or hypoplastic corpus callosum, and dysmorphic facies, 617260 (3),
ZFP161		
Zfp182		
Zfp191		
ZFP26		
Zfp260		
ZFP276		
ZFP28		
Zfp289		
Zfp291	AR	intellectual developmental disorder and retinitis pigmentosa, 618195 (3),
ZFP292	AD	intellectual developmental disorder, 64, 619188 (3),
Zfp293		
ZFP3		
ZFP30		
Zfp312		
ZFP318		
Zfp326		
Zfp346		
ZFP36		
ZFP36L1		
ZFP36L2	AR	oocyte/zygote/embryo maturation arrest 13, 620154 (3),
ZFP37		
ZFP38-L		
Zfp383		
ZFP385		
Zfp393		
ZFP403		
ZFP42		
Zfp422		
Zfp46		
Zfp462	AD	weiss-kruszka syndrome, 618619 (3),
Zfp464		
Zfp467		
Zfp469	AR	brittle cornea syndrome 1, 229200 (3),
Zfp47		
Zfp513	AR	?retinitis pigmentosa 58, 613617 (3),
Zfp520		
Zfp523		
Zfp535		
ZFP57	AR,AD	diabetes mellitus, transient neonatal 1, 601410 (3),
Zfp612		
ZFP62		
Zfp628		
Zfp637		
Zfp638		
ZFP64		
Zfp661		
ZFP67		
ZFP69		
Zfp692		
ZFP69A		
Zfp711	XL	intellectual developmental disorder, 97, 300803 (3),
Zfp74		
Zfp750		?seborrhea-like dermatitis with psoriasiform elements, 610227 (3)
Zfp78		
Zfp9		
ZFP90		
ZFP91		
ZFP93		
ZFP95		
ZFP96		
Zfp98		
ZFPL		
ZFPL1		
ZFPM1		
ZFPM2	AD	diaphragmatic hernia 3, 610187 (3); 46xy sex reversal 9, 616067 (3), ; tetralogy of fallot, 187500 (3),
ZFQR		
ZFR		
ZFR1		
ZFR2		
ZFTA		
ZFTRAF1		
ZFX		
ZFY		
ZFYVE1		
ZFYVE10		
ZFYVE11		
ZFYVE12		
ZFYVE13		
ZFYVE14		
ZFYVE15		
ZFYVE16		
ZFYVE17		
ZFYVE18		
ZFYVE19	AR	cholestasis, progressive familial intrahepatic, 9, 619849 (3),
ZFYVE2		
ZFYVE20		
ZFYVE21		
ZFYVE22		
ZFYVE23		
ZFYVE24		
ZFYVE25	AD	?microcephaly 18, primary, 617520 (3),
ZFYVE26	AR	spastic paraplegia 15, 270700 (3),
ZFYVE27	AD	spastic paraplegia 33, 610244 (3),
ZFYVE28		
ZFYVE29	AD	corneal fleck dystrophy, 121850 (3),
ZFYVE3	XL,XLR	intellectual developmental disorder, syndromic 16, 305400 (3), ; aarskog-scott syndrome, 305400 (3),
ZFYVE30		
ZFYVE4		
ZFYVE5		
ZFYVE6	AR	charcot-marie-tooth disease, type 4h, 609311 (3),
ZFYVE7	AR	cataract 18, 610019 (3),
ZFYVE8		
ZFYVE9		
ZG14P		
ZG16		
ZG16A		
ZG24P		
ZGAP1		
ZGLP1		
ZGPAT		
ZGRF2		
ZGRF3		
ZGRF4		
ZGRF6		
ZGRF7	AR	?progressive external ophthalmoplegia with mitochondrial dna deletions, 5, 618098 (3), ; microcephaly, growth restriction, and increased sister chromatid exchange 2, 618097 (3),
ZHC32		
ZHX1		
ZHX2		
ZHX3		
ZIBRA		
ZIC	AD	?craniosynostosis 6, 616602 (3), ; structural brain anomalies with impaired intellectual development and craniosynostosis, 618736 (3),
ZIC1	AD	?craniosynostosis 6, 616602 (3), ; structural brain anomalies with impaired intellectual development and craniosynostosis, 618736 (3),
ZIC2	AD	holoprosencephaly 5, 609637 (3),
ZIC3	XL,XLR	congenital heart defects, nonsyndromic, 1, 306955 (3), ; heterotaxy, visceral, 1, 306955 (3), ; vacterl association, 314390 (3),
ZIC4		
ZIC5		
ZID		
ZIF-268		
Zif87		
Zimp10	AD	neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies, 618659 (3),
ZIMP7		
ZIN	AR	cerebellar ataxia and hypogonadotropic hypogonadism, 212840 (3),
ZINS4		
ZIP		
ZIP-13	AR	ehlers-danlos syndrome, spondylodysplastic type, 3, 612350 (3),
ZIP-14	AD,AR	?hyperostosis cranalis interna, 144755 (3), ; hypermanganesemia with dystonia 2, 617013 (3),
ZIP-4	AR	acrodermatitis enteropathica, 201100 (3),
ZIP-8	AR	congenital disorder of glycosylation, type iin, 616721 (3),
ZIP1		
ZIP10		
ZIP11		
ZIP12		
ZIP13	AR	ehlers-danlos syndrome, spondylodysplastic type, 3, 612350 (3),
ZIP14	AD,AR	?hyperostosis cranalis interna, 144755 (3), ; hypermanganesemia with dystonia 2, 617013 (3),
Zip2	AR	spermatogenic failure 75, 619949 (3),
ZIP2		
ZIP3		
ZIP4	AR,XL,XLR	acrodermatitis enteropathica, 201100 (3), |spermatogenic failure, 2, 309120 (3),
ZIP4H	XL,XLR	spermatogenic failure, 2, 309120 (3),
ZIP5	AD	myopia 24, 615946 (3),
ZIP6		
Zip67		
ZIP7	AR	agammaglobulinemia 9, 619693 (3),
ZIP8	AR	congenital disorder of glycosylation, type iin, 616721 (3),
ZIP9		
ZIPK		
Zipro1		
ZIR1	AR	adams-oliver syndrome 2, 614219 (3),
ZIR2	AR	developmental and epileptic encephalopathy 23, 615859 (3),
ZIR8	AR	hyper-ige recurrent infection syndrome, 243700 (3),
ZIRD		
ZIRTL		
ZIS		
ZIS1		
ZIS2		
ZIZ1		
ZIZ2		
ZIZ3		
ZK1		
ZKSCAN1		
ZKSCAN10		
ZKSCAN11		
ZKSCAN12		
ZKSCAN14		
ZKSCAN15		
ZKSCAN17		
ZKSCAN19		
ZKSCAN21		
ZKSCAN22		
ZKSCAN23A		
ZKSCAN24		
ZKSCAN3		
ZKSCAN4		
ZKSCAN5		
ZKSCAN6		
ZKSCAN8		
ZKSCAN9		
ZLUT1		
ZLYAR		
ZMAT1		
ZMAT2		
ZMAT3		
ZMAT5		
ZMDA1		
ZMIZ1	AD	neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies, 618659 (3),
ZMIZ2		
ZMIZ3		
ZMIZ4		
ZMIZ5		
ZMIZ6		
ZMIZ7	AR	seckel syndrome 10, 617253 (3),
ZMPOMA1		
ZMPSTE24	AR	mandibuloacral dysplasia with type b lipodystrophy, 608612 (3), ; restrictive dermopathy 1, 275210 (3),
ZMYM2	AD	neurodevelopmental-craniofacial syndrome with variable renal and cardiac abnormalities, 619522 (3),
ZMYM3		
ZMYM4		
ZMYM5		
ZMYM6		
ZMYND1		
ZMYND10	AR	ciliary dyskinesia, primary, 22, 615444 (3),
ZMYND11	AD	intellectual developmental disorder, 30, 616083 (3),
ZMYND14		
ZMYND15	AR	?spermatogenic failure 14, 615842 (3),
ZMYND17		
ZMYND19		
ZMYND2		
ZMYND21		
ZMYND22		
ZMYND23		
ZMYND3		
ZMYND4		
ZMYND5	AD,AR	vulto-van silfout-de vries syndrome, 615828 (3), ; neurodevelopmental disorder with hypotonia, impaired expressive language, and with or without seizures, 617171 (3),
ZMYND6	AD	erythrocytosis, familial, 3, 609820 (3), ; [hemoglobin, high altitude adaptation], 609070 (3),
ZMYND7		
ZMYND8		
ZMYND9		
Zn-15	AD	intellectual developmental disorder, 64, 619188 (3),
Zn-15L		
Zn-16	AD	intellectual developmental disorder, 64, 619188 (3),
ZNEU1		
ZNEUROK1	AR	hypogonadotropic hypogonadism 10 with or without anosmia, 614839 (3),
ZNF-25		
ZNF-kaiso		
ZNF-U69274	AR	intellectual developmental disorder, 69, 618383 (3),
ZNF-X		
ZNF10		
ZNF100		
ZNF101		
ZNF102		
ZNF107		
ZNF112		
ZNF114		
ZNF115		
ZNF117		
ZNF11A		
ZNF11B		
ZNF12		
ZNF120		
ZNF121		
ZNF124		
ZNF125		
ZNF126		
ZNF127	AD	precocious puberty, central, 2, 615346 (3),
ZNF127-AS		
ZNF127AS		
ZNF13		
ZNF131		
ZNF132		
ZNF133		
ZNF134		
ZNF135		
ZNF136		
ZNF137		
ZNF137P		
ZNF138		
ZNF139		
ZNF14		
ZNF140		
ZNF141	AR	?polydactyly, postaxial, type a6, 615226 (3),
ZNF142	AR	neurodevelopmental disorder with impaired speech and hyperkinetic movements, 618425 (3),
ZNF143		
ZNF144	AD	turnpenny-fry syndrome, 618371 (3),
ZNF145		leukemia, acute promyelocytic, pl2f/rara type (3)
ZNF146		
ZNF147		
ZNF148	AD	global developmental delay, absent or hypoplastic corpus callosum, and dysmorphic facies, 617260 (3),
ZNF150		
ZNF151		
ZNF154		
ZNF155		
ZNF157		
ZNF16		
ZNF160		
ZNF161	AD	?cardiomyopathy, dilated, 1oo, 620247 (3),
ZNF162		
ZNF163	AD	?neutropenia, nonimmune chronic idiopathic, of adults, 607847 (3), ; neutropenia, severe congenital 2, 613107 (3),
ZNF163B	AR,AD	bleeding disorder, platelet-type, 17, 187900 (3),
ZNF165		
ZNF166		
ZNF168		
ZNF169		
ZNF17		
ZNF173		
ZNF174		
ZNF175		
ZNF176		
ZNF177		
ZNF179		
ZNF18		
ZNF180		
ZNF181		
ZNF182		
ZNF183	XL	trichothiodystrophy 5, nonphotosensitive, 300953 (3),
ZNF184		
ZNF185		
ZNF186		
ZNF187		
ZNF189		
ZNF19		
ZNF191		
ZNF192		
ZNF193		
ZNF195		
ZNF197		
ZNF198	AD	neurodevelopmental-craniofacial syndrome with variable renal and cardiac abnormalities, 619522 (3),
ZNF198L1		
ZNF198L2		
ZNF198L3		
ZNF198L4		
ZNF2		
ZNF20		
ZNF200		
ZNF201	AD	?craniosynostosis 6, 616602 (3), ; structural brain anomalies with impaired intellectual development and craniosynostosis, 618736 (3),
ZNF202		
ZNF203	XL,XLR	congenital heart defects, nonsyndromic, 1, 306955 (3), ; heterotaxy, visceral, 1, 306955 (3), ; vacterl association, 314390 (3),
ZNF205		
ZNF206		
ZNF207		
ZNF208		
ZNF21		
ZNF210		
ZNF211		
ZNF212		
ZNF213		
ZNF214		
ZNF215		
ZNF216		
ZNF217		
ZNF218		
ZNF219		
ZNF22		
ZNF220	AD	arboleda-tham syndrome, 616268 (3),
ZNF222		
ZNF224		
ZNF228		
ZNF23		
ZNF230		
ZNF231		
ZNF232		
ZNF234		
ZNF235		
ZNF236		
ZNF237		
ZNF238	AD	intellectual developmental disorder, 22, 612337 (3),
ZNF239		
ZNF24		
ZNF25		
ZNF253		
ZNF254		
ZNF255		
ZNF256		
ZNF257		
ZNF258		
ZNF259	AR	?growth restriction, hypoplastic kidneys, alopecia, and distinctive facies, 619321 (3),
ZNF26		
ZNF260		
ZNF261		
ZNF262		
ZNF263		
ZNF264		
ZNF265		
ZNF266		
ZNF267		
ZNF268		
ZNF269		
ZNF27		
ZNF270		
ZNF272		
ZNF273		
ZNF274		
ZNF276		
ZNF277		
ZNF277P		
ZNF278		
ZNF280E	AD	white-sutton syndrome, 616364 (3),
ZNF281		
ZNF282		
ZNF288	AD	primrose syndrome, 259050 (3),
ZNF289		
ZNF29		
ZNF291	AR	intellectual developmental disorder and retinitis pigmentosa, 618195 (3),
ZNF292	AD	intellectual developmental disorder, 64, 619188 (3),
ZNF292L		
ZNF293		
ZNF294		
ZNF295		
ZNF296		
ZNF297		
ZNF297A		
ZNF297B		
ZNF298		
ZNF29K1		
ZNF29P		
ZNF3		
ZNF300		
ZNF304		
ZNF305		
ZNF305P2		
ZNF306		
ZNF307		
ZNF309		
ZNF31		
ZNF310P		
ZNF312		
ZNF312B	AR	hypogonadotropic hypogonadism 22, with or without anosmia, 616030 (3),
ZNF313		
ZNF317		
ZNF318		
ZNF32		
ZNF320		
ZNF322		
ZNF322A		
ZNF323		
ZNF324		
ZNF324A		
ZNF325		
ZNF326		
ZNF328		
ZNF33		
ZNF330		
ZNF331		
ZNF333		
ZNF335	AR	microcephaly 10, primary, 615095 (3),
ZNF336	AR	joint laxity, short stature, and myopia, 617662 (3),
ZNF338		
ZNF339	AD	corneal dystrophy, posterior polymorphous, 1, 122000 (3),
ZNF33A		
ZNF33B		
ZNF34		
ZNF340		
ZNF341	AR	hyper-ige recurrent infection syndrome 3, 618282 (3),
ZNF342		
ZNF346		
ZNF348		
ZNF35		
ZNF350		
ZNF354A		
ZNF354C		
ZNF356		
ZNF358		
ZNF359		
ZNF36		
ZNF360		
ZNF361		
ZNF363		
ZNF364		
ZNF365		{nephrolithiasis, uric acid, susceptibility to}, 605990 (3)
ZNF366		
ZNF367		
ZNF37		
ZNF370		
ZNF372		
ZNF373		
ZNF375		
ZNF376		
ZNF378		
ZNF379	XL	intellectual developmental disorder, syndromic, raymond type, 300799 (3),
ZNF37A		
ZNF38		
ZNF380	XL	intellectual developmental disorder, syndromic, raymond type, 300799 (3),
ZNF382		
ZNF383		
ZNF384		
ZNF385		
ZNF385A		
ZNF385B		
ZNF387		
ZNF388		
ZNF392		
ZNF393		
ZNF394		
ZNF395		
ZNF396		
ZNF397		
ZNF398		
ZNF39L1		
ZNF4	XL	intellectual developmental disorder, 97, 300803 (3),
ZNF40		
ZNF403		
ZNF406		{autoimmune thyroid disease, susceptibility to, 3}, 608175 (3)
ZNF407	AR	simha syndrome, 619557 (3),
ZNF408	AR,AD	retinitis pigmentosa 72, 616469 (3), ; ?exudative vitreoretinopathy 6, 616468 (3),
ZNF409	AD	?marsili syndrome, 147430 (3),
ZNF40A		
ZNF40B	AD	intellectual developmental disorder, 43, 616977 (3),
ZNF40C		
ZNF41		
ZNF410		
ZNF411		
ZNF415		
ZNF418		
ZNF419		
ZNF419A		
ZNF42		
ZNF420		
ZNF422	XL,XLR	intellectual developmental disorder, syndromic, siderius type, 300263 (3),
ZNF423	AR,AD	nephronophthisis 14, 614844 (3), ; joubert syndrome 19, 614844 (3),
ZNF425		
ZNF427		
ZNF43		
ZNF431		
ZNF435		
ZNF436		
ZNF437		
ZNF44		
ZNF443		
ZNF444		
ZNF445		
ZNF449		
ZNF45		
ZNF450	AR	immunodeficiency-centromeric instability-facial anomalies syndrome 2, 614069 (3),
ZNF451		
ZNF452		
ZNF46		
ZNF460		
ZNF461		
ZNF462	AD	weiss-kruszka syndrome, 618619 (3),
ZNF463		
ZNF464		
ZNF467		
ZNF468		
ZNF469	AR	brittle cornea syndrome 1, 229200 (3),
ZNF47		
ZNF471		
ZNF473		
ZNF475		
ZNF477		
ZNF478		
ZNF479		
ZNF480		
ZNF481		
ZNF482		
ZNF489		
ZNF490		
ZNF492		
ZNF494		
ZNF496		
ZNF5	XL	intellectual developmental disorder, 97, 300803 (3),
ZNF50		
ZNF503		
ZNF503L		
ZNF504		
ZNF505		
ZNF508		
ZNF509		
ZNF51		
ZNF510		
ZNF512B		
ZNF513	AR	?retinitis pigmentosa 58, 613617 (3),
ZNF515	AR	diabetes mellitus, neonatal, with congenital hypothyroidism, 610199 (3),
ZNF516		
ZNF518		
ZNF518A		
ZNF518B		
ZNF520		
ZNF521		
ZNF523		
ZNF526	AR	dentici-novelli neurodevelopmental syndrome, 619877 (3),
ZNF528		
ZNF531		
ZNF532		
ZNF533		
ZNF535		
ZNF536		
ZNF537		
ZNF538		
ZNF539		
ZNF540		
ZNF541		
ZNF543		
ZNF547L	XLR,XL	spondyloepiphyseal dysplasia tarda, 313400 (3),
ZNF55		
ZNF565		
ZNF568		
ZNF569		
ZNF58		
ZNF580		
ZNF582		
ZNF588		
ZNF589		
ZNF592		
ZNF593		
ZNF597		
ZNF598		
ZNF6	XL	intellectual developmental disorder, 97, 300803 (3),
ZNF60		
ZNF606		
ZNF609		
ZNF61		
ZNF612		
ZNF618		
ZNF62		
ZNF622		
ZNF627		
ZNF628		
ZNF629		
ZNF630		
ZNF631		
ZNF635	AD	white-sutton syndrome, 616364 (3),
ZNF637		
ZNF638		
ZNF639		
ZNF641		
ZNF642		
ZNF644	AD	myopia 21, 614167 (3),
ZNF646		
ZNF649		
ZNF65		
ZNF650		
ZNF651		
ZNF652		
ZNF653		
ZNF655		
ZNF658		
ZNF661		
ZNF664		
ZNF667		
ZNF668	AR	neurodevelopmental disorder with poor growth, large ears, and dysmorphic facies, 620194 (3),
ZNF673		
ZNF673B		
ZNF674		
ZNF675		
ZNF683		
ZNF687	AD	paget disease of bone 6, 616833 (3),
ZNF689		
ZNF69		
ZNF692		
ZNF693		
ZNF695		
ZNF698	AR,AD	diabetes mellitus, transient neonatal 1, 601410 (3),
ZNF699	AR	degcags syndrome, 619488 (3),
ZNF7		
ZNF70		
ZNF703		
ZNF706		
ZNF71		
ZNF711	XL	intellectual developmental disorder, 97, 300803 (3),
ZNF713		
ZNF717		
ZNF72		
ZNF72AP		
ZNF72BP		
ZNF72P		
ZNF73		
ZNF737		
ZNF739		
ZNF73P		
ZNF74		
ZNF741		
ZNF743		
ZNF744		
ZNF745		
ZNF746		
ZNF75		
ZNF750		?seborrhea-like dermatitis with psoriasiform elements, 610227 (3)
ZNF752		
ZNF754		
ZNF755		
ZNF756		
ZNF757		
ZNF75A		
ZNF75D		
ZNF76		
ZNF764		
ZNF768		
ZNF769		
ZNF77		
ZNF777		
ZNF78L1		
ZNF79		
ZNF794	AD	townes-brocks syndrome 1, 107480 (3), ; townes-brocks branchiootorenal-like syndrome, 107480 (3),
ZNF795	AR	?coloboma, ocular, 216820 (3),
ZNF796		
ZNF797	AD	?ivic syndrome, 147750 (3), ; duane-radial ray syndrome, 607323 (3),
ZNF798		
ZNF799		
ZNF8		
ZNF80		
ZNF801		
ZNF802		
ZNF803		
ZNF804A		
ZNF81		
ZNF816B		
ZNF82		
ZNF822		
ZNF827		
ZNF828	AD	neurodevelopmental disorder with hypotonia, impaired language, and dysmorphic features, 616579 (3),
ZNF83		
ZNF838		
ZNF84		
ZNF842		
ZNF85		
ZNF855		
ZNF856	AD	dias-logan syndrome, 617101 (3),
ZNF856B	AD	immunodeficiency 49, severe combined, 617237 (3), ; intellectual developmental disorder with dysmorphic facies, speech delay, and t-cell abnormalities, 618092 (3),
ZNF857A	AD	macrocephaly, neurodevelopmental delay, lymphoid hyperplasia, and persistent fetal hemoglobin, 619769 (3),
ZNF857B		
ZNF857C		
ZNF875		
ZNF896		
ZNF898		
ZNF899		
ZNF89A		
ZNF89B	AD	diaphragmatic hernia 3, 610187 (3); 46xy sex reversal 9, 616067 (3), ; tetralogy of fallot, 187500 (3),
ZNF9	AD	myotonic dystrophy 2, 602668 (3),
ZNF90		
ZNF900		
ZNF901		
ZNF902		
ZNF903		
ZNF904		
ZNF905		
ZNF906		
ZNF907		
ZNF909		
ZNF91		
ZNF910		
ZNF911		
ZNF912	AD	adenomas, salivary gland pleomorphic, somatic, 181030 (3); silver-russell syndrome 4, 618907 (3),
ZNF913	AR	intellectual developmental disorder, 69, 618383 (3),
ZNF914		
ZNF915		
ZNF916A		
ZNF918		
ZNF91L		
ZNF92		
ZNF921		
ZNF922		
ZNF923		
ZNF925	AR	?lethal congenital contracture syndrome 6, 616248 (3),
ZNF926		
ZNF927		prostate cancer, somatic, 176807 (3)
ZNF928		
ZNF93		
ZNF95		
ZNF96		
ZNF98		
ZNF99		
ZNFD		
ZNFN1A1	AD	immunodeficiency, common variable, 13, 616873 (3),
ZNFN1A2		
ZNFN1A3	AD	?immunodeficiency 84, 619437 (3),
ZNFN1A4		
ZNFN1A5	AD	thrombocytopenia, 7, 619130 (3),
ZNFN2A1		
ZNFN3A1		
ZNFN4A1		
ZNFX1	AR	immunodeficiency 91 and hyperinflammation, 619644 (3),
ZNG1A		
ZNG1B		
ZNG1C		
ZNHIT1		
ZNHIT2		
ZNHIT3	AR	peho syndrome, 260565 (3),
ZNHIT4		
ZNHIT5	AR	orofaciodigital syndrome v, 174300 (3),
ZnR		
ZNRD1		
ZNRD1-AS		
ZNRD1-AS1		
ZNRD1AS		
ZNRD1ASP		
ZNRD2		
ZNRF1		
ZNRF2		
ZNRF3		
ZNRF4		
ZNRP	AR	thrombocytopenia-absent radius syndrome, 274000 (3),
ZnT-10	AR	hypermanganesemia with dystonia 1, 613280 (3),
ZnT-5		
ZnT-8	AD	{diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3),
ZNT1		
ZNT10	AR	hypermanganesemia with dystonia 1, 613280 (3),
ZNT2	AD	zinc deficiency, transient neonatal, 608118 (3),
ZNT3		
ZNT4		
ZNT5		
ZNT6		
ZNT7		
ZNT8	AD,AR	{diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3), |hypermanganesemia with dystonia 1, 613280 (3),
ZNT9	AR	birk-landau-perez syndrome, 617595 (3),
ZNTL1		
ZnTL2		
ZO-1		
ZO-2	AR	hypercholanemia, familial 1, 607748 (3), ; cholestasis, progressive familial intrahepatic 4, 615878 (3),
ZO-3		
ZO2	AR	hypercholanemia, familial 1, 607748 (3), ; cholestasis, progressive familial intrahepatic 4, 615878 (3),
ZOG		
ZONAB		
Zp	AR	?abnormal hair, joint laxity, and developmental delay, 261990 (3),
ZP1	AR	oocyte/zygote/embryo maturation arrest 1, 615774 (3),
ZP1B		
ZP2	AR	oocyte/zygote/embryo maturation arrest 6, 618353 (3),
ZP3	AD	oocyte/zygote/embryo maturation arrest 3, 617712 (3),
ZP3-372	AD	oocyte/zygote/embryo maturation arrest 3, 617712 (3),
ZP3-424	AD	oocyte/zygote/embryo maturation arrest 3, 617712 (3),
ZP3A	AD	oocyte/zygote/embryo maturation arrest 3, 617712 (3),
ZP3B	AD	oocyte/zygote/embryo maturation arrest 3, 617712 (3),
ZP4		
ZPA	AR	oocyte/zygote/embryo maturation arrest 6, 618353 (3),
ZPB		
ZPB1	AR	oocyte/zygote/embryo maturation arrest 1, 615774 (3),
ZPB2		
ZPBP	AR	?spermatogenic failure 66, 619799 (3),
ZPBP1	AR	?spermatogenic failure 66, 619799 (3),
ZPBP2		
ZPBPL		
ZPC	AD	oocyte/zygote/embryo maturation arrest 3, 617712 (3),
ZPI		
ZPK		
ZPKP1		
ZPLD1		
Zpo1		
ZPR1	AR	?growth restriction, hypoplastic kidneys, alopecia, and distinctive facies, 619321 (3),
ZPR9		
ZPRO		
ZRANB1		
ZRANB2		
ZRANB3		
ZRANB4	AR	polyglucosan body myopathy 1 with or without immunodeficiency, 615895 (3),
ZRANB5	XLR,XL	tarp syndrome, 311900 (3),
ZRC1	AR	hypermanganesemia with dystonia 1, 613280 (3),
ZRF1		
ZRP-1		
ZRS	AD,AR	triphalangeal thumb, type i, 174500 (3), ; syndactyly, type iv, 186200 (3), ; laurin-sandrow syndrome, 135750 (3), ; hypoplastic or aplastic tibia with polydactyly, 188740 (3), ; polydactyly, preaxial type ii, 174500 (3), ; acheiropody, 200500 (3), ; triphalangeal thumb-polysyndactyly syndrome, 190605 (3),
ZRSR2		
ZSCAN1		
ZSCAN10		
ZSCAN11		
ZSCAN12		
ZSCAN14		
ZSCAN15		
ZSCAN16		
ZSCAN17		
ZSCAN19		
ZSCAN20		
ZSCAN21		
ZSCAN22		
ZSCAN24		
ZSCAN26		
ZSCAN28		
ZSCAN3		
ZSCAN31		
ZSCAN33		
ZSCAN35		
ZSCAN36		
ZSCAN37		
ZSCAN38		
ZSCAN4		
ZSCAN40		
ZSCAN41		
ZSCAN42		
ZSCAN43		
ZSCAN44		
ZSCAN46		
ZSCAN47		
ZSCAN49		
ZSCAN51		
ZSCAN53		
ZSCAN54A		
ZSCAN6		
ZSCAN7		
ZSCAN8		
ZSCAN9		
ZSG		
ZSG1		
ZSIG37		
ZSIG51		
ZSIG9		
ZSWIM3		
ZSWIM5		
ZSWIM6	AD	neurodevelopmental disorder with movement abnormalities, abnormal gait, and autistic features, 617865 (3), ; acromelic frontonasal dysostosis, 603671 (3),
ZSWIM7	AR	spermatogenic failure 71, 619831 (3), ; ?ovarian dysgenesis 10, 619834 (3),
ZSWIM7AP1		
ZSWIM8		
ZT86		
ZTL1		
ZUBR1		
Zuc		
ZUD		
ZUO1		
zuotin		
ZVNH1		
ZVNR1		
ZW10		
ZWILCH		
ZWINT		
Zwint1		
ZWS	AR	heimler syndrome 1, 234580 (3), ; peroxisome biogenesis disorder 1b (nald/ird), 601539 (3), ; peroxisome biogenesis disorder 1a (zellweger), 214100 (3),
ZWS1	AR	heimler syndrome 1, 234580 (3), ; peroxisome biogenesis disorder 1b (nald/ird), 601539 (3), ; peroxisome biogenesis disorder 1a (zellweger), 214100 (3),
ZWS2	AR	?bile acid synthesis defect, congenital, 5, 616278 (3),
ZWS3	AR	peroxisome biogenesis disorder 5a (zellweger), 614866 (3), ; peroxisome biogenesis disorder 5b, 614867 (3),
ZXDA		
ZXDB		
ZXDC		
ZYG		
ZYG11		
ZYG11A		
ZYG11B		
ZYG11BL		
ZYX		
ZZANK1		
ZZANK2	AD	left ventricular noncompaction 7, 615092 (3),
ZZAPK		
ZZEF1		
ZZZ1		
ZZZ3		
ZZZ4		
ZZZ5		
ZZZ6	AD	left ventricular noncompaction 7, 615092 (3),
Î±4	XLR,XL	?corpus callosum, agenesis of, with impaired intellectual development, ocular coloboma and micrognathia, 300472 (3),
Î±Pix		
Ï2R		
NA		liposarcoma (1)|thalassemia, hispanic gamma-delta-beta, 613985 (3)
